PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Laine, A; Ronai, Z				Laine, A.; Ronai, Z.			Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1	ONCOGENE			English	Article						p53; WWP1; ubiquitin; HECHT; E3 ligases; transcription	UBIQUITIN-PROTEIN LIGASE; KRUPPEL-LIKE FACTOR; DEGRADATION; STABILITY; DEATH; MDM2; ACTIVATION; PROMOTES; PATHWAY; MOTIFS	As a key cellular regulatory protein p53 is subject to tight regulation by several E3 ligases. Here, we demonstrate the role of HECT domain E3 ligase, WWP1, in regulating p53 localization and activity. WWP1 associates with p53 and induces p53 ubiquitylation. Unlike other E3 ligases, WWP1 increases p53 stability; inhibition of WWP1 expression or expression of a ligase-mutant form results in decreased p53 expression. WWP1-mediated stabilization of p53 is associated within creased accumulation of p53 in cytoplasm witha concomitant decrease in its transcriptional activities. WWP1 effects are independent of Mdm2 as they are seen in cells lacking Mdm2 expression. Whereas WWP1 limits p53 activity, p53 reduces expression of WWP1, pointing to a possible feedback loop mechanism. Taken together, these findings identify the first instance of a ubiquitin ligase that causes stabilization of p53 while inactivating its transcriptional activities.	Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ronai, Z (corresponding author), Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA.	ronai@burnham.org		RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA78419, R01 CA078419-08, R01 CA078419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; DORAN D, 2004, NATURE, V429, P86; Galinier R, 2002, BIOCHEMISTRY-US, V41, P14299, DOI 10.1021/bi020125b; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Martin-Serrano J, 2005, J CELL BIOL, V168, P89, DOI 10.1083/jcb.200408155; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang ZX, 2004, ONCOGENE, V23, P8146, DOI 10.1038/sj.onc.1207992; Xu HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	34	100	102	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1477	1483		10.1038/sj.onc.1209924	http://dx.doi.org/10.1038/sj.onc.1209924			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16924229	Green Accepted			2022-12-25	WOS:000244558800012
J	Burdak-Rothkamm, S; Short, SC; Folkard, M; Rothkamm, K; Prise, KM				Burdak-Rothkamm, S.; Short, S. C.; Folkard, M.; Rothkamm, K.; Prise, K. M.			ATR-dependent radiation-induced gamma H2AX foci in bystander primary human astrocytes and glioma cells	ONCOGENE			English	Article						ATR; gamma H2AX; DNA damage; charged particle irradiation; targeted irradiation; bystander signalling	DOUBLE-STRAND BREAKS; CHARGED-PARTICLE MICROBEAM; MEDIATED INTERCELLULAR COMMUNICATION; IONIZING-RADIATION; REACTIVE OXYGEN; HUMAN FIBROBLASTS; IRRADIATED-CELLS; ALPHA-PARTICLES; HISTONE H2AX; GENOMIC INSTABILITY	Radiotherapy is an important treatment for patients suffering from high-grade malignant gliomas. Non-targeted ( bystander) effects may influence these cells' response to radiation and the investigation of these effects may therefore provide new insights into mechanisms of radiosensitivity and responses to radiotherapy as well as de. ne new targets for therapeutic approaches. Normal primary human astrocytes ( NHA) and T98G glioma cells were irradiated with helium ions using the Gray Cancer Institute microbeam facility targeting individual cells. Irradiated NHA and T98G glioma cells generated signals that induced gamma H2AX foci in neighbouring non-targeted bystander cells up to 48 h after irradiation. gamma H2AX bystander foci were also observed in co-cultures targeting either NHA or T98G cells and in medium transfer experiments. Dimethyl sulphoxide, Filipin and antitransforming growth factor (TGF)-beta 1 could suppress gamma H2AX foci in bystander cells, confirming that reactive oxygen species (ROS) and membrane-mediated signals are involved in the bystander signalling pathways. Also, TGF-beta 1 induced gamma H2AX in an ROS- dependent manner similar to bystander foci. ROS and membrane signalling-dependent differences in bystander foci induction between T98G glioma cells and normal human astrocytes have been observed. Inhibition of ataxia telangiectasia mutated (ATM) protein and DNA-PK could not suppress the induction of bystander gamma H2AX foci whereas the mutation of ATM- and rad3-related (ATR) abrogated bystander foci induction. Furthermore, ATR-dependent bystander foci induction was restricted to S-phase cells. These observations may provide additional therapeutic targets for the exploitation of the bystander effect.	Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2JR, Middx, England; Univ Oxford, Gray Canc Inst, Oxford OX1 2JD, England	University of Oxford; University of Oxford	Burdak-Rothkamm, S (corresponding author), Mt Vernon Hosp, Gray Canc Inst, POB 100, Northwood HA6 2JR, Middx, England.	burdak-rothkamm@gci.ac.uk	Rothkamm, Kai/A-2164-2014; Prise, Kevin/N-7872-2015; Burdak-Rothkamm, Susanne/I-2553-2012	Rothkamm, Kai/0000-0001-7414-5729; Prise, Kevin/0000-0001-6134-7946; Burdak-Rothkamm, Susanne/0000-0002-3840-2844; Short, Susan/0000-0003-4423-7256				Ayache N, 2002, OSTEOARTHR CARTILAGE, V10, P344, DOI 10.1053/joca.2001.0499; Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Azzam EI, 2000, CANCER RES, V60, P2623; Bellocq A, 1999, AM J RESP CELL MOL, V21, P128, DOI 10.1165/ajrcmb.21.1.3379; Belyakov OV, 2002, RADIAT PROT DOSIM, V99, P249, DOI 10.1093/oxfordjournals.rpd.a006775; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; Folkard M, 1997, INT J RADIAT BIOL, V72, P387, DOI 10.1080/095530097143167; Gerashchenko BI, 2003, CYTOM PART A, V56A, P71, DOI 10.1002/cyto.a.10092; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200; Hu B, 2005, RADIAT RES, V164, P286, DOI 10.1667/RR3415.1; Hwang YS, 2004, ONCOGENE, V23, P6603, DOI 10.1038/sj.onc.1207867; Kashino G, 2004, MUTAT RES-FUND MOL M, V556, P209, DOI 10.1016/j.mrfmmm.2004.08.009; Kosmidou I, 2002, AM J RESP CELL MOL, V26, P587, DOI 10.1165/ajrcmb.26.5.4598; Leach JK, 2001, CANCER RES, V61, P3894; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Maguire P, 2005, RADIAT RES, V163, P384, DOI 10.1667/RR3325; Mitchell SA, 2004, RADIAT RES, V161, P397, DOI 10.1667/RR3137; Morgan WF, 2003, ONCOGENE, V22, P7094, DOI 10.1038/sj.onc.1206992; Mothersill C, 2004, RADIAT RES, V161, P256, DOI 10.1667/RR3136; Mothersill CE, 2004, INT J RADIAT ONCOL, V58, P575, DOI 10.1016/j.ijrobp.2003.09.038; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Prise KM, 2005, LANCET ONCOL, V6, P520, DOI 10.1016/S1470-2045(05)70246-1; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Ryan KA, 2004, INFECT IMMUN, V72, P2123, DOI 10.1128/IAI.72.4.2123-2130.2004; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shao C, 2005, INT J CANCER, V116, P45, DOI 10.1002/ijc.21003; Shao C, 2003, CANCER RES, V63, P8437; SHAO C, 2006, IN PRESS RAD RES; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2003, RADIAT RES, V160, P318, DOI 10.1667/RR3044; Sokolov MV, 2005, ONCOGENE, V24, P7257, DOI 10.1038/sj.onc.1208886; Souhami R, 2005, CANC ITS MANAGEMENT; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Veuger SJ, 2003, CANCER RES, V63, P6008; Wang HY, 2005, J CELL PHYSIOL, V202, P492, DOI 10.1002/jcp.20141; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Yang HY, 2005, ONCOGENE, V24, P2096, DOI 10.1038/sj.onc.1208439; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	48	153	159	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					993	1002		10.1038/sj.onc.1209863	http://dx.doi.org/10.1038/sj.onc.1209863			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909103				2022-12-25	WOS:000244245400005
J	Ayrault, O; Andrique, L; Fauvin, D; Eymin, B; Gazzeri, S; Seite, P				Ayrault, O.; Andrique, L.; Fauvin, D.; Eymin, B.; Gazzeri, S.; Seite, P.			Human tumor suppressor p14(ARF) negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation	ONCOGENE			English	Article						p14(ARF); rRNA promoter; UBF	POLYMERASE-I TRANSCRIPTION; RDNA TRANSCRIPTION; CELL-PROLIFERATION; TOPOISOMERASE-I; PROTEIN; GENE; P19(ARF); P53; RB; BIOGENESIS	The nucleolar Arf protein has been shown to regulate cell cycle through both p53-dependent and -independent pathways. In addition to the well-characterized Arf-mdm2-p53 pathway, several partners of Arf have recently been described that could participate in alternative regulation process. Among those is the nucleolar protein B23/NPM, involved in the sequential maturation of rRNA. p19(ARF) can interact with B23/NPM in highmolecular complexes and partially inhibit the cleavage of the 32S rRNA, whereas the human p14(ARF) protein has been shown to participate in the degradation of NPM/B23 by the proteasome. These data led to define Arf as a negative regulator of ribosomal RNA maturation. Our recent finding that the human p14ARF protein was able to specifically interact with the rRNA promoter in a p53-independent context, led us to analyse in vitro and in vivo the consequences of this interaction. Luciferase assay and pulse-chase experiments demonstrated that the rRNA transcription was strongly reduced upon p14(ARF) overexpression. Investigations on potential interactions between p14(ARF) and the transcription machinery proteins demonstrated that the upstream binding factor (UBF), required for the initiation of the transcriptional complex, was a new partner of the p14(ARF) protein. We next examined the phosphorylation status of UBF as UBF phosphorylation is required to recruit on the promoter factors involved in the transcriptional complex. Upon p14(ARF) overexpression, UBF was found hypophosphorylated, thus unable to efficiently recruit the transcription complex. Taken together, these data de. ne a new p53-independent pathway that could regulate cell cycle through the negative control of rRNA transcription.	Lab Oncol Mol, EA 3805, F-86022 Poitiers, France; Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, INSERM,Unite U578, La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Seite, P (corresponding author), Lab Oncol Mol, EA 3805, Pole Biol Sante 40,Ave Recteur Pineau, F-86022 Poitiers, France.	paule.seite@univ-poitiers.fr	Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; Seite, Paule/0000-0002-7809-7610; Andrique, Laetitia/0000-0001-7840-8135				Andrique T, 2005, ONCOGENE, V24, P2580, DOI 10.1038/sj/onc.1208457; Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Drakas R, 2004, P NATL ACAD SCI USA, V101, P9272, DOI 10.1073/pnas.0403328101; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; GARG LC, 1987, P NATL ACAD SCI USA, V84, P3185, DOI 10.1073/pnas.84.10.3185; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 2000, ONCOGENE, V19, P4988, DOI 10.1038/sj.onc.1203875; Huang RM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0687com; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Voit R, 2001, P NATL ACAD SCI USA, V98, P13631, DOI 10.1073/pnas.231071698; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000	35	62	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7577	7586		10.1038/sj.onc.1209743	http://dx.doi.org/10.1038/sj.onc.1209743			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16924243				2022-12-25	WOS:000242655500003
J	Newton, GL; Ta, P; Bzymek, KP; Fahey, RC				Newton, Gerald L.; Ta, Philong; Bzymek, Krzysztof P.; Fahey, Robert C.			Biochemistry of the initial steps of mycothiol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-TUBERCULOSIS; INOSITOL MONOPHOSPHATASE; CRYSTAL-STRUCTURE; INOSITOL-1-PHOSPHATE SYNTHASE; STRUCTURAL-ANALYSIS; DEACETYLASE MSHB; ENZYME; IDENTIFICATION; GENE; MYOINOSITOL	Mycothiol is the major thiol produced by mycobacteria and is required for growth of Mycobacterium tuberculosis. The final three steps in the biosynthesis of mycothiol have been fully elucidated but the initial steps have been unclear. A glycosyltransferase, MshA, is required for production of the mycothiol precursor, 1-O-(2-acetamido-2-deoxy-alpha-D-glucopyranosyl)-D-myo-inositol, but its substrates and immediate products were unknown. In this study, we show that the N-acetylglucosamine donor is UDP-N-acetylglucosamine and that the N-acetylglucosamine acceptor is 1L-myo-inositol 1-phosphate. The reaction generates UDP and 1-O-(2-acetamido-2-deoxy-alpha-D-glucopyranosyl)-D-myo-inositol 3-phosphate. Using cell-free extracts of M. smegmatis mc(2)155, little activity was obtained with myo-inositol, 1D-myo-inositol 1-phosphate, or myo-inositol 2-phosphate as the N-acetylglucosamine acceptor. A phosphatase, designated MshA2, is required to dephosphorylate 1-O-(2-acetamido-2-deoxy-D-glucopyranosyl)-D- myo-inositol 3-phosphate to produce 1-O-(2-acetamido-2-deoxy-alpha-D-glucopyranosyl)-D-myo- inositol. The latter is deacetylated, ligated with cysteine, and the cysteinyl amino group acetylated by acetyl-CoA to complete the mycothiol biosynthesis pathway. Uptake and concentration of myo-[C-14] inositol is rapid in Mycobacterium smegmatis and leads to production of radio labeled inositol1-phosphate and my cothiol. This demonstrates the presence of a myo- inositol transporter and a kinase that generates 1L-myo-inositol1-phosphate. The biochemical pathway of mycothiol biosynthesis is now fully elucidated.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Fahey, RC (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92014 USA.	rcfahey@ucsd.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049174, R01AI049174] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49174] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderberg SJ, 1998, J BIOL CHEM, V273, P30391, DOI 10.1074/jbc.273.46.30391; Bachhawat N, 1999, J MOL BIOL, V291, P531, DOI 10.1006/jmbi.1999.2980; BONE R, 1994, BIOCHEMISTRY-US, V33, P9460, DOI 10.1021/bi00198a011; Bornemann C, 1997, BIOCHEM J, V325, P623, DOI 10.1042/bj3250623; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Buchmeier NA, 2003, MOL MICROBIOL, V47, P1723, DOI 10.1046/j.1365-2958.2003.03416.x; Buchmeier NA, 2006, J BACTERIOL, V188, P6245, DOI 10.1128/JB.00393-06; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P12415, DOI 10.1021/bi001517q; DANKERT M, 1972, AN ASOC QUIM ARGENT, V60, P257; Gammon DW, 2003, BIOORG MED CHEM LETT, V13, P2045, DOI 10.1016/S0960-894X(03)00157-4; Gu XL, 2006, BIOCHEM BIOPH RES CO, V339, P897, DOI 10.1016/j.bbrc.2005.11.088; Haites RE, 2005, J BIOL CHEM, V280, P10981, DOI 10.1074/jbc.M413443200; Koledin T, 2002, ARCH MICROBIOL, V178, P331, DOI 10.1007/s00203-002-0462-y; LOEWUS MW, 1982, PLANT PHYSIOL, V70, P1661, DOI 10.1104/pp.70.6.1661; Maynes JT, 2003, J BIOL CHEM, V278, P47166, DOI 10.1074/jbc.M308914200; McCarthy AA, 2004, J MOL BIOL, V335, P1131, DOI 10.1016/j.jmb.2003.11.034; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; Morgan AJ, 2004, J AM CHEM SOC, V126, P15370, DOI 10.1021/ja047360x; Newton GL, 2006, PROTEIN EXPRES PURIF, V47, P542, DOI 10.1016/j.pep.2006.03.003; Newton GL, 2005, J BACTERIOL, V187, P7309, DOI 10.1128/JB.187.21.7309-7316.2005; Newton GL, 2003, J BACTERIOL, V185, P3476, DOI 10.1128/JB.185.11.3476-3479.2003; Newton GL, 2002, ARCH MICROBIOL, V178, P388, DOI 10.1007/s00203-002-0469-4; NEWTON GL, 1995, EUR J BIOCHEM, V230, P821; Newton GL, 2000, J BACTERIOL, V182, P6958, DOI 10.1128/JB.182.24.6958-6963.2000; Newton GL, 2000, BIOCHEMISTRY-US, V39, P10739, DOI 10.1021/bi000356n; Nicholas GM, 2003, BIOORGAN MED CHEM, V11, P2641, DOI 10.1016/S0968-0896(03)00154-8; Nicholas GM, 2003, BIOORGAN MED CHEM, V11, P601, DOI 10.1016/S0968-0896(02)00345-0; Nigou J, 2002, BIOCHEMISTRY-US, V41, P4392, DOI 10.1021/bi0160056; Patel MP, 2001, BIOCHEMISTRY-US, V40, P5119, DOI 10.1021/bi0029144; Patel MP, 1999, BIOCHEMISTRY-US, V38, P11827, DOI 10.1021/bi991025h; Rawat M, 2003, MICROBIOL-SGM, V149, P1341, DOI 10.1099/mic.0.26084-0; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; Rengarajan J, 2005, P NATL ACAD SCI USA, V102, P8327, DOI 10.1073/pnas.0503272102; SAKUDA S, 1994, BIOSCI BIOTECH BIOCH, V58, P1347, DOI 10.1271/bbb.58.1347; Sareen D, 2003, J BACTERIOL, V185, P6736, DOI 10.1228/JB.185.22.6736-6740.2003; Sareen D, 2002, BIOCHEMISTRY-US, V41, P6885, DOI 10.1021/bi012212u; SPIES HSC, 1994, EUR J BIOCHEM, V224, P203, DOI 10.1111/j.1432-1033.1994.tb20013.x; Steffek M, 2003, BIOCHEMISTRY-US, V42, P12067, DOI 10.1021/bi030080u; STEPHENS LR, 1990, BIOCHEM J, V272, P201, DOI 10.1042/bj2720201; Vetting MW, 2006, J BIOL CHEM, V281, P2795, DOI 10.1074/jbc.M510798200; Vetting MW, 2003, PROTEIN SCI, V12, P1954, DOI 10.1110/ps.03153703; Vogt RN, 2003, BIOCHEM J, V374, P657, DOI 10.1042/BJ20030642; Yoshida KI, 2002, J BACTERIOL, V184, P983, DOI 10.1128/jb.184.4.983-991.2002	44	58	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33910	33920		10.1074/jbc.M604724200	http://dx.doi.org/10.1074/jbc.M604724200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16940050	hybrid			2022-12-25	WOS:000241767600012
J	Grkovich, A; Johnson, CA; Buczynski, MW; Dennis, EA				Grkovich, Andrej; Johnson, Christina A.; Buczynski, Matthew W.; Dennis, Edward A.			Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); PROTEIN-KINASE-C; SACCHAROMYCES-CEREVISIAE; INDUCED DIFFERENTIATION; SIGNAL-TRANSDUCTION; WISH CELLS; RAT-LIVER; ACTIVATION; DIACYLGLYCEROL; PATHWAY	Cyclooxygenase (COX) has two isoforms, COX-1 and -2, which catalyze the key step in the conversion of cellular arachidonic acid into prostaglandins. In recent years, interest in COX-2 has significantly increased since it has been a target for the development of specific non-steroidal anti-inflammatory drugs. We report that COX-2 expression is up-regulated in phorbol ester (phorbol myristate acetate, PMA)-differentiated human U937 macrophage-like cells stimulated with lipopolysaccharide (LPS), whereas COX-1 is not up-regulated. We show that the LPS-induced up-regulation of COX-2 depends on the activity of the Mg+2-dependent phosphatidic acid phosphohydrolase 1 (PAP-1). Inhibition of PAP-1 by bromoenol lactone, propranolol, or ethanol resulted in a decrease in LPS-induced COX-2 mRNA transcript production, COX-2 protein expression, and prostaglandin E2 release from U937 macrophages. To ensure that these results did not arise because of PMA treatment of the U937 cells, similar experiments were conducted with the P388D(1) cell line, which does not require PMA differentiation. LPS increased the levels of endogenous cellular diacylglycerol (DAG) within 2 min of stimulation. This increase was observed to be sensitive to the PAP-1 inhibitors. Furthermore, phosphatidic acid phosphohydrolase activity assays showed that the bromoenol lactone-sensitive PAP-1 activity was translocated from the cytosolic fraction to the membrane fraction within 2 min of LPS exposure. Finally, DAG add-back experiments demonstrate that LPS-induced COX-2 expression is enhanced by the addition of exogenous DAG.	Univ Calif San Diego, Dept Pharmacol, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Dept Pharmacol, Dept Chem & Biochem, La Jolla, CA 92093 USA.	edennis@ucsd.edu	Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064611] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK007202] Funding Source: Medline; NIGMS NIH HHS [GM64611] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; Balboa MA, 2003, J IMMUNOL, V171, P989, DOI 10.4049/jimmunol.171.2.989; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bos CL, 2004, INT J BIOCHEM CELL B, V36, P1187, DOI 10.1016/j.biocel.2003.08.006; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Burke JR, 1999, BIOCHEM BIOPH RES CO, V260, P232, DOI 10.1006/bbrc.1999.0887; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; DAY CP, 1992, BIOCHIM BIOPHYS ACTA, V1127, P87, DOI 10.1016/0005-2760(92)90205-A; Elabbadi N, 2002, LIPIDS, V37, P69, DOI 10.1007/s11745-002-0865-7; Fuentes L, 2003, J BIOL CHEM, V278, P44683, DOI 10.1074/jbc.M307209200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Goldfine H, 2000, INFECT IMMUN, V68, P5735, DOI 10.1128/IAI.68.10.5735-5741.2000; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; HASS R, 1989, EUR J CELL BIOL, V48, P282; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Huffman TA, 2002, P NATL ACAD SCI USA, V99, P1047, DOI 10.1073/pnas.022634399; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Jiang YJ, 2003, MOL CELL BIOCHEM, V246, P31, DOI 10.1023/A:1023495626568; Jiang YW, 1996, J BIOL CHEM, V271, P29529, DOI 10.1074/jbc.271.47.29529; Johnson CA, 1999, J BIOL CHEM, V274, P27689, DOI 10.1074/jbc.274.39.27689; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; Lee SC, 2003, MOL CELLS, V15, P320; Lee YN, 2004, BIOCHEM BIOPH RES CO, V318, P839, DOI 10.1016/j.bbrc.2004.04.112; LIN YP, 1989, J BIOL CHEM, V264, P8641; LIN YP, 1990, J BIOL CHEM, V265, P166; Linton MF, 2004, CURR OPIN PHARMACOL, V4, P116, DOI 10.1016/j.coph.2003.12.003; Maestre Nicolas, 2003, J Exp Ther Oncol, V3, P36, DOI 10.1046/j.1359-4117.2003.01065.x; Meier KE, 1998, CELL SIGNAL, V10, P415, DOI 10.1016/S0898-6568(97)00140-X; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Nanjundan M, 2003, AM J PHYSIOL-LUNG C, V284, pL1, DOI 10.1152/ajplung.00029.2002; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; Park DW, 2002, MOL PHARMACOL, V61, P614, DOI 10.1124/mol.61.3.614; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Shen Q, 2003, J MAMMARY GLAND BIOL, V8, P45, DOI 10.1023/A:1025783221557; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Song HW, 2006, BIOCHEMISTRY-US, V45, P1061, DOI 10.1021/bi052065q; STURTON RG, 1980, BIOCHIM BIOPHYS ACTA, V619, P494, DOI 10.1016/0005-2760(80)90101-0; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Van Amersfoort ES, 2003, CLIN MICROBIOL REV, V16, P379, DOI 10.1128/CMR.16.3.379-414.2003; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; Yamamoto H, 1997, BIOCHEM J, V325, P223, DOI 10.1042/bj3250223; Zhang FH, 2001, INT IMMUNOPHARMACOL, V1, P1375, DOI 10.1016/S1567-5769(01)00069-8	46	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					32978	32987		10.1074/jbc.M605935200	http://dx.doi.org/10.1074/jbc.M605935200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950767	Green Published, hybrid			2022-12-25	WOS:000241621400006
J	Knowles, PP; Murray-Rust, J; Kjaer, S; Scott, RP; Hanrahan, S; Santoro, M; Ibanez, CF; McDonald, NQ				Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.			Structure and chemical inhibition of the RET tyrosine kinase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; NEOPLASIA TYPE 2B; C-RET; AUTOPHOSPHORYLATION SITES; MOLECULAR-MECHANISMS; HIRSCHSPRUNG-DISEASE; CRYSTAL-STRUCTURE; POINT MUTATIONS; KEY ENZYME; RECEPTOR	The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands. Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B. We report here the biochemical characterization of the human RET tyrosine kinase domain and the structure determination of the non-phosphorylated and phosphorylated forms. Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status. In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity. Longer forms of RET containing the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain. Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity. We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clinically relevant 4-anilinoquinazoline ZD6474. These structures explain why certain multiple endocrine neoplasia 2-associated RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.	Canc Res UK, Struct Biol Lab, London Res Inst, London WC2A 3PX, England; Univ London Birkbeck Coll, Sch Crystallog, London WC1E 7HX, England; Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, SE-17177 Stockholm, Sweden; Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy	Cancer Research UK; University of London; Birkbeck University London; Karolinska Institutet; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	McDonald, NQ (corresponding author), Canc Res UK, Struct Biol Lab, London Res Inst, 44 Lincolns Inn Fields, London WC2A 3PX, England.	neil.mcdonald@cancer.org.uk	Scott, Rizaldy/AAC-5264-2020; Scott, Rizaldy/Y-7584-2019	Scott, Rizaldy/0000-0002-0288-8862; Kjaer, Susanne/0000-0002-8347-1398				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Anders J, 2001, J BIOL CHEM, V276, P35808, DOI 10.1074/jbc.M104968200; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Blencke S, 2004, CHEM BIOL, V11, P691, DOI 10.1016/j.chembiol.2004.02.029; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Borrello MG, 1995, ONCOGENE, V11, P2419; Buckwalter TLF, 2002, ONCOGENE, V21, P8166, DOI 10.1038/sj.onc.1205938; Carlomagno F, 2004, J CHEMOTHERAPY, V16, P49, DOI 10.1179/joc.2004.16.Supplement-1.49; Carlomagno F, 2005, CURR MED CHEM, V12, P1773, DOI 10.2174/0929867054367266; Carlomagno F, 2004, ONCOGENE, V23, P6056, DOI 10.1038/sj.onc.1207810; Carlomagno F, 2002, CANCER RES, V62, P1077; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Cheetham GMT, 2004, CURR OPIN STRUC BIOL, V14, P700, DOI 10.1016/j.sbi.2004.10.011; Costantini F, 2006, BIOESSAYS, V28, P117, DOI 10.1002/bies.20357; Coulpier M, 2002, J BIOL CHEM, V277, P1991, DOI 10.1074/jbc.M107992200; Craven RA, 2006, PROTEOMICS, V6, P3880, DOI 10.1002/pmic.200500811; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; Drosten M, 2003, HUM GENE THER, V14, P971, DOI 10.1089/104303403766682232; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Frank R, 1996, Methods Mol Biol, V66, P149; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Hubbard SR, 2002, CURR OPIN STRUC BIOL, V12, P735, DOI 10.1016/S0959-440X(02)00383-4; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Iwashita T, 1996, ONCOGENE, V12, P481; Iwashita T, 1996, HUM MOL GENET, V5, P1577, DOI 10.1093/hmg/5.10.1577; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kashuk CS, 2005, P NATL ACAD SCI USA, V102, P8949, DOI 10.1073/pnas.0503259102; Kawamoto Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/jbc.M312600200; Kjaer S, 2003, HUM MOL GENET, V12, P2133, DOI 10.1093/hmg/ddg227; LESLIE AGW, 1992, JOITN CCP4 ESF EAMCB, V26; Li SQ, 2003, J BIOL CHEM, V278, P26007, DOI 10.1074/jbc.M302425200; Liu Y, 1998, BIOORGAN MED CHEM, V6, P1219, DOI 10.1016/S0968-0896(98)00099-6; Lougheed JC, 2004, J BIOL CHEM, V279, P44039, DOI 10.1074/jbc.M406703200; Manley PW, 2005, BBA-PROTEINS PROTEOM, V1754, P3, DOI 10.1016/j.bbapap.2005.07.040; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; MISE N, 2006, IN PRESS ONCOGENE; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Parast CV, 1998, BIOCHEMISTRY-US, V37, P16788, DOI 10.1021/bi981291f; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Ryan AJ, 2005, BRIT J CANCER, V92, pS6, DOI 10.1038/sj.bjc.6602603; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Sariola H, 2003, J CELL SCI, V116, P3855, DOI 10.1242/jcs.00786; Schlessinger J, 2003, SCIENCE, V300, P750, DOI 10.1126/science.1082024; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuringa JJ, 2001, ONCOGENE, V20, P5350, DOI 10.1038/sj.onc.1204715; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Takahashi M, 1998, J INTERN MED, V243, P509; Tegge WJ, 1998, METH MOL B, V87, P99; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Uchino S, 1998, JPN J CANCER RES, V89, P411, DOI 10.1111/j.1349-7006.1998.tb00579.x; Unwin RD, 2005, MOL CELL PROTEOMICS, V4, P1134, DOI 10.1074/mcp.M500113-MCP200; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Waltenberger J, 1999, CIRC RES, V85, P12; Wang WR, 2006, P NATL ACAD SCI USA, V103, P3563, DOI 10.1073/pnas.0600048103; Yuan ZL, 2004, MOL CELL BIOL, V24, P9390, DOI 10.1128/MCB.24.21.9390-9400.2004; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	78	192	202	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33577	33587		10.1074/jbc.M605604200	http://dx.doi.org/10.1074/jbc.M605604200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16928683	hybrid			2022-12-25	WOS:000241621400067
J	Nichol, D; Christian, M; Steel, JH; White, R; Parker, MG				Nichol, Donna; Christian, Mark; Steel, Jennifer H.; White, Roger; Parker, Malcolm G.			RIP140 expression is stimulated by estrogen-related receptor alpha during adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; TRANSCRIPTIONAL REGULATION; COREPRESSOR RIP140; ADIPOCYTE DIFFERENTIATION; NEGATIVE-FEEDBACK; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; GENE-EXPRESSION; C/EBP FAMILY; IN-VIVO	RIP140 is a corepressor for nuclear receptors that regulates energy expenditure in adipose tissue by suppressing the expression of clusters of metabolic genes involved in glucose and lipid metabolism. The gene encoding RIP140/Nrip1 contains only one coding exon but has multiple promoters and 5' non-coding exons that are subject to alternative splicing. In adipocytes we have defined a promoter, referred to as P2, that is preferentially utilized and activated during adipogenesis. Expression studies and chromatin immunoprecipitation experiments indicate that estrogen-related receptor alpha(ERR alpha), the level of which increases during adipogenesis in parallel with RIP140, stimulates transcription from the P2 promoter. Further analysis indicates that ERR alpha is capable of activating RIP140 gene transcription by two mechanisms, directly by binding to an estrogen receptor element/ERR element at -650/-633 and indirectly through Sp1 binding sites in the proximal promoter. Thus, the up-regulation of RIP140 by ERR alpha during adipogenesis may provide an inhibitory feedback mechanism to control the expression of many nuclear receptor target genes.	Imperial Coll, Fac Med, Inst Reprod & Dev Biol, London W12 0NN, England	Imperial College London	Parker, MG (corresponding author), Imperial Coll, Fac Med, Inst Reprod & Dev Biol, Du Cane Rd, London W12 0NN, England.	m.parker@imperial.ac.uk	Steel, Jennifer/B-4737-2013	Steel, Jennifer/0000-0003-4439-0090; Christian, Mark/0000-0002-1616-4179	Wellcome Trust [061930] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Augereau P, 2006, MOL PHARMACOL, V69, P1338, DOI 10.1124/mol.105.017376; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barry JB, 2006, MOL ENDOCRINOL, V20, P302, DOI 10.1210/me.2005-0313; Barry JB, 2005, CANCER RES, V65, P6120, DOI 10.1158/0008-5472.CAN-05-0922; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; CASTET A, 2006, MOL ENDOCRINOL; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Christian M, 2005, MOL CELL BIOL, V25, P9383, DOI 10.1128/MCB.25.21.9383-9391.2005; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Fu MG, 2005, MOL ENDOCRINOL, V19, P2437, DOI 10.1210/me.2004-0539; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Ise R, 2005, FEBS LETT, V579, P1732, DOI 10.1016/j.febslet.2005.02.033; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004; Kamalakaran S, 2005, J BIOL CHEM, V280, P21491, DOI 10.1074/jbc.M409176200; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Kerley JS, 2001, BIOCHEM BIOPH RES CO, V285, P969, DOI 10.1006/bbrc.2001.5274; Leonardsson G, 2004, P NATL ACAD SCI USA, V101, P8437, DOI 10.1073/pnas.0401013101; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Lu DS, 2001, CANCER RES, V61, P6755; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Powelka AM, 2006, J CLIN INVEST, V116, P125, DOI 10.1172/JCI26040; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RITTENHOUSE J, 1984, ANAL BIOCHEM, V138, P442, DOI 10.1016/0003-2697(84)90836-4; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SASTRY M, 1993, BIOCHEMISTRY-US, V32, P6588, DOI 10.1021/bi00077a012; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Steel JH, 1998, EUR J HISTOCHEM, V42, P143; Tong Q, 2005, MOL CELL BIOL, V25, P706, DOI 10.1128/MCB.25.2.706-715.2005; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Viguerie N, 2002, J CLIN ENDOCR METAB, V87, P630, DOI 10.1210/jc.87.2.630; White KA, 2003, J BIOL CHEM, V278, P43889, DOI 10.1074/jbc.C300374200; White R, 2000, NAT MED, V6, P1368, DOI 10.1038/82183; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Yu C, 2005, J BIOL CHEM, V280, P13600, DOI 10.1074/jbc.M409468200	56	47	48	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32140	32147		10.1074/jbc.M604803200	http://dx.doi.org/10.1074/jbc.M604803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16923809	hybrid			2022-12-25	WOS:000241414500011
J	Yang, NY; Pasquale, EB; Owen, LB; Ethell, IM				Yang, Nai-Ying; Pasquale, Elena B.; Owen, Laurie B.; Ethell, Iryna M.			The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC SPINE MORPHOGENESIS; FOCAL-ADHESION-KINASE; TUMOR-GROWTH; MALIGNANT-MELANOMA; LIGAND EPHRIN-B2; UP-REGULATION; R-RAS; ACTIVATION; EXPRESSION; OVEREXPRESSION	Several studies have reported the up-regulation of EphB receptor-tyrosine kinases and ephrin-B ligands in a variety of tumors, suggesting a functional relation between EphB/ephrinB signaling and tumor progression. The ability of the EphB receptors to regulate cell migration and promote angiogenesis likely contributes to tumor progression and metastasis. Here we show that EphB receptors, and especially EphB4, regulate the migration of murine melanoma cells. Highly malignant melanoma cells express the highest levels of EphB4 receptor and migrate faster than less malignant melanoma cells. Furthermore, inhibition of EphB receptor forward signaling by overexpression of a form of EphB4 lacking the cytoplasmic portion or by treatment with competitively acting soluble EphB2-Fc results in slower melanoma cell migration. In contrast, overexpression of active EphB4 significantly enhances cell migration. The effects of EphB4 receptor on cell migration and cell morphology require its kinase activity because the inhibition of EphB4 kinase activity by overexpression of kinase dead EphB4 inhibits cell migration and affects the organization of actin cytoskeleton. Activation of EphB4 receptor with its ligand ephrin-B2-Fc enhances the migratory ability of melanoma cells and increases RhoAactivity, whereas inhibiting EphB receptor forward signaling decreases RhoA activity. Moreover, expression of dominant negative RhoA blocks the effects of active EphB4 on cell migration and actin organization. These data suggest that EphB4 forward signaling contributes to the high migratory ability of invasive melanoma cells by influencing RhoA-mediated actin cytoskeleton reorganization.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Burnham Inst Med Res, La Jolla, CA 92037 USA; BioLegend, San Diego, CA 92121 USA	University of California System; University of California Riverside; Sanford Burnham Prebys Medical Discovery Institute	Ethell, IM (corresponding author), Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA.	iryna.ethell@ucr.edu		Ethell, Iryna/0000-0002-1324-6611				Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Bin Fang W, 2005, ONCOGENE, V24, P7859, DOI 10.1038/sj.onc.1208937; Bogenrieder T, 2002, CRIT REV ONCOL HEMAT, V44, P1, DOI 10.1016/S1040-8428(01)00196-2; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Cowan CW, 2005, NEURON, V46, P205, DOI 10.1016/j.neuron.2005.03.019; Dail M, 2006, J CELL SCI, V119, P1244, DOI 10.1242/jcs.02842; Daniel TO, 1996, KIDNEY INT, V50, pS73; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; Easty DJ, 2000, MELANOMA RES, V10, P401, DOI 10.1097/00008390-200010000-00001; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; EASTY DJ, 1995, CANCER RES, V55, P2528; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; FIDLER IJ, 1981, J NATL CANCER I, V67, P947; Gerety SS, 2002, DEVELOPMENT, V129, P1397; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Hess AR, 2001, CANCER RES, V61, P3250; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Irie F, 2002, NAT NEUROSCI, V5, P1117, DOI 10.1038/nn964; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lamorte L, 2001, Surg Oncol Clin N Am, V10, P271; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Liu W, 2004, BRIT J CANCER, V90, P1620, DOI 10.1038/sj.bjc.6601723; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; Martiny-Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457; Meyer S, 2005, INT J ONCOL, V27, P1197; Miao H, 2005, J BIOL CHEM, V280, P923, DOI 10.1074/jbc.M411383200; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Moeller ML, 2006, J BIOL CHEM, V281, P1587, DOI 10.1074/jbc.M511756200; Nakada M, 2004, CANCER RES, V64, P3179, DOI 10.1158/0008-5472.CAN-03-3667; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Nikolova Z, 1998, J CELL SCI, V111, P2741; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Noren NK, 2004, CELL SIGNAL, V16, P655, DOI 10.1016/j.cellsig.2003.10.006; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Ogawa K, 2006, J CELL SCI, V119, P559, DOI 10.1242/jcs.02777; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Ogita H, 2003, CIRC RES, V93, P23, DOI 10.1161/01.RES.0000079310.81429.C8; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Raynor M, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-14; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Steinle JJ, 2003, CELL SIGNAL, V15, P1011, DOI 10.1016/S0898-6568(03)00072-X; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Takai N, 2001, ONCOL REP, V8, P567; TALMADGE JE, 1982, J NATL CANCER I, V69, P975; Tanaka M, 2003, EMBO J, V22, P847, DOI 10.1093/emboj/cdg088; Uyen HD, 2002, J CELL SCI, V115, P3073; Vindis C, 2004, J BIOL CHEM, V279, P27965, DOI 10.1074/jbc.M401295200; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; Vogt T, 1998, CLIN CANCER RES, V4, P791; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Wu QH, 2004, PATHOL ONCOL RES, V10, P26, DOI 10.1007/BF02893405; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Zelinski DP, 2001, CANCER RES, V61, P2301; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	65	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32574	32586		10.1074/jbc.M604338200	http://dx.doi.org/10.1074/jbc.M604338200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16950769	hybrid			2022-12-25	WOS:000241414500055
J	Darnell, GA; Schroder, WA; Gardner, J; Harrich, D; Yu, H; Medcalf, RL; Warrilow, D; Antalis, TM; Sonza, S; Suhrbier, A				Darnell, Grant A.; Schroder, Wayne A.; Gardner, Joy; Harrich, David; Yu, Hong; Medcalf, Robert L.; Warrilow, David; Antalis, Toni M.; Sonza, Secondo; Suhrbier, Andreas			SerpinB2 is an inducible host factor involved in enhancing HIV-1 transcription and replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMINOGEN-ACTIVATOR INHIBITOR; LONG TERMINAL REPEAT; NF-KAPPA-B; MICROARRAY ANALYSIS REVEALS; PRIMARY HUMAN MACROPHAGES; RETINOBLASTOMA PROTEIN; EPITHELIAL-CELLS; HUMAN-MONOCYTES; REVERSE TRANSCRIPTION	The serine protease inhibitor SerpinB2 (plasminogen activator inhibitor-2) is a major product of activated monocytes and macrophages and is substantially induced during most inflammatory processes. Distinct from its widely described extracellular role as an inhibitor of urokinase plasminogen activator, SerpinB2 has recently been shown to have an intracellular role as a retinoblastoma protein (Rb)-binding protein that inhibits Rb degradation. Here we show that HIV-1 infection and gp120 treatment of human peripheral blood mononuclear cells resulted in induction of SerpinB2. Furthermore, SerpinB2 expression in THP-1 monocyte/macrophage, Jurkat T, and HeLa cell lines increased replication of HIV-1 and enhanced transcription from the HIV-1 long terminal repeat (LTR) promoter by 3-10-fold. Increased HIV-1 gene expression and transcription was also observed in activated macrophages from SerpinB2 (+/+) mice compared with macrophages from SerpinB2(-/-) mice. The SerpinB2-mediated elevation of Rb protein levels appeared to be responsible for enhancing transcription from the core promoter region of the LTR by relieving HDM2-mediated inhibition of Sp1 and/or by increasing the Sp1/Sp3 expression ratios. This is the first report associating HIV-1 replication with SerpinB2 expression and illustrates that SerpinB2 is a potentially important inducible host factor that significantly promotes HIV-1 replication.	Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3800, Australia; Univ Maryland, Sch Med, Dept Physiol, Rockville, MD 20854 USA; Macfarlane Burnet Ctr Med Res, Melbourne, Vic, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Monash University	Suhrbier, A (corresponding author), Royal Brisbane Hosp, Queensland Inst Med Res, PO, Brisbane, Qld 4029, Australia.	Andreas.Suhrbier@qimr.edu.au	Medcalf, Robert L/E-9632-2011; Harrich, David/H-6668-2016	Harrich, David/0000-0003-3690-0150; Suhrbier, Andreas/0000-0001-8986-9025	NATIONAL CANCER INSTITUTE [P30CA134274, R01CA098369] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA098369, P30 CA134274, R01-CA098369] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA H, 1993, NEUROSCI LETT, V164, P233, DOI 10.1016/0304-3940(93)90899-V; Alfano M, 2003, J LEUKOCYTE BIOL, V74, P750, DOI 10.1189/jlb.0403176; Angelici E, 1996, AIDS, V10, P283, DOI 10.1097/00002030-199603000-00007; Antalis TM, 1998, J EXP MED, V187, P1799, DOI 10.1084/jem.187.11.1799; Apolloni A, 2003, J VIROL, V77, P9912, DOI 10.1128/JVI.77.18.9912-9921.2003; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Aziz S, 2005, JAIDS-J ACQ IMM DEF, V38, P23, DOI 10.1097/00126334-200501010-00005; Badou A, 2000, J VIROL, V74, P10551, DOI 10.1128/JVI.74.22.10551-10562.2000; Bossis G, 2002, FEBS LETT, V516, P257, DOI 10.1016/S0014-5793(02)02566-8; Buyru N, 2003, CLIN APPL THROMB-HEM, V9, P333, DOI 10.1177/107602960300900409; Bystrom J, 2004, BLOOD, V103, P868, DOI 10.1182/blood-2003-08-2778; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Chaussabel D, 2003, BLOOD, V102, P672, DOI 10.1182/blood-2002-10-3232; Darnell GA, 2005, J VIROL, V79, P4246, DOI 10.1128/JVI.79.7.4246-4256.2005; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; De Falco G, 2003, ONCOGENE, V22, P6214, DOI 10.1038/sj.onc.1206637; Detweiler CS, 2001, P NATL ACAD SCI USA, V98, P5850, DOI 10.1073/pnas.091110098; Devadas K, 2004, J IMMUNOL, V173, P6735, DOI 10.4049/jimmunol.173.11.6735; Dougherty KM, 1999, P NATL ACAD SCI USA, V96, P686, DOI 10.1073/pnas.96.2.686; Fernandez-Soria V, 2006, INT J ONCOL, V28, P143; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; Gorry PR, 2005, CURR HIV RES, V3, P53, DOI 10.2174/1570162052772951; Haga H, 2002, J HUM GENET, V47, P605, DOI 10.1007/s100380200092; Hammill D, 2005, BIOCHEM BIOPH RES CO, V335, P377, DOI 10.1016/j.bbrc.2005.07.084; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HERBEIN G, 1994, CLIN EXP IMMUNOL, V95, P442, DOI 10.1111/j.1365-2249.1994.tb07016.x; Hooker CW, 2003, J CLIN VIROL, V26, P229, DOI 10.1016/S1386-6532(02)00121-X; Johnson BJ, 2005, J BIOL CHEM, V280, P4037, DOI 10.1074/jbc.M411569200; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Kedzierska K, 2003, REV MED VIROL, V13, P39, DOI 10.1002/rmv.369; Komano J, 2005, JPN J INFECT DIS, V58, P125; Kramer-Hammerle S, 2005, VIRUS RES, V111, P194, DOI 10.1016/j.virusres.2005.04.009; KRISHNAMURTI C, 1989, AM J TROP MED HYG, V40, P102, DOI 10.4269/ajtmh.1989.40.102; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; Lee C, 2005, J LEUKOCYTE BIOL, V78, P1016, DOI 10.1189/jlb.0105056; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Macaluso M, 2006, CELL DEATH DIFFER, V13, P1515, DOI 10.1038/sj.cdd.4401835; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Medcalf RL, 2005, FEBS J, V272, P4858, DOI 10.1111/j.1742-4658.2005.04879.x; Mikhail Meriet, 2003, AIDS Rev, V5, P230; Mirlashari MR, 2001, THROMB RES, V102, P375, DOI 10.1016/S0049-3848(01)00256-0; Misse D, 2001, BLOOD, V98, P541, DOI 10.1182/blood.V98.3.541; Montemurro P, 2001, J INFECT DIS, V183, P1055, DOI 10.1086/319280; Nicolas M, 2003, BIOCHEM J, V371, P265, DOI 10.1042/BJ20021166; Nitkiewicz J, 2004, J NEUROVIROL, V10, P400, DOI 10.1080/13550280490890097; Park JM, 2005, IMMUNITY, V23, P319, DOI 10.1016/j.immuni.2005.08.010; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Perrier P, 2004, J IMMUNOL, V172, P7031, DOI 10.4049/jimmunol.172.11.7031; Praus M, 1999, GENE THER, V6, P227, DOI 10.1038/sj.gt.3300802; Reiter LS, 1997, INT J CANCER, V70, P461, DOI 10.1002/(SICI)1097-0215(19970207)70:4<461::AID-IJC14>3.0.CO;2-I; Rodriguez-Inigo E, 2005, J MED VIROL, V77, P17, DOI [10.1002/jmv.20409, 10.1002/JMV.20409]; Rohr O, 2003, J LEUKOCYTE BIOL, V74, P736, DOI 10.1189/jlb.0403180; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Schols D, 1996, J VIROL, V70, P4953, DOI 10.1128/JVI.70.8.4953-4960.1996; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; Shafren DR, 1999, J VIROL, V73, P7193, DOI 10.1128/JVI.73.9.7193-7198.1999; Shioji G, 2005, J HUM GENET, V50, P507, DOI 10.1007/s10038-005-0285-1; Silverman GA, 2004, CELL MOL LIFE SCI, V61, P301, DOI 10.1007/s00018-003-3240-3; Singh M, 2005, J BIOL CHEM, V280, P37868, DOI 10.1074/jbc.M504877200; Sonza S, 2002, J VIROL, V76, P12611, DOI 10.1128/JVI.76.24.12611-12621.2002; Taoufik Y, 1997, BLOOD, V89, P2842, DOI 10.1182/blood.V89.8.2842; Tapias A, 2005, BBA-GENE STRUCT EXPR, V1730, P126, DOI 10.1016/j.bbaexp.2005.06.002; Theodore TS, 1996, AIDS RES HUM RETROV, V12, P191, DOI 10.1089/aid.1996.12.191; Tyner JW, 2005, NAT MED, V11, P1180, DOI 10.1038/nm1303; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Veazey RS, 2005, NAT MED, V11, P469, DOI 10.1038/nm0505-469; Wahl SM, 1999, J INFECT DIS, V179, pS457, DOI 10.1086/314814; Wahl SM, 2000, J LEUKOCYTE BIOL, V68, P303; Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; Xiao Y, 2001, J PERIODONTAL RES, V36, P25, DOI 10.1034/j.1600-0765.2001.00608.x; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200; Yu H, 2002, BLOOD, V99, P2810, DOI 10.1182/blood.V99.8.2810	77	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31348	31358		10.1074/jbc.M604220200	http://dx.doi.org/10.1074/jbc.M604220200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16923810	Bronze			2022-12-25	WOS:000241235300019
J	Kotaka, M; Ren, J; Lockyer, M; Hawkins, AR; Stammers, DK				Kotaka, Masayo; Ren, Jingshan; Lockyer, Michael; Hawkins, Alastair R.; Stammers, David K.			Structures of R- and T-state Escherichia coli aspartokinase III - Mechanisms of the allosteric transition and inhibition by lysine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ASPARTOKINASE; HOMOSERINE DEHYDROGENASE; CRYSTAL-STRUCTURE; PHENYLALANINE-HYDROXYLASE; CATALYTIC ACTIVITY; SUBUNIT STRUCTURE; ASPARTATE FAMILY; KINASE; ENZYMES; DOMAIN	Aspartokinase III (AKIII) from Escherichia coli catalyzes an initial commitment step of the aspartate pathway, giving biosynthesis of certain amino acids including lysine. We report crystal structures of AKIII in the inactive T-state with bound feedback allosteric inhibitor lysine and in the R-state with aspartate and ADP. The structures reveal an unusual configuration for the regulatory ACT domains, in which ACT2 is inserted into ACT1 rather than the expected tandem repeat. Comparison of R-and T-state AKIII indicates that binding of lysine to the regulatory ACT1 domain in R-state AKIII instigates a series of changes that release a "latch", the beta 15-alpha K loop, from the catalytic domain, which in turn undergoes large rotational rearrangements, promoting tetramer formation and completion of the transition to the T-state. Lysine-induced allosteric transition in AKIII involves both destabilizing the R-state and stabilizing the T-state tetramer. Rearrangement of the catalytic domain blocks the ATP-binding site, which is therefore the structural basis for allosteric inhibition of AKIII by lysine.	Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Arrow Therapeut Ltd, London SE1 1DA, England; Univ Newcastle Upon Tyne, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Oxford; Wellcome Centre for Human Genetics; AstraZeneca; Newcastle University - UK	Stammers, DK (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England.	daves@strubi.ox.ac.uk	Ren, Jingshan/AAT-7729-2021; Kotaka, Masayo/C-4483-2009	Ren, Jingshan/0000-0003-4015-1404; Kotaka, Masayo/0000-0001-9692-3843				Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Blanco J, 2002, ACTA CRYSTALLOGR D, V58, P352, DOI 10.1107/S0907444901020728; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CASSAN M, 1986, J BIOL CHEM, V261, P1052; Chipman DM, 2001, CURR OPIN STRUC BIOL, V11, P694, DOI 10.1016/S0959-440X(01)00272-X; COHEN GN, 1969, J BACTERIOL, V99, P791, DOI 10.1128/JB.99.3.791-801.1969; FALCOZKELLY F, 1969, EUR J BIOCHEM, V8, P146, DOI 10.1111/j.1432-1033.1969.tb00507.x; FALCOZKELLY F, 1972, EUR J BIOCHEM, V28, P507, DOI 10.1111/j.1432-1033.1972.tb01938.x; FUNKHOUSER JD, 1974, J BIOL CHEM, V249, P5478; FUNKHOUSER JD, 1974, J BIOL CHEM, V249, P7580; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Gil-Ortiz F, 2003, J MOL BIOL, V331, P231, DOI 10.1016/S0022-2836(03)00716-2; Grant GA, 1996, PROTEIN SCI, V5, P34; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; Helmstaedt K, 2001, MICROBIOL MOL BIOL R, V65, P404, DOI 10.1128/MMBR.65.3.404-421.2001; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaplun A, 2006, J MOL BIOL, V357, P951, DOI 10.1016/j.jmb.2005.12.077; Keng YF, 1996, ARCH BIOCHEM BIOPHYS, V335, P73, DOI 10.1006/abbi.1996.0483; Kikuchi Y, 1999, FEMS MICROBIOL LETT, V173, P211, DOI 10.1111/j.1574-6968.1999.tb13504.x; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liberles JS, 2005, AMINO ACIDS, V28, P1, DOI 10.1007/s00726-004-0152-y; Marco-Marin C, 2003, J MOL BIOL, V334, P459, DOI 10.1016/j.jmb.2003.09.038; Mas-Droux C, 2006, PLANT CELL, V18, P1681, DOI 10.1105/tpc.105.040451; NILES EG, 1973, BIOCHEMISTRY-US, V12, P1715, DOI 10.1021/bi00733a009; Ogawa-Miyata Y, 2001, BIOSCI BIOTECH BIOCH, V65, P1149, DOI 10.1271/bbb.65.1149; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramon-Maiques S, 2000, J MOL BIOL, V299, P463, DOI 10.1006/jmbi.2000.3779; Ramon-Maiques S, 2002, STRUCTURE, V10, P329, DOI 10.1016/S0969-2126(02)00721-9; RICHAUD C, 1974, EUR J BIOCHEM, V48, P147, DOI 10.1111/j.1432-1033.1974.tb03752.x; RICHAUD C, 1973, EUR J BIOCHEM, V40, P619, DOI 10.1111/j.1432-1033.1973.tb03234.x; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SCHUDSON M, 1995, FORBES MEDIA CRITIC, V2, P76; STADTMAN ER, 1961, J BIOL CHEM, V236, P2033; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Thompson JR, 2005, BIOCHEMISTRY-US, V44, P5763, DOI 10.1021/bi047944b; VERON M, 1972, EUR J BIOCHEM, V28, P520, DOI 10.1111/j.1432-1033.1972.tb01939.x; Viola RE, 2001, ACCOUNTS CHEM RES, V34, P339, DOI 10.1021/ar000057q; Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808; WAMPLER DE, 1968, BIOCHEMISTRY-US, V7, P1661, DOI 10.1021/bi00845a007	43	53	63	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31544	31552		10.1074/jbc.M605886200	http://dx.doi.org/10.1074/jbc.M605886200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16905770				2022-12-25	WOS:000241235300040
J	Lam-Yuk-Tseung, S; Picard, V; Gros, P				Lam-Yuk-Tseung, Steven; Picard, Virginie; Gros, Philippe			Identification of a tyrosine-based motif (YGSI) in the amino terminus of Nramp1 (Slc11a1) that is important for lysosomal targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON TRANSPORTER DMT1; MICROCYTIC ANEMIA; NATURAL-RESISTANCE; PLASMA-MEMBRANE; INTRACELLULAR PARASITES; SUBCELLULAR-LOCALIZATION; RECYCLING-ENDOSOMES; SORTING SIGNALS; MUTATION; INFECTION	In macrophages, Nramp1 (Slc11a1) is expressed in lysosomes and restricts replication of intracellular pathogens by removing divalent metals (Mn2+ and Fe2+) from the phagolysosome. Nramp2 (DMT1, Slc11a2) is expressed both at the duodenal brush border where it mediates uptake of dietary iron and ubiquitously at the plasma membrane/ recycling endosomes of many cell types where it transports transferrin-associated iron across the endosomal membrane. In Nramp2, a carboxyl-terminal cytoplasmic motif ((YLLNT559)-Y-555) is critical for internalization and recycling of the transporter from the plasma membrane. Here we studied the subcellular trafficking properties of Nramp1 and investigated the cis-acting sequences responsible for targeting to lysosomes. For this, we constructed and studied Nramp1/Nramp2 chimeric proteins where homologous domains of each protein were exchanged. Chimeras exchanging the amino- (upstream TM1) and carboxyl-terminal (downstream TM12) cytoplasmic segments of both transporters were stably expressed in porcine LLC-PK1 kidney cells and were studied with respect to expression, maturation, stability, cell surface targeting, transport activity, and subcellular localization. An Nramp2 isoform II chimera bearing the amino terminus of Nramp1 was not expressed at the cell surface but was targeted to lysosomes. This lysosomal targeting was abolished by single alanine substitutions at Tyr(15) and Ile(18) of a (15)YGSI(18) motif present in the amino terminus of Nramp1. These results identify YGSI as a tyrosine-based sorting signal responsible for lysosomal targeting of Nramp1.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Ctr Host Resistance, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Gros, P (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	gros@mcgill.ca						Abel L, 1998, J INFECT DIS, V177, P133, DOI 10.1086/513830; Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920; Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Canonne-Hergaux F, 2001, BLOOD, V98, P3823, DOI 10.1182/blood.V98.13.3823; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; Canonne-Hergaux FS, 2002, KIDNEY INT, V62, P147, DOI 10.1046/j.1523-1755.2002.00405.x; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; Cuellar-Mata P, 2002, J BIOL CHEM, V277, P2258, DOI 10.1074/jbc.M105508200; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Forbes JR, 2003, BLOOD, V102, P1884, DOI 10.1182/blood-2003-02-0425; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; Govoni G, 1999, INFECT IMMUN, V67, P2225, DOI 10.1128/IAI.67.5.2225-2232.1999; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; Gunshin H, 2005, BLOOD, V106, P2221, DOI 10.1182/blood-2005-03-1192; Gunshin H, 2005, J CLIN INVEST, V115, P1258, DOI [10.1172/JCI200524356, 10.1172/JCI24356]; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Iolascon A, 2006, BLOOD, V107, P349, DOI 10.1182/blood-2005-06-2477; Jabado N, 2000, J EXP MED, V192, P1237, DOI 10.1084/jem.192.9.1237; Jabado N, 2003, P NATL ACAD SCI USA, V100, P6127, DOI 10.1073/pnas.0937287100; Lam-Yuk-Tseung S, 2006, BIOCHEMISTRY-US, V45, P2294, DOI 10.1021/bi052307m; Lam-Yuk-Tseung S, 2005, BLOOD CELL MOL DIS, V35, P212, DOI 10.1016/j.bcmd.2005.05.008; Lam-Yuk-Tseung S, 2005, BIOCHEMISTRY-US, V44, P12149, DOI 10.1021/bi050911r; Lam-Yuk-Tseung S, 2003, BLOOD, V101, P3699, DOI 10.1182/blood-2002-07-2108; Lam-Yuk-Tseung S, 2006, BLOOD CELL MOL DIS, V36, P347, DOI 10.1016/j.bcmd.2006.01.011; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Mims MP, 2005, BLOOD, V105, P1337, DOI 10.1182/blood-2004-07-2966; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Picard V, 2000, J BIOL CHEM, V275, P35738, DOI 10.1074/jbc.M005387200; Priwitzerova M, 2005, BLOOD, V106, P3985, DOI 10.1182/blood-2005-04-1550; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Searle S, 1998, J CELL SCI, V111, P2855; Tabuchi M, 2002, MOL BIOL CELL, V13, P4371, DOI 10.1091/mbc.E02-03-0165; Touret N, 2004, BLOOD, V104, P1526, DOI 10.1182/blood-2004-02-0731; Touret N, 2003, J BIOL CHEM, V278, P25548, DOI 10.1074/jbc.M212374200; VIDAL S, 1995, J LEUKOCYTE BIOL, V58, P382, DOI 10.1002/jlb.58.4.382; Vidal SM, 1996, J IMMUNOL, V157, P3559; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D	47	15	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31677	31688		10.1074/jbc.M601828200	http://dx.doi.org/10.1074/jbc.M601828200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16905747	Bronze			2022-12-25	WOS:000241235300053
J	Olivares, AO; Chang, WK; Mooseker, MS; Hackney, DD; De La Cruz, EM				Olivares, Adrian O.; Chang, Wakam; Mooseker, Mark S.; Hackney, David D.; De La Cruz, Enrique M.			The tail domain of myosin Va modulates actin binding to one head	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING; KINETIC MECHANISM; OXYGEN-EXCHANGE; ATPASE ACTIVITY; ACTOMYOSIN-VI; MOTOR; CALCIUM; MEROMYOSIN; MODEL; ADP	Calcium activates full-length myosin Va steady-state enzymatic activity and favors the transition from a compact, folded "off" state to an extended "on" state. However, little is known of how a head-tail interaction alters the individual actin and nucleotide binding rate and equilibrium constants of the ATPase cycle. We measured the effect of calcium on nucleotide and actin filament binding to full-length myosin Va purified from chick brains. Both heads of nucleotide-free myosin Va bind actin strongly, independent of calcium. In the absence of calcium, bound ADP weakens the affinity of one head for actin filaments at equilibrium and upon initial encounter. The addition of calcium allows both heads of myosin Va(.)ADP to bind actin strongly. Calcium accelerates ADP binding to actomyosin independent of the tail but minimally affects ATP binding. Although O-18 exchange and product release measurements favor a mechanism in which actin-activated P-i release from myosin Va is very rapid, independent of calcium and the tail domain, both heads do not bind actin strongly during steady-state cycling, as assayed by pyrene actin fluorescence. In the absence of calcium, inclusion of ADP favors formation of a long lived myosin Va(.)ADP state that releases ADP slowly, even after mixing with actin. Our results suggest that calcium activates myosin Va by allowing both heads to interact with actin and exchange bound nucleotide and indicate that regulation of actin binding by the tail is a nucleotide-dependent process favored by linked conformational changes of the motor domain.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol & Pathol, New Haven, CT 06520 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Yale University; Yale University; Yale University; Carnegie Mellon University	De La Cruz, EM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114, New Haven, CT 06520 USA.	enrique.delacruz@yale.edu	Olivares, Adrian/D-7717-2012	Olivares, Adrian/0000-0002-0895-7988	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F31AR051614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025387, R01DK025387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073823] Funding Source: NIH RePORTER; NIAMS NIH HHS [1F31AR051614-01] Funding Source: Medline; NIDDK NIH HHS [DK25387] Funding Source: Medline; NIGMS NIH HHS [GM073823] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Cameron LC, 1998, ARCH BIOCHEM BIOPHYS, V355, P35, DOI 10.1006/abbi.1998.0700; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2005, J MOL BIOL, V346, P557, DOI 10.1016/j.jmb.2004.11.065; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; Hackney DD, 2005, P NATL ACAD SCI USA, V102, P18338, DOI 10.1073/pnas.0505288102; HACKNEY DD, 1984, P NATL ACAD SCI-BIOL, V81, P5345, DOI 10.1073/pnas.81.17.5345; Hannemann DE, 2005, BIOCHEMISTRY-US, V44, P8826, DOI 10.1021/bi0473509; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; Liu J, 2006, NATURE, V442, P208, DOI 10.1038/nature04719; Martin SR, 2004, FEBS LETT, V567, P166, DOI 10.1016/j.febslet.2004.04.053; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Menetrey J, 2005, NATURE, V435, P779, DOI 10.1038/nature03592; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Nyitrai M, 2004, PHILOS T R SOC B, V359, P1867, DOI 10.1098/rstb.2004.1560; Nyitrai M, 2003, BIOCHEM J, V370, P839, DOI 10.1042/BJ20021519; Nyitrai M, 2002, BIOCHEM J, V365, P19, DOI 10.1042/BJ20020099; Olivares AO, 2005, P NATL ACAD SCI USA, V102, P13719, DOI 10.1073/pnas.0507068102; Prochniewicz E, 2004, BIOCHEMISTRY-US, V43, P10642, DOI 10.1021/bi049914e; Purcell TJ, 2005, P NATL ACAD SCI USA, V102, P13873, DOI 10.1073/pnas.0506441102; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Robblee JP, 2005, BIOCHEMISTRY-US, V44, P10238, DOI 10.1021/bi050232g; Robblee JP, 2004, J BIOL CHEM, V279, P38608, DOI 10.1074/jbc.M403504200; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; SLEEP JA, 1980, J BIOL CHEM, V255, P4094; SLEEP JA, 1978, J BIOL CHEM, V253, P5235; Stafford WF, 2001, J MOL BIOL, V307, P137, DOI 10.1006/jmbi.2000.4490; Tauhata SBF, 2001, J BIOL CHEM, V276, P39812, DOI 10.1074/jbc.M102583200; Thirumurugan K, 2006, NATURE, V442, P212, DOI 10.1038/nature04865; Uemura S, 2004, NAT STRUCT MOL BIOL, V11, P877, DOI 10.1038/nsmb806; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Volkmann N, 2005, MOL CELL, V19, P595, DOI 10.1016/j.molcel.2005.07.015; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; WEBB MR, 1986, J BIOL CHEM, V261, P5557; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v	47	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31326	31336		10.1074/jbc.M603898200	http://dx.doi.org/10.1074/jbc.M603898200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16921171				2022-12-25	WOS:000241235300017
J	Van Bodegom, D; Saifudeen, Z; Dipp, S; Puri, S; Magenheimer, BS; Calvet, JP; El-Dahr, SS				Van Bodegom, Diederik; Saifudeen, Zubaida; Dipp, Susana; Puri, Sanjeev; Magenheimer, Brenda S.; Calvet, James P.; El-Dahr, Samir S.			The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; EPITHELIAL-CELLS; DNA-DAMAGE; POTENTIAL MEDIATOR; RECEPTOR PROMOTER; SIGNALING PATHWAY; INDUCED APOPTOSIS; DOWN-REGULATION; PKD1	This study provides evidence that the tumor suppressor protein, p53, is a transcriptional repressor of PKD1. Kidneys of p53-null mice expressed higher Pkd1 mRNA levels than wild-type littermates; gamma-irradiation suppressed PKD1 gene expression in p53(+/+) but not p53(-/-) cells; and chromatin immunoprecipitation assays demonstrated the binding of p53 to the PKD1 promoter in vivo. In transient transfection assays, p53 repressed PKD1 promoter activity independently of endogenous p21. Deletion analysis mapped p53-mediated repression to the proximal promoter region of PKD1. Mutations of the DNA binding or C-terminal minimal repression domains of p53 abolished its ability to repress PKD1. Moreover, trichostatin A, an inhibitor of histone deacetylase activity, attenuated p53-induced repression of the PKD1 promoter. These findings, together with previous reports showing that dedifferentiated Pkd1-deficient cells express lower p53 and p21 levels, suggest a model whereby PKD1 signaling activates the p53-p21 differentiation pathway. In turn, p53 cooperates with histone deacetylases to repress PKD1 gene transcription. Loss of a p53-mediated negative feedback loop in PKD1 mutant cells may therefore contribute to deregulated PKD1 expression and cystogenesis.	Tulane Univ, Hlth Sci Ctr, Dept Pediat, Sect Pediat Nephrol, New Orleans, LA 70112 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	Tulane University; University of Kansas; University of Kansas Medical Center	El-Dahr, SS (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Pediat, Sect Pediat Nephrol, SL-37,1430 Tulane Ave, New Orleans, LA 70112 USA.	seldahr@tulane.edu		Puri, Sanjeev/0000-0002-4314-9871; Puri, Sanjeev/0000-0002-3967-987X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056264, R01DK062250, P50DK057301] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-57301, DK-62250, DK-56264] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Bogdanova N, 2001, GENOMICS, V74, P333, DOI 10.1006/geno.2001.6568; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Boucher C, 2004, EUR J HUM GENET, V12, P347, DOI 10.1038/sj.ejhg.5201162; Delmas P, 2004, CELL, V118, P145, DOI 10.1016/j.cell.2004.07.007; DERUIJTER AJ, 2003, BIOCHEM J, V30, P737; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fan H, 2005, AM J PHYSIOL-RENAL, V288, pF98, DOI 10.1152/ajprenal.00246.2004; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; Guillaume R, 1999, DEV DYNAM, V214, P337, DOI 10.1002/(SICI)1097-0177(199904)214:4<337::AID-AJA6>3.0.CO;2-O; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; Igarashi P, 2002, J AM SOC NEPHROL, V13, P2384, DOI 10.1097/01.ASN.0000028643.17901.42; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Jen KY, 2005, CANCER RES, V65, P7666, DOI 10.1158/0008-5472.CAN-05-1039; Kaeser MD, 2004, ONCOGENE, V23, P4007, DOI 10.1038/sj.onc.1207536; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim H, 2004, EUR J HUM GENET, V12, P433, DOI 10.1038/sj.ejhg.5201136; Lantinga-van Leeuwen IS, 2005, EUR J HUM GENET, V13, P649, DOI 10.1038/sj.ejhg.5201392; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Manzati E, 2005, EXP CELL RES, V304, P391, DOI 10.1016/j.yexcr.2004.10.023; Marks J, 2003, J BIOL CHEM, V278, P34158, DOI 10.1074/jbc.M304543200; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nishio S, 2005, J CLIN INVEST, V115, P910, DOI 10.1172/JCI200522850; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ogden SK, 2001, J BIOL CHEM, V276, P42057, DOI 10.1074/jbc.C100381200; Ong ACM, 2005, KIDNEY INT, V67, P1234, DOI 10.1111/j.1523-1755.2005.00201.x; Ong ACM, 1999, KIDNEY INT, V56, P1324, DOI 10.1046/j.1523-1755.1999.00659.x; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; Puri S, 2004, J BIOL CHEM, V279, P55455, DOI 10.1074/jbc.M402905200; Rodova M, 2002, J BIOL CHEM, V277, P29577, DOI 10.1074/jbc.M203570200; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Saifudeen Z, 2005, J BIOL CHEM, V280, P23094, DOI 10.1074/jbc.M414575200; Saifudeen Z, 2005, AM J PHYSIOL-RENAL, V288, pF899, DOI 10.1152/ajprenal.00370.2004; Saifudeen Z, 2000, J BIOL CHEM, V275, P15557, DOI 10.1074/jbc.M909810199; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Suehiro T, 2004, MOL CELL ENDOCRINOL, V222, P33, DOI 10.1016/j.mce.2004.05.005; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Sutters M, 2003, J LAB CLIN MED, V141, P91, DOI 10.1067/mlc.2003.13; Thivierge C, 2006, MOL CELL BIOL, V26, P1538, DOI 10.1128/MCB.26.4.1538-1548.2006; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wang P, 2003, J BIOL CHEM, V278, P6363, DOI 10.1074/jbc.M210350200; Wang YX, 1999, FEBS LETT, V445, P269, DOI 10.1016/S0014-5793(99)00136-2; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Zhan MC, 2005, J BIOL CHEM, V280, P4825, DOI 10.1074/jbc.M407450200	60	34	36	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31234	31244		10.1074/jbc.M606510200	http://dx.doi.org/10.1074/jbc.M606510200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16931520	Bronze			2022-12-25	WOS:000241235300008
J	Eckman, EA; Adams, SK; Troendle, FJ; Stodola, BA; Kahn, MA; Fauq, AH; Xiao, HD; Bernstein, KE; Eckman, CB				Eckman, Elizabeth A.; Adams, Stephanie K.; Troendle, Frederick J.; Stodola, Becky A.; Kahn, Murad A.; Fauq, Abdul H.; Xiao, Hong D.; Bernstein, Kenneth E.; Eckman, Christopher B.			Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; A-BETA; IN-VIVO; NEUTRAL ENDOPEPTIDASE-24.11; THERAPEUTIC STRATEGIES; NONPEPTIDIC INHIBITORS; DEGRADING ENZYMES; HEART-FAILURE; PEPTIDE; PROTEIN	The deposition of beta-amyloid in the brain is a pathological hallmark of Alzheimer disease (AD). Normally, the accumulation of beta-amyloid is prevented in part by the activities of several degradative enzymes, including the endothelin-converting enzymes, neprilysin, insulin-degrading enzyme, and plasmin. Recent reports indicate that another metalloprotease, angiotensin-converting enzyme (ACE), can degrade beta-amyloid in vitro and in cellular overexpression experiments. In addition, ACE gene variants are linked to AD risk in several populations. Angiotensin-converting enzyme, neprilysin and endothelin-converting enzyme function as vasopeptidases and are the targets of drugs designed to treat cardiovascular disorders, and ACE inhibitors are commonly prescribed. We investigated the potential physiological role of ACE in regulating endogenous brain beta-amyloid levels for two reasons: first, to determine whether beta-amyloid degradation might be the mechanism by which ACE is associated with AD, and second, to determine whether ACE inhibitor drugs might block beta-amyloid degradation in the brain and potentially increase the risk for AD. We analyzed beta-amyloid accumulation in brains from ACE-deficient mice and in mice treated with ACE inhibitors and found that ACE deficiency did not alter steady-state beta-amyloid concentration. In contrast, beta-amyloid levels are significantly elevated in endothelin-converting enzyme and neprilysin knock-out mice, and inhibitors of these enzymes cause a rapid increase in beta-amyloid concentration in the brain. The results of these studies do not support a physiological role for ACE in the degradation of beta-amyloid in the brain but confirm roles for endothelin-converting enzyme and neprilysin and indicate that reductions in these enzymes result in additive increases in brain amyloid beta-peptide levels.	Mayo Clin Jacksonville, Dept Neurosci, Coll Med, Jacksonville, FL 32224 USA; Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Mayo Clinic; Emory University	Eckman, CB (corresponding author), Mayo Clin Jacksonville, Dept Neurosci, Coll Med, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	eckman@mayo.edu	Eckman, Elizabeth/AAL-7316-2021; Khan, Murad Ali/H-7094-2016	Khan, Murad Ali/0000-0002-8286-5504; Bernstein, Kenneth/0000-0001-8097-3272; Eckman, Elizabeth/0000-0002-5391-4960	NINDS NIH HHS [R01NS042192, R01NS048554] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048554, R01NS042192] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARREGUI A, 1982, J NEUROCHEM, V38, P1490, DOI 10.1111/j.1471-4159.1982.tb07930.x; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; BARNES JM, 1990, J CARDIOVASC PHARM, V16, P234, DOI 10.1097/00005344-199008000-00009; BARNES NM, 1991, EUR J PHARMACOL, V200, P289, DOI 10.1016/0014-2999(91)90584-D; Cole J, 2002, CIRC RES, V90, P87, DOI 10.1161/hh0102.102360; De Lombaert S, 2000, J MED CHEM, V43, P488, DOI 10.1021/jm990507o; DELOMBAERT S, 1994, BIOCHEM BIOPH RES CO, V204, P407, DOI 10.1006/bbrc.1994.2473; DELOMBAERT S, 1995, BIOORG MED CHEM LETT, V5, P151, DOI 10.1016/0960-894X(94)00475-U; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; Eckman EA, 2005, BIOCHEM SOC T, V33, P1101, DOI 10.1042/BST0331101; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Emoto N, 2005, HYPERTENSION, V45, P1145, DOI 10.1161/01.HYP.0000168944.29525.da; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Ertekin-Taner N, 2005, HUM MOL GENET, V14, P447, DOI 10.1093/hmg/ddi041; Facchinetti P, 2003, NEUROSCIENCE, V118, P627, DOI 10.1016/S0306-4522(02)01002-3; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Fauq AH, 2004, SYNTHETIC COMMUN, V34, P775, DOI 10.1081/SCC-120028350; Fukami S, 2002, NEUROSCI RES, V43, P39, DOI 10.1016/S0168-0102(02)00015-9; Golde TE, 2005, BRAIN PATHOL, V15, P84, DOI 10.1111/j.1750-3639.2005.tb00104.x; Hemming ML, 2005, J BIOL CHEM, V280, P37644, DOI 10.1074/jbc.M508460200; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Laws SM, 2003, J NEUROCHEM, V84, P1215, DOI 10.1046/j.1471-4159.2003.01615.x; Lehmann DJ, 2005, AM J EPIDEMIOL, V162, P305, DOI 10.1093/aje/kwi202; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; Melchor JP, 2003, J NEUROSCI, V23, P8867; Mellin V, 2005, J CARDIOVASC PHARM, V46, P390, DOI 10.1097/01.fjc.0000175457.48031.8b; Menard J, 2001, ADV PROTEIN CHEM, V56, P13; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Molinaro G, 2002, CURR OPIN PHARMACOL, V2, P131, DOI 10.1016/S1471-4892(02)00138-8; Oba R, 2005, EUR J NEUROSCI, V21, P733, DOI 10.1111/j.1460-9568.2005.03912.x; Ohrui T, 2004, NEUROLOGY, V63, P1324, DOI 10.1212/01.WNL.0000140705.23869.E9; Ohrui T, 2004, J AM GERIATR SOC, V52, P649, DOI 10.1111/j.1532-5415.2004.52178_7.x; RIVIERE PJM, 1989, BRIT J PHARMACOL, V98, P236, DOI 10.1111/j.1476-5381.1989.tb16887.x; RUPREHT J, 1983, NEUROSCI LETT, V41, P331, DOI 10.1016/0304-3940(83)90472-X; Russell FD, 1999, CIRC RES, V84, P891; Savaskan E, 2001, NEUROBIOL AGING, V22, P541, DOI 10.1016/S0197-4580(00)00259-1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Trapani AJ, 2000, J CARDIOVASC PHARM, V36, pS40, DOI 10.1097/00005344-200036051-00015; Tucker HM, 2004, NEUROSCI LETT, V368, P285, DOI 10.1016/j.neulet.2004.07.011; Turner AJ, 2004, ANN NY ACAD SCI, V1035, P1, DOI 10.1196/annals.1332.001; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; Weber MA, 2001, LANCET, V358, P1525, DOI 10.1016/S0140-6736(01)06584-9; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Xiao HD, 2004, AM J PATHOL, V165, P1019, DOI 10.1016/S0002-9440(10)63363-9; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yanagisawa H, 2000, J CLIN INVEST, V105, P1373, DOI 10.1172/JCI7447	49	163	171	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30471	30478		10.1074/jbc.M605827200	http://dx.doi.org/10.1074/jbc.M605827200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912050	hybrid			2022-12-25	WOS:000241075900022
J	Gallegos, LL; Kunkel, MT; Newton, AC				Gallegos, Lisa L.; Kunkel, Maya T.; Newton, Alexandra C.			Targeting protein kinase C activity reporter to discrete intracellular regions reveals spatiotemporal differences in agonist-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; PHOSPHOLIPASE-C; PLASMA-MEMBRANE; GOLGI-COMPLEX; RECEPTOR AGONISTS; PHORBOL ESTERS; LIVING CELLS; PHOSPHORYLATION; ACTIVATION; EPSILON	Protein kinase C (PKC) family members transduce an abundance of diverse intracellular signals. Here we address the role of spatial and temporal segregation in signal specificity by measuring the activity of endogenous PKC at defined intracellular locations in real time in live cells. We targeted a genetically encoded fluorescence resonance energy transfer-based reporter for PKC activity, C kinase activity reporter(CKAR)( Violin, J. D., Zhang, J., Tsien, R. Y., and Newton, A. C. ( 2003) J. Cell Biol. 161, 899 - 909), to the plasma membrane, Golgi, cytosol, mitochondria, or nucleus by fusing appropriate targeting sequences to the NH2 or COOH terminus of CKAR. Measuring the phosphorylation of the reporter in the presence of PKC inhibitors, activators, and/or phosphatase inhibitors shows that activity at each region is under differential control by phosphatase activity; nuclear activity is completely suppressed by phosphatases, whereas membrane-associated activity is the least suppressed by phosphatases. UTP stimulation of endogenous P2Y receptors in COS 7 cells reveals spatiotemporally divergent PKC responses. Imaging the second messengers Ca2+ and diacylglycerol (DAG) reveal that PKC activity at each location is driven by an initial spike in Ca2+, followed by location-specific diacylglycerol generation. In response to UTP, phosphorylation of GolgiCKAR was sustained the longest, driven by the persistence of DAG, whereas phosphorylation of CytoCKAR was of the shortest duration, driven by high phosphatase activity. Our data reveal that the magnitude and duration of PKC signaling is location-specific and controlled by the level of phosphatase activity and persistence of DAG at each location.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, 9500 Gilman Dr 0721, La Jolla, CA 92039 USA.	anewton@ucsd.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154, R37GM043154] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK54441] Funding Source: Medline; NIGMS NIH HHS [GM-43154] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdel-Raheem IT, 2005, BRIT J PHARMACOL, V145, P415, DOI 10.1038/sj.bjp.0706207; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Carrasco S, 2004, MOL BIOL CELL, V15, P2932, DOI 10.1091/mbc.E03-11-0844; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; England K, 2000, BIOCHEM J, V352, P19, DOI 10.1042/0264-6021:3520019; Fulton D, 2004, J BIOL CHEM, V279, P30349, DOI 10.1074/jbc.M402155200; Giorgione JR, 2006, J BIOL CHEM, V281, P1660, DOI 10.1074/jbc.M510251200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; Insel PA, 2001, CLIN EXP PHARMACOL P, V28, P351, DOI 10.1046/j.1440-1681.2001.03452.x; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; Kang MS, 2005, J MOL CELL CARDIOL, V38, P753, DOI 10.1016/j.yjmcc.2005.02.017; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Murthy KS, 2004, AM J PHYSIOL-CELL PH, V287, pC1679, DOI 10.1152/ajpcell.00257.2004; NAOR Z, 1990, ENDOCR REV, V11, P326, DOI 10.1210/edrv-11-2-326; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Saito K, 2003, FEBS LETT, V541, P126, DOI 10.1016/S0014-5793(03)00324-7; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Sasaki K, 2003, J BIOL CHEM, V278, P30945, DOI 10.1074/jbc.M212167200; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Thore S, 2005, J CELL SCI, V118, P4463, DOI 10.1242/jcs.02577; Vermeulen K, 2003, CELL PROLIFERAT, V36, P165, DOI 10.1046/j.1365-2184.2003.00267.x; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang WL, 2003, J BIOL CHEM, V278, P37705, DOI 10.1074/jbc.M304619200; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	41	144	146	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30947	30956		10.1074/jbc.M603741200	http://dx.doi.org/10.1074/jbc.M603741200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16901905	hybrid			2022-12-25	WOS:000241075900071
J	Lu, GW; Maeda, H; Reddy, SV; Kurihara, N; Leach, R; Anderson, JL; Roodman, GD				Lu, Ganwei; Maeda, Hidefumi; Reddy, Sakamuri V.; Kurihara, Noriyoshi; Leach, Robin; Anderson, Judith L.; Roodman, G. David			Cloning and characterization of the annexin II receptor on human marrow stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLAST-STIMULATING FACTOR; HUMAN-BONE MARROW; A2 HETEROTETRAMER; GENE FAMILY; MEMBRANE; CULTURES; IDENTIFICATION; RESORPTION; DIFFERENTIATION; PRECURSORS	Annexin II is a heterotetramer, consisting of two 11-kDa (p11) and two 36-kDa (p36) subunits, that is produced by osteoclasts and stimulates osteoclast formation. However, its receptor is unknown. We showed that annexin II binds to normal primary human marrow stromal cells and the Paget's marrow-derived PSV10 stromal cell line to induce osteoclast formation. I-125-Labeled annexin II binding assays with PSV10 cells demonstrated that there was a single class of annexin II receptors with a K-d of 5.79 nM and B-max of 2.13 x 10(5) receptors/cell. Annexin III or annexin V did not bind this receptor. Using I-125-labeled annexin II binding to screen NIH3T3 transfected with a human marrow cDNA expression library, we identified a putative annexin II receptor clone, which encoded a novel 26-kDa type I membrane receptor protein when expressed in HEK 293 cells. HEK 293 cells transformed with the cloned annexin II receptor cDNA showed a similar binding affinity to annexin II as that observed in PSV10 cells. Chemical cross-linking experiments with biotinylated annexin II and intact PSV10 cells identified a 55-kDa band on Western blot analysis that reacted with both an anti-p11 antibody and streptavidin but not anti-p36 antibody. A rabbit polyclonal antibody raised against the putative recombinant annexin II receptor also recognized the same 26-kDa protein band detected in PSV10 cells. Importantly, the annexin II receptor antibody dose-dependently blocked the stimulatory effects of annexin II on human osteoclast formation, demonstrating that the receptor mediates the effects of annexin II on osteoclast formation.	VA Pittsburgh Healthcare Syst, Med Hematol Oncol 151U, Pittsburgh, PA 15240 USA; Univ Pittsburgh, Pittsburgh, PA 15240 USA; Kyushu Univ Hosp, Fukuoka 8128581, Japan; Med Univ S Carolina, Childrens Res Inst, Dept Pediat, Charleston, SC 29425 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kyushu University; Medical University of South Carolina; University of Texas System; University of Texas Health San Antonio	Roodman, GD (corresponding author), VA Pittsburgh Healthcare Syst, Med Hematol Oncol 151U, Univ Dr C, Pittsburgh, PA 15240 USA.	roodmangd@upmc.edu	Reddy, Sakamuri/H-6419-2019	Leach, Robin/0000-0002-3201-5579	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044603, R01AR041336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013625] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41336, AR44603] Funding Source: Medline; NIA NIH HHS [AG13625] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; Choi SJ, 2001, J BONE MINER RES, V16, P814, DOI 10.1359/jbmr.2001.16.5.814; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Davis RG, 1995, J IMMUNOL METHODS, V188, P91, DOI 10.1016/0022-1759(95)00207-3; Fey MF, 1996, BBA-GENE STRUCT EXPR, V1306, P160, DOI 10.1016/0167-4781(95)00238-3; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HARDER T, 1992, GENE, V113, P269, DOI 10.1016/0378-1119(92)90406-F; KUKITA T, 1989, LAB INVEST, V60, P532; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; Kurihara N, 2001, J BIOL CHEM, V276, P41035, DOI 10.1074/jbc.M100233200; Kwon MJ, 2005, FRONT BIOSCI-LANDMRK, V10, P300, DOI 10.2741/1529; Laumonnier Y, 2006, BLOOD, V107, P3342, DOI 10.1182/blood-2005-07-2840; Lee KH, 1999, FEBS LETT, V442, P143, DOI 10.1016/S0014-5793(98)01643-3; Lewit-Bentley A, 2000, CELL BIOL INT, V24, P799, DOI 10.1006/cbir.2000.0629; Li FH, 2005, J BONE MINER RES, V20, P1161, DOI 10.1359/JBMR.050207; Liu L, 1997, CELL SIGNAL, V9, P299, DOI 10.1016/S0898-6568(97)89891-9; MACDONALD BR, 1987, ENDOCRINOLOGY, V120, P2326, DOI 10.1210/endo-120-6-2326; Menaa C, 1999, J CLIN INVEST, V103, P1605, DOI 10.1172/JCI6374; Mitaku S, 2002, BIOINFORMATICS, V18, P608, DOI 10.1093/bioinformatics/18.4.608; Mitaku S, 1999, BIOPHYS CHEM, V82, P165, DOI 10.1016/S0301-4622(99)00116-7; Mizwicki MT, 2004, J CELL BIOCHEM, V91, P852, DOI 10.1002/jcb.10783; Munz B, 1997, J INVEST DERMATOL, V108, P307, DOI 10.1111/1523-1747.ep12286470; Oba Y, 2003, J BONE MINER RES, V18, P1332, DOI 10.1359/jbmr.2003.18.7.1332; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Reddy S, 1998, J CELL PHYSIOL, V177, P636, DOI 10.1002/(SICI)1097-4652(199812)177:4<636::AID-JCP14>3.3.CO;2-8; Reddy SV, 2004, CRIT REV EUKAR GENE, V14, P255, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.20; Reddy SV, 1998, CRIT REV EUKAR GENE, V8, P1; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Siever DA, 1997, INT J BIOCHEM CELL B, V29, P1219, DOI 10.1016/S1357-2725(97)00057-5; TAKAHASHI N, 1989, J CLIN INVEST, V83, P543, DOI 10.1172/JCI113916; TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; [No title captured]	37	22	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30542	30550		10.1074/jbc.M607072200	http://dx.doi.org/10.1074/jbc.M607072200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16895901	hybrid			2022-12-25	WOS:000241075900030
J	Oria-Hernandez, J; Riveros-Rosas, H; Ramirez-Silva, L				Oria-Hernandez, Jesus; Riveros-Rosas, Hector; Ramirez-Silva, Leticia			Dichotomic phylogenetic tree of the pyruvate kinase family - K+-dependent and -independent enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; INDUCED CONFORMATIONAL CHANGE; MONOVALENT CATIONS; REGULATORY PROPERTIES; ESCHERICHIA-COLI; RABBIT MUSCLE; ANGSTROM RESOLUTION; UNIVALENT CATIONS; SKELETAL-MUSCLE; CHEMICAL RESCUE	K+ dependence was assumed to be a feature of all pyruvate kinases until it was discovered that some enzymes express K+-independent activity. Almost all the K+-independent pyruvate kinases have Lys at position 117, instead of the Glu present in the K+-dependent muscle enzyme. Mutagenesis studies show that the internal positive charge substitutes for the K+ requirement (Laughlin, L. T. & Reed, G. H. ( 1997) Arch. Biochem. Biophys. 348, 262 - 267). In this work a phylogenetic analysis of pyruvate kinase was performed to ascertain the abundance of K+-independent activities and to explore whether the K+ activating effect is related to the evolutionary history of the enzyme. Of the 230 studied sequences, 46% have Lys at position 117, and the rest have Glu. Pyruvate kinases with Lys(117) and Glu(117) are separated in two clusters. All of the enzymes of the Glu117 cluster that have been characterized are K+-dependent, whereas those of the Lys117 cluster are K+-independent. Thus, there is a strict correlation between the dichotomy of the tree and the dependence of activity on K+.77% of the pyruvate kinases that possess Lys(117) have Lys(113)/Gln(114); they also have Ile, Val, or Leu at position 120. These residues are replaced by Glu117 and Thr(113)/Lys(114)/Thr(120) in 80% of K+-dependent pyruvate kinases. Structural analysis indicates that these residues are in a hinge region involved in the acquisition of the catalytic conformation of the enzyme. The route of conversion from K+-independent to K+-dependent pyruvate kinases is described. A plausible explanation of how enzymes developed K+ dependence is put forth.	Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Ramirez-Silva, L (corresponding author), Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Apartado Postal 70-159, Mexico City 04510, DF, Mexico.	lramirez@bq.unam.mx	Riveros-Rosas, Hector/ABD-6638-2020; Oria-Hernández, Jesús/AAG-1243-2019; Riveros-Rosas, Hector/B-6607-2008	Riveros-Rosas, Hector/0000-0003-0194-2537; Oria-Hernández, Jesús/0000-0001-7147-1879; Riveros-Rosas, Hector/0000-0003-0194-2537				Ahmad A, 2001, BIOCHEMISTRY-US, V40, P1945, DOI 10.1021/bi001933a; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson CE, 2002, J MOL BIOL, V315, P409, DOI 10.1006/jmbi.2001.5248; Asanuma N, 2001, MICROBIOL-UK, V147, P681, DOI 10.1099/00221287-147-3-681; BARANOWSKA B, 1975, MOL CELL BIOCHEM, V6, P197, DOI 10.1007/BF01732078; Belogurov GA, 2002, J BIOL CHEM, V277, P49651, DOI 10.1074/jbc.M210341200; Benson DA, 2000, NUCLEIC ACIDS RES, V28, P15, DOI 10.1093/nar/28.1.15; BUSTO F, 1988, BIOCHEM CELL BIOL, V66, P148, DOI 10.1139/o88-020; CALLENS M, 1991, MOL BIOCHEM PARASIT, V47, P19, DOI 10.1016/0166-6851(91)90144-U; Chen J, 2003, NUCLEIC ACIDS RES, V31, P474, DOI 10.1093/nar/gkg086; Di Cera E, 2004, CR BIOL, V327, P1065, DOI 10.1016/j.crvi.2004.07.011; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; DOOLITTLE WF, 1994, P NATL ACAD SCI USA, V91, P6721, DOI 10.1073/pnas.91.15.6721; Du WS, 2000, EUR J BIOCHEM, V267, P222, DOI 10.1046/j.1432-1327.2000.00994.x; ERNEST I, 1994, MOL BIOCHEM PARASIT, V64, P43, DOI 10.1016/0166-6851(94)90133-3; Iliffe-Lee ER, 2002, MOL MICROBIOL, V44, P819, DOI 10.1046/j.1365-2958.2002.02924.x; JETTEN MSM, 1994, APPL ENVIRON MICROB, V60, P2501, DOI 10.1128/AEM.60.7.2501-2507.1994; Johnsen U, 2003, J BIOL CHEM, V278, P25417, DOI 10.1074/jbc.M210288200; KACHMAR JF, 1953, J BIOL CHEM, V200, P669; KAHN A, 1982, METHOD ENZYMOL, V90, P131; KAYNE FJ, 1971, ARCH BIOCHEM BIOPHYS, V143, P232, DOI 10.1016/0003-9861(71)90204-9; KAYNE FJ, 1965, J AM CHEM SOC, V87, P897, DOI 10.1021/ja01082a035; KAYNE FJ, 1970, J AM CHEM SOC, V92, P220, DOI 10.1021/ja00704a048; Knowles VL, 2001, J BIOL CHEM, V276, P20966, DOI 10.1074/jbc.M008878200; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; Larsen TM, 2001, HANDBOOK ON METALLOPROTEINS, P9; Larsen TM, 1997, ARCH BIOCHEM BIOPHYS, V345, P199, DOI 10.1006/abbi.1997.0257; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; Laughlin LT, 1997, ARCH BIOCHEM BIOPHYS, V348, P262, DOI 10.1006/abbi.1997.0448; Loria JP, 1998, BIOCHEMISTRY-US, V37, P6967, DOI 10.1021/bi972454n; Maeda T, 2003, PARASITOL RES, V89, P259, DOI 10.1007/s00436-002-0739-8; MALCOVATI M, 1982, METHOD ENZYMOL, V90, P170; McCartney SA, 2005, J BIOL CHEM, V280, P33206, DOI 10.1074/jbc.M506876200; MEIXNERMONORI B, 1984, CAN J MICROBIOL, V30, P16, DOI 10.1139/m84-003; MILDVAN AS, 1966, J BIOL CHEM, V241, P1178; MUIRHEAD H, 1987, BIOCHEM SOC T, V15, P996, DOI 10.1042/bst0150996; Munoz ME, 2003, COMP BIOCHEM PHYS B, V135, P197, DOI 10.1016/S1096-4959(03)00081-2; Nairn J, 1998, PROTEIN EXPRES PURIF, V14, P247, DOI 10.1006/prep.1998.0938; NOWAK T, 1972, BIOCHEMISTRY-US, V11, P2819, DOI 10.1021/bi00765a014; Oria-Hernandez J, 2005, J BIOL CHEM, V280, P37924, DOI 10.1074/jbc.M508490200; Qi GY, 2005, BIOINFORMATICS, V21, P2832, DOI 10.1093/bioinformatics/bti420; RamirezSilva L, 1997, EUR J BIOCHEM, V250, P583, DOI 10.1111/j.1432-1033.1997.0583a.x; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P5481, DOI 10.1021/bi00565a003; REUBEN J, 1971, J BIOL CHEM, V246, P6227; RHODES N, 1986, BIOCHEM J, V234, P705, DOI 10.1042/bj2340705; SAKAI H, 1986, J BIOCHEM-TOKYO, V99, P1157, DOI 10.1093/oxfordjournals.jbchem.a135579; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Schramm A, 2000, J BACTERIOL, V182, P2001, DOI 10.1128/JB.182.7.2001-2009.2000; SORGER GJ, 1965, P NATL ACAD SCI USA, V54, P1614, DOI 10.1073/pnas.54.6.1614; Steiner P, 1998, GENE, V220, P31, DOI 10.1016/S0378-1119(98)00418-1; SUELTER CH, 1966, BIOCHEMISTRY-US, V5, P131, DOI 10.1021/bi00865a017; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; SUELTER CH, 1963, J BIOL CHEM, V238, pC4109; Susan-Resiga D, 2003, J BIOL CHEM, V278, P40943, DOI 10.1074/jbc.M306068200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TSAO MU, 1975, MICROBIOS, V12, P125; VALENTINI G, 1979, ITAL J BIOCHEM, V28, P345; Walsh DA, 2005, CURR BIOL, V15, pR237, DOI 10.1016/j.cub.2005.03.034; Wilbanks SM, 1998, BIOCHEMISTRY-US, V37, P7456, DOI 10.1021/bi973046m; Williams DM, 2000, J BIOL CHEM, V275, P38127, DOI 10.1074/jbc.C000606200; YAMADA T, 1975, J BACTERIOL, V124, P562, DOI 10.1128/JB.124.1.562-563.1975	62	23	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30717	30724		10.1074/jbc.M605310200	http://dx.doi.org/10.1074/jbc.M605310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16905543	hybrid			2022-12-25	WOS:000241075900048
J	Grishin, A; Li, H; Levitan, ES; Zaks-Makhina, E				Grishin, Anatoly; Li, Hui; Levitan, Edwin S.; Zaks-Makhina, Elena			Identification of gamma-aminobutyric acid receptor-interacting factor 1 (TRAK2) as a trafficking factor for the K+ channel Kir2.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; SELECTIVE GOLGI EXPORT; COIL DOMAIN PROTEINS; O-GLCNAC; SURFACE EXPRESSION; TRANSPORT SIGNALS; CLONING; FAMILY; BRAIN; STOICHIOMETRY	To identify proteins that regulate potassium channel activity and expression, we performed functional screening of mammalian cDNA libraries in yeast that express the mammalian K+ channel Kir2.1. Growth of Kir2.1-expressing yeast in media with low K+ concentration is a function of K+ uptake via Kir2.1 channels. Therefore, the host strain was transformed with a human cDNA library, and cDNA clones that rescued growth at low K+ concentration were selected. One of these clones was identical to the protein of unknown function isolated previously as gamma-aminobutyric acid receptor-interacting factor 1 (GRIF-1) ( Beck, M., Brickley, K., Wilkinson, H., Sharma, S., Smith, M., Chazot, P., Pollard, S., and Stephenson, F.( 2002) J. Biol. Chem. 277, 30079-30090). GRIF-1 specifically enhanced Kir2.1-dependent growth in yeast and Kir2.1-mediated Rb-86(+) efflux in HEK293 cells. Quantitative microscopy and flow cytometry analysis of immunolabeled surface Kir2.1 channel showed that GRIF-1 significantly increased the number of Kir2.1 channels in the plasma membrane of COS and HEK293 cells. Physical interaction of Kir2.1 channel and GRIF-1 was demonstrated by co-immunoprecipitation from HEK293 lysates and yeast two-hybrid assay. In vivo association of Kir2.1 and GRIF-1 was demonstrated by co-immunoprecipitation from brain lysate. Yeast two-hybrid assays showed that an N-terminal region of GRIF-1 interacts with a C-terminal region of Kir2.1. These results indicate that GRIF-1 binds to Kir2.1 and facilitates trafficking of this channel to the cell surface.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Levitan, ES (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, 220 Lothrop St, Pittsburgh, PA 15261 USA.	levitan@server.pharm.pitt.edu			NHLBI NIH HHS [HL80632, HL55312] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055312, R01HL080632] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson CL, 2006, CIRCULATION, V113, P365, DOI 10.1161/CIRCULATIONAHA.105.570200; Beck M, 2002, J BIOL CHEM, V277, P30079, DOI 10.1074/jbc.M200438200; Brickley K, 2005, J BIOL CHEM, V280, P14723, DOI 10.1074/jbc.M409095200; Chatelain FC, 2005, NEURON, V47, P833, DOI 10.1016/j.neuron.2005.08.022; Chu PJ, 2006, J BIOL CHEM, V281, P365, DOI 10.1074/jbc.M508897200; Deutsch C, 2003, NEURON, V40, P265, DOI 10.1016/S0896-6273(03)00506-3; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gilbert SL, 2006, NAT GENET, V38, P245, DOI 10.1038/ng1715; Griffith LC, 2001, CURR BIOL, V11, pR226, DOI 10.1016/S0960-9822(01)00111-7; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; Hofherr A, 2005, J CELL SCI, V118, P1935, DOI 10.1242/jcs.02322; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; Khidekel N, 2004, P NATL ACAD SCI USA, V101, P13132, DOI 10.1073/pnas.0403471101; Leonoudakis D, 2004, J BIOL CHEM, V279, P22331, DOI 10.1074/jbc.M400285200; Leyland ML, 2004, J BIOL CHEM, V279, P43427, DOI 10.1074/jbc.M407575200; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Michelsen K, 2005, EMBO REP, V6, P717, DOI 10.1038/sj.embor.7400480; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Nagaya N, 1999, RECEPTOR CHANNEL, V6, P229; Nakamura RL, 1997, J BIOL CHEM, V272, P1011, DOI 10.1074/jbc.272.2.1011; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Roti ECR, 2002, J BIOL CHEM, V277, P47779, DOI 10.1074/jbc.M206638200; Sampson LJ, 2003, J BIOL CHEM, V278, P41988, DOI 10.1074/jbc.M307479200; Shikano S, 2005, NAT CELL BIOL, V7, P985, DOI 10.1038/ncb1297; Stockklausner C, 2003, J BIOL CHEM, V278, P17000, DOI 10.1074/jbc.M212243200; Stowers RS, 2002, NEURON, V36, P1063, DOI 10.1016/S0896-6273(02)01094-2; TANG WM, 1995, MOL BIOL CELL, V6, P1231, DOI 10.1091/mbc.6.9.1231; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Zachara NE, 2006, BBA-MOL CELL BIOL L, V1761, P599, DOI 10.1016/j.bbalip.2006.04.007; Zaks-Makhina E, 2004, MOL PHARMACOL, V65, P214, DOI 10.1124/mol.65.1.214; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	34	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30104	30111		10.1074/jbc.M602439200	http://dx.doi.org/10.1074/jbc.M602439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16895905	hybrid			2022-12-25	WOS:000240896300071
J	Carroll, MC; Outten, CE; Proescher, JB; Rosenfeld, L; Watson, WH; Whitson, LJ; Hart, PJ; Jensen, LT; Culotta, VC				Carroll, Mark C.; Outten, Caryn E.; Proescher, Jody B.; Rosenfeld, Leah; Watson, Walter H.; Whitson, Lisa J.; Hart, P. John; Jensen, Laran T.; Culotta, Valeria Cizewski			The effects of glutaredoxin and copper activation pathways on the disulfide and stability of Cu, Zn superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; PROTEIN S-GLUTATHIONYLATION; CU,ZN-SUPEROXIDE DISMUTASE; ESCHERICHIA-COLI; SOD1; CHAPERONE; MUTATIONS; SUPEROXIDE-DISMUTASE-1; AGGREGATION; BINDING	Mutations in Cu, Zn superoxide dismutase (SOD1) can cause amyotrophic lateral sclerosis (ALS) through mechanisms proposed to involve SOD1 misfolding, but the intracellular factors that modulate folding and stability of SOD1 are largely unknown. By using yeast and mammalian expression systems, we demonstrate here that SOD1 stability is governed by post-translational modification factors that target the SOD1 disulfide. Oxidation of the human SOD1 disulfide in vivo was found to involve both the copper chaperone for SOD1 (CCS) and the CCS-independent pathway for copper activation. When both copper pathways were blocked, wild type SOD1 stably accumulated in yeast cells with a reduced disulfide, whereas ALS SOD1 mutants A4V, G93A, and G37R were degraded. We describe here an unprecedented role for the thiol oxidoreductase glutaredoxin in reducing the SOD1 disulfide and destabilizing ALS mutants. Specifically, the major cytosolic glutaredoxin of yeast was seen to reduce the intramolecular disulfide of ALS SOD1 mutant A4V SOD1 in vivo and in vitro. By comparison, glutaredoxin was less reactive toward the disulfide of wild type SOD1. The apo-form of A4V SOD1 was highly reactive with glutaredoxin but not SOD1 containing both copper and zinc. Glutaredoxin therefore preferentially targets the immature form of ALS mutant SOD1 lacking metal co-factors. Overall, these studies implicate a critical balance between cellular reductants such as glutaredoxin and copper activation pathways in controlling the disulfide and stability of SOD1 in vivo.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Xray Crystallog Core Lab, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs,S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Culotta, VC (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm E7626, Baltimore, MD 21205 USA.	vculotta@jhsph.edu	Outten, Caryn E./I-9433-2019	Outten, Caryn E./0000-0003-0335-6531; Proescher, Jody/0000-0002-8100-7866; Jensen, Laran/0000-0003-3199-1743	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES012260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050016, R01GM050016, F32GM066594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039112] Funding Source: NIH RePORTER; NIEHS NIH HHS [K22 ES012260, ES012260, ES 07141] Funding Source: Medline; NIGMS NIH HHS [F32 GM066594, R37 GM050016, GM50016, R01 GM050016] Funding Source: Medline; NINDS NIH HHS [R01 NS039112, NS39112, R01 NS039112-05] Funding Source: Medline; PHS HHS [F32 66594] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Antonyuk S, 2005, PROTEIN SCI, V14, P1201, DOI 10.1110/ps.041256705; Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Assfalg M, 2003, J MOL BIOL, V330, P145, DOI 10.1016/S0022-2836(03)00533-3; Banci L, 2006, J BIOL CHEM, V281, P2333, DOI 10.1074/jbc.M506497200; Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Brown NM, 2004, P NATL ACAD SCI USA, V101, P5518, DOI 10.1073/pnas.0401175101; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Choi J, 2005, J BIOL CHEM, V280, P11648, DOI 10.1074/jbc.M414327200; Cleveland DW, 2000, NAT MED, V6, P1320, DOI 10.1038/82122; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103; Di Noto L, 2005, J BIOL CHEM, V280, P39907, DOI 10.1074/jbc.M506247200; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; Draculic T, 2000, MOL MICROBIOL, V36, P1167, DOI 10.1046/j.1365-2958.2000.01948.x; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Furukawa Y, 2006, P NATL ACAD SCI USA, V103, P7148, DOI 10.1073/pnas.0602048103; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; Hoppe G, 2004, EXP EYE RES, V78, P1085, DOI 10.1016/j.exer.2004.02.001; Jensen LT, 2005, J BIOL CHEM, V280, P41373, DOI 10.1074/jbc.M509142200; Jonsson PA, 2006, BRAIN, V129, P451, DOI 10.1093/brain/awh704; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Liu HB, 2000, BIOCHEMISTRY-US, V39, P8125, DOI 10.1021/bi000846f; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Pedrajas JR, 2002, BIOCHEM J, V364, P617, DOI 10.1042/BJ20020570; Petrovic N, 1996, J BIOL CHEM, V271, P28331, DOI 10.1074/jbc.271.45.28331; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; STEINKUHLER C, 1994, BIOCHEM J, V302, P687, DOI 10.1042/bj3020687; Strange RW, 2006, J MOL BIOL, V356, P1152, DOI 10.1016/j.jmb.2005.11.081; Strange RW, 2003, J MOL BIOL, V328, P877, DOI 10.1016/S0022-2836(03)00355-3; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Valentine J. S., 1981, METAL IONS BIOL, P291; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Wang J, 2003, HUM MOL GENET, V12, P2753, DOI 10.1093/hmg/ddg312; Wang J, 2005, NEUROBIOL DIS, V20, P943, DOI 10.1016/j.nbd.2005.06.005; Wang J, 2006, J NEUROCHEM, V96, P1277, DOI 10.1111/j.1471-4159.2005.03642.x; Zhang QH, 2005, BIOCHEMISTRY-US, V44, P9079, DOI 10.1021/bi050378f; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	56	44	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28648	28656		10.1074/jbc.M600138200	http://dx.doi.org/10.1074/jbc.M600138200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16880213	hybrid, Green Accepted			2022-12-25	WOS:000240680500018
J	Tunnemann, G; Martin, RM; Haupt, S; Patsch, C; Edenhofer, F; Cardoso, MC				Tuennemann, Gisela; Martin, Robert M.; Haupt, Simone; Patsch, Christoph; Edenhofer, Frank; Cardoso, M. Cristina			Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells	FASEB JOURNAL			English	Article						cell-penetrating peptide; protein transduction; PCNA; PBD; Cre recombinase	DNA-LIGASE I; CELLULAR UPTAKE; PENETRATING PEPTIDES; CRE RECOMBINASE; FUSION PROTEINS; REPLICATION FACTORIES; TRANSDUCTION DOMAINS; NUCLEAR ANTIGEN; ENTERS CELLS; MECHANISM	Cell-penetrating peptides (CPPs) are capable of introducing a wide range of cargoes into living cells. Descriptions of the internalization process vary from energy-independent cell penetration of membranes to endocytic uptake. To elucidate whether the mechanism of entry of CPP constructs might be influenced by the properties of the cargo, we used time lapse confocal microscopy analysis of living mammalian cells to directly compare the uptake of the well-studied CPP TAT fused to a protein (> 50 amino acids) or peptide (< 50 amino acids) cargo. We also analyzed various constructs for their subcellular distribution and mobility after the internalization event. TAT fusion proteins were taken up largely into cytoplasmic vesicles whereas peptides fused to TAT entered the cell in a rapid manner that was dependent on membrane potential. Despite their accumulation in the nucleolus, photobleaching of TAT fusion peptides revealed their mobility. The bioavailability of internalized TAT peptides was tested and confirmed by the strong inhibitory effect on cell cycle progression of two TAT fusion peptides derived from the tumor suppressor p21(WAF/Cip) and DNA Ligase I measured in living cells.-Tunnemann, G., Martin, R. M., Haupt, S., Patsch, C., Edenhofer, F., Cardoso, M. C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Bonn, Inst Reconstruct Neurobiol, Stem Cell Engn Grp, Life & Brain Ctr, D-5300 Bonn, Germany; Hertie Fdn, Bonn, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Bonn	Tunnemann, G (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	cardoso@mdc-berlin.de	Edenhofer, Frank/ABG-9458-2020; Cardoso, M. Cristina/F-5215-2011	Edenhofer, Frank/0000-0002-6489-714X; Martin, Robert/0000-0001-5600-7525; Lattig, Gisela/0000-0001-6485-1136				Aidley D.J., 1996, ION CHANNELS MOL ACT; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Cardoso MC, 2002, BIOL CHEM, V383, P1593, DOI 10.1515/BC.2002.180; Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180; Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279; Choi M, 2003, BLOOD, V102, P2259, DOI 10.1182/blood-2002-09-2960; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; Dom G, 2003, NUCLEIC ACIDS RES, V31, P556, DOI 10.1093/nar/gkg160; Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; GODDETTE DW, 1986, J BIOL CHEM, V261, P5970; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Ho A, 2001, CANCER RES, V61, P474; Jo DW, 2001, NAT BIOTECHNOL, V19, P929, DOI 10.1038/nbt1001-929; Joshi SK, 2002, GENESIS, V33, P48, DOI 10.1002/gene.10089; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200; Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; NOLDEN L, 2006, IN PRESS NAT METHODS; Peitz M, 2002, P NATL ACAD SCI USA, V99, P4489, DOI 10.1073/pnas.032068699; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003; Scheller A, 2000, EUR J BIOCHEM, V267, P6043, DOI 10.1046/j.1432-1327.2000.01681.x; SEEWALD N, 2002, PEPTIDES CHEM BIOL; Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636; Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Watanabe Y, 2004, GENE DEV, V18, P889, DOI 10.1101/gad.1179004; Will E, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf059; Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604; Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805	43	318	336	1	74	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1775	1784		10.1096/fj.05-5523com	http://dx.doi.org/10.1096/fj.05-5523com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940149				2022-12-25	WOS:000240267000005
J	Kundu, CN; Balusu, R; Jaiswal, AS; Gairola, CG; Narayan, S				Kundu, C. N.; Balusu, R.; Jaiswal, A. S.; Gairola, C. G.; Narayan, S.			Cigarette smoke condensate-induced level of adenomatous polyposis coli blocks long-patchbase excision repair in breast epithelial cells	ONCOGENE			English	Article						adenomatous polyposis coli; long-patch base excision repair; benzo[a] pyrene; cigarette smoke condensate; breast carcinogenesis	RAS ONCOGENE ACTIVATION; APC GENE-EXPRESSION; TOBACCO-SMOKE; TRANSCRIPTIONAL REGULATION; CHEMICAL-COMPOSITION; PASSIVE SMOKING; ACTIVE SMOKING; DNA-ADDUCTS; CANCER RISK; MUTATIONS	Our previous studies have shown that treatment with cigarette smoke condensate (CSC) transforms normal breast epithelial cell line, MCF-10A. In the present study, the mechanism of CSC-induced transformation of breast epithelial cells was examined. We first determined whether benzo[ a] pyrene (B[a]P)- and CSC-induced levels of APC are capable of inhibiting long-patch base excision repair (LP-BER) since our earlier studies had shown that an interaction of APC with DNA polymerase beta (pol-beta) blocks strand-displacement synthesis. With the use of a novel in vivo LP-BER assay, it was demonstrated that increased and decreased APC levels in different breast cancer cell lines were associated witha decrease or increase in LP-BER activity, respectively. The effect of APC on LP-BER in malignant and pre- malignant breast epithelial cell lines was produced by either overexpression or knockdown of APC. Furthermore, it was shown that the decreased LP-BER in B[a]P- or CSC-treated premalignant breast epithelial cells is associated with an increased level of APC and decreased cell growth. Our results suggest that the decreased growth allows cells to repair the damaged DNA before mitosis, and failure to repair damaged DNA has the potential to transform premalignant breast epithelial cells.	Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY USA	State University System of Florida; University of Florida; University of Kentucky	Narayan, S (corresponding author), Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Canc & Genet Res Complex,Room 255,POB 103633,1376, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu		Kundu, Chanakya/0000-0003-0297-1030	NCI NIH HHS [CA-100247-01, CA-097031-01, R01 CA100247, R01 CA097031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097031, R01CA100247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BARON JA, 1984, AM J EPIDEMIOL, V119, P9, DOI 10.1093/oxfordjournals.aje.a113730; Baron JA, 1996, CANCER EPIDEM BIOMAR, V5, P399; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; Braithwaite E, 1998, CARCINOGENESIS, V19, P1239, DOI 10.1093/carcin/19.7.1239; CAVLIERI EL, 1998, HDB ENV CHEM J, V3, P81; CHAKRAVARTI D, 1995, P NATL ACAD SCI USA, V92, P10422, DOI 10.1073/pnas.92.22.10422; Chakravarti D, 1998, ONCOGENE, V16, P3203, DOI 10.1038/sj.onc.1201853; Chakravarti D, 2000, MUTAT RES-FUND MOL M, V456, P17, DOI 10.1016/S0027-5107(00)00102-0; Coates PJ, 2005, J PATHOL, V205, P221, DOI 10.1002/path.1701; Currier N, 2005, TOXICOL PATHOL, V33, P726, DOI 10.1080/01926230500352226; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; DEMARINI DM, 1995, CARCINOGENESIS, V16, P2535, DOI 10.1093/carcin/16.10.2535; Duell EJ, 2001, CANCER EPIDEM BIOMAR, V10, P217; Egan KM, 2002, EPIDEMIOLOGY, V13, P138, DOI 10.1097/00001648-200203000-00007; ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431; Fink AK, 2003, CANCER CAUSE CONTROL, V14, P497, DOI 10.1023/A:1024922824237; Gram IT, 2005, CANCER EPIDEM BIOMAR, V14, P61; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; HSU TC, 1991, MUTAT RES, V259, P67, DOI 10.1016/0165-1218(91)90110-8; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; Jaiswal AS, 2002, ONCOGENE, V21, P5912, DOI 10.1038/sj.onc.1205789; Jaiswal AS, 2006, CARCINOGENESIS, V27, P252, DOI 10.1093/carcin/bgi225; Jaiswal AS, 2001, J CELL BIOCHEM, V81, P262, DOI 10.1002/1097-4644(20010501)81:2<262::AID-JCB1041>3.0.CO;2-R; Johnson KC, 2000, CANCER CAUSE CONTROL, V11, P211, DOI 10.1023/A:1008906105790; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LONDON SJ, 1989, JNCI-J NATL CANCER I, V81, P1625, DOI 10.1093/jnci/81.21.1625; Mei JX, 2003, BREAST CANCER RES TR, V79, P95, DOI 10.1023/A:1023326121951; MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725; Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2005, J BIOL CHEM, V280, P6942, DOI 10.1074/jbc.M409200200; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Nishikawa A, 2004, CURR DRUG METAB, V5, P363, DOI 10.2174/1389200043335441; Pachkowski BF, 2006, CANCER RES, V66, P2860, DOI 10.1158/0008-5472.CAN-05-3388; PALMER JR, 1993, EPIDEMIOL REV, V15, P145, DOI 10.1093/oxfordjournals.epirev.a036098; Patel AV, 2005, BREAST CANCER RES, V7, pR1168, DOI 10.1186/bcr1355; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; PILLSBURY HC, 1972, J ASSOC OFF ANA CHEM, V55, P636; Porter PC, 2005, DNA REPAIR, V4, P341, DOI 10.1016/j.dnarep.2004.10.007; Raptis S, 2006, EXP SUPPL, V96, P303; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Roemer E, 2004, TOXICOLOGY, V195, P31, DOI 10.1016/j.tox.2003.08.006; RUSSO J, 1991, J CELL SCI, V99, P453; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X; SOULE HD, 1990, CANCER RES, V50, P6075; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stabbert R, 2003, J APPL TOXICOL, V23, P329, DOI 10.1002/jat.924; Steinetz BG, 2006, CARCINOGENESIS, V27, P1146, DOI 10.1093/carcin/bgi353; Terry PD, 2002, CANCER EPIDEM BIOMAR, V11, P953; Terry PD, 2006, CANCER EPIDEM BIOMAR, V15, P602, DOI 10.1158/1055-9965.EPI-05-0853; Wani MA, 2002, MUTAT RES-FUND MOL M, V505, P13, DOI 10.1016/S0027-5107(02)00107-0; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	59	37	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1428	1438		10.1038/sj.onc.1209925	http://dx.doi.org/10.1038/sj.onc.1209925			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16924228				2022-12-25	WOS:000244558800007
J	Takada, Y; Ichikawa, H; Pataer, A; Swisher, S; Aggarwal, BB				Takada, Y.; Ichikawa, H.; Pataer, A.; Swisher, S.; Aggarwal, B. B.			Genetic deletion of PKR abrogates TNF-induced activation of I kappa B alpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation	ONCOGENE			English	Article						PKR; Akt; MAPK; JNK; NF-kappa B; TNF; survival; apoptosis	DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; INFLAMMATORY STIMULI; SIGNAL-TRANSDUCTION; UP-REGULATION; INTERFERON; EXPRESSION; APOPTOSIS	Double-stranded RNA-dependent protein kinase (PKR), a ubiquitously expressed serine/threonine kinase, has been implicated in the regulation or modulation of cell growth through multiple signaling pathways, but how PKR regulates tumor necrosis factor (TNF)-induced signaling pathways is poorly understood. In the present study, we used. broblasts derived from PKR gene-deleted mice to investigate the role of PKR in TNF-induced activation of nuclear factor-kappa B (NF-kappa B), mitogen-activated protein kinases (MAPKs) and growth modulation. We found that in wild-type mouse embryonic fibroblast (MEF), TNF induced NF-kappa B activation as measured by DNA binding but deletion of PKR abolished this activation. This inhibition was associated with suppression of inhibitory subunit of NF-kappa B (I kappa B)alpha kinase (IKK) activation, I kappa B alpha phosphorylation and degradation, p65 phosphorylation and nuclear translocation, and NF-kappa B-dependent reporter gene transcription. TNF-induced Akt activation needed for IKK activation was also abolished by deletion of PKR. NF-kappa B activation was diminished in PKR-deleted cells transfected with TNF receptor ( TNFR) 1, TNFR-associated death domain and TRAF2 plasmids; NF-kappa B activated by NF-kappa B-inducing kinase, IKK or p65, however, was minimally affected. Among the MAPKs, it was interesting that whereas TNF-induced c-Jun N-terminal kinase (JNK) activation was abolished, activation of p44/p42 MAPK and p38 MAPK was potentiated in PKR-deleted cells. TNF induced the expression of NF-kappa B-regulated gene products cyclin D1, c-Myc, matrix metalloproteinase-9, survivin, X-linked inhibitor-of-apoptosis protein (IAP), IAP1, Bcl-x(L), A1/Bfl-1 and Fas-associated death domain protein-like IL-1 beta-converting enzyme-inhibitory protein in wild-type MEF but not in PKR-/- cells. Similarly, TNF induced the proliferation of wild-type cells, but this proliferation was completely suppressed in PKR-deleted cells. Overall, our results indicate that PKR differentially regulates TNF signaling; IKK, Akt and JNK were positively regulated, whereas p44/p42 MAPK and p38 MAPK were negatively regulated.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd,Unit 143, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [P01 CA91844, P50CA97007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844, P50CA097007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bandyopadhyay SK, 2000, J IMMUNOL, V164, P2077, DOI 10.4049/jimmunol.164.4.2077; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Esteves E, 2002, MATH RES LETT, V9, P1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 2004, MOL CELL BIOL, V24, P4502, DOI 10.1128/MCB.24.10.4502-4512.2004; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; Gilbert SJ, 2004, ARTHRITIS RES THER, V6, pR46, DOI 10.1186/ar1024; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GUSELLA GL, 1995, J IMMUNOL, V154, P345; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kronfeld-Kinar Y, 1999, CELL GROWTH DIFFER, V10, P201; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maggi LB, 2003, J BIOL CHEM, V278, P16683, DOI 10.1074/jbc.M211744200; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Ozes ON, 1999, NATURE, V401, P82; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Takizawa T, 2002, EUR J BIOCHEM, V269, P6126, DOI 10.1046/j.1432-1033.2002.03325.x; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	65	82	82	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1201	1212		10.1038/sj.onc.1209906	http://dx.doi.org/10.1038/sj.onc.1209906			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924232				2022-12-25	WOS:000244406400010
J	Sayanova, O; Haslam, R; Guschina, I; Lloyd, D; Christie, WW; Harwood, JL; Napier, JA				Sayanova, Olga; Haslam, Richard; Guschina, Irina; Lloyd, David; Christie, William W.; Harwood, John L.; Napier, Johnathan A.			A bifunctional Delta 12, Delta 15-desaturase from Acanthamoeba castellanii directs the synthesis of highly unusual n-1 series unsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRONT-END-DESATURASES; 4,4-DIMETHYLOXAZOLINE DERIVATIVES; FUNCTIONAL-CHARACTERIZATION; BIOSYNTHETIC-PATHWAY; SKELETONEMA-COSTATUM; TRANSGENIC PLANTS; IN-VIVO; MICROALGA; DIATOM; CDNA	The free-living soil protozoon Acanthamoeba castellanii synthesizes a range of polyunsaturated fatty acids, the balance of which can be altered by environmental changes. We have isolated and functionally characterized in yeast a microsomal desaturase from A. castellanii, which catalyzes the sequential conversion of C-16 and C-18 Delta 9-monounsaturated fatty acids to di- and tri-unsaturated forms. In the case of C-16 substrates, this bifunctional A. castellanii Delta 12, Delta 15-desaturase generated a highly unusual fatty acid, hexadecatrienoic acid (16:3 Delta(9,12,15)(n1)). The identification of a desaturase, which can catalyze the insertion of a double bond between the terminal two carbons of a fatty acid represents a new addition to desaturase functionality and plasticity. We have also co-expressed in yeast the A. castellanii bifunctional Delta 12, Delta 15-desaturase with a microsomal Delta 6-desaturase, resulting in the synthesis of the highly unsaturated C16 fatty acid hexadecatetraenoic acid (16:4 Delta(6,9,12,15)(n-1)), previously only reported in marine microorganisms. Our work therefore demonstrates the feasibility of the heterologous synthesis of polyunsaturated fatty acids of the n-1 series. The presence of a bifunctional Delta 12, Delta 15-desaturase in A. castellanii is also considered with reference to the evolution of desaturases and the lineage of this protist.	Rothamsted Res, Harpenden AL5 2JQ, Herts, England; Univ Cardiff, Cardiff Sch Biosci, Cardiff CF10 1US, S Glam, Wales; Scottish Crop Res Inst, MRS Mylnefield Res Serv, Dundee DD2 5DA, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Cardiff University; James Hutton Institute	Napier, JA (corresponding author), Rothamsted Res, Harpenden AL5 2JQ, Herts, England.	johnathan.napier@bbsrc.ac.uk	Haslam, Richard/B-3865-2009; Harwood, John L/A-4308-2010; Haslam, Richard/C-5966-2014; Lloyd, David/D-2483-2010	Lloyd, David/0000-0002-5656-0571; Napier, Johnathan/0000-0003-3580-3607; Harwood, John/0000-0003-2377-2612; Haslam, Richard/0000-0001-6226-5643	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004156] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		AITZETMULLER K, 1994, J PLANT PHYSIOL, V143, P538, DOI 10.1016/S0176-1617(11)81820-1; [Anonymous], 2003, LIPID ANAL; BERGE JP, 1995, PHYTOCHEMISTRY, V39, P1017, DOI 10.1016/0031-9422(94)00156-N; Blee E, 1998, PROG LIPID RES, V37, P33, DOI 10.1016/S0163-7827(98)00004-6; Christie WW, 2000, EUR J LIPID SCI TECH, V102, P23, DOI 10.1002/(SICI)1438-9312(200001)102:1<23::AID-EJLT23>3.3.CO;2-I; d'Ippolito G, 2004, BBA-MOL CELL BIOL L, V1686, P100, DOI 10.1016/j.bbalip.2004.09.002; Damude HG, 2006, P NATL ACAD SCI USA, V103, P9446, DOI 10.1073/pnas.0511079103; Dayan FE, 2003, J BIOL CHEM, V278, P28607, DOI 10.1074/jbc.M304185200; Domergue F, 2005, BIOCHEM J, V389, P483, DOI 10.1042/BJ20050111; Domergue F, 2003, J BIOL CHEM, V278, P35115, DOI 10.1074/jbc.M305990200; Doolittle WE, 1998, TRENDS GENET, V14, P307; GARBUS J, 1963, J BIOL CHEM, V238, P59; Graeve M, 2002, MAR ECOL PROG SER, V231, P67, DOI 10.3354/meps231067; Gurr M. I, 2002, LIPID BIOCH; Harwood JL, 1998, ANN NY ACAD SCI, V851, P162, DOI 10.1111/j.1749-6632.1998.tb08990.x; Hastings N, 2001, P NATL ACAD SCI USA, V98, P14304, DOI 10.1073/pnas.251516598; Heinz Ernst, 1993, P33; HIGASHI S, 1993, PLANT PHYSIOL, V102, P1275, DOI 10.1104/pp.102.4.1275; HITZ WD, 1994, PLANT PHYSIOL, V105, P635, DOI 10.1104/pp.105.2.635; JONES AL, 1993, BIOCHEM J, V290, P273, DOI 10.1042/bj2900273; JONES AL, 1993, BIOCHEM J, V296, P183, DOI 10.1042/bj2960183; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Kates M., 1986, TECHNIQUES LIPIDOLOG; KORN ED, 1964, J BIOL CHEM, V239, P396; Mansour MP, 1999, J PHYCOL, V35, P710, DOI 10.1046/j.1529-8817.1999.3540710.x; Marciano-Cabral F, 2003, CLIN MICROBIOL REV, V16, P273, DOI 10.1128/CMR.16.2.273-307.2003; McCartney AW, 2004, PLANT J, V37, P156, DOI 10.1111/j.1365-313X.2004.01949.x; Meesapyodsuk D, 2000, BIOCHEMISTRY-US, V39, P11948, DOI 10.1021/bi000756a; Meesapyodsuk D, 2000, BIOCHEM SOC T, V28, P632, DOI 10.1042/BST0280632; Napier JA, 1999, TRENDS PLANT SCI, V4, P2, DOI 10.1016/S1360-1385(98)01357-0; Napier JA, 2004, LIPIDS, V39, P1067, DOI 10.1007/s11745-004-1332-1; Napier JA, 2003, PROSTAG LEUKOTR ESS, V68, P135, DOI 10.1016/S0952-3278(02)00263-6; Napier JA, 2001, LIPIDS, V36, P761, DOI 10.1007/s11745-001-0782-9; PAGE F. C., 1974, Arch. Protistenkunde, V116, P149; Petrini GA, 2004, EUR J BIOCHEM, V271, P1079, DOI 10.1111/j.1432-1033.2004.04005.x; Qi BX, 2002, FEBS LETT, V510, P159, DOI 10.1016/S0014-5793(01)03247-1; Rutter AJ, 2002, BIOCHEM J, V368, P57, DOI 10.1042/BJ20020189; Rychek EA, 2005, LIPIDS, V40, P599, DOI 10.1007/s11745-005-1421-1; Sayanova O, 2006, FEBS LETT, V580, P1946, DOI 10.1016/j.febslet.2006.02.062; Sayanova O, 1999, J EXP BOT, V50, P411, DOI 10.1093/jexbot/50.332.409; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; Sayanova OV, 2004, PHYTOCHEMISTRY, V65, P147, DOI 10.1016/j.phytochem.2003.10.017; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Tonon T, 2005, FEBS J, V272, P3401, DOI 10.1111/j.1742-4658.2005.04755.x; Tripodi KEJ, 2006, FEBS J, V273, P271, DOI 10.1111/j.1742-4658.2005.05049.x; ZHANG JY, 1989, J AM OIL CHEM SOC, V66, P256, DOI 10.1007/BF02546071; Zhukova NV, 2001, BOT MAR, V44, P287, DOI 10.1515/BOT.2001.037	48	69	81	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36533	36541		10.1074/jbc.M605158200	http://dx.doi.org/10.1074/jbc.M605158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16950768	hybrid, Green Published			2022-12-25	WOS:000242220800009
J	Brunk, I; Blex, C; Rachakonda, S; Holtje, M; Winter, S; Pahner, I; Walther, DJ; Ahnert-Hilger, G				Brunk, Irene; Blex, Christian; Rachakonda, Sivaramakrishna; Hoeltje, Markus; Winter, Sandra; Pahner, Ingrid; Walther, Diego J.; Ahnert-Hilger, Gudrun			The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; DOPAMINE NEURONS; CELLS; EXPRESSION; KNOCKOUT; RELEASE; IDENTIFICATION; ACETYLCHOLINE; SEROTONIN; GRANULE	The activity of vesicular monoamine transporters (VMATs) is down-regulated by the G-protein alpha-subunits of G(o2) and G(q), but the signaling pathways are not known. We show here that no such regulation is observed when VMAT1 or VMAT2 are expressed in Chinese hamster ovary (CHO) cells. However, when the intracellular compartments of VMAT-expressing CHO cells are preloaded with different monoamines, transport becomes susceptible to G-protein-dependent regulation, with differences between the two transporter isoforms. Epinephrine induces G-protein-mediated inhibition of transmitter uptake in CHOVMAT1 cells but prevents inhibition induced by dopamine in CHOVMAT2 cells. Epinephrine also antagonizes G-protein-mediated inhibition of monoamine uptake by VMAT2 expressing platelets or synaptic vesicles. In CHOVMAT2 cells G-protein-mediated inhibition of monoamine uptake can be induced by 5-hydroxytryptamine (serotonin) 1B receptor agonists, whereas alpha 1 receptor agonists modulate uptake into CHOVMAT1 cells. Accordingly, 5-hydroxytryptamine 1B receptor antagonists prevent G-protein-mediated inhibition of uptake in partially filled platelets and synaptic vesicles expressing VMAT2. CHO cells expressing VMAT mutants with a shortened first vesicular loop transport monoamines. However, no or a reduced G-protein regulation of uptake can be initiated. In conclusion, vesicular content is involved in the activation of vesicle associated G-proteins via a structure sensing the luminal monoamine content. The first luminal loop of VMATs may represent a G-protein-coupled receptor that adapts vesicular filling.	Charite, AG Funct Cell Biol, Ctr Anat, D-10115 Berlin, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society	Ahnert-Hilger, G (corresponding author), Charite, AG Funct Cell Biol, Ctr Anat, Philippstr 12, D-10115 Berlin, Germany.	gudrun.ahnert@charite.de		Brunk, Irene/0000-0002-2668-7002; Holtje, Markus/0000-0003-3193-4140; Rachakonda, Sivaramakrishna/0000-0002-2319-2821; Blex, Christian/0000-0002-8493-3523				Ahnert-Hilger G, 2000, HANDB EXP PHARM, V145, P557; Ahnert-Hilger G, 2004, REV PHYSIOL BIOCH P, V150, P140, DOI 10.1007/s10254-003-0020-2; Ahnert-Hilger G, 1998, EMBO J, V17, P406, DOI 10.1093/emboj/17.2.406; Brunk I, 2006, HANDB EXP PHARM, V175, P305; Croft BG, 2005, MOL BIOL CELL, V16, P306, DOI 10.1091/mbc.e04-07-0559; Engel D, 2001, J PHYSIOL-LONDON, V535, P473, DOI 10.1111/j.1469-7793.2001.00473.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; Hess HA, 2004, CELL, V119, P209, DOI 10.1016/j.cell.2004.09.025; Holtje M, 2003, J BIOL CHEM, V278, P15850, DOI 10.1074/jbc.M212816200; Holtje M, 2000, J NEUROSCI, V20, P2131; Hutchinson DS, 2002, BRIT J PHARMACOL, V135, P1903, DOI 10.1038/sj.bjp.0704654; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; Le-Niculescu H, 2005, J BIOL CHEM, V280, P22012, DOI 10.1074/jbc.M501833200; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Liu YJ, 1997, J CELL BIOL, V139, P907, DOI 10.1083/jcb.139.4.907; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Nurnberg B, 1996, FEBS LETT, V389, P61, DOI 10.1016/0014-5793(96)00584-4; Pahner I, 2002, EUR J CELL BIOL, V81, P449, DOI 10.1078/0171-9335-00269; PETER D, 1994, J BIOL CHEM, V269, P7231; Pothos EN, 1998, J NEUROSCI, V18, P4106; Pothos EN, 2000, J NEUROSCI, V20, P7297; Pullarkat SR, 1998, J NEUROCHEM, V71, P1059; Scheel AA, 1998, J BIOL CHEM, V273, P2467, DOI 10.1074/jbc.273.4.2467; Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7; Speidel D, 2005, NEURON, V46, P75, DOI 10.1016/j.neuron.2005.02.019; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; Travis ER, 2000, P NATL ACAD SCI USA, V97, P162, DOI 10.1073/pnas.97.1.162; Van der Kloot W, 2000, J PHYSIOL-LONDON, V523, P247, DOI 10.1111/j.1469-7793.2000.00247.x; VANDERKLOOT W, 1991, PROG NEUROBIOL, V36, P93, DOI 10.1016/0301-0082(91)90019-W; Walther DJ, 2003, CELL, V115, P851, DOI 10.1016/S0092-8674(03)01014-6; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; Winter S, 2005, J NEUROSCI, V25, P4672, DOI 10.1523/JNEUROSCI.0549-05.2005; Wojcik SM, 2004, P NATL ACAD SCI USA, V101, P7158, DOI 10.1073/pnas.0401764101	37	53	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33373	33385		10.1074/jbc.M603204200	http://dx.doi.org/10.1074/jbc.M603204200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16926160	hybrid			2022-12-25	WOS:000241621400047
J	Davis-Kaplan, SR; Compton, MA; Flannery, AR; Ward, DM; Kaplan, J; Stevens, TH; Graham, LA				Davis-Kaplan, Sandra R.; Compton, Mark A.; Flannery, Andrew R.; Ward, Diane M.; Kaplan, Jerry; Stevens, Tom H.; Graham, Laurie A.			PKR1 encodes an assembly factor for the yeast V-type ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; ENDOPLASMIC-RETICULUM; GENE ENCODES; MEMBRANE; TRANSPORT; SUBUNIT; MUTANTS; MUTATIONS; HOMOLOG	Deletion of the yeast gene PKR1 (YMR123W) results in an inability to grow on iron-limited medium. Pkr1p is localized to the membrane of the endoplasmic reticulum. Cells lacking Pkr1p show reduced levels of the V-ATPase subunit Vph1p due to increased turnover of the protein in mutant cells. Reduced levels of the V-ATPase lead to defective copper loading of Fet3p, a component of the high affinity iron transport system. Levels of Vph1p in cells lacking Pkr1p are similar to cells unable to assemble a functional V-ATPase due to lack of a V-0 subunit or an endoplasmic reticulum (ER) assembly factor. However, unlike yeast mutants lacking a V-0 subunit or a V-ATPase assembly factor, low levels of Vph1p present in cells lacking Pkr1p are assembled into a V-ATPase complex, which exits the ER and is present on the vacuolar membrane. The V-ATPase assembled in the absence of Pkr1p is fully functional because the mutant cells are able to weakly acidify their vacuoles. Finally, overexpression of the V-ATPase assembly factor Vma21p suppresses the growth and acidification defects of pkr1 Delta cells. Our data indicate that Pkr1p functions together with the other V-ATPase assembly factors in the ER to efficiently assemble the V-ATPase membrane sector.	Univ Utah, Sch Med, Div Cell Biol & Immunol, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	Utah System of Higher Education; University of Utah; University of Oregon	Kaplan, J (corresponding author), Univ Utah, Sch Med, Div Cell Biol & Immunol, Dept Pathol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu; stevens@molbio.uoregon.edu		Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030534, R37DK030534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NCI NIH HHS [CA43014] Funding Source: Medline; NIDDK NIH HHS [DK30534] Funding Source: Medline; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Compton MA, 2006, J BIOL CHEM, V281, P15312, DOI 10.1074/jbc.M600890200; Conibear E, 2002, METHOD ENZYMOL, V351, P408; Davis-Kaplan SR, 2004, J BIOL CHEM, V279, P4322, DOI 10.1074/jbc.M310680200; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; Felice MR, 2005, J BIOL CHEM, V280, P22181, DOI 10.1074/jbc.M414663200; Flannery AR, 2004, J BIOL CHEM, V279, P39856, DOI 10.1074/jbc.M406767200; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Graham LA, 2003, J BIOENERG BIOMEMBR, V35, P301, DOI 10.1023/A:1025772730586; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jackson DD, 1997, J BIOL CHEM, V272, P25928, DOI 10.1074/jbc.272.41.25928; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Malkus P, 2004, MOL BIOL CELL, V15, P5075, DOI 10.1091/mbc.E04-06-0514; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Oluwatosin YE, 1998, MOL CELL BIOL, V18, P1534, DOI 10.1128/MCB.18.3.1534; Oluwatosin YE, 1997, J BIOL CHEM, V272, P28149, DOI 10.1074/jbc.272.44.28149; Perzov N, 2002, J EXP BIOL, V205, P1209; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sambade M, 2004, J BIOL CHEM, V279, P17361, DOI 10.1074/jbc.M314104200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	34	29	31	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					32025	32035		10.1074/jbc.M606451200	http://dx.doi.org/10.1074/jbc.M606451200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16926153	Bronze			2022-12-25	WOS:000241235300088
J	Schmidl, M; Adam, N; Surmann-Schmitt, C; Hattori, T; Stock, M; Dietz, U; de Crombrugghe, B; Poschl, E; von der Mark, K				Schmidl, Martina; Adam, Nadia; Surmann-Schmitt, Cordula; Hattori, Takako; Stock, Michael; Dietz, Uwe; de Crombrugghe, Benoit; Poeschl, Ernst; von der Mark, Klaus			Twisted gastrulation modulates bone morphogenetic protein-induced collagen II and X expression in chondrocytes in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPEMANN ORGANIZER; BMP ANTAGONIST; DIFFERENTIATED PHENOTYPE; CARTILAGE DEVELOPMENT; INDIAN HEDGEHOG; DIRECT BINDING; MOUSE LIMB; CELL-LINE; C-FOS; CHORDIN	Twisted gastrulation (TSG) is an extracellular modulator of bone morphogenetic protein (BMP) activity and regulates dorsoventral axis formation in early Drosophila and Xenopus development. Studies on tsg-deficient mice also indicated a role of this protein in skeletal growth, but the mechanism of TSG activity in this process has not yet been investigated. Here we show for the first time by in situ hybridization and immunohistochemistry that TSG is strongly expressed in bovine and mouse growth plate cartilage as well as in fetal ribs, vertebral cartilage, and cartilage anlagen of the skull. Furthermore we provide evidence that TSG is directly involved in BMP-regulated chondrocyte differentiation and maturation. In vitro, TSG impaired the dose-dependent BMP-2 stimulation of collagen II and X expression in cultures of MC615 chondrocytes and primary mouse chondrocytes. In the presence of chordin, a BMP antagonist, the inhibitory effect of TSG was further enhanced. TSG also inhibited BMP2-stimulated phosphorylation of Smad factors in chondrocytes, confirming the role of TSG as a modulator of BMP signaling. For analysis of TSG functions in cartilage development in vivo, the gene was overexpressed in transgenic mice under the control of the cartilage-specific Col2a1 promoter. As a result, Col10a1 expression was significantly reduced in the growth plates of transgenic embryos and newborns in comparison with wild type littermates as shown by in situ hybridization and by real time PCR analysis. The data suggest that TSG is an important modulator of BMP-regulated cartilage development and chondrocyte differentiation.	Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Dept Expt Med 1, D-91054 Erlangen, Germany; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Erlangen Nuremberg; University of Texas System; UTMD Anderson Cancer Center	von der Mark, K (corresponding author), Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Dept Expt Med 1, Glueckstr 6, D-91054 Erlangen, Germany.	kvdmark@molmed.uni-erlangen.de	Stock, Michael/B-9829-2009; Surmann-Schmitt, Cordula/B-9792-2009; von+der+Mark, Klaus/AAJ-1443-2020	Stock, Michael/0000-0002-3322-0961	NIAMS NIH HHS [P01 AR042919] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Blitz IL, 2003, DEVELOPMENT, V130, P4975, DOI 10.1242/dev.00709; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87; Chang CB, 2001, NATURE, V410, P483, DOI 10.1038/35068583; CHEN P, 1991, EXP CELL RES, V195, P509, DOI 10.1016/0014-4827(91)90403-H; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dietz UH, 1999, DEV DYNAM, V216, P233, DOI 10.1002/(SICI)1097-0177(199911)216:3<233::AID-DVDY2>3.0.CO;2-G; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; Enomoto-Iwamoto M, 1998, J CELL BIOL, V140, P409, DOI 10.1083/jcb.140.2.409; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Gazzerro E, 2005, ENDOCRINOLOGY, V146, P3875, DOI 10.1210/en.2005-0053; Gebhard S, 2004, MATRIX BIOL, V23, P309, DOI 10.1016/j.matbio.2004.05.010; Grimsrud CD, 2001, J ORTHOPAED RES, V19, P18, DOI 10.1016/S0736-0266(00)00017-6; Harland RM, 2001, NATURE, V410, P423, DOI 10.1038/35068657; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Jones CM, 1998, DEV BIOL, V194, P12, DOI 10.1006/dbio.1997.8752; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Katagiri T, 1998, DEV GENET, V22, P340, DOI 10.1002/(SICI)1520-6408(1998)22:4<340::AID-DVG4>3.0.CO;2-6; KIRSCH T, 1991, EUR J BIOCHEM, V196, P575, DOI 10.1111/j.1432-1033.1991.tb15852.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larrain J, 2001, DEVELOPMENT, V128, P4439; Larrain J, 2000, DEVELOPMENT, V127, P821; MALLEINGERIN F, 1993, P NATL ACAD SCI USA, V90, P3289, DOI 10.1073/pnas.90.8.3289; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; Millet C, 2001, MECH DEVELOP, V106, P85, DOI 10.1016/S0925-4773(01)00423-3; Minina E, 2001, DEVELOPMENT, V128, P4523; Nakayama N, 2004, DEVELOPMENT, V131, P229, DOI 10.1242/dev.00901; Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; Nosaka T, 2003, MOL CELL BIOL, V23, P2969, DOI 10.1128/MCB.23.8.2969-2980.2003; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; Oelgeschlager M, 2003, DEVELOPMENT, V130, P4047, DOI 10.1242/dev.00633; Ohyama A, 2001, MECH DEVELOP, V100, P331, DOI 10.1016/S0925-4773(00)00525-6; Pathi S, 1999, DEV BIOL, V209, P239, DOI 10.1006/dbio.1998.9181; Petryk A, 2005, BONE, V36, P617, DOI 10.1016/j.bone.2005.01.018; Petryk A, 2004, DEV BIOL, V267, P374, DOI 10.1016/j.ydbio.2003.11.015; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Pizette S, 1999, DEVELOPMENT, V126, P883; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Poschl E, 1996, EMBO J, V15, P5154, DOI 10.1002/j.1460-2075.1996.tb00899.x; Ray RP, 2001, CELL, V104, P801, DOI 10.1016/S0092-8674(01)00275-6; Reddi AH, 2001, ARTHRITIS RES, V3, P1; Riemer S, 2002, J CELL BIOCHEM, V86, P688, DOI 10.1002/jcb.10260; Ross JJ, 2001, NATURE, V410, P479, DOI 10.1038/35068578; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 2000, DEV DYNAM, V217, P449, DOI 10.1002/(SICI)1097-0177(200004)217:4<449::AID-DVDY12>3.0.CO;2-8; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; Thomas DP, 2000, J CELL SCI, V113, P439; Valcourt U, 1999, EXP CELL RES, V251, P264, DOI 10.1006/excr.1999.4584; Volk SW, 1998, J BONE MINER RES, V13, P1521, DOI 10.1359/jbmr.1998.13.10.1521; Wang CKL, 2004, DEV BIOL, V269, P109, DOI 10.1016/j.ydbio.2004.01.016; Weisser A, 2002, EXP CELL RES, V279, P1, DOI 10.1006/excr.2002.5580; Xie J, 2005, DEVELOPMENT, V132, P383, DOI 10.1242/dev.01577; Yi SE, 2000, DEVELOPMENT, V127, P621; Zakin L, 2005, DEVELOPMENT, V132, P2489, DOI 10.1242/dev.01822; Zakin L, 2004, DEVELOPMENT, V131, P413, DOI 10.1242/dev.00946; Zhang DH, 2002, J BONE MINER RES, V17, P293, DOI 10.1359/jbmr.2002.17.2.293; Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089; ZHOU G, 1995, J CELL SCI, V108, P3677; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	72	29	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31790	31800		10.1074/jbc.M603419200	http://dx.doi.org/10.1074/jbc.M603419200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16905550	Bronze			2022-12-25	WOS:000241235300066
J	Uchiyama, S; Shimizu, T; Shirasawa, T				Uchiyama, Satoshi; Shimizu, Takahiko; Shirasawa, Takuji			CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY LIVER-DISEASE; MANGANESE SUPEROXIDE-DISMUTASE; TRIGLYCERIDE TRANSFER PROTEIN; NONALCOHOLIC STEATOHEPATITIS; STRESS; EXPRESSION; INJURY; GENE; ANTIOXIDANTS; PEROXIDATION	Elevated hepatic reactive oxygen species play an important role in pathogenesis of liver diseases, such as alcohol- induced liver injury, hepatitis C virus infection, and nonalcoholic steato-hepatitis. In the present study, we investigated and compared the hepatic lipid metabolisms of liver-specific Sod2 (superoxide dismutase 2) knock-out (Sod2 KO), Sod1 knock-out (Sod1 KO), and Sod1/liver-specific Sod2 double knock- out mice (double KO). We observed significant increases in lipid peroxidation and triglyceride ( TG) in the liver of Sod1 KO and double KO mice but not in the liver of Sod2 KO mice. We also found that high fat diet enhanced fatty changes of the liver in Sod1 KO and double KO mice but not in Sod2 KO mice. These data indicated that CuZn-SOD deficiency caused lipid accumulation in the liver. To investigate the molecular mechanism of hepatic lipid accumulation in CuZn-SOD-deficient mice, we measured TG secretion rate from liver using Triton WR1339. We found significant decrease of TG secretion in CuZn-SOD-deficient mice. Furthermore, we observed marked degradation of apolipoprotein B (apoB) in the liver and plasma of CuZn-SOD-deficient mice, indicating that degradation of apoB impairs secretion of lipoprotein from the liver. Our data suggest that oxidative stress enhances hepatic lipid accumulation by impaired lipoprotein secretion due to the degradation of apoB in liver.	Tokyo Metropolitan Inst Gerontol, Res Team Mol Biomarkers, Itabashi Ku, Tokyo 1730015, Japan; Tokyo Univ Agr & Technol, United Grad Sch Agr Sci, Fuchu, Tokyo 1838509, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Tokyo 1138421, Japan; Anti Aging Sci Inc, Tokyo 1000011, Japan	Tokyo Metropolitan Institute of Gerontology; Tokyo University of Agriculture & Technology; Tokyo Metropolitan University	Shirasawa, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Res Team Mol Biomarkers, Itabashi Ku, Tokyo 1730015, Japan.	sirasawa@tmig.or.jp						Adams LA, 2005, CAN MED ASSOC J, V172, P899, DOI 10.1503/cmaj.045232; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Busuttil RA, 2005, CANCER RES, V65, P11271, DOI 10.1158/0008-5472.CAN-05-2980; Charlton N, 2002, HEPATOLOGY, V35, P898, DOI 10.1053/jhep.2002.32527; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; FONG LG, 1987, J LIPID RES, V28, P1466; Hashimoto R, 2000, BBA-MOL CELL BIOL L, V1483, P236, DOI 10.1016/S1388-1981(99)00167-5; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Ikegami T, 2002, BIOCHEM BIOPH RES CO, V296, P729, DOI 10.1016/S0006-291X(02)00933-6; Kaplowitz N, 2006, HEPATOLOGY, V43, pS235, DOI 10.1002/hep.20958; Kessova IG, 2003, HEPATOLOGY, V38, P1136, DOI 10.1053/jhep.2003.50450; Laurent A, 2004, HEPATOLOGY, V39, P1277, DOI 10.1002/hep.20177; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liao W, 2003, J LIPID RES, V44, P978, DOI 10.1194/jlr.M300020-JLR200; Musso G, 2003, HEPATOLOGY, V37, P909, DOI 10.1053/jhep.2003.50132; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724; Pan MH, 2004, J CLIN INVEST, V113, P1277, DOI 10.1172/JCI200419197; Portincasa P, 2005, CLIN BIOCHEM, V38, P203, DOI 10.1016/j.clinbiochem.2004.10.014; Sanyal AJ, 2005, NAT CLIN PRACT GASTR, V2, P46, DOI 10.1038/ncpgasthep0084; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Videla LA, 2004, CLIN SCI, V106, P261, DOI 10.1042/CS20030285; Weltman MD, 1998, HEPATOLOGY, V27, P128, DOI 10.1002/hep.510270121; Xia XG, 2006, PLOS GENET, V2, P73, DOI 10.1371/journal.pgen.0020010; Xian-Cheng J, 2005, J BIOL CHEM, V280, P18336, DOI 10.1074/jbc.M500007200; Yesilova Z, 2005, AM J GASTROENTEROL, V100, P850, DOI 10.1111/j.1572-0241.2005.41500.x; Yu Andy S, 2002, Rev Gastroenterol Disord, V2, P11; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X	31	116	120	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31713	31719		10.1074/jbc.M603422200	http://dx.doi.org/10.1074/jbc.M603422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16921198	Bronze			2022-12-25	WOS:000241235300057
J	Hahn, JY; Cho, HJ; Bae, JW; Yuk, HS; Kim, KI; Park, KW; Koo, BK; Chae, IH; Shin, CS; Oh, BH; Choi, YS; Park, YB; Kim, HS				Hahn, Joo-Yong; Cho, Hyun-Ju; Bae, Jang-Whan; Yuk, Hyung-Sun; Kim, Kwang-Il; Park, Kyung-Woo; Koo, Bon-Kown; Chae, In-Ho; Shin, Chan-Soo; Oh, Byung-Hee; Choi, Yun-Shik; Park, Young-Bae; Kim, Hyo-Soo			beta-Catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; SURVIVIN EXPRESSION; CELL-PROLIFERATION; ENDOTHELIAL-CELL; G(1) CYCLIN; CANCER; ANGIOGENESIS; HYPERTROPHY; INHIBITION; APOPTOSIS	beta-Catenin is a transcriptional regulator of several genes involved in survival and proliferation. Although previous studies suggest that beta-catenin may be involved in the process of preconditioning and healing after myocardial infarction (MI),little is known regarding the role of beta-catenin in cardiomyocytes and cardiac fibroblasts. We investigated the role of beta-catenin in cardiomyocytes and cardiac fibroblasts and whether beta-catenin overexpression could reduce MI size. Adenovirus-mediated gene transfer of nonphosphorylatable constitutively active beta-catenin (Ad-catenin) decreased apoptosis in cardiomyocytes and cardiac fibroblasts with increased expression of survivin and Bcl-2. Although Ad-catenin increased the percentage of cells in the S phase with enhanced expression of cyclin D1 and E2 in both cell types, the increase in cell number was only evident in cardiac fibroblasts, whereas hypertrophy and binuclear cells were more prominent in cardiomyocytes. All of these effects of beta-catenin gene transfer were blocked by inhibition of its nuclear translocation. Furthermore, Ad-catenin enhanced the expression of vascular endothelial growth factor in both cells and induced differentiation of cardiac fibroblasts into myofibroblasts. In a rat MI model, injection of Ad-catenin into the infarct border zone resulted in a significantly decreased MI size with anti-apoptotic effect and cell cycle activation in both cardiomyocytes and myofibroblasts. beta-Catenin may play an important role in the healing process after MI by promoting survival and cell cycle not only in cardiomyocytes but also in cardiac fibroblasts with its differentiation into myofibroblasts.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Natl Res Lab Cardiovasc Stem Cell, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Hormone Res Ctr, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital	Kim, HS (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea.	hyosoo@snu.ac.kr	Chae, In-Ho/J-5682-2012; Kim, Hyo Soo/J-2753-2012; Park, Young-Bae/J-5490-2012; Shin, Chan Soo/I-7320-2012; Hahn, Joo-Yong/AAU-7250-2020; Kim, Kwang-il/D-8024-2012; Oh, Byung-Hee/G-9875-2011; Koo, Bon-Kwon/J-5374-2012; Kim, Kwang-il/AAP-7315-2021; Park, Kyung Woo/AAX-3046-2020	Shin, Chan Soo/0000-0002-5829-4465; Hahn, Joo-Yong/0000-0002-4412-377X; Kim, Kwang-il/0000-0002-6658-047X; Oh, Byung-Hee/0000-0002-9945-4306; Kim, Kwang-il/0000-0002-6658-047X; 				Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Barandon L, 2005, CIRC RES, V96, P1299, DOI 10.1161/01.RES.0000171895.06914.2c; Barandon L, 2003, CIRCULATION, V108, P2282, DOI 10.1161/01.CIR.0000093186.22847.4C; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Bergmann MW, 2004, J MOL CELL CARDIOL, V37, P681, DOI 10.1016/j.yjmcc.2004.05.025; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cho HJ, 2005, ARTERIOSCL THROM VAS, V25, P1154, DOI 10.1161/01.ATV.0000164312.20008.93; Choi JH, 2004, J BIOL CHEM, V279, P49430, DOI 10.1074/jbc.M402088200; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Gudas JM, 1999, MOL CELL BIOL, V19, P612; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Hayakawa K, 2003, CIRCULATION, V108, P104, DOI 10.1161/01.CIR.0000074225.62168.68; Kaga S, 2006, J MOL CELL CARDIOL, V40, P138, DOI 10.1016/j.yjmcc.2005.09.009; Kim KI, 2006, ARTERIOSCL THROM VAS, V26, P91, DOI 10.1161/01.ATV.0000193569.12490.4b; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Li FQ, 1997, J MOL CELL CARDIOL, V29, P1553, DOI 10.1006/jmcc.1997.0403; Masszi A, 2004, AM J PATHOL, V165, P1955, DOI 10.1016/S0002-9440(10)63247-6; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Park KW, 2003, ARTERIOSCL THROM VAS, V23, P1364, DOI 10.1161/01.ATV.0000081633.53390.B4; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Santini D, 2004, J CLIN PATHOL, V57, P1321, DOI 10.1136/jcp.2004.018986; Shin CS, 2005, J BONE MINER RES, V20, P2200, DOI 10.1359/JBMR.050809; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55; Yang HM, 2004, CIRCULATION, V110, P301, DOI 10.1161/01.CIR.0000135467.43430.16; Youn TJ, 2002, EUR J HEART FAIL, V4, P713, DOI 10.1016/S1388-9842(02)00120-4; Young CS, 2003, DIFFERENTIATION, V71, P477, DOI 10.1046/j.1432-0436.2003.7108002.x; Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601	36	98	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30979	30989		10.1074/jbc.M603916200	http://dx.doi.org/10.1074/jbc.M603916200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16920707	hybrid			2022-12-25	WOS:000241075900074
J	Iskander, K; Li, J; Han, SH; Zheng, B; Jaiswal, AK				Iskander, Karim; Li, Jessica; Han, Shuhua; Zheng, Biao; Jaiswal, Anil K.			NQO1 and NQO2 regulation of humoral immunity and autoimmunity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H-QUINONE OXIDOREDUCTASE-1 NQO1; DT-DIAPHORASE; PROTEASOMAL DEGRADATION; B-CELLS; GENE; MICE; POLYMORPHISM; DISRUPTION; EXPRESSION; APOPTOSIS	NAD(P) H: quinone oxidoreductase 1 (NQO1)and NRH: quinone oxidoreductase 2 (NQO2) are cytosolic enzymes that catalyze metabolic reduction of quinones and derivatives. NQO1-null and NQO2-null mice were generated that showed decreased lymphocytes in peripheral blood, myeloid hyperplasia, and increased sensitivity to skin carcinogenesis. In this report, we investigated the in vivo role of NQO1 and NQO2 in immune response and autoimmunity. Both NQO1-null and NQO2-null mice showed decreased B-cells in blood, lower germinal center response, altered B cell homing, and impaired primary and secondary immune responses. NQO1-null and NQO2-null mice also showed susceptibility to autoimmune disease as revealed by decreased apoptosis in thymocytes and predisposition to collagen-induced arthritis. Further experiments showed accumulation of NADH and NRH, cofactors for NQO1 and NQO2, indicating altered intracellular redox status. The studies also demonstrated decreased expression and lack of activation of immune-related factor NF-kappa B. Microarray analysis showed altered chemokines and chemokine receptors. These results suggest that the loss of NQO1 and NQO2 leads to altered intracellular redox status, decreased expression and activation of NF-kappa B, and altered chemokines. The results led to the conclusion that NQO1 and NQO2 are endogenous factors in the regulation of immune response and autoimmunity.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	ajaiswal@bcm.tmc.edu			NIEHS NIH HHS [R01 ES07943] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007943] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Carter RH, 2006, MAYO CLIN PROC, V81, P377, DOI 10.4065/81.3.377; Choi Y, 1999, CLIN IMMUNOL, V93, P34, DOI 10.1006/clim.1999.4767; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Corcoran LM, 2005, CURR TOP MICROBIOL, V290, P105; De Silva S, 2005, ARTHRITIS RHEUM-US, V52, P333, DOI 10.1002/art.20736; DHAKSHINAMOORTH.S, 2005, J BIOL CHEM, V279, P50810; Fleisher TA, 2004, J ALLERGY CLIN IMMUN, V114, P227, DOI 10.1016/j.jaci.2004.06.001; Gaikwad A, 2001, J BIOL CHEM, V276, P22559, DOI 10.1074/jbc.M101053200; Iskander K, 2005, CANCER RES, V65, P2054, DOI 10.1158/0008-5472.CAN-04-3157; Iskander K, 2004, CANCER RES, V64, P5925, DOI 10.1158/0008-5472.CAN-04-0763; Iskander K, 2005, CHEM-BIOL INTERACT, V153, P147, DOI 10.1016/j.cbi.2005.03.019; Kabe Y, 2005, ANTIOXID REDOX SIGN, V7, P395, DOI 10.1089/ars.2005.7.395; Kato Y, 1997, CELL IMMUNOL, V177, P103, DOI 10.1006/cimm.1997.1103; Kelsey KT, 1997, BRIT J CANCER, V76, P852, DOI 10.1038/bjc.1997.474; KLAIDMAN LK, ANAL BIOCH, V228, P312; LAZZARINO G, 1989, ANAL BIOCHEM, V181, P239, DOI 10.1016/0003-2697(89)90236-4; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2002, CANCER RES, V62, P3030; Long DJ, 2002, J BIOL CHEM, V277, P46131, DOI 10.1074/jbc.M208675200; Mahoney JA, 2005, CURR OPIN IMMUNOL, V17, P583, DOI 10.1016/j.coi.2005.09.018; Nakken B, 2003, SCAND J IMMUNOL, V58, P478, DOI 10.1046/j.1365-3083.2003.01323.x; Nie YC, 2004, J EXP MED, V200, P1145, DOI 10.1084/jem.20041185; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Ross D, 2004, METHOD ENZYMOL, V382, P115; ROSVOLD EA, 1995, PHARMACOGENETICS, V5, P199, DOI 10.1097/00008571-199508000-00003; Schulz WA, 1998, PHARMACOGENETICS, V8, P453, DOI 10.1097/00008571-199810000-00011; Siegel D, 1999, PHARMACOGENETICS, V9, P113, DOI 10.1097/00008571-199902000-00015; Siegel D, 2001, MOL PHARMACOL, V59, P263, DOI 10.1124/mol.59.2.263; Sneller MC, 1997, BLOOD, V89, P1341, DOI 10.1182/blood.V89.4.1341; TRAVER RD, 1992, CANCER RES, V52, P797; Viau M, 2005, CLIN IMMUNOL, V114, P17, DOI 10.1016/j.clim.2004.08.019; Wang XW, 2006, P NATL ACAD SCI USA, V103, P4204, DOI 10.1073/pnas.0507044103; Wiencke JK, 1997, CANCER EPIDEM BIOMAR, V6, P87; Yokochi T, 1996, FEMS IMMUNOL MED MIC, V15, P1; Zheng B, 2003, J IMMUNOL, V171, P4979, DOI 10.4049/jimmunol.171.10.4979	36	60	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30917	30924		10.1074/jbc.M605809200	http://dx.doi.org/10.1074/jbc.M605809200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16905546	hybrid			2022-12-25	WOS:000241075900067
J	Kawano, M; Kumagai, K; Nishijima, M; Hanada, K				Kawano, Miyuki; Kumagai, Keigo; Nishijima, Masahiro; Hanada, Kentaro			Efficient trafficking of ceramide from the endoplasmic reticulum to the Golgi apparatus requires a VAMP-associated protein-interacting FFAT motif of CERT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; HAMSTER OVARY CELLS; MEMBRANE-PROTEIN; SPHINGOMYELIN SYNTHESIS; SERINE PALMITOYLTRANSFERASE; GOODPASTURE ANTIGEN; MOLECULAR MACHINERY; RAT-LIVER; VAP-A; COMPLEX	Ceramide is synthesized at the endoplasmic reticulum ( ER) and transported to the Golgi apparatus by CERT for its conversion to sphingomyelin in mammalian cells. CERT has a pleckstrin homology (PH) domain for Golgi targeting and a START domain catalyzing the intermembrane transfer of ceramide. The region between the two domains contains a short peptide motif designated FFAT, which is supposed to interact with the ER-resident proteins VAP-A and VAP-B. Both VAPs were actually co-immunoprecipitated with CERT, and the CERT/VAP interaction was abolished by mutations in the FFAT motif. These mutations did not affect the Golgi targeting activity of CERT. Whereas mutations of neither the FFAT motif nor the PH domain inhibited the ceramide transfer activity of CERT in a cell-free system, they impaired the ER-to-Golgi transport of ceramide in intact and in semi-intact cells at near endogenous expression levels. By contrast, when overexpressed, both the FFAT motif and the PH domain mutants of CERT substantially supported the transport of ceramide from the ER to the site where sphingomyelin is produced. These results suggest that the Golgi-targeting PH domain and ER-interacting FFAT motif of CERT spatially restrict the random ceramide transfer activity of the START domain in cells.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Natl Inst Infect Dis, CREST, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID); Japan Science & Technology Agency (JST); National Institute of Infectious Diseases (NIID)	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	hanak@nih.go.jp	Kumagai, Keigo/AAG-1385-2021	KAWANO-KAWADA, Miyuki/0000-0002-1168-9291; Kumagai, Keigo/0000-0002-1663-2905; Hanada, Kentaro/0000-0003-1383-2781				Amarilio R, 2005, J BIOL CHEM, V280, P5934, DOI 10.1074/jbc.M409566200; Ardail D, 2003, BIOCHEM J, V371, P1013, DOI 10.1042/BJ20021834; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Ettayebi K, 2003, J VIROL, V77, P11790, DOI 10.1128/JVI.77.21.11790-11797.2003; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Funakoshi T, 2000, J BIOL CHEM, V275, P29938, DOI 10.1074/jbc.M004470200; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Gao L, 2004, J VIROL, V78, P3480, DOI 10.1128/JVI.78.7.3480-3488.2004; Hamamoto I, 2005, J VIROL, V79, P13473, DOI 10.1128/JVI.79.21.13473-13482.2005; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; HANADA K, 1990, J BIOL CHEM, V265, P22137; Hanada K, 2006, MOL CELL BIOCHEM, V286, P23, DOI 10.1007/s11010-005-9044-z; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Kagiwada S, 1998, J BACTERIOL, V180, P1700, DOI 10.1128/JB.180.7.1700-1708.1998; Kumagai K, 2005, J BIOL CHEM, V280, P6488, DOI 10.1074/jbc.M409290200; Lagace TA, 1999, J LIPID RES, V40, P109; Lapierre LA, 1999, J CELL SCI, V112, P3723; Lehto M, 2003, BBA-MOL CELL BIOL L, V1631, P1, DOI 10.1016/S1388-1981(02)00364-5; Lev S, 2004, EXP CELL RES, V297, P1, DOI 10.1016/j.yexcr.2004.02.033; Levine T, 2004, TRENDS CELL BIOL, V14, P483, DOI 10.1016/j.tcb.2004.07.017; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Litvak V, 2005, NAT CELL BIOL, V7, P225, DOI 10.1038/ncb1221; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Mogelsvang S, 2004, TRAFFIC, V5, P338, DOI 10.1111/j.1398-9219.2004.00186.x; Nishimura Y, 1999, BIOCHEM BIOPH RES CO, V254, P21, DOI 10.1006/bbrc.1998.9876; Perry RJ, 2006, MOL BIOL CELL, V17, P2604, DOI 10.1091/mbc.E06-01-0060; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Raya A, 1999, J BIOL CHEM, V274, P12642, DOI 10.1074/jbc.274.18.12642; Raya A, 2000, J BIOL CHEM, V275, P40392, DOI 10.1074/jbc.M002769200; RIDGWAY ND, 1995, J LIPID RES, V36, P1345; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; Skehel PA, 2000, P NATL ACAD SCI USA, V97, P1101, DOI 10.1073/pnas.97.3.1101; Soussan L, 1999, J CELL BIOL, V146, P301, DOI 10.1083/jcb.146.2.301; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Wang PY, 2005, SCIENCE, V307, P1472, DOI 10.1126/science.1107710; Weir ML, 1998, BIOCHEM J, V333, P247, DOI 10.1042/bj3330247; Wyles JP, 2002, J BIOL CHEM, V277, P29908, DOI 10.1074/jbc.M201191200; Wyles JP, 2004, EXP CELL RES, V297, P533, DOI 10.1016/j.yexcr.2004.03.052; Yasuda S, 2003, J BIOL CHEM, V278, P4176, DOI 10.1074/jbc.M209602200	44	220	227	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30279	30288		10.1074/jbc.M605032200	http://dx.doi.org/10.1074/jbc.M605032200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16895911	hybrid			2022-12-25	WOS:000240896300088
J	McCormick, J; Barry, SP; Sivarajah, A; Stefanutti, G; Townsend, PA; Lawrence, KM; Eaton, S; Knight, RA; Thiemermann, C; Latchman, DS; Stephanou, A				McCormick, James; Barry, Sean P.; Sivarajah, Ahila; Stefanutti, Giorgio; Townsend, Paul A.; Lawrence, Kevin M.; Eaton, Simon; Knight, Richard A.; Thiemermann, Christoph; Latchman, David S.; Stephanou, Anastasis			Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury	FASEB JOURNAL			English	Article						tempol; heart; rat	CARDIAC MYOCYTES; INDUCED APOPTOSIS; ISCHEMIA; EXPRESSION; INDUCTION; PROTECTS; PATHWAY; ATM	The signal transducer and activator of transcription (STAT) family are latent transcription factors involved in a variety of signal transduction pathways, including cell death cascades. STAT1 has been shown to have a crucial role in regulating cardiac cell apoptosis in the myocardium exposed to ischemia/reperfusion (I/R) injury. The free radical scavenger, tempol, is known to have cardioprotective properties, although little is known about the molecular mechanism(s) by which it acts. In the present study, we assessed the levels of phosphorylated STAT1 and STAT3 and examined whether tempol was able to affect STAT activation after in vivo cardiac I/R injury. We observed a reperfusion time-dependent increase in the tyrosine phosphorylation of STAT1 and STAT3 at residues 701 and 705, respectively. Here we show for the first time that tempol dramatically reduced STAT1 and 3 phosphorylation. The reduction in STAT1 and 3 phosphorylation was accompanied by a concomitant decrease in cellular malondialdehyde (MDA) levels. To verify the role of STAT1 in modulating the cardioprotective effect of tempol, rats were injected with the STAT1 activator, IFN-gamma, and tempol during I/R injury. We found that the presence of IFN-gamma abrogated the protective effects of tempol, suggesting that the protective effects of tempol may partly operate by decreasing the phosphorylation of STAT1. This study demonstrates that careful dissection of the molecular mechanisms that underpin I/R injury may reveal cardioprotective targets for future therapy.	UCL, Inst Child Hlth, Dept Med Mol Biol, London WC1N 1EH, England; UCL, Inst Child Hlth, Dept Surg, London WC1N 1EH, England; Queen Mary Univ London, Ctr Expt Med Nephrol & Crit Care, William Harvey Res Inst, St Bartholomews & Royal London Sch Med & Dent, London E1 4NS, England; Univ Southampton, Southampton Gen Hosp, Div Human Genet, Southampton, Hants, England	University of London; University College London; University of London; University College London; University of London; Queen Mary University London; University of Southampton	Stephanou, A (corresponding author), UCL, Inst Child Hlth, Dept Med Mol Biol, 30 Guilford St, London WC1N 1EH, England.	a.stephanou@ich.ucl.ac.uk	Eaton, Simon/C-4942-2008; Townsend, Paul/AAF-8234-2020	Eaton, Simon/0000-0003-0892-9204; Thiemermann, Christoph/0000-0003-4228-9722; Townsend, Paul/0000-0001-8956-9508				Decker T, 2002, J CLIN INVEST, V109, P1271, DOI 10.1172/JCI200215770; Eefting F, 2004, CARDIOVASC RES, V61, P414, DOI 10.1016/j.cardiores.2003.12.023; FLAHERTY JT, 1991, AM J MED S3C, V91, P79; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Hilfiker-Kleiner D, 2004, CIRC RES, V95, P187, DOI 10.1161/01.RES.0000134921.50377.61; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; Maxwell SRJ, 1997, INT J CARDIOL, V58, P95, DOI 10.1016/S0167-5273(96)02854-9; McDonald MC, 1999, FREE RADICAL BIO MED, V27, P493, DOI 10.1016/S0891-5849(99)00100-8; Menegazzi M, 2001, FASEB J, V15, P1309, DOI 10.1096/fj.00-0519fje; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Scarabelli TM, 2002, CIRC RES, V90, P745, DOI 10.1161/01.RES.0000015224.07870.9A; Shen YH, 2005, BIOCHEM BIOPH RES CO, V330, P305, DOI 10.1016/j.bbrc.2005.02.154; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Stefanutti G, 2005, SHOCK, V24, P159, DOI 10.1097/01.shk.0000168871.60531.6f; Stephanou A, 2004, J CELL MOL MED, V8, P519, DOI 10.1111/j.1582-4934.2004.tb00476.x; Stephanou A, 2002, FASEB J, V16, P1841, DOI 10.1096/fj.02-0150fje; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Stephanou A, 2001, CELL DEATH DIFFER, V8, P434, DOI 10.1038/sj.cdd.4400846; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Townsend PA, 2005, J CELL SCI, V118, P1629, DOI 10.1242/jcs.01728; Townsend PA, 2004, FASEB J, V18, P1612, DOI 10.1096/fj.04-1716fje	25	61	62	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2115	+		10.1096/fj.06-6188fje	http://dx.doi.org/10.1096/fj.06-6188fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935931				2022-12-25	WOS:000241156900021
J	Kahn, TG; Schwartz, YB; Dellino, GI; Pirrotta, V				Kahn, Tatyana G.; Schwartz, Yuri B.; Dellino, Gaetano I.; Pirrotta, Vincenzo			Polycomb complexes and the propagation of the methylation mark at the Drosophila Ubx gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE METHYLTRANSFERASE ACTIVITY; H3 LYSINE 9; RESPONSE ELEMENT; GAGA FACTOR; CHROMATIN COMPLEXES; BINDING-SITES; ENHANCER; HP1; MAINTENANCE; REQUIRES	Polycomb group proteins are transcriptional repressors that control many developmental genes. The Polycomb group protein Enhancer of Zeste has been shown in vitro to methylate specifically lysine 27 and lysine 9 of histone H3 but the role of this modification in Polycomb silencing is unknown. We show that H3 trimethylated at lysine 27 is found on the entire Ubx gene silenced by Polycomb. However, Enhancer of Zeste and other Polycomb group proteins stay primarily localized at their response elements, which appear to be the least methylated parts of the silenced gene. Our results suggest that, contrary to the prevailing view, the Polycomb group proteins and methyltransferase complexes are recruited to the Polycomb response elements independently of histone methylation and then loop over to scan the entire region, methylating all accessible nucleosomes. We propose that the Polycomb chromodomain is required for the looping mechanism that spreads methylation over a broad domain, which in turn is required for the stability of the Polycomb group protein complex. Both the spread of methylation from the Polycomb response elements, and the silencing effect can be blocked by the gypsy insulator.	Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Labs, Piscataway, NJ 08854 USA; Univ Geneva, Dept Zool, CH-1211 Geneva, Switzerland	Rutgers State University New Brunswick; University of Geneva	Pirrotta, V (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Labs, 604 Allison Rd, Piscataway, NJ 08854 USA.	pirrotta@biology.rutgers.edu	Dellino, Gaetano Ivan/AAF-6405-2020	DELLINO, GAETANO IVAN/0000-0002-8673-4560				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Busturia A, 2001, DEVELOPMENT, V128, P2163; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHIANG A, 1995, DEVELOPMENT, V121, P1681; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; DECOCK JGR, 1991, NUCLEIC ACIDS RES, V19, P3289, DOI 10.1093/nar/19.12.3289; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Ebert A, 2004, GENE DEV, V18, P2973, DOI 10.1101/gad.323004; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Gelbart W, 2003, NUCLEIC ACIDS RES, V31, P172, DOI 10.1093/nar/gkg094; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Mallin DR, 1998, GENETICS, V148, P331; Mishra RK, 2001, MOL CELL BIOL, V21, P1311, DOI 10.1128/MCB.21.4.1311-1318.2001; Morillon A, 2005, MOL CELL, V18, P723, DOI 10.1016/j.molcel.2005.05.009; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Ng J, 2000, MOL CELL BIOL, V20, P3069, DOI 10.1128/MCB.20.9.3069-3078.2000; Papp B, 2006, GENE DEV, V20, P2041, DOI 10.1101/gad.388706; Peirson SN, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng073; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; PIRROTTA V, 1996, EPIGENETIC MECH GENE, P489; Poux S, 2001, DEVELOPMENT, V128, P75; QIAN S, 1993, EMBO J, V12, P3865, DOI 10.1002/j.1460-2075.1993.tb06065.x; Rastegar M, 2004, MOL CELL BIOL, V24, P8090, DOI 10.1128/MCB.24.18.8090-8103.2004; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015; Ringrose L, 2003, DEV CELL, V5, P759, DOI 10.1016/S1534-5807(03)00337-X; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Schwartz YB, 2005, MOL CELL BIOL, V25, P432, DOI 10.1128/MCB.25.1.432-439.2005; Schwartz YB, 2006, NAT GENET, V38, P700, DOI 10.1038/ng1817; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; SHOPLAND LS, 1995, GENE DEV, V9, P2756, DOI 10.1101/gad.9.22.2756; Sigrist CJA, 1997, GENETICS, V147, P209; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Tie F, 2003, MOL CELL BIOL, V23, P3352, DOI 10.1128/MCB.23.9.3352-3362.2003; Tie F, 2001, DEVELOPMENT, V128, P275; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511	50	77	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29064	29075		10.1074/jbc.M605430200	http://dx.doi.org/10.1074/jbc.M605430200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16887811	hybrid			2022-12-25	WOS:000240680500061
J	Korotkova, N; Cota, E; Lebedin, Y; Monpouet, S; Guignot, J; Servin, AL; Matthews, S; Moseley, SL				Korotkova, Natalia; Cota, Ernesto; Lebedin, Yuri; Monpouet, Severine; Guignot, Julie; Servin, Alain L.; Matthews, Steve; Moseley, Steve L.			A subfamily of Dr adhesins of Escherichia coli bind independently to decay-accelerating factor and the N-domain of carcinoembryonic antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-REACTING ANTIGEN; NONTYPABLE HAEMOPHILUS-INFLUENZAE; AFA-3 GENE-CLUSTER; NEISSERIA-GONORRHOEAE; CEA FAMILY; CELLULAR ADHESION; EPITHELIAL-CELLS; PICHIA-PASTORIS; TYPE-1 FIMBRIAE; TERMINAL DOMAIN	Escherichia coli expressing the Dr family of adhesins adheres to epithelial cells by binding to decay-accelerating factor (DAF) and carcinoembryonic antigen (CEA)-related cell surface proteins. The attachment of bacteria expressing Dr adhesins toDAF induces clustering of DAF around bacterial cells and also recruitment of CEA-related cell adhesion molecules. CEA, CEACAM1, and CEACAM6 have been shown to serve as receptors for some Dr adhesins (AfaE-I, AfaE-III, DraE, and DaaE). We demonstrate that AfaE-I, AfaE-V, DraE, and DaaE adhesins bind to the N-domain of CEA. To identify the residues involved in the N-CEA/DraE interaction, we performed SPR binding analyses of naturally occurring variants and a number of randomly generated mutants in DraE and N-CEA. Additionally, we used chemical shift mapping by NMR to determine the surface of DraE involved in N-CEA binding. These results show a distinct CEA binding site located primarily in the A, B, E, and D strands of the Dr adhesin. Interestingly, this site is located opposite to the beta-sheet encompassing the previously determined binding site for DAF, which implies that the adhesin can bind simultaneously to both receptors on the epithelial cell surface. The recognition of CEACAMs from a highly diverse DrCEA subfamily of Dr adhesins indicates that interaction with these receptors plays an important role in niche adaptation of E. coli strains expressing Dr adhesins.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England; Xema Medica Co, Moscow 105043, Russia; INSERM, U756, Fac Pharm, F-92296 Chatenay Malabry, France	University of Washington; University of Washington Seattle; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Moseley, SL (corresponding author), Univ Washington, Dept Microbiol, Box 957242, Seattle, WA 98195 USA.	moseley@u.washington.edu	Cota, Ernesto/A-5292-2009	Korotkova, Natalia/0000-0002-8696-4892; Guignot, Julie/0000-0001-8890-4028; Matthews, Steve/0000-0003-0676-0927	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064229] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-064229, R01 DK064229] Funding Source: Medline; Wellcome Trust [079819] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson KL, 2004, MOL CELL, V15, P647, DOI 10.1016/j.molcel.2004.08.003; Berger CN, 2004, MOL MICROBIOL, V52, P963, DOI 10.1111/j.1365-2958.2004.04033.x; Boehm MK, 1996, J MOL BIOL, V259, P718, DOI 10.1006/jmbi.1996.0353; Bos MP, 1999, J EXP MED, V190, P331, DOI 10.1084/jem.190.3.331; Bos MP, 1998, P NATL ACAD SCI USA, V95, P9584, DOI 10.1073/pnas.95.16.9584; Carnoy C, 1997, MOL MICROBIOL, V23, P365, DOI 10.1046/j.1365-2958.1997.2231590.x; Das M, 2005, INFECT IMMUN, V73, P6119, DOI 10.1128/IAI.73.9.6119-6126.2005; FOXMAN B, 1995, J INFECT DIS, V172, P1536, DOI 10.1093/infdis/172.6.1536; Garcia MI, 1996, MOL MICROBIOL, V19, P683, DOI 10.1046/j.1365-2958.1996.394935.x; Gray-Owen SD, 2003, SCAND J INFECT DIS, V35, P614, DOI 10.1080/00365540310016042; Guignot J, 2000, INFECT IMMUN, V68, P3554, DOI 10.1128/IAI.68.6.3554-3563.2000; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; HEFTA LJF, 1992, CANCER RES, V52, P5647; Hellwig S, 1999, BIOTECHNOL APPL BIOC, V30, P267; Hill DJ, 2003, MOL MICROBIOL, V48, P117, DOI 10.1046/j.1365-2958.2003.03433.x; Hill DJ, 2001, MOL MICROBIOL, V39, P850, DOI 10.1046/j.1365-2958.2001.02233.x; Hunter I, 1996, BIOCHEM J, V320, P847, DOI 10.1042/bj3200847; Jouve M, 1997, INFECT IMMUN, V65, P4082, DOI 10.1128/IAI.65.10.4082-4089.1997; Kansau I, 2004, INFECT IMMUN, V72, P3733, DOI 10.1128/IAI.72.7.3733-3742.2004; KODERA Y, 1993, BRIT J CANCER, V68, P130, DOI 10.1038/bjc.1993.300; Krop-Watorek A, 1998, BIOCHEM BIOPH RES CO, V242, P79, DOI 10.1006/bbrc.1997.7920; LEUSCH HG, 1991, INFECT IMMUN, V59, P2051, DOI 10.1128/IAI.59.6.2051-2057.1991; Maniatis T., 1982, MOL CLONING LAB MANU; Markel G, 2004, J IMMUNOL, V173, P3732, DOI 10.4049/jimmunol.173.6.3732; McCaw SE, 2004, INFECT IMMUN, V72, P2742, DOI 10.1128/IAI.72.5.2742-2752.2004; MEDOF ME, 1987, J EXP MED, V165, P848, DOI 10.1084/jem.165.3.848; Metze D, 1996, J INVEST DERMATOL, V106, P64, DOI 10.1111/1523-1747.ep12327258; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; NOWICKI B, 1990, INFECT IMMUN, V58, P279, DOI 10.1128/IAI.58.1.279-281.1990; NOWICKI B, 1988, INFECT IMMUN, V56, P1057, DOI 10.1128/IAI.56.5.1057-1060.1988; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; Pettigrew D, 2004, J BIOL CHEM, V279, P46851, DOI 10.1074/jbc.M409284200; Plancon L, 2003, CELL MICROBIOL, V5, P681, DOI 10.1046/j.1462-5822.2003.00308.x; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; Prall F, 1996, J HISTOCHEM CYTOCHEM, V44, P35, DOI 10.1177/44.1.8543780; SAUTER SL, 1991, INFECT IMMUN, V59, P2485, DOI 10.1128/IAI.59.7.2485-2493.1991; SAUTER SL, 1993, J BIOL CHEM, V268, P15510; Selvarangan R, 2000, INFECT IMMUN, V68, P1391, DOI 10.1128/IAI.68.3.1391-1399.2000; Servin AL, 2005, CLIN MICROBIOL REV, V18, P264, DOI 10.1128/CMR.18.2.264-292.2005; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Taheri M, 2000, J BIOL CHEM, V275, P26935; Tan KM, 2002, EMBO J, V21, P2076, DOI 10.1093/emboj/21.9.2076; Toleman M, 2001, CELL MICROBIOL, V3, P33, DOI 10.1046/j.1462-5822.2001.00089.x; Van Loy CP, 2002, MOL MICROBIOL, V45, P439; Virji M, 2000, MOL MICROBIOL, V36, P784, DOI 10.1046/j.1365-2958.2000.01885.x; Virji M, 1999, MOL MICROBIOL, V34, P538, DOI 10.1046/j.1365-2958.1999.01620.x; Virji M, 1996, MOL MICROBIOL, V22, P929, DOI 10.1046/j.1365-2958.1996.01548.x; Watt SM, 2001, BLOOD, V98, P1469, DOI 10.1182/blood.V98.5.1469; You YH, 1998, ANTICANCER RES, V18, P3193	49	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29120	29130		10.1074/jbc.M605681200	http://dx.doi.org/10.1074/jbc.M605681200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16882658	Green Accepted, hybrid			2022-12-25	WOS:000240680500066
J	Hunt, MC; Rautanen, A; Westin, MAK; Svensson, LT; Alexson, SEH				Hunt, Mary C.; Rautanen, Anna; Westin, Maria A. K.; Svensson, L. Thomas; Alexson, Stefan E. H.			Analysis of the mouse and human acyl-CoA thioesterase (ACOT) gene clusters shows that convergent, functional evolution results in a reduced number of human peroxisomal ACOTs	FASEB JOURNAL			English	Article						beta-oxidation; acyl-coenzyme A; peroxisome; fatty acids	ACTIVATED RECEPTORS ALPHA; LONG-CHAIN; FATTY-ACIDS; RAT-LIVER; MOLECULAR-CLONING; IDENTIFICATION; ESTERS; INHIBITION; OXIDASE; PROTEIN	The maintenance of cellular levels of free fatty acids and acyl-CoAs, the activated form of free fatty acids, is extremely important, as imbalances in lipid metabolism have serious consequences for human health. Acyl-coenzyme A (CoA) thioesterases (ACOTs) hydrolyze acyl-CoAs to the free fatty acid and CoASH, and thereby have the potential to regulate intracellular levels of these compounds. We previously identified and characterized a mouse ACOT gene cluster comprised of six genes that apparently arose by gene duplications encoding acyl-CoA thioesterases with localizations in cytosol (ACOT1), mitochondria (ACOT2), and peroxisomes (ACOT3 - 6). However, the corresponding human gene cluster contains only three genes (ACOT1, ACOT2, and ACOT4) coding for full-length thioesterase proteins, of which only one is peroxisomal (ACOT4). We therefore set out to characterize the human genes, and we show here that the human ACOT4 protein catalyzes the activities of three mouse peroxisomal ACOTs (ACOT3, 4, and 5), being active on succinyl-CoA and medium to long chain acyl-CoAs, while ACOT1 and ACOT2 carry out similar functions to the corresponding mouse genes. These data strongly suggest that the human ACOT4 gene has acquired the functions of three mouse genes by a functional convergent evolution that also provides an explanation for the unexpectedly low number of human genes. - Hunt, M. C., Rautanen, A., Westin, M. A. K., Svensson, L. T., Alexson, S. E. H. Analysis of the mouse and human acyl-CoA thioesterase (ACOT) gene clusters shows that convergent, functional evolution results in a reduced number of human peroxisomal ACOTs.	Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem C1 74, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Hunt, MC (corresponding author), Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem C1 74, SE-14186 Stockholm, Sweden.	mary.hunt@ki.se		Svensson, Thomas/0000-0002-9190-2979; Watter, Maria/0000-0001-9047-5517; Hunt, Mary/0000-0001-6415-2992				Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; Branstrom R, 2004, DIABETOLOGIA, V47, P277, DOI 10.1007/s00125-003-1299-x; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; Hostetler HA, 2005, J BIOL CHEM, V280, P18667, DOI 10.1074/jbc.M412062200; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Hunt MC, 2005, J LIPID RES, V46, P2029, DOI 10.1194/jlr.E500003-JLR200; Hunt MC, 2005, EUR J CLIN INVEST, V35, P38, DOI 10.1111/j.1365-2362.2005.01447.x; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Jones JM, 2000, BIOCHEM BIOPH RES CO, V275, P233, DOI 10.1006/bbrc.2000.3285; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; OGIWARA H, 1978, EUR J BIOCHEM, V89, P33, DOI 10.1111/j.1432-1033.1978.tb20893.x; Pawar A, 2003, J BIOL CHEM, V278, P35931, DOI 10.1074/jbc.M306238200; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; SRERE PA, 1965, BIOCHIM BIOPHYS ACTA, V106, P445, DOI 10.1016/0005-2760(65)90061-5; Suga Tetsuya, 2003, Drug Metab Pharmacokinet, V18, P155, DOI 10.2133/dmpk.18.155; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; TAN H, 1990, EUR J BIOCHEM, V190, P107, DOI 10.1111/j.1432-1033.1990.tb15552.x; Taylor EB, 2005, AM J PHYSIOL-ENDOC M, V288, pE1055, DOI 10.1152/ajpendo.00516.2004; Thompson AL, 2000, DIABETES, V49, P1761, DOI 10.2337/diabetes.49.11.1761; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; Wanders RJA, 2004, MOL GENET METAB, V83, P16, DOI 10.1016/j.ymgme.2004.08.016; Wanders RJA, 2004, AM J MED GENET A, V126A, P355, DOI 10.1002/ajmg.a.20661; Westin MAK, 2005, J BIOL CHEM, V280, P38125, DOI 10.1074/jbc.M508479200; Westin MAK, 2004, J BIOL CHEM, V279, P21841, DOI 10.1074/jbc.M313863200; Yamada J, 2005, AMINO ACIDS, V28, P273, DOI 10.1007/s00726-005-0181-1	35	75	82	2	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1855	1864		10.1096/fj.06-6042com	http://dx.doi.org/10.1096/fj.06-6042com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940157	Green Submitted			2022-12-25	WOS:000240267000013
J	Ramjaun, AR; Tomlinson, S; Eddaoudi, A; Downward, J				Ramjaun, A. R.; Tomlinson, S.; Eddaoudi, A.; Downward, J.			Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis	ONCOGENE			English	Article						Smad4; TGF beta; apoptosis; p38; Bmf; Bim	GROWTH-FACTOR-BETA; SMAD-DEPENDENT EXPRESSION; CYTOCHROME-C RELEASE; FAO HEPATOMA-CELLS; FAMILY-MEMBER BIM; P38 MAP KINASE; EPITHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; (TGF-BETA)-INDUCED APOPTOSIS; CASPASE ACTIVATION	Transforming growth factor-beta (TGF beta)-activated signalling pathways can lead to apoptosis, growth arrest or promotion of malignant behaviour, dependent on cellular context. The molecular mechanisms involved in TGF beta-induced apoptosis remain controversial; although changes in gene expression are thought to be pivotal to the process, several different candidate apoptotic initiators and mediators have been proposed. Smad4, a critical component of the TGF beta-induced transcriptional machinery, is shown here to be essential for induction of apoptosis. Gene expression analysis identified the proapoptotic Bcl-2 family members, Bmf and Bim, as induced by TGFb, dependent on both Smad4 and p38 function and the generation of reactive oxygen species. TGF beta-induced Bmf and Bim localize to cellular membranes implicated in apoptosis. Inhibition of the TGF beta-induced expression of both these proteins together provides significant protection of cells from apoptosis. The TGF beta-triggered cell death programme thus involves induction of multiple BH3-only proteins during the induction of apoptosis.	Canc Res UK, London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; Canc Res UK, London Res Inst, Fluorescence Activated Cell Storing Labs, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Downward, J (corresponding author), Canc Res UK, London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@cancer.org.uk	Downward, Julian/A-3251-2012	Eddaoudi, Ayad/0000-0001-5272-6426; Downward, Julian/0000-0002-2331-4729				Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Bakin AV, 2005, FREE RADICAL BIO MED, V38, P375, DOI 10.1016/j.freeradbiomed.2004.10.033; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Coyle B, 2003, J BIOL CHEM, V278, P5920, DOI 10.1074/jbc.M211300200; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Franz Wolfgang, 2000, PERSPEKTIVEN WIRTSCH, V1, P53, DOI DOI 10.1111/1468-2516.00005; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Herrera B, 2001, HEPATOLOGY, V34, P548, DOI 10.1053/jhep.2001.27447; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kanamaru C, 2002, HEPATOL RES, V23, P211, DOI 10.1016/S1386-6346(01)00175-9; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Liao JH, 2001, CELL RES, V11, P89, DOI 10.1038/sj.cr.7290072; Liu JW, 2005, ONCOGENE, V24, P2020, DOI 10.1038/sj.onc.1208385; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; Ohgushi M, 2005, MOL CELL BIOL, V25, P10017, DOI 10.1128/MCB.25.22.10017-10028.2005; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schiffer M, 2004, J BIOL CHEM, V279, P37004, DOI 10.1074/jbc.M403534200; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	47	101	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					970	981		10.1038/sj.onc.1209852	http://dx.doi.org/10.1038/sj.onc.1209852			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909112	Bronze			2022-12-25	WOS:000244245400003
J	Gastwirt, RF; Slavin, DA; McAndrew, CW; Donoghue, DJ				Gastwirt, Randy F.; Slavin, Daniela A.; McAndrew, Christopher W.; Donoghue, Daniel J.			Spy1 expression prevents normal cellular responses to DNA damage - Inhibition of apoptosis and checkpoint activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; S-PHASE CHECKPOINT; GENE-EXPRESSION; HISTONE H2AX; ATAXIA-TELANGIECTASIA; MAMMALIAN-CELLS; CYCLE REGULATOR; ATR; PHOSPHORYLATION; CHK1	Spy1 is the originally identified member of the Speedy/Ringo family of vertebrate cell cycle regulators, which can control cell proliferation and survival through the atypical activation of cyclin-dependent kinases. Here we report a role for Spy1 in apoptosis and checkpoint activation in response to UV irradiation. Using an inducible system allowing for regulated expression of Spy1, we show that Spy1 expression prevents activation of caspase-3 and suppresses apoptosis in response to UV irradiation. Spy1 expression also allows for UV irradiation-resistant DNA synthesis and permits cells to progress into mitosis, as demonstrated by phosphorylation on histone H3, indicating that Spy1 expression can inhibit the S-phase/replication and G(2)/M checkpoints. We demonstrate that Spy1 expression inhibits phosphorylation of Chk1, RPA, and histone H2A. X, which may directly contribute to the decrease in apoptosis and checkpoint bypass. Furthermore, mutation of the conserved Speedy/Ringo box, known to mediate interaction with CDK2, abrogates the ability of Spy1 to inhibit apoptosis and the phosphorylation of Chk1 and RPA. The data presented indicate that Spy1 expression allows cells to evade checkpoints and apoptosis and suggest that Spy1 regulation of CDK2 is important for the response to DNA damage.	Univ Calif San Diego, Dept Chem & Biochem, Moores Univ Calif San Diego Canc Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Program, Moores Univ Calif San Diego Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Donoghue, DJ (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Moores Univ Calif San Diego Canc Ctr, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ddonoghue@ucsd.edu			NCI NIH HHS [T32 CA009523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alexandrow MG, 2005, J CELL BIOL, V168, P875, DOI 10.1083/jcb.200409055; Barnes EA, 2003, CANCER RES, V63, P3701; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Cheng A, 2005, CELL CYCLE, V4, P155, DOI 10.4161/cc.4.1.1347; Cheng Aiyang, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-19; Dinarina A, 2005, BIOCHEM J, V386, P349, DOI 10.1042/BJ20041779; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferby I, 1999, GENE DEV, V13, P2177, DOI 10.1101/gad.13.16.2177; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Garg R, 2004, MOL CANCER RES, V2, P362; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Karaiskou A, 2001, J BIOL CHEM, V276, P36028, DOI 10.1074/jbc.M104722200; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lenormand JL, 1999, EMBO J, V18, P1869, DOI 10.1093/emboj/18.7.1869; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu JS, 2006, DNA REPAIR, V5, P369, DOI 10.1016/j.dnarep.2005.11.007; Liu QH, 2000, GENE DEV, V14, P1448; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Porter LA, 2003, MOL BIOL CELL, V14, P3664, DOI 10.1091/mbc.E02-12-0820; Porter LA, 2002, J CELL BIOL, V157, P357, DOI 10.1083/jcb.200109045; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Taylor William R, 2004, Methods Mol Biol, V281, P293; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu YH, 2004, CELL CYCLE, V3, P1358, DOI 10.4161/cc.3.11.1226; Zucchi I, 2004, P NATL ACAD SCI USA, V101, P18147, DOI 10.1073/pnas.0408260101	56	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35425	35435		10.1074/jbc.M604720200	http://dx.doi.org/10.1074/jbc.M604720200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16951407	hybrid			2022-12-25	WOS:000241933700076
J	Hou, ZJ; Ye, J; Haska, CL; Matherly, LH				Hou, Zhanjun; Ye, Jun; Haska, Christina L.; Matherly, Larry H.			Transmembrane domains 4, 5, 7, 8, and 10 of the human reduced folate carrier are important structural or functional components of the transmembrane channel for folate substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; FOLIC-ACID; METHOTREXATE RESISTANCE; CELLULAR PHARMACOLOGY; MEMBRANE-TRANSPORT; LACTOSE PERMEASE; BINDING DOMAIN; MECHANISM; PROTEIN; GENE	The human reduced folate carrier (hRFC) facilitates membrane transport of folates and antifolates. hRFC is characterized by 12 transmembrane domains (TMDs). To identify residues or domains involved in folate binding, we used substituted cysteine (Cys) accessibility methods (SCAM) with sodium (2-sulfonatoethyl) methanethiosulfonate (MTSES). We previously showed that residues in TMD11 of hRFC were involved in substrate binding, whereas those in TMD12 were not (Hou, Z., Stapels, S. E., Haska, C. L., and Matherly, L. H. (2005) J. Biol. Chem. 280, 36206-36213). In this study, 232 Cys-substituted mutants spanning TMDs 1 - 10 and conserved stretches within the TMD6-7 (residues 204-217) and TMD10-11 connecting loop domains were transiently expressed in hRFC-null HeLa cells. All Cys-substituted mutants showed moderate to high levels of expression on Western blots, and only nine mutants including R133C, I134C, A135C, Y136C, S138C, G163C, Y281C, R373C, and S313C were inactive for methotrexate transport. MTSES did not inhibit transport by any of the mutants in TMDs 1, 3, 6, and 9 or for positions 204-217. Whereas most of the mutants in TMDs 2, 4, 5, 7, 8, and 10, and in the TMD10-11 connecting loop were insensitive to MTSES, this reagent inhibited methotrexate transport (25-75%) by 26 mutants in these TMDs. For 13 of these (Y126C, S137C, V160C, S168C, W274C, S278C, V284C, V288C, A311C, T314C, Y376C, Q377C, and V380C), inhibition was prevented by leucovorin, another hRFC substrate. Combined with our previous findings, these results implicate amino acids in TMDs 4, 5, 7, 8, 10, and 11, but not in TMDs 1, 2, 3, 6, 9, or 12, as important structural or functional components of the putative hydrophilic cavity for binding of anionic folate substrates.	Wayne State Univ, Dev Therapeut Program, Karmanos Canc Inst, Sch Med, Detroit, MI 48201 USA; Wayne State Univ, Canc Biol Program, Sch Med, Detroit, MI 48201 USA; Wayne State Univ, Dept Pharmacol, Sch Med, Detroit, MI 48201 USA; Wayne State Univ, Dept Biochem & Mol Biol, Sch Med, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University; Wayne State University	Matherly, LH (corresponding author), Wayne State Univ, Dev Therapeut Program, Karmanos Canc Inst, Sch Med, 110 E Warren Ave, Detroit, MI 48201 USA.	matherly@kci.wayne.edu	Ye, Jun/J-8823-2012; /S-1117-2019		NCI NIH HHS [CA53535] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Abramson J, 2004, CURR OPIN STRUC BIOL, V14, P413, DOI 10.1016/j.sbi.2004.07.005; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Bailey LB, 2003, J NUTR, V133, p1961S, DOI 10.1093/jn/133.6.1961S; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Cao W, 2004, BIOCHEM J, V378, P201, DOI 10.1042/BJ20031288; Cao W, 2003, BIOCHEM J, V374, P27, DOI 10.1042/BJ20030301; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Flintoff WF, 2003, J BIOL CHEM, V278, P40867, DOI 10.1074/jbc.M302102200; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; FRY DW, 1982, J BIOL CHEM, V257, P1890; Ge Yubin, 2006, Proceedings of the American Association for Cancer Research Annual Meeting, V47, P1015; Gifford AJ, 2002, LEUKEMIA, V16, P2379, DOI 10.1038/sj.leu.2402655; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; Goldman ID, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37461; Guo W, 1999, CLIN CANCER RES, V5, P621; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Hou ZJ, 2005, J BIOL CHEM, V280, P36206, DOI 10.1074/jbc.M507295200; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Liu XY, 2003, BIOCHEM J, V369, P31, DOI 10.1042/BJ20020419; Liu XY, 2001, BIOCHEM J, V358, P511, DOI 10.1042/0264-6021:3580511; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; Marchant JS, 2002, J BIOL CHEM, V277, P33325, DOI 10.1074/jbc.M205955200; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rothem L, 2002, BIOCHEM J, V367, P741, DOI 10.1042/BJ20020801; Sadlish H, 2002, J BIOL CHEM, V277, P42105, DOI 10.1074/jbc.M206459200; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Sharina IG, 2001, MOL PHARMACOL, V59, P1022, DOI 10.1124/mol.59.5.1022; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; Vardy E, 2004, PROTEIN SCI, V13, P1832, DOI 10.1110/ps.04657704; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Witt TL, 2002, BBA-BIOMEMBRANES, V1567, P56, DOI 10.1016/S0005-2736(02)00583-7; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhao R, 2000, CLIN CANCER RES, V6, P3304; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1999, BIOCHEM PHARMACOL, V58, P1615, DOI 10.1016/S0006-2952(99)00257-9; Zhao RB, 2004, CLIN CANCER RES, V10, P8735, DOI 10.1158/1078-0432.CCR-04-0932; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68	50	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33588	33596		10.1074/jbc.M607049200	http://dx.doi.org/10.1074/jbc.M607049200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16923800	hybrid			2022-12-25	WOS:000241621400068
J	Ito, K; Nakajima, Y; Onohara, Y; Takeo, M; Nakashima, K; Matsubara, F; Ito, T; Yoshimoto, T				Ito, Kiyoshi; Nakajima, Yoshitaka; Onohara, Yuko; Takeo, Masahide; Nakashima, Kanako; Matsubara, Futoshi; Ito, Takashi; Yoshimoto, Tadashi			Crystal structure of aminopeptidase N (proteobacteria alanyl aminopeptidase) from Escherichia coli and conformational change of methionine 260 involved in substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; BOMBYX-MORI; BINDING; ENZYME; PURIFICATION; GENE; SPECIFICITY; EXPRESSION; MECHANISM; FAMILIES	Aminopeptidase N from Escherichia coli is a broad specificity zinc exopeptidase belonging to aminopeptidase clan MA, family M1. The structures of the ligand-free form and the enzymebestatin complex were determined at 1.5- and 1.6-A resolution, respectively. The enzyme is composed of four domains: an N-terminal beta-domain (Met(1)-Asp(193)), a catalytic domain (Phe(194)-Gly(444)), a middle beta-domain (Thr(445)-Trp(546)), and a C-terminal alpha-domain (Ser(547)-Ala(870)). The structure of the catalytic domain exhibits similarity to thermolysin, and a metal-binding motif ( HEXXHX18E) is found in the domain. The zinc ion is coordinated by His(297), His(301), Glu(320), and a water molecule. The groove on the catalytic domain that contains the active site is covered by the C-terminal alpha-domain, and a large cavity is formed inside the protein. However, there exists a small hole at the center of the C-terminal alpha-domain. The N terminus of bestatin is recognized by Glu(121) and Glu(264), which are located in the N-terminal and catalytic domains, respectively. Glu(298) and Tyr(381), located near the zinc ion, are considered to be involved in peptide cleavage. A difference revealed between the ligand-free form and the enzyme-bestatin complex indicated that Met(260) functions as a cushion to accept substrates with different N-terminal residue sizes, resulting in the broad substrate specificity of this enzyme.	Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan	Nagasaki University	Yoshimoto, T (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	yosimoto@nagasaki-u.ac.jp	Ito, Kiyoshi/E-9652-2011					Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chandu D, 2003, MICROBIOL-SGM, V149, P3437, DOI 10.1099/mic.0.26518-0; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; FOGLINO M, 1986, GENE, V49, P303, DOI 10.1016/0378-1119(86)90366-5; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; Hiramatsu H, 2003, BIOCHEM BIOPH RES CO, V302, P849, DOI 10.1016/S0006-291X(03)00258-4; HOLMES MA, 1981, BIOCHEMISTRY-US, V20, P6912, DOI 10.1021/bi00527a026; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Huang K, 1997, J BIOCHEM, V122, P779; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; Kabashima T, 1996, J BIOCHEM-TOKYO, V120, P1111; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KITAZONO A, 1992, J BACTERIOL, V174, P7919, DOI 10.1128/JB.174.24.7919-7925.1992; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kyrieleis OJP, 2005, J MOL BIOL, V349, P787, DOI 10.1016/j.jmb.2005.03.070; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Luciani N, 1998, BIOCHEMISTRY-US, V37, P686, DOI 10.1021/bi971705p; MCCAMAN MT, 1982, ARCH BIOCHEM BIOPHYS, V213, P384, DOI 10.1016/0003-9861(82)90564-1; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Nakanishi K, 2002, FEBS LETT, V519, P215, DOI 10.1016/S0014-5793(02)02708-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelmenschikov V, 2002, J BIOL INORG CHEM, V7, P284, DOI 10.1007/s007750100295; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Rudberg PC, 2002, J BIOL CHEM, V277, P1398, DOI 10.1074/jbc.M106577200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; Yaoi K, 1999, FEBS LETT, V463, P221, DOI 10.1016/S0014-5793(99)01626-9; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; YOSHIMOTO T, 1988, AGR BIOL CHEM TOKYO, V52, P217; YOSHIMOTO T, 1980, J BIOL CHEM, V255, P4786	37	117	123	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33664	33676		10.1074/jbc.M605203200	http://dx.doi.org/10.1074/jbc.M605203200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16885166	hybrid			2022-12-25	WOS:000241621400074
J	Morishita, H; Umitsu, M; Murata, Y; Shibata, N; Udaka, K; Higuchi, Y; Akutsu, H; Yamaguchi, T; Yagi, T; Ikegami, T				Morishita, Hirofumi; Umitsu, Masataka; Murata, Yoji; Shibata, Naoki; Udaka, Keiko; Higuchi, Yoshiki; Akutsu, Hideo; Yamaguchi, Tohru; Yagi, Takeshi; Ikegami, Takahisa			Structure of the cadherin-related neuronal receptor/protocadherin-alpha first extracellular cadherin domain reveals diversity across cadherin families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; GENOMIC ORGANIZATION; RESONANCE ASSIGNMENTS; PROTOCADHERIN-ALPHA; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GENE-CLUSTER; SEQUENCE; EVOLUTION	The recent explosion in genome sequencing has revealed the great diversity of the cadherin superfamily. Within the superfamily, protocadherins, which are expressed mainly in the nervous system, constitute the largest subgroup. Nevertheless, the structures of only the classical cadherins are known. Thus, to broaden our understanding of the adhesion repertoire of the cadherin superfamily, we determined the structure of the N-terminal first extracellular cadherin domain of the cadherin-related neuronal receptor/protocadherin-alpha 4. The hydrophobic pocket essential for homophilic adhesiveness in the classical cadherins was not found, and the functional significance of this structural domain was supported by exchanging the first extracellular cadherin domains of protocadherin and classical cadherin. Moreover, potentially crucial variations were observed mainly in the loop regions. These included the protocadherin-specific disulfide-bonded Cys-X-5-Cys motif, which showed Ca2+-induced chemical shifts, and the RGD motif, which has been suggested to be involved in heterophilic cell adhesion via the active form of beta 1 integrin. Our findings reveal that the adhesion repertoire of the cadherin superfamily is far more divergent than would be predicted by studying the classical cadherins alone.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Osaka Univ, KOKORO Biol Grp, Labs Integrated Biol, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Course Med Biosignaling, Suita, Osaka 5650871, Japan; Kochi Med Sch, Dept Immunol, Kochi 7838505, Japan; Natl Inst Physiol Sci, Aichi 4448585, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Saitama 3320012, Japan; Shionogi & Co Ltd, Discovery Res Lab, Osaka 5530002, Japan	Osaka University; Osaka University; Osaka University; Kochi University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Japan Science & Technology Agency (JST); Shionogi & Company Limited	Yagi, T (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yagi@fbs.osaka-u.ac.jp; tiik@protein.osaka-u.ac.jp	Morishita, Hirofumi/J-9619-2015; Shibata, Naoki/AFK-9971-2022; Ikegami, Takahisa/I-9626-2017	Morishita, Hirofumi/0000-0002-1045-1337; Shibata, Naoki/0000-0002-5096-1104; Ikegami, Takahisa/0000-0002-1429-1844; Murata, Yoji/0000-0002-9576-7030; Akutsu, Hideo/0000-0001-7236-5285				Aiyar A, 2000, Methods Mol Biol, V132, P221; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Copie V, 1998, J MOL BIOL, V277, P663; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Esumi S, 2005, NAT GENET, V37, P171, DOI 10.1038/ng1500; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; Gooding JM, 2004, BIOESSAYS, V26, P497, DOI 10.1002/bies.20033; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Koch AW, 2004, CELL MOL LIFE SCI, V61, P1884, DOI 10.1007/s00018-004-4006-2; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Lambert M, 2000, J CELL SCI, V113, P2207; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Maerz AL, 2001, J VIROL, V75, P6635, DOI 10.1128/JVI.75.14.6635-6644.2001; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Mutoh T, 2004, EXP CELL RES, V294, P494, DOI 10.1016/j.yexcr.2003.11.019; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Noonan JP, 2004, GENOME RES, V14, P354, DOI 10.1101/gr.2133704; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Patel SD, 2003, CURR OPIN STRUC BIOL, V13, P690, DOI 10.1016/j.sbi.2003.10.007; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Poumbourios P, 2003, J BIOL CHEM, V278, P42149, DOI 10.1074/jbc.M305223200; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Shan WS, 2004, J BIOL CHEM, V279, P55914, DOI 10.1074/jbc.M407827200; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1999, NEURON, V23, P427, DOI 10.1016/S0896-6273(00)80796-5; SHAPIRO L, 1995, P NATL ACAD SCI USA, V92, P6793, DOI 10.1073/pnas.92.15.6793; Shapiro L, 1998, CURR OPIN NEUROBIOL, V8, P593, DOI 10.1016/S0959-4388(98)80086-X; Sharma D, 2000, J BIOMOL NMR, V18, P165, DOI 10.1023/A:1008398416292; Sugino H, 2004, BIOCHEM BIOPH RES CO, V316, P437, DOI 10.1016/j.bbrc.2004.02.067; Sugino H, 2000, GENOMICS, V63, P75, DOI 10.1006/geno.1999.6066; Suzuki ST, 2000, EXP CELL RES, V261, P13, DOI 10.1006/excr.2000.5039; Tada MN, 2004, GENE, V340, P197, DOI 10.1016/j.gene.2004.07.014; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Torshin I.V., 2002, MED SCI MONITOR, V8, P301; Tsumoto K, 1998, J IMMUNOL METHODS, V219, P119, DOI 10.1016/S0022-1759(98)00127-6; Umitsu M, 2005, J BIOMOL NMR, V31, P365, DOI 10.1007/s10858-005-2450-4; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; Wojtowicz WM, 2004, CELL, V118, P619, DOI 10.1016/j.cell.2004.08.021; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yagi T, 2000, GENE DEV, V14, P1169; Yanase H, 2004, GENOMICS, V83, P717, DOI 10.1016/j.ygeno.2003.09.022	59	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33650	33663		10.1074/jbc.M603298200	http://dx.doi.org/10.1074/jbc.M603298200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16916795	hybrid			2022-12-25	WOS:000241621400073
J	Schmitz, M; Becker, A; Schmitz, A; Weirich, C; Paulsson, M; Zaucke, F; Dinser, R				Schmitz, Markus; Becker, Alexander; Schmitz, Alexander; Weirich, Christian; Paulsson, Mats; Zaucke, Frank; Dinser, Robert			Disruption of extracellular matrix structure may cause pseudoachondroplasia phenotypes in the absence of impaired cartilage oligomeric matrix protein secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; CALCIUM-BINDING; IX COLLAGEN; CELL-TYPE; A-DOMAIN; MUTATION; COMP; TRAFFICKING; GROWTH; MATRILIN-3	Pseudoachondroplasia and multiple epiphyseal dysplasia are two dominantly inherited chondrodysplasias associated with mutations in cartilage oligomeric matrix protein ( COMP). The rarely available patient biopsies show lamellar inclusions in the endoplasmic reticulum. We studied the pathogenesis of these chondrodysplasias by expressing several disease-causing COMP mutations in bovine primary chondrocytes and found that COMP-associated chondrodysplasias are not exclusively storage diseases. Although COMP carrying the mutations D469 Delta and D475N was retained within the endoplasmic reticulum, secretion of COMP H587R was only slightly retarded. All pseudoachondroplasia mutations impair cellular viability and cause a disruption of the extracellular matrix formed in alginate culture irrespective of the degree of cellular retention. The mutation D361Y associated with the clinically milder disease multiple epiphyseal dysplasia gave mild retention and limited matrix alterations, but the transfected cells showed normal viability. The effect of mutated COMP on matrix formation and cell-matrix interaction may be a major element in the pathogenesis of COMP-associated chondrodysplasias.	Univ Hosp Saarland, Dept Internal Med 1, D-66421 Homburg, Germany; Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Univ Giessen, Kerckhoff Hosp, Dept Internal Med & Rheumatol, D-61231 Bad Nauheim, Germany	Universitatsklinikum des Saarlandes; University of Cologne; University of Cologne; Justus Liebig University Giessen; Kerckhoff Clinic	Dinser, R (corresponding author), Univ Hosp Saarland, Dept Internal Med 1, D-66421 Homburg, Germany.	dinser@kerckhoff-klinik.de	Zaucke, Frank/E-2077-2012; Zaucke, Frank/AAT-2688-2021					Bonnemann CG, 2000, P NATL ACAD SCI USA, V97, P1212, DOI 10.1073/pnas.97.3.1212; BREUR GJ, 1992, J BONE JOINT SURG AM, V74A, P516, DOI 10.2106/00004623-199274040-00007; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Cao L, 1999, MATRIX BIOL, V18, P343, DOI 10.1016/S0945-053X(99)00027-X; Carlson CB, 2005, NAT STRUCT MOL BIOL, V12, P910, DOI 10.1038/nsmb997; Chapman KL, 2001, NAT GENET, V28, P393, DOI 10.1038/ng573; Chen FH, 2005, J BIOL CHEM, V280, P32655, DOI 10.1074/jbc.M504778200; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Chen TLL, 2004, MATRIX BIOL, V23, P433, DOI 10.1016/j.matbio.2004.09.005; Cotterill SL, 2005, HUM MUTAT, V26, P557, DOI 10.1002/humu.20263; Czarny-Ratajczak M, 2001, AM J HUM GENET, V69, P969, DOI 10.1086/324023; Deere M, 1998, AM J MED GENET, V80, P510, DOI 10.1002/(SICI)1096-8628(19981228)80:5<510::AID-AJMG14>3.0.CO;2-F; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; Dinser R, 2002, J CLIN INVEST, V110, P505, DOI 10.1172/JCI200214386; Dinser R, 2001, HISTOCHEM CELL BIOL, V116, P69; Hashimoto Y, 2003, AM J PATHOL, V163, P101, DOI 10.1016/S0002-9440(10)63634-6; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; Hecht JT, 2005, MATRIX BIOL, V23, P525, DOI 10.1016/j.matbio.2004.09.006; Hecht JT, 2004, J ORTHOP RES, V22, P759, DOI 10.1016/j.orthres.2003.11.010; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; Hirsch MS, 1997, DEV DYNAM, V210, P249, DOI 10.1002/(SICI)1097-0177(199711)210:3<249::AID-AJA6>3.0.CO;2-G; Holden P, 2005, J BIOL CHEM, V280, P17172, DOI 10.1074/jbc.M411716200; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Hou J, 2000, CELL CALCIUM, V27, P309, DOI 10.1054/ceca.2000.0125; Klatt AR, 2001, J BIOL CHEM, V276, P17267, DOI 10.1074/jbc.M100587200; Kleerekoper Q, 2002, J BIOL CHEM, V277, P10581, DOI 10.1074/jbc.M109944200; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kreppel F, 2002, HUM GENE THER, V13, P1151, DOI 10.1089/104303402320138934; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lo MY, 2004, J ORTHOPAED RES, V22, P140, DOI 10.1016/S0736-0266(03)00117-7; Loughlin J, 1998, HUM MUTAT, pS10; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; Otten C, 2005, J MED GENET, V42, P774, DOI 10.1136/jmg.2004.029462; Paassilta P, 1999, AM J HUM GENET, V64, P1036, DOI 10.1086/302328; Rimoin DL, 1998, AM J MED GENET, V79, P376; ROSENBERG K, 2001, THESIS LUND U LUND; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Spitznagel L, 2004, BIOCHEM J, V377, P479, DOI 10.1042/BJ20031179; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; STANESCU V, 1982, EUR J PEDIATR, V138, P221, DOI 10.1007/BF00441206; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; van Mourik JBA, 1998, AM J MED GENET, V77, P234, DOI 10.1002/(SICI)1096-8628(19980518)77:3<234::AID-AJMG9>3.0.CO;2-P; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; Zaucke F, 2001, BIOCHEM J, V358, P17, DOI 10.1042/0264-6021:3580017	50	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32587	32595		10.1074/jbc.M601976200	http://dx.doi.org/10.1074/jbc.M601976200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16928687	hybrid			2022-12-25	WOS:000241414500056
J	Tanos, B; Pendergast, AM				Tanos, Barbara; Pendergast, Ann Marie			Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DOWN-REGULATION; EGF-RECEPTOR; C-CBL; FAMILY KINASES; BREAST-CANCER; DOMAIN; PHOSPHORYLATION; DEGRADATION; SRC; INTERNALIZATION	Signal attenuation from ligand-activated epidermal growth factor receptor ( EGFR) is mediated in part by receptor endocytosis and trafficking to the lysosomal degradative compartment. Uncoupling the activated EGFR from endocytosis and degradation has emerged as a mechanism for oncogenic activation of the EGFR. The Abl nonreceptor tyrosine kinase is activated by ligand-stimulated EGFR, but the role of Abl in EGFR signaling has not been defined. Here we uncovered a novel role for the activated Abl kinase in the regulation of EGFR endocytosis. We show that activated Abl impairs EGFR internalization. Moreover, we show that activated Abl phosphorylates the EGFR primarily on tyrosine 1173, and that mutation of this site to phenylalanine restores ligand-dependent endocytosis of the EGFR in the presence of activated Abl. Furthermore, we show that activated Abl allows the ligand-activated EGFR to escape Cbl-dependent down-regulation by inhibiting the accumulation of Cbl at the plasma membrane in response to epidermal growth factor stimulation and disrupting the formation of the EGFR center dot Cbl complex without affecting Cbl protein stability. These findings reveal a novel role for Abl in promoting increased cell-surface expression of the EGFR and suggest that Abl/EGFR signaling may cooperate in human tumors.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Pendergast, AM (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	pende014@mc.duke.edu		Pendergast, Ann Marie/0000-0002-1250-6880; Tanos, Barbara/0000-0002-7045-9496	NCI NIH HHS [CA 70940] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Blagoev B, 2004, NAT BIOTECHNOL, V22, P1139, DOI 10.1038/nbt1005; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chen WS, 1999, INT J CANCER, V83, P579, DOI 10.1002/(SICI)1097-0215(19991126)83:5<579::AID-IJC1>3.0.CO;2-R; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; de Melker AA, 2001, J CELL SCI, V114, P2167; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Heimberger AB, 2002, CLIN CANCER RES, V8, P3496; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Huang FT, 2005, MOL BIOL CELL, V16, P1268, DOI 10.1091/mbc.E04-09-0832; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Klapper LN, 2000, CANCER RES, V60, P3384; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Okamoto I, 2003, CANCER SCI, V94, P50, DOI 10.1111/j.1349-7006.2003.tb01351.x; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Plattner R, 2004, MOL CELL BIOL, V24, P2573, DOI 10.1128/mcb.24.6.2573-2583.2004; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Simpson L, 2005, J UROLOGY, V173, P1883, DOI 10.1097/01.ju.0000158448.56888.09; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Zhang BY, 2005, ONCOGENE, V24, P2585, DOI 10.1038/sj.onc.1208453; ZHU GC, 1993, J BIOL CHEM, V268, P1775	51	74	81	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32714	32723		10.1074/jbc.M603126200	http://dx.doi.org/10.1074/jbc.M603126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16943190	hybrid			2022-12-25	WOS:000241414500070
J	Hershko, T; Korotayev, K; Polager, S; Ginsberg, D				Hershko, Tzippi; Korotayev, Katya; Polager, Shirley; Ginsberg, Doron			E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA GLYCOSYLASE; TUMOR SUPPRESSORS; SIGNALING PATHWAY; UP-REGULATION; UV-RADIATION; APOPTOSIS; P53; EXPRESSION; PPM1D; PHOSPHATASE	The E2F family of transcription factors regulates a diverse array of cellular functions, including cell proliferation, cell differentiation, and apoptosis. Recent studies indicate that E2F can also regulate transcription of upstream components of signal transduction pathways. We show here that E2F1 modulates the activity of the p38 MAPK pathway via E2F1-induced transient up-regulation of p38 MAPK phosphorylation. The mechanism by which E2F1 modulates p38 MAPK phosphorylation involves transcriptional induction of the kinase ASK1, a member of the MAPKKK family that phosphorylates p38 MKKs. Subsequent E2F-dependent down-regulation of the p38 signaling pathway is achieved through E2F-induced up-regulation of Wip1, a phosphatase that dephosphorylates and inactivates p38. Both ASK1 and Wip1 are essential mediators of the E2F-p38 connection: knock down of ASK1 inhibits E2F1-induced phosphorylation of p38, whereas knock down of Wip1 prolongs E2F1-induced p38 phosphorylation. Furthermore, Wip1 knock down enhances E2F1-induced apoptosis. Therefore, our data reveal a novel link between a central signaling pathway and the transcription factor E2F and identify Wip1 as a modulator of E2F1-induced apoptosis.	Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel; Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel	Bar Ilan University; Weizmann Institute of Science	Ginsberg, D (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.	ginsbed@mail.biu.ac.il		ginsberg, doron/0000-0002-1257-4920				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Carrassa L, 2003, CELL CYCLE, V2, P604, DOI 10.4161/cc.2.6.503; Chaussepied M, 2004, MOL CELL, V16, P831, DOI 10.1016/j.molcel.2004.11.003; CHAUSSEPIED M, 2005, CELL CYCLE, V4; Dasgupta P, 2004, J BIOL CHEM, V279, P38762, DOI 10.1074/jbc.M312273200; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Engelberg D, 2004, SEMIN CANCER BIOL, V14, P271, DOI 10.1016/j.semcancer.2004.04.006; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; Hershko T, 2005, CELL DEATH DIFFER, V12, P377, DOI 10.1038/sj.cdd.4401575; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ivanova IA, 2006, ONCOGENE, V25, P430, DOI 10.1038/sj.onc.1208999; Jamshidi-Parsian A, 2005, GENE, V344, P67, DOI 10.1016/j.gene.2004.09.030; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Powers JT, 2004, MOL CANCER RES, V2, P203; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Sumbayev VV, 2005, ARCH BIOCHEM BIOPHYS, V436, P406, DOI 10.1016/j.abb.2005.02.021; Takahashi Y, 2000, GENE DEV, V14, P804; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tashiro E, 2003, CANCER RES, V63, P424; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804	45	45	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31309	31316		10.1074/jbc.M601758200	http://dx.doi.org/10.1074/jbc.M601758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16912047	Bronze			2022-12-25	WOS:000241235300015
J	Huang, HY; Kuei, Y; Chao, HY; Chen, SJ; Yeh, LS; Wang, CC				Huang, Hsiao-Yun; Kuei, Yu; Chao, Hen-Yi; Chen, Shun-Jia; Yeh, Lu-Shu; Wang, Chien-Chia			Cross-species and cross-compartmental aminoacylation of isoaccepting tRNAs by a class II tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE TRANSLATION PRODUCT; SACCHAROMYCES-CEREVISIAE; INITIATION CODON; GENE ENCODES; MITOCHONDRIAL; YEAST; AUG; PROTEIN; MECHANISM; SELECTION	It was previously shown that ALA1, the only alanyl-tRNA synthetase gene in Saccharomyces cerevisiae, codes for two functionally exclusive protein isoforms through alternative initiation at two consecutive ACG codons and an in-frame downstream AUG. We reported here the cloning and characterization of a homologous gene from Candida albicans. Functional assays show that this gene can substitute for both the cytoplasmic and mitochondrial functions of ALA1 in S. cerevisiae and codes for two distinct protein isoforms through alternative initiation from two in-frame AUG triplets 8-codons apart. Unexpectedly, although the short form acts exclusively in cytoplasm, the longer form provides function in both compartments. Similar observations are made in fractionation assays. Thus, the alanyl-tRNA synthetase gene of C. albicans has evolved an unusual pattern of translation initiation and protein partitioning and codes for protein isoforms that can aminoacylate isoaccepting tRNAs from a different species and from across cellular compartments.	Tzu Chi Univ, Dept Life Sci, Hualien 97041, Taiwan; Natl Cent Univ, Dept Life Sci, Jungli 32001, Taiwan	Tzu Chi University; National Central University	Yeh, LS (corresponding author), Tzu Chi Univ, Dept Life Sci, Hualien 97041, Taiwan.	susanyeh@mail.tcu.edu.tw; dukewang@cc.ncu.edu.tw		Chen, Shun-Jia/0000-0002-5489-4930				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; Chang KJ, 2006, J BIOL CHEM, V281, P7775, DOI 10.1074/jbc.M511265200; Chang KJ, 2004, J BIOL CHEM, V279, P13778, DOI 10.1074/jbc.M311269200; CHATTON B, 1988, J BIOL CHEM, V263, P52; DAUM G, 1982, J BIOL CHEM, V257, P3028; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lovato MA, 2001, EMBO J, V20, P4846, DOI 10.1093/emboj/20.17.4846; MARECHALDROUARD L, 1993, ANN REV CELL BIOL, V8, P115; MARTINIS SA, 1996, ESCHERICHIA COLI SAL, P887; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pelchat M, 1999, BIOCHEM CELL BIOL, V77, P343, DOI 10.1139/bcb-77-4-343; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; Souciet G, 1999, EUR J BIOCHEM, V266, P848, DOI 10.1046/j.1432-1327.1999.00922.x; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; STEINMETZ A, 1986, METHOD ENZYMOL, V118, P212; Tang HL, 2004, J BIOL CHEM, V279, P49656, DOI 10.1074/jbc.M408081200; Wang CC, 2003, BIOCHEMISTRY-US, V42, P1646, DOI 10.1021/bi025964c; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WOLFE CL, 1994, J BIOL CHEM, V269, P13361; WU M, 1987, J BIOL CHEM, V262, P12275	31	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31430	31439		10.1074/jbc.M601869200	http://dx.doi.org/10.1074/jbc.M601869200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16928688	Bronze			2022-12-25	WOS:000241235300027
J	Kauth, CW; Woehlbier, U; Kern, M; Mekonnen, Z; Lutz, R; Mucke, N; Langowski, J; Bujard, H				Kauth, Christian W.; Woehlbier, Ute; Kern, Michaela; Mekonnen, Zeleke; Lutz, Rolf; Muecke, Norbert; Langowski, Joerg; Bujard, Hermann			Interactions between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEROZOITE SURFACE PROTEIN-1; VACCINE CANDIDATE; ESCHERICHIA-COLI; COMPLEX; ANTIBODIES; PURIFICATION; EXPRESSION; FRAGMENTS; PRECURSOR; INVASION	Merozoites of the malaria parasite Plasmodium falciparum expose at their surface a large multiprotein complex, composed of proteolytically processed, noncovalently associated products of at least three genes, msp-1, msp-6, and msp-7. During invasion of erythrocytes, this complex is shed from the surface except for a small glycosylphosphatidylinositol-anchored portion originating from MSP-1. The proteolytic cleavage separating the C-terminal portion of MSP-1 is required for successful invasion. Little is known about the structure and function of the abundant and essential multipartite complex. Using heterologously produced MSP-1, MSP-6, and MSP-7 in precursor and with the exception of MSP-7 in processed form, we have studied in vitro the complex formation between the different proteins to identify the interaction partners within the complex. Both MSP-6(36) and MSP-7 bind only to MSP-1 subunits that are shed, but although MSP-636 contacts just subunit p38, MSP-7 interacts with p83, p30, and p38. The intact C-terminal region of MSP-6 is required for the association with p38 as well as for its multimerization into tetramers. Furthermore, our data suggest that only the processed form and not the precursor form of MSP-1 interacts with MSP-636. MSP-6-as well as MSP-7-specific rabbit antibodies inhibit parasite multiplication in vitro as shown previously for antibodies directed against MSP-1. Our findings raise interesting questions with regard to proteolysis-mediated mechanisms of maturation of the MSP-1-MSP-6-MSP-7 complex and to the mode by which antibodies directed against this complex interfere with parasite multiplication.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Biophys Macromol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Bujard, H (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	h.bujard@zmbh.uni-heidelberg.de	Langowski, Jörg/A-1843-2011; Mekonnen, Zeleke/AAF-3877-2020	Langowski, Jörg/0000-0001-8600-0666; Mekonnen, Zeleke/0000-0003-3418-7291; Mucke, Norbert/0000-0002-0683-4386; Woehlbier, Ute/0000-0003-3114-9708				Blackman Michael J., 2000, Current Drug Targets, V1, P59, DOI 10.2174/1389450003349461; BLACKMAN MJ, 1992, MOL BIOCHEM PARASIT, V50, P307, DOI 10.1016/0166-6851(92)90228-C; BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389; Burgess BR, 2005, J BIOL CHEM, V280, P37236, DOI 10.1074/jbc.M506753200; Carruthers VB, 2005, MOL MICROBIOL, V55, P1617, DOI 10.1111/j.1365-2958.2005.04483.x; Epp C, 2003, J CHROMATOGR B, V786, P61, DOI 10.1016/S1570-0232(02)00722-5; HOLDER AA, 1984, J EXP MED, V160, P624, DOI 10.1084/jem.160.2.624; Kauth CW, 2003, J BIOL CHEM, V278, P22257, DOI 10.1074/jbc.M302299200; Kumar S, 2002, CHEM IMMUNOL, V80, P262; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7; Mello K, 2004, INFECT IMMUN, V72, P1010, DOI 10.1128/IAI.72.2.1010-1018.2004; Mello K, 2002, EUKARYOT CELL, V1, P915, DOI 10.1128/EC.1.6.915-925.2002; Mills KE, 2002, MOL MICROBIOL, V43, P1401, DOI 10.1046/j.1365-2958.2002.02834.x; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; Mucke N, 2004, J MOL BIOL, V340, P97, DOI 10.1016/j.jmb.2004.04.039; Pachebat JA, 2001, MOL BIOCHEM PARASIT, V117, P83, DOI 10.1016/S0166-6851(01)00336-X; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; PATINO JAG, 1997, J EXP MED, V186, P1689, DOI DOI 10.1084/JEM.186.10.1689); Pearce JA, 2004, INFECT IMMUN, V72, P2321, DOI 10.1128/IAI.72.4.2321-2328.2004; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Pizarro JC, 2003, J MOL BIOL, V328, P1091, DOI 10.1016/S0022-2836(03)00376-0; RALSTON G, 1993, BECKMAN INSTRUMENTS, P43; Singh S, 2005, INFECT IMMUN, V73, P1235, DOI 10.1128/IAI.73.2.1235-1238.2005; STAFFORD WHL, 1994, MOL BIOCHEM PARASIT, V66, P157, DOI 10.1016/0166-6851(94)90048-5; Stafford WHL, 1996, MOL BIOCHEM PARASIT, V80, P159, DOI 10.1016/0166-6851(96)02696-5; Tewari R, 2005, BLOOD, V105, P394, DOI 10.1182/blood-2004-06-2106; Trucco C, 2001, MOL BIOCHEM PARASIT, V112, P91, DOI 10.1016/S0166-6851(00)00350-9; Woehlbier U, 2006, INFECT IMMUN, V74, P1313, DOI 10.1128/IAI.74.2.1313-1322.2006	31	68	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31517	31527		10.1074/jbc.M604641200	http://dx.doi.org/10.1074/jbc.M604641200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16940297	Bronze			2022-12-25	WOS:000241235300037
J	Marasco, EK; Vay, K; Schmidt-Dannert, C				Marasco, Erin K.; Vay, Kimleng; Schmidt-Dannert, Claudia			Identification of carotenoid cleavage dioxygenases from Nostoc sp PCC 7120 with different cleavage activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PAUCIMOBILIS TMY1009; VITAMIN-A FORMATION; BETA-CAROTENE; MOLECULAR-IDENTIFICATION; OXIDATIVE CLEAVAGE; DIRECTED EVOLUTION; ESCHERICHIA-COLI; BIOSYNTHESIS; ENZYMES; CLONING	Carotenoid cleavage dioxygenases (CCDs) are a class of enzymes that oxidatively cleave carotenoids into apocarotenoids. Dioxygenases have been identified in plants and animals and produce a wide variety of cleavage products. Despite what is known about apocarotenoids in higher organisms, very little is known about apocarotenoids and CCDs in microorganisms. This study surveyed cleavage activities of ten putative carotenoid cleavage dioxygenases from five different cyanobacteria in recombinant Escherichia coli cells producing different carotenoid substrates. Three CCD homologs identified in Nostoc sp. PCC 7120 were purified, and their cleavage activities were investigated. Two of the three enzymes showed cleavage of beta,beta-carotene at the 9,10 and 15,15 ' positions, respectively. The third enzyme did not cleave full-length carotenoids but cleaved the apocarotenoid beta-apo-8 '-carotenal at the 9,10 position. 9,10-Apocarotenoid cleavage specificity has previously not been described. The diversity of carotenoid cleavage activities identified in one cyanobacteria suggests that CCDs not only facilitate the degradation of photosynthetic pigments but generate apocarotenals with yet to be determined biological roles in microorganisms.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Schmidt-Dannert, C (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 1479 Gortner Ave, St Paul, MN 55108 USA.	schmi232@umn.edu			NIGMS NIH HHS [T32 GM08347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arpigny JL, 1999, BIOCHEM J, V343, P177, DOI 10.1042/0264-6021:3430177; Booker J, 2004, CURR BIOL, V14, P1232, DOI 10.1016/j.cub.2004.06.061; Bouvier F, 2005, TRENDS PLANT SCI, V10, P187, DOI 10.1016/j.tplants.2005.02.007; Bouvier F, 2003, SCIENCE, V300, P2089, DOI 10.1126/science.1085162; Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; BRITTON G, 1995, CAROTENOIDS TODAY CH, P73; During A, 1996, ANAL BIOCHEM, V241, P199, DOI 10.1006/abio.1996.0400; Gunasekaran K, 2003, J MOL BIOL, V332, P143, DOI 10.1016/S0022-2836(03)00893-3; Hockelmann C, 2005, FLAVOUR FRAG J, V20, P387, DOI 10.1002/ffj.1464; Holger S, 2006, J BIOL CHEM, V281, P9845, DOI 10.1074/jbc.M511668200; Jung KH, 2003, MOL MICROBIOL, V47, P1513, DOI 10.1046/j.1365-2958.2003.03395.x; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P926, DOI 10.1271/bbb.57.926; KAMODA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1866, DOI 10.1271/bbb.59.1866; Kamoda S, 1997, BIOSCI BIOTECH BIOCH, V61, P1575, DOI 10.1271/bbb.61.1575; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P931, DOI 10.1271/bbb.57.931; Kauffmann I, 2001, PROTEIN ENG, V14, P919, DOI 10.1093/protein/14.11.919; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Lakshman MR, 2004, J NUTR, V134, p241S, DOI 10.1093/jn/134.1.241S; Lawrence P, 2006, ANAL CHEM, V78, P1312, DOI 10.1021/ac0516584; Lee PC, 2003, CHEM BIOL, V10, P453, DOI 10.1016/S1074-5521(03)00103-0; Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200; Mijts BN, 2005, CHEM BIOL, V12, P453, DOI 10.1016/j.chembiol.2005.02.010; MOHREN S, 1983, WATER SCI TECHNOL, V15, P221; Moiseyev G, 2006, J BIOL CHEM, V281, P2835, DOI 10.1074/jbc.M508903200; Nagao A, 2004, J NUTR, V134, p237S, DOI 10.1093/jn/134.1.237S; Nagao A, 2003, ACS SYM SER, V851, P322; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; Poliakov E, 2005, J BIOL CHEM, V280, P29217, DOI 10.1074/jbc.M500409200; PRIM N, 2006, COLLOID SURFACE B, V51, P100; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Ruch S, 2005, MOL MICROBIOL, V55, P1015, DOI 10.1111/j.1365-2958.2004.04460.x; Schmidt-Dannert C, 2000, NAT BIOTECHNOL, V18, P750, DOI 10.1038/77319; Schwartz SH, 2004, J BIOL CHEM, V279, P46940, DOI 10.1074/jbc.M409004200; Schwartz SH, 2001, J BIOL CHEM, V276, P25208, DOI 10.1074/jbc.M102146200; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Takagi S, 2005, J SMALL ANIM PRACT, V46, P504, DOI 10.1111/j.1748-5827.2005.tb00280.x; von Lintig J, 2005, BBA-MOL BASIS DIS, V1740, P122, DOI 10.1016/j.bbadis.2004.11.010; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; von Lintig J, 2004, J NUTR, V134, p251S, DOI 10.1093/jn/134.1.251S; von Lintig J, 2001, ARCH BIOCHEM BIOPHYS, V385, P47, DOI 10.1006/abbi.2000.2096; Watts KT, 2004, CHEMBIOCHEM, V5, P500, DOI 10.1002/cbic.200300783; Winterhalter P, 1996, ACS SYM SER, V637, P295; Wolf G, 2001, NUTR REV, V59, P116; Wyss A, 2004, J NUTR, V134, p246S, DOI 10.1093/jn/134.1.246S; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476	47	63	65	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31583	31593		10.1074/jbc.M606299200	http://dx.doi.org/10.1074/jbc.M606299200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920703	Bronze			2022-12-25	WOS:000241235300044
J	Pirbhai, M; Dong, F; Zhong, YM; Pan, KZ; Zhong, GM				Pirbhai, Mustak; Dong, Feng; Zhong, Youmin; Pan, Kelvin Z.; Zhong, Guangming			The secreted protease factor CPAF is responsible for degrading pro-apoptotic BH3-only proteins in Chlamydia trachomatis-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY; PROAPOPTOTIC PROTEINS; MITOCHONDRIA; DEGRADATION; DEATH; ACTIVATION; BAX; PATHOGENESIS; INHIBITION	Chlamydia trachomatis has evolved a profound anti-apoptotic activity that may aid in chlamydial evasion of host defense. The C. trachomatis anti-apoptotic activity has been correlated with blockade of mitochondrial cytochrome c release, inhibition of Bax and Bak activation, and degradation of BH3-only proteins. This study presents evidence that a chlamydia-secreted protease factor designated CPAF is both necessary and sufficient for degrading the BH3-only proteins. When the C. trachomatis-infected cell cytosolic extracts were fractionated by column chromatography, both the CPAF protein and activity elution peaks overlapped with the BH3-only protein degradation activity peak. Depletion of CPAF with a CPAF-specific antibody removed the BH3-only protein degradation activity from the infected cell cytosolic extracts, whereas depletion with control antibodies failed to do so. Notably, recombinant CPAF expressed in bacteria was able to degrade the BH3-only proteins, whereas CPAF mutants similarly prepared from bacteria failed to do so. Finally, bacterium-expressed CPAF also degraded the human BH3-only protein Puma alpha purified from bacteria. These results demonstrate that CPAF contributes to the chlamydial anti-apoptotic activity by degrading the pro-apoptotic BH3-only Bcl-2 subfamily members.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, San Antonio, TX 78229 USA; Med Coll Ohio, Dept Microbiol & Immunol, Toledo, OH 43614 USA	University of Texas System; University of Texas Health San Antonio	Zhong, GM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	Zhongg@uthscsa.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064537, R01AI057450, R01AI047997] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI64537, R01 AI47997, R01 AI57450] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beatty Wandy L., 1994, Trends in Microbiology, V2, P94, DOI 10.1016/0966-842X(94)90542-8; Bouchier-Hayes L, 2005, J CLIN INVEST, V115, P2640, DOI 10.1172/JCI26274; Bouillet P, 2002, J CELL SCI, V115, P1567; Dean D, 2001, INFECT IMMUN, V69, P2442, DOI 10.1128/IAI.69.4.2442-2447.2001; Dong F, 2005, INFECT IMMUN, V73, P1861, DOI 10.1128/IAI.73.3.1861-1864.2005; Dong F, 2004, MOL MICROBIOL, V52, P1487, DOI 10.1111/j.1365-2958.2004.04072.x; Dong F, 2004, INFECT IMMUN, V72, P3869, DOI 10.1128/IAI.72.7.3869-3875.2004; Dong F, 2004, INFECT IMMUN, V72, P3863, DOI 10.1128/IAI.72.7.3863-3868.2004; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Fischer SE, 2004, J EXP MED, V200, P905, DOI 10.1084/jem.20040402; Fischer SF, 2004, INFECT IMMUN, V72, P1107, DOI 10.1128/IAI.72.2.1107-1115.2004; Greene W, 2004, INFECT IMMUN, V72, P451, DOI 10.1128/IAI.72.1.451-460.2004; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hackstadt T, 1997, TRENDS MICROBIOL, V5, P288, DOI 10.1016/S0966-842X(97)01061-5; Hackstadt T, 1998, CURR OPIN MICROBIOL, V1, P82, DOI 10.1016/S1369-5274(98)80146-X; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lanave C, 2004, GENE, V333, P71, DOI 10.1016/j.gene.2004.02.017; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MORRISON RP, 1989, J EXP MED, V170, P1271, DOI 10.1084/jem.170.4.1271; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Sprick MR, 2004, BBA-MOL CELL RES, V1644, P125, DOI 10.1016/j.bbamcr.2003.11.002; Stephens RS, 2003, TRENDS MICROBIOL, V11, P44, DOI 10.1016/S0966-842X(02)00011-2; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wyrick PB, 2000, CELL MICROBIOL, V2, P275, DOI 10.1046/j.1462-5822.2000.00059.x; Xiao YM, 2005, J IMMUNOL, V174, P1701, DOI 10.4049/jimmunol.174.3.1701; Xiao YM, 2004, INFECT IMMUN, V72, P5470, DOI 10.1128/IAI.72.9.5470-5474.2004; Ying SM, 2005, INFECT IMMUN, V73, P1399, DOI 10.1128/IAI.73.3.1399-1403.2005; Zhong GM, 1999, J EXP MED, V189, P1931, DOI 10.1084/jem.189.12.1931; Zhong GM, 1997, P NATL ACAD SCI USA, V94, P13856, DOI 10.1073/pnas.94.25.13856; Zhong GM, 1996, J EXP MED, V184, P2061, DOI 10.1084/jem.184.5.2061; Zhong GM, 2001, J EXP MED, V193, P935, DOI 10.1084/jem.193.8.935; Zhong GM, 2000, J EXP MED, V191, P1525, DOI 10.1084/jem.191.9.1525	40	104	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31495	31501		10.1074/jbc.M602796200	http://dx.doi.org/10.1074/jbc.M602796200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16940052	Bronze			2022-12-25	WOS:000241235300034
J	Wang, JF; Zhang, XQ; Ahlers, BA; Carl, LL; Song, JL; Rothblum, LI; Stahl, RC; Carey, DJ; Cheung, JY				Wang, JuFang; Zhang, Xue-Qian; Ahlers, Belinda A.; Carl, Lois L.; Song, Jianliang; Rothblum, Lawrence I.; Stahl, Richard C.; Carey, David J.; Cheung, Joseph Y.			Cytoplasmic tail of phospholemman interacts with the intracellular loop of the cardiac Na+/Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT MYOCYTES; PROTEIN-KINASE-C; SARCOLEMMAL NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGER; NA-K-ATPASE; FXYD PROTEINS; ALTERS CONTRACTILITY; <CA2+>(I) TRANSIENTS; INTACT MYOCARDIUM; NA/CA EXCHANGER	Phospholemman (PLM), a member of the FXYD family of small ion transport regulators, inhibits cardiac Na+/Ca2+ exchanger (NCX1). NCX1 is made up of N-terminal domain consisting of the first five transmembrane segments ( residues 1-217), a large intracellular loop (residues 218-764), and a C-terminal domain comprising the last four transmembrane segments (residues 765-938). Using glutathione S-transferase (GST) pull-down assay, we demonstrated that the intracellular loop, but not the N- or C-terminal transmembrane domains of NCX1, was associated with PLM. Further analysis using protein constructs of GST fused to various segments of the intracellular loop of NCX1 suggest that PLM bound to residues 218-371 and 508-764 but not 371-508. Split Na+/Ca2+ exchangers consisting of N- or C-terminal domains with different lengths of the intracellular loop were co-expressed with PLM in HEK293 cells that are devoid of endogenous PLM and NCX1. Although expression of N- terminal but not C-terminal domain alone resulted in correct membrane targeting, co-expression of both N- and C-terminal domains was required for correct membrane targeting and functional exchange activity. NCX1 current measurements indicate that PLM decreased NCX1current only when the split exchangers contained residues 218-358 of the intracellular loop. Co-immunoprecipitation experiments with PLM and split exchangers suggest that PLM associated with the N- terminal domain of NCX1 when it contained intracellular loop residues 218-358. TM43, a PLM mutant with its cytoplasmic tail truncated, did not co-immunoprecipitate with wild-type NCX1 when co-expressed in HEK293 cells, confirming little to no interaction between the transmembrane domains of PLM and NCX1. We conclude that PLM interacted with the intracellular loop of NCX1, most likely at residues 218-358.	Penn State Univ, Dept Cellular & Mol Physiol, Milton S Hershey Med Ctr, Hershey, PA 17033 USA; Penn State Univ, Dept Med, Milton S Hershey Med Ctr, Hershey, PA 17033 USA; Geisinger Med Ctr, Weis Ctr Res, Danville, PA 17822 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Geisinger Medical Center	Cheung, JY (corresponding author), Penn State Univ, Dept Cellular & Mol Physiol, Milton S Hershey Med Ctr, MC H166, Hershey, PA 17033 USA.	jyc1@psu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077814, R01HL058672, R01HL074854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925, R01NS041363] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58672, HL-74854, R01 HL074854, R01 HL058672, HL-77814, R01 HL077814] Funding Source: Medline; NIDDK NIH HHS [DK-46678] Funding Source: Medline; NIGMS NIH HHS [R01 GM069841, GM-69841] Funding Source: Medline; NINDS NIH HHS [R01 NS021925, NS-21925, R01 NS041363, NS-41363] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahlers BA, 2005, J BIOL CHEM, V280, P19875, DOI 10.1074/jbc.M414703200; Beevers AJ, 2006, PROTEIN SCI, V15, P1127, DOI 10.1110/ps.051899406; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Chen ZH, 1998, CIRC RES, V82, P367, DOI 10.1161/01.RES.82.3.367; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Davis CE, 2004, NEUROCHEM RES, V29, P177, DOI 10.1023/B:NERE.0000010447.24128.ac; Despa S, 2005, CIRC RES, V97, P252, DOI 10.1161/01.RES.0000176532.97731.e5; Dostanic I, 2004, J BIOL CHEM, V279, P54053, DOI 10.1074/jbc.M410737200; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Geering K, 2006, AM J PHYSIOL-RENAL, V290, pF241, DOI 10.1152/ajprenal.00126.2005; He ZP, 2000, AM J PHYSIOL-CELL PH, V278, pC661, DOI 10.1152/ajpcell.2000.278.4.C661; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; Katanosaka Y, 2005, J BIOL CHEM, V280, P5764, DOI 10.1074/jbc.M410240200; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; LI ZP, 1991, J BIOL CHEM, V266, P1014; LINDEMANN JP, 1986, J BIOL CHEM, V261, P4860; Lindzen M, 2006, J BIOL CHEM, V281, P5947, DOI 10.1074/jbc.M512063200; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; Maack C, 2005, CIRC RES, V96, P91, DOI 10.1161/01.RES.0000151334.48676.68; MacLennan DH, 2003, ANN NY ACAD SCI, V986, P472, DOI 10.1111/j.1749-6632.2003.tb07231.x; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; McDonough AA, 1996, AM J PHYSIOL-CELL PH, V270, pC1221, DOI 10.1152/ajpcell.1996.270.4.C1221; Mirza MA, 2004, AM J PHYSIOL-HEART C, V286, pH1322, DOI 10.1152/ajpheart.00997.2003; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; Morales-Mulia M, 2000, BBA-MOL CELL RES, V1496, P252, DOI 10.1016/S0167-4889(00)00023-9; Moran J, 2001, BBA-MOL CELL RES, V1538, P313, DOI 10.1016/S0167-4889(01)00082-9; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Ottolia M, 2001, J BIOL CHEM, V276, P19603, DOI 10.1074/jbc.M101489200; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; Scriven DRL, 2000, BIOPHYS J, V79, P2682, DOI 10.1016/S0006-3495(00)76506-4; Seidler T, 2003, CIRC RES, V93, P132, DOI 10.1161/01.RES.0000081596.90205.E2; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Song JL, 2005, AM J PHYSIOL-HEART C, V288, pH2342, DOI 10.1152/ajpheart.01133.2004; Song JL, 2002, AM J PHYSIOL-HEART C, V283, pH576, DOI 10.1152/ajpheart.00197.2002; SWEADNER KJ, 1994, CIRC RES, V74, P669, DOI 10.1161/01.RES.74.4.669; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Tadros GM, 2002, AM J PHYSIOL-HEART C, V283, pH1616, DOI 10.1152/ajpheart.00186.2002; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; TUCKER AL, 2006, IN PRESS AM J PHYSL; WAALAS SI, 1994, BIOCHEM J, V304, P635; Zhang XQ, 2006, J BIOL CHEM, V281, P7784, DOI 10.1074/jbc.M512092200; Zhang XQ, 2006, J APPL PHYSIOL, V100, P212, DOI 10.1152/japplphysiol.00757.2005; Zhang XQ, 2003, AM J PHYSIOL-HEART C, V284, pH225, DOI 10.1152/ajpheart.00698.2002; Zhang XQ, 2001, AM J PHYSIOL-HEART C, V281, pH2079, DOI 10.1152/ajpheart.2001.281.5.H2079	54	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					32004	32014		10.1074/jbc.M606876200	http://dx.doi.org/10.1074/jbc.M606876200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16921169	Green Accepted, Bronze			2022-12-25	WOS:000241235300086
J	Ilouz, R; Kowalsman, N; Eisenstein, M; Eldar-Finkelman, H				Ilouz, Ronit; Kowalsman, Noga; Eisenstein, Miriam; Eldar-Finkelman, Hagit			Identification of novel glycogen synthase kinase-3 beta substrate-interacting residues suggests a common mechanism for substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; PEPTIDE INHIBITOR; PHOSPHORYLATION; SPECIFICITY; EXPRESSION; TYROSINE; BINDING; 3-BETA	Substrate recognition and specificity are essential for the reliability and fidelity of protein kinase function. GSK-3 has a unique substrate specificity that requires prior phosphorylation of its substrates. However, how the enzyme selects its phosphorylated substrates is unknown. Here, we combined in silico modeling with mutagenesis and biological studies to identify GSK-3-substrate interaction sites located within its binding cleft. Protein-protein docking of GSK-3 beta and the phosphorylated cAMP responsive element binding protein (pCREB) (using the available experimentally determined structures), identified Phe(67), Gln(89), and Asn(95) of GSK-3 beta as putative binding sites interacting with the CREB phosphorylation motif. Mutations of these residues to alanine impaired GSK-3 beta phosphorylation of several substrates, without abrogating its autocatalytic activity. Subsequently, expression of the GSK-3 beta mutants in cells resulted in decreased phosphorylation of substrates CREB, IRS-1, and beta-catenin, and prevented their suppression of glycogen synthase activity as compared with cells expressing the wildtype GSK-3 beta. Our studies provide important additional understanding of how GSK-3 beta recognizes its substrates: In addition to prior phosphorylation typically required in GSK- 3 substrates, substrate recognition involves interactions with GSK-3 beta residues: Phe(67), Gln(89), and Asn(95), which confer a common basis for substrate binding and selectivity, yet allow for substrate diversity.	Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Chem Res Support, IL-76100 Rehovot, Israel	Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Weizmann Institute of Science	Eldar-Finkelman, H (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel.	heldar@post.tau.ac.il		Eldar-Finkelman, Hagit/0000-0002-8460-9686				Alto NM, 2003, P NATL ACAD SCI USA, V100, P4445, DOI 10.1073/pnas.0330734100; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Ben-Zeev E, 2003, PROTEINS, V52, P24, DOI 10.1002/prot.10391; BERCHANSKI A, 2004, PROTEINS, V351, P309; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bertrand JA, 2003, J MOL BIOL, V333, P393, DOI 10.1016/j.jmb.2003.08.031; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gould TD, 2004, J CLIN PSYCHIAT, V65, P10; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Heifetz A, 2002, PROTEIN SCI, V11, P571, DOI 10.1110/ps.26002; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Liberman Z, 2005, J BIOL CHEM, V280, P4422, DOI 10.1074/jbc.M410610200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Narayana N, 1997, BIOCHEMISTRY-US, V36, P4438, DOI 10.1021/bi961947+; Padilla A, 1997, J PEPT RES, V49, P210; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Woodgett J. R., 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P281, DOI 10.2174/1568008033340153; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe Michael B, 2004, Methods Mol Biol, V250, P237; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870	45	42	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30621	30630		10.1074/jbc.M604633200	http://dx.doi.org/10.1074/jbc.M604633200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16893889	hybrid			2022-12-25	WOS:000241075900038
J	Jors, S; Kazanski, V; Foik, A; Krautwurst, D; Harteneck, C				Joers, Simone; Kazanski, Victor; Foik, Anna; Krautwurst, Dietmar; Harteneck, Christian			Receptor-induced activation of Drosophila TRP gamma by polyunsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-PERMEABLE CATION CHANNEL; CYTOSOLIC PHOSPHOLIPASE A(2); PROTEIN-COUPLED RECEPTOR; STORE-OPERATED CHANNELS; TRANSIENT RECEPTOR; POTENTIAL CHANNELS; HEK-293 CELLS; MELANOGASTER; SUBUNITS; GENE	Cellular calcium homeostasis is regulated by hormones and neurotransmitters, resulting in the activation of a variety of proteins, in particular, channel proteins of the plasma membrane and of intracellular compartments. Such channels are, for example, TRP channels of the TRPC protein family that are activated by various mediators from receptor-stimulated signaling cascades. In Drosophila, two TRPC channels, TRP and TRPL, are involved in phototransduction. In addition, a third Drosophila TRPC channel, TRP gamma, has been identified and described as an auxiliary subunit of TRPL. Beyond it, our data show that heterologously expressed TRP gamma formed a receptor-activated, outwardly rectifying cation channel independent from TRPL coexpression. Analysis of the activation mechanism revealed that TRP gamma is activated by various polyunsaturated fatty acids generated in a phospholipase C- and phospholipase A(2)- dependent manner. The most potent activator of TRP gamma, the stable analogue of arachidonic acid, 5,8,11,14-eicosatetraynoic acid, induced currents in single channel recordings. Here we show that upon heterologous expression TRP gamma forms a homomeric channel complex that is activated by polyunsaturated fatty acids as mediators of receptor- dependent signaling pathways. Reverse transcription PCR analysis showed that TRP gamma is expressed in Drosophila heads and bodies. Its body- wide expression pattern and its activation mechanism suggest that TRP gamma forms a fly cation channel responsible for the regulation of intracellular calcium in a variety of hormonal signaling cascades.	Inst Pharmakol, D-14195 Berlin, Germany; Free Univ Berlin, Fachbereich Biol, D-14195 Berlin, Germany; Deutsch Inst Ernahrungsforsch Potsdam Rehbrucke, Abt Mol Genet, D-14558 Nuthetal, Germany	Free University of Berlin; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Harteneck, C (corresponding author), Inst Pharmakol, Charite Campus Benjamin Franklin,Thielallee 69-73, D-14195 Berlin, Germany.	Christian.Harteneck@charite.de	Krautwurst, Dietmar/AAD-5579-2019	Krautwurst, Dietmar/0000-0002-3350-8682				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bahner M, 2002, NEURON, V34, P83, DOI 10.1016/S0896-6273(02)00630-X; Balfanz S, 2005, J NEUROCHEM, V93, P440, DOI 10.1111/j.1471-4159.2005.03034.x; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Brody T, 2000, J CELL BIOL, V150, pF83, DOI 10.1083/jcb.150.2.F83; Chiang AS, 2004, CURR BIOL, V14, P263, DOI 10.1016/j.cub.2004.02.003; Chubanov V, 2005, N-S ARCH PHARMACOL, V371, pR53; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Clapham DE, 2005, PHARMACOL REV, V57, P427, DOI 10.1124/pr.57.4.6; Finn JT, 1998, BIOPHYS J, V74, P1333, DOI 10.1016/S0006-3495(98)77846-4; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; HARTENECK C, 1995, FEBS LETT, V358, P297, DOI 10.1016/0014-5793(94)01455-A; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Husain S, 1999, BIOCHEM J, V342, P87, DOI 10.1042/0264-6021:3420087; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEURS R, 1994, J NEUROCHEM, V62, P519; Lucas P, 2003, NEURON, V40, P551, DOI 10.1016/S0896-6273(03)00675-5; MacPherson MR, 2005, GENETICS, V169, P1541, DOI 10.1534/genetics.104.035139; Millar NS, 2003, BIOCHEM SOC T, V31, P869, DOI 10.1042/BST0310869; Montell C, 2005, PFLUG ARCH EUR J PHY, V451, P19, DOI 10.1007/s00424-005-1426-2; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Qian F, 2002, DIABETES, V51, pS183, DOI 10.2337/diabetes.51.2007.S183; Radford JC, 2002, J BIOL CHEM, V277, P38810, DOI 10.1074/jbc.M203694200; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Wicher D, 2006, J BIOL CHEM, V281, P3227, DOI 10.1074/jbc.M511741200; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; YU FH, 2004, SCI STKE; Zagranichnaya TK, 2005, J BIOL CHEM, V280, P29559, DOI 10.1074/jbc.M505842200; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	45	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29693	29702		10.1074/jbc.M602215200	http://dx.doi.org/10.1074/jbc.M602215200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16901908	hybrid			2022-12-25	WOS:000240896300031
J	Kajiyama, Y; Tian, JM; Locker, J				Kajiyama, Yasuo; Tian, Jianmin; Locker, Joseph			Characterization of distant enhancers and promoters in the albumin-alpha-fetoprotein locus during active and silenced expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-BINDING; GENE-EXPRESSION; ALPHA-1-FETOPROTEIN GENE; FUNCTIONAL-ANALYSIS; REPRESSION; SITE; REGION; METHYLATION; ELEMENTS; P53	The albumin and alpha-fetoprotein genes are adjacent and express closely related serum proteins. Both genes are strongly expressed in fetal liver, primarily through activation by distant enhancers, but the AFP gene selectively undergoes developmental silencing. We used chromatin immunoprecipitation to study enhancers and promoters during active and silenced gene expression. In adult phenotype cells, the silenced AFP gene was actively repressed at the promoter and two proximal enhancers, characterized by the absence of coactivators and acetylated histone 4, and the presence of corepressors and K9-methylated histone 3. Specific transcription factors, TBP, and RNA polymerase II were all detected on both active and silenced genes, indicating that both states were actively regulated. Surprisingly, promoter-specific factors were also detected on enhancers, especially with reduced chromatin shearing. Under these conditions, an enhancer-specific factor was also detected on the albumin promoter. Association of promoter- and enhancer-specific factors was confirmed by sequential immunoprecipitation. Because no binding was detected on intervening segments, these promoter-enhancer associations suggest looping.	Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Locker, J (corresponding author), Albert Einstein Coll Med, Dept Pathol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	locker@aecom.yu.edu			NCI NIH HHS [CA68440, CA76354] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068440, R01CA076354] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abelev GI, 1999, SEMIN CANCER BIOL, V9, P95, DOI 10.1006/scbi.1998.0084; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BELAYEW A, 1982, MOL CELL BIOL, V2, P1427, DOI 10.1128/MCB.2.11.1427; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; Cui RT, 2005, J BIOL CHEM, V280, P39152, DOI 10.1074/jbc.M504655200; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Dean A, 2006, TRENDS GENET, V22, P38, DOI 10.1016/j.tig.2005.11.001; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Forsberg EC, 2000, BLOOD, V96, P334, DOI 10.1182/blood.V96.1.334.013k17_334_339; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GROUPP ER, 1994, J BIOL CHEM, V269, P22178; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; HU JM, 1992, CELL GROWTH DIFFER, V3, P577; INGRAM RS, 1981, P NATL ACAD SCI-BIOL, V78, P4694, DOI 10.1073/pnas.78.8.4694; Kajiyama Y, 2002, MOL CELL BIOL, V22, P6122, DOI 10.1128/MCB.22.17.6122-6130.2002; Kim A, 2004, P NATL ACAD SCI USA, V101, P7028, DOI 10.1073/pnas.0307985101; Li C, 1996, DNA CELL BIOL, V15, P955, DOI 10.1089/dna.1996.15.955; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LIU Y, 1994, NUCLEIC ACIDS RES, V22, P1079, DOI 10.1093/nar/22.6.1079; Locker J, 2002, NUCLEIC ACIDS RES, V30, P3809, DOI 10.1093/nar/gkf484; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MUGLIA L, 1984, NUCLEIC ACIDS RES, V12, P6751, DOI 10.1093/nar/12.17.6751; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nguyen TT, 2005, MOL CELL BIOL, V25, P2147, DOI 10.1128/MCB.25.6.2147-2157.2005; Patrinos GP, 2004, GENE DEV, V18, P1495, DOI 10.1101/gad.289704; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; Samadani U, 1996, MOL CELL BIOL, V16, P6273; SCHULZ WA, 1988, EXP CELL RES, V174, P433, DOI 10.1016/0014-4827(88)90313-8; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Spear BT, 1999, SEMIN CANCER BIOL, V9, P109, DOI 10.1006/scbi.1998.0087; Tchenio T, 2001, MOL CELL BIOL, V21, P1953, DOI 10.1128/MCB.21.6.1953-1961.2001; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; TURCOTTE B, 1986, NUCLEIC ACIDS RES, V14, P9827, DOI 10.1093/nar/14.24.9827; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; Vorachek WR, 2000, J BIOL CHEM, V275, P29031, DOI 10.1074/jbc.M003039200; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525; Wolffe AP, 2001, ESSAYS BIOCHEM, V37, P45, DOI 10.1042/bse0370045; Young AP, 2004, ONCOGENE, V23, P814, DOI 10.1038/sj.onc.1207187; ZHANG DE, 1991, J BIOL CHEM, V266, P21179	45	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30122	30131		10.1074/jbc.M603491200	http://dx.doi.org/10.1074/jbc.M603491200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16893898	hybrid			2022-12-25	WOS:000240896300073
J	Liiv, A; O'Connor, M				Liiv, Aivar; O'Connor, Michael			Mutations in the intersubunit bridge regions of 23 S rRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESSURE-INDUCED DISSOCIATION; ESCHERICHIA-COLI RIBOSOME; ANGSTROM RESOLUTION; PROTEIN-SYNTHESIS; CRYOELECTRON MICROSCOPY; SUBUNIT ASSOCIATION; CRYO-EM; TRANSLATION; MECHANISM; SELECTION	The large and small subunits of the ribosome are joined by a series of bridges that are conserved among mitochondrial, bacterial, and eukaryal ribosomes. In addition to joining the subunits together at the initiation of protein synthesis, a variety of other roles have been proposed for these bridges. These roles include transmission of signals between the functional centers of the two subunits, modulation of tRNA- ribosome and factor-ribosome interactions, and mediation of the relative movement of large and small ribosomal subunits during translocation. The majority of the bridges involve RNA-RNA interactions, and to gain insight into their function, we constructed mutations in the 23 S rRNA regions involved in forming 7 of the 12 intersubunit bridges in the Escherichia coli ribosome. The majority of the mutants were viable in strains expressing mutant rRNA exclusively but had distinct growth phenotypes, particularly at 30 C, and the mutant ribosomes promoted a variety of miscoding errors. Analysis of subunit association activities both in vitro and in vivo indicated that, with the exception of the bridge B5 mutants, at least one mutation at each bridge site affected 70 S ribosome formation. These results confirm the structural data linking bridges with subunit- subunit interactions and, together with the effects on decoding fidelity, indicate that intersubunit bridges function at multiple stages of protein synthesis.	Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA; Univ Tartu, Estonian Bioctr, EE-51010 Tartu, Estonia	University of Missouri System; University of Missouri Kansas City; Estonian Biocentre; University of Tartu	O'Connor, M (corresponding author), Univ Missouri, Sch Biol Sci, 5007 Rockhill Rd, Kansas City, MO 64110 USA.	oconnormi@umkc.edu	Liiv, aivar/D-3837-2014					Allen GS, 2005, CELL, V121, P703, DOI 10.1016/j.cell.2005.03.023; Asai T, 1999, P NATL ACAD SCI USA, V96, P1971, DOI 10.1073/pnas.96.5.1971; Asai T, 1999, J BACTERIOL, V181, P3803, DOI 10.1128/JB.181.12.3803-3809.1999; Baierlein R, 1974, Methods Enzymol, V30, P328; Blaha G, 2002, BIOPHYS CHEM, V96, P153, DOI 10.1016/S0301-4622(02)00021-2; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-15; Cochella L, 2004, P NATL ACAD SCI USA, V101, P3786, DOI 10.1073/pnas.0307596101; Cukras AR, 2005, J MOL BIOL, V349, P47, DOI 10.1016/j.jmb.2005.03.075; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; DOUTHWAITE S, 1985, P NATL ACAD SCI USA, V82, P8330, DOI 10.1073/pnas.82.24.8330; Firpo MA, 1998, NUCLEIC ACIDS RES, V26, P2156, DOI 10.1093/nar/26.9.2156; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Gao HX, 2003, CELL, V113, P789, DOI 10.1016/S0092-8674(03)00427-6; Gao N, 2005, MOL CELL, V18, P663, DOI 10.1016/j.molcel.2005.05.005; Ghosh S, 2005, RNA, V11, P657, DOI 10.1261/rna.7224305; GODSON GN, 1967, BIOCHIM BIOPHYS ACTA, V149, P476, DOI 10.1016/0005-2787(67)90175-X; Gregory ST, 1998, METH MOL B, V77, P271; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIROKAWA G, 2005, RNA NY, V8, P1317; INFANTE AA, 1982, J BIOL CHEM, V257, P80; INFANTE AA, 1971, P NATL ACAD SCI USA, V68, P1780, DOI 10.1073/pnas.68.8.1780; Knight W, 2005, COMPUT BIOL CHEM, V29, P163, DOI 10.1016/j.compbiolchem.2005.01.001; LARSEN B, 1994, J BACTERIOL, V176, P6842, DOI 10.1128/JB.176.22.6842-6851.1994; LEVIEV I, 1995, NUCLEIC ACIDS RES, V23, P1512; Maivali U, 2004, RNA, V10, P600, DOI 10.1261/rna.5220504; Maldonado R, 1998, J BACTERIOL, V180, P1822, DOI 10.1128/JB.180.7.1822-1830.1998; Matadeen R, 1999, STRUCTURE, V7, P1575, DOI 10.1016/S0969-2126(00)88348-3; MIKKOLA R, 1991, BIOCHIMIE, V73, P1551, DOI 10.1016/0300-9084(91)90190-C; O'Connor M, 2004, NUCLEIC ACIDS RES, V32, P5750, DOI 10.1093/nar/gkh913; OCONNOR M, 1995, J MOL BIOL, V254, P838, DOI 10.1006/jmbi.1995.0659; Ogle JM, 2003, TRENDS BIOCHEM SCI, V28, P259, DOI 10.1016/S0968-0004(03)00066-5; Rackham O, 2006, NAT CHEM BIOL, V2, P254, DOI 10.1038/nchembio783; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Sergiev PV, 2005, J MOL BIOL, V353, P116, DOI 10.1016/j.jmb.2005.08.006; Sharma MR, 2003, CELL, V115, P97, DOI 10.1016/S0092-8674(03)00762-1; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Tama F, 2003, P NATL ACAD SCI USA, V100, P9319, DOI 10.1073/pnas.1632476100; TAPPRICH WE, 1989, P NATL ACAD SCI USA, V86, P4927, DOI 10.1073/pnas.86.13.4927; Thompson J, 2002, J MOL BIOL, V322, P273, DOI 10.1016/S0022-2836(02)00784-2; VANDIGGELEN OP, 1971, FEBS LETT, V19, P115, DOI 10.1016/0014-5793(71)80492-1; Vila-Sanjurjo A, 2003, P NATL ACAD SCI USA, V100, P8682, DOI 10.1073/pnas.1133380100; Wilson DN, 2005, EMBO J, V24, P251, DOI 10.1038/sj.emboj.7600525; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	45	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29850	29862		10.1074/jbc.M603013200	http://dx.doi.org/10.1074/jbc.M603013200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16891309	hybrid			2022-12-25	WOS:000240896300047
J	Owegi, MA; Pappas, DL; Finch, MW; Bilbo, SA; Resendiz, CA; Jacquemin, LJ; Warrier, A; Trombley, JD; McCulloch, KM; Margalef, KLM; Mertz, MJ; Storms, JM; Damin, CA; Parra, KJ				Owegi, Margaret A.; Pappas, Donald L., Jr.; Finch, Mark W.; Bilbo, Sarah A.; Resendiz, Cruz A.; Jacquemin, Lori J.; Warrier, Aswathy; Trombley, John D.; McCulloch, Kathryn M.; Margalef, Katrina L. M.; Mertz, Melissa J.; Storms, Jason M.; Damin, Craig A.; Parra, Karlett J.			Identification of a domain in the V-o subunit d that is critical for coupling of the yeast vacuolar proton-translocating ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO DISSOCIATION; MEMBRANE H+-ATPASE; MUTATIONAL ANALYSIS; SACCHAROMYCES-CEREVISIAE; ELECTRON-MICROSCOPY; ADENOSINE-TRIPHOSPHATASES; 3-DIMENSIONAL STRUCTURE; NONHOMOLOGOUS REGION; THERMUS-THERMOPHILUS; PERIPHERAL STALK	Vacuolar proton-translocating ATPase pumps consist of two domains, V-1 and V-o. Subunit d is a component of Vo located in a central stalk that rotates during catalysis. By generating mutations, we showed that subunit d couples ATP hydrolysis and proton transport. The mutation F94A strongly uncoupled the enzyme, preventing proton transport but not ATPase activity. C-terminal mutations changed coupling as well; ATPase activity was decreased by 59-72%, whereas proton transport was not measurable (E328A) or was moderately reduced (E317A and C329A). Except for W325A, which had low levels of V1Vo, mutations allowed wild-type assembly regardless of the fact that subunits E and d were reduced at the membrane. N- and C-terminal deletions of various lengths were inhibitory and gradually destabilized subunit d, limiting V1Vo formation. Both N and C terminus were required for Vo assembly. The N- terminal truncation 2-19 Delta prevented V1Vo formation, although subunit d was available. The C terminus was required for retention of subunits E and d at the membrane. In addition, the C terminus of its bacterial homolog ( subunit C from T. thermophilus) stabilized the yeast subunit d mutant 310 - 345 Delta and allowed assembly of the rotor structure with subunits A and B. Structural features conserved between bacterial and eukaryotic subunit d and the significance of domain 3 for vacuolar proton-translocating ATPase function are discussed.	Ball State Univ, Dept Chem, Muncie, IN 47306 USA	Ball State University	Parra, KJ (corresponding author), Ball State Univ, Dept Chem, Muncie, IN 47306 USA.	kparrabelky@bsu.edu		McCulloch, Kathryn/0000-0001-9077-3821				Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Fethiere J, 2004, J BIOL CHEM, V279, P40670, DOI 10.1074/jbc.M407086200; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HO MN, 1993, J BIOL CHEM, V268, P18286; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; KANE PM, 1989, J BIOL CHEM, V264, P19236; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makyio H, 2005, EMBO J, V24, P3974, DOI 10.1038/sj.emboj.7600859; Malkus P, 2004, MOL BIOL CELL, V15, P5075, DOI 10.1091/mbc.E04-06-0514; Muller V, 2003, CELL MOL LIFE SCI, V60, P474, DOI 10.1007/s000180300040; Murata T, 2005, SCIENCE, V308, P654, DOI 10.1126/science.1110064; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P46396, DOI 10.1074/jbc.M303924200; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Ohira M, 2006, J BIOL CHEM, V281, P22752, DOI 10.1074/jbc.M601441200; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Owegi MA, 2005, J BIOL CHEM, V280, P18393, DOI 10.1074/jbc.M412567200; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Shao E, 2004, J BIOL CHEM, V279, P48663, DOI 10.1074/jbc.M408278200; Shao E, 2003, J BIOL CHEM, V278, P12985, DOI 10.1074/jbc.M212096200; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Supekova L, 1996, J EXP BIOL, V199, P1147; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 2005, MICRON, V36, P109, DOI 10.1016/j.micron.2004.10.002; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Xie XS, 1996, J BIOL CHEM, V271, P30980; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Yokoyama K, 2003, J BIOL CHEM, V278, P42686, DOI 10.1074/jbc.M305853200; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; Zhang ZY, 2006, FEBS LETT, V580, P2006, DOI 10.1016/j.febslet.2006.03.001	59	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30001	30014		10.1074/jbc.M605006200	http://dx.doi.org/10.1074/jbc.M605006200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16891312	hybrid			2022-12-25	WOS:000240896300061
J	Molina-Sanchez, MD; Martinez-Abarca, F; Toro, N				Molina-Sanchez, Maria Dolores; Martinez-Abarca, Francisco; Toro, Nicolas			Excision of the Sinorhizobium meliloti group II intron RmInt1 as circles in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILE GENETIC ELEMENTS; PODOSPORA-ANSERINA; ENCODED PROTEIN; DNA; TRANSPOSITION; MITOCHONDRIA; SENESCENCE; STRAND; YEAST	Excision of group II introns as circles has been described only for a few eukaryotic introns and little is known about the mechanisms involved, the relevance or consequences of the process. We report that splicing of the bacterial group II intron RmInt1 in vivo leads to the formation of both intron lariat and intron RNA circles. We determined that besides being required for the intron splicing reaction, the maturase domain of the intron-encoded protein also controls the balance between lariat and RNA intron circle production. Furthermore, comparison with in vitro self-splicing products indicates that in vivo, the intron-encoded protein appears to promote the use of a correct EBS1/IBS1 intron-exon interaction as well as cleavage at, or next to, the expected 3' splice site. These findings provide new insights on the mechanism of excision of group II introns as circles.	CSIC, Grp Ecol Genet, Estac Expt Zaidin, E-18008 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)	Toro, N (corresponding author), CSIC, Grp Ecol Genet, Estac Expt Zaidin, Calle Prof Albareda 1, E-18008 Granada, Spain.	ntoro@eez.csic.es	Molina-Sánchez, Maria Dolores/J-1925-2016; Toro, Nicolas/K-4909-2014; Martinez-Abarca, Francisco/K-9263-2014	Molina-Sánchez, Maria Dolores/0000-0002-3627-9360; Toro, Nicolas/0000-0002-3614-807X; Martinez-Abarca, Francisco/0000-0003-0417-6217				Begel O, 1999, MOL CELL BIOL, V19, P4093; Costa M, 2006, BIOCHIMIE, V88, P711, DOI 10.1016/j.biochi.2005.12.007; Dai LX, 2002, NUCLEIC ACIDS RES, V30, P1091, DOI 10.1093/nar/30.5.1091; Lambowitz AM, 2004, ANNU REV GENET, V38, P1, DOI 10.1146/annurev.genet.38.072902.091600; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; Lambowitz AM., 1999, GROUP GROUP 2 RIBOZY, P451; Li-Pook-Than J, 2006, NUCLEIC ACIDS RES, V34, P2782, DOI 10.1093/nar/gkl328; LORSCH JR, 1995, NUCLEIC ACIDS RES, V23, P2811, DOI 10.1093/nar/23.15.2811; Martinez-Abarca F, 2000, MOL MICROBIOL, V35, P1405, DOI 10.1046/j.1365-2958.2000.01804.x; Martinez-Abarca F, 2004, NUCLEIC ACIDS RES, V32, P2880, DOI 10.1093/nar/gkh616; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; Munoz-Adelantado E, 2003, J MOL BIOL, V327, P931, DOI 10.1016/S0022-2836(03)00208-0; Murray HL, 2001, MOL CELL, V8, P201, DOI 10.1016/S1097-2765(01)00300-8; OSIEWACZ HD, 1984, CURR GENET, V8, P299, DOI 10.1007/BF00419728; Podar M, 1998, NATURE, V391, P915, DOI 10.1038/36142; SAINSARDCHANET A, 1994, J MOL BIOL, V242, P630, DOI 10.1006/jmbi.1994.1613; San Filippo J, 2002, J MOL BIOL, V324, P933, DOI 10.1016/S0022-2836(02)01147-6; SCHMIDT WM, 1994, J MOL BIOL, V243, P157, DOI 10.1006/jmbi.1994.1642; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; Toro N, 2003, ENVIRON MICROBIOL, V5, P143, DOI 10.1046/j.1462-2920.2003.00398.x; Vogel J, 1997, NUCLEIC ACIDS RES, V25, P2030, DOI 10.1093/nar/25.10.2030; Vogel J, 2002, EMBO J, V21, P3794, DOI 10.1093/emboj/cdf359; Zimmerly S, 2001, NUCLEIC ACIDS RES, V29, P1238, DOI 10.1093/nar/29.5.1238	24	30	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28737	28744		10.1074/jbc.M602695200	http://dx.doi.org/10.1074/jbc.M602695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16887813	Green Submitted, hybrid			2022-12-25	WOS:000240680500027
J	Varfolomeev, E; Wayson, SM; Dixit, VM; Fairbrother, WJ; Vucic, D				Varfolomeev, Eugene; Wayson, Sarah M.; Dixit, Vishva M.; Fairbrother, Wayne J.; Vucic, Domagoj			The inhibitor of apoptosis protein fusion c-IAP2 center dot MALT1 stimulates NF-kappa B activation independently of TRAF1 AND TRAF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; LYMPHOID-TISSUE LYMPHOMAS; MALT LYMPHOMA; STRUCTURAL BASIS; ML-IAP; MELANOMA INHIBITOR; SIGNALING COMPLEX; UBIQUITIN LIGASE; T(11/18)(Q21,Q21); KINASE	The inhibitors of apoptosis (IAPs) are a family of cell death inhibitors found in viruses and metazoans. All members of the IAP family have at least one baculovirus IAP repeat (BIR) motif that is essential for their anti-apoptotic activity. The t(11, 18)(q21;q21) translocation fuses the BIR domains of c-IAP2 with the paracaspase/MALT1 (mucosa-associated lymphoid tissue) protein, a critical mediator of T cell receptor-stimulated activation of NF-kappa B. The c-IAP2 center dot MALT1 fusion protein constitutively activates the NF-kappa B pathway, and this is considered critical to malignant B cell transformation and lymphoma progression. The BIR domains of c-IAP1 and c-IAP2 interact with tumor necrosis factor receptor-associated factors 1 and 2 (TRAF1 and TRAF2). Here we investigated the importance of TRAF1 and TRAF2 for c-IAP2(.)MALT1-stimulated NF-kappa B activation. We identified a novel epitope within the BIR1 domains of c-IAP1 and c-IAP2 that is crucial for their physical interaction with TRAF1 and TRAF2. The c-IAP2(.)MALT1 fusion protein associates with TRAF1 and TRAF2 using the same binding site. We explored the functional relevance of this interaction and established that binding to TRAF1 and TRAF2 is not required for c-IAP2(.)MALT1-stimulated NF-kappa B activation. Furthermore, gene ablation of TRAF2 or combined down-regulation of TRAF1 and TRAF2 did not affect c-IAP2(.)MALT1 stimulated signaling. However, TRAF1/2-binding mutants of c-IAP2(.)MALT1 still oligomerize and activate NF-kappa B, suggesting that oligomerization might be important for signaling of the fusion protein. Therefore, the t(11, 18)(q21; q21) translocation creating the c-IAP2(.)MALT1 fusion protein activates NF-kappa B and contributes to human malignancy in the absence of signaling adaptors that might otherwise regulate its activity.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94110 USA; Genentech Inc, Dept Physiol Chem, San Francisco, CA 94110 USA	Roche Holding; Genentech; Roche Holding; Genentech	Vucic, D (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way,MS 42, San Francisco, CA 94110 USA.	domagoj@gene.com	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Franklin MC, 2003, BIOCHEMISTRY-US, V42, P8223, DOI 10.1021/bi034227t; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu SM, 2006, J CLIN INVEST, V116, P174, DOI 10.1172/JCI25641; Isaacson PG, 2005, BEST PRACT RES CL HA, V18, P57, DOI 10.1016/j.beha.2004.08.003; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Lee JS, 2004, PROTEOMICS, V4, P3376, DOI 10.1002/pmic.200401000; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Morgan JA, 1999, CANCER RES, V59, P6205; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Snipas SJ, 2004, BIOL CHEM, V385, P1093, DOI 10.1515/BC.2004.142; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2005, BIOCHEM J, V385, P11, DOI 10.1042/BJ20041108; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Ye HT, 2003, BLOOD, V102, P1012, DOI 10.1182/blood-2002-11-3502; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	38	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29022	29029		10.1074/jbc.M605116200	http://dx.doi.org/10.1074/jbc.M605116200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16891304	hybrid			2022-12-25	WOS:000240680500057
J	Cheng, S; Pollock, AS; Mahimkar, R; Olson, JL; Lovett, DH				Cheng, Sunfa; Pollock, Allan S.; Mahimkar, Rajeev; Olson, Jean L.; Lovett, David H.			Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury	FASEB JOURNAL			English	Article						epithelial-mesenchymal transition; chronic kidney disease; tubular atrophy; interstitial fibrosis	MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASES; TRANSFORMING GROWTH-FACTOR-BETA-1; TUBULOINTERSTITIAL FIBROSIS; MYOFIBROBLAST TRANSITION; DIABETIC-NEPHROPATHY; KIDNEY-DISEASE; IV COLLAGENASE; EXPRESSION; INHIBITION	Chronic kidney disease (CKD) and failure are problems of increasing importance. Regardless of the primary etiology, CKD is characterized by tubular atrophy, interstitial fibrosis, and glomerulosclerosis. It has been assumed that diminished matrix metalloproteinase (MMP) activity is responsible for the accumulation of the extracellular matrix (ECM) proteins and collagens that typify the fibrotic kidney. Here we demonstrate that transgenic renal proximal tubular epithelial expression of a specific enzyme, MMP-2, is sufficient to generate the entire spectrum of pathological and functional changes characteristic of human CKD. At the earliest point, MMP-2 leads to structural alterations in the tubular basement membrane, a process that triggers tubular epithelial-mesenchymal transition, with resultant tubular atrophy, fibrosis and renal failure. Inhibition of MMP-2, specifically in the early, prefibrotic stages of disease may offer an additional approach for treatment of these disabling disorders.	Univ Calif San Francisco, Med Serv 111J, SFVAMC, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lovett, DH (corresponding author), Univ Calif San Francisco, Med Serv 111J, SFVAMC, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA.	david.lovett@med.va.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039776, K08DK059383] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK 59383, R01 DK39776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergman MR, 2003, BIOCHEM J, V369, P485, DOI 10.1042/BJ20020707; Cheng SF, 2003, AM J PATHOL, V162, P1937, DOI 10.1016/S0002-9440(10)64327-1; Eknoyan G, 2004, KIDNEY INT, V66, P1310, DOI 10.1111/j.1523-1755.2004.00894.x; Fan WH, 2002, J BIOL CHEM, V277, P9800, DOI 10.1074/jbc.M111213200; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Huang YF, 2003, J CLIN INVEST, V112, P379, DOI 10.1172/JCI200318038; Inkinen KA, 2005, TRANSPLANT INT, V18, P506, DOI 10.1111/j.1432-2277.2004.00053.x; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Jinde K, 2001, AM J KIDNEY DIS, V38, P761, DOI 10.1053/ajkd.2001.27693; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Li YJ, 2003, J CLIN INVEST, V112, P503, DOI 10.1172/JCI200317913; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Lutz J, 2005, TRANSPLANTATION, V79, P655, DOI 10.1097/01.TP.0000151644.85832.B5; Ma LJ, 2005, J AM SOC NEPHROL, V16, P966, DOI 10.1681/ASN.2004060492; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; McLennan SV, 2002, DIABETOLOGIA, V45, P268, DOI 10.1007/s00125-001-0730-4; McLennan SV, 2000, KIDNEY INT, V58, pS81, DOI 10.1046/j.1523-1755.2000.07713.x; Mook ORF, 2003, J HISTOCHEM CYTOCHEM, V51, P821, DOI 10.1177/002215540305100613; Murakami S, 2001, ATHEROSCLEROSIS, V157, P361, DOI 10.1016/S0021-9150(00)00743-7; Ng YY, 1998, KIDNEY INT, V54, P864, DOI 10.1046/j.1523-1755.1998.00076.x; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PORTIKDOBOS V, 2005, IN PRESS AM J PHYSL; RAIJ L, 1984, KIDNEY INT, V26, P137, DOI 10.1038/ki.1984.147; Rastaldi MP, 2002, KIDNEY INT, V62, P137, DOI 10.1046/j.1523-1755.2002.00430.x; Reisdorff J, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015617.39974.FB; Ru Y., 2003, Journal of Submicroscopic Cytology and Pathology, V35, P147; Sato N, 2003, AM J NEPHROL, V23, P334, DOI 10.1159/000072915; SCHAFFNER DL, 1993, AM J PATHOL, V142, P1051; Seomun Y, 2001, BIOCHEM J, V358, P41, DOI 10.1042/0264-6021:3580041; Sinniah R, 1999, ULTRASTRUCT PATHOL, V23, P359, DOI 10.1080/019131299281329; Song WM, 2000, DEV BIOL, V227, P606, DOI 10.1006/dbio.2000.9919; Tang WW, 1997, KIDNEY INT, V51, P926, DOI 10.1038/ki.1997.131; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; Ward C, 2005, TRANSPL P, V37, P977, DOI 10.1016/j.transproceed.2004.12.203; YANG C, 2000, CANCER RES, V63, P8312; Yang JW, 2002, J CLIN INVEST, V110, P1525, DOI 10.1172/JC1200216219; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Zeisberg M, 2003, AM J PHYSIOL-RENAL, V285, pF1060, DOI 10.1152/ajprenal.00191.2002; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7; Zeisberg M, 2002, AM J PATHOL, V160, P2001, DOI 10.1016/S0002-9440(10)61150-9	44	186	202	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1898	+		10.1096/fj.06-5898fje	http://dx.doi.org/10.1096/fj.06-5898fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16891619				2022-12-25	WOS:000240267000023
J	Xu, RJ; Jin, JF; Hu, W; Sun, W; Bielawski, J; Szulc, Z; Taha, T; Obeid, LM; Mao, CG				Xu, Ruijuan; Jin, Junfei; Hu, Wei; Sun, Wei; Bielawski, Jacek; Szulc, Zdzislaw; Taha, Tarek; Obeid, Lina M.; Mao, Cungui			Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P	FASEB JOURNAL			English	Article						placenta; rate-limiting step; serum deprivation; S1P receptor; sphingolipid	MOLECULAR-CLONING; NEUTRAL CERAMIDASE; FUNCTIONAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; EDG-1 FAMILY; GENE FAMILY; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; EXPRESSION; IDENTIFICATION	Sphingosine-1-phosphate (S1P), a sphingolipid metabolite, promotes cell proliferation and survival whereas its precursor, sphingosine, has the opposite effects. However, much remains unknown about their regulation. Here we identify a novel human ceramidase (haCER2) that regulates the levels of both sphingosine and S1P by controlling the hydrolysis of ceramides. haCER2 is localized to the Golgi complex and is highly expressed in the placenta. High ectopic expression of haCER2 caused fragmentation of the Golgi complex and growth arrest in HeLa cells due to sphingosine accumulation. Low ectopic expression of haCER2 increased S1P without sphingosine accumulation, promoting cell proliferation in serum-free medium. This proliferative effect was suppressed by dimethylsphingosine, an inhibitor of the S1P formation, or by the RNA interference (RNAi) - mediated inhibition of S1P(1), a G-protein-coupled receptor for S1P. The RNAi-mediated down-regulation of haCER2 enhanced the serum deprivation-induced growth arrest and apoptosis of HeLa cells, which was inhibited by addition of exogenous S1P. Serum deprivation up-regulated both haCER2 mRNA and activity in HeLa cells. haCER2 mRNA is also up-regulated in some tumors. Taken together, these results suggest that haCER2 is important for the generation of S1P and S1P-mediated cell proliferation and survival, but that its overexpression may cause cell growth arrest due to an accumulation of sphingosine. - Xu, R., Jin, J., Hu, W., Sun, W., Bielawski, J., Szulc, Z., Taha, T., Obeid, L. M., Mao, C. Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Mao, CG (corresponding author), 114 Doughty St,Rm 646,STB,POB 250779, Charleston, SC 29425 USA.	maoc@musc.edu	xu, rui/GRX-5734-2022	obeid, lina/0000-0002-0734-0847; Jin, Junfei/0000-0002-9237-9024	NATIONAL CANCER INSTITUTE [R01CA104834] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104834] Funding Source: Medline; NCRR NIH HHS [P20RR017677] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BIELAWSKI J, 2006, IN PRESS METHODS; Boquet I, 2000, J NEUROBIOL, V42, P33; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; el Bawab Samer, 2002, Subcell Biochem, V36, P187; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Graveel CR, 2001, ONCOGENE, V20, P2704, DOI 10.1038/sj.onc.1204391; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hla T, 2000, ANN NY ACAD SCI, V905, P16; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Hong GY, 1999, FEBS LETT, V460, P513, DOI 10.1016/S0014-5793(99)01400-3; Hu W, 2005, MOL BIOL CELL, V16, P1555, DOI 10.1091/mbc.E04-07-0594; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Jolly PS, 2005, BLOOD, V105, P4736, DOI 10.1182/blood-2004-12-4686; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Mandala SM, 2001, PROSTAG OTH LIPID M, V64, P143, DOI 10.1016/S0090-6980(01)00111-3; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005; Mizutani Y, 2004, FEBS LETT, V563, P93, DOI 10.1016/S0014-5793(04)00274-1; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Nikolova-Karakashian M, 2000, METHOD ENZYMOL, V311, P194; Obeid L.M., 2001, J BIOL CHEM, V16, P16; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Ruwisch L, 2001, N-S ARCH PHARMACOL, V363, P358, DOI 10.1007/s002100000365; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, ANN NY ACAD SCI, V905, P54; Sullards M C, 2001, Sci STKE, V2001, ppl1; Tani M, 2005, J BIOL CHEM, V280, P36592, DOI 10.1074/jbc.M506827200; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Usta J, 2001, BIOCHEMISTRY-US, V40, P9657, DOI 10.1021/bi010535k; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Xu Y, 2001, J SOC GYNECOL INVEST, V8, P1, DOI 10.1016/S1071-5576(00)00092-7; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993	48	108	118	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1813	1825		10.1096/fj.05-5689com	http://dx.doi.org/10.1096/fj.05-5689com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940153				2022-12-25	WOS:000240267000009
J	Bhatt, KV; Hu, R; Spofford, LS; Aplin, AE				Bhatt, K. V.; Hu, R.; Spofford, L. S.; Aplin, A. E.			Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27(Kip1) in human melanoma cells	ONCOGENE			English	Article						adhesion; cell cycle; melanocyte; proteasome	CDK INHIBITOR P27; UBIQUITIN LIGASE; S-PHASE; DEPENDENT DEGRADATION; MALIGNANT-MELANOMA; NUCLEAR EXPORT; BRAF MUTATIONS; SKP2; EXPRESSION; PROGRESSION	Levels of cyclins and cyclin-dependent kinase (Cdk) inhibitors are tightly controlled during normal cell proliferation and are frequently dysregulated in cancerous cells. In melanoma, cyclin D1 is highly expressed and downregulation of the Cdk inhibitor, p27(Kip1), is associated with a poor prognosis. Mutant B-RAF is frequently expressed in melanoma and overrides growth factor and matrix adhesion control of cyclin D1 and p27(Kip1) levels in human melanocytes. Here, we demonstrate that p27(Kip1) expression is regulated by multiple mechanisms in melanoma cells. B-RAF regulates p27(Kip1) mRNA abundance independently of cyclin D1. Additionally, B-RAF and cyclin D1 control the levels of S-phase kinase-associated protein 2 (Skp2) that directs ubiquitin-mediated proteolysis of p27(Kip1). The cofactor for Skp2, Cdc kinase subunit 1 (Cks1) controls levels of Skp2 in melanoma cells and acts jointly with Skp2 to regulate p27(Kip1) levels. Importantly, expression of Cks1 is regulated by B-RAF and cyclin D1 at the mRNA level. Reduced Cks1 or Skp2 expression and enhanced p27(Kip1) levels inhibit melanoma cell growth. In summary, p27(Kip1) expression in melanoma is regulated by B-RAF at the mRNA level, and via B-RAF and cyclin D1 control of Cks1/Skp2- mediated proteolysis.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MC-165,47 New Scotland Ave, Albany, NY 12208 USA.	aplina@mail.amc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Bond M, 2004, J BIOL CHEM, V279, P37304, DOI 10.1074/jbc.M404307200; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Collisson EA, 2003, CANCER RES, V63, P5669; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Garriga J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Hingorani SR, 2003, CANCER RES, V63, P5198; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Katagiri Y, 2006, J DERMATOL SCI, V42, P215, DOI 10.1016/j.jdermsci.2005.12.016; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li Q, 2004, J CUTAN PATHOL, V31, P633, DOI 10.1111/j.0303-6987.2004.00243.x; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rodier G, 2005, J CELL BIOL, V168, P55, DOI 10.1083/jcb.200404146; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sauter ER, 2002, CANCER RES, V62, P3200; Shapira M, 2004, CANCER-AM CANCER SOC, V100, P1615, DOI 10.1002/cncr.20172; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Sumimoto H, 2006, INT J CANCER, V118, P472, DOI 10.1002/ijc.21286; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang W, 2004, ONCOGENE, V23, P1064, DOI 10.1038/sj.onc.1207204; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Woenckhaus C, 2005, HISTOL HISTOPATHOL, V20, P501, DOI 10.14670/HH-20.501; Zhu XH, 2004, MOL CELL BIOL, V24, P6058, DOI 10.1128/MCB.24.13.6058-6066.2004	68	59	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1056	1066		10.1038/sj.onc.1209861	http://dx.doi.org/10.1038/sj.onc.1209861			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16924241				2022-12-25	WOS:000244245400012
J	Borthwick, K; Jackson, VN; Price, NT; Zammit, VA				Borthwick, Karen; Jackson, Vicky N.; Price, Nigel T.; Zammit, Victor A.			The mitochondrial intermembrane loop region of rat carnitine palmitoyltransferase 1A is a major determinant of its malonyl-CoA sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR INTERACTIONS; OUTER MEMBRANES; CPT I; LIVER; INHIBITION; MUSCLE; ACETYLTRANSFERASE; SPECIFICITY; KINETICS; AFFINITY	Carnitine palmitoyltransferase (CPT) 1A adopts a polytopic conformation within the mitochondrial outer membrane, having both the N- and C-terminal segments on the cytosolic aspect of the membrane and a loop region connecting the two transmembrane (TM) segments protruding into the inter membrane space. In this study we demonstrate that the loop exerts major effects on the sensitivity of the enzyme to its inhibitor, malonyl-CoA. Insertion of a 16-residue spacer between the C-terminal part of the loop sequence (i.e. between residues 100 and 101) and TM2 (which is predicted to start at residue 102) increased the sensitivity to malonyl-CoA inhibition of the resultant mutant protein by more than 10-fold. By contrast, the same insertion made between TM1 and the loop had no effects on the kinetic properties of the enzyme, indicating that effects on the catalytic C-terminal segment were specifically induced by loop-TM2 interactions. Enhanced sensitivity was also observed in all mutants in which the native TM2-loop pairing was disrupted either by making chimeras in which the loops and TM2 segments of CPT 1A and CPT 1B were exchanged or by deleting successive 9-residue segments from the loop sequence. The data suggest that the sequence spanning the loop-TM2 boundary determines the disposition of this TM in the membrane so as to alter the conformation of the C-terminal segment and thus affect its interaction with malonyl-CoA.	Univ Warwick, Univ Hosp Coventry & Warwick, Warwick Med Sch, Clin Sci Res Inst, Coventry CV2 2DX, W Midlands, England	University of Warwick	Zammit, VA (corresponding author), Univ Warwick, Univ Hosp Coventry & Warwick, Warwick Med Sch, Clin Sci Res Inst, UHCW Campus,Clifford Bridge Rd, Coventry CV2 2DX, W Midlands, England.	v.a.zammit@warwick.ac.uk						COOK GA, 1984, J BIOL CHEM, V259, P2030; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; Faye A, 2005, BIOCHEM J, V387, P67, DOI 10.1042/BJ20041533; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Fraser F, 2001, J BIOL CHEM, V276, P20182, DOI 10.1074/jbc.M101078200; GRANTHAM BD, 1988, BIOCHEM J, V249, P409, DOI 10.1042/bj2490409; GRANTHAM BD, 1986, BIOCHEM J, V239, P485, DOI 10.1042/bj2390485; Hsiao YS, 2004, J BIOL CHEM, V279, P31584, DOI 10.1074/jbc.M403484200; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; Jogl G, 2004, ANN NY ACAD SCI, V1033, P17, DOI 10.1196/annals.1320.002; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; Kraegen EW, 2006, AM J PHYSIOL-ENDOC M, V290, pE471, DOI 10.1152/ajpendo.00316.2005; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; Morillas M, 2004, BIOCHEM J, V379, P777, DOI 10.1042/BJ20031373; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; ONTKO JA, 1980, BIOCHEM J, V192, P959, DOI 10.1042/bj1920959; Park EA, 1998, MOL CELL BIOCHEM, V180, P27, DOI 10.1023/A:1006874503379; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; van der Leij FR, 2002, J BIOL CHEM, V277, P26994, DOI 10.1074/jbc.M203189200; WONG SH, 1984, BIOCHIM BIOPHYS ACTA, V792, P103, DOI 10.1016/0005-2760(84)90209-1; Zammit VA, 1999, PROG LIPID RES, V38, P199, DOI 10.1016/S0163-7827(99)00002-8; Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; Zammit VA, 1997, ADV ENZYME REGUL, V37, P295, DOI 10.1016/S0065-2571(96)00015-5	30	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					32946	32952		10.1074/jbc.M600843200	http://dx.doi.org/10.1074/jbc.M600843200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16908527	hybrid			2022-12-25	WOS:000241621400003
J	Hu, BL; Gilkes, DM; Farooqi, B; Sebti, SM; Chen, JD				Hu, Baoli; Gilkes, Daniele M.; Farooqi, Bilal; Sebti, Said M.; Chen, Jiandong			MDMX overexpression prevents p53 activation by the MDM2 inhibitor nutlin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGRADATION; PHOSPHORYLATION; UBIQUITINATION; ONCOPROTEIN; EXPRESSION; P53-MDM2; BINDING; PROTEIN; PATHWAY; CELLS	The p53 tumor suppressor plays a key role in maintaining genomic stability and protection against malignant transformation. MDM2 and MDMX are both p53-binding proteins that regulate p53 stability and activity. Recent development of the MDM2 inhibitor Nutlin 3 has greatly facilitated functional analysis of MDM2-p53 binding. We found that although MDMX is homologous to MDM2 and binds to the same region on p53 N terminus, Nutlin does not disrupt p53-MDMX interaction. The ability of Nutlin to activate p53 is compromised in tumor cells overexpressing MDMX. Combination of Nutlin with MDMX siRNA resulted in synergistic activation of p53 and growth arrest. These results suggest that MDMX is also a valid target for p53 activation in tumor cells. Development of novel compounds that are MDMX-specific or optimized for dual-inhibition of MDM2 and MDMX are necessary to achieve full activation of p53 in tumor cells.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC3057A,12902 Magnolia Dr, Tampa, FL 33612 USA.	jchen@moffitt.usf.edu	Gilkes, Daniele M/AAI-8133-2020	Gilkes, Daniele M/0000-0003-3984-9338; Farooqi, Bilal/0000-0002-2618-7171				Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Bottger V, 1996, ONCOGENE, V13, P2141; Chen LH, 2005, MOL CANCER THER, V4, P1019, DOI 10.1158/1535-7163.MCT-04-0342; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Chen LH, 2005, MOL CELL BIOL, V25, P6509, DOI 10.1128/MCB.25.15.6509-6520.2005; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; de Graaf P, 2003, J BIOL CHEM, V278, P38315, DOI 10.1074/jbc.M213034200; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Jin YT, 2006, EMBO J, V25, P1207, DOI 10.1038/sj.emboj.7601010; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LeBron C, 2006, EMBO J, V25, P1196, DOI 10.1038/sj.emboj.7601032; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Marine JC, 2005, BIOCHEM BIOPH RES CO, V331, P750, DOI 10.1016/j.bbrc.2005.03.151; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Ramos YFM, 2001, CANCER RES, V61, P1839; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Vassilev LT, 2004, CELL CYCLE, V3, P419; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103	29	190	197	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33030	33035		10.1074/jbc.C600147200	http://dx.doi.org/10.1074/jbc.C600147200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16905541	hybrid			2022-12-25	WOS:000241621400011
J	Ala, PJ; Gonneville, L; Hillman, MC; Becker-Pasha, M; Wei, M; Reid, BG; Klabe, R; Yue, EW; Wayland, B; Douty, B; Polam, P; Wasserman, Z; Bower, M; Combs, AP; Burn, TC; Hollis, GF; Wynn, R				Ala, Paul J.; Gonneville, Lucie; Hillman, Milton C.; Becker-Pasha, Mary; Wei, Min; Reid, Brian G.; Klabe, Ronald; Yue, Eddy W.; Wayland, Brian; Douty, Brent; Polam, Padmaja; Wasserman, Zelda; Bower, Michael; Combs, Andrew P.; Burn, Timothy C.; Hollis, Gregory F.; Wynn, Richard			Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-BASED DESIGN; INSULIN SENSITIVITY; PHOSPHOTYROSINE MIMETICS; CRYSTAL-STRUCTURE; POTENT; DISCOVERY; MICE; RECEPTOR; COMPLEX; GLUCOSE	Crystal structures of protein- tyrosine phosphatase 1B in complex with compounds bearing a novel isothiazolidinone (IZD) heterocyclic phosphonate mimetic reveal that the heterocycle is highly complementary to the catalytic pocket of the protein. The heterocycle participates in an extensive network of hydrogen bonds with the backbone of the phosphate-binding loop, Phe(182) of the flap, and the side chain of Arg(221). When substituted with a phenol, the small inhibitor induces the closed conformation of the protein and displaces all waters in the catalytic pocket. Saturated IZD-containing peptides are more potent inhibitors than unsaturated analogs because the IZD heterocycle and phenyl ring directly attached to it bind in a nearly orthogonal orientation with respect to each other, a conformation that is close to the energy minimum of the saturated IZD-phenyl moiety. These results explain why the heterocycle is a potent phosphonate mimetic and an ideal starting point for designing small nonpeptidic inhibitors.	Incyte Corp, Expt Stn, Wilmington, DE 19880 USA	DuPont; Incyte	Ala, PJ (corresponding author), Incyte Corp, Expt Stn, Rte 141 & Henry Clay Rd, Wilmington, DE 19880 USA.	pauljala@gmail.com		Burn, Timothy/0000-0001-6648-4333				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Asante-Appiah E, 2002, BIOCHEMISTRY-US, V41, P9043, DOI 10.1021/bi0259554; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bialy L, 2005, ANGEW CHEM INT EDIT, V44, P3814, DOI 10.1002/anie.200461517; Black E, 2005, BIOORG MED CHEM LETT, V15, P2503, DOI 10.1016/j.bmcl.2005.03.068; Blaskovich MA, 2002, EXPERT OPIN THER PAT, V12, P871; Burke TR, 2003, ACCOUNTS CHEM RES, V36, P426, DOI 10.1021/ar020127o; Combs AP, 2006, J MED CHEM, V49, P3774, DOI 10.1021/jm0600904; Combs AP, 2005, J MED CHEM, V48, P6544, DOI 10.1021/jm0504555; Costantino L, 2004, CURR MED CHEM, V11, P2725, DOI 10.2174/0929867043364315; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Jia ZC, 2001, J MED CHEM, V44, P4584, DOI 10.1021/jm010266w; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Johnson TO, 2002, NAT REV DRUG DISCOV, V1, P696, DOI 10.1038/nrd895; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Liu G, 2003, CURR MED CHEM, V10, P1407, DOI 10.2174/0929867033457296; Loladze VV, 2002, J MOL BIOL, V320, P343, DOI 10.1016/S0022-2836(02)00465-5; Pedersen AK, 2004, ACTA CRYSTALLOGR D, V60, P1527, DOI 10.1107/S0907444904015094; Pei ZH, 2004, CURR PHARM DESIGN, V10, P3481, DOI 10.2174/1381612043382954; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sun JP, 2003, J BIOL CHEM, V278, P12406, DOI 10.1074/jbc.M212491200; Szczepankiewicz BG, 2003, J AM CHEM SOC, V125, P4087, DOI 10.1021/ja0296733; Taylor SD, 2004, EXPERT OPIN INV DRUG, V13, P199, DOI 10.1517/eoid.13.3.199.27347; Uehling DE, 2002, J MED CHEM, V45, P567, DOI 10.1021/jm0101500; Yao ZJ, 1998, BIOORGAN MED CHEM, V6, P1799, DOI 10.1016/S0968-0896(98)00140-0; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	32	51	52	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32784	32795		10.1074/jbc.M606873200	http://dx.doi.org/10.1074/jbc.M606873200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16916797	hybrid			2022-12-25	WOS:000241414500077
J	Cremniter, J; Mainardi, JL; Josseaume, N; Quincampoix, JC; Dubost, L; Hugonnet, JE; Marie, A; Gutmann, L; Rice, LB; Arthur, M				Cremniter, Julie; Mainardi, Jean-Luc; Josseaume, Nathalie; Quincampoix, Jean-Charles; Dubost, Lionel; Hugonnet, Jean-Emmanuel; Marie, Arul; Gutmann, Laurent; Rice, Louis B.; Arthur, Michel			Novel mechanism of resistance to glycopeptide antibiotics in Enterococcus faecium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM RESISTANCE; PEPTIDOGLYCAN PRECURSORS; VANCOMYCIN RESISTANCE; STAPHYLOCOCCUS-AUREUS; PENICILLIN; TRANSPEPTIDATION; PROTEINS; BACTERIA; BM4147; ENZYME	Glycopeptides and beta-lactams are the major antibiotics available for the treatment of infections due to Gram-positive bacteria. Emergence of cross-resistance to these drugs by a single mechanism has been considered as unlikely because they inhibit peptidoglycan polymerization by different mechanisms. The glycopeptides bind to the peptidyl-D-Ala(4)-D-Ala(5) extremity of peptidoglycan precursors and block by steric hindrance the essential glycosyltransferase and D, D-transpeptidase activities of the penicillin-binding proteins (PBPs). The beta-lactams are structural analogues of D-Ala(4)-D-Ala(5) and act as suicide substrates of the D, D-transpeptidase module of the PBPs. Here we have shown that bypass of the PBPs by the recently described beta-lactam-insensitive L, D-transpeptidase from Enterococcus faecium (Ldt(fm)) can lead to high level resistance to glycopeptides and beta-lactams. Cross-resistance was selected by glycopeptides alone or serially by beta-lactams and glycopeptides. In the corresponding mutants, UDP-MurNAc-pentapeptide was extensively converted to UDP-MurNAc-tetrapeptide following hydrolysis of D-Ala(5), thereby providing the substrate of Ldt(fm). Complete elimination of D-Ala(5), a residue essential for glycopeptide binding, was possible because Ldtfm uses the energy of the L-Lys(3)-D-Ala(4) peptide bond for cross-link formation in contrast to PBPs, which use the energy of the D-Ala(4)-D-Ala(5) bond. This novel mechanism of glycopeptide resistance was unrelated to the previously identified replacement of D-Ala(5) by D-Ser or D-lactate.	Univ Paris 06, INSERM U655, LRMA, Ctr Rech Biomed Cordeliers, F-75270 Paris, France; Univ Paris 05, Fac Med Rene Descartes, Ctr Rech Biomed Cordeliers, F-75006 Paris, France; Hop Europeen Georges Pompidou, APHP, F-75015 Paris, France; Museum Natl Hist Nat, USM0502, Plateforme Spectrometrie Masse & Prot Museum, Dept Rech Dev & Divers Mol, F-75005 Paris, France; CNRS, UMR 8041, F-75006 Paris, France; Louis Stokes Cleveland Vet Affairs Med Ctr, Med Serv, Cleveland, OH 44106 USA; Louis Stokes Cleveland Vet Affairs Med Ctr, Res Serv, Cleveland, OH 44106 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Arthur, M (corresponding author), Univ Paris 06, INSERM U655, LRMA, Ctr Rech Biomed Cordeliers, 15 Rue Ecole Med, F-75270 Paris, France.	michel.arthur@bhdc.jussieu.fr	MAINARDI, Jean-Luc/E-2714-2014; HUGONNET, Jean-Emmanuel/ABC-7914-2021; Arthur, Michel/G-3680-2013; HUGONNET, Jean-Emmanuel/H-3581-2014	MAINARDI, Jean-Luc/0000-0002-4159-0129; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Arthur, Michel/0000-0003-1007-636X; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; MARIE, Arul/0000-0003-4104-140X; cremniter, julie/0000-0002-2249-8394	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045626] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 45626, R01 AI045626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham EP, 1940, NATURE, V146, P837, DOI 10.1038/146837a0; ALOBEID S, 1992, FEMS MICROBIOL LETT, V91, P79, DOI 10.1111/j.1574-6968.1992.tb05187.x; Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; ARTHUR M, 1992, ANTIMICROB AGENTS CH, V36, P867, DOI 10.1128/AAC.36.4.867; Arthur M, 1996, MOL MICROBIOL, V21, P33, DOI 10.1046/j.1365-2958.1996.00617.x; Arthur M, 1998, MOL MICROBIOL, V30, P819, DOI 10.1046/j.1365-2958.1998.01114.x; ARTHUR M, 1993, J BACTERIOL, V175, P117, DOI 10.1128/JB.175.1.117-127.1993; Arthur M, 1996, TRENDS MICROBIOL, V4, P401, DOI 10.1016/0966-842X(96)10063-9; Baptista M, 1997, MOL MICROBIOL, V25, P93, DOI 10.1046/j.1365-2958.1997.4401812.x; Bellais S, 2006, J BIOL CHEM, V281, P11586, DOI 10.1074/jbc.M600114200; Biarrotte-Sorin S, 2006, J MOL BIOL, V359, P533, DOI 10.1016/j.jmb.2006.03.014; BILLOTKLEIN D, 1994, J BACTERIOL, V176, P2398, DOI 10.1128/JB.176.8.2398-2405.1994; Bouhss A, 2002, J BIOL CHEM, V277, P45935, DOI 10.1074/jbc.M207449200; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P902; Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056/NEJMoa025025; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; Mainard JL, 2002, J BIOL CHEM, V277, P35801, DOI 10.1074/jbc.M204319200; Mainardi JL, 2005, J BIOL CHEM, V280, P38146, DOI 10.1074/jbc.M507384200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; NIETO M, 1971, BIOCHEM J, V123, P789, DOI 10.1042/bj1230789; Rammelkamp CH, 1942, P SOC EXP BIOL MED, V51, P386, DOI 10.3181/00379727-51-13986; Reynolds PE, 2005, ANTIMICROB AGENTS CH, V49, P21, DOI 10.1128/AAC.49.1.21-25.2005; REYNOLDS PE, 1989, EUR J CLIN MICROBIOL, V8, P943, DOI 10.1007/BF01967563; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219	27	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32254	32262		10.1074/jbc.M606920200	http://dx.doi.org/10.1074/jbc.M606920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16943188	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000241414500022
J	Dean, T; Khatri, A; Potetinova, Z; Willick, GE; Gardella, TJ				Dean, Thomas; Khatri, Ashok; Potetinova, Zhanna; Willick, Gordon E.; Gardella, Thomas J.			Role of amino acid side chains in region 17-31 of parathyroid hormone (PTH) in binding to the PTH receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PROTEIN-RECEPTOR; JUXTAMEMBRANE REGION; PTH/PTHRP RECEPTOR; LIGAND INTERACTION; CROSS-LINKING; ANALOGS; PEPTIDE; DOMAIN; DOCKING; SITE	The principal receptor-binding domain (Ser(17)-Val(31)) of parathyroid hormone (PTH) is predicted to form an amphiphilic alpha-helix and to interact primarily with the N-terminal extracellular domain (N domain) of the PTH receptor (PTHR). We explored these hypotheses by introducing a variety of substitutions in region 17-31 of PTH-(1-31) and assessing, via competition assays, their effects on binding to the wild-type PTHR and to PTHR-delNt, which lacks most of the N domain. Substitutions at Arg(20) reduced affinity for the intact PTHR by 200-fold or more, but altered affinity for PTHR-delNt by 4-fold or less. Similar effects were observed for Glu substitutions at Trp(23), Leu(24), and Leu(28), which together form the hydrophobic face of the predicted amphiphilic alpha-helix. Glu substitutions at Arg(25), Lys(26), and Lys(27) (which forms the hydrophilic face of the helix) caused 4-10-fold reductions in affinity for both receptors. Thus, the side chains of Arg(20), together with those composing the hydrophobic face of the ligand's putative amphiphilic alpha-helix, contribute strongly to PTHR-binding affinity by interacting specifically with the N domain of the receptor. The side chains projecting from the opposite helical face contribute weakly to binding affinity by different mechanisms, possibly involving interactions with the extracellular loop/transmembrane domain region of the receptor. The data help define the roles that side chains in the binding domain of PTH play in the PTH-PTHR interaction process and provide new clues for understanding the overall topology of the bimolecular complex.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Research Council Canada	Gardella, TJ (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Wellman Bldg,Rm 503C,50 Blossom St, Boston, MA 02114 USA.	gardella@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbier JR, 2001, BIOCHEMISTRY-US, V40, P8955, DOI 10.1021/bi010460k; BARDEN JA, 1994, BBA-PROTEIN STRUCT M, V1208, P256, DOI 10.1016/0167-4838(94)90111-2; Berlot CH, 2002, J BIOL CHEM, V277, P21080, DOI 10.1074/jbc.M201330200; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; Chen ZG, 2000, BIOCHEMISTRY-US, V39, P12766, DOI 10.1021/bi000882e; COHEN FE, 1991, J BIOL CHEM, V266, P1997; Dean T, 2006, MOL ENDOCRINOL, V20, P931, DOI 10.1210/me.2005-0349; Dong MQ, 2005, MOL ENDOCRINOL, V19, P1821, DOI 10.1210/me.2004-0421; EPAND RM, 1983, MOL CELL BIOCHEM, V57, P41; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069; Gensure RC, 2003, MOL ENDOCRINOL, V17, P2647, DOI 10.1210/me.2003-0275; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200; Jean-Rene B, 2005, J BIOL CHEM, V280, P23771, DOI 10.1074/jbc.M500817200; Jin L, 2000, J BIOL CHEM, V275, P27238; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; NEUGEBAUER W, 1992, BIOCHEMISTRY-US, V31, P2056, DOI 10.1021/bi00122a023; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; Oldenburg KR, 1996, J BIOL CHEM, V271, P17582; Peggion E, 2002, BIOCHEMISTRY-US, V41, P8162, DOI 10.1021/bi0200155; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Reidhaar-Olson JF, 2000, MOL CELL ENDOCRINOL, V160, P135, DOI 10.1016/S0303-7207(99)00211-7; SARGENT DF, 1986, P NATL ACAD SCI USA, V83, P5774, DOI 10.1073/pnas.83.16.5774; Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199; Shimizu M, 2002, BIOCHEMISTRY-US, V41, P13224, DOI 10.1021/bi026162k; Shimizu M, 2001, ENDOCRINOLOGY, V142, P3068, DOI 10.1210/en.142.7.3068; Shimizu N, 2005, J BIOL CHEM, V280, P1797, DOI 10.1074/jbc.M408270200; Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; Takasu H, 1999, J BONE MINER RES, V14, P11, DOI 10.1359/jbmr.1999.14.1.11; Tan YV, 2006, J BIOL CHEM, V281, P12792, DOI 10.1074/jbc.M513305200; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; Wittelsberger A, 2006, BIOCHEMISTRY-US, V45, P2027, DOI 10.1021/bi051833a; YAMAMOTO I, 1988, ENDOCRINOLOGY, V122, P1208, DOI 10.1210/endo-122-4-1208	39	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32485	32495		10.1074/JBC.M606179200	http://dx.doi.org/10.1074/JBC.M606179200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16923805	hybrid			2022-12-25	WOS:000241414500046
J	Hu, RG; Brower, CS; Wang, HQ; Davydov, IV; Sheng, J; Zhou, JM; Kwon, YT; Varshavsky, A				Hu, Rong-Gui; Brower, Christopher S.; Wang, Haiqing; Davydov, Ilia V.; Sheng, Jun; Zhou, Jianmin; Kwon, Yong Tae; Varshavsky, Alexander			Arginyltransferase, its specificity, putative substrates, bidirectional promoter, and splicing-derived isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; RNA-PROTEIN TRANSFERASE; E3 UBIQUITIN LIGASES; MICE LACKING; SUBCELLULAR-LOCALIZATION; COHESIN SUBUNIT; PATHWAY; GENE; DEGRADATION; PROTEASOME	Substrates of the N-end rule pathway include proteins with destabilizing N-terminal residues. Three of them, Asp, Glu, and (oxidized) Cys, function through their conjugation to Arg, one of destabilizing N-terminal residues that are recognized directly by the pathway's ubiquitin ligases. The conjugation of Arg is mediated by arginyltransferase, encoded by ATE1. Through its regulated degradation of specific proteins, the arginylation branch of the N-end rule pathway mediates, in particular, the cardiovascular development, the fidelity of chromosome segregation, and the control of signaling by nitric oxide. We show that mouse ATE1 specifies at least six mRNA isoforms, which are produced through alternative splicing, encode enzymatically active arginyltransferases, and are expressed at varying levels in mouse tissues. We also show that the ATE1 promoter is bidirectional, mediating the expression of both ATE1 and an oppositely oriented, previously uncharacterized gene. In addition, we identified GRP78 (glucose-regulated protein 78) and protein-disulfide isomerase as putative physiological substrates of arginyltransferase. Purified isoforms of arginyltransferase that contain the alternative first exons differentially arginylate these proteins in extract from ATE1(-/-) embryos, suggesting that specific isoforms may have distinct functions. Although the N-end rule pathway is apparently confined to the cytosol and the nucleus, and although GRP78 and protein-disulfide isomerase are located largely in the endoplasmic reticulum, recent evidence suggests that these proteins are also present in the cytosol and other compartments in vivo, where they may become N-end rule substrates.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Meso Scale Discovery, Gaithersburg, MD 20877 USA; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA	California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Varshavsky, A (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	avarsh@caltech.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039520, R56DK039520, R37DK039520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530, R01GM074000, R01GM069482] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39520] Funding Source: Medline; NIGMS NIH HHS [GM 069482, GM 074000, GM 31530] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; An JY, 2006, P NATL ACAD SCI USA, V103, P6212, DOI 10.1073/pnas.0601700103; Ardley HC, 2005, ESSAYS BIOCHEM, V41, P15, DOI 10.1042/EB0410015; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1995, J BIOL CHEM, V270, P12065, DOI 10.1074/jbc.270.20.12065; BAKER RT, 1991, P NATL ACAD SCI USA, V87, P2374; BALZI E, 1990, J BIOL CHEM, V265, P7464; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Du FY, 2002, P NATL ACAD SCI USA, V99, P14110, DOI 10.1073/pnas.172527399; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; Emoto M, 2005, GENE, V357, P47, DOI 10.1016/j.gene.2005.05.009; Erbse A, 2006, NATURE, V439, P753, DOI 10.1038/nature04412; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FIRE A, 2006, Q REV BIOPHYS, V6, P1; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Graciet E, 2006, P NATL ACAD SCI USA, V103, P3078, DOI 10.1073/pnas.0511224103; Grune T, 2002, ARCH BIOCHEM BIOPHYS, V397, P407, DOI 10.1006/abbi.2001.2719; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Hu RG, 2005, NATURE, V437, P981, DOI 10.1038/nature04027; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; Kwon YT, 2003, MOL CELL BIOL, V23, P8255, DOI 10.1128/MCB.23.22.8255-8271.2003; Kwon YT, 2000, MOL CELL BIOL, V20, P4135, DOI 10.1128/MCB.20.11.4135-4148.2000; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Lareau LF, 2004, CURR OPIN STRUC BIOL, V14, P273, DOI 10.1016/j.sbi.2004.05.002; Lee MJ, 2005, P NATL ACAD SCI USA, V102, P15030, DOI 10.1073/pnas.0507533102; Lev-Maor G, 2003, SCIENCE, V300, P1288, DOI 10.1126/science.1082588; LI J, 1995, BIOCHEMISTRY-US, V34, P15829, DOI 10.1021/bi00048a028; Lynch M, 2006, SCIENCE, V311, P1727, DOI 10.1126/science.1118884; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Meier-Noorden M, 2004, GENE, V338, P197, DOI 10.1016/j.gene.2004.05.006; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Patton J, 2006, GENE, V369, P35, DOI 10.1016/j.gene.2005.10.009; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Preger E, 2004, P NATL ACAD SCI USA, V101, P1229, DOI 10.1073/pnas.0307952100; Rai R, 2005, P NATL ACAD SCI USA, V102, P10123, DOI 10.1073/pnas.0504500102; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Rape M, 2002, NAT CELL BIOL, V4, pE113, DOI 10.1038/ncb0502-e113; Rechsteiner M, 2005, TRENDS CELL BIOL, V15, P27, DOI 10.1016/j.tcb.2004.11.003; Saleh A, 2004, IMMUNITY, V21, P55, DOI 10.1016/j.immuni.2004.06.005; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Sheng J, 2002, EMBO J, V21, P6061, DOI 10.1093/emboj/cdf626; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; Siepmann TJ, 2003, J BIOL CHEM, V278, P9448, DOI 10.1074/jbc.M211240200; Stetefeld J, 2005, TRENDS BIOCHEM SCI, V30, P515, DOI 10.1016/j.tibs.2005.07.001; Stockton JD, 2003, BIOCHEMISTRY-US, V42, P12821, DOI 10.1021/bi035087q; Sun FC, 2006, BIOCHEM J, V396, P31, DOI 10.1042/BJ20051916; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Takai D, 2004, MOL BIOL EVOL, V21, P463, DOI 10.1093/molbev/msh040; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Travers MT, 2005, GENOMICS, V85, P71, DOI 10.1016/j.ygeno.2004.10.001; Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Varshavsky A, 2003, NAT CELL BIOL, V5, P373, DOI 10.1038/ncb0503-373; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 2005, METHOD ENZYMOL, V399, P777, DOI 10.1016/S0076-6879(05)99051-4; Varshavsky A, 2004, CURR BIOL, V14, pR181, DOI 10.1016/j.cub.2004.02.014; Varshavsky AV, 2006, PROTEIN SCI, V15, P647, DOI 10.1110/ps.052012306; Vendel AC, 2006, J NEUROSCI, V26, P2635, DOI 10.1523/JNEUROSCI.0067-06.2006; Whitehouse C, 2004, GENE, V326, P87, DOI 10.1016/j.gene.2003.10.008; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Wolf DH, 2004, BBA-MOL CELL RES, V1695, P19, DOI 10.1016/j.bbamcr.2004.10.007; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Yoshida S, 2002, PLANT J, V32, P129, DOI 10.1046/j.1365-313X.2002.01407.x; Zenker M, 2005, NAT GENET, V37, P1345, DOI 10.1038/ng1681	87	55	56	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32559	32573		10.1074/jbc.M604355200	http://dx.doi.org/10.1074/jbc.M604355200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16943202	hybrid, Green Accepted			2022-12-25	WOS:000241414500054
J	Johnson, AA; Sayer, JM; Yagi, H; Patil, SS; Debart, F; Maier, MA; Corey, DR; Vasseur, JJ; Burke, TR; Marquez, VE; Jerina, DM; Pommier, Y				Johnson, Allison A.; Sayer, Jane M.; Yagi, Haruhiko; Patil, Sachindra S.; Debart, Francoise; Maier, Martin A.; Corey, David R.; Vasseur, Jean-Jacques; Burke, Terrence R., Jr.; Marquez, Victor E.; Jerina, Donald M.; Pommier, Yves			Effect of DNA modifications on DNA processing by HIV-1 integrase and inhibitor binding - Role of DNA backbone flexibility and an open catalytic site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 INTEGRASE; DIOL EPOXIDE ADDUCTS; VIRAL-DNA; MINOR-GROOVE; TOPOISOMERASE-I; VACCINIA TOPOISOMERASE; STRAND TRANSFER; CLEAVAGE SITE; DEOXYADENOSINE; POLYMERASE	Integration of the viral cDNA into host chromosomes is required for viral replication. Human immunodeficiency virus integrase catalyzes two sequential reactions, 3'-processing (3'-P) and strand transfer (ST). The first integrase inhibitors are undergoing clinical trial, but interactions of inhibitors with integrase and DNA are not well understood in the absence of a co-crystal structure. To increase our understanding of integrase interactions with DNA, we examined integrase catalysis with oligonucleotides containing DNA backbone, base, and groove modifications placed at unique positions surrounding the 3'-processing site. 3'-Processing was blocked with substrates containing constrained sugars and alpha-anomeric residues, suggesting that integrase requires flexibility of the phosphodiester backbone at the 3'-P site. Of several benzo[a]pyrene 7,8-diol 9,10-epoxide (BaPDE) adducts tested, only the adduct in the minor groove at the 3'-P site inhibited 3'-P, suggesting the importance of the minor groove contacts for 3'-P. ST occurred in the presence of bulky BaP DE DNA adducts attached to the end of the viral DNA suggesting opening of the active site for ST. Position-specific effects of these BaP DE DNA adducts were found for inhibition of integrase by diketo acids. Together, these results demonstrate the importance of DNA structure and specific contacts with the viral DNA processing site for inhibition by integrase inhibitors.	NCI, Mol Pharmacol Lab, Ctr Canc Res, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA; NCI, Ctr Canc Res, Med Chem Lab, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA; Univ Montpellier 2, CNRS, LCOBS, UMR 5625, F-34095 Montpellier, France; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Isis Pharmaceuticals Inc; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, Dept Hlth & Human Serv,NIH, Bldg 37,Rm 5068, Bethesda, MD 20892 USA.	pommier@nih.gov	Marquez, Victor/AAP-3549-2021; Burke, Terrence R/N-2601-2014; Debart, Francoise/D-4320-2019	Debart, Francoise/0000-0003-3422-3926; Vasseur, Jean-Jacques/0000-0002-4379-6139; Burke, Terrence/0000-0001-9925-8586	NATIONAL CANCER INSTITUTE [Z01BC007333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060642] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM 60642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agapkina J, 2006, J BIOL CHEM, V281, P11530, DOI 10.1074/jbc.M512271200; Agapkina J, 2004, EUR J BIOCHEM, V271, P205, DOI 10.1046/j.1432-1033.2003.03921.x; Agapkina JJ, 2004, MOL BIOL+, V38, P718, DOI 10.1023/B:MBIL.0000043941.44399.2f; Aramini JM, 1996, BIOCHEMISTRY-US, V35, P9355, DOI 10.1021/bi960612p; Boyer PL, 2005, J MOL BIOL, V345, P441, DOI 10.1016/j.jmb.2004.10.021; Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2; BUSHMAN FD, 1992, P NATL ACAD SCI USA, V89, P3458, DOI 10.1073/pnas.89.8.3458; Chiapperino D, 2005, J BIOL CHEM, V280, P39684, DOI 10.1074/jbc.M508008200; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Graziewicz MA, 2004, NUCLEIC ACIDS RES, V32, P397, DOI 10.1093/nar/gkh213; Greenwald J, 1999, BIOCHEMISTRY-US, V38, P8892, DOI 10.1021/bi9907173; Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Johnson AA, 2006, J BIOL CHEM, V281, P461, DOI 10.1074/jbc.M511348200; Johnson AA, 2004, J BIOL CHEM, V279, P7947, DOI 10.1074/jbc.M311263200; Khan QA, 2003, P NATL ACAD SCI USA, V100, P12498, DOI 10.1073/pnas.2032456100; King PJ, 1998, J VIROL, V72, P8420, DOI 10.1128/JVI.72.10.8420-8424.1998; King PJ, 2003, VIROLOGY, V306, P147, DOI 10.1016/S0042-6822(02)00042-9; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; Lewinski MK, 2005, ADV GENET, V55, P147, DOI 10.1016/S0065-2660(05)55005-3; Li M, 2006, EMBO J, V25, P1295, DOI 10.1038/sj.emboj.7601005; Lin ZW, 1999, J MED CHEM, V42, P1401, DOI 10.1021/jm980531m; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Marchand C, 2002, J BIOL CHEM, V277, P12596, DOI 10.1074/jbc.M110758200; Marquez VE, 2004, J AM CHEM SOC, V126, P543, DOI 10.1021/ja037929e; Marquez VE, 1996, J MED CHEM, V39, P3739, DOI 10.1021/jm960306+; MAZUMDER A, 1995, NUCLEIC ACIDS RES, V23, P2865, DOI 10.1093/nar/23.15.2865; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; MORVAN F, 1987, NUCLEIC ACIDS RES, V15, P3421, DOI 10.1093/nar/15.8.3421; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P10739, DOI 10.1073/pnas.190312697; Pommier Yves, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P421; Pradhan P, 2001, BIOCHEMISTRY-US, V40, P5870, DOI 10.1021/bi002896q; Renisio JG, 2005, NUCLEIC ACIDS RES, V33, P1970, DOI 10.1093/nar/gki346; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; Sinha S, 2005, J VIROL, V79, P8208, DOI 10.1128/JVI.79.13.8208-8216.2005; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Van Maele B, 2005, AIDS REV, V7, P26; Volk DE, 2000, BIOCHEMISTRY-US, V39, P14040, DOI 10.1021/bi001669l; Wahlestedt C, 2000, P NATL ACAD SCI USA, V97, P5633, DOI 10.1073/pnas.97.10.5633; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wang T, 2001, J BIOL CHEM, V276, P14710, DOI 10.1074/jbc.M007754200; Wang T, 1999, BIOCHEMISTRY-US, V38, P3624, DOI 10.1021/bi982124i; Yakovleva L, 2003, J BIOL CHEM, V278, P42170, DOI 10.1074/jbc.M308079200; YEH HJC, 1995, BIOCHEMISTRY-US, V34, P13570, DOI 10.1021/bi00041a037; Zegar IS, 1998, BIOCHEMISTRY-US, V37, P16516, DOI 10.1021/bi9817616; Zhang XC, 2003, BIOORG MED CHEM LETT, V13, P1215, DOI 10.1016/S0960-894X(03)00059-3	55	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32428	32438		10.1074/jbc.M605101200	http://dx.doi.org/10.1074/jbc.M605101200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16943199	hybrid			2022-12-25	WOS:000241414500040
J	Christen, B; Christen, M; Paul, R; Schmid, F; Folcher, M; Jenoe, P; Meuwly, M; Jenal, U				Christen, Beat; Christen, Matthias; Paul, Ralf; Schmid, Franziska; Folcher, Marc; Jenoe, Paul; Meuwly, Markus; Jenal, Urs			Allosteric control of cyclic di-GMP signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EAL DOMAIN PROTEIN; DIGUANYLATE CYCLASE; RESPONSE REGULATOR; BIOFILM FORMATION; ESCHERICHIA-COLI; ADENYLYL-CYCLASE; GGDEF-DOMAIN; CAULOBACTER-CRESCENTUS; CELLULOSE BIOSYNTHESIS; ACETOBACTER-XYLINUM	Cyclic di-guanosine monophosphate is a bacterial second messenger that has been implicated in biofilm formation, antibiotic resistance, and persistence of pathogenic bacteria in their animal host. Although the enzymes responsible for the regulation of cellular levels of c-di-GMP, diguanylate cyclases (DGC) and phosphodiesterases, have been identified recently, little information is available on the molecular mechanisms involved in controlling the activity of these key enzymes or on the specific interactions of c-di-GMP with effector proteins. By using a combination of genetic, biochemical, and modeling techniques we demonstrate that an allosteric binding site for c-di-GMP (I-site) is responsible for non-competitive product inhibition of DGCs. The I-site was mapped in both multi- and single domain DGC proteins and is fully contained within the GGDEF domain itself. In vivo selection experiments and kinetic analysis of the evolved I-site mutants led to the definition of an RXXD motif as the core c-di-GMP binding site. Based on these results and based on the observation that the I-site is conserved in a majority of known and potential DGC proteins, we propose that product inhibition of DGCs is of fundamental importance for c-di-GMP signaling and cellular homeostasis. The definition of the I-site binding pocket provides an entry point into unraveling the molecular mechanisms of ligand-protein interactions involved in c-di-GMP signaling and makes DGCs a valuable target for drug design to develop new strategies against biofilmrelated diseases.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Univ Basel, Dept Chem, CH-4056 Basel, Switzerland	University of Basel; University of Basel	Jenal, U (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	urs.jenal@unibas.ch	Christen, Beat/AAC-2974-2021	Christen, Matthias/0000-0001-7724-4562; Christen, Beat/0000-0002-9528-3685				Aldridge P, 1999, MOL MICROBIOL, V32, P379, DOI 10.1046/j.1365-2958.1999.01358.x; Aldridge P, 2003, MOL MICROBIOL, V47, P1695, DOI 10.1046/j.1365-2958.2003.03401.x; Ausmees N, 2001, FEMS MICROBIOL LETT, V204, P163, DOI 10.1111/j.1574-6968.2001.tb10880.x; Baker DA, 2004, MOL MICROBIOL, V52, P1229, DOI 10.1111/j.1365-2958.2004.04067.x; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brouillette E, 2005, ANTIMICROB AGENTS CH, V49, P3109, DOI 10.1128/AAC.49.8.3109-3113.2005; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Christen M, 2005, J BIOL CHEM, V280, P30829, DOI 10.1074/jbc.M504429200; ELY B, 1991, METHOD ENZYMOL, V204, P372; Galperin MY, 2001, FEMS MICROBIOL LETT, V204, P213, DOI 10.1016/S0378-1097(01)00434-7; Garcia B, 2004, MOL MICROBIOL, V54, P264, DOI 10.1111/j.1365-2958.2004.04269.x; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; HECHT GB, 1995, J BACTERIOL, V177, P6223, DOI 10.1128/jb.177.21.6223-6229.1995; Hickman JW, 2005, P NATL ACAD SCI USA, V102, P14422, DOI 10.1073/pnas.0507170102; Hisert KB, 2005, MOL MICROBIOL, V56, P1234, DOI 10.1111/j.1365-2958.2005.04632.x; Jenal U, 2004, CURR OPIN MICROBIOL, V7, P185, DOI 10.1016/j.mib.2004.02.007; Kirillina O, 2004, MOL MICROBIOL, V54, P75, DOI 10.1111/j.1365-2958.2004.04253.x; Kulesekara H, 2006, P NATL ACAD SCI USA, V103, P2839, DOI 10.1073/pnas.0511090103; Lestrate P, 2003, INFECT IMMUN, V71, P7053, DOI 10.1128/IAI.71.12.7053-7060.2003; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Mendez-Ortiz MM, 2006, J BIOL CHEM, V281, P8090, DOI 10.1074/jbc.M510701200; OCHI Y, 1981, ACTA ENDOCRINOL-COP, V98, P62, DOI 10.1530/acta.0.0980062; OTOOLE GA, 1999, METHOD ENZYMOL, V34, P586; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Pei JM, 2001, PROTEINS, V42, P210, DOI 10.1002/1097-0134(20010201)42:2<210::AID-PROT80>3.0.CO;2-8; Romling U, 2005, MOL MICROBIOL, V57, P629, DOI 10.1111/j.1365-2958.2005.04697.x; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; ROSS P, 1991, MICROBIOL REV, V55, P35, DOI 10.1128/MMBR.55.1.35-58.1991; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005; Simm R, 2005, J BACTERIOL, V187, P6816, DOI 10.1128/JB.187.19.6816-6823.2005; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Tal R, 1998, J BACTERIOL, V180, P4416, DOI 10.1128/JB.180.17.4416-4425.1998; Tamayo R, 2005, J BIOL CHEM, V280, P33324, DOI 10.1074/jbc.M506500200; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tischler AD, 2002, J BACTERIOL, V184, P4104, DOI 10.1128/JB.184.15.4104-4113.2002; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; Ulrich LE, 2005, TRENDS MICROBIOL, V13, P52, DOI 10.1016/j.tim.2004.12.006; Zhang GY, 1997, NATURE, V388, P204, DOI 10.1038/40675; Zogaj X, 2001, MOL MICROBIOL, V39, P1452, DOI 10.1046/j.1365-2958.2001.02337.x	44	223	240	3	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					32015	32024		10.1074/jbc.M603589200	http://dx.doi.org/10.1074/jbc.M603589200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16923812	Green Accepted, Bronze			2022-12-25	WOS:000241235300087
J	Jawdekar, GW; Hanzlowsky, A; Hovde, SL; Jelencic, B; Feig, M; Geiger, JH; Henry, RW				Jawdekar, Gauri W.; Hanzlowsky, Andrej; Hovde, Stacy L.; Jelencic, Blanka; Feig, Michael; Geiger, James H.; Henry, R. William			The unorthodox SNAP50 zinc finger domain contributes to cooperative promoter recognition by human SNAP(C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; PROXIMAL SEQUENCE ELEMENT; PROTEIN COMPLEX SNAP(C); BOX-BINDING PROTEIN; SNRNA GENE-TRANSCRIPTION; OCT-1 POU DOMAIN; ACTIVATING PROTEIN; DNA-BINDING; SUBUNIT; ENERGY	Human small nuclear RNA gene transcription by RNA polymerases II and III depends upon promoter recognition by the SNAP(C) general transcription factor. DNA binding by SNAP(C) involves direct DNA contacts by the SNAP190 subunit in cooperation with SNAP50 and SNAP43. The data presented herein shows that SNAP50 plays an important role in DNA binding by SNAP(C) through its zinc finger domain. The SNAP50 zinc finger domain contains 15 cysteine and histidine residues configured in two potential zinc coordination arrangements. Individual alanine substitution of each cysteine and histidine residue demonstrated that eight sites are important for DNA binding by SNAP(C). However, metal binding studies revealed that SNAP(C) contains a single zinc atom indicating that only one coordination site functions as a zinc finger. Of the eight residues critical for DNA binding, four cysteine residues were also essential for both U1 and U6 transcription by RNA polymerase II and III, respectively. Surprisingly, the remaining four residues, although critical for U1 transcription could support partial U6 transcription. DNAbinding studies showed that defects in DNA binding by SNAP(C) alone could be suppressed through cooperative DNA binding with another member of the RNA polymerase III general transcription machinery, TFIIIB. These results suggest that these eight cysteine and histidine residues perform different functions during DNA binding with those residues involved in zinc coordination likely performing a dominant role in domain stabilization and the others involved in DNA binding. These data further define the unorthodox SNAP50 zinc finger region as an evolutionarily conserved DNA binding domain.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Geiger, JH (corresponding author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.	henryrw@msu.edu	Feig, Michael/AAI-9540-2021	Geiger, James/0000-0002-9443-4488	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059805, R01GM063894] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM59805, R01-GM063894] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamczak R, 2004, PROTEINS, V56, P753, DOI 10.1002/prot.20176; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Cabart P, 2002, J BIOL CHEM, V277, P26831, DOI 10.1074/jbc.M203119200; Das A, 2005, MOL CELL BIOL, V25, P7314, DOI 10.1128/MCB.25.16.7314-7322.2005; Feig M, 2004, J MOL GRAPH MODEL, V22, P377, DOI 10.1016/j.jmgm.2003.12.005; Ford E, 1998, GENE DEV, V12, P3528, DOI 10.1101/gad.12.22.3528; Gu LP, 2005, J BIOL CHEM, V280, P27697, DOI 10.1074/jbc.M503206200; Hanzlowsky A, 2006, PROTEIN EXPRES PURIF, V48, P215, DOI 10.1016/j.pep.2006.02.015; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Henry RW, 1996, EMBO J, V15, P7129, DOI 10.1002/j.1460-2075.1996.tb01104.x; Henry RW, 1998, GENE DEV, V12, P2664, DOI 10.1101/gad.12.17.2664; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; Hinkley CS, 2003, J BIOL CHEM, V278, P18649, DOI 10.1074/jbc.M204247200; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Hu P, 2004, MOL CELL, V16, P81, DOI 10.1016/j.molcel.2004.09.008; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Im W, 1998, COMPUT PHYS COMMUN, V111, P59, DOI 10.1016/S0010-4655(98)00016-2; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Ma B, 2001, J BIOL CHEM, V276, P5027, DOI 10.1074/jbc.M009301200; Ma BC, 2002, MOL CELL BIOL, V22, P8067, DOI 10.1128/MCB.22.22.8067-8078.2002; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Sadowski CL, 1996, P NATL ACAD SCI USA, V93, P4289, DOI 10.1073/pnas.93.9.4289; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Saxena A, 2005, MOL CELL BIOL, V25, P9406, DOI 10.1128/MCB.25.21.9406-9418.2005; Schimanski B, 2005, MOL CELL BIOL, V25, P7303, DOI 10.1128/MCB.25.16.7303-7313.2005; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Skolnick J, 1997, J MOL BIOL, V265, P217, DOI 10.1006/jmbi.1996.0720; Stumpff-Kane AW, 2006, PROTEINS, V63, P155, DOI 10.1002/prot.20853; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Wang Y, 1998, MOL CELL BIOL, V18, P1570, DOI 10.1128/MCB.18.3.1570; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; YOON JB, 1995, MOL CELL BIOL, V15, P2019; Zhang C, 2005, J MED CHEM, V48, P2325, DOI 10.1021/jm049314d	38	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31050	31060		10.1074/jbc.M603810200	http://dx.doi.org/10.1074/jbc.M603810200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16901896	hybrid			2022-12-25	WOS:000241075900081
J	Liu, PJ; Barkley, LR; Day, T; Bi, XH; Slater, DM; Alexandrow, MG; Nasheuer, HP; Vaziri, C				Liu, Peijun; Barkley, Laura R.; Day, Tovah; Bi, Xiaohui; Slater, Damien M.; Alexandrow, Mark G.; Nasheuer, Heinz-Peter; Vaziri, Cyrus			The Chk1-mediated S-phase checkpoint targets initiation factor Cdc45 via a Cdc25A/Cdk2-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; CELL-CYCLE; PROTEIN PHOSPHATASE; IONIZING-RADIATION; BETA-TRCP; RETINOBLASTOMA PROTEIN; DAMAGE CHECKPOINT; KINASE COMPLEX; REPLICATION; CDC25A	DNA damage induced by the carcinogen benzo[ a] pyrene dihydrodiol epoxide ( BPDE) induces a Chk1-dependent S-phase checkpoint. Here, we have investigated the molecular basis of BPDE-induced S-phase arrest. Chk1-dependent inhibition of DNA synthesis in BPDE-treated cells occurred without detectable changes in Cdc25A levels, Cdk2 activity, or Cdc7/Dbf4 interaction. Overexpression studies showed that Cdc25A, cyclin A/Cdk2, and Cdc7/Dbf4 were not rate-limiting for DNA synthesis when the BPDE-induced S-phase checkpoint was active. To investigate other potential targets of the S-phase checkpoint, we tested the effects of BPDE on the chromatin association of DNA replication factors. The levels of chromatin-associated Cdc45 (but not soluble Cdc45) were reduced concomitantly with BPDE-induced Chk1 activation and inhibition of DNA synthesis. The chromatin association of Mcm7, Mcm10, and proliferating cell nuclear antigen was unaffected by BPDE treatment. However, the association between Mcm7 and Cdc45 in the chromatin fraction was inhibited in BPDE-treated cells. Chromatin immunoprecipitation analyses demonstrated reduced association of Cdc45 with the beta-globin origin of replication in BPDE-treated cells. The inhibitory effects of BPDE on DNA synthesis, Cdc45/Mcm7 associations, and interactions between Cdc45 and the beta-globin locus were abrogated by the Chk1 inhibitor UCN-01. Taken together, our results show that the association between Cdc45 and Mcm7 at origins of replication is negatively regulated by Chk1 in a Cdk2-independent manner. Therefore, Cdc45 is likely to be an important target of the Chk1-mediated S-phase checkpoint.	Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Natl Univ Ireland Univ Coll Galway, Cell Cycle Control Lab, Dept Biochem, Galway, Ireland	Boston University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Ollscoil na Gaillimhe-University of Galway	Vaziri, C (corresponding author), Boston Univ, Sch Med, Dept Genet & Genom, 715 Albany St,E633, Boston, MA 02118 USA.	cvaziri@bu.edu	Nasheuer, Heinz P./B-9025-2008	Barkley, Laura/0000-0001-8026-5284; Nasheuer, Heinz Peter/0000-0002-9218-9079	NIEHS NIH HHS [ES09558, ES12917] Funding Source: Medline; NIGMS NIH HHS [F32 GM019304-02, F32 GM019304-01A1, F32 GM019304] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009558, R29ES009558, R01ES012917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019304] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aladjem MI, 2004, FRONT BIOSCI-LANDMRK, V9, P2540, DOI 10.2741/1415; Alexandrow MG, 2005, J CELL BIOL, V168, P875, DOI 10.1083/jcb.200409055; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bi XH, 2006, MOL CELL BIOL, V26, P3527, DOI 10.1128/MCB.26.9.3527-3540.2006; Bi XH, 2005, J BIOL CHEM, V280, P22343, DOI 10.1074/jbc.M501562200; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Chou DM, 2002, J BIOL CHEM, V277, P40520, DOI 10.1074/jbc.M207226200; CONNEY AH, 1982, CANCER RES, V42, P4875; Cordeiro-Stone M, 2002, CARCINOGENESIS, V23, P959, DOI 10.1093/carcin/23.6.959; CORDEIROSTONE M, 1986, CARCINOGENESIS, V7, P1775, DOI 10.1093/carcin/7.10.1775; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; DIPPLE A, 1995, CARCINOGENESIS, V16, P437, DOI 10.1093/carcin/16.3.437; Dipple A, 1999, INT J ONCOL, V14, P103; Duncker BP, 2003, MUTAT RES-FUND MOL M, V532, P21, DOI 10.1016/j.mrfmmm.2003.08.007; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Furuya K, 2004, GENE DEV, V18, P1154, DOI 10.1101/gad.291104; Garcia V, 2005, DNA REPAIR, V4, P1227, DOI 10.1016/j.dnarep.2005.04.001; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; Guo CY, 2002, J BIOL CHEM, V277, P4839, DOI 10.1074/jbc.M110092200; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Jares P, 2000, EMBO REP, V1, P319, DOI 10.1093/embo-reports/kvd076; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kukimoto I, 1999, EUR J BIOCHEM, V265, P936, DOI 10.1046/j.1432-1327.1999.00791.x; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; PAINTER RB, 1985, MUTAT RES, V145, P63, DOI 10.1016/0167-8817(85)90041-0; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Petersen P, 2006, MOL CELL BIOL, V26, P1997, DOI 10.1128/MCB.26.5.1997-2011.2006; Pollok S, 2003, BIOCHEM SOC T, V31, P266, DOI 10.1042/bst0310266; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Sorensen CS, 2004, CELL CYCLE, V3, P941; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takahashi TS, 2005, GENE DEV, V19, P2295, DOI 10.1101/gad.1339805; Takeda DY, 2005, ONCOGENE, V24, P2827, DOI 10.1038/sj.onc.1208616; TODOROVIC V, 1999, FRONT BIOSCI, V4, P859; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	61	73	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30631	30644		10.1074/jbc.M602982200	http://dx.doi.org/10.1074/jbc.M602982200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912045	hybrid			2022-12-25	WOS:000241075900039
J	Takemura, H; Rao, VA; Sordet, O; Furuta, T; Miao, ZH; Meng, L; Zhang, HL; Pommier, Y				Takemura, Haruyuki; Rao, V. Ashutosh; Sordet, Olivier; Furuta, Takahisa; Miao, Ze-Hong; Meng, LingHua; Zhang, Hongliang; Pommier, Yves			Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; RECURRENT OVARIAN-CANCER; TOPOISOMERASE-I; PROTEIN-KINASE; MRE11 COMPLEX; ATM; PHOSPHORYLATION; DAMAGE; CAMPTOTHECIN; REPAIR	The Mre11(.)Rad50(.)Nbs1 (MRN) complex binds DNA double strand breaks to repair DNA and activate checkpoints. We report MRN deficiency in three of seven colon carcinoma cell lines of the NCI Anticancer Drug Screen. To study the involvement of MRN in replication-mediated DNA double strand breaks, we examined checkpoint responses to camptothecin, which induces replication-mediated DNA double strand breaks after replication forks collide with topoisomerase I cleavage complexes. MRN-deficient cells were deficient for Chk2 activation, whereas Chk1 activation was independent of MRN. Chk2 activation was ataxia telangiectasia mutated (ATM)-dependent and associated with phosphorylation of Mre11 and Nbs1. Mre11 complementation in MRN-deficient HCT116 cells restored Chk2 activation as well as Rad50 and Nbs1 levels. Conversely, Mre11 down-regulation by small interference RNA ( siRNA) in HT29 cells inhibited Chk2 activation and down-regulated Nbs1 and Rad50. Proteasome inhibition also restored Rad50 and Nbs1 levels in HCT116 cells suggesting that Mre11 stabilizes Rad50 and Nbs1. Chk2 activation was also defective in three of four MRN-proficient colorectal cell lines because of low Chk2 levels. Thus, six of seven colon carcinoma cell lines from the NCI Anticancer Drug Screen are functionally Chk2-deficient in response to replication-mediated DNA double strand breaks. We propose that Mre11 stabilizes Nbs1 and Rad50 and that MRN activates Chk2 downstream from ATM in response to replication-mediated DNA double strand breaks. Chk2 deficiency in HCT116 is associated with defective S-phase checkpoint, prolonged G(2) arrest, and hypersensitivity to camptothecin. The high frequency of MRN and Chk2 deficiencies may contribute to genomic instability and therapeutic response to camptothecins in colorectal cancers.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH,Dept Hlth & Human Serv, Convent Dr,Bldg 37,Rm 5068, Bethesda, MD 20892 USA.	pommier@nih.gov	Rao, V Ashutosh/A-3569-2013; Sordet, Olivier/M-3271-2014	Rao, V Ashutosh/0000-0001-6817-8049; Sordet, Olivier/0000-0001-6027-4925	NATIONAL CANCER INSTITUTE [Z01BC006150, ZIABC006150] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Armstrong DK, 2005, ONCOLOGIST, V10, P686, DOI 10.1634/theoncologist.10-9-686; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; Bradbury JM, 2003, BIOCHEM SOC T, V31, P40, DOI 10.1042/bst0310040; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CIPOLLINI G, 2004, ANN ONCOL         S1, V15, P17; Craig AL, 2004, ONCOGENE, V23, P8411, DOI 10.1038/sj.onc.1208035; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; DERZWET MK, 1999, MUTAT RES, V434, P17; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Flatten K, 2005, J BIOL CHEM, V280, P14349, DOI 10.1074/jbc.M411890200; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Giannini G, 2004, ONCOGENE, V23, P2640, DOI 10.1038/sj.onc.1207409; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; GOLDWASSER F, 1995, CANCER RES, V55, P2116; Goldwasser F, 1996, CANCER RES, V56, P4430; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Ioanoviciu A, 2005, J MED CHEM, V48, P4803, DOI 10.1021/jm050076b; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kumar Atul, 2006, Curr Treat Options Oncol, V7, P37, DOI 10.1007/s11864-006-0030-9; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Kwak EL, 2006, CANCER RES, V66, P1923, DOI 10.1158/0008-5472.CAN-05-1237; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee SB, 2001, CANCER RES, V61, P8062; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu QH, 2000, GENE DEV, V14, P1448; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Machida YJ, 2005, CELL, V123, P13, DOI 10.1016/j.cell.2005.09.019; Marchand C, 2006, MOL CANCER THER, V5, P287, DOI 10.1158/1535-7163.MCT-05-0456; Markman M, 2005, ONCOLOGIST, V10, P695, DOI 10.1634/theoncologist.10-9-695; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mitchell SK, 2005, INT J GYNECOL CANCER, V15, P793, DOI 10.1111/j.1525-1438.2005.00138.x; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Penson RT, 2005, ONCOLOGIST, V10, P698, DOI 10.1634/theoncologist.10-9-698; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Pommier Y, 2005, CURR PHARM DESIGN, V11, P2855, DOI 10.2174/1381612054546716; Pommier Y, 2005, TRENDS PHARMACOL SCI, V26, P138, DOI 10.1016/j.tips.2005.01.008; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; POMMIER Y, 2006, IN PRESS NAT REV CAN; Rao VA, 2005, MOL CELL BIOL, V25, P8925, DOI 10.1128/MCB.25.20.8925-8937.2005; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Sergent C, 2002, CANCER CHEMOTH PHARM, V49, P445, DOI 10.1007/s00280-002-0450-6; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shiloh Y, 2004, NAT CELL BIOL, V6, P923, DOI 10.1038/ncb1004-923; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Staker BL, 2005, J MED CHEM, V48, P2336, DOI 10.1021/jm049146p; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Taverna P, 2000, CANCER CHEMOTH PHARM, V46, P507, DOI 10.1007/s002800000186; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yu Q, 2002, CANCER RES, V62, P5743; Yuan SSF, 2002, TOXICOLOGY, V177, P123, DOI 10.1016/S0300-483X(02)00220-2; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	75	97	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30814	30823		10.1074/jbc.M603747200	http://dx.doi.org/10.1074/jbc.M603747200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16905549	hybrid			2022-12-25	WOS:000241075900057
J	McKane, M; Wen, KK; Meyer, A; Rubenstein, PA				McKane, Melissa; Wen, Kuo-Kuang; Meyer, Amanda; Rubenstein, Peter A.			Effect of the substitution of muscle actin-specific subdomain 1 and 2 residues in yeast actin on actin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MYOSIN SUBFRAGMENT-1; F-ACTIN; MUTATIONAL ANALYSIS; ATPASE ACTIVITY; N-TERMINUS; POLYMERIZATION; MUTANT; FILAMENT; PROTEIN	Muscle and yeast actins display distinct behavioral characteristics. To better understand the allosteric interactions that regulate actin function, we created a muscle/ yeast hybrid actin containing a muscle- specific outer domain ( subdomains 1 and 2) and a yeast inner domain ( subdomains 3 and 4). Actin with muscle subdomain 1 and the two yeast N- terminal negative charges supported viability. The four negative charge muscleNterminus in a muscle subdomain 1 background caused death, but in the same background actin with three N- terminal acidic residues ( 3Ac/ Sub1) led to sick but viable cells. Addition of three muscle subdomain 2 residues ( 3Ac/ Sub12) produced no further deleterious effects. These hybrid actins caused depolarized cytoskeletons, abnormal vacuoles, and mitochondrial and endocytosis defects. 3Ac/ Sub1 G- actin exchanged bound epsilon ATP more slowly than wild type actin, and the exchange rate for 3Ac/ Sub12 was even slower, similar to that for muscle actin. The mutant actins polymerized faster and produced less stable and shorter filaments than yeast actin, the opposite of that expected for muscle actin. Unlike wild type actin, in the absence of unbound ATP, polymerization led to ADP- F- actin, which rapidly depolymerized. Like yeast actin, the hybrid actins activated muscle myosin S1 ATPase activity only about one- eighth as well as muscle actin, despite having essentially a muscle actin- specific myosinbinding site. Finally, the hybrid actins behaved abnormally in a yeast Arp2/3- dependent polymerization assay. Our results demonstrate a unique sensitivity of yeast to actin N- terminal negative charge density. They also provide insight into the role of each domain in the control of the various functions of actin.	Univ Iowa, Roy A & Lucille A Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Roy A & Lucille A Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu		Rubenstein, Peter/0000-0003-1225-4414	NIGMS NIH HHS [GM-33689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bobkov AA, 1997, BIOCHEMISTRY-US, V36, P7733, DOI 10.1021/bi963185o; Bryan KE, 2005, J BIOL CHEM, V280, P1696, DOI 10.1074/jbc.M410180200; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; CARLIER MF, 1991, J BIOL CHEM, V266, P1; Chen WZ, 2006, BIOPHYS J, V90, P1308, DOI 10.1529/biophysj.105.064634; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOK RK, 1993, J BIOL CHEM, V268, P2410; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Galkin VE, 2002, CURR BIOL, V12, P570, DOI 10.1016/S0960-9822(02)00742-X; GALLWITZ D, 1980, NUCLEIC ACIDS RES, V8, P1043, DOI 10.1093/nar/8.5.1043; Garner EC, 2004, SCIENCE, V306, P1021, DOI 10.1126/science.1101313; GREER C, 1982, MOL CELL BIOL, V2, P1270, DOI 10.1128/MCB.2.10.1270; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; HITCHCOCK SE, 1980, J BIOL CHEM, V255, P5668; HITCHCOCKDEGREGORI SE, 1988, BIOCHEMISTRY-US, V27, P9182, DOI 10.1021/bi00426a016; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; Kim E, 1996, BIOCHEMISTRY-US, V35, P16566, DOI 10.1021/bi9623892; Lauer P, 2002, J BACTERIOL, V184, P4177, DOI 10.1128/JB.184.15.4177-4186.2002; Lu XY, 2005, J PHYSIOL-LONDON, V564, P65, DOI 10.1113/jphysiol.2004.078055; McKane M, 2005, J BIOL CHEM, V280, P36494, DOI 10.1074/jbc.M506970200; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; Okamoto K, 2001, METHOD CELL BIOL, V65, P277, DOI 10.1016/S0091-679X(01)65017-9; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Saeki K, 2000, BIOCHEMISTRY-US, V39, P1324, DOI 10.1021/bi991297k; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; Wen KK, 2005, J BIOL CHEM, V280, P24168, DOI 10.1074/jbc.M502024200; Wen KK, 2002, J BIOL CHEM, V277, P41101, DOI 10.1074/jbc.M204025200; Wen KK, 2000, J BIOL CHEM, V275, P40594, DOI 10.1074/jbc.M007201200; WERTMAN KF, 1992, GENETICS, V132, P337; Yao XY, 2001, J BIOL CHEM, V276, P25598, DOI 10.1074/jbc.M011797200	37	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29916	29928		10.1074/jbc.M602251200	http://dx.doi.org/10.1074/jbc.M602251200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16882670	hybrid			2022-12-25	WOS:000240896300053
J	Melia, TJ; You, DQ; Tareste, DC; Rothman, JE				Melia, Thomas J.; You, Daoqi; Tareste, David C.; Rothman, James E.			Lipidic antagonists to SNARE-mediated fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; TRANSPORT VESICLES; CRYSTAL-STRUCTURE; COMPLEX; BINDING; CORE; SYNAPTOTAGMIN-1; INHIBITION; EXOCYTOSIS; MECHANISM	SNARE proteins mediate the fusion of lipid bilayers by the directed assembly of coiled- coil domains arising from apposing membranes. We have utilized inverted cone-shaped lipids, antagonists of the necessary membrane deformation during fusion to characterize the extent and range of SNARE assembly up to the moment of stalk formation between bilayers. The inverted cone-shaped lipid family of acyl-CoAs specifically inhibits the completion of fusion in an acyl-chain length-dependent manner. Removal of acyl-CoA from the membrane relieves the inhibition and initiates a burst of membrane fusion with rates exceeding any point in the control curves lacking acyl-CoA. This burst indicates the accumulation of semi- assembled fusion complexes. These preformed complexes are resistant to cleavage by botulinum toxin B and thus appear to have progressed beyond the "loosely zippered" state of docked synaptic vesicles. Surprisingly, application of the soluble domain of VAMP2, which blocks SNARE assembly by competing for binding on the available t-SNAREs, blocks recovery from the acylCoA inhibition. Thus, complexes formed in the presence of a lipidic antagonist to fusion are incompletely assembled, suggesting that the formation of tightly assembled SNARE pairs requires progression all the way through to membrane fusion. In this regard, physiologically docked exocytic vesicles may be anchored by a highly dynamic and potentially even reversible SNAREpin.	Columbia Univ, Dept Physiol & Cellular Biophys, Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Melia, TJ (corresponding author), Columbia Univ, Dept Physiol & Cellular Biophys, Coll Phys & Surg, 1150 St Nicholas Ave, New York, NY 10032 USA.	tm2176@columbia.edu	Tareste, David/L-2639-2017; Tareste, David/P-9249-2019	Tareste, David/0000-0002-8744-7598; Tareste, David/0000-0002-8744-7598				Arac D, 2006, NAT STRUCT MOL BIOL, V13, P209, DOI 10.1038/nsmb1056; Bowen ME, 2005, BIOPHYS J, V89, P690, DOI 10.1529/biophysj.104.054064; Chen XC, 2006, BIOPHYS J, V90, P2062, DOI 10.1529/biophysj.105.071415; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fix M, 2004, P NATL ACAD SCI USA, V101, P7311, DOI 10.1073/pnas.0401779101; Gelamo EL, 2002, BBA-PROTEIN STRUCT M, V1594, P84, DOI 10.1016/S0167-4838(01)00287-4; GINGELL D, 1978, P791; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; GUNTHERAUSBORN S, 1995, J BIOL CHEM, V270, P29279; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; Hua SY, 1999, NAT NEUROSCI, V2, P1078, DOI 10.1038/16005; KOZLOV MM, 1983, BIOFIZIKA+, V28, P242; Lonart G, 2000, J BIOL CHEM, V275, P27703; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Nagy G, 2006, J NEUROSCI, V26, P632, DOI 10.1523/JNEUROSCI.2589-05.2006; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; POWELL GL, 1981, J BIOL CHEM, V256, P2740; Rizo J, 2003, NAT STRUCT BIOL, V10, P417, DOI 10.1038/nsb0603-417; Schuette CG, 2004, P NATL ACAD SCI USA, V101, P2858, DOI 10.1073/pnas.0400044101; Scott BL, 2003, METHOD ENZYMOL, V372, P274; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tamm LK, 2003, CURR OPIN STRUC BIOL, V13, P453, DOI 10.1016/S0959-440X(03)00107-6; Weber T, 2000, J CELL BIOL, V149, P1063, DOI 10.1083/jcb.149.5.1063; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Zhang F, 2004, J BIOL CHEM, V279, P38668, DOI 10.1074/jbc.M404904200	34	30	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29597	29605		10.1074/jbc.M601778200	http://dx.doi.org/10.1074/jbc.M601778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16887809	hybrid			2022-12-25	WOS:000240896300021
J	Xi, XD; Flevaris, P; Stojanovic, A; Chishti, A; Phillips, DR; Lam, SCT; Du, XP				Xi, Xiaodong; Flevaris, Panagiotis; Stojanovic, Aleksandra; Chishti, Athar; Phillips, David R.; Lam, Stephen C. T.; Du, Xiaoping			Tyrosine phosphorylation of the integrin beta(3) subunit regulates beta(3) cleavage by calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROXIMAL REGION; GLYCOPROTEIN-IIB-IIIA; CYTOPLASMIC DOMAIN; GLANZMANN THROMBASTHENIA; TALIN-BINDING; INSIDE-OUT; GPIIB-IIIA; ACTIVATION; ALPHA(IIB)BETA(3); PROTEASE	Outside-in signaling of beta(3) integrins induces and requires phosphorylation at tyrosine 747 (Tyr(747)) and tyrosine 759 (Tyr(759)) of the beta(3) subunit, but the mechanism for this requirement is unclear. On the other hand, a key consequence of integrin signaling, cell spreading, is inhibited by calpain cleavage of beta(3) cytoplasmic domain. Here we show that beta(3) tyrosine phosphorylation inhibits calpain cleavage. Mutating both tyrosines to phenylalanine sensitizes beta(3) to calpain cleavage. Furthermore, phosphorylation at Tyr(747) and Tyr(759) of beta(3) in the focal adhesion sites and the leading edge of spreading platelets was differentially regulated. Selective dephosphorylation of Tyr(759) is associated with calpain cleavage at Tyr(759). Thus, one mechanism by which tyrosine phosphorylation promotes integrin signaling and cell spreading is its inhibition of calpain cleavage of the beta(3) cytoplasmic domain.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Portola Pharmaceut Inc, San Francisco, CA 94080 USA; Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Hematol, Shanghai, Peoples R China	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Shanghai Jiao Tong University	Du, XP (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott Ave,Rm E403, Chicago, IL 60612 USA.	xdu@uic.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062350, R01HL068819] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62350, R01 HL068819, HL68819, R01 HL062350] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arias-Salgado EG, 2005, J BIOL CHEM, V280, P29699, DOI 10.1074/jbc.M503508200; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Bodnar RJ, 1999, J BIOL CHEM, V274, P33474, DOI 10.1074/jbc.274.47.33474; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; de Virgilio M, 2004, J CELL BIOL, V165, P305, DOI 10.1083/jcb.200402064; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DU XP, 1993, J BIOL CHEM, V268, P23087; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Leisner TM, 1999, J BIOL CHEM, V274, P12945, DOI 10.1074/jbc.274.18.12945; Meredith J, 1998, J BIOL CHEM, V273, P19525, DOI 10.1074/jbc.273.31.19525; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Vinogradova O, 2004, P NATL ACAD SCI USA, V101, P4094, DOI 10.1073/pnas.0400742101; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wang RG, 1997, J CLIN INVEST, V100, P2393, DOI 10.1172/JCI119780; Xi XD, 2003, J CELL BIOL, V162, P329, DOI 10.1083/jcb.200303120; Yuan WP, 2006, J CELL BIOL, V172, P169, DOI 10.1083/jcb.200505131	36	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29426	29430		10.1074/jbc.C600039200	http://dx.doi.org/10.1074/jbc.C600039200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16935858	hybrid			2022-12-25	WOS:000240896300003
J	Yacoub, D; Theoret, JF; Villeneuve, L; Abou-Saleh, H; Mourad, W; Allen, BG; Merhi, Y				Yacoub, Daniel; Theoret, Jean-Francois; Villeneuve, Louis; Abou-Saleh, Haissam; Mourad, Walid; Allen, Bruce G.; Merhi, Yahye			Essential role of protein kinase C delta in platelet signaling alpha(IIb)beta(3) activation, and thromboxane A(2) release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; P-SELECTIN ANTAGONISM; RECEPTOR GAMMA-CHAIN; SYNTAXIN 4; COLLAGEN; THROMBIN; ADHESION; TRANSDUCTION; PKC; SECRETION	The protein kinase C (PKC) family is an essential signaling mediator in platelet activation and aggregation. However, the relative importance of the major platelet PKC isoforms and their downstream effectors in platelet signaling and function remain unclear. Using isolated human platelets, we report that PKC delta, but not PKC alpha or PKC beta, is required for collagen-induced phospholipase C-dependent signaling, activation of alpha(IIb)beta(3), and platelet aggregation. Analysis of PKC delta phosphorylation and translocation to the membrane following activation by both collagen and thrombin indicates that it is positively regulated by alpha(IIb)beta(3) outside-in signaling. Moreover, PKC delta triggers activation of the mitogen-activated protein kinase-kinase (MEK)/extra cellular signal regulated kinase (ERK) and the p38 MAPK signaling. This leads to the subsequent release of thromboxane A(2), which is essential for collagen-induced but not thrombin-induced platelet activation and aggregation. This study adds new insight to the role of PKCs in platelet function, where PKC delta signaling, via the MEK/ERK and p38 MAPK pathways, is required for the secretion of thromboxane A(2).	Montreal Heart Inst, Lab Expt Pathol, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Montreal, PQ H1T 1C8, Canada	Universite de Montreal; Universite de Montreal	Merhi, Y (corresponding author), Montreal Heart Inst, Lab Expt Pathol, Res Ctr, 5000 Belanger St, Montreal, PQ H1T 1C8, Canada.	yahye.merhi@icm-mhi.org	Allen, Bruce G/B-4693-2008	Allen, Bruce G/0000-0001-9000-9495; Mourad, Walid/0000-0002-1859-9387				BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BANNO Y, 1988, J BIOL CHEM, V263, P11459; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; Blobe GC, 1996, CANCER SURV, V27, P213; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P581; Caron A, 2002, J CARDIOVASC PHARM, V40, P296, DOI 10.1097/00005344-200208000-00015; Cho MJ, 2003, BLOOD, V101, P2646, DOI 10.1182/blood-2002-05-1363; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Clemetson KJ, 2002, PLATELETS, P65; Coughlin SR, 2001, THROMB HAEMOSTASIS, V86, P298; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; Crosby D, 2003, J BIOL CHEM, V278, P24533, DOI 10.1074/jbc.M301847200; Francischetti IMB, 1998, ARCH BIOCHEM BIOPHYS, V353, P239, DOI 10.1006/abbi.1998.0598; GERRARD JM, 1989, BLOOD, V74, P2405; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Hato T., 2002, PLATELETS, P105; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HYNES RO, 1991, THROMB HAEMOSTASIS, V66, P40; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Levy-Toledano S, 1999, HAEMOSTASIS, V29, P4; Libersan D, 2003, THROMB HAEMOSTASIS, V89, P1016, DOI 10.1055/s-0037-1613403; McNicol A, 1998, BIOCHEM PHARMACOL, V55, P1759, DOI 10.1016/S0006-2952(97)00632-1; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; Moussazadeh M, 1998, FEBS LETT, V438, P225, DOI 10.1016/S0014-5793(98)01302-7; Murugappan S, 2005, BLOOD, V106, P550, DOI 10.1182/blood-2004-12-4866; Murugappan S, 2004, J BIOL CHEM, V279, P2360, DOI 10.1074/jbc.M306960200; Nadal-Wollbold F, 2002, FEBS LETT, V531, P475, DOI 10.1016/S0014-5793(02)03587-1; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; PROJMOVIC MM, 1998, AM HEART J, V135, pS119; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Roberts DE, 2004, J BIOL CHEM, V279, P19421, DOI 10.1074/jbc.M308864200; ROTH GJ, 1994, BLOOD, V83, P885; RUGGERI ZM, 1993, THROMB HAEMOSTASIS, V70, P119; SAELMAN EUM, 1994, BLOOD, V83, P1244; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; Savage B., 2002, PLATELETS, P215; SIESS W, 1988, BIOCHEM J, V255, P309; Soriani A, 2006, J THROMB HAEMOST, V4, P648, DOI 10.1111/j.1538-7836.2006.01806.x; Theoret JF, 2001, J PHARMACOL EXP THER, V298, P658; TOLENTINO AR, 2002, PLATELETS, P117; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; WANG F, 1993, BIOCHEM BIOPH RES CO, V191, P240, DOI 10.1006/bbrc.1993.1208; WOULFE D, 2002, PLATELETS, P197; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471	56	76	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30024	30035		10.1074/jbc.M604504200	http://dx.doi.org/10.1074/jbc.M604504200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16895913	hybrid			2022-12-25	WOS:000240896300063
J	Kozak, SL; Marin, M; Rose, KM; Bystrom, C; Kabat, D				Kozak, Susan L.; Marin, Mariana; Rose, Kristine M.; Bystrom, Cory; Kabat, David			The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN COMPLEX PURIFICATION; MENTAL-RETARDATION PROTEIN; SINGLE-STRANDED-DNA; VIRAL VIF PROTEIN; CYTIDINE DEAMINASE; PUR-ALPHA; STATISTICAL-MODEL; TYPE-1 VIF; TRANSLATION	Deoxycytidine deaminases APOBEC3G(A3G) and APOBEC3F (A3F) (members of the apolipoprotein B mRNA-editing catalytic polypeptide 3 family) have RNA-binding motifs, invade assembling human immunodeficiency virus (HIV-1), and hypermutate reverse transcripts. Antagonistically, HIV-1 viral infectivity factor degrades these enzymes. A3G is enzymatically inhibited by binding RNA within an unidentified large cytosolic ribonucleoprotein, implying that RNA degradation during reverse transcription may activate intravirion A3G at the necessary moment. We purified a biologically active tandem affinity-tagged A3G from human HEK293T cells. Mass spectrometry and coimmunoprecipitation from HEK293T and T lymphocyte extracts identified many RNA-binding proteins specifically associated with A3G and A3F, including poly(A)-binding proteins (PABPs), YB-1, Ro-La, RNA helicases, ribosomal proteins, and Staufen1. Most strikingly, nearly all A3G-associated proteins were known to bind exclusively or intermittently to translating and/ or dormant mRNAs. Accordingly, A3G in HEK293T and T lymphocyte extracts was almost completely in A3G-mRNA-PABP complexes that shifted reversibly between polysomes and dormant pools in response to translational inhibitors. For example arsenite, which inhibits 5'-cap-dependent translational initiation, shifted mRNA-A3G-PABP from polysomes into stress granules in a manner that was blocked and reversed by the elongation inhibitor cycloheximide. Immunofluorescence microscopy showed A3G-mRNA-PABP stress granules only partially overlapping with Staufen1. A3G coimmunoprecipitated HIV-1RNA and many mRNAs. Ribonuclease released nearly all A3G-associated proteins, including A3G homo-oligomers and A3G-A3F hetero-oligomers, but the viral infectivity factor remained bound. Many proteins and RNAs associated with A3G are excluded from A3G-containing virions, implying that A3G competitively partitions into virions based on affinity for HIV-1 RNA.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, Portland, OR 97239 USA	Oregon Health & Science University	Kabat, D (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	kabat@ohsu.edu			NIAID NIH HHS [AI49729] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049729, R21AI049729] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afonina E, 1997, J BIOL CHEM, V272, P2307, DOI 10.1074/jbc.272.4.2307; Ansari SA, 1999, J GEN VIROL, V80, P2629, DOI 10.1099/0022-1317-80-10-2629; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Brendel C, 2004, BIOCHEM J, V384, P239, DOI 10.1042/BJ20040812; BURKA ER, 1964, J MOL BIOL, V9, P439, DOI 10.1016/S0022-2836(64)80218-7; Chatel-Chaix L, 2004, MOL CELL BIOL, V24, P2637, DOI 10.1128/MCB.24.7.2637-2648.2004; Chelico L, 2006, NAT STRUCT MOL BIOL, V13, P392, DOI 10.1038/nsmb1086; Chiu YL, 2006, J BIOL CHEM, V281, P8309, DOI 10.1074/jbc.R500021200; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092; Cullen BR, 2006, J VIROL, V80, P1067, DOI 10.1128/JVI.80.3.1067-1076.2006; Dugre-Brisson S, 2005, NUCLEIC ACIDS RES, V33, P4797, DOI 10.1093/nar/gki794; Forler D, 2003, NAT BIOTECHNOL, V21, P89, DOI 10.1038/nbt773; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gallia GL, 1999, P NATL ACAD SCI USA, V96, P11572, DOI 10.1073/pnas.96.20.11572; Guo XM, 2004, J VIROL, V78, P12781, DOI 10.1128/JVI.78.23.12781-12787.2004; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; KABAT D, 1971, ANAL BIOCHEM, V39, P228, DOI 10.1016/0003-2697(71)90480-5; KABAT D, 1994, J VIROL, V68, P2570, DOI 10.1128/JVI.68.4.2570-2577.1994; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kersey PJ, 2004, PROTEOMICS, V4, P1985, DOI 10.1002/pmic.200300721; Khan MA, 2005, J VIROL, V79, P5870, DOI 10.1128/JVI.79.9.5870-5874.2005; Kim YK, 2005, CELL, V120, P195, DOI 10.1016/j.cell.2004.11.050; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Lau PP, 2001, BIOCHEM BIOPH RES CO, V282, P977, DOI 10.1006/bbrc.2001.4679; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; Luo K, 2005, P NATL ACAD SCI USA, V102, P11444, DOI 10.1073/pnas.0502440102; Luo K, 2004, J VIROL, V78, P11841, DOI 10.1128/JVI.78.21.11841-11852.2004; Madani N, 2000, J VIROL, V74, P5982, DOI 10.1128/JVI.74.13.5982-5987.2000; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2000, J VIROL, V74, P8085, DOI 10.1128/JVI.74.17.8085-8093.2000; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mazroui R, 2002, HUM MOL GENET, V11, P3007, DOI 10.1093/hmg/11.24.3007; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Mehta A, 2002, RNA, V8, P69, DOI 10.1017/S1355838202015649; Mouland AJ, 2000, J VIROL, V74, P5441, DOI 10.1128/JVI.74.12.5441-5451.2000; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Nguyen KL, 2004, VIROLOGY, V319, P163, DOI 10.1016/j.virol.2003.11.021; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Peng G, 2006, J EXP MED, V203, P41, DOI 10.1084/jem.20051512; Platt EJ, 2001, J VIROL, V75, P12266, DOI 10.1128/JVI.75.24.12266-12278.2001; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rose KM, 2005, AIDS RES HUM RETROV, V21, P611, DOI 10.1089/aid.2005.21.611; Rose KM, 2004, J BIOL CHEM, V279, P41744, DOI 10.1074/jbc.M406760200; Schafer A, 2004, VIROLOGY, V328, P163, DOI 10.1016/j.virol.2004.08.006; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Sherrill KW, 2004, J BIOL CHEM, V279, P29066, DOI 10.1074/jbc.M402727200; Shin HJ, 2002, ARCH VIROL, V147, P471, DOI 10.1007/s007050200001; Smith HC, 2004, TRENDS GENET, V20, P224, DOI 10.1016/j.tig.2004.03.012; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; Stefani G, 2004, J NEUROSCI, V24, P7272, DOI 10.1523/JNEUROSCI.2306-04.2004; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Turelli P, 2005, SCIENCE, V307, P1061, DOI 10.1126/science.1105964; Villace P, 2004, NUCLEIC ACIDS RES, V32, P2411, DOI 10.1093/nar/gkh552; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Wichroski MJ, 2006, PLOS PATHOG, V2, pe41, DOI DOI 10.1371/journal.ppat.0020041; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Wortman MJ, 2000, J CELL BIOCHEM, V77, P65, DOI 10.1002/(SICI)1097-4644(20000401)77:1<65::AID-JCB7>3.0.CO;2-U; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	76	145	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29105	29119		10.1074/jbc.M601901200	http://dx.doi.org/10.1074/jbc.M601901200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16887808	hybrid			2022-12-25	WOS:000240680500065
J	Janssen, K; Hofmann, TG; Jans, DA; Hay, RT; Schulze-Osthoff, K; Fischer, U				Janssen, K.; Hofmann, T. G.; Jans, D. A.; Hay, R. T.; Schulze-Osthoff, K.; Fischer, U.			Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies	ONCOGENE			English	Article						apoptin; apoptosis; PML; SUMO; HipK2	CHICKEN-ANEMIA-VIRUS; INDUCED CELL-DEATH; INDUCED APOPTOSIS; GENE-THERAPY; P53 ACTIVITY; TUMOR-CELLS; PML; ACCUMULATION; SUPPRESSOR; EXPRESSION	Apoptin, a protein of the chicken anemia virus (CAV), represents a novel potential anticancer therapeutic, because it induces apoptotic death specifically in tumor but not normal cells. The cellular localization appears to be crucial for apoptin's selective toxicity. In normal cells apoptin remains in the cytoplasm, whereas in transformed cells it migrates into the nucleus and kills the cell. However, the manner by which apoptin is able to distinguish between tumor and normal cells is unknown. Here, we report for the first time that apoptin interacts directly with the promyelocytic leukemia protein (PML) in tumor cells and accumulates in PML nuclear bodies (NBs), which are involved in apoptosis induction and viral replication. We also demonstrate that apoptin is sumoylated and that a sumoylation-deficient apoptin mutant is no longer recruited to PML-NBs, but localizes in the nuclear matrix. This mutant fails to bind PML, but can still induce apoptosis as efficiently as wild-type apoptin. Moreover, apoptin kills also PML-/- cells and promyelocytic leukemia cells with defective PML expression. Our results therefore suggest that apoptin kills tumor cells independently of PML and sumoylation, however, the interaction of apoptin with PML and small ubiquitin-like modifier (SUMO) proteins might be relevant for CAV replication.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Deutsch Krebsforschungszentrum, Res Grp Cellular Senescence, D-6900 Heidelberg, Germany; Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Clayton, Vic 3168, Australia; Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 4HN, Scotland	Heinrich Heine University Dusseldorf; Helmholtz Association; German Cancer Research Center (DKFZ); Monash University; University of Dundee	Fischer, U (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	Ute.Fischer@uni-duesseldorf.de	Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011; Schulze-Osthoff, Klaus/N-9025-2013	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Jans, David/0000-0001-5115-4745				Adair BM, 2000, DEV COMP IMMUNOL, V24, P247, DOI 10.1016/S0145-305X(99)00076-2; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Burek M, 2006, ONCOGENE, V25, P2213, DOI 10.1038/sj.onc.1209258; Chen A, 2006, J CELL BIOCHEM, V98, P895, DOI 10.1002/jcb.20703; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Engels IH, 2005, MOL CELL BIOL, V25, P2808, DOI 10.1128/MCB.25.7.2808-2818.2005; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fischer U, 2005, ONCOGENE, V24, P1231, DOI 10.1038/sj.onc.1208290; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Leliveld SR, 2003, EUR J BIOCHEM, V270, P3619, DOI 10.1046/j.1432-1033.2003.03750.x; Leliveld SR, 2003, J BIOL CHEM, V278, P9042, DOI 10.1074/jbc.M210803200; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; Oro C, 2004, CURR DRUG TARGETS, V5, P179, DOI 10.2174/1389450043490631; Peters MA, 2006, J GEN VIROL, V87, P823, DOI 10.1099/vir.0.81468-0; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pietersen AM, 1999, GENE THER, V6, P882, DOI 10.1038/sj.gt.3300876; Poon IH, 2005, CANCER RES, V65, P7059, DOI 10.1158/0008-5472.CAN-05-1370; Poon IKH, 2005, J VIROL, V79, P1339, DOI 10.1128/JVI.79.2.1339-1341.2005; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Renshaw RW, 1996, J VIROL, V70, P8872, DOI 10.1128/JVI.70.12.8872-8878.1996; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Schoop RAL, 2004, INT J CANCER, V109, P38, DOI 10.1002/ijc.11675; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tavassoli M, 2005, APOPTOSIS, V10, P717, DOI 10.1007/s10495-005-0930-3; van der Eb MM, 2002, CANCER GENE THER, V9, P53, DOI 10.1038/sj.cgt.7700397; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Zhang YH, 1999, CANCER RES, V59, P3010; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939	49	31	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1557	1566		10.1038/sj.onc.1209923	http://dx.doi.org/10.1038/sj.onc.1209923			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16924230				2022-12-25	WOS:000244782500005
J	Wang, DM; Sevcikova, S; Wen, H; Roberts, S; Lipsick, JS				Wang, D-M; Sevcikova, S.; Wen, H.; Roberts, S.; Lipsick, J. S.			v-Myb represses the transcription of Ets-2	ONCOGENE			English	Article						Myb; Ets; repression	MYELOMONOCYTIC GROWTH-FACTOR; AVIAN-MYELOBLASTOSIS VIRUS; DNA-BINDING ACTIVITY; C-MYB; TARGET GENE; TRANS-ACTIVATION; ONCOGENE PRODUCT; E26 VIRUS; B-MYB; EXPRESSION	The v-Myb oncogene causes monoblastic leukemia and transforms only myelomonocytic cells in culture. The vMyb protein is nuclear and binds to specific DNA sequences. To identify genes regulated by v-Myb, we utilized primary cells transformed by a retrovirus encoding a v-Myb-estrogen receptor (ER) fusion protein. The Ets-2 gene was not expressed in v-Myb-ER transformed cells in the presence of estradiol, but was expressed within 4 h after estradiol withdrawal. The expression of Ets-2 also increased dramatically following phorbol ester-induced differentiation of the v-Myb-transformed BM2 cell line. Conversely, CRYP-alpha, encoding a transmembrane tyrosine phosphatase, was expressed in the presence but not the absence of estradiol in v-Myb-ER transformed cells. CRYP-alpha was downregulated during the phorbol ester-induced differentiation of BM2 cells. Although LIM-3 expression was estradiol-inducible in v-Myb-ER transformed monoblasts, LIM-3 was expressed neither in primary yolk sac cells transformed by unfused v-Myb nor in BM2 cells. We conclude that although v-Myb has been intensively studied as a transcriptional activator, v-Myb can repress biologically relevant genes such as Ets-2, which promotes macrophage differentiation. In addition, we have shown that some genes that are regulated by a v-Myb-ER fusion protein may not be relevant to the biological function of the unfused v-Myb protein.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Dept Pathol, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	lipsick@stanford.edu	Sevcikova, Sabina/AAB-4267-2021	Wen, Hong/0000-0001-8739-4572	NATIONAL CANCER INSTITUTE [T32CA009151, R01CA043592] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA43592, T32 CA09151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aperlo C, 1996, MOL CELL BIOL, V16, P6851; Bartley PA, 2003, ONCOGENE, V22, P7570, DOI 10.1038/sj.onc.1207136; Begue A, 1997, GENE EXPRESSION, V6, P333; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; Braas D, 2004, NUCLEIC ACIDS RES, V32, P4750, DOI 10.1093/nar/gkh808; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Chen J, 2002, ONCOGENE, V21, P1859, DOI 10.1038/sj.onc.1205003; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; Engelke U, 1997, J VIROL, V71, P3760, DOI 10.1128/JVI.71.5.3760-3766.1997; Ferrao P, 1997, BLOOD, V90, P4539; GARCIA A, 1991, ONCOGENE, V6, P265; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1988, J VIROL, V62, P4398, DOI 10.1128/JVI.62.11.4398-4402.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KU DH, 1993, J BIOL CHEM, V268, P2255; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; Lei WL, 2004, J BIOL CHEM, V279, P29519, DOI 10.1074/jbc.M403133200; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Lisitsyn N A, 1993, Mol Gen Mikrobiol Virusol, P26; Liu F, 2006, ONCOGENE, V25, P795, DOI 10.1038/sj.onc.1209105; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P325; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PESSANO S, 1979, NEW MICROBIOL, V2, P379; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; White JR, 2000, ONCOGENE, V19, P1196, DOI 10.1038/sj.onc.1203394; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179	42	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1238	1244		10.1038/sj.onc.1209868	http://dx.doi.org/10.1038/sj.onc.1209868			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16909100				2022-12-25	WOS:000244406400014
J	Corral, RS; Iniguez, MA; Duque, J; Lopez-Perez, R; Fresno, M				Corral, R. S.; Iniguez, M. A.; Duque, J.; Lopez-Perez, R.; Fresno, M.			Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells	ONCOGENE			English	Article						cyclooxygenase-2; NFAT; bombesin; migration; colon carcinoma	GASTRIN-RELEASING-PEPTIDE; RECEPTOR TYROSINE KINASE; CANCER CELLS; TRANSCRIPTIONAL REGULATION; INVASION; INHIBITION; MOTILITY; GROWTH; NFAT; INDUCTION	Cyclooxygenase-2 (Cox-2), the gastrin-release peptide (GRP) and its cognate receptor (GRP-R) are over-expressed in a significant percentage of colorectal carcinomas and are associated with cell growth, invasiveness and tumor progression. However, a molecular link between all of them in adenocarcinomas has not been established. Here, we show that bombesin (BBS), a GRP homolog, stimulates the expression of Cox-2 mRNA and protein in human colon adenocarcinoma Caco-2 cells, resulting in enhanced release of prostaglandin E-2. These effects were markedly inhibited by the specific BBS antagonist RC-3940-II. BBS promotes the activation of the nuclear factor of activated T cells (NFAT) through a Ca2+/calcineurin (Cn)linked pathway. Upon BBS stimulation, the NFATc1 isoform translocates into the nucleus witha concomitant increase in NFATc1 binding to two specific recognition sites in the promoter region of the Cox-2 gene. Furthermore, inhibition of Cn activity by the immunosuppressive drug cyclosporin A impaired NFAT activation and diminished Cox-2 expression in BBS-stimulated cells. Interestingly, BBS pretreatment strongly enhances the invasive capacity of carcinoma cells, effect which was inhibited by a Cox-2-specific inhibitor. These. findings provide the. first evidence for the involvement of the Ca2+/Cn/NFAT pathway in BBS-mediated induction of genes involved in colon carcinoma invasiveness such as Cox-2.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Fresno, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	mfresno@cbm.uam.es	Peña, Miguel Angel Iñiguez/J-8518-2012	Peña, Miguel Angel Iñiguez/0000-0001-8262-6119; Lopez-Perez, Ricardo/0000-0001-9495-8604; Fresno Escudero, Manuel/0000-0002-9223-5477				ALBINI A, 1987, CANCER RES, V47, P3239; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; Boss V, 1996, J BIOL CHEM, V271, P10429, DOI 10.1074/jbc.271.18.10429; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; CAI RZ, 1994, P NATL ACAD SCI USA, V91, P12664, DOI 10.1073/pnas.91.26.12664; Carroll RE, 2000, MOL PHARMACOL, V58, P601, DOI 10.1124/mol.58.3.601; Carroll RE, 1999, AM J PHYSIOL-GASTR L, V276, pG655, DOI 10.1152/ajpgi.1999.276.3.G655; Chan TA, 2002, LANCET ONCOL, V3, P166, DOI 10.1016/S1470-2045(02)00680-0; Chen M, 2005, ONCOGENE, V24, P5125, DOI 10.1038/sj.onc.1208729; Cheng HF, 2002, J BIOL CHEM, V277, P45638, DOI 10.1074/JBC.m206040200; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Dixon DA, 2004, CURR PHARM DESIGN, V10, P635, DOI 10.2174/1381612043453171; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Engle MJ, 1998, J CELL PHYSIOL, V174, P362, DOI 10.1002/(SICI)1097-4652(199803)174:3<362::AID-JCP10>3.0.CO;2-B; Fenwick SW, 2003, GASTROENTEROLOGY, V125, P716, DOI 10.1016/S0016-5085(03)01061-8; Festuccia C, 1998, INT J CANCER, V75, P418, DOI 10.1002/(SICI)1097-0215(19980130)75:3<418::AID-IJC16>3.0.CO;2-4; Festuccia C, 2002, EXP CELL RES, V280, P1, DOI 10.1006/excr.2002.5609; Glover S, 2005, AM J PHYSIOL-GASTR L, V288, pG1274, DOI 10.1152/ajpgi.00108.2004; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hecht JR, 1997, PROSTAG OTH LIPID M, V54, P757, DOI 10.1016/S0090-6980(97)00162-7; Hellmich MR, 1999, J BIOL CHEM, V274, P23901, DOI 10.1074/jbc.274.34.23901; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Iishi H, 2003, CLIN EXP METASTAS, V20, P555, DOI 10.1023/A:1025883129932; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jensen JAG, 2001, PEPTIDES, V22, P689, DOI 10.1016/S0196-9781(01)00380-1; Kanashiro CA, 2003, P NATL ACAD SCI USA, V100, P15836, DOI 10.1073/pnas.2536558100; Kawai N, 2002, PROSTAG OTH LIPID M, V68-9, P187, DOI 10.1016/S0090-6980(02)00030-8; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Levine L, 2003, CANCER RES, V63, P3495; Liu WV, 2003, CANCER RES, V63, P3632; Liu ZM, 2004, J BIOL CHEM, V279, P41218, DOI 10.1074/jbc.M406917200; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; PRESTON SR, 1995, BRIT J CANCER, V71, P1087, DOI 10.1038/bjc.1995.210; Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59; Robida AM, 2000, MOL PHARMACOL, V58, P701, DOI 10.1124/mol.58.4.701; Rozengurt E, 2002, EUR J SURG, V168, P23; Ryan FR, 1999, J PHARMACOL EXP THER, V290, P1202; Saurin JC, 2002, CANCER RES, V62, P4829; Saurin JC, 1999, CANCER RES, V59, P962; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Singh B, 2005, INT J ONCOL, V26, P1393; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sun YJ, 2005, MOL CANCER THER, V4, P51; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Yegen BC, 2003, CURR PHARM DESIGN, V9, P1013, DOI 10.2174/1381612033455134; Yiu GK, 2006, J BIOL CHEM, V281, P12210, DOI 10.1074/jbc.M600184200	62	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					958	969		10.1038/sj.onc.1209856	http://dx.doi.org/10.1038/sj.onc.1209856			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909108	Bronze			2022-12-25	WOS:000244245400002
J	Nouvion, AL; Thibaut, J; Lohez, OD; Venet, S; Colas, P; Gillet, G; Lalle, P				Nouvion, A-L; Thibaut, J.; Lohez, O. D.; Venet, S.; Colas, P.; Gillet, G.; Lalle, P.			Modulation of Nr-13 antideath activity by peptide aptamers	ONCOGENE			English	Article						Bcl-2; Nr-13; peptide aptamer; apoptosis; ligand	ANTIAPOPTOTIC PROTEIN NR-13; BCL-2 FAMILY; BH3 DOMAIN; APOPTOTIC FUNCTION; STRUCTURAL BASIS; TUMOR-CELLS; BAX; INHIBITOR; CANCER; IDENTIFICATION	Tumor cells are characterized by deregulated proliferation and resistance to proapoptotic stimuli. The Bcl-2 family of antiapoptotic proteins is overexpressed in a large number of chemoresistant tumors. Downregulation or inhibition of antiapoptotic proteins might result in the sensitization of cancer cells to chemotherapeutic agents. In the present study, we took advantage of the peptide aptamer strategy to target Nr-13, a Bcl-2 antiapoptotic protein involved in neoplastic transformation by the Rous sarcoma virus. We isolated peptide aptamers that behave as Nr-13 regulators, in vitro and in mammalian cells in culture. Some of these aptamers have potential proapoptotic activities. These data suggest that peptide aptamers targeting the Bcl-2 family of apoptosis inhibitors may be useful for the development of anticancer molecules.	Univ Lyon 1, CNRS, IBCP,IFR 128 Biosci, UMR 5086,Equipe Apoptose & Oncogenese, F-69367 Lyon 07, France; Aptanomics SA, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Gillet, G (corresponding author), Univ Lyon 1, CNRS, IBCP,IFR 128 Biosci, UMR 5086,Equipe Apoptose & Oncogenese, 7 Passage Vercors, F-69367 Lyon 07, France.	g.gillet@ibcp.fr	LALLE, Philippe/G-7734-2018; gillet, germain/A-9095-2013	Lohez, Olivier/0000-0001-9446-9915; Colas, Pierre/0000-0001-7436-3718; GILLET, Germain/0000-0002-1514-327X				Aouacheria A, 2002, ONCOGENE, V21, P1171, DOI 10.1038/sj.onc.1205170; Aouacheria A, 2001, ONCOGENE, V20, P5846, DOI 10.1038/sj.onc.1204740; AOUACHERIA A, 2003, RRD MOLEC CELL BIOL, V4, P59; Buerger C, 2003, J BIOL CHEM, V278, P37610, DOI 10.1074/jbc.M301629200; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cartron PF, 2005, J BIOL CHEM, V280, P10587, DOI 10.1074/jbc.M409714200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Cotter FE, 1999, BBA-GENE STRUCT EXPR, V1489, P97, DOI 10.1016/S0167-4781(99)00139-6; Cui QQ, 2005, ONCOGENE, V24, P3864, DOI 10.1038/sj.onc.1208556; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Girard-Egrot A, 2004, J MOL BIOL, V335, P321, DOI 10.1016/j.jmb.2003.10.028; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herold MJ, 2006, J BIOL CHEM, V281, P13663, DOI 10.1074/jbc.M600266200; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Juin P, 2004, BBA-MOL CELL RES, V1644, P251, DOI 10.1016/j.bbamcr.2003.10.010; Klevenz B, 2002, CELL MOL LIFE SCI, V59, P1993, DOI 10.1007/PL00012521; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Kurtz SE, 2003, BIOTECHNOL BIOENG, V82, P38, DOI 10.1002/bit.10538; Lalle P, 2002, BIOCHEM J, V368, P213, DOI 10.1042/BJ20020836; Lanave C, 2004, GENE, V333, P71, DOI 10.1016/j.gene.2004.02.017; Mangeney M, 1996, ONCOGENE, V13, P1441; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032; Moradi-Ameli M, 2002, BIOCHEMISTRY-US, V41, P8540, DOI 10.1021/bi0110286; Nauenburg S, 2001, FASEB J, V15, P592; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Schmidt S, 2002, FEBS LETT, V523, P35, DOI 10.1016/S0014-5793(02)02928-9; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092	50	12	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					701	710		10.1038/sj.onc.1209832	http://dx.doi.org/10.1038/sj.onc.1209832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16909120				2022-12-25	WOS:000243902200007
J	Rokaeus, N; Klein, G; Wiman, KG; Szekely, L; Mattsson, K				Rokaeus, N.; Klein, G.; Wiman, K. G.; Szekely, L.; Mattsson, K.			PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins	ONCOGENE			English	Article						mutant p53; PRIMA-; nucleolus; PML odies; Hsp70	ACUTE PROMYELOCYTIC LEUKEMIA; POLYMERASE-I TRANSCRIPTION; DNA-DAMAGE; PREMATURE SENESCENCE; DEPENDENT APOPTOSIS; ONCOGENIC RAS; C-MYC; CELLS; DEGRADATION; INHIBITION	We have previously identified PRIMA-1, a low molecular weight compound that restores the transcriptional transactivation function to mutant p53 and induction of apoptosis. To explore the molecular mechanism for PRIMA-1-induced mutant p53-dependent apoptosis, we examined the intracellular distribution of mutant p53 upon treatment with PRIMA-1(MET) by immunofluorescence staining. We found that PRIMA-1(MET) induced nucleolar translocation of mutant p53 and the promyelocytic leukemia (PML) nuclear body-associated proteins PML, CBP and Hsp70. Levels of Hsp70 were significantly enhanced by PRIMA-1(MET) treatment. PRIMA-Dead, a compound structurally related to PRIMA-1 but unable to induce mutant p53-dependent apoptosis, failed to induce nucleolar translocation of mutant p53. Our results suggest that redistribution of mutant p53 to nucleoli plays a role in PRIMA-1-induced apoptosis.	Karolinska Univ Hosp, Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; Karolinska Inst, MTC, Microbiol & Tumor Biol Ctr, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Univ Hosp, Karolinska Inst, CCK, Dept Oncol Pathol, R8-04, SE-17176 Stockholm, Sweden.	Klas.Wiman@ki.se	Szekely, Laszlo/B-1268-2009; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Szekely, Laszlo/0000-0001-6144-6573				Amin HM, 2001, BRIT J HAEMATOL, V115, P287, DOI 10.1046/j.1365-2141.2001.03123.x; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Drouin A, 2001, EXP CELL RES, V271, P277, DOI 10.1006/excr.2001.5377; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pespeni M, 2005, METHODS, V35, P158, DOI 10.1016/j.ymeth.2004.08.006; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Rehman A, 2005, BREAST CANCER RES, V7, pR765, DOI 10.1186/bcr1290; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	48	22	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					982	992		10.1038/sj.onc.1209858	http://dx.doi.org/10.1038/sj.onc.1209858			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909106				2022-12-25	WOS:000244245400004
J	Lopez-Anton, N; Rudy, A; Barth, N; Schmitz, LM; Pettit, GR; Schulze-Osthoff, K; Dirsch, VM; Vollmar, AM				Lopez-Anton, Nancy; Rudy, Anita; Barth, Nicole; Schmitz, Lienhard M.; Pettit, George R.; Schulze-Osthoff, Klaus; Dirsch, Verena M.; Vollmar, Angelika M.			The marine product cephalostatin 1 activates an endoplasmic reticulum stress-specific and apoptosome-independent apoptotic signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CELL-DEATH; ER STRESS; CASPASE ACTIVATION; RESISTANCE; PROGRAM; ASK1	Cephalostatin 1, a bis-steroidal marine natural product, has been reported to induce apoptosis without the requirement of an active caspase-8 or mitochondrial cytochrome c release and apoptosome formation. Here we show that despite the absence of these events, caspase-9 activation is essential for cephalostatin 1-induced apoptosis. Cephalostatin 1 initiates a rapid endoplasmic reticulum stress response characterized by phosphorylation of eukaryotic initiation factor-2 alpha-subunit and increased expression of the chaperone immunoglobulin heavy chain-binding protein GRP78 as well as the transcription factor C/EBP homologous protein (CHOP)/GADD153. Cephalostatin 1 activates apoptosis signal-regulating kinase 1 and c-Jun N-terminal kinase (JNK). However, this pathway does not play a major role in cephalostatin 1-induced apoptosis, as assessed by stable expression of a dominant negative apoptosis signal-regulating kinase 1. Importantly, the endoplasmic reticulum-associated caspase-4 is required and as shown by biochemical and genetic inhibition experiments, acts upstream of caspase-9 in cephalostatin-induced apoptosis.	Univ Munich, Dept Pharm, Ctr Drug Res, D-81377 Munich, Germany; Univ Giessen, Inst Biochem, D-35390 Giessen, Germany; Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Arizona State Univ, Inst Canc Res, Tempe, AZ 85287 USA	University of Munich; Justus Liebig University Giessen; Heinrich Heine University Dusseldorf; Arizona State University; Arizona State University-Tempe	Vollmar, AM (corresponding author), Univ Munich, Dept Pharm, Ctr Drug Res, Butenandt Str 5-13, D-81377 Munich, Germany.	Angelika.Vollmar@cup.uni-muenchen.de	Schmitz, M. Lienhard/D-9328-2017; Schulze-Osthoff, Klaus/N-9025-2013	Schmitz, M. Lienhard/0000-0002-6984-7192; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Dirsch, Verena/0000-0002-9261-5293				Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Dirsch VM, 2003, CANCER RES, V63, P8869; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Henderson CJ, 2005, CELL DEATH DIFFER, V12, P1240, DOI 10.1038/sj.cdd.4401729; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hofmann TG, 2001, INT J CANCER, V93, P185, DOI 10.1002/ijc.1316; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Kadowaki H, 2005, CELL DEATH DIFFER, V12, P19, DOI 10.1038/sj.cdd.4401528; Kadowaki H, 2004, J CHEM NEUROANAT, V28, P93, DOI 10.1016/j.jchemneu.2004.05.004; Katayama T, 2004, J CHEM NEUROANAT, V28, P67, DOI 10.1016/j.jchemneu.2003.12.004; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Momoi T, 2004, J CHEM NEUROANAT, V28, P101, DOI 10.1016/j.jchemneu.2004.05.008; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Paschen W, 2003, CELL CALCIUM, V34, P365, DOI 10.1016/S0143-4160(03)00139-8; PETTIT GR, 1988, J AM CHEM SOC, V110, P2006, DOI 10.1021/ja00214a078; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Samraj AK, 2006, J BIOL CHEM, V281, P29652, DOI 10.1074/jbc.M603487200; Samraj AK, 2006, ONCOGENE, V25, P186, DOI 10.1038/sj.onc.1209034; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	39	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33078	33086		10.1074/jbc.M607904200	http://dx.doi.org/10.1074/jbc.M607904200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16945918	hybrid, Green Published			2022-12-25	WOS:000241621400016
J	Ross, EM; Mateu, D; Gomes, AV; Arana, C; Tran, T; Litosch, I				Ross, Elliott M.; Mateu, Dania; Gomes, Aldrin V.; Arana, Carlos; Tran, Thanh; Litosch, Irene			Structural determinants for phosphatidic acid regulation of phospholipase C-beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; PROTEIN-KINASE-C; FEEDBACK-REGULATION; C-BETA(1) ACTIVITY; TERMINAL REGION; BETA; BINDING; ACTIVATION; DOMAIN; MEMBRANES	Signaling from G protein-coupled receptors to phospholipase C-beta (PLC-beta) is regulated by coordinate interactions among multiple intracellular signaling molecules. Phosphatidic acid (PA), a signaling phospholipid, binds to and stimulates PLC-beta(1) through a mechanism that requires the PLC-beta(1) C-terminal domain. PA also modulates G alpha(q) stimulation of PLC-beta(1). These data suggest that PA may have a key role in the regulation of PLC-beta(1) signaling in cells. The present studies addressed the structural requirements and the mechanism for PA regulation of PLC-beta(1). We used a combination of enzymatic assays, PA-binding assays, and circular dichroism spectroscopy to evaluate the interaction of PA with wild-type and mutant PLC-beta(1) proteins and with fragments of theG alpha(q) binding domain. The results identify a region that includes the alpha A helix and flexible loop of the G alpha(q)-binding domain as necessary for PA regulation. A mutant PLC-beta(1) with multiple alanine/glycine replacements for residues (944)LIKEHTTKYNEIQN(957) was markedly impaired in PA regulation. The high affinity and low affinity component of PA stimulation was reduced 70% and PA binding was reduced 45% in this mutant. Relative PLC stimulation by PA increased with PLC-beta(1) concentration in a manner suggesting cooperative binding to PA. Similar concentration dependence was observed in the PLC-beta(1) mutant. These data are consistent with a model for PA regulation of PLC-beta(1) that involves cooperative interactions, probably PLC homodimerization, that require the flexible loop region, as is consistent with the dimeric structure of the G alpha(q)-binding domain. PA regulation of PLC-beta(1) requires unique residues that are not required for G alpha(q) stimulation or GTPase-activating protein activity.	Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Miami; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Litosch, I (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA.	ilitosch@med.miami.edu	Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NIGMS NIH HHS [GM30355, R01 GM030355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avila-Flores A, 2005, J BIOL CHEM, V280, P10091, DOI 10.1074/jbc.M412296200; BAHK YY, 1994, J BIOL CHEM, V269, P8240; Baillie GS, 2002, J BIOL CHEM, V277, P28298, DOI 10.1074/jbc.M108353200; Bastard K, 2006, PROTEINS, V62, P956, DOI 10.1002/prot.20770; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Cox LJ, 2002, REPRODUCTION, V124, P611, DOI 10.1530/rep.0.1240611; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Ghosh S, 2003, J BIOL CHEM, V278, P45690, DOI 10.1074/jbc.M302933200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; HENRY RA, 1995, AM J PHYSIOL-CELL PH, V269, pC349, DOI 10.1152/ajpcell.1995.269.2.C349; Ilkaeva O, 2002, J BIOL CHEM, V277, P4294, DOI 10.1074/jbc.M109612200; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; JONES GA, 1993, J BIOL CHEM, V268, P20845; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Litosch I, 1997, BIOCHEM J, V326, P701, DOI 10.1042/bj3260701; Litosch I, 2000, BIOCHEMISTRY-US, V39, P7736, DOI 10.1021/bi000022y; Litosch I, 2003, BIOCHEMISTRY-US, V42, P1618, DOI 10.1021/bi026414h; Litosch I, 2002, CELL SIGNAL, V14, P259, DOI 10.1016/S0898-6568(01)00251-0; Litosch I, 2002, IUBMB LIFE, V54, P253, DOI 10.1080/15216540215673; Luo B, 2004, CELL SIGNAL, V16, P983, DOI 10.1016/j.cellsig.2004.03.016; Nakahara M, 2005, J BIOL CHEM, V280, P29128, DOI 10.1074/jbc.M503817200; Ouyang YS, 2003, J BIOL CHEM, V278, P11115, DOI 10.1074/jbc.M212606200; PARK DG, 1993, J BIOL CHEM, V268, P3710; Paulssen RH, 1996, J BIOL CHEM, V271, P26622, DOI 10.1074/jbc.271.43.26622; Pawelczyk T, 1999, EUR J BIOCHEM, V262, P291, DOI 10.1046/j.1432-1327.1999.00388.x; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; RYU SH, 1990, J BIOL CHEM, V265, P17941; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Stace CL, 2006, BBA-MOL CELL BIOL L, V1761, P913, DOI 10.1016/j.bbalip.2006.03.006; Wang XM, 2006, PROG LIPID RES, V45, P250, DOI 10.1016/j.plipres.2006.01.005; WU DQ, 1993, J BIOL CHEM, V268, P3704	37	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33087	33094		10.1074/jbc.M606487200	http://dx.doi.org/10.1074/jbc.M606487200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950781	hybrid			2022-12-25	WOS:000241621400017
J	Watanabe, S; Shimada, N; Tajima, K; Kodaki, T; Makino, K				Watanabe, Seiya; Shimada, Naoko; Tajima, Kunihiko; Kodaki, Tsutomu; Makino, Keisuke			Identification and characterization of L-arabonate dehydratase, L-2-keto-3-deoxyarabonate dehydratase, and L-arabinolactonase involved in an alternative pathway of L-arabinose metabolism - Novel evolutionary insight into sugar metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-FUCOSE METABOLISM; DIHYDROXY-ACID DEHYDRATASE; ARCHAEON SULFOLOBUS-SOLFATARICUS; ALPHA-KETOGLUTARIC SEMIALDEHYDE; N-ACETYLNEURAMINATE LYASE; ENTNER-DOUDOROFF PATHWAY; IRON-SULFUR PROTEINS; L-XYLULOSE REDUCTASE; GLUCOSE-DEHYDROGENASE; ASPERGILLUS-NIGER	Azospirillum brasiliense possesses an alternative pathway of L-arabinose metabolism, different from the known bacterial and fungal pathways. In the preceding articles, we identified and characterized L-arabinose-1-dehydrogenase and alpha-ketoglutaric semialdehyde dehydrogenase, which catalyzes the first and final reaction steps in this pathway, respectively (Watanabe, S., Kodaki, T., and Makino, K. (2006) J. Biol. Chem. 281, 2612-2623 and Watanabe, S., Kodaki, T., and Makino, K. (2006) J. Biol. Chem. 281, 28876-28888). We here report the remaining three enzymes, L-arabonate dehydratase, L-2-keto-3-deoxyarabonate (L-KDA) dehydratase, and L-arabinolactonase. N-terminal amino acid sequences of L-arabonate dehydratase and L-KDA dehydratase purified from A. brasiliense cells corresponded to those of AraC and AraD genes, which form a single transcriptional unit together with the L-arabinose-1-dehydrogenase gene. Furthermore, the L-arabinolactonase gene (AraB) was also identified as a component of the gene cluster. Genetic characterization of the alternative L-arabinose pathway suggested a significant evolutional relationship with the known sugar metabolic pathways, including the Entner-Doudoroff (ED) pathway and the several modified versions. L-Arabonate dehydratase belongs to the ILVD/EDD family and spectrophotometric and electron paramagnetic resonance analysis revealed it to contain a [4Fe-4S]2(+) cluster. Site-directed mutagenesis identified three cysteine ligands essential for cluster coordination. L-KDA dehydratase was sequentially similar to DHDPS/NAL family proteins. D-2-Keto-3-deoxygluconate aldolase, a member of the DHDPS/NAL family, catalyzes the equivalent reaction to L-KDA aldolase involved in another alternative L-arabinose pathway, probably associating a unique evolutional event between the two alternative L-arabinose pathways by mutation(s) of a common ancestral enzyme. Site-directed mutagenesis revealed a unique catalytic amino acid residue in L-KDA dehydratase, which may be a candidate for such a natural mutation.	Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan; Kyoto Univ, Fac Engn, Saikyo Ku, Kyoto 6158530, Japan; Kyoto Inst Technol, Dept Biomol Engn, Sakyo Ku, Kyoto 6068585, Japan; Japan Sci & Technol Agcy, JST, CREST, Uji, Kyoto 6110011, Japan	Kyoto University; Kyoto University; Kyoto Institute of Technology; Japan Science & Technology Agency (JST)	Makino, K (corresponding author), Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan.	kmak@iae.kyoto-u.ac.jp						Ahmed H, 2005, BIOCHEM J, V390, P529, DOI 10.1042/BJ20041711; Allard J, 2001, P NATL ACAD SCI USA, V98, P3679, DOI 10.1073/pnas.071380898; Babbitt PC, 1996, BIOCHEMISTRY-US, V35, P16489, DOI 10.1021/bi9616413; Barbosa JARG, 2000, J MOL BIOL, V303, P405, DOI 10.1006/jmbi.2000.4138; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; Buchanan CL, 1999, BIOCHEM J, V343, P563, DOI 10.1042/0264-6021:3430563; CONWAY T, 1992, FEMS MICROBIOL LETT, V103, P1; DAGLEY S, 1965, BIOCHEM J, V95, P48, DOI 10.1042/bj0950048; DAHMS AS, 1972, J BIOL CHEM, V247, P2228; DAHMS AS, 1972, J BIOL CHEM, V247, P2233; DAHMS AS, 1969, BIOCHEM BIOPH RES CO, V36, P809, DOI 10.1016/0006-291X(69)90681-0; DAHMS AS, 1972, J BIOL CHEM, V247, P2222; DAHMS AS, 1972, J BIOL CHEM, V247, P2238; DELEY J, 1957, J BIOL CHEM, V227, P745; Dobson RCJ, 2004, J MOL BIOL, V338, P329, DOI 10.1016/j.jmb.2004.02.060; DONALD A, 1979, J BIOL CHEM, V254, P2132; DUNCAN MJ, 1979, J GEN MICROBIOL, V113, P177, DOI 10.1099/00221287-113-1-177; DUNCAN MJ, 1979, J BACTERIOL, V137, P415, DOI 10.1128/JB.137.1.415-419.1979; Elshafei AM, 2001, ENZYME MICROB TECH, V29, P76, DOI 10.1016/S0141-0229(01)00346-5; ELZAINY TA, 1973, J BACTERIOL, V114, P457, DOI 10.1128/JB.114.1.457-459.1973; ENTNER N, 1952, J BIOL CHEM, V196, P853; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; FLINT DH, 1993, J BIOL CHEM, V268, P14732; FLINT DH, 1988, J BIOL CHEM, V263, P3558; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; GRABOWSKI R, 1993, TRENDS BIOCHEM SCI, V18, P297, DOI 10.1016/0968-0004(93)90040-T; Izard T, 2000, EMBO J, V19, P3849, DOI 10.1093/emboj/19.15.3849; JEFFCOAT R, 1975, BIOCHEM J, V145, P305, DOI 10.1042/bj1450305; JEFFCOAT R, 1969, BIOCHEM J, V115, P977, DOI 10.1042/bj1150977; JOHN J, 1994, STRUCTURE, V2, P385, DOI 10.1016/S0969-2126(00)00040-X; KANAGASUNDARAM V, 1992, BIOCHIM BIOPHYS ACTA, V1171, P198, DOI 10.1016/0167-4781(92)90120-O; Kim S, 2006, J BIOCHEM, V139, P591, DOI 10.1093/jb/mvj057; Kobayashi M, 1998, P NATL ACAD SCI USA, V95, P12787, DOI 10.1073/pnas.95.22.12787; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamble FJ, 2004, FEBS LETT, V576, P133, DOI 10.1016/j.febslet.2004.08.074; Lawrence MC, 1997, J MOL BIOL, V266, P381, DOI 10.1006/jmbi.1996.0769; LELOIR LF, 1951, ARCH BIOCHEM BIOPHYS, V33, P186, DOI 10.1016/0003-9861(51)90096-3; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macchiarulo A, 2004, NAT BIOTECHNOL, V22, P1039, DOI 10.1038/nbt999; MACGEE J, 1954, J BIOL CHEM, V210, P617; MATHIAS AL, 1989, J BACTERIOL, V171, P5206, DOI 10.1128/jb.171.9.5206-5209.1989; Milburn CC, 2006, J BIOL CHEM, V281, P14796, DOI 10.1074/jbc.M601334200; Moore RA, 2004, INFECT IMMUN, V72, P4172, DOI 10.1128/IAI.72.7.4172-4187.2004; Moore S, 1940, J BIOL CHEM, V133, P293; MULLER HM, 1986, ARCH MICROBIOL, V144, P151, DOI 10.1007/BF00414726; NOVICK NJ, 1982, J BACTERIOL, V149, P364, DOI 10.1128/JB.149.1.364-367.1982; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Oro J, 1995, Adv Space Res, V15, P81, DOI 10.1016/S0273-1177(99)80067-2; OTANI M, 1986, J BACTERIOL, V167, P148, DOI 10.1128/jb.167.1.148-152.1986; Oubrie A, 1999, J MOL BIOL, V289, P319, DOI 10.1006/jmbi.1999.2766; PEDROSA FO, 1974, J BACTERIOL, V119, P336, DOI 10.1128/JB.119.1.336-338.1974; PORTSMOUTH D, 1967, J BIOL CHEM, V242, P2751; Richard P, 2002, BIOCHEMISTRY-US, V41, P6432, DOI 10.1021/bi025529i; Richard P, 2001, J BIOL CHEM, V276, P40631, DOI 10.1074/jbc.M104022200; Rodriguez M, 1996, BIOCHEM MOL BIOL INT, V38, P783; Sambrook J, 2001, MOL CLONING LAB MANU; Siebers B, 2005, CURR OPIN MICROBIOL, V8, P695, DOI 10.1016/j.mib.2005.10.014; STOOLMILLER AC, 1966, J BIOL CHEM, V241, P5764; STRYER L, 1988, BIOCHEMISTRY-US, P805; SZUMILO T, 1981, BIOCHIM BIOPHYS ACTA, V661, P240, DOI 10.1016/0005-2744(81)90010-3; Theodossis A, 2004, J BIOL CHEM, V279, P43886, DOI 10.1074/jbc.M407702200; TSAI CS, 1995, ARCH BIOCHEM BIOPHYS, V316, P163, DOI 10.1006/abbi.1995.1024; Verho R, 2004, J BIOL CHEM, V279, P14746, DOI 10.1074/jbc.M312533200; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Watanabe S, 2006, J BIOL CHEM, V281, P2612, DOI 10.1074/jbc.M506477200; Watanabe S, 2006, J BIOL CHEM, V281, P28876, DOI 10.1074/jbc.M602585200; WELMBERG R, 1961, J BIOL CHEM, V236, P629; WELMBERG R, 1955, J BIOL CHEM, V217, P607; ZACHARIOU M, 1986, J BACTERIOL, V167, P863, DOI 10.1128/jb.167.3.863-869.1986	70	63	80	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33521	33536		10.1074/jbc.M606727200	http://dx.doi.org/10.1074/jbc.M606727200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950779				2022-12-25	WOS:000241621400063
J	Eastmond, DL; Nelson, HCM				Eastmond, Dawn L.; Nelson, Hillary C. M.			Genome-wide analysis reveals new roles for the activation domains of the Saccharomyces cerevisiae heat shock transcription factor (Hsf1) during the transient heat shock response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNF1 PROTEIN-KINASE; DNA-BINDING DOMAIN; STRESS-RESPONSE; FACTOR CONTAINS; ENVIRONMENTAL-CHANGES; GLUCOSE STARVATION; COILED-COIL; YEAST; EXPRESSION; GENES	In response to elevated temperatures, cells from many organisms rapidly transcribe a number of mRNAs. In Saccharomyces cerevisiae, this protective response involves two regulatory systems: the heat shock transcription factor (Hsf1) and the Msn2 and Msn4 (Msn2/4) transcription factors. Both systems modulate the induction of specific heat shock genes. However, the contribution of Hsf1, independent of Msn2/4, is only beginning to emerge. To address this question, we constructed an msn2/4 double mutant and used microarrays to elucidate the genomewide expression program of Hsf1. The data showed that 7.6% of the genome was heat-induced. The up-regulated genes belong to a wide range of functional categories, with a significant increase in the chaperone and metabolism genes. We then focused on the contribution of the activation domains of Hsf1 to the expression profile and extended our analysis to include msn2/4 Delta strains deleted for the N-terminal or C-terminal activation domain of Hsf1. Cluster analysis of the heat-induced genes revealed activation domain-specific patterns of expression, with each cluster also showing distinct preferences for functional categories. Computational analysis of the promoters of the induced genes affected by the loss of an activation domain showed a distinct preference for positioning and topology of the Hsf1 binding site. This study provides insight into the important role that both activation domains play for the Hsf1 regulatory system to rapidly and effectively transcribe its regulon in response to heat shock.	Univ Penn, Sch Med, Dept Biochem & Mol Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania	Nelson, HCM (corresponding author), Univ Penn, Sch Med, Dept Biochem & Mol Biophys, Rm 814,Stellar Chance Bldg,422 Curie Blvd, Philadelphia, PA 19104 USA.	hnelson@mail.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044086] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM044086, R01 GM044086-15, R01 GM044086-14S1, R01 GM044086-12, GM 44086, R01 GM044086-16, R01 GM044086-14, R01 GM044086-13] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; Amoros M, 2001, MOL MICROBIOL, V39, P1523, DOI 10.1046/j.1365-2958.2001.02339.x; [Anonymous], 2004, CURRENT PROTOCOLS MO; BALAKRISHNAN R, 2005, SACCHAROMYCES GENOME; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Baniwal SK, 2004, J BIOSCIENCES, V29, P471, DOI 10.1007/BF02712120; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; BONNER JJ, 1992, MOL CELL BIOL, V12, P1021, DOI 10.1128/MCB.12.3.1021; Boy-Marcotte E, 1999, MOL MICROBIOL, V33, P274, DOI 10.1046/j.1365-2958.1999.01467.x; Bulman AL, 2001, J BIOL CHEM, V276, P40254, DOI 10.1074/jbc.M106301200; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CHEN YQ, 1993, EMBO J, V12, P5007, DOI 10.1002/j.1460-2075.1993.tb06194.x; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Ferguson SB, 2005, GENETICS, V169, P1203, DOI 10.1534/genetics.104.034256; FERGUSON SB, 2005, THESIS U PENNSYLVANI; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Grably MR, 2002, MOL MICROBIOL, V44, P21, DOI 10.1046/j.1365-2958.2002.02860.x; Hahn JS, 2004, J BIOL CHEM, V279, P5169, DOI 10.1074/jbc.M311005200; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Heyer LJ, 1999, GENOME RES, V9, P1106, DOI 10.1101/gr.9.11.1106; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Mai B, 1997, MOL CELL BIOL, V17, P6491, DOI 10.1128/MCB.17.11.6491; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Peteranderl R, 1999, BIOCHEMISTRY-US, V38, P3559, DOI 10.1021/bi981774j; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; ROWLEY A, 1993, MOL CELL BIOL, V13, P1034, DOI 10.1128/MCB.13.2.1034; Sakurai H, 2003, GENES CELLS, V8, P951, DOI 10.1046/j.1356-9597.2003.00689.x; Sakurai H, 2001, BIOCHEM BIOPH RES CO, V285, P696, DOI 10.1006/bbrc.2001.5234; Santoro N, 1998, MOL CELL BIOL, V18, P6340, DOI 10.1128/MCB.18.11.6340; SHUEY DJ, 1986, J BIOL CHEM, V261, P7934; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Tachibana T, 2002, J BIOL CHEM, V277, P22140, DOI 10.1074/jbc.M201267200; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Treger JM, 1998, J BIOL CHEM, V273, P26875, DOI 10.1074/jbc.273.41.26875; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; YOUNG MR, 1993, MOL CELL BIOL, V13, P5637, DOI 10.1128/MCB.13.9.5637	63	67	69	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32909	32921		10.1074/jbc.M602454200	http://dx.doi.org/10.1074/jbc.M602454200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16926161	hybrid, Green Accepted			2022-12-25	WOS:000241414500089
J	Promnares, K; Komenda, J; Bumba, L; Nebesarova, J; Vacha, F; Tichy, M				Promnares, Kamoltip; Komenda, Josef; Bumba, Ladislav; Nebesarova, Jana; Vacha, Frantisek; Tichy, Martin			Cyanobacterial small chlorophyll-binding protein ScpD (HliB) is located on the periphery of photosystem II in the vicinity of PsbH and CP47 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS-SP PCC-6803; LIGHT-INDUCIBLE PROTEIN; PHOTOSYNTHETIC ELECTRON-TRANSPORT; ELONGATUS STRAIN PCC-7942; OXYGEN-EVOLVING COMPLEX; DNA MICROARRAY ANALYSIS; CAB-LIKE PROTEINS; ARABIDOPSIS-THALIANA; HIGHER-PLANTS; GENE FAMILY	Cyanobacteria contain several genes coding for small one-helix proteins called SCPs or HLIPs with significant sequence similarity to chlorophyll a/b-binding proteins. To localize one of these proteins, ScpD, in the cells of the cyanobacterium Synechocystis sp. PCC 6803, we constructed several mutants in which ScpD was expressed as a His-tagged protein (ScpDHis). Using two-dimensional native-SDS electrophoresis of thylakoid membranes or isolated Photosystem II (PSII), we determined that after high-light treatment most of the ScpDHis protein in a cell is associated with PSII. The ScpDHis protein was present in both monomeric and dimeric PSII core complexes and also in the core subcomplex lacking CP43. However, the association with PSII was abolished in the mutant lacking the PSII subunit PsbH. In a PSII mutant lacking cytochrome b(559), which does not accumulate PSII, ScpDHis is associated with CP47. The interaction of ScpDHis with PsbH and CP47 was further confirmed by electron microscopy of PSII labeled with Ni-NTA Nanogold. Single particle image analysis identified the location of the labeled ScpDHis at the periphery of the PSII core complex in the vicinity of the PsbH and CP47. Because of the fact that ScpDHis did not form any large structures bound to PSII and because of its accumulation in PSII subcomplexes containing CP47 and PsbH we suggest that ScpD is involved in a process of PSII assembly/repair during the turnover of pigment-binding proteins, particularly CP47.	Acad Sci Czech Republ, Lab Photosynth, Inst Microbiol, Trebon 37981, Czech Republic; Univ S Bohemia, Fac Biol Sci, CZ-37005 Ceske Budejovice, Czech Republic; Univ S Bohemia, Inst Biol Phys, Nove Hrady 37333, Czech Republic; Acad Sci Czech Republ, Ctr Biol, CZ-37005 Ceske Budejovice, Czech Republic; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Czech Academy of Sciences; University of South Bohemia Ceske Budejovice; University of South Bohemia Ceske Budejovice; Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Tichy, M (corresponding author), Acad Sci Czech Republ, Lab Photosynth, Inst Microbiol, Opatovicky Mlyn, Trebon 37981, Czech Republic.	tichym@alga.cz	Bumba, Ladislav/H-2494-2014; Bumba, Ladislav/ABC-9943-2020; Nebesarova, Jana/G-7351-2014; Tichy, Martin/B-6545-2008; Promnares, Kamoltip/S-6106-2019; Komenda, Josef/H-4083-2014; Vacha, Frantisek/G-9555-2014	Bumba, Ladislav/0000-0001-6659-5447; Nebesarova, Jana/0000-0002-0897-7487; Tichy, Martin/0000-0003-2814-1959; Komenda, Josef/0000-0003-4588-0382; Vacha, Frantisek/0000-0002-1738-8764				ADAMSKA I, 1991, PLANT MOL BIOL, V16, P209, DOI 10.1007/BF00020553; Adamska I, 2001, ADV PHOTOSYNTH, V11, P487; Adamska I, 1997, PHYSIOL PLANTARUM, V100, P794, DOI 10.1034/j.1399-3054.1997.1000406.x; ADAMSKA I, 1992, P NATL ACAD SCI USA, V89, P2610, DOI 10.1073/pnas.89.7.2610; ADAMSKA I, 1994, J BIOL CHEM, V269, P30221; Allakhverdiev SI, 2002, PLANT PHYSIOL, V130, P1443, DOI 10.1104/pp.011114; Andersson U, 2003, PLANT PHYSIOL, V132, P811, DOI 10.1104/pp.102.019281; Bhaya D, 2002, FEMS MICROBIOL LETT, V215, P209, DOI 10.1111/j.1574-6968.2002.tb11393.x; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; Binyamin L, 2001, PLANTA, V212, P591, DOI 10.1007/s004250000423; Bruno AK, 2004, J EXP BOT, V55, P2541, DOI 10.1093/jxb/erh273; Bryant D.A., 1991, PHOTOSYNTHETIC APPAR, P257, DOI [10.1016/B978-0-12-715010-9.50014-1, DOI 10.1016/B978-0-12-715010-9.50014-1]; Buchel C, 2001, J MOL BIOL, V312, P371, DOI 10.1006/jmbi.2001.4951; Bumba L, 2005, J STRUCT BIOL, V152, P28, DOI 10.1016/j.jsb.2005.08.001; Bumba L, 2004, EUR J BIOCHEM, V271, P2967, DOI 10.1111/j.1432-1033.2004.04226.x; Casazza AP, 2005, PLANT MOL BIOL, V58, P41, DOI 10.1007/s11103-005-4090-1; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; EATONRYE JJ, 1991, PLANT MOL BIOL, V17, P1165, DOI 10.1007/BF00028733; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; HARAUZ G, 1988, METHOD ENZYMOL, V164, P35; Havaux M, 2003, BBA-BIOENERGETICS, V1557, P21, DOI 10.1016/S0005-2728(02)00391-2; He QF, 2001, J BIOL CHEM, V276, P306, DOI 10.1074/jbc.M008686200; Heddad M, 2000, P NATL ACAD SCI USA, V97, P3741, DOI 10.1073/pnas.050391397; Hihara Y, 2003, J BACTERIOL, V185, P1719, DOI 10.1128/JB.185.5.1719-1725.2003; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; Hutin C, 2003, P NATL ACAD SCI USA, V100, P4921, DOI 10.1073/pnas.0736939100; Jansson S, 2000, PLANT MOL BIOL, V42, P345, DOI 10.1023/A:1006365213954; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Kanesaki Y, 2002, BIOCHEM BIOPH RES CO, V290, P339, DOI 10.1006/bbrc.2001.6201; KE B, 2001, PHOTSYNTHESIS PHOTOB, P215; KIM S, 1992, FEBS LETT, V314, P67, DOI 10.1016/0014-5793(92)81463-V; Komenda J, 2005, PLANT CELL PHYSIOL, V46, P1477, DOI 10.1093/pcp/pci159; Komenda J, 2004, J BIOL CHEM, V279, P48620, DOI 10.1074/jbc.M405725200; Komenda J, 2002, EUR J BIOCHEM, V269, P610, DOI 10.1046/j.0014-2956.2001.02693.x; Kuhl H, 1999, EUR J BIOCHEM, V266, P453, DOI 10.1046/j.1432-1327.1999.00877.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Lagarde D, 2000, APPL ENVIRON MICROB, V66, P64, DOI 10.1128/AEM.66.1.64-72.2000; LERS A, 1991, J BIOL CHEM, V266, P13698; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; MOHAMED A, 1993, MOL GEN GENET, V238, P161, DOI 10.1007/BF00279543; Montane MH, 1997, PLANTA, V202, P293, DOI 10.1007/s004250050131; Montane MH, 2000, GENE, V258, P1, DOI 10.1016/S0378-1119(00)00413-3; Nield J, 2000, J BIOL CHEM, V275, P27940; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; PAKRASI HB, 1989, PLANT CELL, V1, P591, DOI 10.2307/3868946; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Salem K, 2004, PLANT CELL PHYSIOL, V45, P651, DOI 10.1093/pcp/pch072; Salem K, 2004, J BACTERIOL, V186, P1729, DOI 10.1128/JB.186.6.1729-1736.2004; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Singh AK, 2003, PLANT PHYSIOL, V132, P1825, DOI 10.1104/pp.103.024018; Standfuss R, 2005, EMBO J, V24, P919, DOI 10.1038/sj.emboj.7600585; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Tichy M, 2003, PHOTOSYNTHETICA, V41, P583, DOI 10.1023/B:PHOT.0000027524.18385.92; van Waasbergen LG, 2002, J BACTERIOL, V184, P2481, DOI 10.1128/JB.184.9.2481-2490.2002; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Xu H, 2004, J BIOL CHEM, V279, P27971, DOI 10.1074/jbc.M403307200; Xu H, 2002, PLANT MOL BIOL, V49, P149, DOI 10.1023/A:1014900806905	67	61	63	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32705	32713		10.1074/jbc.M606360200	http://dx.doi.org/10.1074/jbc.M606360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16923804	hybrid			2022-12-25	WOS:000241414500069
J	Dias, JS; Macedo, AL; Ferreira, GC; Peterson, FC; Volkman, BF; Goodfellow, BJ				Dias, Jorge S.; Macedo, Anjos L.; Ferreira, Gloria C.; Peterson, Francis C.; Volkman, Brian F.; Goodfellow, Brian J.			The first structure from the SOUL/HBP family of heme-binding proteins, murine P22HBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-AMINOLEVULINATE SYNTHASE; MULTIDRUG TRANSPORTER; CRYSTAL-STRUCTURE; CHEMICAL-SHIFT; NMR; DATABASE; RESONANCE; CELLS; N-15; ELECTROSTATICS	Murine p22HBP, a 22-kDa monomer originally identified as a cytosolic heme-binding protein ubiquitously expressed in various tissues, has 27% sequence identity to murine SOUL, a heme-binding hexamer specifically expressed in the retina. In contrast to murine SOUL, which binds one heme per subunit via coordination of the Fe(III)-heme to a histidine, murine p22HBP binds one heme molecule per subunit with no specific axial ligand coordination of the Fe(III)-heme. Using intrinsic protein fluorescence quenching, the values for the dissociation constants of p22HBP for hemin and protoporphyrin-IX were determined to be in the low nanomolar range. The three-dimensional structure of murine p22HBP, the first for a protein from the SOUL/HBP family, was determined by NMR methods to consist of a 9-stranded distorted beta-barrel flanked by two long alpha-helices. Although homologous domains have been found in three bacterial proteins, two of which are transcription factors, the fold determined for p22HBP corresponds to a novel alpha plus beta fold in a eukaryotic protein. Chemical shift mapping localized the tetrapyrrole binding site to a hydrophobic cleft formed by residues from helix alpha(A) and an extended loop. In an attempt to assess the structural basis for tetrapyrrole binding in the SOUL/HBP family, models for the p22HBP-protoporphyrin-IX complex and the SOUL protein were generated by manual docking and automated methods.	Univ Aveiro, Dept Quim, Ctr Invest Mat Ceram & Compositos, P-3810193 Aveiro, Portugal; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, Ctr Quim Fina & Biotecnol, P-2829516 Caparica, Portugal; Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL 33612 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Universidade de Aveiro; Universidade Nova de Lisboa; State University System of Florida; University of South Florida; Medical College of Wisconsin	Goodfellow, BJ (corresponding author), Univ Aveiro, Dept Quim, Ctr Invest Mat Ceram & Compositos, P-3810193 Aveiro, Portugal.	brian.goodfellow@dq.ua.pt	Goodfellow, Brian J/F-4638-2016; Macedo, Anjos L/D-7216-2013; Dias, Jorge/AAS-4551-2020; Ferreira, Gloria C/A-4709-2012; Volkman, Brian F./ABE-7312-2020; Volkman, Brian F./ABE-7306-2020; da Silva Dias, Jorge/D-7572-2013	Goodfellow, Brian J/0000-0003-3191-7121; Macedo, Anjos L/0000-0002-2613-4838; Dias, Jorge/0000-0001-9725-1882; Ferreira, Gloria C/0000-0001-9279-2217; Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179; da Silva Dias, Jorge/0000-0001-9725-1882	NIDDK NIH HHS [DK63191] Funding Source: Medline; NIGMS NIH HHS [GM64598] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM064598] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Babusiak M, 2005, PROTEOMICS, V5, P340, DOI 10.1002/pmic.200400935; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bertini I, 2005, CHEMBIOCHEM, V6, P1536, DOI 10.1002/cbic.200500124; Billeter M, 1995, J BIOMOL NMR, V5, P1; Blackmon BJ, 2002, ARCH BIOCHEM BIOPHYS, V407, P196, DOI 10.1016/S0003-9861(02)00471-X; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dias JS, 2005, J BIOMOL NMR, V32, P338, DOI 10.1007/s10858-005-0470-8; Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Goodfellow BJ, 2001, FEBS LETT, V505, P325, DOI 10.1016/S0014-5793(01)02818-6; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Keller R., 2004, COMPUTER AIDED RESON, V1; Kwon HJ, 2000, NAT STRUCT BIOL, V7, P424; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; Latunde-Dada GO, 2006, TRENDS BIOCHEM SCI, V31, P182, DOI 10.1016/j.tibs.2006.01.005; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Migeotte I, 2005, J EXP MED, V201, P83, DOI 10.1084/jem.20041277; Munakata H, 2004, J BIOCHEM, V136, P233, DOI 10.1093/jb/mvh112; Newberry KJ, 2004, J BIOL CHEM, V279, P20356, DOI 10.1074/jbc.M400960200; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Romanowski MJ, 2002, PROTEINS, V47, P403, DOI 10.1002/prot.10102; Sato E, 2004, BIOCHEMISTRY-US, V43, P14189, DOI 10.1021/bi048742i; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWILLENS S, 1995, MOL PHARMACOL, V47, P1197; Taketani S, 1998, J BIOL CHEM, V273, P31388, DOI 10.1074/jbc.273.47.31388; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WUTHRICH K, 1968, P NATL ACAD SCI USA, V61, P1199, DOI 10.1073/pnas.61.4.1199; Xu XP, 2001, J BIOMOL NMR, V21, P321, DOI 10.1023/A:1013324104681; Ye YZ, 2003, BIOINFORMATICS, V19, pII246, DOI 10.1093/bioinformatics/btg1086; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6; Zylka MJ, 1999, MOL BRAIN RES, V74, P175, DOI 10.1016/S0169-328X(99)00277-6	36	30	31	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31553	31561		10.1074/jbc.M605988200	http://dx.doi.org/10.1074/jbc.M605988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16905545	Bronze			2022-12-25	WOS:000241235300041
J	El-Shewy, HM; Johnson, KR; Lee, MH; Jaffa, AA; Obeid, LM; Luttrell, LM				El-Shewy, Hesham M.; Johnson, Korey R.; Lee, Mi-Hye; Jaffa, Ayad A.; Obeid, Lina M.; Luttrell, Louis M.			Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2 activation by transactivating sphingosine 1-phosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; BC3H-1 MURINE MYOCYTES; MANNOSE 6-PHOSPHATE; SPHINGOSINE 1-PHOSPHATE; KINASE-C; FACTOR-II/MANNOSE-6-PHOSPHATE RECEPTOR; G(BETA-GAMMA) SUBUNITS; BETA-ARRESTIN; EGF RECEPTOR; CELLS	Although several studies have shown that a subset of insulin-like growth factor (IGF) signals require the activation of heterotrimeric G proteins, the molecular mechanisms underlying IGF-stimulated G protein signaling remain poorly understood. Here, we have studied the mechanism by which endogenous IGF receptors activate the ERK1/2 mitogen-activated protein kinase cascade in HEK293 cells. In these cells, treatment with pertussis toxin and expression of a G alpha(q/11)-305-359) peptide that inhibits G(q/11) signaling additively inhibited IGF-stimulated ERK1/2 activation, indicating that the signal was almost completely G protein-dependent. Treatment with IGF-1 or IGF-2 promoted translocation of green fluorescent protein (GFP)-tagged sphingosine kinase (SK) 1 from the cytosol to the plasma membrane, increased endogenous SK activity within 30 s of stimulation, and caused a statistically significant increase in intracellular and extracellular sphingosine 1-phosphate (S1P) concentration. Using a GFP-tagged S1P(1) receptor as a biological sensor for the generation of physiologically relevant S1P levels, we found that IGF-1 and IGF-2 induced GFP-S1P receptor internalization and that the effect was blocked by pretreatment with the SK inhibitor, dimethylsphingosine. Treating cells with dimethylsphingosine, silencing SK1 expression by RNA interference, and blocking endogenous S1P receptors with the competitive antagonist VPC23019 all significantly inhibited IGF-stimulated ERK1/2 activation, suggesting that IGFs elicit G protein-dependent ERK1/2 activation by stimulating SK1-dependent transactivation of S1P receptors. Given the ubiquity of SK and S1P receptor expression, S1P receptor transactivation may represent a general mechanism for G protein-dependent signaling by non-G protein-coupled receptors.	Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Luttrell, LM (corresponding author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA.	luttrell@musc.edu		obeid, lina/0000-0002-0734-0847; Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58283] Funding Source: Medline; NIGMS NIH HHS [GM62887] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akekawatchai C, 2005, J BIOL CHEM, V280, P39701, DOI 10.1074/jbc.M509829200; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Davis MD, 2005, J BIOL CHEM, V280, P9833, DOI 10.1074/jbc.M412356200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; El-Shewy HM, 2004, MOL ENDOCRINOL, V18, P2727, DOI 10.1210/me.2004-0174; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Gaborik Z, 2004, TRENDS ENDOCRIN MET, V15, P286, DOI 10.1016/j.tem.2004.06.009; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Hassan AB, 2003, AM J PATHOL, V162, P3, DOI 10.1016/S0002-9440(10)63791-1; Hawkes C, 2006, J NEUROSCI, V26, P585, DOI 10.1523/JNEUROSCI.2730-05.2006; Hawkes C, 2003, J COMP NEUROL, V458, P113, DOI 10.1002/cne.10578; Heringdorf DMZ, 2001, EUR J PHARMACOL, V414, P145, DOI 10.1016/S0014-2999(01)00789-0; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Janez A, 2000, J BIOL CHEM, V275, P26870; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kanzaki M, 1997, J BIOL CHEM, V272, P4964, DOI 10.1074/jbc.272.8.4964; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; Luttrell LM, 2005, J MOL NEUROSCI, V26, P253, DOI 10.1385/JMN:26:2-3:253; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1993, FEBS LETT, V334, P143, DOI 10.1016/0014-5793(93)81700-A; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Patel TB, 2004, PHARMACOL REV, V56, P371, DOI 10.1124/pr.56.3.4; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Pyne NJ, 2003, BIOCHEM SOC T, V31, P1220; ROMERO G, 1988, SCIENCE, V240, P509, DOI 10.1126/science.3282305; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Uehara T, 1999, EUR J BIOCHEM, V259, P801, DOI 10.1046/j.1432-1327.1999.00100.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Waters C, 2003, J BIOL CHEM, V278, P6282, DOI 10.1074/jbc.M208560200; Waters D, 2006, FASEB J, V20, pA1058; Watterson KR, 2005, CELL SIGNAL, V17, P289, DOI 10.1016/j.cellsig.2004.09.013; Watterson KR, 2002, J BIOL CHEM, V277, P5767, DOI 10.1074/jbc.M110647200; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yau L, 1999, EUR J BIOCHEM, V266, P1147, DOI 10.1046/j.1432-1327.1999.00968.x; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	58	73	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31399	31407		10.1074/jbc.M605339200	http://dx.doi.org/10.1074/jbc.M605339200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16926156				2022-12-25	WOS:000241235300024
J	Kabe, Y; Ohmori, M; Shinouchi, K; Tsuboi, Y; Hirao, S; Azuma, M; Watanabe, H; Okura, I; Handa, H				Kabe, Yasuaki; Ohmori, Masashi; Shinouchi, Kazuya; Tsuboi, Yasunori; Hirao, Satoshi; Azuma, Motoki; Watanabe, Hajime; Okura, Ichiro; Handa, Hiroshi			Porphyrin accumulation in mitochondria is mediated by 2-oxoglutarate carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE AFFINITY BEADS; OXOGLUTARATE CARRIER; HEART-MITOCHONDRIA; DRUG RECEPTORS; PURIFICATION; PHOSPHORESCENCE; PROTEINS; KINETICS; BINDING; SURFACE	Heme (Fe-protoporphyrin IX), an endogenous porphyrin derivative, is an essential molecule in living aerobic organisms and plays a role in a variety of physiological processes such as oxygen transport, respiration, and signal transduction. For the biosynthesis of heme or the mitochondrial heme proteins, heme or its biosynthetic precursor porphyrin must be transported into mitochondria from cytosol. The mechanism of porphyrin accumulation in the mitochondrial inner membrane is unclear. In the present study, we analyzed the mechanism of mitochondrial translocation of porphyrin derivatives. We showed that palladium meso-tetra(4-carboxyphenyl) porphyrin (PdTCPP), a phosphorescent porphyrin derivative, accumulated in the mitochondria of several cell lines. Using affinity latex beads, we showed that 2-oxoglutarate carrier (OGC), the mitochondrial transporter of 2-oxoglutarate, bound to PdTCPP, and in vitro PdTCPP-inhibited 2-oxoglutarate uptake into mitochondria in a competitive manner (K-i = 15 mu M). Interestingly, all types of porphyrin derivatives examined in this study competitively inhibited 2-oxoglutarate uptake into mitochondria, including protoporphyrin IX, coproporphyrin III, and hemin. Furthermore, mitochondrial accumulation of porphyrins was inhibited by 2-oxoglutarate or OGC inhibitor. These results suggested that porphyrin accumulation in mitochondria is mediated by OGC and that porphyrins are able to competitively inhibit 2-oxoglutarate uptake into mitochondria. This is the first report of a putative mechanism for accumulation of porphyrins in the mitochondrial inner membrane.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan	Tokyo Institute of Technology; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Japan Science & Technology Agency (JST)	Handa, H (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	hhanda@bio.titech.ac.jp	Watanabe, Hajime/S-8957-2019; WATANABE, Hajime/AAJ-8904-2021	Watanabe, Hajime/0000-0001-9657-6554				Bisaccia F, 1996, BBA-PROTEIN STRUCT M, V1292, P281, DOI 10.1016/0167-4838(95)00215-4; BISACCIA F, 1985, BIOCHIM BIOPHYS ACTA, V810, P362, DOI 10.1016/0005-2728(85)90222-1; Brdiczka D, 1986, Adv Exp Med Biol, V194, P55; Capobianco L, 1996, BIOCHEMISTRY-US, V35, P8974, DOI 10.1021/bi960258v; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Hiramoto M, 2002, METHOD ENZYMOL, V353, P81; INDIVERI C, 1987, BIOCHIM BIOPHYS ACTA, V890, P310, DOI 10.1016/0005-2728(87)90158-7; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; INOMATA Y, 1994, J BIOMAT SCI-POLYM E, V5, P293, DOI 10.1163/156856294X00031; Lee SK, 1997, ANAL SCI, V13, P535, DOI 10.2116/analsci.13.535; LOM LW, 1996, ANAL BIOCHEM, V236, P153; Moore MR, 1998, CLIN DERMATOL, V16, P203, DOI 10.1016/S0738-081X(97)00201-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Ohtsu Y, 2005, ANAL BIOCHEM, V338, P245, DOI 10.1016/j.ab.2004.10.006; PALMIERI F, 1992, BIOCHIM BIOPHYS ACTA, V1101, P223; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; RUMSEY WL, 1988, SCIENCE, V241, P1649, DOI 10.1126/science.3420417; Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496; Srere P A, 1986, Adv Exp Med Biol, V194, P13; TAKETANI S, 1994, J BIOL CHEM, V269, P7527; Tibbetts AS, 2002, ARCH BIOCHEM BIOPHYS, V406, P96, DOI 10.1016/S0003-9861(02)00419-8; Tomohiro T, 2002, BIOCONJUGATE CHEM, V13, P163, DOI 10.1021/bc015560h; VAARTJES WJ, 1997, BIOCHIM BIOPHYS ACTA, V548, P38; VERMA A, 1987, P NATL ACAD SCI USA, V84, P2256, DOI 10.1073/pnas.84.8.2256; VINOGRADOV SA, 1994, BIOPHYS J, V67, P2048, DOI 10.1016/S0006-3495(94)80688-5; WILSON DF, 1992, CANCER RES, V52, P3988; Xu WY, 1996, ANAL CHEM, V68, P2605, DOI 10.1021/ac960083v	27	51	52	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31729	31735		10.1074/jbc.M604729200	http://dx.doi.org/10.1074/jbc.M604729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920706	Bronze			2022-12-25	WOS:000241235300059
J	Robinson, JA; Chatterjee-Kishore, M; Yaworsky, PJ; Cullen, DM; Zhao, WG; Li, C; Kharode, Y; Sauter, L; Babij, P; Brown, EL; Hill, AA; Akhter, MP; Johnson, ML; Recker, RR; Komm, BS; Bex, FJ				Robinson, John A.; Chatterjee-Kishore, Moitreyee; Yaworsky, Paul J.; Cullen, Diane M.; Zhao, Weiguang; Li, Christine; Kharode, Yogendra; Sauter, Linda; Babij, Philip; Brown, Eugene L.; Hill, Andrew A.; Akhter, Mohammed P.; Johnson, Mark L.; Recker, Robert R.; Komm, Barry S.; Bex, Frederick J.			Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; WNT; RECEPTOR; LRP5; GENE; MASS; INHIBITION; INCREASES; PROTEINS; PATHWAYS	A preliminary expression profiling analysis of osteoblasts derived from tibia explants of the high bone mass LRP5 G171V transgenic mice demonstrated increased expression of canonical Wnt pathway and Wnt/beta-catenin target genes compared with non-transgenic explant derived osteoblasts. Therefore, expression of Wnt/beta-catenin target genes were monitored after in vivo loading of the tibia of LRP5 G171V transgenic mice compared with non-transgenic mice. Loading resulted in the increased expression of Wnt pathway and Wnt/beta-catenin target genes including Wnt10B, SFRP1, cyclin D1, FzD2, WISP2, and connexin 43 in both genotypes; however, there was a further increased in transcriptional response with the LRP5 G171V transgenic mice. Similar increases in the expression of these genes (except cyclin D1) were observed when non- transgenic mice were pharmacologically treated with a canonical Wnt pathway activator, glycogen synthase kinase 3 beta inhibitor and then subjected to load. These in vivo results were further corroborated by in vitro mechanical loading experiments in which MC3T3-E1 osteoblastic cells were subjected to 3400 microstrain alone for 5 h, which increased the expression of Wnt10B, SFRP1, cyclin D1, FzD2, WISP2, and connexin 43. Furthermore, when MC3T3-E1 cells were treated with either glycogen synthase kinase 3 beta inhibitor or Wnt3A to activate Wnt signaling and then subjected to load, a synergistic up-regulation of these genes was observed compared with vehicle-treated cells. Collectively, the in vivo and in vitro mechanical loading results support that Wnt/beta-catenin signaling is a normal physiological response to load and that activation of the Wnt/beta-catenin pathway enhances the sensitivity of osteoblasts/osteocytes to mechanical loading.	Wyeth Res, Dept Womens Hlth & Musculoskeletal Biol, Collegeville, PA 19426 USA; Wyeth Ayerst Res, Cambridge, MA 02140 USA; Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68131 USA	Pfizer; Pfizer; Creighton University	Robinson, JA (corresponding author), Wyeth Res, Dept Womens Hlth & Musculoskeletal Biol, 500 Arcola Rd,RN3247, Collegeville, PA 19426 USA.	robinsj@wyeth.com						Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002-9440(10)63963-6; Akhter MP, 1998, CALCIFIED TISSUE INT, V63, P442, DOI 10.1007/s002239900554; Akhter MP, 2004, BONE, V35, P162, DOI 10.1016/j.bone.2004.02.018; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Basso N, 2002, BONE, V30, P347, DOI 10.1016/S8756-3282(01)00678-0; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Bex F, 2003, J BONE MINER RES, V18, pS60; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Clement-Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cullen DM, 2002, J BONE MINER RES, V17, pS332; Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014-5793(03)00055-3; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Hughes-Fulford Millie, 2004, Sci STKE, V2004, pRE12; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Johnson M. L., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P135; Johnson ML, 2002, ENDOCRINOLOGIST, V12, P445, DOI 10.1097/00019616-200209000-00012; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Lau KHW, 2006, J BIOL CHEM, V281, P9576, DOI 10.1074/jbc.M509205200; Lecanda F, 2000, J CELL BIOL, V151, P931, DOI 10.1083/jcb.151.4.931; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nomura S, 2000, MATRIX BIOL, V19, P91, DOI 10.1016/S0945-053X(00)00050-0; Pavalko FM, 2003, J CELL PHYSIOL, V194, P194, DOI 10.1002/jcp.10221; Pilbeam Carol C., 1996, P715; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Pommerenke H, 2002, J BONE MINER RES, V17, P603, DOI 10.1359/jbmr.2002.17.4.603; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tang LY, 1997, J BONE MINER RES, V12, P276, DOI 10.1359/jbmr.1997.12.2.276; van den Brink GR, 2004, NAT GENET, V36, P1038, DOI 10.1038/ng1004-1038; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365-2567.2001.01261.x; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Whyte MP, 2004, NEW ENGL J MED, V350, P2096; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200	56	418	445	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31720	31728		10.1074/jbc.M602308200	http://dx.doi.org/10.1074/jbc.M602308200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16908522				2022-12-25	WOS:000241235300058
J	Tomar, A; George, S; Kansal, P; Wang, YH; Khurana, S				Tomar, Alok; George, Sudeep; Kansal, Pallavi; Wang, Yaohong; Khurana, Seema			Interaction of phospholipase C-gamma(1) with villin regulates epithelial cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEINS; IN-VITRO; TYROSINE PHOSPHORYLATION; INTESTINAL EPITHELIUM; CYTOSKELETAL PROTEINS; PROXIMAL TUBULE; C ACTIVITY; GELSOLIN; 4,5-BISPHOSPHATE; IDENTIFICATION	Tyrosine-phosphorylated villin regulates actin dynamics, cell morphology, and cell migration. Previously, we identified four tyrosine phosphorylation sites in the amino-terminal domain of villin. In this study we report six new sites in the carboxyl-terminal region of the villin core. With this study we document all phosphorylatable tyrosine residues in villin and map them to functions of villin. In this study, we identify for the first time the functional relevance of the carboxyl-terminal domains of the villin core. Expression of the carboxyl-terminal phosphorylation site mutant, as well as the villin truncation mutant S1-S3, inhibited cell migration in HeLa and Madin-Darby canine kidney Tet-Off cells, confirming the role of the carboxyl-terminal phosphorylation sites in villin-induced cell migration. The carboxyl-terminal phosphorylation sites were found to be critical for the interaction of villin with its ligand phospholipase C-gamma(1) and for its localization to the developing lamellipodia in a motile cell. The results presented here elucidate the molecular basis for tyrosine-phosphorylated villin-induced changes in cell motility.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Khurana, S (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Nash 402,894 Union Ave, Memphis, TN 38163 USA.	skhurana@utmem.edu		Khurana, Seema/0000-0002-6884-810X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054755, R01DK065006] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-65006, DK-54755] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albers TM, 1996, CELL BIOL INT, V20, P821, DOI 10.1006/cbir.1996.0105; Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; Athman R, 2005, CELL MICROBIOL, V7, P1109, DOI 10.1111/j.1462-5822.2005.00535.x; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; BACCHI CE, 1991, LAB INVEST, V64, P418; BARTHOD F, 1994, J CHIR-PARIS, V131, P221; Brown D, 1997, AM J PHYSIOL-RENAL, V273, pF1003, DOI 10.1152/ajprenal.1997.273.6.F1003; Burtnick LD, 2004, EMBO J, V23, P2713, DOI 10.1038/sj.emboj.7600280; Chang JS, 1997, CANCER RES, V57, P5465; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Chou J, 2002, INT J BIOCHEM CELL B, V34, P776, DOI 10.1016/S1357-2725(01)00177-7; De Corte V, 1999, PROTEIN SCI, V8, P234; DeCorte V, 1997, FEBS LETT, V401, P191, DOI 10.1016/S0014-5793(96)01471-8; FINIDORI J, 1992, J CELL BIOL, V116, P1145, DOI 10.1083/jcb.116.5.1145; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Folger PA, 1999, CANCER RES, V59, P5349; Friederich E, 1999, J BIOL CHEM, V274, P26751, DOI 10.1074/jbc.274.38.26751; GLENNEY JR, 1981, P NATL ACAD SCI-BIOL, V78, P2810, DOI 10.1073/pnas.78.5.2810; GOLENHOFEN N, 1995, KIDNEY INT, V48, P1837, DOI 10.1038/ki.1995.482; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JIN S, 2006, IN PRESS AM J PHYSL; Khurana S, 1997, J BIOL CHEM, V272, P30115, DOI 10.1074/jbc.272.48.30115; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kumar N, 2004, J BIOL CHEM, V279, P45036, DOI 10.1074/jbc.M405424200; Kumar N, 2004, J BIOL CHEM, V279, P24915, DOI 10.1074/jbc.C400110200; Kumar N, 2004, J BIOL CHEM, V279, P3096, DOI 10.1074/jbc.M308878200; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; Lauwaet T, 2003, J BIOL CHEM, V278, P22650, DOI 10.1074/jbc.M300142200; Louvard RAD, 2003, MOL BIOL CELL, V14, P4641, DOI 10.1091/mbc.E03-02-0091; Lueck A, 1998, J CELL SCI, V111, P3633; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; NOMOTO K, 1995, MOL CARCINOGEN, V12, P146, DOI 10.1002/mc.2940120306; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; Panebra A, 2001, AM J PHYSIOL-CELL PH, V281, pC1046, DOI 10.1152/ajpcell.2001.281.3.C1046; Papakonstanti EA, 2000, MOL MED, V6, P303, DOI 10.1007/BF03401939; PARK JG, 1994, CANCER RES, V54, P2240; Phillips MJ, 2003, LANCET, V362, P1112, DOI 10.1016/S0140-6736(03)14467-4; Piccolo E, 2002, ONCOGENE, V21, P6520, DOI 10.1038/sj.onc.1205821; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rieder G, 2005, J BIOL CHEM, V280, P4906, DOI 10.1074/jbc.M413399200; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; SODERQUIST AM, 1992, CANCER RES, V52, P4526; SUN HQ, 1994, J BIOL CHEM, V269, P9473; Tomar A, 2004, MOL BIOL CELL, V15, P4807, DOI 10.1091/mbc.E04-05-0431; Tsukamoto T, 2004, J CANCER RES CLIN, V130, P135, DOI 10.1007/s00432-003-0519-6; Wells A, 2000, ADV CANCER RES, V78, P31; White P, 2000, AM J PHYSIOL-RENAL, V278, pF886, DOI 10.1152/ajprenal.2000.278.6.F886; Yuan XL, 2003, J PROTEOME RES, V2, P476, DOI 10.1021/pr025589a; Zhai LW, 2002, BIOCHEMISTRY-US, V41, P11750, DOI 10.1021/bi0263762; Zhai LW, 2001, J BIOL CHEM, V276, P36163, DOI 10.1074/jbc.C100418200	57	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31972	31986		10.1074/jbc.M604323200	http://dx.doi.org/10.1074/jbc.M604323200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16921170	Bronze			2022-12-25	WOS:000241235300083
J	Xu, W; Tanaka, K; Sun, AQ; You, GF				Xu, Wen; Tanaka, Kunihiko; Sun, An-qiang; You, Guofeng			Functional role of the C terminus of human organic anion transporter hOAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MOLECULAR-CLONING; EXPRESSION CLONING; CARBOXYL-TERMINUS; SUBSTRATE-BINDING; LACTOSE PERMEASE; ESCHERICHIA-COLI; RAT-BRAIN; KIDNEY; IDENTIFICATION	Human organic anion transporter hOAT1 plays critical roles in the body disposition of environmental toxins and clinically important drugs. In the present study, we examined the role of the C terminus of hOAT1 in its function. Combined approaches of cell surface biotinylation and transport analysis were employed for such purposes. It was found that deletion of the last 15 amino acids ( residues 536 - 550) or the last 30 amino acids ( residues 521 - 550) had no significant effect on transport activity. However, deletion of the entire C terminus ( residues 506 - 550) completely abolished transport activity. Alanine scanning mutagenesis within the region of amino acids 506 - 520 led to the discovery of two critical amino acids: Glu-506 and Leu-512. Substitution of negatively charged Glu-506 with neutral amino acids alanine or glutamine resulted in complete loss of transport activity. However, such loss of transport activity could be rescued by substitution of Glu-506 with another negatively charged amino acid aspartic acid, suggesting the importance of negative charge at this position for maintaining the correct tertiary structure of the transporter, possibly by forming a salt bridge with a positively charged amino acid. Substitution of Leu-512 with amino acids carrying progressively smaller side chains including isoleucine, valine, and alanine resulted in mutants (L512I, L512V, and L512A) with increasingly impaired transport activity. However, the cell surface expression of these mutants was not affected. Kinetic analysis of mutant L512V revealed that the reduced transport activity of this mutant resulted mainly from a reduced maximum transport velocity V-max without affecting the binding affinity (1/K-m) of the transporter for its substrates, suggesting that the size of the side chain at position 512 critically affects transporter turnover number. Together, our results are the first to highlight the central role of the C terminus of hOAT1 in the function of this transporter.	Rutgers State Univ, Dept Pharmaceut, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Dept Pharmacol, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Icahn School of Medicine at Mount Sinai	You, GF (corresponding author), Rutgers State Univ, Dept Pharmaceut, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	gyou@rci.rutgers.edu			NIDDK NIH HHS [R01-DK 60034] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; Bauman PA, 2002, ARCH BIOCHEM BIOPHYS, V404, P80, DOI 10.1016/S0003-9861(02)00232-1; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Cihlar T, 1999, MOL PHARMACOL, V56, P570, DOI 10.1124/mol.56.3.570; Ekaratanawong S, 2004, J PHARMACOL SCI, V94, P297, DOI 10.1254/jphs.94.297; Hong M, 2004, J BIOL CHEM, V279, P31478, DOI 10.1074/jbc.M404686200; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kasir J, 1999, J BIOL CHEM, V274, P24873, DOI 10.1074/jbc.274.35.24873; Kilic F, 2003, MOL PHARMACOL, V64, P440, DOI 10.1124/mol.64.2.440; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Kuze K, 1999, J BIOL CHEM, V274, P1519, DOI 10.1074/jbc.274.3.1519; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Lu R, 1999, AM J PHYSIOL-RENAL, V276, pF295, DOI 10.1152/ajprenal.1999.276.2.F295; Miranda M, 2004, J BIOL CHEM, V279, P30760, DOI 10.1074/jbc.M312774200; Monte JC, 2004, BIOCHEM BIOPH RES CO, V323, P429, DOI 10.1016/j.bbrc.2004.08.112; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; Popp C, 2005, MOL PHARMACOL, V67, P1600, DOI 10.1124/mol.104.008839; Sekine T, 1998, FEBS LETT, V429, P179, DOI 10.1016/S0014-5793(98)00585-7; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Vayro S, 1999, AM J PHYSIOL-CELL PH, V276, pC1053, DOI 10.1152/ajpcell.1999.276.5.C1053; Wolff NA, 1997, FEBS LETT, V417, P287, DOI 10.1016/S0014-5793(97)01304-5; You GF, 2004, MED RES REV, V24, P762, DOI 10.1002/med.20014; You GF, 2004, CURR DRUG METAB, V5, P55, DOI 10.2174/1389200043489207; You GF, 2002, MED RES REV, V22, P602, DOI 10.1002/med.10019; Youngblood GL, 2004, AM J PHYSIOL-RENAL, V287, pF236, DOI 10.1152/ajprenal.00012.2004; Zhou FF, 2005, MOL PHARMACOL, V67, P868, DOI 10.1124/mol.104.007583; Zhou FF, 2004, MOL PHARMACOL, V65, P1141, DOI 10.1124/mol.65.5.1141	30	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31178	31183		10.1074/jbc.M605664200	http://dx.doi.org/10.1074/jbc.M605664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920720	Bronze			2022-12-25	WOS:000241235300002
J	Jantaro, S; Ali, Q; Lone, S; He, QF				Jantaro, Saowarath; Ali, Quaisar; Lone, Samea; He, Qingfang			Suppression of the lethality of high light to a quadruple HLI mutant by the inactivation of the regulatory protein PfsR in Synechocystis PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B-BINDING-PROTEINS; CAB-LIKE PROTEINS; SP. PCC 6803; HEME OXYGENASE; OXIDATIVE STRESS; IN-VIVO; INDUCIBLE POLYPEPTIDES; SUPEROXIDE-DISMUTASE; CRYSTAL-STRUCTURE; MAMMALIAN IRON	A regulatory gene, designated pfsR ( photosynthesis, Fe homeostasis and stress-response regulator), was discovered by a genetic screen in Synechocystis PCC 6803. Deletion of the gene from a high light-sensitive strain lacking four hli genes (4Xhli) restored viability to the parental strain under high light conditions. The quintuple mutant pfsR(-)/4Xhli retained photosystem-II and oxygen evolution capacity at levels similar to the wild-type levels under high light conditions. The transcripts of the two bfr genes ( encoding bacterioferritin) were found to be constitutively up-regulated, whereas the transcripts of ho1 gene ( encoding a heme oxygenase) were greatly down-regulated in high light upon deletion of pfsR. Under intermediate high intensity light, the pfsR deletion strains accumulated carotenoids and chlorophyll a to a significantly higher level than their corresponding parental strains. An exacerbated, transient increase in oxygen evolution during the early hours of high light acclimation and a somewhat increased steady-state level of photosystem-II-mediated oxygen evolution observed in the 4Xhli strain were brought back to the wild-type levels upon deletion of pfsR from the strain. The pfsR deletion mutants were found to be less sensitive to iron limitation under low light conditions and to suffer less lipid peroxidation following exposure to high light. Therefore, inactivation of PfsR resulted in tighter control of iron availability, which in turn reduced oxidative stress during photosynthesis in high light. These studies have revealed a critical role of PfsR in regulation of iron homeostasis and stress response.	Univ Arkansas, Dept Appl Sci, Little Rock, AR 72204 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	He, QF (corresponding author), Univ Arkansas, Dept Appl Sci, ETAS 575,2801 S Univ Ave, Little Rock, AR 72204 USA.	qfhe@ualr.edu	He, Qingfang/I-4181-2013					Abdul-Tehrani H, 1999, J BACTERIOL, V181, P1415, DOI 10.1128/JB.181.5.1415-1428.1999; Asada K., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P77; Baranano DE, 2000, J BIOL CHEM, V275, P15166, DOI 10.1074/jbc.275.20.15166; Bhaya D, 2001, P NATL ACAD SCI USA, V98, P7540, DOI 10.1073/pnas.131201098; BOWLER C, 1994, CRIT REV PLANT SCI, V13, P199, DOI 10.1080/713608062; CHAMOVITZ D, 1993, J BIOL CHEM, V268, P17348; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; Coleman ML, 2006, SCIENCE, V311, P1768, DOI 10.1126/science.1122050; Cornejo J, 1998, PLANT J, V15, P99, DOI 10.1046/j.1365-313X.1998.00186.x; COZZI A, 1990, FEBS LETT, V277, P119, DOI 10.1016/0014-5793(90)80823-2; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7; DI MASCIO P, 1990, BIOCHEM SOC T, V18, P1054; DIMASCIO P, 1991, ADV EXP MED BIOL, V283, P71; Dolganov N, 1999, J BACTERIOL, V181, P610, DOI 10.1128/JB.181.2.610-617.1999; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; Durnford DG, 1997, PHOTOSYNTH RES, V53, P229, DOI 10.1023/A:1005815725371; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Foyer C H, 2001, Biologist (London), V48, P115; Fryer MJ, 2003, PLANT J, V33, P691, DOI 10.1046/j.1365-313X.2003.01656.x; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; Halliwell B., 1999, FREE RADICAL BIO MED, P1, DOI DOI 10.1093/ACPROF:OSO/9780198717478.001.0001; Havaux M, 2003, BBA-BIOENERGETICS, V1557, P21, DOI 10.1016/S0005-2728(02)00391-2; He QF, 1998, P NATL ACAD SCI USA, V95, P5830, DOI 10.1073/pnas.95.10.5830; He QF, 2001, J BIOL CHEM, V276, P306, DOI 10.1074/jbc.M008686200; Herranen M, 2001, PHYSIOL PLANTARUM, V112, P531, DOI 10.1034/j.1399-3054.2001.1120410.x; HERTWIG B, 1992, PLANT PHYSIOL, V100, P1547, DOI 10.1104/pp.100.3.1547; Horling F, 2003, PLANT PHYSIOL, V131, P317, DOI 10.1104/pp.010017; Hsiao HY, 2004, J BACTERIOL, V186, P3882, DOI 10.1128/JB.186.12.3882-3888.2004; JACOB J, 1993, PLANT CELL ENVIRON, V16, P785, DOI 10.1111/j.1365-3040.1993.tb00500.x; JURGENS UJ, 1986, J BACTERIOL, V168, P568; Kakhlon O, 2002, FREE RADICAL BIO MED, V33, P1037, DOI 10.1016/S0891-5849(02)01006-7; Keren N, 2004, PLANT PHYSIOL, V135, P1666, DOI 10.1104/pp.104.042770; LAULHERE JP, 1992, BIOCHEM J, V281, P785, DOI 10.1042/bj2810785; LEVY H, 1993, J BIOL CHEM, V268, P20892; LICHTENTHALER H K, 1981, Photosynthesis Research, V2, P115, DOI 10.1007/BF00028752; Meetam M, 1999, PLANT PHYSIOL, V121, P1267, DOI 10.1104/pp.121.4.1267; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; MORAN R, 1982, PLANT PHYSIOL, V69, P1376, DOI 10.1104/pp.69.6.1376; Muramatsu M, 2003, PLANTA, V216, P446, DOI 10.1007/s00425-002-0859-5; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Ort DR, 2002, CURR OPIN PLANT BIOL, V5, P193, DOI 10.1016/S1369-5266(02)00259-5; PELTIER G, 1991, P NATL ACAD SCI USA, V88, P4791, DOI 10.1073/pnas.88.11.4791; PERLTREVES R, 1991, PLANT MOL BIOL, V17, P745, DOI 10.1007/BF00037058; PETER GF, 1991, J BIOL CHEM, V266, P16745; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; REDINBAUGH MG, 1990, P NATL ACAD SCI USA, V87, P6853, DOI 10.1073/pnas.87.17.6853; Sambrook J, 2001, MOL CLONING LAB MANU; St Johnston D, 2002, NAT REV GENET, V3, P176, DOI 10.1038/nrg751; Sugishima M, 2005, BIOCHEMISTRY-US, V44, P4257, DOI 10.1021/bi0480483; Sugishima M, 2004, EUR J BIOCHEM, V271, P4517, DOI 10.1111/j.1432-1033.2004.04411.x; TSANG EWT, 1991, PLANT CELL, V3, P783, DOI 10.1105/tpc.3.8.783; Wai SN, 1996, MOL MICROBIOL, V20, P1127, DOI 10.1111/j.1365-2958.1996.tb02633.x; Xie DX, 1998, SCIENCE, V280, P1091, DOI 10.1126/science.280.5366.1091; Xu H, 2004, J BIOL CHEM, V279, P27971, DOI 10.1074/jbc.M403307200; Xu H, 2002, PLANT MOL BIOL, V49, P149, DOI 10.1023/A:1014900806905; Yabuta Y, 2002, PLANT J, V32, P915, DOI 10.1046/j.1365-313X.2002.01476.x; Zhang XH, 2005, FEBS J, V272, P1012, DOI 10.1111/j.1742-4658.2004.04535.x; ZHONG HH, 1994, PLANT PHYSIOL, V104, P889, DOI 10.1104/pp.104.3.889	61	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30865	30874		10.1074/jbc.M606252200	http://dx.doi.org/10.1074/jbc.M606252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16914546	hybrid			2022-12-25	WOS:000241075900062
J	Kashlan, OB; Maarouf, AB; Kussius, C; Denshaw, RM; Blumenthal, KM; Kleyman, TR				Kashlan, Ossama B.; Maarouf, Ahmad B.; Kussius, Cassandra; Denshaw, Robert M.; Blumenthal, Kenneth M.; Kleyman, Thomas R.			Distinct structural elements in the first membrane-spanning segment of the epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; SUBUNIT STOICHIOMETRY; NA+ CHANNEL; ION PERMEATION; ALPHA-SUBUNIT; GAMMA-SUBUNIT; K+ CHANNEL; RESIDUES; SELECTIVITY; SERVER	Epithelial Na+ channels (ENaCs) comprise three subunits that have been proposed to be arranged in either an alpha(2)beta gamma or a higher ordered configuration. Each subunit has two putative membrane-spanning segments (M1 and M2), intracellular amino and carboxyl termini, and a large extracellular loop. We have used the TOXCAT assay (a reporter assay for transmembrane segment homodimerization) to identify residues within the transmembrane segments of ENaC that may participate in important structural interactions within ENaC, with which we identified a candidate site within alpha M1. We performed site-directed mutagenesis at this site and found that, although the mutants reduced channel activity, ENaC protein expression at the plasma membrane was unaffected. To deduce the role of alpha M1 in the pore structure of ENaC, we performed tryptophan-scanning mutagenesis throughout alpha M1( residues 110-130). We found that mutations within the amino-terminal part of alpha M1 had effects on activity and selectivity with a periodicity consistent with a helical structure but no effect on channel surface expression. We also observed that mutations within the carboxyl-terminal part of alpha M1 had effects on activity and selectivity but with no apparent periodicity. Additionally, these mutants reduced channel surface expression. Our data support a model in which the amino-terminal half of alpha M1 is alpha-helical and packs against structural element(s) that contribute to the ENaC pore. Furthermore, these data suggest that the carboxyl-terminal half of alpha M1 may be helical or assume a different conformation and may be involved in tertiary interactions essential to proper channel folding or assembly. Together, our data suggest that alpha M1 is divided into two distinct regions.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kleyman, TR (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, 3550 Terrace St, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK066883, R01DK054354, T32DK061296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060582] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK066883, DK061296, DK066883, DK054354] Funding Source: Medline; NIGMS NIH HHS [GM060582] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Chalfant ML, 1996, AM J PHYSIOL-RENAL, V271, pF861, DOI 10.1152/ajprenal.1996.271.4.F861; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Kellenberger S, 2005, J BIOL CHEM, V280, P7739, DOI 10.1074/jbc.M409955200; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Labro AJ, 2003, J BIOL CHEM, V278, P50724, DOI 10.1074/jbc.M306097200; Langloh ALB, 2000, AM J PHYSIOL-CELL PH, V278, pC277, DOI 10.1152/ajpcell.2000.278.2.C277; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Pfister Y, 2006, J BIOL CHEM, V281, P11787, DOI 10.1074/jbc.M513692200; Poet M, 2001, EMBO J, V20, P5595, DOI 10.1093/emboj/20.20.5595; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sen TZ, 2005, BIOINFORMATICS, V21, P2787, DOI 10.1093/bioinformatics/bti408; Sheng SH, 2005, J BIOL CHEM, V280, P8513, DOI 10.1074/jbc.M413880200; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhao Y, 2004, NEURON, V41, P859, DOI 10.1016/S0896-6273(04)00116-3	35	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30455	30462		10.1074/jbc.M604615200	http://dx.doi.org/10.1074/jbc.M604615200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912051	hybrid			2022-12-25	WOS:000241075900020
J	Low, C; Macara, IG				Low, Claudia; Macara, Ian G.			Structural analysis of septin 2, 6, and 7 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SEPTIN; PROTEIN INTERACTIONS; YEAST SEPTINS; COILED COILS; ORGANIZATION; FILAMENTS; BINDING; CYTOKINESIS; MUTANT; ROLES	Mammalian septins comprise a family of 13 genes that encode GTP-binding proteins. Specific combinations of septins can hetero-oligomerize and form filaments in vivo and in vitro, by mechanisms that are not understood. Using fluorescence resonance energy transfer, size exclusion chromatography, and multi-angle light scattering techniques, we have characterized the conformation of a complex of filamentous human septins, Sept2, Sept6, and Sept7. We now show that Sept6 and Sept7 interact through a parallel coiled-coil, and that Sept2 interacts with Sept6 through their C-terminal domains. We have also been able to produce soluble, stable individual septins that behave as rod-like monomers and dimers. Taken together, these observations suggest that polymerized filaments could be comprised of laterally arranged septin core subunits.	Univ Virginia, HSC, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Low, C (corresponding author), Univ Virginia, HSC, Sch Med, Ctr Cell Signaling, Box 800577, Charlottesville, VA 22908 USA.	ccl3j@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066306] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM66306] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An HB, 2004, MOL BIOL CELL, V15, P5551, DOI 10.1091/mbc.E04-07-0640; Beites CL, 2005, BIOCHEM J, V385, P347, DOI 10.1042/BJ20041090; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; BYERS B, 1976, J CELL BIOL, V69, P717, DOI 10.1083/jcb.69.3.717; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P549; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Hanai N, 2004, FEBS LETT, V568, P83, DOI 10.1016/j.febslet.2004.05.030; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; Ihara M, 2005, DEV CELL, V8, P343, DOI 10.1016/j.devcel.2004.12.005; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Kinoshita M, 2001, CELL STRUCT FUNCT, V26, P667, DOI 10.1247/csf.26.667; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kremer BE, 2005, MOL BIOL CELL, V16, P4648, DOI 10.1091/mbc.E05-03-0267; Longtine MS, 2003, TRENDS CELL BIOL, V13, P403, DOI 10.1016/S0962-8924(03)00151-X; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438; Martinez C, 2004, BIOCHEM J, V382, P783, DOI 10.1042/BJ20040372; Mendoza M, 2002, CURR BIOL, V12, P1858, DOI 10.1016/S0960-9822(02)01258-7; Nagata K, 2004, J BIOL CHEM, V279, P55895, DOI 10.1074/jbc.M406153200; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Qi MY, 2005, BIOCHEM BIOPH RES CO, V336, P994, DOI 10.1016/j.bbrc.2005.06.212; Sheffield PJ, 2003, J BIOL CHEM, V278, P3483, DOI 10.1074/jbc.M209701200; Spiliotis ET, 2006, J CELL SCI, V119, P4, DOI 10.1242/jcs.02746; Spiliotis ET, 2005, SCIENCE, V307, P1781, DOI 10.1126/science.1106823; Stewart M, 1998, J MOL BIOL, V284, P1517, DOI 10.1006/jmbi.1998.2204; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Tsien RY, 2005, FEBS LETT, V579, P927, DOI 10.1016/j.febslet.2004.11.025; Versele M, 2005, TRENDS CELL BIOL, V15, P414, DOI 10.1016/j.tcb.2005.06.007; Versele M, 2004, MOL BIOL CELL, V15, P4568, DOI 10.1091/mbc.E04-04-0330; WITTINGHOFER F, 1991, ENVIRON HEALTH PERSP, V93, P11, DOI 10.2307/3431161; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	33	50	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30697	30706		10.1074/jbc.M605179200	http://dx.doi.org/10.1074/jbc.M605179200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16914550	hybrid			2022-12-25	WOS:000241075900046
J	Meyn, MA; Wilson, MB; Abdi, FA; Fahey, N; Schiavone, AP; Wu, J; Hochrein, JM; Engen, JR; Smithgall, TE				Meyn, Malcolm A., III; Wilson, Matthew B.; Abdi, Fadi A.; Fahey, Nathalie; Schiavone, Anthony P.; Wu, Jiong; Hochrein, James M.; Engen, John R.; Smithgall, Thomas E.			Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; NEF PROMOTES SURVIVAL; DNA-BINDING ACTIVITY; C-ABL; TYROSINE KINASE; ADAPTER PROTEIN; MYELOID CELLS; SH3 DOMAIN; ACTIVATION; RESISTANCE	Bcr-Abl is the oncogenic protein-tyrosine kinase responsible for chronic myelogenous leukemia. Recently, we observed that inhibition of myeloid Src family kinase activity ( e. g. Hck, Lyn, and Fyn) induces growth arrest and apoptosis in Bcr-Abl-transformed cells, suggesting that cell transformation by Bcr-Abl involves Src family kinases ( Wilson, M. B., Schreiner, S. J., Choi, H. J., Kamens, J., and Smithgall, T. E. ( 2002) Oncogene 21, 8075 8088). Here, we report the unexpected observation that Hck, Lyn, and Fyn strongly phosphorylate the SH3-SH2 region of Bcr- Abl. Seven phosphorylation sites were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry: Tyr(89) and Tyr(134) in the Abl-derived SH3 domain; Tyr(147) in the SH3-SH2 connector; and Tyr(158), Tyr(191), Tyr(204), and Tyr(234) in the SH2 domain. SH3 domain Tyr(89), the most prominent phosphorylation site in vitro, was strongly phosphorylated in chronic myelogenous leukemia cells in a Src family kinase- dependent manner. Substitution of the SH3-SH2 tyrosine phosphorylation sites with phenylalanine substantially reduced Bcr-Abl-mediated transformation of TF-1 myeloid cells to cytokine independence. The positions of these tyrosines in the crystal structure of the c-Abl core and the transformation defect of the corresponding Bcr-Abl mutants together suggest that phosphorylation of the SH3-SH2 region by Src family kinases impacts Bcr- Abl protein conformation and signaling.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Cell Signaling Technol, Beverly, MA 01915 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of New Mexico	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu		Engen, John R./0000-0002-6918-9476	NATIONAL CANCER INSTITUTE [R01CA101828] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070590] Funding Source: NIH RePORTER; NCI NIH HHS [CA101828] Funding Source: Medline; NCRR NIH HHS [RR016480] Funding Source: Medline; NIGMS NIH HHS [R01 GM070590, GM70590] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Briggs SD, 2001, J BIOL CHEM, V276, P25605, DOI 10.1074/jbc.M103244200; Calderwood DJ, 2002, BIOORG MED CHEM LETT, V12, P1683, DOI 10.1016/S0960-894X(02)00195-6; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Choi HJ, 2004, J BIOL CHEM, V279, P51688, DOI 10.1074/jbc.M410068200; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Dorey K, 2001, ONCOGENE, V20, P8075, DOI 10.1038/sj.onc.1205017; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Lionberger JM, 2000, CANCER RES, V60, P1097; Meyn MA, 2005, MOL PHARMACOL, V68, P1320, DOI 10.1124/mol.104.010231; Nagar B, 2002, CANCER RES, V62, P4236; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Smith KM, 2003, MOL CELL, V12, P27, DOI 10.1016/S1097-2765(03)00274-0; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; Van Etten RA, 2002, ONCOGENE, V21, P8643, DOI 10.1038/sj.onc.1206091; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834	43	96	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30907	30916		10.1074/jbc.M605902200	http://dx.doi.org/10.1074/jbc.M605902200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912036	hybrid			2022-12-25	WOS:000241075900066
J	Ruf, F; Park, MJ; Hayot, F; Lin, G; Roysam, B; Ge, YC; Sealfon, SC				Ruf, Frederique; Park, Myung-June; Hayot, Fernand; Lin, Gang; Roysam, Badrinath; Ge, Yongchao; Sealfon, Stuart C.			Mixed analog/digital gonadotrope biosynthetic response to gonadotropin-releasing hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT GENE-TRANSCRIPTION; STEROIDOGENIC FACTOR-I; BETA-GENE; GNRH RECEPTOR; DIFFERENTIAL REGULATION; STOCHASTIC SIMULATION; SITU HYBRIDIZATION; SWITCH; SECRETION; PROTEIN-1	Mammalian reproduction requires gonadotropin-releasing hormone (GnRH)-mediated signaling from brain neurons to pituitary gonadotropes. Because the pulses of released GnRH vary greatly in amplitude, we studied the biosynthetic response of the gonadotrope to varying GnRH concentrations, focusing on extracellular-regulated kinase (ERK) phosphorylation and egr1 mRNA and protein production. The overall average level of ERK activation in populations of cells increased non-cooperatively with increasing GnRH and did not show evidence of either ultrasensitivity or bistability. However, automated image analysis of single-cell responses showed that whereas individual gonadotropes exhibited two response states, inactive and active, both the probability of activation and the average response in activated cells increased with increasing GnRH concentration. These data indicate a hybrid single-cell response having both digital (switch-like) and analog ( graded) features. Mathematical modeling suggests that the hybrid response can be explained by indirect thresholding of ERK activation resulting from the distributed structure of the GnRH-modulated network. The hybrid response mechanism improves the reliability of noisy reproductive signal transmission from the brain to the pituitary.	CUNY Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Ctr Translat Syst Biol, New York, NY 10029 USA; Rensselaer Polytech Inst, Dept Elect Comp & Syst Engn, Troy, NY 12180 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rensselaer Polytechnic Institute	Sealfon, SC (corresponding author), Neurol Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	stuart.sealfon@mssm.edu	Zamojski, Frederique M Ruf/N-5718-2015; Park, Myung-June/D-6465-2013; Ge, Yongchao/AAG-9317-2021	Zamojski, Frederique M Ruf/0000-0002-2451-8598; Park, Myung-June/0000-0001-8779-9326; Ge, Yongchao/0000-0001-6448-5703; SEALFON, Stuart/0000-0001-5791-1217	NIDDK NIH HHS [DK46943] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046943, R56DK046943] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Broccardo CJ, 2004, TOXICOL SCI, V78, P287, DOI 10.1093/toxsci/kfh077; Burger LL, 2004, J MOL ENDOCRINOL, V33, P559, DOI 10.1677/jme.1.01600; Burger LL, 2002, ENDOCRINOLOGY, V143, P3243, DOI 10.1210/en.2002-220216; Caunt CJ, 2006, J BIOL CHEM, V281, P2701, DOI 10.1074/jbc.M507242200; Chan P, 2005, J COMP NEUROL, V482, P50, DOI 10.1002/cne.20377; Chan PM, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni162; Chawla MK, 2004, J NEUROSCI METH, V139, P13, DOI 10.1016/j.jneumeth.2004.04.017; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke IJ, 2002, REPRODUCTION, P1; CLARKE IJ, 1995, J ENDOCRINOL, V145, P271, DOI 10.1677/joe.0.1450271; CLARKE IJ, 1982, ENDOCRINOLOGY, V111, P1737, DOI 10.1210/endo-111-5-1737; Clarke LJ, 2005, ANIM REPROD SCI, V88, P29, DOI 10.1016/j.anireprosci.2005.05.003; Cornish-Bowden A, 2001, EUR J BIOCHEM, V268, P6616, DOI 10.1046/j.0014-2956.2001.02616.x; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; Duan WR, 2002, MOL ENDOCRINOL, V16, P221, DOI 10.1210/me.16.2.221; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; FINK MY, 2003, AM SOC CELL BIOL ANN; French CT, 2004, TOXICOL SCI, V78, P276, DOI 10.1093/toxsci/kfh105; GARCIANAVARRO S, 1991, ENDOCRINOLOGY, V129, P2780, DOI 10.1210/endo-129-5-2780; Gillespie DT, 2001, J CHEM PHYS, V115, P1716, DOI 10.1063/1.1378322; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; Gunawardena J, 2005, P NATL ACAD SCI USA, V102, P14617, DOI 10.1073/pnas.0507322102; Haisenleder Daniel J., 1994, P1793; HAISENLEDER DJ, 1991, ENDOCRINOLOGY, V128, P509, DOI 10.1210/endo-128-1-509; Halvorson LM, 1999, MOL ENDOCRINOL, V13, P106, DOI 10.1210/me.13.1.106; Harding A, 2005, CURR BIOL, V15, P869, DOI 10.1016/j.cub.2005.04.020; Kaiser UB, 2000, MOL ENDOCRINOL, V14, P1235, DOI 10.1210/me.14.8.1235; Krakauer DC, 2002, J THEOR BIOL, V218, P457, DOI 10.1006/jtbi.2002.3092; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Lin G, 2005, CYTOM PART A, V66A, P9, DOI 10.1002/cyto.a.20149; Lin G, 2003, CYTOM PART A, V56A, P23, DOI 10.1002/cyto.a.10079; LIN G, 2004, CYTOMETRY, V63, P20; MacKeigan JP, 2005, MOL CELL BIOL, V25, P4676, DOI 10.1128/MCB.25.11.4676-4682.2005; MADDEN HH, 1978, ANAL CHEM, V50, P1383, DOI 10.1021/ac50031a048; Markevich NI, 2004, J CELL BIOL, V164, P353, DOI 10.1083/jcb.200308060; Moenter SM, 2003, FRONT NEUROENDOCRIN, V24, P79, DOI 10.1016/S0091-3022(03)00013-X; MOENTER SM, 1991, ENDOCRINOLOGY, V129, P1175, DOI 10.1210/endo-129-3-1175; Nair VD, 2004, J BIOL CHEM, V279, P27494, DOI 10.1074/jbc.M312135200; Navratil AM, 2003, J BIOL CHEM, V278, P31593, DOI 10.1074/jbc.M304273200; Ortega F, 2002, P NATL ACAD SCI USA, V99, P1170, DOI 10.1073/pnas.022267399; Ozbudak EM, 2004, NATURE, V427, P737, DOI 10.1038/nature02298; Padmanabhan V, 1997, ENDOCRINOLOGY, V138, P424, DOI 10.1210/en.138.1.424; Pawson AJ, 2005, ANIM REPROD SCI, V88, P75, DOI 10.1016/j.anireprosci.2005.05.010; Ruf F, 2004, TRENDS ENDOCRIN MET, V15, P331, DOI 10.1016/j.tem.2004.07.008; Ruf F, 2003, FRONT NEUROENDOCRIN, V24, P181, DOI 10.1016/S0091-3022(03)00027-X; Samoilov M, 2005, P NATL ACAD SCI USA, V102, P2310, DOI 10.1073/pnas.0406841102; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; Sha W, 2003, P NATL ACAD SCI USA, V100, P975, DOI 10.1073/pnas.0235349100; Skinner DC, 1997, ENDOCRINOLOGY, V138, P4699, DOI 10.1210/en.138.11.4699; Tanaka Tomomi, 1997, Journal of Reproduction and Development, V43, P101, DOI 10.1262/jrd.43.101; Topilko P, 1997, J NEUROSCI RES, V50, P702, DOI 10.1002/(SICI)1097-4547(19971201)50:5<702::AID-JNR7>3.0.CO;2-L; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; Whitehurst A, 2004, MOL CELL BIOL, V24, P10145, DOI 10.1128/MCB.24.23.10145-10150.2004; Wolfe MW, 1999, MOL ENDOCRINOL, V13, P752, DOI 10.1210/me.13.5.752; Wurmbach E, 2001, J BIOL CHEM, V276, P47195, DOI 10.1074/jbc.M108716200; Yuen T, 2002, MOL ENDOCRINOL, V16, P1145, DOI 10.1210/me.16.6.1145	57	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30967	30978		10.1074/jbc.M606486200	http://dx.doi.org/10.1074/jbc.M606486200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16916798	hybrid			2022-12-25	WOS:000241075900073
J	Rybakin, V; Gounko, NV; Spate, K; Honing, S; Majoul, IV; Duden, R; Noegel, AA				Rybakin, Vasily; Gounko, Natalia V.; Spaete, Kira; Hoening, Stefan; Majoul, Irina V.; Duden, Rainer; Noegel, Angelika A.			Crn7 interacts with AP-1 and is required for the maintenance of Golgi morphology and protein export from the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONIN-LIKE PROTEIN; KINASE-D; CRYSTAL-STRUCTURE; PLASMA-MEMBRANE; CHOLERA-TOXIN; TRANSPORT; ACTIN; RECOGNITION; POD-1; CYTOSKELETON	Crn7 is a novel cytosolic mammalian WD-repeat protein of unknown function that associates with Golgi membranes. Here, we demonstrate that Crn7 knockdown by small interfering-RNA results in dramatic changes in the Golgi morphology and function. First, the Golgi ribbon is disorganized in Crn7 KD cells. Second, the Golgi export of several marker proteins including VSV envelope G glycoprotein is greatly reduced but not the retrograde protein import into the Golgi complex. We further establish that Crn7 co-precipitates with clathrin adaptor AP-1 but is not required for AP-1 targeting to Golgi membranes. We identify tyrosine 288-based motif as part of a canonical YXX Phi sorting signal and a major mu 1-adaptin binding site in vitro. This study provides the first insight into the function of mammalian Crn7 protein in the Golgi complex.	Univ Cologne, Fac Med, Inst Biochem 1, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Univ Groningen, Med Ctr, Dept Cell Biol, Electron Microscopy Lab, NL-9713 AV Groningen, Netherlands; Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England	University of Cologne; University of Cologne; University of Groningen; University of London; Royal Holloway University London	Rybakin, V (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr,MC0634, La Jolla, CA 92093 USA.	vrybakin@ucsd.edu	Majoul, Irina V/K-5339-2013; Gounko, Natalia/N-4102-2019; Gounko, Natalia V/J-9085-2015; Duden, Rainer/C-8917-2011; Rybakin, Vasily/J-6310-2019	Gounko, Natalia/0000-0003-0791-9477; Rybakin, Vasily/0000-0002-5093-1757				Appleton BA, 2006, STRUCTURE, V14, P87, DOI 10.1016/j.str.2005.09.013; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Boll W, 2002, TRAFFIC, V3, P590, DOI 10.1034/j.1600-0854.2002.30808.x; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Cai L, 2005, J BIOL CHEM, V280, P31913, DOI 10.1074/jbc.M504146200; de Hostos EL, 1999, TRENDS CELL BIOL, V9, P345, DOI 10.1016/S0962-8924(99)01620-7; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; Grass I, 2004, J BIOL CHEM, V279, P54872, DOI 10.1074/jbc.M409995200; Hasse A, 2005, EUR J NEUROSCI, V21, P1155, DOI 10.1111/j.1460-9568.2005.03917.x; Heldwein EE, 2004, P NATL ACAD SCI USA, V101, P14108, DOI 10.1073/pnas.0406102101; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Honing S, 2005, MOL CELL, V18, P519, DOI 10.1016/j.molcel.2005.04.019; Lauvrak SU, 2004, J CELL SCI, V117, P2321, DOI 10.1242/jcs.01081; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; Nakamura T, 1999, J BIOL CHEM, V274, P13322, DOI 10.1074/jbc.274.19.13322; Nal B, 2004, INT IMMUNOL, V16, P231, DOI 10.1093/intimm/dxh022; Neubrand VE, 2005, EMBO J, V24, P1122, DOI 10.1038/sj.emboj.7600600; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Polishchuk EV, 2003, MOL BIOL CELL, V14, P4470, DOI 10.1091/mbc.E03-01-0033; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rappleye CA, 1999, GENE DEV, V13, P2838, DOI 10.1101/gad.13.21.2838; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Rothenberg ME, 2003, NEURON, V39, P779, DOI 10.1016/S0896-6273(03)00508-7; Rybakin V, 2005, BIOESSAYS, V27, P625, DOI 10.1002/bies.20235; Rybakin V, 2004, FEBS LETT, V573, P161, DOI 10.1016/j.febslet.2004.07.066; Shestakova A, 2006, TRAFFIC, V7, P191, DOI 10.1111/j.1600-0854.2005.00376.x; Spoerl Z, 2002, J BIOL CHEM, V277, P48858, DOI 10.1074/jbc.M205136200; Tikkanen R, 2000, TRAFFIC, V1, P631, DOI 10.1034/j.1600-0854.2000.010807.x; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090	32	27	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31070	31078		10.1074/jbc.M604680200	http://dx.doi.org/10.1074/jbc.M604680200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16905771	Green Published, hybrid			2022-12-25	WOS:000241075900083
J	Yeong, SS; Zhu, Y; Smith, D; Verma, C; Lim, WG; Tan, BJ; Li, QT; Cheung, NS; Cai, M; Zhu, YZ; Zhou, SF; Tan, SL; Duan, W				Yeong, Sui Sum; Zhu, Yimin; Smith, Derek; Verma, Chandra; Lim, Wee Guan; Tan, Bee Jen; Li, Qiu Tian; Cheung, Nam Sang; Cai, Minnie; Zhu, Yi-Zhun; Zhou, Shu-Feng; Tan, Seng-Lai; Duan, Wei			The last 10 amino acid residues beyond the hydrophobic motif are critical for the catalytic competence and function of protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PHOSPHOLIPASE D1; N1E-115 CELLS; PKC-ALPHA; IN-VIVO; PHOSPHORYLATION; ACTIVATION; EPSILON; MELATONIN; DYNAMICS	The segment C-terminal to the hydrophobic motif at the V5 domain of protein kinase C (PKC) is the least conserved both in length and in amino acid identity among all PKC isozymes. By generating serial truncation mutants followed by biochemical and functional analyses, we show here that the very C terminus of PKC alpha is critical in conferring the full catalytic competence to the kinase and for transducing signals in cells. Deletion of one C-terminal amino acid residue caused the loss of similar to 60% of the catalytic activity of the mutant PKC alpha, whereas deletion of 10 C-terminal amino acid residues abrogated the catalytic activity of PKC alpha in immune complex kinase assays. The PKC alpha C-terminal truncation mutants were found to lose their ability to activate mitogen-activated protein kinase, to rescue apoptosis induced by the inhibition of endogenous PKC in COS cells, and to augment melatonin-stimulated neurite outgrowth. Furthermore, molecular dynamics simulations revealed that the deletion of 1 or 10 C-terminal residues results in the deformation of the V5 domain and the ATP-binding pocket, respectively. Finally, PKC alpha immunoprecipitated using an antibody against its C terminus had only marginal catalytic activity compared with that of the PKC alpha immunoprecipitated by an antibody against its N terminus. Therefore, the very C-terminal tail of PKC alpha is a novel determinant of the catalytic activity of PKC and a promising target for selective modulation of PKC alpha function. Molecules that bind preferentially to the very C terminus of distinct PKC isozymes and suppress their catalytic activity may constitute a new class of selective inhibitors of PKC.	Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore 117597, Singapore; Bioinformat Inst, Singapore 138671, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore 117546, Singapore; Temasek Life Sci Lab, Singapore 117604, Singapore; Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai 200032, Peoples R China; Natl Univ Singapore, Fac Sci, Dept Pharm, Singapore 117543, Singapore; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; Deakin Univ, Inst Biotechnol, Geelong, Vic 3216, Australia	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); National University of Singapore; Fudan University; National University of Singapore; Eli Lilly; Deakin University	Duan, W (corresponding author), Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, 8 Med Dr, Singapore 117597, Singapore.	wduan@deakin.edu.au	Zhu, Yi Zhun/ABG-8449-2021; Zhou, Shu-Feng/E-3166-2013; Tan, Seng-Lai/AAQ-2585-2021; Duan, Wei/A-5181-2015	Zhu, Yi Zhun/0000-0001-7700-8041; Zhou, Shu-Feng/0000-0002-5542-6119; Duan, Wei/0000-0001-5782-9184				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Babwah AV, 2003, J BIOL CHEM, V278, P5419, DOI 10.1074/jbc.M211053200; Benitez-King G, 2001, NEUROCHEM INT, V39, P95; Benitez-King G, 2000, J PINEAL RES, V29, P8, DOI 10.1034/j.1600-079X.2000.290102.x; BENITEZKING G, 1990, J PINEAL RES, V9, P209, DOI 10.1111/j.1600-079X.1990.tb00709.x; Bordt SL, 2001, BBA-MOL CELL RES, V1499, P257, DOI 10.1016/S0167-4889(00)00127-0; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; Breitenlechner C, 2004, BIOCHEMISTRY-US, V43, P7743, DOI 10.1021/bi0362525; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chong YP, 2004, J BIOL CHEM, V279, P20752, DOI 10.1074/jbc.M309865200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Duan W, 2000, GENE, V256, P113, DOI 10.1016/S0378-1119(00)00365-6; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Eckart MR, 1996, CURR OPIN BIOTECH, V7, P525, DOI 10.1016/S0958-1669(96)80056-5; ELDAR H, 1992, EXP CELL RES, V202, P259, DOI 10.1016/0014-4827(92)90073-H; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Gokmen-Polar Y, 1998, J BIOL CHEM, V273, P20261, DOI 10.1074/jbc.273.32.20261; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Hu TH, 2005, BIOCHEM BIOPH RES CO, V333, P750, DOI 10.1016/j.bbrc.2005.05.184; Hu TH, 2003, J BIOL CHEM, V278, P2348, DOI 10.1074/jbc.M210093200; Jeon ES, 2005, CELL SIGNAL, V17, P777, DOI 10.1016/j.cellsig.2004.11.004; Johnson LN, 2001, E SCHERING RES FDN W, V34, P47; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kim J, 2004, EXP MOL MED, V36, P103, DOI 10.1038/emm.2004.15; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Kornitzer D, 2002, METHOD ENZYMOL, V351, P639; Kuklin V, 2005, CRIT CARE, V9, pR211, DOI 10.1186/cc3497; Leitges M, 2004, NEURON, V44, P585, DOI 10.1016/j.neuron.2004.10.024; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; Lim WG, 2005, CELL SIGNAL, V17, P1084, DOI 10.1016/j.cellsig.2004.12.003; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Meller J, 2001, PROTEINS, V45, P241, DOI 10.1002/prot.1145; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Messerschmidt A, 2005, J MOL BIOL, V352, P918, DOI 10.1016/j.jmb.2005.07.060; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1994, J BIOL CHEM, V269, P8383; Papa FR, 2003, SCIENCE, V302, P1533, DOI 10.1126/science.1090031; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SOUVIGNET C, 1990, CELL SIGNAL, V2, P171, DOI 10.1016/0898-6568(90)90020-B; Sowadski JM, 1999, PHARMACOL THERAPEUT, V82, P157, DOI 10.1016/S0163-7258(98)00054-0; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; SU LH, 1993, RECEPTOR CHANNEL, V1, P1; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; Taylor SS, 1999, PHARMACOL THERAPEUT, V82, P133, DOI 10.1016/S0163-7258(99)00007-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toker A, 2005, EMBO REP, V6, P310, DOI 10.1038/sj.embor.7400378; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; Wang QMJ, 2004, MOL CANCER RES, V2, P129; Wang WL, 2003, J BIOL CHEM, V278, P37705, DOI 10.1074/jbc.M304619200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yu VPCC, 2005, MOL CELL, V17, P145, DOI 10.1016/j.molcel.2004.11.020	71	18	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30768	30781		10.1074/jbc.M511278200	http://dx.doi.org/10.1074/jbc.M511278200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16895917	hybrid			2022-12-25	WOS:000241075900053
J	Zhu, YM; Marchal, CC; Casbon, AJ; Stull, N; von Lohneysen, K; Knaus, UG; Jesaitis, AJ; McCormick, S; Nauseef, WM; Dinauer, MC				Zhu, Yanmin; Marchal, Christophe C.; Casbon, Amy-Jo; Stull, Natalie; von Lohneysen, Katharina; Knaus, Ulla G.; Jesaitis, Algirdas J.; McCormick, Sally; Nauseef, William M.; Dinauer, Mary C.			Deletion mutagenesis of p22(phox) subunit of flavocytochrome b(558) - Identification of regions critical for gp91(phox) maturation and nadph oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SRC HOMOLOGY-3 DOMAINS; CYTOCHROME-B; NEUTROPHIL CYTOCHROME-B558; CYTOPLASMIC DOMAIN; PLASMA-MEMBRANE; BINDING-SITE; ACTIVATION; SUPEROXIDE; HEME	The heterodimeric flavocytochrome b(558), comprised of the two integral membrane proteins p22(phox) and gp91(phox), mediates the transfer of electrons from NADPH to molecular oxygen in the phagocyte NADPH oxidase to generate the superoxide precursor of microbicidal oxidants. This study uses deletion mutagenesis to identify regions of p22(phox) required for maturation of gp91(phox) and for NADPH oxidase activity. N-terminal, C-terminal, or internal deletions of human p22(phox) were generated and expressed in Chinese hamster ovary cells with transgenes for gp91(phox) and two other NADPH oxidase subunits, p47(phox), and p67(phox). The results demonstrate that p22(phox)-dependent maturation of gp91(phox) carbohydrate, cell surface expression of gp91(phox), and the enzymatic function of flavocytochrome b(558) are closely correlated. Whereas the 5 N-terminal and 25 C-terminal amino acids are dispensable for these functions, the N-terminal 11 amino acids of p22(phox) are required, as is a hydrophilic region between amino acids 65 and 90. Upon deletion of 54 residues at the C terminus of p22(phox) (amino acids 142-195), maturation and cell surface expression of gp91(phox) was still preserved, although NADPH oxidase activity was absent, as expected, due to removal of a proline-rich domain between amino acids 151-160 that is required for recruitment of p47(phox). Antibody binding studies indicate that the extreme N terminus of p22(phox) is inaccessible in the absence of cell permeabilization, supporting a model in which both the N- and C-terminal domains of p22(phox) extend into the cytoplasm, anchored by two membrane-embedded regions.	James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Dept Pediat Hematol Oncol, Indianapolis, IN 46202 USA; James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Dept Microbiol Immunol, Indianapolis, IN 46202 USA; James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; USDA ARS, Tree Fruit Res Lab, Wenatchee, WA 98801 USA; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Iowa, Inflammat Program, Iowa City, IA 52241 USA; Univ Iowa, Dept Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52241 USA	James Whitcomb Riley Hospital Children; James Whitcomb Riley Hospital Children; James Whitcomb Riley Hospital Children; United States Department of Agriculture (USDA); Montana State University System; Montana State University Bozeman; Scripps Research Institute; University of Iowa; University of Iowa	Dinauer, MC (corresponding author), Indiana Univ, Sch Med, Canc Res Inst, 1044 W Walnut St,R4 402C, Indianapolis, IN 46202 USA.	mdinauer@iupui.edu		Jesaitis, Algirdas/0000-0001-9001-5617; Nauseef, William/0000-0003-4032-757X	NCI NIH HHS [P30 CA082709] Funding Source: Medline; NHLBI NIH HHS [HL 53592, R01 HL45635] Funding Source: Medline; NIAID NIH HHS [R01 AI34879, R01 AI26711, R01 AI24838] Funding Source: Medline; NIDDK NIH HHS [T32-DK007519] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA082709] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053592, R01HL045635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838, R01AI026711, R01AI034879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)		Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Biberstine-Kinkade KJ, 2002, J BIOL CHEM, V277, P30368, DOI 10.1074/jbc.M203993200; Biberstine-Kinkade KJ, 2001, J BIOL CHEM, V276, P31105, DOI 10.1074/jbc.M103327200; Burritt JB, 2001, J BIOL CHEM, V276, P2053, DOI 10.1074/jbc.M006236200; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; Cross AR, 2000, BLOOD CELL MOL DIS, V26, P561, DOI 10.1006/bcmd.2000.0333; Dahan I, 2002, J BIOL CHEM, V277, P8421, DOI 10.1074/jbc.M109778200; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Davis AR, 1998, J LEUKOCYTE BIOL, V64, P114, DOI 10.1002/jlb.64.1.114; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; Dinauer M., 2003, NATHAN OSHIS HEMATOL, P923; DINAUER MC, 1991, P NATL ACAD SCI USA, V88, P11231, DOI 10.1073/pnas.88.24.11231; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; HURST JK, 1991, J BIOL CHEM, V266, P1627; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; Inoue Y, 2000, VET IMMUNOL IMMUNOP, V76, P137, DOI 10.1016/S0165-2427(00)00207-5; Kawahara T, 2005, J BIOL CHEM, V280, P31859, DOI 10.1074/jbc.M501882200; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Nobuhisa I, 2006, BIOCHEM J, V396, P183, DOI 10.1042/BJ20051899; Ogura K, 2006, J BIOL CHEM, V281, P3660, DOI 10.1074/jbc.M505193200; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, BIOCHIM BIOPHYS ACTA, V932, P71, DOI 10.1016/0005-2728(88)90140-5; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; Taylor RM, 2004, J IMMUNOL, V173, P7349, DOI 10.4049/jimmunol.173.12.7349; Ueno N, 2005, J BIOL CHEM, V280, P23328, DOI 10.1074/jbc.M414548200; Ueyama T, 2006, MOL CELL BIOL, V26, P2160, DOI 10.1128/MCB.26.6.2160-2174.2006; Yamauchi A, 2001, MICROBIOL IMMUNOL, V45, P249, DOI 10.1111/j.1348-0421.2001.tb02614.x; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	45	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30336	30346		10.1074/jbc.M607191200	http://dx.doi.org/10.1074/jbc.M607191200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16895900	hybrid			2022-12-25	WOS:000241075900007
J	Mundhenk, L; Alfalah, M; Elble, RC; Pauli, BU; Naim, HY; Gruber, AD				Mundhenk, Lars; Alfalah, Marwan; Elble, Randolph C.; Pauli, Bendicht U.; Naim, Hassan Y.; Gruber, Achim D.			Both cleavage products of the mCLCA3 protein are secreted soluble proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CHLORIDE CHANNEL; LACTASE-PHLORHIZIN HYDROLASE; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; MEMBRANE-PROTEINS; SIGNAL PEPTIDES; FAMILY-MEMBERS; EXPRESSION; PREDICTION; GENE	Members of the chloride channels, calcium-activated ( CLCA) family of proteins and in particular the murine mCLCA3 ( alias gob-5) and its human ortholog hCLCA1 have been identified as clinically relevant molecules in diseases with secretory dysfunctions including asthma and cystic fibrosis. Initial studies have indicated that these proteins evoke a calcium-activated chloride conductance when transfected into human embryonic kidney cells 293 cells. However, it is not yet clear whether the CLCA proteins form chloride channels per se or function as mediators of other, yet unknown chloride channels. Here, we present a systematic biochemical analysis of the posttranslational processing and intracellular trafficking of the mCLCA3 protein. Pulse-chase experiments after metabolic protein labeling of mCLCA3-transfected COS-1 or human embryonic kidney 293 cells revealed cleavage of a primary 110-kDa mCLCA3 translation product in the endoplasmic reticulum into a 75-kDa amino-terminal and a 35-kDa carboxyl-terminal protein that were glycosylated and remained physically associated with each other. Confocal fluorescent analyses identified both cleavage products in vesicles of the secretory pathway. Neither cleavage product was associated with the cell membrane at any time. Instead, both subunits were fully secreted into the extracellular environment as a soluble complex of two glycoproteins. These results suggest that the two mCLCA3 cleavage products cannot form an anion channel on their own but may instead act as extracellular signaling molecules. Furthermore, our results point toward significant structural differences between mCLCA3 and its human ortholog, hCLCA1, which is thought to be a single, non-integral membrane protein.	Free Univ Berlin, Dept Vet Pathol, D-14163 Berlin, Germany; Univ Vet Med Hannover, Dept Physiol Chem, D-30559 Hannover, Germany; So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62702 USA; So Illinois Univ, Sch Med, Simmons Cooper Canc Inst, Springfield, IL 62702 USA; Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Program, Ithaca, NY 14853 USA	Free University of Berlin; University of Veterinary Medicine Hannover, Foundation; Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Cornell University	Gruber, AD (corresponding author), Free Univ Berlin, Dept Vet Pathol, Robert Ostertag Str 15, D-14163 Berlin, Germany.	gruber.achim@vetmed.fu-berlin.de	Al Falah, Dr. Marwan/C-6281-2011; Gruber, Achim D./ABA-4514-2021					Abdel-Ghany M, 2003, J BIOL CHEM, V278, P49406, DOI 10.1074/jbc.M309086200; Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; Anton F, 2005, J HISTOCHEM CYTOCHEM, V53, P1011, DOI 10.1369/jhc.4A6599.2005; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Brouillard F, 2005, MOL CELL PROTEOMICS, V4, P1762, DOI 10.1074/mcp.M500098-MCP200; CHINERY R, 1995, BRIT J PHARMACOL, V115, P77, DOI 10.1111/j.1476-5381.1995.tb16322.x; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; Davies JR, 2002, NOVART FDN SYMP, V248, P76; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; Elble RC, 2002, J BIOL CHEM, V277, P18586, DOI 10.1074/jbc.M200829200; Evans SR, 2004, J BIOL CHEM, V279, P41792, DOI 10.1074/jbc.M408354200; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Gaspar KJ, 2000, PHYSIOL GENOMICS, V3, P101, DOI 10.1152/physiolgenomics.2000.3.2.101; Gibson A, 2005, J BIOL CHEM, V280, P27205, DOI 10.1074/jbc.M504654200; Greenwood IA, 2002, J BIOL CHEM, V277, P22119, DOI 10.1074/jbc.C200215200; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 2002, CURR TOP MEMBR, V53, P367; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Gruber AD, 1999, BBA-GENE STRUCT EXPR, V1444, P418, DOI 10.1016/S0167-4781(99)00008-1; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hoffmann W, 2001, HISTOL HISTOPATHOL, V16, P319, DOI 10.14670/HH-16.319; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hoshino M, 2002, AM J RESP CRIT CARE, V165, P1132, DOI 10.1164/ajrccm.165.8.2107068; JACOB R, 2000, J BIOL CHEM, V275, P10650; Jeong SM, 2005, BIOCHEM BIOPH RES CO, V334, P569, DOI 10.1016/j.bbrc.2005.06.122; Komiya T, 1999, BIOCHEM BIOPH RES CO, V255, P347, DOI 10.1006/bbrc.1999.0168; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee D, 1999, BIOCHEM BIOPH RES CO, V264, P933, DOI 10.1006/bbrc.1999.1583; Leverkoehne I, 2002, J HISTOCHEM CYTOCHEM, V50, P829, DOI 10.1177/002215540205000609; Leverkoehne I, 2000, CYTOGENET CELL GENET, V88, P208, DOI 10.1159/000015550; Leverkoehne I, 2006, HISTOCHEM CELL BIOL, V126, P239, DOI 10.1007/s00418-006-0164-7; Loewen ME, 2005, PHYSIOL REV, V85, P1061, DOI 10.1152/physrev.00016.2004; Loewen ME, 2002, BIOCHEM BIOPH RES CO, V298, P531, DOI 10.1016/S0006-291X(02)02498-1; Loewen ME, 2003, AM J PHYSIOL-CELL PH, V285, pC1314, DOI 10.1152/ajpcell.00210.2003; LOEWEN ME, 2004, AM J PHYSIOL-GASTR L, V287, P33; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NIELSEN H, 1998, P 6 INT C INT SYST M, P122; Pawlowski K, 2006, PROTEINS, V63, P424, DOI 10.1002/prot.20887; RAN S, 1992, J BIOL CHEM, V267, P20630; RITZKA M, 2003, GENOME LETT, V2, P149; Rogers DF, 2003, INT J BIOCHEM CELL B, V35, P1, DOI 10.1016/S1357-2725(02)00083-3; Romio L, 1999, GENE, V228, P181, DOI 10.1016/S0378-1119(98)00620-9; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Winpenny JP, 2002, J PHYSIOL-LONDON, V539, p2P; Zhou YH, 2002, NOVART FDN SYMP, V248, P150; ZHU DZ, 1993, INT J CANCER, V53, P628	54	51	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30072	30080		10.1074/jbc.M606489200	http://dx.doi.org/10.1074/jbc.M606489200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16895902	hybrid			2022-12-25	WOS:000240896300068
J	Oh, W; Yang, MR; Lee, EW; Park, KM; Pyo, S; Yang, JS; Lee, HW; Song, J				Oh, Wonkyung; Yang, Mi-Ran; Lee, Eun-Woo; Park, Ki-Moon; Pyo, Suhkneung; Yang, Joo-sung; Lee, Han-Woong; Song, Jaewhan			Jab1 mediates cytoplasmic localization and degradation of West Nile virus capsid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COP9 SIGNALOSOME; JAB1/CSN5; COMPLEX; P27(KIP1); MECHANISM; INFECTION; RESPONSES; RECEPTOR; ALPHA; ENTRY	The clinical manifestations of West Nile virus (WNV), a member of the Flavivirus family, include febrile illness, sporadic encephalitis, and paralysis. The capsid (Cp) of WNV is thought to participate in these processes by inducing apoptosis through mitochondrial dysfunction and activation of caspase-9 and caspase-3. To further identify the molecular mechanism of the WNV capsid protein (WNVCp), yeast two-hybrid assays were employed using WNV-Cp as bait. Jab1, the fifth subunit of the COP9 signalosome, was subsequently identified as a molecule that interacts with WNVCp. Immunoprecipitation and glutathione S-transferase pulldown assays confirmed that direct interaction could occur between WNVCp and Jab1. Immunofluorescence microscopy demonstrated that the overexpressed WNVCp, which localized to the nucleolus, was translocated to the cytoplasm upon its co-expression with Jab1. When treated with leptomycin B, Jab1-facilitated nuclear exclusion of WNVCp was prevented, which indicated that the CRM1 complex is required for Jab1-facilitated nuclear export of WNVCp. Moreover, Jab1 promoted the degradation of WNVCp in a proteasome-dependent way. Consistent with this, WNVCp-mediated cell cycle arrest at the G2 phase in H1299 was prevented by exogenous Jab1. Finally, an analysis of WNVCp deletion mutants indicated that the first 15 amino acids were required for interaction with Jab1. Furthermore, the double-point mutant of the WNVCp, P5A/P8A, was incapable of binding to Jab1. These results indicate that Jab1 has a potential protective effect against pathogenic WNVCp and might provide a novel target site for the treatment of disease caused by WNV.	Sungkyunkwan Univ, Dept Food Sci & Biotechnol, Fac Life Sci & Engn, Suwon 440746, South Korea; Sungkyunkwan Univ, Dept Genet Engn, Suwon 440746, South Korea; Sungkyunkwan Univ, Coll Pharm, Suwon 440746, South Korea; Yonsei Univ, Dept Biochem, Seoul 120749, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Yonsei University	Song, J (corresponding author), Sungkyunkwan Univ, Dept Food Sci & Biotechnol, Fac Life Sci & Engn, Suwon 440746, South Korea.	jso678@skku.edu	Lee, Eun-Woo/AAP-9603-2020	Song, Jaewhan/0000-0001-8152-9210; Lee, Eun-Woo/0000-0002-5156-0003				Akamatsu E, 1998, J BIOL CHEM, V273, P16494, DOI 10.1074/jbc.273.26.16494; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Berse M, 2004, J MOL BIOL, V343, P361, DOI 10.1016/j.jmb.2004.08.043; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Callige M, 2005, MOL CELL BIOL, V25, P4349, DOI 10.1128/MCB.25.11.4349-4358.2005; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Cheeran MCJ, 2005, J NEUROVIROL, V11, P512, DOI 10.1080/13550280500384982; Chu JJH, 2004, J VIROL, V78, P10543, DOI 10.1128/JVI.78.19.10543-10555.2004; Chu JJH, 2002, J MED VIROL, V67, P127, DOI 10.1002/jmv.2201; Chu JJH, 2003, J GEN VIROL, V84, P3305, DOI 10.1099/vir.0.19447-0; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Diamond MS, 2003, VIRAL IMMUNOL, V16, P259, DOI 10.1089/088282403322396082; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Hiscox JA, 2001, J VIROL, V75, P506, DOI 10.1128/JVI.75.1.506-512.2001; Kim BC, 2004, MOL CELL BIOL, V24, P2251, DOI 10.1128/MCB.24.6.2251-2262.2004; Kwok SF, 1998, PLANT CELL, V10, P1779, DOI 10.1105/tpc.10.11.1779; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Ning B, 2004, J VIROL, V78, P13653, DOI 10.1128/JVI.78.24.13653-13668.2004; Oh W, 2006, J BIOL CHEM, V281, P17457, DOI 10.1074/jbc.M601857200; Parquet MD, 2001, FEBS LETT, V500, P17, DOI 10.1016/S0014-5793(01)02573-X; Ramanathan MP, 2006, VIROLOGY, V345, P56, DOI 10.1016/j.virol.2005.08.043; Sampson BA, 2000, HUM PATHOL, V31, P527, DOI 10.1053/hp.2000.8047; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; WESTAWAY EG, 1985, INTERVIROLOGY, V24, P183, DOI 10.1159/000149642; Yang JS, 2002, EMERG INFECT DIS, V8, P1379, DOI 10.3201/eid0812.020224; Yun JS, 2004, J BIOL CHEM, V279, P31296, DOI 10.1074/jbc.M401411200	32	55	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30166	30174		10.1074/jbc.M602651200	http://dx.doi.org/10.1074/jbc.M602651200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16882664	hybrid			2022-12-25	WOS:000240896300077
J	Roberts, DS; Hu, YH; Lund, IV; Brooks-Kayal, AR; Russek, SJ				Roberts, Daniel S.; Hu, Yinghui; Lund, Ingrid V.; Brooks-Kayal, Amy R.; Russek, Shelley J.			Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPORAL-LOBE EPILEPSY; GAMMA-AMINOBUTYRIC-ACID; MESSENGER-RNAS; TRANSCRIPTION FACTOR; DENTATE GRANULE; DOWN-REGULATION; CYCLOSPORINE-A; T-CELLS; EXPRESSION; ZINC	Altered function of gamma-aminobutyric acid type A receptors (GABA(A)Rs) in dentate granule cells of the hippocampus has been associated with temporal lobe epilepsy (TLE) in humans and in animal models of TLE. Such altered receptor function (including increased inhibition by zinc and lack of modulation by benzodiazepines) is related, in part, to changes in the mRNA levels of certain GABA(A)R subunits, including alpha 4, and may play a role in epileptogenesis. The majority of GABA(A)Rs that contain alpha 4 subunits are extra-synaptic due to lack of the gamma 2 subunit and presence of delta. However, it has been hypothesized that seizure activity may result in expression of synaptic receptors with altered properties driven by an increased pool of alpha 4 subunits. Results of our previous work suggests that signaling via protein kinase C (PKC) and early growth response factor 3 (Egr3) is the plasticity trigger for aberrant alpha 4 subunit gene (GABRA4) expression after status epilepticus. We now report that brain derived neurotrophic factor (BDNF) is the endogenous signal that induces Egr3 expression via a PKC/MAPK-dependent pathway. Taken together with the fact that blockade of tyrosine kinase (Trk) neurotrophin receptors reduces basal GABRA4 promoter activity by 50%, our findings support a role for BDNF as the mediator of Egr3-induced GABRA4 regulation in developing neurons and epilepsy and, moreover, suggest that BDNF may alter inhibitory processing in the brain by regulating the balance between phasic and tonic inhibition.	Boston Univ, Sch Med, Mol Neurobiol Lab, Dept Pharmacol, Boston, MA 02118 USA; Univ Penn, Neurosci Grad Grp, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA	Boston University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Russek, SJ (corresponding author), Boston Univ, Sch Med, Mol Neurobiol Lab, Dept Pharmacol, 715 Albany St, Boston, MA 02118 USA.	srussek@bu.edu		Russek, Shelley/0000-0001-7547-3089	NINDS NIH HHS [NS050393] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050393] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albert Y, 2005, J CELL BIOL, V169, P257, DOI 10.1083/jcb.200501156; Benke D, 1997, J NEUROCHEM, V69, P806; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brunig I, 2001, EUR J NEUROSCI, V13, P1320, DOI 10.1046/j.0953-816x.2001.01506.x; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; Christie SB, 2002, J NEUROSCI, V22, P684, DOI 10.1523/JNEUROSCI.22-03-00684.2002; Coulter DA, 2000, EPILEPSIA, V41, pS96, DOI 10.1111/j.1528-1157.2000.tb01565.x; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; Fisher JL, 1998, J NEUROSCI, V18, P2944; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P1924, DOI 10.1152/jn.1997.77.4.1924; Honkaniemi J, 1999, EUR J NEUROSCI, V11, P10, DOI 10.1046/j.1460-9568.1999.00401.x; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Knoflach F, 1996, MOL PHARMACOL, V50, P1253; Koyama R, 2005, NEUROSCIENTIST, V11, P282, DOI 10.1177/1073858405278266; Koyama R, 2004, J NEUROSCI, V24, P7215, DOI 10.1523/JNEUROSCI.2045-04.2004; Mages HW, 1998, MOL CELL BIOL, V18, P7157, DOI 10.1128/MCB.18.12.7157; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; Murray KD, 2000, J COMP NEUROL, V418, P411, DOI 10.1002/(SICI)1096-9861(20000320)418:4<411::AID-CNE4>3.0.CO;2-F; O'Donovan KJ, 1999, MOL CELL BIOL, V19, P4711; Parsian A, 1999, AM J MED GENET, V88, P533, DOI 10.1002/(SICI)1096-8628(19991015)88:5<533::AID-AJMG18>3.0.CO;2-C; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Poulsen FR, 2004, NEUROSCIENCE, V126, P665, DOI 10.1016/j.neuroscience.2004.04.008; Qiao XX, 2001, J NEUROSCI RES, V64, P268, DOI 10.1002/jnr.1075; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Roberts DS, 2005, P NATL ACAD SCI USA, V102, P11894, DOI 10.1073/pnas.0501434102; Russek SJ, 2000, P NATL ACAD SCI USA, V97, P8600, DOI 10.1073/pnas.97.15.8600; RUSSEK SJ, 2003, NATURE ENCY HUMAN GE; Scharfman HE, 2002, EXP NEUROL, V174, P201, DOI 10.1006/exnr.2002.7869; Shetty AK, 2003, J NEUROCHEM, V87, P147, DOI 10.1046/j.1471-4159.2003.01979.x; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; Steiger JL, 2004, PHARMACOL THERAPEUT, V101, P259, DOI 10.1016/j.pharmthera.2003.12.002; Sur C, 1999, MOL PHARMACOL, V56, P110, DOI 10.1124/mol.56.1.110; Takahashi M, 1999, BRAIN RES, V818, P579, DOI 10.1016/S0006-8993(98)01355-9; WHITE G, 1995, NEUROREPORT, V6, P461, DOI 10.1097/00001756-199502000-00014; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yamagata K, 1994, Learn Mem, V1, P140; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; Zhang G, 2004, NEUROSCIENCE, V125, P299, DOI 10.1016/j.neuroscience.2004.01.040	42	99	100	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29431	29435		10.1074/jbc.C600167200	http://dx.doi.org/10.1074/jbc.C600167200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16901909	hybrid			2022-12-25	WOS:000240896300004
J	Viviani, B; Gardoni, F; Bartesaghi, S; Corsini, E; Facchi, A; Galli, CL; Di Luca, M; Marinovich, M				Viviani, Barbara; Gardoni, Fabrizio; Bartesaghi, Stefano; Corsini, Emanuela; Facchi, Alessandra; Galli, Corrado L.; Di Luca, Monica; Marinovich, Marina			Interleukin-1 beta released by gp120 drives neural death through tyrosine phosphorylation and trafficking of NMDA receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; COAT PROTEIN GP120; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; D-ASPARTATE RECEPTOR; SRC FAMILY; POSTSYNAPTIC DENSITIES; ENVELOPE GLYCOPROTEIN; GLUTAMATE RECEPTORS; NEURONAL APOPTOSIS; ARACHIDONIC-ACID	Interleukin-1 beta is a proinflammatory cytokine implicated under pathological conditions involving NMDA receptor activation, including the AIDS dementia complex ( HAD). No information is available on the molecular mechanisms recruited by native interleukin-1 beta produced under this type of condition. Using a sandwich co-culture of primary hippocampal neurons and glia, we investigated whether native interleukin-1 beta released by HIV-gp120-activated glia (i) affects NMDAR functions and (ii) the relevance on neuronal spine density and survival, two specific traits of HAD. Increased phosphorylation of NR2B Tyr-1472 was observed after 24 h of exposure of neurons to 600 pM gp120. This effect occurred only when neurons were treated in the presence of glial cells and was abolished by the interleukin-1 receptor antagonist (IL-1ra). Gp120-induced phosphorylation of NR2B resulted in a sustained elevation of intracellular Ca2+ in neurons and in a significant increase of NR2B binding to PSD95. Increased intracellular Ca2+ was prevented by 10 mu M ifenprodil, that selectively inhibits receptors containing the NR2B, by interleukin-1ra and by Ca-pYEEIE, a Src family SH2 inhibitor peptide. These last two inhibitors, prevented also NR2B binding to PSD95. Finally, gp120 reduced by 35% of the total PSD95 positive spine density after 48 h of treatment and induced by 30% of the neuronal death. Again, both of these effects were blocked by Ca-pYEEIE. Altogether, our data show that gp120 releasing interleukin-1 beta from glia increases tyrosine phosphorylation of NMDAR. Thus, tyrosine phosphorylation may contribute to the sensitization of the receptor increasing its function and synaptic localization. Both of these effects are relevant for neurodegeneration.	Univ Milan, Dept Pharmacol Sci, Toxicol Lab, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy	University of Milan; University of Milan	Viviani, B (corresponding author), Univ Milan, Dept Pharmacol Sci, Toxicol Lab, Via Balzaretti 9, I-20133 Milan, Italy.	Barbara.Viviani@unimi.it	Corsini, Emanuela/B-5602-2011; Gardoni, Fabrizio/A-3135-2009; Viviani, Barbara/B-5663-2011; DiLuca, Monica/A-7632-2012; Bartesaghi, Stefano/G-1916-2015	Gardoni, Fabrizio/0000-0003-4598-5563; Viviani, Barbara/0000-0002-0935-0459; DiLuca, Monica/0000-0003-2298-615X; Bartesaghi, Stefano/0000-0002-2083-7807; Galli, Corrado Lodovico/0000-0003-0078-5488; Marinovich, Marina/0000-0003-0625-8101				Aarts MM, 2004, CURR MOL MED, V4, P137, DOI 10.2174/1566524043479202; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Bagetta G, 1999, NEUROSCIENCE, V89, P1051, DOI 10.1016/S0306-4522(98)00363-7; Barak O, 2002, BRAIN RES, V933, P98, DOI 10.1016/S0006-8993(02)02280-1; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Besshoh S, 2005, J NEUROCHEM, V93, P186, DOI 10.1111/j.1471-4159.2004.03009.x; Bilbo SD, 2005, J NEUROSCI, V25, P8000, DOI 10.1523/JNEUROSCI.1748-05.2005; BLATTEIS CM, 1990, YALE J BIOL MED, V63, P133; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; Cheung HH, 2000, J CEREBR BLOOD F MET, V20, P505, DOI 10.1097/00004647-200003000-00009; Collingridge GL, 2004, NAT REV NEUROSCI, V5, P952, DOI 10.1038/nrn1556; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dreyer EB, 1995, EUR J NEUROSCI, V7, P2502, DOI 10.1111/j.1460-9568.1995.tb01048.x; Dunah AW, 2004, MOL PHARMACOL, V65, P121, DOI 10.1124/mol.65.1.121; Ellis RJ, 1997, ARCH NEUROL-CHICAGO, V54, P416, DOI 10.1001/archneur.1997.00550160054016; GALLO P, 1989, J NEUROIMMUNOL, V23, P109, DOI 10.1016/0165-5728(89)90029-5; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gardoni F, 2003, J BIOL CHEM, V278, P44745, DOI 10.1074/jbc.M303576200; GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haughey NJ, 2002, JAIDS-J ACQ IMM DEF, V31, pS55, DOI 10.1097/00126334-200210012-00005; Haughey NJ, 2001, J NEUROCHEM, V78, P457, DOI 10.1046/j.1471-4159.2001.00396.x; Ilyin SE, 1997, BIOCHEM BIOPH RES CO, V231, P514, DOI 10.1006/bbrc.1997.6131; Kalia LV, 2004, ONCOGENE, V23, P8007, DOI 10.1038/sj.onc.1208158; Kalia LV, 2003, NEUROPHARMACOLOGY, V45, P720, DOI 10.1016/S0028-3908(03)00313-7; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Lavezzari G, 2003, NEUROPHARMACOLOGY, V45, P729, DOI 10.1016/S0028-3908(03)00308-3; Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; Lynch DR, 2002, J PHARMACOL EXP THER, V300, P717, DOI 10.1124/jpet.300.3.717; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; Masliah E, 1996, CRIT REV NEUROBIOL, V10, P57, DOI 10.1615/CritRevNeurobiol.v10.i1.30; Meucci O, 1996, J NEUROSCI, V16, P4080; Milligan ED, 2001, J NEUROSCI, V21, P2808, DOI 10.1523/JNEUROSCI.21-08-02808.2001; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Niimura M, 2005, J NEUROCHEM, V92, P1377, DOI 10.1111/j.1471-4159.2005.02977.x; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Park SH, 2002, BIOORG MED CHEM LETT, V12, P2711, DOI 10.1016/S0960-894X(02)00523-1; PLATASALAMAN CR, 1991, NEUROSCI BIOBEHAV R, V15, P185, DOI 10.1016/S0149-7634(05)80001-6; Prybylowski K, 2005, NEURON, V47, P845, DOI 10.1016/j.neuron.2005.08.016; Pugh CR, 2001, NEUROSCI BIOBEHAV R, V25, P29, DOI 10.1016/S0149-7634(00)00048-8; Pugh CR, 2000, BRAIN RES, V861, P8, DOI 10.1016/S0006-8993(99)02445-2; Quan N, 1996, NEUROIMMUNOMODULAT, V3, P56, DOI 10.1159/000097227; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rong YQ, 2001, J NEUROCHEM, V79, P382, DOI 10.1046/j.1471-4159.2001.00565.x; Ross FM, 2003, J NEUROIMMUNOL, V144, P61, DOI 10.1016/j.jneuroim.2003.08.030; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; SEI Y, 1995, NEUROIMMUNOMODULAT, V2, P121, DOI 10.1159/000096881; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Song C, 2003, J BIOL CHEM, V278, P33364, DOI 10.1074/jbc.M304240200; Takagi N, 1997, J NEUROCHEM, V69, P1060; TAKAHASHI S, 1996, AM J PHYSIOL, V271, P101; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; Vesce S, 1997, FEBS LETT, V411, P107, DOI 10.1016/S0014-5793(97)00674-1; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Viviani B, 2003, J NEUROSCI, V23, P8692; Viviani B, 2001, NEUROSCIENCE, V107, P51, DOI 10.1016/S0306-4522(01)00332-3; Wang K, 2004, J BIOL CHEM, V279, P8779, DOI 10.1074/jbc.M309652200; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676	70	96	99	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30212	30222		10.1074/jbc.M602156200	http://dx.doi.org/10.1074/jbc.M602156200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16887807	Green Published, hybrid			2022-12-25	WOS:000240896300081
J	Kaadige, MR; Ayer, DE				Kaadige, Mohan R.; Ayer, Donald E.			The polybasic region that follows the plant homeodomain zinc finger 1 of Pf1 is necessary and sufficient for specific phosphoinositide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHD FINGER; TRANSCRIPTIONAL REPRESSION; DEACETYLASE COMPLEX; HISTONE H3K4ME3; CELL-CYCLE; CHROMATIN; PROTEIN; DOMAIN; ING2; RECEPTOR	The plant homeodomain (PHD) zinc finger is one of 14 known zinc-binding domains. PHD domains have been found in more than 400 eukaryotic proteins and are characterized by a Cys(4)-His-Cys(3) zinc-binding motif that spans 50-80 residues. The precise function of PHD domains is currently unknown; however, the PHD domains of the ING1 and ING2 tumor suppressors have been shown recently to bind phosphoinositides (PIs). We have recently identified a novel PHD-containing protein, Pf1, as a binding partner for the abundant and ubiquitous transcriptional corepressor mSin3A. Pf1 contains two PHD zinc fingers, PHD1 and PHD2, and functions to bridge mSin3A to the TLE1 corepressor. Here, we show that PHD1, but not PHD2, binds several monophosporylated PIs but most strongly to PI(3) P. Surprisingly, a polybasic region that follows the PHD1 is necessary for PI(3) P binding. Furthermore, this polybasic region binds specifically to PI(3) P when fused to maltose-binding protein, PHD2, or as an isolated peptide, demonstrating that it is sufficient for specific PI binding. By exchanging the polybasic regions between different PHD fingers we show that this region is a strong determinant of PI binding specificity. These findings establish the Pf1 polybasic region as a phosphoinositide-binding module and suggest that the PHD domains function downstream of phosphoinositide signaling triggered by the interaction between polybasic regions and phosphoinositides.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Ayer, DE (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, 2000 Circle Hope,Rm 4365, Salt Lake City, UT 84112 USA.	don.ayer@hci.utah.edu		Ayer, Donald/0000-0002-5595-3269	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055668] Funding Source: NIH RePORTER; NCI NIH HHS [2P30 CA42014] Funding Source: Medline; NIGMS NIH HHS [R01 GM055668] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Cocco L, 2004, EUR J HISTOCHEM, V48, P83; Eberharter A, 2004, EMBO J, V23, P4029, DOI 10.1038/sj.emboj.7600382; Gozani O, 2005, ADV ENZYME REGUL, V45, P171, DOI 10.1016/j.advenzreg.2005.02.010; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Jones DR, 2004, CURR OPIN GENET DEV, V14, P196, DOI 10.1016/j.gde.2004.02.003; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Martelli AM, 2005, J CELL BIOCHEM, V96, P285, DOI 10.1002/jcb.20527; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; Mochizuki Y, 2003, P NATL ACAD SCI USA, V100, P9768, DOI 10.1073/pnas.1333958100; Osborne SL, 2001, J CELL SCI, V114, P2501; Papayannopoulos V, 2005, MOL CELL, V17, P181, DOI 10.1016/j.molcel.2004.11.054; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Pendaries C, 2005, ADV ENZYME REGUL, V45, P201, DOI 10.1016/j.advenzreg.2005.02.006; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Sundaram M, 2004, BIOCHEM CELL BIOL, V82, P191, DOI 10.1139/o03-087; Wang JY, 2002, J BIOL CHEM, V277, P34401, DOI 10.1074/jbc.M203954200; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yochum GS, 2002, MOL CELL BIOL, V22, P7868, DOI 10.1128/MCB.22.22.7868-7876.2002; Yochum GS, 2001, MOL CELL BIOL, V21, P4110, DOI 10.1128/MCB.21.13.4110-4118.2001; YORK JD, 1994, J BIOL CHEM, V269, P7847; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	30	65	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28831	28836		10.1074/jbc.M605624200	http://dx.doi.org/10.1074/jbc.M605624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16893883	hybrid			2022-12-25	WOS:000240680500037
J	Virkki, LV; Murer, H; Forster, IC				Virkki, Leila V.; Murer, Heini; Forster, Ian C.			Mapping conformational changes of a type IIb Na+/P-i cotransporter by voltage clamp fluorometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED PHOSPHATE COTRANSPORTER; FUNCTIONALLY IMPORTANT SITES; SHAKER K+ CHANNEL; TRANSPORTER GAT1; NAPI-IIA; FLUORESCENCE; TRANSITIONS; DYNAMICS; BINDING; ATPASE	The fluorescence of a fluorophore depends on its environment, and if attached to a protein it may report on conformational changes. We have combined two-electrode voltage clamp with simultaneous fluorescence measurements to detect conformational changes in a type IIb Na+/P-i cotransporter expressed in Xenopus oocytes. Four novel Cys, labeled with a fluorescent probe, yielded voltage-and substrate-dependent changes in fluorescence (F). Neither Cys substitution nor labeling significantly altered the mutant electrogenic properties. Different F responses to voltage and substrate were recorded at the four sites. S155C, located in an intracellular re-entrant loop in the first half of the protein, and E451C, located in an extracellular re-entrant loop in the second half of the protein, both showed Na+, Li+, and P-i-dependent F signals. S226C and Q319C, located at opposite ends of a large extracellular loop in the middle of the protein, mainly responded to changes in Na+ and Li+. Hyperpolarization increased F for S155C and S226C but decreased F for Q319C and E451C. The labeling and F response of S155C, confirmed that the intracellular loop containing Ser155 is re-entrant as it is accessible from the extracellular milieu. The behavior of S155C and E451C indicates a strong involvement of the two re-entrant loops in conformational changes during the transport cycle. Moreover, the data for S226C and Q319C suggest that also the large extracellular loop is associated with transport function. Finally, the reciprocal voltage dependences of the S155C-E451C and S226C-Q319C pairs suggest reciprocal conformational changes during the transport cycle for their respective local environments.	Univ Zurich Irchel, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich Irchel, Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP)	Virkki, LV (corresponding author), Univ Zurich Irchel, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	leilav@physiol.unizh.ch		Forster, Ian/0000-0003-3087-9952				Bacconi A, 2005, P NATL ACAD SCI USA, V102, P12606, DOI 10.1073/pnas.0505882102; Cha A, 1998, J GEN PHYSIOL, V112, P391, DOI 10.1085/jgp.112.4.391; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; Ehnes C, 2004, J GEN PHYSIOL, V124, P489, DOI 10.1085/jgp.200409061; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Forster IC, 1997, J MEMBRANE BIOL, V160, P9, DOI 10.1007/s002329900291; Forster IC, 2000, BIOPHYS J, V79, P215, DOI 10.1016/S0006-3495(00)76285-0; Forster IC, 2002, PROG BIOPHYS MOL BIO, V80, P69, DOI 10.1016/S0079-6107(02)00015-9; Geibel S, 2003, ANN NY ACAD SCI, V986, P31, DOI 10.1111/j.1749-6632.2003.tb07136.x; Geibel S, 2003, P NATL ACAD SCI USA, V100, P964, DOI 10.1073/pnas.0337336100; Kohler K, 2002, J GEN PHYSIOL, V120, P693, DOI 10.1085/jgp.20028645; Kohler K, 2002, AM J PHYSIOL-RENAL, V282, pF687, DOI 10.1152/ajprenal.00282.2001; Lambert G, 1999, J GEN PHYSIOL, V114, P637, DOI 10.1085/jgp.114.5.637; Lambert G, 2001, J GEN PHYSIOL, V117, P533, DOI 10.1085/jgp.117.6.533; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Li M, 2002, BIOPHYS J, V83, P206, DOI 10.1016/S0006-3495(02)75162-X; Li M, 2000, J GEN PHYSIOL, V115, P491, DOI 10.1085/jgp.115.4.491; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; Mager S, 1996, J NEUROSCI, V16, P5405; Mager S, 1998, METHOD ENZYMOL, V296, P551; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; Meinild AK, 2002, BIOCHEMISTRY-US, V41, P1250, DOI 10.1021/bi011661r; Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373; Virkki LV, 2006, J GEN PHYSIOL, V127, P539, DOI 10.1085/jgp.200609496; Virkki LV, 2005, AM J PHYSIOL-RENAL, V288, pF969, DOI 10.1152/ajprenal.00293.2004	25	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28837	28849		10.1074/jbc.M603861200	http://dx.doi.org/10.1074/jbc.M603861200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16887801	hybrid, Green Published			2022-12-25	WOS:000240680500038
J	Broderick, KE; Feala, J; McCulloch, A; Paternostro, G; Sharma, VS; Pilz, RB; Boss, GR				Broderick, Kate E.; Feala, Jake; McCulloch, Andrew; Paternostro, Giovanni; Sharma, Vijay S.; Pilz, Renate B.; Boss, Gerry R.			The nitric oxide scavenger cobinamide profoundly improves survival in a Drosophila melanogaster model of bacterial sepsis	FASEB JOURNAL			English	Article						septic shock; cobalamin; cardiac function	IMMUNE-DEFICIENCY IMD; COBALAMIN ANALOGS; ANTIBACTERIAL DEFENSE; INDUCED HYPOTENSION; SYNTHASE ACTIVITY; INHIBITION; SYSTEM; HOST; DYSFUNCTION; MECHANISMS	Septic shock has an extremely high mortality rate, with similar to 200,000 people dying from sepsis annually in the U. S. The high mortality results in part from severe hypotension secondary to high serum NO concentrations. Reducing NO levels should be beneficial in sepsis, but NOS inhibitors have had a checkered history in animal models, and one such agent increased mortality in a clinical trial. An alternative approach to reduce NO levels in sepsis is to use an NO scavenger, which should leave sufficient free NO for normal physiological functions. Using a well-established model of bacterial sepsis in Drosophila melanogaster, we found that cobinamide, a B-12 analog and an effective NO scavenger in vitro, dramatically improved fly survival. Cobinamide augmented the effect of an antibiotic and was beneficial even in immune-deficient flies. Cobinamide's mechanism of action appeared to be from reducing NO levels and improving cardiac function. Broderick, K. E., Feala, J., McCulloch, A., Paternostro, G., Sharma, V. S., Pilz, R. B., Boss, G. R. The nitric oxide scavenger cobinamide profoundly improves survival in a Drosophila melanogaster model of bacterial sepsis.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Burnham Inst Med Res, La Jolla, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gboss@ucsd.edu		Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R01CA090932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051300] Funding Source: NIH RePORTER; NCI NIH HHS [CA90932] Funding Source: Medline; NIAMS NIH HHS [AR051300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aboy M, 2005, IEEE T BIO-MED ENG, V52, P1662, DOI 10.1109/TBME.2005.855725; Agrawal N, 2005, P NATL ACAD SCI USA, V102, P3777, DOI 10.1073/pnas.0500055102; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bier E, 2004, GENE, V342, P1, DOI 10.1016/j.gene.2004.07.018; BOMAN HG, 1972, NATURE, V237, P232, DOI 10.1038/237232a0; Broderick KE, 2005, J BIOL CHEM, V280, P8678, DOI 10.1074/jbc.M410498200; CLANCY RM, 1995, P SOC EXP BIOL MED, V210, P93; COATES ME, 1956, BIOCHEM J, V64, P682, DOI 10.1042/bj0640682; COBB JP, 1992, J EXP MED, V176, P1175, DOI 10.1084/jem.176.4.1175; Danishpajooh IO, 2001, J BIOL CHEM, V276, P27296, DOI 10.1074/jbc.M104043200; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Fedosov SN, 2002, J BIOL CHEM, V277, P9989, DOI 10.1074/jbc.M111399200; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Gonzalez BE, 2003, J PERINAT MED, V31, P60, DOI 10.1515/JPM.2003.009; GREENBERG SS, 1995, J PHARMACOL EXP THER, V273, P257; Heneka MT, 1997, J CLIN INVEST, V99, P47, DOI 10.1172/JCI119132; Ichinose F, 2003, AM J PHYSIOL-HEART C, V285, pH2524, DOI 10.1152/ajpheart.00530.2003; Johnson E, 2002, J COMP PHYSIOL B, V172, P227, DOI 10.1007/s00360-001-0246-8; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; Kim HW, 2002, SHOCK, V17, P423, DOI 10.1097/00024382-200205000-00014; KOLHOUSE JF, 1978, NEW ENGL J MED, V299, P785, DOI 10.1056/NEJM197810122991501; KOLHOUSE JF, 1977, J CLIN INVEST, V60, P1381, DOI 10.1172/JCI108899; KONDO H, 1980, P NATL ACAD SCI-BIOL, V77, P817, DOI 10.1073/pnas.77.2.817; KONDO H, 1992, INT J HEMATOL, V56, P167; KONDO H, 1982, J CLIN INVEST, V70, P889, DOI 10.1172/JCI110685; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; Marshall JC, 2003, NAT REV DRUG DISCOV, V2, P391, DOI 10.1038/nrd1084; McGettigan J, 2005, INSECT BIOCHEM MOLEC, V35, P741, DOI 10.1016/j.ibmb.2005.02.017; Miller A., 1950, BIOL DROSOPHILA, P420; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Needham AJ, 2004, MICROBIOL-SGM, V150, P2347, DOI 10.1099/mic.0.27116-0; Paternostro G, 2001, CIRC RES, V88, P1053, DOI 10.1161/hh1001.090857; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; Poon BY, 2003, CIRCULATION, V108, P1107, DOI 10.1161/01.CIR.0000086321.04702.AC; Price S, 2003, EUR J PHARMACOL, V472, P111, DOI 10.1016/S0014-2999(03)01826-0; Regulski M, 2004, CURR BIOL, V14, pR881, DOI 10.1016/j.cub.2004.09.068; Sharma VS, 2003, BIOCHEMISTRY-US, V42, P8900, DOI 10.1021/bi034469t; SPAIN DA, 1994, J TRAUMA, V36, P720, DOI 10.1097/00005373-199405000-00021; STABLER SP, 1991, J CLIN INVEST, V87, P1422, DOI 10.1172/JCI115148; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; Tickoo S, 2002, CURR OPIN PHARMACOL, V2, P555, DOI 10.1016/S1471-4892(02)00206-0; Vincent JL, 2000, AM J RESP CRIT CARE, V161, P1781, DOI 10.1164/ajrccm.161.6.9812004; Weinberg JB, 1998, BIOCHEM BIOPH RES CO, V246, P393, DOI 10.1006/bbrc.1998.8629; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48	47	26	26	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1865	1873		10.1096/fj.06-5780com	http://dx.doi.org/10.1096/fj.06-5780com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940158				2022-12-25	WOS:000240267000014
J	Reiter, B; Kraft, R; Gunzel, D; Zeissig, S; Schulzke, JD; Fromm, M; Harteneck, C				Reiter, Bettina; Kraft, Robert; Guenzel, Dorothee; Zeissig, Sebastian; Schulzke, Joerg-Dieter; Fromm, Michael; Harteneck, Christian			TRPV4-mediated regulation of epithelial permeability	FASEB JOURNAL			English	Article						transepithelial electrical resistance; paracellular pathway; transcellular pathway; calcium homeostasis; BK channel	CANINE KIDNEY-CELLS; CATION CHANNEL; 2-AMINOETHOXYDIPHENYL BORATE; TIGHT JUNCTIONS; TRPV4 CHANNELS; ACTIVATE TRPV4; ION-CHANNEL; EXPRESSION; RECEPTOR; PROTEIN	TRPV4 is a calcium-permeable channel activated by extracellular hypotonicity, polyunsaturated fatty acids, phorbol esters, and heat. We show that TRPV4 is localized in the basolateral membrane of the mouse mammary cell line HC11. Activation of TRPV4 caused an increase in the intracellular Ca2+ concentration through influx of extracellular Ca2+, triggering two independent chains of events: 1) a rapid increase in transcellular conductance through the activation of apical large conductance calcium-activated (BK) potassium channels that were blockable by paxilline; 2) a slow increase in paracellular permeability for small solutes. The latter effect was accompanied by a down-regulation of the tight junctional proteins claudin -1, -3, -4, -5, -7, and -8 and by dramatic changes in tight junction morphology, including frequent large breaks in the tight junction strands. This dual modulation of epithelial permeability after TRPV4 activation may be involved in regulating the tonicity across mammary gland epithelia. TRPV4 activation may also be responsible for exudation and edema formation during inflammation processes. - Reiter, B., Kraft, R., Gunzel, D., Zeissig, S., Schulzke, J-D., Fromm, M., Harteneck, C. TRPV4-mediated regulation of epithelial permeability.	Inst Pharmakol, D-14195 Berlin, Germany; Free Univ Berlin, Fachbereich Biol Chem Pharm, D-1000 Berlin, Germany; Inst Klin Physiol, Berlin, Germany; Med Klin I Gastroenterol Infektiol & Rheumatol, Berlin, Germany	Free University of Berlin	Harteneck, C (corresponding author), Inst Pharmakol, Charite Campus Benjamin Franklin,Thielallee 69-73, D-14195 Berlin, Germany.	christian.harteneck@charite.de	Fromm, Michael/K-6203-2013; Kraft, Robert/E-9199-2011; Zeissig, Sebastian/B-6297-2012	Fromm, Michael/0000-0003-4497-7983; Kraft, Robert/0000-0002-5774-6001; Zeissig, Sebastian/0000-0001-5124-0897; Gunzel, Dorothee/0000-0002-7998-7164				Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Arniges M, 2004, J BIOL CHEM, V279, P54062, DOI 10.1074/jbc.M409708200; Bravo-Zehnder M, 2000, P NATL ACAD SCI USA, V97, P13114, DOI 10.1073/pnas.240455697; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; den Dekker E, 2003, CELL CALCIUM, V33, P497, DOI 10.1016/S0143-4160(03)00065-4; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Grimm C, 2003, J BIOL CHEM, V278, P21493, DOI 10.1074/jbc.M300945200; Gross GJ, 2005, CARDIOVASC RES, V68, P18, DOI 10.1016/j.cardiores.2005.06.007; Grunnet M, 2005, BBA-BIOMEMBRANES, V1714, P114, DOI 10.1016/j.bbamem.2005.05.012; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; MULLIN M, 2004, SCI STKE, pPE2; Muraki K, 2003, CIRC RES, V93, P829, DOI 10.1161/01.RES.0000097263.10220.0C; Natarajan R, 2003, CURR OPIN PHARMACOL, V3, P198, DOI 10.1016/S1471-4892(03)00015-8; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nguyen DAD, 1998, J MAMMARY GLAND BIOL, V3, P233, DOI 10.1023/A:1018707309361; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; SCHIFFERDECKER E, 1978, PFLUG ARCH EUR J PHY, V377, P125, DOI 10.1007/BF00582842; SCHULZKE JD, 1992, GASTROENTEROLOGY, V102, P497, DOI 10.1016/0016-5085(92)90096-H; Stelwagen K, 1999, MOL CELL ENDOCRINOL, V156, P55, DOI 10.1016/S0303-7207(99)00145-8; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tian W, 2004, AM J PHYSIOL-RENAL, V287, pF17, DOI 10.1152/ajprenal.00397.2003; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Yu ASL, 2003, J BIOL CHEM, V278, P17350, DOI 10.1074/jbc.M213286200	36	87	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1802	1812		10.1096/fj.06-5772com	http://dx.doi.org/10.1096/fj.06-5772com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940152				2022-12-25	WOS:000240267000008
J	Lim, YP; Lim, TT; Chan, YL; Song, ACM; Yeo, BH; Vojtesek, B; Coomber, D; Rajagopal, G; Lane, D				Lim, Y. P.; Lim, T. T.; Chan, Y. L.; Song, A. C. M.; Yeo, B. H.; Vojtesek, B.; Coomber, D.; Rajagopal, G.; Lane, D.			The p53 knowledgebase: an integrated information resource for p53 research	ONCOGENE			English	Article						database; p53; web portal	CELL-CYCLE ARREST; NUCLEAR ACCUMULATION; PROTEIN; INDUCTION; SELECTION; DATABASE; ANTIGEN	The p53 tumor suppressor protein plays a central role in maintaining genomic integrity by occupying a nodal point in the DNA damage control pathway. Here it integrates a wide variety of signals, responding in one of several ways, that is, cell cycle arrest, senescence or programmed cell death (apoptosis). Mutations in the tumor suppressor gene tp53, which affects the key transcriptional regulatory processes in cell growth and death, occur frequently in cancer and helps explain why p53 has been called the guardian of the genome. There is a vast body of published knowledge on all aspects of p53's role in cancer. To facilitate research, it would be helpful if this information could be collected, curated and updated in a format that is easily accessible to the user community. To this end, we initiated the p53 knowledgebase project (http://p53.bii.a-star.edu.sg). The p53 knowledgebase is a user-friendly web portal incorporating visualization and analysis tools that integrates information from the published literature with other manually curated information to facilitate knowledge discovery. This includes curated information on sequence, structural, mutation, polymorphisms, protein-protein interactions, transcription factors, transcriptional targets, antibodies and post-translational modifications that involve p53. The goal is to collect and maintain all relevant data on p53 and present it in an easily accessible format that will be useful to researchers in the field.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Matrix, Bioinformat Inst, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII)	Lane, D (corresponding author), Inst Mol & Cell Biol, 61 Biopolis St, Singapore 138673, Singapore.	d.p.lane@imcb.a-star.edu.sg	Lim, Elaine/H-9032-2016; Lane, David P/C-4920-2008	Rajagopal, Gunaretnam/0000-0003-0111-1936; Lane, David/0000-0003-0551-3545				Bader GD, 2001, NUCLEIC ACIDS RES, V29, P242, DOI 10.1093/nar/29.1.242; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Beroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; FRITSCHE M, 1993, ONCOGENE, V8, P307; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Zhang K, 2005, BIOINFORMATICS, V21, P131, DOI 10.1093/bioinformatics/bth482; Zhao LL, 2005, J SOL-GEL SCI TECHN, V33, P103, DOI 10.1007/s10971-005-6708-9	25	34	35	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1517	1521		10.1038/sj.onc.1209952	http://dx.doi.org/10.1038/sj.onc.1209952			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953220				2022-12-25	WOS:000244782500001
J	Ivanova, IA; Dagnino, L				Ivanova, I. A.; Dagnino, L.			Activation of p38-and CRM1-dependent nuclear export promotes E2F1 degradation during keratinocyte differentiation	ONCOGENE			English	Article						keratinocyte; E2F; differentiation	TRANSCRIPTION FACTORS; EPIDERMAL-KERATINOCYTES; EXPRESSION PATTERNS; WOUND REPAIR; PROLIFERATION; PROTEIN; KINASE; FAMILY; PRB; LOCALIZATION	E2F factors modulate a plethora of cell functions, including proliferation, differentiation, DNA repair and apoptosis. We have shown that differentiation in primary epidermal keratinocytes leads to E2F1 downregulation via activation of protein kinase C and p38 mitogen-activated protein kinase. We now demonstrate that E2F1 downregulation in differentiating keratinocytes involves its ubiquitination, as well as proteasomal degradation subsequent to CRM1-dependent nuclear export. E2F1 nuclear export specifically in response to differentiation requires regions adjacent to the cyclin A-binding domain in the N-terminusof this protein. Significantly, inhibition of p38 interferes with nuclear export and degradation of E2F1 during differentiation, but has no effect on E2F1 in undifferentiated cells. Thus, induction of differentiation in epidermal keratinocytes activates a specific program for post-transcriptional downregulation of E2F1, which involves signaling through p38 and activation of nuclear export pathways.	Univ Western Ontario, Dept Physiol & Pharmacol & Regulatory Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Paediat, Child Hlth Res Inst, London, ON N6A 5C1, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159				Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Asher G, 2005, CELL CYCLE, V4, P1015, DOI 10.4161/cc.4.8.1900; Byrne C, 2003, J ANAT, V202, P113, DOI 10.1046/j.1469-7580.2003.00142.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chang WY, 2004, J BIOL CHEM, V279, P51343, DOI 10.1074/jbc.M408635200; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Gill RM, 2000, J CELL BIOL, V148, P1187, DOI 10.1083/jcb.148.6.1187; GOMEZ DA, 2000, J BIOL CHEM, V275, P13872; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Ivanova IA, 2006, ONCOGENE, V25, P430, DOI 10.1038/sj.onc.1208999; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Muller H, 1997, MOL CELL BIOL, V17, P5508; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Ruiz S, 2006, CELL CYCLE, V5, P625, DOI 10.4161/cc.5.6.2580; Vespa A, 2005, MOL BIOL CELL, V16, P4084, DOI 10.1091/mbc.e05-02-0087	25	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1147	1154		10.1038/sj.onc.1209894	http://dx.doi.org/10.1038/sj.onc.1209894			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924238				2022-12-25	WOS:000244406400005
J	Schwenkert, S; Umate, P; Dal Bosco, C; Volz, S; Mlcochova, L; Zoryan, M; Eichacker, LA; Ohad, I; Herrmann, RG; Meurer, J				Schwenkert, Serena; Umate, Pavan; Dal Bosco, Cristina; Volz, Stefanie; Mlcochova, Lada; Zoryan, Mikael; Eichacker, Lutz A.; Ohad, Itzhak; Herrmann, Reinhold G.; Meurer, Joerg			PsbI affects the stability, function, and phosphorylation patterns of photosystem II assemblies in tobacco	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MASS SUBUNITS; 3.2 ANGSTROM RESOLUTION; CHLOROPHYLL FLUORESCENCE; THERMO-LUMINESCENCE; CRYSTAL-STRUCTURE; CHARGE ACCUMULATION; PRIMARY ACCEPTOR; PROTEIN-KINASE; ELECTRON FLOW; GENE	Photosystem II ( PSII) core complexes consist of CP47, CP43, D1, D2 proteins and of several low molecular weight integral membrane polypeptides, such as the chloroplast-encoded PsbE, PsbF, and PsbI proteins. To elucidate the function of PsbI in the photosynthetic process as well as in the biogenesis of PSII in higher plants, we generated homoplastomic knock-out plants by replacing most of the tobacco psbI gene with a spectinomycin resistance cartridge. Mutant plants are photoautotrophically viable under green house conditions but sensitive to high light irradiation. Antenna proteins of PSII accumulate to normal amounts, but levels of the PSII core complex are reduced by 50%. Bioenergetic and fluorescence studies uncovered that PsbI is required for the stability but not for the assembly of dimeric PSII and supercomplexes consisting of PSII and the outer antenna (PSII-LHCII). Thermoluminescence emission bands indicate that the presence of PsbI is required for assembly of a fully functional Q(A) binding site. We show that phosphorylation of the reaction center proteins D1 and D2 is light and redoxregulated in the wild type, but phosphorylation is abolished in the mutant, presumably due to structural alterations of PSII when PsbI is deficient. Unlike wild type, phosphorylation of LHCII is strongly increased in the dark due to accumulation of reduced plastoquinone, whereas even upon state II light phosphorylation is decreased in Delta psbI. These data attest that phosphorylation of D1/D2, CP43, and LHCII is regulated differently.	Univ Munich, Dept Biol 1, D-80638 Munich, Germany; Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Minerva Ctr Photosynth Res, IL-91904 Jerusalem, Israel	University of Munich; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Meurer, J (corresponding author), Univ Munich, Dept Biol 1, Menzingerstr 67, D-80638 Munich, Germany.	joerg.meurer@lrz.uni-muenchen.de	Meurer, Jörg/F-8479-2010; Schwenkert, Serena/F-8564-2012	Meurer, Jörg/0000-0003-2973-9514; Dal Bosco, Cristina/0000-0002-0280-5369				Adir N, 2003, PHOTOSYNTH RES, V76, P343, DOI 10.1023/A:1024969518145; ALLEN JF, 1981, BIOCHIM BIOPHYS ACTA, V638, P290, DOI 10.1016/0005-2728(81)90239-5; Amann K, 2004, PLANT CELL, V16, P3084, DOI 10.1105/tpc.104.024935; Aro EM, 2005, J EXP BOT, V56, P347, DOI 10.1093/jxb/eri041; Bassi R, 1997, PHYSIOL PLANTARUM, V100, P769, DOI 10.1034/j.1399-3054.1997.1000404.x; Bellafiore S, 2005, NATURE, V433, P892, DOI 10.1038/nature03286; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; Bonardi V, 2005, NATURE, V437, P1179, DOI 10.1038/nature04016; Bondarava N, 2003, J BIOL CHEM, V278, P13554, DOI 10.1074/jbc.M212842200; BOWES JM, 1980, BIOCHIM BIOPHYS ACTA, V590, P373, DOI 10.1016/0005-2728(80)90208-X; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; DEMETER S, 1984, BIOCHIM BIOPHYS ACTA, V764, P24, DOI 10.1016/0005-2728(84)90136-1; Ducruet JM, 2003, J EXP BOT, V54, P2419, DOI 10.1093/jxb/erg268; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; GOVINDJEE, 1990, PHOTOSYNTH RES, V25, P151, DOI 10.1007/BF00033157; Granvogl B, 2006, PROTEOMICS, V6, P3681, DOI 10.1002/pmic.200500924; Haumann M, 2005, SCIENCE, V310, P1019, DOI 10.1126/science.1117551; IKEUCHI M, 1989, FEBS LETT, V251, P155, DOI 10.1016/0014-5793(89)81446-2; IKEUCHI M, 1988, FEBS LETT, V241, P99, DOI 10.1016/0014-5793(88)81039-1; Ikeuchi M, 1995, MOL GEN GENET, V249, P622, DOI 10.1007/BF00418031; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; Keren N, 1997, P NATL ACAD SCI USA, V94, P1579, DOI 10.1073/pnas.94.4.1579; Kern J, 2005, PHOTOSYNTH RES, V84, P153, DOI 10.1007/s11120-004-7077-x; KLUGHAMMER C, 1994, PLANTA, V192, P261, DOI 10.1007/BF01089043; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; KRIEGER A, 1995, BBA-BIOENERGETICS, V1229, P193, DOI 10.1016/0005-2728(95)00002-Z; Krieger-Liszkay A, 1998, BIOCHEMISTRY-US, V37, P17339, DOI 10.1021/bi9822628; KUNSTNER P, 1995, J BIOL CHEM, V270, P9651; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; Minagawa J, 2004, PHOTOSYNTH RES, V82, P241, DOI 10.1007/s11120-004-2079-2; Morais F, 2001, J BIOL CHEM, V276, P31986, DOI 10.1074/jbc.M103935200; Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURATA N, 1988, FEBS LETT, V235, P283, DOI 10.1016/0014-5793(88)81280-8; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Ohad I, 2004, BIOCHEMISTRY-US, V43, P2297, DOI 10.1021/bi0348260; Ossenbuhl F, 2004, PLANT CELL, V16, P1790, DOI 10.1105/tpc.023226; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; PRASIL O, 1992, TOPICS PHOTOSYNTHESI, V2, P293; Regel RE, 2001, J BIOL CHEM, V276, P41473, DOI 10.1074/jbc.M102007200; Rokka A, 2005, BIOCHEM J, V388, P159, DOI 10.1042/BJ20042098; RUTHERFORD AW, 1984, P NATL ACAD SCI-BIOL, V81, P1107, DOI 10.1073/pnas.81.4.1107; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; Shen GZ, 2002, J BIOL CHEM, V277, P20343, DOI 10.1074/jbc.M201103200; Shi LX, 2004, BBA-BIOENERGETICS, V1608, P75, DOI 10.1016/j.bbabio.2003.12.004; SVAB Z, 1990, P NATL ACAD SCI USA, V87, P8526, DOI 10.1073/pnas.87.21.8526; Swiatek M, 2003, MOL GENET GENOMICS, V268, P699, DOI 10.1007/s00438-002-0791-1; Thornton LE, 2005, ADV PHOTO RESPIRAT, V22, P121; TOMO T, 1993, FEBS LETT, V323, P15, DOI 10.1016/0014-5793(93)81438-6; Vainonen JP, 2005, J BIOL CHEM, V280, P33679, DOI 10.1074/jbc.M505729200; VANKOOTEN O, 1990, PHOTOSYNTH RES, V25, P147, DOI 10.1007/BF00033156; Vasil'ev S, 2001, P NATL ACAD SCI USA, V98, P8602, DOI 10.1073/pnas.141239598; Vass I, 1996, PHOTOSYNTH RES, V48, P117, DOI 10.1007/BF00041002; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; Vass I., 1992, TOPICS PHOTOSYNTHESI, P259; WEBBER AN, 1989, FEBS LETT, V242, P259, DOI 10.1016/0014-5793(89)80481-8; WEIS E, 1985, PHOTOSYNTH RES, V6, P73, DOI 10.1007/BF00029047; Zer H, 2003, BIOCHEMISTRY-US, V42, P728, DOI 10.1021/bi020451r; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122; ZILARD A, 2005, PHOTOSYNTH RES, V84, P15; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	65	55	58	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34227	34238		10.1074/jbc.M604888200	http://dx.doi.org/10.1074/jbc.M604888200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16920705	hybrid			2022-12-25	WOS:000241767600043
J	Goodman, OB; Febbraio, M; Simantov, R; Zheng, R; Shen, RQ; Silverstein, RL; Nanus, DM				Goodman, Oscar B., Jr.; Febbraio, Maria; Simantov, Ronit; Zheng, Rong; Shen, Ruoqian; Silverstein, Roy L.; Nanus, David M.			Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; HUMAN ENDOTHELIAL-CELLS; NEUTRAL ENDOPEPTIDASE; EXPRESSION; BINDING; PROTEIN; IDENTIFICATION; HEPARIN; BETA; THROMBOSPONDIN-1	Neprilysin is a cell surface peptidase that catalytically inactivates neuropeptide substrates and functions as a tumor suppressor via its enzymatic function and multiple protein-protein interactions. We investigated whether neutral endopeptidase could inhibit angiogenesis in vivo utilizing a murine corneal pocket angiogenesis model and found that it reduced fibroblast growth factor-2-induced angiogenesis by 85% (p < 0.01) but had no effect on that of vascular endothelial growth factor. Treatment with recombinant neprilysin, but not enzymatically inactive neprilysin, resulted in a slight increase in basic fibroblast growth factor electrophoretic mobility from proteolytic cleavage between amino acids Leu-135 and Gly-136, which was inhibited by the neutral endopeptidase inhibitor CGS24592 and heparin. Cleavage kinetics were rapid, comparable with that of other known neprilysin substrates. Functional studies involving neprilysin-expressing vascular endothelial cells demonstrated that neutral endopeptidase inhibition significantly enhanced fibroblast growth factor-mediated endothelial cell growth, capillary array formation, and signaling, whereas exogenous recombinant neprilysin inhibited signaling. Recombinant constructs confirmed that cleavage products neither promoted capillary array formation nor induced signaling. Moreover, mutation of the cleavage site resulted in concomitant loss of cleavage and increased the potency of fibroblast growth factor-2 to induce capillary array formation. These data indicate that neprilysin proteolytically inactivates fibroblast growth factor-2, resulting in negative regulation of angiogenesis.	Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Urol Oncol Res Lab,Dept Urol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Div Hematol & Med Oncol,Dept Med, New York, NY 10021 USA; Bayer Pharmaceut Inc, West Haven, CT 06516 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital; Bayer AG; Bayer Healthcare Pharmaceuticals; Cleveland Clinic Foundation	Nanus, DM (corresponding author), Cornell Univ, Weill Med Coll, 525 E 68th St,ST-359, New York, NY 10021 USA.	dnanus@med.cornell.edu		Goodman, Oscar/0000-0002-0882-3621	NATIONAL CANCER INSTITUTE [R01CA080240] Funding Source: NIH RePORTER; NCI NIH HHS [CA80240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, COLD SPRING HARB SYM, V51, P657, DOI 10.1101/SQB.1986.051.01.078; Antezana MA, 2002, J INVEST DERMATOL, V119, P1400, DOI 10.1046/j.1523-1747.2002.19618.x; Bagnato A, 2003, TRENDS ENDOCRIN MET, V14, P44, DOI 10.1016/S1043-2760(02)00010-3; Bajo AM, 2004, BRIT J CANCER, V90, P245, DOI 10.1038/sj.bjc.6601404; Carpentier M, 2002, J NEUROPATH EXP NEUR, V61, P849, DOI 10.1093/jnen/61.10.849; CASSCELLS W, 1990, J CLIN INVEST, V85, P433, DOI 10.1172/JCI114456; Chua CC, 2004, CIRC RES, V94, P316, DOI 10.1161/01.RES.0000112965.70691.AC; Cronauer MV, 2003, EUR UROL, V43, P309, DOI 10.1016/S0302-2838(03)00005-8; CUMMINGS BJ, 1993, EXP NEUROL, V124, P315, DOI 10.1006/exnr.1993.1202; Dai J, 2001, CLIN CANCER RES, V7, P1370; Dorkin TJ, 1999, J PATHOL, V189, P564, DOI 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Giri D, 1999, CLIN CANCER RES, V5, P1063; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GRAF K, 1995, HYPERTENSION, V26, P230, DOI 10.1161/01.HYP.26.2.230; Hoffman AD, 1996, CLIN CANCER RES, V2, P1077; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Iwase A, 2004, J BIOL CHEM, V279, P11898, DOI 10.1074/jbc.M212737200; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; KAJIO T, 1992, FEBS LETT, V306, P243, DOI 10.1016/0014-5793(92)81009-B; Kastrup JS, 1997, ACTA CRYSTALLOGR D, V53, P160, DOI 10.1107/S0907444996012711; KENNY J, 1993, BIOCHEM SOC T, V21, P663, DOI 10.1042/bst0210663; Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200; LLORENSCORTES C, 1992, J BIOL CHEM, V267, P14012; Maniara WM, 1998, J CHROMATOGR B, V706, P287, DOI 10.1016/S0378-4347(97)00566-5; NAKAMOTO T, 1992, CANCER RES, V52, P571; Nanus DM, 2003, CLIN CANCER RES, V9, P6307; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; OLSEN E, 1992, INT ARCH ALLERGY IMM, V98, P343, DOI 10.1159/000236209; Osman I, 2004, CLIN CANCER RES, V10, P4096, DOI 10.1158/1078-0432.CCR-04-0120; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Peifley KA, 1998, BIOCHEM BIOPH RES CO, V242, P202, DOI 10.1006/bbrc.1997.7940; Peng H, 2004, BLOOD, V103, P2114, DOI 10.1182/blood-2003-08-2638; Polnaszek N, 2003, CANCER RES, V63, P5754; Ropiquet F, 1997, INT J CANCER, V72, P543, DOI 10.1002/(SICI)1097-0215(19970729)72:3<543::AID-IJC26>3.0.CO;2-B; Sahni A, 2006, BLOOD, V107, P126, DOI 10.1182/blood-2005-06-2460; Schweitzer KM, 1997, LAB INVEST, V76, P25; Shih SJ, 2003, PROSTATE CANCER P D, V6, P131, DOI 10.1038/sj.pcan.4500637; Simantov R, 2001, J CLIN INVEST, V107, P45, DOI 10.1172/JCI9061; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Sumitomo M, 2004, CANCER CELL, V5, P67, DOI 10.1016/S1535-6108(03)00331-3; Sumitomo M, 2001, CANCER RES, V61, P3294; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	46	36	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33597	33605		10.1074/jbc.M602490200	http://dx.doi.org/10.1074/jbc.M602490200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16940054	hybrid			2022-12-25	WOS:000241621400069
J	Leach, RN; Gell, C; Wigneshweraraj, S; Buck, M; Smith, A; Stockley, PG				Leach, Robert N.; Gell, Christopher; Wigneshweraraj, Sivaramesh; Buck, Martin; Smith, Alastair; Stockley, Peter George			Mapping ATP-dependent activation at sigma(54) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL RNA-POLYMERASE; PROMOTER DNA COMPLEX; ESCHERICHIA-COLI; SIGMA-FACTOR; TRANSCRIPTION ACTIVATOR; BINDING-ACTIVITY; FLAP DOMAIN; SUBUNIT; HOLOENZYME; ROLES	The sigma(54) promoter specificity factor is distinct from other bacterial RNA polymerase (RNAP) sigma factors in that it forms a transcriptionally silent closed complex upon promoter binding. Transcriptional activation occurs through a nucleotide-dependent isomerization of sigma(54), mediated via its interactions with an enhancer- binding activator protein that utilizes the energy released in ATP hydrolysis to effect structural changes in sigma(54) and core RNA polymerase. The organization of sigma(54)-promoter and sigma(54)-RNAP-promoter complexes was investigated by fluorescence resonance energy transfer assays using sigma(54) single cysteine-mutants labeled with an acceptor fluorophore and donor fluorophore- labeled DNA sequences containing mismatches that mimic nifH early-and late-melted promoters. The results show that sigma(54) undergoes spatial rearrangements of functionally important domains upon closed complex formation. sigma(54) and sigma(54)-RNAP promoter complexes reconstituted with the different mismatched DNA constructs were assayed by the addition of the activator phage shock protein F in the presence or absence of ATP and of non-hydrolysable analogues. Nucleotide-dependent alterations in fluorescence resonance energy transfer efficiencies identify different functional states of the activator-sigma(54)-RNAP-promoter complex that exist throughout the mechano-chemical transduction pathway of transcriptional activation, i.e. from closed to open promoter complexes. The results suggest that open complex formation only occurs efficiently on replacement of a repressive fork junction with downstream melted DNA.	Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Phys & Astron, Leeds LS2 9JT, W Yorkshire, England; Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, Div Biol, London SW7 2AZ, England	University of Leeds; University of Leeds; Imperial College London	Stockley, PG (corresponding author), Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England.	stockley@bmb.leeds.ac.uk		Gell, Christopher/0000-0002-6628-8292; Wigneshweraraj, Sivaramesh/0000-0002-1418-4029; Stockley, Peter/0000-0002-1360-2751	Biotechnology and Biological Sciences Research Council [B19279] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Bordes P, 2004, MOL MICROBIOL, V54, P489, DOI 10.1111/j.1365-2958.2004.04280.x; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; Burgess RR, 2001, CURR OPIN MICROBIOL, V4, P126, DOI 10.1016/S1369-5274(00)00177-6; Burrows PC, 2004, EMBO J, V23, P4253, DOI 10.1038/sj.emboj.7600406; Burrows PC, 2003, J BIOL CHEM, V278, P29728, DOI 10.1074/jbc.M303596200; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Cannon W, 2003, J BIOL CHEM, V278, P19815, DOI 10.1074/jbc.M301296200; Cannon W, 2002, NUCLEIC ACIDS RES, V30, P886, DOI 10.1093/nar/30.4.886; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon W, 2001, J BIOL CHEM, V276, P386, DOI 10.1074/jbc.M007779200; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Chaney M, 1999, MOL MICROBIOL, V33, P1200, DOI 10.1046/j.1365-2958.1999.01566.x; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Huo YX, 2006, MOL MICROBIOL, V59, P168, DOI 10.1111/j.1365-2958.2005.04943.x; Jovanovic G, 1999, J MOL BIOL, V285, P469, DOI 10.1006/jmbi.1998.2263; Kuznedelov K, 2002, SCIENCE, V295, P855, DOI 10.1126/science.1066303; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; MORRIS L, 1994, J BIOL CHEM, V269, P11563; Mukhopadhyay J, 2001, CELL, V106, P453, DOI 10.1016/S0092-8674(01)00464-0; Rappas M, 2006, J MOL BIOL, V357, P481, DOI 10.1016/j.jmb.2005.12.052; Rombel I, 1998, COLD SPRING HARB SYM, V63, P157, DOI 10.1101/sqb.1998.63.157; Schuler B, 2005, P NATL ACAD SCI USA, V102, P2754, DOI 10.1073/pnas.0408164102; Scott DJ, 2000, BIOCHEM J, V352, P539, DOI 10.1042/0264-6021:3520539; Wang L, 2001, J BIOL CHEM, V276, P8979, DOI 10.1074/jbc.M009587200; Wigneshweplaraj SR, 2005, PROG NUCLEIC ACID RE, V79, P339, DOI 10.1016/S0079-6603(04)79007-8; Wigneshweraraj SR, 2003, METHOD ENZYMOL, V370, P646; Wigneshweraraj SR, 2003, J BIOL CHEM, V278, P3455, DOI 10.1074/jbc.M209442200; Wigneshweraraj SR, 2001, J MOL BIOL, V306, P681, DOI 10.1006/jmbi.2000.4393; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	35	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33717	33726		10.1074/jbc.M605731200	http://dx.doi.org/10.1074/jbc.M605731200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16926155	hybrid			2022-12-25	WOS:000241621400079
J	Fribley, AM; Evenchik, B; Zeng, QH; Park, BK; Guan, JY; Zhang, HL; Hale, TJ; Soengas, MS; Kaufman, RJ; Wang, CY				Fribley, Andrew M.; Evenchik, Benjamin; Zeng, Qinghua; Park, Bae Keun; Guan, Jean Y.; Zhang, Honglai; Hale, Timothy J.; Soengas, Maria S.; Kaufman, Randal J.; Wang, Cun-Yu			Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THAPSIGARGIN-INDUCED APOPTOSIS; UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; BCL-2 FAMILY; KAPPA-B; HEAD; BORTEZOMIB; EXPRESSION; CANCER; CHEMOTHERAPY	Cisplatin is one of the most common DNA-damaging agents used for treating patients with solid tumors such as squamous cell carcinoma (SCC). Unfortunately, significant levels of resistance in SCC cells emerge rapidly following cisplatin treatment. Here we report that the proteasome inhibitor PS-341, the representative of a new class of chemotherapeutic drugs, was capable of inducing apoptosis in cisplatin-resistant SCC cells via the endoplasmic reticulum stress. PS-341 stimulated the phosphorylation of PERK and the unfolded protein response, resulting in the induction of the transcription factor ATF-4. Importantly, the Bcl-2 homology domain 3-only (BH3-only) protein Noxa was found to be strongly induced in cisplatin-resistant SCC cells by PS-341 but not by cisplatin. The knock-down of Noxa using small interference RNA significantly abolished PS-341-mediated apoptosis in SCC cells. Using eIF2 alpha mutant mouse embryonic fibroblasts, we found that functional eIF2 alpha played an essential role in PS-341-induced Noxa expression. Taken together, our novel findings reveal a direct link between PS-341-induced endoplasmic reticulum stress and the mitochondria-dependent apoptotic pathway and suggest that PS-341 may be utilized for overcoming cisplatin-resistance in human SCC.	Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Wang, CY (corresponding author), Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, Sch Dent, 1101 N Univ Ave, Ann Arbor, MI 48109 USA.	cunywang@umich.edu	Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299; Fribley, Andrew/0000-0002-2046-1600	NIDCR NIH HHS [R01DE013848, T32-DE0757, R01DE15964] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013848] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Akervall J, 2004, CLIN CANCER RES, V10, P8204, DOI 10.1158/1078-0432.CCR-04-0722; Akervall J, 2004, ACTA OTO-LARYNGOL, V124, P851, DOI 10.1080/00016480410017323; Ando N, 2003, J CLIN ONCOL, V21, P4592, DOI 10.1200/JCO.2003.12.095; Bradford CR, 2003, HEAD NECK-J SCI SPEC, V25, P654, DOI 10.1002/hed.10274; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Duffey DC, 1999, CANCER RES, V59, P3468; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Foote RL, 2005, CANCER-AM CANCER SOC, V103, P559, DOI 10.1002/cncr.20803; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Futami T, 2005, J BIOL CHEM, V280, P826, DOI 10.1074/jbc.M409948200; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Licitra L, 2003, J CLIN ONCOL, V21, P327, DOI 10.1200/JCO.2003.06.146; Ling YH, 2003, J BIOL CHEM, V278, P33714, DOI 10.1074/jbc.M302559200; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nikrad M, 2005, MOL CANCER THER, V4, P443; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Patel V, 2001, CRIT REV ORAL BIOL M, V12, P55, DOI 10.1177/10454411010120010401; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Qin JZ, 2004, MOL CANCER THER, V3, P895; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SHIRAISHI T, CAN RES, V65, P6364; SIMON NW, 2005, GENE DEV, V19, P1294; Sturgis EM, 2004, SEMIN ONCOL, V31, P726, DOI 10.1053/j.seminoncol.2004.09.013; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Wang XD, 2001, GENE DEV, V15, P2922; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yeung BHY, 2006, J BIOL CHEM, V281, P11923, DOI 10.1074/jbc.M508533200; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004; Zhu HB, 2005, ONCOGENE, V24, P4993, DOI 10.1038/sj.onc.1208683	41	104	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31440	31447		10.1074/jbc.M604356200	http://dx.doi.org/10.1074/jbc.M604356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16928686				2022-12-25	WOS:000241235300028
J	Liu, Y; Sitaraman, S; Chang, A				Liu, Yu; Sitaraman, Sujatha; Chang, Amy			Multiple degradation pathways for misfolded mutants of the yeast plasma membrane ATPase, PMA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOID BASE SYNTHESIS; CELL-SURFACE STABILITY; H+-ATPASE; SACCHAROMYCES-CEREVISIAE; QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; MOLECULAR-GENETICS; ENDOCYTOSIS; ER; IDENTIFICATION	To understand protein sorting and quality control in the secretory pathway, we have analyzed intracellular trafficking of the yeast plasma membrane ATPase, Pma1. Pma1 is ideal for such studies because it is a very abundant polytopic membrane protein, and its localization and activity at the plasma membrane are essential for cell viability and growth. We have tested whether the cytoplasmic amino- and carboxyl-terminal domains of Pma1 carry sorting information. As the sole copy of Pma1, mutants truncated at either NH2 or COOH termini are targeted at least partially to the plasma membrane and have catalytic activity to sustain cell viability. The mutants are also delivered to degradative pathways. Strikingly, NH2- and COOH-terminal Pma1 mutants are differentially recognized for degradation at distinct cellular locales. COOH-terminal mutants are recognized for destruction by endoplasmic reticulum-associated degradation. By contrast, NH2- terminal mutants escape detection by endoplasmic reticulum-associated degradation entirely, and undergo endocytosis for vacuolar degradation after apparently normal cell surface targeting. Both NH2- and COOH-terminal mutants are conformationally abnormal, as revealed by increased sensitivity to tryptic cleavage, but are able to assemble to form oligomers. We propose that different quality control mechanisms may assess discrete domains of Pma1 rather than a global conformational state.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Chang, A (corresponding author), 830 N Univ, Ann Arbor, MI 48109 USA.	amychang@umich.edu	Chang, Amy/AAS-5491-2020; Liu, Yu/X-5864-2019	Chang, Amy/0000-0003-3682-6456; 	NIGMS NIH HHS [GM 58212] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058212, R55GM058212] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arvan P, 2002, TRAFFIC, V3, P771, DOI 10.1034/j.1600-0854.2002.31102.x; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; Chang A, 2002, METHOD ENZYMOL, V351, P339; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; EPPING E, 2002, J BIOL CHEM, V277, P34680; Friant S, 2003, EMBO J, V22, P3783, DOI 10.1093/emboj/cdg375; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; Hasper A, 1999, BBA-BIOMEMBRANES, V1420, P214, DOI 10.1016/S0005-2736(99)00100-5; JONES EW, 1991, J BIOL CHEM, V266, P7963; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Kuhlbrandt W, 2002, SCIENCE, V297, P1692, DOI 10.1126/science.1072574; Lecchi S, 2005, BIOCHEMISTRY-US, V44, P16624, DOI 10.1021/bi051555f; Lee MCS, 2002, J BIOL CHEM, V277, P22395, DOI 10.1074/jbc.M200450200; Liu Y, 2006, J CELL SCI, V119, P360, DOI 10.1242/jcs.02749; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; Mason AB, 2006, J BIOL CHEM, V281, P23887, DOI 10.1074/jbc.M601818200; Michelsen K, 2005, EMBO REP, V6, P717, DOI 10.1038/sj.embor.7400480; Morsomme P, 2000, BBA-REV BIOMEMBRANES, V1469, P133, DOI 10.1016/S0304-4157(00)00015-0; Nothwehr SF, 1996, MOL CELL BIOL, V16, P2700; Portillo F, 2000, BBA-REV BIOMEMBRANES, V1469, P31, DOI 10.1016/S0304-4157(99)00011-8; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rose MD., 1990, METHODS YEAST GENETI; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Sayeed A, 2005, CRIT REV BIOCHEM MOL, V40, P75, DOI 10.1080/10409230590918685; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824	41	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31457	31466		10.1074/jbc.M606643200	http://dx.doi.org/10.1074/jbc.M606643200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16928681	Bronze			2022-12-25	WOS:000241235300030
J	Fawcett, GL; Santi, CM; Butler, A; Harris, T; Covarrubias, M; Salkoff, L				Fawcett, Gloria L.; Santi, Celia M.; Butler, Alice; Harris, Thanawath; Covarrubias, Manuel; Salkoff, Lawrence			Mutant analysis of the Shal (Kv4) voltage-gated fast transient K+ channel in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSED-STATE INACTIVATION; POTASSIUM CHANNELS; ALPHA-SUBUNIT; C-ELEGANS; MUSCLE-CELLS; CURRENT DIVERSITY; SEX DETERMINATION; OUTWARD CURRENT; MOLECULAR-BASIS; GENE FAMILY	Shal (Kv4)alpha-subunits are the most conserved among the family of voltage-gated potassium channels. Previous work has shown that the Shal potassium channel subfamily underlies the predominant fast transient outward current in Drosophila neurons (Tsunoda, S., and Salkoff, L. ( 1995) J. Neurosci. 15, 1741 1754) and the fast transient outward current in mouse heart muscle (Guo, W., Jung, W. E., Marionneau, C., Aimond, F., Xu, H., Yamada, K. A., Schwarz, T. L., Demolombe, S., and Nerbonne, J. M. ( 2005) Circ. Res. 97, 1342 - 1350). We show that Shal channels also play a role as the predominant transient outward current in Caenorhabditis elegans muscle. Green fluorescent protein promoter experiments also revealed SHL-1 expression in a subset of neurons as well as in C. elegans body wall muscle and in male-specific diagonal muscles. The shl-1 (ok1168) null mutant removed all fast transient outward current from muscle cells. SHL-1 currents strongly resembled Shal currents in other species except that they were active in a more depolarized voltage range. We also determined that the remaining delayed-rectifier current in cultured myocytes was carried by the Shaker ortholog SHK-1. In shl-1 ( ok1168) mutants there was a significant compensatory increase in the SHK-1 current. Male shl-1 ( ok1168) animals exhibited reduced mating efficiency resulting from an apparent difficulty in locating the hermaphrodite vulva. SHL-1 channels are apparently important in fine-tuning complex behaviors, such as mating, that play a crucial role in the survival and propagation of the species.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, Philadelphia, PA 19107 USA	Washington University (WUSTL); Washington University (WUSTL); Jefferson University	Salkoff, L (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	salkoffl@pcg.wustl.edu		Covarrubias, Manuel/0000-0002-0881-4143	NCRR NIH HHS [R24 RR017342-01, R24 RR017342] Funding Source: Medline; NIAAA NIH HHS [T32 AA007463] Funding Source: Medline; NIGMS NIH HHS [R01 GM067154-01A1, R01 GM067154] Funding Source: Medline; NINDS NIH HHS [R01 NS032337-12, R01 NS032337-07, R01 NS032337-06, R01 NS032337, R01 NS032337-10, R01 NS032337-08, R01 NS032337-11, R01 NS032337-09A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR017342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Amberg GC, 2003, AM J PHYSIOL-CELL PH, V284, pC583, DOI 10.1152/ajpcell.00301.2002; Amberg GC, 2002, J PHYSIOL-LONDON, V544, P403, DOI 10.1113/jphysiol.2002.025163; Bahring R, 2001, J PHYSIOL-LONDON, V535, P65, DOI 10.1111/j.1469-7793.2001.00065.x; Baro DJ, 1996, J NEUROSCI, V16, P1689; Baro DJ, 2000, J NEUROSCI, V20, P6619, DOI 10.1523/JNEUROSCI.20-17-06619.2000; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; Beck EJ, 2001, BIOPHYS J, V81, P867, DOI 10.1016/S0006-3495(01)75747-5; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Cai X, 2004, NEURON, V44, P351, DOI 10.1016/j.neuron.2004.09.026; Christensen M, 2002, NEURON, V33, P503, DOI 10.1016/S0896-6273(02)00591-3; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P31, DOI 10.1113/jphysiol.1971.sp009366; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; Crowder CM, 1996, ANESTHESIOLOGY, V85, P901, DOI 10.1097/00000542-199610000-00027; Dilks D, 1999, J NEUROPHYSIOL, V81, P1974, DOI 10.1152/jn.1999.81.4.1974; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Garcia LR, 2003, J NEUROSCI, V23, P2696; Garcia LR, 2001, CELL, V107, P777, DOI 10.1016/S0092-8674(01)00600-6; Guo WN, 2005, CIRC RES, V97, P1342, DOI 10.1161/01.RES.0000196559.63223.aa; Guo WN, 1999, J PHYSIOL-LONDON, V521, P587, DOI 10.1111/j.1469-7793.1999.00587.x; Guo WN, 2000, CIRC RES, V87, P73, DOI 10.1161/01.RES.87.1.73; HAGIWARA S, 1961, J PHYSIOL-LONDON, V155, P471; Hahn J, 2003, J NEUROSCI, V23, P10859; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1992, IONIC CHANNELS EXCIT, P76; HODGKIN J, 1984, Journal of Embryology and Experimental Morphology, V83, P103; HODGKIN J, 1987, DEVELOPMENT, V101, P5; HODGKIN J, 1983, NATURE, V304, P267, DOI 10.1038/304267a0; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Jospin M, 2002, J PHYSIOL-LONDON, V544, P373, DOI 10.1113/jphysiol.2002.022293; KOVAC MP, 1982, J NEUROPHYSIOL, V47, P909, DOI 10.1152/jn.1982.47.5.909; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MacLean JN, 2003, NEURON, V37, P109, DOI 10.1016/S0896-6273(02)01104-2; NEHER E, 1971, J GEN PHYSIOL, V58, P36, DOI 10.1085/jgp.58.1.36; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; Ohya S, 1997, FEBS LETT, V420, P47, DOI 10.1016/S0014-5793(97)01483-X; OKKEMA PG, 1993, GENETICS, V135, P385; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; Price MP, 2004, J BIOL CHEM, V279, P53886, DOI 10.1074/jbc.M407708200; Ramakers GMJ, 2002, P NATL ACAD SCI USA, V99, P10144, DOI 10.1073/pnas.152620399; Sah R, 2003, J PHYSIOL-LONDON, V546, P5, DOI 10.1113/jphysiol.2002.026468; Saifee O, 1998, MOL BIOL CELL, V9, P1235, DOI 10.1091/mbc.9.6.1235; Salkoff L, 2001, NEUROSCIENCE, V103, P853, DOI 10.1016/S0306-4522(01)00079-3; Santi CM, 2003, P NATL ACAD SCI USA, V100, P14391, DOI 10.1073/pnas.1935976100; Shibata R, 2000, J NEUROSCI, V20, P4145; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Takahashi E, 2004, NEUROSCI LETT, V359, P37, DOI 10.1016/j.neulet.2004.01.066; THOMPSON SH, 1977, J PHYSIOL-LONDON, V265, P465, DOI 10.1113/jphysiol.1977.sp011725; TSUNODA S, 1995, J NEUROSCI, V15, P1741, DOI 10.1523/JNEUROSCI.15-03-01741.1995; Waterston R., 1988, NEMATODE C ELEGANS, P281; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Xu HD, 1999, J PHYSIOL-LONDON, V519, P11, DOI 10.1111/j.1469-7793.1999.0011o.x; Yuan A, 2003, NEURON, V37, P765, DOI 10.1016/S0896-6273(03)00096-5; Yuan A, 2000, NAT NEUROSCI, V3, P771, DOI 10.1038/77670; Yuan LL, 2002, J NEUROSCI, V22, P4860, DOI 10.1523/JNEUROSCI.22-12-04860.2002; Yuan WL, 2005, J NEUROSCI, V25, P9185, DOI 10.1523/JNEUROSCI.2858-05.2005	62	24	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30725	30735		10.1074/jbc.M605814200	http://dx.doi.org/10.1074/jbc.M605814200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16899454	Green Accepted, hybrid			2022-12-25	WOS:000241075900049
J	Hirao, M; Tamai, N; Tsumaki, N; Yoshikawa, H; Myoui, A				Hirao, Makoto; Tamai, Noriyuki; Tsumaki, Noriyuki; Yoshikawa, Hideki; Myoui, Akira			Oxygen tension regulates chondrocyte differentiation and function during endochondral ossification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BONE MORPHOGENETIC PROTEIN-2; MESENCHYMAL STEM-CELLS; COLLAGEN X PROMOTER; ARTICULAR-CARTILAGE; INDUCED APOPTOSIS; GENE-EXPRESSION; CHONDROGENESIS; C3H10T1/2; GROWTH	Cartilage functions at a lower oxygen tension than most other tissues. To determine the role of oxygen tension in chondrocyte differentiation and function, we investigated the influence of oxygen tension in the pluripotent mesenchymal cell line C3H10T1/2 and 14.5E mice embryo forelimb organ culture. 10T1/2 cells and embryo forelimbs were cultured under normoxia (20% O-2) or hypoxia (5% O-2) in the presence of recombinant human bone morphogenetic protein 2. To elucidate the mechanism by which oxygen tension influences chondrocyte differentiation, the Smad pathway was examined using Smad6 overexpression adenovirus and Smad6 transgenic mice embryo forelimbs. The p38 MAPK pathway was examined using dominant-negative MKK3 and FR167653, a specific p38 MAPK inhibitor. The transcriptional activities of Sox9 and Runx2 were also investigated. Hypoxia promoted bone morphogenetic protein 2-induced glycosaminoglycan production and suppressed alkaline phosphatase activity and mineralization of C3H10T1/2. Thus, hypoxia promoted chondrocytic commitment rather than osteoblastic differentiation. In the mice embryo forelimb organ culture, hypoxia increased cartilaginous matrix synthesis. These effects were primarily mediated by p38 MAPK activation, independent of Sox9. Hypoxia inhibited Col10a1 (type X collagen alpha 1) expression via down-regulation of Runx2 activity by Smad suppression and histone deacetylase 4 activation. In conclusion, hypoxia promotes chondrocytic differentiation and cartilage matrix synthesis and suppresses terminal chondrocyte differentiation. These hypoxia-induced phenomena may act on chondrocytes to enhance and preserve their phenotype and function during chondrocyte differentiation and endochondral ossification.	Osaka Univ Hosp, Med Ctr Translat Res, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Orthopaed, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Myoui, A (corresponding author), Osaka Univ Hosp, Med Ctr Translat Res, 2-15 Yamadaoka, Suita, Osaka 5650871, Japan.	myoi@hp-mctr.med.osaka-u.ac.jp	Myoui, Akira/E-8296-2010; Tamai, Noriyuki/AAO-4939-2021	Tsumaki, Noriyuki/0000-0002-0520-3654				AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005; Atkinson BL, 1997, J CELL BIOCHEM, V65, P325, DOI 10.1002/(SICI)1097-4644(19970601)65:3<325::AID-JCB3>3.0.CO;2-U; Beier F, 1999, BIOCHEM BIOPH RES CO, V262, P50, DOI 10.1006/bbrc.1999.1178; Beitner-Johnson D, 1998, BIOCHEM BIOPH RES CO, V242, P61, DOI 10.1006/bbrc.1997.7907; Bosnakovski D, 2004, EXP HEMATOL, V32, P502, DOI 10.1016/j.exphem.2004.02.009; BRIGHTON CT, 1984, ARTHRITIS RHEUM-US, V27, P1290, DOI 10.1002/art.1780271112; Chauchereau A, 2004, ONCOGENE, V23, P8777, DOI 10.1038/sj.onc.1208128; CONLON RA, 1993, METHOD ENZYMOL, V225, P373; Drissi MH, 2003, J CELL BIOCHEM, V90, P1287, DOI 10.1002/jcb.10677; FALCHUK KH, 1970, AM J MED, V49, P223, DOI 10.1016/S0002-9343(70)80078-X; FERRELL WR, 1992, J PHYSIOL-LONDON, V449, P607, DOI 10.1113/jphysiol.1992.sp019104; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; GIBSON GJ, 1985, J CELL BIOL, V101, P277, DOI 10.1083/jcb.101.1.277; Haas AR, 2000, METH MOL B, V137, P383; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hiraki Y, 1997, J BIOL CHEM, V272, P32419, DOI 10.1074/jbc.272.51.32419; Horiki M, 2004, J CELL BIOL, V165, P433, DOI 10.1083/jcb.200311015; Huang CYC, 2004, ANAT REC PART A, V278A, P428, DOI 10.1002/ar.a.20010; Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kamiya N, 2002, J BONE MINER RES, V17, P1832, DOI 10.1359/jbmr.2002.17.10.1832; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KIAER T, 1988, CLIN ORTHOP RELAT R, V229, P149; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Lee JK, 2004, P NATL ACAD SCI USA, V101, P8815, DOI 10.1073/pnas.0402800101; LEE NH, 1974, CALC TISS RES, V16, P277, DOI 10.1007/BF02008235; Lee RB, 1997, BIOCHEM J, V321, P95, DOI 10.1042/bj3210095; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Lim YB, 2000, BIOCHEM BIOPH RES CO, V273, P609, DOI 10.1006/bbrc.2000.2987; Lim YB, 2003, J CELL BIOCHEM, V88, P713, DOI 10.1002/jcb.10389; MARTCUS RE, 1973, ARTHRITIS RHEUM, V16, P646; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; OLESEN LL, 1970, ARTHRITIS RHEUM, V13, P769; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; OTTE P, 1991, Z RHEUMATOL, V50, P304; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Park JH, 2002, MOL CELL ENDOCRINOL, V192, P197, DOI 10.1016/S0303-7207(02)00036-9; Ratisoontorn C, 2005, BONE, V36, P627, DOI 10.1016/j.bone.2005.01.010; Robins JC, 2005, BONE, V37, P313, DOI 10.1016/j.bone.2005.04.040; Schipani E, 2001, GENE DEV, V15, P2865; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; Sen A, 2001, J CELL BIOCHEM, V81, P312, DOI 10.1002/1097-4644(20010501)81:2<312::AID-JCB1046>3.0.CO;2-Q; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; SILVER IA, 1975, PHILOS T ROY SOC B, V271, P261, DOI 10.1098/rstb.1975.0050; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; TREUHAFT PS, 1971, ARTHRITIS RHEUM, V14, P475, DOI 10.1002/art.1780140407; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; VORKAMP A, 1996, SCIENCE, V273, P613; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zehentner BK, 1999, J BONE MINER RES, V14, P1734, DOI 10.1359/jbmr.1999.14.10.1734; Zhen XC, 2001, J BIOL CHEM, V276, P4879, DOI 10.1074/jbc.M004990200; Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	71	140	145	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31079	31092		10.1074/jbc.M602296200	http://dx.doi.org/10.1074/jbc.M602296200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16905540	hybrid			2022-12-25	WOS:000241075900084
J	Lopez-Contreras, AJ; Lopez-Garcia, C; Jimenez-Cervantes, C; Cremades, A; Penafiel, R				Lopez-Contreras, Andres J.; Lopez-Garcia, Carlos; Jimenez-Cervantes, Celia; Cremades, Asuncion; Penafiel, Rafael			Mouse ornithine decarboxylase-like gene encodes an antizyme inhibitor devoid of ornithine and arginine decarboxylating activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC IRREVERSIBLE INHIBITION; HYDROXY-L-ARGININE; TRANSGENIC MICE; RAT-LIVER; TRANSCRIPTIONAL TARGET; POLYAMINE TRANSPORT; CELL-GROWTH; DEGRADATION; AGMATINE; EXPRESSION	Ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, is a labile protein that is regulated by interacting with antizymes (AZs), a family of polyamine-induced proteins. Recently, a novel human gene highly homologous to ODC, termed ODC-like or ODC-paralogue (ODCp), was cloned, but the studies aimed to determine its function rendered contradictory results. We have cloned the mouse orthologue of human ODCp and studied its expression and possible function. mRNA of mouse Odcp was found in the brain and testes, showing a conserved expression pattern with regard to the human gene. Transfection of mouse Odcp in HEK 293T cells elicited an increase in ODC activity, but no signs of arginine decarboxylase activity were evident. On the other hand, whereas the ODCp protein was mainly localized in the mitochondrial/membrane fraction, ODC activity was found in the cytosolic fraction and was markedly decreased by small interfering RNA against human ODC. Co-transfection experiments with combinations of Odc, Az1, Az2, Az3, antizyme inhibitor (Azi), and Odcp genes showed that ODCp mimics the action of AZI, rescuing ODC from the effects of AZs and prevented ODC degradation by the proteasome. A direct interaction between ODCp and AZs was detected by immunoprecipitation experiments. We conclude that mouse ODCp has no intrinsic decarboxylase activity, but it acts as a novel antizyme inhibitory protein (AZI2).	Univ Murcia, Fac Med, Dept Pharmacol, E-30100 Murcia, Spain; Univ Murcia, Fac Med, Dept Biochem & Mol Biol & Immunol B, E-30100 Murcia, Spain	University of Murcia; University of Murcia	Penafiel, R (corresponding author), Univ Murcia, Fac Med, Dept Biochem & Mol Biol, Campus Espinardo, E-30100 Murcia, Spain.	rapegar@um.es	Lopez-Contreras, Andres J/AAA-1110-2020; Penafiel, Rafael/H-2660-2015; Jimenez-Cervantes, Celia/H-1953-2015	Penafiel, Rafael/0000-0002-5816-1056; Jimenez-Cervantes, Celia/0000-0002-5821-9510; Lopez-Contreras, Andres Joaquin/0000-0002-5517-7327; Lopez-Garcia, Carlos/0000-0001-9848-8216				Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIRECKA H, 1985, PLANT PHYSIOL, V79, P509, DOI 10.1104/pp.79.2.509; BITONTI AJ, 1987, BIOCHEM J, V242, P69, DOI 10.1042/bj2420069; BOUCHER JL, 1994, BIOCHEM BIOPH RES CO, V203, P1614, DOI 10.1006/bbrc.1994.2371; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Coleman CS, 2004, BIOCHEM J, V379, P849, DOI 10.1042/BJ20040035; COLEMAN CS, 1993, J BIOL CHEM, V268, P24572; DAGHIGH F, 1994, BIOCHEM BIOPH RES CO, V202, P174, DOI 10.1006/bbrc.1994.1909; Feith DJ, 2001, CANCER RES, V61, P6073; Fong LYY, 2003, CANCER RES, V63, P3945; Gilad GM, 1996, NEUROSCI LETT, V216, P33; Gruendler C, 2001, J BIOL CHEM, V276, P46533, DOI 10.1074/jbc.M105500200; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; Horyn O, 2005, BIOCHEM J, V388, P419, DOI 10.1042/BJ20041260; Ivanov IP, 2000, P NATL ACAD SCI USA, V97, P4808, DOI 10.1073/pnas.070055897; Iyer RK, 2002, MOL GENET METAB, V75, P209, DOI 10.1006/mgme.2001.3277; Janne J, 2004, EUR J BIOCHEM, V271, P877, DOI 10.1111/j.1432-1033.2004.04009.x; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; Lortie MJ, 1996, J CLIN INVEST, V97, P413, DOI 10.1172/JCI118430; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; Mangold U, 2005, IUBMB LIFE, V57, P671, DOI 10.1080/15216540500307031; Mangold U, 2005, BIOCHEM J, V385, P21, DOI 10.1042/BJ20040547; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MEGOSH L, 1995, CANCER RES, V55, P4205; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; Mistry SK, 2002, AM J PHYSIOL-GASTR L, V282, pG375, DOI 10.1152/ajpgi.00386.2001; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MORRISSEY J, 1995, KIDNEY INT, V47, P1458, DOI 10.1038/ki.1995.204; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Murakami Y, 1996, BIOCHEM J, V317, P77, DOI 10.1042/bj3170077; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699; OSTERMAN AL, 1995, J BIOL CHEM, V270, P11797, DOI 10.1074/jbc.270.20.11797; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Pegg AE, 2003, BIOCHEM SOC T, V31, P356, DOI 10.1042/BST0310356; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; Penafiel R, 1998, EUR COMMISS SCI RES, P79; Pitkanen LT, 2001, BIOCHEM BIOPH RES CO, V287, P1051, DOI 10.1006/bbrc.2001.5703; POULIN R, 1992, J BIOL CHEM, V267, P150; RAASCH W, 1995, LIFE SCI, V56, P2319, DOI 10.1016/0024-3205(95)00226-V; Reddy SG, 1996, J BIOL CHEM, V271, P24945, DOI 10.1074/jbc.271.40.24945; Regunathan S, 2000, J NEUROCHEM, V74, P2201, DOI 10.1046/j.1471-4159.2000.0742201.x; Regunathan S, 1996, J PHARMACOL EXP THER, V276, P1272; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; RUSSELL D, 1968, P NATL ACAD SCI USA, V60, P1420, DOI 10.1073/pnas.60.4.1420; Ruzafa C, 2003, J NUTR BIOCHEM, V14, P333, DOI 10.1016/S0955-2863(03)00055-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sastre M, 1996, J NEUROCHEM, V67, P1761; Sastre M, 1998, BIOCHEM J, V330, P1405, DOI 10.1042/bj3301405; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; Seiler N, 2004, AMINO ACIDS, V26, P217, DOI 10.1007/s00726-004-0070-z; SEILER N, 1983, METHOD ENZYMOL, V94, P10; Shah R, 2004, J BIOL CHEM, V279, P35760, DOI 10.1074/jbc.M405366200; Shantz LM, 1999, INT J BIOCHEM CELL B, V31, P107, DOI 10.1016/S1357-2725(98)00135-6; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; Szymanska G, 1997, ANAL BIOCHEM, V252, P96, DOI 10.1006/abio.1997.2319; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; TOBIAS KE, 1993, EUR J BIOCHEM, V218, P245, DOI 10.1111/j.1432-1033.1993.tb18371.x; TSIRKA S, 1992, J BIOL CHEM, V267, P23057; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Zhu C, 1999, J BIOL CHEM, V274, P26425, DOI 10.1074/jbc.274.37.26425; Zhu MY, 2004, BBA-GEN SUBJECTS, V1670, P156, DOI 10.1016/j.bbagen.2003.11.006	76	51	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30896	30906		10.1074/jbc.M602840200	http://dx.doi.org/10.1074/jbc.M602840200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16916800	hybrid			2022-12-25	WOS:000241075900065
J	Ryjenkov, DA; Simm, R; Romling, U; Gomelsky, M				Ryjenkov, Dmitri A.; Simm, Roger; Romling, Ute; Gomelsky, Mark			The PilZ domain is a receptor for the second messenger c-di-GMP - The PilZ domain protein YcgR controls motility in enterobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; CYCLIC DIGUANYLATE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; ACETOBACTER-XYLINUM; CELLULOSE SYNTHESIS; SIGNALING MOLECULE; ALLOSTERIC CONTROL; BINDING-PROTEIN; EAL DOMAINS	The ubiquitous bacterial second messenger c-di-GMP controls exopolysaccharide synthesis, flagella-and pili-based motility, gene expression, and interactions of bacteria with eukaryotic hosts. With the exception of bacterial cellulose synthases, the identities of c-di-GMP receptors and end targets have remained unknown. Recently, Amikam and Galperin (Amikam, D., and Galperin, M. (2006) Bioinformatics 22, 3-6) hypothesized that the PilZ domains present in the BcsA subunits of bacterial cellulose synthases function in c-di-GMP binding. This hypothesis has been tested here using the Escherichia coli PilZ domain protein YcgR, its individual PilZ domain and the PilZ domain from Gluconacetobacter xylinus BcsA. YcgR was purified and found to bind c-di-GMP tightly and specifically, K-d 0.84 mu M. Individual PilZ domains from YcgR and BcsA also bound c-di-GMP, albeit with lesser affinity, indicating that PilZ is sufficient for binding. The site-directed mutagenesis performed on YcgR implicated the most conserved residues in the PilZ domain directly in c-di-GMP binding. It is suggested that c-di-GMP binding to PilZ brings about conformational changes in the protein that stabilize the bound ligand and initiate the downstream signal transduction cascade. While the identity of the downstream partner(s) of YcgR remains unknown, it is shown that YcgR regulates flagellum-based motility in a c-di-GMP-dependent manner. The inactivation of ycgR improves swimming and swarming motility of the poorly motile yhjH mutants of Salmonella enterica serovar Typhimurium UMR1. Therefore, biochemical and genetic evidence presented here establishes PilZ as a long sought after c-di-GMP-binding domain and YcgR as a c-di-GMP receptor affecting motility in enterobacteria.	Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA; Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden	University of Wyoming; Karolinska Institutet	Romling, U (corresponding author), Univ Wyoming, Dept Mol Biol, 1000 E Univ Ave,Dept 3944, Laramie, WY 82071 USA.	Ute.Romling@ki.se; Gomelsky@uwyo.edu	gomelsky, mark/F-6209-2010; Simm, Roger/AAN-8965-2020	Simm, Roger/0000-0001-5187-2456; Gomelsky, Mark/0000-0003-4077-3932; Romling, Ute/0000-0003-3812-6621				Alm RA, 1996, J BACTERIOL, V178, P46, DOI 10.1128/jb.178.1.46-53.1996; Amikam D, 2006, BIOINFORMATICS, V22, P3, DOI 10.1093/bioinformatics/bti739; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Christen M, 2005, J BIOL CHEM, V280, P30829, DOI 10.1074/jbc.M504429200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Frye J, 2006, J BACTERIOL, V188, P2233, DOI 10.1128/JB.188.6.2233-2243.2006; Gerstel U, 2003, MOL MICROBIOL, V49, P639, DOI 10.1046/j.1365-2958.2003.03594.x; Greer-Phillips SE, 2004, J BACTERIOL, V186, P6595, DOI 10.1128/JB.186.19.6595-6604.2004; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Ko M, 2000, J MOL BIOL, V303, P371, DOI 10.1006/jmbi.2000.4147; MAHARAJ R, 1993, GENE, V136, P267, DOI 10.1016/0378-1119(93)90477-K; MAYER R, 1991, P NATL ACAD SCI USA, V88, P5472, DOI 10.1073/pnas.88.12.5472; MUNOZDORADO J, 1991, CELL, V67, P995, DOI 10.1016/0092-8674(91)90372-6; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Romling U, 1998, J BACTERIOL, V180, P722; Romling U, 2005, MOL MICROBIOL, V57, P629, DOI 10.1111/j.1365-2958.2005.04697.x; Romling U, 2005, CELL MOL LIFE SCI, V62, P1234, DOI 10.1007/s00018-005-4557-x; ROSS P, 1990, J BIOL CHEM, V265, P18933; Ryan RP, 2006, P NATL ACAD SCI USA, V103, P6712, DOI 10.1073/pnas.0600345103; Rychlik I, 2002, ARCH MICROBIOL, V178, P411, DOI 10.1007/s00203-002-0458-7; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005; SCHMIEGER H, 1972, MOL GEN GENET, V119, P75, DOI 10.1007/BF00270447; Schuster-Bockler B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-7; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Tamayo R, 2005, J BIOL CHEM, V280, P33324, DOI 10.1074/jbc.M506500200; Weinhouse H, 1997, FEBS LETT, V416, P207, DOI 10.1016/S0014-5793(97)01202-7; Zhang ZY, 2006, J AM CHEM SOC, V128, P7015, DOI 10.1021/ja0613714	30	367	394	3	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30310	30314		10.1074/jbc.C600179200	http://dx.doi.org/10.1074/jbc.C600179200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16920715	hybrid			2022-12-25	WOS:000241075900003
J	Yang, XC; Purdy, M; Marzluff, WF; Dominski, Z				Yang, Xiao-cui; Purdy, Matthew; Marzluff, William F.; Dominski, Zbigniew			Characterization of 3 ' hExo, a 3 ' exonuclease specifically interacting with the 3 ' end of histone mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNASE ACTIVITY; CELL-CYCLE; C-ELEGANS; 3' END; IDENTIFICATION	The 3' end of mammalian histone mRNAs consisting of a conserved stem-loop and a terminal ACCCA interacts with a recently identified human 3' exonuclease designated 3'hExo. The sequence-specific interaction suggests that 3'hExo may participate in the degradation of histone mRNAs. ERI-1, a Caenorhabditis elegans homologue of 3'hExo, has been implicated in degradation of small interfering RNAs. We introduced a number of mutations to 3'hExo to identify residues required for RNA binding and catalysis. To assure that the introduced mutations specifically target one of these two activities of 3'hExo rather than cause global structural defects, the mutant proteins were tested in parallel for the ability both to bind the stem-loop RNA and to degrade RNA substrates. Our analysis confirms that 3'hExo is a member of the DEDDh family of 3' exonucleases. Specific binding to the RNA requires the SAP domain and two lysines located immediately to its C terminus. 3'hExo binds with the highest affinity to the wild-type 3' end of histone mRNA, and any changes to this sequence reduce efficiency of binding. 3'hExo has only residual, if any, 3' exonuclease activity on DNA substrates and localizes mostly to the cytoplasm, suggesting that in vivo it performs exclusively RNA-specific functions. Efficient degradation of RNA substrates by 3'hExo requires 2' and 3' hydroxyl groups at the last nucleotide. 3'hExo removes 3' overhangs of small interfering RNAs, whereas the double-stranded region is resistant to the enzymatic activity.	Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Dominski, Z (corresponding author), Univ N Carolina, Program Mol Biol & Biotechnol, CB 3280, Chapel Hill, NC 27599 USA.	dominski@med.unc.edu			NIGMS NIH HHS [GM29832] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029832] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Buhler M, 2005, MOL CELL, V18, P307, DOI 10.1016/j.molcel.2005.03.030; Cheng Y, 2004, J MOL BIOL, V343, P305, DOI 10.1016/j.jmb.2004.08.055; Dominski Z, 1999, GENE, V239, P1, DOI 10.1016/S0378-1119(99)00367-4; Dominski Z, 2003, MOL CELL, V12, P295, DOI 10.1016/S1097-2765(03)00278-8; Duchaine TF, 2006, CELL, V124, P343, DOI [10.1016/j.cell.2005.11.036, 10.1016/j.cel.2005.11.036]; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Korner CG, 1997, J BIOL CHEM, V272, P10448; Marzluff WF, 2002, CURR OPIN CELL BIOL, V14, P692, DOI 10.1016/S0955-0674(02)00387-3; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; Ren YG, 2002, J BIOL CHEM, V277, P5982, DOI 10.1074/jbc.M111515200; Sanchez R, 2002, MOL CELL BIOL, V22, P7093, DOI 10.1128/MCB.22.20.7093-7104.2002; Sollner-Webb B, 2001, METHOD ENZYMOL, V342, P378, DOI 10.1016/S0076-6879(01)42560-2; Viswanathan M, 1998, J BIOL CHEM, V273, P35126, DOI 10.1074/jbc.273.52.35126; Viswanathan M, 1999, GENETICS, V151, P929; Zuo YH, 1999, NUCLEIC ACIDS RES, V27, P4077, DOI 10.1093/nar/27.20.4077; Zuo YH, 2002, J BIOL CHEM, V277, P50155, DOI 10.1074/jbc.M207706200; Zuo YH, 2002, J BIOL CHEM, V277, P29654, DOI 10.1074/jbc.M204252200; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	20	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30447	30454		10.1074/jbc.M602947200	http://dx.doi.org/10.1074/jbc.M602947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912046	hybrid, Green Published			2022-12-25	WOS:000241075900019
J	Luo, C; Pan, H; Mines, M; Watson, K; Zhang, JW; Fan, GH				Luo, Cherry; Pan, Heng; Mines, Marjelo; Watson, Kurt; Zhang, Jingwu; Fan, Guo-Huang			CXCL12 induces tyrosine phosphorylation of cortactin, which plays a role in CXC chemokine receptor 4-mediated extracellular signal-regulated kinase activation and chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; CLATHRIN-COATED PITS; ENDOTHELIAL-CELLS; BREAST-CANCER; MEDIATED ENDOCYTOSIS; BINDING-PROTEIN; DOWN-REGULATION; ARP2/3 COMPLEX; DYNAMIC ACTIN; C-SRC	CXC chemokine receptor 4 (CXCR4) plays a role in the development of immune and central nervous systems as well as in cancer growth and metastasis. CXCR4-initiated signaling cascades leading to cell proliferation and chemotaxis are critical for these functions. The present study demonstrated that stimulation of CXCR4 by its ligand, CXCL12, induced transient translocation of cortactin from endosomal compartments to the cell periphery where it colocalized with CXCR4 followed by internalization of CXCR4 together with cortactin into endosomes. Cortactin was co-immunoprecipitated with CXCR4 in response to CXCL12 treatment in a time-dependent manner. Ligand stimulation induced phosphorylation of cortact in at tyrosine 421, and the phosphorylation was both c-Src- and dynamin-dependent. Cortactin overexpression promoted CXCR4 internalization and recycling. However, overexpression of a cortactin mutant in which tyrosine 421 was replaced with alanine (cortactin-Y421A) or knockdown of cortactin with RNA interference (RNAi) reduced CXCR4 internalization in response to CXCL12. CXCR4-mediated activation of extracellular signal-regulated kinases 1 and 2 was significantly prolonged by overexpression of wild-type cortactin but not by the cortactin-Y421A mutant and was inhibited by cortactin knockdown with RNAi. Moreover, CXCL12-induced chemotaxis was enhanced by cortactin overexpression, reduced by overexpression of the cortactin-Y421A mutant, and blocked by cortactin knock-down with RNAi. These data provide strong evidence for an important role of cortactin in CXCR4 signaling and trafficking as well in the receptor-mediated cell migration.	Meharry Med Coll, Dept Vet Affairs, Nashville, TN 37208 USA; Meharry Med Coll, Dept Biomed Sci, Nashville, TN 37208 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China	Meharry Medical College; Meharry Medical College; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Fan, GH (corresponding author), Meharry Med Coll, Dept Vet Affairs, Nashville, TN 37208 USA.	gfan@mmc.edu			NCRR NIH HHS [RR03032-19] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bagri A, 2002, DEVELOPMENT, V129, P4249; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Cabioglu N, 2005, CANCER RES, V65, P6493, DOI 10.1158/0008-5472.CAN-04-1303; Campbell DH, 1999, CANCER RES, V59, P5376; Cantarelli VV, 2000, INFECT IMMUN, V68, P382, DOI 10.1128/IAI.68.1.382-386.2000; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; de Parseval A, 2001, J VIROL, V75, P4528, DOI 10.1128/JVI.75.10.4528-4539.2001; Ding Y, 2006, MOL PHARMACOL, V69, P1269, DOI 10.1124/mol.105.020271; Fan GH, 2004, MOL BIOL CELL, V15, P2456, DOI 10.1091/mbc.E03-09-0706; Fan GH, 2002, J BIOL CHEM, V277, P6590, DOI 10.1074/jbc.M110588200; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Fan GH, 2003, BLOOD, V101, P2115, DOI 10.1182/blood-2002-07-1965; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Inngjerdingen M, 2002, BLOOD, V99, P4318, DOI 10.1182/blood.V99.12.4318; Kaksonen M, 2000, J CELL SCI, V113, P4421; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Lu M, 2002, P NATL ACAD SCI USA, V99, P7090, DOI 10.1073/pnas.092013799; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Muhlberg T, 1997, INVEST OPHTH VIS SCI, V38, P1018; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Peng SB, 2005, MOL CANCER RES, V3, P227; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; SCHUURING E, 1992, CANCER RES, V52, P5229; Tilghman RW, 2002, FASEB J, V16, P1257, DOI 10.1096/fj.01-0969fje; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; Tran PB, 2003, NAT REV NEUROSCI, V4, P444, DOI 10.1038/nrn1116; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 1998, J CELL SCI, V111, P2433; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zhang YY, 2004, STEM CELLS, V22, P1015, DOI 10.1634/stemcells.22-6-1015; Zhao M, 2006, MOL PHARMACOL, V69, P66, DOI 10.1124/mol.105.016923; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	58	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30081	30093		10.1074/jbc.M605837200	http://dx.doi.org/10.1074/jbc.M605837200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16905744	hybrid			2022-12-25	WOS:000240896300069
J	Van Lanen, SG; Lin, SJ; Dorrestein, PC; Kelleher, NL; Shen, B				Van Lanen, Steven G.; Lin, Shuangjun; Dorrestein, Pieter C.; Kelleher, Neil L.; Shen, Ben			Substrate specificity of the adenylation enzyme SgcC1 involved in the biosynthesis of the enediyne antitumor antibiotic C-1027	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; GENE-CLUSTER; SYNTHETASE; DOMAINS	C-1027 is an enediyne antitumor antibiotic composed of a chromophore with four distinct chemical moieties, including an (S)-3-chloro-4,5-dihydroxy-beta-phenylalanine moiety that is derived from L-alpha-tyrosine. SgcC4, a novel aminomutase requiring no added co-factor that catalyzes the formation of the first intermediate (S)-beta-tyrosine and subsequently SgcC1 homologous to adenylation domains of nonribosomal peptide synthetases, was identified as specific for the SgcC4 product and did not recognize any alpha-amino acids. To definitively establish the substrate for SgcC1, a full kinetic characterization of the enzyme was performed using amino acid-dependent ATP-[P-32]PPi exchange assay to monitor amino acid activation and electrospray ionization-Fourier transform mass spectroscopy to follow the loading of the activated alpha-amino acid substrate to the peptidyl carrier protein SgcC2. The data establish (S)-beta-tyrosine as the preferred substrate, although SgcC1 shows promiscuous activity toward aromatic alpha-amino acids such as beta-phenylalanine, 3-chloro-beta-tyrosine, and 3-hydroxy-beta-tyrosine, but all were < 50-fold efficient. A putative active site mutant P571A adjacent to the invariant aspartic acid residue of all alpha-amino acid-specific adenylation domains known to date was prepared as a preliminary attempt to probe the substrate specificity of SgcC1; however the mutation resulted in a loss of activity with all substrates except (S)-beta-tyrosine, which was 142-fold less efficient relative to the wild-type enzyme. In total, SgcC1 is now confirmed to catalyze the second step in the biosynthesis of the (S)-3-chloro-4,5-dihydroxy-beta-phenylalanine moiety of C-1027, presenting downstream enzymes with an (S)-beta-tyrosyl-S-SgcC2 thioester substrate, and represents the first alpha-amino acid-specific adenylation enzyme characterized biochemically.	Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, Madison, WI 53705 USA; Univ Wisconsin, Natl Cooperat Drug Discovery Grp, Madison, WI 53705 USA; Univ Wisconsin, Dept Chem, Madison, WI 53705 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Urbana-Champaign	Shen, B (corresponding author), Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, 777 Highland Ave, Madison, WI 53705 USA.	bshen@pharmacy.wisc.edu	Dorrestein, Pieter/ABF-2930-2020; Dorrestein, Pieter/D-5012-2012		NCI NIH HHS [CA78747, CA1059845, F32 CA105984] Funding Source: Medline; NIAID NIH HHS [AI51687] Funding Source: Medline; NIGMS NIH HHS [GM067725, GM073323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM073323, R01GM067725] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlert J, 2002, SCIENCE, V297, P1173, DOI 10.1126/science.1072105; Belshaw PJ, 1999, SCIENCE, V284, P486, DOI 10.1126/science.284.5413.486; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; Chen HW, 2001, CHEM BIOL, V8, P301, DOI 10.1016/S1074-5521(01)00009-6; Christenson SD, 2003, BIOCHEMISTRY-US, V42, P12708, DOI 10.1021/bi035223r; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Galm U, 2002, ARCH MICROBIOL, V178, P102, DOI 10.1007/s00203-002-0429-z; HU J, 1988, J ANTIBIOT, V41, P1575, DOI 10.7164/antibiotics.41.1575; Hua DH, 2004, J ORG CHEM, V69, P6065, DOI 10.1021/jo0491399; Liu W, 2005, CHEM BIOL, V12, P293, DOI 10.1016/j.chembiol.2004.12.013; Liu W, 2002, SCIENCE, V297, P1170, DOI 10.1126/science.1072110; MAY JJ, 2000, P NATL ACAD SCI USA, V97, P2509; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; Murrell JM, 2004, J NAT PROD, V67, P206, DOI 10.1021/np0340403; OTANI T, 1988, J ANTIBIOT, V41, P1580, DOI 10.7164/antibiotics.41.1580; POPPE L, 2001, CURR OPIN STRUC BIOL, V4, P902; Rausch C, 2005, NUCLEIC ACIDS RES, V33, P5799, DOI 10.1093/nar/gki885; Reiersen H, 2001, TRENDS BIOCHEM SCI, V26, P679, DOI 10.1016/S0968-0004(01)01957-0; Schwarzer D, 2003, NAT PROD REP, V20, P275, DOI 10.1039/b111145k; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; SUGIMOTO Y, 1990, J ANTIBIOT, V43, P417, DOI 10.7164/antibiotics.43.417; Tan CYK, 2002, TETRAHEDRON, V58, P7449, DOI 10.1016/S0040-4020(02)00824-4; Tillett D, 2000, CHEM BIOL, V7, P753, DOI 10.1016/S1074-5521(00)00021-1; Van Lanen SG, 2005, J AM CHEM SOC, V127, P11594, DOI 10.1021/ja052871k; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; Wang Xing-Wang, 1999, Drugs of the Future, V24, P847, DOI 10.1358/dof.1999.024.08.545524; ZHANG JY, 1992, BIOCHEM J, V283, P691, DOI 10.1042/bj2830691	30	29	29	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29633	29640		10.1074/jbc.M605887200	http://dx.doi.org/10.1074/jbc.M605887200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16887797	hybrid			2022-12-25	WOS:000240896300025
J	Moussa, CEH; Fu, QH; Kumar, P; Shtifman, A; Lopez, JR; Allen, PD; LaFerla, F; Weinberg, D; Magrane, J; Aprahamian, T; Walsh, K; Rosen, KM; Querfurth, HW				Moussa, Charbel E-H.; Fu, Qinghao; Kumar, Pravir; Shtifman, Alexander; Lopez, Jose R.; Allen, Paul D.; LaFerla, Frank; Weinberg, David; Magrane, Jordi; Aprahamian, Tamar; Walsh, Kenneth; Rosen, Kenneth M.; Querfurth, Henry W.			Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology	FASEB JOURNAL			English	Article							INCLUSION-BODY MYOSITIS; AMYOTROPHIC-LATERAL-SCLEROSIS; SUPEROXIDE-DISMUTASE; ALPHA-SYNUCLEIN; MOUSE-MODELS; PROTEIN; MUTATION; ACCUMULATION; MYOPATHIES; DISEASES	Intracellular deposition of the beta-amyloid (A beta) peptide is an increasingly recognized pathological hallmark associated with neurodegeneration and muscle wasting in Alzheimer's disease (AD) and inclusion body myositis (IBM), respectively. Previous reports have implicated dysregulation of beta-amyloid precursor protein (beta APP) expression in IBM. Accumulation of full-length beta APP, its various proteolytic derivatives including A beta, and phospho-tau into vacuolated inclusions is an early pathogenic event. We previously reported on a statistical tendency favoring fast twitch fiber involvement in IBM, reminiscent of the tissue specific patterns of misfolded protein deposition seen in neurodegenerative diseases. To test this principle, we generated an animal model in which human wildtype (WT) beta APP expression was limited to postnatal type II skeletal muscle. Hemizygous transgenic mice harboring increased levels of holo beta APP751 and A beta in skeletal muscle fibers became significantly weaker with age compared with nontransgenic littermates and exhibited typical myopathic features. A subpopulation of dissociated muscle fibers from transgenic mice exhibited a 2-fold increase in resting calcium and membrane depolarization compared with nontransgenic littermates. Taken together, these data indicate that overexpression of human beta APP in fast twitch skeletal muscle of transgenic mice is sufficient for the development of some features characteristic of IBM, including abnormal tau histochemistry. The increase in resting calcium and depolarization are novel findings, suggesting both a mechanism for the weakness and an avenue for therapeutic intervention in IBM.	Tufts Univ, Sch Med, Dept Neurol, Caritas St Elizabeths Med Ctr, Boston, MA 02111 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA	St. Elizabeth's Medical Center; Tufts University; University of California System; University of California Irvine; Boston University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Querfurth, HW (corresponding author), Tufts Univ, Sch Med, Dept Neurol, Caritas St Elizabeths Med Ctr, 736 Cambridge St,CBR419, Boston, MA 02111 USA.	henry.querfurth@tufts.edu	Kumar, Pravir/AAR-1207-2020; Kumar, Pravir/B-2164-2015; Magrané, Jordi/AAJ-2967-2020	Kumar, Pravir/0000-0001-7444-2344; Magrané, Jordi/0000-0002-6785-2166; Aprahamian, Tamar/0000-0001-9295-5995	PHS HHS [41373] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARISPE N, 1994, MOL CELL BIOCHEM, V140, P119, DOI 10.1007/BF00926750; Arnardottir S, 2004, J NEUROL NEUROSUR PS, V75, P917, DOI 10.1136/jnnp.2003.018994; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; ASKANAS V, 1992, AM J PATHOL, V141, P31; Askanas V, 2002, CURR OPIN NEUROL, V15, P525, DOI 10.1097/00019052-200210000-00002; Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314; Askanas V, 1997, NEUROREPORT, V8, P2155, DOI 10.1097/00001756-199707070-00012; Askanas V, 1998, ARCH NEUROL-CHICAGO, V55, P915, DOI 10.1001/archneur.55.7.915; ASKANAS V, 1998, INCLUSION BODY MYOSI, P3; Becher MW, 1997, NEUROBIOL DIS, V4, P1; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Bornemann KD, 2000, ANN NY ACAD SCI, V908, P260; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Carpenter S, 1996, J NEUROPATH EXP NEUR, V55, P1105, DOI 10.1097/00005072-199611000-00001; Christensen RA, 2004, J BIOL CHEM, V279, P53524, DOI 10.1074/jbc.M408473200; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dirksen RT, 2002, TRENDS CARDIOVAS MED, V12, P189, DOI 10.1016/S1050-1738(02)00163-9; Emilien G, 2000, ARCH NEUROL-CHICAGO, V57, P176, DOI 10.1001/archneur.57.2.176; Fukuchi K, 1998, AM J PATHOL, V153, P1687, DOI 10.1016/S0002-9440(10)65682-9; Gouras GK, 2005, NEUROBIOL AGING, V26, P1235, DOI 10.1016/j.neurobiolaging.2005.05.022; Gu YJ, 1996, J NEUROCHEM, V67, P1235; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; Jin LW, 1998, AM J PATHOL, V153, P1679, DOI 10.1016/S0002-9440(10)65681-7; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kunst CB, 1997, NAT GENET, V15, P91, DOI 10.1038/ng0197-91; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; McFerrin J, 1998, NEUROREPORT, V9, P3201, DOI 10.1097/00001756-199810050-00013; Mufson EJ, 1999, EXP NEUROL, V158, P469, DOI 10.1006/exnr.1999.7086; Neville C, 1996, DEV GENET, V19, P157, DOI 10.1002/(SICI)1520-6408(1996)19:2<157::AID-DVG7>3.0.CO;2-8; PETTE D, 1986, FED PROC, V45, P2910; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rizzuto R, 2003, NAT GENET, V34, P135, DOI 10.1038/ng0603-135; ROSENBERG NL, 1985, ARCH NEUROL-CHICAGO, V42, P973, DOI 10.1001/archneur.1985.04060090055014; SARKOZI E, 1993, NEUROREPORT, V4, P815, DOI 10.1097/00001756-199306000-00055; SELKOE DJ, 2001, PHYSIOL REV, V81, P751; SERRATRICE G, 1998, INCLUSION BODY MYOST, P81; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; STALBERG E, 1995, ELECTROMYOGR MOTOR C, V97, P145, DOI 10.1016/0924-980X(95)00007-8; Sugarman MC, 2006, NEUROBIOL AGING, V27, P423, DOI 10.1016/j.neurobiolaging.2005.02.011; Sugarman MC, 2002, P NATL ACAD SCI USA, V99, P6334, DOI 10.1073/pnas.082545599; Tawil R, 2002, CURR OPIN RHEUMATOL, V14, P653, DOI 10.1097/00002281-200211000-00004; TESCH P, 1978, ACTA PHYSIOL SCAND, V103, P40, DOI 10.1111/j.1748-1716.1978.tb06188.x; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133	47	29	32	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2165	+		10.1096/fj.06-5763fje	http://dx.doi.org/10.1096/fj.06-5763fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16940437				2022-12-25	WOS:000241156900055
J	Rajasingh, J; Bord, E; Luedemann, C; Asai, J; Hamada, H; Thorne, T; Qin, GJ; Goukassian, D; Zhu, Y; Losordo, DW; Kishore, R				Rajasingh, Johnson; Bord, Evelyn; Luedemann, Corinne; Asai, Jun; Hamada, Hiromichi; Thorne, Tina; Qin, Gangjian; Goukassian, David; Zhu, Yan; Losordo, Douglas W.; Kishore, Raj			IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression	FASEB JOURNAL			English	Article						mRNA stability; AU-rich elements	NECROSIS-FACTOR-ALPHA; AU-RICH ELEMENTS; IN-VIVO BLOCKADE; PROTEIN-KINASE; TRANSCRIPTIONAL REPRESSION; CHRONIC ETHANOL; KAPPA-B; INTERLEUKIN-10; BINDING; MICE	Inflammation plays an essential role in vascular injury and repair. Mononuclear phagocytes are important contributors in these processes, in part, via adhesive interactions and secretion of proinflammatory cytokines. The antiinflammatory cytokine interleukin (IL)-10 suppresses such responses via deactivation of monocytes/macrophages and repression of inflammatory cytokine expression. The mechanisms of IL-10's suppressive action are, however, incompletely characterized. Here, we report that systemic IL-10 treatment after carotid artery denudation in mice blunts inflammatory cell infiltration and arterial tumor necrosis factor (TNF) expression. At the molecular level, in a human monocytic cell line, U937 IL-10 suppressed LPS-induced mRNA expression of a number of inflammatory cytokines, mainly via posttranscriptional mRNA destabilization. Detailed studies on IL-10 regulation of TNF-alpha mRNA expression identified AU-rich elements (ARE) in the 3' untranslated region as a necessary determinant of IL-10-mediated TNF-alpha mRNA destabilization. IL-10 sensitivity to TNF depends on the ability of IL-10 to inhibit the expression and mRNA-stabilizing protein HuR and via IL-10 mediated repression of p38 mitogen-activated protein (MAP) kinase activation. Because IL-10 function and signaling are important components for control of inflammatory responses, these results may provide insights necessary to develop strategies for modulating vascular repair and other accelerated arteriopathies, including transplant vasculopathy and vein graft hyperplasia.	Tufts Univ, Div Cardiovasc Res, Caritas St Elizabeths Med Ctr, Sch Med, Brighton, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University	Kishore, R (corresponding author), Tufts Univ, Div Cardiovasc Res, Caritas St Elizabeths Med Ctr, Sch Med, 736 Cambridge St, Brighton, MA 02135 USA.	raj.kishore@tufts.edu	Losordo, Douglas W/F-9782-2011; Asai, Jun/AAD-4796-2020; Rajasingh, Johnson/AAT-1985-2021	Asai, Jun/0000-0002-7610-0820; Rajasingh, Johnson/0000-0002-6172-4083; Goukassian, David/0000-0001-5270-5270; Losordo, Douglas/0000-0002-6857-7506				Beck ARP, 1996, NUCLEIC ACIDS RES, V24, P3829, DOI 10.1093/nar/24.19.3829; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Brown CY, 1996, J BIOL CHEM, V271, P20108, DOI 10.1074/jbc.271.33.20108; Caligiuri G, 2003, MOL MED, V9, P10, DOI 10.1007/BF03402102; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CLAUSELL N, 1994, CIRCULATION, V89, P2768, DOI 10.1161/01.CIR.89.6.2768; CLAUSELL N, 1995, BRIT HEART J, V73, P534; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Colombo A, 2004, J AM COLL CARDIOL, V43, P24, DOI 10.1016/j.jacc.2003.10.015; Denys A, 2002, J IMMUNOL, V168, P4837, DOI 10.4049/jimmunol.168.10.4837; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Donners MMPC, 2003, ANN MED, V35, P523, DOI 10.1080/07853890310014876; Feldman LJ, 2000, CIRCULATION, V101, P908, DOI 10.1161/01.CIR.101.8.908; Fukuda D, 2004, J AM COLL CARDIOL, V43, P18, DOI 10.1016/j.jacc.2003.08.026; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HANCOCK WW, 1994, AM J PATHOL, V145, P1008; Iwakura A, 2003, CIRCULATION, V108, P3115, DOI 10.1161/01.CIR.0000106906.56972.83; Kamimura M, 2005, CIRC RES, V97, P305, DOI 10.1161/01.RES.0000177893.24574.13; Kishore R, 2005, J CLIN INVEST, V115, P1785, DOI 10.1172/JCI22849; Kishore R, 1999, J IMMUNOL, V162, P2457; Kishore R, 2002, CIRC RES, V91, P307, DOI 10.1161/01.RES.0000031744.06353.D3; Kishore R, 2001, J BIOL CHEM, V276, P41930, DOI 10.1074/jbc.M107181200; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Krasinski K, 2001, CIRCULATION, V104, P1754, DOI 10.1161/hc4001.098046; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LIBBY P, 1992, NOUV REV FR HEMATOL, V34, pS47; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; McMullen MR, 2003, J BIOL CHEM, V278, P38333, DOI 10.1074/jbc.M304566200; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Nagano S, 2002, INT IMMUNOL, V14, P733, DOI 10.1093/intimm/dxf038; Namiki M, 2004, ATHEROSCLEROSIS, V172, P21, DOI 10.1016/j.atherosclerosis.2003.08.032; Pinderski LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA; RENNICK D, 1995, CLIN IMMUNOL IMMUNOP, V76, pS174, DOI 10.1016/S0090-1229(95)90144-2; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Wang EH, 1997, CANCER RES, V57, P5426; Wang YJ, 1999, POLYM-PLAST TECHNOL, V38, P533, DOI 10.1080/03602559909351598; Ward C, 2005, EUR J IMMUNOL, V35, P2728, DOI 10.1002/eji.200425561; WEIEL JE, 1986, J IMMUNOL, V136, P3012	43	125	128	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2112	+		10.1096/fj.06-6084fje	http://dx.doi.org/10.1096/fj.06-6084fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935932				2022-12-25	WOS:000241156900019
J	Borniquel, S; Valle, I; Cadenas, S; Lamas, S; Monsalve, M				Borniquel, Sara; Valle, Inmaculada; Cadenas, Susana; Lamas, Santiago; Monsalve, Maria			Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1 alpha	FASEB JOURNAL			English	Article						NO; endothelium; mitochondria	SOLUBLE GUANYLYL CYCLASE; ENDOTHELIAL-CELLS; LIFE-SPAN; GENE; EXPRESSION; RECEPTOR; ANTIOXIDANT; BIOGENESIS; MECHANISMS; DISEASE	Nitric oxide (NO) has both prooxidant and antioxidant activities in the endothelium; however, the molecular mechanisms involved are still a matter of controversy. PGC-1 alpha [peroxisome proliferators-activated receptor (PPAR) gamma coactivator 1-alpha] induces the expression of several members of the mitochondrial reactive oxygen species (ROS) detoxification system. Here, we show that NO regulates this system through the modulation of PGC-1 alpha expression. Short-term (< 12 h) treatment of endothelial cells with NO donors down-regulates PGC-1 alpha expression, whereas long-term (> 24 h) treatment up-regulates it. Treatment with the NOS inhibitor L-NAME has the opposite effect. Downregulation of PGC-1 alpha by NO is mediated by protein kinase G (PKG). It is blocked by the soluble guanylate cyclase (sGC) inhibitor ODQ and the PKG inhibitor KT5823, and mimicked by the cGMP analog 8-BrcGMP. Changes in PGC-1 alpha expression are in all cases paralleled by corresponding variations in the mitochondrial ROS detoxification system. Cells that transiently overexpress PGC-1 alpha from the cytomeglovirus (CMV) promoter respond poorly to NO donors. Analysis of tissues from eNOS(-/-) mice showed reduced levels of PGC-1 alpha and the mitochondrial ROS detoxification system. These data suggest that NO can regulate the mitochondrial ROS detoxification system both positively and negatively through PGC-1 alpha. -Borniquel, S., Valle, I., Cadenas, S., Lamas, S., and Monsalve, M. Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1 alpha.	Ctr Nacl Invest Cardiovasc, Madrid 28029, Spain; CSIC, Ctr Invest Biol, Madrid, Spain; CSIC, Inst Reina Sofia Invest Nefrol, Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC)	Monsalve, M (corresponding author), Ctr Nacl Invest Cardiovasc, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mmonsalve@cnic.es	Monsalve, Maria/K-4416-2014; Lamas, Santiago/G-7308-2015; Cadenas, Susana/D-1523-2016	Monsalve, Maria/0000-0003-2796-1453; Lamas, Santiago/0000-0001-5166-4155; Cadenas, Susana/0000-0003-0726-0369				Al-Sa'doni HH, 2005, MINI-REV MED CHEM, V5, P247, DOI 10.2174/1389557053175399; Albrecht EWJA, 2003, J PATHOL, V199, P8, DOI 10.1002/path.1250; Aliev G, 2003, NEUROL RES, V25, P665, DOI 10.1179/016164103101201977; Banmeyer I, 2005, FEBS LETT, V579, P2327, DOI 10.1016/j.febslet.2005.03.027; Bellamy TC, 2001, J BIOL CHEM, V276, P4287, DOI 10.1074/jbc.M006677200; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; Bruckdorfer Richard, 2005, Molecular Aspects of Medicine, V26, P3, DOI 10.1016/j.mam.2004.09.002; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Calabrese V, 2005, J NEUROL SCI, V233, P145, DOI 10.1016/j.jns.2005.03.012; Chang TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Duncan Andrew J., 2005, Molecular Aspects of Medicine, V26, P67, DOI 10.1016/j.mam.2004.09.004; Fariss MW, 2005, MOL INTERV, V5, P94, DOI 10.1124/mi.5.2.7; Ferrari R, 2004, CURR PHARM DESIGN, V10, P1699, DOI 10.2174/1381612043384718; Fridell YWC, 2005, CELL METAB, V1, P145, DOI 10.1016/j.cmet.2005.01.005; Galle J, 2003, KIDNEY INT, V63, pS45, DOI 10.1046/j.1523-1755.63.s84.12.x; Gewaltig MT, 2002, CARDIOVASC RES, V55, P250, DOI 10.1016/S0008-6363(02)00327-9; Goth Laszlo, 2004, Mol Diagn, V8, P141; Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110; Griess P., 1879, BER DTSCH CHEM GES, V12, P426, DOI [DOI 10.2147/DDDT.S165440, 10.1002/cber.187901201117., DOI 10.1002/CBER.187901201117]; Harrison D, 2003, AM J CARDIOL, V91, p7A; Heinemann U, 2002, PROG BRAIN RES, V135, P197; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Huang H, 2004, FRONT BIOSCI-LANDMRK, V9, P1100, DOI 10.2741/1298; Imai H, 2003, FREE RADICAL BIO MED, V34, P145, DOI 10.1016/S0891-5849(02)01197-8; Jenner P, 2001, TRENDS NEUROSCI, V24, P245, DOI 10.1016/S0166-2236(00)01789-6; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Kietzmann T, 2005, SEMIN CELL DEV BIOL, V16, P474, DOI 10.1016/j.semcdb.2005.03.010; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Lopez-Ongil S, 1998, BRIT J PHARMACOL, V124, P447, DOI 10.1038/sj.bjp.0701847; Loscalzo J, 2003, BIOCHEM SOC T, V31, P1059; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; Mohanakumar KP, 2002, ANN NY ACAD SCI, V962, P389, DOI 10.1111/j.1749-6632.2002.tb04083.x; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; Ogita H, 2004, ENDOTHELIUM-J ENDOTH, V11, P123, DOI 10.1080/10623320490482664; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Pasupathy S, 2005, EUR J VASC ENDOVASC, V29, P106, DOI 10.1016/j.ejvs.2004.11.005; Patel RP, 2000, CARDIOVASC RES, V47, P465, DOI 10.1016/S0008-6363(00)00086-9; Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Rahman I, 2004, BIOCHEM PHARMACOL, V68, P1255, DOI 10.1016/j.bcp.2004.05.042; Rivero-Vilches FJ, 2003, AM J PHYSIOL-CELL PH, V285, pC891, DOI 10.1152/ajpcell.00590.2002; Russwurm M, 2002, J BIOL CHEM, V277, P24883, DOI 10.1074/jbc.M110570200; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Scandalios JG, 2005, BRAZ J MED BIOL RES, V38, P995, DOI 10.1590/S0100-879X2005000700003; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Suh SH, 1999, PFLUG ARCH EUR J PHY, V438, P612, DOI 10.1007/s004240051084; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Ungvari Zoltan, 2005, Current Vascular Pharmacology, V3, P221, DOI 10.2174/1570161054368607; Valle I, 2005, CARDIOVASC RES, V66, P562, DOI 10.1016/j.cardiores.2005.01.026; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	67	121	130	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1889	+		10.1096/fj.05-5189fje	http://dx.doi.org/10.1096/fj.05-5189fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16891621				2022-12-25	WOS:000240267000020
J	Marathe, C; Bradley, MN; Hong, C; Lopez, F; de Galarreta, CMR; Tontonoz, P; Castrillo, A				Marathe, Chaitra; Bradley, Michelle N.; Hong, Cynthia; Lopez, Felix; Ruiz de Galarreta, Carlos M.; Tontonoz, Peter; Castrillo, Antonio			The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-3; NITRIC-OXIDE SYNTHASE; L-ARGININE; DIFFERENTIAL REGULATION; RECIPROCAL REGULATION; NUCLEAR RECEPTORS; LIPID-METABOLISM; MOUSE MODEL; LXR; CHOLESTEROL	The liver X receptors (LXRs) are ligand-dependent transcription factors that have been implicated in lipid metabolism and inflammation. LXRs also inhibit the expression of inflammatory genes in macrophages, including inducible nitric oxide synthase (iNOS). Some of these actions are mediated through LXR antagonism of NF-kappa B activity. The potential for LXRs to positively regulate the expression of anti-inflammatory molecules, however, has not been explored. Here we show that the arginase II (ArgII) gene is a direct target for LXR regulation. ArgII catalyzes the conversion of L-arginine into L-ornithine and urea, leading to the synthesis of polyamines. Expression of ArgII is induced by LXR agonists in macrophage cell lines and primary murine macrophages in a receptor-dependent manner. The ArgII promoter contains a functional LXR response elements that mediates promoter induction by LXR/RXR (retinoid X receptor) in transfection assays. Since ArgII and iNOS utilize a common substrate, induction of ArgII expression has the potential to exert anti-inflammatory effects by shifting arginine metabolism toward polyamine synthesis at the expense of NO production. In support of this hypothesis, we demonstrate that forced expression of ArgII mimics the inhibitory effect of LXR activation on macrophage NO production. Furthermore, inhibition of arginase activity partially reverses the inhibitory effect of LXR agonists on NO production. These studies suggest that regulation of ArgII may contribute to the immunomodulatory effects of LXRs.	Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Las Palmas Gran Canaria, Dept Bioquim & Biol Mol, Las Palmas Gran Canaria 35016, Spain	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Universidad de Las Palmas de Gran Canaria	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Inst Mol Biol, Box 951662, Los Angeles, CA 90095 USA.	ptontonoz@mednet.ucla.edu; acastrillo@ramonycajal.ulpgc.es		Lopez Blanco, Felix/0000-0003-1167-9787	NHLBI NIH HHS [HL 30568, HL 66088] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, R01HL066088] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Castrillo A, 2004, ANNU REV CELL DEV BI, V20, P455, DOI 10.1146/annurev.cellbio.20.012103.134432; Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8; Cederbaum SD, 2004, MOL GENET METAB, V81, pS38, DOI 10.1016/j.ymgme.2003.10.012; Chang CI, 1998, AM J PHYSIOL-HEART C, V274, pH342, DOI 10.1152/ajpheart.1998.274.1.H342; Colleluori DM, 2001, BIOCHEMISTRY-US, V40, P9356, DOI 10.1021/bi010783g; CORRALIZA IM, 1994, J IMMUNOL METHODS, V174, P231, DOI 10.1016/0022-1759(94)90027-2; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; Grandvaux N, 2005, FEBS J, V272, P3120, DOI 10.1111/j.1742-4658.2005.04726.x; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533; Iyer RK, 2002, MOL CELL BIOL, V22, P4491, DOI 10.1128/MCB.22.13.4491-4498.2002; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Kakuda DK, 1999, BIOCHEM J, V340, P549, DOI 10.1042/0264-6021:3400549; King NE, 2004, J NUTR, V134, p2830S, DOI 10.1093/jn/134.10.2830S; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Laffitte BA, 2003, MOL CELL BIOL, V23, P2182, DOI 10.1128/MCB.23.6.2182-2191.2003; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LOUIS CA, 1999, AM J PHYSIOL, V276, P237; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; Mori M, 2004, J NUTR, V134, p2820S, DOI 10.1093/jn/134.10.2820S; Morris SM, 2005, VASC MED, V10, pS83, DOI 10.1191/1358863x05vm601oa; Morris SM, 2002, ANNU REV NUTR, V22, P87, DOI 10.1146/annurev.nutr.22.110801.140547; Morris SM, 1998, AM J PHYSIOL-ENDOC M, V275, pE740, DOI 10.1152/ajpendo.1998.275.5.E740; Moynagh PN, 2005, TRENDS IMMUNOL, V26, P469, DOI 10.1016/j.it.2005.06.009; NAGASAKI AS, 1999, AM J PHYSIOL, V277, P110; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Panne D, 2004, EMBO J, V23, P4384, DOI 10.1038/sj.emboj.7600453; Redington AE, 2006, EUR J PHARMACOL, V533, P263, DOI 10.1016/j.ejphar.2005.12.069; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Shi O, 2001, MOL CELL BIOL, V21, P811, DOI 10.1128/MCB.21.3.811-813.2001; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tenu JP, 1999, NITRIC OXIDE-BIOL CH, V3, P427, DOI 10.1006/niox.1999.0255; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Zimmermann N, 2006, EUR J PHARMACOL, V533, P253, DOI 10.1016/j.ejphar.2005.12.047	48	77	82	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32197	32206		10.1074/jbc.M605237200	http://dx.doi.org/10.1074/jbc.M605237200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16943198	hybrid			2022-12-25	WOS:000241414500017
J	Ortiz, PA; Ulloque, R; Kihara, GK; Zheng, HY; Kinzy, TG				Ortiz, Pedro A.; Ulloque, Rory; Kihara, George K.; Zheng, Haiyan; Kinzy, Terri Goss			Translation elongation factor 2 anticodon mimicry domain mutants affect fidelity and diphtheria toxin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; PHENOTYPIC SUPPRESSION; RIBOSOMAL TRANSLOCASE; FACTOR-II; PROTEIN; YEAST; DIPHTHAMIDE; MUTATIONS; IDENTIFICATION	Eukaryotic elongation factor 2 (eEF2) mediates translocation in protein synthesis. The molecular mimicry model proposes that the tip of domain IV mimics the anticodon loop of tRNA. His-699 in this region is post-translationally modified to diphthamide, the target for Corynebacterium diphtheriae and Pseudomonas aeruginosa toxins. ADP-ribosylation by these toxins inhibits eEF2 function causing cell death. Mutagenesis of the tip of domain IV was used to assess both functions. A H694A mutant strain was non-functional, whereas D696A, I698A, and H699N strains conferred conditional growth defects, sensitivity to translation inhibitors, and decreased total translation in vivo. These mutant strains and those lacking diphthamide modification enzymes showed increased -1 frameshifting. The effects are not due to reduced protein levels, ribosome binding, or GTP hydrolysis. Functional eEF2 forms substituted in domain IV confer dominant diphtheria toxin resistance, which correlates with an in vivo effect on translation-linked phenotypes. These results provide a new mechanism in which the translational machinery maintains the accurate production of proteins, establishes a role for the diphthamide modification, and provides evidence of the ability to suppress the lethal effect of a toxin targeted to eEF2.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kinzy, TG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	kinzytg@umdnj.edu		Kinzy, Terri/0000-0003-1394-9226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062789, F31GM070068] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062789, F31 GM070068, F31 GM 070068, GM 62789] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO; Burke D., 2000, METHODS YEAST GENETI; Carr-Schmid A, 1999, J BIOL CHEM, V274, P30297, DOI 10.1074/jbc.274.42.30297; Cavallius J, 1998, J BIOL CHEM, V273, P28752, DOI 10.1074/jbc.273.44.28752; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DINMAN JD, 1995, YEAST, V11, P1115, DOI 10.1002/yea.320111202; Dinman JD, 1997, RNA, V3, P870; DUMONTMISCOPEIN A, 1994, FEBS LETT, V356, P283, DOI 10.1016/0014-5793(94)01272-5; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Harger JW, 2002, TRENDS BIOCHEM SCI, V27, P448, DOI 10.1016/S0968-0004(02)02149-7; Harger JW, 2001, VIROLOGY, V286, P216, DOI 10.1006/viro.2001.0997; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jorgensen R, 2004, J BIOL CHEM, V279, P45919, DOI 10.1074/jbc.M406218200; Jorgensen R, 2003, NAT STRUCT BIOL, V10, P379, DOI 10.1038/nsb923; Jorgensen R, 2002, ACTA CRYSTALLOGR D, V58, P712, DOI 10.1107/S0907444902003001; Justice MC, 1998, J BIOL CHEM, V273, P3148, DOI 10.1074/jbc.273.6.3148; KIMATA Y, 1994, J BIOL CHEM, V269, P13497; Liu SH, 2004, MOL CELL BIOL, V24, P9487, DOI 10.1128/MCB.24.21.9487-9497.2004; MATTHEAKIS LC, 1992, MOL CELL BIOL, V12, P4026, DOI 10.1128/MCB.12.9.4026; MATTHEAKIS LC, 1993, GENE, V132, P149, DOI 10.1016/0378-1119(93)90528-B; Merrick WC, 2000, COLD SPRING HARBOR M, V39, P89; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OHYA Y, 1991, J BIOL CHEM, V266, P12784; OPPENHEIMER NJ, 1981, J BIOL CHEM, V256, P8579; Ortiz PA, 2005, NUCLEIC ACIDS RES, V33, P5740, DOI 10.1093/nar/gki882; PALMER E, 1979, NATURE, V277, P148, DOI 10.1038/277148a0; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; PHAN LD, 1993, J BIOL CHEM, V268, P8665; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savelsbergh A, 2000, J MOL BIOL, V300, P951, DOI 10.1006/jmbi.2000.3886; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shin BS, 2002, CELL, V111, P1015, DOI 10.1016/S0092-8674(02)01171-6; SINGH A, 1979, NATURE, V277, P146, DOI 10.1038/277146a0; Spahn CMT, 2004, EMBO J, V23, P1008, DOI 10.1038/sj.emboj.7600102; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Teige M, 2001, P NATL ACAD SCI USA, V98, P5625, DOI 10.1073/pnas.091610798; Valente L, 2003, CELL MOL LIFE SCI, V60, P2115, DOI 10.1007/s00018-003-2334-2; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8	42	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32639	32648		10.1074/jbc.M607076200	http://dx.doi.org/10.1074/jbc.M607076200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16950777	hybrid			2022-12-25	WOS:000241414500062
J	Archambaud, C; Nahori, MA; Pizarro-Cerda, J; Cossart, P; Dussurget, O				Archambaud, Cristel; Nahori, Marie-Anne; Pizarro-Cerda, Javier; Cossart, Pascale; Dussurget, Olivier			Control of Listeria superoxide dismutase by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH-OXIDASE; OXIDATIVE STRESS; MYCOBACTERIUM-TUBERCULOSIS; ESCHERICHIA-COLI; ACTIVATED MACROPHAGES; MONOCYTOGENES ACTA; REACTIVE OXYGEN; EXPRESSION; VIRULENCE; SALMONELLA	Superoxide dismutases (SODs) are enzymes that protect organisms against superoxides and reactive oxygen species (ROS) produced during their active metabolism. ROS are major mediators of phagocytes microbicidal activity. Here we show that the cytoplasmic Listeria monocytogenes MnSOD is phosphorylated on serine and threonine residues and less active when bacteria reach the stationary phase. We also provide evidence that the most active nonphosphorylated form of MnSOD can be secreted via the SecA2 pathway in culture supernatants and in infected cells, where it becomes phosphorylated. A Delta sod deletion mutant is impaired in survival within macrophages and is dramatically attenuated in mice. Together, our results demonstrate that the capacity to counteract ROS is an essential component of L. monocytogenes virulence. This is the first example of a bacterial SOD post-translationally controlled by phosphorylation, suggesting a possible new host innate mechanism to counteract a virulence factor.	Inst Pasteur, Unite Interact Bacteries Cellules, INSERM, U604,INRA,USC2020, F-75015 Paris, France	INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cossart, P (corresponding author), Inst Pasteur, Unite Interact Bacteries Cellules, INSERM, U604,INRA,USC2020, 25 Rue Dr Roux, F-75015 Paris, France.	pcossart@pasteur.fr; odussur@pasteur.fr	Archambaud, Cristel/AAZ-8966-2021	Archambaud, Cristel/0000-0002-6237-0109; Marie-Anne, Nahori/0000-0002-4066-4528; Dussurget, Olivier/0000-0001-9924-0837				ADACHI T, 1991, BIOCHEM J, V279, P263, DOI 10.1042/bj2790263; Ahn BE, 2006, MOL MICROBIOL, V59, P1848, DOI 10.1111/j.1365-2958.2006.05065.x; ALFORD CE, 1991, J EXP MED, V174, P459, DOI 10.1084/jem.174.2.459; ARAI K, 1987, J BIOL CHEM, V262, P16969; Archambaud C, 2005, MOL MICROBIOL, V56, P383, DOI 10.1111/j.1365-2958.2005.04551.x; Arnaud M, 2004, APPL ENVIRON MICROB, V70, P6887, DOI 10.1128/AEM.70.11.6887-6891.2004; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Battistoni A, 2003, BIOCHEM SOC T, V31, P1326; Braunstein M, 2003, MOL MICROBIOL, V48, P453, DOI 10.1046/j.1365-2958.2003.03438.x; BREHM K, 1992, GENE, V118, P121, DOI 10.1016/0378-1119(92)90258-Q; Brown DR, 2005, FOLIA NEUROPATHOL, V43, P229; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Chatterjee SS, 2006, INFECT IMMUN, V74, P1323, DOI 10.1128/IAI.74.2.1323-1338.2006; COOPER HM, 1995, CURR PROTOCOL IMMUNO, P1; Cousens LP, 2000, IMMUNOL REV, V174, P150, DOI 10.1034/j.1600-0528.2002.017407.x; Csar XF, 2001, PROTEOMICS, V1, P435, DOI 10.1002/1615-9861(200103)1:3<435::AID-PROT435>3.3.CO;2-H; DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997; Dramsi S, 2004, MOL MICROBIOL, V53, P639, DOI 10.1111/j.1365-2958.2004.04138.x; Edwards KM, 2001, AM J RESP CRIT CARE, V164, P2213, DOI 10.1164/ajrccm.164.12.2106093; Escuyer V, 1996, MICROB PATHOGENESIS, V20, P41, DOI 10.1006/mpat.1996.0004; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FRANZON VL, 1990, INFECT IMMUN, V58, P529, DOI 10.1128/IAI.58.2.529-535.1990; Gee JM, 2005, INFECT IMMUN, V73, P2873, DOI 10.1128/IAI.73.5.2873-2880.2005; Glaser P, 2001, SCIENCE, V294, P849; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; GOUIN E, 1995, INFECT IMMUN, V63, P2729, DOI 10.1128/IAI.63.7.2729-2737.1995; Hamon M, 2006, NAT REV MICROBIOL, V4, P423, DOI 10.1038/nrmicro1413; Henry R, 2006, CELL MICROBIOL, V8, P107, DOI 10.1111/j.1462-5822.2005.00604.x; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Inaoka T, 1999, J BACTERIOL, V181, P1939, DOI 10.1128/JB.181.6.1939-1943.1999; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kang SK, 2006, PROTEIN EXPRES PURIF, V47, P52, DOI 10.1016/j.pep.2005.11.001; Knirsch L, 2001, BIOCHEMISTRY-US, V40, P7890, DOI 10.1021/bi010197n; Korshunov SS, 2002, MOL MICROBIOL, V43, P95, DOI 10.1046/j.1365-2958.2002.02719.x; Kubori T, 2003, CELL, V115, P333, DOI 10.1016/S0092-8674(03)00849-3; Lauer P, 2002, J BACTERIOL, V184, P4177, DOI 10.1128/JB.184.15.4177-4186.2002; Lenz LL, 2003, P NATL ACAD SCI USA, V100, P12432, DOI 10.1073/pnas.2133653100; Lenz LL, 2002, MOL MICROBIOL, V45, P1043, DOI 10.1046/j.1365-2958.2002.03072.x; Luu PT, 1997, INT J FOOD MICROBIOL, V35, P91, DOI 10.1016/S0168-1605(96)01205-6; Lynch M, 2000, MICROBES INFECT, V2, P1245, DOI 10.1016/S1286-4579(00)01278-8; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Marques MAM, 1998, INFECT IMMUN, V66, P2625, DOI 10.1128/IAI.66.6.2625-2631.1998; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; Miller RA, 1997, CLIN MICROBIOL REV, V10, P1; Myers JT, 2003, J IMMUNOL, V171, P5447, DOI 10.4049/jimmunol.171.10.5447; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; Piddington DL, 2001, INFECT IMMUN, V69, P4980, DOI 10.1128/IAI.69.8.4980-4987.2001; Poussin MA, 2005, INFECT IMMUN, V73, P4410, DOI 10.1128/IAI.73.7.4410-4413.2005; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; SAITO S, 1994, INFECT IMMUN, V62, P1551, DOI 10.1128/IAI.62.5.1551-1556.1994; Saveanu C, 2002, PROTEIN SCI, V11, P2551, DOI 10.1110/ps.0217502; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Steffen P, 2000, CELL MOTIL CYTOSKEL, V45, P58; Steinberg TH, 2003, PROTEOMICS, V3, P1128, DOI 10.1002/pmic.200300434; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; VASCONCELOS JAP, 1994, APPL ENVIRON MICROB, V60, P2360, DOI 10.1128/AEM.60.7.2360-2366.1994; Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655; Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384; Yan H, 1997, BIOCHEM J, V328, P599, DOI 10.1042/bj3280599; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X	64	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31812	31822		10.1074/jbc.M606249200	http://dx.doi.org/10.1074/jbc.M606249200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16905535	Bronze, Green Published			2022-12-25	WOS:000241235300068
J	Itoh, T; Fukuda, M				Itoh, Takashi; Fukuda, Mitsunori			Identification of EPI64 as a GTPase-activating protein specific for Rab27A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRISCELLI-SYNDROME; BINDING DOMAIN; MYOSIN-VA; MELANOSOME DISTRIBUTION; CRITICAL DETERMINANT; RAS SUPERFAMILY; PDZ DOMAIN; C2 DOMAINS; MELANOCYTES; FAMILY	Small GTPase Rab27A plays a pivotal role in melanosome transport in melanocytes and in secretion by various secreting cells. Because the GTP- or GDP-locked mutant of Rab27A causes perinuclear aggregation of melanosomes, appropriate GTP-GDP cycling of Rab27A is essential for melanosome transport, and certain guanine nucleotide exchange factors and GTPase-activating proteins (GAPs) of Rab27A must be present in melanocytes. However, no such regulators of Rab27A have ever been identified. In this study we developed novel methods of rapidly screening 40 different TBC (Tre2/Bub2/Cdc16) proteins, putative Rab-GAPs, for Rab27A-GAP by: (i) searching for TBC proteins that induce melanosome aggregation in melanocytes; (ii) trapping GTP-Rab27A with a Rab27A effector domain (i. e. the SHD of Slac2-a) in cultured cells that express both Rab27A and TBC proteins; and (iii) measuring in vitro Rab27AGAP activity. These methods allowed us to identify EPI64, previously characterized as an EBP50-binding protein that contains an orphan TBC domain, as a specific Rab27A-GAP. We further showed that mutations in the catalytic domain of EPI64 caused complete loss of its ability to induce melanosome aggregation. This is the first report of screening for Rab27A-GAP based on functional interactions, and our screening methods can be applied for other uncharacterized TBC proteins.	Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Lab Membrane Trafficking Mech,Aoba Ku, Sendai, Miyagi 9808578, Japan; RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	Tohoku University; RIKEN	Fukuda, M (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Lab Membrane Trafficking Mech,Aoba Ku, Sendai, Miyagi 9808578, Japan.	nori@mail.tains.tohoku.ac.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; Fukuda M, 2004, J BIOL CHEM, V279, P13065, DOI 10.1074/jbc.M306812200; Fukuda M, 2003, J BIOL CHEM, V278, P15373, DOI 10.1074/jbc.M212341200; Fukuda M, 2005, J BIOCHEM, V137, P9, DOI 10.1093/jb/mvi002; Fukuda M, 2004, J BIOL CHEM, V279, P22314, DOI 10.1074/jbc.401791200; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Gao XD, 2003, J CELL BIOL, V162, P635, DOI 10.1083/jcb.200302038; Haas AK, 2005, NAT CELL BIOL, V7, P887, DOI 10.1038/ncb1290; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; IOTH T, 2006, GENES CELLS, V11, P1023; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Kuroda TS, 2005, METHOD ENZYMOL, V403, P431, DOI 10.1016/S0076-6879(05)03038-7; Kuroda TS, 2004, NAT CELL BIOL, V6, P1195, DOI 10.1038/ncb1197; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Menasche G, 2003, BLOOD, V101, P2736, DOI 10.1182/blood-2002-09-2789; Miinea CP, 2005, BIOCHEM J, V391, P87, DOI 10.1042/BJ20050887; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Pei L, 2002, CANCER RES, V62, P5420; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Raposo G, 2002, TRAFFIC, V3, P237, DOI 10.1034/j.1600-0854.2002.030401.x; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Seabra MC, 2004, CURR OPIN CELL BIOL, V16, P451, DOI 10.1016/j.ceb.2004.06.014; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yonekura H, 2001, ANN NY ACAD SCI, V947, P382; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang XM, 2005, BIOCHEM BIOPH RES CO, V335, P154, DOI 10.1016/j.bbrc.2005.07.070	50	74	78	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31823	31831		10.1074/jbc.M603808200	http://dx.doi.org/10.1074/jbc.M603808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16923811				2022-12-25	WOS:000241235300069
J	Shridas, P; Waechter, CJ				Shridas, Preetha; Waechter, Charles J.			Human dolichol kinase, a polytopic endoplasmic reticulum membrane protein with a cytoplasmically oriented CTP-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-DIACYLGLYCEROL SYNTHASE; SACCHAROMYCES-CEREVISIAE; RAT-LIVER; PYROPHOSPHATE PHOSPHATASE; ENZYMATIC PHOSPHORYLATION; ALCOHOL PHOSPHOKINASE; HUMAN CDNA; IN-VIVO; CLONING; BRAIN	Dolichol kinase (DK) catalyzes the CTP-dependent phosphorylation of dolichol in the biosynthesis de novo and possibly the recycling of dolichyl monophosphate in yeast and mammals. A cDNA clone from human brain encoding the mammalian homologue, hDKp, of the yeast enzyme has recently been identified. In this study hDK has been overexpressed in Chinese hamster ovary cells and shown to be a polytopic membrane protein localized in the endoplasmic reticulum with an N terminus extended into the lumen and a cytoplasmically oriented C terminus. A conserved sequence, (D) under bar XX (A) under bar XXX (G) under bar XXX (G) under barX(8)K (KT) under barX (E) under barG, found in several enzymes utilizing CTP as substrate including DKs, phytol kinases, and several CDP-diacylglycerol synthetases has been identified, and the possibility that it is part of the CTP-binding domain of hDKp has been investigated. Topological studies indicate that the loop between transmembrane domains (TMD) 11 and TMD12 of hDKp, containing the putative CTP binding domain, faces the cytoplasm. Deletion of the loop between TMD11-12, hDK(Delta 459-474), or mutation of selected conserved residues within the cytoplasmic loop results in either a partial or total loss of activity and significant reductions in the affinity for CTP. In addition, the SEC59 gene in the yeast DK mutant was sequenced, and a G420D substitution was found. Conversion of the corresponding residue Gly-443 in hDKp to aspartic acid resulted in inactivation of the mammalian enzyme. These results extend the information on the topological arrangement of hDKp and indicate that the cytoplasmic loop between TMDs 11-12, containing the critical conserved residues, lysine 470 and lysine 471 in the (470)KKTXEG(475) motif, is part of the CTP-binding site in hDK.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Waechter, CJ (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, BBSRB 741 S Limestone St, Lexington, KY 40536 USA.	waechte@uky.edu			NIGMS NIH HHS [GM36035] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR WL, 1983, BIOCHIM BIOPHYS ACTA, V751, P21, DOI 10.1016/0005-2760(83)90252-7; Aebi M, 1996, GLYCOBIOLOGY, V6, P439, DOI 10.1093/glycob/6.4.439; ALLEN CM, 1978, BIOCHEMISTRY-US, V17, P5020, DOI 10.1021/bi00616a025; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BHAT NR, 1991, J NEUROCHEM, V56, P339, DOI 10.1111/j.1471-4159.1991.tb02600.x; BURTON WA, 1979, J BIOL CHEM, V254, P7129; BURTON WA, 1981, J BIOL CHEM, V256, P632; Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145; Fernandez F, 2002, GLYCOBIOLOGY, V12, P555, DOI 10.1093/glycob/cwf068; Fernandez F, 2001, J BIOL CHEM, V276, P41455, DOI 10.1074/jbc.M105544200; Freeze HH, 2005, CURR OPIN STRUC BIOL, V15, P490, DOI 10.1016/j.sbi.2005.08.010; Halford S, 1998, GENOMICS, V54, P140, DOI 10.1006/geno.1998.5547; Heacock AM, 1996, J NEUROCHEM, V67, P2200; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HELLER L, 1992, P NATL ACAD SCI USA, V89, P7013, DOI 10.1073/pnas.89.15.7013; HIGASHI Y, 1970, J BIOL CHEM, V245, P3691; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lykidis A, 1997, J BIOL CHEM, V272, P33402, DOI 10.1074/jbc.272.52.33402; Martin D, 2000, MOL BIOCHEM PARASIT, V110, P93, DOI 10.1016/S0166-6851(00)00260-7; Mitaku S, 1999, PROTEIN ENG, V12, P953, DOI 10.1093/protein/12.11.953; Muller MO, 2000, J BIOL CHEM, V275, P19475, DOI 10.1074/jbc.M002575200; Nakashima A, 1997, J BIOL CHEM, V272, P9567; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; RODRIGUEZVICO F, 1989, ANAL BIOCHEM, V183, P275, DOI 10.1016/0003-2697(89)90479-X; ROSSIGNOL DP, 1981, J BIOL CHEM, V256, P538; ROSSLER HH, 1982, MOL CELL BIOCHEM, V48, P183, DOI 10.1007/BF00421227; Rush JS, 2002, J BIOL CHEM, V277, P45226, DOI 10.1074/jbc.M207076200; SAGAMI H, 1993, J BIOL CHEM, V268, P10109; Saito S, 1997, J BIOL CHEM, V272, P9503; SANDERMA.H, 1971, P NATL ACAD SCI USA, V68, P2441, DOI 10.1073/pnas.68.10.2441; SCHENK B, 2001, GLYCOBIOLOGY, V11, P61; SCHER MG, 1984, ARCH BIOCHEM BIOPHYS, V231, P293, DOI 10.1016/0003-9861(84)90391-6; SCHER MG, 1985, J BIOL CHEM, V260, P3742; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; SUMBILLA C, 1985, METHOD ENZYMOL, V111, P471; SZKOPINSKA A, 1988, ARCH BIOCHEM BIOPHYS, V266, P124, DOI 10.1016/0003-9861(88)90242-1; Thai L, 1999, P NATL ACAD SCI USA, V96, P13080, DOI 10.1073/pnas.96.23.13080; Vainauskas S, 2002, J BIOL CHEM, V277, P30535, DOI 10.1074/jbc.M205402200; Valentin HE, 2006, PLANT CELL, V18, P212, DOI 10.1105/tpc.105.037077; VOLPE JJ, 1987, DEV BRAIN RES, V31, P193, DOI 10.1016/0165-3806(87)90117-9; Volta M, 1999, GENOMICS, V55, P68, DOI 10.1006/geno.1998.5610; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0	46	28	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31696	31704		10.1074/jbc.M604087200	http://dx.doi.org/10.1074/jbc.M604087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16923818	Bronze			2022-12-25	WOS:000241235300055
J	Thomas, KE; Galligan, CL; Newman, RD; Fish, EN; Vogel, SN				Thomas, Karen E.; Galligan, Carole L.; Newman, Raj Deonarain; Fish, Eleanor N.; Vogel, Stefanie N.			Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; KINASE-C-DELTA; A-ASSOCIATED PROTEINS; REGULATORY FACTOR-I; GENE-EXPRESSION; IFN-GAMMA; ALPHA/BETA INTERFERON; MOUSE MACROPHAGES; INDUCIBLE GENES; ENDOTOXIN-SHOCK	Interferon-beta (IFN-beta) has been identified as the signature cytokine induced via the Toll-like receptor (TLR) 4, "MyD88-independent" signaling pathway in macrophages stimulated by Gram-negative bacterial lipopolysaccharide (LPS). In this study, we analyzed the responses of macrophages derived from wildtype (IFN-beta(+/+)) mice or mice with a targeted mutation in IFN-beta (IFN-beta(+/+)) to the prototype TLR4 agonist, Escherichia coli LPS. A comparison of basal and LPS-induced gene expression (by reverse transcription-PCR, real-time PCR, and Affymetrix microarray analyses) resulted in the identification of four distinct patterns of gene expression affected by IFN-beta deficiency. Analysis of a subset of each group of differentially regulated genes by computer-assisted promoter analysis revealed putative IFN-responsive elements in all genes examined. LPS-induced activation of intracellular signaling molecules, STAT1 Tyr-701, STAT1 Ser-727, and Akt, but not p38, JNK, and ERK MAPK proteins, was significantly diminished in IFN-beta(+/+) versus IFN-beta beta(+/+) macrophages. "Priming" of IFN-beta(-/-) macrophages with exogenous recombinant IFN-beta significantly increased levels of LPS-induced gene expression for induction of monocyte chemotactic protein 5, inducible nitric-oxide synthase, IP-10, and IL-12 p40 mRNA, whereas no increase or relatively small increases were observed for IL-1 beta, IL-6, monocyte chemotactic protein 1, and MyD88 mRNA. Finally, IFN-beta(+/+) mice challenged in vivo with LPS exhibited increased survival when compared with wild-type IFN-beta(+/+) controls, indicating that IFN-beta contributes to LPS-induced lethality; however, not to the extent that one observes in mice with more complete pathway deficiencies (e.g. TLR4(-/-) or TRIF-/- mice). Collectively, these findings reveal unanticipated regulatory roles for IFN-beta in response to LPS in vitro and in vivo.	Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Toronto Gen Res Inst, Toronto, ON M5G 2M9, Canada	University System of Maryland; University of Maryland Baltimore; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Vogel, SN (corresponding author), Univ Maryland, Dept Microbiol & Immunol, 660 W Redwood St,Rm 324, Baltimore, MD 21201 USA.	svogel@som.umaryland.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018797, R37AI018797] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18797] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; BARBER SA, 1995, INFECT IMMUN, V63, P601, DOI 10.1128/IAI.63.2.601-608.1995; Bjorkbacka H, 2004, PHYSIOL GENOMICS, V19, P319, DOI 10.1152/physiolgenomics.00128.2004; Bommhardt U, 2004, J IMMUNOL, V172, P7583, DOI 10.4049/jimmunol.172.12.7583; Brierley MM, 2006, FEBS J, V273, P1569, DOI 10.1111/j.1742-4658.2006.05176.x; Cuesta N, 2003, J IMMUNOL, V170, P5739, DOI 10.4049/jimmunol.170.11.5739; Deb DK, 2003, J IMMUNOL, V171, P267, DOI 10.4049/jimmunol.171.1.267; DEMAEYER E, 1971, ANN I PASTEUR PARIS, V120, P438; Deonarain R, 2000, J VIROL, V74, P3404, DOI 10.1128/JVI.74.7.3404-3409.2000; Deonarain R, 2004, CIRCULATION, V110, P3540, DOI 10.1161/01.CIR.0000136824.73458.20; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Doherty TM, 1996, J IMMUNOL, V156, P735; Durand V, 2004, IMMUNOL CELL BIOL, V82, P596, DOI 10.1111/j.0818-9641.2004.01285.x; Erlandsson L, 1998, CURR BIOL, V8, P223, DOI 10.1016/S0960-9822(98)70086-7; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; FULTZ MJ, 1989, J IMMUNOL, V143, P3001; FULTZ MJ, 1995, J ENDOTOXIN RES, V2, P77; GALABRU J, 1985, J GEN VIROL, V66, P711, DOI 10.1099/0022-1317-66-4-711; Gao JJ, 1998, J IMMUNOL, V161, P4803; Gao JJ, 2002, J LEUKOCYTE BIOL, V72, P1234; Gingras S, 2004, J BIOL CHEM, V279, P54702, DOI 10.1074/jbc.M411043200; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Hirotani T, 2005, BIOCHEM BIOPH RES CO, V328, P383, DOI 10.1016/j.bbrc.2004.12.184; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; HOGAN MM, 1988, J IMMUNOL, V141, P4196; HOGAN MM, 1987, J IMMUNOL, V139, P3697; Ishida N, 2005, EXP HEMATOL, V33, P495, DOI 10.1016/j.exphem.2005.01.002; JOSHI VD, 2006, IN PRESS J INTERFERO; Karaghiosoff M, 2003, NAT IMMUNOL, V4, P471, DOI 10.1038/ni910; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kim KI, 2005, METHOD ENZYMOL, V398, P491, DOI 10.1016/S0076-6879(05)98040-3; Lentschat A, 2005, J IMMUNOL, V174, P4252, DOI 10.4049/jimmunol.174.7.4252; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Liu JG, 2004, J BIOL CHEM, V279, P55609, DOI 10.1074/jbc.M406565200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MANTHEY CL, 1994, J IMMUNOL, V152, P825; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MCINTIRE FC, 1967, BIOCHEMISTRY-US, V6, P2363, DOI 10.1021/bi00860a011; Medvedev AE, 2001, J IMMUNOL, V167, P2257, DOI 10.4049/jimmunol.167.4.2257; MOORE RN, 1990, J IMMUNOL, V144, P667; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rhee SH, 2003, J BIOL CHEM, V278, P22506, DOI 10.1074/jbc.M208633200; Sakaguchi S, 2003, BIOCHEM BIOPH RES CO, V306, P860, DOI 10.1016/S0006-291X(03)01049-0; SALKOWSKI CA, 1992, J IMMUNOL, V148, P2770; Salkowski CA, 2000, J IMMUNOL, V165, P3970, DOI 10.4049/jimmunol.165.7.3970; Salkowski CA, 1998, INFECT IMMUN, V66, P3569, DOI 10.1128/IAI.66.8.3569-3578.1998; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Stockinger S, 2004, J IMMUNOL, V173, P7416, DOI 10.4049/jimmunol.173.12.7416; SVETIC A, 1991, J IMMUNOL, V147, P2391; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Toshchakov V, 2003, J ENDOTOXIN RES, V9, P169, DOI 10.1179/096805103125001577; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Treschow AP, 2005, ARTHRITIS RHEUM-US, V52, P3739, DOI 10.1002/art.21496; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; VOGEL SN, 1992, BACTERIAL ENDOTOXIC, P165; Vogel Stefanie N, 2003, Mol Interv, V3, P466, DOI 10.1124/mi.3.8.466; WYNN TA, 1993, J IMMUNOL, V151, P1430; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Zhao KW, 2005, J BIOL CHEM, V280, P42707, DOI 10.1074/jbc.M506178200	64	126	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31119	31130		10.1074/jbc.M604958200	http://dx.doi.org/10.1074/jbc.M604958200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912041	hybrid			2022-12-25	WOS:000241075900087
J	Luster, TA; He, J; Huang, XM; Maiti, SN; Schroit, AJ; de Groot, PG; Thorpe, PE				Luster, Troy A.; He, Jin; Huang, Xianming; Maiti, Sourindra N.; Schroit, Alan J.; de Groot, Philip G.; Thorpe, Philip E.			Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR BLOOD-VESSELS; BETA(2)-GLYCOPROTEIN I; 5TH DOMAIN; BINDING; PHOSPHATIDYLSERINE; AUTOANTIBODIES; COMPLEXES; SEQUENCE; DENSITY; SURFACE	A promising target on tumor vasculature is phosphatidylserine ( PS), an anionic phospholipid that resides exclusively on the inner leaflet of the plasma membrane of resting mammalian cells. We have shown previously that PS becomes exposed on the surface of endothelial cells (EC) in solid tumors. To target PS on tumor vasculature, the murine monoclonal antibody 3G4 was developed. 3G4 localizes to tumor vasculature, inhibits tumor growth, and enhances anti-tumor chemotherapies without toxicity in mice. A chimeric version of 3G4 is in clinical trials. In this study, we investigated the basis for the interaction between 3G4 and EC with surface-exposed PS. We demonstrate that antibody binding to PS is dependent on plasma protein beta-2-glycoprotein 1 (beta 2GP1). beta 2GP1 is a 50-kDa glycoprotein that binds weakly to anionic phospholipids under physiological conditions. We show that 3G4 enhances binding of beta 2GP1 to EC induced to expose PS. We also show that divalent 3G4-beta 2GP1 complexes are required for enhanced binding, since 3G4 Fab' fragments do not bind EC with exposed PS. Finally, we demonstrate that an artificial dimeric beta 2GP1 construct binds to EC with exposed PS in the absence of 3G4, confirming that antibody binding is mediated by dimerization of beta 2GP1. Together, these data indicate that 3G4 targets tumor EC by increasing the avidity of beta 2GP1 for anionic phospholipids through formation of multivalent 3G4-beta 2GP1 complexes.	Univ Texas, SW Med Ctr, Dept Pharmacol, Simmons Comprehens Canc Ctr,Hamon Ctr Therapeut O, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Med Ctr Utrecht, Dept Hematol, NL-3584 CX Utrecht, Netherlands	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; Utrecht University; Utrecht University Medical Center	Thorpe, PE (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Simmons Comprehens Canc Ctr,Hamon Ctr Therapeut O, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	philip.thorpe@utsouthwestern.edu						Beck AW, 2006, INT J CANCER, V118, P2639, DOI 10.1002/ijc.21684; Bevers EM, 2005, BIOCHEM J, V386, P271, DOI 10.1042/BJ20041167; Bevers EM, 2004, CLIN IMMUNOL, V112, P150, DOI 10.1016/j.clim.2004.02.009; BITBOL M, 1987, BIOCHIM BIOPHYS ACTA, V904, P268, DOI 10.1016/0005-2736(87)90376-2; Boyle EM, 1996, ANN THORAC SURG, V62, P1868, DOI 10.1016/S0003-4975(96)00950-2; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; DEVAUX PF, 1992, ANNU REV BIOPH BIOM, V21, P417, DOI 10.1146/annurev.bb.21.060192.002221; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; Galazka M, 1998, THROMB RES, V90, P131, DOI 10.1016/S0049-3848(98)00047-4; Gushiken FC, 2002, THROMB RES, V108, P175, DOI 10.1016/S0049-3848(02)00392-4; Huang XM, 2005, CANCER RES, V65, P4408, DOI 10.1158/0008-5472.CAN-05-0031; HUNT J, 1994, J IMMUNOL, V152, P653; HUNT JE, 1993, P NATL ACAD SCI USA, V90, P2141, DOI 10.1073/pnas.90.6.2141; Jankowski M, 2003, BLOOD, V101, P157, DOI 10.1182/blood-2002-05-1310; JENNEWEIN M, 2005, P AM ASSOC CANC RES, V46, P5261; Kogure K, 2003, CHEM PHYS LIPIDS, V126, P29, DOI 10.1016/S0009-3084(03)00091-4; Lutters BCH, 2001, J BIOL CHEM, V276, P3060, DOI 10.1074/jbc.M008224200; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mehdi H, 2000, EUR J BIOCHEM, V267, P1770, DOI 10.1046/j.1432-1327.2000.01174.x; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; POLZ E, 1980, INT J BIOCHEM, V11, P265, DOI 10.1016/0020-711X(80)90229-3; Ran S, 1998, CANCER RES, V58, P4646; Ran S, 2005, CLIN CANCER RES, V11, P1551, DOI 10.1158/1078-0432.CCR-04-1645; Ran S, 2003, NEOPLASIA, V5, P297, DOI 10.1016/S1476-5586(03)80023-4; Ran S, 2002, INT J RADIAT ONCOL, V54, P1479, DOI 10.1016/S0360-3016(02)03928-7; Ran S, 2002, CANCER RES, V62, P6132; ROUBEY RAS, 1995, J IMMUNOL, V154, P954; SHAUGHNESSY SG, 1989, AM J PATHOL, V134, P787; Sheng YH, 1996, J IMMUNOL, V157, P3744; SOARES FA, 1994, LAB INVEST, V71, P480; STEINKASSERER A, 1992, FEBS LETT, V313, P193, DOI 10.1016/0014-5793(92)81442-O; STEINKASSERER A, 1991, BIOCHEM J, V277, P387, DOI 10.1042/bj2770387; UTSUGI T, 1991, CANCER RES, V51, P3062; Willems GM, 1996, BIOCHEMISTRY-US, V35, P13833, DOI 10.1021/bi960657q; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; ZULUETA JJ, 1995, AM J RESP CELL MOL, V12, P41, DOI 10.1165/ajrcmb.12.1.7529030	37	59	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29863	29871		10.1074/jbc.M605252200	http://dx.doi.org/10.1074/jbc.M605252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16905548	hybrid			2022-12-25	WOS:000240896300048
J	Wilson, EM; Rotwein, P				Wilson, Elizabeth M.; Rotwein, Peter			Control of MyoD function during initiation of muscle differentiation by an autocrine signaling pathway activated by insulin-like growth factor-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOXO TRANSCRIPTION FACTORS; ADULT SKELETAL-MUSCLE; PROTEIN-KINASE; GENE-TRANSCRIPTION; MYOCYTE MATURATION; CELL SURVIVAL; MYOGENIN GENE; MICE LACKING; HYPERTROPHY; EXPRESSION	The insulin-like growth factors (IGFs) play key roles in muscle development, maintenance, and repair, but their mechanisms of action are incompletely defined. We previously identified an autocrine pathway involving production of IGF-II and activation of the IGF-I receptor, phosphatidylinositol 3-kinase, and Akt in myoblast differentiation induced by MyoD in 10T1/2 mesenchymal stem cells and found that blocking this pathway prevented differentiation ( Wilson, E. M., Hsieh, M. M., and Rotwein, P. ( 2003) J. Biol. Chem. 278, 41109 - 41113). We now have analyzed regulation of MyoD function in this model system. Inhibition of IGF-II production impaired the transcriptional actions of MyoD, as seen by a 70-80% decline in activity of transfected reporter genes, including the myogenin and creatine kinase promoters, and by complete inhibition of transcription of the endogenous myogenin gene but had no effect on MyoD protein levels, post-translational modifications, or nuclear localization, and neither blocked the rapid disappearance of the inhibitory molecule Id1 nor altered the nuclear expression or abundance of the MyoD binding partner E12/E47. Impaired signaling through the IGF-I receptor also did not decrease the ability of MyoD or E12/E47 to bind to target DNA sites at the proximal myogenin promoter, as assessed by chromatin immunoprecipitation assay but, rather, blocked chromatin remodeling at this site, as indicated by reduced recruitment of co-activators p300 and P/CAF and diminished acetylation of histones H3 and H4. Taken together, these results show that IGF-II-initiated signaling through the insulin-like growth factor-I receptor targets transcriptional co-regulators that are essential co-factors for MyoD and suggests that the phosphatidylinositol 3-kinase-Akt pathway plays a key role in establishing an amplification cascade that is essential for sustaining the earliest events in muscle differentiation.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Rotwein, P (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Rd, Portland, OR 97239 USA.	rotweinp@ohsu.edu	Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NIDDK NIH HHS [R01 DK42748, R01 DK042748] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042748] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Chan HM, 2001, J CELL SCI, V114, P2363; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen J, 2004, CELL MOL LIFE SCI, V61, P1675, DOI 10.1007/s00018-004-4103-9; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; KOU K, 1993, MOL ENDOCRINOL, V7, P291, DOI 10.1210/me.7.2.291; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Lee SJ, 1999, CURR OPIN GENET DEV, V9, P604, DOI 10.1016/S0959-437X(99)00004-0; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; McKinnell LW, 2004, CELL, V119, P907, DOI 10.1016/j.cell.2004.12.007; McNally EM, 2004, NEW ENGL J MED, V350, P2642, DOI 10.1056/NEJMp048124; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; Miller BS, 2005, CANCER RES, V65, P10123, DOI 10.1158/0008-5472.CAN-05-2752; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Paul AC, 2002, J CELL BIOL, V156, P751, DOI 10.1083/jcb.200105147; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Penn BH, 2004, GENE DEV, V18, P2348, DOI 10.1101/gad.1234304; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473; Rotwein P, 2003, GROWTH HORM IGF RES, V13, P303, DOI 10.1016/j.ghir.2003.09.001; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sabourin LA, 1999, J CELL BIOL, V144, P631, DOI 10.1083/jcb.144.4.631; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351; Wilson EM, 2003, J BIOL CHEM, V278, P41109, DOI 10.1074/jbc.C300299200; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200	70	94	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29962	29971		10.1074/jbc.M605445200	http://dx.doi.org/10.1074/jbc.M605445200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16901893	hybrid			2022-12-25	WOS:000240896300057
J	Jiang, Q; Yan, Z; Feng, J				Jiang, Qian; Yan, Zhen; Feng, Jian			Neurotrophic factors stabilize microtubules and protect against rotenone toxicity on dopaminergic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE BRAIN; SUBSTANTIA-NIGRA NEURONS; GDNF; INHIBITION; RECEPTORS; KINASE; CELLS	Parkinson disease is characterized by the selective degeneration of dopaminergic (DA) neurons in substantia nigra. Long term epidemiological studies have implicated exposure to agricultural pesticides as a significant risk factor. Systemic administration of rotenone, a widely used pesticide, causes selective degeneration of nigral DA neurons and Parkinson disease-like symptoms in rats. Our previous study has shown that the microtubule depolymerizing activity of rotenone plays a critical role in its selective toxicity on DA neurons. Rotenone toxicity is mimicked by the microtubule-depolymerizing drug colchicine and attenuated by the microtubule-stabilizing agent taxol. Here we show that nerve growth factor (NGF) significantly reduced rotenone toxicity on TH+ neurons in midbrain neuronal cultures. The protective effect of NGF was completely abolished by inhibiting the microtubule-associated protein kinase kinase (MEK) and partially reversed by blocking phosphatidylinositol 3-kinase. In addition, NGF decreased colchicine toxicity on TH+ neurons in a manner dependent on MEK but not phosphatidylinositol 3-kinase. The protective effect of NGF against rotenone toxicity was occluded by the microtubule-stabilizing drug taxol. In a MEK-dependent manner, NGF significantly attenuated rotenone- or colchicine-induced microtubule depolymerization and ensuing accumulation of vesicles in the soma and elevation in protein carbonyls. Moreover, other neurotrophic factors such as brain-derived neurotrophic factor and glia cell line-derived neurotrophic factor also reduced rotenone- or colchicine-induced microtubule depolymerization and death of TH+ through a MEK-dependent mechanism. Thus, our results suggest that neurotrophic factors activate the microtubule-associated protein kinase pathway to stabilize microtubules, and this action significantly attenuates rotenone toxicity on dopaminergic neurons.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Feng, J (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	jianfeng@buffalo.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041722] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41722] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barker RA, 2006, LANCET NEUROL, V5, P285, DOI 10.1016/S1474-4422(06)70386-6; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; BRINKLEY BR, 1974, EXP CELL RES, V85, P41, DOI 10.1016/0014-4827(74)90210-9; Cassimeris L, 2001, INT REV CYTOL, V210, P163; CHANCE B, 1963, J BIOL CHEM, V238, P418; Chauhan NB, 2001, J CHEM NEUROANAT, V21, P277, DOI 10.1016/S0891-0618(01)00115-6; Di Monte DA, 2003, LANCET NEUROL, V2, P531, DOI 10.1016/S1474-4422(03)00501-5; Kirik D, 2004, NAT NEUROSCI, V7, P105, DOI 10.1038/nn1175; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Langston JW, 2002, NEUROTOXICOLOGY, V23, P443, DOI 10.1016/S0161-813X(02)00098-0; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; Nishio T, 1998, NEUROREPORT, V9, P2847, DOI 10.1097/00001756-199808240-00030; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; Ren Y, 2005, J BIOL CHEM, V280, P34105, DOI 10.1074/jbc.M503483200; Sariola H, 2003, J CELL SCI, V116, P3855, DOI 10.1242/jcs.00786; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Siegel GJ, 2000, BRAIN RES REV, V33, P199, DOI 10.1016/S0165-0173(00)00030-8; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; TAKEMURA R, 1992, J CELL SCI, V103, P953; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Walker DG, 1998, BRAIN RES, V792, P207, DOI 10.1016/S0006-8993(98)00131-0; Yuen EY, 2005, J NEUROSCI, V25, P5488, DOI 10.1523/JNEUROSCI.1187-05.2005	24	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29391	29400		10.1074/jbc.M602740200	http://dx.doi.org/10.1074/jbc.M602740200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16887804	hybrid			2022-12-25	WOS:000240680500094
J	Targett-Adams, P; Schaller, T; Hope, G; Lanford, RE; Lemon, SM; Martin, A; McLauchlan, J				Targett-Adams, Paul; Schaller, Torsten; Hope, Graham; Lanford, Robert E.; Lemon, Stanley M.; Martin, Annette; McLauchlan, John			Signal peptide peptidase cleavage of GB virus B core protein is required for productive infection in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; CATALYZED INTRAMEMBRANE PROTEOLYSIS; SURROGATE MODEL; LIPID DROPLETS; ALPHA-HELICES; HLA-E; VITRO; MEMBRANE; RESIDUES; CULTURE	Chronic infection by hepatitis C virus (HCV) is a leading cause of liver disease for which better therapies are urgently needed. Because a clearer understanding of the viral life cycle may suggest novel anti-viral approaches, we studied the role of host signal peptide peptidase (SPP) in viral infection. This intramembrane protease cleaves within a C-terminal signal sequence in the viral core protein, but the molecular determinants of cleavage and whether it is required for infection in vivo are unknown. To answer these questions, we studied SPP processing in GB virus B (GBV-B) infection. GBV-B is the closest phylogenetic relative of HCV and offers an accurate surrogate model for HCV infection. We demonstrate that SPP also processes GBV-B core protein and that a serine residue in the hydrophobic region of the signal sequence ( present also in HCV) is critical for efficient SPP cleavage. The small size of the serine side chain combined with its ability to form intra- and interhelical hydrogen bonds likely contributes to recognition of the signal sequence as a substrate for SPP. By introducing mutations with differing effects on SPP processing into an infectious GBV-B molecular clone, we demonstrate that SPP processing of the core protein is required for productive infection in primates. These results broaden our understanding of the mechanism and requirements for SPP cleavage and reveal a functional role in vivo for intramembrane proteolysis in host-pathogen interactions. Moreover, they identify SPP as a potential therapeutic target for reducing the impact of HCV infection.	MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland; SW Fdn Biomed Res, Dept Virol & Immunol, San Antonio, TX USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; CNRS, Unite Genet Mol Virus Respiratoires, URA 1966, Inst Pasteur, F-75724 Paris, France	Texas Biomedical Research Institute; University of Texas System; University of Texas Medical Branch Galveston; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	McLauchlan, J (corresponding author), MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.	j.mclauchlan@mrcvu.gla.ac.uk	Schaller, Torsten/ABC-9153-2020; Martin, Annette/A-2425-2016	Schaller, Torsten/0000-0001-9597-4112; Martin, Annette/0000-0002-3054-3925; Targett-Adams, Paul/0000-0003-4967-1668	Medical Research Council [MC_U130184143, MC_UU_12014/1] Funding Source: Medline; NCRR NIH HHS [R24-RR15081] Funding Source: Medline; NIAID NIH HHS [R01-AI49574, U19-AI40035] Funding Source: Medline; MRC [MC_U130184143] Funding Source: UKRI; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR015081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040035, R01AI049574] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ait-Goughoulte M, 2006, J GEN VIROL, V87, P855, DOI 10.1099/vir.0.81664-0; Ballesteros JA, 2000, BIOPHYS J, V79, P2754, DOI 10.1016/S0006-3495(00)76514-3; Beames B, 2001, ILAR J, V42, P152; Beames B, 2000, J VIROL, V74, P11764, DOI 10.1128/JVI.74.24.11764-11772.2000; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bland FA, 2003, J BIOL CHEM, V278, P33747, DOI 10.1074/jbc.M305593200; Bright H, 2004, J VIROL, V78, P2062, DOI 10.1128/JVI.78.4.2062-2071.2004; Bukh J, 1999, VIROLOGY, V262, P470, DOI 10.1006/viro.1999.9941; Bukh J, 2001, J MED VIROL, V65, P694, DOI 10.1002/jmv.2092; Casso DJ, 2005, GENETICS, V170, P139, DOI 10.1534/genetics.104.039933; Ghibaudo D, 2004, J BIOL CHEM, V279, P24965, DOI 10.1074/jbc.M401148200; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; Grigorenko AP, 2004, P NATL ACAD SCI USA, V101, P14955, DOI 10.1073/pnas.0406462101; Heimann M, 2006, J VIROL, V80, P1915, DOI 10.1128/JVI.80.4.1915-1921.2006; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hope RG, 2000, J GEN VIROL, V81, P1913, DOI 10.1099/0022-1317-81-8-1913; Hope RG, 2006, J GEN VIROL, V87, P623, DOI 10.1099/vir.0.81371-0; Hope RG, 2002, J BIOL CHEM, V277, P4261, DOI 10.1074/jbc.M108798200; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; Jacob JR, 2004, J GEN VIROL, V85, P2525, DOI 10.1099/vir.0.80036-0; Lanford RE, 2003, VIROLOGY, V311, P72, DOI 10.1016/S0042-6822(03)00193-4; Lemberg MK, 2004, FEBS LETT, V564, P213, DOI 10.1016/S0014-5793(04)00192-9; Lemberg MK, 2003, ANAL BIOCHEM, V319, P327, DOI 10.1016/S0003-2697(03)00298-7; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; LI SC, 1994, NAT STRUCT BIOL, V1, P368, DOI 10.1038/nsb0694-368; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Martin A, 2003, P NATL ACAD SCI USA, V100, P9962, DOI 10.1073/pnas.1731505100; Martoglio B, 2003, BIOCHEM SOC T, V31, P1243; Martoglio B, 2003, HUM MOL GENET, V12, pR201, DOI 10.1093/hmg/ddg303; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Nam JH, 2004, J VIROL, V78, P9389, DOI 10.1128/JVI.78.17.9389-9399.2004; Patel J, 1999, J GEN VIROL, V80, P1681, DOI 10.1099/0022-1317-80-7-1681; Rijnbrand R, 2005, HEPATOLOGY, V41, P986, DOI 10.1002/hep.20656; Sbardellati A, 2001, J GEN VIROL, V82, P2437, DOI 10.1099/0022-1317-82-10-2437; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Takikawa S, 2006, P NATL ACAD SCI USA, V103, P3345, DOI 10.1073/pnas.0511297103; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Weihofen A, 2000, J BIOL CHEM, V275, P30951, DOI 10.1074/jbc.M005980200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Yi M, 2006, P NATL ACAD SCI USA, V103, P2310, DOI 10.1073/pnas.0510727103; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	45	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29221	29227		10.1074/jbc.M605373200	http://dx.doi.org/10.1074/jbc.M605373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16882659	hybrid			2022-12-25	WOS:000240680500077
J	Alli, E; Yang, JM; Hait, WN				Alli, E.; Yang, J-M; Hait, W. N.			Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53	ONCOGENE			English	Article						stathmin; cell-cycle arrest; mitosis; apoptosis; breast cancer	DOWN-REGULATION; CYCLE ARREST; EXPRESSION; OVEREXPRESSION; CHECKPOINT; MUTATIONS; GENES; ONCOPROTEIN-18; APOPTOSIS; NETWORK	Cancers harboring dominant-negative p53 mutations are often aggressive and difficult to treat. Direct attempts to restore wild-type p53 function have produced little clinical benefit. We investigated whether targeting a p53-target gene could induce certain tumor-suppressor characteristics. We found that inhibition of stathmin, a microtubule regulator that can be transcriptionally repressed by wildtype p53, restored certain wild-type functions to cancer cells with mutant p53. Silencing of stathmin by small interfering RNA ( siRNA) in mutant p53 cell lines lowered expression to that observed following activation of wildtype p53 by DNA damage in wild-type p53 cell lines. siRNA-induced repression of stathmin decreased cell proliferation, viability and clonogenicity in mutant p53 cell lines. Furthermore, knockdown of stathmin partially restored cell-cycle regulation and activation of apoptosis. Therefore, targeting stathmin, a gene product that is overexpressed in the presence of mutant p53, may represent a novel approach to treating cancers with aberrant p53 function.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Hait, WN (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, 195 Little Albany St, New Brunswick, NJ 08901 USA.	jyang@umdnj.edu; haitwn@umdnj.edu			NCI NIH HHS [CA 78695, CA 72720] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078695, P30CA072720] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Alli E, 2002, CANCER RES, V62, P6864; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Bieche I, 2003, MOL BRAIN RES, V114, P55, DOI 10.1016/S0169-328X(03)00132-3; Bossi G, 2004, ONCOGENE, V23, P418, DOI 10.1038/sj.onc.1207042; Brattsand G, 2000, BRIT J CANCER, V83, P311, DOI 10.1054/bjoc.2000.1264; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chang CL, 2001, PROTEOMICS, V1, P1415, DOI 10.1002/1615-9861(200111)1:11<1415::AID-PROT1415>3.3.CO;2-6; Curmi PA, 2000, BRIT J CANCER, V82, P142, DOI 10.1054/bjoc.1999.0891; FAILLE A, 1994, BRIT J CANCER, V69, P1145, DOI 10.1038/bjc.1994.225; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Meek DW, 2000, PATHOL BIOL, V48, P246; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Oesterreich S, 1999, ENDOCR-RELAT CANCER, V6, P405, DOI 10.1677/erc.0.0060405; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Price DK, 2000, CANCER INVEST, V18, P722, DOI 10.3109/07357900009012204; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SOBEL A, 1983, J BIOL CHEM, V258, P312; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Vecil GG, 2003, J NEURO-ONCOL, V65, P237, DOI 10.1023/B:NEON.0000003653.45635.32; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Zhou Jun, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P65, DOI 10.2174/1568011053352569	43	91	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1003	1012		10.1038/sj.onc.1209864	http://dx.doi.org/10.1038/sj.onc.1209864			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909102				2022-12-25	WOS:000244245400006
J	Thankamony, SP; Knudson, W				Thankamony, Sai P.; Knudson, Warren			Acylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-PROTEIN THIOESTERASE; ARTICULAR CHONDROCYTES; MEDIATED ENDOCYTOSIS; PERICELLULAR MATRIX; PALMITOYLATION; DOMAIN; INTERNALIZATION; UBIQUITINATION; DEGRADATION; ACTIVATION	CD44 is a cell surface receptor for the extracellular matrix macromolecule hyaluronan. In addition, CD44 mediates the endocytosis of hyaluronan leading to its subsequent degradation within lysosomes. Using model systems of COS-7 and Flp-293 cells, we demonstrate that the association of CD44 with lipid rafts is essential for the endocytosis of hyaluronan but not the extracellular binding. Further, we demonstrate that palmitoylation of CD44 on two highly conserved cysteine residues is essential for the association with lipid rafts as determined by density gradient ultracentrifugation. Mutations of either cysteine residues or pretreatment of cells with the palmitic acid analog 2-bromopalmitate, reduced the [H-3] palmitic acid incorporation into CD44 and prevented CD44-lipid rafts association. Preventing CD44 palmitoylation had no effect on the binding of hyaluronan but inhibited hyaluronan internalization. The turnover of the CD44 receptor itself was also affected by blocking its association with lipid rafts. Using cycloheximide to prevent de novo protein synthesis, palmitoylation-deficient cysteine mutants underwent slower turnover from cell surface compared with the palmitoylation-intact wild type, as determined by immunofluorescence and Western blotting. These results indicate that palmitoylation of CD44 is a critical driving determinant to CD44 association with lipid rafts and, concomitantly, the rates of hyaluronan endocytosis and CD44 turnover from cell surface.	Rush Univ, Med Ctr, Rush Med Coll, Dept Biochem, Chicago, IL 60612 USA	Rush University	Knudson, W (corresponding author), Rush Univ, Med Ctr, Rush Med Coll, Dept Biochem, 1735 W Harrison St, Chicago, IL 60612 USA.	Warren_Knudson@rush.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043384, P50AR039239] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR043384-15, R01 AR043384, P50-AR39239, R01-AR43384, P50 AR039239] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067; Aguiar DJ, 1999, EXP CELL RES, V252, P292, DOI 10.1006/excr.1999.4641; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Embry JJ, 2003, ARTHRITIS RHEUM-US, V48, P3431, DOI 10.1002/art.11323; Foger N, 2000, EUR J IMMUNOL, V30, P2888; GUO YJ, 1994, INT IMMUNOL, V6, P213, DOI 10.1093/intimm/6.2.213; GUO YJ, 1993, CELL IMMUNOL, V152, P186, DOI 10.1006/cimm.1993.1278; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; HUA Q, 1993, J CELL SCI, V106, P365; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; Jiang H, 2001, ARTHRITIS RHEUM-US, V44, P2599, DOI 10.1002/1529-0131(200111)44:11<2599::AID-ART440>3.0.CO;2-Y; Knudson CB, 2004, CLIN ORTHOP RELAT R, pS152, DOI 10.1097/01.blo.0000143804.26638.82; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Knudson W, 2004, CHEMISTRY AND BIOLOGY OF HYALURONAN, P83; Knudson W, 2002, MATRIX BIOL, V21, P15, DOI 10.1016/S0945-053X(01)00186-X; KNUDSON W, 2004, CURR OPIN ORTHOP, V15, P369; KNUDSON W, 2005, HYALURONAN STRUCTURE, V1, P213; Li M, 2002, J VIROL, V76, P11845, DOI 10.1128/JVI.76.23.11845-11852.2002; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Munshi UM, 2005, MOL ENDOCRINOL, V19, P749, DOI 10.1210/me.2004-0335; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Radeva G, 2004, BIOCHEM J, V380, P219, DOI 10.1042/BJ20031348; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Roy S, 2005, MOL CELL BIOL, V25, P6722, DOI 10.1128/MCB.25.15.6722-6733.2005; Stickney JT, 2004, CANCER RES, V64, P2717, DOI 10.1158/0008-5472.CAN-03-3798; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; UNDERHILL CB, 1993, DEV BIOL, V155, P324, DOI 10.1006/dbio.1993.1032; Yeh DC, 1999, J BIOL CHEM, V274, P33148, DOI 10.1074/jbc.274.46.33148	36	93	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34601	34609		10.1074/jbc.M601530200	http://dx.doi.org/10.1074/jbc.M601530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16945930	Green Accepted, hybrid			2022-12-25	WOS:000241767600079
J	Rogacheva, M; Ishchenko, A; Saparbaev, M; Kuznetsova, S; Ogryzko, V				Rogacheva, Maria; Ishchenko, Alexander; Saparbaev, Murat; Kuznetsova, Svetlana; Ogryzko, Vasily			High resolution characterization of formamidopyrimidine-DNA glycosylase interaction with its substrate by chemical cross-linking and mass Spectrometry using substrate analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI FPG PROTEIN; EXCISION-REPAIR ENZYMES; ESCHERICHIA-COLI; RESTRICTION-ENDONUCLEASE; CATALYTIC-ACTIVITIES; LESION RECOGNITION; SINGLE MUTATIONS; PHOSPHATE GROUPS; DAMAGED DNA; SITE	Escherichia coli formamidopyrimidine-DNA glycosylase (Fpg) and human 8-oxoguanine-DNA glycosylase (hOgg1) initiate the base excision repair pathway for 7,8-dihydro-8-oxoguanine (8-oxoG) residues present in DNA. Recent structural and biochemical studies of Fpg-DNA and hOgg1-DNA complexes point to the existence of extensive interactions between phosphate groups and amino acids. However, the role of these contacts and their physiological relevance remains unclear. In the present study, we combined chemical cross-linking and electrospray ionization mass spectrometry (ESI/MS/MS) approaches to identify interacting residues in the Fpg-DNA and hOgg1-DNA complexes. The active centers of Fpg and hOgg1 were cross-linked with a series of reactive oligonucleotide duplexes containing both a single 8-oxoG residue and an O-ethyl-substituted pyrophosphate internucleotide (SPI) group at different positions in duplex DNA. The cross-linking efficiency reached 50% for Fpg and 30% for hOgg1. We have identified seven phosphate groups on both strands of the DNA duplex specifically interacting with nucleophilic amino acids in Fpg, and eight in hOgg1. MS/MS analysis of the purified proteolytic fragments suggests that lysine 56 of Fpg and lysine 249 of hOgg1 cross-link to the phosphate located 3' to the 8-oxoG residue. Site-specific mutagenesis analysis of Fpg binding to DNA substrate confirms the conclusions of our approach. Our results are consistent with crystallographic data on the Fpg-DNA complex and provide new data on the hOgg1-DNA interaction. The approach developed in this work provides a useful tool to study pro- and eukaryotic homologues of Fpg as well as other repair enzymes.	Univ Paris Sud, Inst Gustave Roussy, CNRS, UMR 8126,Mol Epigenet Grp, F-94805 Villejuif, France; Moscow MV Lomonosov State Univ, Dept Chem, Lab Nucle Acids Chem, Moscow 119992, Russia; Univ Paris Sud, Inst Gustave Roussy, CNRS, UMR 8126,DNA Repair Grp, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Lomonosov Moscow State University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Ogryzko, V (corresponding author), Univ Paris Sud, Inst Gustave Roussy, CNRS, UMR 8126,Mol Epigenet Grp, F-94805 Villejuif, France.	ogryzko@igr.fr	Ishchenko, Alexander/D-4133-2013; Saparbaev, Murat K/N-3225-2015; Kuznetsova, Svetlana/I-8394-2012; Ogryzko, Vasily/M-6665-2015; Saparbaev, Murat/AAC-5478-2020	Ishchenko, Alexander/0000-0002-0488-8858; Saparbaev, Murat K/0000-0002-4630-1074; Ogryzko, Vasily/0000-0002-8548-1389; Saparbaev, Murat/0000-0002-4630-1074				Back JW, 2003, J MOL BIOL, V331, P303, DOI 10.1016/S0022-2836(03)00721-6; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Castaing B, 1999, NUCLEIC ACIDS RES, V27, P608, DOI 10.1093/nar/27.2.608; CASTAING B, 1993, NUCLEIC ACIDS RES, V21, P2899, DOI 10.1093/nar/21.12.2899; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; Fromme JC, 2003, J BIOL CHEM, V278, P51543, DOI 10.1074/jbc.M307768200; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; Gros L, 2004, NUCLEIC ACIDS RES, V32, P73, DOI 10.1093/nar/gkh165; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; KIRPOTA OO, 2006, MOL BIOL, V5, P512; Kuznetsov SV, 1998, EUR J BIOCHEM, V253, P413, DOI 10.1046/j.1432-1327.1998.2530413.x; Kuznetsova S, 2003, BIOCHIMIE, V85, P511, DOI 10.1016/S0300-9084(03)00067-1; Kuznetsova SA, 1996, NUCLEIC ACIDS RES, V24, P4783, DOI 10.1093/nar/24.23.4783; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; Naryshkin NA, 1997, BIOCHEMISTRY-US, V36, P3496, DOI 10.1021/bi962789p; Norman DPG, 2003, BIOCHEMISTRY-US, V42, P1564, DOI 10.1021/bi026823d; Norman DPG, 2001, J AM CHEM SOC, V123, P359, DOI 10.1021/ja003144m; Ong SE, 2005, NAT CHEM BIOL, V1, P252, DOI 10.1038/nchembio736; PURMAL AA, 1992, NUCLEIC ACIDS RES, V20, P3713, DOI 10.1093/nar/20.14.3713; Rogacheva MV, 2005, BIOCHIMIE, V87, P1079, DOI 10.1016/j.biochi.2005.05.011; Rudakova EA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P640; Saparbaev M, 2002, ENVIRON MOL MUTAGEN, V39, P10, DOI 10.1002/em.10041; Serre L, 2002, EMBO J, V21, P2854, DOI 10.1093/emboj/cdf304; SHABAROVA ZA, 1994, BIOORG KHIM+, V20, P413; Sheflyan GY, 1996, FEBS LETT, V390, P307, DOI 10.1016/0014-5793(96)00645-X; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sidorkina O, 2001, FREE RADICAL BIO MED, V31, P816, DOI 10.1016/S0891-5849(01)00659-1; Sidorkina OM, 1998, NUCLEIC ACIDS RES, V26, P5351, DOI 10.1093/nar/26.23.5351; Sidorkina OM, 2000, J BIOL CHEM, V275, P9924, DOI 10.1074/jbc.275.14.9924; Speina E, 2005, ACTA BIOCHIM POL, V52, P167; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Wiederholt CJ, 2002, BIOCHEMISTRY-US, V41, P15838, DOI 10.1021/bi025903e; Wong SS, 1991, CHEM PROTEIN CONJUGA; Zaika EI, 2004, J BIOL CHEM, V279, P4849, DOI 10.1074/jbc.M310262200; Zharkov DO, 2003, MUTAT RES-FUND MOL M, V531, P141, DOI 10.1016/j.mrfmmm.2003.09.002	40	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32353	32365		10.1074/jbc.M606217200	http://dx.doi.org/10.1074/jbc.M606217200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16928690	hybrid			2022-12-25	WOS:000241414500033
J	Schneider, S; Sharp, KH; Barker, PD; Paoli, M				Schneider, Sabine; Sharp, Katherine H.; Barker, Paul D.; Paoli, Max			An induced fit conformational change underlies the binding mechanism of the heme transport proteobacteria-protein HemS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIGELLA-DYSENTERIAE; YERSINIA-ENTEROCOLITICA; CRYSTAL-STRUCTURE; UPTAKE SYSTEM; IRON; REFINEMENT; IDENTIFICATION; SIDEROPHORES; GENETICS; RECEPTOR	Bacteria rely on their environment and/or host to acquire iron and have evolved specialized systems to sequester and transport heme. The heme uptake system HemRSTUV is common to proteobacteria, and a major challenge is to understand the molecular mechanism of heme binding and transfer between the protein molecules that underlie this heme transport relay process. In the Gram-negative pathogen Yersinia enterocolitica, the HemRSTUV system culminates with the cytoplasmic recipient HemS, which stores and delivers heme for cellular needs. HemS belongs to a family of proteins essential and unique to proteobacteria. Here we report on the binding mechanism of HemS based on structural data from its apo- and ligand-loaded forms. This heme carrier protein associates with its cargo through a novel, partly preformed binding pocket, formed between a large beta-sheet dome and a three-helix subdomain. In addition to a histidine interacting with the iron, the complex is stabilized by a distal non-coordinating arginine that packs along the porphyrin plane and extensive electrostatic contacts that firmly anchor the heme propionate groups within the protein. Comparison of apoand ligand-bound HemS crystal structures reveals striking conformational changes that underlie a "heme- induced fit" binding mechanism. Local shifts in amino acid positions combine with global, rigid body-like domain movements, and together, these bring about a switch from an open, apo- form to a closed, bound state. This is the first report in which both liganded and unliganded forms of a heme transport protein are described, thus providing penetrating insights into its mechanism of heme binding and release.	Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England; Univ Nottingham, Ctr Biomol Sci, Nottingham NG7 2RD, England; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Nottingham; University of Nottingham; University of Cambridge	Paoli, M (corresponding author), Univ Nottingham, Sch Pharm, Univ Pk, Nottingham NG7 2RD, England.	max.paoli@nottingham.ac.uk	Schneider, Sabine/G-2908-2013	Schneider, Sabine/0000-0003-1054-8689				Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; Bracken CS, 1999, J BACTERIOL, V181, P6063, DOI 10.1128/JB.181.19.6063-6072.1999; Braun V, 2001, INT J MED MICROBIOL, V291, P67, DOI 10.1078/1438-4221-00103; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans W, 1997, CHEM BRIT, V33, P22; Faraldo-Gomez JD, 2003, NAT REV MOL CELL BIO, V4, P105, DOI 10.1038/nrm1015; Genco CA, 2001, MOL MICROBIOL, V39, P1, DOI 10.1046/j.1365-2958.2001.02231.x; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Hartshorn MJ, 2002, J COMPUT AID MOL DES, V16, P871, DOI 10.1023/A:1023813504011; Henderson DP, 2001, J BACTERIOL, V183, P2715, DOI 10.1128/JB.183.9.2715-2723.2001; Lansky IB, 2006, J BIOL CHEM, V281, P13652, DOI 10.1074/jbc.M600824200; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; MILLS M, 1995, J BACTERIOL, V177, P3004, DOI 10.1128/jb.177.11.3004-3009.1995; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ochsner UA, 2000, MICROBIOL-UK, V146, P185, DOI 10.1099/00221287-146-1-185; Olczak T, 2001, J BACTERIOL, V183, P5599, DOI 10.1128/JB.183.19.5599-5608.2001; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Paoli M, 1999, NAT STRUCT BIOL, V6, P926; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Schneider S, 2005, ACTA CRYSTALLOGR F, V61, P802, DOI 10.1107/S1744309105023523; Smulevich G, 1998, BIOSPECTROSCOPY, V4, pS3, DOI 10.1002/(SICI)1520-6343(1998)4:5+<S3::AID-BSPY2>3.0.CO;2-R; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; Stojiljkovic I, 2002, DNA CELL BIOL, V21, P281, DOI 10.1089/104454902753759708; Suits MDL, 2005, P NATL ACAD SCI USA, V102, P16955, DOI 10.1073/pnas.0504289102; Thompson JM, 1999, INFECT IMMUN, V67, P3879, DOI 10.1128/IAI.67.8.3879-3892.1999; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; Wilks A, 2001, ARCH BIOCHEM BIOPHYS, V387, P137, DOI 10.1006/abbi.2000.2250; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Wyckoff EE, 1998, MOL MICROBIOL, V28, P1139, DOI 10.1046/j.1365-2958.1998.00873.x	35	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32606	32610		10.1074/jbc.M607516200	http://dx.doi.org/10.1074/jbc.M607516200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16943192	hybrid			2022-12-25	WOS:000241414500058
J	Tsubotao, T; Tajima, R; Ode, K; Kubota, H; Fukuhara, N; Kawabata, T; Maki, S; Maki, H				Tsubotao, Toshiaki; Tajima, Rie; Ode, Kunitomo; Kubota, Hajime; Fukuhara, Naoshi; Kawabata, Takeshi; Maki, Satoko; Maki, Hisaji			Double-stranded DNA binding, an unusual property of DNA polymerase epsilon, promotes epigenetic silencing in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; CELL NUCLEAR ANTIGEN; HISTONE-FOLD; PROTEIN STRUCTURES; S-PHASE; NF-Y; SUBUNIT; REPLICATION; CLONING; IDENTIFICATION	We have previously shown that DNA polymerase is an element of (Pol is an element of) of Saccharomyces cerevisiae binds stably to double-stranded DNA (dsDNA), a property not generally associated with DNA polymerases. Here, by reconstituting Pol is an element of activity from Pol2p-Dpb2p and Dpb3p-Dpb4p, its two component subassemblies, we report that Dpb3p-Dpb4p, a heterodimer of histone-fold motif-containing subunits, is responsible for the dsDNA binding. Substitution of specific lysine residues in Dpb3p, highlighted by homology modeling of Dpb3p-Dpb4p based on the structure of the histone H2A-H2B dimer, indicated that they play roles in binding of dsDNA by Dpb3p-Dpb4p, in a manner similar to the histone-DNA interaction. The lysine-substituted dpb3 mutants also displayed reduced telomeric silencing, whose degree paralleled that of the dsDNA-binding activity of Pol is an element of in the corresponding dpb3 mutants. Furthermore, additional amino acid substitutions to lysines in Dpb4p, to compensate for the loss of positive charges in the Dpb3p mutants, resulted in simultaneous restoration of dsDNA-binding activity by Pol is an element of and telomeric silencing. We conclude that the dsDNA-binding property of Pol is an element of is required for epigenetic silencing at telomeres.	Nara Inst Sci & Technol, Dept Mol Biol, Grad Sch Biol Sci, Nara 6300192, Japan; Nara Inst Sci & Technol, Grad Sch Informat Sci, Nara 6300192, Japan	Nara Institute of Science & Technology; Nara Institute of Science & Technology	Maki, S (corresponding author), Nara Inst Sci & Technol, Dept Mol Biol, Grad Sch Biol Sci, Nara 6300192, Japan.	smaki@bs.naist.jp						Amberg DC, 2005, METHODS YEAST GENETI, P199; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; Asturias FJ, 2006, NAT STRUCT MOL BIOL, V13, P35, DOI 10.1038/nsmb1040; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Caretti G, 1999, MOL CELL BIOL, V19, P8591; Chilkova O, 2003, J BIOL CHEM, V278, P14082, DOI 10.1074/jbc.M211818200; Corona DFV, 2000, EMBO J, V19, P3049, DOI 10.1093/emboj/19.12.3049; Feng WY, 2003, MOL BIOL CELL, V14, P3427, DOI 10.1091/mbc.E03-02-0088; Franco AA, 2004, COLD SPRING HARB SYM, V69, P201, DOI 10.1101/sqb.2004.69.201; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Harp JM, 2000, ACTA CRYSTALLOGR D, V56, P1513, DOI 10.1107/S0907444900011847; Hartlepp KF, 2005, MOL CELL BIOL, V25, P9886, DOI 10.1128/MCB.25.22.9886-9896.2005; Iida T, 2004, MOL CELL BIOL, V24, P217, DOI 10.1128/MCB.24.1.217-227.2004; Jokela M, 1998, NUCLEIC ACIDS RES, V26, P730, DOI 10.1093/nar/26.3.730; Kawabata T, 2000, PROTEINS, V41, P108, DOI 10.1002/1097-0134(20001001)41:1<108::AID-PROT130>3.3.CO;2-J; KESTI T, 1993, J BIOL CHEM, V268, P10238; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Krude T, 2001, CELL MOL LIFE SCI, V58, P665, DOI 10.1007/PL00000890; Kukimoto I, 2004, MOL CELL, V13, P265, DOI 10.1016/S1097-2765(03)00523-9; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Li Y, 1997, J BIOL CHEM, V272, P32337, DOI 10.1074/jbc.272.51.32337; Li Y, 2000, J BIOL CHEM, V275, P23247, DOI 10.1074/jbc.M002548200; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Maki S, 1998, J BIOL CHEM, V273, P21332, DOI 10.1074/jbc.273.33.21332; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; McAinsh AD, 1999, CURR BIOL, V9, P963, DOI 10.1016/S0960-9822(99)80424-2; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Motta MC, 1999, J BIOL CHEM, V274, P1326, DOI 10.1074/jbc.274.3.1326; Ohya T, 2000, NUCLEIC ACIDS RES, V28, P3846, DOI 10.1093/nar/28.20.3846; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Spiga MG, 2004, NUCLEIC ACIDS RES, V32, P4945, DOI 10.1093/nar/gkh811; Tackett AJ, 2005, J CELL BIOL, V169, P35, DOI 10.1083/jcb.200502104; Tsubota T, 2003, GENES CELLS, V8, P873, DOI 10.1046/j.1365-2443.2003.00683.x; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	46	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32898	32908		10.1074/jbc.M606637200	http://dx.doi.org/10.1074/jbc.M606637200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16916794	hybrid			2022-12-25	WOS:000241414500088
J	Brandan, E; Retamal, C; Cabello-Verrugio, C; Marzolo, MP				Brandan, Enrique; Retamal, Claudio; Cabello-Verrugio, Claudio; Marzolo, Maria-Paz			The low density lipoprotein receptor-related protein functions as an Endocytic receptor for decorin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; DERMATAN SULFATE PROTEOGLYCAN; GROWTH-FACTOR-BETA; HEPARAN-SULFATE; TYROSINE PHOSPHORYLATION; ALPHA-2-MACROGLOBULIN RECEPTOR; MYOBLAST DIFFERENTIATION; SYNDECAN-1 EXPRESSION; ANTISENSE INHIBITION; EXTRACELLULAR-MATRIX	Decorin is a small leucine-rich proteoglycan that modulates the activity of transforming growth factor type beta and other growth factors and thereby influences the processes of proliferation and differentiation in a wide array of physiological and pathological reactions. Hence, understanding the regulatory mechanisms of decorin activity has broad implications. Here we report that the extracellular levels of decorin are controlled by receptor-mediated catabolism, involving the low density lipoprotein receptor family member, low density lipoprotein receptor-related protein (LRP). We show that decorin is endocytosed and degraded by C2C12 myoblast cells and that both processes are blocked by suppressing LRP expression using short interfering RNA. The same occurs with CHO cells, but not with CHO cells genetically deficient in LRP. Finally, we show that LRP-null CHO cells, transfected to express mini-LRP polypeptides containing either the second or fourth LRP ligand-binding domains, carry out decorin endocytosis and lysosomal degradation. These findings point to LRP-mediated catabolism as a new control pathway for the biological activities of decorin, specifically for its ability to influence extracellular matrix signaling.	Pontificia Univ Catolica Chile, Fac Ciencias Biol, Ctr Regulac Celular & Patol Joaquin V Luco, Dept Biol Celular & Mol,MIFAB, Santiago, Chile	Pontificia Universidad Catolica de Chile	Marzolo, MP (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Ctr Regulac Celular & Patol Joaquin V Luco, Dept Biol Celular & Mol,MIFAB, Santiago, Chile.	mmarzolo@bio.puc.cl	Cabello-Verrugio, Claudio/AAD-1454-2020; Brandan, Enrique/A-7063-2017	Cabello-Verrugio, Claudio/0000-0001-7273-2102; Brandan, Enrique/0000-0002-6820-5059; Retamal, Claudio/0000-0001-8618-2260				ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; Benes P, 2003, BREAST CANCER RES, V5, pR77, DOI 10.1186/bcr591; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; Biglari A, 2004, CANCER GENE THER, V11, P721, DOI 10.1038/sj.cgt.7700783; BISCHOFF R, 1986, DEV BIOL, V115, P129, DOI 10.1016/0012-1606(86)90234-4; Boucher P, 2002, BBA-MOL BASIS DIS, V1588, P226, DOI 10.1016/S0925-4439(02)00169-2; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; BRANDAN E, 1991, EUR J CELL BIOL, V55, P209; BRANDAN E, 1992, J NEUROSCI RES, V32, P51, DOI 10.1002/jnr.490320107; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1994, J BIOL CHEM, V269, P29874; Bu GJ, 2000, TRENDS CARDIOVAS MED, V10, P148, DOI 10.1016/S1050-1738(00)00045-1; Caceres S, 2000, EUR J CELL BIOL, V79, P173, DOI 10.1078/S0171-9335(04)70020-5; Casar JC, 2004, DEV BIOL, V268, P358, DOI 10.1016/j.ydbio.2003.12.025; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; Cuitino L, 2005, TRAFFIC, V6, P820, DOI 10.1111/j.1600-0854.2005.00320.x; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Desrosiers RR, 2006, PEDIATR BLOOD CANCER, V46, P40, DOI 10.1002/pbc.20566; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; Fuentealba L, 1999, J BIOL CHEM, V274, P37876, DOI 10.1074/jbc.274.53.37876; Gauthier A, 2003, J BIOL CHEM, V278, P11945, DOI 10.1074/jbc.M212989200; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Gonias SL, 2004, THROMB HAEMOSTASIS, V91, P1056, DOI 10.1160/TH04-01-0023; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Harris-White M. E., 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P469, DOI 10.2174/156800705774322102; Hausser H, 1998, ARCH BIOCHEM BIOPHYS, V349, P363, DOI 10.1006/abbi.1997.0471; HAUSSER H, 1991, J CELL BIOL, V114, P45, DOI 10.1083/jcb.114.1.45; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; Hausser H, 1996, EUR J CELL BIOL, V71, P325; HAUSSER H, 1993, EXP CELL RES, V208, P398, DOI 10.1006/excr.1993.1261; HAUSSER H, 1992, J BIOL CHEM, V267, P11559; Hausser H, 1999, BIOCHEM J, V344, P827, DOI 10.1042/0264-6021:3440827; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hollborn M, 2004, INVEST OPHTH VIS SCI, V45, P2033, DOI 10.1167/iovs.03-0656; Huang SS, 2004, FASEB J, V18, P1719, DOI 10.1096/fj.04-1872fje; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Larrain J, 1997, J BIOL CHEM, V272, P18418, DOI 10.1074/jbc.272.29.18418; Larrain J, 1998, J BIOL CHEM, V273, P32288, DOI 10.1074/jbc.273.48.32288; Li YH, 2003, FEBS LETT, V555, P346, DOI 10.1016/S0014-5793(03)01272-9; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Llorente-Cortes V, 2002, CIRCULATION, V106, P3104, DOI 10.1161/01.CIR.0000041434.28573.0B; Lopez-Casillas F, 2003, J BIOL CHEM, V278, P382, DOI 10.1074/jbc.M208520200; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Marzolo MP, 2003, TRAFFIC, V4, P273, DOI 10.1034/j.1600-0854.2003.00081.x; Melo F, 1996, J CELL BIOCHEM, V62, P227, DOI 10.1002/(SICI)1097-4644(199608)62:2<227::AID-JCB11>3.0.CO;2-I; Merle B, 1999, J CELL BIOCHEM, V75, P538; Merle B, 1997, J CELL BIOCHEM, V67, P75; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Mouly V, 2005, ACTA PHYSIOL SCAND, V184, P3, DOI 10.1111/j.1365-201X.2005.01417.x; Nili N, 2003, AM J PATHOL, V163, P869, DOI 10.1016/S0002-9440(10)63447-5; Nykjaer A, 2002, TRENDS CELL BIOL, V12, P273, DOI 10.1016/S0962-8924(02)02282-1; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600; Osses N, 2002, AM J PHYSIOL-CELL PH, V282, pC383, DOI 10.1152/ajpcell.00322.2001; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Riquelme C, 2001, J BIOL CHEM, V276, P3589, DOI 10.1074/jbc.M004602200; Salicioni AM, 2002, J BIOL CHEM, V277, P16160, DOI 10.1074/jbc.M201401200; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHMIDT G, 1990, BIOCHEM J, V266, P591; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; Schonherr E, 2005, J BIOL CHEM, V280, P15767, DOI 10.1074/jbc.M500451200; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; SCOTT JE, 1986, CONNECT TISSUE RES, V14, P267, DOI 10.3109/03008208609017470; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; SCOTT PG, 2003, J BIOL CHEM, V21, P21; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; Stander M, 1998, GENE THER, V5, P1187, DOI 10.1038/sj.gt.3300709; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; TRUPPE W, 1978, EUR J BIOCHEM, V85, P351, DOI 10.1111/j.1432-1033.1978.tb12246.x; Tseng WF, 2004, FEBS LETT, V562, P71, DOI 10.1016/S0014-5793(04)00185-1; Tufvesson E, 2002, FEBS LETT, V530, P124, DOI 10.1016/S0014-5793(02)03439-7; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; Webb DJ, 2000, J CELL SCI, V113, P123; Wilsie LC, 2003, J BIOL CHEM, V278, P15758, DOI 10.1074/jbc.M208786200; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200	86	47	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31562	31571		10.1074/jbc.M602919200	http://dx.doi.org/10.1074/jbc.M602919200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16936287	Bronze			2022-12-25	WOS:000241235300042
J	Galuska, SP; Oltmann-Norden, I; Geyer, H; Weinhold, B; Kuchelmeister, K; Hildebrandt, H; Gerardy-Schahn, R; Geyer, R; Muhlenhoff, M				Galuska, Sebastian P.; Oltmann-Norden, Imke; Geyer, Hildegard; Weinhold, Birgit; Kuchelmeister, Klaus; Hildebrandt, Herbert; Gerardy-Schahn, Rita; Geyer, Rudolf; Muehlenhoff, Martina			Polysialic acid profiles of mice expressing variant allelic combinations of the polysialyltransferases ST8SiaII and ST8SiaIV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; ENDO-BETA-GALACTOSIDASE; CENTRAL-NERVOUS-SYSTEM; II STX; COOPERATIVE POLYSIALYLATION; DIFFERENTIAL BIOSYNTHESIS; ALZHEIMERS-DISEASE; MESSENGER-RNA; MOUSE-BRAIN; RAT-BRAIN	The post-translational modification of the neural cell adhesion molecule ( NCAM) by polysialic acid (polySia) represents a remarkable example of dynamic modulation of homo- and heterophilic cell interactions by glycosylation. The synthesis of this unique carbohydrate polymer depends on the polysialyltransferases ST8SiaII and ST8SiaIV. Aiming to understand in more detail the contributions of ST8SiaII and ST8SiaIV to polySia biosynthesis in vivo, we used mutant mouse lines that differ in the number of functional polysialyltransferase alleles. The 1,2diamino-4,5-methylenedioxybenzene method was used to qualitatively and quantitatively assess the polySia patterns. Similar to the wild-type genotype, long polySia chains (> 50 residues) were detected in all genotypes expressing at least one functional polysialyltransferase allele. However, variant allelic combinations resulted in distinct alterations in the total amount of polySia; the relative abundance of long, medium, and short polymers; and the ratio of polysialylated to non-polysialylated NCAM. In ST8SiaII-null mice, 45% of the brain NCAM was non-polysialylated, whereas a single functional allele of ST8SiaII was sufficient to polysialylate similar to 90% of the NCAM pool. Our data reveal a complex polysialylation pattern and show that, under in vivo conditions, the coordinated action of ST8SiaII and ST8SiaIV is crucial to fine-tune the amount and structure of polySia on NCAM.	Hannover Med Sch, Inst Cellular Chem, D-30625 Hannover, Germany; Univ Giessen, Fac Med, Inst Biochem, D-35392 Giessen, Germany; Univ Giessen, Fac Med, Inst Neuropathol, D-35392 Giessen, Germany	Hannover Medical School; Justus Liebig University Giessen; Justus Liebig University Giessen	Muhlenhoff, M (corresponding author), Hannover Med Sch, Abt Zellulare Chem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	muehlenhoff.martina@mh-hannover.de	Hildebrandt, Herbert/A-7873-2010	Hildebrandt, Herbert/0000-0002-1044-0881				Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2004, J BIOL CHEM, V279, P32603, DOI 10.1074/jbc.M403429200; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; Angata K, 2002, J BIOL CHEM, V277, P36808, DOI 10.1074/jbc.M204632200; BARBEAU D, 1995, P NATL ACAD SCI USA, V92, P2785, DOI 10.1073/pnas.92.7.2785; Dityatev A, 2004, J NEUROSCI, V24, P9372, DOI 10.1523/JNEUROSCI.1702-04.2004; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; GERARDYSCHAHN R, 1994, INT J CANCER, P38; Geyer H, 2001, EUR J BIOCHEM, V268, P6587, DOI 10.1046/j.0014-2956.2001.02613.x; Hayrinen J, 2002, MOL IMMUNOL, V39, P399, DOI 10.1016/S0161-5890(02)00202-X; HE HT, 1987, J CELL BIOL, V105, P2489, DOI 10.1083/jcb.105.6.2489; HEKMAT A, 1990, J COMP NEUROL, V291, P457, DOI 10.1002/cne.902910311; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; Inoue S, 2000, J BIOL CHEM, V275, P29968, DOI 10.1074/jbc.M004150200; Inoue S, 2003, METHOD ENZYMOL, V362, P543; Inoue S, 2001, BIOCHIMIE, V83, P605, DOI 10.1016/S0300-9084(01)01307-4; Inoue S, 2001, J BIOL CHEM, V276, P31863, DOI 10.1074/jbc.M103336200; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Johnson CP, 2005, BIOCHEMISTRY-US, V44, P546, DOI 10.1021/bi048263j; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; Kurosawa N, 1997, J NEUROCHEM, V69, P494; Liedtke S, 2001, GLYCOBIOLOGY, V11, P373, DOI 10.1093/glycob/11.5.373; MANZI AE, 1994, J BIOL CHEM, V269, P23617; Mikkonen M, 1999, EUR J NEUROSCI, V11, P1754, DOI 10.1046/j.1460-9568.1999.00593.x; Mikkonen M, 1998, ANN NEUROL, V44, P923, DOI 10.1002/ana.410440611; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; Muller D, 2000, P NATL ACAD SCI USA, V97, P4315, DOI 10.1073/pnas.070022697; Murata T, 2003, EUR J BIOCHEM, V270, P3709, DOI 10.1046/j.1432-1033.2003.03757.x; NAKAGAWA H, 1980, J BIOL CHEM, V255, P5955; Nakata D, 2005, J BIOL CHEM, V280, P38305, DOI 10.1074/jbc.M508762200; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phillips GR, 1997, DEV BRAIN RES, V102, P143, DOI 10.1016/S0165-3806(97)00069-2; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; Stummeyer K, 2005, NAT STRUCT MOL BIOL, V12, P90, DOI 10.1038/nsmb874; Vaithianathan T, 2004, J BIOL CHEM, V279, P47975, DOI 10.1074/jbc.M407138200; Vutskits L, 2001, EUR J NEUROSCI, V13, P1391, DOI 10.1046/j.0953-816x.2001.01516.x; Weinhold B, 2005, J BIOL CHEM, V280, P42971, DOI 10.1074/jbc.M511097200; Wood GK, 1997, MOL BRAIN RES, V51, P69, DOI 10.1016/S0169-328X(97)00209-X; YANG PF, 1994, J BIOL CHEM, V269, P23039	50	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31605	31615		10.1074/jbc.M606516200	http://dx.doi.org/10.1074/jbc.M606516200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16940046	Bronze			2022-12-25	WOS:000241235300046
J	Kirschner, KM; Wagner, N; Wagner, KD; Wellmann, S; Scholz, H				Kirschner, Karin M.; Wagner, Nicole; Wagner, Kay-Dietrich; Wellmann, Sven; Scholz, Holger			The Wilms tumor suppressor Wt1 promotes cell adhesion through transcriptional activation of the alpha 4integrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-4 INTEGRIN; PROTEIN WT1; MESENCHYMAL TRANSFORMATION; SUBNUCLEAR LOCALIZATION; KIDNEY DEVELOPMENT; BINDING-SITES; SMOOTH-MUSCLE; AVIAN HEART; EXPRESSION; PRODUCT	Cell-matrix interaction through specific adhesion molecules is a critical step during organ development. In addition, down-regulation of cell adhesion receptors may promote tumor invasion and metastasis. We show here that the Wilms tumor suppressor Wt1, which is necessary for normal development of the epicardium, coronary vessels, genitourinary system, and other tissues, activates transcription of the alpha 4integrin gene. Binding of the Wt1(-KTS) form, which is transcriptionally active, to the proximal alpha 4integrin promoter was demonstrated by electrophoretic mobility shift assay and chromatin immunoprecipitation. A reporter construct harboring similar to 1.9 kb of the human alpha 4integrin gene promoter was activated significantly by transient co-transfection of a Wt1(-KTS) expression plasmid. Introducing mutations in two identified Wt1(-KTS) binding motifs in the proximal promoter of the alpha 4integrin gene abrogated this stimulatory effect. Endogenous alpha 4integrin transcripts were increased more than 3-fold in human embryonic kidney 293 cells with stable expression of the Wt1(-KTS) protein. Wt1-overexpressing cells showed augmented adhesion to the alpha 4integrin ligand vascular cell adhesion molecule-1 that was abolished upon incubation with an inhibitory alpha 4integrin antibody. Double immunofluorescent staining revealed co-localization of Wt1 and alpha 4integrin in the developing epicardium of mouse embryos. Cardiac expression of alpha 4integrin was reduced significantly in embryos with a homozygous Wt1 defect (Wt1(-/-)). These findings demonstrate that Wt1 can support cell adhesion through enhanced expression of alpha 4integrin. This transcriptional activation of the alpha 4integrin gene by Wt1(-KTS) might contribute to normal formation of the epicardium and other tissues in the developing embryo.	Univ Med Berlin, Charite, Inst Vegetat Physiol, D-10117 Berlin, Germany; Fac Sci, Ctr Biochim, INSERM U636, F-06108 Nice, France; Univ Basel, Kinderspital Beider, CH-4058 Basel, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Basel	Scholz, H (corresponding author), Univ Med Berlin, Charite, Inst Vegetat Physiol, Tucholskystr 2, D-10117 Berlin, Germany.	holger.scholz@charite.de	Wagner, Kay-Dietrich/E-6119-2016; Wellmann, Sven/A-2771-2017	Wagner, Kay-Dietrich/0000-0001-5483-7760; Wagner, Nicole/0000-0002-2746-0707; Kirschner, Karin/0000-0003-0226-8636				Alberta JA, 2003, BLOOD, V101, P2570, DOI 10.1182/blood-2002-06-1656; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; Baltensperger H, 1997, J BIOL CHEM, V272, P10151; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Carmona R, 2001, CELL TISSUE RES, V303, P173, DOI 10.1007/s004410000307; Chen THP, 2002, DEV BIOL, V250, P198, DOI 10.1006/dbio.2002.0796; Cook DM, 1996, ONCOGENE, V13, P1789; Dame C, 2004, J BIOL CHEM, V279, P2955, DOI 10.1074/jbc.M310404200; Danen EHJ, 2003, J PATHOL, V201, P632, DOI 10.1002/path.1472; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Dettman RW, 1998, DEV BIOL, V193, P169, DOI 10.1006/dbio.1997.8801; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Englert C, 1997, CANCER RES, V57, P1429; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Kennedy D, 1996, NAT GENET, V12, P329, DOI 10.1038/ng0396-329; Kim J, 1999, MOL CELL BIOL, V19, P2289; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KWEE L, 1995, DEVELOPMENT, V121, P489; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lecuit T, 2005, TRENDS CELL BIOL, V15, P34, DOI 10.1016/j.tcb.2004.11.007; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Manner J, 2001, CELLS TISSUES ORGANS, V169, P89, DOI 10.1159/000047867; Mannion BA, 1996, J IMMUNOL, V157, P2039; Moore AW, 1999, DEVELOPMENT, V126, P1845; Morabito CJ, 2001, DEV BIOL, V234, P204, DOI 10.1006/dbio.2001.0254; MORRISON AA, 2006, IN PRESS CANC LETT; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; NEEDHAM LA, 1994, CELL ADHES COMMUN, V2, P87, DOI 10.3109/15419069409004429; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Peeters MPFMV, 1999, ANAT EMBRYOL, V199, P367, DOI 10.1007/s004290050235; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; Pinco KA, 2001, MECH DEVELOP, V100, P99, DOI 10.1016/S0925-4773(00)00503-7; Priestley GV, 2006, BLOOD, V107, P2959, DOI 10.1182/blood-2005-07-2670; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Sengbusch JK, 2002, J CELL BIOL, V157, P873, DOI 10.1083/jcb.200203075; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Wagner KD, 2003, FASEB J, V17, P1364, DOI 10.1096/fj.02-1065fje; Wagner KD, 2002, FASEB J, V16, P1117, DOI 10.1096/fj.01-0986fje; Wagner KD, 2001, J AM SOC NEPHROL, V12, P1188, DOI 10.1681/ASN.V1261188; Wagner KD, 2003, GENE, V305, P217, DOI 10.1016/S0378-1119(02)01231-3; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wagner N, 2005, DEVELOPMENT, V132, P1327, DOI 10.1242/dev.01682; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Wagner N, 2004, J AM SOC NEPHROL, V15, P3044, DOI 10.1097/01.ASN.0000146687.99058.25; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YANG JT, 1995, DEVELOPMENT, V121, P549; Zaniolo K, 2004, INVEST OPHTH VIS SCI, V45, P1692, DOI 10.1167/iovs.03-0908	70	35	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31930	31939		10.1074/jbc.M602668200	http://dx.doi.org/10.1074/jbc.M602668200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920711				2022-12-25	WOS:000241235300079
J	Harant, H; Lettner, N; Hofer, L; Oberhauser, B; de Vries, JE; Lindley, IJD				Harant, Hanna; Lettner, Nicole; Hofer, Lotte; Oberhauser, Berndt; de Vries, Jan E.; Lindley, Ivan J. D.			The translocation inhibitor CAM741 interferes with vascular cell adhesion molecule 1 signal peptide insertion at the translocon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN-CONDUCTING CHANNEL; ER-MEMBRANE; RECOGNITION PARTICLE; SEQUENCE RECOGNITION; COTRANSLATIONAL TRANSLOCATION; NASCENT PREPROLACTIN; SECRETORY PROTEINS; CROSS-LINKING; COMPLEX	The cyclopeptolide CAM741 selectively inhibits cotranslational translocation of vascular cell adhesion molecule 1 (VCAM1), a process that is dependent on its signal peptide. In this study we identified the C-terminal (C-) region upstream of the cleavage site of the VCAM1 signal peptide as most critical for inhibition of translocation by CAM741, but full sensitivity to the compound also requires residues of the hydrophobic (h-) region and the first amino acid of the VCAM1 mature domain. The murine VCAM1 signal peptide, which is less susceptible to translocation inhibition by CAM741, can be converted into a fully sensitive signal peptide by two amino acid substitutions identified as critical for compound sensitivity of the human VCAM1 signal peptide. Using cysteine substitutions of non-critical residues in the human VCAM1 signal peptide and chemical cross-linking of targeted short nascent chains we show that, in the presence of CAM741, the N- and C-terminal segments of the VCAM1 signal peptide could be cross-linked to the cytoplasmic tail of Sec61 beta, indicating altered positioning of the VCAM1 signal peptide relative to this translocon component. Moreover, translocation of a tag fused N- terminal to the VCAM1 signal peptide is selectively inhibited by CAM741. Our data indicate that the compound inhibits translocation of VCAM1 by interfering with correct insertion of its signal peptide into the translocon.	Novartis Inst Biomed Res, A-1235 Vienna, Austria	Novartis	Harant, H (corresponding author), Novartis Inst Biomed Res, Brunner Str 59, A-1235 Vienna, Austria.	Hanna.Harant@novartis.com	Hanna, Harant/AAA-7120-2022	Hanna, Harant/0000-0003-3842-0249				Besemer J, 2005, NATURE, V436, P290, DOI 10.1038/nature03670; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Garrison JL, 2005, NATURE, V436, P285, DOI 10.1038/nature03821; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; Goder V, 2003, EMBO J, V22, P3645, DOI 10.1093/emboj/cdg361; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Heinrich SU, 2003, EMBO J, V22, P3654, DOI 10.1093/emboj/cdg346; HIGH S, 1993, J BIOL CHEM, V268, P26745; Ismail N, 2006, J CELL SCI, V119, P2826, DOI 10.1242/jcs.03018; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Menetret JF, 2005, J MOL BIOL, V348, P445, DOI 10.1016/j.jmb.2005.02.053; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; Morgan DG, 2002, J MOL BIOL, V324, P871, DOI 10.1016/S0022-2836(02)01111-7; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Osborne AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/annurev.cellbio.21.012704.133214; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Song WQ, 2000, CELL, V100, P333, DOI 10.1016/S0092-8674(00)80669-8; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25	43	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30492	30502		10.1074/jbc.M607243200	http://dx.doi.org/10.1074/jbc.M607243200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16914554	hybrid			2022-12-25	WOS:000241075900025
J	Suzuki, H; Takahashi, S; Watanabe, R; Fukushima, Y; Fujita, N; Noguchi, A; Yokoyama, R; Nishitani, K; Nishino, T; Nakayama, T				Suzuki, Hirokazu; Takahashi, Seiji; Watanabe, Ryoko; Fukushima, Yusuke; Fujita, Naoki; Noguchi, Akio; Yokoyama, Ryusuke; Nishitani, Kazuhiko; Nishino, Tokuzo; Nakayama, Toru			An isoflavone conjugate-hydrolyzing beta-glucosidase from the roots of soybean (Glycine max) seedlings - Purification, gene cloning, phylogenetics, and cellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MOLECULAR CHARACTERIZATION; AGLYCONE SPECIFICITY; GLYCOSYL HYDROLASES; CDNA CLONING; EXPRESSION; PLANTS; CLASSIFICATION; BIOSYNTHESIS; SUBSTRATE	Soybeans ( Glycine max ( L.) Merr.) and certain other legumes excrete isoflavones from their roots, which participate in plantmicrobe interactions such as symbiosis and as a defense against infections by pathogens. In G. max, the release of free isoflavones from their conjugates, the latent forms, is mediated by an isoflavone conjugate-hydrolyzing beta-glucosidase. Here we report on the purification and cDNA cloning of this important beta-glucosidase from the roots of G. max seedlings as well as related phylogenetic and cellular localization studies. The purified enzyme, isoflavone conjugate-hydrolyzing beta-glucosidase from roots of G. max seedling (GmICHG), is a homodimeric glycoprotein with a subunit molecular mass of 58 kDa and is capable of directly hydrolyzing genistein 7-O-(6"-O-malonyl-beta-D-glucoside) to produce free genistein (k(cat), 98 s(-1); Km, 25 mu m at 30 degrees C, pH 7.0). GmICHG cDNA was isolated based on the amino acid sequence of the purified enzyme. GmICHG cDNA was abundantly expressed in the roots of G. max seedlings but only negligibly in the hypocotyl and cotyledon. An immunocytochemical analysis using anti-GmICHG antibodies, along with green fluorescent protein imaging analyses of Arabidopsis cultured cells transformed by the GmICHG: GFP fusion gene, revealed that the enzyme is exclusively localized in the cell wall and intercellular space of seedling roots, particularly in the cell wall of root hairs. A phylogenetic analysis revealed that GmICHG is a member of glycoside hydrolase family 1 and can be co-clustered with many other leguminous beta-glucosidases, the majority of which may also be involved in flavonoid-mediated interactions of legumes with microbes.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Sendai, Miyagi 9808578, Japan	Tohoku University; Tohoku University	Nakayama, T (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Yama 6-6-11, Sendai, Miyagi 9808579, Japan.	nakayama@seika.che.tohoku.ac.jp	Takahashi, Seiji/AAE-1509-2019; Suzuki, Hirokazu/AAG-2285-2020	Takahashi, Seiji/0000-0002-2288-4340; Suzuki, Hirokazu/0000-0002-9507-6467; Nishitani, Kazuhiko/0000-0002-0073-9564; Yokoyama, Ryusuke/0000-0003-0326-0433				Ahn YO, 2004, J BIOL CHEM, V279, P23405, DOI 10.1074/jbc.M311379200; Akashi T, 1999, PLANT PHYSIOL, V121, P821, DOI 10.1104/pp.121.3.821; AXELOS M, 1992, PLANT PHYSIOL BIOCH, V30, P123; BARZ W, 1992, RECENT ADV PHYTOCHEM, V26, P139; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHANAN B, 2002, BIOCH MOL BIOL PLANT, P796; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CLARKE JT, 1964, ANN NY ACAD SCI, V121, P428, DOI 10.1111/j.1749-6632.1964.tb14214.x; Conn E. E., 1979, Herbivores: their interaction with secondary plant metabolites, P387; Czjzek M, 2000, P NATL ACAD SCI USA, V97, P13555, DOI 10.1073/pnas.97.25.13555; Dakora FD, 1996, PHYSIOL MOL PLANT P, V49, P1, DOI 10.1006/pmpp.1996.0035; DHARMAWARDHANA DP, 1995, PLANT PHYSIOL, V107, P331, DOI 10.1104/pp.107.2.331; FALK A, 1995, PLANT PHYSIOL, V108, P1369, DOI 10.1104/pp.108.4.1369; Fujiwara H, 1998, PLANT J, V16, P421, DOI 10.1046/j.1365-313x.1998.00312.x; GRAHAM TL, 1991, PLANT PHYSIOL, V95, P594, DOI 10.1104/pp.95.2.594; Graham TL, 2000, PLANT MIC I, V5, P181; Graham TL, 1996, PLANT PHYSIOL, V110, P1123, DOI 10.1104/pp.110.4.1123; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HOSEL W, 1975, EUR J BIOCHEM, V57, P607, DOI 10.1111/j.1432-1033.1975.tb02336.x; Hsieh MC, 2001, PHYTOCHEMISTRY, V58, P995, DOI 10.1016/S0031-9422(01)00380-6; Hungria M, 1997, SOIL BIOL BIOCHEM, V29, P819, DOI 10.1016/S0038-0717(96)00239-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAH R, 1995, J BIOL CHEM, V270, P15789, DOI 10.1074/jbc.270.26.15789; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; Mitsuhara I, 1996, PLANT CELL PHYSIOL, V37, P49, DOI 10.1093/oxfordjournals.pcp.a028913; Nakayama T, 2000, SCIENCE, V290, P1163, DOI 10.1126/science.290.5494.1163; OXTOBY E, 1991, PLANT MOL BIOL, V17, P209, DOI 10.1007/BF00039495; PHILLIPS DA, 1992, RECENT ADV PHYTOCHEM, V26, P201; Rask L, 2000, PLANT MOL BIOL, V42, P93, DOI 10.1023/A:1006380021658; RIVERAVARGAS LI, 1993, PHYTOCHEMISTRY, V32, P851, DOI 10.1016/0031-9422(93)85219-H; Steele CL, 1999, ARCH BIOCHEM BIOPHYS, V367, P146, DOI 10.1006/abbi.1999.1238; Suzuki H, 2002, PLANT PHYSIOL, V130, P2142, DOI 10.1104/pp.010447; Svasti J, 1999, PHYTOCHEMISTRY, V50, P739, DOI 10.1016/S0031-9422(98)00552-4; Verdoucq L, 2004, J BIOL CHEM, V279, P31796, DOI 10.1074/jbc.M402918200; Zhou JM, 2002, PLANT PHYSIOL, V129, P1252, DOI 10.1104/pp.010863	36	131	136	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30251	30259		10.1074/jbc.M605726200	http://dx.doi.org/10.1074/jbc.M605726200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16891302	hybrid			2022-12-25	WOS:000240896300085
J	Kim, SY; Nguyen, AD; Gao, JL; Murphy, PM; Mansfield, BC; Chou, JY				Kim, So Youn; Nguyen, Andrew D.; Gao, Ji-Liang; Murphy, Philip M.; Mansfield, Brian C.; Chou, Janice Yang			Bone marrow-derived cells require a functional glucose 6-phosphate transporter for normal myeloid functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE TYPE 1B; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; PHOSPHOHISTIDINE-ENZYME INTERMEDIATE; LIVER-TRANSPLANTATION; HEXOSE-6-PHOSPHATE DEHYDROGENASE; NEUTROPHIL RECRUITMENT; MICE LACKING; CATALYSIS; IB	Glycogen storage disease type Ib (GSD-Ib) is caused by a deficiency in the ubiquitously expressed glucose 6-phosphate transporter (Glc-6-PT). Glc-6-PT activity has been shown to be critical in the liver and kidney where a deficiency disrupts glucose homeostasis. GSD-Ib patients also have defects in the neutrophil respiratory burst, chemotaxis, and calcium flux. They also manifest neutropenia, but whether Glc-6-PT deficiency in the bone marrow underlies myeloid dysfunctions in GSD-Ib remains controversial. To address this, we transferred bone marrow from Glc-6-PT-deficient (Glc-6-PT-/-) mice to wild-type mice to generate chimeric mice (BM-Glc-6-PT-/-). As a control, we also transferred bone marrow between wild-type mice (BM-Glc-6-PT+/+). While BM-Glc-6-PT+/+ mice have normal myeloid functions, BM-Glc-6-PT-/- mice manifest myeloid abnormalities characteristic of Glc-6-PT-/- mice. Both have impairments in their neutrophil respiratory burst, chemotaxis response, and calcium flux activities and exhibit neutropenia. In the bone marrow of BM-Glc-6-PT-/- and Glc-6-PT-/- mice, the numbers of myeloid progenitor cells are increased, while in the serum there is an increase in granulocyte colony-stimulating factor and chemokine KC levels. Moreover, in an experimental model of peritoneal inflammation, local production of KC and the related chemokine macrophage inflammatory protein-2 is decreased in both BM-Glc-6-PT-/- and Glc-6-PT-/- mice along with depressed peritoneal neutrophil accumulation. The neutrophil recruitment defect was less severe in BM-Glc-6-PT-/- mice than in Glc-6-PT-/- mice. These findings demonstrate that Glc-6-PT expression in bone marrow and neutrophils is required for normal myeloid functions and that non-marrow Glc-6-PT activity also influences some myeloid functions.	NICHD, Sect Cellular Differentiat, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; NIAID, Lab Mol Immunol, Mol Signaling Sect, NIH, Bethesda, MD 20892 USA; Correlog Syst Inc, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chou, JY (corresponding author), NICHD, Sect Cellular Differentiat, Heritable Disorders Branch, NIH, Bldg 10,Rm 9D42, Bethesda, MD 20892 USA.	chouja@mail.nih.gov	Gao, Ji-Liang/Y-4397-2019	Nguyen, Andrew/0000-0002-9492-9472; Mansfield, Brian/0000-0002-8533-2789	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000615, Z01AI000615] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Adachi M, 2004, EUR J PEDIATR, V163, P202, DOI 10.1007/s00431-004-1405-1; BARON EJ, 1982, J IMMUNOL METHODS, V49, P305, DOI 10.1016/0022-1759(82)90130-2; Call DR, 2001, AM J PATHOL, V158, P715, DOI 10.1016/S0002-9440(10)64014-X; Chen LY, 2003, HUM MOL GENET, V12, P2547, DOI 10.1093/hmg/ddg263; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; CHOU JY, 2003, MEMBRANE TRANSPORTER, P191; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Garcia-Ramallo E, 2002, J IMMUNOL, V169, P6467, DOI 10.4049/jimmunol.169.11.6467; Garty BZ, 1996, ISRAEL J MED SCI, V32, P1276; Ghosh A, 2002, J BIOL CHEM, V277, P32837, DOI 10.1074/jbc.M201853200; Ghosh A, 2004, J BIOL CHEM, V279, P12479, DOI 10.1074/jbc.M313271200; GITZELMANN R, 1993, EUR J PEDIATR, V152, P33; Guionie O, 2003, FEBS LETT, V551, P159, DOI 10.1016/S0014-5793(03)00903-7; Hewitt KN, 2005, ENDOCRINOLOGY, V146, P2539, DOI 10.1210/en.2005-0117; LACHAUX A, 1993, J PEDIATR-US, V123, P1005, DOI 10.1016/S0022-3476(05)80403-2; Lavery GG, 2006, J BIOL CHEM, V281, P6546, DOI 10.1074/jbc.M512635200; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Martinez-Olmos MA, 2001, CLIN NUTR, V20, P375, DOI 10.1054/clnu.2001.0432; Matern D, 1999, EUR J PEDIATR, V158, pS43, DOI 10.1007/PL00014320; Mizgerd JP, 2002, SEMIN IMMUNOL, V14, P123, DOI 10.1006/smim.2001.0349; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, P349; Pan CJ, 1998, ARCH BIOCHEM BIOPHYS, V358, P17, DOI 10.1006/abbi.1998.0849; Reutershan J, 2004, CRIT CARE, V8, P453, DOI 10.1186/cc2881; Scriver C.R., 2001, METABOLIC MOL BASIS, VEighth; Shieh JJ, 2003, J BIOL CHEM, V278, P47098, DOI 10.1074/jbc.M309472200; SIEFF CA, 1998, HEMATOLOGY INFANCY C, V1, P161; Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003-0031	27	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28794	28801		10.1074/jbc.M604964200	http://dx.doi.org/10.1074/jbc.M604964200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16891306	hybrid			2022-12-25	WOS:000240680500033
J	Wang, WZ; Chu, XP; Li, MH; Seeds, J; Simon, RP; Xiong, ZG				Wang, Wei-Zhen; Chu, Xiang-Ping; Li, Ming-Hua; Seeds, Joshua; Simon, Roger P.; Xiong, Zhi-Gang			Modulation of acid-sensing ion channel currents, acid-induced increase of intracellular Ca2+, and acidosis-mediated neuronal injury by intracellular pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPREADING DEPRESSION; HIPPOCAMPAL-NEURONS; CEREBRAL-ISCHEMIA; SENSORY NEURONS; NERVOUS-SYSTEM; CONTRIBUTES; RECEPTOR; CALCIUM; EXCITABILITY; DIVALENT	Acid-sensing ion channels (ASICs), activated by lowering extracellular pH (pH(o)), play an important role in normal synaptic transmission in brain and in the pathology of brain ischemia. Like pHo, intracellular pH (pH(i)) changes dramatically in both physiological and pathological conditions. Although it is known that a drop in pHo activates the ASICs, it is not clear whether alterations of pHi have an effect on these channels. Here we demonstrate that the overall activities of ASICs, including channel activation, inactivation, and recovery from desensitization, are tightly regulated by pHi. In cultured mouse cortical neurons, bath perfusion of the intracellular alkalizing agent quinine increased the amplitude of the ASIC current by similar to 50%. In contrast, intracellular acidification by withdrawal of NH4Cl or perfusion of propionate inhibited the current. Increasing pH buffering capacity in the pipette solution with 40 mM HEPES attenuated the effects of quinine and NH4Cl. The effects of intracellular alkalizing/ acidifying agents were mimicked by using intracellular solutions with pH directly buffered at high/low values. Increasing pHi induced a shift in H+ dose-response curve toward less acidic pH but a shift in the steady state inactivation curve toward more acidic pH. In addition, alkalizing pHi induced an increase in the recovery rate of ASICs from desensitization. Consistent with its effect on the ASIC current, changing pHi has a significant influence on the acid-induced increase of intracellular Ca2+, membrane depolarization, and acidosis-mediated neuronal injury. Our findings suggest that changes in pHi may play an important role in determining the overall function of ASICs in both physiological and pathological conditions.	Legacy Clin Res Ctr, Robert S Dow Neurobiol Labs, Portland, OR 97232 USA		Xiong, ZG (corresponding author), Legacy Clin Res Ctr, Robert S Dow Neurobiol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	zxiong@Downeurobiology.org		Chu, Xiang-Ping/0000-0002-6781-0468				Allen NJ, 2002, J PHYSIOL-LONDON, V543, P521, DOI 10.1113/jphysiol.2002.020297; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Babini E, 2002, J BIOL CHEM, V277, P41597, DOI 10.1074/jbc.M205877200; Back T, 2000, ANN NEUROL, V47, P485, DOI 10.1002/1531-8249(200004)47:4<485::AID-ANA12>3.3.CO;2-#; Bonnet U, 2000, NEUROPHARMACOLOGY, V39, P2067, DOI 10.1016/S0028-3908(00)00033-2; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Chu XP, 2004, J NEUROSCI, V24, P8678, DOI 10.1523/JNEUROSCI.2844-04.2004; Chu XP, 2003, J PHYSIOL-LONDON, V550, P385, DOI 10.1113/jphysiol.2003.043091; DEITMER JW, 1980, J PHYSIOL-LONDON, V304, P471, DOI 10.1113/jphysiol.1980.sp013337; Deval E, 2003, NEUROPHARMACOLOGY, V44, P662, DOI 10.1016/S0028-3908(03)00047-9; Dixon DB, 1996, VISION RES, V36, P3925, DOI 10.1016/S0042-6989(96)00129-0; FIEVET B, 1988, RESP PHYSIOL, V74, P99, DOI 10.1016/0034-5687(88)90144-2; Gao J, 2005, NEURON, V48, P635, DOI 10.1016/j.neuron.2005.10.011; GAULT LM, 1994, BRAIN RES, V641, P176, DOI 10.1016/0006-8993(94)91835-X; Gorji A, 2001, BRAIN RES REV, V38, P33, DOI 10.1016/S0165-0173(01)00081-9; HILLE B, 1968, J GEN PHYSIOL, V51, P221, DOI 10.1085/jgp.51.2.221; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; Mamet J, 2002, J NEUROSCI, V22, P10662; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; NEDERGAARD M, 1991, AM J PHYSIOL, V260, P581; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; REHNCRONA S, 1985, ANN EMERG MED, V14, P770, DOI 10.1016/S0196-0644(85)80055-X; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Schubert R, 1996, J VASC RES, V33, P86, DOI 10.1159/000159136; SHARP AP, 1981, J PHYSIOL-LONDON, V312, P71, DOI 10.1113/jphysiol.1981.sp013616; Ugawa S, 2003, J NEUROSCI, V23, P3616; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2004, P NATL ACAD SCI USA, V101, P3621, DOI 10.1073/pnas.0308753101; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100	39	50	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29369	29378		10.1074/jbc.M605122200	http://dx.doi.org/10.1074/jbc.M605122200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16882660	hybrid			2022-12-25	WOS:000240680500092
J	Scambia, G; Lovergine, S; Masciullo, V				Scambia, G.; Lovergine, S.; Masciullo, V.			RB family members as predictive and prognostic factors in human cancer	ONCOGENE			English	Review						pRb; pRb2; p130; prognostic factor; predictive factor	RETINOBLASTOMA GENE-PRODUCT; NUCLEAR ANTIGEN-EXPRESSION; PROTEIN EXPRESSION; CYCLIN D1; ALTERED EXPRESSION; DIFFERENTIAL EXPRESSION; REGULATORY PROTEINS; SUSCEPTIBILITY GENE; ABERRANT EXPRESSION; BREAST-CARCINOMA	The retinoblastoma family members - pRb, pRb2/p130 and p107- are tumor suppressor genes involved in controlling four major cellular processes: growth arrest, apoptosis, differentiation and angiogenesis. Molecular genetic studies have identified abnormalities of these tumor suppressor genes in a large proportion of human cancers. These genetic alterations have emerged as significant factors in the pathogenesis and progression of many types of tumors and are therefore likely to provide relevant information to assess risk in cancer patients. There is a pressing clinical need to identify prognostic and predictive factors for patients with cancer, because there is an undeniable importance in being able to determine which patients will have a favorable outcome without further therapy ( prognostic factor) and which will need some additional treatment ( predictive factor). This review examines the predictive and/or prognostic role of each retinoblastoma family member in human cancer.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Cattolica Sacro Cuore, Div Gynecol Oncol, Rome, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Masciullo, V (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bld,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	masciull@temple.edu						Baldi A, 1996, CLIN CANCER RES, V2, P1239; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Barrett MT, 1996, ONCOGENE, V12, P1873; Bartkova J, 1996, CANCER RES, V56, P5475; Benassi MS, 1999, INT J CANCER, V84, P489, DOI 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D; Bianchi S., 1994, Pathologica (Genoa), V86, P146; Bieche I, 2000, MOL CARCINOGEN, V29, P151, DOI 10.1002/1098-2744(200011)29:3<151::AID-MC4>3.3.CO;2-Y; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; Ceccarelli C, 1998, J CLIN PATHOL, V51, P818, DOI 10.1136/jcp.51.11.818; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Chan MKM, 1998, GYNECOL ONCOL, V68, P156, DOI 10.1006/gyno.1997.4914; Chen JT, 2001, LUNG CANCER, V31, P163, DOI 10.1016/S0169-5002(00)00191-4; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; Claudio PP, 2004, CLIN CANCER RES, V10, P3509, DOI 10.1158/1078-0432.CCR-03-0662; Claudio PP, 2002, CLIN CANCER RES, V8, P1808; CLAUDIO PP, 1994, CANCER RES, V54, P5556; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; Cote RJ, 1998, CANCER RES, V58, P1090; Cui X, 2004, HUM PATHOL, V35, P1189, DOI 10.1016/j.humpath.2004.06.010; D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DODSON MK, 1994, CANCER RES, V54, P610; Dokiya F, 1998, ACTA OTO-LARYNGOL, V118, P759; Dong Y, 1997, INT J CANCER, V74, P407, DOI 10.1002/(SICI)1097-0215(19970822)74:4<407::AID-IJC8>3.0.CO;2-Z; Feakins RM, 2003, HUM PATHOL, V34, P1276, DOI 10.1016/j.humpath.2003.07.005; Feugeas O, 1996, J CLIN ONCOL, V14, P467, DOI 10.1200/JCO.1996.14.2.467; Fung Y K, 1992, Cancer Treat Res, V61, P59; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; Girod SC, 1998, BRIT J ORAL MAX SURG, V36, P252, DOI 10.1016/S0266-4356(98)90708-2; Goldstein NS, 2000, ANN THORAC SURG, V69, P1648, DOI 10.1016/S0003-4975(00)01269-8; Guenova M, 1999, MODERN PATHOL, V12, P1062; Hashiguchi Y, 2004, HUM PATHOL, V35, P165, DOI 10.1016/j.humpath.2003.07.018; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HENSEL CH, 1990, CANCER RES, V50, P3067; Hommura F, 1999, BRIT J CANCER, V81, P696, DOI 10.1038/sj.bjc.6690750; Hui AM, 1999, INT J CANCER, V84, P604, DOI 10.1002/(SICI)1097-0215(19991222)84:6<604::AID-IJC11>3.0.CO;2-Y; Ikeguchi M, 2000, J SURG ONCOL, V73, P104, DOI 10.1002/(SICI)1096-9098(200002)73:2<104::AID-JSO9>3.0.CO;2-7; Ishii H, 1997, AM J HEMATOL, V55, P46, DOI 10.1002/(SICI)1096-8652(199705)55:1<46::AID-AJH9>3.0.CO;2-3; Jahnson S, 1998, J UROLOGY, V160, P1291, DOI 10.1016/S0022-5347(01)62518-7; KARPEH MS, 1995, BRIT J CANCER, V72, P986, DOI 10.1038/bjc.1995.447; KIM TM, 1994, CANCER RES, V54, P605; Kusume T, 1999, CLIN CANCER RES, V5, P4152; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; LIU Y, 1994, INT J CANCER, V58, P663, DOI 10.1002/ijc.2910580508; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Masciullo V, 2000, INT J ONCOL, V17, P897; Massaro-Giordano M, 1999, CLIN CANCER RES, V5, P1455; Milde-Langosch K, 2003, INT J GYNECOL PATHOL, V22, P168, DOI 10.1097/00004347-200304000-00009; Milde-Langosch K, 2001, BRIT J CANCER, V85, P546, DOI 10.1054/bjoc.2001.1923; Minimo C, 1999, PATHOL RES PRACT, V195, P67, DOI 10.1016/S0344-0338(99)80072-7; Mizokami H, 1999, MODERN PATHOL, V12, P47; Morente MM, 1997, BLOOD, V90, P2429; MUNGER K, 1992, CANCER SURV, V12, P197; Nakahara Y, 2000, CANCER LETT, V160, P3, DOI 10.1016/S0304-3835(00)00546-2; Omura K, 1997, J CLIN ONCOL, V15, P3458, DOI 10.1200/JCO.1997.15.12.3458; PIETILAINEN T, 1995, EUR J CANCER, V31A, P329, DOI 10.1016/0959-8049(94)00463-F; Pinto AE, 2005, PATHOLOGY, V37, P45, DOI 10.1080/00313020400011250; Pollack A, 1997, CLIN CANCER RES, V3, P1823; Poller DN, 1997, BRIT J CANCER, V75, P87, DOI 10.1038/bjc.1997.14; Puduvalli VK, 2000, INT J ONCOL, V17, P963; Rolfe KJ, 2001, INT J GYNECOL CANCER, V11, P381, DOI 10.1046/j.1525-1438.2001.01039.x; Russo G, 2005, CLIN CANCER RES, V11, P3265, DOI 10.1158/1078-0432.CCR-04-2508; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sanchez E, 1998, J CLIN ONCOL, V16, P1931, DOI 10.1200/JCO.1998.16.5.1931; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; SAWAN A, 1992, J PATHOL, V168, P23, DOI 10.1002/path.1711680105; SCHEMPER M, 1993, STAT MED, V12, P2377, DOI 10.1002/sim.4780122413; Semczuk A, 2000, PATHOL RES PRACT, V196, P41, DOI 10.1016/S0344-0338(00)80020-5; Skomedal H, 1999, GYNECOL ONCOL, V73, P223, DOI 10.1006/gyno.1999.5346; Song Hong Suk, 2005, Korean Journal of Internal Medicine, V20, P1; SPANDIDOS DA, 1992, ANTICANCER RES, V12, P81; SUN Y, 1993, ONCOGENE, V8, P791; Susini T, 2001, HUM PATHOL, V32, P360, DOI 10.1053/hupa.2001.23514; Susini T, 1998, J CLIN ONCOL, V16, P1085, DOI 10.1200/JCO.1998.16.3.1085; Tonini T, 2004, CLIN CANCER RES, V10, P8085, DOI 10.1158/1078-0432.CCR-04-0996; TRUDEL M, 1992, HUM PATHOL, V23, P1388, DOI 10.1016/0046-8177(92)90059-C; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wakasugi E, 1997, J CLIN PATHOL, V50, P407, DOI 10.1136/jcp.50.5.407; WALTHER MM, 1995, J UROLOGY, V153, P2050, DOI 10.1016/S0022-5347(01)67400-7; WEIDE R, 1994, LEUKEMIA, V8, P97; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; Wurl P, 1999, CANCER LETT, V139, P159, DOI 10.1016/S0304-3835(99)00034-8; Wurl P, 1998, LANGENBECK ARCH SURG, V383, P99, DOI 10.1007/s004230050099; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695; Yamamoto Y, 1998, ONCOL REP, V5, P447; Zamparelli A, 2001, HUM PATHOL, V32, P4, DOI 10.1053/hupa.2001.20371; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zojer N, 2000, BLOOD, V95, P1925, DOI 10.1182/blood.V95.6.1925	93	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5302	5308		10.1038/sj.onc.1209620	http://dx.doi.org/10.1038/sj.onc.1209620			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936751				2022-12-25	WOS:000240064100016
J	Pecquet, C; Nyga, R; Penard-Lacronique, V; Smithgall, TE; Murakami, H; Regnier, A; Lassoued, K; Gouilleux, F				Pecquet, C.; Nyga, R.; Penard-Lacronique, V.; Smithgall, T. E.; Murakami, H.; Regnier, A.; Lassoued, K.; Gouilleux, F.			The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation	ONCOGENE			English	Article						Tel-Abl; Tel-Jak2; Src kinases; Hck; signal transduction; oncogenes	KAPPA-B PATHWAY; BCR-ABL; FUSION PROTEINS; LEUKEMIA-CELLS; C-SRC; ACTIVATION; GENE; FAMILY; LYN; RECEPTOR	Tel-Abl and Tel-Jak2 are fusion proteins associated with human haematologic neoplasms. They possess constitutive tyrosine kinase activity and activate common downstream signalling pathways like Stat-5, PI3-K/Akt, Ras/MapK and NF-kappa B. In this study, we showed the specific requirement of Src family members for the Tel-Abl-mediated cell growth, activation of Stat5, PI3-K/Akt and Ras/MapK while dispensable for Tel-Jak2. Hck was found strongly phosphorylated in Tel-Abl-expressing Ba/F3 cells and sensitive to imatinib mesylate treatment, providing evidence that Hck is a target of Tel-Abl tyrosine kinase activity. Overexpression of a kinase dead form of Hck inhibits the proliferation of Ba/F3 cells expressing Tel-Abl as the phosphorylation of Akt and Erk1/2. These results argue for an important role of Hck in Tel-Abl oncogenic signalling.	Univ Picardie, INSERM, E351, F-80036 Amiens, France; Hop Necker Enfants Malad, INSERM, E210, Paris, France; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Okayama Univ, Dept Biotechnol, Okayama 7008530, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Okayama University	Gouilleux, F (corresponding author), Univ Picardie, INSERM, E351, 3 Rue Louvels, F-80036 Amiens, France.	fabrice.gouilleux@sa.u-picardie.fr	Penard-Lacronique, Virginie/E-5729-2016; Penard-Lacronique, Virginie/R-1938-2019	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Christian, Pecquet/0000-0002-8623-3483; Gouilleux, Fabrice/0000-0001-6047-1718	NCI NIH HHS [CA101828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101828] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Carron C, 2000, BLOOD, V95, P3891; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Chin H, 1998, BLOOD, V91, P3734; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; dos Santos NR, 2006, LEUKEMIA, V20, P182, DOI 10.1038/sj.leu.2404026; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ho JMY, 2002, BLOOD, V100, P1438; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Keung YK, 2002, CANCER GENET CYTOGEN, V138, P139, DOI 10.1016/S0165-4608(02)00609-X; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kuno Y, 2001, BLOOD, V97, P1050, DOI 10.1182/blood.V97.4.1050; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Malinge S, 2006, ONCOGENE, V25, P3589, DOI 10.1038/sj.onc.1209390; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Million RP, 2004, MOL CELL BIOL, V24, P4685, DOI 10.1128/MCB.24.11.4685-4695.2004; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Omura T, 2002, EUR J BIOCHEM, V269, P381, DOI 10.1046/j.0014-2956.2001.02661.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Santos SCR, 2001, FEBS LETT, V497, P148; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Stanglmaier M, 2003, LEUKEMIA, V17, P283, DOI 10.1038/sj.leu.2402778; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tatosyan AG, 2000, BIOCHEMISTRY-MOSCOW+, V65, P49; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Tilbrook PA, 2001, CANCER RES, V61, P2453; Van Limbergen H, 2001, GENE CHROMOSOME CANC, V30, P274, DOI 10.1002/1098-2264(2000)9999:9999<1::AID-GCC1089>3.3.CO;2-T; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008	46	23	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1577	1585		10.1038/sj.onc.1209949	http://dx.doi.org/10.1038/sj.onc.1209949			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953222	Green Published			2022-12-25	WOS:000244782500007
J	Kuang, SQ; Ling, X; Sanchez-Gonzalez, B; Yang, H; Andreeff, M; Garcia-Manero, G				Kuang, S-Q; Ling, X.; Sanchez-Gonzalez, B.; Yang, H.; Andreeff, M.; Garcia-Manero, G.			Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation	ONCOGENE			English	Article						p57KIP2; DNA methylation; leukemia; cell cycle; transforming growth factor-beta	ACUTE LYMPHOCYTIC-LEUKEMIA; BECKWITH-WIEDEMANN-SYNDROME; DEPENDENT KINASE INHIBITOR; CYCLE REGULATORY PATHWAY; ACUTE MYELOID-LEUKEMIA; CDK INHIBITOR; MULTIPLE GENES; P57(KIP2) GENE; VALPROIC ACID; HYPERMETHYLATION	To investigate if the tumor suppressor properties of p57KIP2 are dependent on its DNA methylation status, we studied the impact of several stress stimuli in leukemic cell lines with different p57KIP2 promoter DNA methylation levels. p57KIP2 reactivation was observed after stimulation with transforming growth factor-beta, other cytokines, high-density culture or serum withdrawal in p57KIP2 promoter unmethylated cells but not in methylated cells. In these cells, p57KIP2 reactivation required the use of a hypomethylating agent or a histone deacetylase inhibitor. Overexpression of p57KIP2 in p57KIP2 promoter methylated leukemic cell lines resulted in cell growth arrest and the induction of apoptosis. In contrast, overexpression of p57KIP2 in partially methylated cells only resulted in a moderate inhibition of cell growth and had no impact on apoptosis. Transduction of unmethylated cells expressing high levels of p57KIP2 with p57KIP2 short hairpin RNA resulted in increased cell proliferation. These results suggest that the tumor suppressive properties of p57KIP2 in leukemia may depend on the intrinsic promoter DNA methylation status of the gene.	Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Garcia-Manero, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Box 428,1515 Holcombe Blvd, Houston, TX 77030 USA.	ggarciam@mdanderson.org			NATIONAL CANCER INSTITUTE [R21CA105771, R21CA100067] Funding Source: NIH RePORTER; NCI NIH HHS [CA100067, CA105771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonilla F, 1998, INT J ONCOL, V12, P583; Bueso-Ramos C, 2005, J CLIN ONCOL, V23, P3932, DOI 10.1200/JCO.2005.02.998; Canalli AA, 2005, LEUKEMIA RES, V29, P881, DOI 10.1016/j.leukres.2004.11.023; Garcia-Manero G, 2004, BLOOD, V104, p78A; Garcia-Manero G, 2003, CANCER, V97, P695, DOI 10.1002/cncr.11090; Garcia-Manero G, 2002, CLIN CANCER RES, V8, P2217; Gutierrez MI, 2003, LEUKEMIA, V17, P1845, DOI 10.1038/sj.leu.2403060; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Kondo M, 1996, ONCOGENE, V12, P1365; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Lam WWK, 1999, J MED GENET, V36, P518; Li JQ, 2003, INT J ONCOL, V23, P1537; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Ling XY, 2003, CANCER RES, V63, P298; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Melki JR, 1999, CANCER RES, V59, P3730; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; Orlow I, 1996, CANCER RES, V56, P1219; Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954; Scandura JM, 2004, P NATL ACAD SCI USA, V101, P15231, DOI 10.1073/pnas.0406771101; Shen LL, 2003, BLOOD, V101, P4131, DOI 10.1182/blood-2002-08-2466; Sherr CJ, 2000, CANCER RES, V60, P3689; Sui L, 2002, ANTICANCER RES, V22, P3191; Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P73, DOI 10.1093/oxfordjournals.jbchem.a022586; Taniguchi T, 1997, ONCOGENE, V14, P1201, DOI 10.1038/sj.onc.1200934; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang H, 2005, LEUKEMIA RES, V29, P739, DOI 10.1016/j.leukres.2004.11.022	33	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1439	1448		10.1038/sj.onc.1209907	http://dx.doi.org/10.1038/sj.onc.1209907			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936778				2022-12-25	WOS:000244558800008
J	Delarue, FL; Adnane, J; Joshi, B; Blaskovich, MA; Wang, DA; Hawker, J; Bizouarn, F; Ohkanda, J; Zhu, K; Hamilton, AD; Chellappan, S; Sebti, SM				Delarue, F. L.; Adnane, J.; Joshi, B.; Blaskovich, M. A.; Wang, D-A; Hawker, J.; Bizouarn, F.; Ohkanda, J.; Zhu, K.; Hamilton, A. D.; Chellappan, S.; Sebti, S. M.			Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter	ONCOGENE			English	Article						RhoB; farnesyltransferase inhibitors; geranylgeranyltransferase inhibitors; HDAC1 dissociation; HAT association; histone acetylation	FARNESYL-PROTEIN TRANSFERASE; HUMAN CANCER-CELLS; HUMAN TUMOR-GROWTH; GTPASE RHOB; ANTITUMOR-ACTIVITY; TRANSGENIC MICE; NUDE-MICE; K-RAS; N-RAS; PRENYLATION	Recently, we have shown that RhoB suppresses EGFR-, ErbB2-, Ras- and Akt-mediated malignant transformation and metastasis. In this paper, we demonstrate that the novel antitumor agents farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs) upregulate RhoB expression in a wide spectrum of human cancer cells including those from pancreatic, breast, lung, colon, bladder and brain cancers. RhoB induction by FTI-277 and GGTI-298 occurs at the transcriptional level and is blocked by actinomycin D. Reverse transcription-PCR experiments documented that the increase in RhoB protein levels is due to an increase in RhoB transcription. Furthermore, treatment with FTIs and GGTIs of cancer cells results in HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Thus, promoter acetylation is a novel mechanism by which RhoB expression levels are regulated following treatment with the anticancer agents FTIs and GGTIs.	H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem, Tampa, FL USA; Univ S Florida, Dept Oncol, Tampa, FL USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL USA; Yale Univ, Dept Chem, New Haven, CT USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr,SRB3-DRDIS, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu	Ohkanda, Junko/I-6102-2019	Ohkanda, Junko/0000-0001-9663-5104; Zhu, Kuichun/0000-0002-3594-5616				Adnane J, 2002, CLIN CANCER RES, V8, P2225; Adnane J, 2000, ONCOGENE, V19, P5525, DOI 10.1038/sj.onc.1203920; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Benjamin D, 2001, NUCLEIC ACIDS RES, V29, P3603, DOI 10.1093/nar/29.17.3603; Chaya D, 2001, J BIOL CHEM, V276, P44385, DOI 10.1074/jbc.M108214200; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Dasgupta P, 2004, J BIOL CHEM, V279, P38762, DOI 10.1074/jbc.M312273200; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Du W, 1999, CANCER RES, V59, P5492; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 1999, ANTICANCER RES, V19, P1681; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Gui CY, 2001, MOL CELL BIOL, V21, P1155, DOI 10.1128/MCB.21.4.1155-1163.2001; Holstein SA, 2002, BIOCHEMISTRY-US, V41, P13698, DOI 10.1021/bi026251x; Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200; Hunt JT, 2000, J MED CHEM, V43, P3587, DOI 10.1021/jm000248z; Jiang K, 2004, ONCOGENE, V23, P1136, DOI 10.1038/sj.onc.1207236; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Liu M, 1998, CANCER RES, V58, P4947; MAZIERES J, 2004, CLIN CANCER RES, V10, P2472; NAGASU T, 1995, CANCER RES, V55, P5310; Pan JX, 2005, CANCER RES, V65, P3671, DOI 10.1158/0008-5472.CAN-04-2744; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Wang SW, 2003, ONCOGENE, V22, P6204, DOI 10.1038/sj.onc.1206653; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	5					633	640		10.1038/sj.onc.1209819	http://dx.doi.org/10.1038/sj.onc.1209819			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16909123				2022-12-25	WOS:000243902200001
J	Olsson, AY; Feber, A; Edwards, S; Poele, RT; Giddings, I; Merson, S; Cooper, CS				Olsson, A. Y.; Feber, A.; Edwards, S.; Poele, R. te; Giddings, I.; Merson, S.; Cooper, C. S.			Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells	ONCOGENE			English	Article						cDNA microarray; cellular proliferation; bladder; prostate; cancer; siRNA	COMPARATIVE GENOMIC HYBRIDIZATION; URINARY-BLADDER; CHROMOSOMAL IMBALANCES; GENETIC ALTERATIONS; COPY NUMBER; AMPLIFICATION; CARCINOMA; TUMORS; RB; SPECIFICITY	cation and overexpression of the E2F3 gene at 6p22 in human bladder cancer is associated with increased tumour stage, grade and proliferation index, and in prostate cancer E2F3 overexpression is linked to tumour aggressiveness. We first used small interfering RNA technology to confirm the potential importance of E2F3 overexpression in bladder cancer development. Knockdown of E2F3 expression in bladder cells containing the 6p22 amplicon strongly reduced the extent of bromodeoxyuridine ( BrdU) incorporation and the rate of cellular proliferation. In contrast, knockdown of CDKAL1/FLJ20342, another proposed oncogene, from this amplicon had no effect. Expression cDNA microarray analysis on bladder cancer cells following E2F3 knockdown was then used to identify genes regulated by E2F3, leading to the identification of known E2F3 targets such as Cyclin A and CDC2 and novel targets including pituitary tumour transforming gene 1, Polo-like kinase 1 (PLK1) and Caveolin-2. For both bladder and prostate cancer, we have proposed that E2F3 protein overexpression may cooperate with removal of the E2F inhibitor retinoblastoma tumor suppressor protein (pRB) to drive cellular proliferation. In support of this model, we found that ectopic expression of E2F3a enhanced the BrdU incorporation, a marker of cellular proliferation rate, of prostate cancer DU145 cells, which lack pRB, but had no effect on the proliferation rate of PC3 prostate cancer cells that express wild-type pRB. BrdU incorporation in PC3 cells could, however, be increased by overexpressing E2F3a in cells depleted of pRB. When taken together, these observations indicate that E2F3 levels have a critical role in modifying cellular proliferation rate in human bladder and prostate cancer.	MUCRC, Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England; CRUK Ctr Canc Therapeut, Inst Canc Res, Male Urol Canc Res Ctr, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK	Olsson, AY (corresponding author), MUCRC, Inst Canc Res, Sect Mol Carcinogenesis, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	yvonne.olsson@icr.ac.uk		Giddings, Ian/0000-0003-1078-5780; Feber, Andrew/0000-0001-5282-0498	Medical Research Council [G0501019] Funding Source: Medline; MRC [G0501019] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Bidus MA, 2006, CLIN CANCER RES, V12, P83, DOI 10.1158/1078-0432.CCR-05-0835; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Black EP, 2005, P NATL ACAD SCI USA, V102, P15948, DOI 10.1073/pnas.0504300102; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bruch J, 2000, CANCER RES, V60, P4526; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dolbeare F, 1996, HISTOCHEM J, V28, P531, DOI 10.1007/BF02331377; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Fong A, 2003, AM J CLIN PATHOL, V120, P93, DOI 10.1309/292NHAYNWAVREJ37; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Hovey RM, 1998, CANCER RES, V58, P3555; Humbert PO, 2000, GENE DEV, V14, P690; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; Knowles MA, 2001, J CLIN PATHOL-MOL PA, V54, P215, DOI 10.1136/mp.54.4.215; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Nogawa M, 2005, J CLIN INVEST, V115, P978, DOI 10.1172/JCI200523043; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; PHILLIPS SMA, 1994, BRIT J CANCER, V70, P1252, DOI 10.1038/bjc.1994.482; Prat E, 2001, UROLOGY, V57, P986, DOI 10.1016/S0090-4295(01)00909-8; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richter J, 1999, CANCER RES, V59, P5687; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sambrook J, 2001, MOL CLONING LAB MANU; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Simon R, 2000, INT J ONCOL, V17, P1025; Terracciano L, 1999, J PATHOL, V189, P230, DOI 10.1002/(SICI)1096-9896(199910)189:2<230::AID-PATH407>3.0.CO;2-8; Theodorescu D, 1997, J UROLOGY, V158, P131, DOI 10.1097/00005392-199707000-00040; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; Tomovska S, 2001, INT J ONCOL, V18, P1239; Veltman JA, 2003, CANCER RES, V63, P2872; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10934, DOI 10.1093/nar/16.22.10934; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	43	93	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1028	1037		10.1038/sj.onc.1209854	http://dx.doi.org/10.1038/sj.onc.1209854			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909110	Bronze			2022-12-25	WOS:000244245400009
J	Li, Q; Montalbetti, N; Wu, YL; Ramos, A; Raychowdhury, MK; Chen, XZ; Cantiello, HF				Li, Qiang; Montalbetti, Nicolas; Wu, Yuliang; Ramos, Arnolt; Raychowdhury, Malay K.; Chen, Xing-Zhen; Cantiello, Horacio F.			Polycystin-2 cation channel function is under the control of microtubular structures in primary cilia of renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-RIGHT ASYMMETRY; KIDNEY-DISEASE; PKD2 INTERACTS; TROPONIN-I; PROTEIN; GENE; LOCALIZATION; CYSTIN	Mutations in the gene encoding polycystin-2 (PC2) result in autosomal dominant polycystic kidney disease and defects in left-right asymmetry during embryogenesis. PC2 is a TRP-type Ca2+-permeable non-selective cation channel, which is expressed in kidney and other organs. PC2 is present and functional in microtubule-containing primary cilia of renal epithelial cells. However, no information is yet available as to whether PC2 interacts with microtubules. Here, we assessed the role of microtubular dynamics in regulating PC2 channel function in primary cilia. Isolated ciliary membranes from LLC-PK1 epithelial cells were reconstituted in a lipid bilayer system. The acute addition of the microtubular disrupter colchicine ( 15 mu M) rapidly abolished, whereas the addition of the microtubular stabilizer paclitaxel (taxol, 15 mu M) increased ciliary PC2 channel activity. The further addition of alpha-tubulin plus GTP also stimulated PC2 channel activity in ciliary membranes. However, alpha-tubulin and GTP had no effect on in vitro translated PC2. Using the yeast two-hybrid assay, we found that PC2 interacts with the microtubule-dependent motor kinesin-2 subunit KIF3A, a protein involved in polycystic kidney disease. The interaction occurred through the carboxyl termini domain of both proteins, which was further confirmed by in vitro glutathione S-transferase pull-down and dot blot overlay assays. Co-immunoprecipitation experiments showed that PC2 and KIF3A are in the same complex in native HEK293, Madin-Darby canine kidney cells (MDCK), and LLC-PK1 cells. Immunofluorescent staining also showed substantial PC2 and KIF3A co-localization in primary cilia of renal epithelial cells. The data indicate that microtubular organization regulates PC2 function, which may explain, among others, the regulatory role of PC2 in the sensory function of primary cilia.	Massachusetts Gen Hosp, Renal Unit, Dept Med, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada; Univ Buenos Aires, Fac Farm & Bioquim, Dept Fisioquim & Quim Analit, Lab Canales Ion, RA-1113 Buenos Aires, DF, Argentina	Harvard University; Massachusetts General Hospital; Harvard University; University of Alberta; University of Buenos Aires	Chen, XZ (corresponding author), Massachusetts Gen Hosp, Renal Unit, Dept Med, 149 13th St, Charlestown, MA 02129 USA.	xzchen@ualberta.ca	Montalbetti, Nicolas/T-4212-2019	Montalbetti, Nicolas/0000-0003-2897-9540				Dhani SU, 2003, J BIOL CHEM, V278, P16262, DOI 10.1074/jbc.M209828200; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; GLUCK U, 1994, J CELL SCI, V107, P1773; Gonzalez-Perrett S, 2002, J BIOL CHEM, V277, P24959, DOI 10.1074/jbc.M105084200; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Goswami C, 2004, J NEUROCHEM, V91, P1092, DOI 10.1111/j.1471-4159.2004.02795.x; Hou XY, 2002, J CLIN INVEST, V109, P533, DOI 10.1172/JC1200214099; Howarth FC, 1999, J PHYSIOL-LONDON, V516, P409, DOI 10.1111/j.1469-7793.1999.0409v.x; JOHNSON BD, 1994, PFLUG ARCH EUR J PHY, V429, P14, DOI 10.1007/BF02584025; KARR TL, 1980, J BIOL CHEM, V255, P1853; Li Q, 2005, HUM MOL GENET, V14, P1587, DOI 10.1093/hmg/ddi167; Li Q, 2003, BIOCHEMISTRY-US, V42, P7618, DOI 10.1021/bi034210a; Li Q, 2003, J MOL BIOL, V325, P949, DOI 10.1016/S0022-2836(02)01333-5; Li Q, 2003, BIOCHEMISTRY-US, V42, P450, DOI 10.1021/bi0267792; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Montalbetti N, 2005, J PHYSIOL-LONDON, V566, P309, DOI 10.1113/jphysiol.2005.087072; Morgan D, 1998, NAT GENET, V20, P149, DOI 10.1038/2450; Murcia NS, 2000, DEVELOPMENT, V127, P2347; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; OBrien ET, 1997, CELL MOTIL CYTOSKEL, V36, P125, DOI 10.1002/(SICI)1097-0169(1997)36:2<125::AID-CM3>3.0.CO;2-8; Ong ACM, 2003, LANCET, V361, P774, DOI 10.1016/S0140-6736(03)12662-1; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Pennekamp P, 2002, CURR BIOL, V12, P938, DOI 10.1016/S0960-9822(02)00869-2; Praetorius HA, 2003, J MEMBRANE BIOL, V191, P193, DOI 10.1007/s00232-002-1055-z; Qin HM, 2001, CURR BIOL, V11, P457, DOI 10.1016/S0960-9822(01)00122-1; Raychowdhury MK, 2005, J BIOL CHEM, V280, P34718, DOI 10.1074/jbc.M507793200; Raychowdhury MK, 2004, J BIOL CHEM, V279, P20137, DOI 10.1074/jbc.M311946200; Rundle DR, 2004, J BIOL CHEM, V279, P29728, DOI 10.1074/jbc.M400544200; SNEDECOR GW, 1973, STATISTICAL METHODS, P91; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Unno T, 1999, BRIT J PHARMACOL, V127, P1703, DOI 10.1038/sj.bjp.0702711; Ward CJ, 2003, HUM MOL GENET, V12, P2703, DOI 10.1093/hmg/ddg274; Wilson PD, 2001, J AM SOC NEPHROL, V12, P834, DOI 10.1681/ASN.V124834; Woo DDL, 1997, KIDNEY INT, V51, P1613, DOI 10.1038/ki.1997.222; Xu GM, 2003, J BIOL CHEM, V278, P1457, DOI 10.1074/jbc.M209996200; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Yoder BK, 2002, AM J PHYSIOL-RENAL, V282, pF541, DOI 10.1152/ajprenal.00273.2001	38	176	184	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37566	37575		10.1074/jbc.M603643200	http://dx.doi.org/10.1074/jbc.M603643200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16950792	hybrid			2022-12-25	WOS:000242477100033
J	Vaisanen, T; Vaisanen, MR; Pihlajaniemi, T				Vaisanen, Timo; Vaisanen, Marja-Riitta; Pihlajaniemi, Taina			Modulation of the cellular cholesterol level affects shedding of the type XIII collagen ectodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; ALZHEIMERS BETA-SECRETASE; LIPID RAFTS; PLASMA-MEMBRANE; PHASE-SEPARATION; MICRODOMAINS; DEPLETION; DOMAINS; SURFACE; MATRIX	Type XIII collagen is a transmembrane protein that also exists as a soluble extracellular variant because of ectodomain shedding by proprotein convertases. Because ectodomain shedding in a growing number of transmembrane proteins has recently been shown to be dependent on their localization in cholesterol-enriched detergent-resistant membrane microdomains, this work aimed at analyzing this aspect of type XIII collagen ectodomain processing. In HT-1080 cells type XIII collagen and its cleaving proprotein convertase furin localized partially in detergent-resistant cholesterol-containing membrane microdomains. Disruption of these domains by lowering either the level or availability of the cellular cholesterol reduced ectodomain shedding, implying that, in such membrane domains correct cholesterol level is important for the regulation of type XIII collagen ectodomain processing. In addition, we show here that ectodomain of type XIII collagen is also shed intracellularly. HT-1080 cells released vesicles from the Golgi apparatus, which contained only the cleaved variant. Intracellular processing and the subsequent entry of the cleaved ectodomain into the vesicles was totally blocked by inhibition of the proprotein convertase function by cell-permeable chloromethylketone, but not with cell-impermeable alpha 1-antitrypsin Portland. This supports the hypothesis of type XIII collagen ectodomain also being cleaved intracellularly in the Golgi and suggests that the intracellular cleavage may act as a gating event in the vesicle-mediated ectodomain secretion.	Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Collagen Res Unit, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu; University of Oulu	Pihlajaniemi, T (corresponding author), Univ Oulu, Dept Med Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.	taina.pihlajaniemi@oulu.fi		Pihlajaniemi, Taina/0000-0002-1664-9045				Angelucci A, 2000, CLIN EXP METASTAS, V18, P163, DOI 10.1023/A:1006778000173; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baldwin TA, 2002, J BIOL CHEM, V277, P50333, DOI 10.1074/jbc.M209075200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Danthi P, 2004, J VIROL, V78, P33, DOI 10.1128/JVI.78.1.33-41.2004; Dolo V, 1998, CANCER RES, V58, P4468; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; FOLCH J, 1957, J BIOL CHEM, V226, P497; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; Ginestra A, 1998, ANTICANCER RES, V18, P3433; GOMEZ L, 1993, PLANT CELL, V5, P1113, DOI 10.1105/tpc.5.9.1113; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hagg P, 2001, MATRIX BIOL, V19, P727, DOI 10.1016/S0945-053X(00)00119-0; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; HOLM C, 1986, J BIOL CHEM, V261, P5659; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Karacsonyi C, 2005, J LEUKOCYTE BIOL, V78, P1097, DOI 10.1189/jlb.0405189; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kvist AP, 2001, AM J PATHOL, V159, P1581, DOI 10.1016/S0002-9440(10)62542-4; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Leitinger B, 2002, J CELL SCI, V115, P963; Maile LA, 2002, J BIOL CHEM, V277, P1800, DOI 10.1074/jbc.M108380200; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Phong MC, 2003, BIOCHEM BIOPH RES CO, V300, P563, DOI 10.1016/S0006-291X(02)02886-3; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Radeva G, 2005, FEBS J, V272, P4924, DOI 10.1111/j.1742-4658.2005.04905.x; Rebres RA, 2001, J BIOL CHEM, V276, P34607, DOI 10.1074/jbc.M106107200; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUBRAMANIAM VN, 1992, J BIOL CHEM, V267, P12016; Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200; Upla P, 2004, MOL BIOL CELL, V15, P625, DOI 10.1091/mbc.E03-08-0588; Vaisanen MR, 2006, BIOCHEM J, V393, P43, DOI 10.1042/BJ20051073; Vaisanen MR, 2004, BIOCHEM J, V380, P685, DOI 10.1042/BJ20031974; Vaisanen T, 2005, J PATHOL, V207, P324, DOI 10.1002/path.1836; von Tresckow B, 2004, J IMMUNOL, V172, P4324, DOI 10.4049/jimmunol.172.7.4324; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Wakatsuki S, 2004, J NEUROCHEM, V89, P119, DOI 10.1046/j.1471-4159.2003.02303.x; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Wickstrom SA, 2003, J BIOL CHEM, V278, P37895, DOI 10.1074/jbc.M303569200; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Young WW, 1999, GLYCOBIOLOGY, V9, P689, DOI 10.1093/glycob/9.7.689; Zimina EP, 2005, J BIOL CHEM, V280, P34019, DOI 10.1074/jbc.M503751200	60	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33352	33362		10.1074/jbc.M605896200	http://dx.doi.org/10.1074/jbc.M605896200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950783	hybrid			2022-12-25	WOS:000241621400045
J	Carroll, J; Fearnley, IM; Skehel, JM; Shannon, RJ; Hirst, J; Walker, JE				Carroll, Joe; Fearnley, Ian M.; Skehel, J. Mark; Shannon, Richard J.; Hirst, Judy; Walker, John E.			Bovine complex I is a complex of 45 different subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; PROTON-TRANSLOCATING NADH; NUCLEAR-ENCODED SUBUNITS; ACYL-CARRIER PROTEIN; HEART-MITOCHONDRIA; MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; SUBCOMPLEXES; SEQUENCES; CHAIN	Mammalian mitochondrial complex I is a multisubunit membrane-bound assembly with a molecular mass approaching 1 MDa. By comprehensive analyses of the bovine complex and its constituent subcomplexes, 45 different subunits have been characterized previously. The presence of a 46th subunit was suspected from the consistent detection of a molecular mass of 10,566 by electrospray ionization mass spectrometry of subunits fractionated by reverse-phase high pressure liquid chromatography. The component was found associated with both the intact complex and subcomplex I beta, which represents most of the membrane arm of the complex, and it could not be resolved chromatographically from subunit SGDH( the subunit of bovine complex I with the N-terminal sequence Ser-Gly-Asp-His). It has now been characterized by tandem mass spectrometry of intact protein ions and shown to be a C-terminal fragment of subunit SGDH arising from a specific peptide bond cleavage between Ile-55 and Pro-56 during the electrospray ionization process. Thus, the subunit composition of bovine complex I has been established. It is a complex of 45 different proteins plus non-covalently bound FMN and eight iron-sulfur clusters.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.	walker@mrc-dunn.cam.ac.uk	Hirst, Judy/F-4803-2011	Hirst, Judy/0000-0001-8667-6797; Walker, John/0000-0001-7929-2162	Medical Research Council [MC_U105663148, MC_U105663141] Funding Source: Medline; MRC [MC_U105663148, MC_U105663141] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ARIZMENDI JM, 1992, FEBS LETT, V313, P80, DOI 10.1016/0014-5793(92)81189-S; ARIZMENDI JM, 1992, FEBS LETT, V301, P237, DOI 10.1016/0014-5793(92)80248-F; Baker ME, 1999, CELL MOL LIFE SCI, V55, P450, DOI 10.1007/s000180050301; Breci LA, 2003, ANAL CHEM, V75, P1963, DOI 10.1021/ac026359i; Carroll J, 2005, MOL CELL PROTEOMICS, V4, P693, DOI 10.1074/mcp.M500014-MCP200; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Chen RM, 2004, J BIOL CHEM, V279, P26036, DOI 10.1074/jbc.M402710200; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; FEARNLEY IM, 1994, BIOCHEM SOC T, V22, P551, DOI 10.1042/bst0220551; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; FINEL M, 1994, EUR J BIOCHEM, V226, P237, DOI 10.1111/j.1432-1033.1994.tb20046.x; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Johnson RW, 2005, ANAL BIOCHEM, V341, P22, DOI 10.1016/j.ab.2005.03.009; Murray J, 2003, J BIOL CHEM, V278, P13619, DOI 10.1074/jbc.C300064200; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SACKMANN U, 1991, EUR J BIOCHEM, V200, P463, DOI 10.1111/j.1432-1033.1991.tb16205.x; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Sazanov LA, 2000, J MOL BIOL, V302, P455, DOI 10.1006/jmbi.2000.4079; Schaaff TG, 2000, ANAL CHEM, V72, P899, DOI 10.1021/ac991344e; Schultz BE, 2001, ANNU REV BIOPH BIOM, V30, P23, DOI 10.1146/annurev.biophys.30.1.23; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WIKSTROM M, 1984, FEBS LETT, V169, P300, DOI 10.1016/0014-5793(84)80338-5; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201	34	365	388	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32724	32727		10.1074/jbc.M607135200	http://dx.doi.org/10.1074/jbc.M607135200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16950771	hybrid			2022-12-25	WOS:000241414500071
J	Fiedler, B; Feil, R; Hofmann, F; Willenbockel, C; Drexler, H; Smolenski, A; Lohmann, SM; Wollert, KC				Fiedler, Beate; Feil, Robert; Hofmann, Franz; Willenbockel, Christian; Drexler, Helmut; Smolenski, Albert; Lohmann, Suzanne M.; Wollert, Kai C.			cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN; INDUCED MYOCARDIAL APOPTOSIS; MUSCLE LIM PROTEIN; NF-KAPPA-B; REPERFUSION INJURY; ISCHEMIA-REPERFUSION; CARDIOMYOCYTE APOPTOSIS; ISCHEMIA/REPERFUSION INJURY; INDEPENDENT ACTIVATION	Cardiac myocyte apoptosis during ischemia and reperfusion (I/R) is tightly controlled by a complex network of stress-responsive signaling pathways. One pro-apoptotic pathway involves the interaction of the scaffold protein TAB1 with p38 mitogen-activated protein kinase (p38 MAPK) leading to the autophosphorylation and activation of p38 MAPK. Conversely, NO and its second messenger cGMP protect cardiac myocytes from apoptosis during I/R. We provide evidence that the cGMP target cGMP-dependent protein kinase type I (PKGI) interferes with TAB1-p38 MAPK signaling to protect cardiac myocytes from I/R injury. In isolated neonatal cardiac myocytes, activation of PKGI inhibited the interaction of TAB1 with p38 MAPK, p38 MAPK phosphorylation, and apoptosis induced by simulated I/R. During I/R in vivo, mice with a cardiac myocyte-restricted deletion of PKGI displayed a more pronounced interaction of TAB1 with p38 MAPK and a stronger phosphorylation of p38 MAPK in the myocardial area at risk during reperfusion and more apoptotic cardiac myocytes in the infarct border zone as compared with wild-type littermates. Notably, adenoviral expression of a constitutively active PKGI mutant truncated at the N terminus(PKGI-Delta N1-92) did not inhibit p38 MAPK phosphorylation and apoptosis induced by simulated I/R in vitro, indicating that the N terminus of PKGI is required. As shown by co-immunoprecipitation experiments in HEK293 cells, cGMP-activated PKGI, but not constitutively active PKGI-Delta N1-92 or PKGI mutants carrying point mutations in the N-terminal leucine-isoleucine zipper, interacted with p38 MAPK, and prevented the binding of TAB1 to p38 MAPK. Together, our data identify a novel interaction between the cGMP target PKG I and the TAB1-p38 MAPK signaling pathway that serves as a defense mechanism against myocardial I/R injury.	Hannover Med Sch, Dept Cardiol & Angiol, D-30625 Hannover, Germany; Tech Univ Munich, Inst Pharmacol & Toxicol, D-80802 Munich, Germany; Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	Hannover Medical School; Technical University of Munich; University of Wurzburg	Wollert, KC (corresponding author), Hannover Med Sch, Abt Kardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	wollert.kai@mh-hannover.de	Feil, Robert/B-8918-2014	Feil, Robert/0000-0002-7335-4841; Smolenski, Albert/0000-0001-9210-9406				Agullo L, 1999, AM J PHYSIOL-HEART C, V276, pH1574, DOI 10.1152/ajpheart.1999.276.5.H1574; Arstall MA, 1999, CIRC RES, V85, P829, DOI 10.1161/01.RES.85.9.829; Baines CP, 2005, J MOL CELL CARDIOL, V38, P47, DOI 10.1016/j.yjmcc.2004.11.004; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Eefting F, 2004, CARDIOVASC RES, V61, P414, DOI 10.1016/j.cardiores.2003.12.023; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; Gang L, 2006, J BIOL CHEM, V281, P6087, DOI 10.1074/jbc.M507610200; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Ge BX, 2003, J BIOL CHEM, V278, P2286, DOI 10.1074/jbc.M210918200; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Heineke J, 2005, P NATL ACAD SCI USA, V102, P1655, DOI 10.1073/pnas.0405488102; Heineke J, 2003, CIRCULATION, V107, P1424, DOI 10.1161/01.CIR.0000055319.94801.FC; Hofmann F, 2005, J BIOL CHEM, V280, P1, DOI 10.1074/jbc.R400035200; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; Jones SP, 2006, J MOL CELL CARDIOL, V40, P16, DOI 10.1016/j.yjmcc.2005.09.011; Jones SP, 2004, AM J PHYSIOL-HEART C, V286, pH276, DOI 10.1152/ajpheart.00129.2003; Jones SP, 1999, AM J PHYSIOL-HEART C, V276, pH1567, DOI 10.1152/ajpheart.1999.276.5.H1567; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kang YJ, 2000, J BIOL CHEM, V275, P13690, DOI 10.1074/jbc.275.18.13690; Kempf T, 2006, CIRC RES, V98, P351, DOI 10.1161/01.RES.0000202805.73038.48; Kumar R, 1999, J PHARMACOL EXP THER, V291, P967; Lalu Manoj M, 2002, Heart Fail Rev, V7, P359, DOI 10.1023/A:1020766502316; Li QH, 2003, CIRC RES, V92, P741, DOI 10.1161/01.RES.0000065441.72685.29; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Maejima Y, 2003, CARDIOVASC RES, V59, P308, DOI 10.1016/S0008-6363(03)00425-5; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Matsuyama W, 2003, J IMMUNOL, V171, P3520, DOI 10.4049/jimmunol.171.7.3520; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Oldenburg O, 2004, AM J PHYSIOL-HEART C, V286, pH468, DOI 10.1152/ajpheart.00360.2003; Otsu K, 2003, BIOCHEM BIOPH RES CO, V302, P56, DOI 10.1016/S0006-291X(03)00096-2; Pabla R, 1996, CIRC RES, V78, P65, DOI 10.1161/01.RES.78.1.65; Sasaki N, 2000, CIRCULATION, V101, P439, DOI 10.1161/01.CIR.101.4.439; Schulz R, 2004, CARDIOVASC RES, V61, P402, DOI 10.1016/j.cardiores.2003.09.019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Tanno M, 2003, CIRC RES, V93, P254, DOI 10.1161/01.RES.0000083490.43943.85; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wegener JW, 2002, CIRC RES, V90, P18, DOI 10.1161/hh0102.103222; Weiland U, 2000, CARDIOVASC RES, V45, P671, DOI 10.1016/S0008-6363(99)00347-8; Wollert KC, 2002, HYPERTENSION, V39, P87, DOI 10.1161/hy1201.097292; Yoshida H, 2000, HYPERTENSION, V35, P25, DOI 10.1161/01.HYP.35.1.25; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037; Zingarelli B, 2002, FASEB J, V16, DOI 10.1096/fj.01-0533com	54	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32831	32840		10.1074/jbc.M603416200	http://dx.doi.org/10.1074/jbc.M603416200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16943189	hybrid			2022-12-25	WOS:000241414500081
J	Mangmool, S; Haga, T; Kobayashi, H; Kim, KM; Nakata, H; Nishida, M; Kurose, H				Mangmool, Supachoke; Haga, Tatsuya; Kobayashi, Hiroyuki; Kim, Kyeong-Man; Nakata, Hiroyasu; Nishida, Motohiro; Kurose, Hitoshi			Clathrin required for phosphorylation and internalization of beta(2)-adrenergic receptor by G protein-coupled receptor kinase 2 (GRK2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; ARRESTIN/CLATHRIN INTERACTION; TERMINAL DOMAIN; BINDING; ENDOCYTOSIS; KINASES; LOCALIZATION; DESENSITIZATION; SEQUESTRATION; TRAFFICKING	Clathrin is a major component of clathrin-coated pits and serves as a binding scaffold for endocytic machinery through the binding of a specific sequence known as the clathrin-binding motif. This motif is also found in cellular signaling proteins other than endocytic components, including G protein-coupled receptor kinase 2 (GRK2), which phosphorylates G protein-coupled receptors and promotes uncoupling of receptor-G protein interaction. However, the functions of clathrin in the regulation of GRK2 are unknown. Here we demonstrated that overexpression of GRK2 mutated at the clathrin-binding motif with alanine (GRK2-5A) results in inhibition of phosphorylation and internalization of the beta(2)-adrenergic receptor (beta(2)AR). However, the interaction of beta(2)AR with GRK2-5A is the same as that of wild type GRK2 as determined by bioluminescence resonance energy transfer. Furthermore, GRK2-5A phosphorylates rhodopsin essentially to the same extent as wild type GRK2 in vitro. Depletion of the clathrin heavy chain using small interference RNA inhibits agonist-induced phosphorylation and internalization of beta(2)AR. Thus, clathrin works as a regulator of GRK2 in cells. These results indicate that clathrin is a novel player in cellular functions in addition to being a component of endocytosis.	Kyushu Univ, Dept Pharmacol & Toxicol, Grad Sch Pharmaceut Sci, Higashi Ku, Fukuoka 8128582, Japan; Gakushuin Univ, Fac Sci, Inst Biomol Sci, Tokyo 1718588, Japan; Chonnam Natl Univ, Coll Pharm, Dept Pharmacol, Kwangju 500757, South Korea; Tokyo Metropolitan Inst Neurosci, Dept Mol Cell Signaling, Tokyo 1838526, Japan	Kyushu University; Gakushuin University; Chonnam National University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Kurose, H (corresponding author), Kyushu Univ, Dept Pharmacol & Toxicol, Grad Sch Pharmaceut Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kurose@phar.kyushu-u.ac.jp	Kim, Kyeong-Man/AAA-9847-2020; Kobayashi, Hiroyuki/F-6386-2013	Kobayashi, Hiroyuki/0000-0003-4965-0883; Nishida, Motohiro/0000-0002-2587-5458				Akbarzadeh S, 2002, J BIOL CHEM, V277, P36280, DOI 10.1074/jbc.M204626200; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; HAGA K, 1992, J BIOL CHEM, V267, P2222; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Johnson LR, 2004, MOL CELL BIOL, V24, P10169, DOI 10.1128/MCB.24.23.10169-10179.2004; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KUROSE H, 1994, J BIOL CHEM, V269, P10093; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; Sato Y, 1996, EUR J PHARMACOL, V315, P363, DOI 10.1016/S0014-2999(96)00648-6; Schulz R, 2002, MOL PHARMACOL, V61, P1444, DOI 10.1124/mol.61.6.1444; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; Smith CJ, 1999, TRENDS CELL BIOL, V9, P335, DOI 10.1016/S0962-8924(99)01631-1; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; Wettey FR, 2002, SCIENCE, V297, P1521, DOI 10.1126/science.1074222; Wheeler M, 2006, J CELL PHYSIOL, V206, P586, DOI 10.1002/jcp.20507; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200; Yoshioka K, 2002, FEBS LETT, V523, P147, DOI 10.1016/S0014-5793(02)02965-4	39	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31940	31949		10.1074/jbc.M602832200	http://dx.doi.org/10.1074/jbc.M602832200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920721	Bronze			2022-12-25	WOS:000241235300080
J	Natarajan, A; Ghose, R; Hill, JM				Natarajan, Aswin; Ghose, Ranajeet; Hill, Justine M.			Structure and dynamics of ASC2, a pyrin domain-only protein that regulates inflammatory signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL-FREE APPROACH; DEATH-EFFECTOR DOMAIN; NMR RELAXATION DATA; ORIENTED MACROMOLECULES; CRYSTAL-STRUCTURE; DIRECT REFINEMENT; N-15 RELAXATION; KAPPA-B; APOPTOSIS; INSIGHTS	Pyrin domain (PYD)-containing proteins are key components of pathways that regulate inflammation, apoptosis, and cytokine processing. Their importance is further evidenced by the consequences of mutations in these proteins that give rise to autoimmune and hyperinflammatory syndromes. PYDs, like other members of the death domain ( DD) superfamily, are postulated to mediate homotypic interactions that assemble and regulate the activity of signaling complexes. However, PYDs are presently the least well characterized of all four DD subfamilies. Here we report the three-dimensional structure and dynamic properties of ASC2, a PYD-only protein that functions as a modulator of multidomain PYD-containing proteins involved in NF-KB and caspase-1 activation. ASC2 adopts a six-helix bundle structure with a prominent loop, comprising 13 amino acid residues, between helices two and three. This loop represents a divergent feature of PYDs from other domains with the DD fold. Detailed analysis of backbone N-15 NMR relaxation data using both the Lipari-Szabo model-free and reduced spectral density function formalisms revealed no evidence of contiguous stretches of polypeptide chain with dramatically increased internal motion, except at the extreme N and C termini. Some mobility in the fast, picosecond to nanosecond timescale, was seen in helix 3 and the preceding alpha 2-alpha 3 loop, in stark contrast to the complete disorder seen in the corresponding region of the NALP1 PYD. Our results suggest that extensive conformational flexibility in helix 3 and the alpha 2-alpha 3 loop is not a general feature of pyrin domains. Further, a transition from complete disorder to order of the alpha 2-alpha 3 loop upon binding, as suggested for NALP1, is unlikely to be a common attribute of pyrin domain interactions.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; CUNY City Coll, Dept Chem, New York, NY 10031 USA; CUNY, Grad Ctr, New York, NY 10016 USA	University of Queensland; City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System	Hill, JM (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	j.hill@imb.uq.edu.au	Hill, Justine M/C-5781-2009		NCRR NIH HHS [5G12 RR03060] Funding Source: Medline; NIGMS NIH HHS [P41 GM-66354] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM066354] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Andrec M, 1999, J MAGN RESON, V139, P408, DOI 10.1006/jmre.1999.1839; BOGGS PT, 1989, ACM T MATH SOFTWARE, V15, P348, DOI 10.1145/76909.76913; Burns K, 2003, CURR OPIN IMMUNOL, V15, P26, DOI 10.1016/S0952-7915(02)00017-1; Carrington PE, 2006, MOL CELL, V22, P599, DOI 10.1016/j.molcel.2006.04.018; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Christodoulou C, 2006, CLIN EXP MED, V6, P13, DOI 10.1007/s10238-006-0088-5; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Cordier F, 1999, J BIOMOL NMR, V13, P175, DOI 10.1023/A:1008301415843; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; Dutta K, 2004, BIOCHEMISTRY-US, V43, P8094, DOI 10.1021/bi030268d; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; Eliezer D, 2003, STRUCTURE, V11, P1190, DOI 10.1016/j.str.2003.09.008; Espejo F, 2006, BIOCHEM BIOPH RES CO, V340, P860, DOI 10.1016/j.bbrc.2005.12.087; Espejo F, 2002, J BIOMOL NMR, V23, P151, DOI 10.1023/A:1016398403157; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; Ghose R, 2001, J MAGN RESON, V149, P204, DOI 10.1006/jmre.2001.2295; Hill JM, 2004, J BIOL CHEM, V279, P1474, DOI 10.1074/jbc.M304996200; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Hiller S, 2003, STRUCTURE, V11, P1199, DOI 10.1016/j.str.2003.08.009; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hull KM, 2003, CURR OPIN RHEUMATOL, V15, P61, DOI 10.1097/00002281-200301000-00011; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; Li FY, 2006, J BIOL CHEM, V281, P2960, DOI 10.1074/jbc.M511074200; Liepinsh E, 2003, J MOL BIOL, V332, P1155, DOI 10.1016/j.jmb.2003.07.007; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Liu T, 2003, PROTEIN SCI, V12, P1872, DOI 10.1110/ps.0359603; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Moriya M, 2005, BIOCHEMISTRY-US, V44, P575, DOI 10.1021/bi048374i; Nabuurs SB, 2006, PLOS COMPUT BIOL, V2, P71, DOI 10.1371/journal.pcbi.0020009; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Petrilli V, 2005, CURR BIOL, V15, pR581, DOI 10.1016/j.cub.2005.07.049; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Stehlik C, 2003, BIOCHEM J, V373, P101, DOI 10.1042/BJ20030304; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Ting JPY, 2006, NAT REV IMMUNOL, V6, P183, DOI 10.1038/nri1788; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Vuister G. W., 1999, BIOL MAGNETIC RESONA, V16, P195; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Yang JK, 2005, MOL CELL, V20, P939, DOI 10.1016/j.molcel.2005.10.023; Yu JW, 2006, CELL DEATH DIFFER, V13, P236, DOI 10.1038/sj.cdd.4401734	65	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31863	31875		10.1074/jbc.M605458200	http://dx.doi.org/10.1074/jbc.M605458200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16905547				2022-12-25	WOS:000241235300073
J	Barker, M; de Vries, R; Nield, J; Komenda, J; Nixon, PJ				Barker, Myles; de Vries, Remco; Nield, Jon; Komenda, Josef; Nixon, Peter J.			The Deg proteases protect Synechocystis sp PCC 6803 during heat and light stresses but are not essential for removal of damaged D1 protein during the photosystem two repair cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ESCHERICHIA-COLI; CHLOROPLAST MEMBRANES; PERIPLASMIC PROTEINS; QUALITY-CONTROL; HTRA FAMILY; II COMPLEX; PCC 6803; MOTILITY; GENE	Members of the DegP/HtrA (or Deg) family of proteases are found widely in nature and play an important role in the proteolysis of misfolded and damaged proteins. As yet, their physiological role in oxygenic photosynthetic organisms is unclear, although it has been widely speculated that they participate in the degradation of the photodamaged D1 subunit in the photosystem two complex (PSII) repair cycle, which is needed to maintain PSII activity in both cyanobacteria and chloroplasts. We have examined the role of the three Deg proteases found in the cyanobacterium Synechocystis sp. PCC 6803 through analysis of double and triple insertion mutants. We have discovered that these proteases show overlap in function and are involved in a number of key physiological responses ranging from protection against light and heat stresses to phototaxis. In previous work, we concluded that the Deg proteases played either a direct or an indirect role in PSII repair in a glucose-tolerant version of Synechocystis 6803 (Silva, P., Choi, Y. J., Hassan, H. A., and Nixon, P. J. (2002) Philos. Trans. R. Soc. Lond. B Biol. Sci. 357, 1461-1467). In this work, we have now been able to demonstrate unambiguously, using a triple deg mutant created in the wild type strain of Synechocystis 6803, that the Deg proteases are not obligatory for PSII repair and D1 degradation. We therefore conclude that although the Deg proteases are needed for photo-protection of Synechocystis sp. PCC 6803, they do not play an essential role in D1 turnover and PSII repair in vivo.	Univ London Imperial Coll Sci Technol & Med, Div Biol, Fac Nat Sci, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, Fac Nat Sci, London SW7 2AZ, England; Acad Sci Czech Republ, Inst Microbiol, Trebon 37981, Czech Republic	Imperial College London; Imperial College London; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Nixon, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Biol, Fac Nat Sci, S Kensington Campus,Wolfson Biochem Bldg, London SW7 2AZ, England.	p.nixon@imperial.ac.uk	Komenda, Josef/H-4083-2014; Nield, Jon/C-5892-2013	Komenda, Josef/0000-0003-4588-0382; Nield, Jon/0000-0001-9983-0239; Nixon, Peter/0000-0003-1952-6937				Adir N, 2003, PHOTOSYNTH RES, V76, P343, DOI 10.1023/A:1024969518145; Alba BM, 2001, MOL MICROBIOL, V40, P1323, DOI 10.1046/j.1365-2958.2001.02475.x; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Bhaya D, 2000, MOL MICROBIOL, V37, P941, DOI 10.1046/j.1365-2958.2000.02068.x; Bhaya D, 1999, P NATL ACAD SCI USA, V96, P3188, DOI 10.1073/pnas.96.6.3188; Bhaya D, 2001, P NATL ACAD SCI USA, V98, P7540, DOI 10.1073/pnas.131201098; Boucher JC, 1996, J BACTERIOL, V178, P511, DOI 10.1128/jb.178.2.511-523.1996; Choi JS, 1999, PHOTOCHEM PHOTOBIOL, V70, P95; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; Finn PF, 2005, J BIOL CHEM, V280, P25864, DOI 10.1074/jbc.M502456200; Fulda S, 2000, EUR J BIOCHEM, V267, P5900, DOI 10.1046/j.1432-1327.2000.01642.x; FUNK C, 2001, P 12 INT C PHOT BRIS; Harris Jr, 1999, METH MOL B, V117, P13; Haussuhl K, 2001, EMBO J, V20, P713, DOI 10.1093/emboj/20.4.713; Huang F, 2004, MOL CELL PROTEOMICS, V3, P586, DOI 10.1074/mcp.M300137-MCP200; Huesgen PF, 2005, PHYSIOL PLANTARUM, V123, P413, DOI 10.1111/j.1399-3054.2005.00458.x; Jansen T, 2005, PHOTOSYNTH RES, V84, P57, DOI 10.1007/s11120-005-0475-x; Kanervo E, 2003, BBA-BIOENERGETICS, V1607, P131, DOI 10.1016/j.bbabio.2003.09.007; Kanesaki Y, 2002, BIOCHEM BIOPH RES CO, V290, P339, DOI 10.1006/bbrc.2001.6201; Keren N, 2005, J BIOL CHEM, V280, P6548, DOI 10.1074/jbc.M410218200; Kieselbach T, 2003, PHYSIOL PLANTARUM, V119, P337, DOI 10.1034/j.1399-3054.2003.00199.x; Kolmar H, 1996, J BACTERIOL, V178, P5925, DOI 10.1128/jb.178.20.5925-5929.1996; Komenda J, 2006, J BIOL CHEM, V281, P1145, DOI 10.1074/jbc.M503852200; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; Komenda J, 2002, EUR J BIOCHEM, V269, P610, DOI 10.1046/j.0014-2956.2001.02693.x; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; Lindahl M, 2000, PLANT CELL, V12, P419, DOI 10.1105/tpc.12.3.419; Lupinkova L, 2004, PHOTOCHEM PHOTOBIOL, V79, P152, DOI 10.1562/0031-8655(2004)079<0152:OMOTPI>2.0.CO;2; Nixon P. J., 1990, CURRENT RES PHOTOSYN, VI, P471; Nixon PJ, 2005, J EXP BOT, V56, P357, DOI 10.1093/jxb/eri021; NIXON PJ, 1995, J BIOL CHEM, V270, P14919, DOI 10.1074/jbc.270.25.14919; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Noone D, 2001, J BACTERIOL, V183, P654, DOI 10.1128/JB.183.2.654-663.2001; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; Okamoto S, 2002, PLANT CELL PHYSIOL, V43, P1127, DOI 10.1093/pcp/pcf128; Raffa RG, 2002, MOL MICROBIOL, V45, P1599, DOI 10.1046/j.1365-2958.2002.03112.x; Silva P, 2003, PLANT CELL, V15, P2152, DOI 10.1105/tpc.012609; Silva P, 2002, PHILOS T R SOC B, V357, P1461, DOI 10.1098/rstb.2002.1146; Skorko-Glonek J, 1999, MOL GEN GENET, V262, P342, DOI 10.1007/s004380051092; SMITH D, 1993, FEMS MICROBIOL LETT, V110, P341, DOI 10.1016/0378-1097(93)90126-M; Sokolenko A, 2002, CURR GENET, V41, P291, DOI 10.1007/s00294-002-0309-8; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; Tichy M, 2003, BBA-BIOENERGETICS, V1605, P55, DOI 10.1016/S0005-2728(03)00064-1; Waller PRH, 1996, J BACTERIOL, V178, P1146, DOI 10.1128/jb.178.4.1146-1153.1996; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Yamamoto Y, 2001, PLANT CELL PHYSIOL, V42, P121, DOI 10.1093/pcp/pce022; YOKOYAMA E, 1991, PLANT CELL PHYSIOL, V32, P827; Yoshihara S, 2001, PLANT CELL PHYSIOL, V42, P63, DOI 10.1093/pcp/pce007; Zak E, 2001, P NATL ACAD SCI USA, V98, P13443, DOI 10.1073/pnas.241503898	52	52	59	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30347	30355		10.1074/jbc.M601064200	http://dx.doi.org/10.1074/jbc.M601064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912048	hybrid			2022-12-25	WOS:000241075900008
J	Godoi, PHC; Galhardo, RS; Luche, DD; Van Sluys, MA; Menck, CFM; Oliva, G				Godoi, Paulo H. C.; Galhardo, Rodrigo S.; Luche, Douglas D.; Van Sluys, Marie-Anne; Menck, Carlos F. M.; Oliva, Glaucius			Structure of the thiazole biosynthetic enzyme THI1 from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIAMIN BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; CRASSA CYPBP37; PROTEIN; YEAST; GENE; ORIGIN; MOIETY; SEQUENCE; FAMILY	Thiamin pyrophosphate is an essential coenzyme in all organisms that depend on fermentation, respiration or photosynthesis to produce ATP. It is synthesized through two independent biosynthetic routes: one for the synthesis of 2-methyl-4-amino5-hydroxymethylpyrimidine pyrophosphate (pyrimidine moiety) and another for the synthesis of 4-methyl-5-(beta-hydroxyethyl) thiazole phosphate ( thiazole moiety). Herein, we will describe the three-dimensional structure of THI1 protein from Arabidopsis thaliana determined by single wavelength anomalous diffraction to 1.6 angstrom resolution. The protein was produced using heterologous expression in bacteria, unexpectedly bound to 2-carboxylate-4-methyl-5-beta-(ethyladenosine 5'-diphosphate) thiazole, a potential intermediate of the thiazole biosynthesis in Eukaryotes. THI1 has a topology similar to dinucleotide binding domains and although details concerning its function are unknown, this work provides new clues about the thiazole biosynthesis in Eukaryotes.	Univ Sao Paulo, Inst Fis Sao Carlos, Dept Fis & Informat, BR-13560970 Sao Carlos, SP, Brazil; Univ Sao Paulo, Inst Quim Sao Carlos, Dept Quim Fis, BR-13560970 Sao Carlos, SP, Brazil; Univ Sao Paulo, Inst Biociencias, Dept Bot, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Oliva, G (corresponding author), Univ Sao Paulo, Inst Fis Sao Carlos, Dept Fis & Informat, CP 369, BR-13560970 Sao Carlos, SP, Brazil.	oliva@if.sc.usp.br	Menck, Carlos FM/G-6321-2011; Godoi, Paulo HC/B-9847-2012; Galhardo, Rodrigo/L-2238-2016; Van Sluys, Marie-Anne/A-8483-2012; Oliva, Glaucius/B-9059-2012	Menck, Carlos FM/0000-0003-1941-0694; Godoi, Paulo HC/0000-0003-1859-3513; Galhardo, Rodrigo/0000-0002-5686-9704; Van Sluys, Marie-Anne/0000-0002-6506-2734; Oliva, Glaucius/0000-0003-2719-0302				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bond CS, 2003, BIOINFORMATICS, V19, P311, DOI 10.1093/bioinformatics/19.2.311; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; Chatterjee A, 2006, J AM CHEM SOC, V128, P7158, DOI 10.1021/ja061413o; Denessiouk KA, 2001, PROTEINS, V44, P282, DOI 10.1002/prot.1093; DUGAS H, 1996, BIOORG CHEM, P560; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; Faou P, 2004, J MOL BIOL, V344, P1147, DOI 10.1016/j.jmb.2004.09.097; Faou P, 2003, J MOL BIOL, V333, P831, DOI 10.1016/j.jmb.2003.09.003; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JULLIARD JH, 1991, P NATL ACAD SCI USA, V88, P2042, DOI 10.1073/pnas.88.6.2042; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; Lawhorn BG, 2004, ORG BIOMOL CHEM, V2, P2538, DOI 10.1039/b405429f; Machado CR, 1997, J MOL BIOL, V273, P114, DOI 10.1006/jmbi.1997.1302; Machado CR, 1996, PLANT MOL BIOL, V31, P585, DOI 10.1007/BF00042231; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Medina-Silva R, 2006, RES MICROBIOL, V157, P275, DOI 10.1016/j.resmic.2005.07.004; Morett E, 2003, NAT BIOTECHNOL, V21, P790, DOI 10.1038/nbt834; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; OGUR M, 1957, SCIENCE, V125, P928, DOI 10.1126/science.125.3254.928; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papini-Terzi FS, 2003, PLANT CELL PHYSIOL, V44, P856, DOI 10.1093/pcp/pcg104; Park JH, 2003, BIOCHEMISTRY-US, V42, P12430, DOI 10.1021/bi034902z; Pearl F, 2005, NUCLEIC ACIDS RES, V33, pD247, DOI 10.1093/nar/gki024; PRAEKELT UM, 1994, YEAST, V10, P481, DOI 10.1002/yea.320100407; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; Settembre EC, 2003, BIOCHEMISTRY-US, V42, P2971, DOI 10.1021/bi026916v; Settembre EC, 2004, BIOCHEMISTRY-US, V43, P11647, DOI 10.1021/bi0488911; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Singleton Charles K., 2001, Current Molecular Medicine (Hilversum), V1, P197, DOI 10.2174/1566524013363870; TAZUYA K, 1987, BIOCHIM BIOPHYS ACTA, V924, P210, DOI 10.1016/0304-4165(87)90089-4; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tong L, 1997, METHOD ENZYMOL, V276, P594, DOI 10.1016/S0076-6879(97)76080-4; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WHITE RL, 1979, BIOCHEM J, V179, P315, DOI 10.1042/bj1790315; WHITE RL, 1982, J AM CHEM SOC, V104, P4934, DOI 10.1021/ja00382a033; Wightman R, 2003, MICROBIOL-SGM, V149, P1447, DOI 10.1099/mic.0.26194-0; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698	44	44	52	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30957	30966		10.1074/jbc.M604469200	http://dx.doi.org/10.1074/jbc.M604469200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912043	hybrid			2022-12-25	WOS:000241075900072
J	Mackenzie, J; Pedersen, L; Arent, S; Henriksen, A				Mackenzie, Jenny; Pedersen, Lise; Arent, Susan; Henriksen, Anette			Controlling electron transfer in acyl-CoA oxidases and dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIUM-CHAIN; CRYSTAL-STRUCTURES; BETA-OXIDATION; 3-DIMENSIONAL STRUCTURE; LIVER MITOCHONDRIA; RAT-LIVER; SUBSTRATE; ENZYME; PURIFICATION; MECHANISM	Plants produce a unique peroxisomal short chain-specific acyl-CoA oxidase (ACX4) for beta-oxidation of lipids. The short chain-specific oxidase has little resemblance to other peroxisomal acyl-CoA oxidases but has an similar to 30% sequence identity to mitochondrial acyl-CoA dehydrogenases. Two biochemical features have been linked to structural properties by comparing the structures of short chain-specific Arabidopsis thaliana ACX4 with and without a substrate analogue bound in the active site to known acyl-CoA oxidases and dehydrogenase structures: (i) a solvent-accessible acyl binding pocket is not required for oxygen reactivity, and (ii) the oligomeric state plays a role in substrate pocket architecture but is not linked to oxygen reactivity. The structures indicate that the acyl-CoA oxidases may encapsulate the electrons for transfer to molecular oxygen by blocking the dehydrogenase substrate interaction site with structural extensions. A small binding pocket observed adjoining the flavin adenine dinucleotide N5 and C4a atoms could increase the number of productive encounters between flavin adenine dinucleotide and O-2.	Carlsberg Lab, Biostruct Grp, DK-2500 Copenhagen, Denmark		Henriksen, A (corresponding author), Carlsberg Lab, Biostruct Grp, G Carlsberg Vej 10, DK-2500 Copenhagen, Denmark.	anette@crc.dk		Henriksen, Anette/0000-0003-4051-5079; Pedersen, Lise/0000-0002-0057-208X				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Adham AR, 2005, PLANT J, V41, P859, DOI 10.1111/j.1365-313X.2005.02343.x; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; AOYAMA T, 1994, J BIOL CHEM, V269, P19088; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bansal M, 2000, J BIOMOL STRUCT DYN, V17, P811, DOI 10.1080/07391102.2000.10506570; Battaile KP, 2004, J BIOL CHEM, V279, P16526, DOI 10.1074/jbc.M400034200; Battaile KP, 2002, J BIOL CHEM, V277, P12200, DOI 10.1074/jbc.M111296200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Castillo MC, 2004, PLANT PHYSIOL, V135, P85, DOI 10.1104/pp.104.039925; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; De Bellis L, 2000, PLANT PHYSIOL, V123, P327, DOI 10.1104/pp.123.1.327; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; Eastmond PJ, 2000, BIOCHEM SOC T, V28, P755, DOI 10.1042/BST0280755; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Fu ZJ, 2004, BIOCHEMISTRY-US, V43, P9674, DOI 10.1021/bi049290c; Ghisla S, 2004, EUR J BIOCHEM, V271, P494, DOI 10.1046/j.1432-1033.2003.03946.x; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Graham IA, 2002, PROG LIPID RES, V41, P156, DOI 10.1016/S0163-7827(01)00022-4; Hayashi H, 1999, J BIOL CHEM, V274, P12715, DOI 10.1074/jbc.274.18.12715; Hoard-Fruchey HM, 2004, J BIOL CHEM, V279, P13786, DOI 10.1074/jbc.M313914200; Hooks MA, 1999, PLANT J, V20, P1, DOI 10.1046/j.1365-313X.1999.00559.x; IKEDA Y, 1985, J BIOL CHEM, V260, P1326; IZAI K, 1992, J BIOL CHEM, V267, P1027; JIANG ZY, 1983, BIOCHEMISTRY-US, V22, P3752, DOI 10.1021/bi00285a006; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KLEYWEGT GJ, 2001, INT TABLES CRYSTALLO, VF; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; Lee HJ, 1996, BIOCHEMISTRY-US, V35, P12412, DOI 10.1021/bi9607867; LESLIE A, 1999, MOSFLM; Li CY, 2005, PLANT CELL, V17, P971, DOI 10.1105/tpc.104.029108; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakajima Y, 2002, J BIOCHEM, V131, P365, DOI 10.1093/oxfordjournals.jbchem.a003111; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; Pedersen L, 2005, J MOL BIOL, V345, P487, DOI 10.1016/j.jmb.2004.10.062; Pedersen L, 2004, ACTA CRYSTALLOGR D, V60, P1125, DOI 10.1107/S0907444904007577; PEDERSEN L, 2004, THESIS U COPENHAGEN; Satoh A, 2003, J BIOCHEM, V134, P297, DOI 10.1093/jb/mvg143; Souri M, 1998, J BIOL CHEM, V273, P4227, DOI 10.1074/jbc.273.7.4227; Souri M, 1998, FEBS LETT, V426, P187, DOI 10.1016/S0014-5793(98)00343-3; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; Toogood HS, 2004, J BIOL CHEM, V279, P32904, DOI 10.1074/jbc.M404884200; Umhau S, 2000, P NATL ACAD SCI USA, V97, P12463, DOI 10.1073/pnas.97.23.12463; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; WANG R, 1991, BIOCHEMISTRY-US, V30, P7895, DOI 10.1021/bi00246a004; WANG R, 1991, ARCH BIOCHEM BIOPHYS, V286, P504, DOI 10.1016/0003-9861(91)90072-Q; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	54	17	18	4	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31012	31020		10.1074/jbc.M603405200	http://dx.doi.org/10.1074/jbc.M603405200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16887802	hybrid			2022-12-25	WOS:000241075900077
J	Ronnebaum, SM; Ilkayeva, O; Burgess, SC; Joseph, JW; Lu, D; Stevens, RD; Becker, TC; Sherry, AD; Newgard, CB; Jensen, MV				Ronnebaum, Sarah M.; Ilkayeva, Olga; Burgess, Shawn C.; Joseph, Jamie W.; Lu, Danhong; Stevens, Robert D.; Becker, Thomas C.; Sherry, A. Dean; Newgard, Christopher B.; Jensen, Mette V.			A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; METABOLIC COUPLING FACTORS; NMR ISOTOPOMER ANALYSIS; MALONYL-COA; PENTOSE CYCLE; ISLETS; ANAPLEROSIS; SHUTTLE; MITOCHONDRIA; SUPPRESSION	Glucose-stimulated insulin secretion (GSIS) from pancreatic islet beta-cells is central to control of mammalian fuel homeostasis. Glucose metabolism mediates GSIS in part via ATP-regulated K+ (K-ATP) channels, but multiple lines of evidence suggest participation of other signals. Here we investigated the role of cytosolic NADP-dependent isocitrate dehydrogenase (ICDc) in control of GSIS in beta-cells. Delivery of small interfering RNAs specific for ICDc caused impairment of GSIS in two independent robustly glucose-responsive rat insulinoma (INS-1-derived) cell lines and in primary rat islets. Suppression of ICDc also attenuated the glucose-induced increments in pyruvate cycling activity and in NADPH levels, a predicted by-product of pyruvate cycling pathways, as well as the total cellular NADP( H) content. Metabolic profiling of eight organic acids in cell extracts revealed that suppression of ICDc caused increases in lactate production in both INS-1-derived cell lines and primary islets, consistent with the attenuation of pyruvate cycling, with no significant changes in other intermediates. Based on these studies, we propose that a pyruvate cycling pathway involving ICDc plays an important role in control of GSIS.	Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27704 USA; Univ Texas, SW Med Ctr, Ralph & Mary Nell Rogers NMR Ctr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Adv Imaging Res Ctr, Dept Radiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	Duke University; Duke University; Duke University; Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Newgard, CB (corresponding author), Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Independence Pk Facil,4321 Med Pk Dr,Ste 200, Durham, NC 27704 USA.	newga002@mc.duke.edu	; Sherry, Dean/P-2348-2018	Ronnebaum, Sarah/0000-0003-4787-754X; Sherry, Dean/0000-0001-7150-8301	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42583, DK58398] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amin R, 2002, J PHARMACOL EXP THER, V303, P82, DOI 10.1124/jpet.102.036160; Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT F M, 1991, Current Opinion in Cell Biology, V3, P671, DOI 10.1016/0955-0674(91)90040-6; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; Bain JR, 2004, DIABETES, V53, P2190, DOI 10.2337/diabetes.53.9.2190; Boucher A, 2004, J BIOL CHEM, V279, P27263, DOI 10.1074/jbc.M401167200; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; Chouinard SW, 2000, RECEPTOR CHANNEL, V7, P237; Cline GW, 2004, J BIOL CHEM, V279, P44370, DOI 10.1074/jbc.M311842200; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Henquin JC, 2004, DIABETES, V53, pS48, DOI 10.2337/diabetes.53.suppl_3.S48; Herrero L, 2005, DIABETES, V54, P462, DOI 10.2337/diabetes.54.2.462; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; Ivarsson R, 2005, DIABETES, V54, P2132, DOI 10.2337/diabetes.54.7.2132; Jensen MV, 2006, J BIOL CHEM, V281, P22342, DOI 10.1074/jbc.M604350200; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; Kim JY, 2002, AM J PHYSIOL-ENDOC M, V282, pE1014, DOI 10.1152/ajpendo.00233.2001; Lee SH, 2004, INT J RADIAT BIOL, V80, P635, DOI 10.1080/09553000400007680; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MacDonald MJ, 2000, J BIOL CHEM, V275, P34025, DOI 10.1074/jbc.C000411200; MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004; MACDONALD MJ, 1992, HORM METAB RES, V24, P158, DOI 10.1055/s-2007-1003284; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MacDonald MJ, 2003, METABOLISM, V52, P993, DOI 10.1016/S0026-0495(03)00149-5; MacDonald MJ, 2003, BBA-GEN SUBJECTS, V1619, P77, DOI 10.1016/S0304-4165(02)00443-9; MacDonald MJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE302, DOI 10.1152/ajpendo.00041.2002; MacDonald PE, 2003, DIABETOLOGIA, V46, P1046, DOI 10.1007/s00125-003-1159-8; MacDonald PE, 2003, J PHYSIOL-LONDON, V546, P647, DOI 10.1113/jphysiol.2002.035709; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; Minich T, 2003, J NEUROCHEM, V86, P605, DOI 10.1046/j.1471-4159.2003.01871.x; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; NABER SP, 1980, DIABETOLOGIA, V19, P439, DOI 10.1007/BF00281823; Newgard CB, 2002, DIABETES, V51, pS389, DOI 10.2337/diabetes.51.2007.S389; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Rabaglia ME, 2005, AM J PHYSIOL-ENDOC M, V289, pE218, DOI 10.1152/ajpendo.00573.2004; Ramanadham S, 2002, BBA-MOL CELL BIOL L, V1580, P40, DOI 10.1016/S1388-1981(01)00189-5; Schisler JC, 2005, P NATL ACAD SCI USA, V102, P7297, DOI 10.1073/pnas.0502168102; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SNYDER PJ, 1970, AM J PHYSIOL, V219, P876, DOI 10.1152/ajplegacy.1970.219.4.876; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; WATKINS DT, 1977, ENDOCRINOLOGY, V100, P1461, DOI 10.1210/endo-100-5-1461	52	179	181	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30593	30602		10.1074/jbc.M511908200	http://dx.doi.org/10.1074/jbc.M511908200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912049	hybrid			2022-12-25	WOS:000241075900035
J	Shulga, N; Pastorino, JG				Shulga, Nataly; Pastorino, John G.			Acyl coenzyme A-binding protein augments Bid-induced mitochondrial damage and cell death by activating mu-calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; BCL-2 FAMILY; PERMEABILITY TRANSITION; BAX; CLEAVAGE; ISCHEMIA/REPERFUSION; RETICULUM; RECEPTORS; PATHWAYS	Activation of calpain has been shown to occur in some contexts of cell injury and to be essential for loss of cell viability. Part of this may be mediated at the mitochondrial level. It has been demonstrated that calpain activity is necessary for the complete discharge of apoptosis-inducing factor from the mitochondrial intermembrane space and can cause the cleavage of full-length Bid to a more potent truncated form (Polster, B. M., Basanez, G., Etxebarria, A., Hardwick, J. M., and Nicholls, D. G. ( 2005) J. Biol. Chem. 280, 6447 - 6454). In this study, we identify acyl-CoA-binding protein ( ACBP) as playing a critical role in the activation of calpain upon exposure of mitochondria to both full-length Bid and truncated Bid (t-Bid). Suppression of ACBP levels by small interfering RNA inhibited the t-Bid-induced activation of mitochondrial mu-calpain and release of apoptosis-inducing factor from the mitochondrial intermembrane space and the cleavage of full-length Bid to t-Bid. Moreover, ACBP required the presence of the peripheral benzodiazepine receptor ( for which ACBP is a ligand) to be retained at the mitochondria, to activate mu-calpain, and to amplify Bid-induced mitochondrial damage.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA	Jefferson University	Pastorino, JG (corresponding author), Thomas Jefferson Univ, Dept Pathol, Jefferson Alumni Hall,Rm 272,1020 Locust St, Philadelphia, PA 19107 USA.	John.Pastorino@jefferson.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K01AA000330, R01AA012897] Funding Source: NIH RePORTER; NIAAA NIH HHS [1R01 AA012897-05, 5K01 AA000330-05] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Beurdeley-Thomas A, 2000, J NEURO-ONCOL, V46, P45, DOI 10.1023/A:1006456715525; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Fulceri R, 1997, BIOCHEM J, V325, P423, DOI 10.1042/bj3250423; Garcia M, 2005, BIOCHEM BIOPH RES CO, V338, P1241, DOI 10.1016/j.bbrc.2005.10.081; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; KNUDSEN J, 1993, MOL CELL BIOCHEM, V123, P129, DOI 10.1007/BF01076484; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Melloni E, 2000, J BIOL CHEM, V275, P82, DOI 10.1074/jbc.275.1.82; Neess D, 2006, MOL CELL BIOCHEM, V284, P149, DOI 10.1007/s11010-005-9039-9; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Petrescu AD, 2003, J BIOL CHEM, V278, P51813, DOI 10.1074/jbc.M303858200; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; ROUCOU X, 2000, BIOCHEM J, V368, P915; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Van Loo G, 2002, CELL DEATH DIFFER, V9, P301, DOI 10.1038/sj.cdd.4400966; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yin XM, 2006, GENE, V369, P7, DOI 10.1016/j.gene.2005.10.038; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030	34	28	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30824	30833		10.1074/jbc.M602503200	http://dx.doi.org/10.1074/jbc.M602503200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16908521	hybrid			2022-12-25	WOS:000241075900058
J	Wang, W; Kirsch, T				Wang, Wei; Kirsch, Thorsten			Annexin V/beta 5 integrin interactions regulate apoptosis of growth plate chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HORMONE-RELATED PEPTIDE; PROGRAMMED CELL-DEATH; ANNEXIN-V; ARTICULAR-CARTILAGE; ENDOCHONDRAL OSSIFICATION; TERMINAL DIFFERENTIATION; OSTEOARTHRITIC CARTILAGE; MATRIX VESICLES; PKC-ALPHA	Apoptosis of terminally differentiated chondrocytes allows the replacement of growth plate cartilage by bone. Despite its importance, little is known about the regulation of chondrocyte apoptosis. We show that overexpression of annexin V, which binds to the cytoplasmic domain of beta 5 integrin and protein kinase C alpha(PKC alpha), stimulates apoptotic events in hypertrophic growth plate chondrocytes. To determine whether the balance between the interactions of annexin V/beta 5 integrin and annexin V/active PKC alpha play a role in the regulation of terminally differentiated growth plate chondrocyte apoptosis, a peptide mimic of annexin V ( Penetratin (Pen)-VVISYSMPD) that binds to beta 5 integrin but not to PKC alpha was used. This peptide stimulated apoptotic events in growth plate chondrocytes. Suppression of annexin V expression using small interfering ribonucleic acid decreased caspase-3 activity and increased cell viability in Pen-VVISYSMPD-treated growth plate chondrocytes. An activator of PKC resulted in a further decrease of cell viability and further increase of caspase-3 activity in Pen-VVISYSMPD-treated growth plate chondrocytes, whereas inhibitors of PKC alpha led to an increase of cell viability and decrease of caspase-3 activity of Pen-VVISYSMPD-treated cells. These findings suggest that binding of annexin V to active PKC alpha stimulates apoptotic events in growth plate chondrocytes and that binding of annexin V to beta 5 integrin controls these interactions and ultimately apoptosis.	Univ Maryland, Dept Orthoped, Sch Med, Musculoskeletal Res Labs, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Kirsch, T (corresponding author), Univ Maryland, Dept Orthoped, Sch Med, Musculoskeletal Res Labs, 20 Penn St HSFII S003D, Baltimore, MD 21201 USA.	tkirsch@umoa.umm.edu	Kirsch, Thorsten/GQP-1157-2022		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049074, R01AR046245] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR049074, AR046245] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; ANNEFELD M, 1992, PATHOL RES PRACT, V188, P649, DOI 10.1016/S0344-0338(11)80073-7; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; Cardo-Vila M, 2003, MOL CELL, V11, P1151, DOI 10.1016/S1097-2765(03)00138-2; Chen CT, 2001, J ORTHOPAED RES, V19, P703, DOI 10.1016/S0736-0266(00)00066-8; Chrysis D, 2003, J ENDOCRINOL, V176, P331, DOI 10.1677/joe.0.1760331; de Thonel A, 2001, BLOOD, V98, P3770, DOI 10.1182/blood.V98.13.3770; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Dubois T, 1998, BIOCHEM J, V330, P1277, DOI 10.1042/bj3301277; Gibson G, 1998, MICROSC RES TECHNIQ, V43, P191, DOI 10.1002/(SICI)1097-0029(19981015)43:2<191::AID-JEMT10>3.0.CO;2-T; GIBSON GJ, 1995, DEV DYNAM, V203, P468, DOI 10.1002/aja.1002030409; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1266, DOI 10.1002/1529-0131(199807)41:7<1266::AID-ART18>3.0.CO;2-Y; HATORI M, 1995, J BONE MINER RES, V10, P1960, DOI 10.1002/jbmr.5650101216; Hausler G, 2002, CALCIFIED TISSUE INT, V71, P212, DOI 10.1007/s00223-001-2083-x; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; Horton WE, 1998, MATRIX BIOL, V17, P107, DOI 10.1016/S0945-053X(98)90024-5; Huang XZ, 2000, MOL CELL BIOL, V20, P755, DOI 10.1128/MCB.20.3.755-759.2000; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; Jao HC, 2001, SHOCK, V15, P130, DOI 10.1097/00024382-200115020-00009; Johnson KA, 2005, J BIOL CHEM, V280, P15004, DOI 10.1074/jbc.M500962200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; Kirsch T, 2000, OSTEOARTHR CARTILAGE, V8, P294, DOI 10.1053/joca.1999.0304; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; Kirsch T, 2003, J BONE MINER RES, V18, P1872, DOI 10.1359/jbmr.2003.18.10.1872; Le Gat L, 2001, CELL COMMUN ADHES, V8, P99; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Mollenhauer J, 1999, J HISTOCHEM CYTOCHEM, V47, P209, DOI 10.1177/002215549904700209; Nakashima S, 2002, J BIOCHEM, V132, P669, DOI 10.1093/oxfordjournals.jbchem.a003272; Ostergaard K, 1998, ANN RHEUM DIS, V57, P303, DOI 10.1136/ard.57.5.303; ROTHHUT B, 1995, EUR J BIOCHEM, V232, P865; SCHLAEPFER DD, 1992, BIOCHEMISTRY-US, V31, P1886, DOI 10.1021/bi00121a043; Spitaler M, 1999, ANTICANCER RES, V19, P3969; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; Tchetina EV, 2005, J RHEUMATOL, V32, P876; Wang W, 2003, J BIOL CHEM, V278, P3762, DOI 10.1074/jbc.M208868200; Wang W, 2002, J CELL BIOL, V157, P1061, DOI 10.1083/jcb.200203014; Wang W, 2005, EXP CELL RES, V305, P156, DOI 10.1016/j.yexcr.2004.12.022	39	31	35	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30848	30856		10.1074/jbc.M605937200	http://dx.doi.org/10.1074/jbc.M605937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16914549	hybrid			2022-12-25	WOS:000241075900060
J	Yegutkin, GG; Samburski, SS; Jalkanen, S; Novak, I				Yegutkin, Gennady G.; Samburski, Sergei S.; Jalkanen, Sirpa; Novak, Ivana			ATP-consuming and ATP-generating enzymes secreted by pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHOKINASE; PHOSPHOTRANSFER REACTIONS; CONFOCAL MICROSCOPY; ENDOTHELIAL-CELLS; EXOCRINE PANCREAS; ADENYLATE KINASE; AIRWAY SURFACES; RAT PANCREAS; DIPHOSPHOHYDROLASE; IDENTIFICATION	Pancreatic acini release ATP in response to various stimuli, including cholecystokinin octapeptide (CCK-8), as we show in the present study. There were indications that pancreatic juice also contains enzymes that could hydrolyze ATP during its passage through the ductal system. The aim of this study was to determine which ATP-degrading and possibly ATP-generating enzymes were present in pancreatic secretion. For this purpose, pancreatic juice was collected from anesthetized rats stimulated with infusion of CCK-8. Purine-converting activities in juice samples were assayed by TLC using either [gamma-P-32] ATP or C-14/H-3-labeled and unlabeled nucleotides as appropriate substrates. Data show that the juice contains the enzyme ecto-nucleoside triphosphate diphosphohydrolase that can hydrolyze both [C-14]ATP and [H-3]ADP about equally well, i.e. CD39. Reverse-phase high-performance liquid chromatography analysis additionally shows that this enzyme has broad substrate specificity toward other nucleotides, UTP, UDP, ITP, and IDP. In addition, secretion contains ecto-5'-nucleotidase, CD73, further converting [H-3]AMP to adenosine. Along with highly active hydrolytic enzymes, there were also ATP-generating enzymes in pancreatic juice, adenylate kinase, and NDP kinase, capable of sequentially phosphorylating AMP via ADP to ATP. Activities of nonspecific phosphatases, nucleotide pyrophosphatase/phosphodiesterases, and adenosine deaminase were negligible. Taken together, CCK-8 stimulation of pancreas causes release of both ATP-consuming and ATP-generating enzymes into pancreatic juice. This newly discovered richness of secreted enzymes underscores the importance of purine signaling between acini and pancreatic ducts lumen and implies regulation of the purine-converting enzymes release.	Univ Copenhagen, Inst Mol Biol & Physiol, DK-2100 Copenhagen 0, Denmark; Turku Univ, MediCity Res Lab, FIN-2050 Turku, Finland; Turku Univ, Dept Med Microbiol, FIN-2050 Turku, Finland; Natl Publ Hlth Inst, FIN-2050 Turku, Finland	University of Copenhagen; University of Turku; University of Turku; Finland National Institute for Health & Welfare	Novak, I (corresponding author), Univ Copenhagen, Inst Mol Biol & Physiol, August Krogh Bldg,Universitetsparken 13, DK-2100 Copenhagen 0, Denmark.	inovak@aki.ku.dk	Yegutkin, Gennady G./K-3815-2014; Novak, Ivana/M-2791-2014	Yegutkin, Gennady G./0000-0001-6684-7982; Novak, Ivana/0000-0002-8917-8010				Airas L, 1997, J CELL BIOL, V136, P421, DOI 10.1083/jcb.136.2.421; Bigonnesse F, 2004, BIOCHEMISTRY-US, V43, P5511, DOI 10.1021/bi0362222; Braun N, 2000, BIOCHEM J, V351, P639, DOI 10.1042/0264-6021:3510639; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Dorsam RT, 2004, J CLIN INVEST, V113, P340, DOI 10.1172/JCI200420986; Goding JW, 2003, BBA-MOL BASIS DIS, V1638, P1, DOI 10.1016/S0925-4439(03)00058-9; HAMLYN JM, 1983, BIOCHEM J, V214, P59, DOI 10.1042/bj2140059; HARPER F, 1978, CAN J BIOCHEM CELL B, V56, P565, DOI 10.1139/o78-086; Hede SE, 1999, J BIOL CHEM, V274, P31784, DOI 10.1074/jbc.274.45.31784; Henttinen T, 2003, J BIOL CHEM, V278, P24888, DOI 10.1074/jbc.M300779200; Hugel B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/physiol.00029.2004; JANSEN JWCM, 1980, BIOCHIM BIOPHYS ACTA, V599, P315, DOI 10.1016/0005-2736(80)90077-2; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kittel A, 2004, J HISTOCHEM CYTOCHEM, V52, P861, DOI 10.1369/jhc.3A6167.2004; Kittel A, 2002, J HISTOCHEM CYTOCHEM, V50, P549, DOI 10.1177/002215540205000412; Kordas KS, 2004, PANCREAS, V29, P53, DOI 10.1097/00006676-200407000-00056; Kukulski F, 2005, Purinergic Signal, V1, P193, DOI 10.1007/s11302-005-6217-x; LALIBERTE JF, 1982, J BIOL CHEM, V257, P3869; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; LEBEL D, 1986, BIOCHEM CELL BIOL, V64, P13, DOI 10.1139/o86-003; MARTEAU C, 1993, DIGEST DIS SCI, V38, P2090, DOI 10.1007/BF01297090; Novak I, 2002, CELL PHYSIOL BIOCHEM, V12, P83, DOI 10.1159/000063784; Novak I, 2003, NEWS PHYSIOL SCI, V18, P12, DOI 10.1152/nips.01409.2002; Picher M, 2003, J BIOL CHEM, V278, P11256, DOI 10.1074/jbc.M208071200; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; Sevigny J, 1998, AM J PHYSIOL-GASTR L, V275, pG473, DOI 10.1152/ajpgi.1998.275.3.G473; Sorensen CE, 2003, J PHYSIOL-LONDON, V551, P881, DOI 10.1113/jphysiol.2003.049411; Sorensen CE, 2001, J BIOL CHEM, V276, P32925, DOI 10.1074/jbc.M103313200; UCHIYAMA Y, 1983, CELL TISSUE RES, V230, P411; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; Yegutkin GG, 2003, FASEB J, V17, P1328, DOI 10.1096/fj.02-1136fje; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	35	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29441	29447		10.1074/jbc.M602480200	http://dx.doi.org/10.1074/jbc.M602480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16885159	hybrid			2022-12-25	WOS:000240896300006
J	Joe, YS; Jeong, JH; Yang, S; Kang, H; Motoyama, N; Pandolfi, PP; Chung, JH; Kim, MK				Joe, YeonSoo; Jeong, Jae-Hoon; Yang, Shutong; Kang, Hyeog; Motoyama, Noburu; Pandolfi, Pier Paolo; Chung, Jay H.; Kim, Myung K.			ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT PROTEIN-KINASE; DNA-DAMAGE CHECKPOINT; ATAXIA-TELANGIECTASIA; HISTONE H2AX; CELL-LINES; ACTIVATION; PHOSPHORYLATION; PATHWAY; P53	Arsenic trioxide (ATO) is a potent anti-leukemic chemotherapeutic agent for acute promyelocytic leukemia (APL) that results from a t (15, 17) chromosomal translocation that produces PML-RAR alpha, a fusion protein between a tumor suppressor PML and the retinoic acid receptor RAR alpha. APL patients are initially treated with retinoic acid, but most develop resistance and relapse. In contrast, ATO induces prolonged remissions even in the relapsed cases. However, the molecular mechanisms by which ATO kills the leukemic cells are not fully understood. We find that ATO induces apoptosis, at least in part, by activating proapoptotic kinase Chk2. ATO does this by stimulating ATR (ataxia telangiectasia mutated and Rad3-related) kinase, a Chk2-activating kinase. In conjunction, ATO degrades PML-RAR alpha, resulting in the restoration of PML, which is required for autophosphorylation and full activation of Chk2. As a result, the p53-dependent apoptosis pathway is activated. Based on this, we propose that a pathway composed of ATR, PML, Chk2, and p53 plays a role in ATO-mediated apoptosis, a notion that is consistent with the observation that Chk2 is genetically intact and mutations in the p53 gene are extremely rare in APL.	Natl Inst Hlth, NHLBI, Lab Biochem Genet, Bethesda, MD 20892 USA; Natl Inst Longev Sci, Dept Geriatr Res, Obu, Aichi 4748522, Japan; Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chung, JH (corresponding author), Natl Inst Hlth, NHLBI, Lab Biochem Genet, Bldg 10,Rm 7D14,10 Ctr Dr, Bethesda, MD 20892 USA.	ChungJ@nhlbi.nih.gov; KimM@nhlbi.nih.gov		kang, hyeog/0000-0001-8935-1103	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002243, Z01HL002243] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown EJ, 2000, GENE DEV, V14, P397; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen GQ, 1997, BLOOD, V89, P3345; Davison K, 2004, BLOOD, V103, P3496, DOI 10.1182/blood-2003-05-1412; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Fojo T, 2002, CELL CYCLE, V1, P183, DOI 10.4161/cc.1.3.123; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Gurrieri C, 2004, BLOOD, V103, P2358, DOI 10.1182/blood-2003-07-2200; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Li J, 2005, J BIOL CHEM, V280, P12041, DOI 10.1074/jbc.M412445200; Liu QH, 2000, GENE DEV, V14, P1448; LONGO L, 1993, LEUKEMIA LYMPHOMA, V11, P405, DOI 10.3109/10428199309067933; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rojewski MT, 2002, BRIT J HAEMATOL, V116, P555, DOI 10.1046/j.0007-1048.2001.03298.x; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Verma A, 2002, J BIOL CHEM, V277, P44988, DOI 10.1074/jbc.M207176200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; YANG S, 2006, J BIOL CHEM; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	38	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28764	28771		10.1074/jbc.M604392200	http://dx.doi.org/10.1074/jbc.M604392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16891316	hybrid			2022-12-25	WOS:000240680500030
J	Koivunen, P; Hirsila, M; Kivirikko, KI; Myllyharju, J				Koivunen, Peppi; Hirsila, Maija; Kivirikko, Kari I.; Myllyharju, Johanna			The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN SENSING PATHWAY; PROLINE HYDROXYLATION; HIF-ALPHA; HYDROXYPROLINE; HIF-1-ALPHA; FAMILY; RECOGNITION; DESTRUCTION; SUBUNIT; DOMAINS	Three hypoxia-inducible factor prolyl 4-hydroxylases (HIF-P4Hs) regulate the HIFs by hydroxylating prolines at two separate sites in the oxygen-dependent degradation domain (ODDD) of their alpha subunits. We compared in vitro hydroxylation by purified recombinant human HIF-P4Hs of 19-20- and 35-residue peptides corresponding to the two sites in HIF-alpha s and purified recombinant HIF-1 alpha and HIF-2 alpha ODDDs of 248 and 215 residues. The increase in the length of peptides representing the C-terminal site from 19 to 20 to 35 residues reduced the K-m values to 90-800 nM, i.e. to 0.7-11% of those for the shorter peptides, whereas those representing the N-terminal site were 10-470 mu M, i.e. 10-135%. The K-m values of HIF-P4H-1 for the recombinant HIF-alpha ODDDs were 10-20 nM, whereas those of HIF-P4H-2 and -3 were 60-140 nM, identical values being found for the wild-type HIF-1 alpha ODDD and its N site mutant. The K-m values for the C site mutant were about 5-10 times higher but only 0.2-3% of those for the 35-residue N site peptides, and this marked difference suggested that the HIF-P4Hs may become bound first to the C-terminal site of an ODDD and that this binding may enhance subsequent binding to the N-terminal site. The K-m values of HIF-P4H-2 for oxygen determined with the HIF-1 alpha ODDD and both its mutants as substrates were all about 100 mu M, being 40% of those reported for the three HIF-P4Hs with a 19-residue peptide. Even this value is high compared with tissue O-2 levels, indicating that HIF-P4Hs are effective oxygen sensors.	Univ Oulu, Collagen Res Unit, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu	Myllyharju, J (corresponding author), Univ Oulu, Collagen Res Unit, Bioctr Oulu, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						ACKER H, 2003, OXYGEN SENSING RESPO, P507; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; DEJONG L, 1984, BIOCHIM BIOPHYS ACTA, V787, P105; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2005, FASEB J, V19, P1308, DOI 10.1096/fj.04-3399fje; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JUVA K, 1966, ANAL BIOCHEM, V15, P77, DOI 10.1016/0003-2697(66)90249-1; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kageyama Y, 2004, FASEB J, V18, P1028, DOI 10.1096/fj.03-1233fje; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Kukkola L, 2004, J BIOL CHEM, V279, P18656, DOI 10.1074/jbc.M401514200; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Li DX, 2004, J BIOL CHEM, V279, P55051, DOI 10.1074/jbc.M410287200; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	34	111	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28712	28720		10.1074/jbc.M604628200	http://dx.doi.org/10.1074/jbc.M604628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16885164	hybrid			2022-12-25	WOS:000240680500024
J	Smid, O; Horakova, E; Vilimova, V; Hrdy, I; Cammack, R; Horvath, A; Lukes, J; Tachezy, J				Smid, Ondrej; Horakova, Eva; Vilimova, Vanda; Hrdy, Ivan; Cammack, Richard; Horvath, Anton; Lukes, Julius; Tachezy, Jan			Knock-downs of iron-sulfur cluster assembly proteins IscS and IscU down-regulate the active mitochondrion of procyclic Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; RNA INTERFERENCE; TRICHOMONAS-VAGINALIS; SCAFFOLD PROTEIN; GENE-EXPRESSION; BIOGENESIS; EUKARYOTES; MATURATION; GENOME; HYDROGENOSOMES	Transformation of the metabolically down-regulated mitochondrion of the mammalian bloodstream stage of Trypanosoma brucei to the ATP-producing mitochondrion of the insect procyclic stage is accompanied by the de novo synthesis of citric acid cycle enzymes and components of the respiratory chain. Because these metabolic pathways contain multiple iron-sulfur (FeS) proteins, their synthesis, including the formation of FeS clusters, is required. However, nothing is known about FeS cluster biogenesis in trypanosomes, organisms that are evolutionarily distant from yeast and humans. Here we demonstrate that two mitochondrial proteins, the cysteine desulfurase TbiscS and the metallochaperone TbiscU, are functionally conserved in trypanosomes and essential for this parasite. Knock-downs of TbiscS and TbiscU in the procyclic stage by means of RNA interference resulted in reduced activity of the marker FeS enzyme aconitase in both the mitochondrion and cytosol because of the lack of FeS clusters. Moreover, down-regulation of TbiscS and TbiscU affected the metabolism of procyclic T. brucei so that their mitochondria resembled the organelle of the bloodstream stage; mitochondrial ATP production was impaired, the activity of the respiratory chain protein complex ubiquinol-cytochrome-c reductase was reduced, and the production of pyruvate as an end product of glucose metabolism was enhanced. These results indicate that mitochondrial FeS cluster assembly is indispensable for completion of the T. brucei life cycle.	Charles Univ Prague, Dept Parasitol, Fac Sci, CR-12844 Prague 2, Czech Republic; Univ S Bohemia, Fac Biol, Ceske Budejovice 35007, Czech Republic; Acad Sci Czech Republ, Inst Parasitol, Ceske Budejovice 35007, Czech Republic; Comenius Univ, Fac Nat Sci, Bratislava 84215, Slovakia; Kings Coll London, Dept Life Sci, London WC2R 2LS, England	Charles University Prague; University of South Bohemia Ceske Budejovice; Czech Academy of Sciences; Comenius University Bratislava; University of London; King's College London	Tachezy, J (corresponding author), Charles Univ Prague, Dept Parasitol, Fac Sci, Vinicna 7, CR-12844 Prague 2, Czech Republic.	tachezy@natur.cuni.cz	Horakova, Eva/G-9322-2014; Janštová, Vanda/AAD-5465-2022; Horvath, Anton/I-3626-2014; Cammack, Richard/B-7841-2008; Horvath, Anton/V-1097-2018; Lukes, Julius/H-6760-2012; Horáková, Eva/AAD-9124-2021; Hrdý, Ivan/K-8931-2017; Janštová, Vanda/H-7107-2017	Janštová, Vanda/0000-0002-5950-5738; Horvath, Anton/0000-0003-0785-4204; Lukes, Julius/0000-0002-0578-6618; Horáková, Eva/0000-0002-3730-8979; Hrdý, Ivan/0000-0002-5595-9177; Janštová, Vanda/0000-0002-5950-5738				ACKRELL BAC, 1984, J BIOL CHEM, V259, P4015; Balk J, 2005, TRENDS PLANT SCI, V10, P324, DOI 10.1016/j.tplants.2005.05.002; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Besteiro S, 2005, TRENDS PARASITOL, V21, P185, DOI 10.1016/j.pt.2005.02.008; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; CALLENS M, 1992, MOL BIOCHEM PARASIT, V50, P235, DOI 10.1016/0166-6851(92)90220-E; Cavalier-Smith T, 2004, P ROY SOC B-BIOL SCI, V271, P1251, DOI 10.1098/rspb.2004.2705; Chaudhuri M, 1998, MOL BIOCHEM PARASIT, V95, P53, DOI 10.1016/S0166-6851(98)00091-7; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; Dolezal P, 2005, P NATL ACAD SCI USA, V102, P10924, DOI 10.1073/pnas.0500349102; Embley TM, 2006, NATURE, V440, P623, DOI 10.1038/nature04546; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Foldynova-Trantirkova S, 2005, INT J PARASITOL, V35, P359, DOI 10.1016/j.ijpara.2004.12.012; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Heise N, 1999, MOL BIOCHEM PARASIT, V99, P21, DOI 10.1016/S0166-6851(98)00176-5; Hendriks E, 2000, BIOCHEM SOC T, V28, P531, DOI 10.1042/bst0280531; Horvath A, 2005, MOL MICROBIOL, V58, P116, DOI 10.1111/j.1365-2958.2005.04813.x; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; LaGier MJ, 2003, MICROBIOL-SGM, V149, P3519, DOI 10.1099/mic.0.26365-0; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Lauhon CT, 2004, J BIOL CHEM, V279, P19551, DOI 10.1074/jbc.M401261200; Li KY, 2006, J BIOL CHEM, V281, P12344, DOI 10.1074/jbc.M600582200; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lukes J, 2005, CURR GENET, V48, P277, DOI 10.1007/s00294-005-0027-0; Michels PAM, 2005, MOL MEMBR BIOL, V22, P133, DOI 10.1080/09687860400024186; Motyka SA, 2004, CURR OPIN MICROBIOL, V7, P362, DOI 10.1016/j.mib.2004.06.004; Moyersoen J, 2003, EUR J BIOCHEM, V270, P2059, DOI 10.1046/j.1432-1033.2003.03582.x; Panigrahi AK, 2001, MOL CELL BIOL, V21, P6833, DOI 10.1128/MCB.21.20.6833-6840.2001; Regoes A, 2005, J BIOL CHEM, V280, P30557, DOI 10.1074/jbc.M500787200; Saas J, 2000, J BIOL CHEM, V275, P2745, DOI 10.1074/jbc.275.4.2745; Simpson AGB, 2004, CURR BIOL, V14, pR693, DOI 10.1016/j.cub.2004.08.038; Sutak R, 2004, P NATL ACAD SCI USA, V101, P10368, DOI 10.1073/pnas.0401319101; Tachezy J, 2001, MOL BIOL EVOL, V18, P1919, DOI 10.1093/oxfordjournals.molbev.a003732; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; Tovar J, 2003, NATURE, V426, P172, DOI 10.1038/nature01945; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; van Weelden SWH, 2005, J BIOL CHEM, V280, P12451, DOI 10.1074/jbc.M412447200; Vanacova S, 2001, MICROBIOL-UK, V147, P53; Vondruskova E, 2005, J BIOL CHEM, V280, P2429, DOI 10.1074/jbc.M405933200; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540	52	57	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28679	28686		10.1074/jbc.M513781200	http://dx.doi.org/10.1074/jbc.M513781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16882667	hybrid			2022-12-25	WOS:000240680500021
J	Ubeda, M; Rukstalis, JM; Habener, JF				Ubeda, Mariano; Rukstalis, J. Michael; Habener, Joel F.			Inhibition of cyclin-dependent kinase 5 activity protects pancreatic beta cells from glucotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; OXIDATIVE STRESS; GLUCOSE-CONCENTRATION; BINDING; EXPRESSION; CDK5; REDUCTION; MECHANISM; RIPE3B1	Type 2 diabetes (T2D) and Alzheimer disease are degenerative diseases that may share common pathophysiologic mechanisms. Neuronal dysfunction in Alzheimer patients has been linked to overactivity of the cyclin-dependent kinase 5 (CDK5) and its activator p35. Both of these proteins are expressed in the insulin-producing beta cells of the pancreas. Further, glucose enhances p35 gene expression, promoting the formation of active p35/CDK5 complexes that regulate the expression of the insulin gene. In T2D, chronic elevations of glucose, glucotoxicity, impair beta cell function. We therefore postulated that CDK5 and p35 may be responsible for this beta cell impairment and that inhibition of CDK5 might have a beneficial effect. To test this hypothesis, the pancreatic cell line INS-1 was selected as a known in vitro model of glucotoxicity, and roscovitine (10 mu M) was used as a CDK5 inhibitor. Chronic exposure of INS-1 cells to high glucose (20-30 mM) reduced both insulin mRNA levels and the activity of an insulin promoter reporter gene. Inhibition of CDK5 prevented this decrease of insulin gene expression. We used DNA binding (gel shift) assays and Western immunoblots to demonstrate that cellular levels of the transcription factor PDX-1, normally decreased by glucotoxicity, were preserved with CDK5 inhibition, as was the binding of PDX-1 to the insulin promoter. Analyses of nuclear and cytoplasmic PDX-1 protein levels revealed that CDK5 inhibition restores nuclear PDX-1, without affecting its cytoplasmic concentration, suggesting that CDK5 regulates the nuclear/cytoplasm partitioning of PDX-1. Using a Myc-tagged PDX-1 construct, we showed that the translocation of PDX-1 from the nucleus to the cytoplasm during glucotoxic conditions was prevented when CDK5 was inhibited. These studies indicate that CDK5 plays a role in the loss of beta cell function under glucotoxic conditions and that CDK5 inhibitors could have therapeutic value for T2D.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Endocrinol Lab, Boston, MA 02114 USA; Howard Hughes Med Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	Ubeda, M (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Endocrinol Lab, THEIR 320,55 Fruit St, Boston, MA 02114 USA.	jhabener@partners.org	Ubeda, Mariano/ABB-2691-2021		NIDDK NIH HHS [DK057521-06, DK55365] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055365, P30DK057521] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cruz JC, 2004, TRENDS MOL MED, V10, P452, DOI 10.1016/j.molmed.2004.07.001; Habener JF, 2002, DRUG NEWS PERSPECT, V15, P491, DOI 10.1358/dnp.2002.15.8.740224; Harmon JS, 2005, J BIOL CHEM, V280, P11107, DOI 10.1074/jbc.M410345200; Harmon JS, 1998, DIABETES, V47, P900, DOI 10.2337/diabetes.47.6.900; Kaiser N, 2003, J PEDIATR ENDOCR MET, V16, P5, DOI 10.1515/JPEM.2003.16.1.5; Kajimoto Y, 2004, ANN NY ACAD SCI, V1011, P168, DOI 10.1196/annals.1293.017; Kawamori D, 2003, DIABETES, V52, P2896, DOI 10.2337/diabetes.52.12.2896; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; Lim ACB, 2003, J ALZHEIMERS DIS, V5, P329, DOI 10.3233/JAD-2003-5409; Lu M, 1997, J BIOL CHEM, V272, P28349, DOI 10.1074/jbc.272.45.28349; Nguyen MD, 2003, NEUROSIGNALS, V12, P215, DOI 10.1159/000074623; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; Olson LK, 1998, MOL ENDOCRINOL, V12, P207, DOI 10.1210/me.12.2.207; Otth C, 2003, NEUROREPORT, V14, P2403, DOI 10.1097/00001756-200312190-00023; PARK BH, 1995, BIOCHEM BIOPH RES CO, V210, P1, DOI 10.1006/bbrc.1995.1619; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; Seufert J, 1998, J CLIN INVEST, V101, P2528, DOI 10.1172/JCI2401; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Srinivasan S, 2002, AM J PHYSIOL-ENDOC M, V283, pE784, DOI 10.1152/ajpendo.00177.2002; Strocchi P, 2003, J CELL BIOCHEM, V88, P758, DOI 10.1002/jcb.10391; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Tsai LH, 2004, BBA-PROTEINS PROTEOM, V1697, P137, DOI 10.1016/j.bbapap.2003.11.019; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258	25	102	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28858	28864		10.1074/jbc.M604690200	http://dx.doi.org/10.1074/jbc.M604690200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16887799	hybrid			2022-12-25	WOS:000240680500040
J	Pastural, E; Takahashi, N; Dong, WF; Bainbridge, M; Hull, A; Pearson, D; Huang, S; Lowsky, R; DeCoteau, JF; Geyer, CR				Pastural, E.; Takahashi, N.; Dong, W-F; Bainbridge, M.; Hull, A.; Pearson, D.; Huang, S.; Lowsky, R.; DeCoteau, J. F.; Geyer, C. R.			RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines	ONCOGENE			English	Article						chronic myeloid leukemia; RIZ1; IGF-1; histone methyltransferase	ZINC-FINGER PROTEIN; TUMOR-SUPPRESSOR GENE; ERYTHROID-DIFFERENTIATION; PR DOMAIN; HISTONE METHYLTRANSFERASE; BINDING; IDENTIFICATION; INACTIVATION; EXPRESSION; MUTATIONS	RIZ1 is a histone methyltransferase whose expression and activity are reduced in many cancers. In chronic myelogenous leukemia (CML), blastic transformation is associated with loss of heterozygosity in the region where RIZ1 is located and with decreased RIZ1 expression. Forced RIZ1 expression in model CML blast crisis (BC) cell lines decreases proliferation, increases apoptosis and enhances differentiation. We characterized molecular mechanisms that may contribute to potential CML tumor suppressor properties of RIZ1. Several RIZ1-regulated genes involved in insulin-like growth factor-1 (IGF-1) signaling were identified using cDNA microarrays. RIZ1 was shown to associate with promoter regions of IGF-1 and to increase histone H3 lysine 9 methylation using chromatin immunoprecipitation assays. IGF-1-blocking antibody was used to demonstrate the importance of autocrine IGF-1 signaling in CML-BC cell line viability. Forced RIZ1 expression in CML-BC cell lines decreases IGF-1 receptor activation and activation of downstream signaling components extracellular signal-regulated kinase 1/2 and AKT. These results highlight the therapeutic potential of inhibiting IGF-1 pathway in the acute phase of CML.	Univ Saskatchewan, Genom Med & Pathobiol Grp, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 0W0, Canada; Burnham Inst, Canc Genet & Epigenet Program, La Jolla, CA 92037 USA; Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; Sanford Burnham Prebys Medical Discovery Institute; Stanford University	DeCoteau, JF (corresponding author), Saskatoon Canc Ctr, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	john.decoteau@usask.ca; ron.geyer@usask.ca						Abbondanza C, 2000, P NATL ACAD SCI USA, V97, P3130, DOI 10.1073/pnas.050015697; Aro ALA, 2002, LEUKEMIA RES, V26, P831, DOI 10.1016/S0145-2126(02)00006-1; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Carling T, 2004, MOL CELL BIOL, V24, P7032, DOI 10.1128/MCB.24.16.7032-7042.2004; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; CHANG HW, 2004, INT J CANCER, V110, P212; Dong WF, 2003, BLOOD, V102, p579A; Du Y, 2001, CANCER RES, V61, P8094; Dumas AR, 2004, LEUKEMIA RES, V28, P1329, DOI 10.1016/j.leukres.2004.04.013; ENDO K, 1993, BRIT J HAEMATOL, V85, P653, DOI 10.1111/j.1365-2141.1993.tb03205.x; Francki A, 2003, J CELL BIOCHEM, V88, P802, DOI 10.1002/jcb.10424; Gazzerro P, 2006, EXP CELL RES, V312, P340, DOI 10.1016/j.yexcr.2005.11.002; HICKS DG, 1985, EXP HEMATOL, V13, P273; Hoeflich A, 2001, CANCER RES, V61, P8601; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Kang CD, 1999, EXP MOL MED, V31, P76, DOI 10.1038/emm.1999.13; Kim KC, 2003, CANCER RES, V63, P7619; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Medici N, 1999, BIOCHEM BIOPH RES CO, V264, P983, DOI 10.1006/bbrc.1999.1604; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x; PEPE MG, 1987, J CELL PHYSIOL, V133, P219, DOI 10.1002/jcp.1041330204; Piao Z, 2000, CANCER RES, V60, P4701; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SHAPIRO VS, 1995, GENE, V163, P329, DOI 10.1016/0378-1119(95)00420-B; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Takahashi N, 2005, BLOOD, V106, p352A; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Woessmann W, 2004, CELL BIOL INT, V28, P403, DOI 10.1016/j.cellbi.2004.03.009; Woessmann W, 2001, EXP CELL RES, V264, P193, DOI 10.1006/excr.2000.5124; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360	34	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1586	1594		10.1038/sj.onc.1209959	http://dx.doi.org/10.1038/sj.onc.1209959			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953217				2022-12-25	WOS:000244782500008
J	Oliva-Trastoy, M; Berthonaud, V; Chevalier, A; Ducrot, C; Marsolier-Kergoat, MC; Mann, C; Leteurtre, F				Oliva-Trastoy, M.; Berthonaud, V.; Chevalier, A.; Ducrot, C.; Marsolier-Kergoat, M-C; Mann, C.; Leteurtre, F.			The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase	ONCOGENE			English	Article						Wip1 oncogene; PPM1D; PPZC phosphatase; Chk2 tumour suppressor; DNA damage checkpoints	DNA-DAMAGE RESPONSE; PROTEIN PHOSPHATASE; IONIZING-RADIATION; PP2C PHOSPHATASES; CHECKPOINT; PHOSPHORYLATION; AUTOPHOSPHORYLATION; OLIGOMERIZATION; INACTIVATION; INTERACTS	We previously demonstrated that type 2C protein phosphatases (PP2C) Ptc2 and Ptc3 are required for DNA checkpoint inactivation after DNA double-strand break repair or adaptation in Saccharomyces cerevisiae. Here, we show the conservation of this pathway in mammalian cells. In response to DNA damage, ataxia telangiectasia mutated (ATM) phosphorylates the Chk2 tumour suppressor kinase at threonine 68 (Thr68), allowing Chk2 kinase dimerization and activation by autophosphorylations in the T-loop. The oncogenic protein Wip1, a PP2C phosphatase, binds Chk2 and dephosphorylates phospho-Thr68. Consequently, Wip1 opposes Chk2 activation by ATM after ionizing irradiation of cells. In HCT15 colorectal cancer cells corrected for functional Chk2 activity, Wip1 overexpression suppressed the contribution of Chk2 to the G2/M DNA damage checkpoint. These results indicate that Wip1 is one of the phosphatases regulating the activity of Chk2 in response to DNA damage.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol Joliot Curie, F-91191 Gif Sur Yvette, France; Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Uniformed Services University of the Health Sciences - USA	Mann, C (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 144, F-91191 Gif Sur Yvette, France.	carl.mann@cea.fr; francois.leteurtre@cea.fr		Mann, Carl/0000-0001-7212-1512; Francois, Leteurtre/0000-0001-7373-6180				Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Craig AL, 2004, ONCOGENE, V23, P8411, DOI 10.1038/sj.onc.1208035; Dozier C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Lee SB, 2001, CANCER RES, V61, P8062; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Liang XB, 2006, INT J MOL MED, V17, P703; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; NANNENGA B, 2006, IN PRESS MOL CARCINO; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Schweighofer A, 2004, TRENDS PLANT SCI, V9, P236, DOI 10.1016/j.tplants.2004.03.007; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	92	96	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1449	1458		10.1038/sj.onc.1209927	http://dx.doi.org/10.1038/sj.onc.1209927			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936775				2022-12-25	WOS:000244558800009
J	Ong, CK; Leong, C; Tan, PH; Van, T; Huynh, H				Ong, C. K.; Leong, C.; Tan, P. H.; Van, T.; Huynh, H.			The role of 5 ' untranslated region in translational suppression of OKL38 mRNA in hepatocellular carcinoma	ONCOGENE			English	Article						OKL38; hepatocellular carcinoma; cell death; 5 ' untranslated region; translational suppression	OPEN READING FRAMES; GROWTH INHIBITOR; EXPRESSION; CANCER; MECHANISMS; SEQUENCES; ELEMENT; GLAND; GENE	Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide. OKL38 is a pregnancy-induced growth inhibitory gene and its expression is lost in various breast cancer cell lines and kidney tumor. To determine the role of OKL38 expression in HCC, we investigated its expression in various HCC samples and liver cancer cell lines. Western blot analysis revealed that OKL38 protein was absent or reduced in 64.2% ( 18 of 28) of the HCCs examined and four liver cancer cell lines. Immunohistochemistry study demonstrated that OKL38 protein was undetectable in 41.3% ( 38 of 92) of HCC, whereas 39.1% ( 36 of 92) of HCC showed low expression of the protein. Lost or reduced expression level of OKL38 protein was significantly correlated to high tumor stages in HCC ( P = 0.0042). Overexpression of the OKL38 caused cell death in Chang liver cells. 50 Untranslated region (5'UTR) deletion studies demonstrated that OKL38 was downregulated via translation suppression associated with the 5'UTR of its mRNA. Taken together, the 5'UTRs of OKL38 might play an important role in downregulation of its protein and the absence of OKL38 could lead to the development or progression of HCC.	Natl Canc Ctr Singapore, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore; Singapore Gen Hosp, Dept Pathol, Singapore 0316, Singapore; Binh Dan Hosp, Ho Chi Minh City, Vietnam	National Cancer Centre Singapore (NCCS); Singapore General Hospital	Huynh, H (corresponding author), Natl Canc Ctr Singapore, Div Cellular & Mol Res, Mol Endocrinol Lab, 11 Hosp Dr, Singapore 169610, Singapore.	cmrhth@nccs.com.sg		Ong, Choon Kiat/0000-0001-6402-4288				Akriviadis EA, 1998, BRIT J SURG, V85, P1319; Altman D.G., 2000, STAT CONFIDENCE, Vsecond; CHAN ES, 2000, COCHRANE DB SYST REV, pPP199; Claudio PP, 2002, CLIN CANCER RES, V8, P1808; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Harigai M, 1996, ONCOGENE, V12, P1369; HUGUET CSF, 2000, SURG LIVER BILLARY T, P1365; Huynh H, 2002, CELL GROWTH DIFFER, V13, P115; Huynh H, 2001, ENDOCRINOLOGY, V142, P3607, DOI 10.1210/en.142.8.3607; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; LAI E, 1994, SURG LIVER BILIARY T, P1349; LAI ECS, 1995, ANN SURG, V221, P291, DOI 10.1097/00000658-199503000-00012; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; Ong CK, 2004, ENDOCRINOLOGY, V145, P4763, DOI 10.1210/en.2004-0446; Ong CK, 2004, J BIOL CHEM, V279, P743, DOI 10.1074/jbc.M308668200; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Riou P, 2002, CLIN CANCER RES, V8, P3178; SPIESSL B, 1992, ILLUSTRATED GUIDE TN, P104; Takenaka K, 1996, ARCH SURG-CHICAGO, V131, P71; Wang T, 2005, J BIOL CHEM, V280, P4374, DOI 10.1074/jbc.M408708200; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2	29	15	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1155	1165		10.1038/sj.onc.1209896	http://dx.doi.org/10.1038/sj.onc.1209896			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924236				2022-12-25	WOS:000244406400006
J	Weber, RG; Hoischen, A; Ehrler, M; Zipper, P; Kaulich, K; Blaschke, B; Becker, AJ; Weber-Mangal, S; Jauch, A; Radlwimmer, B; Schramm, J; Wiestler, OD; Lichter, P; Reifenberger, G				Weber, R. G.; Hoischen, A.; Ehrler, M.; Zipper, P.; Kaulich, K.; Blaschke, B.; Becker, A. J.; Weber-Mangal, S.; Jauch, A.; Radlwimmer, B.; Schramm, J.; Wiestler, O. D.; Lichter, P.; Reifenberger, G.			Frequent loss of chromosome 9, homozygous CDKN2A/p14ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas	ONCOGENE			English	Article						pleomorphic xanthoastrocytomas; comparative genomic hybridization; molecular genetics; tumor-suppressor gene; DNA-microarray	COMPARATIVE GENOMIC HYBRIDIZATION; SCLEROSIS GENE TSC1; GLIOMA PROGRESSION; CELL CARCINOMA; P53 MUTATION; IMBALANCES; GROWTH; TUMORS; 9Q34	The molecular pathogenesis of pleomorphic xanthoastrocytoma (PXA), a rare astrocytic brain tumor with a relatively favorable prognosis, is still poorly understood. We characterized 50 PXAs by comparative genomic hybridization (CGH) and found the most common imbalance to be loss on chromosome 9 in 50% of tumors. Other recurrent losses affected chromosomes 17 (10%), 8, 18, 22 (4% each). Recurrent gains were identified on chromosomes X (16%), 7, 9q, 20 (8% each), 4, 5, 19 ( 4% each). Two tumors demonstrated amplifications mapping to 2p23-p25, 4p15, 12q13, 12q21, 21q21 and 21q22. Analysis of 10 PXAs with available high molecular weight DNA by high-resolution array-based CGH indicated homozygous 9p21.3 deletions involving the CDKN2A/p14(ARF)/CDKN2B loci in six tumors (60%). Interphase fluorescence in situ hybridization to tissue sections confirmed the presence of tumor cells with homozygous 9p21.3 deletions. Mutational analysis of candidate genes on 9q, PTCH and TSC1, revealed no mutations in PXAs with 9q loss and no evidence of TSC1 promoter methylation. However, PXAs consistently showed low TSC1 transcript levels. Taken together, our study identifies loss of chromosome 9 as the most common chromosomal imbalance in PXAs and suggests important roles for homozygous CDKN2A/p14ARF/CDKN2B deletion as well as low TSC1 mRNA expression in these tumors.	Univ Bonn, Dept Human Genet, D-53111 Bonn, Germany; Otto Von Guericke Univ, Dept Human Genet, Magdeburg, Germany; Univ Dusseldorf, Dept Neuropathol, D-4000 Dusseldorf, Germany; Univ Bonn, Dept Neuropathol, D-5300 Bonn, Germany; Univ Heidelberg, Dept Human Genet, D-6900 Heidelberg, Germany; German Canc Res Ctr, D-6900 Heidelberg, Germany; Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany	University of Bonn; Otto von Guericke University; Heinrich Heine University Dusseldorf; University of Bonn; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Bonn	Weber, RG (corresponding author), Univ Bonn, Dept Human Genet, Wilhelmstr 31, D-53111 Bonn, Germany.	ruthild.weber@ukb.uni-bonn.de	Hoischen, Alexander/AGF-7293-2022; Becker, Albert J/F-6248-2012; Radlwimmer, Bernhard F/I-3229-2013; Hoischen, Alexander/D-1282-2013; Reifenberger, Guido/AAE-3599-2019; Weber, Ruthild/E-2906-2015	Hoischen, Alexander/0000-0002-8072-4476; Radlwimmer, Bernhard F/0000-0002-4553-7800; Hoischen, Alexander/0000-0002-8072-4476; Weber, Ruthild/0000-0001-6610-1080				Becker AJ, 2001, NEUROPATH APPL NEURO, V27, P105, DOI 10.1046/j.0305-1846.2001.00302.x; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; Giannini C, 2001, NEUROGENETICS, V3, P159, DOI 10.1007/s100480100116; Giannini C, 1999, CANCER, V85, P2033, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.3.CO;2-Q; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kaulich K, 2002, J NEUROPATH EXP NEUR, V61, P1092, DOI 10.1093/jnen/61.12.1092; Kepes JJ, 2000, WHO CLASSIFICATION T, P52; Knowles MA, 2003, CANCER RES, V63, P7652; Li YS, 1995, CANCER GENET CYTOGEN, V84, P46, DOI 10.1016/0165-4608(95)00065-8; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Mollemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575; Paulus W, 1996, ACTA NEUROPATHOL, V91, P293, DOI 10.1007/s004010050428; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Reifenberger G, 2004, J MOL MED, V82, P656, DOI 10.1007/s00109-004-0564-x; Reifenberger G, 2003, ACTA NEUROPATHOL, V105, P358, DOI 10.1007/s00401-002-0652-3; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Reifenberger J, 1996, J NEUROPATH EXP NEUR, V55, P822, DOI 10.1097/00005072-199607000-00007; Sambrook J., 2002, MOL CLONING LAB MANU; SAWYER JR, 1991, CANCER GENET CYTOGEN, V55, P225, DOI 10.1016/0165-4608(91)90081-5; SAWYER JR, 1992, CANCER GENET CYTOGEN, V60, P152, DOI 10.1016/0165-4608(92)90008-V; Schwaenen C, 2004, P NATL ACAD SCI USA, V101, P1039, DOI 10.1073/pnas.0304717101; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Weber RG, 1996, ONCOGENE, V13, P983; Yin XL, 2002, CANCER GENET CYTOGEN, V132, P14, DOI 10.1016/S0165-4608(01)00512-X; Zielinski B, 2005, GENE CHROMOSOME CANC, V43, P294, DOI 10.1002/gcc.20186	32	70	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1088	1097		10.1038/sj.onc.1209851	http://dx.doi.org/10.1038/sj.onc.1209851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909113				2022-12-25	WOS:000244245400015
J	Aburaya, M; Tanaka, KI; Hoshino, T; Tsutsumi, S; Suzuki, K; Makise, M; Akagi, R; Mizushima, T				Aburaya, Mayuko; Tanaka, Ken-Ichiro; Hoshino, Tatsuya; Tsutsumi, Shinji; Suzuki, Keitarou; Makise, Masaki; Akagi, Reiko; Mizushima, Tohru			Heme oxygenase-1 protects gastric mucosal cells against non-steroidal anti-inflammatory drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NRF2 TRANSCRIPTION FACTOR; HEAT-SHOCK PROTEINS; OXIDATIVE STRESS; INDUCED APOPTOSIS; ENDOTHELIAL-CELLS; ENZYME INDUCERS; PRIMARY CULTURE; UP-REGULATION; NITRIC-OXIDE; LUNG INJURY	Gastric mucosal cell death by non-steroidal anti-inflammatory drugs (NSAIDs) is suggested to be involved in NSAID-induced gastric lesions. Therefore, cellular factors that suppress this cell death are important for protection of the gastric mucosa from NSAIDs. Heme oxygenase-1 (HO-1) is up-regulated by various stressors and protects cells against stressors. Here, we have examined up-regulation of HO-1 by NSAIDs and the contribution of HO-1 to the protection of gastric mucosal cells against NSAIDs both in vitro and in vivo. In cultured gastric mucosal cells, all NSAIDs tested up-regulated HO-1. In rats, orally administered indomethacin up-regulated HO-1, induced apoptosis, and produced lesions at gastric mucosa. An inhibitor of HO-stimulated NSAID-induced apoptosis in vitro and in vivo and also stimulated NSAID-produced gastric lesions, suggesting that NSAID-induced up-regulation of HO-1 protects the gastric mucosa from NSAID-induced gastric lesions by inhibiting NSAID-induced apoptosis. Indomethacin activated the HO-1 promoter and caused nuclear accumulation of NF-E2-related factor 2 (Nrf2), a transcription factor for the HO-1 gene. Examination of phosphorylation of p38 mitogen-activated protein kinase (MAPK) and experiments with its inhibitor strongly suggest that the nuclear accumulation of Nrf2 and resulting up-regulation of HO-1 by NSAIDs is mediated through NSAID-dependent activation (phosphorylation) of p38 MAPK. This is the first report showing the protective role of HO-1 against irritant-induced gastric lesions.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan; Okayama Prefectural Univ, Fac Hlth & Welfare Sci, Soja 7191197, Japan	Kumamoto University; Okayama Prefectural University	Mizushima, T (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan.	mizu@gpo.kumamoto-u.ac.jp						Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alam J, 2000, J BIOL CHEM, V275, P27694; Alcaraz MJ, 2001, BBA-GEN SUBJECTS, V1526, P13, DOI 10.1016/S0304-4165(01)00112-X; BARRIER CH, 1989, ARTHRITIS RHEUM, V32, P926; Ben-Chetrit E, 2005, RHEUMATOL INT, V25, P332, DOI 10.1007/s00296-004-0442-4; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Buckley BJ, 2003, BIOCHEM BIOPH RES CO, V307, P973, DOI 10.1016/S0006-291X(03)01308-1; Cantoni L, 2003, J HEPATOL, V38, P776, DOI 10.1016/S0168-8278(03)00095-3; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Chou YH, 2005, INT J BIOCHEM CELL B, V37, P604, DOI 10.1016/j.biocel.2004.08.006; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; Gehrmann M, 2004, CLIN CANCER RES, V10, P3354, DOI 10.1158/1078-0432.CCR-03-0382; Ghattas MH, 2002, INT J BIOCHEM CELL B, V34, P1619, DOI 10.1016/S1357-2725(02)00097-3; Gong PF, 2003, J BIOL CHEM, V278, P29693, DOI 10.1074/jbc.M304728200; Grosser N, 2003, BIOCHEM BIOPH RES CO, V308, P956, DOI 10.1016/S0006-291X(03)01504-3; Hawkey CJ, 2000, GASTROENTEROLOGY, V119, P521, DOI 10.1053/gast.2000.9561; Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663; Hirakawa T, 1996, GASTROENTEROLOGY, V111, P345, DOI 10.1053/gast.1996.v111.pm8690199; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Hou CC, 2005, ANN NY ACAD SCI, V1042, P235, DOI 10.1196/annals.1338.026; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kawai S, 1998, EUR J PHARMACOL, V347, P87, DOI 10.1016/S0014-2999(98)00078-8; Kiemer AK, 2003, ENDOCRINOLOGY, V144, P802, DOI 10.1210/en.2002-220610; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; Kwak MK, 2004, MUTAT RES-FUND MOL M, V555, P133, DOI 10.1016/j.mrfmmm.2004.06.041; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Lee TS, 2003, J BIOL CHEM, V278, P19325, DOI 10.1074/jbc.M300498200; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Lichtenberger LM, 2001, BIOCHEM PHARMACOL, V61, P631, DOI 10.1016/S0006-2952(00)00576-1; Linden T, 1998, NEUROSCI LETT, V247, P103, DOI 10.1016/S0304-3940(98)00278-X; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Mathew A, 1998, ANN NY ACAD SCI, V851, P99, DOI 10.1111/j.1749-6632.1998.tb08982.x; Mima S, 2005, CANCER RES, V65, P1868, DOI 10.1158/0008-5472.CAN-04-2770; Nakahira K, 2003, BIOCHEM PHARMACOL, V66, P1091, DOI 10.1016/S0006-2952(03)00444-1; Nascimento-Silva V, 2005, AM J PHYSIOL-CELL PH, V289, pC557, DOI 10.1152/ajpcell.00045.2005; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rockwell P, 2004, CELL SIGNAL, V16, P343, DOI 10.1016/j.cellsig.2003.08.006; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schroeder CR, 2004, CANCER BIOL THER, V3, P847, DOI 10.4161/cbt.3.9.1037; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; Takano T, 2002, DIGEST DIS SCI, V47, P1546, DOI 10.1023/A:1015819203084; Takeda A, 2000, J BIOL CHEM, V275, P5395, DOI 10.1074/jbc.275.8.5395; Tanaka K, 2005, J BIOL CHEM, V280, P31059, DOI 10.1074/jbc.M502956200; TANAKA Y, 1983, CHEM PHARM BULL, V31, P3656; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tomisato W, 2004, BIOCHEM BIOPH RES CO, V323, P1032, DOI 10.1016/j.bbrc.2004.08.205; Tomisato W, 2004, BIOCHEM PHARMACOL, V67, P575, DOI 10.1016/j.bcp.2003.09.020; Tomisato W, 2002, DIGEST DIS SCI, V47, P2125, DOI 10.1023/A:1019653719397; Tomisato W, 2001, BIOL PHARM BULL, V24, P887, DOI 10.1248/bpb.24.887; Tomisato W, 2001, AM J PHYSIOL-GASTR L, V281, pG1092, DOI 10.1152/ajpgi.2001.281.4.G1092; Tomisato W, 2000, DIGEST DIS SCI, V45, P1674, DOI 10.1023/A:1005597902470; Tsutsumi S, 2006, ONCOGENE, V25, P1018, DOI 10.1038/sj.onc.1209139; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Tsutsumi S, 2003, EXP BIOL MED, V228, P1089, DOI 10.1177/153537020322800917; Tsutsumi S, 2002, BBA-MOL CELL RES, V1589, P168, DOI 10.1016/S0167-4889(02)00171-4; VALAES T, 1994, PEDIATRICS, V93, P1; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200	68	72	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33422	33432		10.1074/jbc.M602074200	http://dx.doi.org/10.1074/jbc.M602074200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16945925	hybrid			2022-12-25	WOS:000241621400052
J	Drinane, M; Walsh, J; Mollmark, J; Simons, M; Mulligan-Kehoe, MJ				Drinane, Mary; Walsh, Jannine; Mollmark, Jessica; Simons, Michael; Mulligan-Kehoe, Mary Jo			The anti-angiogenic activity of rPAI-1(23) inhibits fibroblast growth factor-2 functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; IN-VIVO; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; PROTEIN-KINASE; TUMOR-GROWTH; APOPTOSIS; EXPRESSION; ALPHA; JNK2	Many angiogenesis inhibitors are breakdown products of endogenous extracellular matrix proteins. Plasmin and matrix metalloproteinase-3 generate breakdown products of matrix-bound plasminogen activator inhibitor-1(PAI-1). We produced a truncated form of PAI-1, rPAI-1(23), that possesses significant anti- angiogenic activity and stimulates high levels of apoptosis in quiescent arterial endothelial cells. Quiescent endothelial cells are less susceptible to apoptosis than angiogenic endothelial cells. The present study was designed to determine the mechanism of the rPAI-1(23) effects in bovine aortic endothelial cells. Apoptosis was measured in annexin V and caspase 3 assays. Expression of death and survival signaling molecules were examined by Western blot and kinase activity. Fibroblast growth factor 2 (FGF2) functions were analyzed in angiogenesis assays. The early response to rPAI-1(23) was an increase in annexin V-positive cells and phosphorylated (p)JNK isoform expression followed by an increase in p-Akt and p-c-Jun expression. Caspase 3 was activated at 4 h, whereas p-Akt was reduced to control levels. By 6 h of rPAI-1(23) treatment cell number was reduced by 35%, and p-c-Jun and p-JNK were degraded by proteasomes. Confocal microscopic images showed increased amounts of FGF2 in the extracellular matrix. However, rPAI-1(23) blocked FGF2 signaling through FGF receptor 1 and syndecan-4, inhibiting cell migration, tubulogenesis, and proliferation. Exogenous FGF2 stimulation could not reverse these effects. We conclude that rPAI-1(23) stimulation of apoptosis in BAEC triggers a cascade of death versus survival events that includes release of FGF2. The rPAI-1(23) anti- angiogenic activity inhibits FGF2 pro-angiogenic functions by blocking FGF2 signaling through FGF receptor 1 and syndecan-4 and downstream effectors p-Akt, p-JNK, and p-c-Jun.	Dartmouth Med Sch, Dept Surg, Vasc Sect, Lebanon, NH 03756 USA; Dartmouth Med Sch, Dept Med, Cardiol Sect, Lebanon, NH 03756 USA; Dartmouth Med Sch, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; Dartmouth Med Sch, Angiogenesis Res Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College	Mulligan-Kehoe, MJ (corresponding author), Dartmouth Med Sch, Dept Surg, Vasc Sect, Borwell 530E,1 Med Ctr Dr, Lebanon, NH 03756 USA.	mary.j.mulligan-kehoe@dartmouth.edu	Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734; Drinane, Mary/0000-0001-6081-5330	NHLBI NIH HHS [HL069948, HL62289] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062289, R01HL069948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asselin E, 2001, CANCER RES, V61, P1862; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Doseff AI, 2004, STEM CELLS DEV, V13, P473, DOI 10.1089/1547328042417255; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; Kuntzen C, 2005, CANCER RES, V65, P6780, DOI 10.1158/0008-5472.CAN-04-2618; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Lijnen HR, 2000, J BIOL CHEM, V275, P37645, DOI 10.1074/jbc.M006475200; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Mulligan-Kehoe MJ, 2002, J BIOL CHEM, V277, P49077, DOI 10.1074/jbc.M208757200; Mulligan-Kehoe MJ, 2001, J BIOL CHEM, V276, P8588, DOI 10.1074/jbc.M006434200; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Partovian C, 2004, CELL SIGNAL, V16, P951, DOI 10.1016/j.cellsig.2004.01.008; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Schwabe RF, 2004, FASEB J, V18, P720, DOI 10.1096/fj.03-0771fje; Simons M, 2004, MOL CELL BIOCHEM, V264, P99, DOI 10.1023/B:MCBI.0000044379.25823.03; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Stupack DG, 2003, ONCOGENE, V22, P9022, DOI 10.1038/sj.onc.1207110; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; vanMeijer M, 1997, BLOOD, V90, P1874, DOI 10.1182/blood.V90.5.1874; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; VOLK RSJ, J BIOL CHEM, V274, P24417; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188	45	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33336	33344		10.1074/jbc.M607097200	http://dx.doi.org/10.1074/jbc.M607097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950776	hybrid			2022-12-25	WOS:000241621400043
J	He, YW; Wang, C; Zhou, L; Song, HW; Dow, JM; Zhang, LH				He, Ya-Wen; Wang, Chao; Zhou, Lian; Song, Haiwei; Dow, J. Maxwell; Zhang, Lian-Hui			Dual signaling functions of the hybrid sensor kinase RpfC of Xanthomonas campestris involve either phosphorelay or receiver domain-protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT SYSTEM; PATHOGENICITY; GENE; EXPRESSION; VIRULENCE; ENZYMES	The hybrid sensor kinase RpfC positively regulates the expression of a range of virulent genes and negatively modulates the synthesis of the quorum sensing signal diffusible signal factor (DSF) in Xanthomonas campestris. Three conserved amino acid residues of RpfC implicated in phosphorelay (His(198) in the histidine kinase domain, Asp(512) in the receiver domain, and His(657) in the histidine phosphotransfer domain) were essential for activation of the production of extracellular enzymes and extracellular polysaccharide (EPS) virulence factors but were not essential for repression of DSF biosynthesis. Domain deletion and subsequent in trans expression analysis revealed that the receiver domain of RpfC alone was sufficient to repress DSF overproduction in an rpfC deletion mutant. Further deletion and alanine scanning mutagenesis analyses identified a peptide of 107 amino acids and three amino acid residues (Gln(496), Glu(504), and Ile(552)) involved in modulating DSF production. Co-immunoprecipitation and far Western blot analyses suggested an interaction between the receiver domain and RpfF, the enzyme involved in DSF biosynthesis. These data support a model in which RpfC modulates two different functions ( virulence factor synthesis and DSF synthesis) by utilization of a conserved phosphorelay system and a novel domain-specific protein-protein interaction mechanism, respectively. This latter mechanism represents an added dimension to conventional two-component signaling paradigms.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Natl Univ Ireland Univ Coll Cork, Biosci Inst, Dept Microbiol, BIOMERIT Res Ctr, Cork, Ireland	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University College Cork	Zhang, LH (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	lianhui@imcb.a-star.edu.sg	song, haiwei/H-6082-2011					ARICO B, 1989, P NATL ACAD SCI USA, V86, P6671, DOI 10.1073/pnas.86.17.6671; Barber CE, 1997, MOL MICROBIOL, V24, P555, DOI 10.1046/j.1365-2958.1997.3721736.x; Bijisma JJE, 2003, TRENDS MICROBIOL, V11, P359, DOI 10.1016/S0966-842X(03)00176-8; BOYER MH, 1984, J BIOTECHNOL, V1, P229, DOI 10.1016/0168-1656(84)90008-7; Dow JM, 2003, P NATL ACAD SCI USA, V100, P10995, DOI 10.1073/pnas.1833360100; Galperin MY, 2006, J BACTERIOL, V188, P4169, DOI 10.1128/JB.01887-05; Galperin MY, 2004, ENVIRON MICROBIOL, V6, P552, DOI 10.1111/j.1462-2920.2004.00633.x; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; Hall Randy A, 2004, Methods Mol Biol, V261, P167; He YW, 2006, MOL MICROBIOL, V59, P610, DOI 10.1111/j.1365-2958.2005.04961.x; HRABAK EM, 1992, J BACTERIOL, V174, P3011, DOI 10.1128/JB.174.9.3011-3020.1992; HWANG IY, 1994, P NATL ACAD SCI USA, V91, P4639, DOI 10.1073/pnas.91.11.4639; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; Jourlin C, 1996, MOL MICROBIOL, V20, P1297, DOI 10.1111/j.1365-2958.1996.tb02648.x; Kwon O, 2000, J BACTERIOL, V182, P3858, DOI 10.1128/JB.182.13.3858-3862.2000; Lenz DH, 2004, CELL, V118, P69, DOI 10.1016/j.cell.2004.06.009; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Qian W, 2005, GENOME RES, V15, P757, DOI 10.1101/gr.3378705; Rodrigue A, 2000, TRENDS MICROBIOL, V8, P498, DOI 10.1016/S0966-842X(00)01833-3; Ryan RP, 2006, P NATL ACAD SCI USA, V103, P6712, DOI 10.1073/pnas.0600345103; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEED PC, 1995, J BACTERIOL, V177, P654, DOI 10.1128/jb.177.3.654-659.1995; Slater H, 2000, MOL MICROBIOL, V38, P986, DOI 10.1046/j.1365-2958.2000.02196.x; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Swift S, 1999, INFECT IMMUN, V67, P5192, DOI 10.1128/IAI.67.10.5192-5199.1999; TANG JL, 1991, MOL GEN GENET, V226, P409, DOI 10.1007/BF00260653; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; Uhl MA, 1996, J BIOL CHEM, V271, P33176, DOI 10.1074/jbc.271.52.33176; Wang LH, 2004, MOL MICROBIOL, V51, P903, DOI 10.1046/j.1365-2958.2003.03883.x; Wolanin PM, 2002, GENOME BIOL, V3; Zhang HB, 2002, P NATL ACAD SCI USA, V99, P4638, DOI 10.1073/pnas.022056699; Zhang LH, 1997, P NATL ACAD SCI USA, V94, P9984, DOI 10.1073/pnas.94.18.9984	33	94	109	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33414	33421		10.1074/jbc.M606571200	http://dx.doi.org/10.1074/jbc.M606571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16940295	hybrid			2022-12-25	WOS:000241621400051
J	Akimova, OA; Grygorczyk, A; Bundey, RA; Bourcier, N; Gekle, M; Insel, PA; Orlov, SN				Akimova, Olga A.; Grygorczyk, Alexandra; Bundey, Richard A.; Bourcier, Nathalie; Gekle, Michael; Insel, Paul A.; Orlov, Sergei N.			Transient activation and delayed inhibition of Na+, K+, Cl- cotransport in ATP-treated C11-MDCK cells involve distinct P2Y receptor subtypes and signaling mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; CATION-CHLORIDE COTRANSPORTERS; ALANINE-RICH KINASE; CANINE KIDNEY-CELLS; NA+-K+-2CL(-) COTRANSPORTER; EPITHELIAL-CELLS; C7-MDCK CELLS; EXPRESSION; CLONING; RAT	In C11-MDCK cells, which resemble intercalated cells from collecting ducts of the canine kidney, P2Y agonists promote transient activation of the Na+, K+, Cl- cotransporter (NKCC), followed by its sustained inhibition. We designed this study to identify P2Y receptor subtypes involved in dual regulation of this carrier. Real time polymerase chain reaction analysis demonstrated that C11-MDCK cells express abundant P2Y(1) and P2Y(2) mRNA compared with that of other P2Y receptor subtypes. The rank order of potency of agents (ATP similar to UTP >> 2-(methylthio)-ATP (2MeSATP); adenosine 5' -[beta-thio]diphosphate (ADP beta S) inactive) indicated that P2Y(2) rather than P2Y(1) receptors mediate a 3-4-fold activation of NKCC within the first 5-10 min of nucleotide addition. NKCC activation in ATP-treated cells was abolished by the intracellular calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid, calmodulin (CaM) antagonists trifluoroperazine and W-7, and KN-62, an inhibitor of Ca2+/CaM-dependent protein kinase II. By contrast with the transient activation, 30-min incubation with nucleotides produced up to 4-5-fold inhibition of NKCC, and this inhibition exhibited a rank order of potency (2MeSATP > ADP beta S > ATP >> UTP) typical of P2Y(1) receptors. Unlike the early response, delayed inhibition of NKCC occurred in 1,2-bis(2-aminophenoxy)ethane-N, N, N', N'-tetraacetic acid-loaded cells and was completely abolished by the P2Y(1) antagonists MRS2179 and MRS2500. Transient activation and delayed inhibition of NKCC in C11 cell monolayers were observed after the addition of ATP to mucosal and serosal solutions, respectively. NKCC inhibition triggered by basolateral application of ADP beta S was abolished by MRS2500. Our results thus show that transient activation and delayed inhibition of NKCC in ATP-treated C11-MDCK cells is mediated by Ca2+/CaM-dependent protein kinase II- and Ca2+-independent signaling triggered by apical P2Y(2) and basolateral P2Y(1) receptors, respectively.	CHUM, Ctr Rech, Montreal, PQ H1W 4A4, Canada; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Wurzburg, Dept Physiol, D-97070 Wurzburg, Germany	Universite de Montreal; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Wurzburg	Orlov, SN (corresponding author), CHUM, Ctr Rech, 2901 Rachel Es Rm 313, Montreal, PQ H1W 4A4, Canada.	sergei.n.orlov@umontreal.ca	ORLOV, SERGEI/I-4071-2013; Akimova, Olga/I-2669-2014	Grygorczyk, Alexandra/0000-0001-9416-6316	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM66232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akar F, 2001, AM J PHYSIOL-CELL PH, V281, pC579, DOI 10.1152/ajpcell.2001.281.2.C579; Akimova AO, 2005, J PHYSIOL-LONDON, V568, P789, DOI 10.1113/jphysiol.2005.094375; Anfinogenova YJ, 2004, PFLUG ARCH EUR J PHY, V449, P42, DOI 10.1007/s00424-004-1316-z; Anfinogenova YJ, 2001, CELL PHYSIOL BIOCHEM, V11, P295, DOI 10.1159/000047816; Bailey MA, 2000, KIDNEY INT, V58, P1893, DOI 10.1111/j.1523-1755.2000.00361.x; Bailey MA, 2000, J AUTONOM NERV SYST, V81, P264, DOI 10.1016/S0165-1838(00)00125-9; Berra-Romani R, 2004, J VASC RES, V41, P166, DOI 10.1159/000077146; Bourcier N, 2002, J MEMBRANE BIOL, V186, P131, DOI 10.1007/s00232-001-0141-y; BREYER MD, 1994, ANNU REV PHYSIOL, V56, P711, DOI 10.1146/annurev.ph.56.030194.003431; Brindikova TA, 2003, AM J PHYSIOL-CELL PH, V285, pC1445, DOI 10.1152/ajpcell.00386.2002; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Cattaneo M, 2004, BIOCHEM PHARMACOL, V68, P1995, DOI 10.1016/j.bcp.2004.06.026; Chan CM, 1998, EXP NEPHROL, V6, P200; DELLES C, 1995, J PHYSIOL-LONDON, V486, P557, DOI 10.1113/jphysiol.1995.sp020834; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Delpire E, 2000, NEWS PHYSIOL SCI, V15, P309, DOI 10.1152/physiologyonline.2000.15.6.309; Drakulich DA, 2004, EUR J PHARMACOL, V485, P137, DOI 10.1016/j.ejphar.2003.11.056; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Gagnon F, 1998, BBA-BIOMEMBRANES, V1369, P233, DOI 10.1016/S0005-2736(97)00225-3; Gagnon F, 1999, J MEMBRANE BIOL, V167, P193, DOI 10.1007/s002329900483; Gagnon KBE, 2006, MOL CELL BIOL, V26, P689, DOI 10.1128/MCB.26.2.689-698.2006; Gagnon KBE, 2006, AM J PHYSIOL-CELL PH, V290, pC134, DOI 10.1152/ajpcell.00037.2005; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; Gamba G., 2004, AM J PHYSIOL, V288, pF245; GEKLE M, 1994, PFLUG ARCH EUR J PHY, V428, P157, DOI 10.1007/BF00374853; Greger R, 2000, AM J MED SCI, V319, P51, DOI 10.1097/00000441-200001000-00005; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Joseph SM, 2003, J BIOL CHEM, V278, P23331, DOI 10.1074/jbc.M302680200; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Lazarowski ER, 2001, NEWS PHYSIOL SCI, V16, P1; Mount DB, 1998, J EXP BIOL, V201, P2091; Orlov SN, 1996, J MEMBRANE BIOL, V153, P125, DOI 10.1007/s002329900116; Orlov SN, 1996, AM J PHYSIOL-CELL PH, V270, pC1388, DOI 10.1152/ajpcell.1996.270.5.C1388; Orlov SN, 1999, J MEMBRANE BIOL, V172, P225, DOI 10.1007/s002329900599; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; PAULMICHL M, 1991, J CELL PHYSIOL, V147, P68, DOI 10.1002/jcp.1041470110; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Qi AD, 2005, J BIOL CHEM, V280, P29169, DOI 10.1074/jbc.M501301200; RICE WR, 1995, AM J RESP CELL MOL, V12, P27, DOI 10.1165/ajrcmb.12.1.7811468; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Schwiebert EM, 2002, AM J PHYSIOL-RENAL, V282, pF763, DOI 10.1152/ajprenal.0337.2000; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; Takeda M, 1998, BIOCHEM MOL BIOL INT, V44, P657; Taurin S, 2002, J PHYSIOL-LONDON, V543, P835, DOI 10.1113/jphysiol.2002.023259; TOKUYAMA Y, 1995, BIOCHEM BIOPH RES CO, V211, P211, DOI 10.1006/bbrc.1995.1798; Vassort G, 2001, PHYSIOL REV, V81, P767, DOI 10.1152/physrev.2001.81.2.767; von Kugelgen I, 2006, PHARMACOL THERAPEUT, V110, P415, DOI 10.1016/j.pharmthera.2005.08.014; Williams M, 2000, BIOCHEM PHARMACOL, V59, P1173, DOI 10.1016/S0006-2952(99)00341-X; Wolff SC, 2005, AM J PHYSIOL-CELL PH, V288, pC624, DOI 10.1152/ajpcell.00338.2004; Zambon AC, 2000, AM J PHYSIOL-RENAL, V279, pF1045, DOI 10.1152/ajprenal.2000.279.6.F1045	51	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31317	31325		10.1074/jbc.M602117200	http://dx.doi.org/10.1074/jbc.M602117200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16916802	Bronze			2022-12-25	WOS:000241235300016
J	Choudhury, P; Srivastava, S; Li, Z; Ko, K; Albaqumi, M; Narayan, K; Coetzee, WA; Lemmon, MA; Skolnik, EY				Choudhury, Papiya; Srivastava, Shekhar; Li, Zhai; Ko, Kyung; Albaqumi, Mamdouh; Narayan, Kartik; Coetzee, William A.; Lemmon, Mark A.; Skolnik, Edward Y.			Specificity of the myotubularin family of phosphatidylinositol-3-phosphatase is determined by the PH/GRAM domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; CA2+-ACTIVATED K+ CHANNEL; PHOSPHOINOSITIDE PHOSPHATASES; CAENORHABDITIS-ELEGANS; BINDING DOMAIN; GRAM DOMAIN; IN-VIVO; MYOPATHY; 3-PHOSPHATE; DISEASE	Myotubularins (MTM) are a large subfamily of lipid phosphatases that specifically dephosphorylate at the D3 position of phosphatidylinositol 3-phosphate (PI(3)P) in PI(3)P and PI(3,5)P-2. We recently found that MTMR6 specifically inhibits the Ca2+-activated K+ channel, KCa3.1, by dephosphorylating PI(3)P. We now show that inhibition is specific for MTMR6 and other MTMs do not inhibit KCa3.1. By replacing either or both of the coiled-coil (CC) and pleckstrin homology/GRAM (PH/G) domains of MTMs that failed to inhibit KCa3.1 with the CC and PH/ G domains of MTMR6, we found that chimeric MTMs containing both the MTMR6 CC and PH/G domains functioned like MTMR6 to inhibit KCa3.1 channel activity, whereas chimeric MTMs containing either domain alone did not. Immunofluorescent microscopy demonstrated that both the MTMR6 CC and PH/G domains are required to co-localize MTMR6 to the plasma membrane with KCa3.1. These findings support a model in which two specific low affinity interactions are required to co-localize MTMR6 with KCa3.1: 1) between the CC domains on MTMR6 and KCa3.1 and (2) between the PH/G domain and a component of the plasma membrane. Our inability to detect significant interaction of the MTMR6 G/PH domain with phosphoinositides suggests that this domain may bind a protein. Identifying the specific binding partners of the CC and PH/G domains on other MTMs will provide important clues to the specific functions regulated by other MTMs as well as the mechanism(s) whereby loss of some MTMs lead to disease.	NYU, Sch Med, Skirball Inst, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pediat Cardiol, New York, NY 10016 USA; NYU, Sch Med, Dept Nephrol, New York, NY 10016 USA; Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	New York University; New York University; New York University; University of Pennsylvania	Skolnik, EY (corresponding author), NYU, Sch Med, Skirball Inst, Dept Med, 550 1St Ave, New York, NY 10016 USA.	Skolnik@saturn.med.nyu.edu		Coetzee, William/0000-0003-1522-8326; Lemmon, Mark/0000-0002-3379-5319; Srivastava, Shekhar/0000-0001-5165-7385				Begley MJ, 2006, P NATL ACAD SCI USA, V103, P927, DOI 10.1073/pnas.0510006103; Begley MJ, 2005, CURR OPIN STRUC BIOL, V15, P614, DOI 10.1016/j.sbi.2005.10.016; Begley MJ, 2003, MOL CELL, V12, P1391, DOI 10.1016/S1097-2765(03)00486-6; Berger P, 2003, P NATL ACAD SCI USA, V100, P12177, DOI 10.1073/pnas.2132732100; Bolino A, 2000, NAT GENET, V25, P17, DOI 10.1038/75542; Clague MJ, 2005, TRAFFIC, V6, P1063, DOI 10.1111/j.1600-0854.2005.00338.x; Dang H, 2004, MOL BIOL CELL, V15, P189, DOI 10.1091/mbc.E03-08-0605; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P483, DOI 10.1016/S0968-0004(00)01664-9; Fournier E, 2003, CURR BIOL, V13, P1858, DOI 10.1016/j.cub.2003.09.034; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; Kim SA, 2003, P NATL ACAD SCI USA, V100, P4492, DOI 10.1073/pnas.0431052100; Kim SA, 2002, J BIOL CHEM, V277, P4526, DOI 10.1074/jbc.M111087200; Laporte J, 2003, HUM MOL GENET, V12, pR285, DOI 10.1093/hmg/ddg273; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Lemmon MA, 2004, BIOCHEM SOC T, V32, P707, DOI 10.1042/BST0320707; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Lorenzo O, 2005, J CELL SCI, V118, P2005, DOI 10.1242/jcs.02325; Mochizuki Y, 2003, P NATL ACAD SCI USA, V100, P9768, DOI 10.1073/pnas.1333958100; Nandurkar HH, 2003, P NATL ACAD SCI USA, V100, P8660, DOI 10.1073/pnas.1033097100; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Senderek J, 2003, HUM MOL GENET, V12, P349, DOI 10.1093/hmg/ddg030; Srivastava S, 2005, MOL CELL BIOL, V25, P3630, DOI 10.1128/MCB.25.9.3630-3638.2005; Srivastava S, 2006, MOL BIOL CELL, V17, P146, DOI 10.1091/mbc.e05-08-0763; Srivastava S, 2006, MOL CELL BIOL, V26, P5595, DOI 10.1128/MCB.00352-06; Syme CA, 2003, J BIOL CHEM, V278, P8476, DOI 10.1074/jbc.M210072200; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Taylor GS, 2003, METHOD ENZYMOL, V366, P43; Tsujita K, 2004, J BIOL CHEM, V279, P13817, DOI 10.1074/jbc.M312294200; Wishart MJ, 2001, CURR OPIN CELL BIOL, V13, P172, DOI 10.1016/S0955-0674(00)00195-2; Xue YZ, 2003, J BIOL CHEM, V278, P34380, DOI 10.1074/jbc.M303259200; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8	33	32	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31762	31769		10.1074/jbc.M606344200	http://dx.doi.org/10.1074/jbc.M606344200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16914545	Bronze			2022-12-25	WOS:000241235300063
J	dela Cruz, RGC; Jairajpuri, MA; Bock, SC				dela Cruz, Richard Glenn C.; Jairajpuri, Mohamad Aman; Bock, Susan C.			Disruption of a tight cluster surrounding tyrosine 131 in the native conformation of antithrombin III activates it for factor Xa inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN ACTIVATION; HIGH-AFFINITY; HELIX-D; MECHANISM; BINDING; SEQUENCE; ELIMINATION; EXPRESSION; RESIDUES; DELETION	The native conformation of antithrombin III (ATIII) is a poor inhibitor of its coagulation pathway target enzymes because of the partial insertion of its reactive center loop (RCL) in its central A beta-sheet. This study focused on tyrosine 131, which is located at the helix D-sheet A interface, adjacent to the ATIII pentasaccharide and heparin cofactor-binding sites and some 17 A away from the RCL insertion. Crystallographic structures show that the Tyr(131) ring is buried in native ATIII and then becomes exposed when pentasaccharide binds to the inhibitor and activates it. This change suggested that Tyr(131) might serve as a switch for ATIII conformational activation. The hypothesis is supported by results from this study, which progressively removed atoms from the Tyr(131) side chain. Rates of heparin-independent Y131L and Y131A factor Xa inhibition were 25 and 29 times faster than for the control and Y131F, suggesting that Tyr(131) ring interactions with neighboring helix D and strand 2A residues shift the uncatalyzed native-to-activated conformational equilibrium toward the RCL-inserted state. Thermal denaturation experiments showed Y131A and Y131L were less stable than the control and Y131F, implying an increased tendency toward A-sheet mobility in these genetically activated molecules. Thus, the tight Tyr(131)-Asn(127)-Leu(130)-Leu(140)-Ser(142) cluster at the helix D-strand 2A interface of native antithrombin contributes significantly to the stability of the ground state conformation, and tyrosine 131 serves as a heparin-responsive molecular switch during the allosteric activation of ATIII anticoagulant activity.	Univ Utah, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84132 USA; Univ Utah, Dept Bioengn, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bock, SC (corresponding author), Univ Utah, Hlth Sci Ctr, Div Pulm, Wintrobe 739,50 N Med Dr, Salt Lake City, UT 84132 USA.	Susan.Bock@m.cc.utah.edu	Jairajpuri, Mohamad/AAS-2556-2020		NHLBI NIH HHS [HL76819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 2000, BIOCHEMISTRY-US, V39, P8512, DOI 10.1021/bi9928243; Backovic M, 2002, J PROTEOME RES, V1, P367, DOI 10.1021/pr025515z; Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; BJORK I, 1992, BIOCHEM J, V286, P793; BOCK SC, 1982, NUCLEIC ACIDS RES, V10, P8113, DOI 10.1093/nar/10.24.8113; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; Desai U, 2000, J BIOL CHEM, V275, P18976, DOI 10.1074/jbc.M001340200; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; Futamura A, 2000, J BIOL CHEM, V275, P4092, DOI 10.1074/jbc.275.6.4092; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jairajpuri MA, 2003, J BIOL CHEM, V278, P15941, DOI 10.1074/jbc.M212319200; Jairajpuri MA, 2002, J BIOL CHEM, V277, P24460, DOI 10.1074/jbc.M203127200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2006, EMBO J, V25, P2029, DOI 10.1038/sj.emboj.7601089; Johnson DJD, 2003, BIOCHEMISTRY-US, V42, P8712, DOI 10.1021/bi034524y; Meagher JL, 1996, J BIOL CHEM, V271, P29353, DOI 10.1074/jbc.271.46.29353; Meagher JL, 2000, J BIOL CHEM, V275, P2698, DOI 10.1074/jbc.275.4.2698; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1991, J BIOL CHEM, V266, P6342; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P198, DOI 10.1016/S1050-1738(02)00160-3; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PICARD V, 1996, METHODS MOL BIOL PCR, P183; Raja SM, 2003, J BIOL CHEM, V278, P13688, DOI 10.1074/jbc.M300062200; Rezaie AR, 2002, J BIOL CHEM, V277, P1235, DOI 10.1074/jbc.M108544200; Schedin-Weiss S, 2002, BIOCHEMISTRY-US, V41, P4779, DOI 10.1021/bi012163l; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492	30	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31668	31676		10.1074/jbc.M604826200	http://dx.doi.org/10.1074/jbc.M604826200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16940049	Bronze			2022-12-25	WOS:000241235300052
J	Mercante, J; Suzuki, K; Cheng, XD; Babitzke, P; Romeo, T				Mercante, Jeffrey; Suzuki, Kazushi; Cheng, Xiaodong; Babitzke, Paul; Romeo, Tony			Comprehensive alanine-scanning mutagenesis of Escherichia coli CsrA defines two subdomains of critical functional importance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; BINDING ATTENUATION PROTEIN; GLOBAL REGULATOR CSRA; RNA-BINDING; STRUCTURAL BASIS; GENE-EXPRESSION; CRYSTAL-STRUCTURE; EXTRACELLULAR ENZYMES; GLYCOGEN BIOSYNTHESIS; RECEPTOR INTERACTIONS	The RNA-binding protein CsrA (carbon storage regulator) of Escherichia coli is a global regulator of gene expression and is representative of the CsrA/RsmA family of bacterial proteins. These proteins act by regulating mRNA translation and stability and are antagonized by binding to small noncoding RNAs. Although the RNA target sequence and structure for CsrA binding have been well defined, little information exists concerning the protein requirements for RNA recognition. The three-dimensional structures of three CsrA/RsmA proteins were recently solved, revealing a novel protein fold consisting of two interdigitated monomers. Here, we performed comprehensive alanine- scanning mutagenesis on csrA of E. coli and tested the 58 resulting mutants for regulation of glycogen accumulation, motility, and biofilm formation. Quantitative effects of these mutations on expression of glgCA'-'lacZ, flhDC'-'lacZ, and pgaA'-'lacZ translational fusions were also examined, and eight of the mutant proteins were purified and tested for RNA binding. These studies identified two regions of the amino acid sequence that were critical for regulation and RNA binding, located within the first (beta(1), residues 2-7) and containing the last (beta(5), residues 40-47) beta-strands of CsrA. The beta(1) and beta(5) strands of opposite monomers lie adjacent and parallel to each other in the three-dimensional structure of this protein. Given the symmetry of the CsrA dimer, these findings imply that two distinct RNA binding surfaces or functional subdomains lie on opposite sides of the protein.	Emory Univ, Sch Med, Dept Immunol & Microbiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Emory University; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Romeo, T (corresponding author), Emory Univ, Sch Med, Dept Immunol & Microbiol, 3105 Rollins Res Ctr,1510 Clifton Rd NE, Atlanta, GA 30322 USA.	romeo@microbio.emory.edu	Suzuki, Kazushi/I-4509-2016; Babitzke, Paul/AAL-3048-2020	Babitzke, Paul/0000-0003-2481-1062; Mercante, Jeffrey/0000-0003-2553-1230	NIGMS NIH HHS [R01 GM059969] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059969] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; Altier C, 2000, MOL MICROBIOL, V35, P635, DOI 10.1046/j.1365-2958.2000.01734.x; Altier C, 2000, INFECT IMMUN, V68, P6790, DOI 10.1128/IAI.68.12.6790-6797.2000; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; BAASE WA, 1992, FARADAY DISCUSS, V93, P173, DOI 10.1039/fd9929300173; Baker CS, 2002, MOL MICROBIOL, V44, P1599, DOI 10.1046/j.1365-2958.2002.02982.x; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; Boyd D, 2000, J BACTERIOL, V182, P842, DOI 10.1128/JB.182.3.842-847.2000; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; CUI Y, 1995, J BACTERIOL, V177, P5108, DOI 10.1128/jb.177.17.5108-5115.1995; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; De Guzman RN, 1998, BIOPOLYMERS, V48, P181, DOI 10.1002/(SICI)1097-0282(1998)48:2<181::AID-BIP7>3.0.CO;2-L; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Dubey AK, 2005, RNA, V11, P1579, DOI 10.1261/rna.2990205; Dubey AK, 2003, J BACTERIOL, V185, P4450, DOI 10.1128/JB.185.15.4450-4460.2003; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; Fortune DR, 2006, INFECT IMMUN, V74, P331, DOI 10.1128/IAI.74.1.331-339.2006; Gollnick P, 2005, ANNU REV GENET, V39, P47, DOI 10.1146/annurev.genet.39.073003.093745; Griffith KL, 2002, BIOCHEM BIOPH RES CO, V290, P397, DOI 10.1006/bbrc.2001.6152; Gutierrez P, 2005, J BACTERIOL, V187, P3496, DOI 10.1128/JB.187.10.3496-3501.2005; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Heeb S, 2006, J MOL BIOL, V355, P1026, DOI 10.1016/j.jmb.2005.11.045; Heurlier K, 2004, J BACTERIOL, V186, P2936, DOI 10.1128/JB.186.10.2936-2945.2004; Jackson DW, 2002, J BACTERIOL, V184, P290, DOI 10.1128/JB.184.1.290-301.2002; Jovine L, 1996, STRUCTURE, V4, P621, DOI 10.1016/S0969-2126(96)00066-4; KELLY PA, 1994, HORM RES, V42, P133, DOI 10.1159/000184185; KIMURA M, 1979, SCI AM, V241, P98, DOI 10.1038/scientificamerican1179-98; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lenz DH, 2005, MOL MICROBIOL, V58, P1186, DOI 10.1111/j.1365-2958.2005.04902.x; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Liu MY, 1997, J BACTERIOL, V179, P4639, DOI 10.1128/jb.179.14.4639-4642.1997; Liu MY, 1997, J BIOL CHEM, V272, P17502, DOI 10.1074/jbc.272.28.17502; Liu Y, 1998, MOL MICROBIOL, V29, P219, DOI 10.1046/j.1365-2958.1998.00924.x; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; MacLennan DH, 1998, ACTA PHYSIOL SCAND, V163, P55; Maris C, 2005, FEBS J, V272, P2118, DOI 10.1111/j.1742-4658.2005.04653.x; Messias AC, 2004, ACCOUNTS CHEM RES, V37, P279, DOI 10.1021/ar030034m; Molofsky AB, 2003, MOL MICROBIOL, V50, P445, DOI 10.1046/j.1365-2958.2003.03706.x; Norton RS, 2004, CURR MED CHEM, V11, P3041, DOI 10.2174/0929867043363947; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Rife C, 2005, PROTEINS, V61, P449, DOI 10.1002/prot.20502; ROMEO T, 1993, J BACTERIOL, V175, P4744, DOI 10.1128/JB.175.15.4744-4755.1993; SABNIS NA, 1995, J BIOL CHEM, V270, P29096, DOI 10.1074/jbc.270.49.29096; Sasaki N, 1998, ADV BIOPHYS, V35, P1; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stefl R, 2005, EMBO REP, V6, P33, DOI 10.1038/sj.embor.7400325; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valverde C, 2004, J BIOL CHEM, V279, P25066, DOI 10.1074/jbc.M401870200; van den Worm SHE, 1998, NUCLEIC ACIDS RES, V26, P1345, DOI 10.1093/nar/26.5.1345; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Wang X, 2005, MOL MICROBIOL, V56, P1648, DOI 10.1111/j.1365-2958.2005.04648.x; Wei BDL, 2001, MOL MICROBIOL, V40, P245, DOI 10.1046/j.1365-2958.2001.02380.x; Weilbacher T, 2003, MOL MICROBIOL, V48, P657, DOI 10.1046/j.1365-2958.2003.03459.x; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; Wiesmann C, 2001, CELL MOL LIFE SCI, V58, P748, DOI 10.1007/PL00000898; Wilusz CJ, 2005, NAT STRUCT MOL BIOL, V12, P1031, DOI 10.1038/nsmb1037; Yakhnin AV, 2000, J BIOL CHEM, V275, P4519, DOI 10.1074/jbc.275.6.4519	65	87	91	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31832	31842		10.1074/jbc.M606057200	http://dx.doi.org/10.1074/jbc.M606057200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16923806				2022-12-25	WOS:000241235300070
J	Demarest, SJ; Hopp, J; Chung, J; Hathaway, K; Mertsching, E; Cao, X; George, J; Miatkowski, K; LaBarre, MJ; Shields, M; Kehry, MR				Demarest, Stephen J.; Hopp, Jennifer; Chung, Julie; Hathaway, Karen; Mertsching, Elisabeth; Cao, Xianjun; George, Judy; Miatkowski, Konrad; LaBarre, Michael J.; Shields, Michael; Kehry, Marilyn R.			An intermediate pH unfolding transition abrogates the ability of IgE to interact with its high affinity receptor Fc epsilon RI alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; HUMAN-IMMUNOGLOBULIN E; MAST-CELLS; PROTEIN INTERACTIONS; CYTOKINE PRODUCTION; CRYSTAL-STRUCTURE; ANTIBODY; DOMAIN; BINDING; SURVIVAL	The interaction between IgE-Fc (Fc epsilon) and its high affinity receptor Fc epsilon RI on the surface of mast cells and basophils is a key event in allergen-induced allergic inflammation. Recently, several therapeutic strategies have been developed based on this interaction, and some include Fc epsilon-containing moieties. Unlike well characterized IgG therapeutics, the stability and folding properties of IgE are not well understood. Here, we present comparative biophysical analyses of the pH stability and thermostability of Fc epsilon and IgG1-Fc (Fc gamma). Fc gamma was found to be significantly less stable than Fc gamma under all pH and NaCl conditions tested. Additionally, the C epsilon 3C epsilon 4 domains of Fc epsilon were shown to become intrinsically unfolded at pH values below 5.0. The interaction between Fc epsilon and an Fc gamma-Fc epsilon RI alpha fusion protein was studied between pH 4.5 and 7.4 using circular dichroism and a combination of differential scanning calorimetry and isothermal titration calorimetry. Under neutral pH conditions, the apparent affinity of Fc epsilon for the dimeric fusion protein was extremely high compared with published values for the monomeric receptor (K-D < 10(-12) M). Titration to pH 6.0 did not significantly change the binding affinity, and titration to pH 5.5 only modestly attenuated affinity. At pH values below 5.0, the receptor binding domains of Fc epsilon unfolded, and interaction of Fc epsilon with the Fc gamma-Fc epsilon RI alpha fusion protein was abrogated. The unusual pH sensitivity of Fc epsilon may play a role in antigen-dependent regulation of receptor-bound, non-circulating IgE.	Biogen Idec Inc, Dept Prot Chem, San Diego, CA 92122 USA	Biogen	Demarest, SJ (corresponding author), Biogen Idec Inc, Dept Prot Chem, 5200 Res Pl, San Diego, CA 92122 USA.	stephen.demarest@biogenidec.com						Belostotsky R, 2004, CLIN IMMUNOL, V110, P89, DOI 10.1016/j.clim.2003.08.014; BONNEFOY JY, 1995, CURR OPIN IMMUNOL, V7, P355, DOI 10.1016/0952-7915(95)80110-3; Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; Brezinsky SCG, 2003, J IMMUNOL METHODS, V277, P141, DOI 10.1016/S0022-1759(03)00108-X; Demarest SJ, 2004, J MOL BIOL, V335, P41, DOI 10.1016/j.jmb.2003.10.040; FURUICHI K, 1986, J IMMUNOL, V136, P1015; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Glaser SM, 2005, J BIOL CHEM, V280, P41494, DOI 10.1074/jbc.M508739200; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Helm BA, 1996, J BIOL CHEM, V271, P7494, DOI 10.1074/jbc.271.13.7494; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; Henry AJ, 2000, BIOCHEMISTRY-US, V39, P7406, DOI 10.1021/bi9928391; Hunt J, 2005, J BIOL CHEM, V280, P16808, DOI 10.1074/jbc.M500965200; Kabat EA, 1991, SEQUENCES PROTEINS I; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kawakami T, 2005, J IMMUNOL, V175, P4167, DOI 10.4049/jimmunol.175.7.4167; Keown MB, 1998, BIOCHEMISTRY-US, V37, P8863, DOI 10.1021/bi972354h; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kitaura J, 2004, J IMMUNOL, V173, P4317, DOI 10.4049/jimmunol.173.7.4317; Kubo S, 2003, J IMMUNOL, V170, P775, DOI 10.4049/jimmunol.170.2.775; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MacGlashan D, 2005, CLIN REV ALLERG IMMU, V29, P49, DOI 10.1385/CRIAI:29:1:049; McDonnell JM, 2001, NAT STRUCT BIOL, V8, P437, DOI 10.1038/87603; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nakamura T, 2000, INT J IMMUNOPHARMACO, V22, P131, DOI 10.1016/S0192-0561(99)00068-5; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; Price NE, 2005, J BIOL CHEM, V280, P2324, DOI 10.1074/jbc.M409458200; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; Sechi S, 1996, J BIOL CHEM, V271, P19256, DOI 10.1074/jbc.271.32.19256; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 2002, IMMUNOL LETT, V82, P51, DOI 10.1016/S0165-2478(02)00018-4; URLAUB G, 1985, SOMAT CELL MOLEC GEN, V11, P71, DOI 10.1007/BF01534736; Vermeer AWP, 2000, BIOPHYS J, V78, P394, DOI 10.1016/S0006-3495(00)76602-1; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6; Wurzburg BA, 2002, MOL IMMUNOL, V38, P1063, DOI 10.1016/S0161-5890(02)00035-4; Xu K, 1998, J CELL SCI, V111, P2385; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	41	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30755	30767		10.1074/jbc.M605190200	http://dx.doi.org/10.1074/jbc.M605190200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16905745	hybrid			2022-12-25	WOS:000241075900052
J	Devgan, V; Nguyen, BC; Oh, H; Dotto, GP				Devgan, Vikram; Nguyen, Bach-Cuc; Oh, Heysun; Dotto, G. Paolo			p21(WAF1/Cip1) suppresses keratinocyte differentiation independently of the cell cycle through transcriptional up-regulation of the IGF-I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSTAINED ACTIVATION; GROWTH; EXPRESSION; P21(CIP1/WAF1); RECEPTOR; INHIBITOR; APOPTOSIS; P21; RESISTANCE; PROTEINS	p21 plays a dual role in keratinocyte growth and differentiation control. It restricts the number of keratinocyte stem cell populations while inhibiting the later stages of differentiation independently of the cell cycle. The molecular/biochemical mechanism for the differentiation suppressive function of p21 is unknown. Here we show that elevated p21 expression leads to activation of MAPK family members in a keratinocyte-specific and cell cycle-independent manner, and up-regulation of MAPK activity can explain the inhibitory effects of p21 on differentiation. p21 induces transcription of several genes with MAPK activation potential. Although several of these genes are induced by p21 in a MAPK-dependent manner, expression of IGF-I is induced upstream of MAPK activation. IGF-I stimulation is by itself sufficient to cause MAPK activation and inhibit differentiation and suppression of IGF-I signaling by knock down of the cognate receptor (IGF-R1), diminishing the ability of p21 to activate MAPK and suppress differentiation. Thus, in keratinocytes, the ability of p21 to suppress differentiation can be explained by cell type-specific activation of the MAPK cascade by transcriptional up-regulation of the IGF-I gene.	Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	University of Lausanne; Harvard University; Massachusetts General Hospital; Harvard University	Dotto, GP (corresponding author), Univ Lausanne, Dept Biochem, Chem Bovaresses 155, CH-1066 Epalinges, Switzerland.	Gian-Paolo.Dotto@unil.ch			NATIONAL CANCER INSTITUTE [P01CA016038, R01CA073796] Funding Source: NIH RePORTER; NCI NIH HHS [CA73796, CA16038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamo ML., 1995, DIABETES REV, V3, P2; Aoki M, 2004, J BIOL CHEM, V279, P32643, DOI 10.1074/jbc.M313247200; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bellosta P, 2003, J BONE MINER RES, V18, P818, DOI 10.1359/jbmr.2003.18.5.818; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fritah A, 2005, MOL CELL BIOL, V25, P2419, DOI 10.1128/MCB.25.6.2419-2430.2005; Fuhler GM, 2005, J LEUKOCYTE BIOL, V77, P257, DOI 10.1189/jlb.0504306; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; HARPER JW, 1993, CELL, V75, P805; HEALY E, 1995, J INVEST DERMATOL, V105, P274, DOI 10.1111/1523-1747.ep12318430; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; KIKUCHI K, 1992, J BIOL CHEM, V267, P21505; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Ng IOL, 1999, ORAL ONCOL, V35, P63, DOI 10.1016/S1368-8375(98)00083-9; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Oh H, 2002, P NATL ACAD SCI USA, V99, P5430, DOI 10.1073/pnas.082123999; RISTOW HJ, 1993, GROWTH REGULAT, V3, P129; Rudman SM, 1997, J INVEST DERMATOL, V109, P770, DOI 10.1111/1523-1747.ep12340934; Sadagurski M, 2006, MOL CELL BIOL, V26, P2675, DOI 10.1128/MCB.26.7.2675-2687.2006; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Wang J, 2005, J BIOL CHEM, V280, P37725, DOI 10.1074/jbc.M507976200; Weger N, 2005, J INVEST DERMATOL, V125, P873, DOI 10.1111/j.0022-202X.2005.23946.x; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; ZENDEGUI J G, 1988, Journal of Cellular Physiology, V136, P257, DOI 10.1002/jcp.1041360207; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	43	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30463	30470		10.1074/jbc.M604684200	http://dx.doi.org/10.1074/jbc.M604684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912042	hybrid			2022-12-25	WOS:000241075900021
J	Kanekura, K; Nishimoto, I; Aiso, S; Matsuoka, M				Kanekura, Kohsuke; Nishimoto, Ikuo; Aiso, Sadakazu; Matsuoka, Masaaki			Characterization of amyotrophic lateral sclerosis-linked P56S mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; MOTOR-NEURON DEGENERATION; OXYSTEROL-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; INO1 EXPRESSION; ALS2 GENE; MUTANT; PRODUCT; DEATH; ACTIVATION	The P56S mutation in VAPB (vesicle-associated membrane protein-associated protein B) causes autosomal dominant motoneuronal diseases. Although it was reported that the P56S mutation induces localization shift of VAPB from endoplasmic reticulum ( ER) to non-ER compartments, it remains unclear what the physiological function of VAPB is and how the P56S mutation in VAPB causes motoneuronal diseases. Here we demonstrate that overexpression of wild type VAPB (wt-VAPB) promotes unfolded protein response (UPR), which is an ER reaction to suppress accumulation of misfolded proteins, and that small interfering RNA for VAPB attenuates UPR to chemically induced ER stresses, indicating that VAPB is physiologically involved in UPR. The P56S mutation nullifies the function of VAPB to mediate UPR by inhibiting folding of VAPB that results in insolubility and aggregate formation of VAPB in non-ER fractions. Furthermore, we have found that expression of P56S-VAPB inhibits UPR, mediated by endogenous wt-VAPB, by inducing aggregate formation and mislocalization into non-ER fractions of wt-VAPB. Consequently, the P56S mutation in a single allele of the VAPB gene may diminish the activity of VAPB to mediate UPR to less than half the normal level. We thus speculate that the malfunction of VAPB to mediate UPR, caused by the P56S mutation, may contribute to the development of motoneuronal degeneration linked to VAPB/ALS8.	Keio Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Matsuoka, M (corresponding author), Keio Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	sakimatu@sc.itc.keio.ac.jp						Amarilio R, 2005, J BIOL CHEM, V280, P5934, DOI 10.1074/jbc.M409566200; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Berg S, 2005, J BIOL CHEM, V280, P5651, DOI 10.1074/jbc.M411418200; Brickner JH, 2004, PLOS BIOL, V2, P1843, DOI 10.1371/journal.pbio.0020342; Brown B, 2001, J LAW MED ETHICS, V29, P166; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chen YZ, 2004, AM J HUM GENET, V74, P1128, DOI 10.1086/421054; Chiba T, 2004, J NEUROSCI RES, V78, P542, DOI 10.1002/jnr.20305; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Ghadge GD, 1997, J NEUROSCI, V17, P8756; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hadano S, 2006, HUM MOL GENET, V15, P233, DOI 10.1093/hmg/ddi440; Hamamoto I, 2005, J VIROL, V79, P13473, DOI 10.1128/JVI.79.21.13473-13482.2005; Iwawaki T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970; Kagiwada S, 2003, J BIOCHEM, V133, P515, DOI 10.1093/jb/mvg068; Kagiwada S, 1998, J BACTERIOL, V180, P1700, DOI 10.1128/JB.180.7.1700-1708.1998; Kaiser SE, 2005, STRUCTURE, V13, P1035, DOI 10.1016/j.str.2005.04.010; Kanekura K, 2004, J BIOL CHEM, V279, P19247, DOI 10.1074/jbc.M313236200; Kanekura K, 2005, J BIOL CHEM, V280, P4532, DOI 10.1074/jbc.M410508200; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lehto M, 2005, EXP CELL RES, V310, P445, DOI 10.1016/j.yexcr.2005.08.003; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; NIKAWA J, 1995, J BIOCHEM, V118, P39, DOI 10.1093/oxfordjournals.jbchem.a124889; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; Nishimura AL, 2004, AM J HUM GENET, V75, P822, DOI 10.1086/425287; Nishimura AL, 2005, HUM GENET, V118, P499, DOI 10.1007/s00439-005-0031-y; Nishimura Y, 1999, BIOCHEM BIOPH RES CO, V254, P21, DOI 10.1006/bbrc.1998.9876; Obata Y, 2005, J NEUROSCI RES, V81, P720, DOI 10.1002/jnr.20594; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Perry RJ, 2006, MOL BIOL CELL, V17, P2604, DOI 10.1091/mbc.E06-01-0060; Schofield CM, 2004, BIOCHEMISTRY-US, V43, P10058, DOI 10.1021/bi036159g; Shults CW, 2006, P NATL ACAD SCI USA, V103, P1661, DOI 10.1073/pnas.0509567103; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; Wyles JP, 2002, J BIOL CHEM, V277, P29908, DOI 10.1074/jbc.M201191200; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160	43	157	163	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30223	30233		10.1074/jbc.M605049200	http://dx.doi.org/10.1074/jbc.M605049200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16891305	hybrid			2022-12-25	WOS:000240896300082
J	Muller, MR; Zheng, F; Werner, S; Alzheimer, C				Mueller, Mischa Roland; Zheng, Fang; Werner, Sabine; Alzheimer, Christian			Transgenic mice expressing dominant-negative activin receptor IB in forebrain neurons reveal novel functions of activin at glutamatergic synapses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BRAIN-INJURY; BETA; INDUCTION; ISOFORMS; REPAIR; SIGNAL	The transforming growth factor beta family member activin is an important regulator of development and tissue repair. It is strongly up-regulated after acute injury to the adult brain, and application of exogenous activin protects neurons in several lesion models. To explore the role of endogenous activin in the normal and acutely damaged brain, we generated transgenic mice expressing a dominant-negative activin receptor IB (dnActRIB) mutant in forebrain neurons. The functionality of the transgene was verified in vivo. Hippocampal neurons from dnActRIB mice were significantly more vulnerable to intracerebroventricular injection of the excitotoxin kainic acid than those from control littermates, indicating a crucial role of endogenous activin in the rescue of neurons from excitotoxic insult. Because dnActRIB is only expressed in neurons, but not in glial cells, activin affords protection at least in part through a direct action on endangered neurons. Unexpectedly, the transgenic mice also revealed a prominent novel role of activin in glutamatergic neurotransmission in the intact adult brain. Electrophysiologic examination of excitatory synapses onto CA1 pyramidal cells in hippocampal slices of dnActRIB mice showed a reduced NMDA current response, which was associated with impaired long term potentiation. This is the first demonstration that activin receptor signaling is essential to optimize the performance of neuronal circuits in the mature brain under physiological conditions.	Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Kiel, Inst Physiol, D-24098 Kiel, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Kiel	Werner, S (corresponding author), Swiss Fed Inst Technol, Inst Cell Biol, HPM D42, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch; c.alzheimer@physiologie.uni-kiel.de		Zheng, Fang/0000-0002-5699-8063; Werner, Sabine/0000-0001-7397-8710				Alzheimer C, 2002, ADV EXP MED BIOL, V513, P335; ANDREASSON K, 1995, NEUROSCIENCE, V69, P781, DOI 10.1016/0306-4522(95)00245-E; [Anonymous], CYTOKINE HDB; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Bamberger C, 2005, AM J PATHOL, V167, P733, DOI 10.1016/S0002-9440(10)62047-0; Bao YL, 2005, J ENDOCRINOL, V184, P493, DOI 10.1677/joe.1.05978; Dow AL, 2005, J NEUROSCI, V25, P4908, DOI 10.1523/JNEUROSCI.5155-04.2005; Gamer LW, 2005, DEV BIOL, V285, P156, DOI 10.1016/j.ydbio.2005.06.012; Hughes PE, 1999, NEUROSCIENCE, V92, P197, DOI 10.1016/S0306-4522(98)00724-6; Inokuchi K, 1996, FEBS LETT, V382, P48, DOI 10.1016/0014-5793(96)00135-4; Iwahori Y, 1997, BRAIN RES, V760, P52, DOI 10.1016/S0006-8993(97)00275-8; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; Lai M, 1997, NEUROREPORT, V8, P2691, DOI 10.1097/00001756-199708180-00011; Mansuy IM, 1998, NEURON, V21, P257, DOI 10.1016/S0896-6273(00)80533-4; MATHEWS LS, 1993, RECEPTOR, V3, P173; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Soderstrom S, 1996, CELL TISSUE RES, V286, P269, DOI 10.1007/s004410050697; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tretter YP, 2000, NAT MED, V6, P812, DOI 10.1038/77548; Tretter YP, 1996, NEUROREPORT, V7, P1819, DOI 10.1097/00001756-199607290-00026; Tsuchida K, 2004, MOL CELL ENDOCRINOL, V220, P59, DOI 10.1016/j.mce.2004.03.009; Werner S, 2006, CYTOKINE GROWTH F R, V17, P157, DOI 10.1016/j.cytogfr.2006.01.001; Wu DD, 1999, BRAIN RES, V835, P369, DOI 10.1016/S0006-8993(99)01638-8; Yang H, 1999, J HISTOCHEM CYTOCHEM, V47, P431, DOI 10.1177/002215549904700402; Zhou YL, 2000, MOL ENDOCRINOL, V14, P2066, DOI 10.1210/me.14.12.2066	27	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29076	29084		10.1074/jbc.M604959200	http://dx.doi.org/10.1074/jbc.M604959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16885157	hybrid			2022-12-25	WOS:000240680500062
J	Raffa, GD; Wohlschlegel, J; Yates, JR; Boddy, MN				Raffa, Grazia D.; Wohlschlegel, James; Yates, John R., III; Boddy, Michael N.			SUMO-binding motifs mediate the Rad60-dependent response to replicative stress and self-association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHECKPOINT KINASE CDS1; FISSION YEAST; FHA DOMAIN; PROTEINS; IDENTIFICATION; RECOMBINATION; TOLERANCE; COMPLEXES; FAMILY; MUS81	In fission yeast, the replication checkpoint is enforced by the kinase Cds1 ( human Chk2), which regulates both cell cycle progression and DNA repair factors to ensure that the genome is faithfully duplicated prior to mitosis. Cds1 contains a forkhead-associated domain that mediates its interaction with phosphorylated residues in target proteins. One target of Cds1 is the essential nuclear protein Rad60, which contains the unique structural feature of tandem SUMO homology domains at its C terminus. Hypomorphic mutants of Rad60 cause profound defects in DNA repair and replication stress tolerance. To explore the physiological significance of the Cds1-Rad60 interaction, we have examined the phosphorylation of Rad60 by Cds1 in vitro and the in vivo phosphorylation of Rad60 in response to replication blocks. We find that the N terminus but not the SUMO-like domain of Rad60 is phosphorylated in both conditions. Three important Rad60 phosphorylation sites were identified: Thr(72), Ser(32), and Ser(34). Rad(60) Thr(72) mediates the Cds1-Rad60 interaction and is required for the Cds1-dependent phosphorylation of Rad60 in response to replication arrest. Phosphorylation of Rad60 Ser32 and Ser34 in a putative SUMO-binding motif is critical for the survival of replication stress. In addition, mutation of Rad60 Ser32 and Ser34 to alanine is lethal in cells deleted for the RecQ DNA helicase Rqh1. Finally, we find that Rad60 self-associates via its C-terminal SUMO-like domain and putative SUMO-binding motifs.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Boddy, MN (corresponding author), Scripps Res Inst, Dept Mol Biol, MB107,10550 N Torrey Pines Rd,MB-3, La Jolla, CA 92037 USA.	nboddy@scripps.edu	Boddy, Michael/A-7214-2009	raffa, grazia daniela/0000-0002-5072-5240	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068608] Funding Source: NIH RePORTER; NCRR NIH HHS [RR11823-08] Funding Source: Medline; NIGMS NIH HHS [GM068608] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn JS, 2005, EMBO J, V24, P2011, DOI 10.1038/sj.emboj.7600670; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2003, MOL CELL BIOL, V23, P5939, DOI 10.1128/MCB.23.16.5939-5946.2003; Branzei D, 2005, CURR OPIN CELL BIOL, V17, P568, DOI 10.1016/j.ceb.2005.09.003; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Hannich JT, 2005, J BIOL CHEM, V280, P4102, DOI 10.1074/jbc.M413209200; Hartmann-Petersen R, 2004, SEMIN CELL DEV BIOL, V15, P247, DOI 10.1016/j.semcdb.2003.12.006; Hecker CM, 2006, J BIOL CHEM, V281, P16117, DOI 10.1074/jbc.M512757200; Kai M, 2005, GENE DEV, V19, P919, DOI 10.1101/gad.1304305; Kai M, 2003, MUTAT RES-FUND MOL M, V532, P59, DOI 10.1016/j.mrfmmm.2003.08.010; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Meister P, 2005, J CELL BIOL, V168, P537, DOI 10.1083/jcb.200410006; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morishita T, 2002, MOL CELL BIOL, V22, P3537, DOI 10.1128/MCB.22.10.3537-3548.2002; Novatchkova M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-22; Pfander B, 2005, NATURE, V436, P428, DOI 10.1038/nature03665; Shiozaki K, 1997, METHOD ENZYMOL, V283, P506; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Upadhya SC, 2003, TRENDS BIOCHEM SCI, V28, P280, DOI 10.1016/S0968-0004(03)00092-6	25	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27973	27981		10.1074/jbc.M601943200	http://dx.doi.org/10.1074/jbc.M601943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16880212	hybrid			2022-12-25	WOS:000240534400034
J	Jackson-Bernitsas, DG; Ichikawa, H; Takada, Y; Myers, JN; Lin, XL; Darnay, BG; Chaturvedi, MM; Aggarwal, BB				Jackson-Bernitsas, D. G.; Ichikawa, H.; Takada, Y.; Myers, J. N.; Lin, X. L.; Darnay, B. G.; Chaturvedi, M. M.; Aggarwal, B. B.			Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappa B activation and proliferation in human head and neck squamous cell carcinoma	ONCOGENE			English	Article						head and neck squamous cell carcinoma; nuclear factor-kappa B; tumor necrosis factor; proliferation	TUMOR-NECROSIS-FACTOR; GENE-EXPRESSION; FACTOR-RECEPTOR; GROWTH-FACTOR; ALPHA; TNF; APOPTOSIS; REQUIRES; CURCUMIN; SURVIVAL	Constitutively activated nuclear factor-kappa B (NF-kappa B) has been associated with a variety of aggressive tumor types, including head and neck squamous cell carcinoma (HNSCC); however, the mechanism of its activation is not fully understood. Therefore, we investigated the molecular pathway that mediates constitutive activation of NF-kappa B in a series of HNSCC cell lines. We confirmed that NF-kappa B was constitutively active in all HNSCC cell lines (FaDu, LICR-LON-HN5 and SCC4) examined as indicated by DNA binding, immunocytochemical localization of p65, by NF-kappa B-dependent reporter gene expression and its inhibition by dominant-negative (DN)-inhibitory subunit of NF-kappa B (I kappa B alpha), the natural inhibitor of NF-kappa B. Constitutive NF-kappa B activation in HNSCC was found to be due to constitutive activation of IjBa kinase (IKK); and this correlated with constitutive expression of phosphorylated forms of I kappa B alpha and p65 proteins. All HNSCC showed the expression of p50, p52, p100 and receptor-interacting protein; all linked with NF-kappa B activation. The expression of constitutively active NF-kappa B in HNSCC is mediated through the tumor necrosis factor (TNF) signaling pathway, as NF-kappa B reporter activity was inhibited by DN-TNF receptor-associated death domain ( TRADD), DN-TNF receptor-associated factor ( TRAF) 2, DN-receptor-interacting protein ( RIP), DN-transforming growth factor-beta-activated kinase 1 (TAK1), DN-kappa-Ras, DN-AKT and DN-IKK but not by DN-TRAF5 or DN-TRAF6. Constitutive NF-kappa B activation was also associated with the autocrine expression of TNF, TNF receptors and receptor-activator of NF-kappa B and its ligand in HNSCC cells but not interleukin (IL)-1 beta. All HNSCC cell lines expressed IL-6, a NF-kappa B-regulated gene product. Furthermore, treatment of HNSCC cells with anti-TNF antibody downregulated constitutively active NF-kappa B, and this was associated with inhibition of IL-6 expression and cell proliferation. Our results clearly demonstrate that constitutive activation of NF-kappa B is mediated through the TRADD-TRAF2-RIP-TAK1-IKK pathway, making TNF a novel target in the treatment of head and neck cancer.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut,Unit 143, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut,Unit 143, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 1996, CANCER RES, V56, P5156; Aggarwal BB, 2006, E SCHERING RES FDN W, V56, P161; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal S, 2004, INT J CANCER, V111, P679, DOI 10.1002/ijc.20333; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Buchholz TA, 2005, CLIN CANCER RES, V11, P8398, DOI 10.1158/1078-0432.CCR-05-0885; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Dong G, 2001, CANCER RES, V61, P4797; Duffey DC, 1999, CANCER RES, V59, P3468; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; ESTROV Z, 1993, J EXP MED, V177, P763, DOI 10.1084/jem.177.3.763; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Izzo JG, 2006, J CLIN ONCOL, V24, P748, DOI 10.1200/JCO.2005.03.8810; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; LoTempio MM, 2005, CLIN CANCER RES, V11, P6994, DOI 10.1158/1078-0432.CCR-05-0301; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Ozes ON, 1999, NATURE, V401, P82; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Thomas GR, 2004, CANCER IMMUNOL IMMUN, V53, P33, DOI 10.1007/s00262-003-0433-4; Wang YF, 2002, HEAD NECK-J SCI SPEC, V24, P850, DOI 10.1002/hed.10145; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Woods KV, 1998, CANCER RES, V58, P3142	39	164	171	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1385	1397		10.1038/sj.onc.1209945	http://dx.doi.org/10.1038/sj.onc.1209945			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953224				2022-12-25	WOS:000244558800003
J	Inamoto, S; Iwata, S; Inamoto, T; Nomura, S; Sasaki, T; Urasaki, Y; Hosono, O; Kawasaki, H; Tanaka, H; Dang, NH; Morimoto, C				Inamoto, S.; Iwata, S.; Inamoto, T.; Nomura, S.; Sasaki, T.; Urasaki, Y.; Hosono, O.; Kawasaki, H.; Tanaka, H.; Dang, N. H.; Morimoto, C.			Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7	ONCOGENE			English	Article						Cas-L; Smad6; Smad7; TGF-beta; cancer	FOCAL ADHESION KINASE; MEDIATED TYROSINE PHOSPHORYLATION; CAS-L; DOCKING PROTEIN; INTEGRIN; HEF1; CELLS; EXPRESSION; RECEPTOR; IDENTIFICATION	Crk-associated substrate lymphocyte type (Cas-L) is a 105 kDa docking protein with diverse functional properties, including regulation of cell division, proliferation, migration and adhesion. Cas-L is also involved in beta 1 integrin- or antigen receptor-mediated signaling in B and T cells. In the present study, we demonstrate that Cas-L potentiates transforming growth factor-beta (TGF-beta) signaling pathway by interacting with Smad6 and Smad7. Immunoprecipitation experiments reveal that single domain deletion of full-length Cas-L completely abolishes its docking function with Smad6 and Smad7, suggesting that the natural structure of Cas-L is necessary for its association with Smad6 and Smad7. On the other hand, both N-terminal and C-terminal deletion mutants of Smad6 and Smad7 still retain their docking ability to Cas-L, suggesting that Smad6 and Smad7 possess several binding motifs to Cas-L. Moreover, Cas-L interaction with Mad-homology (MH)2 domain, but not with MH1 domain of Smad6 or Smad7, ameliorates TGF-beta-induced signaling pathway. Finally, depletion of Cas-L by small-interfering RNA oligo attenuates TGF-beta-induced growth inhibition of Huh-7 cells, with a concomitant reduction in phosphorylation of Smad2 and Smad3. These results strongly suggest that Cas-L is a potential regulator of TGF-beta signaling pathway.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Osaka Med Coll, Dept Med, Osaka, Japan; Nevada Canc Inst, Dept Hematol Malignancies, Las Vegas, NV USA	University of Tokyo; Osaka Medical College; University of California System; University of California San Diego	Morimoto, C (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	morimoto@ims.u-tokyo.ac.jp	Iwata, Satoshi/A-8819-2011					Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fashena SJ, 2002, J CELL SCI, V115, P99; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ito Y, 2001, J BIOL CHEM, V276, P44163, DOI 10.1074/jbc.M011424200; Iwata S, 2005, ONCOGENE, V24, P1262, DOI 10.1038/sj.onc.1208261; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kamiguchi K, 1999, J IMMUNOL, V163, P563; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; Krishnan P, 2001, DEV GROWTH DIFFER, V43, P115; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Lee HY, 2002, CANCER RES, V62, P3530; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Miyake-Nishijima R, 2003, ARTHRITIS RHEUM, V48, P1890, DOI 10.1002/art.11047; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ohashi Y, 1999, J IMMUNOL, V163, P3727; Ohashi Y, 1998, J BIOL CHEM, V273, P6446, DOI 10.1074/jbc.273.11.6446; Ohnuma K, 2004, P NATL ACAD SCI USA, V101, P14186, DOI 10.1073/pnas.0405266101; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Sasaki T, 2005, STROKE, V36, P2457, DOI 10.1161/01.STR.0000185672.10390.30; Seo S, 2005, J IMMUNOL, V175, P3492, DOI 10.4049/jimmunol.175.6.3492; Sugano Y, 2003, ONCOGENE, V22, P2309, DOI 10.1038/sj.onc.1206305; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tanaka J, 1999, BIOCHEM BIOPH RES CO, V264, P938, DOI 10.1006/bbrc.1999.1617; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yagil C, 2005, CIRC RES, V96, P617, DOI 10.1161/01.RES.0000160556.52369.61; Zhang ZY, 2000, J BIOL CHEM, V275, P37219, DOI 10.1074/jbc.M001818200	42	17	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2007	26	6					893	904		10.1038/sj.onc.1209848	http://dx.doi.org/10.1038/sj.onc.1209848			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909115				2022-12-25	WOS:000244063800010
J	Cody, NAL; Ouellet, V; Manderson, EN; Quinn, MCJ; Filali-Mouhim, A; Tellis, P; Zietarska, M; Provencher, DM; Mes-Masson, AM; Chevrette, M; Tonin, PN				Cody, N. A. L.; Ouellet, V.; Manderson, E. N.; Quinn, M. C. J.; Filali-Mouhim, A.; Tellis, P.; Zietarska, M.; Provencher, D. M.; Mes-Masson, A-M; Chevrette, M.; Tonin, P. N.			Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p	ONCOGENE			English	Article						ovarian cancer; chromosome 3p; radiation hybrids; tumor suppressor gene	ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; PRIMARY CULTURES; SOLID TUMORS; TRANSCRIPTION FACTORS; LOW-GRADE; CARCINOMA; HETEROZYGOSITY; LOCUS; ADENOCARCINOMA	Multiple chromosome 3p tumor suppressor genes (TSG) have been proposed in the pathogenesis of ovarian cancer based on complex patterns of 3p loss. To attain functional evidence in support of TSGs and identify candidate regions, we applied a chromosome transfer method involving cell fusions of the tumorigenic OV90 human ovarian cancer cell line, monoallelic for 3p and an irradiated mouse cell line containing a human chromosome 3 in order to derive OV90 hybrids containing normal 3p fragments. The resulting hybrids showed complete or incomplete suppression of tumorigenicity in nude mouse xenograft assays, and varied in their ability to form colonies in soft agarose and three-dimensional spheroids in a manner consistent with alteration of their in vivo tumorigenic phenotypes. Expression microarray analysis identified a set of common differentially expressed genes, such as SPARC, DAB2 and VEGF, some of which have been shown implicated in ovarian cancer. Genotyping assays revealed that they harbored normal 3p fragments, some of which overlapped candidate TSG regions (3p25p26, 3p24 and 3p14-pcen) identified previously in loss of heterozygosity analyses of ovarian cancers. However, only the 3p12-pcen region was acquired in common by all hybrids where expression microarray analysis identified differentially expressed genes. The correlation of 3p12peen transfer and tumor suppression with a concerted reprogramming of the cellular transcriptome suggest that the putative TSG may have affected key underlying events in ovarian cancer.	McGill Univ, Dept Human Genet, Montreal, PQ H3H 1P3, Canada; McGill Univ, Res Inst, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; Univ Montreal, Inct Canc Montreal, Ctr Rech, Ctr Hosp, Montreal, PQ, Canada; Univ Montreal, Div Gynecol Oncol, Montreal, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Surg, Div Urol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada	McGill University; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University	Tonin, PN (corresponding author), Montreal Gen Hosp, Room L10-120,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	patricia.tonin@mcgill.ca		Mes-Masson, Anne-Marie/0000-0002-6498-266X				Adams J, 2002, CURR OPIN CHEM BIOL, V6, P486, DOI 10.1016/S1367-5931(02)00357-5; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Akutagawa N, 2002, JPN J CANCER RES, V93, P644, DOI 10.1111/j.1349-7006.2002.tb01302.x; Arcand SL, 2004, MOL CARCINOGEN, V41, P17, DOI 10.1002/mc.20038; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bayani J, 2002, CANCER RES, V62, P3466; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chen HH, 2004, J BIOL CHEM, V279, P30800, DOI 10.1074/jbc.M400154200; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; Davidson B, 2003, CANCER METAST REV, V22, P103, DOI 10.1023/A:1022272204045; DODSON MK, 1993, CANCER RES, V53, P4456; Doherty AMO, 2003, MAMM GENOME, V14, P583, DOI 10.1007/s00335-003-4002-0; DORIN JR, 1992, HUM MOL GENET, V1, P53, DOI 10.1093/hmg/1.1.53; EHLEN T, 1990, ONCOGENE, V5, P219; Fullwood P, 1999, CANCER RES, V59, P4662; GENTLEMAN R, 2003, VISUALIZATION ANNOTA; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hoglund M, 2001, GENE CHROMOSOME CANC, V31, P156; Hoglund M, 2003, CANCER RES, V63, P3378; Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655; KRUK PA, 1990, LAB INVEST, V63, P132; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Lacerte A, 2004, MOL ENDOCRINOL, V18, P1558, DOI 10.1210/me.2003-0470; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; Lott ST, 1998, CANCER RES, V58, P3533; Lounis H, 1998, ONCOGENE, V17, P2359, DOI 10.1038/sj.onc.1202152; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Lovell M, 1999, CANCER RES, V59, P2182; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; Manderson EN, 2002, MOL CARCINOGEN, V34, P78, DOI 10.1002/mc.10051; Manderson EN, 2002, GENOME RES, V12, P112, DOI 10.1101/gr.174202; Manning AP, 1999, MOL CARCINOGEN, V24, P218, DOI 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A; McMahon G, 2000, Oncologist, V5 Suppl 1, P3; Mertens F, 1997, CANCER RES, V57, P2765; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Mok SC, 1996, ONCOGENE, V12, P1895; Novak JP, 2002, GENOMICS, V79, P104, DOI 10.1006/geno.2001.6675; Paley PJ, 1997, CANCER, V80, P98, DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; Petursdottir TE, 2004, GENE CHROMOSOME CANC, V41, P232, DOI 10.1002/gcc.20072; Presneau N, 2005, MOL CARCINOGEN, V43, P141, DOI 10.1002/mc.20096; Presneau N, 2003, ONCOGENE, V22, P1568, DOI 10.1038/sj.onc.1206219; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; RIMESSI P, 1994, ONCOGENE, V9, P3467; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Simon R, 2000, GENE CHROMOSOME CANC, V28, P106, DOI 10.1002/(SICI)1098-2264(200005)28:1<106::AID-GCC13>3.3.CO;2-J; Speevak MD, 1996, MOL CELL BIOL, V16, P2214; SPEEVAK MD, 1995, CYTOGENET CELL GENET, V69, P63, DOI 10.1159/000133939; Taetle R, 1999, GENE CHROMOSOME CANC, V25, P290, DOI 10.1002/(SICI)1098-2264(199907)25:3<290::AID-GCC12>3.3.CO;2-7; Taetle R, 1999, GENE CHROMOSOME CANC, V25, P46, DOI 10.1002/(SICI)1098-2264(199905)25:1<46::AID-GCC7>3.3.CO;2-F; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187; Tse C, 2002, CANCER RES, V62, P542; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Xiang RH, 2002, CANCER RES, V62, P2637; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Yonescu R, 1996, CANCER GENET CYTOGEN, V87, P167, DOI 10.1016/0165-4608(95)00241-3; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104; ZHENG JP, 1991, CANCER RES, V51, P4045	70	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					618	632		10.1038/sj.onc.1209821	http://dx.doi.org/10.1038/sj.onc.1209821			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16909122				2022-12-25	WOS:000243731600014
J	Nagy, G; Ward, J; Mosser, DD; Koncz, A; Gergely, P; Stancato, C; Qian, YM; Fernandez, D; Niland, B; Grossman, CE; Telarico, T; Banki, K; Perl, A				Nagy, Gyorgy; Ward, Jeffrey; Mosser, Dick D.; Koncz, Agnes; Gergely, Peter, Jr.; Stancato, Christina; Qian, Yueming; Fernandez, David; Niland, Brian; Grossman, Craig E.; Telarico, Tiffany; Banki, Katalin; Perl, Andras			Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 VPU PROTEIN; HUMAN TRANSALDOLASE; T-CELLS; ENDOGENOUS RETROVIRUSES; MEDIATED DEGRADATION; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN; MAMMALIAN-CELLS; DOWN-MODULATION	A novel 2986-base transcript encoded by the antisense strand of the HRES-1 human endogenous retrovirus was isolated from peripheral blood lymphocytes. This transcript codes for a 218-amino acid protein, termed HRES-1/Rab4, based on homology to the Rab4 family of small GTPases. Antibody 13407 raised against recombinant HRES-1/Rab4 detected a native protein of identical molecular weight in human T cells. HRES-1 nucleotides 2151-1606, located upstream of HRES-1/Rab4 exon 1, have promoter activity when oriented in the direction of HRES1/Rab4 transcription. The human immunodeficiency virus, type 1 (HIV-1), tat gene stimulates transcriptional activity of the HRES-1/Rab4 promoter via trans-activation of the HRES-1 long terminal repeat. Transfection of HIV-1 tat into HeLa cells or infection of H9 and Jurkat cells by HIV-1 increased HRES-1/Rab4 protein levels. Overexpression of HRES-1/Rab4 in Jurkat cells abrogated HIV infection, gag p24 production, and apoptosis, whereas dominant- negative HRES-1/Rab4(S27N) had the opposite effects. HRES-1/Rab4 inhibited surface expression of CD4 and targeted it for lysosomal degradation. HRES-1/Rab4(S27N) enhanced surface expression, recycling, and total cellular CD4 content. Infection by HIV elicited a coordinate downregulation of CD4 and up-regulation of HRES-1/Rab4 in PBL. Moreover, overexpression of HRES-1/Rab4 reduced CD4 expression on peripheral blood CD4+ T cells. Stimulation by HIV-1 of HRES-1/Rab4 expression and its regulation of CD4 recycling reveal novel coordinate interactions between an infectious retrovirus and the human genome.	SUNY Syracuse, Coll Med, Dept Med, Syracuse, NY 13210 USA; SUNY Syracuse, Coll Med, Dept Microbiol & Immunol, Syracuse, NY 13210 USA; SUNY Syracuse, Coll Med, Dept Pathol, Syracuse, NY 13210 USA; Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	State University of New York (SUNY) System; State University of New York (SUNY) System; State University of New York (SUNY) System; University of Guelph	Perl, A (corresponding author), SUNY Syracuse, Coll Med, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.	perla@upstate.edu	Mosser, Dick D/A-7391-2008; Nagy, György/W-6254-2019	Nagy, György/0000-0003-1198-3228; Ward, Jeffrey/0000-0002-9707-895X; Caza, Tiffany/0000-0001-8988-8998; Perl, Andras/0000-0002-5017-1348; Qian, Yueming/0000-0001-7340-6421; Mosser, Richard/0000-0002-9183-2288	FOGARTY INTERNATIONAL CENTER [F05TW005421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048079, R56AI048079, R21AI061066] Funding Source: NIH RePORTER; FIC NIH HHS [F05 TW05421] Funding Source: Medline; NIAID NIH HHS [AI 61066, AI 48079] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Baban S, 1996, GENOMICS, V33, P463, DOI 10.1006/geno.1996.0221; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; BANKI K, 1994, J BIOL CHEM, V269, P2847; Banki K, 1996, FEBS LETT, V378, P161, DOI 10.1016/0014-5793(95)01446-2; BANKI K, 1992, P NATL ACAD SCI USA, V89, P1939, DOI 10.1073/pnas.89.5.1939; Banki K, 1999, J IMMUNOL, V162, P1466; BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0; BERKHOUT B, 1991, NUCLEIC ACIDS RES, V19, P6169, DOI 10.1093/nar/19.22.6169; CAPUTO A, 1990, J ACQ IMMUN DEF SYND, V3, P372; COFFIN JM, 1997, RETROVIRUSES, P343; Collins KL, 2004, MICROBES INFECT, V6, P494, DOI 10.1016/j.micinf.2003.12.014; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grossman CE, 2004, BIOCHEM J, V382, P725, DOI 10.1042/BJ20040413; Grossman CE, 2004, J BIOL CHEM, V279, P12190, DOI 10.1074/jbc.M307039200; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Hastings ML, 1997, NUCLEIC ACIDS RES, V25, P4296, DOI 10.1093/nar/25.21.4296; HOXIE JA, 1986, J IMMUNOL, V137, P1194; Huthoff H, 2004, RNA, V10, P412, DOI 10.1261/rna.5161304; JACOB MC, 1991, CYTOMETRY, V12, P550, DOI 10.1002/cyto.990120612; KARACOSTAS V, 1989, P NATL ACAD SCI USA, V86, P8964, DOI 10.1073/pnas.86.22.8964; Kazazian HH, 2000, SCIENCE, V289, P1152, DOI 10.1126/science.289.5482.1152; LERNER A, 1993, J IMMUNOL, V151, P3152; Li AW, 1997, MOL CELL ENDOCRINOL, V133, P177, DOI 10.1016/S0303-7207(97)00148-2; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Luikenhuis S, 2001, MOL CELL BIOL, V21, P8512, DOI 10.1128/MCB.21.24.8512-8520.2001; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marodon G, 2001, IMMUNOL LETT, V79, P165, DOI 10.1016/S0165-2478(01)00286-3; Massie B, 1998, J VIROL, V72, P2289, DOI 10.1128/JVI.72.3.2289-2296.1998; Meusser B, 2004, MOL CELL, V14, P247, DOI 10.1016/S1097-2765(04)00212-6; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; NAGY K, 1994, J VIROL, V68, P757, DOI 10.1128/JVI.68.2.757-765.1994; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; Perl A, 2003, RHEUM DIS CLIN N AM, V29, P123, DOI 10.1016/S0889-857X(02)00098-4; PERL A, 1989, NUCLEIC ACIDS RES, V17, P6841, DOI 10.1093/nar/17.17.6841; PERL A, 1991, GENOMICS, V11, P1172, DOI 10.1016/0888-7543(91)90052-G; Perl A, 2001, J RHEUMATOL, V28, P461; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; Rose JJ, 2005, J BIOL CHEM, V280, P7413, DOI 10.1074/jbc.M409420200; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Segal DJ, 2004, J BIOL CHEM, V279, P14509, DOI 10.1074/jbc.M400349200; STEIMER KS, 1986, VIROLOGY, V150, P283, DOI 10.1016/0042-6822(86)90289-8; Thoulouze MI, 2006, IMMUNITY, V24, P547, DOI 10.1016/j.immuni.2006.02.016; Tiganos E, 1997, J VIROL, V71, P4452, DOI 10.1128/JVI.71.6.4452-4460.1997; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wilkinson D. A., 1994, RETROVIRIDAE, P465	54	48	52	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34574	34591		10.1074/jbc.M606301200	http://dx.doi.org/10.1074/jbc.M606301200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16935861	hybrid			2022-12-25	WOS:000241767600077
J	McMillan, PJ; Arscott, LD; Ballou, DP; Becker, K; Williams, CH; Muller, S				McMillan, Paul J.; Arscott, L. David; Ballou, David P.; Becker, Katja; Williams, Charles H., Jr.; Mueller, Sylke			Identification of acid-base catalytic residues of high-M-r thioredoxin reductase from Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; GLUTATHIONE-REDUCTASE; ESCHERICHIA-COLI; ACTIVE-SITE; LIPOAMIDE DEHYDROGENASE; DROSOPHILA-MELANOGASTER; AZOTOBACTER-VINELANDII; HIS450-GLU455 DIAD; MUTATED ENZYMES; WILD-TYPE	High-M-r thioredoxin reductase from the malaria parasite Plasmodium falciparum (PfTrxR) contains three redox active centers (FAD, Cys-88/Cys-93, and Cys-535/Cys-540) that are in redox communication. The catalytic mechanism of PfTrxR, which involves dithiol-disulfide interchanges requiring acid-base catalysis, was studied by steady-state kinetics, spectral analyses of anaerobic static titrations, and rapid kinetics analysis of wild-type enzyme and variants involving the His-509-Glu-514 dyad as the presumed acid-base catalyst. The dyad is conserved in all members of the enzyme family. Substitution of His-509 with glutamine and Glu-514 with alanine led to TrxR with only 0.5 and 7% of wild type activity, respectively, thus demonstrating the crucial roles of these residues for enzymatic activity. The H509Q variant had rate constants in both the reductive and oxidative half-reactions that were dramatically less than those of wild-type enzyme, and no thiolate-flavin charge-transfer complex was observed. Glu-514 was shown to be involved in dithiol-disulfide interchange between the Cys-88/Cys-93 and Cys-535/Cys-540 pairs. In addition, Glu-514 appears to greatly enhance the role of His-509 in acid-base catalysis. It can be concluded that the His-509-Glu-514 dyad, in analogy to those in related oxidoreductases, acts as the acid-base catalyst in PfTrxR.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Glasgow, Inst Biomed & Life Sci Infect & Immun, Glasgow G12 8TA, Lanark, Scotland; Univ Glasgow, Wellcome Ctr Mol Parasitol, Glasgow G12 8TA, Lanark, Scotland; Univ Giessen, Interdisciplinary Res Ctr, D-35392 Giessen, Germany	University of Michigan System; University of Michigan; University of Glasgow; University of Glasgow; Justus Liebig University Giessen	Williams, CH (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	chaswill@umich.edu; s.muller@bio.gla.ac.uk	dballou@umich.edu, David P/A-1298-2007; McMillan, Paul/B-5081-2008; McMillan, Paul James/P-6441-2019	McMillan, Paul James/0000-0001-5629-1175	NIGMS NIH HHS [GM11106] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andricopulo AD, 2006, BIOORG MED CHEM LETT, V16, P2283, DOI 10.1016/j.bmcl.2006.01.027; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Baier M, 2005, J EXP BOT, V56, P1449, DOI 10.1093/jxb/eri161; Bauer H, 2003, J BIOL CHEM, V278, P33020, DOI 10.1074/jbc.M303762200; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; BENEN J, 1991, EUR J BIOCHEM, V202, P863, DOI 10.1111/j.1432-1033.1991.tb16444.x; BENEN J, 1992, EUR J BIOCHEM, V207, P487, DOI 10.1111/j.1432-1033.1992.tb17075.x; Biterova EI, 2005, P NATL ACAD SCI USA, V102, P15018, DOI 10.1073/pnas.0504218102; Bohme CC, 2000, J BIOL CHEM, V275, P37317, DOI 10.1074/jbc.M007695200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braman J, 1996, Methods Mol Biol, V57, P31; Brandt W, 2005, CHEMBIOCHEM, V6, P386, DOI 10.1002/cbic.200400276; Coombs GH, 2004, J BIOL CHEM, V279, P5249, DOI 10.1074/jbc.M304359200; Davioud-Charvet E, 2003, BIOCHEMISTRY-US, V42, P13319, DOI 10.1021/bi0353629; Davioud-Charvet E, 1999, ANAL BIOCHEM, V268, P1, DOI 10.1006/abio.1998.3061; Gelhaye E, 2005, CELL MOL LIFE SCI, V62, P24, DOI 10.1007/s00018-004-4296-4; Gilberger TW, 1997, J BIOL CHEM, V272, P29584, DOI 10.1074/jbc.272.47.29584; Gilberger TW, 1998, FEBS LETT, V425, P407, DOI 10.1016/S0014-5793(98)00270-1; Gladyshev VN, 1999, BIOCHEM BIOPH RES CO, V259, P244, DOI 10.1006/bbrc.1999.0765; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Hirt RP, 2002, TRENDS PARASITOL, V18, P302, DOI 10.1016/S1471-4922(02)02293-6; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; Kabe Y, 2005, ANTIOXID REDOX SIGN, V7, P395, DOI 10.1089/ars.2005.7.395; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; Krnajski Z, 2002, J BIOL CHEM, V277, P25970, DOI 10.1074/jbc.M203539200; Krnajski Z, 2001, MOL BIOCHEM PARASIT, V112, P219, DOI 10.1016/S0166-6851(00)00372-8; Krnajski Z, 2000, J BIOL CHEM, V275, P40874, DOI 10.1074/jbc.M008443200; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Maitland K, 2004, CURR OPIN INFECT DIS, V17, P405, DOI 10.1097/00001432-200410000-00004; Nakamoto H, 2004, BBA-MOL CELL RES, V1694, P111, DOI 10.1016/j.bbamcr.2004.02.012; PAI EF, 1983, J BIOL CHEM, V258, P1752; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; PRONGAY AJ, 1992, J BIOL CHEM, V267, P25181; RIETVELD P, 1994, BIOCHEMISTRY-US, V33, P13888, DOI 10.1021/bi00250a043; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Stewart LB, 2004, ANN TROP MED PARASIT, V98, P763, DOI 10.1179/000349804X3144; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121	43	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					32967	32977		10.1074/jbc.M601141200	http://dx.doi.org/10.1074/jbc.M601141200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950793	hybrid			2022-12-25	WOS:000241621400005
J	DeBosch, B; Sambandam, N; Weinheimer, C; Courtois, M; Muslin, AJ				DeBosch, Brian; Sambandam, Nandakumar; Weinheimer, Carla; Courtois, Michael; Muslin, Anthony J.			Akt2 regulates cardiac metabolism and cardiomyocyte survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MYOCARDIAL-INFARCTION; GLYCOGEN-SYNTHASE; GLUCOSE-UPTAKE; MICE LACKING; MOUSE HEART; IN-VITRO; HYPERTROPHY; GROWTH; PHOSPHORYLATION	The Akt family of serine-threonine kinases participates in diverse cellular processes, including the promotion of cell survival, glucose metabolism, and cellular protein synthesis. All three known Akt family members, Akt1, Akt2 and Akt3, are expressed in the myocardium, although Akt1 and Akt2 are most abundant. Previous studies demonstrated that Akt1 and Akt3 overexpression results in enhanced myocardial size and function. Yet, little is known about the role of Akt2 in modulating cardiac metabolism, survival, and growth. Here, we utilize murine models with targeted disruption of the akt2 or the akt1 genes to demonstrate that Akt2, but not Akt1, is required for insulin-stimulated 2-[H-3] deoxyglucose uptake and metabolism. In contrast, akt2 (-/-) mice displayed normal cardiac growth responses to provocative stimulation, including ligand stimulation of cultured cardiomyocytes, pressure overload by transverse aortic constriction, and myocardial infarction. However, akt2 (-/-) mice were found to be sensitized to cardiomyocyte apoptosis in response to ischemic injury, and apoptosis was significantly increased in the peri-infarct zone of akt2 (-/-) hearts 7 days after occlusion of the left coronary artery. These results implicate Akt2 in the regulation of cardiomyocyte metabolism and survival.	Washington Univ, Sch Med, Dept Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Muslin, AJ (corresponding author), Washington Univ, Sch Med, Dept Med, Cardiovasc Res Ctr, 4940 Parkview Pl,Box 8086,Rm 9912 CSRB, St Louis, MO 63110 USA.	amuslin@im.wustl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278, T32HL007873, R01HL076670, R01HL061567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, P30DK056341] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL057278-090006, HL 057278, T32 HL 07873, HL 076670, T32 HL007873, P01 HL057278-100006, R01 HL061567, R01 HL076670-01A2, HL 61567, P01 HL057278, R01 HL076670] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-06, P30 DK056341, P30 DK056341-05S2, P30 DK052574, P30 DK 52574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2004, CURR HYPERTENS REP, V6, P416, DOI 10.1007/s11906-004-0034-4; Belke DD, 1999, AM J PHYSIOL-REG I, V277, pR1210, DOI 10.1152/ajpregu.1999.277.4.R1210; Cheatham B, 2000, TRENDS ENDOCRIN MET, V11, P356, DOI 10.1016/S1043-2760(00)00308-8; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Colao A, 2004, EUR J ENDOCRINOL, V151, pS93, DOI 10.1530/eje.0.151S093; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeBosch B, 2006, CIRCULATION, V113, P2097, DOI 10.1161/CIRCULATIONAHA.105.595231; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Harris IS, 2004, CIRCULATION, V110, P718, DOI 10.1161/01.CIR.0000138190.50127.6A; Kanno S, 2002, J AM SOC ECHOCARDIOG, V15, P601, DOI 10.1067/mje.2002.117560; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Matsui T, 2005, J MOL CELL CARDIOL, V38, P63, DOI 10.1016/j.yjmcc.2004.11.005; McMullen JR, 2004, MOL CELL BIOL, V24, P6231, DOI 10.1128/MCB.24.14.6231-6240.2004; McMullen JR, 2003, P NATL ACAD SCI USA, V100, P12355, DOI 10.1073/pnas.1934654100; Mora A, 2005, FEBS LETT, V579, P3632, DOI 10.1016/j.febslet.2005.05.040; Ren J, 2005, J MOL CELL CARDIOL, V38, P617, DOI 10.1016/j.yjmcc.2005.01.012; Rota M, 2005, CIRC RES, V97, P1332, DOI 10.1161/01.RES.0000196568.11624.ae; Sambrano GR, 2002, NATURE, V420, P712, DOI 10.1038/nature01306; Serneri GGN, 2001, CIRC RES, V89, P977, DOI 10.1161/hh2301.100982; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Southgate RJ, 2005, FASEB J, V19, P2072, DOI 10.1096/fj.05-3993fje; TNIYAMA Y, 2005, J BIOL CHEM, V38, P375; Yamada E, 2005, J CELL BIOL, V168, P921, DOI 10.1083/jcb.200408182	29	131	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32841	32851		10.1074/jbc.M513087200	http://dx.doi.org/10.1074/jbc.M513087200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16950770	Green Accepted, hybrid			2022-12-25	WOS:000241414500082
J	Lee, WC; Ohshiro, T; Matsubara, T; Izumi, Y; Tanokura, M				Lee, Woo Cheol; Ohshiro, Takashi; Matsubara, Toshiyuki; Izumi, Yoshikazu; Tanokura, Masaru			Crystal structure and desulfurization mechanism of 2 '-hydroxybiphenyl-2-sulfinic acid desulfinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROBIAL DESULFURIZATION; DIBENZOTHIOPHENE; PROGRAM; SEQUENCE; HYDRODESULFURIZATION; CRYSTALLOGRAPHY; CATALYSIS; MOLSCRIPT; ENZYME; DSZB	The desulfurization of dibenzothiophene in Rhodococcus erythropolis is catalyzed by two monooxygenases, DszA and DszC, and a desulfinase, DszB. In the last step of this pathway, DszB hydrolyzes 2'-hydroxybiphenyl-2-sulfinic acid into 2-hydroxybiphenyl and sulfite. We report on the crystal structures of DszB and an inactive mutant of DszB in complex with substrates at resolutions of 1.8 angstrom or better. The overall fold of DszB is similar to those of periplasmic substrate-binding proteins. In the substrate complexes, biphenyl rings of substrates are recognized by extensive hydrophobic interactions with the active site residues. Binding of substrates accompanies structural changes of the active site loops and recruits His(60) to the active site. The sulfinate group of bound substrates forms hydrogen bonds with side chains of Ser(27), His(60), and Arg(70), each of which is shown by site-directed mutagenesis to be essential for the activity. In our proposed reaction mechanism, Cys(27) functions as a nucleophile and seems to be activated by the sulfinate group of substrates, whereas His(60) and Arg(70) orient the syn orbital of sulfinate oxygen to the sulfhydryl hydrogen of Cys(27) and stabilize the negatively charged reaction intermediate. Cys, His, and Arg residues are conserved in putative proteins homologous to DszB, which are presumed to constitute a new family of desulfinases.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; Tottori Univ, Dept Biotechnol, Tottori 6808552, Japan	University of Tokyo; Tottori University	Tanokura, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1Yayoi, Tokyo 1138657, Japan.	amtanok@mail.ecc.u-tokyo.ac.jp		Tanokura, Masaru/0000-0001-5072-2480				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campobasso N, 1998, BIOCHEMISTRY-US, V37, P15981, DOI 10.1021/bi981673l; *COLL COMP PROJ 4, 1995, ACTA CRYSTALLOGR D, V50, P760; Dall'Acqua W, 2000, PROTEIN SCI, V9, P1; DENOME SA, 1994, J BACTERIOL, V176, P6707, DOI 10.1128/JB.176.21.6707-6716.1994; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FUJIHARA H, 1990, CHEM SULFINIC ACIDS, P275; GALLAGHER JR, 1993, FEMS MICROBIOL LETT, V107, P31, DOI 10.1111/j.1574-6968.1993.tb05999.x; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Graber R, 1999, J BIOL CHEM, V274, P31203, DOI 10.1074/jbc.274.44.31203; Gray KA, 2003, CURR OPIN MICROBIOL, V6, P229, DOI 10.1016/S1369-5274(03)00065-1; Gray KA, 1996, NAT BIOTECHNOL, V14, P1705, DOI 10.1038/nbt1296-1705; HANSON G, 1981, J ORG CHEM, V46, P5441, DOI 10.1021/jo00339a048; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOUALLA M, 1980, J CATAL, V61, P523, DOI 10.1016/0021-9517(80)90400-5; IZUMI Y, 1994, APPL ENVIRON MICROB, V60, P223, DOI 10.1128/AEM.60.1.223-226.1994; Kabe T, 1997, IND ENG CHEM RES, V36, P5146, DOI 10.1021/ie970297i; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kahnert A, 2000, J BIOL CHEM, V275, P31661, DOI 10.1074/jbc.M005820200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee WC, 2004, ACTA CRYSTALLOGR D, V60, P1636, DOI 10.1107/S0907444904017627; LOUIE GV, 1992, NATURE, V359, P33, DOI 10.1038/359033a0; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MONTICELLO DJ, 1985, ANNU REV MICROBIOL, V39, P371, DOI 10.1146/annurev.mi.39.100185.002103; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakayama N, 2002, BBA-PROTEINS PROTEOM, V1598, P122, DOI 10.1016/S0167-4838(02)00365-5; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PIDDINGTON CS, 1995, APPL ENVIRON MICROB, V61, P468, DOI 10.1128/AEM.61.2.468-475.1995; POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; SODA K, 1987, METHOD ENZYMOL, V143, P453; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Van Hamme JD, 2003, MICROBIOL MOL BIOL R, V67, P503, DOI 10.1128/MMBR.67.4.503-549.2003; [No title captured]	42	31	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32534	32539		10.1074/jbc.M602974200	http://dx.doi.org/10.1074/jbc.M602974200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16891315	hybrid			2022-12-25	WOS:000241414500051
J	Yamaguchi, Y; Shirai, Y; Matsubara, T; Sanse, K; Kuriyama, M; Oshiro, N; Yoshino, KI; Yonezawa, K; Ono, Y; Saito, N				Yamaguchi, Yasuto; Shirai, Yasuhito; Matsubara, Takehiro; Sanse, Koichi; Kuriyama, Masamitsu; Oshiro, Noriko; Yoshino, Ken-ichi; Yonezawa, Kazuyoshi; Ono, Yoshitaka; Saito, Naoaki			Phosphorylation and up-regulation of diacylglycerol kinase gamma via its interaction with protein kinase C gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR HETEROGENEITY; NUCLEAR-LOCALIZATION; MEDIATED ACTIVATION; SPATIAL REGULATION; PLASMA-MEMBRANE; PKC-GAMMA; ALPHA; ZETA; TRANSLOCATION; DOMAIN	Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (DGK). Therefore, DGK is thought to be a negative regulator of PKC activation. Here we show molecular mechanisms of functional coupling of the two kinases. gamma PKC directly associated with DGK gamma through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/diolein in vitro. Mass spectrometric analysis and mutation studies revealed that gamma PKC phosphorylated Ser-776 and Ser-779 in the AD of DGK gamma. The phosphorylation by gamma KC resulted in activation of DGK gamma because a DGK gamma mutant in which Ser-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild typeDGK gamma and an unphosphorylatable DGK gamma mutant. Importantly, the interaction of the two kinases and the phosphorylation of DGK gamma by gamma PKC could be confirmed in vivo, and overexpression of the AD of DGK gamma inhibited re-translocation of gamma PKC. These results demonstrate that localization and activation of the functionally correlated kinases, gamma PKC and DGK gamma, are spatio-temporally orchestrated by their direct association and phosphorylation, contributing to subtype-specific regulation of DGK gamma and DAG signaling.	Kobe Univ, Biosignal Res Ctr, Nada Ku, Kobe, Hyogo 6578501, Japan	Kobe University	Saito, N (corresponding author), Kobe Univ, Biosignal Res Ctr, Nada Ku, Rokkodai Cho 1-1, Kobe, Hyogo 6578501, Japan.	naosaito@kobe-u.ac.jp	Shirai, Yasuhito/O-3255-2018					Adachi N, 2005, MOL BRAIN RES, V139, P288, DOI 10.1016/j.molbrainres.2005.06.007; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Baldanzi G, 2004, ONCOGENE, V23, P4828, DOI 10.1038/sj.onc.1207633; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Caricasole A, 2002, J BIOL CHEM, V277, P4790, DOI 10.1074/jbc.M110249200; Chen DH, 2003, AM J HUM GENET, V72, P839, DOI 10.1086/373883; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cipres A, 2003, J BIOL CHEM, V278, P35629, DOI 10.1074/jbc.M305635200; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; Davidson L, 2004, J BIOL CHEM, V279, P11906, DOI 10.1074/jbc.M310784200; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Eto M, 2002, NEURON, V36, P1145, DOI 10.1016/S0896-6273(02)01107-8; Goto K, 1999, CHEM PHYS LIPIDS, V98, P109, DOI 10.1016/S0009-3084(99)00023-7; Hogan A, 2001, J BIOL CHEM, V276, P26526, DOI 10.1074/jbc.M104156200; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; Imai S, 2005, J BIOL CHEM, V280, P39870, DOI 10.1074/jbc.M500669200; Imai S, 2004, BIOCHEM J, V382, P957, DOI 10.1042/BJ20040681; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; Ito M, 2002, NAT REV NEUROSCI, V3, P896, DOI 10.1038/nrn962; Jiang Y, 2000, J BIOL CHEM, V275, P34092, DOI 10.1074/jbc.M004914200; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Luo B, 2003, J CELL BIOL, V160, P929, DOI 10.1083/jcb.200208120; Luo B, 2003, J BIOL CHEM, V278, P39542, DOI 10.1074/jbc.M307153200; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Pettitt TR, 1999, J BIOL CHEM, V274, P36181, DOI 10.1074/jbc.274.51.36181; PREISS J, 1986, J BIOL CHEM, V261, P8597; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Saito N, 2002, J BIOCHEM, V132, P683, DOI 10.1093/oxfordjournals.jbchem.a003274; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Shindo M, 2003, J BIOL CHEM, V278, P18448, DOI 10.1074/jbc.M300400200; Shindo M, 2001, BIOCHEM BIOPH RES CO, V289, P451, DOI 10.1006/bbrc.2001.5935; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Baal J, 2005, J BIOL CHEM, V280, P9870, DOI 10.1074/jbc.M409301200; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Yamada K, 1997, BIOCHEM J, V321, P59, DOI 10.1042/bj3210059	46	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31627	31637		10.1074/jbc.M606992200	http://dx.doi.org/10.1074/jbc.M606992200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16905533				2022-12-25	WOS:000241235300048
J	Zha, WJ; Rubin-Pitel, SB; Zhao, HM				Zha, Wenjuan; Rubin-Pitel, Sheryl B.; Zhao, Huimin			Characterization of the substrate specificity of PhlD, a type III polyketide synthase from Pseudomonas fluorescens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHALCONE SYNTHASE; ANTIBIOTIC 2,4-DIACETYLPHLOROGLUCINOL; BACTERIAL POLYKETIDE; STREPTOMYCES-GRISEUS; GENE-CLUSTER; ACTIVE-SITE; BIOSYNTHESIS; PHLOROGLUCINOL; MUTAGENESIS; STILBENE	PhlD, a type III polyketide synthase from Pseudomonas fluorescens, catalyzes the synthesis of phloroglucinol from three molecules of malonyl-CoA. Kinetic analysis by direct measurement of the appearance of the CoASH product (k(cat) = 24 +/- 4 min(-1) and Km = 13 +/- 1 mu M) gave a k(cat) value more than an order of magnitude higher than that of any other known type III polyketide synthase. PhlD exhibits broad substrate specificity, accepting C-4-C-12 aliphatic acyl-CoAs and phenylacetyl-CoA as the starters to form C6-polyoxoalkylated alpha-pyrones from sequential condensation with malonyl-CoA. Interestingly, when primed with long chain acyl-CoAs, PhlD catalyzed extra polyketide elongation to form up to heptaketide products. A homology structural model of PhlD showed the presence of a buried tunnel extending out from the active site to assist the binding of long chain acyl-CoAs. To probe the structural basis for the unusual ability of PhlD to accept long chain acyl-CoAs, both site-directed mutagenesis and saturation mutagenesis were carried out on key residues lining the tunnel. Three mutations, M21I, H24V, and L59M, were found to significantly reduce the reactivity of PhlD with lauroyl-CoA while still retaining its physiological activity to synthesize phloroglucinol. Our homology modeling and mutational studies indicated that even subtle changes in the tunnel volume could affect the ability of PhlD to accept long chain acyl-CoAs. This suggested novel strategies for combinatorial biosynthesis of unnatural pharmaceutically important polyketides.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Dept Biomol Engn & Chem, Ctr Biophys & Computat Biol, Inst Genom Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Zhao, HM (corresponding author), Univ Illinois, Dept Chem, 600 S Mathews Ave, Urbana, IL 61801 USA.	zhao5@uiuc.edu						Abe I, 2005, J AM CHEM SOC, V127, P12709, DOI 10.1021/ja053945v; Achkar J, 2005, J AM CHEM SOC, V127, P5332, DOI 10.1021/ja042340g; Austin MB, 2004, J BIOL CHEM, V279, P45162, DOI 10.1074/jbc.M406567200; Austin MB, 2004, CHEM BIOL, V11, P1179, DOI 10.1016/j.chembiol.2004.05.024; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; Bangera MG, 1999, J BACTERIOL, V181, P3155, DOI 10.1128/JB.181.10.3155-3163.1999; Bangera MG, 1996, MOL PLANT MICROBE IN, V9, P83, DOI 10.1094/MPMI-9-0083; Chen HW, 2001, P NATL ACAD SCI USA, V98, P14901, DOI 10.1073/pnas.221582098; Chockalingam K, 2005, P NATL ACAD SCI USA, V102, P5691, DOI 10.1073/pnas.0409206102; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; EDWARDS ML, 1990, J MED CHEM, V33, P1948, DOI 10.1021/jm00169a021; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Funa N, 2002, J BIOL CHEM, V277, P4628, DOI 10.1074/jbc.M110357200; Georgescu Radu, 2003, Methods Mol Biol, V231, P75; Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jez JM, 2000, CHEM BIOL, V7, P919, DOI 10.1016/S1074-5521(00)00041-7; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Keating TA, 1999, CURR OPIN CHEM BIOL, V3, P598, DOI 10.1016/S1367-5931(99)00015-0; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; Lee JK, 2006, J BACTERIOL, V188, P6179, DOI 10.1128/JB.00259-06; Moore BS, 2001, CHEMBIOCHEM, V2, P35, DOI 10.1002/1439-7633(20010105)2:1<35::AID-CBIC35>3.3.CO;2-T; Rawlings BJ, 2001, NAT PROD REP, V18, P231, DOI 10.1039/b100191o; Rawlings BJ, 1999, NAT PROD REP, V16, P425, DOI 10.1039/a900566h; Sankaranarayanan R, 2004, NAT STRUCT MOL BIOL, V11, P894, DOI 10.1038/nsmb809; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Saxena P, 2003, J BIOL CHEM, V278, P44780, DOI 10.1074/jbc.M306714200; SCHUZ R, 1983, J BIOL CHEM, V258, P6730; SHEN B, 1993, SCIENCE, V262, P1535, DOI 10.1126/science.8248801; Shen B, 2000, TOP CURR CHEM, V209, P1; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; TROPF S, 1995, J BIOL CHEM, V270, P7922, DOI 10.1074/jbc.270.14.7922; Tseng CC, 2004, BIOCHEMISTRY-US, V43, P970, DOI 10.1021/bi035714b; UEDA K, 1995, J ANTIBIOT, V48, P638, DOI 10.7164/antibiotics.48.638	36	50	54	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					32036	32047		10.1074/jbc.M606500200	http://dx.doi.org/10.1074/jbc.M606500200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16931521	Bronze			2022-12-25	WOS:000241235300089
J	Choi, SJ; Chung, SS; Rho, EJ; Lee, HW; Lee, MH; Choi, HS; Seol, JH; Baek, SH; Bang, OS; Chung, CH				Choi, Soo Joon; Chung, Sung Soo; Rho, Eun Jung; Lee, Hyung Woo; Lee, Moon Hee; Choi, Hueng-Sik; Seol, Jae Hong; Baek, Sung Hee; Bang, Ok Sun; Chung, Chin Ha			Negative modulation of RXR alpha transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; E3 LIGASE; DEPENDENT TRANSCRIPTION; GLUCOCORTICOID RECEPTOR; ANDROGEN RECEPTOR; NUCLEAR-PORE; X-RECEPTOR; SUMOYLATION; BINDING; REPRESSION	Retinoid X receptor alpha(RXR alpha) belongs to a family of ligand-activated transcription factors that regulate many aspects of metazoan life. Here we demonstrate that RXR alpha is a target substrate of a small ubiquitin-related modifier ( SUMO)-specific protease, SUSP1, which is capable of controlling the transcriptional activity of RXR alpha. RXR alpha was modified by SUMO-1 in vivo as well as in vitro, and the Lys-108 residue within the IKPP sequence of RXR alpha AF-1 domain was identified as the major SUMO-1 acceptor site. Prevention of SUMO modification by Lys-to-Arg mutation led to an increase not only in the transcriptional activity of RXR alpha but also in the activity of its heterodimeric complex with retinoic acid receptor-alpha or peroxisome proliferator-activated receptor-gamma ( PPAR gamma). SUSP1 co-localized with RXR alpha in the nucleus and removed SUMO-1 from RXR alpha but not from androgen receptor or PPAR gamma. Moreover, overexpression of SUSP1 caused an increase in the transcriptional activity of RXR alpha, whereas small hairpin RNA-mediated knockdown of endogenous SUSP1 led to a decrease in RXR alpha activity. These results suggest that SUSP1 plays an important role in the control of the transcriptional activity of RXR alpha and thus in the RXR alpha-mediated cellular processes.	Seoul Natl Univ, Sch Biol Sci, Natl Res Lab Prot Biochem, Seoul 151742, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Sch Biol Sci & Technol, Kwangju 500757, South Korea	Seoul National University (SNU); Chonnam National University	Bang, OS (corresponding author), Seoul Natl Univ, Sch Biol Sci, Natl Res Lab Prot Biochem, Seoul 151742, South Korea.	osbang@snu.ac.kr; chchung@snu.ac.kr	Lee, Hyungwoo/AAX-4011-2020					Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang CC, 2005, J BIOL CHEM, V280, P10164, DOI 10.1074/jbc.M409161200; Cheng JK, 2005, J BIOL CHEM, V280, P14492, DOI 10.1074/jbc.M412185200; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Desterro JMP, 2005, MOL BIOL CELL, V16, P5115, DOI 10.1091/mbc.E05-06-0536; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; Pichler A, 2004, NAT STRUCT MOL BIOL, V11, P984, DOI 10.1038/nsmb834; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Salinas S, 2004, J CELL BIOL, V165, P767, DOI 10.1083/jcb.200310136; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Szanto A, 2004, MOL CELL BIOL, V24, P8154, DOI 10.1128/MCB.24.18.8154-8166.2004; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, CELL CYCLE, V2, P528, DOI 10.4161/cc.2.6.597; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	47	59	66	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30669	30677		10.1074/jbc.M604033200	http://dx.doi.org/10.1074/jbc.M604033200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912044	hybrid			2022-12-25	WOS:000241075900043
J	Domercq, M; Brambilla, L; Pilati, E; Marchaland, J; Volterra, A; Bezzi, P				Domercq, Maria; Brambilla, Liliana; Pilati, Ethel; Marchaland, Julie; Volterra, Andrea; Bezzi, Paola			P2Y1 receptor-evoked glutamate exocytosis from astrocytes - Control by tumor necrosis factor-alpha and prostaglandins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CALCIUM OSCILLATIONS; DORSAL SPINAL-CORD; GLIAL-CELLS; P2X RECEPTORS; SYNAPTIC-TRANSMISSION; REGULATED EXOCYTOSIS; MOLECULAR PHYSIOLOGY; NEURONAL-ACTIVITY; ATP RELEASE; P2Y(1)	ATP, released by both neurons and glia, is an important mediator of brain intercellular communication. We find that selective activation of purinergic P2Y1 receptors (P2Y1R) in cultured astrocytes triggers glutamate release. By total internal fluorescence reflection imaging of fluorescence-labeled glutamatergic vesicles, we document that such release occurs by regulated exocytosis. The stimulus-secretion coupling mechanism involves Ca2+ release from internal stores and is controlled by additional transductive events mediated by tumor necrosis factor-alpha (TNF alpha) and prostaglandins (PG). P2Y1R activation induces release of both TNF alpha and PGE2 and blocking either one significantly reduces glutamate release. Accordingly, astrocytes from TNF alpha-deficient (TNF-/-) or TNF type 1 receptor-deficient (TNFR1(-/-)) mice display altered P2Y1R-dependent Ca2+ signaling and deficient glutamate release. In mixed hippocampal cultures, the P2Y1R-evoked process occurs in astrocytes but not in neurons or microglia. P2Y1R stimulation induces Ca2+-dependent glutamate release also from acute hippocampal slices. The process in situ displays characteristics resembling those in cultured astrocytes and is distinctly different from synaptic glutamate release evoked by high K+ stimulation as follows: (a) it is sensitive to cyclooxygenase inhibitors; (b) it is deficient in preparations from TNF-/- and TNFR1(-/-) mice; and (c) it is inhibited by the exocytosis blocker bafilomycin A1 with a different time course. No glutamate release is evoked by P2Y1R-dependent stimulation of hippocampal synaptosomes. Taken together, our data identify the coupling of purinergic P2Y1R to glutamate exocytosis and its peculiar TNF alpha- and PG-dependent control, and we strongly suggest that this cascade operates selectively in astrocytes. The identified pathway may play physiological roles in glial-glial and glial-neuronal communication.	Univ Lausanne, Dept Morfol & Biol Celular, CH-1005 Lausanne, Switzerland; Univ Milan, Dept Pharmacol Sci, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy	University of Lausanne; University of Milan	Bezzi, P (corresponding author), Univ Lausanne, Dept Morfol & Biol Celular, Rue Bugnon 9, CH-1005 Lausanne, Switzerland.	Paola.Bezzi@unil.ch	Brambilla, Liliana/AAA-3303-2021; Domercq, Maria/Z-2274-2019; Bezzi, Paola/AAP-2440-2020	Brambilla, Liliana/0000-0001-5714-3625; Domercq, Maria/0000-0002-4918-9276; Volterra, Andrea/0000-0003-1069-1602				Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Araque A, 1998, J NEUROSCI, V18, P6822; Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Auld DS, 2003, NEURON, V40, P389, DOI 10.1016/S0896-6273(03)00607-X; Avery J, 2000, J CELL BIOL, V148, P317, DOI 10.1083/jcb.148.2.317; Baker DA, 2002, J NEUROSCI, V22, P9134; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bernardinelli Y, 2004, P NATL ACAD SCI USA, V101, P14937, DOI 10.1073/pnas.0405315101; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; Chen XK, 2005, J NEUROSCI, V25, P9236, DOI 10.1523/JNEUROSCI.1640-05.2005; Cheviet S, 2006, J CELL SCI, V119, P2912, DOI 10.1242/jcs.03037; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Crippa D, 2006, J PHYSIOL-LONDON, V570, P567, DOI 10.1113/jphysiol.2005.094052; D'Arcangelo G, 2000, EUR J NEUROSCI, V12, P1241, DOI 10.1046/j.1460-9568.2000.00011.x; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; Fam SR, 2003, J NEUROSCI, V23, P4437; Fam SR, 2000, J NEUROSCI, V20, P2800; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fellin T, 2006, PHYSIOLOGY, V21, P208, DOI 10.1152/physiol.00161.2005; Fiacco TA, 2004, J NEUROSCI, V24, P722, DOI 10.1523/JNEUROSCI.2859-03.2004; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; Franks KM, 2003, J NEUROSCI, V23, P3186; Glavinovic MI, 1999, PFLUG ARCH EUR J PHY, V437, P462, DOI 10.1007/s004240050802; Goddard DR, 2001, GLIA, V34, P267, DOI 10.1002/glia.1060; Gordon GRJ, 2005, NAT NEUROSCI, V8, P1078, DOI 10.1038/nn1498; Gundersen V, 1998, J NEUROSCI, V18, P6059; HO C, 1995, BRIT J PHARMACOL, V116, P2909, DOI 10.1111/j.1476-5381.1995.tb15944.x; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kang N, 2004, J NEUROPHYSIOL, V92, P873, DOI 10.1152/jn.01231.2003; Kawamura M, 2004, J NEUROSCI, V24, P10835, DOI 10.1523/JNEUROSCI.3028-04.2004; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kreft M, 2004, GLIA, V46, P437, DOI 10.1002/glia.20018; Liu QS, 2004, P NATL ACAD SCI USA, V101, P3172, DOI 10.1073/pnas.0306731101; Metea MR, 2006, J NEUROSCI, V26, P2862, DOI 10.1523/JNEUROSCI.4048-05.2006; Montana V, 2004, J NEUROSCI, V24, P2633, DOI 10.1523/JNEUROSCI.3770-03.2004; Moran-Jimenez MJ, 2000, MOL BRAIN RES, V78, P50, DOI 10.1016/S0169-328X(00)00067-X; Mori M, 2001, J PHYSIOL-LONDON, V535, P115, DOI 10.1111/j.1469-7793.2001.t01-1-00115.x; Mothet JP, 2005, P NATL ACAD SCI USA, V102, P5606, DOI 10.1073/pnas.0408483102; Mulligan SJ, 2004, NATURE, V431, P195, DOI 10.1038/nature02827; Newman EA, 2003, J NEUROSCI, V23, P1659, DOI 10.1523/jneurosci.23-05-01659.2003; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; Newman EA, 1998, J NEUROSCI, V18, P4022; Newman EA, 2003, TRENDS NEUROSCI, V26, P536, DOI 10.1016/S0166-2236(03)00237-6; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Panatier A, 2006, CELL, V125, P775, DOI 10.1016/j.cell.2006.02.051; Pankratov Y, 1998, EUR J NEUROSCI, V10, P3898, DOI 10.1046/j.1460-9568.1998.00419.x; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Parri HR, 2001, NAT NEUROSCI, V4, P803, DOI 10.1038/90507; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Perea G, 2005, J NEUROSCI, V25, P2192, DOI 10.1523/JNEUROSCI.3965-04.2005; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rodrigues RJ, 2005, J NEUROSCI, V25, P6286, DOI 10.1523/JNEUROSCI.0628-05.2005; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rouach N, 2000, J CELL BIOL, V149, P1513, DOI 10.1083/jcb.149.7.1513; Sanzgiri RP, 1999, J NEUROBIOL, V41, P221, DOI 10.1002/(SICI)1097-4695(19991105)41:2<221::AID-NEU5>3.3.CO;2-1; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Schipke CG, 2001, FASEB J, V15, P255, DOI 10.1096/fj.01-0514fje; Serrano A, 2006, J NEUROSCI, V26, P5370, DOI 10.1523/JNEUROSCI.5255-05.2006; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Suadicani SO, 2006, J NEUROSCI, V26, P1378, DOI 10.1523/JNEUROSCI.3902-05.2006; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Takano T, 2006, NAT NEUROSCI, V9, P260, DOI 10.1038/nn1623; Takano T, 2005, P NATL ACAD SCI USA, V102, P16466, DOI 10.1073/pnas.0506382102; Tian GF, 2005, NAT MED, V11, P973, DOI 10.1038/nm1277; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; VOLTERRA A, 2002, TRIPATITE SYNAPSE GL; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Yang YL, 2003, P NATL ACAD SCI USA, V100, P15194, DOI 10.1073/pnas.2431073100; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zenisek D, 2000, NATURE, V406, P849, DOI 10.1038/35022500; Zhang JM, 2003, NEURON, V40, P971, DOI 10.1016/S0896-6273(03)00717-7; Zhang Q, 2004, J BIOL CHEM, V279, P12724, DOI 10.1074/jbc.M312845200; Zhang Q, 2004, P NATL ACAD SCI USA, V101, P9441, DOI 10.1073/pnas.0401960101; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x; Zonta M, 2003, J PHYSIOL-LONDON, V553, P407, DOI 10.1113/jphysiol.2003.046706; Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980	93	166	171	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30684	30696		10.1074/jbc.M606429200	http://dx.doi.org/10.1074/jbc.M606429200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16882655	hybrid			2022-12-25	WOS:000241075900045
J	Singh, RD; Liu, YD; Wheatley, CL; Holicky, EL; Makino, A; Marks, DL; Kobayashi, T; Subramaniam, G; Bittman, R; Pagano, RE				Singh, Raman Deep; Liu, Yidong; Wheatley, Christine L.; Holicky, Eileen L.; Makino, Asami; Marks, David L.; Kobayashi, Toshihide; Subramaniam, Gopal; Bittman, Robert; Pagano, Richard E.			Caveolar endocytosis and microdomain association of a glycosphingolipid analog is dependent on its sphingosine stereochemistry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CHOLERA-TOXIN; SPECTRAL PROPERTIES; GOLGI-APPARATUS; LIPID RAFTS; INTERNALIZATION; TRANSPORT; SPHINGOLIPIDS; SPHINGOMYELIN; VESICLES	We have previously shown that glycosphingolipid analogs are internalized primarily via caveolae in various cell types. This selective internalization was not dependent on particular carbohydrate headgroups or sphingosine chain length. Here, we examine the role of sphingosine structure in the endocytosis of BODIPY (TM)-tagged lactosylceramide ( LacCer) analogs via caveolae. We found that whereas the LacCer analog with the natural (D-erythro) sphingosine stereochemistry is internalized mainly via caveolae, the non-natural (L-threo) LacCer analog is taken up via clathrin-, RhoA-, and Cdc42-dependent mechanisms and largely excluded from uptake via caveolae. Unlike the D-erythro-LacCer analog, the L-threo analog did not cluster in membrane microdomains when added at higher concentrations (5-20 mu M). In vitro studies using small unilamellar vesicles and giant unilamellar vesicles demonstrated that L-threo-LacCer did not undergo a concentration-dependent excimer shift in fluorescence emission such as that seen with BODIPY (TM)-sphingolipids with natural stereochemistry. Molecular modeling studies suggest that in D-erythro-LacCer, the disaccharide moiety extends above and in the same plane as the sphingosine hydrocarbon chain, while in L-threo-LacCer the carbohydrate group is nearly perpendicular to the hydrocarbon chain. Together, these results suggest that the altered stereochemistry of the sphingosine group in L-threo-LacCer results in a perturbed structure, which is unable to pack closely with natural membrane lipids, leading to a reduced inclusion in plasma membrane microdomains and decreased uptake by caveolar endocytosis. These findings demonstrate the importance of the sphingolipid stereochemistry in the formation of membrane microdomains.	Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA; RIKEN Frontier Res Syst, Wako, Saitama 3510198, Japan	Mayo Clinic; City University of New York (CUNY) System; Queens College NY (CUNY); RIKEN	Pagano, RE (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 1st St,SW, Rochester, MN 55905 USA.	pagano.richard@mayo.edu	KOBAYASHI, TOSHIHIDE/S-8313-2019; Takhter, Ramandeep/AAG-8977-2019; Kobayashi, Toshihide/B-6298-2015	KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Kobayashi, Toshihide/0000-0002-4811-7270; Takhter, Ramandeep/0000-0002-1441-2722	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R24HL083187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022942, R37GM022942] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-083187] Funding Source: Medline; NIGMS NIH HHS [GM-22942] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; ALLINGER NL, 1977, J AM CHEM SOC, V99, P8127, DOI 10.1021/ja00467a001; AMVAMZOLLO PH, 1986, CARBOHYD RES, V150, P199, DOI 10.1016/0008-6215(86)80016-7; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; Cheng ZJ, 2006, MOL BIOL CELL, V17, P3197, DOI 10.1091/mbc.E05-12-1101; Cheng ZJ, 2006, MOL MEMBR BIOL, V23, P101, DOI 10.1080/09687860500460041; He LL, 1999, J ORG CHEM, V64, P6049, DOI 10.1021/jo9906375; HEHRE W, 2003, GUIDE MOL MECH QUANT, P343; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Ishitsuka R, 2004, BIOPHYS J, V86, P296, DOI 10.1016/S0006-3495(04)74105-3; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Liu YD, 2006, CHEM PHYS LIPIDS, V142, P58, DOI 10.1016/j.chemphyslip.2006.03.001; London E, 2005, BBA-MOL CELL RES, V1746, P203, DOI 10.1016/j.bbamcr.2005.09.002; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Masserini M, 2001, BBA-MOL CELL BIOL L, V1532, P149, DOI 10.1016/S1388-1981(01)00128-7; Mineo C, 2001, HISTOCHEM CELL BIOL, V116, P109; Nichols BJ, 2003, CURR BIOL, V13, P686, DOI 10.1016/S0960-9822(03)00209-4; Norkin LC, 1999, IMMUNOL REV, V168, P13, DOI 10.1111/j.1600-065X.1999.tb01279.x; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; PIETRO WJ, 1982, J AM CHEM SOC, V104, P5039, DOI 10.1021/ja00383a007; PULAY P, 1982, J COMPUT CHEM, V3, P556, DOI 10.1002/jcc.540030413; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sharma DK, 2005, CANCER RES, V65, P8233, DOI 10.1158/0008-5472.CAN-05-0803; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; Torgersen ML, 2001, J CELL SCI, V114, P3737; Wang TY, 2000, BIOPHYS J, V79, P1478, DOI 10.1016/S0006-3495(00)76399-5	41	45	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30660	30668		10.1074/jbc.M606194200	http://dx.doi.org/10.1074/jbc.M606194200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16893900	hybrid			2022-12-25	WOS:000241075900042
J	Schoeber, JP; Topala, CN; Wang, XH; Diepens, RJ; Lambers, TT; Hoenderop, JG; Bindels, RJ				Schoeber, Joost P.; Topala, Catalin N.; Wang, Xinhua; Diepens, Robin J.; Lambers, Tim T.; Hoenderop, Joost G.; Bindels, Rene J.			RGS2 inhibits the epithelial Ca2+ channel TRPV6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD-INTRACELLULAR LOOP; CALCIUM-ABSORPTION; INTRACELLULAR LOOP; PLASMA-MEMBRANE; ANKYRIN REPEAT; G-PROTEINS; EXPRESSION; ARCHITECTURE; FAMILY; KIDNEY	The epithelial Ca2+ channels TRPV5 and TRPV6 constitute the apical Ca2+ entry pathway in the process of active Ca2+ (re)absorption. By yeast two-hybrid and glutathione S-transferase pulldown analysis we identified RGS2 as a novel TRPV6-associated protein. RGS proteins determine the inactivation kinetics of heterotrimeric G-protein-coupled receptor (GPCR) signaling by regulating the GTPase activity of G(alpha) subunits. Here we demonstrate that TRPV6 interacts with the NH2-terminal domain of RGS2 in a Ca2+-independent fashion and that overexpression of RGS2 reduces the Na+ and Ca2+ current of TRPV6 but not that of TRPV5-transfected human embryonic kidney 293 (HEK293) cells. In contrast, overexpression of the deletion mutant Delta N-RGS2, lacking the NH2-terminal domain of RGS2, in TRPV6-expressing HEK293 cells did not show this inhibition. Furthermore, cell surface biotinylation indicated that the inhibitory effect of RGS2 on TRPV6 activity is not mediated by differences in trafficking or retrieval of TRPV6 from the plasma membrane. This effect probably results from the direct interaction between RGS2 and TRPV6, affecting the gating properties of the channel. Finally, the scaffolding protein spinophilin, shown to recruit RGS2 and regulate GPCR-signaling via G(alpha), did not affect RGS2 binding and electrophysiological properties of TRPV6, indicating a GPCR-independent mechanism of TRPV6 regulation by RGS2.	Radboud Univ Nijmegen, Med Ctr, Dept Physiol, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	Radboud University Nijmegen; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bindels, RJ (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Physiol, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands.	R.Bindels@ncmls.ru.nl	Bindels, René JM/B-9824-2013; Hoenderop, Joost G.J./H-8047-2014	Bindels, René JM/0000-0003-1167-1339; Hoenderop, Joost G.J./0000-0002-1816-8544				Abramow-Newerly M, 2006, CELL SIGNAL, V18, P579, DOI 10.1016/j.cellsig.2005.08.010; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Birnbaumer L, 2003, CELL CALCIUM, V33, P419, DOI 10.1016/S0143-4160(03)00068-X; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; den Dekker E, 2003, CELL CALCIUM, V33, P497, DOI 10.1016/S0143-4160(03)00065-4; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; Hague C, 2005, J BIOL CHEM, V280, P27289, DOI 10.1074/jbc.M502365200; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Kehrl JH, 2002, INT J BIOCHEM CELL B, V34, P432, DOI 10.1016/S1357-2725(01)00141-8; Lambers TT, 2004, J BIOL CHEM, V279, P28855, DOI 10.1074/jbc.M313637200; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2003, CELL CALCIUM, V33, P409, DOI 10.1016/S0143-4160(03)00053-8; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Nijenhuis T, 2003, J AM SOC NEPHROL, V14, P2731, DOI 10.1097/01.ASN.0000094081.78893.E8; Nilius B, 2002, J BIOL CHEM, V277, P30852, DOI 10.1074/jbc.M202418200; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Putney JW, 2003, CELL CALCIUM, V34, P339, DOI 10.1016/S0143-4160(03)00143-X; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587; Van Abel M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022423.34922.2A; van de Graaf SFJ, 2006, MOL CELL BIOL, V26, P303, DOI 10.1128/MCB.26.1.303-312.2006; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; van de Graaf SFJ, 2006, PFLUG ARCH EUR J PHY, V452, P407, DOI 10.1007/s00424-006-0051-z; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2004, J BIOL CHEM, V279, P15223, DOI 10.1074/jbc.M312076200; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200	33	36	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29669	29674		10.1074/jbc.M606233200	http://dx.doi.org/10.1074/jbc.M606233200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16895908	Green Published, hybrid			2022-12-25	WOS:000240896300028
J	Yan, ZY; Lei-Butters, DCM; Liu, XM; Zhang, YL; Zhang, L; Luo, MH; Zak, R; Engelhardt, JF				Yan, Ziying; Lei-Butters, Diana C. M.; Liu, Xiaoming; Zhang, Yulong; Zhang, Liang; Luo, Meihui; Zak, Roman; Engelhardt, John F.			Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOASSOCIATED VIRUS TYPE-2; PROTEASOME-MODULATING AGENTS; CYSTIC-FIBROSIS; GENE-TRANSFER; INTRACELLULAR TRAFFICKING; EFFICIENT TRANSDUCTION; MURINE FIBROBLASTS; MAXILLARY SINUS; APICAL SURFACES; VIRAL VECTORS	The choice of adeno- associated virus serotypes for clinical applications is influenced by the animal model and model system used to evaluate various serotypes. In the present study, we sought to compare the biologic properties of rAAV2/ 1, rAAV2/ 2, and rAAV2/ 5 transduction in polarized human airway epithelia using viruses purified by a newly developed common column chromatography method. Results demonstrated that apical transduction of human airway epithelia with rAAV2/ 1 was 100- fold more efficient than rAAV2/ 2 and rAAV2/ 5. This transduction profile in human airway epithelia ( rAAV2/ 1 >> rAAV2/ 2 = rAAV2/ 5) was significantly different from that seen following nasal administration of these vectors to mouse lung ( rAAV2/ 5 > rAAV2/ 1 >> rAAV2/ 2), emphasizing differences in transduction of these serotypes between these two species. In stark contrast to rAAV2/ 2 and rAAV2/ 5, rAAV2/ 1 transduced both the apical and basolateral membraneofhumanairway epithelia with similar efficiency. However, the overall level of transduction across serotypes did not correlate with vector internalization. We hypothesized that differences in post-entry processing of these serotypes might influence the efficiency of apical transduction. To this end, we tested the effectiveness of proteasome inhibitors to augment nuclear translocation and gene expression from the three serotypes. Augmentation of rAAV2/ 1 apical transduction of human polarized airway epithelia was 10- fold lower than that for rAAV2/ 2 and rAAV2/ 5. Cellular fractionation studies demonstrated that proteasome inhibitors more significantly enhanced rAAV2/ 2 and rAAV2/ 5 translocation to the nucleus than rAAV2/ 1. These results demonstrate that AAV1 transduction biology in human airway epithelia differs from that ofAAV2andAAV5by virtue of altered ubiquitin/ proteasome sensitivities that influence nuclear translocation.	Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Ctr Gene Therapy Cyst Fibrosis & Other Genet Dis, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Engelhardt, JF (corresponding author), Univ Iowa, Coll Med, Dept Anat & Cell Biol, Rm 1 111 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	john-engelhardt@uiowa.edu		LIU, XIAOMING/0000-0002-3902-9105; ZHANG, Liang/0000-0003-3100-8593; Yan, Ziying/0000-0001-8210-5567; Engelhardt, John/0000-0003-2389-9277	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL058340, R01 HL58340] Funding Source: Medline; NIDDK NIH HHS [P30 DK054759, DK54759] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aitken ML, 2001, HUM GENE THER, V12, P1907, DOI 10.1089/104303401753153956; Auricchio A, 2002, J CLIN INVEST, V110, P499, DOI 10.1172/JCI200215780; BERNS KI, 1996, CURRENT TOPICS MICRO, V218; BLACKLOW N R, 1988, P165; Ding W, 2006, MOL THER, V13, P671, DOI 10.1016/j.ymthe.2005.12.002; Ding W, 2003, J VIROL, V77, P7361, DOI 10.1128/JVI.77.13.7361-7366.2003; Ding W, 2005, GENE THER, V12, P873, DOI 10.1038/sj.gt.3302527; Douar AM, 2001, J VIROL, V75, P1824, DOI 10.1128/JVI.75.4.1824-1833.2001; Duan DS, 2000, J CLIN INVEST, V105, P1573, DOI 10.1172/JCI8317; Duan DS, 1998, HUM GENE THER, V9, P2761, DOI 10.1089/hum.1998.9.18-2761; Flotte TR, 2005, CURR GENE THER, V5, P361, DOI 10.2174/1566523054064986; Gao GP, 2005, CURR GENE THER, V5, P285, DOI 10.2174/1566523054065057; Grimm D., 2003, Current Gene Therapy, V3, P281, DOI 10.2174/1566523034578285; Halbert CL, 2001, J VIROL, V75, P6615, DOI 10.1128/JVI.75.14.6615-6624.2001; Hansen J, 2000, J VIROL, V74, P992, DOI 10.1128/JVI.74.2.992-996.2000; Hansen J, 2001, J VIROL, V75, P4080, DOI 10.1128/JVI.75.9.4080-4090.2001; Karp Philip H, 2002, Methods Mol Biol, V188, P115; Liu XM, 2006, AM J RESP CELL MOL, V34, P56, DOI 10.1165/rcmb.2005-0189OC; Louboutin JP, 2005, J GENE MED, V7, P442, DOI 10.1002/jgm.686; Mori S, 2004, VIROLOGY, V330, P375, DOI 10.1016/j.virol.2004.10.012; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; Romano G, 2005, DRUG NEWS PERSPECT, V18, P311, DOI 10.1358/dnp.2005.18.5.917326; Srivastava A, 2002, J CELL BIOCHEM, P39, DOI 10.1002/jcb.10053; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Thomas CE, 2004, J VIROL, V78, P3110, DOI 10.1128/JVI.78.6.3110-3122.2004; Virella-Lowell I, 2005, J GENE MED, V7, P842, DOI 10.1002/jgm.759; Wagner JA, 2002, HUM GENE THER, V13, P1349, DOI 10.1089/104303402760128577; Wagner JA, 1998, HUM GENE THER, V9, P889, DOI 10.1089/hum.1998.9.6-889; Wagner JA, 1999, LARYNGOSCOPE, V109, P266, DOI 10.1097/00005537-199902000-00017; Walters RW, 2001, J BIOL CHEM, V276, P20610, DOI 10.1074/jbc.M101559200; Xiao W, 2002, J VIROL, V76, P11505, DOI 10.1128/JVI.76.22.11505-11517.2002; Yan ZY, 2002, J VIROL, V76, P2043, DOI 10.1128/JVI.76.5.2043-2053.2002; Yan ZY, 2004, J VIROL, V78, P2863, DOI 10.1128/JVI.78.6.2863-2874.2004; Zabner J, 2000, J VIROL, V74, P3852, DOI 10.1128/JVI.74.8.3852-3858.2000; Zhang LN, 2004, MOL THER, V10, P990, DOI 10.1016/j.ymthe.2004.08.009; Zhong L, 2004, HUM GENE THER, V15, P1207, DOI 10.1089/hum.2004.15.1207; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	38	37	52	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29684	29692		10.1074/jbc.M604099200	http://dx.doi.org/10.1074/jbc.M604099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16899463	Green Accepted, hybrid			2022-12-25	WOS:000240896300030
J	Fontaine, JM; Sun, XK; Hoppe, AD; Simon, S; Vicart, P; Welsh, MJ; Benndorf, R				Fontaine, Jean-Marc; Sun, Xiankui; Hoppe, Adam D.; Simon, Stephanie; Vicart, Patrick; Welsh, Michael J.; Benndorf, Rainer			Abnormal small heat shock protein interactions involving neuropathy-associated HSP22 (HSPB8) mutants	FASEB JOURNAL			English	Article						distal hereditary motor neuropathy; Charcot-Marie-Tooth disease; fluorescence resonance energy transfer	ALPHA-B-CRYSTALLIN; MARIE-TOOTH-DISEASE; HEREDITARY MOTOR; MUTATION; DYNAMICS; TISSUES	Two mutations (K141E, K141N) in the small heat shock protein ( sHSP) HSP22 (HSPB8) are associated with the inherited peripheral motor neuron disorders distal hereditary motor neuropathy type II and axonal Charcot-Marie-Tooth disease type 2L. HSP22 is known to form homodimers, heterodimers with other sHSPs, and larger oligomers. In an effort to elucidate the cellular basis for these diseases, we have determined the ability of mutant HSP22 to interact with itself, with wild-type HSP22, and with other sHSPs that are abundant in neurons. Using the yeast two-hybrid method, quantitative fluorescence resonance energy transfer in live cells, and cross-linking, we found aberrantly increased interactions of mutant HSP22 forms with themselves, with wild-type HSP22, and with the other sHSPs, alpha B-crystallin, and HSP27. Interaction with HSP20 was not affected by the mutations. The data suggest that each mutant form of HSP22 has a characteristic pattern of abnormal interaction properties. A mutation (S135F) in HSP27 that is also associated with these disorders showed increased interaction with wild-type HSP22 also, suggesting linkage of these two etiologic factors, HSP22 and HSP27, into one common pathway. Increased interactions involving mutant sHSPs may be the molecular basis for their increased tendency to form cytoplasmic protein aggregates, and for the occurrence of the associated neuropathies.	Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Paris 07, UFR Biochim, Paris, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; UDICE-French Research Universities; Universite Paris Cite	Benndorf, R (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	rbenndo@umich.edu	Stephanie, Simon/A-3845-2013; Welsh, Michael/B-1968-2008; Hoppe, Adam/U-8563-2019	Hoppe, Adam/0000-0003-4180-0840	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011188] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01ES11188] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ackerley S, 2006, HUM MOL GENET, V15, P347, DOI 10.1093/hmg/ddi452; Benndorf R, 2004, NAT GENET, V36, P547, DOI 10.1038/ng0604-547; Dierick I, 2005, ANN MED, V37, P413, DOI 10.1080/07853890500296410; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Fontaine JM, 2005, BIOCHEM BIOPH RES CO, V337, P1006, DOI 10.1016/j.bbrc.2005.09.148; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; HARDING AE, 1980, BRAIN, V103, P259, DOI 10.1093/brain/103.2.259; Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006-3495(02)75365-4; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Inagaki N, 2006, BIOCHEM BIOPH RES CO, V342, P379, DOI 10.1016/j.bbrc.2006.01.154; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328; Irobi J, 2004, HUM MOL GENET, V13, pR195, DOI 10.1093/hmg/ddh226; Kijima K, 2005, J HUM GENET, V50, P473, DOI 10.1007/s10038-005-0280-6; Lelj-Garolla B, 2005, J MOL BIOL, V345, P631, DOI 10.1016/j.jmb.2004.10.056; Liu CH, 1999, BIOCHEM BIOPH RES CO, V255, P256, DOI 10.1006/bbrc.1999.0174; Liu Xiao-min, 2005, Zhonghua Yixue Yichuanxue Zazhi, V22, P510; Lowe J, 2001, ADV EXP MED BIOL, V487, P169; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Sanbe A, 2004, P NATL ACAD SCI USA, V101, P10132, DOI 10.1073/pnas.0401900101; Selcen D, 2003, ANN NEUROL, V54, P804, DOI 10.1002/ana.10767; Shy ME, 2004, CURR OPIN NEUROL, V17, P579, DOI 10.1097/00019052-200410000-00008; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Sun XK, 2006, CELL STRESS CHAPERON, V11, P61, DOI 10.1379/CSC-149R.1; Sun XK, 2004, J BIOL CHEM, V279, P2394, DOI 10.1074/jbc.M311324200; Tang BS, 2005, HUM GENET, V116, P222, DOI 10.1007/s00439-004-1218-3; Verschuure P, 2003, EUR J CELL BIOL, V82, P523, DOI 10.1078/0171-9335-00337; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wigley WC, 1999, J CELL BIOL, V145, P481; Zobel ATC, 2003, HUM MOL GENET, V12, P1609, DOI 10.1093/hmg/ddg173	33	70	75	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2168	+		10.1096/fj.06-5911fje	http://dx.doi.org/10.1096/fj.06-5911fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935933	Green Submitted			2022-12-25	WOS:000241156900057
J	HuangFu, WC; Omori, E; Akira, S; Matsumoto, K; Ninomiya-Tsuji, J				HuangFu, Wei-Chun; Omori, Emily; Akira, Shizuo; Matsumoto, Kunihiro; Ninomiya-Tsuji, Jun			Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-mediated NF-kappa B activation - TAO2 regulates TAK1 pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE PATHWAYS; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; JNK; COMPLEX; TAB1; APOPTOSIS; ASK1; CASPASE-2; NECROSIS	Osmotic stress activates MAPKs, including JNK and p38, which play important roles in cellular stress responses. Transforming growth factor-beta-activated kinase 1 (TAK1) is a member of the MAPK kinase kinase ( MAPKKK) family and can activate JNK and p38. TAK1 can also activate I kappa B kinase (IKK) that leads to degradation of I kappa B and subsequent NF-kappa B activation. We found that TAK1 is essential for osmotic stress-induced activation of JNK but is not an exclusive mediator of p38 activation. Furthermore, we found that although TAK1 was highly activated upon osmotic stress, it could not induce degradation of I kappa B or activation of NF-kappa B. These results suggest that TAK1 activity is somehow modulated to function specifically in osmotic stress signaling, leading to the activation of JNK but not of IKK. To elucidate the mechanism underlying this modulation, we screened for potential TAK1-binding proteins. We found that TAO2 (thousand-and-one amino acid kinase 2) associates with TAK1 and can inhibit TAK1-mediated activation of NF-kappa B but not of JNK. We observed that TAO2 can interfere with the interaction between TAK1 and IKK and thus may regulate TAK1 function. TAK1 is activated by many distinct stimuli, including cytokines and stresses, and regulation by TAO2 may be important to activate specific intracellular signaling pathways that are unique to osmotic stress.	N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; Nagoya Univ, Grad Sch Sci, Dept Biol Mol, Nagoya, Aichi 4648602, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Host Def, Osaka 5650871, Japan; Japan Sci & Technol Agcy, Kawaguchi 3320012, Japan	University of North Carolina; North Carolina State University; Nagoya University; Osaka University; Japan Science & Technology Agency (JST)	Ninomiya-Tsuji, J (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	Jun_Tsuji@ncsu.edu	Akira, Shizuo/C-3134-2009	Ninomiya-Tsuji, Jun/0000-0002-5584-0176	NIAMS NIH HHS [R21 AR050972, AR050972] Funding Source: Medline; NIGMS NIH HHS [R01 GM068812, GM068812] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR050972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Chen Z, 2003, J BIOL CHEM, V278, P22278, DOI 10.1074/jbc.M301173200; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kishida S, 2005, GENES CELLS, V10, P447, DOI 10.1111/j.1365-2443.2005.00852.x; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Mochida Y, 2000, J BIOL CHEM, V275, P32747, DOI 10.1074/jbc.M003042200; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Ono K, 2001, J BIOL CHEM, V276, P24396, DOI 10.1074/jbc.M102631200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Sheikh-Hamad D, 2004, AM J PHYSIOL-RENAL, V287, pF1102, DOI 10.1152/ajprenal.00225.2004; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Uemura N, 2006, J BIOL CHEM, V281, P7863, DOI 10.1074/jbc.M509834200; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556	39	49	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28802	28810		10.1074/jbc.M603627200	http://dx.doi.org/10.1074/jbc.M603627200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16893890	hybrid, Green Accepted			2022-12-25	WOS:000240680500034
J	Morrison, AR; Moss, J; Stevens, LA; Evans, JE; Farrell, C; Merithew, E; Lambright, DG; Greiner, DL; Mordes, JP; Rossini, AA; Bortell, R				Morrison, Alan R.; Moss, Joel; Stevens, Linda A.; Evans, James E.; Farrell, Caitlin; Merithew, Eric; Lambright, David G.; Greiner, Dale L.; Mordes, John P.; Rossini, Aldo A.; Bortell, Rita			ART2, a T cell surface mono-ADP-ribosyltransferase, generates extracellular poly(ADP-ribose)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADENOSINE DIPHOSPHATE RIBOSE); NICOTINAMIDE ADENINE-DINUCLEOTIDE; CRYSTAL-STRUCTURE; NAD GLYCOHYDROLASE; IN-VITRO; RAT; RIBOSYLATION; RT6; POLYMERASE; ACTIVATION	NAD functions in multiple aspects of cellular metabolism and signaling through enzymes that covalently transfer ADP-ribose from NAD to acceptor proteins, thereby altering their function. NAD is a substrate for two enzyme families, mono-ADP-ribosyltransferases (mARTs) and poly(ADP-ribose) polymerases (PARPs), that covalently transfer an ADP-ribose monomer or polymer, respectively, to acceptor proteins. ART2, a mART, is a phenotypic marker of immunoregulatory cells found on the surface of T lymphocytes, including intestinal intraepithelial lymphocytes (IELs). We have shown that the auto-ADP-ribosylation of the ART2.2 allelic protein is multimeric. Our backbone structural alignment of ART2 (two alleles of the rat art2 gene have been reported, for simplicity, the ART2.2 protein investigated in this study will be referred to as ART2) and PARP suggested that multimeric auto-ADP-ribosylation of ART2 may represent an ADP-ribose polymer, rather than multiple sites of mono-ADP-ribosylation. To investigate this, we used highly purified recombinant ART2 and demonstrated that ART2 catalyzes the formation of an ADP-ribose polymer by sequencing gel and by HPLC and MS/MS mass spectrometry identification of PR-AMP, a breakdown product specific to poly(ADP-ribose). Furthermore, we identified the site of ADP-ribose polymer attachment on ART2 as Arg-185, an arginine in a crucial loop of its catalytic core. We found that endogenous ART2 on IELs undergoes multimeric auto-ADP-ribosylation more efficiently than ART2 on peripheral T cells, suggesting that these distinct lymphocyte populations differ in their ART2 surface topology. Furthermore, ART2.2 IELs are more resistant to NAD-induced cell death than ART2.1 IELs that do not have multimeric auto-ADP-ribosylation activity. The data suggest that capability of polymerizing ADP-ribose may not be unique to PARPs and that poly(ADP-ribosylation), an established nuclear activity, may occur extracellularly and modulate cell function.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA; NHLBI, Pulm & Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bortell, R (corresponding author), Diabet Div, Suite 218,373 Plantat St, Worcester, MA 01605 USA.	rita.bortell@umassmed.edu	Morrison, Alan R./ABH-3831-2020	Morrison, Alan R./0000-0002-2412-7669	Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [DK25306, DK32520, DK36024, DK49106] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025306, R01DK049106, R01DK025306, P30DK032520, R01DK036024] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; Anderson RM, 2003, SCIENCE, V302, P2124, DOI 10.1126/science.1088697; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; Bortell R, 2001, J IMMUNOL, V167, P2049, DOI 10.4049/jimmunol.167.4.2049; Chen J, 2006, J IMMUNOL, V176, P4590, DOI 10.4049/jimmunol.176.8.4590; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Hara N, 1996, J BIOL CHEM, V271, P29552, DOI 10.1074/jbc.271.47.29552; IKEJIMA M, 1985, BIOCHEMISTRY-US, V24, P5039, DOI 10.1021/bi00340a013; INAGAKI F, 1978, BIOCHEM BIOPH RES CO, V85, P415, DOI 10.1016/S0006-291X(78)80058-8; JUNG S, 1994, J MOL BIOL, V244, P114, DOI 10.1006/jmbi.1994.1709; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; MIWA M, 1981, J BIOL CHEM, V256, P2916; MIWA M, 1977, NUCLEIC ACIDS RES, V4, P3997, DOI 10.1093/nar/4.11.3997; Mordes JP, 2002, DIABETES, V51, P3254, DOI 10.2337/diabetes.51.11.3254; MOSS J, 1980, J BIOL CHEM, V255, P7835; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; Mueller-Dieckmann C, 2002, J MOL BIOL, V322, P687, DOI 10.1016/S0022-2836(02)00818-5; Okazaki IJ, 1999, ANNU REV NUTR, V19, P485, DOI 10.1146/annurev.nutr.19.1.485; Okazaki IJ, 1996, J BIOL CHEM, V271, P22052, DOI 10.1074/jbc.271.36.22052; OPPENHEIMER NJ, 1978, J BIOL CHEM, V253, P4907; Rigby MR, 1996, J IMMUNOL, V156, P4259; Rigby MR, 1996, DIABETES, V45, P1419, DOI 10.2337/diabetes.45.10.1419; Ruf A, 1998, J MOL BIOL, V278, P57, DOI 10.1006/jmbi.1998.1673; Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Stevens LA, 2003, J BIOL CHEM, V278, P19591, DOI 10.1074/jbc.M210364200; SUGIMURA T, 1994, MOL CELL BIOCHEM, V138, P5, DOI 10.1007/BF00928437; TAKADA T, 1994, J BIOL CHEM, V269, P9420; Todd D, 1999, J IMMUNOL METHODS, V224, P111, DOI 10.1016/S0022-1759(99)00015-0; Todd DJ, 2004, J IMMUNOL, V172, P5356, DOI 10.4049/jimmunol.172.9.5356; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; WAITE DJ, 1993, CELL IMMUNOL, V152, P82, DOI 10.1006/cimm.1993.1269; WILLIAMS GT, 1985, EXP CELL RES, V160, P419, DOI 10.1016/0014-4827(85)90189-2; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	37	24	25	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33363	33372		10.1074/jbc.M607259200	http://dx.doi.org/10.1074/jbc.M607259200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16931513	hybrid			2022-12-25	WOS:000241621400046
J	Hozumi, K; Suzuki, N; Nielsen, PK; Nomizu, M; Yamada, Y				Hozumi, Kentaro; Suzuki, Nobuharu; Nielsen, Peter K.; Nomizu, Motoyoshi; Yamada, Yoshihiko			Laminin alpha 1 chain LG4 module promotes cell attachment through syndecans and cell spreading through integrin alpha 2 beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; SITE-DIRECTED MUTAGENESIS; G-DOMAIN; BINDING-SITES; DYSTROGLYCAN-BINDING; SYNTHETIC PEPTIDES; GLOBULAR DOMAIN; BASEMENT-MEMBRANES; CARCINOMA CELLS; SWISS-MODEL	The laminin alpha 1 chain is a subunit of laminin-1, a heterotrimeric basement membrane protein. The LG4-5 module at the C terminus of laminin alpha 1 contains major binding sites for heparin, sulfatide, and alpha-dystroglycan and plays a critical role in early embryonic development. We previously identified active synthetic peptides AG73 and EF-1 from the sequence of laminin alpha 1 LG4 for binding to syndecan and integrin alpha 2 beta 1, respectively. However, their activity and functional relationship within the laminin-1 and LG4 as well as the functional relation between these sites and alpha-dystroglycan binding sites in LG4 are not clear. To address these questions, we created mutant recombinant LG4 proteins containing alanine substitutions within the AG73 (M1), EF-1 (M2, M3), and alpha-dystroglycan binding sites (M4, M5) and analyzed their activities. We found that recombinant proteins rec-M1 and rec-M5, containing mutations within M1 and M5, respectively, did not bind heparin or lymphoid cell lines expressing syndecans. These results suggest that LG4 binds to heparin and syndecans through M1 and M5. Rec-M1 and rec-M5 reduced fibroblast attachment, whereas mutant rec-M2 and rec-M3 retained cell attachment activity but did not promote cell spreading. Fibroblast attachment to rec- LG4 was inhibited by heparin but not by integrin antibodies. Spreading of fibroblasts on rec-LG4 was inhibited by anti-integrin alpha 2 and beta 1 but not by anti-integrin alpha 1 and alpha 6. These results suggest that the M1 and M5 sites are necessary for cell attachment on LG4 through syndecans and that the EF-1 site is for cell spreading activity through integrin alpha 2 beta 1. In contrast, laminin-1-mediated fibroblast attachment and spreading were not inhibited by heparin or anti-integrin alpha 2. Our findings indicate that LG4 has a unique function distinct from laminin-1 and suggest that laminin alpha 1 LG4-5 may also be produced by a proteolytic cleavage in certain tissues where it exerts its activity.	NIDCR, Mol Biol Sect, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Tokyo Univ Pharm & Life Sci, Sch Pharm, Hachioji, Tokyo 1920392, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Tokyo University of Pharmacy & Life Sciences	Yamada, Y (corresponding author), NIDCR, Mol Biol Sect, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Rm 407,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.	yoshi.yamada@nih.gov		Hozumi, Kentaro/0000-0002-6671-4386	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000483, ZIADE000485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000485, Z01DE000483] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Aumailley M, 2003, MATRIX BIOL, V22, P49, DOI 10.1016/S0945-053X(03)00013-1; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Dogic D, 1998, J CELL SCI, V111, P793; Durbeej M, 2001, DIFFERENTIATION, V69, P121, DOI 10.1046/j.1432-0436.2001.690206.x; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoffman MP, 2001, J BIOL CHEM, V276, P22077, DOI 10.1074/jbc.M100774200; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; Kikkawa Y, 2002, J BIOL CHEM, V277, P44864, DOI 10.1074/jbc.M208731200; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; Kusano Y, 2004, J BIOCHEM, V135, P129, DOI 10.1093/jb/mvh015; Langford JK, 1998, J BIOL CHEM, V273, P29965, DOI 10.1074/jbc.273.45.29965; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Makino M, 2002, EXP CELL RES, V277, P95, DOI 10.1006/excr.2002.5540; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Nielsen PK, 2001, J BIOL CHEM, V276, P10906, DOI 10.1074/jbc.M008743200; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Okazaki I, 2002, J BIOL CHEM, V277, P37070, DOI 10.1074/jbc.M201672200; Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; SASAKI M, 1988, J BIOL CHEM, V263, P16536; Scheele S, 2005, P NATL ACAD SCI USA, V102, P1502, DOI 10.1073/pnas.0405095102; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Smirnov SP, 2002, J BIOL CHEM, V277, P18928, DOI 10.1074/jbc.M201880200; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; Sung U, 1997, EUR J BIOCHEM, V250, P138, DOI 10.1111/j.1432-1033.1997.00138.x; Suzuki N, 2005, CONNECT TISSUE RES, V46, P142, DOI 10.1080/03008200591008527; Suzuki N, 2003, BIOCHEMISTRY-US, V42, P12625, DOI 10.1021/bi030014s; Suzuki N, 2003, J BIOL CHEM, V278, P45697, DOI 10.1074/jbc.M304667200; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Talts JF, 1999, FEBS LETT, V458, P319, DOI 10.1016/S0014-5793(99)01180-1; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Utani A, 2003, J BIOL CHEM, V278, P34483, DOI 10.1074/jbc.M304827200; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Wilson R, 2005, J BIOL CHEM, V280, P15544, DOI 10.1074/jbc.M410758200; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X	55	64	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32929	32940		10.1074/jbc.M605708200	http://dx.doi.org/10.1074/jbc.M605708200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16945929	hybrid			2022-12-25	WOS:000241414500091
J	Ukropec, J; Anunciado, RP; Ravussin, Y; Hulver, MW; Kozak, LP				Ukropec, Jozef; Anunciado, Rea P.; Ravussin, Yann; Hulver, Matthew W.; Kozak, Leslie P.			UCP1-independent thermogenesis in white adipose tissue of cold-acclimated Ucp1(-/-) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; DEPENDENT PROTEIN-KINASE; FATTY-ACID OXIDATION; DIET-INDUCED OBESITY; UCP1-DEFICIENT MICE; BROWN ADIPOCYTES; PHOSPHOLAMBAN PHOSPHORYLATION; NONSHIVERING THERMOGENESIS; CELLULAR PLASTICITY; CA2+-ATPASE	Apart from UCP1-based nonshivering thermogenesis in brown adipocytes, the identity of thermogenic mechanisms that can be activated to reduce a positive energy balance is largely unknown. To identify potentially useful mechanisms, we have analyzed physiological and molecular mechanisms that enable mice, genetically deficient in UCP1 and sensitive to acute exposure to the cold at 4 C, to adapt to long term exposure at 4 C. UCP1-deficient mice that can adapt to the cold have increased oxygen consumption and show increased oxidation of both fat and glucose as indicated from serum metabolite levels and liver glycogen content. Enhanced energy metabolism in inguinal fat was also indicated by increased oxygen consumption and fat oxidation in tissue suspensions and increased AMP kinase activity in dissected tissues. Analysis of gene expression in skeletal muscle showed surprisingly little change between cold-adapted Ucp1(+/+) and Ucp1(+/+) mice, whereas in inguinal fat a robust induction occurred for type 2 deiodinase, sarcoendoplasmic reticulum Ca2+-ATPase, mitochondrial glycerol 3-phosphate dehydrogenase, PGC1 alpha, CoxII, and mitochondrial DNA content. Western blot analysis showed an induction of total phospholamban and its phosphorylated form in inguinal fat and other white fat depots, but no induction was apparent in muscle. We conclude that alternative thermogenic mechanisms, based in part upon the enhanced capacity for ion and substrate cycling associated with brown adipocytes in white fat depots, are induced in UCP1-deficient mice by gradual cold adaptation.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Kozak, LP (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	kozaklp@pbrc.edu	Ravussin, Yann/ABE-8061-2021; Ukropec, Jozef/D-5960-2018; Ukropec, Jozef/AAI-5590-2020; Ravussin, Yann/AAE-1440-2020	Ravussin, Yann/0000-0002-6699-3944; Ukropec, Jozef/0000-0001-8401-6621; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD008431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD08431] Funding Source: Medline; NIDDK NIH HHS [P30 DK072476] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; BLOCK BA, 1994, J CELL BIOL, V127, P1275, DOI 10.1083/jcb.127.5.1275; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; CAREY FG, 1982, SCIENCE, V216, P1327, DOI 10.1126/science.7079766; Cinti S, 2002, J HISTOCHEM CYTOCHEM, V50, P21, DOI 10.1177/002215540205000103; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Commins SP, 2001, AM J PHYSIOL-ENDOC M, V280, pE372; COUSIN B, 1992, J CELL SCI, V103, P931; Crosson SM, 2003, J CLIN INVEST, V111, P1423, DOI 10.1172/JCI200317975; De Meis L, 1998, AM J PHYSIOL-CELL PH, V274, pC1738, DOI 10.1152/ajpcell.1998.274.6.C1738; de Meis L, 2005, BIOSCIENCE REP, V25, P181, DOI 10.1007/s10540-005-2884-7; de Meis L, 2003, J BIOL CHEM, V278, P41856, DOI 10.1074/jbc.M308280200; de Meis L, 2006, J BIOL CHEM, V281, P16384, DOI 10.1074/jbc.M600678200; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Golozoubova V, 2001, FASEB J, V15, P2048, DOI 10.1096/fj.00-0536fje; Gordon CJ, 1993, TEMPERATURE REGULATI, DOI 10.1017/CBO9780511565595; Granneman JG, 2005, AM J PHYSIOL-ENDOC M, V289, pE608, DOI 10.1152/ajpendo.00009.2005; Granneman JG, 2003, AM J PHYSIOL-ENDOC M, V285, pE1230, DOI 10.1152/ajpendo.00197.2003; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Guerra C, 1998, J CLIN INVEST, V102, P1724, DOI 10.1172/JCI4532; HAWKINS C, 1995, MOL CELL BIOCHEM, V142, P131, DOI 10.1007/BF00928934; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Himms-Hagen J, 2000, AM J PHYSIOL-CELL PH, V279, pC670, DOI 10.1152/ajpcell.2000.279.3.C670; Himms-Hagen J, 2004, CNS NEUROL DISORD-DR, V3, P389, DOI 10.2174/1568007043337076; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; Hofmann WE, 2001, J BIOL CHEM, V276, P12460, DOI 10.1074/jbc.M100466200; Hulver MW, 2005, CELL METAB, V2, P251, DOI 10.1016/j.cmet.2005.09.002; Hulver MW, 2003, AM J PHYSIOL-ENDOC M, V284, pE741, DOI 10.1152/ajpendo.00514.2002; Inokuma K, 2005, DIABETES, V54, P1385, DOI 10.2337/diabetes.54.5.1385; INUI M, 1986, J BIOL CHEM, V261, P1794; Isoda T, 2003, FASEB J, V17, P144, DOI 10.1096/fj.01-0981com; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Landeira-Fernandez AM, 2004, AM J PHYSIOL-REG I, V286, pR398, DOI 10.1152/ajpregu.00392.2003; Li JH, 2003, BIOCHEMISTRY-US, V42, P10674, DOI 10.1021/bi034708c; Li PP, 2005, AM J PHYSIOL-ENDOC M, V289, pE617, DOI 10.1152/ajpendo.00010.2005; Liu XT, 2003, J CLIN INVEST, V111, P399, DOI 10.1172/JCI200315737; Liu YW, 1997, AM J PHYSIOL-CELL PH, V273, pC1915, DOI 10.1152/ajpcell.1997.273.6.C1915; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Matejkova O, 2004, FEBS LETT, V569, P245, DOI 10.1016/j.febslet.2004.06.002; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Ojamaa K, 2000, ENDOCRINOLOGY, V141, P2139, DOI 10.1210/en.141.6.2139; SHOLTE HR, 1997, MOL CELL BIOCHEM, V174, P61; Solinas G, 2004, FEBS LETT, V577, P539, DOI 10.1016/j.febslet.2004.10.066; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; Ukropec J, 2006, ENDOCRINOLOGY, V147, P2468, DOI 10.1210/en.2005-1216; Wang YX, 2006, PFLUG ARCH EUR J PHY, V452, P363, DOI 10.1007/s00424-005-0036-3; YOUNG P, 1984, FEBS LETT, V167, P10, DOI 10.1016/0014-5793(84)80822-4	51	204	205	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31894	31908		10.1074/jbc.M606114200	http://dx.doi.org/10.1074/jbc.M606114200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16914547				2022-12-25	WOS:000241235300076
J	Baran, K; Ciccone, A; Peters, C; Yagita, H; Bird, PI; Villadangos, JA; Trapani, JA				Baran, Katherine; Ciccone, Annette; Peters, Christoph; Yagita, Hideo; Bird, Phillip I.; Villadangos, Jose A.; Trapani, Joseph A.			Cytotoxic T lymphocytes from cathepsin B-deficient mice survive normally in vitro and in vivo after encountering and killing target cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORIN-MEDIATED LYSIS; PORE-FORMING PROTEIN; GRANZYME-B; CYTOLYTIC LYMPHOCYTES; CASPASE ACTIVATION; TOXIC GRANULES; KILLER-CELLS; C2 DOMAIN; BINDING; RESISTANCE	The lysosomal protease cathepsin B has been proposed to protect cytotoxic T lymphocytes from the membrane-disruptive effects of perforin secreted during the execution phase of target cell death. Accordingly, cathepsin B that translocates to the lymphocyte surface upon degranulation has been postulated to cleave and inactivate perforin molecules that diffuse back to the killer cell. We have found that recombinant perforin is cleaved inefficiently by cathepsin B and shows no significant reduction in its lytic activity following co-incubation. Furthermore, purified CD8+ cytotoxic T lymphocytes of cathepsin B-null gene-targeted mice were able to induce normal death of target cells both in vitro and in vivo and to survive the encounter with target cells as efficiently as cathepsin B-expressing killer cells. We conclude that cathepsin B is not essential for protection of cytotoxic lymphocytes from the toxic effects of their secreted perforin.	Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia; Walter & Eliza Hall Inst Med Res, Div Immunol, Parkville, Vic 3052, Australia; Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3600, Australia	Peter Maccallum Cancer Center; Walter & Eliza Hall Institute; University of Freiburg; Juntendo University; Monash University	Trapani, JA (corresponding author), Peter MacCallum Canc Ctr, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	joe.trapani@petermac.org	Villadangos, Jose A/AAU-1404-2020	Villadangos, Jose A/0000-0001-6771-8891; Trapani, Joseph/0000-0003-0983-1532; Bird, Phillip/0000-0002-6695-606X				ANTIA R, 1992, IMMUNOL LETT, V32, P153, DOI 10.1016/0165-2478(92)90108-Z; Balaji KN, 2002, J EXP MED, V196, P493, DOI 10.1084/jem.20011836; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Coles RM, 2002, J IMMUNOL, V168, P834, DOI 10.4049/jimmunol.168.2.834; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; ISAAZ S, 1995, EUR J IMMUNOL, V25, P1071, DOI 10.1002/eji.1830250432; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; JIANG S, 1990, J IMMUNOL, V144, P998; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAWASAKI A, 1990, INT IMMUNOL, V2, P677, DOI 10.1093/intimm/2.7.677; Keefe D, 2005, IMMUNITY, V23, P249, DOI 10.1016/j.immuni.2005.08.001; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; MARTZ E, 1976, TRANSPLANTATION, V21, P5, DOI 10.1097/00007890-197601000-00002; MULLER C, 1994, J IMMUNOL, V153, P2470; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGLERANDERSON C, 1988, J IMMUNOL, V141, P3299; OJCIUS DM, 1991, MOL IMMUNOL, V28, P1011, DOI 10.1016/0161-5890(91)90187-O; OJCIUS DM, 1991, P NATL ACAD SCI USA, V88, P4621, DOI 10.1073/pnas.88.11.4621; Ondr JK, 2004, J BIOL CHEM, V279, P27525, DOI 10.1074/jbc.M400304200; PERSECHINI PM, 1990, J CELL BIOL, V110, P2109, DOI 10.1083/jcb.110.6.2109; Rochel N, 1996, CHEM BIOL, V3, P31, DOI 10.1016/S1074-5521(96)90081-2; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 2006, TRANSPLANTATION, V81, P146, DOI 10.1097/01.tp.0000191939.68451.d9; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Trapani JA, 1998, INT REV CYTOL, V182, P111, DOI 10.1016/S0074-7696(08)62169-5; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Uellner R, 1997, EMBO J, V16, P7287, DOI 10.1093/emboj/16.24.7287; VERRET CR, 1987, J EXP MED, V166, P1536, DOI 10.1084/jem.166.5.1536; Voskoboinik I, 2005, J BIOL CHEM, V280, P8426, DOI 10.1074/jbc.M413303200; Voskoboinik I, 2004, J EXP MED, V200, P811, DOI 10.1084/jem.20040776; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200; Yamamoto A, 1997, J BIOCHEM-TOKYO, V121, P974	36	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30485	30491		10.1074/jbc.M602007200	http://dx.doi.org/10.1074/jbc.M602007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16914553	hybrid			2022-12-25	WOS:000241075900024
J	Bhattacharya, N; Ghosh, S; Sept, D; Cooper, JA				Bhattacharya, Nandini; Ghosh, Shatadal; Sept, David; Cooper, John A.			Binding of myotrophin/V-1 to actin-capping protein - Implications for how capping protein binds to the filament barbed end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; V-1	The heterodimeric actin-capping protein (CP) regulates actin assembly and cell motility by binding tightly to the barbed end of the actin filament. Here we demonstrate that myotrophin/V-1 binds directly to CP in a 1: 1 molar ratio with a K-d of 10-50 nM. V-1 binding inhibited the ability of CP to cap the barbed ends of actin filaments. The actin-binding COOH-terminal region, the "tentacle," of the CP beta subunit was important for binding V-1, with lesser contributions from the alpha subunit COOH- terminal region and the body of the protein. V-1 appears to be unable to bind to CP that is on the barbed end, based on the observations that V-1 had no activity in an uncapping assay and that the V-1(.)CP complex had no capping activity. Two loops of V-1, which extend out from the alpha-helical backbone of this ankyrin repeat protein, were necessary for V-1 to bind CP. Parallel computational studies determined a bound conformation of the beta tentacle with V-1 that is consistent with these findings, and they offered insight into experimentally observed differences between the alpha 1 and alpha 2 isoforms as well as the mutant lacking the alpha tentacle. These results support and extend our "wobble" model for CP binding to the actin filament, in which the two COOH- terminal regions of CP bind independently to the actin filament, and bound CP is able to wobble when attached only via its mobile beta-subunit tentacle. This model is also supported by molecular dynamics simulations of CP reported here. The existence of the wobble state may be important for actin dynamics in cells.	Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Dept Biomed Engn, St Louis, MO 63110 USA; Washington Univ, Ctr Computat Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Cooper, JA (corresponding author), Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	jcooper@wustl.edu	Sept, David/F-6497-2011; Bhattacharya, Nandini/HGU-4374-2022; Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Sept, David/0000-0003-3719-2483; Cooper, John/0000-0002-0933-4571	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007873] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038542, R01GM067246] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007873] Funding Source: Medline; NIGMS NIH HHS [GM067246, R01 GM038542, R01 GM038542-18, GM38542, R01 GM067246-04, R01 GM067246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KM, 1999, J MOL CELL CARDIOL, V31, P705, DOI 10.1006/jmcc.1998.0903; Braun P, 2002, P NATL ACAD SCI USA, V99, P2654, DOI 10.1073/pnas.042684199; Canton DA, 2005, MOL CELL BIOL, V25, P3519, DOI 10.1128/MCB.25.9.3519-3534.2005; Carlsson AE, 2004, BIOPHYS J, V86, P1074, DOI 10.1016/S0006-3495(04)74182-X; Furukawa Y, 2003, NEUROMUSCULAR DISORD, V13, P32, DOI 10.1016/S0960-8966(02)00185-2; Ghosh J, 2004, MOL MICROBIOL, V51, P203, DOI 10.1046/j.1365-2958.2003.03816.x; Hart MC, 1997, CELL MOTIL CYTOSKEL, V38, P120, DOI 10.1002/(SICI)1097-0169(1997)38:2<120::AID-CM2>3.0.CO;2-B; Hart MC, 1999, J CELL BIOL, V147, P1287, DOI 10.1083/jcb.147.6.1287; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Mosavi LK, 2002, P NATL ACAD SCI USA, V99, P16029, DOI 10.1073/pnas.252537899; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; PENNICA D, 1995, GENE, V158, P305, DOI 10.1016/0378-1119(95)00131-O; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rosenfeld RJ, 2003, J COMPUT AID MOL DES, V17, P525, DOI 10.1023/B:JCAM.0000004604.87558.02; Sarkar S, 2004, J BIOL CHEM, V279, P20422, DOI 10.1074/jbc.M308488200; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SCHAIBLE UE, 1994, CELL ADHES COMMUN, V2, P465, DOI 10.3109/15419069409014211; SEN S, 1990, J BIOL CHEM, V265, P16635; SIL P, 1995, CIRC RES, V76, P1020, DOI 10.1161/01.RES.76.6.1020; SIL P, 1993, CIRC RES, V73, P98, DOI 10.1161/01.RES.73.1.98; Song SY, 1996, ENDOCRINOLOGY, V137, P1423, DOI 10.1210/en.137.4.1423; TAOKA M, 1994, J BIOL CHEM, V269, P9946; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; URUNO T, 2006, J BIOL CHEM; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Wear MA, 2004, TRENDS BIOCHEM SCI, V29, P418, DOI 10.1016/j.tibs.2004.06.003; Wear MA, 2004, J BIOL CHEM, V279, P14382, DOI 10.1074/jbc.M313412200; Yamakuni T, 1998, J BIOL CHEM, V273, P27051, DOI 10.1074/jbc.273.42.27051; Yamashita A, 2003, EMBO J, V22, P1529, DOI 10.1093/emboj/cdg167; Yang CS, 2005, DEV CELL, V9, P209, DOI 10.1016/j.devcel.2005.06.008; Yang YW, 1998, STRUCTURE, V6, P619, DOI 10.1016/S0969-2126(98)00063-X; Yang YW, 1997, PROTEIN SCI, V6, P1347, DOI 10.1002/pro.5560060625	40	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31021	31030		10.1074/jbc.M606278200	http://dx.doi.org/10.1074/jbc.M606278200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16895918	hybrid, Green Accepted			2022-12-25	WOS:000241075900078
J	Bouchard, R; Bailly, A; Blakeslee, JJ; Oehring, SC; Vincenzetti, V; Lee, OR; Paponov, I; Palme, K; Mancuso, S; Murphy, AS; Schulz, B; Geisler, M				Bouchard, Rodolphe; Bailly, Aurelien; Blakeslee, Joshua J.; Oehring, Sophie C.; Vincenzetti, Vincent; Lee, Ok Ran; Paponov, Ivan; Palme, Klaus; Mancuso, Stefano; Murphy, Angus S.; Schulz, Burkhard; Geisler, Markus			Immunophilin-like TWISTED DWARF1 modulates auxin efflux activities of Arabidopsis P-glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; FK506-BINDING PROTEIN; PROLYL ISOMERASE; POLAR TRANSPORT; ABC TRANSPORTER; LATERAL ROOT; PLANT; GENE; GROWTH; INHIBITION	The immunophilin-like protein TWISTED DWARF1 (TWD1/FKBP42) has been shown to physically interact with the multidrug resistance/P-glycoprotein (PGP) ATP-binding cassette transporters PGP1 and PGP19 (MDR1). Overlapping phenotypes of pgp1/pgp19 and twd1 mutant plants suggested a positive regulatory role of TWD1 in PGP-mediated export of the plant hormone auxin, which controls plant development. Here, we provide evidence at the cellular and plant levels that TWD1 controls PGP-mediated auxin transport. twd1 and pgp1/pgp19 cells showed greatly reduced export of the native auxin indole-3-acetic acid (IAA). Constitutive overexpression of PGP1 and PGP19, but not TWD1, enhanced auxin export. Coexpression of TWD1 and PGP1 in yeast and mammalian cells verified the specificity of the regulatory effect. Employing an IAA-specific microelectrode demonstrated that IAA influx in the root elongation zone was perturbed and apically shifted in pgp1/pgp19 and twd1 roots. Mature roots of pgp1/pgp19 and twd1 plants revealed elevated levels of free IAA, which seemed to account for agravitropic root behavior. Our data suggest a novel mode of PGP regulation via FK506-binding protein-like immunophilins, implicating possible alternative strategies to overcome multidrug resistance.	Univ Zurich, Inst Plant Biol, Zurich Basel Plant Sci Ctr, CH-8008 Zurich, Switzerland; Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; Univ Florence, Dept Hort, I-50019 Sesto Fiorentino, Italy	University of Zurich; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Freiburg; University of Florence	Geisler, M (corresponding author), Univ Zurich, Inst Plant Biol, Zurich Basel Plant Sci Ctr, Zollikerstr 107, CH-8008 Zurich, Switzerland.	markus.geisler@botinst.unizh.ch	Palme, Klaus/A-9524-2013; Mancuso, Stefano/G-6515-2012; Geisler, Markus M/B-3921-2012; Paponov, Ivan A./H-9680-2016; Blakeslee, Joshua/G-4420-2011	Palme, Klaus/0000-0002-2728-3835; Mancuso, Stefano/0000-0003-1752-3986; Geisler, Markus M/0000-0002-6641-5810; Paponov, Ivan A./0000-0002-2138-0722; 				Aghdasi B, 2001, P NATL ACAD SCI USA, V98, P2425, DOI 10.1073/pnas.041614198; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Arndt C, 1999, MICROBIOL-SGM, V145, P1989, DOI 10.1099/13500872-145-8-1989; Baluska F, 2003, TRENDS CELL BIOL, V13, P282, DOI 10.1016/S0962-8924(03)00084-9; Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3; Blakeslee JJ, 2005, CURR OPIN PLANT BIOL, V8, P494, DOI 10.1016/j.pbi.2005.07.014; Blakeslee JJ, 2004, PLANT PHYSIOL, V134, P28, DOI 10.1104/pp.103.031690; Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Castro AF, 1999, BIOCHEM PHARMACOL, V58, P1723, DOI 10.1016/S0006-2952(99)00288-9; Cruz MC, 1999, MOL CELL BIOL, V19, P4101; Dunnwald M, 1999, MOL BIOL CELL, V10, P329, DOI 10.1091/mbc.10.2.329; Faure JD, 1998, DEVELOPMENT, V125, P909; Folkes LK, 2003, CANCER RES, V63, P776; Friml J, 2003, CURR OPIN PLANT BIOL, V6, P7, DOI 10.1016/S1369526602000031; Friml J, 2005, ANNU PLANT REV, V16, P1; Geisler M, 2006, FEBS LETT, V580, P1094, DOI 10.1016/j.febslet.2005.11.054; Geisler M, 2005, PLANT J, V44, P179, DOI 10.1111/j.1365-313X.2005.02519.x; Geisler M, 2004, MOL BIOL CELL, V15, P3393, DOI 10.1091/mbc.E03-11-0831; Geisler M, 2003, MOL BIOL CELL, V14, P4238, DOI 10.1091/mbc.E02-10-0698; Geisler M, 2000, PLANT PHYSIOL, V124, P1814, DOI 10.1104/pp.124.4.1814; GOLDSMITH MHM, 1977, ANNU REV PLANT PHYS, V28, P439, DOI 10.1146/annurev.pp.28.060177.002255; Harrar Y, 2001, TRENDS PLANT SCI, V6, P426, DOI 10.1016/S1360-1385(01)02044-1; Hemenway CS, 1996, J BIOL CHEM, V271, P18527, DOI 10.1074/jbc.271.31.18527; Hrycyna CA, 1998, METHOD ENZYMOL, V292, P456; Jasinski M, 2003, PLANT PHYSIOL, V131, P1169, DOI 10.1104/pp.102.014720; Kamphausen T, 2002, PLANT J, V32, P263, DOI 10.1046/j.1365-313X.2002.01420.x; Krishna Rajesh, 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P163, DOI 10.2174/1568011013354705; Kurek I, 2002, PLANTA, V215, P119, DOI 10.1007/s00425-001-0722-0; Lariguet P, 2004, PLANT J, V40, P826, DOI 10.1111/j.1365-313X.2004.02256.x; Li JS, 2005, SCIENCE, V310, P121, DOI 10.1126/science.1115711; Lin RC, 2005, PLANT PHYSIOL, V138, P949, DOI 10.1104/pp.105.061572; LOMAX TL, 1985, P NATL ACAD SCI USA, V82, P6541, DOI 10.1073/pnas.82.19.6541; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Mancuso S, 2005, ANAL BIOCHEM, V341, P344, DOI 10.1016/j.ab.2005.03.054; Mancuso S, 2006, PLANT CELL PHYSIOL, V47, P401, DOI 10.1093/pcp/pcj007; Martinoia E, 2002, PLANTA, V214, P345, DOI 10.1007/s004250100661; Mealey KL, 1999, CANCER CHEMOTH PHARM, V44, P152, DOI 10.1007/s002800050960; Muday GK, 2001, TRENDS PLANT SCI, V6, P535, DOI 10.1016/S1360-1385(01)02101-X; Multani DS, 2003, SCIENCE, V302, P81, DOI 10.1126/science.1086072; Murphy AS, 2002, PLANT PHYSIOL, V128, P935, DOI 10.1104/pp.010519; Noh B, 2003, NATURE, V423, P999, DOI 10.1038/nature01716; Noh B, 2001, PLANT CELL, V13, P2441, DOI 10.1105/tpc.13.11.2441; Nuhse TS, 2004, PLANT CELL, V16, P2394, DOI 10.1105/tpc.104.023150; Ottenschlager I, 2003, P NATL ACAD SCI USA, V100, P2987, DOI 10.1073/pnas.0437936100; Peer WA, 2004, PLANT CELL, V16, P1898, DOI 10.1105/tpc.021501; Perez-Perez JM, 2004, PLANT PHYSIOL, V134, P101, DOI 10.1104/pp.103.032524; Petrasek J, 2006, SCIENCE, V312, P914, DOI 10.1126/science.1123542; Prusty R, 2004, P NATL ACAD SCI USA, V101, P4153, DOI 10.1073/pnas.0400659101; Ramaen O, 2005, BIOCHEM J, V391, P481, DOI 10.1042/BJ20050897; Romano P, 2005, NEW PHYTOL, V166, P753, DOI 10.1111/j.1469-8137.2005.01373.x; Santelia D, 2005, FEBS LETT, V579, P5399, DOI 10.1016/j.febslet.2005.08.061; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Schlicht M, 2006, PLANT SIGNAL BEHAV, V1, P122, DOI 10.4161/psb.1.3.2759; Sidler M, 1998, PLANT CELL, V10, P1623, DOI 10.1105/tpc.10.10.1623; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; Terasaka K, 2005, PLANT CELL, V17, P2922, DOI 10.1105/tpc.105.035816; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; Ueda M, 2004, DEVELOPMENT, V131, P2101, DOI 10.1242/dev.01096; Vespa L, 2004, PLANT PHYSIOL, V134, P1283, DOI 10.1104/pp.103.028050; Vittorioso P, 1998, MOL CELL BIOL, V18, P3034, DOI 10.1128/MCB.18.5.3034; Vucich VA, 1996, MOL GEN GENET, V252, P510, DOI 10.1007/BF02172397; Weiergraber OH, 2006, FEBS LETT, V580, P251, DOI 10.1016/j.febslet.2005.12.007	63	156	162	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30603	30612		10.1074/jbc.M604604200	http://dx.doi.org/10.1074/jbc.M604604200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16887800	Green Published, hybrid			2022-12-25	WOS:000241075900036
J	Franzke, CW; Has, C; Schulte, C; Huilaja, L; Tasanen, K; Aumailley, M; Bruckner-Tuderman, L				Franzke, Claus-Werner; Has, Cristina; Schulte, Carsten; Huilaja, Laura; Tasanen, Kaisa; Aumailley, Monique; Bruckner-Tuderman, Leena			C-terminal truncation impairs glycosylation of transmembrane collagen XVII and leads to intracellular accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENIGN EPIDERMOLYSIS-BULLOSA; PEMPHIGOID ANTIGEN BPAG2; GLYCINE SUBSTITUTION; CELL-ADHESION; MUTATIONS; PROTEIN; COL17A1; GENE; ECTODOMAIN; LAMININ-5	Collagen XVII, a type II transmembrane protein in hemidesmosomes, is involved in the anchorage of stratified epithelia to the underlying mesenchyme. Its functions are regulated by ectodomain shedding, and its genetic defects lead to epidermal detachment in junctional epidermolysis bullosa ( JEB), a heritable skin fragility syndrome, but the molecular disease mechanisms remain elusive. Here we used a spontaneously occurring homozygous COL17A1 deletion mutant in JEB to discern glycosylation of collagen XVII. The mutation truncated the distal ectodomain and positioned the only N-glycosylation site 34 amino acids from the newly formed C terminus, which impaired efficient N-glycosylation. Immunofluorescence staining of authentic JEB keratinocytes and of COS-7 cells transfected with the mutant indicated intracellular accumulation of collagen XVII precursor molecules. Cell surface biotinylation and quantification of ectodomain shedding demonstrated that only about 15% of the truncated collagen XVII reached the cell surface. The cell surface-associated molecules were N-glycosylated in a normal manner, in contrast to the molecules retained within the cells, indicating that N-glycosylation of the ectodomain is required for targeting of collagen XVII to the plasma membrane and that reduced accessibility of the N-glycosylation site negatively regulates this process. Functional consequences of the strong reduction of collagen XVII on the cell surface included scattered deposition of cell adhesion molecule laminin 5 into the extracellular environment and, as a consequence of faulty collagen XVII-laminin ligand interactions, aberrant motility of the mutant cells.	Univ Freiburg, Med Ctr, Dept Dermatol, D-79104 Freiburg, Germany; Univ Cologne, Fac Med, Dept Biochem, D-50923 Cologne, Germany; Univ Oulu, Dept Dermatol, Oulu 90014, Finland; Oulu Univ Hosp, Clin Res Ctr, Oulu 90014, Finland; Univ Cologne, Ctr Mol Med Cologne, D-50923 Cologne, Germany	University of Freiburg; University of Cologne; University of Oulu; University of Oulu; University of Cologne	Bruckner-Tuderman, L (corresponding author), Univ Freiburg, Med Ctr, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	bruckner_tuderman@haut.ukl.uni-freiburg.de	Has, Cristina/B-3310-2017; Schulte, Carsten/R-2370-2016; Has, Cristina/AGF-7185-2022; Has, Cristina/V-2132-2019	Has, Cristina/0000-0001-6066-507X; Schulte, Carsten/0000-0002-7554-5342; Has, Cristina/0000-0001-6066-507X; Has, Cristina/0000-0001-6066-507X; Tasanen, Kaisa/0000-0001-8056-5949				Conti LR, 2002, J BIOL CHEM, V277, P25416, DOI 10.1074/jbc.M203109200; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; Esapa CT, 2005, HUM MOL GENET, V14, P295, DOI 10.1093/hmg/ddi026; FINE JD, 1988, ARCH DERMATOL, V124, P713, DOI 10.1001/archderm.124.5.713; Floeth M, 1998, J INVEST DERMATOL, V111, P528, DOI 10.1046/j.1523-1747.1998.00325.x; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2004, J BIOL CHEM, V279, P24521, DOI 10.1074/jbc.M308835200; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Gagnoux-Palacios L, 2001, J CELL BIOL, V153, P835, DOI 10.1083/jcb.153.4.835; Gatalica B, 1997, AM J HUM GENET, V60, P352; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; JONKMAN MF, 1995, J CLIN INVEST, V95, P1345, DOI 10.1172/JCI117785; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; MAHONEY WC, 1979, J BIOL CHEM, V254, P6572; McGrath JA, 1996, J INVEST DERMATOL, V106, P771, DOI 10.1111/1523-1747.ep12345821; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; Pulkkinen L, 1998, EXP DERMATOL, V7, P46, DOI 10.1111/j.1600-0625.1998.tb00304.x; Pulkkinen L, 1999, MATRIX BIOL, V18, P29, DOI 10.1016/S0945-053X(98)00005-5; Sabbagh Y, 2001, HUM MOL GENET, V10, P1539, DOI 10.1093/hmg/10.15.1539; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Schumann H, 1997, AM J HUM GENET, V60, P1344, DOI 10.1086/515463; Schumann H, 2000, AM J PATHOL, V156, P685, DOI 10.1016/S0002-9440(10)64772-4; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Tasanen K, 2004, AM J PATHOL, V164, P2027, DOI 10.1016/S0002-9440(10)63762-5; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093; Tasanen K, 2000, J INVEST DERMATOL, V115, P207, DOI 10.1046/j.1523-1747.2000.00049.x; Tunggal L, 2002, AM J PATHOL, V160, P459, DOI 10.1016/S0002-9440(10)64865-1; Vaisanen L, 2005, J INVEST DERMATOL, V125, P1112, DOI 10.1111/j.0022-202X.2005.23943.x; Walmsley AR, 2003, BIOCHEM J, V370, P351, DOI 10.1042/BJ20021303; White JK, 2004, BIOCHEM J, V382, P811, DOI 10.1042/BJ20040808; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241	33	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30260	30268		10.1074/jbc.M604464200	http://dx.doi.org/10.1074/jbc.M604464200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16899459	hybrid			2022-12-25	WOS:000240896300086
J	Paquet, M; Asay, MJ; Fam, SR; Inuzuka, H; Castleberry, AM; Oller, H; Smith, Y; Yun, CC; Traynelis, SF; Hall, RA				Paquet, Maryse; Asay, Matthew J.; Fam, Sami R.; Inuzuka, Hiroyuki; Castleberry, Amanda M.; Oller, Heide; Smith, Yoland; Yun, C. Chris; Traynelis, Stephen F.; Hall, Randy A.			The PDZ scaffold NHERF-2 interacts with mGluR5 and regulates receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; BORDER NA+/H+ EXCHANGER; GROUP-I; UP-REGULATION; HIPPOCAMPAL ASTROCYTES; SHANK FAMILY; SPINAL-CORD; PROTEIN; EXPRESSION; ASSOCIATION	The two members of the group I metabotropic glutamate receptor family, mGluR1 and mGluR5, both couple to G(q) to mediate rises in intracellular calcium. The alternatively spliced C termini (CT) of mGluRs 1 & 5 are known to be critical for regulating receptor activity and to terminate in motifs suggestive of potential interactions with PDZ domains. We therefore screened the CTs of both mGluR1a and mGluR5 against a PDZ domain proteomic array. Out of 96 PDZ domains examined, the domain that bound most strongly to mGluR5-CT was the second PDZ domain of the Na+/H+ exchanger regulatory factor 2 (NHERF-2). This interaction was confirmed by reverse overlay, and a single point mutation to the mGluR5-CT was found to completely disrupt the interaction. Full-length mGluR5 robustly associated with full-length NHERF-2 in cells, as assessed by co-immunoprecipitation and confocal microscopy experiments. In contrast, mGluR1a was found to bind NHERF-2 in vitro with a weaker affinity than mGluR5, and furthermore mGluR1a did not detectably associate with NHERF-2 in a cellular context. Immunohistochemical experiments revealed that NHERF-2 and mGluR5 exhibit overlapping patterns of expression in mouse brain, being found most abundantly in astrocytic processes and postsynaptic neuronal elements. In functional experiments, the interaction of NHERF-2 with mGluR5 in cells was found to prolong mGluR5-mediated calcium mobilization and to also potentiate mGluR5-mediated cell death, whereas co-expression of mGluR1a with NHERF-2 had no evident effects on mGluR1a functional activity. These observations reveal that NHERF-2 can selectively modulate mGluR5 signaling, which may contribute to cell-specific regulation of mGluR5 activity.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Div Digest Dis, Dept Med, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5113 Rollins Res Ctr,1510 Clifton Rd, Atlanta, GA 30322 USA.	rhall@pharm.emory.edu		Hall, Randy/0000-0002-8318-8728	NIDDK NIH HHS [R01 DK061418-03, R01 DK061418-02, R01 DK061418-04, R01 DK061418] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061418] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albasanz JL, 2002, MOL BRAIN RES, V99, P54; Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Aronica E, 2001, NEUROSCIENCE, V105, P509, DOI 10.1016/S0306-4522(01)00181-6; Aronica E, 2003, EPILEPSIA, V44, P785, DOI 10.1046/j.1528-1157.2003.54802.x; Aronica E, 2000, EUR J NEUROSCI, V12, P2333, DOI 10.1046/j.1460-9568.2000.00131.x; Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009; Cai ZH, 2000, GLIA, V29, P70, DOI 10.1002/(SICI)1098-1136(20000101)29:1<70::AID-GLIA7>3.0.CO;2-V; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Fagni L, 2004, SEMIN CELL DEV BIOL, V15, P289, DOI 10.1016/j.semcdb.2003.12.018; Fam SR, 2005, P NATL ACAD SCI USA, V102, P8042, DOI 10.1073/pnas.0408818102; Ferraguti F, 2001, EXP BRAIN RES, V137, P1, DOI 10.1007/s002210000633; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Geurts JJG, 2003, BRAIN, V126, P1755, DOI 10.1093/brain/awg179; Gwak YS, 2005, EXP NEUROL, V195, P236, DOI 10.1016/j.expneurol.2005.05.012; He JQ, 2006, J BIOL CHEM, V281, P2820, DOI 10.1074/jbc.M509503200; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Hubert GW, 2004, J COMP NEUROL, V475, P95, DOI 10.1002/cne.20163; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Hwang JI, 2005, J BIOL CHEM, V280, P12467, DOI 10.1074/jbc.M410740200; JOLY C, 1995, J NEUROSCI, V15, P3970; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Kew JNC, 2004, PHARMACOL THERAPEUT, V104, P233, DOI 10.1016/j.pharmthera.2004.08.010; Kitano J, 2002, J NEUROSCI, V22, P1280, DOI 10.1523/JNEUROSCI.22-04-01280.2002; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Lee-Kwon W, 2005, AM J PHYSIOL-CELL PH, V288, pC942, DOI 10.1152/ajpcell.00417.2004; Lee-Kwon W, 2003, AM J PHYSIOL-CELL PH, V285, pC1527, DOI 10.1152/ajpcell.00017.2003; Martin M, 1998, BBA-LIPID LIPID MET, V1393, P186, DOI 10.1016/S0005-2760(98)00036-8; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Moghaddam B, 2004, PSYCHOPHARMACOLOGY, V174, P39, DOI 10.1007/s00213-004-1792-z; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Paquet M, 2006, J COMP NEUROL, V494, P752, DOI 10.1002/cne.20854; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Rong R, 2003, NAT NEUROSCI, V6, P1153, DOI 10.1038/nn1134; Sala C, 2005, J NEUROSCI, V25, P4587, DOI 10.1523/JNEUROSCI.4822-04.2005; Schools GP, 1999, J NEUROSCI RES, V58, P533, DOI 10.1002/(SICI)1097-4547(19991115)58:4<533::AID-JNR6>3.0.CO;2-G; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Smith Y, 2001, J CHEM NEUROANAT, V22, P13, DOI 10.1016/S0891-0618(01)00098-9; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Ulas J, 2000, GLIA, V30, P352, DOI 10.1002/(SICI)1098-1136(200006)30:4<352::AID-GLIA40>3.0.CO;2-6; Valenti O, 2002, J CELL PHYSIOL, V191, P125, DOI 10.1002/jcp.10081; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	49	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29949	29961		10.1074/jbc.M602262200	http://dx.doi.org/10.1074/jbc.M602262200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16891310	Green Accepted, hybrid			2022-12-25	WOS:000240896300056
J	Sonobe, H; Ohira, T; Ieki, K; Maeda, S; Ito, Y; Ajimura, M; Mita, K; Matsumoto, H; Wilder, MN				Sonobe, Haruyuki; Ohira, Tsuyoshi; Ieki, Katsunori; Maeda, Sayaka; Ito, Yoichi; Ajimura, Masahiro; Mita, Kazuei; Matsumoto, Hitoshi; Wilder, Marcy N.			Purification, kinetic characterization, and molecular cloning of a novel enzyme, ecdysteroid 22-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY EMBRYONIC-DEVELOPMENT; BOMBYX-MORI; DIAPAUSE EGGS; CYTOCHROME-P450 ENZYME; CRYSTAL-STRUCTURE; NONDIAPAUSE EGGS; PHOSPHORIC ESTER; FOLLICLE CELLS; P450 ENZYMES; SILKWORM	This is the first report succeeding in the isolation and characterization of an enzyme and its gene involved in the phosphorylation of a steroid hormone. It has been demonstrated that ecdysteroid 22-phosphates in insect ovaries, which are physiologically inactive, serve as a "reservoir" that supplies active free ecdysteroids during early embryonic development and that their dephosphorylation is catalyzed by a specific enzyme, ecdysteroid-phosphate phosphatase (Yamada, R., and Sonobe, H. (2003), J. Biol. Chem. 278, 26365-26373). In this study, ecdysteroid 22-kinase (EcKinase) was purified from the cytosol of the silkworm Bombyx mori ovaries to about 1,800-fold homogeneity in six steps of column chromatography and biochemically characterized. Results obtained indicated that the reciprocal conversion of free ecdysteroids and ecdysteroid 22-phosphates by two enzymes, EcKinase and ecdysteroid-phosphate phosphatase, plays an important role in ecdysteroid economy of the ovary-egg system of B. mori. On the basis of the partial amino acid sequence obtained from purified EcKinase, the nucleotide sequence of the cDNA encoding EcKinase was determined. The full-length cDNA of EcKinase was composed of 1,850 bp with an open reading frame encoding a protein of 386 amino acid residues. The cloned cDNA was confirmed to encode the functional EcKinase using the transformant harboring the open reading frame of EcKinase. A data base search showed that EcKinase has an amino acid sequence characteristic of phosphotransferases, in that it harbors Brenner's motif and putative ATP binding sites, but there are no functional proteins that share high identity with the amino acid sequence of EcKinase.	Konan Univ, Fac Sci & Engn, Dept Biol, Kobe, Hyogo 6588501, Japan; Japan Int Res Ctr Agr Sci, Tsukuba, Ibaraki 3058686, Japan; Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058634, Japan	Konan University; Japan International Research Center for Agricultural Sciences; National Institute of Agrobiological Sciences - Japan	Sonobe, H (corresponding author), Konan Univ, Fac Sci & Engn, Dept Biol, Kobe, Hyogo 6588501, Japan.	sonobe@konan-u.ac.jp	WILDER, MARCY/CAH-4807-2022					Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Aoyama C, 2000, J LIPID RES, V41, P452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BULLIERE D, 1979, ROUX ARCH DEV BIOL, V186, P103, DOI 10.1007/BF00848172; Chavez VM, 2000, DEVELOPMENT, V127, P4115; Coughtrie MWH, 1998, CHEM-BIOL INTERACT, V109, P3, DOI 10.1016/S0009-2797(97)00117-8; Fukuda S., 1951, Proceedings of the Japan Academy, V27, P672; GHARIB B, 1981, J INSECT PHYSIOL, V27, P711, DOI 10.1016/0022-1910(81)90008-1; GHARIB B, 1981, EXPERIENTIA, V37, P1107, DOI 10.1007/BF02085039; Gilbert LI, 2004, MOL CELL ENDOCRINOL, V215, P1, DOI 10.1016/j.mce.2003.11.003; Hagedorn H.H., 1985, P205; Hochberg RB, 1998, ENDOCR REV, V19, P331, DOI 10.1210/er.19.3.331; Hoffmann J.A., 1985, P435; Horike N, 1999, ARCH INSECT BIOCHEM, V41, P9, DOI 10.1002/(SICI)1520-6327(1999)41:1&lt;9::AID-ARCH3&gt;3.0.CO;2-G; Horike N, 2000, EUR J BIOCHEM, V267, P6914, DOI 10.1046/j.1432-1033.2000.01796.x; KABBOUH M, 1991, INSECT BIOCHEM, V21, P57, DOI 10.1016/0020-1790(91)90064-L; Kamba M, 2000, NAT PROD LETT, V14, P349, DOI 10.1080/10575630008043767; KAMBA M, 1994, INSECT BIOCHEM MOLEC, V24, P395, DOI 10.1016/0965-1748(94)90032-9; Kamba M, 2000, NAT PROD LETT, V14, P469, DOI 10.1080/10575630008043787; Kamba Mari, 1995, Journal of Sericultural Science of Japan, V64, P333; KAPPLER C, 1986, INT J INVER REP DEV, V9, P17, DOI 10.1080/01688170.1986.10510177; KOOLMAN J, 1990, ZOOL SCI, V7, P563; Kozlova T, 2003, SCIENCE, V301, P1911, DOI 10.1126/science.1087419; Lafont R., 1984, P196; Lafont R., 2005, COMPREHENSIVE MOL IN, V3, P125, DOI DOI 10.1016/B0-44-451924-6/00035-1; LAFONT R, 2002, ECOYSONE HDB; LAGUEUX M, 1979, J INSECT PHYSIOL, V25, P709, DOI 10.1016/0022-1910(79)90123-9; Lanot R., 1989, P262; Lee DC, 2003, J BIOL CHEM, V278, P31412, DOI 10.1074/jbc.M213154200; Makka T, 2000, ZOOL SCI, V17, P89, DOI 10.2108/zsj.17.89; Makka T, 2002, ARCH INSECT BIOCHEM, V51, P111, DOI 10.1002/arch.10055; MAMIYA Y, 1995, EXPERIENTIA, V51, P363, DOI 10.1007/BF01928896; Matsumoto E, 2003, BIOSCI BIOTECH BIOCH, V67, P1780, DOI 10.1271/bbb.67.1780; Nakatsuji T, 2004, GEN COMP ENDOCR, V135, P358, DOI 10.1016/j.ygcen.2003.11.001; Niwa R, 2004, J BIOL CHEM, V279, P35942, DOI 10.1074/jbc.M404514200; OHNISHI E, 1981, INSECT BIOCHEM, V11, P155, DOI 10.1016/0020-1790(81)90090-1; OHNISHI E, 1989, INSECT BIOCHEM, V19, P95, DOI 10.1016/0020-1790(89)90014-0; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; Peisach D, 2003, STRUCTURE, V11, P703, DOI 10.1016/S0969-2126(03)00094-7; Petryk A, 2003, P NATL ACAD SCI USA, V100, P13773, DOI 10.1073/pnas.2336088100; Raftogianis R, 2000, J Natl Cancer Inst Monogr, P113; Rees H.H., 1984, P181; REES HH, 1995, EUR J ENTOMOL, V92, P9; REES HH, 1984, COMPREHENSIVE MOL IN, P181; RYBCZYNSKI R, 2005, COMPREHENSIVE MOL IN, V3, P61; SCALIA S, 1987, INSECT BIOCHEM, V17, P227, DOI 10.1016/0020-1790(87)90164-8; Sieglaff DH, 2005, INSECT BIOCHEM MOLEC, V35, P471, DOI 10.1016/j.ibmb.2005.01.011; SONOBE H, 1991, EXPERIENTIA, V47, P948, DOI 10.1007/BF01929889; Sonobe H, 1999, ZOOL SCI, V16, P935, DOI 10.2108/zsj.16.935; SONOBE H, 1986, J INSECT PHYSIOL, V32, P215, DOI 10.1016/0022-1910(86)90061-2; SONOBE H, 1970, DEV GROWTH DIFFER, V12, P41; Sonobe H, 2004, ZOOL SCI, V21, P503, DOI 10.2108/zsj.21.503; TAKAHASHI SY, 1992, ZOOL SCI, V9, P169; Tawfik AI, 1999, ARCH INSECT BIOCHEM, V41, P134, DOI 10.1002/(SICI)1520-6327(1999)41:3&lt;134::AID-ARCH4&gt;3.0.CO;2-6; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; Wang YL, 2004, J BIOL CHEM, V279, P39132, DOI 10.1074/jbc.M405982200; WARREN JT, 1986, J LIQ CHROMATOGR, V9, P1759, DOI 10.1080/01483918608076716; Warren JT, 2004, INSECT BIOCHEM MOLEC, V34, P991, DOI 10.1016/j.ibmb.2004.06.009; Warren JT, 2002, P NATL ACAD SCI USA, V99, P11043, DOI 10.1073/pnas.162375799; WATANABE K, 1984, ZOOL SCI, V1, P114; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Yamada R, 2002, PROCEEDINGS OF THE 21ST CONFERENCE OF EUROPEAN COMPARATIVE ENDOCRINOLOGISTS, P179; Yamada R, 2003, J BIOL CHEM, V278, P26365, DOI 10.1074/jbc.M304158200; Yamada R, 2005, ZOOL SCI, V22, P187, DOI 10.2108/zsj.22.187	67	20	22	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29513	29524		10.1074/jbc.M604035200	http://dx.doi.org/10.1074/jbc.M604035200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16899460	hybrid			2022-12-25	WOS:000240896300013
J	Chen, YW; Dokholyan, NV				Chen, Yiwen; Dokholyan, Nikolay V.			Insights into allosteric control of vinculin function from its large scale conformational dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING MEMBRANE PROTRUSION; LOCAL-STRUCTURE MODEL; MOLECULAR-DYNAMICS; CELL-ADHESION; BINDING-SITE; INTRAMOLECULAR ASSOCIATION; UNFOLDING TRANSITION; ACIDIC PHOSPHOLIPIDS; GLOBULAR-PROTEINS; STRUCTURAL BASIS	Vinculin is an important constituent of both cell-cell and cell-matrix junctions, where it plays crucial roles in the regulation of cell adhesion and migration. When activated, it mediates the linkage between cadherins (cell-cell) or integrins (cell-matrix) and the actin cytoskeleton through interactions with various proteins. The activation of vinculin requires structural conversions from an autoinhibited conformation to the "open" conformations in which the occluded binding sites of its different ligands become exposed, while the structural dynamics underlying the vinculin activation remains largely unknown. Here we report the first computational study of large scale conformational dynamics of full-length vinculin. We find that the "holding" and "releasing" motions between vinculin tail and pincer-like structure formed by first three domains of vinculin are the dominant motions near the native state of vinculin, indicating that an inherent flexibility of vinculin has a large influence on its allostery. We also find a cooperative dissociation between the head and tail domains of vinculin with increasing temperature in both thermodynamic and kinetic simulations, implying that vinculin may function as an allosteric switch in response to external signals. We show that the kinetics of vinculin unfolding exhibits specific sequential patterns, suggesting that a sophisticated interplay between domains may synergistically contribute to vinculin activation. We further find that the interaction between vinculin-binding site peptide from talin and vinculin significantly destabilizes the intramolecular head-tail interactions, suggesting a direct role of talin binding in vinculin activation.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Dokholyan, NV (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	dokh@med.unc.edu	Dokholyan, Nikolay/D-8081-2018; Dokholyan, Nikolay/B-2238-2009	Dokholyan, Nikolay/0000-0002-8225-4025; Dokholyan, Nikolay/0000-0002-8225-4025				ABE H, 1981, BIOPOLYMERS, V20, P1013, DOI 10.1002/bip.1981.360200512; AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Berendsen HJC, 2000, CURR OPIN STRUC BIOL, V10, P165, DOI 10.1016/S0959-440X(00)00061-0; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bois PRJ, 2006, J BIOL CHEM, V281, P7228, DOI 10.1074/jbc.M510397200; Cohen DM, 2005, J BIOL CHEM, V280, P17109, DOI 10.1074/jbc.M414704200; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; DeMali KA, 2004, TRENDS BIOCHEM SCI, V29, P565, DOI 10.1016/j.tibs.2004.09.001; DeMali KA, 2003, J CELL SCI, V116, P2389, DOI 10.1242/jcs.00605; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Ding F, 2006, STRUCTURE, V14, P5, DOI 10.1016/j.str.2005.09.008; Ding F, 2002, J MOL BIOL, V324, P851, DOI 10.1016/S0022-2836(02)01112-9; Ding F, 2002, BIOPHYS J, V83, P3525, DOI 10.1016/S0006-3495(02)75352-6; Dokholyan NV, 1998, FOLD DES, V3, P577, DOI 10.1016/S1359-0278(98)00072-8; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GO N, 1981, BIOPOLYMERS, V20, P991, DOI 10.1002/bip.1981.360200511; ICHIYE T, 1991, PROTEINS, V11, P205, DOI 10.1002/prot.340110305; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; Onuchic JN, 2000, ADV PROTEIN CHEM, V53, P87; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; Pokutta S, 2002, CURR OPIN STRUC BIOL, V12, P255, DOI 10.1016/S0959-440X(02)00318-4; RAPAPORT DC, 2004, ART MOL DYNAMICS STI, P391; Sanchez R, 1997, CURR OPIN STRUC BIOL, V7, P206, DOI 10.1016/S0959-440X(97)80027-9; Smith SW, 1997, J COMPUT PHYS, V134, P16, DOI 10.1006/jcph.1996.5510; Subauste MC, 2004, J CELL BIOL, V165, P371, DOI 10.1083/jcb.200308011; Tobi D, 2005, P NATL ACAD SCI USA, V102, P18908, DOI 10.1073/pnas.0507603102; VOLBERG T, 1995, J CELL SCI, V108, P2253; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Xu WM, 1998, DEVELOPMENT, V125, P327; Zamir E, 2001, J CELL SCI, V114, P3583	38	30	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29148	29154		10.1074/jbc.M605512200	http://dx.doi.org/10.1074/jbc.M605512200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16891659	hybrid, Green Published			2022-12-25	WOS:000240680500069
J	Lee, JF; Zeng, Q; Ozaki, H; Wang, LC; Hand, AR; Hla, T; Wang, E; Lee, MJ				Lee, Jen-Fu; Zeng, Qun; Ozaki, Harunobu; Wang, Lichun; Hand, Arthur R.; Hla, Timothy; Wang, Eugenia; Lee, Menq-Jer			Dual roles of tight junction-associated protein, Zonula Occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR EDG-1; BLOOD-BRAIN-BARRIER/; ARP2/3 COMPLEX; MULTIPLE-SCLEROSIS; CELL-ADHESION; IN-VITRO; ZO-1; CORTACTIN; ACTIN; SPHINGOSINE-1-PHOSPHATE	In this report, sphingosine-1-phosphate (S1P), a serum-borne bioactive lipid, is shown to activate tight-junction-associated protein Zonula Occludens-1 (ZO-1), which in turn plays a critical role in regulating endothelial chemotaxis and barrier integrity. After S1P stimulation, ZO-1 was redistributed to the lamellipodia and cell-cell junctions via the S1P1/G(i)/Akt/Rac pathway. Similarly, both endothelial barrier integrity and cell motility were significantly enhanced in S1P-treated cells through the G(i)/Akt/Rac pathway. Importantly, S1P-enhanced barrier integrity and cell migration were abrogated in ZO-1 knockdown cells, indicating ZO-1 is functionally indispensable for these processes. To investigate the underlying mechanisms, we demonstrated that cortactin plays a critical role in S1P-induced ZO-1 redistribution to the lamellipodia. In addition, S1P significantly induced the formation of endothelial tight junctions. ZO-1 and alpha-catenin polypeptides were colocalized in S1P-induced junctional structures; whereas, cortactin was not observed in these regions. Together, these results suggest that S1P induces the formation of two distinct ZO-1 complexes to regulate two different endothelial functions: ZO-1/cortactin complexes to regulate chemotactic response and ZO-1/alpha-catenin complexes to regulate endothelial barrier integrity. The concerted operation of these two ZO-1 complexes may coordinate two important S1P-mediated functions, i.e. migration and barrier integrity, in vascular endothelial cells.	Univ Louisville, Hlth Sci Ctr, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Dept Microbiol & Immunol, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Gheens Ctr Aging, Louisville, KY 40202 USA; Keihanna Hosp, Dept Cardiol, Hirakata, Osaka 5730153, Japan; Univ Connecticut, Hlth Ctr, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA; Univ Connecticut, Hlth Ctr, Dept Pediat Dent, Farmington, CT 06030 USA	University of Louisville; University of Louisville; University of Louisville; University of Connecticut; University of Connecticut	Lee, MJ (corresponding author), Univ Louisville, Hlth Sci Ctr, Dept Biochem & Mol Biol, 580 S Preston St, Louisville, KY 40202 USA.	menqjer.lee@louisville.edu	wang, lichun/D-3969-2013; Hla, Timothy/G-5873-2012; LEE, JEN-FU/GRO-3670-2022	Hla, Timothy/0000-0001-8355-4065; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067330, R01HL071071] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL067330, R01HL071071] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; Andersson LM, 2001, J NEUROVIROL, V7, P542, DOI 10.1080/135502801753248123; Bussolino F, 2001, INT J BIOCHEM CELL B, V33, P371, DOI 10.1016/S1357-2725(01)00024-3; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FENSTERMACHER JD, 2000, BLOOD BRAIN BARRIER; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gumbleton M, 2001, J PHARM SCI-US, V90, P1681, DOI 10.1002/jps.1119; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Hunter AW, 2005, MOL BIOL CELL, V16, P5686, DOI 10.1091/mbc.E05-08-0737; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Kalaria RN, 2002, CEREBROVASC DIS, V13, P48, DOI 10.1159/000049150; Kalman D, 1999, MOL BIOL CELL, V10, P1665, DOI 10.1091/mbc.10.5.1665; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Keese CR, 2004, P NATL ACAD SCI USA, V101, P1554, DOI 10.1073/pnas.0307588100; KRUMPKONVALINKO.V, 2005, ARTERIOSCLER THROMB, V25, P1; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Lee SH, 2006, INTERMETALLICS, V14, P1, DOI 10.1016/j.intermet.2005.02.010; Li YS, 2004, EXP CELL RES, V298, P107, DOI 10.1016/j.yexcr.2004.03.023; Miyakawa T, 2002, ANN NY ACAD SCI, V977, P303, DOI 10.1111/j.1749-6632.2002.tb04830.x; Muller SL, 2005, J BIOL CHEM, V280, P3747, DOI 10.1074/jbc.M411365200; Plumb J, 2002, BRAIN PATHOL, V12, P154; Rosenberg GA, 2002, NEUROSCIENTIST, V8, P586, DOI 10.1177/1073858402238517; Smalley KSM, 2005, AM J PATHOL, V166, P1541, DOI 10.1016/S0002-9440(10)62370-X; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595; Zhu C, 2005, MICROSC MICROANAL, V11, P244, DOI 10.1017/S143192760505049X	33	135	139	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29190	29200		10.1074/jbc.M604310200	http://dx.doi.org/10.1074/jbc.M604310200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16891661	hybrid			2022-12-25	WOS:000240680500074
J	Ma, L; Robinson, LN; Towle, HC				Ma, Lin; Robinson, Luke N.; Towle, Howard C.			ChREBP center dot Mlx is the principal mediator of glucose-induced gene expression in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; TRIGLYCERIDE TRANSFER PROTEIN; STIMULATED INSULIN-SECRETION; LIPOGENIC ENZYME GENES; PYRUVATE-KINASE GENE; FATTY-ACID SYNTHESIS; IN-VIVO SECRETION; BINDING PROTEIN; TRANSCRIPTION FACTORS; APOLIPOPROTEIN-B	In mammals, glucose-regulated gene expression has been best characterized in the liver, where increased glucose metabolism induces transcription of genes encoding enzymes involved in de novo lipogenesis. ChREBP and Mlx dimerize and function together as a glucose-responsive transcription factor to regulate target genes, such as liver-type pyruvate kinase, acetyl-CoA carboxylase 1, and fatty acid synthase. To identify additional glucose-responsive genes in the liver, we used microarray analysis to compare gene expression patterns in low and high glucose conditions in hepatocytes. Target genes of ChREBP center dot Mlx were simultaneously identified by gene profiling in the presence or absence of a dominant negative Mlx. Of 224 genes that are induced by glucose, 139 genes (62%) were also inhibited by the dominant negative Mlx. Lipogenic enzyme genes involved in the entire pathway of de novo lipogenesis were found to be glucose-responsive target genes of ChREBP center dot Mlx. Genes encoding enzymes in other metabolic pathways and numerous regulators of metabolism were also identified. To determine if any of these genes are direct targets of ChREBP center dot Mlx, we searched for ChoRE-like sequences in the 5'-flanking regions of several genes that responded rapidly to glucose. ChoRE sequences that bound to ChREBP center dot Mlx and supported a glucose response were identified in two additional genes. Combining all of the known ChoRE sequences, we generated a modified ChoRE consensus sequence, CAYGNGN(5)CNCRTG. In summary, ChREBP center dot Mlx is the principal transcription factor regulating glucose-responsive genes in the liver and coordinately regulates a family of genes required for glucose utilization and energy storage.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Towle, HC (corresponding author), 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	towle@mail.ahc.umn.edu						Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; Bartels ED, 2002, DIABETES, V51, P1233, DOI 10.2337/diabetes.51.4.1233; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; Billin AN, 2000, MOL CELL BIOL, V20, P8845, DOI 10.1128/MCB.20.23.8845-8854.2000; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; Boucher A, 2004, J BIOL CHEM, V279, P27263, DOI 10.1074/jbc.M401167200; Brown LJ, 2002, J BIOL CHEM, V277, P32899, DOI 10.1074/jbc.M202409200; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Corpe CP, 1996, AM J PHYSIOL-GASTR L, V271, pG211, DOI 10.1152/ajpgi.1996.271.1.G211; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Dentin R, 2004, J BIOL CHEM, V279, P20314, DOI 10.1074/jbc.M312475200; Donnelly KL, 2004, J NUTR, V134, P1475, DOI 10.1093/jn/134.6.1475; Dvorak CMT, 2005, VET IMMUNOL IMMUNOP, V105, P301, DOI 10.1016/j.vetimm.2005.02.006; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Liao W, 1999, BIOCHEMISTRY-US, V38, P7532, DOI 10.1021/bi9904196; LIU ML, 1992, J BIOL CHEM, V267, P11673; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; Ma L, 2005, J BIOL CHEM, V280, P12019, DOI 10.1074/jbc.M413063200; MARIE S, 1993, J BIOL CHEM, V268, P23881; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Meroni G, 2000, ONCOGENE, V19, P3266, DOI 10.1038/sj.onc.1203634; Minn AH, 2005, ENDOCRINOLOGY, V146, P2397, DOI 10.1210/en.2004-1378; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Nishimura T, 2000, BBA-GENE STRUCT EXPR, V1492, P203, DOI 10.1016/S0167-4781(00)00067-1; O'Callaghan BL, 2001, J BIOL CHEM, V276, P16033, DOI 10.1074/jbc.M101557200; Olson DP, 1998, J BIOL CHEM, V273, P3375, DOI 10.1074/jbc.273.6.3375; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200; Shalev A, 2002, ENDOCRINOLOGY, V143, P3695, DOI 10.1210/en.2002-220564; SHIH HM, 1994, J BIOL CHEM, V269, P9380; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Stoeckman AK, 2004, J BIOL CHEM, V279, P15662, DOI 10.1074/jbc.M311301200; Swierczynski J, 2003, MOL CELL BIOCHEM, V254, P55, DOI 10.1023/A:1027332523114; Tietge UJF, 1999, J LIPID RES, V40, P2134; Towle HC, 2005, TRENDS ENDOCRIN MET, V16, P489, DOI 10.1016/j.tem.2005.10.003; VANSCHAFTINGEN E, 1994, DIABETOLOG, V37, P43; WAEBER G, 1994, J BIOL CHEM, V269, P26912; Wang HY, 2002, J BIOL CHEM, V277, P32746, DOI 10.1074/jbc.M201635200; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298	56	286	300	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28721	28730		10.1074/jbc.M601576200	http://dx.doi.org/10.1074/jbc.M601576200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16885160	hybrid			2022-12-25	WOS:000240680500025
J	Catlett, MG; Kaplan, KB				Catlett, Michael G.; Kaplan, Kenneth B.			Sgt1p is a unique co-chaperone that acts as a client adaptor to link Hsp90 to Skp1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEINS; DISEASE RESISTANCE PROTEIN; UBIQUITIN-LIGASE COMPLEX; TETRATRICOPEPTIDE REPEAT; MOLECULAR CHAPERONE; SACCHAROMYCES-CEREVISIAE; ATPASE ACTIVITY; KINETOCHORE COMPLEX; ESSENTIAL COMPONENT; YEAST KINETOCHORE	Sgt1p is a conserved, essential protein required for kinetochore assembly in both yeast and animal cells. Sgt1p has homology to both TPR and p23 domains, sequences often found in proteins that interact with and regulate the molecular chaperone, Hsp90. The presence of these domains and the recent findings that Sgt1p interacts with Hsp90 has led to the speculation that Sgt1p and Hsp90 form a co-chaperone complex. To test this possibility, we have used purified recombinant proteins to characterize the in vitro interactions between yeast Sgt1p and Hsp82p (an Hsp90 homologue in yeast). We show that Sgt1p interacts directly with Hsp82p via its p23 homology region in a nucleotide-dependent manner. However, Sgt1p binding does not alter the enzymatic activity of Hsp82p, suggesting that it is distinct from other co-chaperones. We find that Sgt1p can form a ternary chaperone complex with Hsp82p and Sti1p, a well characterized Hsp90 co-chaperone. Sgt1p interacts with its binding partner Skp1p through its TPR domains and links Skp1p to the core Hsp82p-Sti1p co-chaperone complex. The multidomain nature of Sgt1p and its ability to bridge the interaction between Skp1p and Hsp82p argue that Sgt1p acts as a "client adaptor" recruiting specific clients to Hsp82p co-chaperone complexes.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Kaplan, KB (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave,Briggs 149, Davis, CA 95616 USA.	kbkaplan@ucdavis.edu			NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P20MD000262] Funding Source: NIH RePORTER; NIMHD NIH HHS [P20MD000262] Funding Source: Medline	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Bansal PK, 2004, MOL CELL BIOL, V24, P8069, DOI 10.1128/MCB.24.18.8069-8079.2004; Bieri S, 2004, PLANT CELL, V16, P3480, DOI 10.1105/tpc.104.026682; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Dubacq C, 2002, EUKARYOT CELL, V1, P568, DOI 10.1128/EC.1.4.568-582.2002; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Holt BF, 2005, SCIENCE, V309, P929, DOI 10.1126/science.1109977; Hubert DA, 2003, EMBO J, V22, P5679, DOI 10.1093/emboj/cdg547; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lee P, 2004, MOL BIOL CELL, V15, P1785, DOI 10.1091/mbc.E03-07-0480; Lee YT, 2004, J BIOL CHEM, V279, P16511, DOI 10.1074/jbc.M400215200; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Lingelbach LB, 2004, MOL CELL BIOL, V24, P8938, DOI 10.1128/MCB.24.20.8938-8950.2004; Liu YL, 2004, J BIOL CHEM, V279, P2101, DOI 10.1074/jbc.M310029200; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Millson SH, 2005, EUKARYOT CELL, V4, P849, DOI 10.1128/EC.4.5.849-860.2005; Muskett P, 2003, MICROBES INFECT, V5, P969, DOI 10.1016/S1286-4579(03)00183-7; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Niikura Y, 2006, ONCOGENE, V25, P4133, DOI 10.1038/sj.onc.1209461; Oxelmark E, 2003, J BIOL CHEM, V278, P36547, DOI 10.1074/jbc.M305960200; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pearl LH, 2005, CURR OPIN GENET DEV, V15, P55, DOI 10.1016/j.gde.2004.12.011; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter K, 2004, J MOL BIOL, V342, P1403, DOI 10.1016/j.jmb.2004.07.064; Richter K, 2003, J BIOL CHEM, V278, P10328, DOI 10.1074/jbc.M213094200; Rodrigo-Brenni MC, 2004, MOL BIOL CELL, V15, P3366, DOI 10.1091/mbc.E03-12-0887; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Russell ID, 1999, J CELL BIOL, V145, P933, DOI 10.1083/jcb.145.5.933; Sangster TA, 2004, BIOESSAYS, V26, P348, DOI 10.1002/bies.20020; Schadick K, 2002, EUKARYOT CELL, V1, P558, DOI 10.1128/EC.1.4.558-567.2002; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Siligardi G, 2004, J BIOL CHEM, V279, P51989, DOI 10.1074/jbc.M410562200; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stemmann O, 2002, P NATL ACAD SCI USA, V99, P8585, DOI 10.1073/pnas.082223899; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Takahashi A, 2003, P NATL ACAD SCI USA, V100, P11777, DOI 10.1073/pnas.2033934100; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024	64	98	100	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33739	33748		10.1074/jbc.M603847200	http://dx.doi.org/10.1074/jbc.M603847200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16945921	hybrid			2022-12-25	WOS:000241621400081
J	Gardner, LA; Tavalin, SJ; Goehring, AS; Scott, JD; Bahouth, SW				Gardner, Lidia A.; Tavalin, Steven J.; Goehring, April S.; Scott, John D.; Bahouth, Suleiman W.			AKAP79-mediated targeting of the cyclic AMP-dependent protein kinase to the beta(1)-arenergic receptor promotes recycling and functional resensitization of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA(1)-ADRENERGIC RECEPTOR; TRANSFER FRET MICROSCOPY; BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; ANCHORING PROTEINS; GLUTAMATE RECEPTORS; SCAFFOLD PROTEIN; BETA-ARRESTIN; CAMP; PHOSPHORYLATION	Resensitization of G protein-coupled receptors (GPCR) following prolonged agonist exposure is critical for restoring the responsiveness of the receptor to subsequent challenges by agonist. The 3'-5' cyclic AMP- dependent protein kinase (PKA) and serine 312 in the third intracellular loop of the human beta(1)- adrenergic receptor (beta(1)-AR) were both necessary for efficient recycling and resensitization of the agonist- internalized beta(1)-AR (Gardner, L. A., Delos Santos, N. M., Matta, S. G., Whitt, M. A., and Bahouth, S. W. (2004) J. Biol. Chem. 279, 21135 - 21143). Because PKA is compartmentalized near target substrates by interacting with protein kinase A anchoring proteins (AKAPs), the present study was undertaken to identify the AKAP involved in PKA- mediated phosphorylation of the beta(1)-AR and in its recycling and resensitization. Here, we report that Ht-31 peptide- mediated disruption of PKA/ AKAP interactions prevented the recycling and functional resensitization of heterologously expressed beta(1)-AR in HEK- 293 cells and endogenously expressed beta(1)-AR in SK-N-MC cells and neonatal rat cortical neurons. Whereas several endogenous AKAPs were identified in HEK-293 cells, small interfering RNA- mediated down- regulation of AKAP79 prevented the recycling of the beta(1)-AR in this cell line. Co-immunoprecipitations and fluorescence resonance energy transfer (FRET) microscopy experiments in HEK-293 cells revealed that the beta(1)-AR, AKAP79, and PKA form a ternary complex at the carboxyl terminus of the beta(1)-AR. This complex was involved in PKA- mediated phosphorylation of the third intracellular loop of the beta(1)- AR because disruption of PKA/ AKAP interactions or small interfering RNA- mediated down- regulation of AKAP79 both inhibited this response. Thus, AKAP79 provides PKA to phosphorylate the beta(1)-AR and thereby dictate the recycling and resensitization itineraries of the beta(1)- AR.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Oregon Hlth & Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97239 USA	University of Tennessee System; University of Tennessee Health Science Center; Howard Hughes Medical Institute; Oregon Health & Science University	Bahouth, SW (corresponding author), 874 Union Ave, Memphis, TN 38163 USA.	sbahouth@utmem.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046661] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-71419] Funding Source: Medline; NIGMS NIH HHS [GM-18231] Funding Source: Medline; NINDS NIH HHS [NS-46661] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bahouth SW, 1996, MOL PHARMACOL, V49, P1049; BAHOUTH SW, 1995, BIOCHEM J, V307, P831, DOI 10.1042/bj3070831; Bahouth SW, 2001, BIOCHEM PHARMACOL, V62, P1211, DOI 10.1016/S0006-2952(01)00789-4; Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; Delos Santos NM, 2006, J BIOL CHEM, V281, P12896, DOI 10.1074/jbc.M508500200; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fan GF, 2001, J BIOL CHEM, V276, P24005, DOI 10.1074/jbc.M011199200; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gage RM, 2005, J BIOL CHEM, V280, P3305, DOI 10.1074/jbc.M406934200; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gardner LA, 2004, J BIOL CHEM, V279, P21135, DOI 10.1074/jbc.M313652200; Garland AM, 1996, MOL PHARMACOL, V49, P438; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Gu Y, 2004, J MICROSC-OXFORD, V215, P162, DOI 10.1111/j.0022-2720.2004.01365.x; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; He JQ, 2006, J BIOL CHEM, V281, P2820, DOI 10.1074/jbc.M509503200; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hu LYA, 2003, J BIOL CHEM, V278, P26295, DOI 10.1074/jbc.M212352200; Katsura T, 1997, Am J Physiol, V272, pF817; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kim C, 2005, SCIENCE, V307, P690, DOI 10.1126/science.1104607; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lohse MJ, 2003, CIRC RES, V93, P896, DOI 10.1161/01.RES.0000102042.83024.CA; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Lynch MJ, 2005, J BIOL CHEM, V280, P33178, DOI 10.1074/jbc.M414316200; Malbon CC, 2004, BIOCHEM SOC T, V32, P861, DOI 10.1042/BST0320861; Oliveria SF, 2003, J CELL BIOL, V160, P101, DOI 10.1083/jcb.200209127; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Snyder EM, 2005, J BIOL CHEM, V280, P16962, DOI 10.1074/jbc.M409693200; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Suvarna NU, 2002, J PHARMACOL EXP THER, V302, P249, DOI 10.1124/jpet.302.1.249; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Vanhoose AM, 2003, J NEUROSCI, V23, P5827; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; WU JZ, 1994, BIOCHEMISTRY-US, V33, P14825, DOI 10.1021/bi00253a022; Xiao RP, 2004, TRENDS PHARMACOL SCI, V25, P358, DOI 10.1016/j.tips.2004.05.007; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; YU SS, 1993, J BIOL CHEM, V268, P337; YUTING T, 1999, P NATL ACAD SCI USA, V96, P12559	62	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33537	33553		10.1074/jbc.M601809200	http://dx.doi.org/10.1074/jbc.M601809200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16940053	Green Submitted, hybrid			2022-12-25	WOS:000241621400064
J	Poulalhon, N; Farge, D; Roos, N; Tacheau, C; Neuzillet, C; Michel, L; Mauviel, A; Verrecchia, F				Poulalhon, Nicolas; Farge, Dominique; Roos, Nina; Tacheau, Charlotte; Neuzillet, Cindy; Michel, Laurence; Mauviel, Alain; Verrecchia, Franck			Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin - A direct role as an antifibrotic agent?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; DIFFERENTIAL REGULATION; AMINO-ACID; TRANSCRIPTION; DISTINCT; ALPHA; FIBRONECTIN; ACTIVATION; INDUCTION; SIROLIMUS	We have examined whether rapamycin, an immunosuppressive drug, may exert part of its antifibrotic activity by directly targeting fibroblast extracellular matrix deposition. Incubation of human lung fibroblast (WI-26) cultures with rapamycin led to dose-and time-dependent reduction in the expression of types I and III collagens, both at the protein and mRNA levels. Rapamycin had no effect on collagen promoter activity but accelerated mRNA decay, indicating post-transcriptional control of collagen gene expression. In contrast, rapamycin significantly enhanced the expression of interstitial collagenase (MMP-1) at the protein and mRNA levels and transcriptionally. We determined that rapamycin efficiently activates AP-1-driven transcription by rapidly inducing c-jun/AP-1 phosphorylation with activation of the c-Jun N-terminal kinase (JNK) cascade, resulting in enhanced binding of AP-1(.)DNA complex formation and AP-1-dependent gene transactivation. Conversely, the JNK inhibitor SP600125 inhibited rapamycin-induced MMP-1 gene transactivation and AP-1/DNA interactions. A c-jun antisense expression vector efficiently prevented rapamycin-induced MMP-1 gene transcription. Pharmacological inhibition of either ERK or p38 MAPK pathways was without effect on rapamycin-induced MMP-1 gene expression. It thus appears that rapamycin may exert direct antifibrotic activities independent from its immunosuppressive action.	Hop St Louis, INSERM, U697, F-75010 Paris, France; Hop St Louis, Serv Med Interne, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Verrecchia, F (corresponding author), Hop St Louis, INSERM, U697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	franck.verrecchia@stlouis.inserm.fr	MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018; Michel, Laurence/E-8605-2017; NEUZILLET, Cindy/K-1378-2017	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793; NEUZILLET, Cindy/0000-0001-7037-7477				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Asano Y, 2005, ARTHRITIS RHEUM-US, V52, P1237, DOI 10.1002/art.20934; Biecker E, 2004, LIVER INT, V24, P345, DOI 10.1111/j.1478-3231.2004.0933.x; BOAST S, 1990, J BIOL CHEM, V265, P13351; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Cardenas M E, 1995, Curr Opin Nephrol Hypertens, V4, P472, DOI 10.1097/00041552-199511000-00002; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Eckes B, 1996, BIOCHEM J, V315, P549, DOI 10.1042/bj3150549; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Jaeschke A, 2003, CURR TOP MICROBIOL, V279, P283; Kahan BD, 1998, TRANSPLANTATION, V66, P1040, DOI 10.1097/00007890-199810270-00013; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KRUPSKY M, 1994, BBA-GENE STRUCT EXPR, V1219, P335, DOI 10.1016/0167-4781(94)90057-4; Krupsky M, 1997, J BIOL CHEM, V272, P13864, DOI 10.1074/jbc.272.21.13864; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; MUDRYJ M, 1988, NUCLEIC ACIDS RES, V16, P7513, DOI 10.1093/nar/16.15.7513; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Pridohl O, 2001, TRANSPLANT P, V33, P3229, DOI 10.1016/S0041-1345(01)02373-9; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; Schuck S, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-6; Sehgal S N, 1995, Curr Opin Nephrol Hypertens, V4, P482, DOI 10.1097/00041552-199511000-00004; Shegogue D, 2004, J BIOL CHEM, V279, P23166, DOI 10.1074/jbc.M401238200; Simler NR, 2002, EUR RESPIR J, V19, P1124, DOI 10.1183/09031936.02.00281602; Uitto J, 2000, J DERMATOL SCI, V24, pS60, DOI 10.1016/S0923-1811(00)00143-2; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Verrecchia F, 2004, CELL SIGNAL, V16, P873, DOI 10.1016/j.cellsig.2004.02.007; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Verrecchia F, 2002, EMBO REP, V3, P1069, DOI 10.1093/embo-reports/kvf219; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Verrecchia Franck, 2002, Curr Rheumatol Rep, V4, P143, DOI 10.1007/s11926-002-0010-4; Webster AC, 2006, TRANSPLANTATION, V81, P1234, DOI 10.1097/01.tp.0000219703.39149.85; Wendling J, 2003, MOL PHARMACOL, V64, P707, DOI 10.1124/mol.64.3.707; Zhu JL, 1999, GASTROENTEROLOGY, V117, P1198, DOI 10.1016/S0016-5085(99)70406-3	39	68	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33045	33052		10.1074/jbc.M606366200	http://dx.doi.org/10.1074/jbc.M606366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16914544	hybrid			2022-12-25	WOS:000241621400013
J	Topark-Ngarm, A; Golonzhka, O; Peterson, VJ; Barrett, B; Martinez, B; Crofoot, K; Filtz, TM; Leid, M				Topark-Ngarm, Acharawan; Golonzhka, Olga; Peterson, Valerie J.; Barrett, Brian, Jr.; Martinez, Brigetta; Crofoot, Kristi; Filtz, Theresa M.; Leid, Mark			CTIP2 associates with the NuRD complex on the promoter of p57KIP2, a newly identified CTIP2 target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLATION; CELL FATE; BCL11B; EXPRESSION; P57(KIP2); FAMILY; SIR2; DIFFERENTIATION	Chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2 (CTIP2), also known as Bcl11b, is a transcriptional repressor that functions by direct, sequence-specific DNA binding activity or by recruitment to the promoter template by interaction with COUP-TF family members. CTIP2 is essential for both T cell development and axonal projections of corticospinal motor neurons in the central nervous system. However, little is known regarding the molecular mechanism(s) by which CTIP2 contributes to either process. CTIP2 complexes that were isolated from SK-N-MC neuroblastoma cells were found to harbor substantial histone deacetylase activity, which was likely conferred by the nucleosome remodeling and deacetylation ( NuRD) complex. CTIP2 was found to associate with the NuRD complex through direct interaction with both RbAp46 and RbAp48, and components of the NuRD complex were found to be recruited to an artificial promoter template in a CTIP2-dependent manner in transfected cells. Finally, the NuRD complex and CTIP2 were found to co-occupy the promoter template of p57KIP2, a gene encoding a cyclin-dependent kinase inhibitor, and identified herein as a novel transcriptional target of CTIP2 in SK-N-MC cells. Therefore, it seems likely that the NuRD complex may be involved in transcriptional repression of CTIP2 target genes and contribute to the function(s) of CTIP2 within a neuronal context.	Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA	Oregon State University; Oregon State University; Oregon State University	Leid, M (corresponding author), Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Corvallis, OR 97331 USA.	Mark.Leid@oregonstate.edu		Filtz, Theresa/0000-0002-5348-1114	NIEHS NIH HHS [T35 ES 07316, ES 00210, P30 ES000210] Funding Source: Medline; NIGMS NIH HHS [GM 60852, R01 GM060852, R01 GM060852-04] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T35ES007316, P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060852] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arlotta P, 2005, NEURON, V45, P207, DOI 10.1016/j.neuron.2004.12.036; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Bezrookove V, 2004, CANCER GENET CYTOGEN, V149, P72, DOI 10.1016/S0165-4608(03)00302-9; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Chen B, 2005, P NATL ACAD SCI USA, V102, P17184, DOI 10.1073/pnas.0508732102; Christian M, 2004, J BIOL CHEM, V279, P15645, DOI 10.1074/jbc.M313906200; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; Cunningham JJ, 2001, CELL GROWTH DIFFER, V12, P387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hohl M, 2005, EUR J NEUROSCI, V22, P2216, DOI 10.1111/j.1460-9568.2005.04404.x; Hong W, 2005, EMBO J, V24, P2367, DOI 10.1038/sj.emboj.7600703; Joseph B, 2003, P NATL ACAD SCI USA, V100, P15619, DOI 10.1073/pnas.2635658100; Kantor B, 2003, GENE EXPR PATTERNS, V3, P697, DOI 10.1016/j.modgep.2003.07.003; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Leid M, 2004, GENE EXPR PATTERNS, V4, P733, DOI 10.1016/j.modgep.2004.03.009; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; MacLeod RAF, 2003, GENE CHROMOSOME CANC, V37, P84, DOI 10.1002/gcc.10194; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Molyneaux BJ, 2005, NEURON, V47, P817, DOI 10.1016/j.neuron.2005.08.030; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; Nagel S, 2003, CANCER RES, V63, P5329; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Sakata J, 2004, CARCINOGENESIS, V25, P1069, DOI 10.1093/carcin/bgh094; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Senawong T, 2005, ARCH BIOCHEM BIOPHYS, V434, P316, DOI 10.1016/j.abb.2004.10.028; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Solari F, 1999, DEVELOPMENT, V126, P2483; Su XY, 2004, GENE CHROMOSOME CANC, V41, P243, DOI 10.1002/gcc.20088; von Zelewsky T, 2000, DEVELOPMENT, V127, P5277; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Wang Y, 2004, COLD SPRING HARB SYM, V69, P161, DOI 10.1101/sqb.2004.69.161; Williams CJ, 2004, IMMUNITY, V20, P719, DOI 10.1016/j.immuni.2004.05.005; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	45	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32272	32283		10.1074/jbc.M602776200	http://dx.doi.org/10.1074/jbc.M602776200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16950772	Green Accepted, hybrid			2022-12-25	WOS:000241414500024
J	Chung, MC; Popova, TG; Millis, BA; Mukherjee, DV; Zhou, WD; Liotta, LA; Petricoin, EF; Chandhoke, V; Bailey, C; Popov, SG				Chung, Myung-Chul; Popova, Taissia G.; Millis, Bryan A.; Mukherjee, Dhritiman V.; Zhou, Weidong; Liotta, Lance A.; Petricoin, Emanuel F.; Chandhoke, Vikas; Bailey, Charles; Popov, Serguei G.			Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; HEPARAN-SULFATE PROTEOGLYCANS; PSEUDOMONAS-AERUGINOSA; INHALATIONAL ANTHRAX; LETHAL FACTOR; CYTOKINE RESPONSE; SYNDECAN-1; PLASMINOGEN; TOXIN; VIRULENCE	To evaluate the pathogenic potential of Bacillus anthracissecreted proteases distinct from lethal toxin, two neutral zinc metalloproteases were purified to apparent homogeneity from the culture supernatant of a non-virulent delta Ames strain (pXO1(-), pXO2(-)). The first (designated Npr599) is a thermolysin-like enzyme highly homologous to bacillolysins from other Bacillus species. The second (designated InhA) is a homolog of the Bacillus thuringiensis immune inhibitor A. These proteases belong to the M4 and M6 families, respectively. Both enzymes digested various substrates, including extracellular matrix proteins, endogenous inhibitors, and coagulation proteins, with some differences in specificity. In addition, InhA accelerated urokinase-mediated plasminogen activation, suggesting that InhA acts as a modulator of plasmin in the host inflammatory system. Relevant to epithelial barrier function, Npr599 and InhA significantly enhanced syndecan-1 shedding from cultured normal murine mammary gland cells without affecting their viability through stimulation of the host cell ectodomain shedding mechanism. In addition, Npr599 and InhA directly cleaved recombinant syndecan-1 fused to glutathione S-transferase. Mass spectrometric analysis suggested that the cleavage sites of Npr599 and InhA are the Asp(39)-Asp(40) and Gly(48)-Thr(49) bonds, respectively. We propose that Npr599 and InhA from B. anthracis are multifunctional pathogenic factors that may contribute to anthrax pathology through direct degradation of host tissues, increases in barrier permeability, and/or modulation of host defenses.	George Mason Univ, Natl Ctr Biodef & Infect Dis, Manassas, VA 20110 USA; George Mason Univ, Ctr Appl Proteom & Mol Med, Manassas, VA 20110 USA; George Mason Univ, Coll Arts & Sci, Manassas, VA 20110 USA	George Mason University; George Mason University; George Mason University	Popov, SG (corresponding author), George Mason Univ, Natl Ctr Biodef & Infect Dis, MSN 1H8,10900 Univ Blvd, Manassas, VA 20110 USA.	spopov@gmu.edu		Millis, Bryan/0000-0002-5770-627X				ABRAMOVA FA, 1993, P NATL ACAD SCI USA, V90, P2291, DOI 10.1073/pnas.90.6.2291; Agrawal A, 2003, NATURE, V424, P329, DOI 10.1038/nature01794; Andrian E, 2006, ORAL MICROBIOL IMMUN, V21, P123, DOI 10.1111/j.1399-302X.2006.00248.x; Antelmann H, 2005, PROTEOMICS, V5, P3684, DOI 10.1002/pmic.200401218; Aronson AI, 2005, J BACTERIOL, V187, P3133, DOI 10.1128/JB.187.9.3133-3138.2005; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Barrett AJ, 2004, CURR OPIN DRUG DISC, V7, P334; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BONVENTRE PF, 1963, J BACTERIOL, V85, P490, DOI 10.1128/JB.85.2.490-491.1963; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; Charlton S, 1999, J APPL MICROBIOL, V87, P241, DOI 10.1046/j.1365-2672.1999.00878.x; Chitlaru T, 2006, J BACTERIOL, V188, P3551, DOI 10.1128/JB.188.10.3551-3571.2006; COOK L, 1988, BIOCHEM INT, V17, P637; Dinwiddie R, 2000, RESPIRATION, V67, P3, DOI 10.1159/000029453; Elenius V, 2004, J BIOL CHEM, V279, P41928, DOI 10.1074/jbc.M404506200; Grinberg LM, 2001, MODERN PATHOL, V14, P482, DOI 10.1038/modpathol.3880337; Guarner J, 2003, AM J PATHOL, V163, P701, DOI 10.1016/S0002-9440(10)63697-8; Guidi-Rontani C, 2001, MOL MICROBIOL, V42, P931, DOI 10.1046/j.1365-2958.2001.02695.x; Haynes A, 2005, INFECT IMMUN, V73, P7914, DOI 10.1128/IAI.73.12.7914-7921.2005; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Jernigan DB, 2002, EMERG INFECT DIS, V8, P1019, DOI 10.3201/eid0810.020353; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; LAHTEENMAKI K, 1995, INFECT IMMUN, V63, P3659; Lahteenmaki K, 2005, TRENDS MICROBIOL, V13, P79, DOI 10.1016/j.tim.2004.12.003; Lamonica JM, 2005, INFECT IMMUN, V73, P3646, DOI 10.1128/IAI.73.6.3646-3658.2005; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Loy JA, 2001, BIOCHEMISTRY-US, V40, P14686, DOI 10.1021/bi011309d; Marshall LJ, 2003, J IMMUNOL, V171, P2057, DOI 10.4049/jimmunol.171.4.2057; McCain DF, 2004, J BIOL CHEM, V279, P14713, DOI 10.1074/jbc.M312488200; Miyoshi S, 2000, MICROBES INFECT, V2, P91, DOI 10.1016/S1286-4579(00)00280-X; Narasaki R, 2005, J BIOL CHEM, V280, P14278, DOI 10.1074/jbc.M500241200; Park PW, 2004, J BIOL CHEM, V279, P251, DOI 10.1074/jbc.M308537200; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Park PW, 2000, J BIOL CHEM, V275, P3057, DOI 10.1074/jbc.275.5.3057; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; Pickering AK, 2004, INFECT IMMUN, V72, P6382, DOI 10.1128/IAI.72.11.6382-6389.2004; Popov SG, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-25; Popov SG, 2004, CELL MICROBIOL, V6, P225, DOI 10.1046/j.1462-5822.2003.00358.x; Popova TG, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-8; Ralevic V, 1998, PHARMACOL REV, V50, P413; Read TD, 2003, NATURE, V423, P81, DOI 10.1038/nature01586; Schmidt A, 2005, J BIOL CHEM, V280, P34441, DOI 10.1074/jbc.M501903200; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shoop WL, 2005, P NATL ACAD SCI USA, V102, P7958, DOI 10.1073/pnas.0502159102; Stoker AW, 2005, J ENDOCRINOL, V185, P19, DOI 10.1677/joe.1.06069; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Supuran CT, 2003, MED RES REV, V23, P535, DOI 10.1002/med.10047; TRAVIS J, 1995, TRENDS MICROBIOL, V3, P405, DOI 10.1016/S0966-842X(00)88988-X; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Wang ZH, 2005, BIOCHEMISTRY-US, V44, P12355, DOI 10.1021/bi050620i; Warfel JM, 2005, AM J PATHOL, V166, P1871, DOI 10.1016/S0002-9440(10)62496-0; WETMORE DR, 1992, MOL MICROBIOL, V6, P1593, DOI 10.1111/j.1365-2958.1992.tb00884.x; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281	57	86	90	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31408	31418		10.1074/jbc.M605526200	http://dx.doi.org/10.1074/jbc.M605526200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16926147	Bronze			2022-12-25	WOS:000241235300025
J	Lu, HL; Krementsova, EB; Trybus, KM				Lu, Hailong; Krementsova, Elena B.; Trybus, Kathleen M.			Regulation of myosin V processivity by calcium at the single molecule level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSIN; CALMODULIN; DOMAIN; ACTIN; MOTOR	Calcium can affect myosin V (myoV) function in at least two ways. The full-length molecule, which adopts a folded inhibited conformation in EGTA, becomes extended and active in the presence of calcium. Calcium also dissociates one or more calmodulin molecules from the extended neck. Here we investigated at the single molecule level how calcium regulates the processive run length of full-length myosin V (dFull) and a truncated dimeric construct (dHMM), which cannot adopt the folded conformation. The processivity of dFull and dHMM is tightly controlled by the calcium and calmodulin concentration, with shorter runs occurring at higher calcium concentration. The data indicate that a calcium-dependent dissociation of calmodulin from the neck region of myoV terminates its processive run. dFull showed unexpected processive movement in EGTA, suggesting that a small population of extended, active molecules are in equilibrium with the inhibited, folded form. Single turnover assays showed that the ATPase activity of the folded full-length molecule is inhibited by more than 50-fold compared with the extended molecule. The results imply that activation and termination of the processive runs of myoV can be accomplished by multiple mechanisms.	Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, 149 Beaumont Ave, Burlington, VT 05405 USA.	trybus@uvm.edu	lu, hailong/C-7754-2009		NHLBI NIH HHS [HL38113] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038113, R29HL038113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; BURGER D, 1983, J BIOL CHEM, V258, P4733; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COX JA, 1988, BIOCHEM J, V249, P621, DOI 10.1042/bj2490621; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Krementsova EB, 2006, J BIOL CHEM, V281, P6079, DOI 10.1074/jbc.M510041200; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; Liu J, 2006, NATURE, V442, P208, DOI 10.1038/nature04719; Martin SR, 2004, FEBS LETT, V567, P166, DOI 10.1016/j.febslet.2004.04.053; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Nguyen H, 2005, NAT STRUCT MOL BIOL, V12, P127, DOI 10.1038/nsmb894; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Trybus KM, 2005, NAT CELL BIOL, V7, P854, DOI 10.1038/ncb0905-854; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; Watanabe M, 2005, MOL BIOL CELL, V16, P4519, DOI 10.1091/mbc.E05-03-0252; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	21	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31987	31994		10.1074/jbc.M605181200	http://dx.doi.org/10.1074/jbc.M605181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920704	Bronze			2022-12-25	WOS:000241235300084
J	Zeold, A; Pormuller, L; Dentice, M; Harney, JW; Curcio-Morelli, C; Tente, SM; Bianco, AC; Gereben, B				Zeold, Aniko; Pormuller, Livia; Dentice, Monica; Harney, John W.; Curcio-Morelli, Cyntia; Tente, Susana M.; Bianco, Antonio C.; Gereben, Balazs			Metabolic instability of type 2 deiodinase is transferable to stable proteins independently of subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM-ASSOCIATED DEGRADATION; THYROID-HORMONE ACTIVATION; ENDOPLASMIC-RETICULUM; UBIQUITIN LIGASE; IODOTHYRONINE SELENODEIODINASES; MEMBRANE-PROTEINS; ANCHORED PROTEIN; GOLGI-APPARATUS; O-GLYCOSYLATION; RETENTION	Thyroid hormone activation is catalyzed by two deiodinases, D1 and D2. Whereas D1 is a stable plasma membrane protein, D2 is resident in the endoplasmic reticulum (ER) and has a 20-min half-life due to selective ubiquitination and proteasomal degradation. Here we have shown that stable retention explains D2 residency in the ER, a mechanism that is nevertheless overridden by fusion to the long-lived plasma membrane protein, sodium-iodine symporter. Fusion to D2, but not D1, dramatically shortened sodium-iodine symporter half-life through a mechanism dependent on an 18-amino acid D2-specific instability loop. Similarly, the D2-specific loop-mediated protein destabilization was also observed after D2, but not D1, was fused to the stable ER resident protein SEC62. This indicates that the instability loop in D2, but not its subcellular localization, is the key determinant of D2 susceptibility to ubiquitination and rapid turnover rate. Our data also show that the 6 N-terminal amino acids, but not the 12 C-terminal ones, are the ones required for D2 recognition by WSB-1.	Hungarian Acad Sci, Inst Expt Med, Lab Endocrine Neurobiol, H-1083 Budapest, Hungary; Brigham & Womens Hosp, Thyroid Sect, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gereben, B (corresponding author), Hungarian Acad Sci, Inst Expt Med, Lab Endocrine Neurobiol, Szigony St 43, H-1083 Budapest, Hungary.	gereben@koki.hu	Bianco, Antonio/AAK-6336-2020; Bianco, Antonio C/A-4965-2008	Bianco, Antonio/0000-0001-7737-6813; Bianco, Antonio C/0000-0001-7737-6813	FIC NIH HHS [TW006467] Funding Source: Medline; NIDDK NIH HHS [DK58538, DK36246] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW006467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058538] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; BAQUI M, 2002, J BIOL CHEM, V4, P4; Baqui MMA, 2000, ENDOCRINOLOGY, V141, P4309, DOI 10.1210/en.141.11.4309; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Botero D, 2002, MOL ENDOCRINOL, V16, P1999, DOI 10.1210/me.2002-0135; Callebaut I, 2003, J BIOL CHEM, V278, P36887, DOI 10.1074/jbc.M305725200; Curcio-Morelli C, 2003, J CLIN INVEST, V112, P189, DOI 10.1172/JCI200318348; Dentice M, 2005, NAT CELL BIOL, V7, P698, DOI 10.1038/ncb1272; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; Gereben B, 2000, MOL ENDOCRINOL, V14, P1697, DOI 10.1210/me.14.11.1697; Hardt B, 2002, BIOCHEM BIOPH RES CO, V291, P751, DOI 10.1006/bbrc.2002.6515; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kim BW, 2003, MOL ENDOCRINOL, V17, P2603, DOI 10.1210/me.2003-0082; Kreft SG, 2006, J BIOL CHEM, V281, P4646, DOI 10.1074/jbc.M512215200; LEONARD JL, 1981, SCIENCE, V214, P571, DOI 10.1126/science.7291997; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Mentuccia D, 2002, DIABETES, V51, P880, DOI 10.2337/diabetes.51.3.880; Pedrazzini E, 2000, J CELL BIOL, V148, P899, DOI 10.1083/jcb.148.5.899; PILLER V, 1990, J BIOL CHEM, V265, P9264; Ravid T, 2006, EMBO J, V25, P533, DOI 10.1038/sj.emboj.7600946; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Steinsapir J, 1998, J CLIN INVEST, V102, P1895, DOI 10.1172/JCI4672; STGERMAIN DL, 1988, ENDOCRINOLOGY, V122, P1860, DOI 10.1210/endo-122-5-1860; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Vasiliauskas D, 1999, MECH DEVELOP, V82, P79, DOI 10.1016/S0925-4773(99)00014-3; Wrzeszczynski KO, 2004, CELL MOL LIFE SCI, V61, P1341, DOI 10.1007/s00018-004-4005-3; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884	29	38	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31538	31543		10.1074/jbc.M604728200	http://dx.doi.org/10.1074/jbc.M604728200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16928685	Bronze			2022-12-25	WOS:000241235300039
J	Chen, Q; Yang, YY; Li, L; Zhang, JT				Chen, Qun; Yang, Youyun; Li, Lang; Zhang, Jian-Ting			The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE TOPOLOGY; LEUKOTRIENE C-4; PROTEIN MRP1; GLYCOSYLATION; REGIONS; BINDING; DOMAINS; CANCER	Multidrug resistance is a serious problem in successful cancer chemotherapy. Studies using model cell lines have demonstrated that overexpression of some members of the ATP-binding cassette (ABC) transporter superfamily, such as ABCC1, causes enhanced efflux and, thus, decreased accumulation of multiple anticancer drugs, which leads to increased cell survival. Unlike most other ABC transporters, ABCC1 has an additional membrane-spanning domain (MSD0) with a putative extracellular amino terminus of 32 amino acids. However, the function of MSD0 and the role of the extracellular amino terminus are largely unknown. In this study, we examined the structural folding and the function of the amino terminus. We found that it has a U-shaped folding with the bottom of the U-structure facing cytoplasm and both ends in extracellular space. We also found that this U-shaped amino terminus probably functions as a gate to regulate the drug transport activity of human ABCC1.	Indiana Univ, Sch Med, IUCC, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Div Biostat, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Zhang, JT (corresponding author), Indiana Univ, Sch Med, IUCC, Dept Pharmacol & Toxicol, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015		NATIONAL CANCER INSTITUTE [R01CA094961, R01CA120221] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007910] Funding Source: NIH RePORTER; NCI NIH HHS [CA94961, CA120221] Funding Source: Medline; NHLBI NIH HHS [T32 HL07910] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Chen Q, 2002, BIOCHEMISTRY-US, V41, P9052, DOI 10.1021/bi025634s; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Dean M, 2005, ANNU REV GENOM HUM G, V6, P123, DOI 10.1146/annurev.genom.6.080604.162122; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Han B., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P31, DOI 10.2174/1568011043482205; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Karwatsky J, 2003, BIOCHEMISTRY-US, V42, P3286, DOI 10.1021/bi0268807; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; Lee SH, 2003, BIOCHEM J, V370, P357, DOI 10.1042/BJ20021452; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; LING V, 1997, CANC CHEMOTHER PHA S, V40, P3; Muller M, 2002, BIOCHEMISTRY-US, V41, P10123, DOI 10.1021/bi026075s; Westlake CJ, 2005, MOL BIOL CELL, V16, P2483, DOI 10.1091/mbc.E04-12-1113; Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200; Zhang JT, 2000, BIOCHEM J, V348, P597, DOI 10.1042/0264-6021:3480597	24	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31152	31163		10.1074/jbc.M603529200	http://dx.doi.org/10.1074/jbc.M603529200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16914551	hybrid			2022-12-25	WOS:000241075900090
J	Hu, YL; Fay, AW; Schmid, B; Makar, B; Ribbe, MW				Hu, Yilin; Fay, Aaron W.; Schmid, Benedikt; Makar, Beshoie; Ribbe, Markus W.			Molecular insights into nitrogenase FeMoco insertion - TRP-444 of MoFe protein alpha-subunit locks FeMoco in its binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; STRUCTURAL BASIS; BIOSYNTHESIS; MECHANISM; CLUSTERS; MUTANT	Biosynthesis of the FeMo cofactor (FeMoco) of nitrogenase MoFe protein is arguably one of the most complex processes in metalloprotein biochemistry. Here we investigate the role of a MoFe protein residue (Trp-alpha 444) in the final step of FeMoco assembly, which involves the insertion of FeMoco into its binding site. Mutations of this aromatic residue to small uncharged ones result in significantly decreased levels of FeMoco insertion/retention and drastically reduced activities of MoFe proteins, suggesting that Trp-alpha 444 may lock the FeMoco tightly in its binding site through the sterically restricting effect of its bulky, aromatic side chain. Additionally, these mutations cause partial conversion of the P-cluster to a more open conformation, indicating a potential connection between FeMoco insertion and P-cluster assembly. Our results provide some of the initial molecular insights into the FeMoco insertion process and, moreover, have useful implications for the overall scheme of nitrogenase assembly.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Erlangen Nurnberg, Dept Biotechnol, D-91052 Erlangen, Germany	University of California System; University of California Irvine; University of Erlangen Nuremberg	Ribbe, MW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	mribbe@uci.edu			NIGMS NIH HHS [GM-67626] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067626] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Bursey EH, 1998, J BIOL CHEM, V273, P16927, DOI 10.1074/jbc.273.27.16927; Bursey EH, 1998, J BIOL CHEM, V273, P29678, DOI 10.1074/jbc.273.45.29678; Christiansen J, 2001, ANNU REV PLANT PHYS, V52, P269, DOI 10.1146/annurev.arplant.52.1.269; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; Corbett MC, 2006, P NATL ACAD SCI USA, V103, P1238, DOI 10.1073/pnas.0507853103; Corbett MC, 2004, J BIOL CHEM, V279, P28276, DOI 10.1074/jbc.M403156200; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Curatti L, 2006, P NATL ACAD SCI USA, V103, P5297, DOI 10.1073/pnas.0601115103; Dos Santos PC, 2004, CHEM REV, V104, P1159, DOI 10.1021/cr020608l; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; GAVINI N, 1992, J BIOL CHEM, V267, P21179; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HU Y, 2006, IN PRESS P NATL ACAD; Hu YL, 2004, J BIOL CHEM, V279, P54963, DOI 10.1074/jbc.M408983200; Hu YL, 2005, P NATL ACAD SCI USA, V102, P13825, DOI 10.1073/pnas.0506967102; Hu YL, 2005, P NATL ACAD SCI USA, V102, P3236, DOI 10.1073/pnas.0409201102; Igarashi RY, 2003, CRIT REV BIOCHEM MOL, V38, P351, DOI 10.1080/10409230390242380; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; Peters JW, 2006, CURR OPIN CHEM BIOL, V10, P101, DOI 10.1016/j.cbpa.2006.02.019; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; Rees DC, 2005, PHILOS T R SOC A, V363, P971, DOI 10.1098/rsta.2004.1539; Rees DC, 2002, ANNU REV BIOCHEM, V71, P221, DOI 10.1146/annurev.biochem.71.110601.135406; Rees DC, 2003, SCIENCE, V300, P929, DOI 10.1126/science.1083075; Ribbe MW, 2002, J BIOL CHEM, V277, P23469, DOI 10.1074/jbc.M202061200; Rubio LM, 2005, J BACTERIOL, V187, P405, DOI 10.1128/JB.187.2.405-414.2005; Schmid B, 2002, SCIENCE, V296, P352, DOI 10.1126/science.1070010; Schwarz G, 2006, ANNU REV PLANT BIOL, V57, P623, DOI 10.1146/annurev.arplant.57.032905.105437; Seefeldt LC, 2004, BIOCHEMISTRY-US, V43, P1401, DOI 10.1021/bi036038g; Smith BE, 1999, ADV INORG CHEM, V47, P159, DOI 10.1016/S0898-8838(08)60078-1; Stiebritz MT, 2006, ACTA CRYSTALLOGR D, V62, P648, DOI 10.1107/S0907444906013333; SURERUS KK, 1992, J AM CHEM SOC, V114, P8579, DOI 10.1021/ja00048a034; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3	39	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30534	30541		10.1074/jbc.M605527200	http://dx.doi.org/10.1074/jbc.M605527200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16893897	hybrid			2022-12-25	WOS:000241075900029
J	Ma, L; Wang, HY				Ma, Li; Wang, Hsien-yu			Suppression of cyclic GMP-dependent protein kinase is essential to the Wnt/cGMP/Ca2+ pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F9 TERATOCARCINOMA CELLS; ADP-RIBOSYLATION; XENOPUS EMBRYOS; WNT; RAT; ACTIVATION; DROSOPHILA; RECEPTOR; FAMILY; CA2+	Novel downstream effectors sensing changes in intracellular concentrations of Ca2+ and cyclic GMP in response to activation of the Wnt/Frizzled-2 pathway were sought. Activation of Frizzled-2 suppressed protein kinase G activity while activating NF-AT-dependent transcription. Each of these responses was abolished by pertussis toxin and by knock-down of the expression of either G alpha(t2) or G alpha(o). Activation of NF-AT-dependent transcription in response to Wnt5a stimulation was suppressed by activation of protein kinase G and by buffering intracellular Ca2+. Elevation of intracellular cyclic GMP either by inhibition of cyclic GMP phosphodiesterase or by addition of 8-bromocyclic GMP was shown to activate protein kinase G, to block Ca2+ mobilization, as well as to markedly attenuate activation of NF-AT-dependent transcription in response to Wnt5a stimulation. Chemical inhibition of protein kinase G by Rp-8-pCPT-cGMP, conversely, was shown to provoke increased NF-AT gene transcription and Ca2+ mobilization in the absence of Wnt stimulation. Protein kinase G is shown to be a critical downstream effector of the noncanonical Wnt-Frizzled-2/cGMP/Ca2+ pathway.	SUNY Stony Brook, Sch Med, Diabet & Metab Dis Res Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Diabet & Metab Dis Res Ctr, Dept Pharmacol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wang, HY (corresponding author), SUNY Stony Brook, Sch Med, Diabet & Metab Dis Res Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	wangh@pharm.stonybrook.edu	Ma, Li/AAG-4109-2020	Ma, Li/0000-0001-8470-0378	NIGMS NIH HHS [GM 069375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; DeCostanzo AJ, 2002, N-S ARCH PHARMACOL, V365, P341, DOI 10.1007/s00210-002-0540-3; Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; LUGNIER C, 1986, BIOCHEM PHARMACOL, V35, P1743, DOI 10.1016/0006-2952(86)90333-3; MANNING DR, 1984, J BIOL CHEM, V259, P749; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MURAYAMA T, 1984, J BIOL CHEM, V259, P761; NORDSTROM O, 1981, BRAIN RES, V213, P467, DOI 10.1016/0006-8993(81)90255-9; OUEDRAOGO S, 1994, BRIT J PHARMACOL, V112, P867, DOI 10.1111/j.1476-5381.1994.tb13160.x; Quaiser T, 2006, BIOESSAYS, V28, P339, DOI 10.1002/bies.20386; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; VANDOP C, 1984, J BIOL CHEM, V259, P23; Wang H, 2004, BIOCHEM SOC T, V32, P792, DOI 10.1042/BST0320792; Wang HY, 1997, J BIOL CHEM, V272, P1817, DOI 10.1074/jbc.272.3.1817; Wang HY, 2003, SCIENCE, V300, P1529, DOI 10.1126/science.1085259; Wang YS, 1996, J BIOL CHEM, V271, P4468; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; WOLFE L, 1987, J BIOL CHEM, V262, P16906	30	49	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30990	31001		10.1074/jbc.M603603200	http://dx.doi.org/10.1074/jbc.M603603200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16920709	hybrid			2022-12-25	WOS:000241075900075
J	Triantafilou, M; Gamper, FGJ; Haston, RM; Mouratis, MA; Morath, S; Hartung, T; Triantafilou, K				Triantafilou, Martha; Gamper, Frederick G. J.; Haston, Rowenna M.; Mouratis, Marios Angelos; Morath, Siegfried; Hartung, Thomas; Triantafilou, Kathy			Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; INNATE IMMUNE-SYSTEM; LIPOTEICHOIC ACID; BACTERIAL LIPOPOLYSACCHARIDE; GOLGI-APPARATUS; PLASMA-MEMBRANE; CUTTING EDGE; STRANDED-RNA; LIPID RAFTS; RECOGNITION	Toll-like receptors (TLRs) are receptors of the innate immune system responsible for recognizing pathogen-associated molecular patterns. TLR2 seems to be the most promiscuous TLR receptor able to recognize the most diverse set of pathogen-associated patterns. Its promiscuity has been attributed to its unique ability to heterodimerize with TLRs 1 and 6 and, most recently, to its association with CD36 in response to diacylated lipoproteins. Thus, it seems that TLR2 forms receptor clusters in response to different microbial ligands. In this study we investigated TLR2 cell surface heterotypic interactions in response to different ligands as well as internalization and intracellular trafficking. Our data show that TLR2 forms heterodimers with TLR1 and TLR6 and that these heterodimer pre-exist and are not induced by the ligand. Upon stimulation by the specific ligand, these heterodimers are recruited within lipid rafts. In contrast, heterotypic associations of TLR2/6 with CD36 are not preformed and are ligand-induced. All TLR2 receptor clusters accumulate in lipid rafts and are targeted to the Golgi apparatus. This localization and targeting is ligand-specific. Activation occurs at the cell surface, and the observed trafficking is independent of signaling.	Univ Sussex, Sch Life Sci, Infect & Immun Grp, Brighton BN1 9QG, E Sussex, England; Univ Konstanz, Dept Biochem Pharmacol, D-78457 Constance, Germany	University of Sussex; University of Konstanz	Triantafilou, K (corresponding author), Univ Sussex, Sch Life Sci, Infect & Immun Grp, JMS Bldg, Brighton BN1 9QG, E Sussex, England.	K.Triantafilou@sussex.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akira S, 2001, ADV IMMUNOL, V78, P1, DOI 10.1016/S0065-2776(01)78001-7; Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Buwitt-Beckmann U, 2005, EUR J IMMUNOL, V35, P282, DOI 10.1002/eji.200424955; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Heine H, 2003, INT ARCH ALLERGY IMM, V130, P180, DOI 10.1159/000069517; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Kenworthy AK, 1999, METH MOL B, V116, P37; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Means TK, 1999, J IMMUNOL, V163, P6748; Morath S, 2002, INFECT IMMUN, V70, P938, DOI 10.1128/IAI.70.2.938-944.2002; Morr M, 2002, EUR J IMMUNOL, V32, P3337, DOI 10.1002/1521-4141(2002012)32:12<3337::AID-IMMU3337>3.0.CO;2-I; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Stuart LM, 2005, J CELL BIOL, V170, P477, DOI 10.1083/jcb.200501113; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; Triantafilou M, 2004, J BIOL CHEM, V279, P40882, DOI 10.1074/jbc.M400466200; Triantafilou M, 2004, BIOCHEM J, V381, P527, DOI 10.1042/BJ20040172; Triantafilou M, 2004, J CELL SCI, V117, P4007, DOI 10.1242/jcs.01270; Triantafilou M, 2003, J ENDOTOXIN RES, V9, P331, DOI 10.1179/096805103225002557; Triantafilou M, 2002, J CELL SCI, V115, P2603; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Wang PY, 1996, J INFLAMM, V47, P126; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Yoshimura A, 1999, J IMMUNOL, V163, P1	38	343	353	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31002	31011		10.1074/jbc.M602794200	http://dx.doi.org/10.1074/jbc.M602794200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16880211	hybrid			2022-12-25	WOS:000241075900076
J	Goswami, T; Andrews, NC				Goswami, Tapasree; Andrews, Nancy C.			Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFERRIC TRANSFERRIN; RECEPTOR; EXPRESSION; HEPCIDIN; BINDING; ANEMIA	HFE and transferrin receptor 2 (TFR2) are membrane proteins integral to mammalian iron homeostasis and associated with human hereditary hemochromatosis. Here we demonstrate that HFE and TFR2 interact in cells, that this interaction is not abrogated by disease-associated mutations of HFE and TFR2, and that TFR2 competes with TFR1 for binding to HFE. We propose a new model for the mechanism of iron status sensing that results in the regulation of iron homeostasis.	Harvard Univ, Sch Med, Childrens Hosp Boston, Karp Family Res Labs,Div Hematol Oncol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Andrews, NC (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Karp Family Res Labs,Div Hematol Oncol, Rm 8-125,1,Blackfan Circle, Boston, MA 02115 USA.	nancy_andrews@hms.harvard.edu		Andrews, Nancy/0000-0003-0243-4462	NIDDK NIH HHS [R01 DK53813, R01 DK053813-10, R01 DK053813] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053813] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, CURRENT PROTOCOLS MO; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; Griffiths WJH, 2003, J HISTOCHEM CYTOCHEM, V51, P613, DOI 10.1177/002215540305100507; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; HUBERT N, 1993, J HEPATOL, V18, P301, DOI 10.1016/S0168-8278(05)80274-0; Johnson MB, 2004, BLOOD, V104, P4287, DOI 10.1182/blood-2004-06-2477; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Le Gac G, 2005, EUR J HUM GENET, V13, P1172, DOI 10.1038/sj.ejhg.5201490; Levy JE, 1999, BLOOD, V94, P9, DOI 10.1182/blood.V94.1.9.413a43_9_11; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Robb A, 2004, BLOOD, V104, P4294, DOI 10.1182/blood-2004-06-2481; Roetto A, 2002, BLOOD CELL MOL DIS, V29, P465, DOI 10.1006/bcmd.2002.0585; Sidis Y, 2006, ENDOCRINOLOGY, V147, P3586, DOI 10.1210/en.2006-0089; Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260; West AP, 2001, J MOL BIOL, V313, P385, DOI 10.1006/jmbi.2001.5048; West AP, 2000, J BIOL CHEM, V275, P38135, DOI 10.1074/jbc.C000664200; Wilkins SJ, 2006, BLOOD, V107, P1659, DOI 10.1182/blood-2005-07-2614; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674	20	260	270	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28494	28498		10.1074/jbc.C600197200	http://dx.doi.org/10.1074/jbc.C600197200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16893896	hybrid			2022-12-25	WOS:000240680500002
J	Jang, LT; Buu, LM; Lee, FJS				Jang, Li-Ting; Buu, Leh-Miauh; Lee, Fang-Jen S.			Determinants of Rbp1p localization in specific cytoplasmic mRNA-processing foci, P-bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN STRESS GRANULES; SACCHAROMYCES-CEREVISIAE; BINDING PROTEINS; YEAST; MECHANISMS; TURNOVER; TRANSLATION; STABILITY; COMPLEXES; CELLS	Rbp1p, a yeast RNA-binding protein, decreases the level of mitochondrial porin mRNA by enhancing its degradation, but the intracellular location of the Rbp1p-mediated degradation complex remains unknown. We show here that Rbp1p in xrn1 Delta mutant yeast localizes in specific cytoplasmic foci that are known as P-bodies. The N-terminal and RNA recognition motif (RRM) 1 domains of Rbp1p are necessary but not sufficient for its localization in P bodies. Rbp1p forms oligomers through its C-terminal domain in vivo; N-terminal-delete, or RRM1-mutated Rbp1p can be more efficiently recruited to P-bodies in an xrn1 Delta strain, expressing a full-length Rbp1p. Although POR1 mRNA is localized to P bodies in an xrn1 Delta strain, this localization does not depend on Rbp1p. Decapping activator Dhh1p directly interacts with Rbp1p. However, the recruitment of Rbp1p to P-bodies does not require Dhh1p or Ccr4p. In wildtype cells, Rbp1p can localize to P-bodies under glucose deprivation or treatment with KCl. In addition, Rbp1p-mediated porin mRNA decay is elicited by Xrn1p, a 5' to 3' exonuclease. These results provide new insight into the mechanism of Rbp1p function.	Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan; Natl Taiwan Univ, Sch Med, Inst Mol Med, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University	Lee, FJS (corresponding author), Natl Taiwan Univ Hosp, Dept Med Res, 7 Chung Shan S Rd, Taipei, Taiwan.	fangjen@ha.mc.ntu.edu.tw		LEE, FANG-JEN/0000-0002-2167-2426				Beck ARP, 1998, P NATL ACAD SCI USA, V95, P2331, DOI 10.1073/pnas.95.5.2331; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Buu LM, 2004, J BIOL CHEM, V279, P453, DOI 10.1074/jbc.M309278200; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032; Coller JM, 2001, RNA, V7, P1717, DOI 10.1017/S135583820101994X; Deutschbauer AM, 2002, P NATL ACAD SCI USA, V99, P15530, DOI 10.1073/pnas.202604399; Fischer N, 2002, EMBO J, V21, P2788, DOI 10.1093/emboj/21.11.2788; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; HEYER WD, 1995, MOL CELL BIOL, V15, P2728; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; LEE FJS, 1994, J BIOL CHEM, V269, P20931; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; LEE FJS, 1993, J BIOL CHEM, V268, P15080; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sherman F., 1986, METHODS YEAST GENETI; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; Teixeira D, 2005, RNA, V11, P371, DOI 10.1261/rna.7258505; Tharun S, 2001, MOL CELL, V8, P1075, DOI 10.1016/S1097-2765(01)00395-1; Tseng-Rogenski SSI, 2003, NUCLEIC ACIDS RES, V31, P4995, DOI 10.1093/nar/gkg712; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; VERENT T, 1987, GENE, V52, P225; Wickens M, 2003, SCIENCE, V300, P753, DOI 10.1126/science.1084512; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025	34	11	12	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29379	29390		10.1074/jbc.M601573200	http://dx.doi.org/10.1074/jbc.M601573200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16885161	hybrid			2022-12-25	WOS:000240680500093
J	Carretero, J; Medina, PP; Blanco, R; Smit, L; Tang, M; Roncador, G; Maestre, L; Conde, E; Lopez-Rios, F; Clevers, HC; Sanchez-Cespedes, M				Carretero, J.; Medina, P. P.; Blanco, R.; Smit, L.; Tang, M.; Roncador, G.; Maestre, L.; Conde, E.; Lopez-Rios, F.; Clevers, H. C.; Sanchez-Cespedes, M.			Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer	ONCOGENE			English	Article						LKB1; AMPK; lung cancer; energy stress	ACTIVATED PROTEIN-KINASE; TUBEROUS SCLEROSIS COMPLEX; MAMMALIAN TARGET; UPSTREAM KINASE; DOWN-REGULATION; LKB1; AKT; GROWTH; CELLS; RAPAMYCIN	LKB1, mutated in Peutz-Jeghers and in sporadic lung tumours, phosphorylates a group of protein kinases named AMP-activated protein kinase (AMPK)-related kinases. Among them is included the AMPK, a sensor of cellular energy status. To investigate the relevance of LKB1 in lung carcinogenesis, we study several lung cancer cells with and without LKB1-inactivating mutations. We report that LKB1-mutant cells are deficient for AMPK activity and refractory to mTOR inhibition upon glucose depletion but not growth-factor deprivation. The requirement for wild-type LKB1 to properly activate AMPK is further demonstrated in genetically modified cancer cells. In addition, LKB1-deficient lung primary tumours had diminished AMPK activity, assessed by complete absence or low level of phosphorylation of its critical substrate, acetyl-CoA carboxylase. We also demonstrate that LKB1 wild-type cells are more resistant to cell death upon glucose withdrawal than their mutant counterparts. Finally, modulation of AMPK activity did not affect PI3K/AKT signalling, an advantage for the potential use of AMPK as a target for cancer therapy in LKB1 wildtype tumours. Thus, sustained abrogation of cell energetic checkpoint control, through alterations at key genes, appear to be an obligatory step in the development of some lung tumours.	Spanish Natl Canc Ctr, Lung Canc Grp, CNIO, Madrid 28029, Spain; Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; Univ Madrid, Hosp 12 Octubre, CNIO, Monoclonal Antibodies Unit, Madrid 3, Spain; Univ Madrid, Hosp 12 Octubre, Dept Pathol, Madrid 3, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre	Sanchez-Cespedes, M (corresponding author), Spanish Natl Canc Ctr, Lung Canc Grp, CNIO, Madrid 28029, Spain.	msanchez@cnio.es	Maestre, Lorena/L-1352-2014; Roncador, Giovanna/L-1764-2014; Sanchez-Cespedes, Montse/H-8485-2012; Carretero, Julian/N-5214-2014; Blanco, Raquel/M-4290-2015; Vico, Pedro Pablo Medina/D-1688-2013	Maestre, Lorena/0000-0001-8743-0422; Roncador, Giovanna/0000-0002-9807-2875; Sanchez-Cespedes, Montse/0000-0002-6045-5627; Carretero, Julian/0000-0001-7269-8506; Blanco, Raquel/0000-0001-5477-5379; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Smit, Linda/0000-0003-0025-269X				Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Conde E, 2006, CLIN CANCER RES, V12, P710, DOI 10.1158/1078-0432.CCR-05-1362; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fernandez P, 2004, ONCOGENE, V23, P5084, DOI 10.1038/sj.onc.1207665; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; MASON DY, 1983, TECHNIQUES IMMUNOCYT, P17; Nakau M, 2002, CANCER RES, V62, P4549; NELLIST M, 1993, CELL, V75, P1305; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	41	119	123	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1616	1625		10.1038/sj.onc.1209951	http://dx.doi.org/10.1038/sj.onc.1209951			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953221				2022-12-25	WOS:000244782500011
J	Pu, YM; Peach, ML; Garfield, SH; Wincovitch, S; Marquez, VE; Blumberg, PM				Pu, Yongmei; Peach, Megan L.; Garfield, Susan H.; Wincovitch, Stephen; Marquez, Victor E.; Blumberg, Peter M.			Effects on ligand interaction and membrane translocation of the positively charged arginine residues situated along the C1 domain binding cleft in the atypical protein kinase C isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL 12-MYRISTATE 13-ACETATE; PKC-IOTA; NUCLEAR IMPORT; DELTA; ZETA; INHIBITION; DIACYLGLYCEROLS; LOCALIZATION; ACTIVATION; ISOZYMES	The C1 domain zinc finger structure is highly conserved among the protein kinase C (PKC) superfamily members. As the interaction site for the second messenger sn-1,2-diacylglycerol (DAG) and for the phorbol esters, the C1 domain has been an important target for developing selective ligands for different PKC isoforms. However, the C1 domains of the atypical PKC members are DAG/phorbol ester-insensitive. Compared with the DAG/phorbol ester-sensitive C1 domains, the rim of the binding cleft of the atypical PKC C1 domains possesses four additional positively charged arginine residues ( at positions 7, 10, 11, and 20). In this study, we showed that mutation to arginines of the four corresponding sites in the C1b domain of PKC delta abolished its high potency for phorbol 12,13-dibutyrate in vitro, with only marginal remaining activity for phorbol 12-myristate 13-acetate in vivo. We also demonstrated both in vitro and in vivo that the loss of potency to ligands was cumulative with the introduction of the arginine residues along the rim of the binding cavity rather than the consequence of loss of a single, specific residue. Computer modeling reveals that these arginine residues reduce access of ligands to the binding cleft and change the electrostatic profile of the C1 domain surface, whereas the basic structure of the binding cleft is still maintained. Finally, mutation of the four arginine residues of the atypical PKC C1 domains to the corresponding residues in the delta C1b domain conferred response to phorbol ester. We speculate that the arginine residues of the C1 domain of atypical PKCs may provide an opportunity for the design of ligands selective for the atypical PKCs.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA; NCI, Med Chem Lab, Ctr Canc Res, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blumberg, PM (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bldg 37,Rm 4048,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	blumberp@dc37a.nci.nih.gov	Marquez, Victor/AAP-3549-2021	Peach, Megan/0000-0002-4290-5268	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Braun DC, 2005, MOL CANCER THER, V4, P141; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Goekjian PG, 1999, CURR MED CHEM, V6, P877; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; Hall C, 2005, TRENDS BIOCHEM SCI, V30, P169, DOI 10.1016/j.tibs.2005.02.003; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; Hurley JH, 1997, PROTEIN SCI, V6, P477; Ito Y, 2001, CELL DEATH DIFFER, V8, P794, DOI 10.1038/sj.cdd.4400886; Jacquel A, 2006, ONCOGENE, V25, P781, DOI 10.1038/sj.onc.1209119; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; Kato M, 2005, IMMUNOLOGY, V116, P193, DOI 10.1111/j.1365-2567.2005.02210.x; Kazanietz MG, 2005, BBA-PROTEINS PROTEOM, V1754, P296, DOI 10.1016/j.bbapap.2005.07.034; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Kedei N, 2004, CANCER RES, V64, P3243, DOI 10.1158/0008-5472.CAN-03-3403; Lewin Nancy E, 2003, Methods Mol Biol, V233, P129; Marquez VE, 2003, ACCOUNTS CHEM RES, V36, P434, DOI 10.1021/ar020124b; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perander M, 2001, J BIOL CHEM, V276, P13015, DOI 10.1074/jbc.M010356200; Pu YM, 2005, J BIOL CHEM, V280, P27329, DOI 10.1074/jbc.M414132200; RAPPAPORT HP, 1979, J THEOR BIOL, V79, P157, DOI 10.1016/0022-5193(79)90244-3; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; Slater SJ, 1996, J BIOL CHEM, V271, P4627; Sun RH, 2005, CANCER RES, V65, P1433, DOI 10.1158/0008-5472.CAN-04-1163; Suzuki A, 2003, J BIOCHEM, V133, P9, DOI 10.1093/jb/mvg018; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1993, CANCER RES, V53, P2507; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Tortora G, 2003, SEMIN ONCOL, V30, P26, DOI 10.1016/S0093-7754(03)00282-3; Violin JD, 2003, IUBMB LIFE, V55, P653, DOI 10.1080/152165401310001642216; Wang QMJ, 2001, J BIOL CHEM, V276, P19580, DOI 10.1074/jbc.M010089200; WAYS DK, 1992, J BIOL CHEM, V267, P4799; Williams SA, 2004, J BIOL CHEM, V279, P42008, DOI 10.1074/jbc.M402124200; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263	50	41	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33773	33788		10.1074/jbc.M606560200	http://dx.doi.org/10.1074/jbc.M606560200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950780	hybrid			2022-12-25	WOS:000241621400084
J	Hara, S; Motohashi, K; Arisaka, F; Romano, PGN; Hosoya-Matsuda, N; Kikuchi, N; Fusada, N; Hisabori, T				Hara, Satoshi; Motohashi, Ken; Arisaka, Fumio; Romano, Patrick G. N.; Hosoya-Matsuda, Naomi; Kikuchi, Nobuhiro; Fusada, Naoki; Hisabori, Toru			Thioredoxin-h1 reduces and reactivates the oxidized cytosolic malate dehydrogenase dimer in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; REFINED CRYSTAL-STRUCTURE; CELL-FREE SYNTHESIS; ARABIDOPSIS-THALIANA; REDUCTIVE ACTIVATION; STRUCTURAL BASIS; CHLOROPLAST THIOREDOXIN; LIGHT; PROTEINS; SYSTEM	Cytosolic malate dehydrogenase (cytMDH) was captured by thioredoxin affinity chromatography as a possible target protein of cytosolic thioredoxin (Yamazaki, D., Motohashi, K., Kasama, T., Hara, Y., and Hisabori, T. (2004) Plant Cell Physiol. 45, 18-27). To further dissect this interaction, we aimed to determine whether cytMDH can interact with the cytosolic thioredoxin and whether its activity is redox-regulated. We obtained the active recombinant cytMDH that could be oxidized and rendered inactive. Inactivation was reversed by incubation with low concentrations of dithiothreitol in the presence of recombinant Arabidopsis thaliana thioredoxin-h1. Inactivation of cytMDH was found to result from formation of a homodimer. By cysteine mutant analysis and peptide mapping analysis, we were able to determine that the cytMDH homodimer occurs by formation of a disulfide bond via the Cys330 residue. Moreover, we found this bond to be efficiently reduced by the reduced form of thioredoxin-h1. These results demonstrate that the oxidized form cytMDH dimer is a preferable target protein of the reduced form thioredoxin-h1 as suggested by thioredoxin affinity chromatography.	Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Corp, ATP Syst Project, ERATO, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biomol Proc, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Tokyo Institute of Technology	Hisabori, T (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Nagatsuta 4259-R1-8, Yokohama, Kanagawa 2268503, Japan.	thisabor@res.titech.ac.jp	Hara, Satoshi/C-1341-2015; Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Hara, Satoshi/0000-0001-6275-6469; Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277				Ballicora MA, 2000, J BIOL CHEM, V275, P1315, DOI 10.1074/jbc.275.2.1315; Balmer Y, 2004, P NATL ACAD SCI USA, V101, P2642, DOI 10.1073/pnas.0308583101; Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; Brehelin C, 2004, PHOTOSYNTH RES, V79, P295, DOI 10.1023/B:PRES.0000017165.55488.ca; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; CRAWFORD NA, 1989, ARCH BIOCHEM BIOPHYS, V271, P223, DOI 10.1016/0003-9861(89)90273-7; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; Dalhus B, 2002, J MOL BIOL, V318, P707, DOI 10.1016/S0022-2836(02)00050-5; Entus R, 2002, PLANT PHYSIOL, V129, P1866, DOI 10.1104/pp.002626; FASKE M, 1995, BBA-PROTEIN STRUCT M, V1247, P135, DOI 10.1016/0167-4838(94)00203-S; FLORENCIO FJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P496, DOI 10.1016/0003-9861(88)90282-2; Gelhaye E, 2004, P NATL ACAD SCI USA, V101, P14545, DOI 10.1073/pnas.0405282101; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; GLEASON WB, 1994, BIOCHEMISTRY-US, V33, P2078, DOI 10.1021/bi00174a014; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; Hisabori T, 2005, J EXP BOT, V56, P1463, DOI 10.1093/jxb/eri170; HOCK B, 1982, ANN NY ACAD SCI, V386, P350, DOI 10.1111/j.1749-6632.1982.tb21427.x; Igamberdiev AU, 2003, BBA-BIOENERGETICS, V1606, P117, DOI 10.1016/S0005-2728(03)00106-3; Irimia A, 2004, J MOL BIOL, V335, P343, DOI 10.1016/j.jmb.2003.10.054; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; Laloi C, 2004, PLANT PHYSIOL, V134, P1006, DOI 10.1104/pp.103.035782; Laloi C, 2001, P NATL ACAD SCI USA, V98, P14144, DOI 10.1073/pnas.241340898; Lemaire M, 1996, EUR J BIOCHEM, V236, P947, DOI 10.1111/j.1432-1033.1996.00947.x; Lemaire M, 1996, FEBS LETT, V382, P137, DOI 10.1016/0014-5793(96)00153-6; Lemaire SD, 2004, P NATL ACAD SCI USA, V101, P7475, DOI 10.1073/pnas.0402221101; Lindahl M, 2003, P NATL ACAD SCI USA, V100, P16107, DOI 10.1073/pnas.2534397100; Marchand C, 2004, PROTEOMICS, V4, P2696, DOI 10.1002/pmic.200400805; Meyer Y, 2005, PHOTOSYNTH RES, V86, P419, DOI 10.1007/s11120-005-5220-y; Miller SS, 1998, PLANT J, V15, P173, DOI 10.1046/j.1365-313X.1998.00192.x; Motohashi K, 2003, J BIOL CHEM, V278, P31848, DOI 10.1074/jbc.M304258200; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; OCHERETINA O, 1993, BIOCHIM BIOPHYS ACTA, V1163, P10, DOI 10.1016/0167-4838(93)90272-S; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; Ruelland E, 1997, J BIOL CHEM, V272, P19851, DOI 10.1074/jbc.272.32.19851; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sasaki Y, 1997, P NATL ACAD SCI USA, V94, P11096, DOI 10.1073/pnas.94.20.11096; SCHEIBE R, 1981, BIOCHIM BIOPHYS ACTA, V636, P58, DOI 10.1016/0005-2728(81)90075-X; SCHEIBE R, 1991, BIOCHIM BIOPHYS ACTA, V1076, P1, DOI 10.1016/0167-4838(91)90212-I; Scheibe R, 2004, PHYSIOL PLANTARUM, V120, P21, DOI 10.1111/j.0031-9317.2004.0222.x; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Stumpp MT, 1999, BIOCHEM J, V341, P157, DOI 10.1042/0264-6021:3410157; Taniguchi M, 2002, PLANT CELL PHYSIOL, V43, P706, DOI 10.1093/pcp/pcf109; Trejo F, 2001, PROTEIN ENG, V14, P911, DOI 10.1093/protein/14.11.911; Vignols F, 2005, P NATL ACAD SCI USA, V102, P16729, DOI 10.1073/pnas.0506880102; WALK RA, 1978, BIOCHEM BIOPH RES CO, V81, P636, DOI 10.1016/0006-291X(78)91583-8; Yamazaki D, 2004, PLANT CELL PHYSIOL, V45, P18, DOI 10.1093/pcp/pch019; Yano H, 2001, P NATL ACAD SCI USA, V98, P4794, DOI 10.1073/pnas.071041998; Zhang N, 1999, P NATL ACAD SCI USA, V96, P9438, DOI 10.1073/pnas.96.16.9438	51	51	52	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32065	32071		10.1074/jbc.M605784200	http://dx.doi.org/10.1074/jbc.M605784200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16945919	hybrid			2022-12-25	WOS:000241414500003
J	Bowman, BJ; McCall, ME; Baertsch, R; Bowman, EJ				Bowman, Barry J.; McCall, Mary E.; Baertsch, Robert; Bowman, Emma Jean			A model for the proteolipid ring and bafilomycin/concanamycin-binding site in the vacuolar ATPase of Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST V-ATPASE; H+-ATPASE; SUBUNIT-C; SACCHAROMYCES-CEREVISIAE; PROTON PUMP; ENTEROCOCCUS-HIRAE; MEMBRANE DOMAIN; CONCANAMYCIN-A; NA+-ATPASE; PROTEIN	The vacuolar ATPase has been implicated in a variety of physiological processes in eukaryotic cells. Bafilomycin and concanamycin, highly potent and specific inhibitors of the vacuolar ATPase, have been widely used to investigate the enzyme. Derivatives have been developed as possible therapeutic drugs. We have used random mutagenesis and site-directed mutagenesis to identify 23 residues in the c subunit involved in binding these drugs. We generated a model for the structure of the ring of c subunits in Neurospora crassa by using data from the crystal structure of the homologous subunits of the bacterium Enterococcus hirae (Murata, T., Yamato, I., Kakinuma, Y., Leslie, A. G., and Walker, J.E. (2005) Science 308, 654-659). In the model 10 of the 11 mutation sites that confer the highest degree of resistance are closely clustered. They form a putative drug-binding pocket at the interface between helices 1 and 2 on one c subunit and helix 4 of the adjacent c subunit. The excellent fit of the N. crassa sequence to the E. hirae structure and the degree to which the structural model predicts the clustering of these residues suggest that the folding of the bacterial and eukaryotic polypeptides is very similar.	Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Bowman, EJ (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.	bowman@biology.ucsc.edu		Baertsch, Robert/0000-0002-4733-2649	NIGMS NIH HHS [GM058903] Funding Source: Medline; PHS HHS [22XS013A] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM058903] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI H, 1988, J BIOL CHEM, V263, P8796; BAKER GH, 1987, TETRAHEDRON LETT, V28, P5565, DOI 10.1016/S0040-4039(00)96783-2; Beutler JA, 2003, CURR MED CHEM, V10, P787, DOI 10.2174/0929867033457827; Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; Bowman EJ, 2000, J BIOL CHEM, V275, P167, DOI 10.1074/jbc.275.1.167; Bowman EJ, 2004, J BIOL CHEM, V279, P33131, DOI 10.1074/jbc.M404638200; Bowman EJ, 2003, J BIOL CHEM, V278, P44147, DOI 10.1074/jbc.M306595200; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOWMAN EJ, 1997, BIOMEMBRANE, P861; Boyd MR, 2001, J PHARMACOL EXP THER, V297, P114; Chavez C, 2006, J BIOL CHEM, V281, P27052, DOI 10.1074/jbc.M603883200; DAVIS RH, 2000, NEUROSPORA CONTRIBUT, P273; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Drose S, 1997, J EXP BIOL, V200, P1; Farina C, 2001, FARMACO, V56, P113, DOI 10.1016/S0014-827X(01)01013-8; Farina C, 2002, CURR PHARM DESIGN, V8, P2033, DOI 10.2174/1381612023393369; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Harrison M, 2003, J BIOENERG BIOMEMBR, V35, P337, DOI 10.1023/A:1025728915565; Harrison M, 2000, BIOCHEMISTRY-US, V39, P7531, DOI 10.1021/bi000159o; Harrison MA, 1999, J BIOL CHEM, V274, P25461, DOI 10.1074/jbc.274.36.25461; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Izumi H, 2003, CANCER TREAT REV, V29, P541, DOI 10.1016/S0305-7372(03)00106-3; JOHN UP, 1986, FEBS LETT, V207, P79, DOI 10.1016/0014-5793(86)80016-3; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kawasaki-Nishi S, 2003, J BIOL CHEM, V278, P41908, DOI 10.1074/jbc.M308026200; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Margolin BS, 1997, FUNGAL GENET NEWSLET, V44, P34, DOI [10.4148/1941-4765.1281, DOI 10.1128/EC.00244-07]; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; Melnik VI, 1996, BBA-BIOENERGETICS, V1273, P77, DOI 10.1016/0005-2728(95)00144-1; Murata T, 2005, SCIENCE, V308, P654, DOI 10.1126/science.1110064; Murata T, 2003, J BIOL CHEM, V278, P21162, DOI 10.1074/jbc.M301620200; NAKAI H, 1992, ACTA CRYSTALLOGR C, V48, P1519, DOI 10.1107/S0108270191014749; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Rohl CA, 2004, METHOD ENZYMOL, V383, P66; Sachs MS, 1997, NUCLEIC ACIDS RES, V25, P2389, DOI 10.1093/nar/25.12.2389; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SEBALD W, 1979, EUR J BIOCHEM, V93, P587, DOI 10.1111/j.1432-1033.1979.tb12859.x; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; SIGRISTNELSON K, 1978, EUR J BIOCHEM, V92, P9, DOI 10.1111/j.1432-1033.1978.tb12717.x; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Sun-Wada GH, 2004, BBA-BIOENERGETICS, V1658, P106, DOI 10.1016/j.bbabio.2004.04.013; Venzke D, 2005, J MOL BIOL, V349, P659, DOI 10.1016/j.jmb.2005.04.033; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; Wang YR, 2005, J BIOL CHEM, V280, P40481, DOI 10.1074/jbc.M509106200; Whyteside G, 2005, BIOCHEMISTRY-US, V44, P15024, DOI 10.1021/bi051529h; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Yokoyama K, 2005, J BIOENERG BIOMEMBR, V37, P405, DOI 10.1007/s10863-005-9480-1	57	59	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31885	31893		10.1074/jbc.M605532200	http://dx.doi.org/10.1074/jbc.M605532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16912037	Bronze			2022-12-25	WOS:000241235300075
J	Clarke, EE; Churcher, I; Ellis, S; Wrigley, JDJ; Lewis, HD; Harrison, T; Shearman, MS; Beher, D				Clarke, Earl E.; Churcher, Ian; Ellis, Semantha; Wrigley, Jonathan D. J.; Lewis, Huw D.; Harrison, Timothy; Shearman, Mark S.; Beher, Dirk			Intra- or intercomplex binding to the gamma-secretase enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; SIGNAL PEPTIDE PEPTIDASE; ACTIVE-SITE; MISSENSE MUTATIONS; INHIBITOR BINDING; BETA-APP; PRESENILIN; COMPLEX; NICASTRIN	gamma-Secretase is one of the critical enzymes required for the generation of amyloid-beta peptides from the beta-amyloid precursor protein. Because amyloid-beta peptides are generally accepted to play a key role in Alzheimer disease, gamma-secretase inhibition holds the promise for a disease-modifying therapy for this neurodegenerative condition. Although recent progress has enhanced the understanding of the biology and composition of the gamma-secretase enzyme complex, less information is available on the actual interaction of various inhibitor classes with the enzyme. Here we show that the two principal classes of inhibitor described in the scientific and patent literature, aspartyl protease transition state analogue and small molecule non-transition state inhibitors, display fundamental differences in the way they interact with the enzyme. Taking advantage of a gamma-secretase enzyme overexpressing cellular system and different radiolabeled gamma-secretase inhibitors, we observed that the maximal binding of nontransition state gamma-secretase inhibitors accounts only for half the number of catalytic sites of the recombinant enzyme complex. This characteristic stoichiometry can be best accommodated with a model whereby the non-transition state inhibitors bind to a unique site at the interface of a dimeric enzyme. Subsequent competition studies confirm that this site appears to be targeted by the main classes of small molecule gamma-secretase inhibitor. In contrast, the non-steroidal anti-inflammatory drug gamma-secretase modulator sulindac sulfide displayed noncompetitive antagonism for all types of inhibitor. This finding suggests that non-steroidal anti-inflammatory drug-type gamma-secretase modulators target an alternative site on the enzyme, thereby changing the conformation of the binding sites for gamma-secretase inhibitors.	Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Dept Mol & Cellular Neurosci, Harlow CM20 2QR, Essex, England; Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Dept Med Chem, Harlow CM20 2QR, Essex, England	Merck & Company; GlaxoSmithKline; Merck & Company	Beher, D (corresponding author), Amgen Inc, Dept Neurosci, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	dbeher@amgen.com		Beher, Dirk/0000-0001-8005-5359				Barten DM, 2005, J PHARMACOL EXP THER, V312, P635, DOI 10.1124/jpet.104.075408; Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Beher D, 2003, BIOCHEMISTRY-US, V42, P8133, DOI 10.1021/bi034045z; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Churcher I, 2003, J MED CHEM, V46, P2275, DOI 10.1021/jm034058a; Churcher I, 2003, BIOORG MED CHEM LETT, V13, P179, DOI 10.1016/S0960-894X(02)00909-5; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Guo W, 2005, P NATL ACAD SCI USA, V102, P17495, DOI 10.1073/pnas.0508950102; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harrison T, 2004, CURR OPIN DRUG DISC, V7, P709; Hebert SS, 2004, NEUROBIOL DIS, V17, P260, DOI 10.1016/j.nbd.2004.08.002; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lewis SJ, 2005, BIOORG MED CHEM LETT, V15, P373, DOI 10.1016/j.bmcl.2004.10.062; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheer JM, 2006, P NATL ACAD SCI USA, V103, P7595, DOI 10.1073/pnas.0602571103; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Searfoss GH, 2003, J BIOL CHEM, V278, P46107, DOI 10.1074/jbc.M307757200; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29; SMITH DW, 2005, Patent No. 6967196; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Teall M, 2005, BIOORG MED CHEM LETT, V15, P2685, DOI 10.1016/j.bmcl.2004.12.017; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang J, 2006, J NEUROCHEM, V96, P218, DOI 10.1111/j.1471-4159.2005.03548.x; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Wrigley JDJ, 2005, J BIOL CHEM, V280, P12523, DOI 10.1074/jbc.M413086200; Wrigley JDJ, 2004, J NEUROCHEM, V90, P1312, DOI 10.1111/j.1471-4159.2004.02596.x; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	51	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31279	31289		10.1074/jbc.M605051200	http://dx.doi.org/10.1074/jbc.M605051200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16899457	Bronze			2022-12-25	WOS:000241235300012
J	Durkin, SS; Ward, MD; Fryrear, KA; Semmes, OJ				Durkin, Sarah S.; Ward, Michael D.; Fryrear, Kimberly A.; Semmes, O. John			Site-specific phosphorylation differentiates active from inactive forms of the human T-cell leukemia virus type 1 Tax oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I TAX; NF-KAPPA-B; TANDEM MASS-SPECTROMETRY; DNA-BINDING; ACTIVATION; PROTEINS; TRANSCRIPTION; DOMAIN; UBIQUITINATION; TRANSFORMATION	The human T-cell leukemia virus type 1 oncoprotein Tax is a phosphoprotein with a predominately nuclear subcellular localization that accomplishes multiple functions via protein-protein interactions. It has been proposed that regulation of this protein's pleiotropic functions may be accomplished through phosphorylation of specific amino acid residues. We have conducted a phosphoryl mapping of mammalian-expressed Tax protein using a combination of affinity purification, liquid chromatography tandem mass spectrometry, and site-directed substitution mutational analysis. We achieved physical coverage of 77% of the Tax sequence and identified four novel sites of phosphorylation at Thr-48, Thr-184, Thr-215, and Ser-336. Previously identified potential serine phosphorylation sites at Ser-10, Ser-77, and Ser-274 could not be confirmed by mass spectrometry. The functional significance of these novel phosphorylation events was evaluated by mutational analysis and subsequent evaluation for activity via both CREB and NF-kappa B-responsive promoters. Our results demonstrate that phosphorylation at Thr-215 is associated with loss of both Tax functions, phosphorylation at Thr-48 was specifically deficient for activation via NF-kappa B, and phosphorylation at Thr-184 and Ser-336 had no effect on these Tax functions. Semiquantitation of phosphopeptides revealed that the majority of Tax was phosphorylated at Thr-48, Thr-184, Thr-215, and Ser-336, whereas only a minor population of Tax was phosphorylated at either Ser-300 or Ser-301. These results suggest that both positive and negative phosphorylation signals result in the maintenance of a subfraction of Tax as "active" protein.	Eastern Virginia Med Sch, Ctr Biomed Proteom, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23507 USA	Eastern Virginia Medical School	Semmes, OJ (corresponding author), Eastern Virginia Med Sch, Ctr Biomed Proteom, Dept Microbiol & Mol Cell Biol, 700 W Olney Rd, Norfolk, VA 23507 USA.	semmesoj@evms.edu	Semmes, Oliver/GQA-5179-2022		NCI NIH HHS [R01 CA076595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Arnott David, 2003, J Biomol Tech, V14, P205; Basbous J, 2003, J VIROL, V77, P13028, DOI 10.1128/JVI.77.24.13028-13035.2003; Bex F, 1999, J VIROL, V73, P738, DOI 10.1128/JVI.73.1.738-745.1999; Boehm AK, 1999, J BIOMED SCI, V6, P206, DOI 10.1007/BF02255904; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; GESSAIN A, 1985, LANCET, V2, P407; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jaffe H, 1998, BIOCHEMISTRY-US, V37, P16211, DOI 10.1021/bi981264p; JEANG KT, 1988, MECHANISMS CONTROL G, P181; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; KIM JS, 1993, PROTEIN SCI, V2, P348; Kimzey AL, 1999, J BIOL CHEM, V274, P34226, DOI 10.1074/jbc.274.48.34226; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128/MCB.25.23.10391-10406.2005; Loyet KM, 2005, MOL CELL PROTEOMICS, V4, P235, DOI 10.1074/mcp.R400011-MCP200; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; Majone F, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-45; Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976; Matsuoka M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-27; McLachlin DT, 2001, CURR OPIN CHEM BIOL, V5, P591, DOI 10.1016/S1367-5931(00)00250-7; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; OSAME M, 1986, LANCET, V1, P1031; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RADONOVICH M, 1989, J VIROL, V63, P2987, DOI 10.1128/JVI.63.7.2987-2994.1989; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	49	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31705	31712		10.1074/jbc.M607011200	http://dx.doi.org/10.1074/jbc.M607011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16923801	Bronze			2022-12-25	WOS:000241235300056
J	Noguera-Mazon, V; Lemoine, J; Walker, O; Rouhier, N; Salvador, A; Jacquot, JP; Lancelin, JM; Krimm, I				Noguera-Mazon, Valerie; Lemoine, Jerome; Walker, Olivier; Rouhier, Nicolas; Salvador, Arnaud; Jacquot, Jean-Pierre; Lancelin, Jean-Marc; Krimm, Isabelle			Glutathionylation induces the dissociation of 1-Cys D-peroxiredoxin non-covalent homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 2-CYS PEROXIREDOXIN; THIOL PEROXIDASE; MYCOBACTERIUM-TUBERCULOSIS; HYDROPEROXIDE REDUCTASE; ANGSTROM RESOLUTION; II PEROXIREDOXIN; PROTEIN FUNCTION; SULFINIC ACID; GLUTAREDOXIN	1-Cys peroxiredoxins (1-Cys Prxs) are antioxidant enzymes that catalyze the reduction of hydroperoxides into alcohols using a strictly conserved cysteine. 1-Cys B-Prxs, homologous to human PrxVI, were recently shown to be reactivated by glutathione S-transferase (GST) pi via the formation of a GST-Prx heterodimer and Prx glutathionylation. In contrast, 1-Cys D-Prxs, homologous to human PrxV, are reactivated by the glutaredoxin-glutathione system through an unknown mechanism. To investigate the mechanistic events that mediate the 1-Cys D-Prx regeneration, interaction of the Prx with glutathione was studied by mass spectrometry and NMR. This work reveals that the Prx can be glutathionylated on its active site cysteine. Evidences are reported that the glutathionylation of 1-Cys D-Prx induces the dissociation of the Prx non-covalent homodimer, which can be recovered by reduction with dithiothreitol. This work demonstrates for the first time the existence of a redox-dependent dimer-monomer switch in the Prx family, similar to the decamer-dimer switch for the 2-Cys Prxs.	Univ Lyon 1, RMN Biomol, ESPCE Lyon, CNRS,Unite Mixte Rech 5180 Sci Analyt, F-69622 Villeurbanne, France; Univ Nancy 1, INRA, Unite Mixte Rech 1136, IFR110 Genom Ecophysiol & Ecol Fonct, F-54506 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; INRAE; Universite de Lorraine	Krimm, I (corresponding author), Univ Lyon 1, RMN Biomol, ESPCE Lyon, CNRS,Unite Mixte Rech 5180 Sci Analyt, Domaine Sci Doua, F-69622 Villeurbanne, France.	isabelle@hikari.cpe.fr	WALKER, Olivier/B-2580-2016; Lancelin, Jean-marc/AAC-5686-2019; Jacquot, Jean-Pierre/A-1571-2012; lemoine, jerome/C-4272-2014; Krimm, Isabelle/O-4972-2014; Salvador, Arnaud/R-7846-2017	WALKER, Olivier/0000-0001-7284-2555; Jacquot, Jean-Pierre/0000-0003-4975-8587; lemoine, jerome/0000-0002-5497-6880; Krimm, Isabelle/0000-0002-5981-109X; Rouhier, Nicolas/0000-0002-2036-7884; Salvador, Arnaud/0000-0002-5981-3028				Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Bouillac S, 2004, J BIOMOL NMR, V30, P105, DOI 10.1023/B:JNMR.0000042965.46172.1b; Brehelin C, 2003, PLANT PHYSIOL, V132, P2045, DOI 10.1104/pp.103.022533; Cha MK, 2004, J BIOL CHEM, V279, P11035, DOI 10.1074/jbc.M312657200; Chang TS, 2004, J BIOL CHEM, V279, P50994, DOI 10.1074/jbc.M409482200; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Choi J, 2005, PROTEINS, V61, P1146, DOI 10.1002/prot.20704; Choi JK, 2003, J BIOL CHEM, V278, P49478, DOI 10.1074/jbc.M309015200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Echalier A, 2005, BIOCHEMISTRY-US, V44, P1755, DOI 10.1021/bi048226s; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Fratelli M, 2003, PROTEOMICS, V3, P1154, DOI 10.1002/pmic.200300436; Ghezzi P, 2005, FREE RADICAL RES, V39, P573, DOI 10.1080/10715760500072172; Giustarini D, 2004, J CELL MOL MED, V8, P201, DOI 10.1111/j.1582-4934.2004.tb00275.x; Guimaraes BG, 2005, J BIOL CHEM, V280, P25735, DOI 10.1074/jbc.M503076200; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kim SJ, 2003, J BIOL CHEM, V278, P10790, DOI 10.1074/jbc.M209553200; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Krishnan VV, 1998, J BIOMOL NMR, V12, P177, DOI 10.1023/A:1008226330666; Li S, 2005, J MOL BIOL, V346, P1035, DOI 10.1016/j.jmb.2004.12.046; Manevich Y, 2004, P NATL ACAD SCI USA, V101, P3780, DOI 10.1073/pnas.0400181101; Michelet L, 2005, P NATL ACAD SCI USA, V102, P16478, DOI 10.1073/pnas.0507498102; Mizohata E, 2005, J MOL BIOL, V354, P317, DOI 10.1016/j.jmb.2005.09.006; Parsonage D, 2005, BIOCHEMISTRY-US, V44, P10583, DOI 10.1021/bi050448i; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Ralat LA, 2006, BIOCHEMISTRY-US, V45, P360, DOI 10.1021/bi0520737; Rouhier N, 2006, BIOCHEM BIOPH RES CO, V341, P1300, DOI 10.1016/j.bbrc.2006.01.099; Rouhier N, 2003, FEBS LETT, V554, P149, DOI 10.1016/S0014-5793(03)01156-6; Rouhier N, 2002, J BIOL CHEM, V277, P13609, DOI 10.1074/jbc.M111489200; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; Sarma GN, 2005, J MOL BIOL, V346, P1021, DOI 10.1016/j.jmb.2004.12.022; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Trivelli X, 2003, BIOCHEMISTRY-US, V42, P14139, DOI 10.1021/bi035551r; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Woo HA, 2005, J BIOL CHEM, V280, P3125, DOI 10.1074/jbc.C400496200; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	43	56	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31736	31742		10.1074/jbc.M602188200	http://dx.doi.org/10.1074/jbc.M602188200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16916801	Green Published, Bronze			2022-12-25	WOS:000241235300060
J	Zhao, W; Chen, TLL; Vertel, BM; Colley, KJ				Zhao, Weihan; Chen, Tung-Ling L.; Vertel, Barbara M.; Colley, Karen J.			The CMP-sialic acid transporter is localized in the medial-trans Golgi and possesses two specific endoplasmic reticulum export motifs in its carboxyl-terminal cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SUGAR TRANSPORTER; GDP-MANNOSE TRANSPORTER; UDP-GALACTOSE TRANSPORTER; POLYSIALIC ACID; LEUKOCYTE-ADHESION; CAENORHABDITIS-ELEGANS; SUBSTRATE RECOGNITION; FUNCTIONAL EXPRESSION; CONGENITAL DISORDERS; GLYCOSYLATION	The addition of sialic acid to glycoproteins and glycolipids requires Golgi sialyltransferases to have access to their glycoconjugate substrates and nucleotide sugar donor, CMP-sialic acid. CMP-sialic acid is transported into the lumen of the Golgi complex through the CMP-sialic acid transporter, an antiporter that also functions to transport CMP into the cytosol. We localized the transporter using immunofluorescence and deconvolution microscopy to test the prediction that it is broadly distributed across the Golgi stack to serve the many sialyltransferases involved in glycoconjugate sialylation. The transporter co-localized with ST6GalI in the medial and trans Golgi, showed partial overlap with a medial Golgi marker and little overlap with early Golgi or trans Golgi network markers. Endoplasmic reticulum-retained forms of sialyltransferases did not redistribute the transporter from the Golgi to the endoplasmic reticulum, suggesting that transporter-sialyltransferase complexes are not involved in transporter localization. Next we evaluated the role of the transporter's N- and C-terminal cytoplasmic tails in its trafficking and localization. The N- tail was not required for either endoplasmic reticulum export or Golgi localization. The C-tail was required for endoplasmic reticulum export and contained di-Ile and terminal Val motifs at its very C terminus that function as independent endoplasmic reticulum export signals. Deletion of the last four amino acids of the C-tail (IIGV) eliminated these export signals and prevented endoplasmic reticulum export of the transporter. This form of the transporter supplied limited amounts of CMP-sialic acid to Golgi sialyltransferases but was unable to completely rescue the transporter defect of Lec2 Chinese hamster ovary cells.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Rosalind Franklin Univ Med & Sci, Dept Cell Biol & Anat, N Chicago, IL 60064 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rosalind Franklin University Medical & Science	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, 900 S Ashland Ave,M-C 669, Chicago, IL 60607 USA.	karenc@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048134] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM48134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe M, 2004, J CELL SCI, V117, P5687, DOI 10.1242/jcs.01491; Aoki K, 2003, J BIOL CHEM, V278, P22887, DOI 10.1074/jbc.M302620200; Aoki K, 2001, J BIOL CHEM, V276, P21555, DOI 10.1074/jbc.M101462200; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Bellis SL, 2004, BBA-BIOMEMBRANES, V1663, P52, DOI 10.1016/j.bbamem.2004.03.012; BERNACKI RJ, 1975, EUR J BIOCHEM, V58, P477, DOI 10.1111/j.1432-1033.1975.tb02395.x; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; Chen TLL, 2003, GLYCOBIOLOGY, V13, P109, DOI 10.1093/glycob/cwg015; Chiaramonte M, 2001, BIOCHEMISTRY-US, V40, P14260, DOI 10.1021/bi011262w; COATES SW, 1980, J BIOL CHEM, V255, P9225; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Corse E, 2002, J VIROL, V76, P1273, DOI 10.1128/JVI.76.3.1273-1284.2002; Crocker PR, 2005, CURR OPIN PHARMACOL, V5, P431, DOI 10.1016/j.coph.2005.03.003; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; Dall'Olio F, 2001, GLYCOCONJUGATE J, V18, P841, DOI 10.1023/A:1022288022969; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Fenteany FH, 2005, J BIOL CHEM, V280, P5423, DOI 10.1074/jbc.M412396200; Freeze HH, 2005, CURR OPIN STRUC BIOL, V15, P490, DOI 10.1016/j.sbi.2005.08.010; Fukuda M, 1996, CANCER RES, V56, P2237; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Giraudo CG, 2003, J BIOL CHEM, V278, P40262, DOI 10.1074/jbc.M305455200; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; Glick BS, 1997, FEBS LETT, V414, P177, DOI 10.1016/S0014-5793(97)00984-8; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helmus Y, 2006, BLOOD, V107, P3959, DOI 10.1182/blood-2005-08-3334; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Hildebrandt H, 1998, CANCER RES, V58, P779; Hirschberg CB, 2001, J CLIN INVEST, V108, P3; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Kabuss R, 2005, GLYCOBIOLOGY, V15, P905, DOI 10.1093/glycob/cwi085; Kean EL, 2004, BBA-GEN SUBJECTS, V1673, P56, DOI 10.1016/j.bbagen.2004.04.006; Kiss JZ, 2001, BRAIN RES REV, V36, P175, DOI 10.1016/S0165-0173(01)00093-5; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE EU, 1989, J BIOL CHEM, V264, P13848; LOCKER JK, 1994, J BIOL CHEM, V269, P28263; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Ma JY, 1999, J BIOL CHEM, V274, P8046, DOI 10.1074/jbc.274.12.8046; Maccioni HJF, 1999, BBA-MOL CELL BIOL L, V1437, P101, DOI 10.1016/S1388-1981(99)00002-5; Maccioni HJF, 2002, NEUROCHEM RES, V27, P629, DOI 10.1023/A:1020271932760; Martinez-Duncker I, 2005, BLOOD, V105, P2671, DOI 10.1182/blood-2004-09-3509; MATSUOKA Y, 1994, J BIOL CHEM, V269, P22565; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nufer O, 2002, J CELL SCI, V115, P619; Opat AS, 2001, BIOCHIMIE, V83, P763, DOI 10.1016/S0300-9084(01)01312-8; Orci L, 2003, P NATL ACAD SCI USA, V100, P4586, DOI 10.1073/pnas.0730885100; Park EI, 2005, P NATL ACAD SCI USA, V102, P17125, DOI 10.1073/pnas.0508537102; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; RABOUILLE C, 1995, J CELL SCI, V108, P1617; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Schnaar RL, 2004, ARCH BIOCHEM BIOPHYS, V426, P163, DOI 10.1016/j.abb.2004.02.019; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; Sewell R, 2006, J BIOL CHEM, V281, P3586, DOI 10.1074/jbc.M511826200; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Sprong H, 2003, MOL BIOL CELL, V14, DOI 10.1091/mbc.E03-03-0130; Suda T, 2004, J BIOL CHEM, V279, P26469, DOI 10.1074/jbc.M311353200; Tiralongo J, 2006, GLYCOBIOLOGY, V16, P73, DOI 10.1093/glycob/cwj029; Toma L, 1996, J BIOL CHEM, V271, P3897; Trucco A, 2004, NAT CELL BIOL, V6, P1071, DOI 10.1038/ncb1180; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Weinhold B, 2005, J BIOL CHEM, V280, P42971, DOI 10.1074/jbc.M511097200	88	36	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31106	31118		10.1074/jbc.M605564200	http://dx.doi.org/10.1074/jbc.M605564200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16923816	hybrid			2022-12-25	WOS:000241075900086
J	Coppe, JP; Kauser, K; Campisi, J; Beausejour, CM				Coppe, Jean-Philippe; Kauser, Katalin; Campisi, Judith; Beausejour, Christian M.			Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATIVE LIFE-SPAN; CELLULAR SENESCENCE; HUMAN-CELLS; IN-VIVO; EXPRESSION; CANCER; P53; ANGIOGENESIS; SENSITIVITY; VPF/VEGF	Cellular senescence prevents the proliferation of cells at risk for neoplastic transformation. Nonetheless, the senescence response is thought to be antagonistically pleiotropic and thus contribute to aging phenotypes, including, ironically, late life cancers. The cancer- promoting activity of senescent cells is likely due to secreted molecules, the identity of which remains largely unknown. Here, we have shown that senescent fibroblasts, much more than presenescent fibroblasts, stimulate tumor vascularization in mice. Weakly malignant epithelial cells co- injected with senescent fibroblasts had larger and greater numbers of blood vessels compared with controls. Accordingly, increased vascular endothelial growth factor ( VEGF) expression was a frequent characteristic of senescent human and mouse fibroblasts in culture. Importantly, conditioned medium from senescent fibroblasts, more than medium from presenescent cells, stimulates cultured human umbilical vein endothelial cells to invade a basement membrane, a hallmark of angiogenesis. Increased VEGF expression was specific to the senescent phenotype and increased whether senescence was induced by replicative exhaustion, overexpression of p16(Ink4a), or overexpression of oncogenic RAS. The senescence-dependent increase in VEGF production was accompanied by very little increase in hypoxic- inducible ( transcription) factor 1 alpha protein levels, and hypoxia further inducedVEGFin senescent cells. This result suggests the rise in VEGF expression at senescence is not a hypoxic response. Our findings may in part explain why senescent cells stimulate tumorigenesis in vivo and support the idea that senescent cells may facilitate age- associated cancer development by secreting factors that promote malignant progression.	Univ Montreal, Ctr Hosp Univ Ste Justine, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3T 1C5, Canada; Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; Berlex Biosci, Richmond, CA 94804 USA; Buck Inst Age Res, Novato, CA 94945 USA	Universite de Montreal; Universite de Montreal; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Buck Institute for Research on Aging	Beausejour, CM (corresponding author), Univ Montreal, Ctr Hosp Univ Ste Justine, 3175 Chemin Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	christian.beausejour@recherche-ste-justine.qc.ca			NIA NIH HHS [AG09909] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG009909, R01AG009909, R56AG009909] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; Collins CJ, 2003, AGING CELL, V2, P145, DOI 10.1046/j.1474-9728.2003.00048.x; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hara E, 1996, DEV GENET, V18, P161; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Mukhopadhyay D, 2004, SEMIN CANCER BIOL, V14, P123, DOI 10.1016/j.semcancer.2003.09.019; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Neri D, 2005, NAT REV CANCER, V5, P436, DOI 10.1038/nrc1627; Ohuchida K, 2004, CANCER RES, V64, P3215, DOI 10.1158/0008-5472.CAN-03-2464; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sasaki M, 2005, J PATHOL, V205, P451, DOI 10.1002/path.1729; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Vasile E, 2001, FASEB J, V15, P458, DOI 10.1096/fj.00-0051com	38	374	382	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29568	29574		10.1074/jbc.M603307200	http://dx.doi.org/10.1074/jbc.M603307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16880208	hybrid			2022-12-25	WOS:000240896300018
J	Hamacher-Brady, A; Brady, NR; Gottlieb, RA				Hamacher-Brady, Anne; Brady, Nathan R.; Gottlieb, Roberta A.			Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; AUTOPHAGIC CELL-DEATH; 3-KINASE INHIBITORS; HL-1 CELLS; APOPTOSIS; MITOCHONDRIA; PROTEINS; YEAST; RAB7; DEGRADATION	Cardiac myocytes undergo programmed cell death as a result of ischemia/ reperfusion (I/ R). One feature of I/ R injury is the increased presence of autophagosomes. However, to date it is not known whether macroautophagy functions as a protective pathway, contributes to programmed cell death, or is an irrelevant event during cardiac I/ R injury. We employed simulated I/ R of cardiac HL-1 cells as an in vitro model of I/ R injury to the heart. To assess macroautophagy, we quantified autophagosome generation and degradation ( autophagic flux), as determined by steady- state levels of autophagosomes in relation to lysosomal inhibitor- mediated accumulation of autophagosomes. We found that I/ R impaired both formation and downstream lysosomal degradation of autophagosomes. Overexpression of Beclin1 enhanced autophagic flux following I/ R and significantly reduced activation of pro- apoptotic Bax, whereas RNA interference knockdown of Beclin1 increased Bax activation. Bcl-2 and Bcl-x(L) were protective against I/ R injury, and expression of a Beclin1 Bcl-2/-x(L) binding domain mutant resulted in decreased autophagic flux and did not protect against I/ R injury. Overexpression of Atg5, a component of the autophagosomal machinery downstream of Beclin1, did not affect cellular injury, whereas expression of a dominant negative mutant of Atg5 increased cellular injury. These results demonstrate that autophagic flux is impaired at the level of both induction and degradation and that enhancing autophagy constitutes a powerful and previously uncharacterized protective mechanism against I/ R injury to the heart cell.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Gottlieb, RA (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,MEM-220, La Jolla, CA 92037 USA.	robbieg@scripps.edu	Hamacher-Brady, Anne/G-4268-2013; Brady, Nathan/H-2452-2013	Hamacher-Brady, Anne/0000-0001-5042-1338; Brady, Nathan/0000-0002-1901-5996	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060590] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL60590] Funding Source: Medline; PHS HHS [R01-AJ21568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amarzguioui M, 2005, FEBS LETT, V579, P5974, DOI 10.1016/j.febslet.2005.08.070; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Brady NR, 2006, BBA-BIOENERGETICS, V1757, P667, DOI 10.1016/j.bbabio.2006.04.011; Brocheriou V, 2000, J GENE MED, V2, P326, DOI 10.1002/1521-2254(200009/10)2:5<326::AID-JGM133>3.0.CO;2-1; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57; DECKER RS, 1980, AM J PATHOL, V98, P425; Depre C, 2004, CIRC RES, V95, P433, DOI 10.1161/01.RES.0000138301.42713.18; Finn PF, 2005, J BIOL CHEM, V280, P25864, DOI 10.1074/jbc.M502456200; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; GORDON PB, 1993, J BIOL CHEM, V268, P26107; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; HAMACHERBRADY A, 2006, IN PRESS CELL DEATH; Huang JH, 2005, CIRCULATION, V112, P76, DOI 10.1161/CIRCULATIONAHA.105.535740; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Imahashi K, 2004, CIRC RES, V95, P734, DOI 10.1161/01.RES.0000143898.67182.4c; Ishii T, 2005, BIOCHEMISTRY-US, V44, P13893, DOI 10.1021/bi051336u; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Karwatowska-Prokopczuk E, 1998, CIRC RES, V82, P1139, DOI 10.1161/01.RES.82.11.1139; Kiffin R, 2004, MOL BIOL CELL, V15, P4829, DOI 10.1091/mbc.E04-06-0477; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lamparska-Przybysz M, 2005, J Physiol Pharmacol, V56 Suppl 3, P159; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu CL, 2005, NEUROSCIENCE, V134, P1273, DOI 10.1016/j.neuroscience.2005.05.015; Liu JB, 2006, FASEB J, V20, P362, DOI 10.1096/fj.05-4869fje; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Obara K, 2006, MOL BIOL CELL, V17, P1527, DOI 10.1091/mbc.E05-09-0841; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Powell SR, 2005, ANTIOXID REDOX SIGN, V7, P538, DOI 10.1089/ars.2005.7.538; Priault M, 2005, CELL DEATH DIFFER, V12, P1613, DOI 10.1038/sj.cdd.4401697; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Row PE, 2001, BIOCHEM J, V353, P655, DOI 10.1042/0264-6021:3530655; Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759; Saftig P, 2001, TRENDS MOL MED, V7, P37, DOI 10.1016/S1471-4914(00)01868-2; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shibata M, 2006, J BIOL CHEM, V281, P14474, DOI 10.1074/jbc.M600364200; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Stein MP, 2003, TRAFFIC, V4, P754, DOI 10.1034/j.1600-0854.2003.00133.x; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; White SM, 2004, AM J PHYSIOL-HEART C, V286, pH823, DOI 10.1152/ajpheart.00986.2003; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yan L, 2005, P NATL ACAD SCI USA, V102, P13807, DOI 10.1073/pnas.0506843102; Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246	75	460	483	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29776	29787		10.1074/jbc.M603783200	http://dx.doi.org/10.1074/jbc.M603783200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16882669	hybrid			2022-12-25	WOS:000240896300040
J	Zhang, F; Hamanaka, RB; Bobrovnikova-Marjon, E; Gordan, JD; Dai, MS; Lu, H; Simon, MC; Diehl, JA				Zhang, Fang; Hamanaka, Robert B.; Bobrovnikova-Marjon, Ekaterina; Gordan, John D.; Dai, Mu-Shui; Lu, Hua; Simon, M. Celeste; Diehl, J. Alan			Ribosomal stress couples the unfolded protein response to p53-dependent cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSLATIONAL CONTROL; ER STRESS; P53; PERK; INHIBITION; KINASE; HDM2; MDM2; RNA	Protein misfolding in the endoplasmic reticulum (ER) triggers a signaling pathway termed the unfolded protein response pathway (UPR). UPR signaling is transduced through the transmembrane ER effectors PKR-like ER kinase (PERK), inositol requiring kinase-1 (IRE-1), and activating transcription factor 6 (ATF6). PERK activation triggers phosphorylation of eIF2 alpha leading to repression of protein synthesis, thereby relieving ER protein load and directly inhibiting cyclin D1 translation thereby contributing to cell cycle arrest. However, PERK-/- murine embryonic fibroblasts have an attenuated G(1)/S arrest that is not attributable to cyclin D1 loss, suggesting a cyclin D1-independent mechanism. Here we show that the UPR triggers p53 accumulation and activation. UPR induction promotes enhanced interaction between the ribosome proteins (rpL5, rpL11, and rpL23) and Hdm2 in a PERK-dependent manner. Interaction with ribosomal proteins results in inhibition of Hdm2-mediated ubiquitination and degradation of p53. Our data demonstrate that ribosomal subunit: Hdm2 association couples the unfolded protein response to p53-dependent cell cycle arrest.	Leonard & Madlyn Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Biochem & Mol Biol, Portland, OR 97201 USA	University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania; Oregon Health & Science University	Diehl, JA (corresponding author), Leonard & Madlyn Abramson Family Canc Res Inst, Dept Canc Biol, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021		NCI NIH HHS [P01 CA104838, CA093614, CA095441] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA104838, R01CA093614, R01CA095441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pluquet O, 2005, MOL CELL BIOL, V25, P9392, DOI 10.1128/MCB.25.21.9392-9405.2005; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Rosorius O, 2000, J BIOL CHEM, V275, P12061, DOI 10.1074/jbc.275.16.12061; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; WALDMAN T, 1995, CANCER RES, V55, P5187; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	41	90	90	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30036	30045		10.1074/jbc.M604674200	http://dx.doi.org/10.1074/jbc.M604674200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16893887	hybrid			2022-12-25	WOS:000240896300064
J	Wang, JG; Barsky, LW; Davicioni, E; Weinberg, KI; Triche, TJ; Zhang, XK; Wu, LT				Wang, Jian-guang; Barsky, Lora W.; Davicioni, Elai; Weinberg, Kenneth I.; Triche, Timothy J.; Zhang, Xiao-kun; Wu, Lingtao			Retinoic acid induces leukemia cell G(1) arrest and transition into differentiation by inhibiting cyclin-dependent kinase-activating kinase binding and phosphorylation of PML/RAR alpha	FASEB JOURNAL			English	Article						MAT1 degradation; cell cycle; proliferation/differentiation transition	TRANSCRIPTION FACTOR TFIIH; UBIQUITIN PROTEIN LIGASE; RAR-ALPHA; NUCLEAR RECEPTORS; T(15-17) TRANSLOCATION; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; ASSEMBLY FACTOR; CAK ACTIVITY; S-PHASE	Acute promyelocytic leukemia (APL) cells express promyelocytic leukemia/retinoic acid receptor alpha (PML/RAR alpha) fusion protein, which leads to the blocking of APL cell differentiation. Treatment of APL with all-trans-retinoic acid ( ATRA) induces disease remission by in vivo differentiation of APL cells. Differentiation requires cell cycle exit; yet how ATRA couples cell cycle exit to differentiation of APL remains largely unknown. We previously found that ATRA-induced cell differentiation accompanies ubiquitination-proteolysis of menage a trois 1 ( MAT1), an assembly factor and targeting subunit of cyclin-dependent kinase (CDK)-activating kinase (CAK) that regulates G(1) exit. We report here that CAK binds to and phosphorylates PML/RAR alpha in actively proliferating APL cells. In response to ATRA, PML/RAR alpha is dissociated from CAK, leading to MAT1 degradation, G(1) arrest, and decreased CAK phosphorylation of PML/RAR alpha. CAK phosphorylation of PML/RAR alpha is inhibited when MAT1 levels are reduced. Both MAT1 degradation and PML/RAR alpha hypophosphorylation occur in ATRA-induced G(1)-arresting cells undergoing differentiation but not in the synchronized G(1) cells that do not differentiate. These findings reveal a novel ATRA signaling on APL cell differentiation, in which ATRA coordinates G(1) arrest and transition into differentiation by inducing MAT1 degradation and PML/RAR alpha hypophosphorylation through disrupting PML/RAR alpha binding and phosphorylation by CAK.	Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Dept Pathol,Saban Res Inst, Los Angeles, CA 90027 USA; Burnham Inst, Ctr Canc, La Jolla, CA 92037 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA USA; Childrens Hosp Los Angeles, Saban Res Inst, Div Res Immunol BMT, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Sanford Burnham Prebys Medical Discovery Institute; University of Southern California; Children's Hospital Los Angeles	Wu, LT (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Dept Pathol,Saban Res Inst, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@usc.edu		Davicioni, Elai/0000-0001-9136-099X				Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Crowe David L, 2002, Cancer Cell Int, V2, P15, DOI 10.1186/1475-2867-2-15; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Egea PF, 2001, J MOL BIOL, V307, P557, DOI 10.1006/jmbi.2000.4409; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Glass CK, 2000, GENE DEV, V14, P121; He QJ, 2004, FASEB J, V18, P1734, DOI 10.1096/fj.04-2182fje; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slack JL, 2000, ANN HEMATOL, V79, P227, DOI 10.1007/s002770050585; Slack JL, 1999, CANC TREAT, V99, P75; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang JW, 2002, J BIOL CHEM, V277, P43369, DOI 10.1074/jbc.M206792200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; Wu LT, 1999, J BIOL CHEM, V274, P5564, DOI 10.1074/jbc.274.9.5564; WU LT, 1994, ONCOGENE, V9, P2089; WU LT, 1993, INT J ONCOL, V3, P859; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yee A, 1996, J BIOL CHEM, V271, P471, DOI 10.1074/jbc.271.1.471; YEE A, 1995, CANCER RES, V55, P6058; Zhang SN, 2004, CANCER RES, V64, P2977, DOI 10.1158/0008-5472.CAN-03-4018; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	69	30	36	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2142	+		10.1096/fj.06-5900fje	http://dx.doi.org/10.1096/fj.06-5900fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935935				2022-12-25	WOS:000241156900039
J	Shi, L; Adkins, JN; Coleman, JR; Schepmoes, AA; Dohnkova, A; Mottaz, HM; Norbeck, AD; Purvine, SO; Manes, NP; Smallwood, HS; Wang, HX; Forbes, J; Gros, P; Uzzau, S; Rodland, KD; Heffron, F; Smith, RD; Squier, TC				Shi, Liang; Adkins, Joshua N.; Coleman, James R.; Schepmoes, Athena A.; Dohnkova, Alice; Mottaz, Heather M.; Norbeck, Angela D.; Purvine, Samuel O.; Manes, Nathan P.; Smallwood, Heather S.; Wang, Haixing; Forbes, John; Gros, Philippe; Uzzau, Sergio; Rodland, Karin D.; Heffron, Fred; Smith, Richard D.; Squier, Thomas C.			Proteomic analysis of Salmonella enterica serovar Typhimurium isolated from RAW 264.7 macrophages - Identification of a novel protein that contributes to the replication of serovar Typhimurium inside macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ANTIMICROBIAL PEPTIDES; CHROMOSOMAL GENES; ESCHERICHIA-COLI; ACCURATE MASS; EXPRESSION; VIRULENCE; PEPTIDOGLYCAN; RESISTANCE; TRANSPORT	To evade host resistance mechanisms, Salmonella enterica serovar Typhimurium (STM), a facultative intracellular pathogen, must alter its proteome following macrophage infection. To identify new colonization and virulence factors that mediate STM pathogenesis, we have isolated STM cells from RAW 264.7 macrophages at various time points following infection and used a liquid chromatography-mass spectrometry-based proteomic approach to detect the changes in STM protein abundance. Because host resistance to STM infection is strongly modulated by the expression of a functional host-resistant regulator, i.e. natural resistance-associated macrophage protein 1 (Nramp1, also called Slc11a1), we have also examined the effects of Nramp1 activity on the changes of STM protein abundances. A total of 315 STM proteins have been identified from isolated STM cells, which are largely housekeeping proteins whose abundances remain relatively constant during the time course of infection. However, 39 STM proteins are strongly induced after infection, suggesting their involvement in modulating colonization and infection. Of the 39 induced proteins, 6 proteins are specifically modulated by Nramp1 activity, including STM3117, as well as STM3118-3119 whose time-dependent abundance changes were confirmed using Western blot analysis. Deletion of the gene encoding STM3117 resulted in a dramatic reduction in the ability of STM to colonize wild-type RAW 264.7 macrophages, demonstrating a critical involvement of STM3117 in promoting the replication of STM inside macrophages. The predicted function common for STM3117-3119 is biosynthesis and modification of the peptidoglycan layer of the STM cell wall.	Pacific NW Natl Lab, Microbiol Grp, Richland, WA 99354 USA; Univ Sassari, I-07100 Sassari, Italy; McGill Univ, Montreal, PQ H3G 1Y6, Canada; Univ Sassari, I-07100 Sassari, Italy; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of Sassari; McGill University; University of Sassari; Oregon Health & Science University	Shi, L (corresponding author), Pacific NW Natl Lab, Microbiol Grp, 902 Battelle Blvd,POB 999, Richland, WA 99354 USA.	liang.shi@pnl.gov	Purvine, Samuel O/O-3358-2017; Adkins, Joshua/B-9881-2013; Uzzau, Sergio/F-3233-2015; Rodland, Karin/R-6186-2019; Manes, Nathan P/E-2817-2012; Smith, Richard D/J-3664-2012	Purvine, Samuel O/0000-0002-2257-2400; Adkins, Joshua/0000-0003-0399-0700; Uzzau, Sergio/0000-0001-6246-2794; Manes, Nathan P/0000-0001-6701-3314; Smith, Richard D/0000-0002-2381-2349; Smallwood, Heather/0000-0001-5711-5771	NIAID NIH HHS [Y1-AI-4894-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkins JN, 2006, MOL CELL PROTEOMICS, V5, P1450, DOI 10.1074/mcp.M600139-MCP200; ANAKIRAMAN A, 2000, MOL MICROBIOL, V35, P1146; Bader MW, 2005, CELL, V122, P461, DOI 10.1016/j.cell.2005.05.030; Becker D, 2006, NATURE, V440, P303, DOI 10.1038/nature04616; Blanc-Potard AB, 1999, J BACTERIOL, V181, P998, DOI 10.1128/JB.181.3.998-1004.1999; Boneca IG, 2005, CURR OPIN MICROBIOL, V8, P46, DOI 10.1016/j.mib.2004.12.008; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; Chakravortty D, 2005, EMBO J, V24, P2043, DOI 10.1038/sj.emboj.7600676; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; Coldham NG, 2004, J PROTEOME RES, V3, P595, DOI 10.1021/pr034129u; Cuellar-Mata P, 2002, J BIOL CHEM, V277, P2258, DOI 10.1074/jbc.M105508200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Elias DA, 2005, PROTEOMICS, V5, P3120, DOI 10.1002/pmic.200401140; Encheva V, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-42; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; FOSTER JW, 1995, ANNU REV MICROBIOL, V49, P145, DOI 10.1146/annurev.micro.49.1.145; Garmendia J, 2003, MICROBIOL-SGM, V149, P2385, DOI 10.1099/mic.0.26397-0; Govoni G, 1999, INFECT IMMUN, V67, P2225, DOI 10.1128/IAI.67.5.2225-2232.1999; Guignot J, 2004, J CELL SCI, V117, P1033, DOI 10.1242/jcs.00949; Hashim S, 2000, J BIOL CHEM, V275, P16281, DOI 10.1074/jbc.275.21.16281; Hensel M, 2000, MOL MICROBIOL, V36, P1015, DOI 10.1046/j.1365-2958.2000.01935.x; Holden DW, 2002, TRAFFIC, V3, P161, DOI 10.1034/j.1600-0854.2002.030301.x; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; Kehres DG, 2002, J BACTERIOL, V184, P3159, DOI 10.1128/JB.184.12.3159-3166.2002; Kim I, 2004, J BACTERIOL, V186, P7229, DOI 10.1128/JB.186.21.7229-7235.2004; Knodler LA, 2003, TRAFFIC, V4, P587, DOI 10.1034/j.1600-0854.2003.00118.x; Lam-Yuk-Tseung S, 2003, CELL MICROBIOL, V5, P299, DOI 10.1046/j.1462-5822.2003.00276.x; Mangan MW, 2006, MOL MICROBIOL, V59, P1831, DOI 10.1111/j.1365-2958.2006.05062.x; Marshall DG, 1999, MOL MICROBIOL, V34, P134, DOI 10.1046/j.1365-2958.1999.01587.x; MARTINUSSEN J, 1995, J BACTERIOL, V177, P271, DOI 10.1128/jb.177.1.271-274.1995; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Mouslim C, 2002, MOL MICROBIOL, V45, P1019, DOI 10.1046/j.1365-2958.2002.03070.x; Navarre WW, 2005, MOL MICROBIOL, V56, P492, DOI 10.1111/j.1365-2958.2005.04553.x; Pasa-Tolic L, 2004, BIOTECHNIQUES, V37, P621, DOI 10.2144/04374RV01; Peters-Wendisch P, 2005, APPL ENVIRON MICROB, V71, P7139, DOI 10.1128/AEM.71.11.7139-7144.2005; Pucciarelli MG, 2003, MOL MICROBIOL, V48, P573, DOI 10.1046/j.1365-2958.2003.03469.x; Qi SY, 1996, J BACTERIOL, V178, P5032, DOI 10.1128/jb.178.16.5032-5038.1996; Quintela JC, 1997, MOL MICROBIOL, V23, P693, DOI 10.1046/j.1365-2958.1997.2561621.x; RichterDahlfors A, 1997, J EXP MED, V186, P569, DOI 10.1084/jem.186.4.569; Rosenberger CM, 2004, P NATL ACAD SCI USA, V101, P2422, DOI 10.1073/pnas.0304455101; Rosenberger CM, 2002, J BIOL CHEM, V277, P18753, DOI 10.1074/jbc.M110649200; Salcedo SP, 2001, CELL MICROBIOL, V3, P587, DOI 10.1046/j.1462-5822.2001.00137.x; Smith RD, 2002, PROTEOMICS, V2, P513, DOI 10.1002/1615-9861(200205)2:5<513::AID-PROT513>3.0.CO;2-W; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; Strittmatter EF, 2004, J PROTEOME RES, V3, P760, DOI 10.1021/pr049965y; Takaya A, 2004, INFECT IMMUN, V72, P1364, DOI 10.1128/IAI.72.3.1364-1373.2004; Uzzau S, 2002, MOL MICROBIOL, V46, P147, DOI 10.1046/j.1365-2958.2002.03145.x; Uzzau S, 2001, P NATL ACAD SCI USA, V98, P15264, DOI 10.1073/pnas.261348198; van Heijenoort J, 1998, CELL MOL LIFE SCI, V54, P300, DOI 10.1007/s000180050155; Vazquez-Torres A, 2001, MICROBES INFECT, V3, P1313, DOI 10.1016/S1286-4579(01)01492-7; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wijburg OLC, 2000, EUR J IMMUNOL, V30, P944, DOI 10.1002/1521-4141(200003)30:3<944::AID-IMMU944>3.3.CO;2-T; Yoon H, 2003, FEMS MICROBIOL LETT, V226, P391, DOI 10.1016/S0378-1097(03)00641-4; Zaharik ML, 2002, P NATL ACAD SCI USA, V99, P15705, DOI 10.1073/pnas.252415599	57	121	122	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29131	29140		10.1074/jbc.M604640200	http://dx.doi.org/10.1074/jbc.M604640200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16893888	hybrid			2022-12-25	WOS:000240680500067
J	Waheed, AA; Ablan, SD; Mankowski, MK; Cummins, JE; Ptak, RG; Schaffner, CP; Freed, EO				Waheed, Abdul A.; Ablan, Sherimay D.; Mankowski, Marie K.; Cummins, James E.; Ptak, Roger G.; Schaffner, Carl P.; Freed, Eric O.			Inhibition of HIV-1 replication by amphotericin B methyl ester - Selection for resistant variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRION-ASSOCIATED CHOLESTEROL; GP41 CYTOPLASMIC TAIL; CELL-SURFACE EXPRESSION; TYROSINE-BASED SIGNAL; ENVELOPE GLYCOPROTEIN; LIPID RAFTS; ANTIRETROVIRAL THERAPY; MEMBRANE CHOLESTEROL; CLATHRIN ADAPTER	Membrane cholesterol plays an important role in human immunodeficiency virus type 1 (HIV-1) particle production and infectivity. Here, we have investigated the target and mechanism of action of a cholesterol-binding compound, the polyene antifungal antibiotic amphotericin B methyl ester (AME). We found that AME potently inhibited the replication of a highly divergent panel of HIV-1 isolates in various T-cell lines and primary cells irrespective of clade or target cell tropism. The defects in HIV-1 replication caused by AME were due to profoundly impaired viral infectivity as well as a defect in viral particle production. To elucidate further the mechanism of action of AME, we selected for and characterized AME-resistant HIV-1 variants. Mutations responsible for AME resistance mapped to a highly conserved and functionally important endocytosis motif in the cytoplasmic tail of the transmembrane glycoprotein gp41. Interestingly, truncation of the gp41 cytoplasmic tail in the context of either HIV-1 or rhesus macaque simian immunodeficiency virus also conferred resistance to AME. The infectivity of HIV-1 virions bearing murine leukemia virus or vesicular stomatitis virus glycoproteins was unaffected by AME. Our data define the target and mechanism of action of AME and provide support for the concept that cholesterol-binding compounds should be pursued as antiretroviral drugs to disrupt HIV-1 replication.	NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA; So Res Inst, Infect Dis Res Dept, Frederick, MD 21701 USA; Rutgers State Univ, Waksman Inst, Dept Microbiol & Biochem, New Brunswick, NJ 08903 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rutgers State University New Brunswick	Freed, EO (corresponding author), NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, NIH, Bldg 535,Rm 108, Frederick, MD 21702 USA.	efreed@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berlioz-Torrent C, 1999, J VIROL, V73, P1350, DOI 10.1128/JVI.73.2.1350-1361.1999; Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773; Bowers K, 2000, TRAFFIC, V1, P661, DOI 10.1034/j.1600-0854.2000.010810.x; Brajtburg J, 1996, CLIN MICROBIOL REV, V9, P512, DOI 10.1128/CMR.9.4.512; Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103; Campbell S, 2004, J VIROL, V78, P10556, DOI 10.1128/JVI.78.19.10556-10565.2004; Campbell SM, 2002, AIDS, V16, P2253, DOI 10.1097/00002030-200211220-00004; Campbell SM, 2001, J CLIN VIROL, V22, P217, DOI 10.1016/S1386-6532(01)00193-7; Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Deschambeault J, 1999, J VIROL, V73, P5010, DOI 10.1128/JVI.73.6.5010-5017.1999; Ding LM, 2003, J VIROL, V77, P1916, DOI 10.1128/JVI.77.3.1916-1926.2003; Doms RW, 2000, VIROLOGY, V276, P229, DOI 10.1006/viro.2000.0612; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; Edwards TG, 2002, J VIROL, V76, P2683, DOI 10.1128/JVI.76.6.2683-2691.2002; FREED EO, 1995, J VIROL, V69, P1984, DOI 10.1128/JVI.69.3.1984-1989.1995; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; Freed EO, 1996, J VIROL, V70, P341, DOI 10.1128/JVI.70.1.341-351.1996; FREED EO, 1994, J VIROL, V68, P2503, DOI 10.1128/JVI.68.4.2503-2512.1994; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; Fultz PN, 2001, J VIROL, V75, P278, DOI 10.1128/JVI.75.1.278-291.2001; Graham DRM, 2003, J VIROL, V77, P8237, DOI 10.1128/JVI.77.15.8237-8248.2003; Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002; Halwani R, 2003, J VIROL, V77, P3973, DOI 10.1128/JVI.77.7.3973-3984.2003; HANSEN JES, 1990, ANTIVIR RES, V14, P149, DOI 10.1016/0166-3542(90)90031-2; HANSEN JES, 1992, SCAND J INFECT DIS, V24, P35, DOI 10.3109/00365549209048398; Hartsell TL, 1996, J PHARMACOL EXP THER, V277, P1158; Holm K, 2003, J VIROL, V77, P4805, DOI 10.1128/JVI.77.8.4805-4817.2003; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Hug P, 2000, J VIROL, V74, P6377, DOI 10.1128/JVI.74.14.6377-6385.2000; JOLY V, 1992, J INFECT DIS, V165, P337, DOI 10.1093/infdis/165.2.337; Kalia V, 2005, J VIROL, V79, P2097, DOI 10.1128/JVI.79.4.2097-2107.2005; Khanna KV, 2002, J CLIN INVEST, V109, P205; Kiernan RE, 1998, J VIROL, V72, P4116, DOI 10.1128/JVI.72.5.4116-4126.1998; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; LABRANCHE CC, 1995, J VIROL, V69, P5217, DOI 10.1128/JVI.69.9.5217-5227.1995; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690; Liao ZH, 2003, AIDS RES HUM RETROV, V19, P675, DOI 10.1089/088922203322280900; Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001; Lodge R, 1997, EMBO J, V16, P695, DOI 10.1093/emboj/16.4.695; MAEBA R, 1994, BBA-LIPID LIPID MET, V1215, P79, DOI 10.1016/0005-2760(94)90094-9; Moncunill G, 2005, AIDS, V19, P1697, DOI 10.1097/01.aids.0000183517.60384.db; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; Murakami T, 2004, J VIROL, V78, P1026, DOI 10.1128/JVI.78.2.1026-1031.2004; Murakami T, 2000, P NATL ACAD SCI USA, V97, P343, DOI 10.1073/pnas.97.1.343; Negredo E, 2006, AIDS, V20, P619, DOI 10.1097/01.aids.0000210617.90954.0e; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Ono A, 2005, ADV VIRUS RES, V64, P311, DOI 10.1016/S0065-3527(05)64010-9; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Palmer S, 1999, AIDS, V13, P661, DOI 10.1097/00002030-199904160-00006; Pickl WF, 2001, J VIROL, V75, P7175, DOI 10.1128/JVI.75.15.7175-7183.2001; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; PLESCIA OJ, 1989, PROTECTION LYMPHOCYT, P485; Pleskoff O, 1996, J VIROL, V70, P8247, DOI 10.1128/JVI.70.11.8247-8251.1996; PLESKOFF O, 1995, J VIROL, V69, P570, DOI 10.1128/JVI.69.1.570-574.1995; Pontani D, 1990, ANTIVIR CHEM CHEMOTH, V1, P67, DOI 10.1177/095632029000100111; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; Rousso I, 2000, P NATL ACAD SCI USA, V97, P13523, DOI 10.1073/pnas.240459697; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; SCHAFFNER CP, 1986, BIOCHEM PHARMACOL, V35, P4110, DOI 10.1016/0006-2952(86)90037-7; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sklar PA, 2005, AIDS, V19, P1109, DOI 10.1097/01.aids.0000174461.31794.50; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; Vzorov AN, 2005, VIROLOGY, V332, P89, DOI 10.1016/j.virol.2004.10.044; Wyma DJ, 2004, J VIROL, V78, P3429, DOI 10.1128/JVI.78.7.3429-3435.2004; Wyss S, 2005, J VIROL, V79, P12231, DOI 10.1128/JVI.79.19.12231-12241.2005; Ye L, 2004, J VIROL, V78, P13409, DOI 10.1128/JVI.78.24.13409-13419.2004; YEE JK, 1994, METHOD CELL BIOL, V43, P99	73	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28699	28711		10.1074/jbc.M603609200	http://dx.doi.org/10.1074/jbc.M603609200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16882663	hybrid			2022-12-25	WOS:000240680500023
J	Sironi, M; Pozzoli, U; Comi, GP; Riva, S; Bordoni, A; Bresolin, N; Nag, DK				Sironi, Manuela; Pozzoli, Uberto; Comi, Giacomo P.; Riva, Stefania; Bordoni, Andreina; Bresolin, Nereo; Nag, Dilip K.			A region in the dystrophin gene major hot spot harbors a cluster of deletion breakpoints and generates double-strand breaks in yeast	FASEB JOURNAL			English	Article						DMD/BMD; yeast meiosis	MEIOTIC RECOMBINATION; SACCHAROMYCES-CEREVISIAE; MUSCULAR-DYSTROPHY; CHROMOSOMAL TRANSLOCATIONS; HISTOCOMPATIBILITY COMPLEX; DMD GENE; DNA; SEQUENCE; MEIOSIS; IDENTIFICATION	Deletions within the dystrophin gene (DMD) account for > 70% of mutations leading to Duchenne and Becker muscular dystrophies (DMD and BMD). Deletion breakpoints were reported to be scattered within regions that also represent meiotic recombination hot spots. Recent studies indicates that deletion junctions arise from nonhomologous end joining (NHEJ), a major pathway for repairing DNA double-strand breaks (DSBs) in mammals. Here we show that a region in intron 47 (i. e., a major deletion hot spot in the DMD gene) generates DSBs during meiosis in yeast and harbors a cluster of previously sequenced deletion breaks. Mapping of breakpoints in 26 BMD/ DMD patients indicated that the frequency of breakpoint occurrence around this region is 3-fold higher than expected by chance. These findings suggest that DSBs mediate deletion formation in intron 47 and possibly account for the high frequency of meiotic recombination in the region. Statistical analysis indicated the presence of at least one other breakpoint cluster in intron 47. Taken together, these results suggest that the primary events in deletion formation occur within discrete regions and that the scattered breakpoint distribution reflects both a variable degree of DSB end processing and the availability of a small (compared to the huge regions involved) deletion junction sample.	IRCCS E Medea, Inst Sci, I-23842 Bosisio Parini, LC, Italy; Wadsworth Ctr, Ctr Med Sci, Mol Genet Program, Albany, NY USA; Univ Milan, Dino Ferrari Ctr, Dept Neurol Sci,Mangiagalli & Regina Elena Fdn, IRCCS,Osped Maggiore Policlin, Milan, Italy; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12222 USA	IRCCS Eugenio Medea; Wadsworth Center; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Sironi, M (corresponding author), IRCCS E Medea, Inst Sci, Via Don L Monza 20, I-23842 Bosisio Parini, LC, Italy.	msironi@bp.lnf.it	Pozzoli, Uberto/K-6587-2016; Sironi, manuela/K-5633-2016; Comi, Giacomo P/K-5702-2016; Pozzoli, Uberto/AAH-5492-2019	Pozzoli, Uberto/0000-0003-0670-7106; Sironi, manuela/0000-0002-2267-5266; Comi, Giacomo P/0000-0002-1383-5248; Pozzoli, Uberto/0000-0003-0670-7106; Bresolin, Nereo/0000-0001-6694-3595	NIGMS NIH HHS [GM56266] Funding Source: Medline; Telethon [GTF02008] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056266] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Bacolla A, 2004, P NATL ACAD SCI USA, V101, P14162, DOI 10.1073/pnas.0405974101; BEGGS AH, 1990, HUM GENET, V86, P45; Blumental-Perry A, 2000, EMBO REP, V1, P232, DOI 10.1093/embo-reports/kvd047; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; Cullen M, 2002, AM J HUM GENET, V71, P759, DOI 10.1086/342973; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; Fan QQ, 1996, MOL CELL BIOL, V16, P2037; Gusev VD, 1999, BIOINFORMATICS, V15, P994; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Kelmenson PM, 2005, GENETICS, V169, P833, DOI 10.1534/genetics.104.035063; Klein S, 1996, NAT GENET, V13, P481, DOI 10.1038/ng0896-481; KOENIG M, 1989, AM J HUM GENET, V45, P498; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lemoine FJ, 2005, CELL, V120, P587, DOI 10.1016/j.cell.2004.12.039; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lobachev KS, 1998, GENETICS, V148, P1507; LOVE DR, 1991, GENOMICS, V10, P57, DOI 10.1016/0888-7543(91)90484-V; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; McNaughton JC, 1998, GENE, V222, P41, DOI 10.1016/S0378-1119(98)00466-1; Nag DK, 1997, GENETICS, V146, P835; NAG DK, 1989, NATURE, V340, P318, DOI 10.1038/340318a0; NISHIO H, 1994, J CLIN INVEST, V94, P1037, DOI 10.1172/JCI117417; Nobile C, 2002, HUM GENET, V110, P418, DOI 10.1007/s00439-002-0721-7; OHTA K, 1994, EMBO J, V13, P5754, DOI 10.1002/j.1460-2075.1994.tb06913.x; OUDET C, 1992, HUM MOL GENET, V1, P599, DOI 10.1093/hmg/1.8.599; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pecina A, 2002, CELL, V111, P173, DOI 10.1016/S0092-8674(02)01002-4; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; ROONEY SM, 1995, P NATL ACAD SCI USA, V92, P2141, DOI 10.1073/pnas.92.6.2141; Rose MD., 1990, METHODS YEAST GENETI; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Schneider KU, 2005, AM J HUM GENET, V77, P89, DOI 10.1086/431655; SIKORSKI RS, 1989, GENETICS, V122, P19; Sironi M, 2003, HUM GENET, V112, P272, DOI 10.1007/s00439-002-0881-5; Toffolatti L, 2002, GENOMICS, V80, P523, DOI 10.1006/geno.2002.6861; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; Visser R, 2005, AM J HUM GENET, V76, P52, DOI 10.1086/426950; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x	44	12	12	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2006	20	11					1910	+		10.1096/fj.05-5635fje	http://dx.doi.org/10.1096/fj.05-5635fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16891620				2022-12-25	WOS:000240267000027
J	Achison, M; Boylan, MT; Hupp, TR; Spruce, BA				Achison, M.; Boylan, M. T.; Hupp, T. R.; Spruce, B. A.			HIF-1 alpha contributes to tumour-selective killing by the sigma receptor antagonist rimcazole	ONCOGENE			English	Article						HIF-1 alpha; hypoxia; rimcazole; p53	HYPOXIA-INDUCIBLE FACTOR-1; GROWTH-FACTOR EXPRESSION; HUMAN CANCER-CELLS; TRANSCRIPTIONAL REPRESSION; FACTOR 1-ALPHA; P53; CARCINOMA; APOPTOSIS; HIF-1; DEATH	We have previously reported tumour-selective killing by the sigma(sigma) receptor ligand rimcazole. We now report that rimcazole elevates hypoxia inducible factor-1 alpha (HIF-1 alpha) protein levels under normoxic conditions in colorectal (HCT-116) and mammary carcinoma (MDA MB 231) cells but fails to induce HIF-1 alpha in normal fibroblasts or mammary epithelial cells. Combining the sigma-1 agonist (+)-pentazocine with rimcazole substantially reduces the accumulation of HIF-1 alpha, confirming that the effect is mediated at least partly by antagonism of sigma-1 sites. HIF-1 alpha knockdown by RNA interference attenuates rimcazole-induced cell death in both cell types. Thus, the induction of HIF-1 alpha by rimcazole contributes to tumour cell killing. In a comparison of HCT-116p53(+/+) and HCT-116p53(-/-) cells, HIF-1 alpha levels are consistently higher after rimcazole treatment in HCT-116p53(+/+) cells. Furthermore, although rimcazole kills HCT-116p53(-/-) cells, it has a more potent apoptosis-inducing effect in HCT-116p53+/+ cells. This suggests that the presence of functional p53 protein may enhance death induction by rimcazole in part through greater induction of HIF-1 alpha p53 is not required, however, for the rimcazole-induced engagement of HIF-1 alpha in proapoptotic mode as HIF-1 alpha knockdown attenuates rimcazole-induced death to comparable extents in p53 mutant and wild-type cell systems. Knowledge of HIF-1 alpha involvement may assist the re-pro. ling of rimcazole and other sigma ligands as cancer therapeutics.	Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Edinburgh, Western Gen Hosp, CRUK Canc Res Labs, Signal Transduct Unit P53, Edinburgh, Midlothian, Scotland	University of Dundee; University of Edinburgh	Spruce, BA (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.	b.a.spruce@dundee.ac.uk						Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arends JW, 2000, J PATHOL, V190, P412; Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Fels DR, 2005, TRENDS BIOCHEM SCI, V30, P426, DOI 10.1016/j.tibs.2005.06.009; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giaccia AJ, 1998, SCIENCE, V279, P12; Gilmore DL, 2004, CNS DRUG REV, V10, P1; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Krishnamachary B, 2003, CANCER RES, V63, P1138; Langa F, 2003, EUR J NEUROSCI, V18, P2188, DOI 10.1046/j.1460-9568.2003.02950.x; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Schmid T, 2004, BIOCHEM J, V380, P289, DOI 10.1042/BJ20031299; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Spruce BA, 2004, CANCER RES, V64, P4875, DOI 10.1158/0008-5472.CAN-03-3180; WALDMAN T, 1995, CANCER RES, V55, P5187; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Yim S, 2003, J BIOL CHEM, V278, P38260, DOI 10.1074/jbc.M306016200; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598	34	18	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1137	1146		10.1038/sj.onc.1209890	http://dx.doi.org/10.1038/sj.onc.1209890			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924239				2022-12-25	WOS:000244406400004
J	Choi, YL; Tsukasaki, K; O'Neill, MC; Yamada, Y; Onimaru, Y; Matsumoto, K; Ohashi, J; Yamashita, Y; Tsutsumi, S; Kaneda, R; Takada, S; Aburatani, H; Kamihira, S; Nakamura, T; Tomonaga, M; Mano, H				Choi, Y. L.; Tsukasaki, K.; O'Neill, M. C.; Yamada, Y.; Onimaru, Y.; Matsumoto, K.; Ohashi, J.; Yamashita, Y.; Tsutsumi, S.; Kaneda, R.; Takada, S.; Aburatani, H.; Kamihira, S.; Nakamura, T.; Tomonaga, M.; Mano, H.			A genomic analysis of adult T-cell leukemia	ONCOGENE			English	Article						adult T-cell leukemia; DNA microarray; MET; artificial neural network	HEPATOCYTE GROWTH-FACTOR; VIRUS TYPE-I; C-MET PROTOONCOGENE; GENE-EXPRESSION; HOMOZYGOUS DELETIONS; HTLV-I; LYMPHOMA; IDENTIFICATION; LEUKEMIA/LYMPHOMA; FEATURES	Adult T-cell leukemia (ATL) is an intractable malignancy of CD4(+) T cells that is etiologically associated with infection by human T-cell leukemia virus-type I. Most individuals in the chronic stage of ATL eventually undergo progression to a highly aggressive acute stage. To clarify the mechanism responsible for this stage progression, we isolated CD4(+) cells from individuals in the chronic ( n =19) or acute ( n = 22) stages of ATL and subjected them to pro. ling of gene expression with DNA micro-arrays containing > 44 000 probe sets. Changes in chromosome copy number were also examined for 24 cell specimens with the use of microarrays harboring similar to 50 000 probe sets. Stage-dependent changes in gene expression pro. le and chromosome copy number were apparent. Furthermore, expression of the gene for MET, a receptor tyrosine kinase for hepatocyte growth factor (HGF), was shown to be specific to the acute stage of ATL, and the plasma concentration of HGF was increased in individuals in either the acute or chronic stage. HGF induced proliferation of a MET-positive ATL cell line, and this effect was blocked by antibodies to HGF. The HGF-MET signaling pathway is thus a potential therapeutic target for ATL.	Jichi Med Univ, Div Funct Genom, Shimotsukeshi, Tochigi 3290498, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Nagasaki 852, Japan; Univ Maryland, Dept Biol Sci, Baltimore, MD 21201 USA; Nagasaki Univ, Dept Lab Med, Grad Sch Biomed Sci, Nagasaki 852, Japan; Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Osaka, Japan; Univ Tokyo, Grad Sch Med, Dept Human Genet, Tokyo, Japan; Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan	Jichi Medical University; Nagasaki University; University System of Maryland; University of Maryland Baltimore; Nagasaki University; Osaka University; University of Tokyo; University of Tokyo	Mano, H (corresponding author), Jichi Med Univ, Div Funct Genom, 3311-1 Yakushiji, Shimotsukeshi, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	Matsumoto, Kunio/D-8441-2015; OHASHI, JUN/G-5907-2015	Matsumoto, Kunio/0000-0002-6532-4482; Takada, Shuji/0000-0002-9406-4683				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Ariyama Y, 1999, J HUM GENET, V44, P357, DOI 10.1007/s100380050178; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; CESARMAN E, 1992, BLOOD, V80, P3205; Choi YL, 2004, LEUKEMIA, V18, P556, DOI 10.1038/sj.leu.2403261; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0; Funakoshi H, 2003, CLIN CHIM ACTA, V327, P1, DOI 10.1016/S0009-8981(02)00302-9; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Imaizumi Y, 2003, CLIN CANCER RES, V9, P181; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Lockett A, 2005, J MANAGE INQUIRY, V14, P139, DOI 10.1177/1056492605276645; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOTOKURA T, 1988, BIOCHEM BIOPH RES CO, V154, P1182, DOI 10.1016/0006-291X(88)90265-3; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Nosaka K, 2000, CANCER RES, V60, P1043; O'Neill MC, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-13; Oshiro A, 2006, BLOOD, V107, P4500, DOI 10.1182/blood-2005-09-3801; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Sasaki H, 2005, BLOOD, V105, P1204, DOI 10.1182/blood-2004-03-1222; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206; Tamiya S, 1998, BLOOD, V91, P3935; TAMURA M, 1993, J BIOL CHEM, V268, P8140; Tsukasaki K, 2004, INT J CANCER, V109, P875, DOI 10.1002/ijc.20028; Tsukasaki K, 2001, BLOOD, V97, P3875, DOI 10.1182/blood.V97.12.3875; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; Yamada Y, 1996, LEUKEMIA LYMPHOMA, V21, P443, DOI 10.3109/10428199609093442; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	38	61	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1245	1255		10.1038/sj.onc.1209898	http://dx.doi.org/10.1038/sj.onc.1209898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16909099				2022-12-25	WOS:000244406400015
J	Castellano, E; De las Rivas, J; Guerrero, C; Santos, E				Castellano, E.; De Las Rivas, J.; Guerrero, C.; Santos, E.			Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses	ONCOGENE			English	Article						H-Ras; N-Ras; microarray; genomics; transcriptome; cluster analysis; differential gene expression	K-RAS; PLASMA-MEMBRANE; DIFFERENTIAL ACTIVATION; INTERFERON-ALPHA; GENE-EXPRESSION; PROTEIN-KINASE; MOUSE; TRANSFORMATION; GROWTH; RECEPTOR	We characterized differential gene expression profiles of fibroblast cell lines harboring single or double-homozygous null mutations in H-ras and N-ras. Whereas the expression level of the individual H-, N- and K-ras genes appeared unaffected by the presence or absence of the other ras loci, significant differences were observed between the expression profiles of cells missing N-ras and/or H-ras. Absence of N-ras produced much stronger effects than absence of H-ras over the pro. le of the cellular transcriptome. N-ras(-/-) and H-ras(-/-). broblasts displayed rather antagonistic expression profiles and the transcriptome of H-ras(-/-) cells was significantly closer to that of wild-type. broblasts than to that of N- ras(-/-) cells. Classifying all differentially expressed genes into functional categories suggested specific roles for H-Ras and N-Ras. It was particularly strikingin N-ras(-/-) cells the upregulation of a remarkable number of immunity-related genes, as well as of several loci involved in apoptosis. Reverse-phase protein array assays demonstrated in the same N- ras(-/-) cells the overexpression and nuclear migration of tyrosine phosphorylated signal transducer and activator of transcription 1 (Stat1) which was concomitant with transcriptional activation mediated by interferon-stimulated response elements. Significantly enhanced numbers of apoptotic cells were also detected in cultures of N-ras(-/-) cells. Our data support the notion that different Ras isoforms play functionally distinct cellular roles and indicate that N-Ras is significantly involved in immune modulation/host defense and apoptotic responses.	Univ Salamanca, Ctr Invest Canc, CSIC, USAL,Inst Biol Mol & Celular Canc, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Santos, E (corresponding author), Univ Salamanca, Ctr Invest Canc, CSIC, USAL,Inst Biol Mol & Celular Canc, Salamanca 37007, Spain.	esantos@usal.es	Guerrero, Carmen/F-1776-2010; 2007, Secribsal/A-1556-2012; Sánchez, Esther Castellano/AAA-8087-2020; De Las Rivas, Javier/G-5936-2014	Guerrero, Carmen/0000-0002-8747-6831; Sánchez, Esther Castellano/0000-0002-8449-4081; De Las Rivas, Javier/0000-0002-0984-9946				Barash Y, 2004, BIOINFORMATICS, V20, P839, DOI 10.1093/bioinformatics/btg487; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BOS JL, 1989, CANCER RES, V49, P4682; Brem R, 2001, ONCOGENE, V20, P2854, DOI 10.1038/sj.onc.1204403; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Croonquist PA, 2003, BLOOD, V102, P2581, DOI 10.1182/blood-2003-04-1227; DAVIES SA, 1989, BIOCHIM BIOPHYS ACTA, V1013, P173, DOI 10.1016/0167-4889(89)90046-3; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Eskandarpour M, 2005, INT J CANCER, V115, P65, DOI 10.1002/ijc.20873; Espina V, 2003, PROTEOMICS, V3, P2091, DOI 10.1002/pmic.200300592; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Hamilton M, 1998, J BIOL CHEM, V273, P28155, DOI 10.1074/jbc.273.43.28155; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Herrmann PC, 2003, PROTEOMICS, V3, P1801, DOI 10.1002/pmic.200300461; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Improta T, 1997, CYTOKINE, V9, P383, DOI 10.1006/cyto.1996.0180; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liao JH, 2003, J BIOL CHEM, V278, P31871, DOI 10.1074/jbc.M301931200; MAHER J, 1995, ONCOGENE, V11, P1639; Matallanas D, 2006, MOL CELL BIOL, V26, P100, DOI 10.1128/MCB.26.1.100-116.2006; Murtagh F., 1985, COMPSTAT LECT, V4; Ohnami S, 2003, BIOCHEM BIOPH RES CO, V309, P798, DOI 10.1016/j.bbrc.2003.08.073; Oliva JL, 2004, J BIOL CHEM, V279, P33480, DOI 10.1074/jbc.M404058200; Perez de Castro I, 2004, MOL CELL BIOL, V24, P3485, DOI 10.1128/MCB.24.8.3485-3496.2004; Perez de Castro I, 2003, CANCER RES, V63, P1615; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; PINEDA JA, 1994, COGNITIVE BRAIN RES, V2, P1, DOI 10.1016/0926-6410(94)90015-9; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rojas Jose M., 2002, Current Genomics, V3, P295, DOI 10.2174/1389202023350381; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Ruiz-Vela A, 2005, EMBO REP, V6, P379, DOI 10.1038/sj.embor.7400375; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Takahashi C, 2006, NAT GENET, V38, P118, DOI 10.1038/ng1703; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Vasseur Sophie, 2003, Mol Cancer, V2, P19, DOI 10.1186/1476-4598-2-19; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002; Wulfkuhle JD, 2003, PROTEOMICS, V3, P2085, DOI 10.1002/pmic.200300591; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	61	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					917	933		10.1038/sj.onc.1209845	http://dx.doi.org/10.1038/sj.onc.1209845			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909116				2022-12-25	WOS:000244063800012
J	Lacreusette, A; Nguyen, JM; Pandolfino, MC; Khammari, A; Dreno, B; Jacques, Y; Godard, A; Blanchard, F				Lacreusette, A.; Nguyen, J-M; Pandolfino, M-C; Khammari, A.; Dreno, B.; Jacques, Y.; Godard, A.; Blanchard, F.			Loss of oncostatin M receptor beta in metastatic melanoma cells	ONCOGENE			English	Article						oncostatin M; interleukin-6; STAT3; histone acetylation; melanoma	HISTONE DEACETYLASE INHIBITORS; TUMOR-INFILTRATING LYMPHOCYTES; INDUCED GROWTH-INHIBITION; INTERLEUKIN-6; EXPRESSION; STAT3; RESPONSIVENESS; ACETYLATION; PROGRESSION; ACTIVATION	Oncostatin M (OSM) is an interleukin-6 (IL-6) type cytokine originally described by its capacity to inhibit melanoma proliferation in vitro. Here, the mechanisms involved in resistance to growth inhibition by OSM were analysed for the first time on a large panel of metastatic melanoma cell lines. OSM resistance did not strictly correlate with IL-6, interferon-gamma or tumor necrosis factor-alpha resistance. Rather, it correlated with a specific loss of the OSM receptor-beta (OSMR beta) subunit, in conjunction with a lower level of histone acetylation in the OSMR beta promoter region. Treatment of various OSM-resistant melanoma cells with the histone deacetylase inhibitor Trichostatin A increased activity and histone acetylation of the OSMR beta promoter as well as expression of OSMR beta mRNA and protein, allowing OSM to activate the signal transducer and activator of transcription 3 (STAT3) and to inhibit proliferation. Other defects associated with OSM resistance were identified at the level of OSMR beta transcription or protein expression, as well as downstream of or parallel to STAT3 activation. Altogether, our results suggest a role for OSM in the prevention of melanoma progression and that metastatic melanoma cells could escape this growth control by the epigenetic silencing of OSMR beta.	INSERM, U601, Grp Rech Cytokines & Receteurs, Inst Biol, F-44035 Nantes 1, France; Univ Nantes, Inst Biol, IFR26, UFR, F-44035 Nantes, France; PIMESP, Nantes, France; CHU Nantes, Unit Skin Canc, F-44035 Nantes 01, France; CHU Nantes, Biochim Lab, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Godard, A (corresponding author), INSERM, U601, Grp Rech Cytokines & Receteurs, Inst Biol, 0 Quai Moncousu, F-44035 Nantes 1, France.	agodard@nantes.inserm.fr; frederic.blanchard@univ-nantes.fr	Blanchard, Frederic/AAS-1930-2021; NGUYEN, JEAN-MICHEL/K-7665-2015; Blanchard, Frederic/K-8018-2015	Blanchard, Frederic/0000-0003-1055-2573; NGUYEN, JEAN-MICHEL/0000-0001-8815-7640; Blanchard, Frederic/0000-0003-1055-2573				Bani MR, 1996, CANCER RES, V56, P3075; Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4; Blanchard F, 2003, HEPATOLOGY, V38, P1516, DOI 10.1016/j.hep.2003.09.029; Blanchard F, 2002, ONCOGENE, V21, P6264, DOI 10.1038/sj.onc.1205777; Blanchard F, 1997, INT IMMUNOL, V9, P1775, DOI 10.1093/intimm/9.12.1775; Bohm M, 2001, J INVEST DERMATOL, V117, P132, DOI 10.1046/j.0022-202x.2001.01372.x; Boing I, 2006, CELL SIGNAL, V18, P50, DOI 10.1016/j.cellsig.2005.03.015; Boyle GM, 2005, PIGM CELL RES, V18, P160, DOI 10.1111/j.1600-0749.2005.00228.x; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Chipoy C, 2004, J BONE MINER RES, V19, P1850, DOI 10.1359/JBMR.040817; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; Dagoneau N, 2004, AM J HUM GENET, V74, P298, DOI 10.1086/381715; Dreno B, 2002, CANCER IMMUNOL IMMUN, V51, P539, DOI 10.1007/s00262-002-0315-1; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; GERVOIS N, 1990, EUR J IMMUNOL, V20, P825, DOI 10.1002/eji.1830200417; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HEYMANN D, 1995, IMMUNOL LETT, V46, P245, DOI 10.1016/0165-2478(95)00049-B; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jarry A, 2004, MOL CELL PROBE, V18, P349, DOI 10.1016/j.mcp.2004.05.004; Kim H, 1999, MOL CELL BIOL, V19, P5326; Klausen P, 2000, ONCOGENE, V19, P3675, DOI 10.1038/sj.onc.1203707; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Labarriere N, 2002, CANCER IMMUNOL IMMUN, V51, P532, DOI 10.1007/s00262-002-0313-3; LU C, 1993, CANCER RES, V53, P2708; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULE JJ, 1990, J EXP MED, V171, P629, DOI 10.1084/jem.171.3.629; Nawrocki S, 2000, IMMUNOL LETT, V74, P81, DOI 10.1016/S0165-2478(00)00253-4; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Ozbek S, 2001, ONCOGENE, V20, P972, DOI 10.1038/sj.onc.1204180; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Sandor V, 2002, CLIN CANCER RES, V8, P718; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Yannelli JR, 2004, VACCINE, V23, P97, DOI 10.1016/j.vaccine.2003.12.036; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	44	36	37	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					881	892		10.1038/sj.onc.1209844	http://dx.doi.org/10.1038/sj.onc.1209844			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909117				2022-12-25	WOS:000244063800009
J	Hosoya-Ohmura, S; Mochizuki, N; Suzuki, M; Ohneda, O; Ohneda, K; Yamamoto, M				Hosoya-Ohmura, Sakie; Mochizuki, Naomi; Suzuki, Mikiko; Ohneda, Osamu; Ohneda, Kinuko; Yamamoto, Masayuki			GATA-4 incompletely substitutes for GATA-1 in promoting both primitive and definitive erythropoiesis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; ZINC-FINGER PROTEIN; SMALL MAF PROTEINS; ERYTHROID-DIFFERENTIATION; SELF-ASSOCIATION; EKLF; DROSOPHILA; HEMATOPOIESIS; SURVIVAL	Vertebrate GATA transcription factors have been classified into two subgroups; GATA-1, GATA-2, and GATA-3 are expressed in hematopoietic cells, whereas GATA-4, GATA-5, and GATA-6 are expressed in mesoendoderm-derived tissues. We previously discovered that expression of GATA-2 or GATA-3 under the transcriptional control for the Gata1 gene eliminates lethal anemia in Gata1 germ line mutant mice (Gata1.05/Y). Here, we show that the GATA-4 expression by the same regulatory cassette prolongs the life span of Gata1.05/Y embryos from embryonic day 12.5 to 15.5 but fails to abrogate its embryonic lethality. Gata1.05/Y mice bearing the GATA-4 transgene showed impaired maturation of both primitive and definitive erythroid cells and defective erythroid cell expansion in fetal liver. Moreover, the incidence of apoptosis was observed prominently in primitive erythroid cells. In contrast, a GATA4- GATA-1 chimeric protein prepared by linking the N-terminal region of GATA-4 to the C-terminal region of GATA-1 significantly promoted the differentiation and survival of primitive erythroid cells, although this protein is still insufficient for rescuing Gata1.05/Y embryos from lethal anemia. These data thus show a functional incompatibility between hematopoietic and endodermal GATA factors in vivo and provide evidence indicating specific roles of the C-terminal region of GATA-1 in primitive erythropoiesis.	Univ Tsukuba, Grad Sch Comprehens Human Sci, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Environm Response Project, Exploratory Res adv Technol, Japan Sci & Technol Corp, Tsukuba, Ibaraki 3058577, Japan	University of Tsukuba; Japan Science & Technology Agency (JST); University of Tsukuba	Ohneda, K (corresponding author), Takasaki Univ Hlth & Welfare, Dept Pharm, Fac Pharm, 60 Nalaorui, Takasaki, Gumma 3700033, Japan.	kohneda@takasaki-u.ac.jp; masi@tara.tsukuba.ac.jp	Yamamoto, Masayuki/A-4873-2010; Suzuki, Mikiko/B-5177-2010; Ohneda, Kinuko/AAC-8822-2019	Yamamoto, Masayuki/0000-0002-9073-9436; 				Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Drissen R, 2005, MOL CELL BIOL, V25, P5205, DOI 10.1128/MCB.25.12.5205-5214.2005; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gajewski K, 1999, DEVELOPMENT, V126, P5679; Hodge D, 2006, BLOOD, V107, P3359, DOI 10.1182/blood-2005-07-2888; Hung HL, 1999, MOL CELL BIOL, V19, P3496; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Katsuoka F, 2000, EMBO J, V19, P2980, DOI 10.1093/emboj/19.12.2980; Kawamura T, 2005, J BIOL CHEM, V280, P19682, DOI 10.1074/jbc.M412428200; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Nishikawa K, 2003, MOL CELL BIOL, V23, P8295, DOI 10.1128/MCB.23.22.8295-8305.2003; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Ohneda K, 2002, ACTA HAEMATOL-BASEL, V108, P237, DOI 10.1159/000065660; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; Osawa M, 2002, BLOOD, V100, P2769, DOI 10.1182/blood-2002-01-0182; Pan XQ, 2005, J BIOL CHEM, V280, P22385, DOI 10.1074/jbc.M500081200; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; PERKINS AC, 1995, NATURE, V375, P318; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; Rhodes MM, 2005, BLOOD, V106, P1857, DOI 10.1182/blood-2004-11-4344; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Saleque S, 2002, GENE DEV, V16, P301, DOI 10.1101/gad.959102; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Suzuki N, 2006, P NATL ACAD SCI USA, V103, P2202, DOI 10.1073/pnas.0508928103; Takahashi S, 2000, BLOOD, V96, P910, DOI 10.1182/blood.V96.3.910.015k29_910_916; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; TEPASS U, 1994, DEVELOPMENT, V120, P1829; Wagner KU, 2000, DEVELOPMENT, V127, P4949; WASSARMAN PM, 1993, GUIDE TECHNIQUES MOU; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Zhang J, 2003, BLOOD, V102, P3938, DOI 10.1182/blood-2003-05-1479; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	43	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32820	32830		10.1074/jbc.M605735200	http://dx.doi.org/10.1074/jbc.M605735200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16945928	hybrid			2022-12-25	WOS:000241414500080
J	Liu, Y; Denlinger, CE; Rundall, BK; Smith, PW; Jones, DR				Liu, Yuan; Denlinger, Chadrick E.; Rundall, Brian K.; Smith, Philip W.; Jones, David R.			Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HISTONE DEACETYLASE INHIBITOR; CELL LUNG-CANCER; AKT/PROTEIN KINASE-B; PHASE-I; DEPENDENT TRANSCRIPTION; COACTIVATOR P300; PROTEIN-KINASE; APOPTOSIS; INDUCTION	We have previously demonstrated that the transcription factor NF-kappa B is activated by histone deacetylase inhibitors in a PI3K/Akt-dependent manner. The molecular mechanisms governing this process have not been well described. By virtue of their inhibitory action, it is unclear whether the addition of histone deacetylase inhibitors simply preserves the acetylation status of RelA/p65 or whether they actively stimulate signaling cascades that result in increased acetylation and transcription of NF-kappa B. Here we provide evidence that suberoylanilide hydroxamic acid stimulates NF-kappa B transcription through a signaling cascade that involves activation of both the serine/threonine kinase Akt and the p300 acetyltransferase. Using newly developed phosphospecific antibodies to p300 (pSer(1834)), and site-directed mutant proteins, we find that suberoylanilide hydroxamic acid stimulates Akt activity, which is required to phosphorylate p300 at Ser(1834). Akt-mediated phosphorylation of p300 dramatically increases its acetyltransferase activity as measured by an increased acetylation of RelA/p65 at Lys(310), a modification that is required for full NF-kappa B transcription. Importantly, coordinate activation of Akt/p300 pathway by suberoylanilide hydroxamic acid occurs at the chromatin level, resulting in recruitment of activated Akt (pSer(473)), p300 (pSer(1834)), acetylated RelA/p65 (Lys(310)), and RNA polymerase II to the NF-kappa B-dependent cIAP-2 and Bfl-1/A1 promoters. These studies provide evidence that histone deacetylase inhibitors, such as suberoylanilide hydroxamic acid, not only inhibit deacetylase activity but also stimulate active NF-kappa B transcription and cell survival through signaling pathways involving Akt and increased p300 acetyltransferase activity.	Univ Virginia, Sch Med, Dept Surg, Charlottesville, VA 22908 USA	University of Virginia	Jones, DR (corresponding author), Univ Virginia, Sch Med, Dept Surg, Box 800679, Charlottesville, VA 22908 USA.	djones@virginia.edu	Liu, Yuan/E-6100-2010; Smith, Philip/P-7736-2019	Smith, Philip/0000-0003-3441-1062; Jones, David/0000-0002-3318-0146	NATIONAL CANCER INSTITUTE [K08CA083920, F32CA101497] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA83920, F32 CA101497] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Brognard J, 2001, CANCER RES, V61, P3986; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Chen J, 2004, CELL MOL LIFE SCI, V61, P1675, DOI 10.1007/s00018-004-4103-9; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Denlinger CE, 2005, J THORAC CARDIOV SUR, V130, P1422, DOI 10.1016/j.jtcvs.2005.06.051; Denlinger Chadrick E, 2004, Semin Thorac Cardiovasc Surg, V16, P28, DOI 10.1053/j.semtcvs.2003.12.004; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; Gilbert J, 2001, CLIN CANCER RES, V7, P2292; Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; Rahmani M, 2003, ONCOGENE, V22, P6231, DOI 10.1038/sj.onc.1206646; Reid T, 2004, LUNG CANCER, V45, P381, DOI 10.1016/j.lungcan.2004.03.002; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Rundall BK, 2005, SURGERY, V138, P360, DOI 10.1016/j.surg.2005.06.016; Sandor V, 2002, CLIN CANCER RES, V8, P718; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; VAN LC, 1996, GENE EXPRESSION, V5, P245; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xu WS, 2005, CANCER RES, V65, P7832, DOI 10.1158/0008-5472.CAN-04-4608; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	43	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31359	31368		10.1074/jbc.M604478200	http://dx.doi.org/10.1074/jbc.M604478200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16926151				2022-12-25	WOS:000241235300020
J	Korbas, M; Vogt, S; Meyer-Klaucke, W; Bill, E; Lyon, EJ; Thauer, RK; Shima, S				Korbas, Malgorzata; Vogt, Sonja; Meyer-Klaucke, Wolfram; Bill, Eckhard; Lyon, Erica J.; Thauer, Rudolf K.; Shima, Seigo			The iron-sulfur cluster-free hydrogenase (Hmd) is a metalloenzyme with a novel iron binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-ONLY HYDROGENASE; H-2-FORMING METHYLENETETRAHYDROMETHANOPTERIN DEHYDROGENASE; METAL-FREE HYDROGENASE; ACTIVE-SITE; METHANOBACTERIUM-THERMOAUTOTROPHICUM; CRYSTAL-STRUCTURE; N5,N10-METHYLENETETRAHYDROMETHANOPTERIN DEHYDROGENASE; DESULFOVIBRIO-DESULFURICANS; METHANOGENIC ARCHAEA; CATALYTIC MECHANISM	The iron-sulfur cluster-free hydrogenase (Hmd) from methanogenic archaea harbors an iron-containing cofactor of yet unknown structure. X-ray absorption spectroscopy of the active, as isolated enzyme from Methanothermobacter marburgensis (mHmd) and of the active, reconstituted enzyme from Methanocaldococcus jannaschii (jHmd) revealed the presence of mononuclear iron with two CO, one sulfur and one or two N/O in coordination distance. In jHmd, the single sulfur ligand is most probably provided by Cys(176), as deduced from a comparison of the activity and of the x-ray absorption and Mossbauer spectra of the enzyme mutated in any of the three conserved cysteines. In the isolated Hmd cofactor, two CO, one sulfur, and two nitrogen/oxygen atoms coordinate the iron, the sulfur ligand being most probably provided by mercaptoethanol, which is absolutely required for the extraction of the iron-containing cofactor from the holoenzyme and for the stabilization of the extracted cofactor. In active mHmd holoenzyme, the number of iron ligands increased by one when one of the Hmd inhibitors ( CO or KCN)were present, indicating that in active Hmd, the iron contains an open coordination site, which is proposed to be the site of H-2 interaction.	Deutsch Elektronen Synchrotron DESY, Outstn Hamburg, EMBL, D-22603 Hamburg, Germany; Max Planck Inst Terr Microbiol, D-35043 Marburg, Germany; Max Planck Inst Bioinorgan Chem, D-45470 Mulheim, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; Max Planck Society	Meyer-Klaucke, W (corresponding author), Deutsch Elektronen Synchrotron DESY, Outstn Hamburg, EMBL, Notkestr 85, D-22603 Hamburg, Germany.	Wolfram@embl-hamburg.de; shima@mpi-marburg.mpg.de	Meyer-Klaucke, Wolfram/G-1148-2010; Korbas, Malgorzata/B-4024-2009	Korbas, Malgorzata/0000-0003-3064-0132; Oduaran, Erica/0000-0001-9298-5721				Afting C, 1998, ARCH MICROBIOL, V169, P206, DOI 10.1007/s002030050562; Armstrong FA, 2004, CURR OPIN CHEM BIOL, V8, P133, DOI 10.1016/j.cbpa.2004.02.004; Bennett B, 2000, BIOCHEMISTRY-US, V39, P7455, DOI 10.1021/bi992583z; Berkessel A, 2001, CURR OPIN CHEM BIOL, V5, P486, DOI 10.1016/S1367-5931(00)00245-3; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; Buurman G, 2000, FEBS LETT, V485, P200, DOI 10.1016/S0014-5793(00)02225-0; Chen CH, 2004, DALTON T, P137, DOI 10.1039/b311059a; DeBord JRD, 1997, ACTA CRYSTALLOGR C, V53, P45, DOI 10.1107/S0108270196011584; Frey M, 2002, CHEMBIOCHEM, V3, P153, DOI 10.1002/1439-7633(20020301)3:2/3<153::AID-CBIC153>3.0.CO;2-B; Hartmann GC, 1996, J BIOL INORG CHEM, V1, P446, DOI 10.1007/s007750050077; Huyett JE, 1997, J AM CHEM SOC, V119, P9291, DOI 10.1021/ja9700919; Liu ZP, 2002, J AM CHEM SOC, V124, P5175, DOI 10.1021/ja0118690; Loscher S, 2005, FEBS LETT, V579, P4287, DOI 10.1016/j.febslet.2005.06.063; Lyon EJ, 2004, EUR J BIOCHEM, V271, P195, DOI 10.1046/j.1432-1033.2003.03920.x; Lyon EJ, 2004, J AM CHEM SOC, V126, P14239, DOI 10.1021/ja046818s; Mijovilovich A, 2003, J SYNCHROTRON RADIAT, V10, P64, DOI 10.1107/S0909049502017296; MOORE JT, 1993, PROTEIN EXPRES PURIF, V4, P160, DOI 10.1006/prep.1993.1022; Nicolet Y, 2002, J INORG BIOCHEM, V91, P1, DOI 10.1016/S0162-0134(02)00392-6; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Nicolet Y, 2001, J AM CHEM SOC, V123, P1596, DOI 10.1021/ja0020963; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; PETTIFER RF, 1985, J APPL CRYSTALLOGR, V18, P404, DOI 10.1107/S0021889885010627; Pilak O, 2006, J MOL BIOL, V358, P798, DOI 10.1016/j.jmb.2006.02.035; SCHWORER B, 1993, EUR J BIOCHEM, V212, P255, DOI 10.1111/j.1432-1033.1993.tb17657.x; Shima S, 2005, J AM CHEM SOC, V127, P10430, DOI 10.1021/ja051895o; Shima S, 2004, ANGEW CHEM INT EDIT, V43, P2547, DOI 10.1002/anie.200353763; Shima S, 2001, METHOD ENZYMOL, V331, P317; Shokes JE, 2005, FEBS LETT, V579, P1741, DOI 10.1016/j.febslet.2005.02.034; STERN EA, 1993, PHYS REV B, V48, P9825, DOI 10.1103/PhysRevB.48.9825; Strub MP, 2003, STRUCTURE, V11, P1359, DOI 10.1016/j.str.2003.09.014; Thauer RK, 1996, CHEM REV, V96, P3031, DOI 10.1021/cr9500601; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; Volbeda A, 2005, J BIOL INORG CHEM, V10, P239, DOI 10.1007/s00775-005-0632-x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Zhou TJ, 2004, INORG CHEM, V43, P923, DOI 10.1021/ic0342301; ZIRNGIBL C, 1990, FEBS LETT, V261, P112, DOI 10.1016/0014-5793(90)80649-4	36	114	118	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30804	30813		10.1074/jbc.M605306200	http://dx.doi.org/10.1074/jbc.M605306200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16887798	hybrid			2022-12-25	WOS:000241075900056
J	Du, WL; McMahon, TJ; Zhang, ZS; Stiber, JA; Meissner, G; Eu, JP				Du, Wanglei; McMahon, Timothy J.; Zhang, Zhu-Shan; Stiber, Jonathan A.; Meissner, Gerhard; Eu, Jerry P.			Excitation-contraction coupling in airway smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR SUBTYPES; CA2+ RELEASE CHANNELS; CALCIUM-CHANNELS; PULMONARY-ARTERY; HYPOXIC VASOCONSTRICTION; SKELETAL-MUSCLE; CELLS; STORES; ACETYLCHOLINE; BRONCHOCONSTRICTION	Excitation-contraction (EC) coupling in striated muscles is mediated by the cardiac or skeletal muscle isoform of voltage-dependent L-type Ca2+ channel (Ca(v)1.2 and Ca(v)1.1, respectively) that senses a depolarization of the cell membrane, and in response, activates its corresponding isoform of intracellular Ca2+ release channel/ryanodine receptor (RyR) to release stored Ca2+, thereby initiating muscle contraction. Specifically, in cardiac muscle following cell membrane depolarization, Cav1.2 activates cardiac RyR (RyR2) through an influx of extracellular Ca2+. In contrast, in skeletal muscle, Cav1.1 activates skeletal muscle RyR (RyR1) through a direct physical coupling that negates the need for extracellular Ca2+. Since airway smooth muscle (ASM) expresses Ca(v)1.2 and all three RyR isoforms, we examined whether a cardiac muscle type of EC coupling also mediates contraction in this tissue. We found that the sustained contractions of rat ASM preparations induced by depolarization with KCl were indeed partially reversed (similar to 40%) by 200 mu M ryanodine, thus indicating a functional coupling of L-type channels and RyRs in ASM. However, KCl still caused transient ASM contractions and stored Ca2+ release in cultured ASM cells without extracellular Ca2+. Further analyses of rat ASM indicated that this tissue expresses as many as four L-type channel isoforms, including Cav1.1. Moreover, Cav1.1 and RyR1 in rat ASM cells have a similar distribution near the cell membrane in rat ASM cells and thus may be directly coupled as in skeletal muscle. Collectively, our data implicate that EC-coupling mechanisms in striated muscles may also broadly transduce diverse smooth muscle functions.	Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill	Eu, JP (corresponding author), Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, MSRB 241,Res Dr, Durham, NC 27710 USA.	eu000001@duke.edu	McMahon, Tim/K-3986-2012	McMahon, Tim/0000-0002-3404-3223	NIAMS NIH HHS [AR18687] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bergner A, 2002, J GEN PHYSIOL, V119, P187, DOI 10.1085/jgp.119.2.187; BOURREAU JP, 1991, AM J PHYSIOL, V261, pC497, DOI 10.1152/ajpcell.1991.261.3.C497; BOURREAU JP, 1993, AM J PHYSIOL, V265, pC28, DOI 10.1152/ajpcell.1993.265.1.C28; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; Deshpande DA, 2005, AM J PHYSIOL-LUNG C, V288, pL773, DOI 10.1152/ajplung.00217.2004; Du WL, 2005, J BIOL CHEM, V280, P26287, DOI 10.1074/jbc.M502905200; FANTA CH, 1982, AM REV RESPIR DIS, V125, P61; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; FLEISCHMANN BK, 1994, P NATL ACAD SCI USA, V91, P11914, DOI 10.1073/pnas.91.25.11914; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Fritz N, 2005, J CELL SCI, V118, P2261, DOI 10.1242/jcs.02344; Gelband CH, 1997, CIRCULATION, V96, P3647; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Jabr RI, 1997, BRIT J PHARMACOL, V122, P21, DOI 10.1038/sj.bjp.0701326; Janssen LJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1161, DOI 10.1152/ajplung.00452.2001; JANSSEN LJ, 2004, AM J PHYSIOL, V287, pL8528; Koschak A, 2001, J BIOL CHEM, V276, P22100, DOI 10.1074/jbc.M101469200; Kovac JR, 2005, AM J PHYSIOL-GASTR L, V289, pG998, DOI 10.1152/ajpgi.00529.2004; Meissner G, 2004, CELL CALCIUM, V35, P621, DOI 10.1016/j.ceca.2004.01.015; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; Morio Y, 2002, J APPL PHYSIOL, V92, P527, DOI 10.1152/jappl.2002.92.2.527; MORTON ME, 1987, J BIOL CHEM, V262, P11904; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; Rosenberg P, 2004, P NATL ACAD SCI USA, V101, P9387, DOI 10.1073/pnas.0308179101; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TOMASIC M, 1992, AM J PHYSIOL, V263, pC106, DOI 10.1152/ajpcell.1992.263.1.C106; Wang YX, 2004, AM J PHYSIOL-CELL PH, V286, pC538, DOI 10.1152/ajpcell.00106.2003; Weir EK, 2005, NEW ENGL J MED, V353, P2042, DOI 10.1056/NEJMra050002; Xu WF, 2001, J NEUROSCI, V21, P5944, DOI 10.1523/JNEUROSCI.21-16-05944.2001; Yang XR, 2005, AM J PHYSIOL-LUNG C, V289, pL338, DOI 10.1152/ajplung.00328.2004; Zhang Z, 2005, CIRCULATION, V112, P1936, DOI 10.1161/CIRCULATIONAHA.105.540070; Zheng YM, 2005, J GEN PHYSIOL, V125, P427, DOI 10.1085/jgp.200409232	40	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30143	30151		10.1074/jbc.M606541200	http://dx.doi.org/10.1074/jbc.M606541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16891657	Green Published, hybrid			2022-12-25	WOS:000240896300075
J	Bell, CJ; Bright, NA; Rutter, GA; Griffiths, EJ				Bell, Christopher J.; Bright, Nicholas A.; Rutter, Guy A.; Griffiths, Elinor J.			Atp regulation in adult rat cardiomyocytes time-resolved decoding of rapid mitochondrial calcium spiking imaged with targeted photoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT CARDIAC MYOCYTES; TO-BEAT OSCILLATIONS; NA-CA EXCHANGE; VENTRICULAR MYOCYTES; HEART-MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; METABOLIC INHIBITION; RYANODINE RECEPTOR; INSULIN-SECRETION; CYTOSOLIC CALCIUM	The mechanisms that enable the heart to rapidly increase ATP supply in line with increased demand have not been fully elucidated. Here we used an adenoviral system to express the photoproteins luciferase and aequorin, targeted to the mitochondria or cytosol of adult cardiomyocytes, to investigate the interrelationship between ATP and Ca2+ in these compartments. In neither compartment were changes in free [ATP] observed upon increased workload (addition of isoproterenol) in myocytes that were already beating. However, when myocytes were stimulated to beat rapidly from rest, in the presence of isoproterenol, a significant but transient drop in mitochondrial [ATP] ([ATP](m)) occurred ( on average to 10% of the initial signal). Corresponding changes in cytosolic [ATP] ([ATP](C)) were much smaller (< 5%), indicating that [ATP](C) was effectively buffered in this compartment. Although mitochondrial [Ca2+] ([Ca2+](m)) is an important regulator of respiratory chain activity and ATP production in other cells, the kinetics of mitochondrial Ca2+ transport are controversial. Parallel experiments in cells expressing mitochondrial aequorin showed that the drop in [ATP](m) occurred over the same time scale as average [Ca2+](m) was increasing. Conversely, in the absence or presence of isoproterenol, clear beat-to-beat peaks in [Ca2+](m) were observed at 0.9 or 1.3 mu M, respectively, concentrations similar to those observed in the cytosol. These results suggest that mitochondrial Ca2+ transients occur during the contractile cycle and are translated into a time-averaged increase in mitochondrial ATP production that keeps pace with increased cytosolic demand.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Bristol, Bristol Heart Inst, Bristol BS8 1TD, Avon, England; Univ Bristol, Henry Wellcome Labs Integrated Cell Signalling, Bristol BS8 1TD, Avon, England; Univ London Imperial Coll Sci Technol & Med, Dept Cell Biol, Div Med, London SW7 2AZ, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Bristol; University of Bristol; University of Bristol; Imperial College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Griffiths, EJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	Elinor.Griffiths@bristol.ac.uk		Rutter, Guy/0000-0001-6360-0343	Medical Research Council [G9721484] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G9721484] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ainscow EK, 2001, BIOCHEM J, V353, P175, DOI 10.1042/0264-6021:3530175; Balaban RS, 2002, J MOL CELL CARDIOL, V34, P1259, DOI 10.1006/jmcc.2002.2082; Bers DM, 1996, ANN NY ACAD SCI, V779, P430, DOI 10.1111/j.1749-6632.1996.tb44818.x; Beutner G, 2001, J BIOL CHEM, V276, P21482, DOI 10.1074/jbc.M101486200; Beutner G, 2005, BBA-BIOMEMBRANES, V1717, P1, DOI 10.1016/j.bbamem.2005.09.016; BOWERS KC, 1992, J MOL CELL CARDIOL, V24, P213, DOI 10.1016/0022-2828(92)93159-H; Brandes R, 2002, BIOPHYS J, V83, P587, DOI 10.1016/S0006-3495(02)75194-1; Brandes R, 1997, CIRC RES, V80, P82, DOI 10.1161/01.RES.80.1.82; Brandes R, 1996, BIOPHYS J, V71, P1024, DOI 10.1016/S0006-3495(96)79303-7; BROWN GC, 1992, BIOCHEM J, V284, P1; Buntinas L, 2001, BBA-BIOENERGETICS, V1504, P248, DOI 10.1016/S0005-2728(00)00254-1; Chacon E, 1996, FEBS LETT, V382, P31, DOI 10.1016/0014-5793(96)00138-X; CHANCE B, 1956, J BIOL CHEM, V221, P477; COX DA, 1993, J CARDIOVASC PHARM, V21, P595, DOI 10.1097/00005344-199304000-00013; Csordas G, 2001, TRENDS CARDIOVAS MED, V11, P269, DOI 10.1016/S1050-1738(01)00123-2; DAS AM, 1990, CARDIOVASC RES, V24, P411, DOI 10.1093/cvr/24.5.411; DILISA F, 1995, J PHYSIOL-LONDON, V486, P1; ENG J, 1989, BIOPHYS J, V55, P621, DOI 10.1016/S0006-3495(89)82859-0; Filippin L, 2005, CELL CALCIUM, V37, P129, DOI 10.1016/j.ceca.2004.08.002; Filippin L, 2003, J BIOL CHEM, V278, P39224, DOI 10.1074/jbc.M302301200; Griffiths EJ, 1999, FEBS LETT, V453, P400, DOI 10.1016/S0014-5793(99)00726-7; Griffiths EJ, 1997, AM J PHYSIOL-CELL PH, V273, pC37, DOI 10.1152/ajpcell.1997.273.1.C37; Griffiths EJ, 1997, CELL CALCIUM, V21, P321, DOI 10.1016/S0143-4160(97)90120-2; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HEINEMAN FW, 1993, AM J PHYSIOL, V264, pH433, DOI 10.1152/ajpheart.1993.264.2.H433; Huser J, 2000, J BIOENERG BIOMEMBR, V32, P27, DOI 10.1023/A:1005556227425; Ingwall JS, 2004, J MOL CELL CARDIOL, V37, P613, DOI 10.1016/j.yjmcc.2004.05.020; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; KATZ LA, 1987, FEBS LETT, V221, P270, DOI 10.1016/0014-5793(87)80939-0; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; MATLIB MA, 1985, BIOCHEM BIOPH RES CO, V128, P290, DOI 10.1016/0006-291X(85)91677-8; MATLIB MA, 1983, LIFE SCI, V32, P2837, DOI 10.1016/0024-3205(83)90319-3; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Mitcheson JS, 1998, CARDIOVASC RES, V39, P280, DOI 10.1016/S0008-6363(98)00128-X; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; NICHOLLS DG, 1980, FEBS LETT, V111, P261, DOI 10.1016/0014-5793(80)80806-4; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Ravier MA, 2005, DIABETES, V54, P1789, DOI 10.2337/diabetes.54.6.1789; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robert V, 2001, EMBO J, V20, P4998, DOI 10.1093/emboj/20.17.4998; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Saghir AN, 2001, BIOCHEM J, V356, P557, DOI 10.1042/0264-6021:3560557; SCHOLZ TD, 1995, AM J PHYSIOL-HEART C, V268, pH82, DOI 10.1152/ajpheart.1995.268.1.H82; Searle S, 1998, J CELL SCI, V111, P2855; Sharma VK, 2000, J BIOENERG BIOMEMBR, V32, P97, DOI 10.1023/A:1005520714221; SHEU SS, 1994, J BIOENERG BIOMEMBR, V26, P487, DOI 10.1007/BF00762733; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Territo PR, 2000, AM J PHYSIOL-CELL PH, V278, pC423, DOI 10.1152/ajpcell.2000.278.2.C423; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; White RL, 1995, BIOPHYS J, V69, P2790, DOI 10.1016/S0006-3495(95)80152-9; WHITE RL, 1993, BIOPHYS J, V65, P196, DOI 10.1016/S0006-3495(93)81058-0; Zhou Z, 1998, J PHYSIOL-LONDON, V507, P379, DOI 10.1111/j.1469-7793.1998.379bt.x	57	76	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28058	28067		10.1074/jbc.M604540200	http://dx.doi.org/10.1074/jbc.M604540200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16882672	hybrid			2022-12-25	WOS:000240534400043
J	Yu, W; Imoto, I; Inoue, J; Onda, M; Emi, M; Inazawa, J				Yu, W.; Imoto, I.; Inoue, J.; Onda, M.; Emi, M.; Inazawa, J.			A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity	ONCOGENE			English	Article						DUSP26; ATC; amplification; p38; array-CGH	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; TUMOR-SUPPRESSOR; MICROARRAY ANALYSIS; PHOSPHATASE; EXPRESSION; APOPTOSIS; BREAST; PATHWAYS; IDENTIFICATION	Anaplastic thyroid cancer (ATC) is one of the most lethal of all human tumors, but cytogenetic information concerning ATC is extremely limited. Using our in-house array-based comparative genomic hybridization and 14 ATC cell lines with further fluorescence in situ hybridization analysis, we demonstrated ampli. cation of the DUSP26 gene, known by another report as MAP kinase phosphatase-8. DUSP26 was overexpressed in ATC cell lines and primary ATC tumor samples. When overexpressed, either exogenously or endogenously, DUSP26 promoted growth of the ATC cells. DUSP26 encodes a protein containing a dual-specificity phosphatase domain that can dephosphorylate itself. DUSP26 effectively dephosphorylates p38 and has a little effect on extracellular signal-regulated kinase in ATC cells. DUSP26 protein formed a physical complex with p38, and promoted survival of ATC cells by inhibiting p38-mediated apoptosis. Our findings suggest that DUSP26 may act as an oncogene in ATC, and might be a useful diagnostic marker and therapeutic target of this disease.	Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; 21st Century Ctr Excellence COE, Program Mol Destruct & Reconstruct Tooth & Bone, Tokyo, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo, Japan; Nippon Med Sch, Inst Gerontol, Dept Mol Biol, Kanagawa, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Nippon Medical School	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; yu, wei/B-5859-2011; Imoto, Issei/AAD-5799-2020					BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Hoornaert I, 2003, ONCOGENE, V22, P7728, DOI 10.1038/sj.onc.1207089; Hu YZ, 2006, MOL CELL BIOL, V26, P3282, DOI 10.1128/MCB.26.8.3282-3294.2006; Imoto I, 2003, CANCER RES, V63, P5691; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092; Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; McMullen ME, 2005, J BIOL CHEM, V280, P20995, DOI 10.1074/jbc.M407060200; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Onda M, 2004, ENDOCR-RELAT CANCER, V11, P843, DOI 10.1677/erc.1.00818; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Passler C, 1999, LANGENBECK ARCH SURG, V384, P284, DOI 10.1007/s004230050205; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Simon R, 2001, CANCER RES, V61, P4514; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Vasudevan SA, 2005, BIOCHEM BIOPH RES CO, V330, P511, DOI 10.1016/j.bbrc.2005.03.028; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Walentinsson A, 2001, CANCER RES, V61, P8263; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wiseman SM, 2003, HEAD NECK-J SCI SPEC, V25, P662, DOI 10.1002/hed.10277; Wu JJ, 2005, J BIOL CHEM, V280, P16461, DOI 10.1074/jbc.M501762200; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x; Yu W, 2003, J HUM GENET, V48, P331, DOI 10.1007/s10038-003-0026-2	45	75	78	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1178	1187		10.1038/sj.onc.1209899	http://dx.doi.org/10.1038/sj.onc.1209899			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924234				2022-12-25	WOS:000244406400008
J	Ose, T; Kadowaki, Y; Fukuhara, H; Kazumori, H; Ishihara, S; Udagawa, J; Otani, H; Takasawa, S; Okamoto, H; Kinoshita, Y				Ose, T.; Kadowaki, Y.; Fukuhara, H.; Kazumori, H.; Ishihara, S.; Udagawa, J.; Otani, H.; Takasawa, S.; Okamoto, H.; Kinoshita, Y.			Reg I-knockout mice reveal its role in regulation of cell growth that is required in generation and maintenance of the villous structure of small intestine	ONCOGENE			English	Article						Reg; knockout mice; growth factor; small intestine	TRANSGENIC MICE; FACTOR-ALPHA; REGENERATING ISLETS; MENETRIERS DISEASE; PROGENITOR CELLS; GASTRIC-MUCOSA; GENE FAMILY; STEM-CELL; PROTEIN; EXPRESSION	Reg I (regenerating gene product I) is a growth factor that plays a central role in the generation and regeneration of the gastric mucosal architecture. On the other hand, mouse Reg I mRNA is expressed at the highest levels in the small intestine among the gastrointestinal tissues. In the current study, with the aim to clarify the role of Reg I protein in the small intestine, the temporal and spatial pattern of Reg I expression and the phenotype of Reg I-knockout mice in the tissue were examined. In the wild-type mice, immunohistochemistry localized Reg I protein expression in absorptive cells located in the lower half of the intestinal villi. Reg I expression was undetectable until embryonic day 13 (E13), when the fetal intestine still lacks villous structure; however, it dramatically increased at E17 along with the formation and maturation of the fetal intestinal villi. In the small intestine of the adult Reg I-knockout mice, less densely packed, round-shaped aberrant morphology of the absorptive cells was observed light microscopically, and electron microscopical examination revealed a strikingly loose connection of these cells to the basement membrane. Antiproliferating cell nuclear antigen staining and anti-Ki67 staining demonstrated the marked decrease in the number of proliferating cells in the small intestinal mucosa of the knockout mice. The cell migration speed visualized by one shot labeling of 5-bromodeoxyuridine was significantly slower in the knockout mice. These phenotypes of Reg I-knockout mice emerged, in accordance with the temporal pattern of Reg I expression described above, from E17. Reg I was considered to be a regulator of cell growth that is required to generate and maintain the villous structure of the small intestine.	Shimane Univ, Dept Gastroenterol & Hepatol, Sch Med, Izumo, Shimane 6938501, Japan; Shimane Univ, Dept Anat, Sch Med, Izumo, Shimane 6938501, Japan; Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 980, Japan; Tohoku Univ, Grad Sch Med, Dept Adv Biol Sci Regenerat, Kotobiken Med Labs, Sendai, Miyagi 980, Japan	Shimane University; Shimane University; Tohoku University; Tohoku University	Kadowaki, Y (corresponding author), Shimane Univ, Dept Gastroenterol & Hepatol, Sch Med, 89-1 Enya cho, Izumo, Shimane 6938501, Japan.	y-kado@momo.so-net.ne.jp						Asahara M, 1996, GASTROENTEROLOGY, V111, P45, DOI 10.1053/gast.1996.v111.pm8698224; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Brittan M, 2004, GUT, V53, P899, DOI 10.1136/gut.2003.025478; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Fukui H, 1998, GASTROENTEROLOGY, V115, P1483, DOI 10.1016/S0016-5085(98)70027-7; Hartupee JC, 2001, BBA-GENE STRUCT EXPR, V1518, P287, DOI 10.1016/S0167-4781(00)00284-0; Kadowaki Y, 2002, FEBS LETT, V530, P59, DOI 10.1016/S0014-5793(02)03398-7; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; Kazumori H, 2000, GASTROENTEROLOGY, V119, P1610, DOI 10.1053/gast.2000.20262; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lickert H, 2001, MECH DEVELOP, V105, P181, DOI 10.1016/S0925-4773(01)00390-2; Macadam RCA, 2000, BRIT J CANCER, V83, P188; Miyaoka Y, 2004, ONCOGENE, V23, P3572, DOI 10.1038/sj.onc.1207333; Perfetti R, 1996, J GERONTOL A-BIOL, V51, pB308, DOI 10.1093/gerona/51A.5.B308; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x; SBARBATI R, 1982, J ANAT, V135, P477; SHARP R, 1995, DEVELOPMENT, V121, P149; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TERAZONO K, 1990, DIABETOLOGIA, V33, P250, DOI 10.1007/BF00404804; Unno M, 2002, DIABETES, V51, pS478, DOI 10.2337/diabetes.51.2007.S478; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; Walters JRF, 2005, CURR OPIN GASTROEN, V21, P135, DOI 10.1097/01.mog.0000153309.13080.8b; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; Zenilman ME, 1996, GASTROENTEROLOGY, V110, P1208, DOI 10.1053/gast.1996.v110.pm8613011	31	39	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					349	359		10.1038/sj.onc.1209799	http://dx.doi.org/10.1038/sj.onc.1209799			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16909126				2022-12-25	WOS:000243544000004
J	Sun, L; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL				Sun, L.; Trausch-Azar, J. S.; Ciechanover, A.; Schwartz, A. L.			E2A protein degradation by the ubiquitin-proteasome system is stage-dependent during muscle differentiation	ONCOGENE			English	Article						E2A; E12; E47; ubiquitin; proteasome; muscle differentiation	LOOP-HELIX PROTEINS; LYMPHOCYTE DEVELOPMENT; MEDIATED DEGRADATION; DNA-BINDING; TRANSCRIPTION; LOCALIZATION; E47; MYOD; ASSOCIATION; TURNOVER	The E2A proteins are basic helix-loop-helix transcription factors that regulate proliferation and differentiation in many cell types. In muscle cells, the E2A proteins form heterodimers with muscle regulatory factors such as MyoD, which then bind to DNA and regulate the transcription of target genes essential for muscle differentiation. We now demonstrate that E2A proteins are primarily localized in the nucleus in both C2C12 myoblasts and myotubes, and are degraded by the ubiquitin proteasome system evidenced by stabilization following treatment with the proteasome inhibitor, MG132. During the differentiation from myoblast to myotube, the cellular abundance of E2A proteins is relatively unaltered, despite significant changes ( each similar to 5-fold) in the relative rates of protein synthesis and protein degradation via the ubiquitin-proteasome system. The rate of ubiquitin-proteasome-mediated E2A protein degradation depends on the myogenic differentiation state (t 1/2 similar to 2 h in proliferating myoblasts versus t 1/2 > 10h in differentiated myotubes), and is also associated with cell cycle in non-muscle cells. Our findings reveal an important role for both translational and post-translational regulatory mechanisms in mediating the complex program of muscle differentiation determined by the E2A proteins.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63178 USA; Technion Israel Inst Technol, Fac Med, Vasc & Tumor Biol Res Ctr, Haifa, Israel	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	Schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Dearth LR, 2003, J BIOL CHEM, V278, P11246, DOI 10.1074/jbc.M207930200; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lazorchak A, 2005, TRENDS IMMUNOL, V26, P334, DOI 10.1016/j.it.2005.03.011; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Nie L, 2003, EMBO J, V22, P5780, DOI 10.1093/emboj/cdg567; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Riera L, 2003, FEBS LETT, V550, P23, DOI 10.1016/S0014-5793(03)00808-1; Riley RL, 2005, SEMIN IMMUNOL, V17, P330, DOI 10.1016/j.smim.2005.05.011; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; Sun LP, 2005, J BIOL CHEM, V280, P26448, DOI 10.1074/jbc.M500373200; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; Van der Put E, 2004, J IMMUNOL, V173, P818, DOI 10.4049/jimmunol.173.2.818; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317	26	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					441	448		10.1038/sj.onc.1209793	http://dx.doi.org/10.1038/sj.onc.1209793			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16909127				2022-12-25	WOS:000243544000012
J	Hochman, E; Castiel, A; Jacob-Hirsch, J; Amariglio, N; Izraeli, S				Hochman, Eldar; Castiel, Asher; Jacob-Hirsch, Jasmine; Amariglio, Ninnette; Izraeli, Shai			Molecular pathways regulating pro-migratory effects of Hedgehog signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORPHOGEN SONIC HEDGEHOG; RESPONSIVE GENE; TUBE FORMATION; AXON GUIDANCE; IN-VITRO; NEUROPILIN-1; GROWTH; ANGIOGENESIS; EXPRESSION; CELLS	The Hedgehog proteins play a crucial role in metazoan embryo development. Constitutive activation of the pathway is associated with multiple types of cancer. Recent experimental data suggest involvement of Hedgehog signaling in vascular remodeling, germ cell migration, and axon guidance. The molecular mechanisms underlying these effects remain elusive. Here we show that yolk sac-derived endothelial cells and embryonic fibroblasts can directly respond to the Hedgehog signal by increased migration in an in vitro scratch (wound) assay. We also identify Hedgehog transcriptional target genes in these cells, many of which participate in cell migration, axon guidance, and angiogenesis processes. Inhibition of one such molecular pathway, neuropilin-flavomonooxygenase, blocks Hedgehog-induced cell migration. These findings suggest that Hedgehog signaling directly affects embryonic endothelial and fibroblast cell migration via molecules and pathways known to regulate cell migration in response to a variety of environmental cues.	Safra Childrens Hosp, Sheba Med Ctr, Sheba Canc Res Ctr, Res Sect Childhood Malignancies, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Fac Med, IL-52621 Tel Hashomer, Israel	Chaim Sheba Medical Center; Tel Aviv University	Izraeli, S (corresponding author), Safra Childrens Hosp, Sheba Med Ctr, Sheba Canc Res Ctr, Res Sect Childhood Malignancies, IL-52621 Tel Hashomer, Israel.	sizraeli@sheba.health.gov.il						Abe I, 2000, BIOCHEM BIOPH RES CO, V268, P767, DOI 10.1006/bbrc.2000.2217; Abe I, 2000, FEBS LETT, V483, P131, DOI 10.1016/S0014-5793(00)02100-1; Asai J, 2006, CIRCULATION, V113, P2413, DOI 10.1161/CIRCULATIONAHA.105.603167; BANERJEE S, 2006, IN PRESS MOL CARCINO; Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Briscoe J, 1999, SEMIN CELL DEV BIOL, V10, P353, DOI 10.1006/scdb.1999.0295; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Byrd N, 2002, DEVELOPMENT, V129, P361; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Charron F, 2003, CELL, V113, P11, DOI 10.1016/S0092-8674(03)00199-5; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Deshpande G, 2001, CELL, V106, P759, DOI 10.1016/S0092-8674(01)00488-3; Eichmann A, 2005, GENE DEV, V19, P1013, DOI 10.1101/gad.1305405; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447; Garg V, 2001, DEV BIOL, V235, P62, DOI 10.1006/dbio.2001.0283; Gering M, 2005, DEV CELL, V8, P389, DOI 10.1016/j.devcel.2005.01.010; Gonzalez-Quevedo R, 2005, J CELL BIOL, V168, P453, DOI 10.1083/jcb.200409078; Herzog Y, 2001, MECH DEVELOP, V109, P115, DOI 10.1016/S0925-4773(01)00518-4; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975; Kato K, 2004, DEVELOPMENT, V131, P5253, DOI 10.1242/dev.01404; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kellner K, 2002, TISSUE ENG, V8, P561, DOI 10.1089/107632702760240481; Kolpak A, 2005, J NEUROSCI, V25, P3432, DOI 10.1523/JNEUROSCI.4938-04.2005; Kondo T, 2002, CANCER LETT, V180, P139, DOI 10.1016/S0304-3835(02)00007-1; Kusano KF, 2005, NAT MED, V11, P1197, DOI 10.1038/nm1313; Latil A, 2000, INT J CANCER, V89, P167, DOI 10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9; LIN L, 2006, IN PRESS DEV BIOL; Louro ID, 2002, CANCER RES, V62, P5867; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Matthies AM, 2002, AM J PATHOL, V160, P289, DOI 10.1016/S0002-9440(10)64372-6; Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Ochiumi T, 2006, INT J ONCOL, V29, P105; Oh H, 2002, P NATL ACAD SCI USA, V99, P383, DOI 10.1073/pnas.012074399; Pearse RV, 1998, J EXP ZOOL, V282, P677, DOI 10.1002/(SICI)1097-010X(19981215)282:6<677::AID-JEZ4>3.0.CO;2-F; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Smoak IW, 2005, DEV BIOL, V283, P357, DOI 10.1016/j.ydbio.2005.04.029; Suzuki T, 2002, J BIOL CHEM, V277, P14933, DOI 10.1074/jbc.M111842200; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Testaz S, 2001, P NATL ACAD SCI USA, V98, P12521, DOI 10.1073/pnas.221108698; Ventura A., 2002, SCI STKE, V2002, pPE44; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Vokes SA, 2004, DEVELOPMENT, V131, P4371, DOI 10.1242/dev.01304; Wang SJ, 1996, IN VITRO CELL DEV-AN, V32, P292; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200	56	61	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33860	33870		10.1074/jbc.M605905200	http://dx.doi.org/10.1074/jbc.M605905200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16943197	hybrid			2022-12-25	WOS:000241767600007
J	Bentle, MS; Reinicke, KE; Bey, EA; Spitz, DR; Boothman, DA				Bentle, Melissa S.; Reinicke, Kathryn E.; Bey, Erik A.; Spitz, Douglas R.; Boothman, David A.			Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; NAD(P)H-QUINONE OXIDOREDUCTASE-1; OXIDATIVE STRESS; GLUCOSE DEPRIVATION; PANCREATIC-CANCER; ACTIVATION; TUMOR; INHIBITION; SYNTHETASE; APOPTOSIS	After genotoxic stress poly(ADP-ribose) polymerase-1 (PARP-1) can be hyperactivated, causing (ADP-ribosyl) ation of nuclear proteins ( including itself), resulting in NAD+ and ATP depletion and cell death. Mechanisms of PARP-1-mediated cell death and downstream proteolysis remain enigmatic. beta-lapachone (beta-lap) is the first chemotherapeutic agent to elicit a Ca2+-mediated cell death by PARP-1 hyperactivation at clinically relevent doses in cancer cells expressing elevated NAD(P)H: quinone oxidoreductase 1 (NQO1) levels. beta-lap induces the generation of NQO1-dependent reactive oxygen species (ROS), DNA breaks, and triggers Ca2+-dependent gamma-H2AX formation and PARP-1 hyperactivation. Subsequent NAD(+) and ATP losses suppress DNA repair and cause cell death. Reduction of PARP-1 activity or Ca2+ chelation protects cells. Interestingly, Ca2+ chelation abrogates hydrogen peroxide ( H2O2), but not N-Methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced PARP-1 hyperactivation and cell death. Thus, Ca2+ appears to be an important co-factor in PARP-1 hyperactivation after ROS-induced DNA damage, which alters cellular metabolism and DNA repair.	Univ Texas, SW Med Ctr, Lab Mol Stress Responses, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Iowa, Holden Comprehens Canc Ctr, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; Case Western Reserve University; University of Iowa	Boothman, DA (corresponding author), Univ Texas, SW Med Ctr, Lab Mol Stress Responses, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	David.Boothman@UTSouthwestern.edu	Boothman, David/Q-7776-2019	Spitz, Douglas/0000-0002-1254-8765; Srougi, Melissa/0000-0003-2183-0233	NATIONAL CANCER INSTITUTE [R01CA100045, P30CA142543, P30CA043703, R01CA102792] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703, 1R01CA10279201, P30CA43703-12, 1R01CA100045, P30 CA142543, R01 CA102792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Barbouti A, 2001, FREE RADICAL BIO MED, V31, P490, DOI 10.1016/S0891-5849(01)00608-6; Beigi RD, 2000, J IMMUNOL, V165, P7189, DOI 10.4049/jimmunol.165.12.7189; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; BOOTHMAN DA, 1989, P NATL ACAD SCI USA, V86, P4963, DOI 10.1073/pnas.86.13.4963; BOOTHMAN DA, 1992, INT J RADIAT ONCOL, V24, P939, DOI 10.1016/0360-3016(92)90478-Z; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; Britigan BE, 1998, BIOCHEM PHARMACOL, V55, P287, DOI 10.1016/S0006-2952(97)00463-2; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Cipriani G, 2005, J BIOL CHEM, V280, P17227, DOI 10.1074/jbc.M414526200; Cullen JJ, 2003, CANCER RES, V63, P5513; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; Fitzsimmons SA, 1996, J NATL CANCER I, V88, P259, DOI 10.1093/jnci/88.5.259; Fonfria E, 2004, BRIT J PHARMACOL, V143, P186, DOI 10.1038/sj.bjp.0705914; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; HOLLANDER PM, 1975, ARCH BIOCHEM BIOPHYS, V169, P560, DOI 10.1016/0003-9861(75)90200-3; HORNBURG S, 2000, J CELL BIOL, V150, P293; Jacobson EL, 1997, METHOD ENZYMOL, V280, P221; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Jornot L, 1998, BIOCHEM J, V335, P85, DOI 10.1042/bj3350085; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kun E, 2004, BIOCHEMISTRY-US, V43, P210, DOI 10.1021/bi0301791; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Lewis A, 2004, CLIN CANCER RES, V10, P4550, DOI 10.1158/1078-0432.CCR-03-0667; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manna SK, 1999, BIOCHEM PHARMACOL, V57, P763, DOI 10.1016/S0006-2952(98)00354-2; MCLICK J, 1987, BIOCHIM BIOPHYS ACTA, V909, P71, DOI 10.1016/0167-4781(87)90047-9; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; OGATA N, 1981, J BIOL CHEM, V256, P4135; OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587; Pardee AB, 2002, CURR CANCER DRUG TAR, V2, P227, DOI 10.2174/1568009023333854; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pink JJ, 2000, EXP CELL RES, V255, P144, DOI 10.1006/excr.1999.4790; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; RASBAND W, 2005, IMAGE J INT; Reinicke KE, 2005, CLIN CANCER RES, V11, P3055, DOI 10.1158/1078-0432.CCR-04-2185; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X; Siegel D, 1998, CLIN CANCER RES, V4, P2065; Siegel D, 2004, MOL PHARMACOL, V65, P1238, DOI 10.1124/mol.65.5.1238; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Tagliarino C, 2001, J BIOL CHEM, V276, P19150, DOI 10.1074/jbc.M100730200; Tagliarino C, 2003, CANCER BIOL THER, V2, P141, DOI 10.4161/cbt.2.2.237; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; TANUMA SI, 1986, J BIOL CHEM, V261, P965; Virag L, 1999, MOL PHARMACOL, V56, P824; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	53	97	99	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33684	33696		10.1074/jbc.M603678200	http://dx.doi.org/10.1074/jbc.M603678200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16920718	hybrid			2022-12-25	WOS:000241621400076
J	Hitchens, TK; Zhan, YP; Richardson, LV; Richardson, JP; Rule, GS				Hitchens, T. Kevin; Zhan, Yiping; Richardson, Lislott V.; Richardson, John P.; Rule, Gordon S.			Sequence-specific interactions in the RNA-binding domain of Escherichia coli transcription termination factor Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGONUCLEOTIDE COFACTORS; DEPENDENT TERMINATION; MESSENGER-RNA; PROTEIN; RECOGNITION; ACTIVATION; RESONANCE; HELICASE; SITES	Rho factor is an essential protein that causes termination of transcription in a wide variety of bacteria by an RNA-dependent helicase activity. Rho is activated by transcripts that contain a high proportion of cytidine residues. The interaction between Rho and two adjacent cytidine residues within the bound RNA has been identified by previous crystallographic studies (Skordalakes, E., and Berger, J.M. (2003) Cell 114, 135-146). In this study, NMR methods were used to investigate the sequence dependence of the binding of oligonucleotides to the RNA-binding domain of Rho protein (rho130). A comparison of the NMR spectra obtained for rho130 bound to single-stranded oligonucleotides ACTTCCA or ATTTCCA showed that the 5'-cytidine residue interacts with Rho at a site that is distinct from the CC binding site identified by crystallographic studies. Two amino acid residues within this new cytidine binding site, Arg(88) and Phe(89), were altered to Glu and Ser, respectively. These mutant forms of Rho were defective in transcriptional termination, suggesting that those residues play an important role in the activation of Rho by bound RNA.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Carnegie Mellon University; Indiana University System; Indiana University Bloomington	Rule, GS (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.	rule@andrew.cmu.edu	Rule, Gordon S/Q-2422-2015	Rule, Gordon S/0000-0002-4396-3363	NIGMS NIH HHS [GM 56095] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SP, 1983, J AM CHEM SOC, V105, P661, DOI 10.1021/ja00341a078; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Briercheck DM, 1996, J BIOMOL NMR, V8, P429; Burgess BR, 2001, J BIOL CHEM, V276, P4182, DOI 10.1074/jbc.M007066200; Burgess BR, 2001, J BIOL CHEM, V276, P17106, DOI 10.1074/jbc.M101856200; Chen X, 2004, J BIOL CHEM, V279, P16301, DOI 10.1074/jbc.M313640200; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; Graham JE, 1998, J BIOL CHEM, V273, P20764, DOI 10.1074/jbc.273.33.20764; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; Kim DE, 2001, J BIOL CHEM, V276, P13902, DOI 10.1074/jbc.M011043200; Lian L. Y., 1993, NMR MACROMOLECULES P, P153; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MODRAK D, 1994, BIOCHEMISTRY-US, V33, P8292, DOI 10.1021/bi00193a016; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; RICHARDSON LV, 1992, GENE, V118, P103, DOI 10.1016/0378-1119(92)90255-N; Richardson LV, 1996, J BIOL CHEM, V271, P21597, DOI 10.1074/jbc.271.35.21597; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; TABOR S, 1991, CURRENT PROTOCOLS MO; WANG Y, 1993, J BIOL CHEM, V268, P13940; WANG Y, 1993, J BIOL CHEM, V268, P13947; Wei RR, 2001, J BIOL CHEM, V276, P28380, DOI 10.1074/jbc.M102444200; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011	30	8	8	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33697	33703		10.1074/jbc.M605312200	http://dx.doi.org/10.1074/jbc.M605312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16908525	hybrid			2022-12-25	WOS:000241621400077
J	Hou, JC; Suzuki, N; Pessin, JE; Watson, RT				Hou, June Chunqiu; Suzuki, Naoko; Pessin, Jeffrey E.; Watson, Robert T.			A specific dileucine motif is required for the GGA-dependent entry of newly synthesized insulin-responsive aminopeptidase into the insulin-responsive compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; GLUCOSE-TRANSPORTER GLUT4; RAT ADIPOSE-CELLS; REGULATED MEMBRANE AMINOPEPTIDASE; ENDOSOMAL RECYCLING COMPARTMENT; SKELETAL-MUSCLE CELLS; PLASMA-MEMBRANE; STORAGE COMPARTMENT; 3T3-L1 ADIPOCYTES; 3T3L1 ADIPOCYTES	In muscle and adipose cells, the insulin-responsive aminopeptidase ( IRAP) is localized to intracellular storage sites and undergoes insulin-dependent redistribution to the cell surface. Following expression, the newly synthesized IRAP protein traffics to the perinuclear insulin-sensitive compartment and acquires insulin sensitivity 6-9 h following biosynthesis. Knockdown of GGA1 by RNA interference prevented IRAP from entering, but not exiting, the insulin-responsive compartment. Mutation of the dileucine motif at positions 76 and 77 (EGFP-IRAP/AA(76,77)),but not the dileucine motif at positions 53 and 54, resulted in the rapid default of the reporter to the cell surface beginning at 3 h following biosynthesis. Alanine substitution of 9 residues amino- or carboxyl-terminal to LL76,77 did not perturb basal intracellular sequestration or abrogate insulin-stimulated IRAP translocation. Moreover, a dominant interfering GGA mutant (VHS-GAT) potently inhibited insulin-stimulated translocation of EGFP-IRAP/WT but did not block the constitutive exocytotic trafficking of EGFP-IRAP/AA(76,77). In addition, the EGFP-IRAP/WT and EGFP-IRAP/AA(76,77) constructs occupied morphologically distinct tubulovesicular compartments in the perinuclear region. Taken together, these data indicate that LL76,77 functions during the GGA-dependent sorting of newly made IRAP into the insulin-responsive storage compartment.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Watson, RT (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	Watson@pharm.stonybrook.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R37DK033823, R01DK055811] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55811, DK33823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2004, MOL ENDOCRINOL, V18, P2491, DOI 10.1210/me.2004-0175; Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Bogan JS, 2003, NATURE, V425, P727, DOI 10.1038/nature01989; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Brozinick JT, 2004, J BIOL CHEM, V279, P40699, DOI 10.1074/jbc.M402697200; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; El-Jack AK, 1999, MOL BIOL CELL, V10, P1581, DOI 10.1091/mbc.10.5.1581; Elmendorf JS, 1999, J BIOL CHEM, V274, P37357, DOI 10.1074/jbc.274.52.37357; Ghosh P, 2004, EUR J CELL BIOL, V83, P257, DOI 10.1078/0171-9335-00374; Gleeson PA, 2004, TRAFFIC, V5, P315, DOI 10.1111/j.1398-9219.2004.00182.x; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hirst J, 2001, MOL BIOL CELL, V12, P3573, DOI 10.1091/mbc.12.11.3573; Hosaka T, 2005, MOL BIOL CELL, V16, P2882, DOI 10.1091/mbc.E05-01-0072; Hou JCQ, 2003, MOL BIOL CELL, V14, P3578, DOI 10.1091/mbc.E03-02-0012; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Johnson AO, 2001, MOL BIOL CELL, V12, P367, DOI 10.1091/mbc.12.2.367; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Keller SR, 2003, FRONT BIOSCI-LANDMRK, V8, pS410, DOI 10.2741/1078; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Khan AH, 2004, J BIOL CHEM, V279, P37505, DOI 10.1074/jbc.M405694200; Koumanov F, 2005, CELL METAB, V2, P179, DOI 10.1016/j.cmet.2005.08.007; Ladinsky MS, 2002, MOL BIOL CELL, V13, P2810, DOI 10.1091/mbc.01-12-0593; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Lampson MA, 2000, J CELL SCI, V113, P4065; Li LV, 2005, MOL ENDOCRINOL, V19, P2145, DOI 10.1210/me.2005-0032; Liu G, 2005, AM J PHYSIOL-ENDOC M, V289, pE746, DOI 10.1152/ajpendo.00175.2005; Lizunov VA, 2005, J CELL BIOL, V169, P481, DOI 10.1083/jcb.200412069; Martin S, 1997, J CELL SCI, V110, P2281; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Munro S, 2004, NAT CELL BIOL, V6, P469, DOI 10.1038/ncb0604-469; Palacios S, 2001, J BIOL CHEM, V276, P3371, DOI 10.1074/jbc.M006739200; Patel N, 2003, MOL CELL BIOL, V23, P4611, DOI 10.1128/MCB.23.13.4611-4626.2003; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; Rodriguez-Boulan E, 2005, BBA-MOL CELL RES, V1744, P455, DOI 10.1016/j.bbamcr.2005.04.007; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; SATOH S, 1993, J BIOL CHEM, V268, P17820; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; Sumitani S, 1997, ENDOCRINOLOGY, V138, P1029, DOI 10.1210/en.138.3.1029; Tang BL, 2005, BBA-MOL CELL RES, V1744, P293, DOI 10.1016/j.bbamcr.2005.02.007; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Traub LM, 2005, BBA-MOL CELL RES, V1744, P415, DOI 10.1016/j.bbamcr.2005.04.005; Watson RT, 2004, EMBO J, V23, P2059, DOI 10.1038/sj.emboj.7600159; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; YANG J, 1993, J BIOL CHEM, V268, P4600; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V278, pE1019, DOI 10.1152/ajpendo.2000.278.6.E1019	67	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33457	33466		10.1074/jbc.M601583200	http://dx.doi.org/10.1074/jbc.M601583200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16945927	hybrid			2022-12-25	WOS:000241621400056
J	Ong, LL; Lin, PC; Zhang, X; Chia, SM; Yu, H				Ong, Lee-Lee; Lin, Pao-Chun; Zhang, Xin; Chia, Ser-Mien; Yu, Hanry			Kinectin-dependent assembly of translation elongation factor-1 complex on endoplasmic reticulum regulates protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; AMINOACYL-TRANSFER RNA; KINESIN-BINDING PROTEIN; MOLECULAR-CLONING; MESSENGER-RNAS; RAT-LIVER; MEMBRANE; PHOSPHORYLATION; ORGANIZATION; ARTEMIA	Kinectin is an integral membrane protein with many isoforms primarily found on the endoplasmic reticulum. It has been found to bind kinesin, Rho GTPase, and translation elongation factor-1 delta. None of the existing models for the quaternary organization of the elongation factor-1 complex in higher eukaryotes involves kinectin. We have investigated here the assembly of the elongation factor-1 complex onto endoplasmic reticulum via kinectin using in vitro and in vivo assays. We established that the entire elongation factor-1 complex can be anchored to endoplasmic reticulum via kinectin, and the interacting partners are as follows. Kinectin binds EF-1 delta, which in turn binds EF-1 gamma but not EF-1 beta; EF-1 gamma binds EF-1 delta and EF-1 beta but not kinectin. In vivo splice blocking of the kinectin exons 36 and 37 produced kinectin lacking the EF-1 delta binding domain, which disrupted the membrane localization of EF-1 delta, EF-1 gamma, and EF-1 beta on endoplasmic reticulum, similar to the disruptions seen with the overexpression of kinectin fragments containing the EF-1 delta binding domain. The disruptions of the EF-1 delta/kinectin interaction inhibited expression of membrane proteins but enhanced synthesis of cytosolic proteins in vivo. These findings suggest that anchoring the elongation factor-1 complex onto endoplasmic reticulum via EF-1 delta/kinectin interaction is important for regulating protein synthesis in eukaryotic cells.	Natl Univ Singapore, Dept Physiol, Singapore 117597, Singapore; Natl Univ Singapore, Natl Univ Med Inst, Singapore 117597, Singapore; Natl Univ Singapore, Grad Program Bioengn, Singapore 117597, Singapore; Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117597, Singapore; Natl Univ Singapore, NUSTEP, Singapore 117597, Singapore; Singapore MIT Alliance, Singapore 117576, Singapore; Agcy Sci Technol & Res, Inst Bioengn & Technol, Singapore 138669, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; Massachusetts Institute of Technology (MIT); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Singapore-MIT Alliance for Research & Technology Centre (SMART); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Bioengineering & Bioimaging (IBB); A*STAR - Institute of Bioengineering & Nanotechnology (IBN)	Yu, H (corresponding author), Natl Univ Singapore, Dept Physiol, Block MD11,04-01A,10 Med Dr, Singapore 117597, Singapore.	phsyuh@nus.edu.sg	Yu, Hanry/C-1031-2013; Yu, Hanry/L-6050-2019; Yu, Hanry/C-7375-2011	Yu, Hanry/0000-0002-0339-3685; Yu, Hanry/0000-0002-0339-3685; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARBARESE E, 1995, J CELL SCI, V108, P2781; BEC G, 1994, J BIOL CHEM, V269, P2086; BIRBECK MS, 1961, NATURE, V189, P558, DOI 10.1038/189558a0; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; DALLNER G, 1966, J CELL BIOL, V30, P97, DOI 10.1083/jcb.30.1.97; DALLNER G, 1966, J CELL BIOL, V30, P73, DOI 10.1083/jcb.30.1.73; DEUTSCHER MP, 1984, J CELL BIOL, V99, P373, DOI 10.1083/jcb.99.2.373; Diehn M, 2000, NAT GENET, V25, P58, DOI 10.1038/75603; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISENSTEIN RS, 1984, J BIOL CHEM, V259, P9922; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FULTON AB, 1980, CELL, V20, P849, DOI 10.1016/0092-8674(80)90331-1; FUTTERER A, 1995, MOL BIOL CELL, V6, P161; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; Harlow E., 1988, ANTIBODIES LAB MANUA; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; HICKS SJ, 1969, SCIENCE, V164, P584, DOI 10.1126/science.164.3879.584; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; Kaether C, 1997, EUR J CELL BIOL, V74, P133; KIMBALL SR, 1989, AM J PHYSIOL, V256, pC28, DOI 10.1152/ajpcell.1989.256.1.C28; Kumar J, 1998, J BIOL CHEM, V273, P31738, DOI 10.1074/jbc.273.48.31738; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; Lerner RS, 2003, RNA, V9, P1123, DOI 10.1261/rna.5610403; Leung E, 1996, IMMUNOL CELL BIOL, V74, P421, DOI 10.1038/icb.1996.72; Mansilla F, 2002, BIOCHEM J, V365, P669, DOI 10.1042/BJ20011681; MERRICK WC, 2000, TRANSLATIONAL CONTRO; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; Minella O, 1998, BIOSCIENCE REP, V18, P119, DOI 10.1023/A:1020140527930; MORRISON TG, 1975, J BIOL CHEM, V250, P6955; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; OGILVIE A, 1979, BIOCHIM BIOPHYS ACTA, V565, P293, DOI 10.1016/0005-2787(79)90206-5; Ong LL, 2000, J BIOL CHEM, V275, P32854, DOI 10.1074/jbc.M005650200; Ong LL, 2003, J BIOL CHEM, V278, P32115, DOI 10.1074/jbc.M210917200; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pelham HRB, 1996, CELL STRUCT FUNCT, V21, P413, DOI 10.1247/csf.21.413; Potter MD, 2001, TRENDS CELL BIOL, V11, P112, DOI 10.1016/S0962-8924(00)01905-X; PRINT CG, 1994, GENE, V144, P221, DOI 10.1016/0378-1119(94)90381-6; RAPOPORT TA, 1989, BIOCHEM SOC T, V17, P325, DOI 10.1042/bst0170325; REDMAN CM, 1966, J BIOL CHEM, V241, P1150; RICHTER JD, 1981, CELL, V27, P183, DOI 10.1016/0092-8674(81)90372-X; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; RYAZANOV AG, 1987, BIOSYSTEMS, V20, P275, DOI 10.1016/0303-2647(87)90035-9; Sanders J, 1996, J CELL SCI, V109, P1113; Santama N, 2004, J CELL SCI, V117, P4537, DOI 10.1242/jcs.01326; Sheu GT, 1999, MOL CELL BIOCHEM, V191, P181, DOI 10.1023/A:1006802125856; Sheu GT, 1997, J BIOL CHEM, V272, P33290, DOI 10.1074/jbc.272.52.33290; SIVARAM P, 1990, P NATL ACAD SCI USA, V87, P3665, DOI 10.1073/pnas.87.10.3665; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; Toyoshima I, 1996, NEUROSCI LETT, V211, P171, DOI 10.1016/0304-3940(96)12752-X; Tsokas P, 2005, J NEUROSCI, V25, P5833, DOI 10.1523/JNEUROSCI.0599-05.2005; VANDAMME H, 1991, EUR J BIOCHEM, V197, P505, DOI 10.1111/j.1432-1033.1991.tb15938.x; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; VASSALLI P, 1971, J MOL BIOL, V56, P1, DOI 10.1016/0022-2836(71)90080-5; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wang HC, 2004, BIOCHEM CELL BIOL, V82, P321, DOI 10.1139/o04-003; Xu JW, 2002, MOL REPROD DEV, V62, P37, DOI 10.1002/mrd.10066; YU H, 1995, MOL BIOL CELL, V6, P171, DOI 10.1091/mbc.6.2.171	69	26	27	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33621	33634		10.1074/jbc.M607555200	http://dx.doi.org/10.1074/jbc.M607555200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950774	hybrid			2022-12-25	WOS:000241621400071
J	Francke, F; Ward, RJ; Jenkins, L; Kellett, E; Richter, D; Milligan, G; Bachner, D				Francke, Felix; Ward, Richard J.; Jenkins, Laura; Kellett, Elaine; Richter, Dietmar; Milligan, Graeme; Baechner, Dietmar			Interaction of neurochondrin with the melanin-concentrating hormone receptor 1 interferes with G protein-coupled signal transduction but not agonist-mediated internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TAIL; HORMONE-RECEPTOR; RAT-BRAIN; SCAFFOLDING PROTEINS; TARGETED DISRUPTION; NEURITE-OUTGROWTH; NERVOUS-SYSTEM; MESSENGER-RNA; EXPRESSION; GENE	Screening of a human brain cDNA library using the C-terminal tail of the melanin-concentrating hormone receptor 1(MCHR1) as bait in a yeast two-hybrid assay resulted in the identification of the neurite-outgrowth related factor, neurochondrin. This interaction was verified in overlay, pulldown, and co-immunoprecipitation assays. Deletion mapping confined the binding to the C terminus of neurochondrin and to the proximal C terminus of MCHR1, a region known to be involved in G protein binding and signal transduction. This region of the MCHR1 is also able to interact with the actin- and intermediate filament-binding protein, periplakin. Interactions of MCHR1 with neurochondrin and periplakin were competitive, indicating that these two proteins bind to overlapping regions of MCHR1. Although neurochondrin did not interfere with melanin-concentrating hormone-mediated internalization of the receptor, it did inhibit G protein-coupled signal transduction via both G alpha(i/o) and G alpha(q/11) family G proteins as measured by each of melanin-concentrating hormone-induced G protein-activated inwardly rectifying K+ channel activity of voltage-clamped amphibian oocytes, by calcium mobilization in transfected mammalian cells, and by reduction in the capacity of melanin-concentrating hormone to promote binding of [S-35]guanosine 5'-3-O-(thio)triphosphate to both G alpha(o1) and G alpha(11). Immunohistochemistry revealed co-expression of neurochondrin and MCHR1 within the rodent brain, suggesting that neurochondrin may be involved in the regulation of MCHR1 signaling and play a role in modulating melanin-concentrating hormone-mediated functions in vivo.	Univ Hamburg, Inst Cell Biochem & Clin Neurol, D-20246 Hamburg, Germany; Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Hamburg; University of Glasgow	Bachner, D (corresponding author), Univ Hamburg, Sch Life Sci, Martinistr 52, D-20246 Hamburg, Germany.	baechner@uke.uni-hamburg.de	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				Bachner D, 2002, FEBS LETT, V526, P124, DOI 10.1016/S0014-5793(02)03115-0; Bachner D, 1999, FEBS LETT, V457, P522, DOI 10.1016/S0014-5793(99)01092-3; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Bockers TM, 2001, J BIOL CHEM, V276, P40104, DOI 10.1074/jbc.M102454200; Borowsky B, 2002, NAT MED, V8, P825, DOI 10.1038/nm741; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Canals M, 2006, J BIOL CHEM, V281, P16757, DOI 10.1074/jbc.M601121200; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Chen YY, 2002, ENDOCRINOLOGY, V143, P2469, DOI 10.1210/en.143.7.2469; Dateki M, 2005, J BIOL CHEM, V280, P20503, DOI 10.1074/jbc.M414033200; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Hawes BE, 2000, ENDOCRINOLOGY, V141, P4524, DOI 10.1210/en.141.12.4524; Hervieu GJ, 2000, EUR J NEUROSCI, V12, P1194, DOI 10.1046/j.1460-9568.2000.00008.x; Ishizuka Y, 1999, BBA-MOL CELL RES, V1450, P92, DOI 10.1016/S0167-4889(99)00039-7; Istvanffy R, 2004, DEV GENES EVOL, V214, P206, DOI 10.1007/s00427-004-0396-2; Kobayashi T, 2002, BRIT J PHARMACOL, V135, P313, DOI 10.1038/sj.bjp.0704475; Kowalski TJ, 2004, EUR J PHARMACOL, V497, P41, DOI 10.1016/j.ejphar.2004.06.027; Kreienkamp HJ, 2002, CURR OPIN PHARMACOL, V2, P581, DOI 10.1016/S1471-4892(02)00203-5; Ktistakis NT, 2003, BIOCHEM SOC T, V31, P94, DOI 10.1042/bst0310094; Liu S, 2002, J BIOL CHEM, V277, P25707, DOI 10.1074/jbc.M201015200; Marsh DJ, 2002, P NATL ACAD SCI USA, V99, P3240, DOI 10.1073/pnas.052706899; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; MITCHELL FM, 1991, FEBS LETT, V287, P171, DOI 10.1016/0014-5793(91)80043-3; Mochizuki R, 2003, BIOCHEM BIOPH RES CO, V310, P1219, DOI 10.1016/j.bbrc.2003.09.153; Mochizuki R, 1999, BBA-GENE STRUCT EXPR, V1446, P397, DOI 10.1016/S0167-4781(99)00120-7; MULLANEY I, 1988, BIOCHEM J, V256, P649, DOI 10.1042/bj2560649; Murdoch H, 2005, J BIOL CHEM, V280, P8208, DOI 10.1074/jbc.M405215200; Ohoka Y, 2001, BIOCHEM BIOPH RES CO, V280, P237, DOI 10.1006/bbrc.2000.4080; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pissios P, 2003, ENDOCRINOLOGY, V144, P3514, DOI 10.1210/en.2002-0004; Saito Y, 2004, PEPTIDES, V25, P1597, DOI 10.1016/j.peptides.2004.03.026; Saito Y, 2001, J COMP NEUROL, V435, P26, DOI 10.1002/cne.1191; Saito Y, 2000, TRENDS ENDOCRIN MET, V11, P299, DOI 10.1016/S1043-2760(00)00290-3; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Shinozaki K, 1999, MOL BRAIN RES, V71, P364, DOI 10.1016/S0169-328X(99)00181-3; Shinozaki K, 1997, BIOCHEM BIOPH RES CO, V240, P766, DOI 10.1006/bbrc.1997.7660; Takekawa S, 2002, EUR J PHARMACOL, V438, P129, DOI 10.1016/S0014-2999(02)01314-6; Tan CP, 2002, GENOMICS, V79, P785, DOI 10.1006/geno.2002.6771; Tetsuka M, 2004, ENDOCRINOLOGY, V145, P3712, DOI 10.1210/en.2003-1638; Tritos NA, 1999, NEUROPEPTIDES, V33, P339, DOI 10.1054/npep.1999.0055; Vitale RM, 2004, PROTEINS, V56, P430, DOI 10.1002/prot.20125; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	44	22	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32496	32507		10.1074/jbc.M602889200	http://dx.doi.org/10.1074/jbc.M602889200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16945926	hybrid			2022-12-25	WOS:000241414500047
J	Andersson, MX; Hamberg, M; Kourtchenko, O; Brunnstrom, A; McPhail, KL; Gerwick, WH; Gobel, C; Feussner, I; Ellerstrom, M				Andersson, Mats X.; Hamberg, Mats; Kourtchenko, Olga; Brunnstrom, Asa; McPhail, Kerry L.; Gerwick, William H.; Goebel, Cornelia; Feussner, Ivo; Ellerstrom, Mats			Oxylipin profiling of the hypersensitive response in Arabidopsis thaliana - Formation of a novel oxo-phytodienoic acid-containing galactolipid, arabidopside E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT STRESS RESPONSES; CELL-DEATH; TOBACCO-LEAVES; ACYLGALACTOSYL DIGLYCERIDE; SIGNALING NETWORK; LIPOXYGENASE; PATHWAY; HYDROPEROXIDES; RESISTANCE; ALPHA	Oxidation products of unsaturated fatty acids, collectively known as oxylipins, function as signaling molecules in plants during development, wounding, and insect and pathogen attack. Certain oxylipins are also known to have direct cytotoxic effects on pathogens. We used inducible expression of bacterial avirulence proteins in planta to study the involvement of oxylipins in race-specific defense against bacterial pathogens. We demonstrate that recognition of the Pseudomonas syringae avirulence protein AvrRpm1 induces 9- and 13-lipoxygenase-dependent oxylipin synthesis in Arabidopsis thaliana. The major oxylipins accumulated were jasmonic acid, 12-oxo-phytodienoic acid, and dinor-oxo-phytodienoic acid. The majority of the newly formed oxylipins (> 90%) was found to be esterified to glycerolipids, whereby 12-oxo-phytodienoic acid and dinor-oxo-phytodienoic acid were found to be esterified to a novel galactolipid. The structure of the substance was determined as a monogalactosyldiacylglycerol containing two 12-oxo-phytodienoic acids and one dinor-oxo-phytodienoic acid acyl chain and was given the trivial name arabidopside E. This substance accumulated to surprisingly high levels, 7 - 8% of total lipid content, and was shown to inhibit growth of a bacterial pathogen in vitro. Arabidopside E was formed also after recognition of the avirulence protein AvrRpt2, suggesting that this could be a conserved feature of defense reactions against bacterial pathogens. In conclusion, the data presented suggest a role of enzymatically formed oxylipins, especially the octadecanoids and arabidopside E in race-specific resistance against bacterial pathogens.	Univ Gothenburg, Dept Plant & Environm Sci, SE-40530 Gothenburg, Sweden; Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Biolipox AB, SE-17165 Solna, Sweden; Oregon State Univ, Coll Pharm, Corvallis, OR 97331 USA; Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA; Univ Gottingen, Albrecht Haller Inst Plant Sci, D-37077 Gottingen, Germany	University of Gothenburg; Karolinska Institutet; Oregon State University; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Gottingen	Ellerstrom, M (corresponding author), Univ Gothenburg, Dept Plant & Environm Sci, SE-40530 Gothenburg, Sweden.	mats.ellerstrom@botany.gu.se	Feussner, Ivo/H-9320-2013; Andersson, Mats/E-7958-2010	Feussner, Ivo/0000-0002-9888-7003; Andersson, Mats/0000-0003-4279-6572; Hamberg, Mats/0000-0002-8910-7810; McPhail, Kerry/0000-0003-2076-1002				Andersson MX, 2006, PLANT J, V47, P947, DOI 10.1111/j.1365-313X.2006.02844.x; Blee E, 2002, TRENDS PLANT SCI, V7, P315, DOI 10.1016/S1360-1385(02)02290-2; Buseman CM, 2006, PLANT PHYSIOL, V142, P28, DOI 10.1104/pp.106.082115; Cacas JL, 2005, PLANT CELL ENVIRON, V28, P1367, DOI 10.1111/j.1365-3040.2005.01369.x; Devoto A, 2005, PHYSIOL PLANTARUM, V123, P161, DOI 10.1111/j.1399-3054.2004.00418.x; Farmer EE, 2003, CURR OPIN PLANT BIOL, V6, P372, DOI 10.1016/S1369-5266(03)00045-1; Feussner I, 2002, ANNU REV PLANT BIOL, V53, P275, DOI 10.1146/annurev.arplant.53.100301.135248; FISCHER W, 1973, H-S Z PHYSIOL CHEM, V354, P1115, DOI 10.1515/bchm2.1973.354.2.1115; Gobel C, 2002, BBA-MOL CELL BIOL L, V1584, P55, DOI 10.1016/S1388-1981(02)00268-8; Gobel C, 2001, J BIOL CHEM, V276, P6267, DOI 10.1074/jbc.M008606200; Graner G, 2003, PHYTOCHEMISTRY, V63, P89, DOI 10.1016/S0031-9422(02)00724-0; Hamberg M, 2003, J BIOL CHEM, V278, P51796, DOI 10.1074/jbc.M310514200; Hamberg M, 2002, PROSTAG OTH LIPID M, V68-9, P363, DOI 10.1016/S0090-6980(02)00040-0; HAMBERG M, 1988, LIPIDS, V23, P469, DOI 10.1007/BF02535522; HEINZ E, 1967, BIOCHIM BIOPHYS ACTA, V144, P333, DOI 10.1016/0005-2760(67)90162-2; HEINZ E, 1969, H-S Z PHYSIOL CHEM, V350, P493, DOI 10.1515/bchm2.1969.350.1.493; HEINZ E, 1967, BIOCHIM BIOPHYS ACTA, V144, P321, DOI 10.1016/0005-2760(67)90161-0; Hisamatsu Y, 2005, J NAT PROD, V68, P600, DOI 10.1021/np0495938; Hisamatsu Y, 2003, TETRAHEDRON LETT, V44, P5553, DOI 10.1016/S0040-4039(03)01148-1; Hisamatsu Y, 2006, Z NATURFORSCH C, V61, P363; Howe GA, 2002, CURR OPIN PLANT BIOL, V5, P230, DOI 10.1016/S1369-5266(02)00250-9; La Camera S, 2004, IMMUNOL REV, V198, P267, DOI 10.1111/j.0105-2896.2004.0129.x; Lorenzo O, 2005, CURR OPIN PLANT BIOL, V8, P532, DOI 10.1016/j.pbi.2005.07.003; Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; Montillet JL, 2005, PLANT PHYSIOL, V138, P1516, DOI 10.1104/pp.105.059907; Montillet JL, 2002, PLANT PHYSIOL BIOCH, V40, P633, DOI 10.1016/S0981-9428(02)01402-X; Mueller MJ, 2004, CURR OPIN PLANT BIOL, V7, P441, DOI 10.1016/j.pbi.2004.04.001; Nimchuk Z, 2003, ANNU REV GENET, V37, P579, DOI 10.1146/annurev.genet.37.110801.142628; PFEFFER PE, 1977, J AM OIL CHEM SOC, V54, P380, DOI 10.1007/BF02802040; PFEFFER PE, 1992, LIPIDS, V27, P258; Prost I, 2005, PLANT PHYSIOL, V139, P1902, DOI 10.1104/pp.105.066274; Rusterucci C, 1999, J BIOL CHEM, V274, P36446, DOI 10.1074/jbc.274.51.36446; Schaller F, 2004, J PLANT GROWTH REGUL, V23, P179, DOI 10.1007/s00344-004-0047-x; Stelmach BA, 2001, J BIOL CHEM, V276, P12832, DOI 10.1074/jbc.M010743200; Stenzel I, 2003, PLANT MOL BIOL, V51, P895, DOI 10.1023/A:1023049319723; Thomma BPHJ, 2001, CURR OPIN IMMUNOL, V13, P63, DOI 10.1016/S0952-7915(00)00183-7; VICK BA, 1979, LIPIDS, V14, P734, DOI 10.1007/BF02533899; Vollenweider S, 2000, PLANT J, V24, P467, DOI 10.1046/j.1365-313x.2000.00897.x; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wasternack C, 2002, PROG NUCLEIC ACID RE, V72, P165, DOI 10.1016/S0079-6603(02)72070-9; Weber H, 1997, P NATL ACAD SCI USA, V94, P10473, DOI 10.1073/pnas.94.19.10473; Weichert H, 1999, FEBS LETT, V464, P133, DOI 10.1016/S0014-5793(99)01697-X; Welti R, 2002, J BIOL CHEM, V277, P31994, DOI 10.1074/jbc.M205375200	44	114	118	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31528	31537		10.1074/jbc.M604820200	http://dx.doi.org/10.1074/jbc.M604820200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16923817				2022-12-25	WOS:000241235300038
J	Higashimoto, Y; Sato, H; Sakamoto, H; Takahashi, K; Palmer, G; Noguchi, M				Higashimoto, Yuichiro; Sato, Hideaki; Sakamoto, Hiroshi; Takahashi, Kenichi; Palmer, Graham; Noguchi, Masato			The reactions of heme- and verdoheme-heme oxygenase-1 complexes with FMN-depleted NADPH-cytochrome P450 reductase - Electrons required for verdoheme oxidation can be transferred through a pathway not involving FMN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450 REDUCTASE; FERROUS-NO FORMS; CRYSTAL-STRUCTURE; RAT HEME; CATALYTIC IMPLICATIONS; ALPHA-HYDROXYHEME; SOLUBLE FORM; DEGRADATION; SYSTEM; BILIVERDIN	Electrons utilized in the heme oxygenase (HO) reaction are provided by NADPH-cytochrome P450 reductase (CPR). To investigate the electron transfer pathway from CPR to HO, we examined the reactions of heme and verdoheme, the second intermediate in the heme degradation, complexed with rat HO-1 (rHO-1) using a rat FMN-depleted CPR; the FMN-depleted CPR was prepared by dialyzing the CPR mutant, Y140A/Y178A, against 2 M KBr. Degradation of heme in complex with rHO-1 did not occur with FMN-depleted CPR, notwithstanding that the FMN-depleted CPR was able to associate with the heme-rHO-1 complex with a binding affinity comparable with that of the wild-type CPR. Thus, the first electron to reduce the ferric iron of heme complexed with rHO-1 must be transferred from FMN. In contrast, verdoheme was converted to the ferric biliverdin-iron chelate with FMN-depleted CPR, and this conversion was inhibited by ferricyanide, indicating that electrons are certainly required for conversion of verdoheme to a ferric biliverdin-iron chelate and that they can be supplied from the FMN-depleted CPR through a pathway not involving FMN, probably via FAD. This conclusion was supported by the observation that verdoheme dimethyl esters were accumulated in the reaction of the ferriprotoporphyrin IX dimethyl ester-rHO-1 complex with the wild-type CPR. Ferric biliverdin-iron chelate, generated with the FMN-depleted CPR, was converted to biliverdin by the addition of the wild-type CPR or desferrioxamine.	Kurume Univ, Sch Med, Dept Med Biochem, Kurume, Fukuoka 8300011, Japan; Kyushu Inst Technol, Dept Biosci & Bioinformat, Iizuka, Fukuoka 8208502, Japan; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Kurume University; Kyushu Institute of Technology; Rice University	Higashimoto, Y (corresponding author), Kurume Univ, Sch Med, Dept Med Biochem, Kurume, Fukuoka 8300011, Japan.	higashiy@med.kurume-u.ac.jp; mnoguchi@med.kurume-u.ac.jp	Sakamoto, Hiroshi/A-3181-2011	Higashimoto, Yuichiro/0000-0003-1382-8598	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055807] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55807] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auclair K., 2003, PORPHYRIN HDB, V12, P183; de Montellano PRO, 2000, CURR OPIN CHEM BIOL, V4, P221; FRYDMAN RB, 1981, BIOCHEMISTRY-US, V20, P5177, DOI 10.1021/bi00521a012; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Hayashi S, 2003, PROTEIN EXPRES PURIF, V29, P1, DOI 10.1016/S1046-5928(03)00023-8; Higashimoto Y, 2005, J BIOL CHEM, V280, P729, DOI 10.1074/jbc.M406203200; Iyanagi T, 2005, BIOCHEM BIOPH RES CO, V338, P520, DOI 10.1016/j.bbrc.2005.08.043; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; Lad L, 2004, J INORG BIOCHEM, V98, P1686, DOI 10.1016/j.jinorgbio.2004.07.004; Lad L, 2004, BIOCHEMISTRY-US, V43, P3793, DOI 10.1021/bi035451l; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Lad L, 2003, J BIOL CHEM, V278, P7834, DOI 10.1074/jbc.M211450200; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Matsui T, 2005, J BIOL CHEM, V280, P36833, DOI 10.1074/jbc.M503529200; Murataliev MB, 2004, BBA-PROTEINS PROTEOM, V1698, P1, DOI 10.1016/j.bbapap.2003.10.003; Omata Y, 1998, ACTA CRYSTALLOGR D, V54, P1017, DOI 10.1107/S0907444998003448; Sakamoto H, 1999, J BIOL CHEM, V274, P18196, DOI 10.1074/jbc.274.26.18196; Sakamoto H, 2005, BIOCHEM BIOPH RES CO, V338, P578, DOI 10.1016/j.bbrc.2005.08.176; Sakamoto H, 2002, EUR J BIOCHEM, V269, P5231, DOI 10.1046/j.1432-1033.2002.03230.x; Sakamoto H, 2000, J INORG BIOCHEM, V82, P113, DOI 10.1016/S0162-0134(00)00149-5; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; SHEN AL, 1989, J BIOL CHEM, V264, P7584; Strobel Henry W., 1995, P225; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2003, BIOCHEMISTRY-US, V42, P9898, DOI 10.1021/bi027268i; Sugishima M, 2003, J BIOL CHEM, V278, P32352, DOI 10.1074/jbc.M303682200; Sugishima M, 2002, BIOCHEMISTRY-US, V41, P7293, DOI 10.1021/bi025662a; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TOMARO ML, 1984, BIOCHIM BIOPHYS ACTA, V791, P342, DOI 10.1016/0167-4838(84)90345-5; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; VERMILION JL, 1976, FLAVINS FLAVOPROTEIN, P674; Wang JL, 2006, BIOCHEMISTRY-US, V45, P61, DOI 10.1021/bi051645k; Wang JL, 2005, J BIOL CHEM, V280, P2797, DOI 10.1074/jbc.M411229200; Wang JL, 2003, J BIOL CHEM, V278, P20069, DOI 10.1074/jbc.M300989200; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; Zhou H, 2000, J AM CHEM SOC, V122, P8311, DOI 10.1021/ja0002868	44	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31659	31667		10.1074/jbc.M606163200	http://dx.doi.org/10.1074/jbc.M606163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16928691	Bronze			2022-12-25	WOS:000241235300051
J	Nakamura, S; Oda, M; Kataoka, S; Ueda, S; Uchiyama, S; Yoshida, T; Kobayashi, Y; Ohkubo, T				Nakamura, Shota; Oda, Masayuki; Kataoka, Sachiyo; Ueda, Shigeru; Uchiyama, Susumu; Yoshida, Takuya; Kobayashi, Yuji; Ohkubo, Tadayasu			Apo- and holo-structures of 3 alpha-hydroxysteroid dehydrogenase from Pseudomonas sp B-0831 - Loop-helix transition induced by coenzyme binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CHAIN; PROGRAM; REFINEMENT; REDUCTASES; PATTERN	Bacterial 3 alpha-hydroxysteroid dehydrogenase, which belongs to a short-chain dehydrogenase/reductase family and forms a dimer composed of two 26-kDa subunits, catalyzes the oxidoreduction of hydroxysteroids in a coenzyme-dependent manner. This enzyme also catalyzes the oxidoreduction of nonsteroid compounds that play an important role in xenobiotic metabolism of bacteria. We performed an x-ray analysis on the crystal of Ps3 alpha HSD, the enzyme from Pseudomonas sp. B-0831 complexed with NADH. The resulting crystal structure at 1.8 angstrom resolution showed that Ps3 alpha HSD exists as a structural heterodimer composed of apo- and holo-subunits. A distinct structural difference between them was found in the 185-207-amino acid region, where the structure in the apo- subunit is disordered whereas that in the holo-subunit consists of two alpha-helices. This fact proved that the NADH binding allows the helical structures to form the substrate binding pocket even in the absence of the substrate, although the region corresponds to the so-called "substrate-binding loop." The induction of alpha-helices in solution by the coenzyme binding was also confirmed by the CD experiment. In addition, the CD experiment revealed that the helix-inducing ability of NADH is stronger than that of NAD. We discuss the negative cooperativity for the coenzyme binding, which is caused by the effect of the structural change transferred between the subunits of the heterodimer.	Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan; Kyoto Prefectural Univ, Grad Sch Agr, Sakyo Ku, Kyoto 6068522, Japan; Asahi Kasei Pharma Corp, Diagnost Dept, Shizuoka 4102321, Japan; Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan; Osaka Univ Pharmaceut Sci, Takatsuki, Osaka 5691094, Japan	Osaka University; Kyoto Prefectural University; Asahi Kasei Pharma Corporation; Osaka University; Osaka University of Pharmaceutical Sciences	Ohkubo, T (corresponding author), Osaka Univ, Grad Sch Pharmaceut Sci, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan.	ohkubo@protein.osaka-u.ac.jp	UCHIYAMA, Susumu/F-9590-2017; Nakamura, Shota/E-3033-2010	UCHIYAMA, Susumu/0000-0002-5181-179X; Nakamura, Shota/0000-0003-2058-5942; Oda, Masayuki/0000-0002-8568-4223; Yoshida, Takuya/0000-0002-3491-9344; Ueda, Shigeru/0000-0001-9328-4943				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; Grimm C, 2000, J BIOL CHEM, V275, P41333, DOI 10.1074/jbc.M007559200; Hill AV, 1910, J PHYSIOL-LONDON, V40, P190; INANO H, 1977, J STEROID BIOCHEM, V8, P41, DOI 10.1016/0022-4731(77)90215-1; Ito K, 2006, J MOL BIOL, V355, P722, DOI 10.1016/j.jmb.2005.10.072; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kataoka S, 2006, ACTA CRYSTALLOGR F, V62, P569, DOI 10.1107/S1744309106016861; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MASER E, 1995, BIOCHEM PHARMACOL, V49, P421, DOI 10.1016/0006-2952(94)00330-O; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Michael G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nakanishi M, 1997, J BIOL CHEM, V272, P2218, DOI 10.1074/jbc.272.4.2218; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Oppermann UCT, 2000, TOXICOLOGY, V144, P71, DOI 10.1016/S0300-483X(99)00192-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENNING TM, 1986, STEROIDS, V47, P221; PENNING TM, 1993, CHEM-BIOL INTERACT, V89, P1, DOI 10.1016/0009-2797(93)03203-7; ROSSMANN MG, 1973, J MOL BIOL, V76, P533, DOI 10.1016/0022-2836(73)90491-9; Shi R, 2004, J BIOL CHEM, V279, P16778, DOI 10.1074/jbc.M313156200; Shigeyuki I, 2004, J BIOL MACROMOL, V4, P23; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; TAUROG JD, 1975, BIOCHEMISTRY-US, V14, P810, DOI 10.1021/bi00675a026; Ueda S, 2004, EUR J BIOCHEM, V271, P1774, DOI 10.1111/j.1432-1033.2004.04089.x; Ueda S, 2004, J BIOL MACROMOL, V4, P29; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Valencia E, 2004, J MOL BIOL, V341, P1049, DOI 10.1016/j.jmb.2004.06.037; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wilson DR, 1997, PROTEIN ENG, V10, P519, DOI 10.1093/protein/10.5.519; WIMPENNY JW, 1972, J BACTERIOL, V11, P24, DOI 10.1128/JB.111.1.24-32.1972	34	16	16	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31876	31884		10.1074/jbc.M604226200	http://dx.doi.org/10.1074/jbc.M604226200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16905772	Bronze			2022-12-25	WOS:000241235300074
J	Kondo, H; Shirakawa, R; Higashi, T; Kawato, M; Fukuda, M; Kita, T; Horiuchi, H				Kondo, Hirokazu; Shirakawa, Ryutaro; Higashi, Tomohito; Kawato, Mitsunori; Fukuda, Mitsunori; Kita, Toru; Horiuchi, Hisanori			Constitutive GDP/GTP exchange and secretion-dependent GTP hydrolysis activity for Rab27 in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE GRANULE SECRETION; CA2+-INDUCED ALPHA-GRANULE; EPIDERMAL-GROWTH-FACTOR; MEMBRANE-FUSION; MYOSIN-VA; ACTIVATION; PROTEINS; CELLS; IDENTIFICATION; EFFECTOR	We have previously demonstrated that Rab27 regulates dense granule secretion in platelets. Here, we analyzed the activation status of Rab27 using the thin layer chromatography method analyzing nucleotides bound to immunoprecipitated Rab27 and the pull-down method quantifying Rab27 bound to the GTP-Rab27-binding domain (synaptotagmin-like protein (Slp)-homology domain) of its specific effector, Slac2-b. We found that Rab27 was predominantly present in the GTP-bound form in unstimulated platelets due to constitutive GDP/GTP exchange activity. The GTP-bound Rab27 level drastically decreased due to enhanced GTP hydrolysis activity upon granule secretion. In permeabilized platelets, increase of Ca2+ concentration induced dense granule secretion with concomitant decrease of GTP-Rab27, whereas in non-hydrolyzable GTP analogue GppNHp (beta-gamma-imidoguanosine 5'-triphosphate)-loaded permeabilized platelets, the GTP (GppNHp)-Rab27 level did not decrease upon the Ca2+-induced secretion. These data suggested that GTP hydrolysis of Rab27 was not necessary for inducing the secretion. Taken together, Rab27 is maintained in the active status in unstimulated platelets, which could function to keep dense granules in a preparative status for secretion.	Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan; RIKEN, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan; Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Lab Membrane Trafficking Mechanisms,Aoba Ku, Sendai, Miyagi 9808578, Japan	Kyoto University; RIKEN; Tohoku University	Horiuchi, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan.	horiuchi@kuhp.kyoto-u.ac.jp	Higashi, Tomohito/AHE-7942-2022; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853; Higashi, Tomohito/0000-0001-5616-1477				Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Barral DC, 2002, J CLIN INVEST, V110, P247, DOI 10.1172/JCI200215058; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Bodie SL, 2001, BIOCHEM BIOPH RES CO, V287, P71, DOI 10.1006/bbrc.2001.5547; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRASS LF, 2005, HEMATOLOGY MOL BASIS, P1889; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; Chen XQ, 2003, J BIOL CHEM, V278, P50053, DOI 10.1074/jbc.M309910200; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Choi W, 2006, BLOOD, V107, P3145, DOI 10.1182/blood-2005-09-3563; COORSSEN JR, 1993, FEBS LETT, V316, P170, DOI 10.1016/0014-5793(93)81209-I; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Fukuda M, 2005, J BIOCHEM, V137, P9, DOI 10.1093/jb/mvi002; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Goishi K, 2004, BIOCHEM BIOPH RES CO, V324, P294, DOI 10.1016/j.bbrc.2004.09.050; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; Horiuchi H, 2006, ANN MED, V38, P162, DOI 10.1080/07853890600640657; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Imai A, 2004, J CELL SCI, V117, P1945, DOI 10.1242/jcs.01048; Jordens I, 2005, TRAFFIC, V6, P1070, DOI 10.1111/j.1600-0854.2005.00336.x; KNIGHT DE, 1982, NATURE, V296, P256, DOI 10.1038/296256a0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; NAGATA K, 1990, FEBS LETT, V275, P29, DOI 10.1016/0014-5793(90)81431-M; Neeft M, 2005, MOL BIOL CELL, V16, P731, DOI 10.1091/mbc.E04-10-0923; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Shirakawa R, 2005, METHOD ENZYMOL, V403, P778, DOI 10.1016/S0076-6879(05)03067-3; Shirakawa R, 2004, J BIOL CHEM, V279, P10730, DOI 10.1074/jbc.M309426200; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Yoshioka A, 2001, ANN NY ACAD SCI, V947, P403; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	46	38	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28657	28665		10.1074/jbc.M603227200	http://dx.doi.org/10.1074/jbc.M603227200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16880209	hybrid, Green Submitted			2022-12-25	WOS:000240680500019
J	Bublil, EM; Yeger-Azuz, S; Gershoni, JM				Bublil, Erez M.; Yeger-Azuz, Sharon; Gershoni, Jonathan M.			Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120	FASEB JOURNAL			English	Article						mapitope algorithm; combinatorial phage display peptide library; epitope mapping; vaccine design	HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 BINDING-SITE; BORRELIA-BURGDORFERI; CRYSTAL-STRUCTURE; FAB FRAGMENTS; TYPE-1; IDENTIFICATION; PEPTIDE; VACCINE; IMMUNOGENICITY	Backtracking from antibodies to their corresponding epitopes is a rational approach for vaccine design. Here we apply such a reverse immunological strategy for mapping the cross-reactive neutralizing epitope corresponding to the monoclonal antibody (mAb) b12 specific for HIV-1 gp120. b12 was used to screen a combinatorial phage display random peptide library and nineteen 12mer cysteine-looped peptides were affinity purified. These were used as input for analysis with the predictive algorithm Mapitope. Based on the input panel of peptides and the antigen's atomic structure, Mapitope predicts candidate epitopes on the surface of the antigen. Two major clusters were predicted as candidate b12 epitopes. These could be discriminated by a series of experiments, which included point mutagenesis of selected residues and binding assays. Moreover, the prediction of the b12 epitope was further strengthened by comparison with additional predictions for two competing antibodies, b6 and m14. Finally, support of our prediction was obtained in view of the fact that b12, m14, and b6 were found to compete against mAb 17b binding to gp120. The b12 epitope is predicted to consist of four peptide segments of gp120 (residues V254-T257, D368-F376, E381-Y384, and I420-I424), which lie at the periphery of the CD4 binding site. - Bublil, E. M., Yeger-Azuz, S., Gershoni, J. M. Computational prediction of the cross-reactive neutralizing epitope corresponding to monoclonal antibody b12 specific for HIV-1 gp120.	Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gershoni, JM (corresponding author), Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.	gershoni@tauex.tau.ac.il						Alaedini A, 2005, J NEUROIMMUNOL, V159, P192, DOI 10.1016/j.jneuroim.2004.10.014; Andre FE, 2003, VACCINE, V21, P593, DOI 10.1016/S0264-410X(02)00702-8; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9339, DOI 10.1073/pnas.89.19.9339; Barquet N, 1997, ANN INTERN MED, V127, P635, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00010; Berthet-Colominas C, 1999, EMBO J, V18, P1124, DOI 10.1093/emboj/18.5.1124; Bolz DD, 2004, AUTOIMMUNITY, V37, P387, DOI 10.1080/08916930410001713098; Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284; Boots LJ, 1997, AIDS RES HUM RETROV, V13, P1549, DOI 10.1089/aid.1997.13.1549; Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; CONLEY AJ, 1994, J VIROL, V68, P6994, DOI 10.1128/JVI.68.11.6994-7000.1994; Donnelly JJ, 2005, J IMMUNOL, V175, P633, DOI 10.4049/jimmunol.175.2.633; Douek DC, 2006, CELL, V124, P677, DOI 10.1016/j.cell.2006.02.005; Enshell-Seijffers D, 2003, J MOL BIOL, V334, P87, DOI 10.1016/j.jmb.2003.09.002; Enshell-Seijffers D, 2001, Nucleic Acids Res, V29, pE50, DOI 10.1093/nar/29.10.e50; ENSHELLSEIFFERS D, 2002, CURRENT PROTOCOLS IM, V2; GERSHONI JM, 1993, FASEB J, V7, P1185, DOI 10.1096/fasebj.7.12.7690724; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; JAMES JS, 2003, AIDS TREAT NEWS, V6; KELLER PM, 1993, VIROLOGY, V193, P709, DOI 10.1006/viro.1993.1179; Khurana S, 2005, J VIROL, V79, P6791, DOI 10.1128/JVI.79.11.6791-6800.2005; Kwong PD, 2004, STRUCTURE, V12, P173, DOI 10.1016/j.str.2004.01.018; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lehner T, 2003, VACCINE, V21, pS68, DOI 10.1016/S0264-410X(03)00204-4; Lehner T, 2002, AIDS, V16, pS125, DOI 10.1097/00002030-200216004-00017; Mascola JR, 2003, CURR MOL MED, V3, P209, DOI 10.2174/1566524033479799; Mascola JR, 1997, J VIROL, V71, P7198, DOI 10.1128/JVI.71.10.7198-7206.1997; Meissner HC, 2004, PEDIATRICS, V114, P1065, DOI 10.1542/peds.2004-0440; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Pantophlet R, 2003, J VIROL, V77, P642, DOI 10.1128/JVI.77.1.642-658.2003; PANTOPHLET R, 2006, ANN REV IMMUNOL; Raveche ES, 2005, J CLIN MICROBIOL, V43, P850, DOI 10.1128/JCM.43.2.850-856.2005; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Ruf BR, 2004, INFECTION, V32, P191, DOI 10.1007/s15010-004-3204-z; Ruprecht RM, 2003, VACCINE, V21, P3370, DOI 10.1016/S0264-410X(03)00335-9; Rustgi VK, 1995, VACCINE, V13, P1665, DOI 10.1016/0264-410X(95)00118-K; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9; Stern B, 1997, FASEB J, V11, P147, DOI 10.1096/fasebj.11.2.9039957; STEWARD MW, 1995, J VIROL, V69, P7668, DOI 10.1128/JVI.69.12.7668-7673.1995; Tarnovitski N, 2006, J MOL BIOL, V359, P190, DOI 10.1016/j.jmb.2006.03.008; *UNAIDS WHO, 2005, AIDS EP UPD; Vidor E, 2004, EUR J CLIN MICROBIOL, V23, P300, DOI 10.1007/s10096-003-1094-0; Villard S, 2003, BLOOD, V102, P949, DOI 10.1182/blood-2002-06-1886; Willett TA, 2004, P NATL ACAD SCI USA, V101, P1303, DOI 10.1073/pnas.0305680101; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Zhang MY, 2004, J VIROL, V78, P9233, DOI 10.1128/JVI.78.17.9233-9242.2004; Zhang YJ, 1997, J INFECT DIS, V176, P1180, DOI 10.1086/514111; Zolla-Pazner S, 2004, NAT REV IMMUNOL, V4, P199, DOI 10.1038/nri1307; Zwick MB, 2001, J VIROL, V75, P6692, DOI 10.1128/JVI.75.14.6692-6699.2001; 2003, AIDS ALERT, V41, P43	58	28	30	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1762	1774		10.1096/fj.05-5509rev	http://dx.doi.org/10.1096/fj.05-5509rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940148				2022-12-25	WOS:000240267000004
J	Launay, JM; Schneider, B; Loric, S; Da Prada, M; Kellermann, O				Launay, Jean-Marie; Schneider, Benoit; Loric, Sylvain; Da Prada, Mose; Kellermann, Odile			Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells	FASEB JOURNAL			English	Article						SERT; neuronal differentiation; transporter(s)	BINDING-SITES; NITRIC-OXIDE; PHOSPHORYLATION; BRAIN; DEPRESSION; EXPRESSION; PLATELETS; CLONING; 5-HYDROXYTRYPTAMINE; PURIFICATION	The plasma membrane 5-HT transporter (SERT) is the major protagonist in regulating extracellular 5-HT concentration and constitutes the target of drugs used to treat a host of metabolic and psychiatric disorders. The exact mechanisms sustaining SERT function still remain elusive. The present work exploits the properties of the 1C11 neuroectodermal progenitor, which acquires, upon 4 days of differentiation, a functional SERT within an integrated serotonergic phenotype to investigate regulatory mechanisms involved in SERT onset and functions. We show that poly(A) addition precedes SERT mRNA translation on day 2 of the serotonergic program. The newly translated transporter molecules immediately bind cocaine. Day 4 must be awaited to monitor antidepressant recognition and 5-HT uptake. Because external 5-HT reduces both 5-HT transport and SERT antidepressant binding, we identify 5-HT2B receptors as key players in controlling the overall 5-HT transport system. In the absence of external 5-HT, 5-HT2B receptor coupling to NO production ensures SERT phosphorylation to basal level and maximal 5-HT uptake. In the presence of 5-HT, the 5-HT2B receptor-PKC coupling promotes additional phosphorylations of both SERT and Na+, K+-ATPase alpha-subunit, impairing the electrochemical gradient necessary to 5-HT uptake. SERT hyperphosphorylation also affects antidepressant recognition. Finally, such 5-HT2B receptor-mediated control of SERT activity operates in primary neurons from raphe nuclei. Altogether, our data shed new light on the 5-HT-driven post-translational modifications involved in the control of SERT activity. - Launay, J-M., Schneider, B., Loric, S., Da Prada, M., Kellermann, O. Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells.	Hop Lariboisiere, Serv Biochim, IFR 139, F-75475 Paris 10, France; Univ Paris 05, Biol Cellulaire Lab, EA3621, Fac Pharm, Paris, France; CNRS, UPR 1983, Inst Andre Lwoff, Villejuif, France; Inst Pasteur, Dept Biol Cellulaire & Infect, Paris, France; Hoffmann La Roche Ag, Pharma Res Dept, CH-4002 Basel, Switzerland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Roche Holding	Launay, JM (corresponding author), Hop Lariboisiere, Serv Biochim, IFR 139, F-75475 Paris 10, France.	jean-marie.launay@lrb.aphp.fr	loric, sylvain/F-7224-2011; Schneider, Benoit/AAF-3850-2019					AGREZ MV, 1984, BIOGENIC AMINES, V1, P223; AKUNNE HC, 1992, NEUROCHEM RES, V17, P1275, DOI 10.1007/BF00968412; Audia JE, 1996, J MED CHEM, V39, P2773, DOI 10.1021/jm960062t; BECK O, 1993, BIOCHEM BIOPH RES CO, V196, P260, DOI 10.1006/bbrc.1993.2243; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Bonaventure P, 2002, BRAIN RES, V943, P38, DOI 10.1016/S0006-8993(02)02504-0; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; BRILEY MS, 1980, SCIENCE, V209, P303, DOI 10.1126/science.7384806; BUCCARON MH, 1990, P NATL ACAD SCI USA, V87, P1922, DOI 10.1073/pnas.87.5.1922; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; CATTERALL W, 2001, LOCAL ANESTHETICS; CELSI G, 1991, AM J PHYSIOL, V260, pF192, DOI 10.1152/ajprenal.1991.260.2.F192; DAPRADA M, 1988, EXPERIENTIA, V44, P115; DOUCET A, 1979, AM J PHYSIOL, V237, pF105, DOI 10.1152/ajprenal.1979.237.2.F105; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; GRAY EG, 1962, J ANAT, V96, P79; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; Jacobs B. L., 1998, SOC NEUR ABSTR, V24, P1992; Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476-5381.1996.tb15519.x; Lauder J M, 1983, Monogr Neural Sci, V9, P3; LAUNAY JM, 1994, AM J PHYSIOL, V266, pR526, DOI 10.1152/ajpregu.1994.266.2.R526; LAUNAY JM, 1992, J BIOL CHEM, V267, P11344; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Lieberman JA, 1998, BIOL PSYCHIAT, V44, P1099, DOI 10.1016/S0006-3223(98)00187-5; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; LORIC S, 1995, MOL PHARMACOL, V47, P458; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324; MARCUSSON JO, 1990, PSYCHOPHARMACOLOGY, V102, P145, DOI 10.1007/BF02245915; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; Nelson N, 1998, J NEUROCHEM, V71, P1785; OREILLY CA, 1988, J BIOL CHEM, V263, P6115; OWENS MJ, 1994, CLIN CHEM, V40, P288; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POLIARD A, 1993, J CELL SCI, V106, P503; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Read RL, 2002, J CELL BIOCHEM, V87, P258, DOI 10.1002/jcb.10300; Rotondo A, 1996, NEUROCHEM INT, V28, P299, DOI 10.1016/0197-0186(95)00080-1; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SARRIAS MJ, 1990, J NEUROCHEM, V54, P783, DOI 10.1111/j.1471-4159.1990.tb02319.x; SCHLOSS P, 1995, BIOCHEMISTRY-US, V34, P12590, DOI 10.1021/bi00039a014; SHUEY DL, 1992, TERATOLOGY, V46, P367, DOI 10.1002/tera.1420460407; Svenningsson P, 2006, SCIENCE, V311, P77, DOI 10.1126/science.1117571; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; TUOMISTO J, 1976, NATURE, V262, P596, DOI 10.1038/262596a0; VANDENBERGH DJ, 1991, DEV BIOL, V148, P10, DOI 10.1016/0012-1606(91)90313-R; Vaughan RA, 2004, J PHARMACOL EXP THER, V310, P1, DOI 10.1124/jpet.103.052423; WALKER RF, 1983, LIFE SCI, V33, P1915, DOI 10.1016/0024-3205(83)90676-8; White KJ, 2005, AAPS J, V7; Wong ML, 2001, NAT REV NEUROSCI, V2, P343, DOI 10.1038/35072566; Zhang YW, 2005, NEUROPHARMACOLOGY, V49, P791, DOI 10.1016/j.neuropharm.2005.06.019; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462	62	80	82	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1843	1854		10.1096/fj.06-5724com	http://dx.doi.org/10.1096/fj.06-5724com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940156				2022-12-25	WOS:000240267000012
J	Caporali, A; Wark, L; Vermolen, BJ; Garini, Y; Mai, S				Caporali, A.; Wark, L.; Vermolen, B. J.; Garini, Y.; Mai, S.			Telomeric aggregates and end-to-end chromosomal fusions require myc box II	ONCOGENE			English	Article						three-dimensional nuclear organization; telomere aggregates; c-Myc; genomic instability; telomeric fusions	C-MYC; CELL-CYCLE; NUCLEAR ARCHITECTURE; GENOMIC INSTABILITY; GENE; DYNAMICS; ORGANIZATION; ACTIVATION; MITOSIS; DOMAIN	Telomeres of tumor cells form telomeric aggregates (TAs) within the three-dimensional (3D) interphase nucleus. Some of these TAs represent end-to-end chromosomal fusions and may subsequently initiate breakage-bridge fusion cycles. Wild-type (wt) and myc box II mutant (mt) Myc induce different types of genomic instability when conditionally expressed in mouse proB cells (Ba/F3). Only wt Myc overexpressing Ba/F3 cells are capable of tumor formation in severe combined immunodeficient mice. In this study, we investigated whether telomere dysfunction leading to TA formation is linked to the genetic changes that permit wt c-Myc-dependent transformation of Ba/F3 cells. To this end, we examined the 3D organization of telomeres after the deregulated expression of deletion myc box II mutant (D106) or wt Myc. D106-Myc overexpression did not induce TAs, whereas wt-Myc deregulation did. Instead, D106-Myc remodelled the 3D telomeric organization such that telomeres aligned in the center of the 3D interphase nucleus forming a telomeric disk owing to a D106-induced G1/S cell cycle arrest. In contrast, wt-Myc overexpression led to distorted telomere distribution and TA formation. Analysis of chromosomal alterations using spectral karyotyping confirmed D106-Myc and wt-Myc-associated genomic instability. A significant number of chromosomal end-to-end fusions indicative of telomere dysfunction were noted in wt-Myc-expressing cells only. This study suggests that TAs may play a fundamental role in Myc-induced tumorigenesis and provides a novel way to dissect tumor initiation.	Univ Parma, Dipartimento Med Sperimentale, Sez Biochim Biochim Clin & Biochim Esercizio Fis, I-43100 Parma, Italy; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada; Univ Manitoba, Genom Ctr Canc Res & Diag, Winnipeg, MB, Canada; Delft Univ Technol, Fac Sci Appl, Dept Imaging Sci & Technol, Delft, Netherlands	University of Parma; University of Manitoba; University of Manitoba; Delft University of Technology	Mai, S (corresponding author), Manitoba Inst Cell Biol Physiol Biochem & Med Gen, 675 McDermot, Winnipeg, MB R3E 0V9, Canada.	smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017; Vermolen, Bart/C-4739-2008	Mai, Sabine/0000-0002-5797-2201; Garini, Yuval/0000-0002-8783-2015				Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Barber CB, 1996, ACM T MATH SOFTWARE, V22, P469, DOI 10.1145/235815.235821; Chuang TCY, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-12; Cremer M, 2003, J CELL BIOL, V162, P809, DOI 10.1083/jcb.200304096; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Deb-Basu D, 2006, CELL CYCLE, V5, P1348, DOI 10.4161/cc.5.12.2860; DePinho RA, 2004, NAT GENET, V36, P932, DOI 10.1038/ng0904-932; Ermler S, 2004, EUR J CELL BIOL, V83, P681, DOI 10.1078/0171-9335-00430; Essers J, 2005, MOL BIOL CELL, V16, P769, DOI 10.1091/mbc.e04-10-0876; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Fest T, 2005, ONCOGENE, V24, P2944, DOI 10.1038/sj.onc.1208467; Fest T, 2002, ONCOGENE, V21, P2981, DOI 10.1038/sj/onc/1205274; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; Gerlich D, 2003, CELL, V112, P751, DOI 10.1016/S0092-8674(03)00189-2; Kozubek S, 1999, CHROMOSOMA, V108, P426, DOI 10.1007/s004120050394; Kuschak TI, 2002, ONCOGENE, V21, P909, DOI 10.1038/sj.onc.1205145; Kuschak TI, 1999, GENE, V238, P351, DOI 10.1016/S0378-1119(99)00341-8; KUTTLER F, 2005, GENOME DIS GENOME DY, V1, P171; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Louis SF, 2005, P NATL ACAD SCI USA, V102, P9613, DOI 10.1073/pnas.0407512102; Mai S, 2006, J CELL BIOCHEM, V97, P904, DOI 10.1002/jcb.20760; Mai S, 2005, CELL CYCLE, V4, P1327, DOI 10.4161/cc.4.10.2082; Mai Sabine, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P179; Mai Sabine, 1999, Neoplasia (New York), V1, P241, DOI 10.1038/sj.neo.7900030; McClintock B, 1941, GENETICS, V26, P234; Molenaar C, 2003, EMBO J, V22, P6631, DOI 10.1093/emboj/cdg633; Neves H, 1999, BLOOD, V93, P1197, DOI 10.1182/blood.V93.4.1197.404k33_1197_1207; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; Schaefer LH, 2001, J MICROSC-OXFORD, V204, P99, DOI 10.1046/j.1365-2818.2001.00949.x; Solovei I, 2002, EXP CELL RES, V276, P10, DOI 10.1006/excr.2002.5513; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Vermolen BJ, 2005, CYTOM PART A, V67A, P144, DOI 10.1002/cyto.a.20159; Walter J, 2003, J CELL BIOL, V160, P685, DOI 10.1083/jcb.200211103	41	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1398	1406		10.1038/sj.onc.1209928	http://dx.doi.org/10.1038/sj.onc.1209928			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953226				2022-12-25	WOS:000244558800004
J	An, J; Chervin, AS; Nie, A; Ducoff, HS; Huang, Z				An, J.; Chervin, A. S.; Nie, A.; Ducoff, H. S.; Huang, Z.			Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor	ONCOGENE			English	Article						Bcl-2; HA14-1; p53; radiosensitization; apoptosis; ROS; JNK	N-TERMINAL KINASE; CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; TUMOR-CELLS; DNA-DAMAGE; RADIATION; DEATH; ACTIVATION; JNK; BAX	Bcl-2 overexpression is an important mechanism underlying the aggressive behavior of prostate cancer cells and their resistance to radio- or chemotherapy. HA14-1, a recently discovered organic Bcl-2 inhibitor, potently induces apoptosis in various human cancer cells. Sequential exposure of radioresistant LNCaP (wild-type (wt) p53), LNCaP/Bcl-2 (wt p53) and PC3 (mutant p53) prostate cancer cells to a minimally cytotoxic concentration of 10 mu M HA14-1 for 1 h followed by 1-6 Gy gamma radiation, resulted in a highly synergistic (combination index < 1.0) induction of cell death as determined by an apoptosis assay at 72 h, and a clonogenicity assay at 12 days, after the initial treatment. The reverse treatment sequence did not cause a synergistic induction of cell death. When compared to individual treatments, cell death induced by the combined treatment was associated with dramatically increased reactive oxygen species (ROS) generation, c-Jun N-terminal kinase (JNK) activation, Bcl-2 phosphorylation, cytochrome c release, caspase-3 activation and DNA fragmentation. Exposure to either 200 mu g/ml of the antioxidant alpha-tocopherol or 10 mu M JNK inhibitor SP600125 before the combined treatment resulted in decreased activation of JNK and caspase-3 as well as decreased DNA fragmentation. However, treatment with the pancaspase inhibitor carbobenzoxyl-valyl-alanyl-aspartyl-[O-methyl]-fuoromethylketone before the combined treatment inhibited apoptosis without affecting JNK activation, and this inhibitory effect was enhanced in the presence of alpha-tocopherol or SP600125. Taken together, our results indicate that HA14-1 potently sensitizes radioresistant LNCaP and PC3 cells to gamma radiation, regardless of the status of p53. ROS and JNK are important early signals that trigger both caspase-dependent and -independent cell death pathways and contribute to the apoptotic synergy induced by the combined treatments.	Burnham Inst Med Res, La Jolla, CA 92037 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	An, J (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jingan@burnham.org						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Autorino R, 2003, UROL INT, V70, P1, DOI 10.1159/000067704; Bauer JJ, 1996, J UROLOGY, V156, P1511, DOI 10.1016/S0022-5347(01)65641-6; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chaudhary KS, 2001, J PATHOL, V193, P522, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH821>3.0.CO;2-Y; Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038/sj.onc.1207284; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Denmeade SR, 1996, PROSTATE, V28, P251; DEWEY WC, 1971, P NATL ACAD SCI USA, V68, P667, DOI 10.1073/pnas.68.3.667; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Garzotto M, 1999, CANCER RES, V59, P5194; Hahn P, 1996, INT J RADIAT ONCOL, V34, P41, DOI 10.1016/0360-3016(95)02024-1; Hering F L, 2001, Sao Paulo Med J, V119, P138; Higuchi Y, 2003, BIOCHEM PHARMACOL, V66, P1527, DOI 10.1016/S0006-2952(03)00508-2; Kimura K, 1999, CANCER RES, V59, P1606; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lickliter JD, 2003, LEUKEMIA, V17, P2074, DOI 10.1038/sj.leu.2403102; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Lin X, 2003, CANCER RES, V63, P3413; Marchal S, 2004, BIOCHEMISTRY-MOSCOW+, V69, P45, DOI 10.1023/B:BIRY.0000016350.61894.be; McConkey DJ, 1996, CANCER RES, V56, P5594; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; Milella M, 2002, BLOOD, V99, P3461, DOI 10.1182/blood.V99.9.3461; Mishra KP, 2004, J ENVIRON PATHOL TOX, V23, P61, DOI 10.1615/JEnvPathToxOncol.v23.i1.60; Ortiz MA, 2001, CANCER RES, V61, P8504; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; Phillips DC, 2002, ARCH BIOCHEM BIOPHYS, V407, P15, DOI 10.1016/S0003-9861(02)00496-4; RAFFO AJ, 1995, CANCER RES, V55, P4438; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Rosser CJ, 2003, INT J RADIAT ONCOL, V56, P1, DOI 10.1016/S0360-3016(02)04468-1; Scherr DS, 1999, J UROLOGY, V162, P12, DOI 10.1097/00005392-199907000-00003; Scott SL, 2002, CANCER BIOTHER RADIO, V17, P647, DOI 10.1089/108497802320970253; Shaffer DR, 2003, LANCET ONCOL, V4, P407, DOI 10.1016/S1470-2045(03)01138-0; Szostak MJ, 2000, ONCOL REP, V7, P699; Tang DG, 1997, PROSTATE, V32, P284; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Todaro M, 2002, J CELL BIOCHEM, V86, P162, DOI 10.1002/jcb.10203; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Yamaguchi H, 2002, CANCER RES, V62, P466; Yu NF, 2000, TETRAHEDRON LETT, V41, P6993, DOI 10.1016/S0040-4039(00)01195-3; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310	49	85	92	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					652	661		10.1038/sj.onc.1209830	http://dx.doi.org/10.1038/sj.onc.1209830			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16909121				2022-12-25	WOS:000243902200003
J	Yao, YC; Zebboudj, AF; Shao, E; Perez, M; Bostrom, K				Yao, Yucheng; Zebboudj, Amina F.; Shao, Esther; Perez, Martin; Bostrom, Kristina			Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SHEAR-STRESS; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-EXPRESSION; TGF-BETA; RECEPTOR; CALCIFICATION; ANGIOGENESIS; BINDING; MICE	Matrix GLA protein (MGP) has previously been shown to enhance expression of vascular endothelial growth factor (VEGF) through the activin-like kinase receptor 1 (ALK1) in bovine aortic endothelial cells. MGP has also been identified as an inhibitor of bone morphogenetic protein-2 (BMP-2). This study showed that the effect of MGP on ALK1 signaling and VEGF expression in bovine aortic endothelial cells was dose-dependent, that a progressive increase of MGP levels ceased to be stimulatory and instead turned inhibitory. We identified a new regulatory pathway involving BMP that may explain this response. BMP-2 and BMP-4 induced expression of ALK1 in a dose-dependent fashion as determined by real-time PCR and immunoblotting. Activation of ALK1 signaling induced expression of MGP in addition to that of VEGF, allowing for negative feedback regulation of BMP by MGP. MGP inhibited BMP-4 activity similarly to that of BMP-2 and interacted with BMP-4 on a protein level as determined by co-immunoprecipitation. The dose-dependent effect on ALK1 expression and the stimulation of MGP and VEGF expression were dependent on signaling by transforming growth factor-beta(TGF-beta) and ALK1. Inhibition of TGF-alpha by neutralizing antibodies abolished the inhibitory effect of high BMP-4 levels on ALK1 expression and the induction of MGP and VEGF. Depletion of ALK1 by small interfering RNA abolished the induction of MGP and VEGF. MGP promoter activity was also stimulated by BMP-4 in a TGF-beta dependent fashion. The results suggest that the effects of BMP on endothelial cells occur in part through induction of ALK1, an effect that may be limited by ALK1-induced MGP.	Univ Calif Los Angeles, Div Cardiol, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Bostrom, K (corresponding author), Univ Calif Los Angeles, Div Cardiol, David Geffen Sch Med, Box 951679, Los Angeles, CA 90095 USA.	kbostrom@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, K08HL004270] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568, HL04270, HL81397] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bianchi F, 2004, CLIN CANCER RES, V10, P6023, DOI 10.1158/1078-0432.CCR-04-0619; Bostrom K, 2004, J BIOL CHEM, V279, P52904, DOI 10.1074/jbc.M406868200; Carvalho RLC, 2004, DEVELOPMENT, V131, P6237, DOI 10.1242/dev.01529; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; Engelse MA, 2001, CARDIOVASC RES, V52, P281, DOI 10.1016/S0008-6363(01)00375-3; Fan CW, 2001, CANCER LETT, V165, P63, DOI 10.1016/S0304-3835(01)00416-5; Garfinkel A, 2004, P NATL ACAD SCI USA, V101, P9247, DOI 10.1073/pnas.0308436101; Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432-1327.2000.01325.x; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; HALE JE, 1991, J BIOL CHEM, V266, P21145; Harrison RE, 2005, CIRCULATION, V111, P435, DOI 10.1161/01.CIR.0000153798.78540.87; Kirfel J, 1997, P NATL ACAD SCI USA, V94, P2227, DOI 10.1073/pnas.94.6.2227; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Lee H, 2000, CIRC RES, V87, P516; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Moser M, 2005, THROMB HAEMOSTASIS, V94, P713, DOI 10.1160/TH05-05-0312; Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003; Murshed M, 2004, J CELL BIOL, V165, P625, DOI 10.1083/jcb.200402046; Newman JH, 2004, J AM COLL CARDIOL, V43, p33S, DOI 10.1016/j.jacc.2004.02.028; Nishimoto SK, 2005, MATRIX BIOL, V24, P353, DOI 10.1016/j.matbio.2005.05.004; Panchenko MP, 1996, AM J PHYSIOL-LUNG C, V270, pL547, DOI 10.1152/ajplung.1996.270.4.L547; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Prado CM, 2006, J HYPERTENS, V24, P503, DOI 10.1097/01.hjh.0000209987.51606.23; Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400; Raftery LA, 2003, TRENDS GENET, V19, P701, DOI 10.1016/j.tig.2003.10.009; Raida M, 2005, J CANCER RES CLIN, V131, P741, DOI 10.1007/s00432-005-0024-1; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L; Schurgers LJ, 2004, BLOOD, V104, P3231, DOI 10.1182/blood-2004-04-1277; Simes DC, 2003, J BONE MINER RES, V18, P244, DOI 10.1359/jbmr.2003.18.2.244; Sorescu GP, 2004, CIRC RES, V95, P773, DOI 10.1161/01.RES.0000145728.22878.45; Sorescu GP, 2003, J BIOL CHEM, V278, P31128, DOI 10.1074/jbc.M300703200; SUGIYAMA S, 1995, ARTERIOSCL THROM VAS, V15, P1968, DOI 10.1161/01.ATV.15.11.1968; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Vogt RR, 2006, J CELL BIOCHEM, V98, P1196, DOI 10.1002/jcb.20831; Wallin R, 2000, THROMB HAEMOSTASIS, V84, P1039; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200; Zhao JS, 1997, AM J PHYSIOL-LUNG C, V273, pL282, DOI 10.1152/ajplung.1997.273.1.L282	41	96	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33921	33930		10.1074/jbc.M604239200	http://dx.doi.org/10.1074/jbc.M604239200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16950789	hybrid			2022-12-25	WOS:000241767600013
J	Kweon, MH; Adhami, VM; Lee, JS; Mukhtar, H				Kweon, Mee-Hyang; Adhami, Vaqar Mustafa; Lee, Jeong-Sang; Mukhtar, Hasan			Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PROSTATE-CANCER CELLS; NF-E2-RELATED FACTOR-2; MOLECULAR-MECHANISMS; OXIDATIVE STRESS; EPITHELIAL-CELLS; GENE-EXPRESSION; UP-REGULATION; NITRIC-OXIDE; TUMOR-CELLS	Epigallocatechin 3-gallate (EGCG), the major polyphenol found in green tea, exerts antiproliferative and proapoptotic effects in many cancer cells. However, we found that among many cancer cells human lung adenocarcinoma A549 cells are markedly resistant to apoptosis induction by EGCG ( even at 100 mu M for 72 h). Heme oxygenase-1 (HO-1) induced by stress stimuli represents a prime cellular defense mechanism, but it may be associated with enhanced cell proliferation and chemoresistance in some cancer cells. Because we found that A549 cells constitutively overexpress HO-1 and its associated transcription factor Nrf2, we tested an hypothesis that EGCG resistance in these cells may be linked with Nrf2-mediated HO-1 overexpression. HO-1 inhibition with tin-protoporphyrin IX and silencing with RNA interference rendered cells more sensitive to apoptosis induction by EGCG and classical prooxidants. Interestingly, EGCG at high concentration (> 200 mu M) induced apoptosis by suppressing expression of HO-1 protein and mRNA, and this effect correlated with a decrease in both Nrf2-ARE binding and HO-1-ARE- luciferase activity, suggesting Nrf2-driven transcriptional activation of ho-1. Because we observed notably high levels of phosphorylated protein kinase C alpha and its suppression by EGCG and deferoxamine (an iron chelator), a possible mechanism involving phosphorylated protein kinase C alpha and iron in Nrf2-HO-1 activation was further investigated. Collectively, our findings suggest that Nrf2-mediated HO- 1 overexpression confers resistance to apoptosis induction by EGCG; therefore, its inactivation may be a target for overcoming the resistance to chemoprevention and chemotherapy.	Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Madison, WI 53706 USA; Seoul Natl Univ, Coll Pharm, Natl Res Lab Mol Carcinogenesis & Chemoprevent, Seoul 151742, South Korea	University of Wisconsin System; University of Wisconsin Madison; Seoul National University (SNU)	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Med Sci Ctr, 1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Adhami, Vaqar/AAY-2837-2020	Adhami, Vaqar/0000-0002-2048-4570	NATIONAL CANCER INSTITUTE [R01CA101039, R01CA078809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA78809, R01-CA101039] Funding Source: Medline; NIDDK NIH HHS [P50-DK065303-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Alam J, 2000, J BIOL CHEM, V275, P27694; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anning PB, 1999, FEBS LETT, V447, P111, DOI 10.1016/S0014-5793(99)00250-1; BARKER S, 1995, FEBS LETT, V369, P263, DOI 10.1016/0014-5793(95)00725-O; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Bonini P, 2004, J NEUROSCI RES, V75, P83, DOI 10.1002/jnr.10822; Bundy RE, 2005, ANTIOXID REDOX SIGN, V7, P14, DOI 10.1089/ars.2005.7.14; Carter EP, 2004, AM J PHYSIOL-LUNG C, V287, pL24, DOI 10.1152/ajplung.00097.2004; Chen CY, 2005, BIOCHEM BIOPH RES CO, V331, P993, DOI 10.1016/j.bbrc.2005.03.237; Chen GG, 2004, J CELL BIOCHEM, V92, P1246, DOI 10.1002/jcb.20157; Chen M, 2006, PEDIATR NEPHROL, V21, P382, DOI 10.1007/s00467-005-2140-1; Cho HY, 2004, FASEB J, V18, P1258, DOI 10.1096/fj.03-1127fje; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Elbling L, 2005, FASEB J, V19, P807, DOI 10.1096/fj.04-2915fje; Esposito F, 2004, NEUROCHEM RES, V29, P617, DOI 10.1023/B:NERE.0000014832.78725.1a; Fang J, 2003, CANCER RES, V63, P3567; Fang J, 2004, INT J CANCER, V109, P1, DOI 10.1002/ijc.11644; Fang J, 2004, APOPTOSIS, V9, P27, DOI 10.1023/B:APPT.0000012119.83734.4e; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Ikuta K, 2005, BIOL PHARM BULL, V28, P707, DOI 10.1248/bpb.28.707; Khan N, 2006, CANCER RES, V66, P2500, DOI 10.1158/0008-5472.CAN-05-3636; Kim SG, 2004, ARCH PHARM RES, V27, P757, DOI 10.1007/BF02980145; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Kweon MH, 2006, FREE RADICAL BIO MED, V40, P1349, DOI 10.1016/j.freeradbiomed.2005.12.002; Kweon MH, 2004, FREE RADICAL BIO MED, V36, P40, DOI 10.1016/j.freeradbiomed.2003.09.023; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Mandel SA, 2005, NEUROSIGNALS, V14, P46, DOI 10.1159/000085385; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Mumby S, 2004, CRIT CARE MED, V32, P1130, DOI 10.1097/01.CCM.0000124869.86399.F2; Nakagawa H, 2004, CARCINOGENESIS, V25, P1567, DOI 10.1093/carcin/bgh168; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; Nowis D, 2006, ONCOGENE, V25, P3365, DOI 10.1038/sj.onc.1209378; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; Reznichenko L, 2006, J NEUROCHEM, V97, P527, DOI 10.1111/j.1471-4159.2006.03770.x; Ryter SW, 2002, ANTIOXID REDOX SIGN, V4, P625, DOI 10.1089/15230860260220120; Saleem M, 2005, CANCER RES, V65, P11203, DOI 10.1158/0008-5472.CAN-05-1965; Saleem M, 2005, CARCINOGENESIS, V26, P1956, DOI 10.1093/carcin/bgi157; Sasaki T, 2005, VIRCHOWS ARCH, V446, P525, DOI 10.1007/s00428-005-1247-x; Schweyer S, 2004, INT J ONCOL, V25, P1671; Seve Pascal, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P73, DOI 10.2174/1568011053352604; Shih A, 2004, MOL CANCER THER, V3, P1355; Sikorski EM, 2004, AM J PHYSIOL-RENAL, V286, pF425, DOI 10.1152/ajprenal.00297.2003; Speit G, 2003, MUTAGENESIS, V18, P545, DOI 10.1093/mutage/geg028; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Tanaka S, 2003, BRIT J CANCER, V88, P902, DOI 10.1038/sj.bjc.6600830; Viktorsson K, 2005, BIOCHEM BIOPH RES CO, V331, P868, DOI 10.1016/j.bbrc.2005.03.192; Wang TL, 2005, CANCER RES, V65, P10338, DOI 10.1158/0008-5472.CAN-04-4614; Wu CC, 2006, LIFE SCI, V78, P2889, DOI 10.1016/j.lfs.2005.11.013; Zhou YD, 2004, J NAT PROD, V67, P2063, DOI 10.1021/np040140c	56	189	203	3	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33761	33772		10.1074/jbc.M604748200	http://dx.doi.org/10.1074/jbc.M604748200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950787	hybrid			2022-12-25	WOS:000241621400083
J	Wade, M; Wong, ET; Tang, M; Stommel, JM; Wahl, GM				Wade, Mark; Wong, Ee Tsin; Tang, Mengjia; Stommel, Jayne M.; Wahl, Geoffrey M.			Hdmx modulates the outcome of P53 activation in human tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE ANTAGONISTS; DNA-DAMAGE; IN-VIVO; EMBRYONIC LETHALITY; DEPENDENT DEGRADATION; MDM2-DEFICIENT MICE; P53-BINDING PROTEIN; NEGATIVE REGULATOR; PROVIDES INSIGHT; MDM2 ONCOPROTEIN	Tumors that express wild-type P53 provide a target for therapies designed to reactivate P53 function. This is supported by the potent activation of P53 in tumor cells by Nutlin, a cis-imidazoline that inhibits the Hdm2-P53 interaction. The efficacy of Hdm2(.)P53 antagonists could be compromised if they do not antagonize Hdmx, an Hdm2 homolog that inhibits P53 transactivation. We evaluated the role of Hdmx expression in sensitivity to Nutlin in a range of cancer cell lines. Nutlin reduced Hdmx levels in normal cells and some cancer cell lines, whereas other cancer cells were refractory to such down-regulation. Strikingly, Nutlin did not disrupt Hdmx(.)P53 complexes, and in cell lines where no Hdmx degradation occurred, Nutlin failed to induce apoptosis. shRNA-mediated reduction of Hdmx sensitized cells to apoptosis, but caspase-3 was neither required nor sufficient for Hdmx degradation or apoptosis. Our data imply that Hdmx is an important determinant of the outcome of P53 activation. Thus, targeting Hdmx may be a therapeutic strategy that complements drugs such as Nutlin.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program, Div Biol Sci, La Jolla, CA 92037 USA	Salk Institute; University of California System; University of California San Diego	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wahl@salk.edu	Wade, Mark/B-6719-2009; Stommel, Jayne M/M-3439-2017	Wade, Mark/0000-0002-2688-5965; Wade, Mark/0000-0002-8355-9680	NATIONAL CANCER INSTITUTE [R01CA061449] Funding Source: NIH RePORTER; NCI NIH HHS [CA61449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brummelkamp TR, 2006, NAT CHEM BIOL, V2, P202, DOI 10.1038/nchembio774; Buolamwini JK, 2005, CURR CANCER DRUG TAR, V5, P57, DOI 10.2174/1568009053332672; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; Finch RA, 2002, CANCER RES, V62, P3221; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; ICHIKAWA A, 1993, LEUKEMIA LYMPHOMA, V11, P21, DOI 10.3109/10428199309054727; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jin YT, 2006, EMBO J, V25, P1207, DOI 10.1038/sj.emboj.7601010; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kmet LM, 2003, CANCER, V97, P389, DOI 10.1002/cncr.11064; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lavin MF, 2005, MUTAT RES-FUND MOL M, V569, P123, DOI 10.1016/j.mrfmmm.2004.04.020; LeBron C, 2006, EMBO J, V25, P1196, DOI 10.1038/sj.emboj.7601032; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; LUNA RMD, 1995, NATURE, V378, P203; Marine JC, 2005, BIOCHEM BIOPH RES CO, V331, P750, DOI 10.1016/j.bbrc.2005.03.151; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Secchiero P, 2006, BLOOD, V107, P4122, DOI 10.1182/blood-2005-11-4465; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; SHCWARTZBERG L, 2006, J SUPPORT ONCOL S1, V42, P3; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Smith ND, 2003, J UROLOGY, V169, P1219, DOI 10.1097/01.ju.0000056085.58221.80; Stad R, 2000, J BIOL CHEM, V275, P28039; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stuhmer T, 2005, BLOOD, V106, P3609, DOI 10.1182/blood-2005-04-1489; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; TIAN LF, 2006, BIOCHEM BIOPH RES CO, V2, P2; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vega-Stromberg Teri, 2003, J Infus Nurs, V26, P353, DOI 10.1097/00129804-200311000-00004; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2006, CELL DEATH DIFFER, V13, P973, DOI 10.1038/sj.cdd.4401911; Wahl GM, 2005, 25 YEARS OF P53 RESEARCH, P73, DOI 10.1007/1-4020-2922-5_4; Wendt J, 2006, ONCOGENE, V25, P972, DOI 10.1038/sj.onc.1209031; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	59	131	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33036	33044		10.1074/jbc.M605405200	http://dx.doi.org/10.1074/jbc.M605405200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16905769	hybrid			2022-12-25	WOS:000241621400012
J	Anthonisen, AN; Clausen, JD; Andersen, JP				Anthonisen, Anne Nyholm; Clausen, Johannes D.; Andersen, Jens Peter			Mutational analysis of the conserved TGES loop of sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; FUNCTIONAL CONSEQUENCES; PHOSPHOENZYME INTERMEDIATE; CRYSTAL-STRUCTURE; AMINO-ACIDS; DOMAIN-A; CA-2+-ATPASE; DEPHOSPHORYLATION; ION; PHOSPHORYLATION	Crystal structures have shown that the conserved TGES loop of the Ca2+-ATPase is isolated in the Ca(2)E1 state but becomes inserted in the catalytic site in E2 states. Here, we have examined the kinetics of the partial reaction steps of the transport cycle and the binding of the phosphoryl analogs BeF, AlF, MgF, and vanadate in mutants with alterations to the TGES residues. The mutations encompassed variation of size, polarity, and charge of the side chains. Differential effects on the Ca(2)E1P -> E2P, E2P -> E2, and E2 -> Ca(2)E1 reactions and the binding of the phosphoryl analogs were observed. In the E183D mutant, the E2P -> E2 dephosphorylation reaction proceeded at a rate as high as one-third that of the wild type, whereas it was very slow in the other Glu(183) mutants, including E183Q, thus demonstrating the need for a negatively charged carboxylate group to catalyze dephosphorylation. By contrast, the Ca(2)E1P -> E2P transition was accomplished at a reasonable rate with glutamine in place of Glu(183), but not with aspartate, indicating that the length of the Glu(183) side chain, in addition to its hydrogen bonding potential, is critical for Ca2E1P -> E2P. This transition was also slowed in mutants with alteration to other TGES residues. The data provide functional evidence in support of the proposed role of Glu(183) in activating the water molecule involved in the E2P -> E2 dephosphorylation and suggest a direct participation of the side chains of the TGES loop in the control and facilitation of the insertion of the loop in the catalytic site. The interactions of the TGES loop furthermore seem to facilitate its disengagement from the catalytic site during the E2 -> Ca(2)E1 transition.	Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, JP (corresponding author), Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, Ole Worms Alle 1160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk		Andersen, Jens Peter/0000-0003-0654-4300				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2006, J BIOL CHEM, V281, P9471, DOI 10.1074/jbc.M512371200; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HASSELBACH W, 1963, BIOCHEM Z, V339, P94; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Lenoir G, 2004, J BIOL CHEM, V279, P9156, DOI 10.1074/jbc.M311411200; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sorensen TLM, 2004, J BIOL CHEM, V279, P46355, DOI 10.1074/jbc.C400414200; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Wang GL, 2005, J BIOL CHEM, V280, P26508, DOI 10.1074/jbc.M503789200; WEBER K, 1969, J BIOL CHEM, V244, P4406; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200	37	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31572	31582		10.1074/jbc.M605194200	http://dx.doi.org/10.1074/jbc.M605194200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16893884				2022-12-25	WOS:000241235300043
J	Corcoran, JA; Salsman, J; de Antueno, R; Touhami, A; Jericho, MH; Clancy, EK; Duncan, R				Corcoran, Jennifer A.; Salsman, Jayme; de Antueno, Roberto; Touhami, Ahmed; Jericho, Manfred H.; Clancy, Eileen K.; Duncan, Roy			The p14 fusion-associated small transmembrane (FAST) protein effects membrane fusion from a subset of membrane microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; HUMAN-IMMUNODEFICIENCY-VIRUS; DISTINCT LIPID MICRODOMAINS; ELEMENT-BINDING PROTEINS; CELL-MEMBRANES; PLASMA-MEMBRANE; REPTILIAN REOVIRUS; RAFT MICRODOMAINS; DOMAIN-STRUCTURE; BABOON REOVIRUS	The reovirus fusion-associated small transmembrane (FAST) proteins are a unique family of viral membrane fusion proteins. These nonstructural viral proteins induce efficient cell-cell rather than virus-cell membrane fusion. We analyzed the lipid environment in which the reptilian reovirus p14 FAST protein resides to determine the influence of the cell membrane on the fusion activity of the FAST proteins. Topographical mapping of the surface of fusogenic p14-containing liposomes by atomic force microscopy under aqueous conditions revealed that p14 resides almost exclusively in thickened membrane microdomains. In transfected cells, p14 was found in both Lubrol WX-and Triton X-100-resistant membrane complexes. Cholesterol depletion of donor cell membranes led to preferential disruption of p14 association with Lubrol WX (but not Triton X-100)resistant membranes and decreased cell-cell fusion activity, both of which were reversed upon subsequent cholesterol repletion. Furthermore, co-patching analysis by fluorescence microscopy indicated that p14 did not co-localize with classical lipid anchored raft markers. These data suggest that the p14 FAST protein associates with heterogeneous membrane microdomains, a distinct subset of which is defined by cholesterol-dependent Lubrol WX resistance and which may be more relevant to the membrane fusion process.	Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 1X5, Canada; Dalhousie Univ, Dept Phys, Halifax, NS B3H 1X5, Canada	Dalhousie University; Dalhousie University	Duncan, R (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 1X5, Canada.	roy.duncan@dal.ca		Duncan, Roy/0000-0002-5162-5081; Clancy, Eileen/0000-0001-9565-7985				Bared SM, 2004, MOL BIOL CELL, V15, P5399, DOI 10.1091/mbc.E04-03-0182; Bavari S, 2002, J EXP MED, V195, P593, DOI 10.1084/jem.20011500; Bentz J, 2000, BIOPHYS J, V78, P886, DOI 10.1016/S0006-3495(00)76646-X; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brugger B, 2004, J BIOL CHEM, V279, P7530, DOI 10.1074/jbc.M310207200; Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003; Chernomordik L, 1996, CHEM PHYS LIPIDS, V81, P203, DOI 10.1016/0009-3084(96)02583-2; Cleverley DZ, 1997, EXP CELL RES, V233, P288, DOI 10.1006/excr.1997.3573; Cohen FS, 2004, J MEMBRANE BIOL, V199, P1, DOI 10.1007/s00232-004-0669-8; Corcoran JA, 2004, J BIOL CHEM, V279, P51386, DOI 10.1074/jbc.M406990200; Corcoran JA, 2004, J VIROL, V78, P4342, DOI 10.1128/JVI.78.8.4342-4351.2004; Dawe S, 2005, J VIROL, V79, P6216, DOI 10.1128/JVI.79.10.6216-6226.2005; Dawe S, 2002, J VIROL, V76, P2131, DOI 10.1128/JVI.76.5.2131-2140.2002; DEANTUENO RJ, 1994, LIPIDS, V29, P327, DOI 10.1007/BF02537185; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Duncan R, 2004, VIROLOGY, V319, P131, DOI 10.1016/j.virol.2003.10.025; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; Hansen GH, 2001, J BIOL CHEM, V276, P32338, DOI 10.1074/jbc.M102667200; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Henderson RA, 2004, NEWS PHYSIOL SCI, V19, P39, DOI 10.1152/nips.01505.2003; Huttner WB, 2001, CURR OPIN CELL BIOL, V13, P478, DOI 10.1016/S0955-0674(00)00239-8; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; Kielian M, 2000, Subcell Biochem, V34, P409; Kozak SL, 2002, J VIROL, V76, P1802, DOI 10.1128/JVI.76.4.1802-1815.2002; Kozlov MM, 1998, BIOPHYS J, V75, P1384, DOI 10.1016/S0006-3495(98)74056-1; KUNIMOTO M, 1989, J BIOCHEM-TOKYO, V105, P190, DOI 10.1093/oxfordjournals.jbchem.a122638; Lawrence JC, 2003, BIOPHYS J, V84, P1827, DOI 10.1016/S0006-3495(03)74990-X; Liao ZH, 2003, AIDS RES HUM RETROV, V19, P675, DOI 10.1089/088922203322280900; Lichtenberg D, 2005, TRENDS BIOCHEM SCI, V30, P430, DOI 10.1016/j.tibs.2005.06.004; Markosyan RM, 2004, BIOPHYS J, V87, P3291, DOI 10.1529/biophysj.104.047696; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Nicolini C, 2006, J AM CHEM SOC, V128, P192, DOI 10.1021/ja055779x; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Reviakine I, 2000, LANGMUIR, V16, P1806, DOI 10.1021/la9903043; Ridgway ND, 2003, BIOCHEM J, V372, P811, DOI 10.1042/BJ20030252; Rinia HA, 2001, FEBS LETT, V501, P92, DOI 10.1016/S0014-5793(01)02636-9; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Saslowsky DE, 2003, J MEMBRANE BIOL, V194, P153, DOI 10.1007/s00232-003-2035-7; Saslowsky DE, 2002, J BIOL CHEM, V277, P26966, DOI 10.1074/jbc.M204669200; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Shmulevitz M, 2004, J VIROL, V78, P2808, DOI 10.1128/JVI.78.6.2808-2818.2004; Shmulevitz M, 2003, J VIROL, V77, P9769, DOI 10.1128/JVI.77.18.9769-9779.2003; Shmulevitz M, 2000, EMBO J, V19, P902, DOI 10.1093/emboj/19.5.902; Shogomori H, 2003, BIOL CHEM, V384, P1259, DOI 10.1515/BC.2003.139; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; Takeda M, 2003, P NATL ACAD SCI USA, V100, P14610, DOI 10.1073/pnas.2235620100; Top D, 2005, EMBO J, V24, P2980, DOI 10.1038/sj.emboj.7600767; Tsukamoto K, 2001, BIOCHEM BIOPH RES CO, V287, P757, DOI 10.1006/bbrc.2001.5575; van Duyl BY, 2003, FEBS LETT, V547, P101, DOI 10.1016/S0014-5793(03)00678-1; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vetrivel KS, 2005, J BIOL CHEM, V280, P25892, DOI 10.1074/jbc.M503570200; Vyas KA, 2001, BIOL CHEM, V382, P241, DOI 10.1515/BC.2001.031; Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574	66	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31778	31789		10.1074/jbc.M602566200	http://dx.doi.org/10.1074/jbc.M602566200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16936325	Green Published, Bronze			2022-12-25	WOS:000241235300065
J	Gautier-Stein, A; Zitoun, C; Lalli, E; Mithieux, G; Rajas, F				Gautier-Stein, Amandine; Zitoun, Carine; Lalli, Enzo; Mithieux, Gilles; Rajas, Fabienne			Transcriptional regulation of the glucose-6-phosphatase gene by cAMP/vasoactive intestinal peptide in the intestine - Role of HNF4 alpha, CREM, HNF1 alpha, and C/EBP alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-4-ALPHA; RAT SMALL-INTESTINE; DEPENDENT DIABETES-MELLITUS; PORTAL GLUCOSE-INFUSION; CAMP RESPONSE-ELEMENT; CATALYTIC SUBUNIT; BINDING-PROTEIN; CYCLIC-AMP; ACETYLTRANSFERASE ACTIVITY; ADENYLATE-CYCLASE	Gluconeogenesis is induced in both the liver and intestine by increased cAMP levels. However, hepatic and intestinal glucose production can have opposite effects on glucose homeostasis. Glucose release into the portal vein by the intestine increases glucose uptake and reduces food intake. In contrast, glucose production by the liver contributes to hyperglycemia in type II diabetes. Glucose-6-phosphatase (Glc6Pase) is the key enzyme of gluconeogenesis in both the liver and intestine. Here we specify the cAMP/protein kinase A regulation of the Glc6Pase gene in the intestine compared with the liver. Similarly to the liver, the molecular mechanism of cAMP/protein kinase A regulation involves cAMP-response element-binding protein, HNF4 alpha, CAAT/enhancer-binding protein, and HNF1. In contrast to the situation in the liver, we find that different isoforms of CAAT/enhancer-binding protein and HNF1 contribute to the specific regulation of the Glc6Pase gene in the intestine. Moreover, we show that cAMP-response element binding modulator specifically contributes to the regulation of the Glc6Pase gene in the intestine but not in the liver. These results allow us to identify intestine-specific regulators of the Glc6Pase gene and to improve the understanding of the differences in the regulation of gluconeogenesis in the intestine compared with the liver.	INSERM, Fac Med Laennec, U449, F-69372 Lyon 08, France; INRA, U1235, F-69372 Lyon, France; Univ Lyon 1, F-69372 Lyon, France; Inst Fed Rech Laennec 62, F-69372 Lyon, France; CNRS, UMR 6097, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Gautier-Stein, A (corresponding author), INSERM, Fac Med Laennec, U449, Rue Guillaume Paradin, F-69372 Lyon 08, France.	Amandine.Gautier@univ-lyon1.fr	Lalli, Enzo/F-7052-2013; RAJAS, Fabienne/P-4091-2016	Lalli, Enzo/0000-0002-0584-5681; RAJAS, Fabienne/0000-0002-9233-7633; Gilles, Mithieux/0000-0003-3579-8529; Gautier-Stein, Amandine/0000-0002-6003-1891				AMIRANOFF B, 1978, BIOCHIM BIOPHYS ACTA, V544, P474, DOI 10.1016/0304-4165(78)90321-5; Antes TJ, 2001, DNA CELL BIOL, V20, P67, DOI 10.1089/104454901750070265; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Boudreau F, 2001, J BIOL CHEM, V276, P32122, DOI 10.1074/jbc.M102002200; Boustead JN, 2003, BIOCHEM J, V369, P17, DOI 10.1042/BJ20021382; Burcelin R, 2000, DIABETES, V49, P1635, DOI 10.2337/diabetes.49.10.1635; Cardin S, 1999, J APPL PHYSIOL, V87, P1470, DOI 10.1152/jappl.1999.87.4.1470; Carriere V, 2005, J BIOL CHEM, V280, P20094, DOI 10.1074/jbc.M502192200; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; Clore JN, 2000, DIABETES, V49, P969, DOI 10.2337/diabetes.49.6.969; Croset M, 2001, DIABETES, V50, P740, DOI 10.2337/diabetes.50.4.740; DEFRONZO RA, 1992, DIABETOLOGIA, V35, P389, DOI 10.1007/BF00401208; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Erickson RH, 2000, BIOCHEM BIOPH RES CO, V270, P235, DOI 10.1006/bbrc.2000.2420; Fimia GM, 2001, J CELL SCI, V114, P1971; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GARDEMANN A, 1986, FEBS LETT, V202, P255, DOI 10.1016/0014-5793(86)80697-4; Gautier-Stein A, 2005, MOL ENDOCRINOL, V19, P163, DOI 10.1210/me.2004-0105; Gautier-Stein A, 2003, NUCLEIC ACIDS RES, V31, P5238, DOI 10.1093/nar/gkg747; GERICH JE, 1991, DIABETOLOGIA, V34, P607, DOI 10.1007/BF00400282; Gevrey JC, 2004, DIABETOLOGIA, V47, P926, DOI 10.1007/s00125-004-1380-0; Gevrey JC, 2002, J BIOL CHEM, V277, P22407, DOI 10.1074/jbc.M201624200; Gresh L, 2004, EMBO J, V23, P1657, DOI 10.1038/sj.emboj.7600160; Hornbuckle LA, 2004, AM J PHYSIOL-ENDOC M, V286, pE795, DOI 10.1152/ajpendo.00455.2003; Kimmins S, 2004, REPRODUCTION, V128, P5, DOI 10.1530/rep.1.00170; LABURTHE M, 1987, J BIOL CHEM, V262, P10180; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEFF T, 1989, J BIOL CHEM, V264, P16132; Lin BC, 1997, BIOCHEMISTRY-US, V36, P14096, DOI 10.1021/bi9703249; Lin BC, 1998, DNA CELL BIOL, V17, P967, DOI 10.1089/dna.1998.17.967; LIU JS, 1991, J BIOL CHEM, V266, P19095; Manna PR, 2002, MOL ENDOCRINOL, V16, P184, DOI 10.1210/me.16.1.184; Massillon D, 2001, J BIOL CHEM, V276, P4055, DOI 10.1074/jbc.M007939200; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Minassian C, 1996, MOL CELL BIOCHEM, V155, P37, DOI 10.1007/BF00714331; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Mithieux G, 2004, AM J PHYSIOL-ENDOC M, V286, pE370, DOI 10.1152/ajpendo.00299.2003; Mithieux G, 2004, J BIOL CHEM, V279, P44231, DOI 10.1074/jbc.R400011200; Mithieux G, 2005, CELL METAB, V2, P321, DOI 10.1016/j.cmet.2005.09.010; Montminy M, 2004, ANN ENDOCRINOL-PARIS, V65, P73, DOI 10.1016/S0003-4266(04)95634-X; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Olsen L, 2005, AM J PHYSIOL-GASTR L, V289, pG220, DOI 10.1152/ajpgi.00449.2004; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; PINTO M, 1983, BIOL CELL, V47, P323; PRIETO JC, 1979, EUR J BIOCHEM, V96, P229, DOI 10.1111/j.1432-1033.1979.tb13033.x; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rajas F, 2000, DIABETES, V49, P1165, DOI 10.2337/diabetes.49.7.1165; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Rowley CW, 2006, AM J PHYSIOL-GASTR L, V290, pG466, DOI 10.1152/ajpgi.00431.2005; Sauvaget D, 2002, J BIOL CHEM, V277, P34540, DOI 10.1074/jbc.M206074200; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Sindelar DK, 1997, AM J PHYSIOL-ENDOC M, V273, pE972, DOI 10.1152/ajpendo.1997.273.5.E972; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Streeper RS, 2000, J BIOL CHEM, V275, P12108, DOI 10.1074/jbc.275.16.12108; Streeper RS, 2001, J BIOL CHEM, V276, P19111, DOI 10.1074/jbc.M101442200; Swenson ES, 1999, AM J PHYSIOL-GASTR L, V276, pG728, DOI 10.1152/ajpgi.1999.276.3.G728; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; Vander Kooi BT, 2003, J BIOL CHEM, V278, P11782, DOI 10.1074/jbc.M212570200; Vander Kooi CW, 2006, BIOCHEMISTRY-US, V45, P121, DOI 10.1021/bi051787e; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Wang D, 2006, ENDOCRINOLOGY, V147, P350, DOI 10.1210/en.2005-1014; Yang JQ, 2005, J BIOL CHEM, V280, P38689, DOI 10.1074/jbc.M503486200	72	42	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31268	31278		10.1074/jbc.M603258200	http://dx.doi.org/10.1074/jbc.M603258200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16893891	Green Published, Bronze			2022-12-25	WOS:000241235300011
J	Mueller, S; Kleinau, G; Jaeschke, H; Neumann, S; Krause, G; Paschke, R				Mueller, Sandra; Kleinau, Gunnar; Jaeschke, Holger; Neumann, Susanne; Krause, Gerd; Paschke, Ralf			Significance of ectodomain cysteine boxes 2 and 3 for the activation mechanism of the thyroid-stimulating hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN TSH RECEPTOR; EXTRACELLULAR DOMAIN; CONSTITUTIVE ACTIVITY; TRANSMEMBRANE DOMAIN; INVERSE AGONIST; MUTATIONS; IDENTIFICATION; PHYSIOLOGY; RESIDUES; PORTION	Recently, we identified constitutively activating mutations at positions Asp-403, Glu-404, and Asn-406 in the third extracellular cysteine box (C-b3) of the thyroid-stimulating hormone receptor. We hypothesized that this region could act as a molecular interface between the extracellular and serpentine domain. In this study we present a model for properties of potential interaction partners for this region. Moreover, we show that Pro-400 and Pro-407 adjacent to this epitope are also important for stabilizing the partially active, basal conformation of the wild-type (WT) thyroid-stimulating hormone receptor. Furthermore, the mutation K291A in the second extracellular cysteine box (C-b2) was identified as a new constitutively activating mutation that releases the basal conformation of the WT receptor like the known tryptic cleavage in its close vicinity. Taken together, we provide an activation scenario at the C-b2/C-b3 unit. Three anchor fragments (anchors I-III) most likely constrain the basal conformation. The three anchor fragments are tightly packed. A disulfide bridge holds the C-b2/C-b3 portions in close positions. Independent of the type of conformational interference such as side chain modifications, tryptic cleavage, or hormone stimulation that act on the constrained C-b2/C-b3 WT conformation, it will always release one of the anchor fragments. Subsequently, this results in a conformational displacement of the C-b2/C-b3 portions relative to each other, inducing receptor activation.	Univ Leipzig, Dept Med 3, D-04103 Leipzig, Germany; Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; NIDDK, NIH, Clin Endocrinol Branch, Bethesda, MD 20892 USA	Leipzig University; Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Paschke, R (corresponding author), Univ Leipzig, Dept Med 3, Str 27, D-04103 Leipzig, Germany.	pasr@medizin.uni-leipzig.de	Neumann, Susanne/GPK-6035-2022; Kleinau, Gunnar/GPX-6330-2022		Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bozon W, 2002, PROTEIN EXPRES PURIF, V25, P114, DOI 10.1006/prep.2002.1617; Chen CR, 2003, ENDOCRINOLOGY, V144, P3821, DOI 10.1210/en.2003-0430; Claus M, 2005, ENDOCRINOLOGY, V146, P5197, DOI 10.1210/en.2005-0713; deRoux N, 1996, J CLIN ENDOCR METAB, V81, P4229, DOI 10.1210/jc.81.12.4229; Duprez L, 1997, FEBS LETT, V409, P469, DOI 10.1016/S0014-5793(97)00532-2; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; Gruters A, 1998, J CLIN ENDOCR METAB, V83, P1431, DOI 10.1210/jc.83.5.1431; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Hjorth SA, 1998, MOL ENDOCRINOL, V12, P78, DOI 10.1210/mend.12.1.0045; Ho SC, 2005, MOL CELL ENDOCRINOL, V245, P158, DOI 10.1016/j.mce.2005.11.008; Ho SC, 2001, ENDOCRINOLOGY, V142, P2760, DOI 10.1210/en.142.7.2760; Jaeschke H, 2006, ENDOCRINOLOGY, V147, P1753, DOI 10.1210/en.2005-1138; Karges B, 2005, MOL ENDOCRINOL, V19, P2086, DOI 10.1210/me.2004-0378; Kleinau G, 2004, J BIOL CHEM, V279, P51590, DOI 10.1074/jbc.M404748200; Kopp P, 1997, J CLIN INVEST, V100, P1634, DOI 10.1172/JCI119687; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; Nakabayashi K, 2003, MOL CELL ENDOCRINOL, V202, P139, DOI 10.1016/S0303-7207(03)00075-3; Neumann S, 2005, EUR J ENDOCRINOL, V152, P625, DOI 10.1530/eje.1.01891; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; Smits G, 2002, MOL ENDOCRINOL, V16, P722, DOI 10.1210/me.16.4.722; Stavrou SS, 1998, J CLIN ENDOCR METAB, V83, P2091, DOI 10.1210/jc.83.6.2091; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; VanSande J, 1996, MOL CELL ENDOCRINOL, V119, P161, DOI 10.1016/0303-7207(96)03804-X; Vlaeminck-Guillem V, 2002, MOL ENDOCRINOL, V16, P736, DOI 10.1210/me.16.4.736; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; Wonerow P, 2001, J MOL MED, V79, P707, DOI 10.1007/s001090100279; Zhang M, 2000, ENDOCRINOLOGY, V141, P3514, DOI 10.1210/en.141.9.3514; ZHANG ML, 1995, BIOCHEM BIOPH RES CO, V211, P205, DOI 10.1006/bbrc.1995.1797; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	35	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31638	31646		10.1074/jbc.M604770200	http://dx.doi.org/10.1074/jbc.M604770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16899458	Bronze			2022-12-25	WOS:000241235300049
J	Stuart, JR; Gonzalez, FH; Kawai, H; Yuan, ZM				Stuart, Jeremy R.; Gonzalez, Francis H.; Kawai, Hidehiko; Yuan, Zhi-Min			c-Abl interacts with the WAVE2 signaling complex to induce membrane ruffling and cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; TYROSINE KINASE-ACTIVITY; SYNDROME PROTEIN; ACTIN CYTOSKELETON; ARP2/3 COMPLEX; N-WASP; RAC; PHOSPHORYLATION; ACTIVATION; REORGANIZATION	The Wiskott-Aldrich syndrome-related protein WAVE2 promotes Arp2/3-dependent actin polymerization downstream of Rho-GTPase activation. The Abelson-interacting protein-1 (Abi-1) forms the core of the WAVE2 complex and is necessary for proper stimulation of WAVE2 activity. Here we have shown that the Abl-tyrosine kinase interacts with the WAVE2 complex and that Abl kinase activity facilitates interaction between Abl and WAVE2 complex members. We have characterized various interactions between Abl and members of the WAVE2 complex and revealed that Abi-1 promotes interaction between Abl and WAVE2 members. We have demonstrated that Abl-dependent phosphorylation of WAVE2 is necessary for its activation in vivo, which is highlighted by the findings that RNA interference of WAVE2 expression in Abl/Arg(-/-) cells has no additive effect on the amount of membrane ruffling. Furthermore, Abl phosphorylates WAVE2 on tyrosine 150, and WAVE2-deficient cells rescued with a Y150F mutant fail to regain their ability to ruffle and form microspikes, unlike cells rescued with wild-type WAVE2. Together, these data show that c-Abl activates WAVE2 via tyrosine phosphorylation to promote actin remodeling in vivo and that Abi-1 forms the crucial link between these two factors.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave,HSPH-1,Rm 508, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu		Kawai, Hidehiko/0000-0003-2213-7166	NCI NIH HHS [R29 CA85679] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085679] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Borm B, 2005, EXP CELL RES, V302, P83, DOI 10.1016/j.yexcr.2004.08.034; Cestra G, 2005, P NATL ACAD SCI USA, V102, P1731, DOI 10.1073/pnas.0409376102; Echarri A, 2004, MOL CELL BIOL, V24, P4979, DOI 10.1128/MCB.24.11.4979-4993.2004; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Gautreau A, 2004, P NATL ACAD SCI USA, V101, P4379, DOI 10.1073/pnas.0400628101; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Hantschel O, 2005, MOL CELL, V19, P461, DOI 10.1016/j.molcel.2005.06.030; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Innocenti M, 2005, NAT CELL BIOL, V7, P969, DOI 10.1038/ncb1304; Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Leng Y, 2005, P NATL ACAD SCI USA, V102, P1098, DOI 10.1073/pnas.0409120102; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Schulte RJ, 2003, BIOCHEMISTRY-US, V42, P9424, DOI 10.1021/bi034519u; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Tani K, 2003, J BIOL CHEM, V278, P21685, DOI 10.1074/jbc.M301447200; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Yan C, 2003, EMBO J, V22, P3602, DOI 10.1093/emboj/cdg350; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	31	64	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31290	31297		10.1074/jbc.M602389200	http://dx.doi.org/10.1074/jbc.M602389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16899465	Bronze			2022-12-25	WOS:000241235300013
J	Lager, I; Looger, LL; Hilpert, M; Lalonde, S; Frommer, WB				Lager, Ida; Looger, Loren L.; Hilpert, Melanie; Lalonde, Sylvie; Frommer, Wolf B.			Conversion of a putative agrobacterium sugar-binding protein into a FRET sensor with high selectivity for sucrose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT NANOSENSORS; SINORHIZOBIUM-MELILOTI; COS-7 CELLS; TRANSPORT; TREHALOSE; MALTOSE; ARABIDOPSIS; CYTOSOL; PHLOEM	Glucose is the main sugar transport form in animals, whereas plants use sucrose to supply non-photosynthetic organs with carbon skeletons and energy. Many aspects of sucrose transport, metabolism, and signaling are not well understood, including the route of sucrose efflux from leaf mesophyll cells and transport across vacuolar membranes. Tools that can detect sucrose with high spatial and temporal resolution in intact organs may help elucidate the players involved. Here, FRET sensors were generated by fusing putative sucrose-binding proteins to green fluorescent protein variants. Plant-associated bacteria such as Rhizobium and Agrobacterium can use sucrose as a nutrient source; sugar-binding proteins were, thus, used as scaffolds for developing sucrose nanosensors. Among a set of putative sucrose-binding protein genes cloned in between eCFP and eYFP and tested for sugar-dependent FRET changes, an Agrobacterium sugar-binding protein bound sucrose with 4 mu M affinity. This FLIPsuc-4 mu protein also recognized other sugars including maltose, trehalose, and turanose and, with lower efficiency, glucose and palatinose. Homology modeling enabled the prediction of binding pocket mutations to modulate the relative affinity of FLIPsuc-4 mu for sucrose, maltose, and glucose. Mutant nanosensors showed up to 50- and 11-fold increases in specificity for sucrose over maltose and glucose, respectively, and the sucrose binding affinity was simultaneously decreased to allow detection in the physiological range. In addition, the signal-to-noise ratio of the sucrose nanosensor was improved by linker engineering. This novel reagent complements FLIPs for glucose, maltose, ribose, glutamate, and phosphate and will be used for analysis of sucrose-derived carbon flux in bacterial, fungal, plant, and animal cells.	Carnegie Inst, Dept Plant Biol, Stanford, CA 94305 USA	Carnegie Institution for Science	Frommer, WB (corresponding author), Carnegie Inst, Dept Plant Biol, 260 Panama St, Stanford, CA 94305 USA.	wfrommer@stanford.edu	Frommer, Wolf B/A-8256-2008; Frommer, Wolf B/K-5042-2017	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115				Barra L, 2003, FEMS MICROBIOL LETT, V229, P183, DOI 10.1016/S0378-1097(03)00819-X; Carpaneto A, 2005, J BIOL CHEM, V280, P21437, DOI 10.1074/jbc.M501785200; Deuschle K, 2005, PROTEIN SCI, V14, P2304, DOI 10.1110/ps.051508105; DEUSCHLE K, 2006, IN PRESS PLANT CELL; Diez J, 2001, J MOL BIOL, V305, P905, DOI 10.1006/jmbi.2000.4203; Endler A, 2006, PLANT PHYSIOL, V141, P196, DOI 10.1104/pp.106.079533; Farre EM, 2001, PLANT PHYSIOL, V127, P685, DOI 10.1104/pp.127.2.685; Fehr M, 2005, MOL CELL BIOL, V25, P11102, DOI 10.1128/MCB.25.24.11102-11112.2005; Fehr M, 2005, BIOCHEM SOC T, V33, P287, DOI 10.1042/BST0330287; Fehr M, 2004, J FLUORESC, V14, P603, DOI 10.1023/B:JOFL.0000039347.94943.99; Fehr M, 2003, J BIOL CHEM, V278, P19127, DOI 10.1074/jbc.M301333200; Fehr M, 2002, P NATL ACAD SCI USA, V99, P9846, DOI 10.1073/pnas.142089199; Gage DJ, 1998, J BACTERIOL, V180, P5739, DOI 10.1128/JB.180.21.5739-5748.1998; Gerrits N, 2001, PLANT PHYSIOL, V125, P926, DOI 10.1104/pp.125.2.926; Guntas G, 2005, P NATL ACAD SCI USA, V102, P11224, DOI 10.1073/pnas.0502673102; HEINEKE D, 1994, PLANTA, V194, P29, DOI 10.1007/BF00201031; Jensen JB, 2002, J BACTERIOL, V184, P2978, DOI 10.1128/JB.184.11.2978-2986.2002; Kuhn C, 2003, PLANT PHYSIOL, V131, P102, DOI 10.1104/pp.011676; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lager I, 2003, FEBS LETT, V553, P85, DOI 10.1016/S0014-5793(03)00976-1; Lalonde S, 2004, ANNU REV PLANT BIOL, V55, P341, DOI 10.1146/annurev.arplant.55.031903.141758; Magnusson U, 2002, J BIOL CHEM, V277, P14077, DOI 10.1074/jbc.M200514200; Marvin JS, 2001, NAT STRUCT BIOL, V8, P795, DOI 10.1038/nsb0901-795; Muller J, 2001, PLANT PHYSIOL, V125, P1086, DOI 10.1104/pp.125.2.1086; Nagai T, 2004, BIOCHEM BIOPH RES CO, V319, P72, DOI 10.1016/j.bbrc.2004.04.147; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Weise SE, 2005, PLANT PHYSIOL, V137, P756, DOI 10.1104/pp.104.055996; Willis LB, 1999, J BACTERIOL, V181, P4176, DOI 10.1128/JB.181.14.4176-4184.1999	28	76	82	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30875	30883		10.1074/jbc.M605257200	http://dx.doi.org/10.1074/jbc.M605257200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912038	hybrid			2022-12-25	WOS:000241075900063
J	Metcalf, CE; Wassarman, DA				Metcalf, Chad E.; Wassarman, David A.			DNA binding properties of TAF1 isoforms with two AT-hooks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROMOTER ELEMENTS; GROUP PROTEIN I; TRANSCRIPTION; GENE; SELECTIVITY; COMPLEX; DOWNSTREAM; RECOGNIZES; REPRESSION; EXPRESSION	TATA-binding protein-associated factor 1 (TAF1) is an essential component of the general transcription factor IID ( TFIID), which nucleates assembly of the preinitiation complex for transcription by RNA polymerase II. TATA-binding protein and TAF1 (,) TAF2 heterodimers are the only components of TFIID shown to bind specific DNA sequences ( the TATA box and initiator, respectively), raising the question of how TFIID localizes to gene promoters that lack binding sites for these proteins. Here we demonstrate that Drosophila TAF1 protein isoforms TAF1-2 and TAF1-4 directly bind DNA independently of TAF2. DNA binding by TAF1 isoforms is mediated by cooperative interactions of two identical AT-hook motifs, one of which is encoded by an alternatively spliced exon. Electrophoretic mobility shift assays revealed that TAF1-2 bound the minor groove of adenine-thymine-rich DNA with a preference for the sequence AAT. Alanine-scanning mutagenesis of the alternatively spliced AT-hook indicated that Lys and Arg residues made essential DNA contacts, whereas Gly and Pro residues within the Arg-Gly-Arg-Pro core sequence were less important for DNA binding, suggesting that AT-hooks are more divergent than previously predicted. TAF1-2 bound with variable affinity to the transcription start site of several Drosophila genes, and binding to the hsp70 promoter was reduced by mutation of a single base pair at the transcription start site. Collectively, these data indicate that AT-hooks serve to anchor TAF1 isoforms to the minor groove of adenine-thymine-rich Drosophila gene promoters and suggest a model in which regulated expression of TAF1 isoforms by alternative splicing contributes to gene-specific transcription.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Wassarman, DA (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Madison, WI 53706 USA.	dawassarman@wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066204] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM066204] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aerts S, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-34; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Banks GC, 1999, J BIOL CHEM, V274, P16536, DOI 10.1074/jbc.274.23.16536; Bell B, 2001, MOL CELL, V8, P591, DOI 10.1016/S1097-2765(01)00325-2; Blumer N, 2002, MECH DEVELOP, V110, P97, DOI 10.1016/S0925-4773(01)00577-9; Caiafa P, 2005, J CELL BIOCHEM, V94, P257, DOI 10.1002/jcb.20325; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Chen BS, 2002, CURR BIOL, V12, pR620, DOI 10.1016/S0960-9822(02)01134-X; Christiansen H, 1996, PLANT MOL BIOL, V32, P809, DOI 10.1007/BF00020479; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; CLAUS P, 1994, J BIOL CHEM, V269, P33042; Dehm SM, 2004, MOL CELL BIOL, V24, P2296, DOI 10.1128/MCB.24.6.2296-2307.2004; Dragan AI, 2003, J MOL BIOL, V327, P393, DOI 10.1016/S0022-2836(03)00050-0; Falender AE, 2005, GENE DEV, V19, P794, DOI 10.1101/gad.1290105; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Frank O, 1998, J BIOL CHEM, V273, P20015, DOI 10.1074/jbc.273.32.20015; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Hiller M, 2004, DEVELOPMENT, V131, P5297, DOI 10.1242/dev.01314; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; Hochheimer A, 2003, GENE DEV, V17, P1309, DOI 10.1101/gad.1099903; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Koonin EV, 2000, CELL, V101, P573, DOI 10.1016/S0092-8674(00)80867-3; KORFHAGE U, 1994, PLANT CELL, V6, P695, DOI 10.1105/tpc.6.5.695; Lee DH, 2005, MOL CELL BIOL, V25, P9674, DOI 10.1128/MCB.25.21.9674-9686.2005; Lours C, 2003, NUCLEIC ACIDS RES, V31, P5389, DOI 10.1093/nar/gkg724; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Matangkasombut O, 2004, ADV PROTEIN CHEM, V67, P67; Maxam A M, 1980, Methods Enzymol, V65, P499; Muller F, 2004, EMBO J, V23, P2, DOI 10.1038/sj.emboj.7600027; Nurminsky DI, 1998, NATURE, V396, P572, DOI 10.1038/25126; Ohler U, 2002, GENOME BIOL, V3, DOI [10.1186/gb-2002-3-12-research0087, DOI 10.1186/GB-2002-3-12-RESEARCH0087]; Pointud JC, 2003, J CELL SCI, V116, P1847, DOI 10.1242/jcs.00391; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Santel A, 2000, NUCLEIC ACIDS RES, V28, P1439, DOI 10.1093/nar/28.6.1439; Schawaroch V, 2002, BIOL J LINN SOC, V76, P21, DOI 10.1111/j.1095-8312.2002.tb01711.x; Schwanbeck R, 2000, J BIOL CHEM, V275, P1793, DOI 10.1074/jbc.275.3.1793; Schwanbeck R, 2000, BIOCHEMISTRY-US, V39, P14419, DOI 10.1021/bi0011274; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; Turlure F, 2006, NUCLEIC ACIDS RES, V34, P1653, DOI 10.1093/nar/gkl052; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; Wu CH, 2001, MOL CELL BIOL, V21, P1593, DOI 10.1128/MCB.21.5.1593-1602.2001; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649	49	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30015	30023		10.1074/jbc.M606289200	http://dx.doi.org/10.1074/jbc.M606289200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16893881	hybrid			2022-12-25	WOS:000240896300062
J	Ng, CJ; Bourquard, N; Grijalva, V; Hama, S; Shih, DM; Navab, M; Fogelman, AM; Lusis, AJ; Young, S; Reddy, ST				Ng, Carey J.; Bourquard, Noam; Grijalva, Victor; Hama, Susan; Shih, Diana M.; Navab, Mohamad; Fogelman, Alan M.; Lusis, Aldons J.; Young, Stephen; Reddy, Srinivasa T.			Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins - Anti-atherogenic role for paraoxonase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; REVERSE CHOLESTEROL TRANSPORT; SERUM PARAOXONASE; OXIDIZED PHOSPHOLIPIDS; OXIDATIVE MODIFICATION; INSERTIONAL MUTATIONS; TRANSGENIC MICE; ARTERY-DISEASE; GENE	Paraoxonases (PONs) are a family of proteins that may play a significant role in providing relief from both toxic environmental chemicals as well as physiological oxidative stress. Although the physiological roles of the PON family of proteins, PON1, PON2, and PON3, remain unknown, epidemiological, biochemical, and mouse genetic studies of PON1 suggest an anti-atherogenic function for paraoxonases. To determine whether PON2 plays a role in the development of atherosclerosis in vivo, we generated PON2-deficient mice. When challenged with a high fat, high cholesterol diet for 15 weeks, serum levels of high density lipoprotein cholesterol, triglycerides, and glucose were not significantly different between wild-type and PON2-deficient mice. In contrast, serum levels of very low density lipoprotein (VLDL)/low density lipoprotein (LDL) cholesterol were significantly lower (-32%) in PON2-deficient mice compared with wild-type mice. However, despite lower levels of VLDL/LDL cholesterol, mice deficient in PON2 developed significantly larger (2.7-fold) atherosclerotic lesions compared with their wild-type counterparts. Enhanced inflammatory properties of LDL, attenuated anti-atherogenic capacity of high density lipoprotein, and a heightened state of oxidative stress coupled with an exacerbated inflammatory response from PON2-deficient macrophages appear to be the main mechanisms behind the larger atherosclerotic lesions in PON2-deficient mice. These results demonstrate that PON2 plays a protective role in atherosclerosis.	Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Reddy, ST (corresponding author), Univ Calif Los Angeles, Dept Med, Div Cardiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	sreddy@mednet.ucla.edu			NHLBI NIH HHS [R01 HL071776, 1R01 HL-71776, HL-30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071776, P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ansell BJ, 2003, CIRCULATION, V108, P2751, DOI 10.1161/01.CIR.0000103624.14436.4B; AUERBACH BJ, 1992, ANAL BIOCHEM, V201, P375, DOI 10.1016/0003-2697(92)90354-A; Aviram M, 1999, FREE RADICAL BIO MED, V26, P892, DOI 10.1016/S0891-5849(98)00272-X; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Castellani LW, 1997, J CLIN INVEST, V100, P464, DOI 10.1172/JCI119554; Chen Q, 2003, AM J HUM GENET, V72, P13, DOI 10.1086/345312; Draganov DI, 2000, J BIOL CHEM, V275, P33435, DOI 10.1074/jbc.M004543200; Draganov DI, 2005, J LIPID RES, V46, P1239, DOI 10.1194/jlr.M400511-JLR200; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Forte TM, 2002, J LIPID RES, V43, P477; Janka Z, 2002, MOL PSYCHIATR, V7, P110, DOI 10.1038/sj/mp/4000916; Jarvik GP, 2000, ARTERIOSCL THROM VAS, V20, P2441, DOI 10.1161/01.ATV.20.11.2441; Li BL, 2003, J BIOL CHEM, V278, P43276, DOI 10.1074/jbc.M306361200; Mackness B, 2003, CIRCULATION, V107, P2775, DOI 10.1161/01.CIR.0000070954.00271.13; Mackness B, 2001, ARTERIOSCL THROM VAS, V21, P1451, DOI 10.1161/hq0901.094247; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; Millar JS, 2005, J LIPID RES, V46, P2023, DOI 10.1194/jlr.D500019-JLR200; Navab M, 2002, CURR OPIN LIPIDOL, V13, P363, DOI 10.1097/00041433-200208000-00003; Navab M, 2001, ARTERIOSCL THROM VAS, V21, P481, DOI 10.1161/01.ATV.21.4.481; Nayernia K, 2003, J BIOL CHEM, V278, P48377, DOI 10.1074/jbc.M309583200; Ng CJ, 2005, FREE RADICAL BIO MED, V38, P153, DOI 10.1016/j.freeradbiomed.2004.09.035; Ng CJ, 2001, J BIOL CHEM, V276, P44444, DOI 10.1074/jbc.M105660200; Ozer EA, 2005, FEMS MICROBIOL LETT, V253, P29, DOI 10.1016/j.femsle.2005.09.023; Pan Ju-Pin, 2002, Zhonghua Yi Xue Za Zhi (Taipei), V65, P415; Pan MH, 2004, J CLIN INVEST, V113, P1277, DOI 10.1172/JCI200419197; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; PrimoParmo SL, 1996, GENOMICS, V33, P498, DOI 10.1006/geno.1996.0225; Reardon CA, 2004, J LIPID RES, V45, P1347, DOI 10.1194/jlr.M400075-JLR200; Reddy ST, 2001, ARTERIOSCL THROM VAS, V21, P542, DOI 10.1161/01.ATV.21.4.542; Rosenblat M, 2003, ARTERIOSCL THROM VAS, V23, P468, DOI 10.1161/01.ATV.0000059385.95664.4D; Roshon M, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-2; Sanghera DK, 1998, AM J HUM GENET, V62, P36, DOI 10.1086/301669; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Townley DJ, 1997, GENOME RES, V7, P293, DOI 10.1101/gr.7.3.293; Tsimikas S, 2005, NEW ENGL J MED, V353, P46, DOI 10.1056/NEJMoa043175; Tward A, 2002, CIRCULATION, V106, P484, DOI 10.1161/01.CIR.0000023623.87083.4F; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; [王丽琼 Wang LiQiong], 2003, [应用化学, Chinese Journal of Applied Chemistry], V20, P219; Yang F, 2005, FEBS LETT, V579, P3713, DOI 10.1016/j.febslet.2005.05.060; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178	43	127	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29491	29500		10.1074/jbc.M605379200	http://dx.doi.org/10.1074/jbc.M605379200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16891303	hybrid			2022-12-25	WOS:000240896300011
J	Pashov, AD; Plaxco, J; Kaveri, SV; Monzavi-Karbassi, B; Harn, D; Kieber-Emmons, T				Pashov, Anastas D.; Plaxco, Jason; Kaveri, Srinivas V.; Monzavi-Karbassi, Behjatolah; Harn, Donald; Kieber-Emmons, Thomas			Multiple antigenic mimotopes of HIV carbohydrate antigens - Relating structure and antigenicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SUPERANTIGEN-BINDING SITE; CONCANAVALIN-A; PEPTIDE MIMOTOPES; NEUTRALIZING ANTIBODIES; LINKED OLIGOSACCHARIDES; MAACKIA-AMURENSIS; LECTIN; GP120; INFECTION	Carbohydrate mimetic peptides are designable, and they can carry T-cell epitopes and circumvent tolerance. A mimic- based human immunodeficiency virus (HIV) vaccine can be a viable alternative to carbohydrate- based antigens if the diversity of epitopes found on gp120 can be recapitulated. To improve existing mimics, an attempt was made to study the structural correlates of the observed polyspecificity of carbohydrate mimetic peptides based on the Y( P/ R) Y motif in more detail. A carbohydrate mimetic peptide, D002 ( RGGLCYCRYRYCVCVGR), bound a number of lectins with different specificities. Although this peptide reacted strongly with both lotus and concanavalinA ( ConA) lectins, it bound to lotus stronger than ConA. By varying the central motif RYRY, five versions were produced in multiple antigen peptide format, and their avidity for lotus and ConA lectins was tested by surface plasmon resonance. Although the kinetic parameters were similar, the version based on the sequence YPYRY had an optimal affinity for both lectins as well as improved avidity for wheat germ agglutinin and phytohemagglutinin. Thus, as far as lectin specificity is concerned, YPYRY had improved multiple antigenic properties. Both RYRY and YPYRY precipitated antibodies from human IgG for intravenous use that bound to gp120 in vitro and immunoprecipitated gp120 from transfected CHO- PI cells. Thus, Y( P/ R) Y motifs mimic multiple carbohydrate epitopes, many of which are found on HIV, and preimmune human IgG antibodies that bind to HIV carbohydrates cross- react to a comparable extent with both RYRY and YPYRY carbohydrate mimetic peptides.	Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; INSERM, U681, Inst Biomed Cordeliers, F-75006 Paris, France; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	University of Arkansas System; University of Arkansas Medical Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Harvard University; Harvard T.H. Chan School of Public Health	Kieber-Emmons, T (corresponding author), Univ Arkansas Med Sci, Dept Pathol, 4301 W Markham St, Little Rock, AR 72205 USA.	tke@uams.edu	Pashov, Anastas/AAE-7997-2019	Pashov, Anastas/0000-0002-6033-3566	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049092, R01AI049092] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-49092] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agadjanyan M, 1997, NAT BIOTECHNOL, V15, P547, DOI 10.1038/nbt0697-547; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; Balzarini J, 2005, MOL PHARMACOL, V67, P1556, DOI 10.1124/mol.104.005082; Balzarini O, 2005, LANCET INFECT DIS, V5, P726, DOI 10.1016/S1473-3099(05)70271-1; Basu A, 2003, ANGEW CHEM INT EDIT, V42, P2504, DOI 10.1002/anie.200250859; Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; Bouvet JP, 2001, J AUTOIMMUN, V16, P163, DOI 10.1006/jaut.2000.0472; Cunto-Amesty G, 2003, INT J PARASITOL, V33, P597, DOI 10.1016/S0020-7519(03)00054-7; Cunto-Amesty G, 2001, J BIOL CHEM, V276, P30490, DOI 10.1074/jbc.M103257200; Dacheux L, 2004, J VIROL, V78, P12625, DOI 10.1128/JVI.78.22.12625-12637.2004; Dam TK, 2000, J BIOL CHEM, V275, P14223, DOI 10.1074/jbc.275.19.14223; Dudkin VY, 2004, J AM CHEM SOC, V126, P9560, DOI 10.1021/ja047720g; DUK M, 1994, GLYCOCONJUGATE J, V11, P371, DOI 10.1007/BF00731211; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; Ferrantelli F, 2003, AIDS, V17, P301, DOI 10.1097/00002030-200302140-00003; GATTEGNO L, 1992, AIDS RES HUM RETROV, V8, P27, DOI 10.1089/aid.1992.8.27; Geng XD, 2004, ANGEW CHEM INT EDIT, V43, P2562, DOI 10.1002/anie.200353626; GEYER H, 1988, J BIOL CHEM, V263, P11760; GOLDSTEIN IJ, 1981, J BIOL CHEM, V256, P3890; HAMMAR L, 1995, AIDS RES HUM RETROV, V11, P87, DOI 10.1089/aid.1995.11.87; HANSEN JES, 1991, J VIROL, V65, P6461, DOI 10.1128/JVI.65.12.6461-6467.1991; HANSEN JES, 1989, AIDS, V3, P635, DOI 10.1097/00002030-198910000-00003; Harris SL, 1997, P NATL ACAD SCI USA, V94, P2454, DOI 10.1073/pnas.94.6.2454; Harrison BA, 1998, J IMMUNOL METHODS, V212, P29, DOI 10.1016/S0022-1759(98)00012-X; HORTIN GL, 1990, ANAL BIOCHEM, V191, P262, DOI 10.1016/0003-2697(90)90217-W; Hutchins WA, 1996, MOL IMMUNOL, V33, P503, DOI 10.1016/0161-5890(96)00012-0; Jain D, 2000, BIOCHEM BIOPH RES CO, V272, P843, DOI 10.1006/bbrc.2000.2871; Jain D, 2000, J BIOL CHEM, V275, P16098, DOI 10.1074/jbc.275.21.16098; KALININ NL, 1995, ANAL BIOCHEM, V228, P238, DOI 10.1006/abio.1995.1345; Karray S, 1997, P NATL ACAD SCI USA, V94, P1356, DOI 10.1073/pnas.94.4.1356; Karray S, 1998, J IMMUNOL, V161, P6681; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430; LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101; Llorente M, 1999, SCAND J IMMUNOL, V50, P270; MacKenzie CR, 1996, J BIOL CHEM, V271, P1527, DOI 10.1074/jbc.271.3.1527; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; Mandal M, 2004, ANGEW CHEM INT EDIT, V43, P2557, DOI 10.1002/anie.200353625; MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519; Mizuochi T, 1988, Biomed Chromatogr, V2, P260; Monzavi-Karbassi B, 2003, VACCINE, V21, P753, DOI 10.1016/S0264-410X(02)00703-X; Monzavi-Karbassi B, 2001, BIOLOGICALS, V29, P249, DOI 10.1006/biol.2001.0307; MULLER WEG, 1991, J ACQ IMMUN DEF SYND, V4, P694; MULLER WEG, 1990, AIDS, V4, P159, DOI 10.1097/00002030-199002000-00010; Murali R, 1997, J MOL RECOGNIT, V10, P269, DOI 10.1002/(SICI)1099-1352(199711/12)10:6<269::AID-JMR370>3.0.CO;2-9; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; Pashov A, 2005, VACCINE, V23, P2168, DOI 10.1016/j.vaccine.2005.01.045; Pashov A, 2005, J BIOL CHEM, V280, P28959, DOI 10.1074/jbc.M502964200; Pashov A, 2002, INT IMMUNOL, V14, P453, DOI 10.1093/intimm/14.5.453; Quan CP, 2001, J AUTOIMMUN, V17, P81, DOI 10.1006/jaut.2001.0529; ROBINSON WE, 1987, AIDS RES HUM RETROV, V3, P265, DOI 10.1089/aid.1987.3.265; Scanlan CN, 2003, ADV EXP MED BIOL, V535, P205; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; Sharon N, 2002, J AGR FOOD CHEM, V50, P6586, DOI 10.1021/jf020190s; Sharon N, 2001, ADV EXP MED BIOL, V491, P1; Shin JS, 2002, J IMMUNOL, V168, P6273, DOI 10.4049/jimmunol.168.12.6273; Shinohara Y, 1997, GLYCOBIOLOGY, V7, P1201, DOI 10.1093/glycob/7.8.1201; TOMIYAMA T, 1991, BIOCHEM BIOPH RES CO, V177, P279, DOI 10.1016/0006-291X(91)91979-M; Wang LX, 2006, CURR OPIN DRUG DISC, V9, P194; WANG WC, 1988, J BIOL CHEM, V263, P4576; WEISS CD, 1993, J VIROL, V67, P7060, DOI 10.1128/JVI.67.12.7060-7066.1993; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; YAMAMOTO K, 1981, BIOCHEMISTRY-US, V20, P5894, DOI 10.1021/bi00523a037; Yan LY, 1997, GLYCOCONJUGATE J, V14, P45, DOI 10.1023/A:1018508914551	66	19	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29675	29683		10.1074/jbc.M604137200	http://dx.doi.org/10.1074/jbc.M604137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16899462	hybrid			2022-12-25	WOS:000240896300029
J	Sitailo, LA; Tibudan, SS; Denning, MF				Sitailo, Leonid A.; Tibudan, Shalini S.; Denning, Mitchell F.			The protein kinase C delta catalytic fragment targets Mcl-1 for degradation to trigger apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; UVB-INDUCED APOPTOSIS; BCL-2 FAMILY-MEMBER; PKC-DELTA; HUMAN KERATINOCYTES; DNA-DAMAGE; PHOSPHOLIPID SCRAMBLASE-3; MITOCHONDRIAL APOPTOSIS; INDUCED PHOSPHORYLATION; PROTEOLYTIC ACTIVATION	Proteolytic cleavage and subsequent activation of protein kinaseC( PKC) delta is required for apoptosis induced by a variety of genotoxic agent, including UV radiation. In addition, overexpression of the constitutively active PKC delta catalytic fragment (PKC delta-cat) is sufficient to trigger Bax activation, cytochrome c release, and apoptosis. While PKC delta is a key apoptotic effector, the downstream target( s) responsible for the mitochondrial apoptotic cascade are not known. We found that expression of the active PKC delta- cat in HaCaT cells triggers a reduction in the antiapoptotic protein Mcl-1, similar to UV radiation. The downregulation of Mcl-1 induced by PKC delta- cat was not at the mRNA level but was due to decreased protein half- life. Overexpression of Mcl-1 protected HaCaT cells from both UV and PKC delta- catinduced apoptosis and blocked the release of cytochrome c from the mitochondria, indicating that Mcl-1 down- regulation was required for apoptosis signaling. Indeed, down- regulation of Mcl-1 with siRNA slightly increased the basal apoptotic rate of HaCaT cells and dramatically sensitized them to UV or PKC delta cat- induced apoptosis. HaCaT cells with down- regulated Mcl-1 had higher activated Bax protein, as measured by Bax cross-linking, indicating that Mcl-1 down- regulation is sufficient for Bax activation. Finally, recombinant PKC delta could phosphorylate Mcl-1 in vitro, identifying Mcl-1 as a direct target for PKC delta. Overall our results identify Mcl-1 as an important target for PKC delta-cat that can mediate its pro- apoptotic effects on mitochondria to amplify the apoptotic signaling induced by a wide range of apoptotic stimuli.	Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Dept Pathol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Inst Oncol, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Denning, MF (corresponding author), Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Dept Pathol, Rm 304,2160 S 1st Ave, Maywood, IL 60153 USA.	mdennin@lumc.edu			NATIONAL CANCER INSTITUTE [R01CA083784] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA083784, R01 CA083784-06A2, CA83784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Croxton R, 2002, ONCOGENE, V21, P1563, DOI 10.1038/sj.onc.1205232; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; D'Costa AM, 2005, CELL DEATH DIFFER, V12, P224, DOI 10.1038/sj.cdd.4401558; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Han J, 2005, J BIOL CHEM, V280, P16383, DOI 10.1074/jbc.M411377200; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; He YW, 2005, CANCER RES, V65, P10016, DOI 10.1158/0008-5472.CAN-05-1688; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu JH, 2003, CANCER RES, V63, P1153; Ma YH, 2003, MOL CANCER THER, V2, P73; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Qin JZ, 2004, J CELL PHYSIOL, V200, P155, DOI 10.1002/jcp.20017; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Rinkenberger JL, 2000, GENE DEV, V14, P23; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Takasawa R, 2003, APOPTOSIS, V8, P291, DOI 10.1023/A:1023629023696; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	50	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29703	29710		10.1074/jbc.M607351200	http://dx.doi.org/10.1074/jbc.M607351200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16901898	hybrid, Green Accepted			2022-12-25	WOS:000240896300032
J	Thompson, A; Rolfe, MD; Lucchini, S; Schwerk, P; Hinton, JCD; Tedin, K				Thompson, Arthur; Rolfe, Matthew D.; Lucchini, Sacha; Schwerk, Peter; Hinton, Jay C. D.; Tedin, Karsten			The bacterial signal molecule, ppGpp, mediates the environmental regulation of both the invasion and intracellular virulence gene programs of Salmonella	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; III SECRETION SYSTEM; PATHOGENICITY ISLAND 2; ESCHERICHIA-COLI; STATIONARY-PHASE; HILA EXPRESSION; SSRA-SSRB; RELA; INFECTION; HOST	During infection of mammalian hosts, facultative intracellular pathogens have to adjust rapidly to different environmental conditions encountered during passage through the gastrointestinal tract and following uptake into epithelial cells and macrophages. Successful establishment within the host therefore requires the coordinated expression of a large number of virulence genes necessary for the adaptation between the extracellular and intracellular phases of infection. In this study we show that the bacterial signal molecule, ppGpp, plays a major role in mediating the environmental signals involved in the regulation of both the extracellular and intracellular virulence gene programs. Under oxygen limiting conditions, we observed a strong ppGpp dependence for invasion gene expression, the result of severe reductions in expression of the Salmonella pathogenicity island (SPI) 1 transcriptional regulator genes hilA, C, and D and invF. Overexpression of the non-SPI1-encoded regulator RtsA restored hilA expression in the absence of ppGpp. SPI2-encoded genes, required for intracellular proliferation in macrophages, were activated in the wild type strain under aerobic, late log phase growth conditions. The expression of SPI2 genes was also shown to be ppGpp-dependent under these conditions. The results from this study suggest a mechanism for the alternate regulation of the opposing extracellular and intracellular virulence gene programs and indicate a remarkable specificity for ppGpp in the regulation of genes involved in virulence compared with the rest of the genome. This is the first demonstration that this highly conserved regulatory system is involved in bacterial virulence gene expression on a global scale.	Food Res Inst, Mol Microbiol Grp, Norwich NR4 7UA, Norfolk, England; Free Univ Berlin, Inst Mikrobiol & Tierseuchen, D-10115 Berlin, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; Free University of Berlin	Thompson, A (corresponding author), Food Res Inst, Mol Microbiol Grp, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	Arthur.Thompson@bbsrc.ac.uk	Hinton, Jay C. D./B-2142-2008	Hinton, Jay C. D./0000-0003-2671-6026; Tedin, Karsten/0000-0003-2109-0730				Adak GK, 2002, GUT, V51, P832, DOI 10.1136/gut.51.6.832; Arricau N, 1998, MOL MICROBIOL, V29, P835, DOI 10.1046/j.1365-2958.1998.00976.x; Bajaj V, 1996, MOL MICROBIOL, V22, P703, DOI 10.1046/j.1365-2958.1996.d01-1718.x; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beuzon CR, 1999, MOL MICROBIOL, V33, P806, DOI 10.1046/j.1365-2958.1999.01527.x; BlancPotard AB, 1997, EMBO J, V16, P5376, DOI 10.1093/emboj/16.17.5376; Brown NF, 2005, PLOS PATHOG, V1, P252, DOI 10.1371/journal.ppat.0010032; Brumell JH, 2004, CURR OPIN MICROBIOL, V7, P78, DOI 10.1016/j.mib.2003.12.005; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; Cirillo DM, 1998, MOL MICROBIOL, V30, P175, DOI 10.1046/j.1365-2958.1998.01048.x; Clements MO, 2002, P NATL ACAD SCI USA, V99, P8784, DOI 10.1073/pnas.132047099; DaCosta XJ, 1997, J BACTERIOL, V179, P5211, DOI 10.1128/jb.179.16.5211-5217.1997; Deiwick J, 1999, MOL MICROBIOL, V31, P1759, DOI 10.1046/j.1365-2958.1999.01312.x; Dennis PP, 2004, MICROBIOL MOL BIOL R, V68, P639, DOI 10.1128/MMBR.68.4.639-668.2004; Drecktrah D, 2006, TRAFFIC, V7, P39, DOI 10.1111/j.1600-0854.2005.00360.x; Ellermeier CD, 2005, MOL MICROBIOL, V57, P691, DOI 10.1111/j.1365-2958.2005.04737.x; Ellermeier CD, 2003, J BACTERIOL, V185, P5096, DOI 10.1128/JB.185.17.5096-5108.2003; Erickson DL, 2004, INFECT IMMUN, V72, P5638, DOI 10.1128/IAI.72.10.5638-5645.2004; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; Garmendia J, 2003, MICROBIOL-SGM, V149, P2385, DOI 10.1099/mic.0.26397-0; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; Hammer BK, 1999, MOL MICROBIOL, V33, P721, DOI 10.1046/j.1365-2958.1999.01519.x; Hansen-Wester I, 2004, INFECT IMMUN, V72, P2879, DOI 10.1128/IAI.72.5.2879-2888.2004; Haralalka S, 2003, J BACTERIOL, V185, P4672, DOI 10.1128/JB.185.16.4672-4682.2003; Hensel M, 2004, INT J MED MICROBIOL, V294, P95, DOI 10.1016/j.ijmm.2004.06.025; Hensel M, 1997, MOL MICROBIOL, V24, P155, DOI 10.1046/j.1365-2958.1997.3271699.x; Hensel M, 1998, MOL MICROBIOL, V30, P163, DOI 10.1046/j.1365-2958.1998.01047.x; Herikstad H, 2002, EPIDEMIOL INFECT, V129, P1, DOI 10.1017/S0950268802006842; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; Hinton JCD, 2004, CURR OPIN MICROBIOL, V7, P277, DOI 10.1016/j.mib.2004.04.009; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Johnston C, 1996, MOL MICROBIOL, V22, P715, DOI 10.1046/j.1365-2958.1996.d01-1719.x; Kelly A, 2004, MICROBIOL-SGM, V150, P2037, DOI 10.1099/mic.0.27209-0; Knodler LA, 2005, J BIOL CHEM, V280, P9058, DOI 10.1074/jbc.M412588200; Lee AK, 2000, J BACTERIOL, V182, P771, DOI 10.1128/JB.182.3.771-781.2000; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; Linehan SA, 2005, INFECT IMMUN, V73, P4354, DOI 10.1128/IAI.73.7.4354-4362.2005; Lucas RL, 2000, MOL MICROBIOL, V36, P1024, DOI 10.1046/j.1365-2958.2000.01961.x; Lucas RL, 2001, J BACTERIOL, V183, P2733, DOI 10.1128/JB.183.9.2733-2745.2001; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P585; Morgan E, 2004, MOL MICROBIOL, V54, P994, DOI 10.1111/j.1365-2958.2004.04323.x; Murray RA, 2000, INFECT IMMUN, V68, P5050, DOI 10.1128/IAI.68.9.5050-5055.2000; Na HS, 2006, VACCINE, V24, P2027, DOI 10.1016/j.vaccine.2005.11.031; Paul BJ, 2005, P NATL ACAD SCI USA, V102, P7823, DOI 10.1073/pnas.0501170102; Paul BJ, 2004, CELL, V118, P311, DOI 10.1016/j.cell.2004.07.009; Pizarro-Cerda J, 2004, MOL MICROBIOL, V52, P1827, DOI 10.1111/j.1365-2958.2004.04122.x; Primm TP, 2000, J BACTERIOL, V182, P4889, DOI 10.1128/JB.182.17.4889-4898.2000; Rhen M, 2005, INT J MED MICROBIOL, V294, P487, DOI 10.1016/j.ijmm.2004.11.004; Schechter LM, 1999, MOL MICROBIOL, V32, P629, DOI 10.1046/j.1365-2958.1999.01381.x; Schmidt H, 2004, CLIN MICROBIOL REV, V17, P14, DOI 10.1128/CMR.17.1.14-56.2004; Song MY, 2004, J BIOL CHEM, V279, P34183, DOI 10.1074/jbc.M313491200; Taylor CA, 2002, J BACTERIOL, V184, P621, DOI 10.1128/JB.184.3.621-628.2002; Tedin K, 2001, J BACTERIOL, V183, P6184, DOI 10.1128/JB.183.21.6184-6196.2001; Thompson A, 2006, CURR OPIN MICROBIOL, V9, P109, DOI 10.1016/j.mib.2005.12.010; Vazquez-Torres A, 1999, NATURE, V401, P804, DOI 10.1038/44593; Waterman SR, 2003, CELL MICROBIOL, V5, P501, DOI 10.1046/j.1462-5822.2003.00294.x; XIAO H, 1991, J BIOL CHEM, V266, P5980; Yang YH, 2002, NAT REV GENET, V3, P579, DOI 10.1038/nrg863; Zaharik ML, 2002, P NATL ACAD SCI USA, V99, P15705, DOI 10.1073/pnas.252415599; Zusman T, 2002, J BACTERIOL, V184, P67, DOI 10.1128/JB.184.1.67-75.2002	64	56	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30112	30121		10.1074/jbc.M605616200	http://dx.doi.org/10.1074/jbc.M605616200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16905537	hybrid			2022-12-25	WOS:000240896300072
J	Armstrong, MT; Theg, SM; Braun, N; Wainwright, N; Pardy, RL; Armstrong, PB				Armstrong, Margaret T.; Theg, Steven M.; Braun, Nikolai; Wainwright, Norman; Pardy, R. L.; Armstrong, Peter B.			Histochemical evidence for lipid A (endotoxin) in eukaryote chloroplasts	FASEB JOURNAL			English	Article						lipopolysaccaride; E. coli; LALF; prokaryote	CRYSTAL-STRUCTURE; POLYMYXIN-B; BINDING; LIPOPOLYSACCHARIDE	Lipopolysaccharide (LPS) (a. k. a., endotoxin) is an essential component of the outer leaflet of the outer membrane of Gram-negative bacteria and is a potent activator of the innate immune system of animals. Lipid A, the glycolipid core of LPS, is the agent responsible for disease and death from Gram-negative sepsis, an important cause of human mortality and morbidity. Although it is generally accepted that lipid A is restricted to the prokaryotes, recent efforts to purify molecules from green algae with structural features unique to lipid A have met with success. Furthermore, the vascular plant Arabidopsis thaliana has been found to contain genes that encode all of the enzymes of the biosynthetic pathway for lipid A. It is not known whether vascular plants synthesize lipid A or where lipid A might be located in the tissues. For the present study, we used affinity reagents for lipid A to probe green alga and tissues of the garden pea for a light microscopic localization of lipid A in these eukaryote cells. We find staining for lipid A in free-living and endosymbiotic green algae and in the chloroplasts of vascular plants, indicating that this molecule is not restricted to prokaryotes, but is found also in select eukaryotes.	Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Plant Biol, Davis, CA 95616 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE USA	University of California System; University of California Davis; University of California System; University of California Davis; Marine Biological Laboratory - Woods Hole; University of Nebraska System; University of Nebraska Lincoln	Armstrong, PB (corresponding author), Univ Calif Davis, Dept Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	pbarmstrong@ucdavis.edu		Armstrong, Peter/0000-0001-5197-1999				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ARMSTRONG PB, 1982, EXP CELL RES, V140, P15, DOI 10.1016/0014-4827(82)90150-1; Bedick JC, 2001, NATURWISSENSCHAFTEN, V88, P482, DOI 10.1007/s00114-001-0269-8; Bedick JC, 2000, J INSECT PHYSIOL, V46, P1481, DOI 10.1016/S0022-1910(00)00073-1; BOGGS JM, 1985, BIOCHIM BIOPHYS ACTA, V816, P221, DOI 10.1016/0005-2736(85)90489-4; CLINE K, 1985, J BIOL CHEM, V260, P3691; Diks SH, 2004, CURR TOP MED CHEM, V4, P1115, DOI 10.2174/1568026043388141; Hoess A, 1995, Prog Clin Biol Res, V392, P327; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; Kimbrell DA, 2001, NAT REV GENET, V2, P256, DOI 10.1038/35066006; KUBESCH P, 1987, BIOCHEMISTRY-US, V26, P2139, DOI 10.1021/bi00382a012; LEVIN J, 1988, HORSESHOE CRAB MODEL, P3; Margulis Lynn, 1970, ORIGIN EUKARYOTE CEL; MIKHEYSKAYA LV, 1977, J BACTERIOL, V130, P1; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; PETERSON AA, 1985, J BACTERIOL, V164, P1256, DOI 10.1128/JB.164.3.1256-1261.1985; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RICKLES FR, 1979, J LAB CLIN MED, V93, P128; RICKLES FR, 1977, J LAB CLIN MED, V89, P792; Ried C, 1996, J BIOL CHEM, V271, P28120, DOI 10.1074/jbc.271.45.28120; ROTH RI, 1993, TRANSFUSION, V33, P919, DOI 10.1046/j.1537-2995.1993.331194082383.x; Royce CL, 1996, J ENDOTOXIN RES, V3, P437, DOI 10.1177/096805199600300601; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; Seydel U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P195; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992	26	22	22	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2145	+		10.1096/fj.05-5484fje	http://dx.doi.org/10.1096/fj.05-5484fje			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935939				2022-12-25	WOS:000241156900041
J	Bennasser, Y; Yeung, ML; Jeang, KT				Bennasser, Yamina; Yeung, Man Lung; Jeang, Kuan-Teh			HIV-1 TAR RNA subverts RNA interference in transfected cells through sequestration of TAR RNA-binding protein, TRBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; MICRORNA EXPRESSION; VIRAL SUPPRESSOR; KINASE; DICER; RECOGNITION; ARGONAUTE2; INHIBITOR; STRATEGY	TAR RNA-binding protein, TRBP, was recently discovered to be an essential partner for Dicer and a crucial component of the RNA-induced silencing complex ( RISC), a critical element of the RNA interference (RNAi) of the cell apparatus. Human TRBP was originally characterized and cloned 15 years ago based on its high affinity for binding the HIV-1 encoded leader RNA, TAR. RNAi is used, in part, by cells to defend against infection by viruses. Here, we report that transfected TAR RNA can attenuate the RNAi machinery in human cells. Our data suggest that TAR RNA sequesters TRBP rendering it unavailable for downstream Dicer-RISC complexes. TAR-induced inhibition of Dicer-RISC activity in transfected cells was partially relieved by exogenous expression of TRBP.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bldg 4,Rm 306,Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Jeang, Kuan-Teh/A-2424-2008; Bennasser, Yamina/M-4833-2017; Yeung, Man Lung/E-9903-2010	Yeung, Man Lung/0000-0002-6117-7884	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI000547] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson MG, 2005, J VIROL, V79, P9556, DOI 10.1128/JVI.79.15.9556-9565.2005; Bennasser Y, 2005, IMMUNITY, V22, P607, DOI 10.1016/j.immuni.2005.03.010; Bennasser Y, 2006, CURR OPIN HIV AIDS, V1, P208, DOI 10.1097/01.COH.0000221593.49412.56; BERKHOUT B, 1991, NUCLEIC ACIDS RES, V19, P6169, DOI 10.1093/nar/19.22.6169; Brady J, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-69; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Das AT, 2004, J VIROL, V78, P2601, DOI 10.1128/JVI.78.5.2601-2605.2004; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FOSTERMANN K, 2005, PLOS BIOL, V3, pE236; Gatignol A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-65; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; He YP, 2002, VIRAL IMMUNOL, V15, P95, DOI 10.1089/088282402317340260; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Le Page C, 2000, Rev Immunogenet, V2, P374; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942; Lichner Z, 2003, J GEN VIROL, V84, P975, DOI 10.1099/vir.0.18987-0; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Lu SH, 2004, J VIROL, V78, P12868, DOI 10.1128/JVI.78.23.12868-12876.2004; Meister G, 2005, CURR BIOL, V15, P2149, DOI 10.1016/j.cub.2005.10.048; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206; Rossi JJ, 2005, EMBO REP, V6, P927, DOI 10.1038/sj.embor.7400531; Saumet A, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-3; Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265; Shi R, 2005, BIOTECHNIQUES, V39, P519, DOI 10.2144/000112010; Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147; Voinnet O, 2005, NAT REV GENET, V6, P206, DOI 10.1038/nrg1555; Westerhout EM, 2005, NUCLEIC ACIDS RES, V33, P796, DOI 10.1093/nar/gki220; Ye KQ, 2003, NATURE, V426, P874, DOI 10.1038/nature02213; Yeung ML, 2005, CELL RES, V15, P935, DOI 10.1038/sj.cr.7290371; Yeung ML, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-81	42	92	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27674	27678		10.1074/jbc.C600072200	http://dx.doi.org/10.1074/jbc.C600072200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16887810	hybrid			2022-12-25	WOS:000240534400003
J	McDermott, SP; Ranheim, EA; Leatherberry, VS; Khwaja, SS; Klos, KS; Alexander, CM				McDermott, S. P.; Ranheim, E. A.; Leatherberry, V. S.; Khwaja, S. S.; Klos, K. S.; Alexander, C. M.			Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development	ONCOGENE			English	Article						syndecan-1 heparan sulfate proteoglycan; mouse tumor; DMBA	BREAST-CANCER CELLS; PROGENITOR CELLS; HEPARAN-SULFATE; STEM-CELLS; MOUSE; IDENTIFICATION; ACTIVATION; EXPRESSION; INDUCTION; RECOMMENDATIONS	We previously showed that mice with a null mutation in syndecan-1 (Sdc1; CD138) were resistant to Wnt1-induced mammary tumor initiation. The absence of Sdc1 inhibited the increase in the mammary stem cell fraction that is characteristic of preneoplasia in this model. As the tumor precursor cells are recruited from the stem/progenitor cell compartment, tumor development was also inhibited (Liu et al., 2004; PNAS 101, 4158). Although Sdc1(-/-) mice are grossly normal, they are systemically smaller, suggesting that developmental abnormalities may extend further than their mammary glands. We have therefore evaluated the multi-organ response of Sdc1(-/-) mice to carcinogen-induced tumor development (7,12-dimethylbenz[a] anthracene, DMBA), and find these mice to be resistant to tumorigenesis in all the predominant carcinogen-susceptible lineages. Thus, Sdc1(-/-) mice administered DMBA during juvenile development are resistant not only to epithelial tumors, including liver (60-80%) and lung tumors (C57BL6 mice, 60-80%), but also to lymphoma ( over 70%, depending upon strain and carcinogen dose). We demonstrate that CD138 is expressed ( heterogeneously) in the hematopoietic stem cell fraction ( and not only in pre-B and plasma cells), and that tumors arise in both myeloid and lymphoid lineages. Furthermore, carcinogen-induced mammary tumors are bilineal, implying a bipotent precursor cell. Both observations imply that the DMBA-induced tumor precursor cells are drawn from the stem/progenitor fraction, and we suggest that pathogenic activation of these cells could be abnormal in Sdc1(-/-) mice.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pathol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Alexander, CM (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	alexander@oncology.wisc.edu	McDermott, Sean/I-2978-2013; Ranheim, Erik/AAY-6505-2021	McDermott, Sean/0000-0001-7820-2399; 	NCI NIH HHS [T32 CA09135, CA 90877] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA090877] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAMATSU Y, 1975, J NATL CANCER I, V55, P893, DOI 10.1093/jnci/55.4.893; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FLAKS A, 1968, European Journal of Cancer, V4, P579, DOI 10.1016/0014-2964(68)90042-X; Forsberg EC, 2005, PLOS GENET, V1, P281, DOI 10.1371/journal.pgen.0010028; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Gotte M, 2002, INVEST OPHTH VIS SCI, V43, P1135; Heidel SM, 2000, CANCER RES, V60, P3454; Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592; Kenney Nicholas J., 2001, Journal of Biomedicine and Biotechnology, V1, P133, DOI 10.1155/S1110724301000304; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu BY, 2003, ONCOGENE, V22, P9243, DOI 10.1038/sj.onc.1207217; Maeda T, 2006, ONCOGENE, V25, P1408, DOI 10.1038/sj.onc.1209168; Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008-5472.CAN-03-2439; Mehta RG, 2000, EUR J CANCER, V36, P1275, DOI 10.1016/S0959-8049(00)00100-3; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Paguirigan A, 2006, EUR J CANCER, V42, P1225, DOI 10.1016/j.ejca.2006.01.048; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Ranheim EA, 2005, BLOOD, V105, P2487, DOI 10.1182/blood-2004-06-2334; ROE FJC, 1968, FOOD COSMET TOXICOL, V6, P581, DOI 10.1016/0015-6264(68)90302-7; SHACKLEFORD GM, 1988, P NATL ACAD SCI USA, V85, P9655, DOI 10.1073/pnas.85.24.9655; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev; VANLEEUWEN F, 1995, SEMIN CANCER BIOL, V6, P127, DOI 10.1006/scbi.1995.0018; WALTERS MA, 1966, BRIT J CANCER, V20, P148, DOI 10.1038/bjc.1966.17; Whitelock JM, 2005, CHEM REV, V105, P2745, DOI 10.1021/cr010213m	37	49	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1407	1416		10.1038/sj.onc.1209930	http://dx.doi.org/10.1038/sj.onc.1209930			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953225				2022-12-25	WOS:000244558800005
J	Kaur, M; Pop, M; Shi, D; Brignone, C; Grossman, SR				Kaur, M.; Pop, M.; Shi, D.; Brignone, C.; Grossman, S. R.			hHR23B is required for genotoxic-specific activation of p53 and apoptosis	ONCOGENE			English	Article						p53; hHR23; ubiquitin; proteasome; DNA damage; chromatin	NUCLEOTIDE EXCISION-REPAIR; UBIQUITIN-PROTEASOME SYSTEM; DNA-REPAIR; IN-VIVO; POLYUBIQUITIN CHAINS; UV-IRRADIATION; C PROTEIN; DEGRADATION; RAD23; DOMAINS	Rad23 proteins function in both DNA repair and protein stability regulation. As ubiquitinated forms of p53 are stabilized after DNA damage in concert with p53 functional activation, and human Rad23 proteins (hHR23A and B) regulate p53 stability in unstressed cells, the role of hHR23B in post-genotoxin regulation of p53 was investigated. Depletion of hHR23B by specific short interfering RNA before genotoxic exposure attenuated p53, p21 and bax induction, abrogated the accumulation of ubiquitinated p53 and suppressed apoptosis. Expression of ubiquitin derivatives with all lysines mutated except K48 or K63 demonstrated that K48-linked p53-ubiquitin conjugates were specifically induced after DNA damage. hHR23B, along with native and ubiquitinated p53, accumulated in chromatin after genotoxic exposure, and the accumulation of ubiquitinated p53 in chromatin was prevented by hHR23B depletion. Chromatin immunoprecipitation analysis demonstrated that hHR23B and p53 both localized to the p21 promoter shortly after DNA damage. hHR23B thus plays a critical role in the activation and function of p53 after specific genotoxic exposures.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Gastrointestinal Canc Program, Worcester, MA 01605 USA; Univ Massachusetts, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Grossman, SR (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB419,364 Plantat St, Worcester, MA 01605 USA.	steven.grossman@umassmed.edu			NATIONAL CANCER INSTITUTE [R01CA107532] Funding Source: NIH RePORTER; NCI NIH HHS [CA107532, R01 CA107532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Cutts SM, 2003, MOL CANCER THER, V2, P661; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hsieh HC, 2005, BIOCHEM BIOPH RES CO, V335, P181, DOI 10.1016/j.bbrc.2005.07.067; Itoh T, 2005, DNA REPAIR, V4, P1457, DOI 10.1016/j.dnarep.2005.08.008; Kruczynski A, 2004, CLIN CANCER RES, V10, P3156, DOI 10.1158/1078-0432.CCR-1305-2; Lee YJ, 2006, CARCINOGENESIS, V27, P446, DOI 10.1093/carcin/bgi254; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Ng JMY, 2002, MOL CELL BIOL, V22, P1233, DOI 10.1128/MCB.22.4.1233-1245.2002; Ortolan TG, 2004, NUCLEIC ACIDS RES, V32, P6490, DOI 10.1093/nar/gkh987; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Robles AI, 1999, ONCOGENE, V18, P4681, DOI 10.1038/sj.onc.1202862; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Soria G, 2006, ONCOGENE, V25, P2829, DOI 10.1038/sj.onc.1209315; Sweder K., 2002, Journal of Biomedicine & Biotechnology, V2, P94, DOI 10.1155/S1110724302205033; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang XY, 2003, SPECTROSC SPECT ANAL, V23, P42; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xie ZW, 2004, NUCLEIC ACIDS RES, V32, P5981, DOI 10.1093/nar/gkh934	28	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1231	1237		10.1038/sj.onc.1209865	http://dx.doi.org/10.1038/sj.onc.1209865			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924240	Green Accepted			2022-12-25	WOS:000244406400013
J	Duan, XY; Liang, YY; Feng, XH; Lin, X				Duan, Xueyan; Liang, Yao-Yun; Feng, Xin-Hua; Lin, Xia			Protein serine/threonine phosphatase PPM1A dephosphorylates Smad1 in the bone morphogenetic protein signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; IDENTIFICATION; DEGRADATION; CELLS	Bone morphogenetic proteins (BMPs) are secreted polypeptides belonging to the transforming growth factor-ss(TGF-ss) superfamily that activates a broad range of biological responses in the metazoan organism. The BMP-initiated signaling pathway is under tight control by processes including regulation of the ligands, the receptors, and the key downstream intracellular effector Smads. A critical point of control in BMP signaling is the phosphorylation of Smad1, Smad5, and Smad8 in their C-terminal SXS motif. Although such phosphorylation, which is mediated by the type I BMP receptor kinases in response to BMP stimulation, iswellcharacterized, biochemical mechanisms underlying Smad dephosphorylation remain to be elucidated. In this study, we have found that PPM1A, a metal ion-dependent protein serine/threonine phosphatase, physically interacts with and dephosphorylates Smad1 both in vitro and in vivo. Functionally, overexpression of PPM1A abolishes BMP-induced transcriptional responses, whereas RNA interference-mediated knockdown of PPM1A enhances BMP signaling. Collectively, our study suggests that PPM1A plays an important role in controlling BMP signaling through catalyzing Smad dephosphorylation.	Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Lin, X (corresponding author), Baylor Coll Med, Dept Surg, 1 Baylor Plaza,Rm 139D, Houston, TX 77030 USA.	xialin@bcm.edu			NCI NIH HHS [R01CA108454, R21CA11293] Funding Source: Medline; NIAMS NIH HHS [R01 AR053591-04, R01 AR053591-03, R01 AR053591-01A2, R01 AR053591-02, R01 AR053591, R01 AR053591-05] Funding Source: Medline; NIDDK NIH HHS [R01DK073932] Funding Source: Medline; NIGMS NIH HHS [R01GM63773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chen HB, 2006, GENE DEV, V20, P648, DOI 10.1101/gad.1384706; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Feng XH, 2006, SMAD SIGNAL TRANSDUC, P253; Gilardelli CN, 2004, DEV DYNAM, V230, P494, DOI 10.1002/dvdy.20073; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jackson MD, 2003, BIOCHEMISTRY-US, V42, P8513, DOI 10.1021/bi034074+; Kishigami S, 2005, CYTOKINE GROWTH F R, V16, P265, DOI 10.1016/j.cytogfr.2005.04.002; Knockaert M, 2006, P NATL ACAD SCI USA, V103, P11940, DOI 10.1073/pnas.0605133103; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; MIYAZONO K, 2002, SCI STKE, pE40; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Pardali K, 2005, J CELL PHYSIOL, V204, P260, DOI 10.1002/jcp.20304; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Tres LL, 2004, MOL REPROD DEV, V68, P1, DOI 10.1002/mrd.20056; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Wrighton KH, 2006, J BIOL CHEM, V281, P38365, DOI 10.1074/jbc.M607246200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Zhang JW, 2005, DEV BIOL, V284, P1, DOI 10.1016/j.ydbio.2005.05.009	27	85	93	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36526	36532		10.1074/jbc.M605169200	http://dx.doi.org/10.1074/jbc.M605169200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16931515	hybrid			2022-12-25	WOS:000242220800008
J	Hoe, HS; Tran, TS; Matsuoka, Y; Howell, BW; Rebeck, GW				Hoe, Hyang-Sook; Tran, Tracy S.; Matsuoka, Yasuji; Howell, Brian W.; Rebeck, G. William			DAB1 and Reelin effects on amyloid precursor protein and apoE receptor 2 trafficking and processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; ADAPTER PROTEIN; DISABLED 1; MICE LACKING; F-SPONDIN; FE65; BINDING; LIGAND; DOMAIN; PHOSPHORYLATION	Numerous cytoplasmic adaptor proteins, including JIP1, FE65, and X11 alpha, affect amyloid precursor protein (APP) processing and A beta production. Dab1 is another adaptor protein that interacts with APP as well as with members of the apoE receptor family. We examined the effect of Dab1 on APP and apoEr2 processing in transfected cells and primary neurons. Dab1 interacted with APP and apoEr2 and increased levels of their secreted extracellular domains and their cytoplasmic C-terminal fragments. These effects depended on the NPXY domains of APP and apoEr2 and on the phosphotyrosine binding domain of Dab1 but did not depend on phosphorylation of Dab1. Dab1 decreased the levels of APP beta-C-terminal fragment and secreted A beta. Full-length Dab1 or its phosphotyrosine binding domain alone increased surface levels of APP, as determined by surface protein biotinylation and live cell staining. A ligand for apoEr2, the extracellular matrix protein Reelin, significantly increased the interaction of apoEr2 with Dab1. Surprisingly, we also found that Reelin treatment significantly increased the interaction of APP and Dab1. Moreover, Reelin treatment increased cleavage of APP and apoEr2 and decreased production of the beta-C-terminal fragment of APP and A beta. Together, these data suggest that Dab1 alters trafficking and processing of APP and apoEr2, and this effect is influenced by extracellular ligands.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA; NINDS, Neurogenet Branch, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Rebeck, GW (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW, Washington, DC 20057 USA.	gwr2@georgetown.edu	Rebeck, George William/J-2192-2012; Tran, Tracy/M-2173-2019	Rebeck, George William/0000-0001-6276-248X; Howell, Brian/0000-0002-0204-0773; Tran, Tracy/0000-0002-2179-5725	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG022455, R01AG014473] Funding Source: NIH RePORTER; NIA NIH HHS [K01 AG022455, R01 AG14473] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Arnaud L, 2003, MOL CELL BIOL, V23, P9293, DOI 10.1128/MCB.23.24.9293-9302.2003; Bar I, 2000, EUR J MORPHOL, V38, P321, DOI 10.1076/ejom.38.5.321.7361; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chang Y, 2003, J BIOL CHEM, V278, P51100, DOI 10.1074/jbc.M309561200; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Guenette S, 2006, EMBO J, V25, P420, DOI 10.1038/sj.emboj.7600926; Guenette SY, 2002, J NEUROCHEM, V82, P755, DOI 10.1046/j.1471-4159.2002.01009.x; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Herrick TM, 2004, MOL BRAIN RES, V126, P121, DOI 10.1016/j.molbrainres.2004.03.022; Ho A, 2004, P NATL ACAD SCI USA, V101, P2548, DOI 10.1073/pnas.0308655100; Ho A, 2003, P NATL ACAD SCI USA, V100, P1409, DOI 10.1073/pnas.252774899; Hoe HS, 2005, MOL CELL BIOL, V25, P9259, DOI 10.1128/MCB.25.21.9259-9268.2005; Hoe HS, 2005, MOL BRAIN RES, V137, P31, DOI 10.1016/j.molbrainres.2005.02.013; Hoe HS, 2006, J BIOL CHEM, V281, P24521, DOI 10.1074/jbc.M600728200; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Horikoshi Y, 2004, BIOCHEM BIOPH RES CO, V319, P733, DOI 10.1016/j.bbrc.2004.05.051; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1999, MOL CELL BIOL, V19, P5179; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Lee JH, 2004, J BIOL CHEM, V279, P49099, DOI 10.1074/jbc.M405602200; Morimura T, 2005, J BIOL CHEM, V280, P16901, DOI 10.1074/jbc.M409048200; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; PARISIADOU L, 2006, IN PRESS NEUROBIOL A; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Pramatarova A, 2003, MOL CELL BIOL, V23, P7210, DOI 10.1128/MCB.23.20.7210-7221.2003; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200	35	126	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35176	35185		10.1074/jbc.M602162200	http://dx.doi.org/10.1074/jbc.M602162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16951405	hybrid			2022-12-25	WOS:000241933700051
J	Nomiyama, T; Nakamachi, T; Gizard, F; Heywood, EB; Jones, KL; Ohkura, N; Kawamori, R; Conneely, OM; Bruemmer, D				Nomiyama, Takashi; Nakamachi, Takafumi; Gizard, Florence; Heywood, Elizabeth B.; Jones, Karrie L.; Ohkura, Naganari; Kawamori, Ryuzo; Conneely, Orla M.; Bruemmer, Dennis			The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; MINICHROMOSOME MAINTENANCE PROTEINS; NGFI-B; TRANSCRIPTIONAL REGULATION; CARDIOVASCULAR-DISEASE; GENE-EXPRESSION; NURR1; ATHEROSCLEROSIS; KINASE; ACTIVATION	Members of the nuclear hormone receptor superfamily function as key transcriptional regulators of inflammation and proliferation in cardiovascular diseases. In addition to the ligand-dependent peroxisome proliferator-activated receptors and liver X receptors, this family of transcription factors includes a large number of orphan receptors, and their role in vascular diseases remains to be investigated. The neuron-derived orphan receptor-1 (NOR1) belongs to the ligand-independent NR4A subfamily, which has been implicated in cell proliferation, differentiation, and apoptosis. In this study, we demonstrate NOR1 expressionin vascular smooth muscle cells (SMC) of human atherosclerotic lesions. In response to mitogenic stimulation with platelet-derived growth factor ( PDGF), SMC rapidly express NOR1 through an ERK-MAPK-dependent signaling pathway. 5'- Deletion analysis, site-directed mutagenesis, and transactivation experiments demonstrate that PDGF-induced NOR1 expression is mediated through a cAMP-response element-binding protein (CREB)-dependent transactivation of the NOR1 promoter. Consequently, short interfering RNA mediated depletion of CREB abolished PDGF-induced NOR1 expression in SMC. Furthermore, PDGF induced Ser-133 phosphorylation of CREB and subsequent binding to the CRE sites of the endogenous NOR1 promoter. Functional analysis demonstrated that PDGF induces NOR1 transactivation of its consensus NGFI-B-response elements (NBRE) in SMC. We finally demonstrate that SMC isolated from NOR1-deficient mice exhibit decreased cell proliferation and characterize cyclin D1 and D2 as NOR1 target genes in SMC. These experiments indicate that PDGF-induced NOR1 transcription in SMC is mediated through CREB-dependent transactivation of the NOR1 promoter and further demonstrate that NOR1 functions as a key transcriptional regulator of SMC proliferation.	Univ Kentucky, Coll Med, Div Endocrinol & Mol Med, Lexington, KY 40536 USA; Natl Canc Ctr, Tumor Endocrinol Project, Tokyo 1040045, Japan; Juntendo Univ, Sch Med, Dept Med Metab & Endocrinol, Tokyo 1138421, Japan; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Kentucky; National Cancer Center - Japan; Juntendo University; Baylor College of Medicine	Bruemmer, D (corresponding author), Wethington Hlth Sci Bldg,Rm 575,900 S Limestone S, Lexington, KY 40536 USA.	Dennis.Bruemmer@uky.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084611] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL084611-01, R01 HL084611] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blaschke F, 2004, CIRC RES, V95, pE110, DOI 10.1161/01.RES.0000150368.56660.4f; Bonta PI, 2006, ARTERIOSCL THROM VAS, V26, P2288, DOI 10.1161/01.ATV.0000238346.84458.5d; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; Bruemmer D, 2005, INT J OBESITY, V29, pS26, DOI 10.1038/sj.ijo.0802910; Bruemmer D, 2003, AM J MED, V115, P87, DOI 10.1016/j.amjmed.2003.09.014; Bruemmer D, 2003, EXP CELL RES, V290, P28, DOI 10.1016/S0014-4827(03)00311-2; Bruemmer D, 2003, CIRC RES, V93, pE38, DOI 10.1161/01.RES.0000088344.15288.E6; Bruemmer D, 2003, MOL ENDOCRINOL, V17, P1005, DOI 10.1210/me.2002-0410; Bruemmer D, 2003, EUR J PHARMACOL, V466, P225, DOI 10.1016/S0014-2999(03)01556-5; Bruemmer D, 2003, J CLIN INVEST, V112, P1318, DOI 10.1172/JCI200318141; Castro DS, 2001, J BIOL CHEM, V276, P43277, DOI 10.1074/jbc.M107013200; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Codina A, 2004, J BIOL CHEM, V279, P53338, DOI 10.1074/jbc.M409096200; Costa MA, 2005, CIRCULATION, V111, P2257, DOI 10.1161/01.CIR.0000163587.36485.A7; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gennaro G, 2004, CIRCULATION, V110, P3367, DOI 10.1161/01.CIR.0000147773.86866.CD; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; Hsueh WA, 2004, HYPERTENSION, V43, P297, DOI 10.1161/01.HYP.0000113626.76571.5b; Hu YH, 2000, ARTERIOSCL THROM VAS, V20, P18, DOI 10.1161/01.ATV.20.1.18; Inuzuka H, 2002, FEBS LETT, V522, P88, DOI 10.1016/S0014-5793(02)02890-9; Klemm DJ, 2001, J BIOL CHEM, V276, P46132, DOI 10.1074/jbc.M104769200; Laffitte Bryan A, 2002, Curr Atheroscler Rep, V4, P213; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; Martinez-Gonzalez J, 2003, CIRC RES, V92, P96, DOI 10.1161/01.ES.0000050921.53008.47; MARUYAMA K, 1995, CANCER LETT, V96, P117, DOI 10.1016/0304-3835(95)03921-I; Maruyama K, 1998, INT J ONCOL, V12, P1237; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mii S, 1996, AM J PHYSIOL-HEART C, V270, pH142, DOI 10.1152/ajpheart.1996.270.1.H142; Millette E, 2005, CIRC RES, V96, P172, DOI 10.1161/01.RES.0000154595.87608.db; Ogawa D, 2005, CIRC RES, V96, P59, DOI 10.1161/01.RES.0000163630.86796.17; Ohkubo T, 2000, MOL CELL ENDOCRINOL, V162, P151, DOI 10.1016/S0303-7207(00)00222-7; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; Ohkura N, 1998, GENE, V211, P79, DOI 10.1016/S0378-1119(98)00095-X; Ohkura N, 1999, BBA-GENE STRUCT EXPR, V1444, P69, DOI 10.1016/S0167-4781(98)00247-4; Pei LM, 2006, NAT MED, V12, P1048, DOI 10.1038/nm1471; Pei LM, 2006, MOL ENDOCRINOL, V20, P786, DOI 10.1210/me.2005-0331; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Pirih FQ, 2003, BIOCHEM BIOPH RES CO, V306, P144, DOI 10.1016/S0006-291X(03)00931-8; Ponnio T, 2004, MOL CELL BIOL, V24, P9070, DOI 10.1128/MCB.24.20.9070-9078.2004; Ponnio T, 2002, MOL CELL BIOL, V22, P935, DOI 10.1128/MCB.22.3.935-945.2002; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004; Rius J, 2004, ARTERIOSCL THROM VAS, V24, P697, DOI 10.1161/01.ATV.0000121570.00515.dc; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Tokunou T, 2003, CIRCULATION, V108, P1246, DOI 10.1161/01.CIR.0000085164.13439.89; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Watson PA, 2002, ENDOCRINOLOGY, V143, P2922, DOI 10.1210/en.143.8.2922; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Xiong W, 1997, AM J PHYSIOL-LUNG C, V272, pL1205, DOI 10.1152/ajplung.1997.272.6.L1205; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656	60	99	104	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33467	33476		10.1074/jbc.M603436200	http://dx.doi.org/10.1074/jbc.M603436200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16945922	Green Accepted, hybrid			2022-12-25	WOS:000241621400057
J	Denti, S; Fernandez-Sanchez, ME; Rogge, L; Bianchi, E				Denti, Simona; Fernandez-Sanchez, Maria Elena; Rogge, Lars; Bianchi, Elisabetta			The COP9 signalosome regulates Skp2 levels and proliferation of human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEIN; UBIQUITIN-LIGASE; CAENORHABDITIS-ELEGANS; FISSION YEAST; CYCLIN-E; DROSOPHILA-MELANOGASTER; DNA-DAMAGE; S-PHASE; DEGRADATION; COMPLEX	The COP9 signalosome (CSN) is a conserved, multisubunit complex first identified as a developmental regulator in plants. Gene inactivation of single CSN subunits results in early embryonic lethality in mice, indicating that the CSN is essential for mammalian development. The pleiotropic function of the CSN may be related to its ability to remove the ubiquitin-like peptide Nedd8 from cullin-RING ubiquitin ligases, such as the SCF complex, and therefore regulate their activity. However, the mechanism of CSN regulatory action on cullins has been debated, since, paradoxically, the CSN has an inhibitory role in vitro, while genetic evidence supports a positive regulatory role in vivo. We have targeted expression of CSN subunits 4 and 5 in human cells by lentivirus-mediated small hairpin RNA delivery. Down-regulation of either subunit resulted in disruption of the CSN complex and in Cullin1 hyperneddylation. Functional consequences of CSN down-regulation were decreased protein levels of Skp2, the substrate recognition subunit of SCFSkp2, and stabilization of a Skp2 target, the cyclin-dependent kinase inhibitor p27Kip1. CSN down-regulation caused an impairment in cell proliferation, which could be partially reversed by suppression of p27Kip1. Moreover, restoring Skp2 levels in CSN-deficient cells recovered cell cycle progression, indicating that loss of Skp2 in these cells plays an important role in their proliferation defect. Our data indicate that the CSN is necessary to ensure the assembly of a functional SCFSkp2 complex and therefore contributes to cell cycle regulation of human cells.	Inst Pasteur, Immunoregulat Lab, Dept Immunol, F-75724 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bianchi, E (corresponding author), Inst Pasteur, Immunoregulat Lab, Dept Immunol, 25 Rue Dr Roux, F-75724 Paris, France.	ebianchi@pasteur.fr	Rogge, Lars/GYJ-6142-2022	Rogge, Lars/0000-0003-1262-9204; Fernandez Sanchez, Maria Elena/0000-0001-8083-8863				Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bondar T, 2006, MOL CELL BIOL, V26, P2531, DOI 10.1128/MCB.26.7.2531-2539.2006; Bondar T, 2004, J BIOL CHEM, V279, P9937, DOI 10.1074/jbc.M312570200; CLANDININ TR, 1993, GENETICS, V134, P199; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Cope Gregory A., 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-1; Dohmann EMN, 2005, PLANT CELL, V17, P1967, DOI 10.1105/tpc.105.032870; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Freilich S, 1999, CURR BIOL, V9, P1187, DOI 10.1016/S0960-9822(00)80023-8; Fukumoto A, 2005, FEBS LETT, V579, P1047, DOI 10.1016/j.febslet.2004.12.076; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Gemmill RM, 2005, ONCOGENE, V24, P3503, DOI 10.1038/sj.onc.1208509; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; He Q, 2005, GENE DEV, V19, P1518, DOI 10.1101/gad.1322205; Hetfeld BKJ, 2005, CURR BIOL, V15, P1217, DOI 10.1016/j.cub.2005.05.059; Higa LA, 2006, CELL CYCLE, V5, P71, DOI 10.4161/cc.5.1.2266; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Jones D, 2000, DEV BIOL, V226, P152, DOI 10.1006/dbio.2000.9847; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Li Y, 2004, J BIOL CHEM, V279, P11074, DOI 10.1074/jbc.M312301200; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Oron E, 2002, DEVELOPMENT, V129, P4399; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Qian X, 2005, BIOCHEM J, V389, P389, DOI 10.1042/BJ20050297; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Srayko M, 2000, GENE DEV, V14, P1072; Staub JM, 1996, PLANT CELL, V8, P2047, DOI 10.1105/tpc.8.11.2047; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tomoda K, 2004, J BIOL CHEM, V279, P43013, DOI 10.1074/jbc.M406559200; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Wee S, 2005, NAT CELL BIOL, V7, P387, DOI 10.1038/ncb1241; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; Wu JT, 2005, NAT CELL BIOL, V7, P1014, DOI 10.1038/ncb1301; Yan J, 2003, MOL CELL BIOL, V23, P6798, DOI 10.1128/MCB.23.19.6798-6808.2003; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	56	60	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32188	32196		10.1074/jbc.M604746200	http://dx.doi.org/10.1074/jbc.M604746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16943200	hybrid			2022-12-25	WOS:000241414500016
J	He, HJ; Zhu, TN; Xie, Y; Fan, JS; Kole, S; Saxena, S; Bernier, M				He, Hua-Jun; Zhu, Tie-Nian; Xie, Yi; Fan, Jinshui; Kole, Sutapa; Saxena, Satya; Bernier, Michel			Pyrrolidine dithiocarbamate inhibits interleukin-6 signaling through impaired STAT3 activation and association with transcriptional coactivators in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN ENDOTHELIAL-CELLS; C/EBP-BETA; INSULIN-RESISTANCE; OXIDATIVE STRESS; GENE-EXPRESSION; DNA-BINDING; ALPHA(2)-MACROGLOBULIN GENE; TYROSINE PHOSPHORYLATION; HAPTOGLOBIN GENE	Interleukin (IL)-6 is a proinflammatory cytokine that has been implicated in the expression of acute phase plasma proteins and hepatic insulin resistance through activation of the JAK/STAT3 pathway. Although previous studies have demonstrated that pyrrolidine dithiocarbamate (PDTC) exerts protection against inflammatory responses, its role in the regulation of IL-6 receptor signaling remains unclear. Here we show that treatment of cultured HepG2 hepatoma cells with PDTC inhibits IL-6-stimulated tyrosine phosphorylation and subsequent nuclear translocation of STAT3 in a dose- and time-dependent fashion. No inhibition of JAK-1 activity was observed. To provide insight into PDTC signaling, we constructed a conditionally active STAT3 by fusing it with the ligand binding domain of the estrogen receptor (STAT3-ER). In the presence of 4-hydroxytamoxifen STAT3-ER was translocated in the nucleus of HepG2 cells in a phosphorylation-independent manner, and treatment with PDTC mitigated the response. Although STAT3 coprecipitated with heat-shock protein 90 (Hsp90) in control cells, coprecipitation of the two proteins was greatly reduced after PDTC treatment or after exposure to geldanamycin, an Hsp90 inhibitor. As a result there was a decrease in IL-6-induced association of STAT3 with the transcriptional coactivators FOXO1a and C/EBP beta together with significant reduction in the expression of SOCS-3 protein and that of two major acute phase plasma proteins. Importantly, treatment of HepG2 cells and a primary culture of rat hepatocytes with PDTC restored insulin responsiveness that was abrogated by IL-6. These studies are consistent with the ability of PDTC to down-regulate IL-6-induced STAT3 activation by altering the stability of STAT3-Hsp90 complex.	NIA, Diabet Sect, Clin Invest Lab, NIH, Baltimore, MD 21224 USA; NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; NIA, Proteom & Mass Spectrometry Unit, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bernier, M (corresponding author), NIA, Diabet Sect, Clin Invest Lab, NIH, Box 23,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	Bernierm@mail.nih.gov	Bernier, Michel/Y-7139-2019; Bernier, Michel/AAO-3983-2021	Bernier, Michel/0000-0002-5948-368X	NATIONAL INSTITUTE ON AGING [ZIAAG000892, Z01AG000892] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Bogojevic D, 2003, GEN PHYSIOL BIOPHYS, V22, P279; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bruck R, 2004, LIVER INT, V24, P169, DOI 10.1111/j.1478-3231.2004.00900.x; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Buck M, 2001, EMBO J, V20, P6712, DOI 10.1093/emboj/20.23.6712; Carballo M, 1999, J BIOL CHEM, V274, P17580, DOI 10.1074/jbc.274.25.17580; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Cabo R, 2003, EXP GERONTOL, V38, P631, DOI 10.1016/S0531-5565(03)00055-X; Di Gregorio GB, 2004, AM J PHYSIOL-ENDOC M, V287, pE182, DOI 10.1152/ajpendo.00189.2003; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Gatto L, 2004, J BIOL CHEM, V279, P13746, DOI 10.1074/jbc.M308999200; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Guo GG, 2002, J INTERF CYTOK RES, V22, P555, DOI 10.1089/10799900252982034; He B, 2003, BIOCHEM BIOPH RES CO, V301, P386, DOI 10.1016/S0006-291X(02)03071-1; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Johnston AM, 2003, FEBS LETT, V546, P32, DOI 10.1016/S0014-5793(03)00438-1; Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2; Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972; Kim HJ, 2004, DIABETES, V53, P1060, DOI 10.2337/diabetes.53.4.1060; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kortylewski M, 2003, J BIOL CHEM, V278, P5242, DOI 10.1074/jbc.M205403200; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Marette A, 2002, CURR OPIN CLIN NUTR, V5, P377, DOI 10.1097/00075197-200207000-00005; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Milocco LH, 1999, MOL CELL BIOL, V19, P2913; Milosavljevic T, 2003, GEN PHYSIOL BIOPHYS, V22, P181; Milosavljevic TS, 2002, BIOCHEMISTRY-MOSCOW+, V67, P918, DOI 10.1023/A:1019922805828; Munoz C, 1996, J IMMUNOL, V157, P3587; Munoz C, 1996, BLOOD, V88, P3482, DOI 10.1182/blood.V88.9.3482.bloodjournal8893482; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; PAJOVIC S, 1994, J BIOL CHEM, V269, P2215; Pilipuk GP, 2003, J BIOL CHEM, V278, P35668, DOI 10.1074/jbc.M305182200; Piwien-Pilipuk G, 2002, J BIOL CHEM, V277, P44557, DOI 10.1074/jbc.M206886200; Ramadori G, 1999, SEMIN LIVER DIS, V19, P141, DOI 10.1055/s-2007-1007106; Sato N, 2003, BIOCHEM BIOPH RES CO, V300, P847, DOI 10.1016/S0006-291X(02)02941-8; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200; Shah M, 2002, J BIOL CHEM, V277, P45662, DOI 10.1074/jbc.M205935200; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Streetz KL, 2003, GASTROENTEROLOGY, V125, P532, DOI 10.1016/S0016-5085(03)00901-6; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Tsuchihashi S, 2003, SURGERY, V133, P556, DOI 10.1067/msy.2003.124; Wang YP, 2001, REDOX REP, V6, P379, DOI 10.1179/135100001101536580; Waris G, 2005, J VIROL, V79, P1569, DOI 10.1128/JVI.79.3.1569-1580.2005; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	67	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31369	31379		10.1074/jbc.M603762200	http://dx.doi.org/10.1074/jbc.M603762200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16926159				2022-12-25	WOS:000241235300021
J	Liu, XS; Shi, Y; Birnbaum, MJ; Ye, KQ; De Jong, R; Oltersdorf, T; Giranda, VL; Luo, Y				Liu, Xuesong; Shi, Yan; Birnbaum, Morris J.; Ye, Keqiang; De Jong, Ron; Oltersdorf, Tillman; Giranda, Vincent L.; Luo, Yan			Quantitative analysis of anti-apoptotic function of Akt in Akt1 and Akt2 double knock-out mouse embryonic fibroblast cells under normal and stressed conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; MOLECULAR-CLONING; CRITICAL ROLES; CANCER CELLS; MICE LACKING; GROWTH; PHOSPHORYLATION; IDENTIFICATION; RESISTANCE; ONCOGENE	The serine/threonine kinases Akt1/PKB alpha, Akt2/PKB beta, and Akt3/PKB gamma have been implicated in preventing cells from undergoing apoptosis. Although several small molecule inhibitors of Akt have been reported to induce apoptosis in cancer cells, these inhibitors may have additional targets. In the current study, we used an Akt3 small interfering RNA (Akt3 siRNA) to analyze apoptosis induction in Akt1 and Akt2 double knock-out mouse embryonic fibroblast cells (MEF-Akt1,2-DKO). Our data indicated that Akt3 siRNA inhibited Akt3 protein expression in a dose-dependent manner. As a result, phosphorylation of Akt and its downstream targets, including FKHRL1 and GSK3 alpha/beta, were reduced accordingly. The treatment also induced apoptosis in MEF-Akt1,2-DKO cells. However, apoptosis induction is significant only when more than 80% of Akt3 protein was depleted. Reintroducing Akt3 totally rescued Akt3-siRNA-induced apoptosis in MEF-Akt1,2-DKO cells. In addition, reintroducing Akt1 also inhibited apoptosis induced by Akt3 siRNA. Moreover, Akt3 siRNA potentiated different stress-induced apoptosis in MEF-Akt1,2-DKO cells at a lower dose when compared with what is required for apoptosis induction by itself. Our study suggests that only a small portion of Akt is active in wild-type MEF cells and a threshold of Akt inhibition is required to induce apoptosis by pure Akt inhibitors. In addition, our data indicate that cells under stress require more Akt for its survival.	Abbott Labs, Dept Canc Res R47S, Abbott Pk, IL 60064 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Idun Pharmaceut, San Diego, CA 92121 USA	Abbott Laboratories; University of Pennsylvania; Emory University	Luo, Y (corresponding author), Abbott Labs, Dept Canc Res R47S, 100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	Yan.luo@abbott.com		Birnbaum, Morris/0000-0001-9972-8680				Ahn JY, 2004, EMBO J, V23, P3995, DOI 10.1038/sj.emboj.7600392; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clark AS, 2002, MOL CANCER THER, V1, P707; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P670, DOI 10.1093/nar/gkg141; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Liu X, 2005, J NEUROCHEM, V93, P892, DOI 10.1111/j.1471-4159.2005.03064.x; Liu XS, 2004, ANTICANCER RES, V24, P2697; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; Mandal M, 2005, BRIT J CANCER, V92, P1899, DOI 10.1038/sj.bjc.6602595; Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271	32	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31380	31388		10.1074/jbc.M606603200	http://dx.doi.org/10.1074/jbc.M606603200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16923802				2022-12-25	WOS:000241235300022
J	Mellody, KT; Freeman, LJ; Baldock, C; Jowitt, TA; Siegler, V; Raynal, BDE; Cain, SA; Wess, TJ; Shuttleworth, CA; Kielty, CM				Mellody, Kieran T.; Freeman, Lyle J.; Baldock, Clair; Jowitt, Thomas A.; Siegler, Veronique; Raynal, Bertrand D. E.; Cain, Stuart A.; Wess, Tim J.; Shuttleworth, C. Adrian; Kielty, Cay M.			Marfan syndrome-causing mutations in fibrillin-1 result in gross morphological alterations and highlight the structural importance of the second hybrid domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE SCATTERING; CALCIUM-BINDING PROPERTIES; LOW-RESOLUTION STRUCTURE; RAY SOLUTION SCATTERING; EGF-LIKE DOMAINS; MICROFIBRIL ORGANIZATION; RICH MICROFIBRILS; CODING SEQUENCE; ELASTIC FIBERS; PAIR	Mutations in fibrillin-1 result in Marfan syndrome, which affects the cardiovascular, skeletal and ocular systems. The multiorgan involvement and wide spectrum of associated phenotypes highlights the complex pathogenesis underlying Marfan syndrome. To elucidate the genotype to phenotype correlations, we engineered four Marfan syndrome causing mutations into a fibrillin-1 fragment encoded by exons 18-25, a region known to interact with tropoelastin. Biophysical and biochemical approaches, including small angle x-ray scattering, analytical ultracentrifugation, and circular dichroism, were used to study the impact of these mutations upon the structure and function of the protein. Mutations G880S, C862R, and C908R, situated within the second hybrid domain, disrupted the ratio of alpha-helix to beta-sheet leading to a more compact conformation. These data clearly demonstrate the importance of the previously uncharacterized hybrid domain in fibrillin-1 structure. In contrast, mutation K1023N situated within the linker region between the third eight cysteine motif and cbEGF 11 markedly extended the length of the fragment. However, none of the mutations affected tropoelastin binding. The profound effects of all four mutations on fragment conformation suggest that they contribute to the pathogenesis of Marfan syndrome by disrupting protein folding and its assembly into fibrillin-rich microfibrils.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF10 3NB, Wales	University of Manchester; Cardiff University	Kielty, CM (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.	cay.kielty@manchester.ac.uk	Cain, Stuart A/G-2836-2017	Cain, Stuart/0000-0001-8417-1058; Mellody, Kieran/0000-0002-8164-9148; raynal, Bertrand/0000-0001-5634-0408; Baldock, Clair/0000-0003-3497-1959; Jowitt, Thomas/0000-0002-4045-0933	MRC [G0300379] Funding Source: UKRI; Medical Research Council [G0300379] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ashworth JL, 2000, BRIT J OPHTHALMOL, V84, P1312, DOI 10.1136/bjo.84.11.1312; Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; Baldock C, 2006, P NATL ACAD SCI USA, V103, P11922, DOI 10.1073/pnas.0601609103; Bernocco S, 2003, J BIOL CHEM, V278, P7199, DOI 10.1074/jbc.M210857200; Cardy CM, 1998, J MOL BIOL, V276, P855, DOI 10.1006/jmbi.1997.1593; Chatterjee S, 2004, CLIN EXP RHEUMATOL, V22, P617; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; Dietz HC, 2000, MATRIX BIOL, V19, P481, DOI 10.1016/S0945-053X(00)00101-3; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hayward C, 1997, HUM MUTAT, V10, P415, DOI 10.1002/(SICI)1098-1004(1997)10:6<415::AID-HUMU1>3.3.CO;2-2; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; Katzke S, 2002, HUM MUTAT, V20, P197, DOI 10.1002/humu.10112; Kielty CM, 2005, ADV PROTEIN CHEM, V70, P405, DOI 10.1016/S0065-3233(04)70012-1; KIELTY CM, 1995, J CELL SCI, V108, P1317; Kielty CM, 2002, J CELL SCI, V115, P2817; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; Loeys BL, 2003, ACTA CLIN BELG, V58, P3, DOI 10.1179/acb.2003.58.1.001; Lu YH, 2005, J MOL BIOL, V349, P73, DOI 10.1016/j.jmb.2005.03.066; Marquez JA, 2003, EMBO J, V22, P4616, DOI 10.1093/emboj/cdg448; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; Ng CM, 2004, J CLIN INVEST, V114, P1586, DOI 10.1172/JCI22715; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Pereira L, 1999, P NATL ACAD SCI USA, V96, P3819, DOI 10.1073/pnas.96.7.3819; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; Robinson PN, 2001, CELL MOL LIFE SCI, V58, P1698, DOI 10.1007/PL00000807; ROBINSON PN, 2006, IN PRESS J MED GENET; Rock MJ, 2004, J BIOL CHEM, V279, P23748, DOI 10.1074/jbc.M400212200; Rommel Kathrin, 2002, Hum Mutat, V20, P406, DOI 10.1002/humu.9075; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Scott DJ, 2002, J MOL BIOL, V315, P1179, DOI 10.1006/jmbi.2001.5306; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Sherratt MJ, 2001, MICRON, V32, P185, DOI 10.1016/S0968-4328(99)00082-7; Smallridge RS, 2003, J BIOL CHEM, V278, P12199, DOI 10.1074/jbc.M208266200; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; SVEDBERG T, 1940, ULTRACENTRIFUGE, P296; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; TANFORD C, 1961, PHYSICAL CHEM MACROM, P306; Tiecke F, 2001, EUR J HUM GENET, V9, P13, DOI 10.1038/sj.ejhg.5200582; TYNAN K, 1993, HUM MOL GENET, V2, P1813, DOI 10.1093/hmg/2.11.1813; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; Whiteman P, 1998, PROTEIN ENG, V11, P957, DOI 10.1093/protein/11.11.957; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Yuan XM, 2002, J MOL BIOL, V316, P113, DOI 10.1006/jmbi.2001.5329	56	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31854	31862		10.1074/jbc.M602743200	http://dx.doi.org/10.1074/jbc.M602743200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16905551	Bronze			2022-12-25	WOS:000241235300072
J	Benjannet, S; Rhainds, D; Hamelin, JE; Seidah, NG; Seidah, NG				Benjannet, Suzanne; Rhainds, David; Hamelin, Josee; Nassoury, Nasha; Seidah, Nabil G.			The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA; DENSITY-LIPOPROTEIN RECEPTOR; SECRETORY PATHWAY; LDL RECEPTOR; TARGET GENES; MOUSE-LIVER; IN-VITRO; PROTEIN; CHOLESTEROL; PRECURSOR	PCSK9 is the ninth member of the proprotein convertase ( PC) family. Some of its natural mutations have been genetically associated with the development of a dominant form of familial hyper- or hypocholesterolemia. The exact mechanism of action of PCSK9 is not clear, although it is known to enhance the intracellular degradation of the low density lipoprotein (LDL) receptor in acidic compartments, likely the endosomes/lysosomes. We analyzed the post-translational modifications of PCSK9 and show that it is sulfated within its prosegment at Tyr(38). We also examined the susceptibility of PCSK9 to proteolytic cleavage by the other members of the PC family. The data show that the natural gain-of-function mutations R218S, F216L, and D374Y associated with hypercholesterolemia result in total or partial loss of furin/PC5/6A processing at the motif RFHR218 down arrow. In contrast, the loss-of-function mutations A443T and C679X lead either to the lack of trans-Golgi network/recycling endosome localization and an enhanced susceptibility to furin cleavage (A443T) or to the inability of PCSK9 to exit the endoplasmic reticulum (C679X). Furthermore, we report the presence of both native and furin-like cleaved forms of PCSK9 in circulating human plasma. Thus, we propose that PCSK9 levels are finely regulated by the basic amino acid convertases furin and PC5/6A. The latter may reduce the lifetime of this proteinase and its ability to degrade the cell-surface LDL receptor, thereby regulating the levels of circulating LDL cholesterol.	[Benjannet, Suzanne; Rhainds, David; Hamelin, Josee; Nassoury, Nasha; Seidah, Nabil G.] Clin Res Inst Montreal, Lab Biochem Neuroendocrinol, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Seidah, NG (corresponding author), Clin Res Inst Montreal, Lab Biochem Neuroendocrinol, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	seidahn@ircm.qc.ca	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Allard Delphine, 2005, Hum Mutat, V26, P497, DOI 10.1002/humu.9383; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Attie AD, 2005, CELL METAB, V1, P290, DOI 10.1016/j.cmet.2005.04.006; Attie AD, 2004, ARTERIOSCL THROM VAS, V24, P1337, DOI 10.1161/01.ATV.0000137288.82390.04; Bedard K, 2005, INT REV CYTOL, V245, P91, DOI 10.1016/S0074-7696(05)45004-4; Benjannet S, 2004, BIOCHEM BIOPH RES CO, V325, P235, DOI 10.1016/j.bbrc.2004.10.019; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; Berge KE, 2006, ARTERIOSCL THROM VAS, V26, P1094, DOI 10.1161/01.ATV.0000204337.81286.1c; Bergeron E, 2005, BIOCHEM BIOPH RES CO, V326, P554, DOI 10.1016/j.bbrc.2004.11.063; Brennan SO, 1995, J CLIN INVEST, V96, P2854, DOI 10.1172/JCI118356; Cameron J, 2006, HUM MOL GENET, V15, P1551, DOI 10.1093/hmg/ddl077; Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842; Cheng D, 1999, J BIOL CHEM, V274, P22805, DOI 10.1074/jbc.274.32.22805; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Decroly E, 1997, FEBS LETT, V405, P68, DOI 10.1016/S0014-5793(97)00156-7; Dubuc G, 2004, ARTERIOSCL THROM VAS, V24, P1454, DOI 10.1161/01.ATV.0000134621.14315.43; Essalmani R, 2006, MOL CELL BIOL, V26, P354, DOI 10.1128/MCB.26.1.354-361.2006; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Jin WJ, 2005, J BIOL CHEM, V280, P36551, DOI 10.1074/jbc.M502264200; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kotowski IK, 2006, AM J HUM GENET, V78, P410, DOI 10.1086/500615; Lalanne F, 2005, J LIPID RES, V46, P1312, DOI 10.1194/jlr.M400396-JLR200; Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Leren TP, 2004, CLIN GENET, V65, P419, DOI 10.1111/j.0009-9163.2004.0238.x; Lonnqvist L, 1998, HUM MOL GENET, V7, P2039, DOI 10.1093/hmg/7.13.2039; Maxwell KN, 2005, P NATL ACAD SCI USA, V102, P2069, DOI 10.1073/pnas.0409736102; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; Maxwell KN, 2003, J LIPID RES, V44, P2109, DOI 10.1194/jlr.M300203-JLR200; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; Naoumova RP, 2005, ARTERIOSCL THROM VAS, V25, P2654, DOI 10.1161/01.ATV.0000190668.94752.ab; Naureckiene S, 2003, ARCH BIOCHEM BIOPHYS, V420, P55, DOI 10.1016/j.abb.2003.09.011; Nour N, 2005, MOL BIOL CELL, V16, P5215, DOI 10.1091/mbc.E05-06-0504; PAQUET L, 1994, J BIOL CHEM, V269, P19279; Park SW, 2004, J BIOL CHEM, V279, P50630, DOI 10.1074/jbc.M410077200; Pisciotta L, 2006, ATHEROSCLEROSIS, V188, P398, DOI 10.1016/j.atherosclerosis.2005.11.016; Pisciotta L, 2006, ATHEROSCLEROSIS, V186, P433, DOI 10.1016/j.atherosclerosis.2005.08.015; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Roebroek AJM, 2004, J BIOL CHEM, V279, P53442, DOI 10.1074/jbc.M407152200; Seidah NG, 2006, BIOL CHEM, V387, P871, DOI 10.1515/BC.2006.110; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Timms KM, 2004, HUM GENET, V114, P349, DOI 10.1007/s00439-003-1071-9; Tsuji A, 2006, BIOCHEM J, V396, P51, DOI 10.1042/BJ20051524; Xiang Y, 2000, MOL BIOL CELL, V11, P1257, DOI 10.1091/mbc.11.4.1257; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913	58	215	264	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30561	30572		10.1074/jbc.M606495200	http://dx.doi.org/10.1074/jbc.M606495200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912035	hybrid			2022-12-25	WOS:000241075900032
J	Covian, R; Trumpower, BL				Covian, Raul; Trumpower, Bernard L.			Regulatory interactions between ubiquinol oxidation and ubiquinone reduction sites in the dimeric cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; BOVINE HEART-MITOCHONDRIA; ELECTRON-TRANSFER; DOMAIN MOVEMENT; C REDUCTASE; SACCHAROMYCES-CEREVISIAE; RESPIRATORY-CHAIN; CRYSTAL-STRUCTURE; Q(O) SITE; QI SITE	We have obtained evidence for conformational communication between ubiquinol oxidation ( center P) and ubiquinone reduction (center N) sites of the yeast bc(1) complex dimer by analyzing antimycin binding and heme b(H) reduction at center N in the presence of different center P inhibitors. When stigmatellin was occupying center P, concentration-dependent binding of antimycin occurred only to half of the center N sites. The remaining half of the bc(1) complex bound antimycin with a slower rate that was independent of inhibitor concentration, indicating that a slow conformational change needed to occur before half of the enzyme could bind antimycin. In contrast, under conditions where the Rieske protein was not fixed proximal to heme b(L) at center P, all center N sites bound antimycin with fast and concentration-dependent kinetics. Additionally, the extent of fast cytochrome b reduction by menaquinol through center N in the presence of stigmatellin was approximately half of that observed when myxothiazol was bound at center P. The reduction kinetics of the b(H) heme by decylubiquinol in the presence of stigmatellin or myxothiazol were also consistent with a model in which fixation of the Rieske protein close to heme b(L) in both monomers allows rapid binding of ligands only to one center N. Decylubiquinol at high concentrations was able to abolish the biphasic binding of antimycin in the presence of stigmatellin but did not slow down antimycin binding rates. These results are discussed in terms of half-of-the-sites activity of the dimeric bc(1) complex.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Berry EA, 2004, PHOTOSYNTH RES, V81, P251, DOI 10.1023/B:PRES.0000036888.18223.0e; Cooley JW, 2005, BIOCHEMISTRY-US, V44, P10520, DOI 10.1021/bi050571+; Covian R, 2005, J BIOL CHEM, V280, P22732, DOI 10.1074/jbc.M413592200; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; Huang LS, 2005, J MOL BIOL, V351, P573, DOI 10.1016/j.jmb.2005.05.053; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Izrailev S, 1999, BIOPHYS J, V77, P1753, DOI 10.1016/S0006-3495(99)77022-0; Kramer D, 2004, METHOD ENZYMOL, V382, P21; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Valkova-Valchanova M, 2000, BIOCHEMISTRY-US, V39, P15484, DOI 10.1021/bi000751d; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200; YU CA, 1972, J BIOL CHEM, V247, P1012; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	29	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30925	30932		10.1074/jbc.M604694200	http://dx.doi.org/10.1074/jbc.M604694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16908520	hybrid			2022-12-25	WOS:000241075900068
J	Kaneko, R; Kato, H; Kawamura, Y; Esumi, S; Hirayama, T; Hirabayashi, T; Yagi, T				Kaneko, Ryosuke; Kato, Hiroyuki; Kawamura, Yoshimi; Esumi, Shigeyuki; Hirayama, Teruyoshi; Hirabayashi, Takahiro; Yagi, Takeshi			Allelic gene regulation of Pcdh-alpha and Pcdh-gamma clusters involving both monoallelic and biallelic expression in single Purkinje cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC ORGANIZATION; PROTOCADHERIN-ALPHA; X-CHROMOSOME; FAMILY; PATTERNS; SEQUENCE; MOUSE; INTERLEUKIN-2; INACTIVATION; TRANSCRIPTS	The molecular basis for providing the identity and diversity of single neurons is a key for realizing the brain system. Diverse protocadherin isoforms encoded by the Pcdh-alpha and Pcdh-gamma gene clusters are expressed in all of the vertebrates studied. For the Pcdh-alpha isoforms, differential expression patterns have been found in single Purkinje cells by unusual monoallelic and combinatorial types of gene regulation. Here we investigated total allelic gene regulation in the Pcdh-alpha and -gamma clusters, including the C-type variable exons (C1 to C5) and the Pcdh-gamma A and -gamma B variable exons in single Purkinje cells. Using split single-cell reverse transcription-PCR analysis, almost all of the Purkinje cells at postnatal day 21 biallelically expressed all the C-type isoforms, whereas the Pcdh-alpha isoforms showed both monoallelic and combinatorial expression. The Pcdh-gamma A and -gamma B isoforms also showed differential regulation in each cell with both monoallelic and combinatorial gene regulation. These data indicated that different types of allelic gene regulation ( monoallelic versus biallelic) occurred in the Pcdh-alpha and -gamma clusters, although they were spliced into the same constant exons. It has been reported that each C-type Pcdh-alpha or -gamma transcript has a different expression pattern during brain development, suggesting that the different C-type variable exons may code temporal diversity, although the Pcdh-alpha, -gamma A, and -gamma B isoforms were differential and combinatorial gene regulation within a single cell. Thus, the multiple gene regulations in the Pcdh-alpha and -gamma clusters had a potential mechanism for increasing the diversity of individual neurons in the brain.	Osaka Univ, Grad Sch Frontier Biosci, Labs Integrated Biol, KOKORO Biol Grp, Suita, Osaka 5650871, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Morphol Neurol Sci, Kumamoto 8608556, Japan	Osaka University; Kumamoto University	Yagi, T (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Labs Integrated Biol, KOKORO Biol Grp, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	yagi@fbs.osaka-u.ac.jp	Kawamura, Yoshimi/L-1289-2013	Kawamura, Yoshimi/0000-0002-9864-7974				Bayley JP, 2003, EUR J IMMUNOL, V33, P2142, DOI 10.1002/eji.200323976; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Esumi S, 2005, NAT GENET, V37, P171, DOI 10.1038/ng1500; Frank M, 2005, MOL CELL NEUROSCI, V29, P603, DOI 10.1016/j.mcn.2005.05.001; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; Hamada S, 2001, NEUROSCI RES, V41, P207, DOI 10.1016/S0168-0102(01)00281-4; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; Kelly BL, 2000, J IMMUNOL, V165, P2982, DOI 10.4049/jimmunol.165.6.2982; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Murata Y, 2004, J BIOL CHEM, V279, P49508, DOI 10.1074/jbc.M408771200; Mutoh T, 2004, EXP CELL RES, V294, P494, DOI 10.1016/j.yexcr.2003.11.019; Noonan JP, 2004, GENOME RES, V14, P2397, DOI 10.1101/gr.2972804; Nutt SL, 1999, BIOL CHEM, V380, P601, DOI 10.1515/BC.1999.077; Nutt SL, 1999, NAT GENET, V21, P390, DOI 10.1038/7720; Oberdick J, 1998, TRENDS NEUROSCI, V21, P383, DOI 10.1016/S0166-2236(98)01325-3; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; Rhoades KL, 2000, CURR BIOL, V10, P789, DOI 10.1016/S0960-9822(00)00565-0; Sano Y, 2001, GENOME RES, V11, P1833, DOI 10.1101/gr.194301; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sugino H, 2004, BIOCHEM BIOPH RES CO, V316, P437, DOI 10.1016/j.bbrc.2004.02.067; Sugino H, 2000, GENOMICS, V63, P75, DOI 10.1006/geno.1999.6066; Tada MN, 2004, GENE, V340, P197, DOI 10.1016/j.gene.2004.07.014; Taguchi Y, 2005, MOL BIOL EVOL, V22, P1433, DOI 10.1093/molbev/msi130; Takei Y, 2001, GENOMICS, V72, P321, DOI 10.1006/geno.2000.6468; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Wang XZ, 2002, GENE DEV, V16, P1890, DOI 10.1101/gad.1004802; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301; Wu Q, 2005, GENETICS, V169, P2179, DOI 10.1534/genetics.104.037606; Wu Q, 2000, P NATL ACAD SCI USA, V97, P3124, DOI 10.1073/pnas.060027397; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yagi T, 2000, GENE DEV, V14, P1169; Yanase H, 2004, GENOMICS, V83, P717, DOI 10.1016/j.ygeno.2003.09.022; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	35	134	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30551	30560		10.1074/jbc.M605677200	http://dx.doi.org/10.1074/jbc.M605677200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16893882	hybrid			2022-12-25	WOS:000241075900031
J	Liu, GM; Ding, W; Neiman, J; Mulder, KM				Liu, Guangming; Ding, Wei; Neiman, Jill; Mulder, Kathleen M.			Requirement of Smad3 and CREB-1 in mediating transforming growth factor-beta (TGF beta) induction of TGF beta 3 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; CAMP-RESPONSE ELEMENT; BREAST-CANCER CELLS; EPITHELIAL-CELLS; TRANSCRIPTION FACTOR; DIFFERENTIAL EXPRESSION; INDUCED PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR	Because increased transforming growth factor-beta (TGF beta) production by tumor cells contributes to cancer progression through paracrine mechanisms, identification of critical points that can be targeted to block TGF beta production is important. Previous studies have identified the precise signaling components and promoter elements required for TGF beta induction of TGF beta 1 expression in epithelial cells (Yue, J., and Mulder, K. M. (2000) J. Biol. Chem. 275, 30765-30773). To determine how regulation of TGF beta 3 expression differs from that of TGF beta 1, we identified the precise signaling pathways and transcription factor-binding sites that are required for TGF beta 3 gene expression. By using mutational analysis in electrophoresis mobility shift assays (EMSAs), we demonstrated that the c-AMP-responsive element (CRE) site in the TGF beta 3 promoter was required for TGF beta-inducible TGF beta 3 expression. Electrophoresis mobility supershift assays indicated that CRE-binding protein 1 (CREB1) and Smad3 were the major components present in this TGF beta-inducible complex. Furthermore, by using chromatin immunoprecipitation assays, we demonstrated that CREB-1, ATF-2, and c-Jun bound constitutively at the TGF beta 3 promoter (-100 to +1), whereas Smad3 bound at this site only after TGF beta stimulation. In addition, inhibition of JNK and p38 suppressed TGF beta induction of TGF beta 3 transactivation, whereas inhibition of ERK and protein kinase A had no effect. Small interfering RNA-CREB1 and small interfering RNA-Smad3 significantly inhibited TGF beta stimulation of TGF beta 3 promoter reporter activity and TGF beta 3 production. Our results indicate that TGF beta activation of the TGF beta 3 promoter CRE site, which leads to TGF beta 3 production, is required for TGF beta RII, JNK, p38, and Smad3 but was independent of protein kinase A, ERK, and Smad4.	Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Univ, Coll Med, Dept Pharmacol, 500 Univ Dr, Hershey, PA 17033 USA.	kmm15@psu.edu			NCI NIH HHS [CA92889, CA100239, CA90765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090765, R01CA100239, R01CA092889] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bocharov EV, 2002, J BIOL CHEM, V277, P46273, DOI 10.1074/jbc.M206274200; Chaturvedi K, 2004, ENDOCRINOLOGY, V145, P706, DOI 10.1210/en.2003-1063; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cho HR, 2004, J KOREAN MED SCI, V19, P853, DOI 10.3346/jkms.2004.19.6.853; Copland IB, 2002, PLACENTA, V23, P311, DOI 10.1053/plac.2001.0778; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Devling TWP, 2005, P NATL ACAD SCI USA, V102, P7280, DOI 10.1073/pnas.0501475102; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; Furumatsu T, 2005, J BIOL CHEM, V280, P8343, DOI 10.1074/jbc.M413913200; Gold LI, 2000, J PATHOL, V190, P579, DOI 10.1002/(SICI)1096-9896(200004)190:5<579::AID-PATH548>3.0.CO;2-I; Gustin JA, 2004, AM J PHYSIOL-CELL PH, V286, pC547, DOI 10.1152/ajpcell.00332.2002; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Hentges S, 2000, ENDOCRINOLOGY, V141, P859, DOI 10.1210/en.141.3.859; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hu PPC, 1999, MOL ENDOCRINOL, V13, P2039, DOI 10.1210/me.13.12.2039; Ionescu AM, 2003, EXP CELL RES, V288, P198, DOI 10.1016/S0014-4827(03)00181-2; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kloen P, 1997, CANCER, V80, P2230; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; Lammerts E, 2002, INT J CANCER, V102, P453, DOI 10.1002/ijc.10722; Liu GM, 2001, P NATL ACAD SCI USA, V98, P7510, DOI 10.1073/pnas.131195198; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Masutani H, 2004, MOL NEUROBIOL, V29, P229, DOI 10.1385/MN:29:3:229; Mora-Garcia P, 2003, STEM CELLS, V21, P123, DOI 10.1634/stemcells.21-2-123; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Oki N, 2000, J BIOL CHEM, V275, P10831, DOI 10.1074/jbc.275.15.10831; Parada David, 2004, Arch Esp Urol, V57, P93; Park SW, 2005, ONCOGENE, V24, P6689, DOI 10.1038/sj.onc.1208816; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; Ranganathan G, 2002, J BIOL CHEM, V277, P43281, DOI 10.1074/jbc.M202560200; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; Samatar AA, 2002, J BIOL CHEM, V277, P28118, DOI 10.1074/jbc.M203686200; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tudela C, 2002, INT J DEV BIOL, V46, P333; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; Weeber EJ, 2002, NEURON, V33, P845, DOI 10.1016/S0896-6273(02)00634-7; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yamazaki H, 2002, AM J PHYSIOL-ENDOC M, V283, pE536, DOI 10.1152/ajpendo.00094.2001; Yang F, 2003, J BIOL CHEM, V278, P32173, DOI 10.1074/jbc.M305149200; Yue J, 2004, J CELL PHYSIOL, V199, P284, DOI 10.1002/jcp.10469; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Yue JB, 2000, METH MOL B, V142, P125; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7	62	40	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29479	29490		10.1074/jbc.M600579200	http://dx.doi.org/10.1074/jbc.M600579200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16891311	hybrid			2022-12-25	WOS:000240896300010
J	Vincent, HA; Deutscher, MP				Vincent, Helen A.; Deutscher, Murray P.			Substrate recognition and catalysis by the exoribonuclease RNase R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYNUCLEOTIDE PHOSPHORYLASE; MESSENGER-RNA; RIBONUCLEASE-II; QUALITY-CONTROL; DEGRADATION; BINDING	RNase R is a processive, 3' to 5' hydrolytic exoribonuclease that together with polynucleotide phosphorylase plays an important role in the degradation of structured RNAs. However, RNase R differs from other exoribonucleases in that it can by itself degrade RNAs with extensive secondary structure provided that a single-stranded 3' overhang is present. Using a variety of specifically designed substrates, we show here that a 3' overhang of at least 7 nucleotides is required for tight binding and activity, whereas optimum binding and activity are achieved when the overhang is 10 or more nucleotides in length. In contrast, duplex RNAs with no overhang or with a 4- nucleotide overhang bind extremely poorly to RNase R and are inactive as substrates. A duplex RNA with a 10- nucleotide 5' overhang also is not a substrate. Interestingly, this molecule is bound only weakly, indicating that RNase R does not simply recognize singlestranded RNA, but the RNA must thread into the enzyme with 3' to 5' polarity. We also show that ribose moieties are required for recognition of the substrate as a whole since RNase R is unable to bind or degrade single- stranded DNA. However, RNA molecules with deoxyribose or dideoxyribose residues at their 3' termini can be bound and degraded. Based on these data and a homology model of RNase R, derived from the structure of the closely related enzyme, RNase II, we present a model for how RNase R interacts with its substrates and degrades RNA.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.	mdeutsch@med.miami.edu	Vincent, Helen/GZK-3422-2022		NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CANNISTRARO VJ, 1994, J MOL BIOL, V243, P930, DOI 10.1006/jmbi.1994.1693; Carpousis AJ, 2002, BIOCHEM SOC T, V30, P150, DOI 10.1042/bst0300150; Cheng ZF, 2005, MOL CELL, V17, P313, DOI 10.1016/j.molcel.2004.11.048; Cheng ZF, 2003, P NATL ACAD SCI USA, V100, P6388, DOI 10.1073/pnas.1231041100; Cheng ZF, 2002, J BIOL CHEM, V277, P21624, DOI 10.1074/jbc.M202942200; Deutscher MP, 2006, NUCLEIC ACIDS RES, V34, P659, DOI 10.1093/nar/gkj472; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; Li ZW, 2002, EMBO J, V21, P1132, DOI 10.1093/emboj/21.5.1132; Lin PH, 2005, P NATL ACAD SCI USA, V102, P16590, DOI 10.1073/pnas.0500994102; Liou GG, 2002, J BIOL CHEM, V277, P41157, DOI 10.1074/jbc.M206618200; Lorentzen E, 2005, MOL CELL, V20, P473, DOI 10.1016/j.molcel.2005.10.020; Oussenko IA, 2000, J BACTERIOL, V182, P2639, DOI 10.1128/JB.182.9.2639-2642.2000; Tanaka N, 2005, BIOCHEMISTRY-US, V44, P9795, DOI 10.1021/bi050407m; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	15	184	191	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29769	29775		10.1074/jbc.M606744200	http://dx.doi.org/10.1074/jbc.M606744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16893880	hybrid			2022-12-25	WOS:000240896300039
J	Lei, XB; Chen, YY; Du, GH; Yu, WY; Wang, XH; Qu, H; Xia, B; He, HP; Mao, JH; Zong, WX; Liao, XD; Mehrpour, M; Hao, XJ; Chen, Q				Lei, Xiaobo; Chen, Yingyu; Du, Guanhua; Yu, Wenyu; Wang, Xiaohui; Qu, Hong; Xia, Bin; He, Hongping; Mao, Jianhua; Zong, Weixing; Liao, Xudong; Mehrpour, Maryam; Hao, Xiaojiang; Chen, Quan			Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2	FASEB JOURNAL			English	Article						mitochondria; Bcl-2 inhibitors; drug screening	PERMEABILITY TRANSITION PORE; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; CASPASE ACTIVATION; FAMILY PROTEINS; CANCER-CELLS; X-L; BAX; AUTOPHAGY; ABSENCE	Cells without Bak and Bax are largely resistant to apoptosis (1; 2), despite the presence of other key components of the apoptotic machinery. We screened 7,800 natural compounds and found several that could specifically induce caspase activation and the release of cytochrome c (cyto c) in the bak(-/-)/bax(-/-) cells. One of these was gossypol, a polyphenolic compound naturally found in cottonseed that has been used in antifertility trials. We found that gossypol, but not other Bcl-2-interacting molecules, induced cyto c release and loss of mitochondrial membrane potential (Delta Psi m) independently of mPTP and Bak/Bax activation. Furthermore, we found that gossypol induced an allosteric change in Bcl-2 in both bak(-/-)/bax(-/-) cells and Bcl-2 overexpressing cells. This change in Bcl-2 conformation led to the release of cyto c in the presence of Bcl-2 and Bcl-xL in reconstituted proteoliposomes. We also observed that gossypol substantially reduced the growth of tumor xenografts from Bcl- 2 overexpressing cells in nude mice. We conclude that gossypol converts the antiapoptotic molecule Bcl-2 into a proapoptotic molecule that can mediate the release of cyto c and induce apoptosis	Chinese Acad Sci, Lab Apoptosis & Canc Biol, State Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Beijing 100080, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; Peking Univ, Ctr Human Dis Genom, Beijing 100871, Peoples R China; Acad Med Sci, Inst Mat Med, Beijing, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Chinese Acad Sci, State Key Lab Phytochem & Plant Resources W China, Kunming Inst Bot, Beijing, Peoples R China; Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Inst Gustave Roussy PR1, INSERM, U 487, Lab Cytokines & Immunol Tumeurs Humaines, Villejuif, France	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Materia Medica - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking University; Chinese Academy of Sciences; Kunming Institute of Botany, CAS; University of Pennsylvania; Pennsylvania Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Chen, Q (corresponding author), Chinese Acad Sci, Lab Apoptosis & Canc Biol, State Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Bei Si Huan Xi Rd 25, Beijing 100080, Peoples R China.	chenq@ioz.ac.cn	Xia, Bin/O-1160-2016; Mehrpour, Maryam/D-8640-2017; Mao, Jianhua/GOK-2713-2022; lei, xiaobo/GLN-4194-2022; chen, ying/HHS-8254-2022	Xia, Bin/0000-0002-2197-6403; Chen, Quan/0000-0001-7539-8728				Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; BERNARDI P, 1984, BIOCHIM BIOPHYS ACTA, V766, P277, DOI 10.1016/0005-2728(84)90242-1; Castelli M, 2004, CELL DEATH DIFFER, V11, P906, DOI 10.1038/sj.cdd.4401433; Chanan-Khan A, 2005, BLOOD REV, V19, P213, DOI 10.1016/j.blre.2004.11.002; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Claveria C, 2004, J BIOL CHEM, V279, P1368, DOI 10.1074/jbc.M309819200; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Kim YK, 2004, INT J CONTROL AUTOM, V2, P523; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; LIU G-Z, 1981, Reproduccion, V5, P189; Lugovskoy AA, 2002, J AM CHEM SOC, V124, P1234, DOI 10.1021/ja011239y; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mohammad RM, 2005, MOL CANCER THER, V4, P13; Oliver CL, 2005, MOL CANCER THER, V4, P23; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Paglin S, 2001, CANCER RES, V61, P439; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; SHEPU X, 1980, SCI SINICA, V232, P642; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xia T, 2002, FEBS LETT, V510, P62, DOI 10.1016/S0014-5793(01)03228-8; Xu L, 2005, MOL CANCER THER, V4, P197; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Zhang MC, 2003, BIOCHEM PHARMACOL, V66, P93, DOI 10.1016/S0006-2952(03)00248-X; Zheng YH, 2005, ONCOGENE, V24, P3339, DOI 10.1038/sj.onc.1208484; Zheng YH, 2004, ONCOGENE, V23, P1239, DOI 10.1038/sj.onc.1207205; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	39	97	102	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2147	+		10.1096/fj.05-5665fje	http://dx.doi.org/10.1096/fj.05-5665fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935937				2022-12-25	WOS:000241156900043
J	Roy, H; Bhardwaj, S; Babu, M; Kokina, I; Uotila, S; Ahtialansaari, T; Laitinen, T; Hakumaki, J; Laakso, M; Herzig, KH; Yla-Herttuala, S				Roy, Himadri; Bhardwaj, Shalini; Babu, Mohan; Kokina, Ilze; Uotila, Sanna; Ahtialansaari, Tiia; Laitinen, Teemu; Hakumaki, Juhana; Laakso, Markku; Herzig, Karl-Heinz; Yla-Herttuala, Seppo			VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-kappa B, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits	FASEB JOURNAL			English	Article						diabetes; dyslipidemia; atherosclerosis; vascular endothelial growth factor; plaque angiogenesis	INSULIN-RESISTANCE; METABOLIC SYNDROME; SKELETAL-MUSCLE; IN-VIVO; EXPRESSION; PATHOPHYSIOLOGY; ABNORMALITIES; CONSEQUENCES; ANGIOGENESIS; PROGRESSION	Plaque angiogenesis may be associated with the development of unstable and vulnerable plaques. Vascular endothelial growth factors (VEGFs) are potent angiogenic factors that can affect plaque neovascularization. Our objective was to determine the effect of diabetes on atherosclerosis and on the expression of angiogenesis-related genes in atherosclerotic lesions. Alloxan was used to induce diabetes in male Watanabe heritable hyperlipidemic (WHHL) rabbits that were sacrificed 2 and 6 months after the induction of diabetes. Nondiabetic WHHL rabbits served as controls. Blood glucose (Glc), serum-free fatty acids (FFA), and serum triglyceride levels were significantly higher in diabetic rabbits. Accelerated atherogenesis was observed in the diabetic WHHL rabbits together with increased intramyocellular lipids (IMCL), as determined by 1H-NMR spectroscopy. Atherosclerotic lesions in the diabetic rabbits had an increased content of macrophages and showed significant increases in immunostainings for vascular endothelial growth factor (VEGF)-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, RAGE, and NF-kappa B. VEGF-A(165) and VEGFR-2 mRNA levels were significantly increased in aortas of the diabetic rabbits, where a trend toward increased plaque vascularization was also observed. These results suggest that diabetes accelerates atherogenesis, up-regulates VEGF-A, VEGF-D, and VEGF receptor-2 expression, and increases NF-kappa B, RAGE, and inflammatory responses in atherosclerotic lesions in WHHL rabbits.	Univ Kuopio, Dept Biotechnol & Mol Med, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Med, SF-70210 Kuopio, Finland; Kuopio Univ Hosp, Gene Therapy Unit, SF-70210 Kuopio, Finland; Univ Kuopio, Dept Biomed NMR, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland	University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland	Yla-Herttuala, S (corresponding author), Univ Kuopio, Dept Mol Med, AI Virtanen Inst, POB 1627, FIN-70211 Kuopio, Finland.	seppo.ylaherttuala@uku.fi	Mohan, Babu P./I-7362-2019; Bhardwaj, Shalini/AAE-6796-2021; Babu, Mohan/I-7416-2012; Hakumäki, Juhana/AAH-1058-2021	Babu, Mohan/0000-0001-5482-2622; Yla-Herttuala, Seppo/0000-0001-7593-2708; Hakumaki, Juhana/0000-0001-7341-5440				Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Bhardwaj S, 2005, EUR J CLIN INVEST, V35, P669, DOI 10.1111/j.1365-2362.2005.01555.x; Brasen JH, 2003, ATHEROSCLEROSIS, V166, P13, DOI 10.1016/S0021-9150(02)00130-2; Brey EM, 2003, J HISTOCHEM CYTOCHEM, V51, P575, DOI 10.1177/002215540305100503; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Cipollone F, 2003, CIRCULATION, V108, P1070, DOI 10.1161/01.CIR.0000086014.80477.0D; Creager MA, 2003, CIRCULATION, V108, P1527, DOI 10.1161/01.CIR.0000091257.27563.32; Ezzahiri R, 2002, CARDIOVASC RES, V56, P269, DOI 10.1016/S0008-6363(02)00544-8; Garwood M, 2001, J MAGN RESON, V153, P155, DOI 10.1006/jmre.2001.2340; Hayden MR, 2004, CARDIOVASC DIABETOL, V3, DOI 10.1186/1475-2840-3-1; Hayden MR, 2002, CARDIOVASC DIABETOL, V1, DOI 10.1186/1475-2840-1-3; Hofstaetter JG, 2004, BIOCHEM BIOPH RES CO, V324, P667, DOI 10.1016/j.bbrc.2004.09.103; Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121; Jacob S, 1999, DIABETES, V48, P1113, DOI 10.2337/diabetes.48.5.1113; Kuhlmann J, 2003, DIABETES, V52, P138, DOI 10.2337/diabetes.52.1.138; Laakso M, 1999, DIABETES, V48, P937, DOI 10.2337/diabetes.48.5.937; Moreno PR, 2004, CIRCULATION, V110, P2032, DOI 10.1161/01.CIR.0000143233.87854.23; Naka Y, 2004, ARTERIOSCL THROM VAS, V24, P1342, DOI 10.1161/01.ATV.0000133191.71196.90; Niemeijer-Kanters SDJM, 2001, NETH J MED, V58, P214, DOI 10.1016/S0300-2977(01)00105-X; Okamoto T, 2002, FASEB J, V16, P1928, DOI 10.1096/fj.02-0030fje; Renard CB, 2004, J CLIN INVEST, V114, P659, DOI 10.1172/JCI200417867; Rutanen J, 2003, CARDIOVASC RES, V59, P971, DOI 10.1016/S0008-6363(03)00518-2; SCHICK F, 1993, MAGN RESON MED, V29, P158, DOI 10.1007/BF01769418; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sinha R, 2002, DIABETES, V51, P1022, DOI 10.2337/diabetes.51.4.1022; Taskinen MR, 2003, DIABETES RES CLIN PR, V61, pS19, DOI 10.1016/S0168-8227(03)00126-8; Verges BL, 1999, DIABETES METAB, V25, P32; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971; ZHANG B, 1991, ATHEROSCLEROSIS, V91, P277, DOI 10.1016/0021-9150(91)90175-3	31	30	32	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2159	+		10.1096/fj.05-5029fje	http://dx.doi.org/10.1096/fj.05-5029fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935942				2022-12-25	WOS:000241156900051
J	Konishi, H; Tashiro, K; Murata, Y; Nabeshi, H; Yamauchi, E; Taniguchi, H				Konishi, Hiroaki; Tashiro, Kyoko; Murata, Yasunobu; Nabeshi, Hiromi; Yamauchi, Emiko; Taniguchi, Hisaaki			CFBP is a novel tyrosine-phosphorylated protein that might function as a regulator of CIN85/CD2AP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD2-ASSOCIATED PROTEIN; SIGNALING NETWORKS; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; DOWN-REGULATION; SH3 DOMAINS; RECEPTOR; CBL; COMPLEX; CYTOSKELETAL	To decipher the global network of the epidermal growth factor (EGF) receptor-mediated signaling pathway, a large scale proteomic analysis of tyrosine-phosphorylated proteins was conducted. Here, we focus on characterizing a novel protein, CFBP (CIN85/CD2AP family binding protein), identified in the study. CFBP was found to be phosphorylated at tyrosine 204 upon EGF stimulation, and the CIN85/CD2AP family was identified as a binding partner. A proline-rich motif of CFBP is recognized by one of the three Src-homology 3 domains of CIN85/CD2AP, and the affinity of the interaction is regulated by the tyrosine phosphorylation of CFBP. They co-localize in actinen-riched structures, and overexpression of CFBP induced morphological changes with actin reorganization. Furthermore, CFBP accelerated the EGF receptor's down-regulation by facilitating the recruitment of Cbl to the CD2AP/CIN85 complex. Two spliced variants of CFBP lacking either exon 5 or 8 are also expressed, and the variant lacking exon 5 without the proline-rich motif lacks the ability to bind to the CIN85/CD2AP family. The CFBP protein seems to play a key role in the ligand-mediated internalization and down-regulation of the EGF receptor.	Univ Tokushima, Ins Enzyme Res, Tokushima 7708503, Japan	Tokushima University	Konishi, H (corresponding author), Univ Tokushima, Ins Enzyme Res, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	konishi@ier.tokushima-u.ac.jp	Taniguchi, Hisaaki/I-9171-2012; Murata, Yasunobu/Y-5799-2019	Murata, Yasunobu/0000-0001-5757-2497				Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Blagoev B, 2004, NAT BIOTECHNOL, V22, P1139, DOI 10.1038/nbt1005; Borthwick EB, 2004, J MOL BIOL, V343, P1135, DOI 10.1016/j.jmb.2004.08.075; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Hutchings NJ, 2003, J BIOL CHEM, V278, P22396, DOI 10.1074/jbc.M302540200; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Johnson SA, 2005, NAT METHODS, V2, P17, DOI 10.1038/NMETH731; Kikuchi M, 2004, J BIOL CHEM, V279, P421, DOI 10.1074/jbc.M305623200; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Kurakin AV, 2003, J BIOL CHEM, V278, P34102, DOI 10.1074/jbc.M305264200; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5838, DOI 10.1073/pnas.0501253102; Liu YH, 2005, J BIOL CHEM, V280, P8884, DOI 10.1074/jbc.M412200200; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Matsubara M, 2004, EMBO J, V23, P712, DOI 10.1038/sj.emboj.7600093; Mayer BJ, 2001, J CELL SCI, V114, P1253; Monzo P, 2005, MOL BIOL CELL, V16, P2891, DOI 10.1091/mbc.E04-09-0773; Nelson JM, 1997, EXP CELL RES, V233, P383, DOI 10.1006/excr.1997.3571; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Schiffer M, 2004, J BIOL CHEM, V279, P37004, DOI 10.1074/jbc.M403534200; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Szymkiewicz I, 2004, BIOCHEM J, V383, P1, DOI 10.1042/BJ20040913; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tibaldi EV, 2003, INT IMMUNOL, V15, P313, DOI 10.1093/intimm/dxg032; Welsch T, 2001, AM J PHYSIOL-RENAL, V281, pF769, DOI 10.1152/ajprenal.2001.281.4.F769; Yamauchi E, 2003, NAT STRUCT BIOL, V10, P226, DOI 10.1038/nsb900	36	28	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28919	28931		10.1074/jbc.M605693200	http://dx.doi.org/10.1074/jbc.M605693200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16895919	hybrid			2022-12-25	WOS:000240680500046
J	Kroemer, G				Kroemer, G.			Mitochondria in cancer	ONCOGENE			English	Editorial Material							CELL-DEATH	Prominent features of cancer cells include metabolic imbalances and enhanced resistance to mitochondrial apoptosis. The fact that tumors rely heavily on glycolysis to meet their metabolic demands has been recognized since the beginning of the twentieth century, yet a complete elucidation of the so-called Warburg effect has not been achieved. Several mechanisms have been proposed to explain this phenomenon, including the upregulation of rate-limiting steps of glycolysis, the accumulation of mutations in the mitochondrial genome, the hypoxia-induced switch from mitochondrial respiration to glycolysis or the metabolic reprogramming resulting from the loss-of-function of enzymes like fumarate and succinate dehydrogenases. How aerobic glycolysis and apoptosis resistance are linked remains to be elucidated. On the one hand, these alterations may be acquired independently by cancer cells during multistep oncogenesis. On the other hand, the suppression of the intrinsic apoptotic program may be achieved through mechanisms that directly lead to the Warburg phenotype. Cancer-specific mitochondrial alterations and bioenergetics may be taken advantage for the development of two novel classes of antineoplastic agents. A first approach would target glycolysis and/or revert the Warburg phenomenon, whereas a second approach would aim at inducing apoptosis by targeting mitochondrial proteins and membranes. In both instances, encouraging pre-clinical results have been obtained.	Inst Gustave Roussy, CNRS, FRE2939, F-94800 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE2939, Rue Camille Desmoulins, F-94800 Villejuif, France.		KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; 				Alirol E, 2006, ONCOGENE, V25, P4706, DOI 10.1038/sj.onc.1209600; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Cereghetti GM, 2006, ONCOGENE, V25, P4717, DOI 10.1038/sj.onc.1209605; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Cheng WC, 2006, ONCOGENE, V25, P4697, DOI 10.1038/sj.onc.1209596; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Fantin VR, 2006, ONCOGENE, V25, P4787, DOI 10.1038/sj.onc.1209599; Fontenay M, 2006, ONCOGENE, V25, P4757, DOI 10.1038/sj.onc.1209606; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601; Ohta S, 2006, ONCOGENE, V25, P4768, DOI 10.1038/sj.onc.1209602; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Warburg O. H., 1930, METABOLISM TUMOURS I; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZHIVOTOVSKY B, 2004, NAT REV MOL CELL BIO, V117, P4461	21	155	178	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	34					4630	4632		10.1038/sj.onc.1209589	http://dx.doi.org/10.1038/sj.onc.1209589			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892077				2022-12-25	WOS:000239687000001
J	Jones, RA; Campbell, CI; Gunther, EJ; Chodosh, LA; Petrik, JJ; Khokha, R; Moorehead, RA				Jones, R. A.; Campbell, C. I.; Gunther, E. J.; Chodosh, L. A.; Petrik, J. J.; Khokha, R.; Moorehead, R. A.			Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation	ONCOGENE			English	Article						IGF-IR; transgenic mice; mammary tumorigenesis; mammary development	GROWTH-FACTOR-I; BREAST-CANCER; GENE-EXPRESSION; FACTOR RECEPTOR; INSULIN; ACTIVATION; STAT3; MICE; RISK; PROLIFERATION	Overexpression and hyperactivation of the type I insulin-like growth factor receptor (IGF-IR) has been observed in human breast tumor biopsies. In addition, in vitro studies indicate that overexpression of IGF-IR is sufficient to transform cells such as mouse embryo fibroblasts and this receptor promotes proliferation and survival in breast cancer cell lines. To fully understand the function of the IGF-IR in tumor initiation and progression, transgenic mice containing human IGF-IR under a doxycycline-inducible MMTV promoter system were generated. Administration of 2 mg/ml doxycycline in the animals' water supply beginning at 21 days of age resulted in elevated levels of IGF-IR in mammary epithelial cells as detected by Western blotting and immunohistochemistry. Whole mount analysis of 55-day-old mouse mammary glands revealed that IGF-IR overexpression significantly impaired ductal elongation. Moreover, histological analyses revealed multiple hyperplasic lesions in the mammary glands of these 55-day-old mice. The formation of palpable mammary tumors was evident at approximately 2 months of age and was associated with increased levels of IGF-IR signaling molecules including phosphorylated Akt, Erk1/Erk2 and STAT3. Therefore, these transgenic mice provide evidence that IGF-IR overexpression is sufficient to induce mammary epithelial hyperplasia and tumor formation in vivo and provide a model to further understand the function of IGF-IR in mammary epithelial transformation.	Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; Penn State Hershey Med Sch, Hershey, PA USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Toronto, Princess Margaret Hosp, Hlth Network, Toronto, ON, Canada	University of Guelph; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Pennsylvania; Pennsylvania Medicine; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Moorehead, RA (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Room 3605, Guelph, ON N1G 2W1, Canada.	rmoorehe@uoguelph.ca		, Roger/0000-0001-9539-6295; Jones, Robert/0000-0001-7665-9301				Adams TE, 2004, GROWTH FACTORS, V22, P89, DOI 10.1080/08977190410001700998; Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bonnette SG, 2001, ENDOCRINOLOGY, V142, P4937, DOI 10.1210/en.142.11.4937; Butler AA, 1998, CANCER RES, V58, P3021; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Clarke M, 1998, LANCET, V351, P1451; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Diaz N, 2006, CLIN CANCER RES, V12, P20, DOI 10.1158/1078-0432.CCR-04-1749; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; ELLIS MJC, 1994, BREAST CANCER RES TR, V31, P249, DOI 10.1007/BF00666158; Giani C, 1996, BREAST CANCER RES TR, V41, P43, DOI 10.1007/BF01807035; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Helle SI, 1996, ACTA ONCOL, V35, P19, DOI 10.3109/02841869609083963; Kumar R, 2005, CANCER RES, V65, P2511, DOI 10.1158/0008-5472.CAN-05-0189; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Linnerth NM, 2005, INT J CANCER, V114, P977, DOI 10.1002/ijc.20814; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PAPA V, 1993, CANCER RES, V53, P3736; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Resnik JL, 1998, CANCER RES, V58, P1159; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Richards RG, 2004, ENDOCRINOLOGY, V145, P3106, DOI 10.1210/en.2003-1112; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Ruan WF, 1999, ENDOCRINOLOGY, V140, P5075, DOI 10.1210/en.140.11.5075; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Takahashi T, 1999, CIRC RES, V85, P884; Turner BC, 1997, CANCER RES, V57, P3079; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; Wetterau LA, 1999, MOL GENET METAB, V68, P161, DOI 10.1006/mgme.1999.2920; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	47	101	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1636	1644		10.1038/sj.onc.1209955	http://dx.doi.org/10.1038/sj.onc.1209955			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953219				2022-12-25	WOS:000244782500013
J	Matta, H; Surabhi, RM; Zhao, J; Punj, V; Sun, Q; Schamus, S; Mazzacurati, L; Chaudhary, PM				Matta, H.; Surabhi, R. M.; Zhao, J.; Punj, V.; Sun, Q.; Schamus, S.; Mazzacurati, L.; Chaudhary, P. M.			Induction of spindle cell morphology in human vascular endothelial cells by human herpesvirus 8-encoded viral FLICE inhibitory protein K13	ONCOGENE			English	Article						KSHV; HHV8; vFLIP; Kaposi's sarcoma; NF-kappa B; spindle cells	NF-KAPPA-B; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; INDUCED APOPTOSIS; ACTIVATION; TRANSFORMATION; EXPRESSION; HUMAN-HERPESVIRUS-8; VFLIP; GENE	Human herpesvirus 8(HHV8), also known as Kaposi's sarcoma-associated herpesvirus, is linked to the development of Kaposi's sarcoma, a disease characterized by the presence of distinctive proliferating spindle-like cells. Although HHV8 can induce spindle cell transformation of vascular endothelial cells in vitro, the viral gene(s) responsible for this phenotype remain to be identified. We demonstrate that expression of HHV8-encoded viral Fas-associated death domain protein-like IL-1 beta-converting enzyme inhibitory protein K13 is sufficient to induce spindle cell phenotype in human umbilical vein endothelial cells (HUVEC), which is associated with the activation of the nuclear factor-kappa B (NF-kappa B) pathway and can be blocked by Bay-11-7082, a specific inhibitor of this pathway. K13 induces the expression of several genes known to be upregulated in HHV8-transformed vascular endothelial cells, such as interleukin (IL)-6, IL-8, CXC ligand 3 (CXCL3), orphan G protein coupled receptor (RDC1), cyclooxygenase-2 (COX-2) and dual-specificity phosphatase 5 (DUSP5). Furthermore, similar to K13, HHV8-induced spindle cell transformation of HUVEC is associated with NF-kappa B activation and can be blocked by Bay-11-7082. Thus, ectopic expression of a single latent gene of HHV8 is sufficient for the acquisition of spindle cell phenotype by vascular endothelial cells and NF-kappa B activation plays an essential role in this process.	Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018	mazzacurati, lucia/0000-0002-8336-8032	NATIONAL CANCER INSTITUTE [R01CA085177] Funding Source: NIH RePORTER; NCI NIH HHS [CA85177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; BECKSTEAD JH, 1985, AM J PATHOL, V119, P294; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; CORBEIL J, 1991, J IMMUNOL, V146, P2972; ENSOLI B, 1995, P ASSOC AM PHYSICIAN, V107, P8; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Hu SM, 1997, J BIOL CHEM, V272, P9621; Kennedy MM, 1998, J CLIN PATHOL-MOL PA, V51, P14, DOI 10.1136/mp.51.1.14; Liu J, 2002, J VIB CONTROL, V8, P277, DOI 10.1177/107754602023821; Masood Rizwan, 1993, Current Opinion in Oncology, V5, P831, DOI 10.1097/00001622-199309000-00010; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Moore PS, 2001, PHILOS T R SOC B, V356, P499, DOI 10.1098/rstb.2000.0777; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Naranatt PP, 2004, CANCER RES, V64, P72, DOI 10.1158/0008-5472.CAN-03-2767; Picard D, 2000, METHOD ENZYMOL, V327, P385, DOI 10.1016/S0076-6879(00)27291-1; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0	25	36	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1656	1660		10.1038/sj.onc.1209931	http://dx.doi.org/10.1038/sj.onc.1209931			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16936773				2022-12-25	WOS:000244782500016
J	Inoue, T; Hiratsuka, M; Osaki, M; Yamada, H; Kishimoto, I; Yamaguchi, S; Nakano, S; Katoh, M; Ito, H; Oshimura, M				Inoue, T.; Hiratsuka, M.; Osaki, M.; Yamada, H.; Kishimoto, I.; Yamaguchi, S.; Nakano, S.; Katoh, M.; Ito, H.; Oshimura, M.			SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress	ONCOGENE			English	Article						SIRT2; mitotic checkpoint; endoreduplication; epigenetic modi. cation; subcellular localization	DIFFERENTIALLY-EXPRESSED GENES; NUCLEAR EXPORT SIGNALS; GLIOMA-CELL-LINES; POLO-LIKE KINASES; PROMOTER HYPERMETHYLATION; SPINDLE CHECKPOINT; DOWN-REGULATION; CHFR; CYCLE; CANCERS	We previously identified SIRT2, an nicotinamide adenine dinucleotide (NAD)-dependent tubulin deacetylase, as a protein downregulated in gliomas and glioma cell lines, which are characterized by aneuploidy. Other studies reported SIRT2 to be involved in mitotic progression in the normal cell cycle. We herein investigated whether SIRT2 functions in the mitotic checkpoint in response to mitotic stress caused by microtubule poisons. By monitoring chromosome condensation, the exogenously expressed SIRT2 was found to block the entry to chromosome condensation and subsequent hyperploid cell formation in glioma cell lines with a persistence of the cyclin B/cdc2 activity in response to mitotic stress. SIRT2 is thus a novel mitotic checkpoint protein that functions in the early metaphase to prevent chromosomal instability (CIN), characteristics previously reported for the CHFR protein. We further found that histone deacetylation, but not the aberrant DNA methylation of SIRT2 5'untranslated region is involved in the downregulation of SIRT2. Although SIRT2 is normally exclusively located in the cytoplasm, the rapid accumulation of SIRT2 in the nucleus was observed after treatment with a nuclear export inhibitor, leptomycin B and ionizing radiation in normal human. fibroblasts, suggesting that nucleo-cytoplasmic shuttling regulates the SIRT2 function. Collectively, our results suggest that the further study of SIRT2 may thus provide new insights into the relationships among CIN, epigenetic regulation and tumorigenesis.	Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Dept Biomed Sci, Yonago, Tottori 6838503, Japan; Tottori Univ, Grad Sch Med Sci, Dept Human Genome Sci, Yonago, Tottori 6838503, Japan; Tottori Univ, Fac Med, Dept Pathol & Microbiol, Div Organ Pathol, Yonago, Tottori 683, Japan	Tottori University; Tottori University; Tottori University	Oshimura, M (corresponding author), Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Dept Biomed Sci, 86 Nichi Cho, Yonago, Tottori 6838503, Japan.	oshimura@grape.med.tottori-u.ac.jp						Alonso M, 2003, MOL CANCER THER, V2, P139; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Bertholon J, 2003, ONCOGENE, V22, P8956, DOI 10.1038/sj.onc.1207078; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; Brandes JC, 2005, CARCINOGENESIS, V26, P1152, DOI 10.1093/carcin/bgi058; Chu YW, 1999, CYTOMETRY, V36, P333, DOI 10.1002/(SICI)1097-0320(19990801)36:4<333::AID-CYTO8>3.0.CO;2-F; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Cortez D, 2000, NATURE, V406, P354, DOI 10.1038/35019227; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Honda T, 2004, BRIT J CANCER, V90, P2013, DOI 10.1038/sj.bjc.6601849; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nishigaki R, 2005, PROTEOMICS, V5, P3205, DOI 10.1002/pmic.200401307; Nitta M, 2002, GENES CELLS, V7, P151, DOI 10.1046/j.1356-9597.2001.00509.x; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Qian K, 2005, MOL HUM REPROD, V11, P245, DOI 10.1093/molehr/gah147; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Takahashi T, 2004, CLIN CANCER RES, V10, P6126, DOI 10.1158/1078-0432.CCR-04-0579; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tsuiki H, 2001, ONCOGENE, V20, P420, DOI 10.1038/sj.onc.1204126; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538	43	181	193	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					945	957		10.1038/sj.onc.1209857	http://dx.doi.org/10.1038/sj.onc.1209857			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909107				2022-12-25	WOS:000244245400001
J	Bush, EW; Hood, DB; Papst, PJ; Chapo, JA; Minobe, W; Bristow, MR; Olson, EN; McKinsey, TA				Bush, Erik W.; Hood, David B.; Papst, Philip J.; Chapo, Joseph A.; Minobe, Wayne; Bristow, Michael R.; Olson, Eric N.; McKinsey, Timothy A.			Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; CARDIAC-HYPERTROPHY; CATION CHANNELS; TRPC3 CHANNELS; EXPRESSION; INHIBITION; MECHANISM; MYOCYTES; PROTEIN; CELLS	The calcium/calmodulin-dependent phosphatase calcineurin plays a central role in the control of cardiomyocyte hypertrophy in response to pathological stimuli. Although calcineurin is present at high levels in normal heart, its activity appears to be unaffected by calcium during the course of a cardiac cycle. The mechanism(s) whereby calcineurin is selectively activated by calcium under pathological conditions has remained unclear. Here, we demonstrate that diverse signals for cardiac hypertrophy stimulate expression of canonical transient receptor potential (TRPC) channels. TRPC consists of a family of seven membrane-spanning nonselective cation channels that have been implicated in the nonvoltage-gated influx of calcium in response to G protein-coupled receptor signaling, receptor tyrosine kinase signaling, and depletion of internal calcium stores. TRPC3 expression is up-regulated in multiple rodent models of pathological cardiac hypertrophy, whereas TRPC5 expression is induced in failing human heart. We demonstrate that TRPC promotes cardiomyocyte hypertrophy through activation of calcineurin and its downstream effector, the nuclear factor of activated T cells transcription factor. These results define a novel role for TRPC channels in the control of cardiac growth, and suggest that a TRPC-derived pool of calcium contributes to selective activation of calcineurin in diseased heart.	Myogen Inc, Westminster, CO 80021 USA; Univ Texas, SW Med Ctr, Dallas, TX 75390 USA; Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Bush, EW (corresponding author), Myogen Inc, Westminster, CO 80021 USA.	erik.bush@myogen.com	bristow, michael r/G-7850-2011					Barritt G, 2005, NAT CELL BIOL, V7, P105, DOI 10.1038/ncb0205-105; Bush E, 2004, P NATL ACAD SCI USA, V101, P2870, DOI 10.1073/pnas.0308723101; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Harrison BC, 2004, MOL CELL BIOL, V24, P10636, DOI 10.1128/MCB.24.24.10636-10649.2004; HASS GJ, 1995, AM HEART J, V130, P806, DOI 10.1016/0002-8703(95)90081-0; He LP, 2005, J BIOL CHEM, V280, P10997, DOI 10.1074/jbc.M411797200; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hunton DL, 2004, AM J PHYSIOL-HEART C, V286, pH1124, DOI 10.1152/ajpheart.00162.2003; Hunton DL, 2002, J BIOL CHEM, V277, P14266, DOI 10.1074/jbc.M107167200; Kunichika N, 2004, AM J RESP CRIT CARE, V170, P1101, DOI 10.1164/rccm.200312-1668OC; Kwan HY, 2004, P NATL ACAD SCI USA, V101, P2625, DOI 10.1073/pnas.0304471101; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Lievremont JP, 2005, MOL PHARMACOL, V68, P758, DOI 10.1124/mol.105.012856; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NILIUS B, 2005, SCI STKE, pRE8; Pigozzi D, 2006, CELL CALCIUM, V39, P401, DOI 10.1016/j.ceca.2006.01.003; Putney JW, 2005, PFLUG ARCH EUR J PHY, V451, P29, DOI 10.1007/s00424-005-1416-4; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Rosenberg P, 2004, P NATL ACAD SCI USA, V101, P9387, DOI 10.1073/pnas.0308179101; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Seth M, 2004, P NATL ACAD SCI USA, V101, P16683, DOI 10.1073/pnas.0407537101; Trevillyan JM, 2001, J BIOL CHEM, V276, P48118, DOI 10.1074/jbc.M107919200; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vazquez G, 2004, J BIOL CHEM, V279, P40521, DOI 10.1074/jbc.M405280200; Venkatesh N, 2004, P NATL ACAD SCI USA, V101, P8969, DOI 10.1073/pnas.0402803101; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Zitt C, 2004, J BIOL CHEM, V279, P12427, DOI 10.1074/jbc.M309297200	35	222	234	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33487	33496		10.1074/jbc.M605536200	http://dx.doi.org/10.1074/jbc.M605536200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950785	hybrid			2022-12-25	WOS:000241621400059
J	Zhou, SP; Olson, JS; Fabian, M; Weiss, MJ; Gow, AJ				Zhou, Suiping; Olson, John S.; Fabian, Marian; Weiss, Mitchell J.; Gow, Andrew J.			Biochemical fates of alpha hemoglobin bound to alpha hemoglobin-stabilizing protein AHSP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MECHANISM; BETA-THALASSEMIA; AUTOXIDATION; OXYHEMOGLOBIN; REDUCTION; DISSOCIATION; OXIDATION; CHAPERONE; BINDING; CHAINS	Alpha hemoglobin-stabilizing protein (AHSP) is an erythroid protein that binds free alpha hemoglobin (alpha Hb) to maintain its structure and limit its pro-oxidant activity. Prior studies have defined two different alpha Hb center dot AHSP complexes. Binding of AHSP to Fe(II) alpha Hb induces an unusual configuration in which the F helix of the globin becomes disordered and the heme ring becomes solvent-exposed. Over time, this intermediate oxidizes to form a stable hemichrome in which the proximal (F8) and distal (E7) histidines are coordinated to the heme iron atom. The addition of alpha Hb to either Fe( II) or Fe(III) alpha Hb center dot AHSP displaces AHSP to generate tetrameric (alpha(2)beta(2)) HbA species. The biochemical properties and in vivo significance of the two alpha Hb center dot AHSP complexes are poorly understood. Here we show that Fe( III) alpha Hb center dot AHSP forms from auto-oxidation of oxygenated alpha Hb bound to AHSP and that this process is greatly accelerated at physiologic temperature and oxygen pressures. In contrast to free Fe( III) alpha Hb hemichromes, AHSP-bound Fe( III) alpha Hb does not precipitate and can be recycled into functional HbA. This requires enzymatic reduction of AHSP-bound alpha Hb, either prior to or after extraction by beta subunits. In contrast, reaction of Fe( II) alpha Hb-AHSP with beta Hb generates functional HbA directly. Our findings support a model in which AHSP can either stabilize alpha Hb transiently en route to HbA formation during normal erythropoiesis or convert excessive free alpha Hb into a more chemically inert state from which recovery of alpha Hb is possible by redox cycling.	Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Rutgers State Univ, Dept Pharmacol, Piscataway, NJ 08854 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Rutgers State University New Brunswick; Rice University	Weiss, MJ (corresponding author), Childrens Hosp Philadelphia, Div Hematol, 3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	weissmi@email.chop.edu; gow@rci.rutgers.edu	Weiss, Mitchell J/W-9814-2018; Gow, Andrew/N-8566-2013; Gow, Andrew/AAR-2309-2020; Weiss, Mitchell J/A-1245-2013	Weiss, Mitchell J/0000-0003-2460-3036; Gow, Andrew/0000-0003-0876-5158; Gow, Andrew/0000-0003-0876-5158; Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649, R01GM055807] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIDDK NIH HHS [R01 DK 61692, R01 DK061692] Funding Source: Medline; NIGMS NIH HHS [GM 35649, GM 55807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BANERJEE R, 1969, J MOL BIOL, V42, P337, DOI 10.1016/0022-2836(69)90047-3; Baudin-Creuza V, 2004, J BIOL CHEM, V279, P36530, DOI 10.1074/jbc.M405389200; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; dos Santos CO, 2005, HEMATOLOGY, V10, P157, DOI 10.1080/10245330500067280; Feng L, 2005, NATURE, V435, P697, DOI 10.1038/nature03609; Feng L, 2004, CELL, V119, P629, DOI 10.1016/j.cell.2004.11.025; Gell D, 2002, J BIOL CHEM, V277, P40602, DOI 10.1074/jbc.M206084200; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; Herold S, 2004, J BIOL CHEM, V279, P22841, DOI 10.1074/jbc.M313732200; HULTQUIST DE, 1971, NATURE-NEW BIOL, V229, P252, DOI 10.1038/newbio229252a0; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; Kong Y, 2004, J CLIN INVEST, V114, P1457, DOI 10.1172/JCI200421982; KONG Y, 2003, BLOOD, V102, P46; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; MISRA HP, 1972, J BIOL CHEM, V247, P3170; RACHMILEWITZ EA, 1971, J BIOL CHEM, V246, P3356; Tsuruga M, 1998, J BIOL CHEM, V273, P8607, DOI 10.1074/jbc.273.15.8607; Vasseur-Godbillon C, 2006, PROTEIN ENG DES SEL, V19, P91, DOI 10.1093/protein/gzj006; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; ZAVODNIK I V, 1992, Molekulyarnaya Biologiya (Moscow), V26, P321; ZHANG L, 1991, J BIOL CHEM, V266, P24698	24	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32611	32618		10.1074/jbc.M607311200	http://dx.doi.org/10.1074/jbc.M607311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16901899	hybrid			2022-12-25	WOS:000241414500059
J	Norstrom, EA; Tran, S; Steen, M; Dahlback, B				Norstrom, Eva A.; Tran, Sinh; Steen, Marten; Dahlback, Bjorn			Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-DERIVED MICROPARTICLES; PEPTIDE-BOND CLEAVAGES; BLOOD-COAGULATION; BINDING-SITE; ANTICOAGULANT ACTIVITY; THROMBOTIC DISEASE; FACTOR VA(R506Q); HEAVY-CHAIN; HONG-KONG; INACTIVATION	Activated protein C inhibits the procoagulant function of activated factor V (FVa) through proteolytic cleavages at Arg-306, Arg-506, and Arg-679. The cleavage at Arg-506 is kinetically favored but protected by factor Xa (FXa). Protein S has been suggested to annihilate the inhibitory effect of FXa, a proposal that has been challenged. To elucidate the effects of FXa and protein S on the individual cleavage sites of FVa, we used recombinant FVa:Q306/Q679 and FVa: Q506/Q679 variants, which can only be cleaved at Arg-506 and Arg-306, respectively. In the presence of active site blocked FXa (FXa-1.5-dansyl-GluGly-Arg), the FVa inactivation was followed over time, and apparent second order rate constants were calculated. Consistent with results on record, we observed that FXa-1.5-dansylGlu-Gly- Arg decreased the Arg-506 cleavage by 20-fold, with a half-maximum inhibition of similar to 2 nM. Interestingly and in contrast to the inhibitory effect of FXa on the 506 cleavage, FXa stimulated the Arg-306 cleavage. Protein S counteracted the inhibition by FXa of the Arg-506 cleavage, whereas protein S and FXa yielded additive stimulatory effect of the cleavage at Arg-306. This suggests that FXa and protein S interact with distinct sites on FVa, which is consistent with the observed lack of inhibitory effect on FXa binding to FVa by protein S. We propose that the apparent annihilation of the FXa protection of the Arg-506 cleavage by protein S is due to an enhanced rate of Arg-506 cleavage of FVa not bound to FXa, resulting in depletion of free FVa and dissociation of FXa-FVa complexes.	Lund Univ, Dept Lab Med Clin Chem, Lund, Sweden; Univ Hosp Malmo, Wallenberg Lab, SE-20502 Malmo, Sweden	Lund University; Lund University; Skane University Hospital	Dahlback, B (corresponding author), Lund Univ, Dept Lab Med Clin Chem, Lund, Sweden.	bjorn.dahlback@med.lu.se		Dahlback, Bjorn/0000-0003-1546-0328				Autin L, 2006, PROTEINS, V63, P440, DOI 10.1002/prot.20848; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Chan WP, 1998, BLOOD, V91, P1135, DOI 10.1182/blood.V91.4.1135; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; FISKE CH, 1925, J BIOL CHEM, V66, P374; Franco RF, 1998, BRIT J HAEMATOL, V103, P888; Gale AJ, 1997, PROTEIN SCI, V6, P132; Gale AJ, 2002, PROTEIN SCI, V11, P2091, DOI 10.1110/ps.0210002; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; Kalafatis M, 2001, ADV EXP MED BIOL, V489, P31; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Nicolaes GAF, 2002, ARTERIOSCL THROM VAS, V22, P530, DOI 10.1161/01.ATV.0000012665.51263.B7; Norstrom E, 2002, BLOOD, V100, P524, DOI 10.1182/blood-2002-02-0343; Norstrom EA, 2003, J BIOL CHEM, V278, P24904, DOI 10.1074/jbc.M303829200; Rosing J, 1997, THROMB HAEMOSTASIS, V78, P427; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; Shen L, 1997, BIOCHEMISTRY-US, V36, P16025, DOI 10.1021/bi971730v; Shen MC, 2001, THROMB HAEMOSTASIS, V85, P270; Smirnov MD, 1999, BLOOD, V94, P3839, DOI 10.1182/blood.V94.11.3839.423k07_3839_3846; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; Steen M, 2002, J BIOL CHEM, V277, P50022, DOI 10.1074/jbc.M205609200; Steen M, 2002, J BIOL CHEM, V277, P38424, DOI 10.1074/jbc.M204972200; Sun YH, 2004, J BIOL CHEM, V279, P47528, DOI 10.1074/jbc.M407366200; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TANS G, 1991, BLOOD, V77, P2641; Toso R, 2004, J BIOL CHEM, V279, P21643, DOI 10.1074/jbc.M402107200; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; Williamson D, 1998, BLOOD, V91, P1140, DOI 10.1182/blood.V91.4.1140	43	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31486	31494		10.1074/jbc.M606441200	http://dx.doi.org/10.1074/jbc.M606441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16935856	Green Submitted, Bronze			2022-12-25	WOS:000241235300033
J	Sagher, D; Brunell, D; Brot, N; Vallee, BL; Weissbach, H				Sagher, Daphna; Brunell, David; Brot, Nathan; Vallee, Bert L.; Weissbach, Herbert			Selenocompounds can serve as oxidoreductants with the methionine sulfoxide reductase enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; THIOREDOXIN REDUCTASE; LIFE-SPAN; METALLOTHIONEIN; EXPRESSION; SUBSTRATE; OXIDATION; CLONING; NADPH	In a recent study on the reducing requirement for the methionine sulfoxide reductases (Msr) (Sagher, D., Brunell, D., Hejtmancik, J. F., Kantorow, M., Brot, N. & Weissbach, H. ( 2006) Proc. Natl. Acad. Sci. U. S. A. 103, 8656 - 8661), we have shown that thioredoxin, although an excellent reducing system for Escherichia coli MsrA and MsrB and bovine MsrA, is not an efficient reducing agent for either human MsrB2 (hMsrB2) or human MsrB3 (hMsrB3). In a search for another reducing agent for hMsrB2 and hMsrB3, it was recently found that thionein, the reduced, metal-free form of metallothionein, could function as a reducing system for hMsrB3, with weaker activity using hMsrB2. In the present study, we provide evidence that some selenium compounds are potent reducing agents for both hMsrB2 and hMsrB3.	Florida Atlantic Univ, Ctr Mol Biol & Biotechnol, Boca Raton, FL 33431 USA; Cornell Univ, Weill Med Coll, Hosp Special Surg, Dept Microbiol & Immunol, New York, NY 10021 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	State University System of Florida; Florida Atlantic University; Cornell University; Harvard University; Harvard Medical School	Weissbach, H (corresponding author), Florida Atlantic Univ, Ctr Mol Biol & Biotechnol, 777 Glades Rd, Boca Raton, FL 33431 USA.	hweissba@fau.edu						Antoine M, 2003, J BIOL CHEM, V278, P45352, DOI 10.1074/jbc.M307471200; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; CHAUDIERE J, 1992, ARCH BIOCHEM BIOPHYS, V296, P328, DOI 10.1016/0003-9861(92)90580-P; Chen Y, 2001, EUR J BIOCHEM, V268, P3346, DOI 10.1046/j.1432-1327.2001.02250.x; Etienne F, 2003, BIOCHEM BIOPH RES CO, V312, P1005, DOI 10.1016/j.bbrc.2003.10.203; Francesconi KA, 2004, CLIN CHEM, V50, P2240, DOI 10.1373/clinchem.2004.039875; Kim HY, 2005, PLOS BIOL, V3, P2080, DOI 10.1371/journal.pbio.0030375; Kim HY, 2004, MOL BIOL CELL, V15, P1055, DOI 10.1091/mbc.E03-08-0629; KLEIN D, 1994, ANAL BIOCHEM, V221, P405, DOI 10.1006/abio.1994.1434; Koc A, 2004, P NATL ACAD SCI USA, V101, P7999, DOI 10.1073/pnas.0307929101; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; LAVINE TF, 1947, J BIOL CHEM, V169, P477; Lowther WT, 2000, BIOCHEMISTRY-US, V39, P13307, DOI 10.1021/bi0020269; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; Lowther WT, 2002, NAT STRUCT BIOL, V9, P348, DOI 10.1038/nsb783; MINETTI G, 1994, ITAL J BIOCHEM, V43, P273; Moskovitz J, 2003, P NATL ACAD SCI USA, V100, P7486, DOI 10.1073/pnas.1332607100; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; RAHMAN MA, 1992, J BIOL CHEM, V267, P15549; Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199; Saghert D, 2006, P NATL ACAD SCI USA, V103, P8656, DOI 10.1073/pnas.0602826103; Weissbach H, 2005, BBA-PROTEINS PROTEOM, V1703, P203, DOI 10.1016/j.bbapap.2004.10.004; Zhao R, 2002, J BIOL CHEM, V277, P39456, DOI 10.1074/jbc.M206452200	26	42	45	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31184	31187		10.1074/jbc.M606962200	http://dx.doi.org/10.1074/jbc.M606962200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16916796	Bronze			2022-12-25	WOS:000241235300003
J	Zhou, XY; Yang, WX; Li, JY				Zhou, Xueyuan; Yang, Wenxiu; Li, Junying			Ca2+- and protein kinase C-dependent signaling pathway for nuclear factor-kappa B activation, inducible nitric-oxide synthase expression, and tumor necrosis factor-alpha production in lipopolysaccharide-stimulated rat peritoneal macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; MEDIATED INHIBITION; MURINE MACROPHAGES; RECEPTOR AGONISTS; BINDING PROTEIN; IKK; TNF; PHOSPHORYLATION	Lipopolysaccharide (LPS)-activated macrophages are pivotal in innate immunity. With LPS treatment, extracellular signals are transduced into macrophages via Toll-like receptor 4 and induce inflammatory mediator production by activating signaling pathways, including the nuclear factor-kappa B (NF-kappa B) pathway and the mitogen-activated protein kinase (MAPK) pathway. However, the mechanisms by which the intracellular free Ca2+ concentration ([Ca2+](i)) increases and protein kinase C (PKC) is activated remain unclear. Therefore, we investigated the signaling pathway for Ca2+- and PKC-dependent NF-kappa B activation, inducible nitric-oxide synthase expression, and tumor necrosis factor-alpha (TNF-alpha) production in LPS-stimulated rat peritoneal macrophages. The results demonstrated that the LPS- induced transient ([Ca2+](i)) increase is due to Ca2+ release and influx. Extracellular and intracellular Ca2+ chelators inhibited phosphorylation of PKC alpha and PKC beta. A PKC beta-specific and a general PKC inhibitor blunted phosphorylation of serine in mitogen-activated/extracellular signal-regulated kinase kinase kinase (MEKK) 1. Moreover, aMEKK inhibitor reduced activation of inhibitory kappa B kinase and NF-kappa B. Upstream of the [Ca2+](i) increase, a proteintyrosine kinase inhibitor reduced phosphorylation of phospholipase C (PLC) gamma. Furthermore, a PLC inhibitor eliminated the Ktransient [Ca2+](i) )increase and decreased the amount of activated PKC. Therefore, these results revealed the following roles of Ca2+- and PKC in the signaling pathway for NF-kappa B activation in LPS-stimulated macrophages. After LPS treatment, protein-tyrosine kinase mediates PLC gamma 1/2 phosphorylation, which is followed by a [Ca2+](i) increase. Several PKCs are activated, and PKC beta regulates phosphorylation of serine in MEKK1. Moreover, MEKKs regulate inhibitory kappa B kinase activation. Sequentially, NF-kappa B is activated, and inducible nitric-oxide synthase and tumor necrosis factor-alpha production is promoted.	Nankai Univ, Dept Biophys, Tianjin 300071, Peoples R China; Nankai Univ, Sch Phys, Key Lab Bioact Mat Educ Minist, Tianjin 300071, Peoples R China	Nankai University; Nankai University	Yang, WX (corresponding author), Nankai Univ, Dept Biophys, Tianjin 300071, Peoples R China.	yangwenx@nankai.edu.cn						Ajizian SJ, 1999, J INFECT DIS, V179, P939, DOI 10.1086/314659; Aki D, 2005, GENES CELLS, V10, P357, DOI 10.1111/j.1365-2443.2005.00839.x; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Chandrasekar B, 2004, BIOCHEM BIOPH RES CO, V319, P304, DOI 10.1016/j.bbrc.2004.04.185; Chen F, 1999, CLIN CHEM, V45, P7; Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103; Cuschieri J, 2004, J SURG RES, V121, P76, DOI 10.1016/j.jss.2004.04.005; Dos Santos CC, 2000, J APPL PHYSIOL, V89, P1645, DOI 10.1152/jappl.2000.89.4.1645; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; Fronhofer V, 2006, J LEUKOCYTE BIOL, V79, P408, DOI 10.1189/jlb.0805438; FUJIHARA M, 1994, J BIOL CHEM, V269, P12773; GEPPERT TD, 1994, MOL MED, V1, P93; Gertsch J, 2004, FEBS LETT, V577, P563, DOI 10.1016/j.febslet.2004.10.064; Greenberg SS, 1998, ALCOHOL, V16, P167, DOI 10.1016/S0741-8329(97)00187-0; Haddad JJE, 2001, BIOCHEM J, V355, P29, DOI 10.1042/bj3550029; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Horwood NJ, 2006, J IMMUNOL, V176, P3635, DOI 10.4049/jimmunol.176.6.3635; Hsu HY, 2004, J IMMUNOL, V173, P5989, DOI 10.4049/jimmunol.173.10.5989; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200; Kim MJ, 2000, EXP MOL MED, V32, P101, DOI 10.1038/emm.2000.18; Lee HZ, 2000, EUR J PHARMACOL, V403, P195, DOI 10.1016/S0014-2999(00)00495-7; LETARI O, 1991, J IMMUNOL, V147, P980; Liu YW, 2006, CELL SIGNAL, V18, P1492, DOI 10.1016/j.cellsig.2005.12.001; Mancuso G, 2005, INFECT IMMUN, V73, P5620, DOI 10.1128/IAI.73.9.5620-5627.2005; Marshall JC, 2001, CRIT CARE MED, V29, pS99, DOI 10.1097/00003246-200107001-00032; Matsubara M, 2005, BIOCHEM PHARMACOL, V69, P433, DOI 10.1016/j.bcp.2004.10.006; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; Moynagh Paul N, 2005, J Cell Sci, V118, P4589, DOI 10.1242/jcs.02579; Rangaswami H, 2005, J BIOL CHEM, V280, P19381, DOI 10.1074/jbc.M414204200; REIMANN T, 1994, J IMMUNOL, V153, P5740; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Seabra V, 1998, J LEUKOCYTE BIOL, V64, P615, DOI 10.1002/jlb.64.5.615; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shen FM, 2004, SHOCK, V21, P556, DOI 10.1097/01.shk.0000126647.51109.5c; Shinji H, 1997, J IMMUNOL, V158, P1370; Su GL, 2002, AM J PHYSIOL-GASTR L, V283, pG256, DOI 10.1152/ajpgi.00550.2001; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; [王辉 Wang Hui], 2002, [生物物理学报, Acta Biophysica Sinica], V18, P345; Wang XM, 2006, AM J RESP CELL MOL, V34, P434, DOI 10.1165/rcmb.2005-0376OC; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wheeler M, 2000, FASEB J, V14, P476, DOI 10.1096/fasebj.14.3.476; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang L, 2003, EMBO J, V22, P4443, DOI 10.1093/emboj/cdg440; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhong J, 2004, MOL CELL BIOL, V24, P9165, DOI 10.1128/MCB.24.20.9165-9175.2004; Zhou LM, 2003, AM J RESP CELL MOL, V28, P762, DOI 10.1165/rcmb.2002-0261OC	50	132	138	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31337	31347		10.1074/jbc.M602739200	http://dx.doi.org/10.1074/jbc.M602739200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16923814				2022-12-25	WOS:000241235300018
J	Goede, B; Naji, S; von Kampen, O; Ilg, K; Thomm, M				Goede, Bernd; Naji, Souad; von Kampen, Oliver; Ilg, Karin; Thomm, Michael			Protein-protein interactions in the archaeal transcriptional machinery - Binding studies of isolated RNA polymerase subunits and transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-B; INITIATION; DNA; SITE; ARCHITECTURE; CONTACTS; HOMOLOG; COMPLEX; TFIIB; RPB4	Transcription in Archaea is directed by a pol II-like RNA polymerase and homologues of TBP and TFIIB (TFB) but the crystal structure of the archaeal enzyme and the subunits involved in recruitment of RNA polymerase to the promoter-TBP-TFB-complex are unknown. We described here the cloning expression and purification of 11 bacterially expressed subunits of the Pyrococcus furiosus RNAP. Protein interactions of subunits with each other and of archaeal transcription factors TFB and TFB with RNAP subunits were studied by Far-Western blotting and reconstitution of subcomplexes from single subunits in solution. In silico comparison of a consensus sequence of archaeal RNAP subunits with the sequence of yeast pol II subunits revealed a high degree of conservation of domains of the enzymes forming the cleft and catalytic center of the enzyme. Interaction studies with the large subunits were complicated by the low solubility of isolated subunits B, A', and A", but an interaction network of the smaller subunits of the enzyme was established. Far-Western analyses identified subunit D as structurally important key polypeptide of RNAP involved in interactions with subunits B, L, N, and P and revealed also a strong interaction of subunits E' and F. Stable complexes consisting of subunits E' and F, of D and L and a BDLNP-subcomplex were reconstituted and purified. Gel shift analyses revealed an association of the BDLNP subcomplex with promoter-bound TBP-TFB. These results suggest a major role of subunit B (Rpb2) in RNAP recruitment to the TBP-TFB promoter complex.	Univ Regensburg, Lehrstuhl Mikrobiol, D-93053 Regensburg, Germany; Univ Regensburg, Archaeenzentrum, D-93053 Regensburg, Germany; Univ Kiel, Lehrstuhl Allgemeine Mikrobiol, D-24107 Kiel, Germany	University of Regensburg; University of Regensburg; University of Kiel	Thomm, M (corresponding author), Univ Regensburg, Lehrstuhl Mikrobiol, Univ Str 31, D-93053 Regensburg, Germany.	michael.thomm@biologie.uni-regensburg.de						Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; Bartlett MS, 2005, CURR OPIN MICROBIOL, V8, P677, DOI 10.1016/j.mib.2005.10.016; Bartlett MS, 2004, J BIOL CHEM, V279, P5894, DOI 10.1074/jbc.M311429200; Bell SD, 2000, J BIOL CHEM, V275, P12934, DOI 10.1074/jbc.275.17.12934; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; Burgess RR, 1996, METHOD ENZYMOL, V273, P145; Burgess RR, 2000, METHOD ENZYMOL, V328, P141, DOI 10.1016/S0076-6879(00)28396-1; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Chen HT, 2004, CELL, V119, P169, DOI 10.1016/j.cell.2004.09.028; Chen HT, 2003, MOL CELL, V12, P437, DOI 10.1016/S1097-2765(03)00306-X; Choder M, 2004, TRENDS BIOCHEM SCI, V29, P674, DOI 10.1016/j.tibs.2004.10.007; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Ehlers C, 2002, J BACTERIOL, V184, P1028, DOI 10.1128/jb.184.4.1028-1040.2002; Eloranta JJ, 1998, NUCLEIC ACIDS RES, V26, P5562, DOI 10.1093/nar/26.24.5562; Geiduschek EP, 2005, MOL MICROBIOL, V56, P1397, DOI 10.1111/j.1365-2958.2005.04627.x; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; Jasiak AJ, 2006, MOL CELL, V23, P71, DOI 10.1016/j.molcel.2006.05.013; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; LANZENDORFER M, 1994, SYST APPL MICROBIOL, V16, P656; Magill CP, 2001, J BIOL CHEM, V276, P46693, DOI 10.1074/jbc.C100567200; Meka H, 2005, NUCLEIC ACIDS RES, V33, P6435, DOI 10.1093/nar/gki945; Miyao T, 1998, P NATL ACAD SCI USA, V95, P15281, DOI 10.1073/pnas.95.26.15281; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; Renfrow MB, 2004, J BIOL CHEM, V279, P2825, DOI 10.1074/jbc.M311433200; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SCHNABEL R, 1983, EMBO J, V2, P751, DOI 10.1002/j.1460-2075.1983.tb01495.x; Spitalny P, 2003, J BIOL CHEM, V278, P30497, DOI 10.1074/jbc.M303633200; Todone F, 2001, MOL CELL, V8, P1137, DOI 10.1016/S1097-2765(01)00379-3; Vierke G, 2003, J BIOL CHEM, V278, P18, DOI 10.1074/jbc.M209250200; Werner F, 2000, NUCLEIC ACIDS RES, V28, P4299, DOI 10.1093/nar/28.21.4299; Werner F, 2005, MOL CELL BIOL, V25, P8344, DOI 10.1128/MCB.25.18.8344-8355.2005; Werner F, 2002, MOL CELL, V10, P635, DOI 10.1016/S1097-2765(02)00629-9	36	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30581	30592		10.1074/jbc.M605209200	http://dx.doi.org/10.1074/jbc.M605209200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16885163	hybrid			2022-12-25	WOS:000241075900034
J	Ikegami, K; Mukai, M; Tsuchida, J; Heier, RL; MacGregor, GR; Setou, M				Ikegami, Koji; Mukai, Masahiro; Tsuchida, Jun-ichi; Heier, Robb L.; MacGregor, Grant R.; Setou, Mitsutoshi			TTLL7 is a mammalian beta-tubulin polyglutamylase required for growth of MAP2-positive neurites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; ALPHA-TUBULIN; AXONAL-TRANSPORT; RNA INTERFERENCE; TYROSINE LIGASE; NERVOUS-SYSTEM; PC12 CELLS; IN-VITRO; OUTGROWTH; BRAIN	Microtubules form a cytoskeletal framework that influences cell shape and provides structural support for the cell. Microtubules in the nervous system undergo a unique post-translational modification, polyglutamylation of the C termini of their tubulin subunits. The mammalian enzymes that perform beta-tubulin polyglutamylation as well as their physiological functions in the neuronal tissue remain elusive. We report identification of a mammalian polyglutamylase with specificity for beta-tubulin as well as its distribution and function in neurite growth. To identify putative tubulin polyglutamylases, we searched tubulin tyrosine ligase-like (TTLL) proteins for those predominantly expressed in the nervous system. Of 13 TTLL proteins, TTLL7 was transcribed at the highest level in the nervous system. Recombinant TTLL7 catalyzed tubulin polyglutamylation with high preference to beta-tubulin in vitro. When expressed in HEK293T cells, TTLL7 demonstrated specificity for beta-tubulin and not for beta-tubulin or nucleosome assembly protein 1. Consistent with these findings, knockdown of TTLL7 in a primary culture of superior cervical ganglion neurons caused a loss of polyglutamylated beta-tubulin. Following stimulation of PC12 cells with nerve growth factor to differentiate, the level of TTLL7 increased concomitantly with polyglutamylation of beta-tubulin. Short interference RNA-mediated knockdown of TTLL7 repressed nerve growth factor-stimulated MAP ( microtubule-associated protein) 2- positive neurite growth in PC12 cells. Consistent with having a role in the growth of MAP2-positive neurites, TTLL7 accumulated within a MAP2-enriched somatodendritic portion of superior cervical ganglion, as did polyglutamylated beta-tubulin. Anti-TTLL7 antibody revealed that TTLL7 was distributed in a somatodendritic compartment in the mouse brain. These findings indicate that TTLL7 is a beta-tubulin polyglutamylase and is required for the growth of MAP2- positive neurites in PC12 cells.	Natl Inst Physiol Sci, Okazaki, Aichi 4448787, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama, Japan; Mitsubishi Pharma Corp, Aoba Ku, Yokohama, Kanagawa 2270033, Japan; Univ Calif Irvine, Dept Dev & Cell Biol, Ctr Dev Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Mitsubishi Kagaku Institute of Life Sciences (MITILS); Japan Science & Technology Agency (JST); Mitsubishi Tanabe Pharma Corporation; University of California System; University of California Irvine; University of California System; University of California Irvine	Setou, M (corresponding author), Natl Inst Physiol Sci, 5-1 Higashiyama,Myodaiji Cho, Okazaki, Aichi 4448787, Japan.	setou@nips.ac.jp			NICHD NIH HHS [U01 HD045913-02, U01 HD045913-03, U01 HD045913-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD045913] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARGARANA CE, 1978, MOL CELL BIOCHEM, V19, P17; AUDEBERT S, 1994, J CELL SCI, V107, P2313; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BLACK MM, 1986, J CELL BIOL, V103, P545, DOI 10.1083/jcb.103.2.545; BLOOM GS, 1984, J CELL BIOL, V98, P320, DOI 10.1083/jcb.98.1.320; Bobinnec Y, 1998, CELL MOTIL CYTOSKEL, V39, P223, DOI 10.1002/(SICI)1097-0169(1998)39:3<223::AID-CM5>3.3.CO;2-3; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; BRUGG B, 1993, NEUROSCIENCE, V52, P489, DOI 10.1016/0306-4522(93)90401-Z; BRUGG B, 1988, J CELL BIOL, V107, P643, DOI 10.1083/jcb.107.2.643; CAMBRAYDEAKIN MA, 1987, CELL MOTIL CYTOSKEL, V8, P284, DOI 10.1002/cm.970080309; Campbell PK, 2002, GENETICS, V162, P307; Castoldi M, 2003, PROTEIN EXPRES PURIF, V32, P83, DOI 10.1016/S1046-5928(03)00218-3; Dideberg O, 1998, TRENDS BIOCHEM SCI, V23, P57, DOI 10.1016/S0968-0004(97)01149-3; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; Fontaine-Lenoir V, 2006, P NATL ACAD SCI USA, V103, P4711, DOI 10.1073/pnas.0600113103; Galperin MY, 1997, PROTEIN SCI, V6, P2639; GREENE LA, 1983, J CELL BIOL, V96, P76, DOI 10.1083/jcb.96.1.76; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Ikegami K, 2003, NEUROSCIENCE, V122, P617, DOI 10.1016/j.neuroscience.2003.08.057; Janke C, 2005, SCIENCE, V308, P1758, DOI 10.1126/science.1113010; Larcher JC, 1996, J BIOL CHEM, V271, P22117, DOI 10.1074/jbc.271.36.22117; LEWIS SA, 1986, J CELL BIOL, V102, P2106, DOI 10.1083/jcb.102.6.2106; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; Luduena RF, 1998, INT REV CYTOL, V178, P207; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MATUS A, 1981, P NATL ACAD SCI-BIOL, V78, P3010, DOI 10.1073/pnas.78.5.3010; Naito Y, 2004, NUCLEIC ACIDS RES, V32, pW124, DOI 10.1093/nar/gkh442; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PENG I, 1986, J CELL BIOL, V102, P252, DOI 10.1083/jcb.102.1.252; Przyborski SA, 1997, DEV BRAIN RES, V100, P133, DOI 10.1016/S0165-3806(97)00031-X; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; Regnard C, 2003, J CELL SCI, V116, P4181, DOI 10.1242/jcs.00743; Regnard C, 1998, BIOCHEMISTRY-US, V37, P8395, DOI 10.1021/bi9804131; Regnard C, 2000, J BIOL CHEM, V275, P15969, DOI 10.1074/jbc.M000045200; Regnard C, 1999, J CELL SCI, V112, P4281; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2004, J NEUROBIOL, V58, P201, DOI 10.1002/neu.10324; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Szebenyi G, 2005, CURR BIOL, V15, P1820, DOI 10.1016/j.cub.2005.08.069; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; WOLFF A, 1992, EUR J CELL BIOL, V59, P425	47	116	120	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30707	30716		10.1074/jbc.M603984200	http://dx.doi.org/10.1074/jbc.M603984200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16901895	Green Accepted, hybrid			2022-12-25	WOS:000241075900047
J	Samra, HS; Gao, F; He, F; Hoang, E; Chen, ZG; Gegenheimer, PA; Berrie, CL; Richter, ML				Samra, Hardeep S.; Gao, Fei; He, Feng; Hoang, Etter; Chen, Zugen; Gegenheimer, Peter A.; Berrie, Cindy L.; Richter, Mark L.			Structural analysis of the regulatory dithiol-containing domain of the chloroplast ATP synthase gamma subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; NUCLEOTIDE-BINDING-SITES; ENERGY-DEPENDENT CHANGES; EPSILON-SUBUNIT; C-TERMINUS; ESCHERICHIA-COLI; F-1-ATPASE; CONFORMATION; INHIBITION; PHOTOPHOSPHORYLATION	The gamma subunit of the F-1 portion of the chloroplast ATP synthase contains a critically placed dithiol that provides a redox switch converting the enzyme from a latent to an active ATPase. The switch prevents depletion of intracellular ATP pools in the dark when photophosphorylation is inactive. The dithiol is located in a special regulatory segment of about 40 amino acids that is absent from the gamma subunits of the eubacterial and mitochondrial enzymes. Site-directed mutagenesis was used to probe the relationship between the structure of the gamma regulatory segment and its function in ATPase regulation via its interaction with the inhibitory epsilon subunit. Mutations were designed using a homology model of the chloroplast gamma subunit based on the analogous structures of the bacterial and mitochondrial homologues. The mutations included (a) substituting both of the disulfide-forming cysteines (Cys(199) and Cys(205)) for alanines, (b) deleting nine residues containing the dithiol, (c) deleting the region distal to the dithiol (residues 224-240), and (d) deleting the entire segment between residues 196 and 241 with the exception of a small spacer element, and (e) deleting pieces from a small loop segment predicted by the model to interact with the dithiol domain. Deletions within the dithiol domain and within parts of the loop segment resulted in loss of redox control of the ATPase activity of the F-1 enzyme. Deleting the distal segment, the whole regulatory domain, or parts of the loop segment had the additional effect of reducing the maximum extent of inhibition obtained upon adding the epsilon subunit but did not abolish epsilon binding. The results suggest a mechanism by which the gamma and epsilon subunits interact with each other to induce the latent state of the enzyme.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Univ Kansas, Dept Chem, Lawrence, KS 66045 USA	University of Kansas; University of Kansas	Richter, ML (corresponding author), Univ Kansas, Dept Mol Biosci, 1200 Sunnyside Ave, Lawrence, KS 66045 USA.	richter@ku.edu	Gegenheimer, Peter Albert/E-2271-2013	Gegenheimer, Peter Albert/0000-0001-9863-1545	NIGMS NIH HHS [GM08545] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Averboukh L, 1996, BIOTECHNIQUES, V20, P918; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Capaldi RA, 2000, BBA-BIOENERGETICS, V1458, P263, DOI 10.1016/S0005-2728(00)00078-5; CHEN ZG, 1992, FEBS LETT, V298, P69, DOI 10.1016/0014-5793(92)80024-B; Cipriano DJ, 2006, J BIOL CHEM, V281, P501, DOI 10.1074/jbc.M509986200; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; CRUZ JA, 1995, PLANT PHYSIOL, V109, P1379, DOI 10.1104/pp.109.4.1379; GAO F, 1995, J BIOL CHEM, V270, P9763, DOI 10.1074/jbc.270.17.9763; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; Hara KY, 2001, J BIOL CHEM, V276, P23969, DOI 10.1074/jbc.M009303200; Hightower KE, 1996, BIOCHEMISTRY-US, V35, P4846, DOI 10.1021/bi952913p; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; Hisabori T, 1998, J BIOL CHEM, V273, P15901, DOI 10.1074/jbc.273.26.15901; HU NM, 1993, J BIOL CHEM, V268, P8536; Johnson EA, 2002, BIOCHEMISTRY-US, V41, P2446, DOI 10.1021/bi011939f; Keis S, 2006, J BACTERIOL, V188, P3796, DOI 10.1128/JB.00040-06; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; KOMATSUTAKAKI M, 1992, J BIOL CHEM, V267, P2360; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; MORONEY JV, 1982, J BIOL CHEM, V257, P5915; NALIN CM, 1983, J BIOL CHEM, V258, P3376; Nowak KF, 2004, BIOCHEMISTRY-US, V43, P3273, DOI 10.1021/bi035820d; Nowak KF, 2002, BIOCHEMISTRY-US, V41, P15130, DOI 10.1021/bi026594v; Oster G, 2000, BBA-BIOENERGETICS, V1458, P482, DOI 10.1016/S0005-2728(00)00096-7; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; Richter ML, 2005, J BIOENERG BIOMEMBR, V37, P467, DOI 10.1007/s10863-005-9493-9; Richter ML, 2004, PHOTOSYNTH RES, V79, P319, DOI 10.1023/B:PRES.0000017157.08098.36; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; RICHTER ML, 1987, PROGR PHOTOSYNTHESIS, V3, P57; RICHTER ML, 1996, ADV PHOTOSYNTH, V4, P453; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SHAPIRO AB, 1991, J BIOL CHEM, V266, P17276; Shi XB, 2001, BIOCHEMISTRY-US, V40, P10825, DOI 10.1021/bi015551w; Sokolov M, 1999, J BIOL CHEM, V274, P13824, DOI 10.1074/jbc.274.20.13824; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Tucker WC, 2004, J BIOL CHEM, V279, P47415, DOI 10.1074/jbc.C400269200; Tucker WC, 2001, EUR J BIOCHEM, V268, P2179, DOI 10.1046/j.1432-1327.2001.02110.x; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; XUING H, 1998, BIOCHEMISTRY-US, V37, P16423	50	27	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31041	31049		10.1074/jbc.M603315200	http://dx.doi.org/10.1074/jbc.M603315200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16895914	hybrid			2022-12-25	WOS:000241075900080
J	Starnes, GL; Jewett, TJ; Carruthers, VB; Sibley, LD				Starnes, G. Lucas; Jewett, Travis J.; Carruthers, Vern B.; Sibley, L. David			Two separate, conserved acidic amino acid domains within the Toxoplasma gondii MIC2 cytoplasmic tail are required for parasite survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE ADHESINS; GLIDING MOTILITY; MICRONEME PROTEIN; ACTIN CYTOSKELETON; INVASION; GENE; ALDOLASE; THROMBOSPONDIN; SEQUENCE; INFECTION	Apicomplexan parasites rely on actin-based motility to drive host cell invasion. Motility and invasion also require thrombospondin-related anonymous protein ( TRAP) adhesins, which are secreted apically and translocated to the posterior end of the parasite before they are shed by the activity of a rhomboid protease. TRAP orthologs, including Toxoplasma gondii MIC2 ( microneme protein 2), possess a short cytoplasmic tail, which is essential for motility. Previous studies have shown that aldolase forms a critical bridge between actin filaments and the cytoplasmic domains of MIC2 and TRAP. The cytoplasmic tails of TRAP family members harbor a conserved penultimate tryptophan, which is essential for aldolase binding, and clustered acidic residues. Herein, we determined the role of the conserved acidic residues by using alanine point mutants to investigate aldolase binding in vitro and to test functionality in the parasite. Our studies revealed two separate acidic residue clusters in the cytoplasmic domain of MIC2 that are essential for parasite survival. One region, located at the extreme C terminus, is required for the direct interaction with aldolase, whereas the second upstream acidic region is not necessary for aldolase binding but is nonetheless essential to parasite survival. Both acidic domains are conserved throughout TRAP orthologs, implicating a central role for these motifs in apicomplexan motility.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63130 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Washington University (WUSTL); University of Michigan System; University of Michigan	Sibley, LD (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, POB 8230,660 S Euclid Ave, St Louis, MO 63130 USA.	sibley@borcim.wustl.edu	Sibley, L. David/C-4616-2008	Carruthers, Vern/0000-0001-6859-8895	NIAID NIH HHS [R01 AI046675, R01 AI034036, AI017172, AI034036] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046675, R01AI034036] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barragan A, 2003, TRENDS MICROBIOL, V11, P426, DOI 10.1016/S0966-842X(03)00205-1; Baum J, 2006, J BIOL CHEM, V281, P5197, DOI 10.1074/jbc.M509807200; Brecht S, 2001, J BIOL CHEM, V276, P4119, DOI 10.1074/jbc.M008294200; Brossier F, 2005, INT J BIOCHEM CELL B, V37, P2266, DOI 10.1016/j.biocel.2005.06.006; Brossier F, 2005, P NATL ACAD SCI USA, V102, P4146, DOI 10.1073/pnas.0407918102; Brossier F, 2003, J BIOL CHEM, V278, P6229, DOI 10.1074/jbc.M209837200; Buscaglia CA, 2006, J BIOL CHEM, V281, P1324, DOI 10.1074/jbc.M506346200; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 2002, ACTA TROP, V81, P111, DOI 10.1016/S0001-706X(01)00201-7; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Dessens JT, 1999, EMBO J, V18, P6221, DOI 10.1093/emboj/18.22.6221; Dobrowolski JM, 1997, CELL MOTIL CYTOSKEL, V37, P253, DOI 10.1002/(SICI)1097-0169(1997)37:3&lt;253::AID-CM7&gt;3.0.CO;2-7; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; Dowse TJ, 2005, INT J PARASITOL, V35, P747, DOI 10.1016/j.ijpara.2005.04.001; DUBREMETZ JF, 1993, PARASITOL RES, V79, P402, DOI 10.1007/BF00931830; Gaskins E, 2004, J CELL BIOL, V165, P383, DOI 10.1083/jcb.200311137; Huynh MH, 2004, CELL MICROBIOL, V6, P771, DOI 10.1111/j.1462-5822.2004.00403.x; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Jewett TJ, 2004, J BIOL CHEM, V279, P9362, DOI 10.1074/jbc.M312590200; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; Meissner M, 2002, SCIENCE, V298, P837, DOI 10.1126/science.1074553; Menard R, 2001, CELL MICROBIOL, V3, P63, DOI 10.1046/j.1462-5822.2001.00097.x; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; Opitz C, 2002, MOL MICROBIOL, V45, P597, DOI 10.1046/j.1365-2958.2002.03056.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; Sahoo N, 2006, MOL BIOL CELL, V17, P895, DOI 10.1091/mbc.E05-06-0512; Sibley LD, 2004, SCIENCE, V304, P248, DOI 10.1126/science.1094717; Spano F, 1998, MOL BIOCHEM PARASIT, V92, P147, DOI 10.1016/S0166-6851(97)00243-0; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; TOMLEY FM, 1991, MOL BIOCHEM PARASIT, V49, P277, DOI 10.1016/0166-6851(91)90071-D; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; Wetzel DM, 2003, MOL BIOL CELL, V14, P396, DOI 10.1091/mbc.E02-08-0458; Yuda M, 1999, J EXP MED, V190, P1711, DOI 10.1084/jem.190.11.1711	37	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30745	30754		10.1074/jbc.M606523200	http://dx.doi.org/10.1074/jbc.M606523200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16923803	hybrid			2022-12-25	WOS:000241075900051
J	Xiao, ZS; Zhang, SQ; Mahlios, J; Zhou, G; Magenheimer, BS; Guo, DY; Dallas, SL; Maser, R; Calvet, JP; Bonewald, L; Quarles, LD				Xiao, Zhousheng; Zhang, Shiqin; Mahlios, Josh; Zhou, Gan; Magenheimer, Brenda S.; Guo, Dayong; Dallas, Sarah L.; Maser, Robin; Calvet, James P.; Bonewald, Lynda; Quarles, Leigh Darryl			Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY-DISEASE; TRANSCRIPTION FACTOR; BONE-FORMATION; MECHANOTRANSDUCTION; DIFFERENTIATION; CELLS; GENE; SKELETAL; CALCIUM; STRAIN	We examined the osteoblast/osteocyte expression and function of polycystin-1 (PC1), a transmembrane protein that is a component of the polycystin-2 (PC2)-ciliary mechano-sensor complex in renal epithelial cells. We found that MC3T3-E1 osteoblasts and MLO-Y4 osteocytes express transcripts for PC1, PC2, and the ciliary proteins Tg737 and Kif3a. Immunohistochemical analysis detected cilia-like structures in MC3T3-E1 osteoblastic and MLO-Y4 osteocyte-like cell lines as well as primary osteocytes and osteoblasts from calvaria. Pkd1(m1Bei) mice have inactivating missense mutations of Pkd1 gene that encode PC1. Pkd1m1Bei homozygous mutant mice demonstrated delayed endochondral and intramembranous bone formation, whereas heterozygous Pkd1(m1Bei) mutant mice had osteopenia caused by reduced osteoblastic function. Heterozygous and homozygous Pkd1m1Bei mutant mice displayed a gene dose-dependent decrease in the expression of Runx2 and osteoblast-related genes. In addition, overexpression of constitutively active PC1 C-terminal constructs in MC3T3-E1 osteoblasts resulted in an increase in Runx2 P1 promoter activity and endogenous Runx2 expression as well as an increase in osteoblast differentiation markers. Conversely, osteoblasts derived from Pkd1m1Bei homozygous mutant mice had significant reductions in endogenous Runx2 expression, osteoblastic markers, and differentiation capacity ex vivo. Co-expression of constitutively active PC1 C-terminal construct into Pkd1m1Bei homozygous osteoblasts was sufficient to normalize Runx2 P1 promoter activity. These findings are consistent with a possible functional role of cilia and PC1 in anabolic signaling in osteoblasts/ osteocytes.	Univ Kansas, Med Ctr, Kidney Inst, Kansas City, KS 66160 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA	University of Kansas; University of Kansas Medical Center; University of Missouri System; University of Missouri Kansas City	Quarles, LD (corresponding author), Univ Kansas, Med Ctr, Kidney Inst, 3901 Rainbow Blvd,6018 Wahl Hall E, Kansas City, KS 66160 USA.	dquarles@kumc.edu	Bonewald, Lynda/Q-3638-2019	Quarles, L. Darryl/0000-0002-5082-7896	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049712, P01AR046798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057301, R01DK083303] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049712, P01-AR46798, R01-AR049712, P01 AR046798] Funding Source: Medline; NIDDK NIH HHS [R01 DK083303, P50 DK057301, P50-DK057301] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Bhalal L, 2005, ADV ANAT PATHOL, V12, P126, DOI 10.1097/01.pap.0000163959.29032.1f; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098; Chung Choo-ryung J., 2004, Journal of Medical and Dental Sciences, V51, P105; Costessi A, 2005, BONE, V36, P418, DOI 10.1016/j.bone.2004.10.016; Delmas P, 2005, PFLUG ARCH EUR J PHY, V451, P264, DOI 10.1007/s00424-005-1431-5; Delmas P, 2004, BIOCHEM BIOPH RES CO, V322, P1374, DOI 10.1016/j.bbrc.2004.08.044; FEDERMAN M, 1974, CALC TISS RES, V17, P81, DOI 10.1007/BF02547216; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Garner SC, 2001, ENDOCRINOLOGY, V142, P3996, DOI 10.1210/en.142.9.3996; Geng L, 2000, BBA-MOL BASIS DIS, V1535, P21, DOI 10.1016/S0925-4439(00)00079-X; Guay-Woodford LM, 2003, AM J PHYSIOL-RENAL, V285, pF1034, DOI 10.1152/ajprenal.00195.2003; Guillaume R, 2000, MECH DEVELOP, V93, P179, DOI 10.1016/S0925-4773(00)00257-4; Guillaume R, 1999, DEV DYNAM, V214, P337, DOI 10.1002/(SICI)1097-0177(199904)214:4<337::AID-AJA6>3.0.CO;2-O; Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Herron BJ, 2002, NAT GENET, V30, P185, DOI 10.1038/ng812; Hou XY, 2002, J CLIN INVEST, V109, P533, DOI 10.1172/JC1200214099; Hughes-Fulford Millie, 2004, Sci STKE, V2004, pRE12; Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087; Jensen CG, 2004, CELL BIOL INT, V28, P101, DOI 10.1016/j.cellbi.2003.11.007; Kalajzic I, 2004, BONE, V35, P74, DOI 10.1016/j.bone.2004.03.006; Kottgen M, 2005, PFLUG ARCH EUR J PHY, V451, P286, DOI 10.1007/s00424-005-1417-3; LANYON LE, 1987, J BIOMECH, V20, P1083, DOI 10.1016/0021-9290(87)90026-1; Le NH, 2004, J BIOL CHEM, V279, P27472, DOI 10.1074/jbc.M312183200; Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200; Lin FM, 2003, P NATL ACAD SCI USA, V100, P5286, DOI 10.1073/pnas.0836980100; Lin FM, 2004, CURR OPIN PEDIATR, V16, P171, DOI 10.1097/00008480-200404000-00010; Lu WN, 2001, HUM MOL GENET, V10, P2385, DOI 10.1093/hmg/10.21.2385; Marino JH, 2003, J IMMUNOL METHODS, V283, P291, DOI 10.1016/S0022-1759(03)00103-0; Nanci A, 1996, MICROSC RES TECHNIQ, V33, P214; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nauli SM, 2006, J AM SOC NEPHROL, V17, P1015, DOI 10.1681/ASN.2005080830; Nims N, 2003, BIOCHEMISTRY-US, V42, P13035, DOI 10.1021/bi035074c; Ontiveros C, 2003, J CELL BIOCHEM, V88, P427, DOI 10.1002/jcb.10410; Papachristou DJ, 2005, HISTOCHEM CELL BIOL, V124, P215, DOI 10.1007/s00418-005-0026-8; Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284; Pazour GJ, 2003, CURR OPIN CELL BIOL, V15, P105, DOI 10.1016/S0955-0674(02)00012-1; Praetorius HA, 2003, J MEMBRANE BIOL, V191, P69, DOI 10.1007/s00232-002-1042-4; Puri S, 2004, J BIOL CHEM, V279, P55455, DOI 10.1074/jbc.M402905200; Quarles LD, 1997, J CELL BIOCHEM, V65, P11; Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028; Salingcarnboriboon R, 2006, ENDOCRINOLOGY, V147, P2296, DOI 10.1210/en.2005-1020; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Sutters M, 2003, J LAB CLIN MED, V141, P91, DOI 10.1067/mlc.2003.13; Takaoki Muneo, 2004, Biol Sci Space, V18, P181; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Wang FS, 2002, J BIOL CHEM, V277, P10931, DOI 10.1074/jbc.M104587200; Ward CJ, 2003, HUM MOL GENET, V12, P2703, DOI 10.1093/hmg/ddg274; Whitfield JF, 2003, J CELL BIOCHEM, V89, P233, DOI 10.1002/jcb.10509; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200; Xiao ZS, 2003, J CELL BIOCHEM, V88, P493, DOI 10.1002/jcb.10375; Xiao ZS, 2005, DEV BIOL, V283, P345, DOI 10.1016/j.ydbio.2005.04.028; Xiao ZS, 2004, J BIOL CHEM, V279, P20307, DOI 10.1074/jbc.M401109200; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Yoder BK, 2002, AM J PHYSIOL-RENAL, V282, pF541, DOI 10.1152/ajprenal.00273.2001; Zerath E, 1998, ADV SPACE RES, V21, P1049, DOI 10.1016/S0273-1177(98)00026-X; Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200	60	171	179	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30884	30895		10.1074/jbc.M604772200	http://dx.doi.org/10.1074/jbc.M604772200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16905538	hybrid, Green Accepted			2022-12-25	WOS:000241075900064
J	Matsushima, R; Harada, N; Webster, NJG; Tsutsumi, YM; Nakaya, Y				Matsushima, Rie; Harada, Nagakatsu; Webster, Nicholas J. G.; Tsutsumi, Yasuo M.; Nakaya, Yutaka			Effect of TRB3 on insulin and nutrient-stimulated hepatic p70 S6 kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE-RHEB; B C-AKT; MAMMALIAN TARGET; AMINO-ACID; GLUCOSE-INTOLERANCE; TRIBBLES HOMOLOG; MTOR; PHOSPHORYLATION; ACTIVATION; RAPAMYCIN	Insulin and nutrients activate hepatic p70 S6 kinase ( S6K1) to regulate protein synthesis. Paradoxically, activation of S6K1 also leads to the development of insulin resistance. In this study, we investigated the effect of TRB3, which acts as an endogenous inhibitor of Akt, on S6K1 activity in vitro and in vivo. In cultured cells, overexpression of TRB3 completely inhibited insulinstimulated S6K1 activation by mammalian target of rapamycin, whereas knockdown of endogenous TRB3 increased both basal and insulin- stimulated activity. In C57BL/ 6 mice, adenoviral overexpression of TRB3 inhibited insulin- stimulated activation of hepatic S6K1. In contrast, overexpression of TRB3 did not inhibit nutrient- stimulated S6K1 activity. We also investigated the effect of starvation, feeding, or insulin treatment on TRB3 levels and S6K1 activity in the liver of C57BL/ 6 and db/ db mice. Both insulin and feeding activate S6K1 in db/ db mice, but only insulin activates in the C57BL/ 6 strain. TRB3 levels were 3.5fold higher in db/ db mice than C57BL/ 6 mice and were unresponsive to feeding or insulin, whereas both treatments reduced TRB3 in C57BL/ 6 mice. Akt was activated by insulin alone in the C57BL/ 6 strain and but not in db/ db mice. Both insulin and feeding activated mammalian target of rapamycin similarly in these mice; however, feeding was unable to activate the downstream targetS6K1inC57BL/ 6mice. These results suggest that the nutrient excess in the hyperphagic, hyperinsulinemic db/ dbmouse primes the hepatocyte to respond to nutrients resulting in elevated S6K1 activity. The combination of elevated TRB3 and constitutive S6K1 activity results in decreased insulin signaling via the IRS- 1/ phosphatidylinositol 3- kinase/ Akt pathway.	Univ Tokushima, Grad Sch, Dept Nutr & Metab, Inst Hlth Biosci, Tokushima 7708503, Japan; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, Med Res Serv, San Diego, CA 92161 USA	Tokushima University; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Matsushima, R (corresponding author), Univ Tokushima, Grad Sch, Dept Nutr & Metab, Inst Hlth Biosci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	amocoerie@sbcglobal.net	Tsutsumi, Yasuo M/G-1972-2012; Webster, Nick/AAI-8410-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD047400] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD047400] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Bachmann RA, 2006, J BIOL CHEM, V281, P7357, DOI 10.1074/jbc.M512218200; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Coffer PJ, 1998, BIOCHEM J, V335, P1; Draznin B, 2000, ENDOCRINOLOGY, V141, P1310, DOI 10.1210/en.141.4.1310; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, GENE DEV, V15, P2852; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hinault C, 2004, FASEB J, V18, P1894, DOI 10.1096/fj.03-1409fje; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; ICHIHARA A, 1982, MOL CELL BIOCHEM, V43, P145; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jonassen AK, 2004, BIOCHEM BIOPH RES CO, V315, P160, DOI 10.1016/j.bbrc.2004.01.029; Kanezaki Y, 2004, ENDOCR J, V51, P133, DOI 10.1507/endocrj.51.133; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Mothe-Satney I, 2004, J BIOL CHEM, V279, P42628, DOI 10.1074/jbc.M405173200; Mueckler M, 2005, J BIOL CHEM, V280, P39562, DOI 10.1074/jbc.M509050200; Murray JT, 2002, TRAFFIC, V3, P416, DOI 10.1034/j.1600-0854.2002.30605.x; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Prudente S, 2005, DIABETES, V54, P2807, DOI 10.2337/diabetes.54.9.2807; Saito K, 2005, J BIOCHEM, V137, P423, DOI 10.1093/jb/mvi046; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schwarzer R, 2006, CELL SIGNAL, V18, P899, DOI 10.1016/j.cellsig.2005.08.002; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Stein MP, 2003, TRAFFIC, V4, P754, DOI 10.1034/j.1600-0854.2003.00133.x; Takahashi K, 2005, J BIOL CHEM, V280, P32768, DOI 10.1074/jbc.M506280200; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	50	55	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29719	29729		10.1074/jbc.M511636200	http://dx.doi.org/10.1074/jbc.M511636200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16887816	hybrid			2022-12-25	WOS:000240896300034
J	Fu, Q; McKnight, RA; Yu, X; Callaway, CW; Lane, RH				Fu, Qi; McKnight, Robert A.; Yu, Xing; Callaway, Christopher W.; Lane, Robert H.			Growth retardation alters the epigenetic characteristics of hepatic dual specificity phosphatase 5	FASEB JOURNAL			English	Article						DNA methylation; chromatin; insulin receptor substrate	INSULIN-RECEPTOR SUBSTRATE-1; COACTIVATOR-1 GENE-EXPRESSION; UTEROPLACENTAL INSUFFICIENCY; DNA METHYLATION; RETARDED FETAL; TYROSINE PHOSPHORYLATION; HISTONE ACETYLATION; GLUCOSE-TOLERANCE; RAT; LIVER	Uteroplacental insufficiency leads to intrauterine growth retardation ( IUGR) and adult onset insulin resistance in both humans and rats. IUGR rat liver is characterized by persistent changes in histone 3 lysine 9 and lysine 14 acetylation, which may induce postnatal changes in gene expression. We hypothesized that it would be possible to identify hepatic genes whose epigenetic characteristics and mRNA levels are altered due to IUGR using chromatin immunoprecipitation (ChIP) coupled with random primed differential display polymerase chain reaction (PCR). One of the isolated sequences identified contained exon 2 of the dual specificity phosphatase-5 gene (DUSP5). IUGR affected hepatic DUSP5 mRNA levels and exon 2 DNA methylation into adulthood in the rat. DUSP5 dephosphorylates Erk1 and Erk2 within the MAPK signaling cascade, which in turn affects serine 612 phosphorylation of insulin receptor substrate - 1 (p612 IRS-1). In adult rat liver, IUGR increased Erk1/Erk2 phosphorylation and p612 IRS-1 phosphorylation. Increased serine phosphorylation of hepatic IRS-1 may contribute to the insulin resistance that characterizes these animals. We conclude that intrauterine growth retardation induced by uteroplacental insufficiency 1) affects the hepatic epigenetic characteristics and mRNA of the DUSP-5 and 2) increases hepatic insulin receptor substrate-1 phosphorylation at serine 612 in adult rats.	Univ Utah, Sch Med, Dept Pediat, Div Neonatol, Salt Lake City, UT 84158 USA	Utah System of Higher Education; University of Utah	Lane, RH (corresponding author), Univ Utah, Sch Med, Dept Pediat, Div Neonatol, POB 581289, Salt Lake City, UT 84158 USA.	robert.lane@hsc.utah.edu		Callaway, Christopher/0000-0003-2072-0972	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041075] Funding Source: NIH RePORTER; NICHD NIH HHS [HD41075] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bard-Chapeau EA, 2005, NAT MED, V11, P567, DOI 10.1038/nm1227; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1995, BRIT MED J, V310, P703, DOI 10.1136/bmj.310.6981.703; Baserga M, 2005, AM J PHYSIOL-REG I, V289, pR1348, DOI 10.1152/ajpregu.00211.2005; Baserga M, 2004, EARLY HUM DEV, V79, P93, DOI 10.1016/j.earlhumdev.2004.04.015; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Burke JP, 2004, DIABETES CARE, V27, P2512, DOI 10.2337/diacare.27.10.2512; BUSSEY ME, 1985, PEDIATR RES, V19, P363, DOI 10.1203/00006450-198519040-00010; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Clark JA, 2005, AM J PHYSIOL-GASTR L, V288, pG755, DOI 10.1152/ajpgi.00172.2004; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Fayyad AM, 2005, EARLY HUM DEV, V81, P865, DOI 10.1016/j.earlhumdev.2005.09.005; Fu Q, 2004, PHYSIOL GENOMICS, V20, P108, DOI 10.1152/physiolgenomics.00175.2004; Gual P, 2003, DIABETOLOGIA, V46, P1532, DOI 10.1007/s00125-003-1223-4; HA DEB, 2006, AUST NZJ OBSTET GYNA, V46, P4; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hevroni D, 1998, J MOL NEUROSCI, V10, P75, DOI 10.1007/BF02737120; Houdijk ECAM, 2000, J ENDOCRINOL, V166, P599, DOI 10.1677/joe.0.1660599; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Kang S, 2003, EUR J ENDOCRINOL, V148, P147, DOI 10.1530/eje.0.1480147; Ke X, 2006, PHYSIOL GENOMICS, V25, P16, DOI 10.1152/physiolgenomics.00093.2005; Ke XR, 2005, AM J PHYSIOL-REG I, V288, pR1038, DOI 10.1152/ajpregu.00701.2004; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Lane RH, 2003, PEDIATR RES, V53, P994, DOI 10.1203/01.PDR.0000064583.40495.51; Lane RH, 2002, ENDOCRINOLOGY, V143, P2486, DOI 10.1210/en.143.7.2486; Lane RH, 1998, PEDIATR RES, V43, P563, DOI 10.1203/00006450-199805000-00001; Lane RH, 2001, BRAIN RES, V895, P186, DOI 10.1016/S0006-8993(01)02074-1; Lane RH, 2001, AM J PHYSIOL-REG I, V280, pR183, DOI 10.1152/ajpregu.2001.280.1.R183; Lane RH, 2001, PEDIATR RES, V50, P83, DOI 10.1203/00006450-200107000-00016; Lane RH, 1999, AM J PHYSIOL-ENDOC M, V276, pE135, DOI 10.1152/ajpendo.1999.276.1.E135; Lane RH, 1996, BIOCHEM MOL MED, V59, P192, DOI 10.1006/bmme.1996.0087; Lane RH, 1996, PEDIATR RES, V39, P390, DOI 10.1203/00006450-199603000-00003; Lane RH, 2000, PEDIATR RES, V47, P792, DOI 10.1203/00006450-200006000-00019; LANE RH, 2003, PEDIAT RES, V535; Liu L, 2003, MECH AGEING DEV, V124, P989, DOI 10.1016/j.mad.2003.08.001; Lopez-Jaramillo P, 2005, J HYPERTENS, V23, P1121, DOI 10.1097/01.hjh.0000170371.49010.4a; MacLennan NK, 2004, PHYSIOL GENOMICS, V18, P43, DOI 10.1152/physiolgenomics.00042.2004; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; McNairn AJ, 2003, BIOESSAYS, V25, P647, DOI 10.1002/bies.10305; Morino K, 2005, J CLIN INVEST, V115, P3587, DOI 10.1172/JCI25151; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; OGATA ES, 1986, METABOLISM, V35, P970, DOI 10.1016/0026-0495(86)90064-8; OGATA ES, 1985, PEDIATR RES, V19, P32, DOI 10.1203/00006450-198501000-00010; OGATA ES, 1990, PEDIATR RES, V27, P56, DOI 10.1203/00006450-199001000-00017; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Pham TD, 2003, AM J PHYSIOL-REG I, V285, pR962, DOI 10.1152/ajpregu.00201.2003; Roberts CL, 2005, MED J AUSTRALIA, V182, P332, DOI 10.5694/j.1326-5377.2005.tb06730.x; Rosseland CM, 2005, HEPATOLOGY, V42, P200, DOI 10.1002/hep.20762; Sadiq HF, 1999, BRAIN RES, V823, P96, DOI 10.1016/S0006-8993(99)01145-2; Simmons RA, 2001, DIABETES, V50, P2279, DOI 10.2337/diabetes.50.10.2279; Singh R, 2004, PEDIATR DIABETES, V5, P154, DOI 10.1111/j.1399-543X.2004.00060.x; Smith R A, 2005, Minerva Ginecol, V57, P379; Taniguchi CM, 2005, J CLIN INVEST, V115, P718, DOI 10.1172/JCI200523187; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; Tsirka AE, 2001, J ENDOCRINOL, V169, P373, DOI 10.1677/joe.0.1690373; Vilatoba M, 2005, TRANSPL P, V37, P399, DOI 10.1016/j.transproceed.2004.12.053; World Medical Association, 2002, AM J PHYSIOL-REG I, V283, pR281, DOI DOI 10.1152/AJPREGU.00279.2002	65	55	58	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2127	+		10.1096/fj.06-6179fje	http://dx.doi.org/10.1096/fj.06-6179fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16940436				2022-12-25	WOS:000241156900029
J	Baldan, A; Tarr, P; Vales, CS; Frank, J; Shimotake, TK; Hawgood, S; Edwards, PA				Baldan, Angel; Tarr, Paul; Vales, Charisse S.; Frank, Joy; Shimotake, Thomas K.; Hawgood, Sam; Edwards, Peter A.			Deletion of the transmembrane transporter ABCG1 results in progressive pulmonary lipidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIARY CHOLESTEROL SECRETION; HIGH-DENSITY-LIPOPROTEIN; BETA-C RECEPTOR; ALVEOLAR PROTEINOSIS; DIETARY-CHOLESTEROL; SURFACTANT PROTEINS; PHOSPHOLIPID EFFLUX; DEFICIENT MICE; MESSENGER-RNA; LUNG-DISEASE	We show that mice lacking the ATP-binding cassette transmembrane transporter ABCG1 show progressive and age-dependent severe pulmonary lipidosis that recapitulates the phenotypes of different respiratory syndromes in both humans and mice. The lungs of chow-fed Abcg1(-/-) mice, > 6-months old, exhibit extensive subpleural cellular accumulation, macrophage, and pneumocyte type 2 hypertrophy, massive lipid deposition in both macrophages and pneumocytes and increased levels of surfactant. No such abnormalities are observed at 3 months of age. However, gene expression profiling reveals significant changes in the levels of mRNAs encoding key genes involved in lipid metabolism in both 3- and 8- month-old Abcg1(-/-) mice. These data suggest that the lungs of young Abcg1(-/-) mice maintain normal lipid levels by repressing lipid biosynthetic pathways and that such compensation is inadequate as the mice mature. Studies with A-549 cells, a model for pneumocytes type 2, demonstrate that overexpression of ABCG1 specifically stimulates the efflux of cellular cholesterol by a process that is dependent upon phospholipid secretion. In addition, we demonstrate that Abcg1(-/-), but not wild-type macrophages, accumulate cholesterol ester droplets when incubated with surfactant. Together, these data provide a mechanism to explain the lipid accumulation in the lungs of Abcg1(-/-) mice. In summary, our results demonstrate that ABCG1 plays essential roles in pulmonary lipid homeostasis.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94118 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94118 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Edwards, PA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, CHS 33-257,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	pedwards@mednet.ucla.edu			PHS HHS [NIH30568, NIH68445] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agassandian M, 2004, AM J RESP CELL MOL, V31, P227, DOI 10.1165/rcmb.2004-0038OC; Anderson RA, 1999, MOL GENET METAB, V68, P333, DOI 10.1006/mgme.1999.2904; Arai T, 2004, RESP MED, V98, P1227, DOI 10.1016/j.rmed.2004.08.011; BATENBURG JJ, 1992, AM J PHYSIOL, V262, P367; Bates SR, 2005, AM J PHYSIOL-LUNG C, V289, pL980, DOI 10.1152/ajplung.00234.2005; Bewig B, 2000, EUR RESPIR J, V15, P350, DOI 10.1034/j.1399-3003.2000.15b22.x; Bullard JE, 2005, AM J RESP CRIT CARE, V172, P1026, DOI 10.1164/rccm.200503-504OC; Chintagari NR, 2006, AM J RESP CELL MOL, V34, P677, DOI 10.1165/rcmb.2005-0418OC; Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Gelissen IC, 2006, ARTERIOSCL THROM VAS, V26, P534, DOI 10.1161/01.ATV.0000200082.58536.e1; Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X; Hawgood S, 2002, AM J PHYSIOL-LUNG C, V283, pL1002, DOI 10.1152/ajplung.00118.2002; Hubacek J A, 2001, Hum Mutat, V18, P359, DOI 10.1002/humu.1206; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Kim HJ, 2002, J LIPID RES, V43, P1750, DOI 10.1194/jlr.M100433-JLR200; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Lian XM, 2004, AM J PHYSIOL-LUNG C, V286, pL801, DOI 10.1152/ajplung.00335.2003; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Nakamura K, 2004, J BIOL CHEM, V279, P45980, DOI 10.1074/jbc.M408652200; NISHINAKAMURA R, 1995, IMMUNITY, V2, P211, DOI 10.1016/1074-7613(95)90046-2; Nogee LM, 2004, ANNU REV PHYSIOL, V66, P601, DOI 10.1146/annurev.physiol.66.032102.134711; NOTTER RH, 2000, LUNG SURFACTANTS BAS; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Reid KBM, 1998, IMMUNOBIOLOGY, V199, P200, DOI 10.1016/S0171-2985(98)80027-2; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Sampath H, 2005, ANNU REV NUTR, V25, P317, DOI 10.1146/annurev.nutr.25.051804.101917; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; Soccio RE, 2004, ARTERIOSCL THROM VAS, V24, P1150, DOI 10.1161/01.ATV.0000131264.66417.d5; Sommerer D, 2004, J PHARMACEUT BIOMED, V35, P199, DOI 10.1016/j.jpba.2003.12.016; Sparrow CP, 2002, J BIOL CHEM, V277, P10021, DOI 10.1074/jbc.M108225200; Tamminen M, 1999, ARTERIOSCL THROM VAS, V19, P847, DOI 10.1161/01.ATV.19.4.847; Ulven SM, 2005, PROSTAG LEUKOTR ESS, V73, P59, DOI 10.1016/j.plefa.2005.04.009; Vaughan AM, 2005, J BIOL CHEM, V280, P30150, DOI 10.1074/jbc.M505368200; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; White T, 1998, ANAL BIOCHEM, V258, P109, DOI 10.1006/abio.1997.2545; WRIGHT JR, 1989, CLIN CHEST MED, V10, P83; Wright JR, 2004, BIOL NEONATE, V85, P326, DOI 10.1159/000078172; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; Zhou JM, 2004, J LIPID RES, V45, P1758, DOI 10.1194/jlr.M400179-JLR200	46	89	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29401	29410		10.1074/jbc.M606597200	http://dx.doi.org/10.1074/jbc.M606597200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16887795	hybrid			2022-12-25	WOS:000240680500095
J	Mancek-Keber, M; Jerala, R				Mancek-Keber, Mateja; Jerala, Roman			Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2	FASEB JOURNAL			English	Article						bacteria; Toll-like receptor; LPS	CRYSTAL-STRUCTURE; LIPOPOLYSACCHARIDE; BINDING; ENDOTOXIN; CONFERS; PROTEIN; RESPONSIVENESS; ANTAGONIST; ALLERGEN; COMPLEX	Toll-like receptors (TLRs) belong to the family of pattern recognition receptors, as they recognize molecules sharing a broad structural pattern rather than a single defined structure. Bacterial LPS is recognized by MD-2, which is associated with the extracellular domain of TLR4. Understanding the molecular recognition pattern of MD-2 could lead to efficient inhibitors of the excessive LPS signaling needed for early treatment of sepsis. The effect of the acyl chain variability of lipid A on its biological activity indicates that in addition to electrostatic interactions, the recognition must also involve hydrophobic interactions. We show that the fluorescent hydrophobic probe bis-ANS binds to MD-2 with a dissociation constant in the 10 nanomolar range, both to glycosylated and to nonglycosylated MD-2, and requires its native conformation. The binding site of bis-ANS overlaps with the binding site of LPS and is in the proximity of the single tryptophan residue. Furthermore, photoincorporation of bis-ANS by UV light inhibits the ability of MD-2 to confer the LPS responsiveness to the TLR4-transfected HEK293 cell line. Our results show that the structural pattern recognized by MD-2 is defined by the hydrophobic patch and a pair of separated negative charges. Mancek-Keber, M., Jerala, R. Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2.	Natl Inst Chem, Biotechnol Lab, Ljubljana 1000, Slovenia	National Institute of Chemistry - Slovenia	Jerala, R (corresponding author), Natl Inst Chem, Biotechnol Lab, Hajdrihova 19, Ljubljana 1000, Slovenia.	roman.jerala@ki.si	Jerala, Roman/H-9850-2015	Jerala, Roman/0000-0002-6337-5251				Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Bothra A, 1998, J BIOMOL STRUCT DYN, V15, P959, DOI 10.1080/07391102.1998.10508216; Collini M, 2003, PROTEIN SCI, V12, P1596, DOI 10.1110/ps.0304403; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Hawkins LD, 2004, CURR TOP MED CHEM, V4, P1147, DOI 10.2174/1568026043388123; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Keber MM, 2005, J ENDOTOXIN RES, V11, P186, DOI 10.1179/096805105X35206; Lee HJ, 2003, EUR J BIOCHEM, V270, P3988, DOI 10.1046/j.1432-1033.2003.03787.x; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Mogensen JE, 2002, J BIOL CHEM, V277, P23684, DOI 10.1074/jbc.M202065200; Mueller M, 2005, J ENDOTOXIN RES, V11, P299, DOI 10.1179/096805105X46574; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Muller M, 2003, J ENDOTOXIN RES, V9, P181, DOI 10.1179/096805103125001595; Muroi M, 2006, J BIOL CHEM, V281, P5484, DOI 10.1074/jbc.M509193200; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Pastukhov AV, 2003, PROTEINS, V53, P607, DOI 10.1002/prot.10401; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Re F, 2003, J IMMUNOL, V171, P5272, DOI 10.4049/jimmunol.171.10.5272; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Saitoh S, 2004, INT IMMUNOL, V16, P961, DOI 10.1093/intimm/dxh097; Seale JW, 1998, METHOD ENZYMOL, V290, P318, DOI 10.1016/S0076-6879(98)90028-3; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Stevens A, 1997, EUR J BIOCHEM, V243, P792, DOI 10.1111/j.1432-1033.1997.00792.x; Triantafilou M, 2004, BIOCHEM J, V381, P527, DOI 10.1042/BJ20040172; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2005, J IMMUNOL, V175, P6465, DOI 10.4049/jimmunol.175.10.6465; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; Wright CS, 2004, J MOL BIOL, V342, P585, DOI 10.1016/j.jmb.2004.07.063; Wright CS, 2000, J MOL BIOL, V304, P411, DOI 10.1006/jmbi.2000.4225	40	43	44	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1836	1842		10.1096/fj.06-5862com	http://dx.doi.org/10.1096/fj.06-5862com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940155				2022-12-25	WOS:000240267000011
J	Movafagh, S; Hobson, JP; Spiegel, S; Kleinman, HK; Zukowska, Z				Movafagh, Sharareh; Hobson, John P.; Spiegel, Sarah; Kleinman, Hynda K.; Zukowska, Zofia			Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors	FASEB JOURNAL			English	Article						bimodal dose-response curve; chemotaxis; mitogenesis; oligomerization; GPCRs	SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; THERAPEUTIC IMPLICATIONS; ISCHEMIC ANGIOGENESIS; MOLECULAR-MECHANISMS; NPY; SUBTYPES; HORMONE; NEURONS; NEOVASCULARIZATION	sPreviously we discovered that NPY induces ischemic angiogenesis by activating Y2 and Y5 receptors. The receptors that mediate specific steps of the complex process of angiogenesis are unknown. Here, we studied in vitro NPY receptors subtypes involved in migration, proliferation, and differentiation of human endothelial cells. In cells that expressed Y1, Y2, and Y5 receptors, NPY bimodally stimulated migration and proliferation with a 2-fold increase at 10(-12) M and 10(-8) M (high- and low-affinity peaks, respectively). Preincubation of cells with NPY up-regulated the Y5 receptor and markedly enhanced endothelial cell migration and proliferation. NPY-induced endothelial cell migration was mimicked by agonists and fully blocked by antagonists for any specific NPY receptors (Y1, Y2, or Y5), while proliferation was blocked by any two antagonists (Y1 + Y2, Y1 + Y5, or Y2 + Y5), and capillary tube formation on Matrigel was blocked by all three (Y1 + Y2 + Y5). Thus, NPY-induced angiogenesis requires participation of Y1, Y2, and Y5 receptor subtypes, with the Y5 receptor acting as an enhancer. We propose that these receptors form heteromeric complexes, and the Y1/ Y2/ Y5 receptor oligomer may be the uncloned Y3 receptor.	Georgetown Univ, Med Ctr, Dept Physiol & Biophys, Washington, DC 20057 USA; Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA USA; Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA	Georgetown University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Zukowska, Z (corresponding author), Georgetown Univ, Med Ctr, Dept Physiol & Biophys, Washington, DC 20057 USA.	zzukow01@georgetown.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000230] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL0553, HL67357] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; ALLEN JM, 1983, J AUTONOM NERV SYST, V9, P559, DOI 10.1016/0165-1838(83)90013-9; Anderson RL, 2001, J COMP NEUROL, V429, P419, DOI 10.1002/1096-9861(20010115)429:3<419::AID-CNE5>3.0.CO;2-D; BALASUBRAMANIAM A, 1990, PEPTIDES, V11, P545, DOI 10.1016/0196-9781(90)90057-C; Berglund MM, 2003, EXP BIOL MED, V228, P217, DOI 10.1177/153537020322800301; BOUALI SM, 1995, BRAIN RES BULL, V36, P131, DOI 10.1016/0361-9230(94)00177-3; Bouis Diane, 2001, Angiogenesis, V4, P91, DOI 10.1023/A:1012259529167; Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cavadas C, 2001, J CLIN ENDOCR METAB, V86, P5956, DOI 10.1210/jc.86.12.5956; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; DESAI KS, 1973, J LIPID RES, V14, P647; Duhault J, 2000, CAN J PHYSIOL PHARM, V78, P173, DOI 10.1139/cjpp-78-2-173; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Folkman J, 1974, Symp Soc Dev Biol, V30, P43; GEROZISSIS K, 1987, BRAIN RES, V416, P54, DOI 10.1016/0006-8993(87)91495-8; Ghersi G, 2001, PEPTIDES, V22, P453, DOI 10.1016/S0196-9781(01)00340-0; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; Grigor'ev E I, 2003, Radiats Biol Radioecol, V43, P358; GRUNDEMAR L, 1991, J PHARMACOL EXP THER, V258, P633; Gupta SK, 2001, IMMUNOL LETT, V78, P29, DOI 10.1016/S0165-2478(01)00228-0; Herzog H, 1997, GENOMICS, V41, P315, DOI 10.1006/geno.1997.4684; Husum H, 2002, NEUROPEPTIDES, V36, P363, DOI 10.1016/S0143-4179(02)00086-0; JIH Y, 2002, ANGIOGENESIS, V4, P313; Jinde S, 2002, NEUROSCIENCE, V115, P1035, DOI 10.1016/S0306-4522(02)00545-6; Kim J, 1998, REGUL PEPTIDES, V75-6, P201, DOI 10.1016/S0167-0115(98)00069-X; Kitlinska J, 2005, CANCER RES, V65, P1719, DOI 10.1158/0008-5472.CAN-04-2192; Kitlinska J, 2002, PEPTIDES, V23, P71, DOI 10.1016/S0196-9781(01)00581-2; Klagsbrun M, 1992, Semin Cancer Biol, V3, P81; Koulu M, 2004, ANN MED, V36, P232, DOI 10.1080/07853890410031236; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Lee EW, 2003, PEPTIDES, V24, P99, DOI 10.1016/S0196-9781(02)00281-4; Li LJ, 2003, ARTERIOSCL THROM VAS, V23, P1204, DOI 10.1161/01.ATV.0000071349.30914.25; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P477, DOI 10.1111/j.1748-1716.1982.tb07171.x; Mannon PJ, 1998, BIOCHEM BIOPH RES CO, V246, P91, DOI 10.1006/bbrc.1998.8577; MORL K, 2004, 7 INT NPY M COIMBR; Nakamura J, 2003, NUCLEIC ACIDS RES, V31, P1790, DOI 10.1093/nar/gkg263; NAN YS, 2003, AM J PHYSIOL, V286, pH1027; OH-ISHI T, 1981, Hokkaido Journal of Medical Science, V56, P421; PALMER JM, 1989, MOL CELL ENDOCRINOL, V63, P167, DOI 10.1016/0303-7207(89)90093-2; PATZ A, 1978, NEW ENGL J MED, V298, P1451, DOI 10.1056/NEJM197806292982605; Phillips JK, 1998, BRIT J PHARMACOL, V124, P1403, DOI 10.1038/sj.bjp.0701976; Pons J, 2003, CAN J PHYSIOL PHARM, V81, P177, DOI 10.1139/Y02-166; Price ML, 2001, J NEUROSCI, V21, P2833, DOI 10.1523/JNEUROSCI.21-08-02833.2001; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rosen Lee S, 2002, Cancer Control, V9, P36; SCHOBER DS, 2004, 7 INT NPY M COIMBR; SCHWEIGERER L, 1989, Z KARDIOL, V78, P12; Smialowska M, 1997, POL J PHARMACOL, V49, P357; Vezzani A, 2000, EPILEPSIA, V41, pS115, DOI 10.1111/j.1528-1157.2000.tb01569.x; Zukowska Z, 2003, TRENDS CARDIOVAS MED, V13, P86, DOI 10.1016/S1050-1738(02)00232-3; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187; ZUKOWSKAGROJEC Z, 1988, LIFE SCI, V42, P1615, DOI 10.1016/0024-3205(88)90440-7; ZUKOWSKAGROJEC Z, 1993, PEPTIDES, V14, P263, DOI 10.1016/0196-9781(93)90040-N	55	100	109	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1924	+		10.1096/fj.05-4770fje	http://dx.doi.org/10.1096/fj.05-4770fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16891622				2022-12-25	WOS:000240267000032
J	Wallez, Y; Cand, F; Cruzalegui, F; Wernstedt, C; Souchelnytskyi, S; Vilgrain, I; Huber, P				Wallez, Y.; Cand, F.; Cruzalegui, F.; Wernstedt, C.; Souchelnytskyi, S.; Vilgrain, I.; Huber, P.			Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site	ONCOGENE			English	Article						angiogenesis; adherens junctions; VE-cadherin; tyrosine kinases	FOCAL ADHESION KINASE; VE-CADHERIN; C-SRC; INDUCED ANGIOGENESIS; BETA-CATENIN; CELL; PROTEIN; BINDING; ASSOCIATION; FAMILY	Src-family tyrosine kinases are regulatory proteins that play a pivotal role in the disorganization of cadherin-dependent cell-cell contacts. We previously showed that Src was associated with vascular endothelial (VE)cadherin and that tyrosine phosphorylation level of VE-cadherin was dramatically increased in angiogenic tissues as compared to quiescent tissues. Here, we examined whether VE-cadherin was a direct substrate for Src in vascular endothelial growth factor ( VEGF)induced VE-cadherin phosphorylation, and we identified the target tyrosine sites. Co-transfections of Chinese hamster ovary cells (CHO) cells with VE-cadherin and constitutively active Src (Y530F) resulted in a robust tyrosine phosphorylation of VE-cadherin that was not detected with kinase-dead Src (K298M). In an in vitro Src assay, the VE-cadherin cytoplasmic domain is directly phosphorylated by purified Src as well as the tyrosine residue 685 (Tyr)685-containing peptide RPSLY(685)AQVQ. VE-cadherin peptide mapping from human umbilical vein endothelial cells stimulated by VEGF and VE-cadherin-CHO cells transfected with active Src revealed that Y685 was the unique phosphorylated site. The presence of Phospho Y685 was confirmed by its ability to bind to C-terminal Src kinase-SH2 domain in a pull-down assay. Finally, we found that in a VEGF-induced wound-healing assay, cadherin adhesive activity was impaired by Src kinase inhibitors. These data identify that VEGF-induced-VE- cadherin tyrosine phosphorylation is mediated by Src on Y685, a process that appears to be critical for VEGF-induced endothelial cell migration.	Univ Grenoble 1, ISERE, CEA Grenoble,INSERM,Dept Rech & Dynam Cellulaires, EMI 0219,Lab Dev & Viellissement Endothelium, F-38054 Grenoble 9, France; SERVIER, Inst Rech, Croissy, Croissy Sur Seine, France; Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Servier; Ludwig Institute for Cancer Research	Vilgrain, I (corresponding author), Univ Grenoble 1, ISERE, CEA Grenoble,INSERM,Dept Rech & Dynam Cellulaires, EMI 0219,Lab Dev & Viellissement Endothelium, 17 Rue Martyrs, F-38054 Grenoble 9, France.	ivilgrain@cea.fr	Wallez, Yann/H-1033-2013; Souchelnytskyi, Serhiy/J-9446-2014; Souchelnytskyi, Serhiy/G-6491-2011; Huber, Philippe/C-7971-2019	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Huber, Philippe/0000-0002-4153-7694; Wallez, Yann/0000-0001-9654-6187; VILGRAIN, Isabelle/0000-0002-5511-5871				Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Calcerrada MC, 2002, NEUROCHEM RES, V27, P313, DOI 10.1023/A:1014911329489; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Esser S, 1998, J CELL SCI, V111, P1853; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Hudry-Clergeon H, 2005, FASEB J, V19, P512, DOI 10.1096/fj.04-2202com; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; Lambeng N, 2005, CIRC RES, V96, P384, DOI 10.1161/01.RES.0000156652.99586.9f; Lampugnani MG, 1999, METH MOL B, V96, P177; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Lauder H, 1998, Angiogenesis, V2, P67, DOI 10.1023/A:1009006527462; Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029; Lindquist JA, 2003, IMMUNOL REV, V191, P165, DOI 10.1034/j.1600-065X.2003.00007.x; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200; Shasby DM, 2002, AM J PHYSIOL-LUNG C, V282, pL1330, DOI 10.1152/ajplung.00329.2001; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; Su WH, 2002, BLOOD, V100, P3597, DOI 10.1182/blood-2002-01-0303; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; van Oijen MGCT, 1998, J ORAL PATHOL MED, V27, P147; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Wallez Y, 2006, TRENDS CARDIOVAS MED, V16, P55, DOI 10.1016/j.tcm.2005.11.008; Zhao Y, 1998, J CELL PHYSIOL, V174, P370, DOI 10.1002/(SICI)1097-4652(199803)174:3<370::AID-JCP11>3.0.CO;2-D	42	152	157	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1067	1077		10.1038/sj.onc.1209855	http://dx.doi.org/10.1038/sj.onc.1209855			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909109				2022-12-25	WOS:000244245400013
J	Basso, M; Massignan, T; Samengo, G; Cheroni, C; De Biasi, S; Salmona, M; Bendotti, C; Bonetto, V				Basso, Manuela; Massignan, Tania; Samengo, Giuseppina; Cheroni, Cristina; De Biasi, Silvia; Salmona, Mario; Bendotti, Caterina; Bonetto, Valentina			Insoluble mutant SOD1 is partly oligoubiquitinated in amyotrophic lateral sclerosis mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEXES; ALS-LINKED SOD1; SUPEROXIDE-DISMUTASE; MOUSE MODEL; CU,ZN-SUPEROXIDE DISMUTASE; PROTEIN AGGREGATION; DISEASE PROGRESSION; TRANSGENIC MICE; ALPHA-SYNUCLEIN; SPINAL-CORD	Mutations in the Cu,Zn-superoxide dismutase (SOD1) gene cause a familial form of amyotrophic lateral sclerosis (ALS) through an unknown gain-of-function mechanism. Mutant SOD1 aggregation may be the toxic property. In fact, proteinaceous inclusions rich in mutant SOD1 have been found in tissues from the familial form of ALS patients and in mutant SOD1 animals, before disease onset. However, very little is known of the constituents and mechanism of formation of aggregates in ALS. We and others have shown that there is a progressive accumulation of detergent-insoluble mutant SOD1 in the spinal cord of G93A SOD1 mice. To investigate the mechanism of SOD1 aggregation, we characterized by proteome technologies SOD1 isoforms in a Triton X-100-insoluble fraction of spinal cord from G93A SOD1 mice at different stages of the disease. This showed that at symptomatic stages of the disease, part of the insoluble SOD1 is unambiguously mono-and oligoubiquitinated, in spinal cord and not in hippocampus, and that ubiquitin branches at Lys(48), the major signal for proteasome degradation. At presymptomatic stages of the disease, only insoluble unmodified SOD1 is recovered. Partial ubiquitination of SOD1-rich inclusions was also confirmed by immunohistochemical and electron microscopy analysis of lumbar spinal cord sections from symptomatic G93A SOD1 mice. On the basis of these results, we propose that ubiquitination occurs only after SOD1 aggregation and that oligoubiquitination may underline alternative mechanisms in disease pathogenesis.	Dulbecco Telethon Inst, I-20157 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Mol Biol & Pharmacol, I-20157 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Neurosci, I-20157 Milan, Italy; Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy	Fondazione Telethon; Dulbecco Telethon Institute (DTI); Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan	Bonetto, V (corresponding author), Dulbecco Telethon Inst, Via Eritrea 62, I-20157 Milan, Italy.	bonetto@marionegri.it	Cheroni, Cristina/AAO-2316-2020; Bonetto, Valentina/I-4694-2018; salmona, mario/ABI-4066-2020; Bonetto, Valentina/ABB-6383-2020; salmona, mario/AAA-7116-2020; Bendotti, Caterina/AAB-2273-2020; Basso, Manuela/AAA-9147-2020	Bonetto, Valentina/0000-0003-0456-2054; Bonetto, Valentina/0000-0003-0456-2054; salmona, mario/0000-0002-9098-9873; Bendotti, Caterina/0000-0003-1055-1271; Basso, Manuela/0000-0002-9278-8960; massignan, tania/0000-0002-6176-2696; Cheroni, Cristina/0000-0002-0832-2333	Telethon [GGP06063, TCP01010] Funding Source: Medline	Telethon(Fondazione Telethon)		Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bendotti C, 2004, J NEUROPATH EXP NEUR, V63, P113, DOI 10.1093/jnen/63.2.113; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Casoni F, 2005, J BIOL CHEM, V280, P16295, DOI 10.1074/jbc.M413111200; Cheroni C, 2005, NEUROBIOL DIS, V18, P509, DOI 10.1016/j.nbd.2004.12.007; Choi J, 2005, J BIOL CHEM, V280, P11648, DOI 10.1074/jbc.M414327200; Cooper HJ, 2004, ANAL CHEM, V76, P6982, DOI 10.1021/ac0401063; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Di Noto L, 2005, J BIOL CHEM, V280, P39907, DOI 10.1074/jbc.M506247200; Doskeland AP, 2006, AMINO ACIDS, V30, P99, DOI 10.1007/s00726-005-0227-4; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Gilchrist CA, 2005, NEUROPATH APPL NEURO, V31, P20, DOI 10.1111/j.1365-2990.2004.00604.x; Gray DA, 2001, NEUROPATH APPL NEURO, V27, P89, DOI 10.1046/j.1365-2990.2001.00321.x; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kabashi E, 2004, J NEUROCHEM, V89, P1325, DOI 10.1111/j.1471-4159.2004.02453.x; Khare SD, 2004, P NATL ACAD SCI USA, V101, P15094, DOI 10.1073/pnas.0406650101; Kikuchi H, 2006, P NATL ACAD SCI USA, V103, P6025, DOI 10.1073/pnas.0509227103; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; Lindberg MJ, 2004, P NATL ACAD SCI USA, V101, P15893, DOI 10.1073/pnas.0403979101; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Manfredi G, 2005, MITOCHONDRION, V5, P77, DOI 10.1016/j.mito.2005.01.002; MATSUI SI, 1982, P NATL ACAD SCI-BIOL, V79, P1535, DOI 10.1073/pnas.79.5.1535; Olsson I, 2002, PROTEOMICS, V2, P1630, DOI 10.1002/1615-9861(200211)2:11<1630::AID-PROT1630>3.0.CO;2-N; Ouyang YB, 2001, NEUROSCI LETT, V298, P159, DOI 10.1016/S0304-3940(00)01721-3; Pastorelli R, 2006, MOL CELL PROTEOMICS, V5, P882, DOI 10.1074/mcp.M500415-MCP200; Persson C, 2005, METHODS, V35, P37, DOI 10.1016/j.ymeth.2004.07.006; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Puttaparthi K, 2005, EXP NEUROL, V196, P441, DOI 10.1016/j.expneurol.2005.08.027; Puttaparthi K, 2003, J NEUROCHEM, V87, P851, DOI 10.1046/j.1471-4159.2003.02028.x; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sampathu DM, 2003, AM J PATHOL, V163, P91, DOI 10.1016/S0002-9440(10)63633-4; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Stieber A, 2000, J NEUROL SCI, V173, P53, DOI 10.1016/S0022-510X(99)00300-7; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200; Tortarolo M, 2003, MOL CELL NEUROSCI, V23, P180, DOI 10.1016/S1044-7431(03)00022-8; Tummala H, 2005, J BIOL CHEM, V280, P17725, DOI 10.1074/jbc.M501705200; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; WENISCH E, 1994, ELECTROPHORESIS, V15, P647, DOI 10.1002/elps.1150150191; Wood JD, 2003, NEUROPATH APPL NEURO, V29, P529, DOI 10.1046/j.0305-1846.2003.00518.x	49	78	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33325	33335		10.1074/jbc.M603489200	http://dx.doi.org/10.1074/jbc.M603489200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16943203	hybrid, Green Published			2022-12-25	WOS:000241621400042
J	Zaitseva, J; Lu, JP; Olechoski, KL; Lamb, AL				Zaitseva, Jelena; Lu, Jingping; Olechoski, Kelli L.; Lamb, Audrey L.			Two crystal structures of the isochorismate pyruvate lyase from Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALICYLATE BIOSYNTHESIS; MYCOBACTERIUM-TUBERCULOSIS; SIDEROPHORE BIOSYNTHESIS; CHORISMATE MUTASE; TRANSITION-STATE; ESCHERICHIA-COLI; SYNTHASE; PROGRAM; REARRANGEMENT; PURIFICATION	Enzymatic systems that exploit pericyclic reaction mechanisms are rare. A recent addition to this class is the enzyme PchB, an 11.4-kDa isochorismate pyruvate lyase from Pseudomonas aeruginosa. The apo and pyruvate-bound structures of PchB reveal that the enzyme is a structural homologue of chorismate mutases in the AroQ alpha class despite low sequence identity (20%). The enzyme is an intertwined dimer of three helices with connecting loops, and amino acids from each monomer participate in each of two active sites. The apo structure (2.35 angstrom resolution) has one dimer per asymmetric unit with nitrate bound in an open active site. The loop between the first and second helices is disordered, providing a gateway for substrate entry and product exit. The pyruvate-bound structure (1.95 angstrom resolution) has two dimers per asymmetric unit. One has two open active sites like the apo structure, and the other has two closed active sites with the loop between the first and second helices ordered for catalysis. Determining the structure of PchB is part of a larger effort to elucidate protein structures involved in siderophore biosynthesis, as these enzymes are crucial for bacterial iron uptake and virulence and have been identified as antimicrobial drug targets.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	University of Kansas	Lamb, AL (corresponding author), Univ Kansas, Dept Mol Biosci, 1200 Sunnyside Ave, Lawrence, KS 66045 USA.	lamb@ku.edu		Lamb, Audrey/0000-0002-2352-2130				ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COPLEY SD, 1985, J AM CHEM SOC, V107, P5306, DOI 10.1021/ja00304a064; Crosa JH, 2002, MICROBIOL MOL BIOL R, V66, P223, DOI 10.1128/MMBR.66.2.223-249.2002; DeClue MS, 2005, J AM CHEM SOC, V127, P15002, DOI 10.1021/ja055871t; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Ferreras JA, 2005, NAT CHEM BIOL, V1, P29, DOI 10.1038/nchembio706; Gaille C, 2003, J BIOL CHEM, V278, P16893, DOI 10.1074/jbc.M212324200; Gaille C, 2002, J BIOL CHEM, V277, P21768, DOI 10.1074/jbc.M202410200; Gallagher DT, 2001, PROTEINS, V44, P304, DOI 10.1002/prot.1095; Harrison AJ, 2005, ACTA CRYSTALLOGR F, V61, P121, DOI 10.1107/S1744309104031215; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Kerbarh O, 2006, J MOL BIOL, V357, P524, DOI 10.1016/j.jmb.2005.12.078; Kerbarh O, 2005, J BACTERIOL, V187, P5061, DOI 10.1128/JB.187.15.5061-5066.2005; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunzler D, 2005, J BIOL CHEM, V280, P32827, DOI 10.1074/jbc.M506883200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Nakai T, 2000, J BIOCHEM, V128, P29, DOI 10.1093/oxfordjournals.jbchem.a022727; Okvist M, 2006, J MOL BIOL, V357, P1483, DOI 10.1016/j.jmb.2006.01.069; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Payne RJ, 2005, ORG BIOMOL CHEM, V3, P1825, DOI 10.1039/b503800f; Quadri LEN, 1998, CHEM BIOL, V5, P631, DOI 10.1016/S1074-5521(98)90291-5; Raymond KN, 2003, P NATL ACAD SCI USA, V100, P3584, DOI 10.1073/pnas.0630018100; SERINO L, 1995, MOL GEN GENET, V249, P217, DOI 10.1007/BF00290369; Serino L, 1997, J BACTERIOL, V179, P248, DOI 10.1128/jb.179.1.248-257.1997; Spraggon G, 2001, P NATL ACAD SCI USA, V98, P6021, DOI 10.1073/pnas.111150298; SRIYOSACHATI S, 1986, INFECT IMMUN, V52, P885, DOI 10.1128/IAI.52.3.885-891.1986; Strajbl M, 2003, J AM CHEM SOC, V125, P10228, DOI 10.1021/ja0356481; Visca P, 2002, MOL MICROBIOL, V45, P1177, DOI 10.1046/j.1365-2958.2002.03088.x; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Zhang XD, 2005, BIOCHEMISTRY-US, V44, P10443, DOI 10.1021/bi050886p	38	30	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33441	33449		10.1074/jbc.M605470200	http://dx.doi.org/10.1074/jbc.M605470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16914555	hybrid			2022-12-25	WOS:000241621400054
J	Adams, DJ; Head, GA; Markus, MA; Lovicu, FJ; van der Weyden, L; Kontgen, F; Arends, MJ; Thiru, S; Mayorov, DN; Morris, BJ				Adams, David J.; Head, Geoffrey A.; Markus, M. Andrea; Lovicu, Frank J.; van der Weyden, Louise; Koentgen, Frank; Arends, Mark J.; Thiru, Sathia; Mayorov, Dmitry N.; Morris, Brian J.			Renin enhancer is critical for control of renin gene expression and cardiovascular function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSINOGEN-DEFICIENT MICE; BLOOD-PRESSURE; JUXTAGLOMERULAR CELLS; AUTONOMIC CONTROL; TRANSGENIC MICE; MACULA DENSA; MOUSE; RECEPTOR; PROMOTER; ELEMENTS	The important cardiovascular regulator renin contains a strong in vitro enhancer 2.7 kb upstream of its gene. Here we tested the in vivo role of the mouse Ren-1(c) enhancer. In reninexpressing As4.1 cells stably transfected with Ren-1c promoter with or without enhancer, expression of linked beta-geo reporter, stable expression, and colony formation were dependent on the presence of the enhancer. We then generated mice carrying a targeted deletion of the enhancer (REKO mice) and found marked depletion of renin in renal juxtaglomerular and submandibular ductal cells, as well as hyperplasia of macula densa cells. Plasma creatinine was increased, but electrolytes were normal. Male REKO mice implanted with telemetry devices had 9 +/- 1 mm Hg lower mean arterial pressure (p < 0.001), which was partly normalized by a high NaCl diet. Locomotor activity was lower, and baroreflex sensitivity was normal. Markedly reduced mean arterial pressure variability in the midfrequency band indicated a contribution of reduced sympathetic vasomotor tone to the hypotension. In conclusion, the renin enhancer is critical for renin gene expression and physiological sequelae, including response to alteration in salt intake. The REKO mouse may be useful as a low renin expression model.	Univ Sydney, Sch Med Sci, Basic & Clin Genom Lab, Sydney, NSW 2006, Australia; Bosch Inst, Sydney, NSW 2006, Australia; Baker Heart Res Inst, Melbourne, Vic 8008, Australia; Ozgene Pty Ltd, Bentley, WA 6102, Australia; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Sydney; Baker Heart and Diabetes Institute; University of Cambridge	Morris, BJ (corresponding author), Univ Sydney, Sch Med Sci, Basic & Clin Genom Lab, Bldg F13, Sydney, NSW 2006, Australia.	brianm@medsci.usyd.edu.au	van der Weyden, Louise/AAV-5711-2021; Head, Geoffrey A./B-2177-2010	van der Weyden, Louise/0000-0002-0645-1879; Head, Geoffrey A./0000-0002-7623-137X; Adams, David/0000-0001-9490-0306; Markus, Andrea/0000-0003-2305-3394				BERTINIERI G, 1988, AM J PHYSIOL, V254, pH377, DOI 10.1152/ajpheart.1988.254.2.H377; BUHRLE CP, 1986, LAB INVEST, V54, P462; Butz GM, 2001, PHYSIOL GENOMICS, V5, P89, DOI 10.1152/physiolgenomics.2001.5.2.89; Chen YF, 2005, AM J PHYSIOL-REG I, V288, pR1071, DOI 10.1152/ajpregu.00231.2004; Clark AF, 1997, J BIOL CHEM, V272, P18185, DOI 10.1074/jbc.272.29.18185; DELLABRUNA R, 1995, KIDNEY INT, V47, P1266, DOI 10.1038/ki.1995.181; Esther CR, 1997, J CLIN INVEST, V99, P2375, DOI 10.1172/JCI119419; Feng YQ, 2005, MOL CELL BIOL, V25, P3864, DOI 10.1128/MCB.25.10.3864-3874.2005; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; GOMEZ RA, 1990, AM J PHYSIOL, V259, pF660, DOI 10.1152/ajprenal.1990.259.4.F660; GOMEZ RA, 1989, AM J PHYSIOL, V257, pF850, DOI 10.1152/ajprenal.1989.257.5.F850; Gross V, 2000, J HYPERTENS, V18, P955, DOI 10.1097/00004872-200018070-00018; Gross V, 2002, HYPERTENSION, V40, P207, DOI 10.1161/01.HYP.0000027279.69240.75; Head GA, 2004, ENDOCRINOLOGY, V145, P4286, DOI 10.1210/en.2004-0421; Head GA, 2001, IEEE ENG MED BIOL, V20, P43, DOI 10.1109/51.917723; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Holmer SR, 1997, J HYPERTENS, V15, P1471, DOI 10.1097/00004872-199715120-00015; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; Janssen BJA, 2002, AM J PHYSIOL-REG I, V282, pR1545, DOI 10.1152/ajpregu.00714.2001; Jenkins TA, 1997, CLIN EXP HYPERTENS, V19, P645, DOI 10.3109/10641969709083176; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; Kim HS, 1999, J BIOL CHEM, V274, P14210, DOI 10.1074/jbc.274.20.14210; KON Y, 1992, ANAT RECORD, V232, P393, DOI 10.1002/ar.1092320309; KONTGEN F, 1993, METHOD ENZYMOL, V225, P878; KORNER PI, 1987, BRAIN RES, V435, P258, DOI 10.1016/0006-8993(87)91609-X; Massiera F, 2001, ENDOCRINOLOGY, V142, P5220, DOI 10.1210/en.142.12.5220; Merrill DC, 1996, J CLIN INVEST, V97, P1047, DOI 10.1172/JCI118497; MORRIS BJ, 2000, HDB PHYSL 7, V3, P3; Mullins LJ, 2000, J BIOL CHEM, V275, P40378, DOI 10.1074/jbc.M007315200; Navakatikyan MA, 2002, IEEE T BIO-MED ENG, V49, P662, DOI 10.1109/TBME.2002.1010849; Niimura F, 1995, J CLIN INVEST, V96, P2947, DOI 10.1172/JCI118366; NORWOOD VF, 1994, KIDNEY INT, V45, P1333, DOI 10.1038/ki.1994.174; Okuyama S, 1999, NEUROSCI LETT, V261, P167, DOI 10.1016/S0304-3940(99)00002-6; Pan L, 2005, HYPERTENSION, V45, P3, DOI 10.1161/01.HYP.0000149717.55920.45; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; Raghavendra V, 1998, NEUROPEPTIDES, V32, P275, DOI 10.1016/S0143-4179(98)90048-8; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Shi Q, 1999, CIRC RES, V85, P479, DOI 10.1161/01.RES.85.6.479; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; SKOTT O, 1987, SCIENCE, V237, P1618, DOI 10.1126/science.3306925; Sun ZJ, 2003, HYPERTENSION, V41, P322, DOI 10.1161/01.HYP.0000050964.96018.FA; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; van der Weyden L, 2000, HYPERTENSION, V36, P1093, DOI 10.1161/01.HYP.36.6.1093; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; West AG, 2005, HUM MOL GENET, V14, pR101, DOI 10.1093/hmg/ddi104; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yan Y, 1997, CIRC RES, V81, P558, DOI 10.1161/01.RES.81.4.558; Yanai K, 2000, J BIOL CHEM, V275, P5, DOI 10.1074/jbc.275.1.5; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	51	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31753	31761		10.1074/jbc.M605720200	http://dx.doi.org/10.1074/jbc.M605720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16895910	Bronze			2022-12-25	WOS:000241235300062
J	Glerup, S; Kloverpris, S; Oxvig, C				Glerup, Simon; Kloverpris, Soren; Oxvig, Claus			The proform of the eosinophil major basic protein binds the cell surface through a site distinct from its C-type lectin ligand-binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTAMINE-RELEASE; GROWTH-FACTOR; HEPARAN-SULFATE; PRECURSOR; INHIBITION; ACTIVATION; GENERATION; BASOPHIL; PROMBP; SERUM	The highly basic eosinophil major basic protein (MBP), present in the crystalloid core of eosinophil leukocyte granules, has both cytotoxic and cytostimulatory properties and is directly implicated in a number of diseases. The crystal structure of MBP resembles that of the C-type lectin (CTL) superfamily, and recent data showed that MBP binds heparan sulfate glycosaminoglycan (GAG), with the CTL ligand-binding region as the binding site. MBP is synthesized as a proform (pro-MBP) containing an acidic propiece believed to neutralize the basic MBP domain. Using flow cytometry and site-directed mutagenesis, we demonstrate here that the MBP domain of pro-MBP binds to heparan sulfate GAG on the cell surface and that this is independent of GAG covalently bound to pro-MBP. Eight basic residues located in the CTL ligand-binding region of MBP were hypothesized previously to mediate GAG binding, but we found that surface binding was not compromised by the substitution of these residues with alanine. However, the analysis of a series of mutants with surface-exposed residues substituted with alanine showed that Ser-166, Arg-168, and Arg-171 are involved in surface binding. A binding site formed by these residues is located in the MBP domain between loop 1 and beta-strand 5, outside the CTL ligand-binding region. The binding of a cell-surface heparan sulfate proteoglycan may be important in MBP action, and our findings suggest that two regions shown previously to contain the cytotoxic and cytostimulatory properties of MBP are accessible for ligand interaction in cell surface-bound MBP.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Aarhus University	Oxvig, C (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	co@mb.au.dk		Oxvig, Claus/0000-0002-4715-9719				ABUGHAZALEH RI, 1992, J MEMBRANE BIOL, V128, P153; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BONNO M, 1994, LAB INVEST, V71, P560; Christiansen M, 2000, CLIN CHEM, V46, P1099; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FOXALL C, 1995, ANAL BIOCHEM, V231, P366, DOI 10.1006/abio.1995.0065; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Glerup S, 2005, J BIOL CHEM, V280, P9823, DOI 10.1074/jbc.M413228200; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; Laursen LS, 2002, J BIOL CHEM, V277, P47225, DOI 10.1074/jbc.M209155200; MOY JN, 1990, J IMMUNOL, V145, P2626; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; Overgaard MT, 2004, FEBS LETT, V560, P147, DOI 10.1016/S0014-5793(04)00095-X; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; OXVIG C, 1993, J BIOL CHEM, V268, P12243; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Piliponsky AM, 2001, J ALLERGY CLIN IMMUN, V107, P993, DOI 10.1067/mai.2001.114656; Popken-Harris P, 1998, BLOOD, V92, P623, DOI 10.1182/blood.V92.2.623.414k32_623_631; POPKENHARRIS P, 1994, J ALLERGY CLIN IMMUN, V94, P1282, DOI 10.1016/0091-6749(94)90343-3; POPKENHARRIS P, 1995, J IMMUNOL, V155, P1472; Rochester CL, 1996, J IMMUNOL, V156, P4449; Swaminathan GJ, 2005, BIOCHEMISTRY-US, V44, P14152, DOI 10.1021/bi051112b; Swaminathan GJ, 2001, J BIOL CHEM, V276, P26197, DOI 10.1074/jbc.M100848200; Temkin V, 2004, J ALLERGY CLIN IMMUN, V113, P703, DOI 10.1016/j.jaci.2003.11.038; Thomas LL, 2001, IMMUNOL LETT, V78, P175, DOI 10.1016/S0165-2478(01)00249-8; THOMAS LL, 1989, IMMUNOLOGY, V66, P611; WEILER JM, 1988, J IMMUNOL, V140, P1605; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	34	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31509	31516		10.1074/jbc.M605824200	http://dx.doi.org/10.1074/jbc.M605824200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16940047				2022-12-25	WOS:000241235300036
J	Merz, F; Hoffmann, A; Rutkowska, A; Zachmann-Brand, B; Bukau, B; Deuerling, E				Merz, Frieder; Hoffmann, Anja; Rutkowska, Anna; Zachmann-Brand, Beate; Bukau, Bernd; Deuerling, Elke			The C-terminal domain of Escherichia coli trigger factor represents the central module of its chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS/TRANS ISOMERASE ACTIVITY; NEWLY SYNTHESIZED PROTEINS; NASCENT POLYPEPTIDES; PROLYL ISOMERASE; FUNCTIONAL DISSECTION; ENZYMATIC CATALYSIS; IN-VIVO; DNAK; RIBOSOME; BINDING	In bacteria, ribosome-bound Trigger Factor assists the folding of newly synthesized proteins. The N-terminal domain (N) of Trigger Factor mediates ribosome binding, whereas the middle domain (P) harbors peptidyl-prolyl isomerase activity. The function of the C-terminal domain (C) has remained enigmatic due to structural instability in isolation. Here, we have characterized a stabilized version of the C domain (C-S), designed on the basis of the recently solved atomic structure of Trigger Factor. Strikingly, only the isolated C-S domain or domain combinations thereof (NCS, PCS) revealed substantial chaperone activity in vitro and in vivo. Furthermore, to disrupt the C domain without affecting the overall Trigger Factor structure, we generated a mutant (Delta 53) by deletion of the C-terminal 53 amino acid residues. This truncation caused the complete loss of the chaperone activity of Trigger Factor in vitro and severely impaired its function in vivo. Therefore, we conclude that the chaperone activity of Trigger Factor critically depends on its C-terminal domain as the central structural chaperone module. Intriguingly, a structurally similar module is found in the periplasmic chaperone SurA and in MPN555, a protein of unknown function. We speculate that this conserved module can exist solely or in combination with additional domains to fulfill diverse chaperone functions in the cell.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Deuerling, E (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	e.deuerling@zmbh.uni-heidelberg.de		Bukau, Bernd/0000-0003-0521-7199				Behrens S, 2001, EMBO J, V20, P285, DOI 10.1093/emboj/20.1.285; Bitto E, 2002, STRUCTURE, V10, P1489, DOI 10.1016/S0969-2126(02)00877-8; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1996, FEBS LETT, V385, P67, DOI 10.1016/0014-5793(96)00351-1; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Hoffmann A, 2006, J BIOL CHEM, V281, P6539, DOI 10.1074/jbc.M512345200; Huang GC, 2000, PROTEIN SCI, V9, P1254, DOI 10.1110/ps.9.6.1254; Kramer G, 2004, J BACTERIOL, V186, P3777, DOI 10.1128/JB.186.12.3777-3784.2004; Kramer G, 2004, J BIOL CHEM, V279, P14165, DOI 10.1074/jbc.M313635200; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; Liu CP, 2005, J BIOL CHEM, V280, P13315, DOI 10.1074/jbc.M414151200; Liu CP, 2004, BIOCHEM BIOPH RES CO, V313, P509, DOI 10.1016/j.bbrc.2003.11.142; Ludlam AV, 2004, P NATL ACAD SCI USA, V101, P13436, DOI 10.1073/pnas.0405868101; MUCKE M, 1992, BIOCHEMISTRY-US, V31, P7848; Patzelt H, 2002, BIOL CHEM, V383, P1611, DOI 10.1515/BC.2002.182; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Schaffitzel E, 2001, BIOL CHEM, V382, P1235, DOI 10.1515/BC.2001.154; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; Schulze-Gahmen U, 2005, ACTA CRYSTALLOGR D, V61, P1343, DOI [10.1107/S090744490502264X, 10.1107/S09074490502264X]; Stoller G, 1996, FEBS LETT, V384, P117, DOI 10.1016/0014-5793(96)00282-7; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Tomic S, 2006, FEBS LETT, V580, P72, DOI 10.1016/j.febslet.2005.11.050; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Vorderwulbecke S, 2004, FEBS LETT, V559, P181, DOI 10.1016/S0014-5793(04)00052-3; Wegrzyn RD, 2005, CELL MOL LIFE SCI, V62, P2727, DOI 10.1007/s00018-005-5292-z; Zarnt T, 1997, J MOL BIOL, V271, P827, DOI 10.1006/jmbi.1997.1206; ZENG LL, 2005, BIOCHIMIE PARIS	37	73	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31963	31971		10.1074/jbc.M605164200	http://dx.doi.org/10.1074/jbc.M605164200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16926148				2022-12-25	WOS:000241235300082
J	Panasyuk, G; Nemazanyy, I; Zhyvoloup, A; Bretner, M; Litchfield, DW; Filonenko, V; Gout, IT				Panasyuk, Ganna; Nemazanyy, Ivan; Zhyvoloup, Alexander; Bretner, Maria; Litchfield, David W.; Filonenko, Valeriy; Gout, Ivan T.			Nuclear export of S6K1II is regulated by protein kinase CK2 phosphorylation at Ser-17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; INSULIN-RECEPTOR SUBSTRATE-1; CASEIN KINASE-2; LOCALIZATION; SUBUNITS; ACTIVATION; TRANSFORMATION; INHIBITOR; RAPAMYCIN; P70(S6K)	Ribosomal S6 kinases (S6Ks) are principal players in the regulation of cell growth and energy metabolism. Signaling via phosphatidylinositol 3- kinase and mammalian target of rapamycin pathways mediates the activation of S6K in response to various mitogenic stimuli. The family of S6Ks consists of two forms, S6K1 and -2, that have cytoplasmic and nuclear splicing variants, S6K1 II and S6K1 I, respectively. Nuclear-cytoplasmic shuttling of both isoforms induced by mitogenic stimuli has been reported recently. Here we present the identification of protein kinase CK2 (CK2) as a novel binding and regulatory partner for S6K1 II. The interaction between S6K1 II and CK2 beta regulatory subunit was initially identified in a yeast two-hybrid screen and further confirmed by co-immunoprecipitation of transiently expressed and endogenous proteins. The interaction between S6K1 II and CK2 was found to occur in serum-starved and serum-stimulated cells. In addition, we found that S6K1 II is a substrate for CK2. The localization of the CK2 phosphorylation site was narrowed down to Ser-17 in S6K1 II. Mutational analysis and the use of phosphospecific antibody indicate that Ser-17 is a major in vitro and in vivo phosphorylation site for CK2. Functional studies reveal that, in contrast to the wild type kinase, the phosphorylation-mimicking mutant of S6K1 II (S17E) retains its cytoplasmic localization in serum-stimulated cells. Treatment of cells with the nuclear export inhibitor leptomycin B revealed that the S17E mutant accumulates in the nucleus to the same extent as S6K1 II wild type. These results indicate that nuclear import of the S17E mutant is not affected, although the export is significantly enhanced. We also provide evidence that nuclear export of S6K1 is mediated by a CRM1-dependent mechanism. Taken together, this study establishes a functional link between S6K1 II and CK2 signaling, which involves the regulation of S6K1 II nuclear export by CK2-mediated phosphorylation of Ser-17.	UCL, Sch Med, Dept Biochem & Mol Biol, London WC1E 6BT, England; Natl Acad Sci Ukraine, Inst Mol Biol & Genet, UA-03143 Kiev, Ukraine; Ludwig Inst Canc Res, London W1W 7BS, England; Univ Western Ontario, Schulich Sch Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada; Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	University of London; University College London; UCL Medical School; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; Ludwig Institute for Cancer Research; Western University (University of Western Ontario); Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Gout, IT (corresponding author), UCL, Sch Med, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	i.gout@ucl.ac.uk	Panasyuk, Ganna/A-4133-2018; Filonenko, Valeriy V/D-5447-2015; Panasyuk, Ganna/AAF-4350-2021; Litchfield, David/E-4636-2015	Panasyuk, Ganna/0000-0002-5591-848X; Filonenko, Valeriy V/0000-0003-1839-3335; Panasyuk, Ganna/0000-0002-5591-848X; Litchfield, David/0000-0002-2425-6620; Bretner, Maria/0000-0002-9643-0843				ANDRES JL, 1987, J BIOL CHEM, V262, P14389; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Canton DA, 2001, BIOCHEM J, V358, P87, DOI 10.1042/0264-6021:3580087; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Faust M, 2002, CELL MOL LIFE SCI, V59, P2155, DOI 10.1007/s000180200022; Faust M, 2001, MOL CELL BIOCHEM, V227, P73, DOI 10.1023/A:1013129410551; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Litchfield DW, 2001, MOL CELL BIOCHEM, V227, P21, DOI 10.1023/A:1013188101465; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Marin O, 1999, J BIOL CHEM, V274, P29260, DOI 10.1074/jbc.274.41.29260; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Miyata Y, 2004, MOL CELL BIOL, V24, P4065, DOI 10.1128/MCB.24.9.4065-4074.2004; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Panasyuk G, 2004, BIOTECHNIQUES, V36, P40, DOI 10.2144/04361BM03; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Sarno S, 2005, MOL CELL BIOCHEM, V274, P69, DOI 10.1007/s11010-005-3079-z; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shi XY, 2001, J BIOL CHEM, V276, P2075, DOI 10.1074/jbc.M008583200; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Val'ovka T I, 2000, Ukr Biokhim Zh (1999), V72, P31; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; Valovka T, 2003, MOL CELL BIOL, V23, P852, DOI 10.1128/MCB.23.3.852-863.2003; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Wilson LK, 1997, J BIOL CHEM, V272, P12961, DOI 10.1074/jbc.272.20.12961; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200; Zien P, 2003, BIOCHEM BIOPH RES CO, V306, P129, DOI 10.1016/S0006-291X(03)00928-8	42	32	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31188	31201		10.1074/jbc.M602618200	http://dx.doi.org/10.1074/jbc.M602618200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16895915	Bronze			2022-12-25	WOS:000241235300004
J	Shao, CH; Zhang, FM; Kemp, MM; Linhardt, RJ; Waisman, DM; Head, JF; Seaton, BA				Shao, Chenghua; Zhang, Fuming; Kemp, Melissa M.; Linhardt, Robert J.; Waisman, David M.; Head, James F.; Seaton, Barbara A.			Crystallographic analysis of calcium-dependent heparin binding to annexin A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; II TETRAMER; PROTEIN; SULFATE; CONFORMATION; MECHANISM; DYNAMICS; NMR	Annexin A2 and heparin bind to one another with high affinity and in a calcium-dependent manner, an interaction that may play a role in mediating fibrinolysis. In this study, three heparin-derived oligosaccharides of different lengths were co-crystallized with annexin A2 to elucidate the structural basis of the interaction. Crystal structures were obtained at high resolution for uncomplexed annexin A2 and three complexes of heparin oligosaccharides bound to annexin A2. The common heparin-binding site is situated at the convex face of domain IV of annexin A2. At this site, annexin A2 binds up to five sugar residues from the nonreducing end of the oligosaccharide. Unlike most heparin-binding consensus patterns, heparin binding at this site does not rely on arrays of basic residues; instead, main-chain and side-chain nitrogen atoms and two calcium ions play important roles in the binding. Especially significant is a novel calcium-binding site that forms upon heparin binding. Two sugar residues of the heparin derivatives provide oxygen ligands for this calcium ion. Comparison of all four structures shows that heparin binding does not elicit a significant conformational change in annexin A2. Finally, surface plasmon resonance measurements were made for binding interactions between annexin A2 and heparin polysaccharide in solution at pH 7.4 or 5.0. The combined data provide a clear basis for the calcium dependence of heparin binding to annexin A2.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Rensselaer Polytech Inst, Dept Chem & Biol Chem, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Biol & Chem Engn, Troy, NY 12180 USA; Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 1X5, Canada	Boston University; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; Dalhousie University	Seaton, BA (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 715 Albany St, Boston, MA 02118 USA.	seatonba@bu.edu		Waisman, David/0000-0002-5097-9662; Head, James/0000-0002-6226-4146; Seaton, Barbara/0000-0003-4654-7709	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622, R01HL062244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044554, R01GM038060, R29GM044554] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL062244, HL62244, R01 HL062244-06, R01 HL052622-09, R01 HL062244-05A1, R01 HL052622] Funding Source: Medline; NIGMS NIH HHS [R01 GM038060-18, R01 GM038060, GM44554, R01 GM038060-17, R01 GM038060-16A2, GM3806] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell J, 2003, BLOOD COAGUL FIBRIN, V14, P229, DOI 10.1097/01.mbc.0000061292.28953.c5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; Capila I, 2001, STRUCTURE, V9, P57, DOI 10.1016/S0969-2126(00)00549-9; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; DELANO WL, 2002, PHYMOL MOL GRAPHICS; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Hajjar KA, 2000, ANN NY ACAD SCI, V902, P265; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Hernaiz M, 2000, BIOCHEM BIOPH RES CO, V276, P292, DOI 10.1006/bbrc.2000.3453; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liang JF, 2000, THROMB RES, V97, P349, DOI 10.1016/S0049-3848(99)00188-7; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rosengarth A., 2004, ANNEXINS, V1, P129; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592	23	80	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31689	31695		10.1074/jbc.M604502200	http://dx.doi.org/10.1074/jbc.M604502200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16882661	Green Accepted			2022-12-25	WOS:000241235300054
J	Flaugh, SL; Mills, IA; King, J				Flaugh, Shannon L.; Mills, Ishara A.; King, Jonathan			Glutamine deamidation destabilizes human gamma D-crystallin and lowers the kinetic barrier to unfolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; HUMAN SENILE CATARACTOGENESIS; HELICAL COILED-COILS; ALPHA-B-CRYSTALLIN; X-RAY-ANALYSIS; EYE LENS; GUANIDINE-HYDROCHLORIDE; ELECTROSTATIC INTERACTIONS; ASPARAGINE DEAMIDATION; MOLECULAR CHAPERONE	Human eye lens transparency requires life long stability and solubility of the crystallin proteins. Aged crystallins have high levels of covalent damage, including glutamine deamidation. Human gamma D-crystallin (H gamma D-Crys) is a two-domain beta-sheet protein of the lens nucleus. The two domains interact through interdomain side chain contacts, including Gln-54 and Gln-143, which are critical for stability and folding of the N-terminal domain of H gamma D-Crys. To test the effects of interface deamidation on stability and folding, single and double glutamine to glutamate substitutions were constructed. Equilibrium unfolding/refolding experiments of the proteins were performed in guanidine hydrochloride at pH 7.0, 37 degrees C, or urea at pH 3.0, 20 degrees C. Compared with wild type, the deamidation mutants were destabilized at pH 7.0. The proteins populated a partially unfolded intermediate that likely had a structured C-terminal domain and unstructured N-terminal domain. However, at pH 3.0, equilibrium unfolding transitions of wild type and the deamidation mutants were indistinguishable. In contrast, the double alanine mutant Q54A/Q143A was destabilized at both pH 7.0 and 3.0. Thermal stabilities of the deamidation mutants were also reduced at pH 7.0. Similarly, the deamidation mutants lowered the kinetic barrier to unfolding of the N-terminal domain. These data indicate that interface deamidation decreases the thermodynamic stability of H gamma D-Crys and lowers the kinetic barrier to unfolding due to introduction of a negative charge into the domain interface. Such effects may be significant for cataract formation by inducing protein aggregation or insolubility.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	King, J (corresponding author), MIT, Dept Biol, 31 Ames St,Rm 68-330, Cambridge, MA 02139 USA.	jaking@mit.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017980, R01GM017980] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17980] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Bagby S, 1998, J MOL BIOL, V276, P669, DOI 10.1006/jmbi.1997.1563; Basak A, 2003, J MOL BIOL, V328, P1137, DOI 10.1016/S0022-2836(03)00375-9; Bateman OA, 2003, EXP EYE RES, V77, P409, DOI 10.1016/S0014-4835(03)00173-8; BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; Bilsel O, 1999, BIOCHEMISTRY-US, V38, P1018, DOI 10.1021/bi982365q; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BOYLE D, 1994, EXP EYE RES, V58, P9, DOI 10.1006/exer.1994.1190; CARRELL RW, 1994, AM J RESP CRIT CARE, V150, pS171, DOI 10.1164/ajrccm/150.6_Pt_2.S171; CLARK AC, 1993, J BIOL CHEM, V268, P10773; Das BK, 1998, INT J BIOL MACROMOL, V23, P191, DOI 10.1016/S0141-8130(98)00048-8; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; Evans P, 2004, J MOL BIOL, V343, P435, DOI 10.1016/j.jmb.2004.08.050; FERNALD RD, 1983, NATURE, V301, P618, DOI 10.1038/301618a0; Fitch CA, 2002, BIOPHYS J, V82, P3289, DOI 10.1016/S0006-3495(02)75670-1; Flaugh SL, 2005, PROTEIN SCI, V14, P2030, DOI 10.1110/ps.051460505; Flaugh SL, 2005, PROTEIN SCI, V14, P571, DOI 10.1110/ps.041111405; Forsyth WR, 2002, PROTEINS, V48, P388, DOI 10.1002/prot.10174; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Fu L, 2002, FEBS LETT, V513, P213, DOI 10.1016/S0014-5793(02)02313-X; GEIGER T, 1987, J BIOL CHEM, V262, P785; GREENE RF, 1974, J BIOL CHEM, V249, P5388; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Gupta R, 2004, J BIOL CHEM, V279, P44258, DOI 10.1074/jbc.M405648200; Gupta R, 2004, INVEST OPHTH VIS SCI, V45, P206, DOI 10.1167/iovs.03-0720; HAGIHARA Y, 1994, J MOL BIOL, V237, P336, DOI 10.1006/jmbi.1994.1234; Hanson SRA, 1998, EXP EYE RES, V67, P301, DOI 10.1006/exer.1998.0530; Hanson SRA, 2000, EXP EYE RES, V71, P195, DOI 10.1006/exer.2000.0868; Harms MJ, 2004, PROTEIN SCI, V13, P678, DOI 10.1110/ps.03427504; HOPE JN, 1994, J BIOL CHEM, V269, P21141; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Jiang X, 2001, BIOCHEMISTRY-US, V40, P11442, DOI 10.1021/bi011194d; Kim YH, 2002, BIOCHEMISTRY-US, V41, P14076, DOI 10.1021/bi026288h; Kmoch S, 2000, HUM MOL GENET, V9, P1779, DOI 10.1093/hmg/9.12.1779; KODAMA T, 1995, BBA-GEN SUBJECTS, V1245, P269, DOI 10.1016/0304-4165(95)00092-P; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; Kosinski-Collins MS, 2004, PROTEIN SCI, V13, P2223, DOI 10.1110/ps.04627004; Kosinski-Collins MS, 2003, PROTEIN SCI, V12, P480, DOI 10.1110/ps.0225503; Lampi KJ, 1998, EXP EYE RES, V67, P31, DOI 10.1006/exer.1998.0481; Lampi KJ, 2006, BIOCHEMISTRY-US, V45, P3146, DOI 10.1021/bi052051k; Lampi KJ, 1997, J BIOL CHEM, V272, P2268; Lampi KJ, 2002, MOL VIS, V8, P359; Lampi KJ, 2001, EXP EYE RES, V72, P279, DOI 10.1006/exer.2000.0950; Lapko VN, 2002, BIOCHEMISTRY-US, V41, P8638, DOI 10.1021/bi015924t; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; Macdonald JT, 2005, PROTEIN SCI, V14, P1282, DOI 10.1110/ps.041227805; MAYR EM, 1994, J MOL BIOL, V235, P84, DOI 10.1016/S0022-2836(05)80017-8; MCFADDEN PN, 1983, BIOCHEM BIOPH RES CO, V113, P418, DOI 10.1016/0006-291X(83)91742-4; MCFADDEN PN, 1986, MECH AGEING DEV, V34, P91, DOI 10.1016/0047-6374(86)90107-7; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MONERA OD, 1994, PROTEIN SCI, V3, P1984, DOI 10.1002/pro.5560031110; *NAT COMM CLIN LAB, 2002, PERF STAND ANT SUSC, P22; Nguyen DM, 2004, J MOL BIOL, V341, P565, DOI 10.1016/j.jmb.2004.05.066; Nilsson MR, 2003, PROTEIN SCI, V12, P2637, DOI 10.1110/ps.0360403; Nilsson MR, 2002, PROTEIN SCI, V11, P342, DOI 10.1110/ps.48702; Palme S, 1997, PROTEIN SCI, V6, P1529; Pande A, 2000, P NATL ACAD SCI USA, V97, P1993, DOI 10.1073/pnas.040554397; Pande A, 2001, P NATL ACAD SCI USA, V98, P6116, DOI 10.1073/pnas.101124798; Searle BC, 2005, J PROTEOME RES, V4, P546, DOI 10.1021/pr049781j; SEN AC, 1992, J BIOL CHEM, V267, P11898; SLINGSBY C, 1990, BIOCHEMISTRY-US, V29, P6592, DOI 10.1021/bi00480a007; Takemoto L, 2000, MOL VIS, V6, P164; Takemoto L, 2001, EXP EYE RES, V72, P559, DOI 10.1006/exer.2001.0983; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0; Zhang ZL, 2003, EXP EYE RES, V77, P259, DOI 10.1016/S0014-4835(03)00159-3	70	89	90	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30782	30793		10.1074/jbc.M603882200	http://dx.doi.org/10.1074/jbc.M603882200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16891314	hybrid			2022-12-25	WOS:000241075900054
J	Pey, AL; Martinez, A; Charubala, R; Maitland, DJ; Teigen, K; Calvo, A; Pfleiderer, W; Wood, JM; Schallreuter, KU				Pey, Angel L.; Martinez, Aurora; Charubala, Ramamurthy; Maitland, Derek J.; Teigen, Knut; Calvo, Ana; Pfleiderer, Wolfgang; Wood, John M.; Schallreuter, Karin U.			Specific interaction of the diastereomers 7(R)- and 7(S)-tetrahydrobiopterin with phenylalanine hydroxylase: implications for understanding primapterinuria and vitiligo	FASEB JOURNAL			English	Article						pterin 4a-carbinolamine dehydratase; NMR; isothermal titration calorimetry	PTERIN-4A-CARBINOLAMINE DEHYDRATASE DEFICIENCY; AMINO-ACID HYDROXYLASES; 7-SUBSTITUTED PTERINS; TYROSINE-HYDROXYLASE; PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; ACTIVE-SITE; TETRAHYDROBIOPTERIN; COFACTOR	Pterin-4a-carbinolamine dehydratase (PCD) is an essential component of the phenylalanine hydroxylase (PAH) system, catalyzing the regeneration of the essential cofactor 6(R)-L-erythro-5,6,7,8-tetrahydrobiopterin [6(R)BH4]. Mutations in PCD or its deactivation by hydrogen peroxide result in the generation of 7( R, S) BH4, which is a potent inhibitor of PAH that has been implicated in primapterinuria, a variant form of phenylketonuria, and in the skin depigmentation disorder vitiligo. We have synthesized and separated the 7( R) and 7( S) diastereomers confirming their structure by NMR. Both 7(R)- and 7(S)BH4 function as poor cofactors for PAH, whereas only 7( S) BH4 acts as a potent competitive inhibitor vs. 6 R)BH4 (K-i = 2.3 - 4.9 mu M). Kinetic and binding studies, as well as characterization of the pterin-enzyme complexes by fluorescence spectroscopy, revealed that the inhibitory effects of 7( R, S) BH4 on PAH are in fact specifically based on 7( S) BH4 binding. The molecular dynamics simulated structures of the pterin-PAH complexes indicate that 7( S) BH4 inhibition is due to its interaction with the polar region at the pterin binding site close to Ser-251, whereas its low efficiency as cofactor is related to a suboptimal positioning toward the catalytic iron. 7( S) BH4 is not an inhibitor for tyrosine hydroxylase (TH) in the physiological range, presumably due to the replacement of Ser-251 by the corresponding Ala297. Taken together, our results identified structural determinants for the specific regulation of PAH and TH by 7(S) BH4, which in turn aid in the understanding of primapterinuria and acute vitiligo.	Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England; Univ Bergen, Dept Biomed, Bergen, Norway; Univ Konstanz, Fachbereich Chem, D-7750 Constance, Germany; Univ Bradford, Dept Chem Sci, Bradford BD7 1DP, W Yorkshire, England; Univ Bradford, Dept Forens Sci, Bradford BD7 1DP, W Yorkshire, England	University of Bradford; University of Bergen; University of Konstanz; University of Bradford; University of Bradford	Schallreuter, KU (corresponding author), Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England.	k.schallreuter@bradford.ac.uk	Teigen, Knut/K-3934-2012; Martinez, Aurora/M-3088-2019	Teigen, Knut/0000-0002-7031-9215; Martinez, Aurora/0000-0003-1643-6506; Pey, Angel Luis/0000-0001-7706-3243				ADLER C, 1992, J INHERIT METAB DIS, V15, P405, DOI 10.1007/BF02435989; ADLER C, 1992, EUR J BIOCHEM, V208, P139, DOI 10.1111/j.1432-1033.1992.tb17167.x; Andersen OA, 2002, J MOL BIOL, V320, P1095, DOI 10.1016/S0022-2836(02)00560-0; BAILEY SW, 1978, J BIOL CHEM, V253, P1598; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; Bjorgo E, 1998, EUR J BIOCHEM, V257, P1, DOI 10.1046/j.1432-1327.1998.2570001.x; BLAU N, 1989, J INHERIT METAB DIS, V12, P335, DOI 10.1007/BF03335415; Blau N., 2001, METABOLIC MOL BASIS, P1725; CITRON BA, 1993, AM J HUM GENET, V53, P768; CURTIUS HC, 1988, BIOCHEM BIOPH RES CO, V153, P715, DOI 10.1016/S0006-291X(88)81153-7; CURTIUS HC, 1990, BIOCHEM BIOPH RES CO, V172, P1060, DOI 10.1016/0006-291X(90)91554-6; DAVIS MD, 1992, P NATL ACAD SCI USA, V89, P10109, DOI 10.1073/pnas.89.21.10109; DAVIS MD, 1991, FEBS LETT, V285, P17, DOI 10.1016/0014-5793(91)80714-E; DAVIS MD, 1991, P NATL ACAD SCI USA, V88, P385, DOI 10.1073/pnas.88.2.385; Depaepe V, 2000, MOL BRAIN RES, V75, P76, DOI 10.1016/S0169-328X(99)00297-1; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; Erlandsen H, 2000, BIOCHEMISTRY-US, V39, P2208, DOI 10.1021/bi992531+; Erlandsen H, 2004, P NATL ACAD SCI USA, V101, P16903, DOI 10.1073/pnas.0407256101; Flatmark T, 1999, EUR J BIOCHEM, V262, P840, DOI 10.1046/j.1432-1327.1999.00445.x; Flatmark T, 1999, CHEM REV, V99, P2137, DOI 10.1021/cr980450y; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; HAAVIK J, 1986, EUR J BIOCHEM, V160, P1, DOI 10.1111/j.1432-1033.1986.tb09932.x; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; Haavik J, 1997, J NEUROCHEM, V68, P328; Hevel JM, 2006, MOL GENET METAB, V88, P38, DOI 10.1016/j.ymgme.2005.11.014; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KNAPPSKOG PM, 1995, BIOCHEMISTRY-US, V34, P11790, DOI 10.1021/bi00037a017; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Luque I, 2002, PROTEINS, V49, P181, DOI 10.1002/prot.10208; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; Matulis D, 2005, BIOCHEMISTRY-US, V44, P5258, DOI 10.1021/bi048135v; Olafsdottir S, 1999, J BIOL CHEM, V274, P6280, DOI 10.1074/jbc.274.10.6280; Pey AL, 2004, J AM CHEM SOC, V126, P13670, DOI 10.1021/ja047713s; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P3836, DOI 10.1021/bi00312a007; REINHARD S, 1986, PUBLIC HEALTH NURS, V3, P3, DOI 10.1111/j.1525-1446.1986.tb00461.x; Resibois A, 1999, HISTOCHEM CELL BIOL, V111, P381, DOI 10.1007/s004180050371; Schallreuter KU, 1998, BIOCHEM BIOPH RES CO, V243, P395, DOI 10.1006/bbrc.1997.8107; Schallreuter KU, 2005, MOL GENET METAB, V86, pS27, DOI 10.1016/j.ymgme.2005.07.023; SCHALLREUTER KU, 1994, SCIENCE, V263, P1444, DOI 10.1126/science.8128228; Schallreuter KU, 2001, J INVEST DERMATOL, V116, P167, DOI 10.1046/j.1523-1747.2001.00220.x; SCRIVER CR, 2001, METABOLIC MOL BASES, P1667; Solstad T, 2003, EUR J BIOCHEM, V270, P981, DOI 10.1046/j.1432-1033.2003.03471.x; Spencer JD, 2005, J ENDOCRINOL, V187, P293, DOI 10.1677/joe.1.06275; Teigen K, 1999, J MOL BIOL, V294, P807, DOI 10.1006/jmbi.1999.3288; Teigen K, 2004, J MED CHEM, V47, P5962, DOI 10.1021/jm0497646; Teigen K, 2003, J BIOMOL STRUCT DYN, V20, P733, DOI 10.1080/07391102.2003.10506889; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Thony B, 1998, HUM GENET, V103, P162, DOI 10.1007/s004390050800; Thorolfsson M, 2003, BIOCHEMISTRY-US, V42, P3419, DOI 10.1021/bi034021s; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; WOOD JM, 2005, PTERIDINES, V16, P93	52	28	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2130	+		10.1096/fj.06-5835fje	http://dx.doi.org/10.1096/fj.06-5835fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935936				2022-12-25	WOS:000241156900031
J	Hess, F; Estrugo, D; Fischer, A; Belka, C; Cordes, N				Hess, F.; Estrugo, D.; Fischer, A.; Belka, C.; Cordes, N.			Integrin-linked kinase interacts with caspase-9 and-8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells	ONCOGENE			English	Article						apoptosis; ILK; caspase-8; caspase-9; ECM; radiation	RESISTANCE CAM-DR; LUNG-CANCER CELLS; IN-VITRO; PROTEIN-KINASE; IONIZING-RADIATION; ALPHA-4-BETA-1 INTEGRIN; CD95-INDUCED APOPTOSIS; RNA INTERFERENCE; CYTOTOXIC DRUGS; SURVIVAL	Integrin-mediated adhesion of leukemia cells to extracellular matrix proteins reduces apoptosis following radiation-induced genotoxic injury. To evaluate the role of integrin-linked kinase ( ILK) in this process, HL60 human acute promyelocytic leukemia cells were stably transfected with ILK wild-type or kinase-hyperactive overexpression vectors. Suspension or. bronectin (FN) adhesion cultures were irradiated with X-rays and processed for measurement of apoptosis, mitochondrial transmembrane potential and caspase activation. Adhesion to FN pronouncedly reduced radiation-induced apoptosis of HL60 cells and vector controls. Intriguingly, overexpressed ILK enhanced apoptosis after irradiation by combined activation of caspase-3 through caspase-8 and -9 in irradiated FN cultures. Irradiation of ILK suspension cultures lacked caspase-8 activation, but showed serial cleavage of caspase-9, -3 and poly (ADPribose) polymerase. These findings further characterize the cell death-promoting function of ILK in DNA-damaged cells. Moreover, ILK might represent a potential therapeutic target for innovative chemo- and radiooncological approaches in hematological malignancies.	Tech Univ Dresden, Fac Med, D-01307 Dresden, Germany; Bundeswehr Inst Radiobiol, Munich, Germany; Univ Tubingen, Dept Radiat Oncol, Tubingen, Germany	Technische Universitat Dresden; Eberhard Karls University of Tubingen	Cordes, N (corresponding author), Tech Univ Dresden, Fac Med, Fetscherstasse 74-PF, D-01307 Dresden, Germany.	nils.cordes@oncoray.de		Cordes, Nils/0000-0001-5684-629X				Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014-4827(03)00342-2; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Chanan-Khan Asher, 2004, Curr Treat Options Oncol, V5, P261, DOI 10.1007/s11864-004-0017-3; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cordes N, 2006, ONCOGENE, V25, P1378, DOI 10.1038/sj.onc.1209164; Cordes N, 2004, STRAHLENTHER ONKOL, V180, P157, DOI 10.1007/s00066-004-1144-2; Cordes N, 2004, CANCER RES, V64, P5683, DOI 10.1158/0008-5472.CAN-04-1056; Cordes N, 2004, INT J RADIAT ONCOL, V58, P453, DOI 10.1016/j.ijrobp.2003.09.069; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; de la Fuente MT, 2002, J LEUKOCYTE BIOL, V71, P495; Duxbury MS, 2005, CLIN CANCER RES, V11, P3433, DOI 10.1158/1078-0432.CCR-04-1510; Eke I, 2006, RADIOTHER ONCOL, V80, P178, DOI 10.1016/j.radonc.2006.07.028; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Finkelstein LD, 2000, BIOCHEM J, V345, P385, DOI 10.1042/0264-6021:3450385; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gendron S, 2003, J BIOL CHEM, V278, P48633, DOI 10.1074/jbc.M305169200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jan YW, 2004, CELL, V116, P751, DOI 10.1016/S0092-8674(04)00204-1; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Kremer CL, 2006, PROSTATE, V66, P88, DOI 10.1002/pros.20316; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Seidler J, 2005, RADIOTHER ONCOL, V76, P129, DOI 10.1016/j.radonc.2005.06.018; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544; Soldatenkov VA, 2000, INT J CANCER, V90, P59, DOI 10.1002/(SICI)1097-0215(20000420)90:2<59::AID-IJC1>3.0.CO;2-4; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sun EW, 2001, PHARMACOL THERAPEUT, V92, P135, DOI 10.1016/S0163-7258(01)00164-4; Tamagiku Y, 2004, BIOCHEM BIOPH RES CO, V323, P445, DOI 10.1016/j.bbrc.2004.08.115; Zhang H, 2002, CANCER, V95, P896, DOI 10.1002/cncr.10751	47	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1372	1384		10.1038/sj.onc.1209947	http://dx.doi.org/10.1038/sj.onc.1209947			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936772				2022-12-25	WOS:000244558800002
J	Kong, LJ; Chang, JT; Bild, AH; Nevins, JR				Kong, L-J; Chang, J. T.; Bild, A. H.; Nevins, J. R.			Compensation and specificity of function within the E2F family	ONCOGENE			English	Article						E2F; cell cycle; expression signatures	TRANSCRIPTION FACTOR; DNA-REPLICATION; CELL-CYCLE; S-PHASE; EXPRESSION; PROLIFERATION; INDUCTION; PATHWAY; CANCER; LEADS	Functions encoded by single genes in lower organisms are often represented by multiple related genes in the mammalian genome. An example is the retinoblastoma and E2F families of proteins that regulate transcription during the cell cycle. Analysis of gene function using germline mutations is often confounded by overlapping function resulting in compensation. Indeed, in cells deleted of the E2F1 or E2F3 genes, there is an increase in the expression of the other family member. To avoid complications of compensatory effects, we have used small-interfering RNAs that target individual E2F proteins to generate a temporary loss of E2F function. We find that both E2F1 and E2F3 are required for cells to enter the S phase from a quiescent state, whereas only E2F3 is necessary for the S phase in growing cells. We also find that the acute loss of E2F3 activity affects the expression of genes encoding DNA replication and mitotic activities, whereas loss of E2F1 affects a limited number of genes that are distinct from those regulated by E2F3. We conclude that the long-term loss of E2F activity does lead to compensation by other family members and that the analysis of acute loss of function reveals specific and distinct roles for these proteins.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Inst Genome Sci & Policy, Durham, NC 27710 USA	Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Inst Genome Sci & Policy, Durham, NC 27710 USA.	j.nevins@duke.edu			NCI NIH HHS [CA104663, CA106520, CA112952] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104663, R01CA106520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Humbert PO, 2000, GENE DEV, V14, P690; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller M J, 2001, Obes Rev, V2, P15; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith DS, 2000, CELL GROWTH DIFFER, V11, P625; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	28	69	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					321	327		10.1038/sj.onc.1209817	http://dx.doi.org/10.1038/sj.onc.1209817			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16909124				2022-12-25	WOS:000243544000001
J	Bertani, I; Rusconi, L; Bolognese, F; Forlani, G; Conca, B; De Monte, L; Badaracco, G; Landsberger, N; Kilstrup-Nielsen, C				Bertani, Ilaria; Rusconi, Laura; Bolognese, Fabrizio; Forlani, Greta; Conca, Barbara; De Monte, Lucia; Badaracco, Gianfranco; Landsberger, Nicoletta; Kilstrup-Nielsen, Charlotte			Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY-ONSET SEIZURES; RETT-SYNDROME; MECP2; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; VARIANT; REGION; DOMAIN; ERK7	Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation. Disease-causing mutations are distributed in both the catalytic domain and in the large COOH terminus. In this report, we examine the functional consequences of some Rett mutations of CDKL5 together with some synthetically designed derivatives useful to underline the functional domains of the protein. The mutated CDKL5 derivatives have been subjected to in vitro kinase assays and analyzed for phosphorylation of the TEY (Thr-Glu-Tyr) motif within the activation loop, their subcellular localization, and the capacity of CDKL5 to interact with itself. Whereas wild-type CDKL5 autophosphorylates and mediates the phosphorylation of the methyl-CpG-binding protein 2 (MeCP2) in vitro, Rett-mutated proteins show both impaired and increased catalytic activity suggesting that a tight regulation of CDKL5 is required for correct brain functions. Furthermore, we show that CDKL5 can self-associate and mediate the phosphorylation of its own TEY (Thr-Glu-Tyr) motif. Eventually, we show that the COOH terminus regulates CDKL5 properties; in particular, it negatively influences the catalytic activity and is required for its proper sub-nuclear localization. We propose a model in which CDKL5 phosphorylation is required for its entrance into the nucleus whereas a portion of the COOH-terminal domain is responsible for a stable residency in this cellular compartment probably through protein-protein interactions.	Univ Insubria, Dipartimento Biol Strutturale & Funz, I-21052 Busto Arsizio, VA, Italy; San Raffaele Sci Inst, I-20132 Milan, Italy	University of Insubria; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Landsberger, N (corresponding author), Univ Insubria, Dipartimento Biol Strutturale & Funz, I-21052 Busto Arsizio, VA, Italy.	landsben@uninsubria.it; c.kilstrup-nielsen@uninsubria.it	DeMonte, Lucia/AAN-8336-2020; Kilstrup-Nielsen, Charlotte/A-6348-2014	Kilstrup-Nielsen, Charlotte/0000-0003-4977-4077; De Monte, Lucia/0000-0002-9406-7809; FORLANI, GRETA/0000-0003-1987-7761; Bertani, Ilaria/0000-0003-3175-8677; Landsberger, Nicoletta/0000-0003-0820-3155	Telethon [GGP05119] Funding Source: Medline	Telethon(Fondazione Telethon)		Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Abe MK, 1999, MOL CELL BIOL, V19, P1301; Archer HL, 2006, J MED GENET, V43, P729, DOI 10.1136/jmg.2006.041467; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; den Dunnen JT, 2000, HUM MUTAT, V15, P7; Evans JC, 2005, EUR J HUM GENET, V13, P1113, DOI 10.1038/sj.ejhg.5201451; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Huopaniemi L, 2000, HUM MUTAT, V16, P307, DOI 10.1002/1098-1004(200010)16:4<307::AID-HUMU3>3.0.CO;2-L; Kalscheuer VM, 2003, AM J HUM GENET, V72, P1401, DOI 10.1086/375538; Lin C, 2005, HUM MOL GENET, V14, P3775, DOI 10.1093/hmg/ddi391; Mari F, 2005, HUM MOL GENET, V14, P1935, DOI 10.1093/hmg/ddi198; Montini E, 1998, GENOMICS, V51, P427, DOI 10.1006/geno.1998.5391; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Scala E, 2005, J MED GENET, V42, P103, DOI 10.1136/jmg.2004.026237; Tao J, 2004, AM J HUM GENET, V75, P1149, DOI 10.1086/426460; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Van Esch H, 2005, AM J HUM GENET, V77, P442, DOI 10.1086/444549; Weaving LS, 2004, AM J HUM GENET, V75, P1079, DOI 10.1086/426462; Zheng QL, 2004, J BIOL CHEM, V279, P8787, DOI 10.1074/jbc.M310212200	22	110	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					32048	32056		10.1074/jbc.M606325200	http://dx.doi.org/10.1074/jbc.M606325200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16935860	Green Published, Bronze			2022-12-25	WOS:000241235300090
J	Gruegelsiepe, H; Brandt, O; Hartmann, RK				Gruegelsiepe, Heike; Brandt, Ole; Hartmann, Roland K.			Antisense inhibition of RNase P - Mechanistic aspects and application to live bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-EXPRESSION; RIBONUCLEASE-P; M1 RNA; OLIGONUCLEOTIDES; HYBRIDIZATION; PEPTIDES; POTENT	We explored bacterial RNase P as a drug target using antisense oligomers against the P15 loop region of Escherichia coli RNase P RNA. An RNA 14-mer, or locked nucleic acid (LNA) and peptide nucleic acid (PNA) versions thereof, disrupted local secondary structure in the catalytic core, forming hybrid duplexes over their entire length. Binding of the PNA and LNA 14-mers to RNase PRNA in vitro was essentially irreversible and even resisted denaturing PAGE. Association rates for the RNA, LNA, and PNA 14-mers were similar to 10(5) M-1 s(-1) with a rate advantage for PNA and were thus rather fast despite the need to disrupt local structure. Conjugates in which the PNA 14-mer was coupled to an invasive peptide via a novel monoglycine linker showed RNase P RNA-specific growth inhibition of E. coli cells. Cell growth could be rescued when expressing a second bacterial RNase P RNA with an unrelated sequence in the target region. We report here for the first time specific and growth-inhibitory drug targeting of RNase P in live bacteria. This is also the first example of a duplex-forming oligomer that invades a structured catalytic RNA and inactivates the RNA by (i) trapping it in a state in which the catalytic core is partially unfolded, (ii) sterically interfering with substrate binding, and (iii) perturbing the coordination of catalytically relevant Mg2+ ions.	Univ Marburg, Inst Pharmazeut Chem, D-35037 Marburg, Germany; Deutsch Krebsforschungszentrum, Dept Funct Genome Anal, D-69120 Heidelberg, Germany	Philipps University Marburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Hartmann, RK (corresponding author), Univ Marburg, Inst Pharmazeut Chem, Marbacher Weg 6, D-35037 Marburg, Germany.	roland.hartmann@staff.uni-marburg.de						Brandt O, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng120; Brannvall M, 2003, J MOL BIOL, V325, P697, DOI 10.1016/S0022-2836(02)01195-6; Childs JL, 2002, P NATL ACAD SCI USA, V99, P11091, DOI 10.1073/pnas.172391199; Childs JL, 2003, RNA, V9, P1437, DOI 10.1261/rna.5780503; Dias N, 2002, J MOL BIOL, V320, P489, DOI 10.1016/S0022-2836(02)00474-6; Dong HJ, 1996, J MOL BIOL, V261, P303, DOI 10.1006/jmbi.1996.0461; Eckardt S, 1997, BIOCHEMISTRY-US, V36, P12711, DOI 10.1021/bi9707234; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Elayadi AN, 2002, BIOCHEMISTRY-US, V41, P9973, DOI 10.1021/bi025907j; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Geller BL, 2003, ANTIMICROB AGENTS CH, V47, P3233, DOI 10.1128/AAC.47.10.3233-3239.2003; Good L, 2001, NAT BIOTECHNOL, V19, P360, DOI 10.1038/86753; Good L, 1998, P NATL ACAD SCI USA, V95, P2073, DOI 10.1073/pnas.95.5.2073; Gruegelsiepe H, 2003, CHEMBIOCHEM, V4, P1049, DOI 10.1002/cbic.200300675; HARDT WD, 1993, NUCLEIC ACIDS RES, V21, P3521, DOI 10.1093/nar/21.15.3521; KIRSEBOM LA, 1994, EMBO J, V13, P4870, DOI 10.1002/j.1460-2075.1994.tb06814.x; Kolb FA, 2000, EMBO J, V19, P5905, DOI 10.1093/emboj/19.21.5905; Kurreck J, 2003, EUR J BIOCHEM, V270, P1628, DOI 10.1046/j.1432-1033.2003.03555.x; Nekhotiaeva N, 2004, MOL THER, V10, P652, DOI 10.1016/j.ymthe.2004.07.006; Nielsen KE, 2004, BIOCONJUGATE CHEM, V15, P449, DOI 10.1021/bc034145h; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Rebuffat AG, 2002, FASEB J, V16, P1426, DOI 10.1096/fj.01-0706fje; Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862; SEKIGUCHI M, 1967, P NATL ACAD SCI USA, V58, P2315, DOI 10.1073/pnas.58.6.2315; Singh SK, 1998, CHEM COMMUN, P1247, DOI 10.1039/a801571f; SMITH D, 1992, J BIOL CHEM, V267, P2429; Tackett AJ, 2002, NUCLEIC ACIDS RES, V30, P950, DOI 10.1093/nar/30.4.950; Tomac S, 1996, J AM CHEM SOC, V118, P5544, DOI 10.1021/ja960495l; Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P27, DOI 10.1093/nar/gki142; Vaara M, 1996, ANTIMICROB AGENTS CH, V40, P1801, DOI 10.1128/AAC.40.8.1801; Wahlestedt C, 2000, P NATL ACAD SCI USA, V97, P5633, DOI 10.1073/pnas.97.10.5633; WAUGH DS, 1990, J BACTERIOL, V172, P6316, DOI 10.1128/jb.172.11.6316-6322.1990; Wegscheid B, 2006, EMBO REP, V7, P411, DOI 10.1038/sj.embor.7400641; Willkomm DK, 2003, CHEMBIOCHEM, V4, P1041, DOI 10.1002/cbic.200300674; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	35	35	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30613	30620		10.1074/jbc.M603346200	http://dx.doi.org/10.1074/jbc.M603346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16901906	Green Published, hybrid			2022-12-25	WOS:000241075900037
J	Hoff, RH; Czyryca, PG; Sun, MH; Leyh, TS; Hengge, AC				Hoff, Richard H.; Czyryca, Przemyslaw G.; Sun, Meihao; Leyh, Thomas S.; Hengge, Alvan C.			Transition state of the sulfuryl transfer reaction of estrogen sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SULFATE ESTERS; HYDROLYSIS; NITROPHENYL; PHOSPHORYL; SUBSTRATE; MECHANISM	Kinetic isotope effects have been measured for the estrogen sulfotransferase-catalyzed sulfuryl (SO3) transfer from p-nitrophenyl sulfate to the 5'-phosphoryl group of 3'-phosphoadenosine 5'-phosphate. (18)(V/K)(nonbridge) = 1.0016 +/- 0.0005, (18)(V/K) bridge = 1.0280 +/- 0.0006, and 15(V/K) = 1.0014 +/- 0.0004. ((15)(V/K) refers to the nitro group in p-nitrophenyl sulfate). The kinetic isotope effects indicate substantial S - O bond fission in the transition state, with partial charge neutralization of the leaving group. The small kinetic isotope effect in the nonbridging sulfuryl oxygen atoms suggests no significant change in bond orders of these atoms occurs, consistent with modest nucleophilic involvement. A comparison of the data for enzymatic and uncatalyzed sulfuryl transfer reactions suggests that both proceed through very similar transition states.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; US Mil Acad, Dept Chem & Life Sci, West Point, NY 10996 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Yeshiva University; Albert Einstein College of Medicine; United States Department of Defense; United States Army; United States Military Academy; Utah System of Higher Education; Utah State University	Leyh, TS (corresponding author), Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA.	leyh@aecom.yu.edu; hengge@cc.usu.edu	Hengge, Alvan C/C-8667-2011	Hengge, Alvan C/0000-0002-5696-2087	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054469, R01GM056248, R29GM047297, R01GM047297] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM056248, GM054469, R01 GM047297, GM47297] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson MA, 2001, J AM CHEM SOC, V123, P9246, DOI 10.1021/ja011025g; BADDILEY J, 1958, J CHEM SOC, P1000, DOI 10.1039/jr9580001000; BAUMANN E, 1876, BER DTSCH CHEM GES, V9, P54, DOI DOI 10.1002/(ISSN)1099-0682; BEDFORD CT, 1995, BIOORGAN MED CHEM, V3, P167, DOI 10.1016/0968-0896(95)00015-9; BENKOVIC SJ, 1966, J AM CHEM SOC, V88, P5504, DOI 10.1021/ja00975a026; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; BOURNE N, 1985, J AM CHEM SOC, V107, P4327, DOI 10.1021/ja00300a042; Chapman E, 2003, P NATL ACAD SCI USA, V100, P910, DOI 10.1073/pnas.0337638100; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; DROZARIO P, 1984, J AM CHEM SOC, V106, P5027, DOI 10.1021/ja00329a078; FENDLER EJ, 1968, J ORG CHEM, V33, P3852, DOI 10.1021/jo01274a035; Gibby SG, 2004, J PHYS ORG CHEM, V17, P541, DOI 10.1002/poc.775; Hengge AC, 2002, ACCOUNTS CHEM RES, V35, P105, DOI 10.1021/ar000143q; HENGGE AC, 1995, J AM CHEM SOC, V117, P5919, DOI 10.1021/ja00127a003; HENGGE AC, 1994, J AM CHEM SOC, V116, P11256, DOI 10.1021/ja00104a007; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; Hoff RH, 2001, J AM CHEM SOC, V123, P9338, DOI 10.1021/ja0163974; HOPKINS A, 1983, J AM CHEM SOC, V105, P6062, DOI 10.1021/ja00357a017; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; Marlier JF, 2001, ACCOUNTS CHEM RES, V34, P283, DOI 10.1021/ar000054d; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; OLEARY MH, 1979, J AM CHEM SOC, V101, P3300, DOI 10.1021/ja00506a027; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; ROBBINS PW, 1956, J AM CHEM SOC, V78, P2652, DOI 10.1021/ja01592a097; Zhang HP, 1998, J BIOL CHEM, V273, P10888, DOI 10.1074/jbc.273.18.10888	27	16	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30645	30649		10.1074/jbc.M604205200	http://dx.doi.org/10.1074/jbc.M604205200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16899461	hybrid			2022-12-25	WOS:000241075900040
J	Iwai, S; Hanamoto, D; Chaen, S				Iwai, Sosuke; Hanamoto, Daisuke; Chaen, Shigeru			A point mutation in the SH1 helix alters elasticity and thermal stability of myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN; DICTYOSTELIUM-DISCOIDEUM; ATP HYDROLYSIS; MOTOR DOMAIN; IN-VITRO; ACTIN; MYH9; SUBFRAGMENT-1; FECHTNER; MOVEMENT	Movement generated by the myosin motor is generally thought to be driven by distortion of an elastic element within the myosin molecule and subsequent release of the resulting strain. However, the location of this elastic element in myosin remains unclear. The myosin motor domain consists of four major subdomains connected by flexible joints. The SH1 helix is the joint that connects the converter subdomain to the other domains, and is thought to play an important role in arrangements of the converter relative to the motor. To investigate the involvement of the SH1 helix in elastic distortion in myosin, we have introduced a point mutation into the SH1 helix of Dictyostelium myosin II (R689H), which in human nonmuscle myosin IIA causes nonsyndromic hereditary deafness, DFNA17. The mutation resulted in a significant impairment in motile activities, whereas actin-activated ATPase activity was only slightly affected. Single molecule mechanical measurements using optical trap showed that the step size was not shortened by the mutation, suggesting that the slower motility is caused by altered kinetics. The single molecule measurements demonstrated that the mutation significantly reduced cross-bridge stiffness. Motile activities produced by mixtures of wild-type and mutant myosins also suggested that the mutation affected the elasticity of myosin. These results suggest that the SH1 helix is involved in modulation of myosin elasticity, presumably by modulating the converter flexibility. Consistent with this, the mutation was also shown to reduce thermal stability and induce thermal aggregation of the protein, which might be implicated in the disease process.	Nihon Univ, Dept Integrated Sci Phys & Biol, Coll Humanities & Sci, Setagaya Ku, Tokyo 1568550, Japan	Nihon University	Chaen, S (corresponding author), Nihon Univ, Dept Integrated Sci Phys & Biol, Coll Humanities & Sci, Setagaya Ku, 3-25-40 Sakurajousui, Tokyo 1568550, Japan.	chaen@phys.chs.nihon-u.ac.jp		Iwai, Sosuke/0000-0002-0794-9767				Baker JE, 2002, BIOPHYS J, V82, P2134, DOI 10.1016/S0006-3495(02)75560-4; BURKE M, 1977, BIOCHEMISTRY-US, V16, P5559, DOI 10.1021/bi00644a026; Chaen S, 1996, J BIOCHEM-TOKYO, V120, P788; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; Cuda G, 1997, BIOPHYS J, V72, P1767, DOI 10.1016/S0006-3495(97)78823-4; del Pino IMP, 2000, PROTEINS, V40, P58, DOI 10.1002/(SICI)1097-0134(20000701)40:1<58::AID-PROT80>3.0.CO;2-M; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DELOZANNE A, 1985, P NATL ACAD SCI USA, V82, P6807, DOI 10.1073/pnas.82.20.6807; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Franke JD, 2005, BLOOD, V105, P161, DOI 10.1182/blood-2004-06-2067; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; HARRIS DE, 1994, J MUSCLE RES CELL M, V15, P11, DOI 10.1007/BF00123828; Heath KE, 2001, AM J HUM GENET, V69, P1033, DOI 10.1086/324267; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Himmel DM, 2002, P NATL ACAD SCI USA, V99, P12645, DOI 10.1073/pnas.202476799; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; Howard J., 2001, MECH MOTOR PROTEINS; Hu AH, 2002, J BIOL CHEM, V277, P46512, DOI 10.1074/jbc.M208506200; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Ito K, 2003, J BIOL CHEM, V278, P31049, DOI 10.1074/jbc.M304138200; Kelley MJ, 2000, NAT GENET, V26, P106, DOI 10.1038/79069; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kohler J, 2002, P NATL ACAD SCI USA, V99, P3557, DOI 10.1073/pnas.062415899; Kunishima S, 2003, LAB INVEST, V83, P115, DOI 10.1097/01.LAB.0000050960.48774.17; Kunishima S, 2001, BLOOD, V97, P1147, DOI 10.1182/blood.V97.4.1147; Kurganov BI, 2002, BIOCHEMISTRY-MOSCOW+, V67, P409, DOI 10.1023/A:1015277805345; Lalwani AK, 2000, AM J HUM GENET, V67, P1121, DOI 10.1016/S0002-9297(07)62942-5; Liu X, 2000, BIOCHEM BIOPH RES CO, V271, P75, DOI 10.1006/bbrc.2000.2582; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Palmiter KA, 1999, J PHYSIOL-LONDON, V519, P669, DOI 10.1111/j.1469-7793.1999.0669n.x; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sasaki N, 2003, BIOCHEMISTRY-US, V42, P90, DOI 10.1021/bi026051l; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Seri M, 2000, NAT GENET, V26, P103; SERI M, 2001, MED BALTIMORE, V82, P203; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Uyeda TQP, 2002, BIOCHEMISTRY-US, V41, P9525, DOI 10.1021/bi026177i; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; WELLS JA, 1980, J BIOL CHEM, V255, P1135	45	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30736	30744		10.1074/jbc.M605365200	http://dx.doi.org/10.1074/jbc.M605365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16901894	hybrid			2022-12-25	WOS:000241075900050
J	Orsi, A; Fioriti, L; Chiesa, R; Sitia, R				Orsi, Andrea; Fioriti, Luana; Chiesa, Roberto; Sitia, Roberto			Conditions of endoplasmic reticulum stress favor the accumulation of cytosolic prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN; TRANSMEMBRANE FORM; ER STRESS; MESSENGER-RNA; TRANSLOCATION; XBP1; PRP; SIGNAL; ATF6; DEGRADATION	After signal sequence-dependent targeting to the endoplasmic reticulum (ER), prion protein (PrP) undergoes several post-translational modifications, including glycosylation, disulfide bond formation, and the addition of a glycosylphosphatidylinositol anchor. As a result, multiple isoforms are generated. Because of the intrinsic weakness of the PrP signal sequence, a fraction of newly synthesized molecules fails to translocate and localizes to the cytosol. The physiopathologic role of this cytosolic isoform is still being debated. Here we have shown that, in both cultured cell lines and primary neurons, ER stress conditions weaken PrP co-translational translocation, favoring accumulation of aggregation-prone cytosolic species, which retain the signal sequence but lack N-glycans and disulfides. Inhibition of pro-teasomes further increases the levels of cytosolic PrP. Overexpression of spliced XBP1 facilitates ER translocation, suggesting that downstream elements of the Ire1-XBP1 pathway are involved in PrP targeting. These studies reveal a link between ER stress and the formation of cytosolic PrP isoforms potentially endowed with novel signaling or cytotoxic functions.	Univ Vita Salute San Raffaele, DIBIT, Ist Sci San Raffaele, I-20132 Milan, Italy; Dulbecco Telethon Inst, I-20157 Milan, Italy; Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Sitia, R (corresponding author), Univ Vita Salute San Raffaele, DIBIT, Ist Sci San Raffaele, Via Olgettina 58, I-20132 Milan, Italy.	r.sitia@hsr.it	Sitia, Roberto/AAB-5005-2019; Longo, Kenneth A/A-5631-2010; Fioriti, Luana/AAN-7207-2021; Chiesa, Roberto/G-1561-2017	Sitia, Roberto/0000-0001-7086-4152; Chiesa, Roberto/0000-0002-3842-3733; Orsi, Andrea/0000-0003-2839-1640; fioriti, luana/0000-0003-2429-8967	Telethon [TCP00083] Funding Source: Medline	Telethon(Fondazione Telethon)		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brodsky JL, 1998, INT REV CYTOL, V178, P277; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Capellari S, 1999, J BIOL CHEM, V274, P34846, DOI 10.1074/jbc.274.49.34846; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Cenci S, 2006, EMBO J, V25, P1104, DOI 10.1038/sj.emboj.7601009; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Credle JJ, 2005, P NATL ACAD SCI USA, V102, P18773, DOI 10.1073/pnas.0509487102; DeArmond SJ, 1999, J NEUROPATH EXP NEUR, V58, P1000, DOI 10.1097/00005072-199909000-00010; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; Fioriti L, 2005, J BIOL CHEM, V280, P11320, DOI 10.1074/jbc.M412441200; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8; Gass JN, 2002, J BIOL CHEM, V277, P49047, DOI 10.1074/jbc.M205011200; Gewurz BE, 2002, J BIOL CHEM, V277, P11306, DOI 10.1074/jbc.M107904200; Grenier C, 2006, J NEUROCHEM, V97, P1456, DOI 10.1111/j.1471-4159.2006.03837.x; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Menendez-Benito V, 2005, HUM MOL GENET, V14, P2787, DOI 10.1093/hmg/ddi312; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nozaki J, 2004, GENES CELLS, V9, P261, DOI 10.1111/j.1356-9597.2004.00721.x; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RAMBOLD AS, 2006, MOL BIOL CELL; Rane NS, 2004, EMBO J, V23, P4550, DOI 10.1038/sj.emboj.7600462; Roucou X, 2005, CELL DEATH DIFFER, V12, P783, DOI 10.1038/sj.cdd.4401629; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Stewart RS, 2005, J NEUROSCI, V25, P3469, DOI 10.1523/JNEUROSCI.0105-05.2005; Stewart RS, 2003, J BIOL CHEM, V278, P45960, DOI 10.1074/jbc.M307833200; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stimson E, 1999, BIOCHEMISTRY-US, V38, P4885, DOI 10.1021/bi982330q; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tirosh B, 2005, J EXP MED, V202, P505, DOI 10.1084/jem.20050575; Tirosh B, 2005, J VIROL, V79, P2768, DOI 10.1128/JVI.79.5.2768-2779.2005; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; Wang XH, 2005, J BIOL CHEM, V280, P317, DOI 10.1074/jbc.M410649200; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4	58	86	88	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30431	30438		10.1074/jbc.M605320200	http://dx.doi.org/10.1074/jbc.M605320200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16908519	hybrid			2022-12-25	WOS:000241075900017
J	Prickett, TD; Brautigan, DL				Prickett, Todd D.; Brautigan, David L.			The alpha 4 regulatory subunit exerts opposing allosteric effects on protein phosphatases PP6 and PP2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR DRUG FOSTRIECIN; CATALYTIC SUBUNIT; SERINE/THREONINE PHOSPHATASES; OKADAIC ACID; CRYSTAL-STRUCTURE; 2A; BINDING; TOR; PURIFICATION; ASSOCIATION	The protein Ser/Thr phosphatase family contains three enzymes called PP2A, PP4, and PP6 with separate biological functions inferred from genetics of the yeast homologues Pph21/22, Pph3, and Sit4. These catalytic subunits associate with a common subunit called alpha 4 ( related to yeast Tap42). Here, we characterized recombinant PP6 and PP2A catalytic monomers and alpha 4(.)phosphatase heterodimers. Monomeric PP6 and PP2A showed identical kinetics using either p-nitrophenyl phosphate (pNPP) or P-32-myelin basic protein (MBP) as substrates, with matching K-m and V-max values. Using pNPP as substrate, PP6 and PP2A gave the same IC50 with active site inhibitors okadaic acid, microcystin-LR, calyculin A, and cantharidin. However, with MBP as substrate, PP6 was inhibited at 5-fold lower concentrations of toxins relative to PP2A, suggesting PP6 might be a preferred in vivo target of toxins. Heterodimeric alpha 4(.)PP6 and alpha 4(.)PP2A were starkly different. With MBP as substrate the alpha 4(.)PP2A heterodimer had a 100-fold higher Vmax than alpha 4(.)PP6, and neither heterodimer was active with pNPP. Thus, these phosphatases are distinguished by their different responses to allosteric binding of the common regulatory subunit alpha 4. Transient expression of alpha 4 differentially increased or decreased phosphorylation of endogenous phosphoproteins, consistent with opposing effects on PP2A and PP6.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA.	db8g@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA077584] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bastians H, 1996, J CELL SCI, V109, P2865; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Brautigan DL, 2005, BIOCHEMISTRY-US, V44, P11067, DOI 10.1021/bi0508845; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Evans DRH, 2001, FEBS LETT, V498, P110, DOI 10.1016/S0014-5793(01)02448-6; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Gauss CM, 1997, BIOORGAN MED CHEM, V5, P1751, DOI 10.1016/S0968-0896(97)00145-4; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Hastie CJ, 1998, FEBS LETT, V431, P357, DOI 10.1016/S0014-5793(98)00775-3; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Kita A, 2002, STRUCTURE, V10, P715, DOI 10.1016/S0969-2126(02)00764-5; Kloeker S, 2003, PROTEIN EXPRES PURIF, V31, P19, DOI 10.1016/S1046-5928(03)00141-4; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; Maynes JT, 2001, J BIOL CHEM, V276, P44078, DOI 10.1074/jbc.M107656200; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1999, FEBS LETT, V446, P108, DOI 10.1016/S0014-5793(99)00189-1; Price NE, 2000, BIOCHEMISTRY-US, V39, P11312, DOI 10.1021/bi0008478; Prickett TD, 2004, J BIOL CHEM, V279, P38912, DOI 10.1074/jbc.M401444200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017	31	78	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30503	30511		10.1074/jbc.M601054200	http://dx.doi.org/10.1074/jbc.M601054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16895907	hybrid			2022-12-25	WOS:000241075900026
J	Huang, Y; Wendt-Pienkowski, E; Shen, B				Huang, Yong; Wendt-Pienkowski, Evelyn; Shen, Ben			A dedicated phosphopantetheinyl transferase for the fredericamycin polyketide synthase from Streptomyces griseus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; BIOSYNTHETIC GENE-CLUSTER; FATTY-ACID SYNTHASE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; POSTTRANSLATIONAL MODIFICATION; HETEROLOGOUS EXPRESSION; CLONING; ACYLTRANSFERASE; OVERPRODUCTION	Polyketide synthases cannot be functional unless their apoacyl carrier proteins (apo-ACPs) are post-translationally modified by covalent attachment of the 4'-phosphopantetheine group to the highly conserved serine residue, and this reaction is catalyzed by phosphopantetheinyl transferases (PPTases). Cloning and sequence analysis of the 33-kb fredericamycin (FDM) biosynthetic gene cluster from Streptomyces griseus revealed fdmW, whose deduced gene product showed significant sequence homology to known PPTases. Biochemical characterization of FdmW in vitro confirmed that it is a PPTase. Inactivation of fdmW resulted in similar to 93% reduction of FDM production, and complementation of the fdmW::aac (3) IV mutant by expressing fdmW in trans restored FDM production to a level comparable with that of the wild-type strain. Although FdmW can phosphopantetheinylate various ACPs, it prefers its cognate substrate, the FdmH ACP, with a K-m of 5.8 mu M and a k(cat)/K-m of 8.1 mu M(-1.)min(-1), to heterologous ACPs, such as the TcmM ACP with a K-m of 1.0 x 10(2) mu M and a k(cat)/K-m of 0.6 mu M(-1.)min(-1). These findings suggest that FdmW is specific for FDM biosynthesis. FdmW therefore represents the first holo-ACP synthase-type PPTase identified from an aromatic polyketide biosynthetic gene cluster.	Univ Wisconsin, Div Pharmaceut Sci, Sch Pharm, Madison, WI 53705 USA; Univ Wisconsin, Natl Cooperat Drug Discovery Grp, Madison, WI 53705 USA; Univ Wisconsin, Dept Chem, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Shen, B (corresponding author), Univ Wisconsin, Div Pharmaceut Sci, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA.	bshen@pharmacy.wisc.edu		Huang, Yong/0000-0002-3163-1716	NATIONAL CANCER INSTITUTE [U19CA113297, R01CA035381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051687] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; Buttner M. J., 2000, PRACTICAL STREPTOMYC, P1; Cheng YQ, 2003, P NATL ACAD SCI USA, V100, P3149, DOI 10.1073/pnas.0537286100; Crump MP, 1997, BIOCHEMISTRY-US, V36, P6000, DOI 10.1021/bi970006+; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; Fichtlscherer F, 2000, EUR J BIOCHEM, V267, P2666, DOI 10.1046/j.1432-1327.2000.01282.x; Finking R, 2002, J BIOL CHEM, V277, P50293, DOI 10.1074/jbc.M205042200; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Galm U, 2002, ARCH MICROBIOL, V178, P102, DOI 10.1007/s00203-002-0429-z; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Gokhale RS, 1999, SCIENCE, V284, P482, DOI 10.1126/science.284.5413.482; Gross F, 2005, APPL MICROBIOL BIOT, V68, P66, DOI 10.1007/s00253-004-1836-7; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; Ichinose K, 2003, MICROBIOL-SGM, V149, P1633, DOI 10.1099/mic.0.26310-0; Ichinose K, 1998, CHEM BIOL, V5, P647, DOI 10.1016/S1074-5521(98)90292-7; Jakobi K, 2004, J AM CHEM SOC, V126, P2298, DOI 10.1021/ja0390698; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; KHOSLA C, 1992, MOL MICROBIOL, V6, P3237, DOI 10.1111/j.1365-2958.1992.tb01778.x; Kremer L, 2001, J BIOL CHEM, V276, P27967, DOI 10.1074/jbc.M103687200; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; Li AY, 2002, CHEM BIOL, V9, P1017, DOI 10.1016/S1074-5521(02)00223-5; Lomovskaya N, 1999, J BACTERIOL, V181, P305, DOI 10.1128/JB.181.1.305-318.1999; McAllister KA, 2000, J BIOL CHEM, V275, P30864, DOI 10.1074/jbc.M004475200; Mootz HD, 2001, J BIOL CHEM, V276, P37289, DOI 10.1074/jbc.M103556200; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; Novakova R, 2002, GENE, V297, P197, DOI 10.1016/S0378-1119(02)00889-2; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Sambrook J., 2001, MOL CLONING LAB MANU, P1, DOI DOI 10.1002/HUMU.1186.ABS; Sanchez C, 2001, CHEM BIOL, V8, P725, DOI 10.1016/S1074-5521(01)00047-3; Shen B, 2000, TOP CURR CHEM, V209, P1; Silakowski B, 1999, J BIOL CHEM, V274, P37391, DOI 10.1074/jbc.274.52.37391; TAKIFF HE, 1992, J BACTERIOL, V174, P1544, DOI 10.1128/jb.174.5.1544-1553.1992; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1; Wang LR, 2001, MICROBIOL-SGM, V147, P1535, DOI 10.1099/00221287-147-6-1535; Wendt-Pienkowski E, 2005, J AM CHEM SOC, V127, P16442, DOI 10.1021/ja054376u; Westrich L, 1999, FEMS MICROBIOL LETT, V170, P381, DOI 10.1111/j.1574-6968.1999.tb13398.x; Zhang L, 2003, J BIOL CHEM, V278, P40067, DOI 10.1074/jbc.M306121200; [No title captured]	41	27	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29660	29668		10.1074/jbc.M604895200	http://dx.doi.org/10.1074/jbc.M604895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16895912	hybrid			2022-12-25	WOS:000240896300027
J	Kanda, M; Ihara, Y; Murata, H; Urata, Y; Kono, T; Yodoi, J; Seto, S; Yano, K; Kondo, T				Kanda, Munetake; Ihara, Yoshito; Murata, Hiroaki; Urata, Yoshishige; Kono, Takaaki; Yodoi, Junji; Seto, Shinji; Yano, Katsusuke; Kondo, Takahito			Glutaredoxin modulates platelet-derived growth factor-dependent cell signaling by regulating the redox status of low molecular weight protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA-RECEPTOR; GLUTATHIONE/GLUTAREDOXIN REDUCTASE SYSTEM; TUMOR-SUPPRESSOR PTEN; ACTIVE-SITE CYSTEINE; SMOOTH-MUSCLE-CELLS; IN-VIVO; THIOLTRANSFERASE GLUTAREDOXIN; REVERSIBLE INACTIVATION; HYDROGEN-PEROXIDE; REACTIVE OXYGEN	Glutaredoxin (GRX) is a glutathione-disulfide oxidoreductase involved in various cellular functions, including the redox-dependent regulation of certain integral proteins. Here we demonstrated that overexpression of GRX suppressed the proliferation of myocardiac H9c2 cells treated with platelet-derived growth factor (PDGF)-BB. After stimulation with PDGF-BB, the phosphorylation of PDGF receptor (PDGFR) beta was suppressed in GRX gene-transfected cells, compared with controls. Conversely, the phosphorylation was enhanced by depletion of GRX by RNA interference. In this study we focused on the role of low molecular weight protein-tyrosine phosphatase (LMW-PTP) in the dephosphorylation of PDGFR beta via a redox-dependent mechanism. We found that depletion of LMW-PTP using RNA interference enhanced the PDGF-BB-induced phosphorylation of PDGFR beta, indicating that LMW-PTP works for PDGFR beta. The enhancement of the phosphorylation of PDGFR beta was well correlated with inactivation of LMW-PTP by cellular peroxide generated in the cells stimulated with PDGF-BB. In vitro, with hydrogen peroxide treatment, LMW-PTP showed decreased activity with the concomitant formation of dithiothreitol-reducible oligomers. GRX protected LMW-PTP from hydrogen peroxide-induced oxidation and inactivation in concert with glutathione, NADPH, and glutathione disulfide reductase. This strongly suggests that retention of activity of LMW-PTP by enhanced GRX expression suppresses the proliferation of cells treated with PDGF-BB via enhanced dephosphorylation of PDGFR beta. Thus, GRX plays an important role in PDGF-BB-dependent cell proliferation by regulating the redox state of LMW-PTP.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Biochem & Mol Biol Dis, Atom Bomb Dis Inst, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Internal Med 3, Nagasaki 8528523, Japan; Kyoto Univ, Inst Viral Res, Dept Biol Responses, Kyoto 6068507, Japan	Nagasaki University; Nagasaki University; Kyoto University	Ihara, Y (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Biochem & Mol Biol Dis, Atom Bomb Dis Inst, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	y-ihara@net.nagasaki-u.ac.jp	Murata, Hiroaki/AAA-8374-2020	Murata, Hiroaki/0000-0002-6185-5059				Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Arabaci G, 2002, BIOORG MED CHEM LETT, V12, P3047, DOI 10.1016/S0960-894X(02)00681-9; Arabaci G, 1999, J AM CHEM SOC, V121, P5085, DOI 10.1021/ja9906756; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Brostrom MA, 2002, J CELL BIOCHEM, V84, P736, DOI 10.1002/jcb.10085; Caplan JF, 2004, J BIOL CHEM, V279, P7740, DOI 10.1074/jbc.M313049200; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; CASELLI A, 1995, FEBS LETT, V374, P249, DOI 10.1016/0014-5793(95)01120-4; Chen AP, 2003, J BIOL CHEM, V278, P23381, DOI 10.1074/jbc.M212042200; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CIRRI P, 1995, BBA-GEN SUBJECTS, V1243, P129, DOI 10.1016/0304-4165(94)00055-3; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; GAN ZR, 1986, J BIOL CHEM, V261, P996; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kikawa KD, 2002, J BIOL CHEM, V277, P39274, DOI 10.1074/jbc.M207127200; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Landino LM, 2004, BIOCHEM BIOPH RES CO, V323, P112, DOI 10.1016/j.bbrc.2004.08.065; Landino LM, 2004, BIOCHEM BIOPH RES CO, V314, P555, DOI 10.1016/j.bbrc.2003.12.126; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LEVEEN P, 1994, GENET DEV, V8, P1857; Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101; Lind C, 1998, BIOCHEM BIOPH RES CO, V247, P481, DOI 10.1006/bbrc.1998.8695; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu J, 2005, REGUL PEPTIDES, V127, P11, DOI 10.1016/j.regpep.2004.10.018; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Markova B, 2003, BIOCHEMISTRY-US, V42, P2691, DOI 10.1021/bi0265574; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Ramponi G, 1997, BBA-PROTEIN STRUCT M, V1341, P137, DOI 10.1016/S0167-4838(97)00087-3; Raugei G, 2002, CELL MOL LIFE SCI, V59, P941, DOI 10.1007/s00018-002-8481-z; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; SARZANI R, 1991, HYPERTENSION, V17, P888, DOI 10.1161/01.HYP.17.6.888; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Shimizu H, 2001, BIOCHEM BIOPH RES CO, V289, P602, DOI 10.1006/bbrc.2001.6007; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tallquist M, 2004, CYTOKINE GROWTH F R, V15, P205, DOI 10.1016/j.cytogfr.2004.03.003; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Wang J, 2003, P NATL ACAD SCI USA, V100, P5103, DOI 10.1073/pnas.0931345100; WO YYP, 1992, J BIOL CHEM, V267, P10856; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687	67	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28518	28528		10.1074/jbc.M604359200	http://dx.doi.org/10.1074/jbc.M604359200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16893901	hybrid			2022-12-25	WOS:000240680500005
J	Pacheco-Alvarez, D; Cristobal, PS; Meade, P; Moreno, E; Vazquez, N; Munoz, E; Diaz, A; Juarez, ME; Gimenez, I; Gamba, G				Pacheco-Alvarez, Diana; Cristobal, Pedro San; Meade, Patricia; Moreno, Erika; Vazquez, Norma; Munoz, Eva; Diaz, Abigail; Juarez, Maria Eugenia; Gimenez, Ignacio; Gamba, Gerardo			The Na+: Cl- cotransporter is activated and phosphorylated at the amino-terminal domain upon intracellular chloride depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-2CL(-) COTRANSPORTER; REGULATORY PHOSPHORYLATION; FUNCTIONAL EXPRESSION; NA-K-2CL COTRANSPORT; MOLECULAR PHYSIOLOGY; NACL COTRANSPORTER; CELL-VOLUME; KINASE; WNK1; MODULATION	The renal N-a+:Cl- cotransporter rNCC is mutated in human disease, is the therapeutic target of thiazide-type diuretics, and is clearly involved in arterial blood pressure regulation. rNCC belongs to an electroneutral cation-coupled chloride cotransporter family (SLC12A) that has two major branches with inverse physiological functions and regulation: sodium-driven cotransporters (NCC and NKCC1/2) that mediate cellular Cl- influx are activated by phosphorylation, whereas potassium-driven cotransporters (KCCs) that mediate cellular Cl- efflux are activated by dephosphorylation. A cluster of three threonine residues at the amino-terminal domain has been implicated in the regulation of NKCC1/2 by intracellular chloride, cell volume, vasopressin, and WNK/STE-20 kinases. Nothing is known, however, about rNCC regulatory mechanisms. By using rNCC heterologous expression in Xenopus laevis oocytes, here we show that two independent intracellular chloride-depleting strategies increased rNCC activity by 3-fold. The effect of both strategies was synergistic and dose-dependent. Confocal microscopy of enhanced green fluorescent protein-tagged rNCC showed no changes in rNCC cell surface expression, whereas immunoblot analysis, using the R5-anti-NKCC1-phosphoantibody, revealed increased phosphorylation of rNCC amino-terminal domain threonine residues Thr(53) and Thr(58). Elimination of these threonines together with serine residue Ser(71) completely prevented rNCC response to intracellular chloride depletion. We conclude that rNCC is activated by a mechanism that involves amino-terminal domain phosphorylation.	Univ Nacl Autonoma Mexico, Mol Physiol Unit, Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Inst Inves Biomed, Mexico City, DF, Mexico; Univ Autonoma Estado Hidalgo, Inst Ciencias Salud, Hidalgo 42160, Mexico; Univ Zaragoza, Fac Med, Dept Pharmacol & Physiol, E-50009 Zaragoza, Spain	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Universidad Nacional Autonoma de Mexico; Universidad Autonoma del Estado de Hidalgo; University of Zaragoza	Gamba, G (corresponding author), Univ Nacl Autonoma Mexico, Mol Physiol Unit, Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Inst Inves Biomed, Vasco Quiroga 15, Mexico City, DF, Mexico.	gamba@biomedicas.unam.mx	Giménez, Ignacio/B-6322-2013; Meade, Patricia/H-8825-2015; Gamba, Gerardo/P-4873-2016	Giménez, Ignacio/0000-0002-6043-4869; Meade, Patricia/0000-0002-3587-6622; Pacheco-Alvarez, Diana/0000-0001-5454-9267; Gamba, Gerardo/0000-0002-4378-9043; Moreno Martinez, Reyna Erika/0000-0002-7563-0379	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064635] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; Adragna NC, 2004, J MEMBRANE BIOL, V201, P109, DOI 10.1007/s00232-004-0695-6; Cai H, 2006, KIDNEY INT, V69, P2162, DOI 10.1038/sj.ki.5000333; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COSTANZO LS, 1985, AM J PHYSIOL, V248, pF527, DOI 10.1152/ajprenal.1985.248.4.F527; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; de Jong JC, 2003, J BIOL CHEM, V278, P24302, DOI 10.1074/jbc.M303101200; De Jong JC, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017904.77985.03; Delpire E, 2000, NEWS PHYSIOL SCI, V15, P309, DOI 10.1152/physiologyonline.2000.15.6.309; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; ELLISON DH, 1987, AM J PHYSIOL, V253, pF546, DOI 10.1152/ajprenal.1987.253.3.F546; Flatman PW, 2002, BBA-BIOMEMBRANES, V1566, P140, DOI 10.1016/S0005-2736(02)00586-2; Flemmer AW, 2002, J BIOL CHEM, V277, P37551, DOI 10.1074/jbc.M206294200; Gagnon KBE, 2006, AM J PHYSIOL-CELL PH, V290, pC134, DOI 10.1152/ajpcell.00037.2005; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Gimenez I, 2005, AM J PHYSIOL-RENAL, V289, pF1341, DOI 10.1152/ajprenal.00214.2005; Gimenez I, 2003, J BIOL CHEM, V278, P26946, DOI 10.1074/jbc.M303435200; Hebert SC, 2004, PFLUG ARCH EUR J PHY, V447, P580, DOI 10.1007/s00424-003-1066-3; Hoover RS, 2003, J AM SOC NEPHROL, V14, P271, DOI 10.1097/01.ASN.0000043903.93452.D0; Kahle KT, 2005, P NATL ACAD SCI USA, V102, P16783, DOI 10.1073/pnas.0508307102; KEICHER E, 1994, J PHYSIOL-LONDON, V475, P45, DOI 10.1113/jphysiol.1994.sp020048; Kunchaparty S, 1999, AM J PHYSIOL-RENAL, V277, pF643, DOI 10.1152/ajprenal.1999.277.4.F643; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Lu J, 1999, J NEUROBIOL, V39, P558, DOI 10.1002/(SICI)1097-4695(19990615)39:4<558::AID-NEU9>3.0.CO;2-5; Lytle C, 2002, AM J PHYSIOL-CELL PH, V283, pC1422, DOI 10.1152/ajpcell.00130.2002; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Mastroianni N, 1996, AM J HUM GENET, V59, P1019; Mayan H, 2002, J CLIN ENDOCR METAB, V87, P3248, DOI 10.1210/jc.87.7.3248; Mercado A, 2004, NEUROCHEM RES, V29, P17, DOI 10.1023/B:NERE.0000010432.44566.21; Monroy A, 2000, AM J PHYSIOL-RENAL, V279, pF161, DOI 10.1152/ajprenal.2000.279.1.F161; Moreno E, 2004, J BIOL CHEM, V279, P16553, DOI 10.1074/jbc.M400602200; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Piechotta K, 2003, J BIOL CHEM, V278, P52848, DOI 10.1074/jbc.M309436200; Plata C, 2002, J BIOL CHEM, V277, P11004, DOI 10.1074/jbc.M110442200; Plotkin MD, 1996, KIDNEY INT, V50, P174, DOI 10.1038/ki.1996.300; Rinehart J, 2005, P NATL ACAD SCI USA, V102, P16777, DOI 10.1073/pnas.0508303102; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Sabath E, 2004, AM J PHYSIOL-RENAL, V287, pF195, DOI 10.1152/ajprenal.00044.2004; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Song LY, 2002, MOL BRAIN RES, V103, P91, DOI 10.1016/S0169-328X(02)00190-0; Subramanya AR, 2006, AM J PHYSIOL-RENAL, V290, pF619, DOI 10.1152/ajprenal.00280.2005; Vazquez N, 2002, AM J PHYSIOL-RENAL, V282, pF599, DOI 10.1152/ajprenal.00284.2001; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Wang XY, 2001, J CLIN INVEST, V108, P215, DOI 10.1172/JCI200110366; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443	52	188	191	0	28	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28755	28763		10.1074/jbc.M603773200	http://dx.doi.org/10.1074/jbc.M603773200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16887815	hybrid			2022-12-25	WOS:000240680500029
J	Dehe, PM; Dichtl, B; Schaft, D; Roguev, A; Pamblanco, M; Lebrun, R; Rodriguez-Gil, A; Mkandawire, M; Landsberg, K; Shevchenko, A; Shevchenko, A; Rosaleny, LE; Tordera, V; Chavez, S; Stewart, AF; Geli, V				Dehe, Pierre-Marie; Dichtl, Bernhard; Schaft, Daniel; Roguev, Assen; Pamblanco, Merce; Lebrun, Regine; Rodriguez-Gil, Alfonso; Mkandawire, Msau; Landsberg, Katarina; Shevchenko, Anna; Shevchenko, Andrej; Rosaleny, Lorena E.; Tordera, Vicente; Chavez, Sebastian; Stewart, A. Francis; Geli, Vincent			Protein interactions within the Set1 complex and their roles in the regulation of histone 3 lysine 4 methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; H3 LYSINE-4; METHYLTRANSFERASE COMPLEX; PAF1 COMPLEX; TRANSCRIPTIONAL ELONGATION; H2B UBIQUITYLATION; TRITHORAX FAMILY; COMPASS; UBIQUITINATION; TRIMETHYLATION	Set1 is the catalytic subunit and the central component of the evolutionarily conserved Set1 complex (Set1C) that methylates histone 3 lysine 4 (H3K4). Here we have determined protein/protein interactions within the complex and related the substructure to function. The loss of individual Set1 C subunits differentially affects Set1 stability, complex integrity, global H3K4 methylation, and distribution of H3K4 methylation along active genes. The complex requires Set1, Swd1, and Swd3 for integrity, and Set1 amount is greatly reduced in the absence of the Swd1-Swd3 heterodimer. Bre2 and Sdc1 also form a heteromeric subunit, which requires the SET domain for interaction with the complex, and Sdc1 strongly interacts with itself. Inactivation of either Bre2 or Sdc1 has very similar effects. Neither is required for complex integrity, and their removal results in an increase of H3K4 mono- and dimethylation and a severe decrease of trimethylation at the 5' end of active coding regions but a decrease of H3K4 dimethylation at the 3' end of coding regions. Cells lacking Spp1 have a reduced amount of Set1 and retain a fraction of trimethylated H3K4, whereas cells lacking Shg1 show slightly elevated levels of both di- and trimethylation. Set1C associates with both serine 5- and serine 2-phosphorylated forms of polymerase II, indicating that the association persists to the 3' end of transcribed genes. Taken together, our results suggest that Set1C subunits stimulate Set1 catalytic activity all along active genes.	Tech Univ Dresden, Biotec Res Ctr, BioInnovat Zentrum, D-01307 Dresden, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; CNRS, Lab Instabilite Genome & Cancerogenese, Inst Biol Struct & Microbiol, F-13402 Marseille, France; Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain; Univ Seville, Fac Biol, Dept Genet, E-41012 Seville, Spain	Technische Universitat Dresden; Max Planck Society; University of Zurich; Centre National de la Recherche Scientifique (CNRS); University of Valencia; University of Sevilla	Stewart, AF (corresponding author), Tech Univ Dresden, Biotec Res Ctr, BioInnovat Zentrum, Am Tatzberg 47, D-01307 Dresden, Germany.	stewart@biotec.tu-dresden.de; geli@ibsm.cnrs-mrs.fr	Pamblanco, Merce/H-6688-2015; Stewart, A. Francis/E-7789-2010; IBIS, GENICA/O-1906-2015; Dehe, Pierre-Marie/D-4135-2017; Chavez, Sebastian S/F-7574-2011; Rodríguez-Gil, Alfonso/O-2475-2016; Rosaleny, Lorena E./AAF-6352-2019	Pamblanco, Merce/0000-0003-0180-5751; Dehe, Pierre-Marie/0000-0003-1558-6983; Chavez, Sebastian S/0000-0002-8064-4839; Rodríguez-Gil, Alfonso/0000-0003-4430-077X; Rosaleny, Lorena E./0000-0002-8481-7303; Dichtl, Bernhard/0000-0001-5514-4982				Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Carvin CD, 2004, J BIOL CHEM, V279, P33057, DOI 10.1074/jbc.M405033200; Cheng HL, 2004, MOL CELL BIOL, V24, P2932, DOI 10.1128/MCB.24.7.2932-2943.2004; Corda Y, 1999, NAT GENET, V21, P204, DOI 10.1038/5991; Dehe PM, 2005, J MOL BIOL, V353, P477, DOI 10.1016/j.jmb.2005.08.059; Dichtl E, 2004, RNA, V10, P965, DOI 10.1261/rna.7090104; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Gildea JJ, 2000, GENETICS, V156, P645; Gully D, 2006, PROTEOMICS, V6, P282, DOI 10.1002/pmic.200500115; HSU DR, 1995, DEVELOPMENT, V121, P3323; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Karimova G, 2005, J BACTERIOL, V187, P2233, DOI 10.1128/JB.187.7.2233-2243.2005; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Laribee RN, 2005, CURR BIOL, V15, P1487, DOI 10.1016/j.cub.2005.07.028; Lee JH, 2005, J BIOL CHEM, V280, P41725, DOI 10.1074/jbc.M508312200; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Morillon A, 2005, MOL CELL, V18, P723, DOI 10.1016/j.molcel.2005.05.009; Mueller CL, 2004, MOL CELL, V14, P447, DOI 10.1016/S1097-2765(04)00257-6; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Poveda A, 2004, J BIOL CHEM, V279, P16033, DOI 10.1074/jbc.M314228200; Roguev A, 2004, MOL CELL PROTEOMICS, V3, P125, DOI 10.1074/mcp.M300081-MCP200; Roguev A, 2003, J BIOL CHEM, V278, P8487, DOI 10.1074/jbc.M209562200; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Santos-Rosa H, 2004, J BIOL CHEM, V279, P47506, DOI 10.1074/jbc.M407949200; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schlichter A, 2005, EMBO J, V24, P1222, DOI 10.1038/sj.emboj.7600607; Schneider J, 2005, MOL CELL, V19, P849, DOI 10.1016/j.molcel.2005.07.024; Shahbazian MD, 2005, MOL CELL, V19, P271, DOI 10.1016/j.molcel.2005.06.010; Sollier J, 2004, EMBO J, V23, P1957, DOI 10.1038/sj.emboj.7600204; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Tresaugues L, 2006, J MOL BIOL, V359, P1170, DOI 10.1016/j.jmb.2006.04.050; Wood A, 2005, MOL CELL, V20, P589, DOI 10.1016/j.molcel.2005.09.010; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zhang K, 2005, CELL, V122, P723, DOI 10.1016/j.cell.2005.06.021; Zhang L, 2005, EMBO J, V24, P2379, DOI 10.1038/sj.emboj.7600711	48	115	119	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35404	35412		10.1074/jbc.M603099200	http://dx.doi.org/10.1074/jbc.M603099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16921172	Green Published, hybrid			2022-12-25	WOS:000241933700074
J	Broniowska, KA; Zhang, YH; Hogg, N				Broniowska, Katarzyna A.; Zhang, Yanhong; Hogg, Neil			Requirement of transmembrane transport for S-nitrosocysteine-dependent modification of intracellular thiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; L-CYSTEINE; IN-VIVO; NITROSOTHIOL FORMATION; NORADRENALINE RELEASE; ENDOTHELIAL-CELLS; RAT HIPPOCAMPUS; NITROSOGLUTATHIONE; NITROSYLATION; MECHANISMS	S-Nitrosothiols have been implicated as intermediary transducers of nitric oxide bioactivity; however, the mechanisms by which these compounds affect cellular functions have not been fully established. In this study, we have examined the effect of S-nitrosothiol transport on intracellular thiol status and upon the activity of a target protein (caspase-3), in bovine aortic endothelial cells. We have previously demonstrated that the specific transport of amino acid-based S-nitrosothiols (S-nitroso-L-cysteine and S-nitrosohomocysteine) occurs via amino acid transport system L to generate high levels of intracellular protein S-nitrosothiols (Zhang, Y., and Hogg, N. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 7891 - 7896). In this study, we demonstrate that the transport of S-nitrosothiols is essential for these compounds to affect intracellular thiol levels and to modify intracellular protein activity. Importantly, the ability of these compounds to affect intracellular processes occurs independently of nitric oxide formation. These findings suggest that the major action of these compounds is not to liberate nitric oxide in the extracellular space but to be specifically transported into cells where they are able to modify cellular functions through nitric oxide-independent mechanisms.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Hogg, N (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	nhogg@mcw.edu		Broniowska, Katarzyna/0000-0002-8000-9093	NIGMS NIH HHS [R29 GM055792, GM55792, R01 GM055792, R01 GM055792-10A2] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055792, R01GM055792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1971, FRONT BIOL, P1; Bryan NS, 2004, P NATL ACAD SCI USA, V101, P4308, DOI 10.1073/pnas.0306706101; Butzer U, 1999, FEBS LETT, V445, P274, DOI 10.1016/S0014-5793(99)00139-8; Crawford JH, 2004, BLOOD, V104, P1375, DOI 10.1182/blood-2004-03-0880; Davisson RL, 1996, CIRC RES, V79, P256, DOI 10.1161/01.RES.79.2.256; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; Gordge MP, 1998, BIOCHEM PHARMACOL, V55, P657, DOI 10.1016/S0006-2952(97)00498-X; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Jensen DE, 1998, BIOCHEM J, V331, P659, DOI 10.1042/bj3310659; Jourd'heuil D, 2000, BIOCHEM BIOPH RES CO, V273, P22, DOI 10.1006/bbrc.2000.2892; Kettenhofen N, 2005, FREE RADICAL BIO MED, V39, pS101; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; LANDER HM, 1997, J BIOL CHEM, V272, P7323; Li HF, 1999, AM J PHYSIOL-CELL PH, V276, pC803, DOI 10.1152/ajpcell.1999.276.4.C803; Li S, 2005, J BIOL CHEM, V280, P20102, DOI 10.1074/jbc.M413164200; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Moellering D, 1999, FEBS LETT, V448, P292, DOI 10.1016/S0014-5793(99)00371-3; Poteser M, 2001, J BIOL CHEM, V276, P14797, DOI 10.1074/jbc.M008244200; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Satoh S, 1997, J NEUROCHEM, V69, P2197; Satoh S, 1996, J CELL PHYSIOL, V169, P87, DOI 10.1002/(SICI)1097-4652(199610)169:1<87::AID-JCP9>3.0.CO;2-A; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; TOYOOKA T, 1983, J CHROMATOGR, V282, P495, DOI 10.1016/S0021-9673(00)91626-1; Wang SW, 2004, J BIOL CHEM, V279, P25535, DOI 10.1074/jbc.M400944200; Wang XD, 2004, P NATL ACAD SCI USA, V101, P11477, DOI 10.1073/pnas.0402201101; Zaman K, 2004, BIOCHEM J, V380, P67, DOI 10.1042/BJ20031687; Zeigler MM, 2003, J BIOL CHEM, V278, P12894, DOI 10.1074/jbc.M213125200; Zeng H, 2001, AM J PHYSIOL-HEART C, V281, pH432, DOI 10.1152/ajpheart.2001.281.1.H432; Zhang YH, 2005, FREE RADICAL BIO MED, V38, P874, DOI 10.1016/j.freeradbiomed.2004.12.012; Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101; Zhang YH, 2004, AM J PHYSIOL-LUNG C, V287, pL467, DOI 10.1152/ajplung.00350.2003	39	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33835	33841		10.1074/jbc.M603248200	http://dx.doi.org/10.1074/jbc.M603248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16893892	Green Accepted, hybrid			2022-12-25	WOS:000241767600004
J	Simonovic, M; Zhang, Z; Cianci, CD; Steitz, TA; Morrow, JS				Simonovic, Miljan; Zhang, Zhushan; Cianci, Carol D.; Steitz, Thomas A.; Morrow, Jon S.			Structure of the calmodulin alpha II-spectrin complex provides insight into the regulation of cell plasticity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXON INITIAL SEGMENTS; BETA-IV-SPECTRIN; MU-CALPAIN; CRYSTAL-STRUCTURE; BINDING DOMAIN; FODRIN; CLEAVAGE; ACTIVATION; SITE; SEQUENCE	alpha II-spectrin is a major cortical cytoskeletal protein contributing to membrane organization and integrity. The Ca2+-activated binding of calmodulin to an unstructured insert in the 11th repeat unit of alpha II-spectrin enhances the susceptibility of spectrin to calpain cleavage but abolishes its sensitivity to several caspases and to at least one bacterially derived pathologic protease. Other regulatory inputs including phosphorylation by c-Src also modulate the proteolytic susceptibility of alpha II-spectrin. These pathways, acting through spectrin, appear to control membrane plasticity and integrity in several cell types. To provide a structural basis for understanding these crucial biological events, we have solved the crystal structure of a complex between bovine calmodulin and the calmodulin-binding domain of human alpha II-spectrin (Protein Data Bank ID code 2FOT). The structure revealed that the entire calmodulin-spectrin-binding interface is hydrophobic in nature. The spectrin domain is also unique in folding into an amphiphilic helix once positioned within the calmodulin-binding groove. The structure of this complex provides insight into the mechanisms by which calmodulin, calpain, caspase, and tyrosine phosphorylation act on spectrin to regulate essential cellular processes.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University	Morrow, JS (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St BML 140, New Haven, CT 06520 USA.	jon.morrow@yale.edu	Steitz, Thomas A./C-6559-2009	Simonovic, Miljan/0000-0002-1576-2222	NHLBI NIH HHS [R01-HL28560] Funding Source: Medline; NIGMS NIH HHS [GM22778] Funding Source: Medline; NINDS NIH HHS [P01-NS35476] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035476] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An XL, 2004, BIOCHEMISTRY-US, V43, P310, DOI 10.1021/bi035653h; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Aoyagi M, 2003, EMBO J, V22, P766, DOI 10.1093/emboj/cdg078; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; BRUNGER AT, 1991, ACTA CRYSTALLOGR A, V47, P195, DOI 10.1107/S0108767390011795; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Canizalez-Roman A, 2003, MOL MICROBIOL, V48, P947, DOI 10.1046/j.1365-2958.2003.03492.x; Clapperton JA, 2002, BIOCHEMISTRY-US, V41, P14669, DOI 10.1021/bi026660t; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cuerrier D, 2005, J BIOL CHEM, V280, P40632, DOI 10.1074/jbc.M506870200; DE M, 2000, J CELL SCI, V113, P2331; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; DIAMOND R, 1992, PROTEIN SCI, V1, P1279, DOI 10.1002/pro.5560011006; DOSEMECI A, 1995, SYNAPSE, V20, P91, DOI 10.1002/syn.890200113; Dubreuil RR, 2000, J MUSCLE RES CELL M, V21, P705, DOI 10.1023/A:1005699608893; Dutta PR, 2002, INFECT IMMUN, V70, P7105, DOI 10.1128/IAI.70.12.7105-7113.2002; Faddis BT, 1997, J NEUROSCI, V17, P951; FOWLER VM, 1992, J CELL BIOL, V119, P1559, DOI 10.1083/jcb.119.6.1559; Gascard P, 2000, CURR OPIN HEMATOL, V7, P123, DOI 10.1097/00062752-200003000-00009; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HARRIS AS, 1988, J NEUROSCI, V8, P2640; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Melloni E, 1998, J BIOL CHEM, V273, P12827, DOI 10.1074/jbc.273.21.12827; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORROW JS, 1997, HDB PHYSIOL 14, P485; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nedrelow JH, 2003, J BIOL CHEM, V278, P7735, DOI 10.1074/jbc.M210988200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas G, 2002, MOL CELL BIOL, V22, P3527, DOI 10.1128/MCB.22.10.3527-3536.2002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkinson NJ, 2001, NAT GENET, V29, P61, DOI 10.1038/ng710; PONTREMOLI S, 1985, BIOCHEM BIOPH RES CO, V129, P389, DOI 10.1016/0006-291X(85)90163-9; Pradhan D, 2002, IMMUNITY, V17, P303, DOI 10.1016/S1074-7613(02)00396-5; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHEPPARD A, 1991, SYNAPSE, V9, P231, DOI 10.1002/syn.890090310; SHEPPARD AM, 1993, SYNAPSE, V15, P239, DOI 10.1002/syn.890150309; Sihag RK, 1996, J NEUROSCI RES, V44, P430, DOI 10.1002/(SICI)1097-4547(19960601)44:5<430::AID-JNR3>3.0.CO;2-G; Stabach PR, 1997, BIOCHEMISTRY-US, V36, P57, DOI 10.1021/bi962034i; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; Villaseca JM, 2000, INFECT IMMUN, V68, P5920, DOI 10.1128/IAI.68.10.5920-5927.2000; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Williams ST, 2003, APOPTOSIS, V8, P353, DOI 10.1023/A:1024168901003; Yamauchi E, 2003, NAT STRUCT BIOL, V10, P226, DOI 10.1038/nsb900; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L	63	39	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34333	34340		10.1074/jbc.M604613200	http://dx.doi.org/10.1074/jbc.M604613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16945920	hybrid			2022-12-25	WOS:000241767600053
J	Joyce, CW; Wagner, EM; Basso, F; Amar, MJ; Freeman, LA; Shamburek, RD; Knapper, CL; Syed, J; Wu, J; Vaisman, BL; Fruchart-Najib, J; Billings, EM; Paigen, B; Remaley, AT; Santamarina-Fojo, S; Brewer, HB				Joyce, Charles W.; Wagner, Elke M.; Basso, Federica; Amar, Marcelo J.; Freeman, Lita A.; Shamburek, Robert D.; Knapper, Catherine L.; Syed, Jafri; Wu, Justina; Vaisman, Boris L.; Fruchart-Najib, Jamila; Billings, Eric M.; Paigen, Beverly; Remaley, Alan T.; Santamarina-Fojo, Silvia; Brewer, H. Bryan, Jr.			ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER 1; REVERSE CHOLESTEROL TRANSPORT; PLASMA RATIO METHOD; TANGIER-DISEASE; TRANSGENIC MICE; AORTIC ATHEROSCLEROSIS; HEPATIC ABCA1; KNOCKOUT MICE; IN-VIVO	The identification of ABCA1 as a key transporter responsible for cellular lipid efflux has led to considerable interest in defining its role in cholesterol metabolism and atherosclerosis. In this study, the effect of overexpressing ABCA1 in the liver of LDLr-KO mice was investigated. Compared with LDLr-KO mice, ABCA1-Tg x LDLr-KO (ABCA1-Tg) mice had significantly increased plasma cholesterol levels, mostly because of a 2.8-fold increase in cholesterol associated with a large pool of apoB-lipoproteins. ApoB synthesis was unchanged but the catabolism of I-125-apoB-VLDL and -LDL were significantly delayed, accounting for the 1.35-fold increase in plasma apoB levels in ABCA1-Tg mice. We also found rapid in vivo transfer of free cholesterol from HDL to apoB-lipoproteins in ABCA1-Tg mice, associated with a significant 2.7-fold increase in the LCAT-derived cholesteryl linoleate content found primarily in apoB-lipoproteins. ABCA1-Tg mice had 1.4-fold increased hepatic cholesterol concentrations, leading to a compensatory 71% decrease in de novo hepatic cholesterol synthesis, as well as enhanced biliary cholesterol, and bile acid secretion. CAV-1, CYP2b10, and ABCG1 were significantly induced in ABCA1-overexpressing livers; however, no differences were observed in the hepatic expression of CYP7 alpha 1, CYP27 alpha 1, or ABCG5/G8 between ABCA1-Tg and control mice. As expected from the pro-atherogenic plasma lipid profile, aortic atherosclerosis was increased 10-fold in ABCA1-Tg mice. In summary, hepatic overexpression of ABCA1 in LDLr-KO mice leads to: 1) expansion of the pro-atherogenic apoB-lipoprotein cholesterol pool size via enhanced transfer of HDL-cholesterol to apoB-lipoproteins and delayed catabolism of cholesterol-enriched apoB-lipoproteins; 2) increased cholesterol concentration in the liver, resulting in up-regulated hepatobiliary sterol secretion; and 3) significantly enhanced aortic atherosclerotic lesions.	NHLBI, NIH, Mol Dis Sect, Bethesda, MD 20892 USA; NHLBI, NIH, Bioinformat Core Facil, Bethesda, MD 20892 USA; Inst Pasteur, Dept Atherosclerose, F-59019 Lille, France; Cardiovasc Res Inst, Washington, DC 20010 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Wagner, EM (corresponding author), NHLBI, NIH, Mol Dis Sect, Bldg 10,Rm 7N105, Bethesda, MD 20892 USA.	ewagner@mail.nih.gov	Vaisman, Boris L/B-3453-2008; Amar, Marcelo/AAD-5599-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002064, Z01HL002058, ZIAHL002058] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Amar MJA, 1998, J LIPID RES, V39, P2436; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brewer HB, 2004, NEW ENGL J MED, V350, P1491, DOI 10.1056/NEJMp048023; Brewer HB, 2004, ARTERIOSCL THROM VAS, V24, P387, DOI 10.1161/01.ATV.0000121505.88326.d2; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; Brunham LR, 2006, J CLIN INVEST, V116, P1052, DOI 10.1172/JCI27352; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; CHEN CH, 1982, J LIPID RES, V23, P680; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; DESILVA HV, 1994, J LIPID RES, V35, P1297; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; FIELDING CJ, 1995, J LIPID RES, V36, P211; Flood C, 2004, ARTERIOSCL THROM VAS, V24, P564, DOI 10.1161/01.ATV.0000117174.19078.85; Furbee JW, 2002, J LIPID RES, V43, P428; GAMBLE W, 1978, J LIPID RES, V19, P1068; GLOMSET JA, 1968, J LIPID RES, V9, P155; Gnerre C, 2005, J LIPID RES, V46, P1633, DOI 10.1194/jlr.M400453-JLR200; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Groen AK, 2001, J CLIN INVEST, V108, P843, DOI 10.1172/JCI12473; Joyce C, 2003, ARTERIOSCL THROM VAS, V23, P965, DOI 10.1161/01.ATV.0000055194.85073.FF; Joyce CW, 2002, P NATL ACAD SCI USA, V99, P407, DOI 10.1073/pnas.012587699; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee RG, 2005, J LIPID RES, V46, P1205, DOI 10.1194/jlr.M500018-JLR200; MARCEL YL, 1988, ARTERIOSCLEROSIS, V8, P832, DOI 10.1161/01.ATV.8.6.832; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; METCALFE LD, 1966, ANAL CHEM, V38, P514, DOI 10.1021/ac60235a044; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; Moreno M, 2003, HEPATOLOGY, V38, P1477, DOI 10.1016/j.hep.2003.09.011; Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Ragozin S, 2005, ARTERIOSCL THROM VAS, V25, P1433, DOI 10.1161/01.ATV.0000166616.86723.d0; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rudel LL, 1998, ARTERIOSCL THROM VAS, V18, P1818, DOI 10.1161/01.ATV.18.11.1818; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Schwartz CC, 2004, J LIPID RES, V45, P1594, DOI 10.1194/jlr.M300511-JLR200; Schwarz M, 1998, J LIPID RES, V39, P1833; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915; Tsukamoto K, 1997, J LIPID RES, V38, P1869; TURLEY SD, 1994, J LIPID RES, V35, P328; TURLEY SD, 1981, J LIPID RES, V22, P569; VAISMAN BL, 1995, J BIOL CHEM, V270, P12269, DOI 10.1074/jbc.270.20.12269; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Van Eck M, 2006, ARTERIOSCL THROM VAS, V26, P929, DOI 10.1161/01.ATV.0000208364.22732.16; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; VAUGHAN AM, 2006, IN PRESS J LIPID RES; Wang HB, 2003, CURR DRUG METAB, V4, P515, DOI 10.2174/1389200033489262; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wellington CL, 2003, J LIPID RES, V44, P1470, DOI 10.1194/jlr.M300110-JLR200; Wu JE, 2004, J BIOL CHEM, V279, P22913, DOI 10.1074/jbc.M402838200; ZILVERSMIT DB, 1974, J LIPID RES, V15, P465; Zollner G, 2006, AM J PHYSIOL-GASTR L, V290, pG923, DOI 10.1152/ajpgi.00490.2005	65	69	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33053	33065		10.1074/jbc.M604526200	http://dx.doi.org/10.1074/jbc.M604526200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16928680	hybrid			2022-12-25	WOS:000241621400014
J	Lee, J; Kim, HK; Rho, JY; Han, YM; Kim, J				Lee, Jungwoon; Kim, Hye Kyoung; Rho, Jeung-Yon; Han, Yong-Mahn; Kim, Jungho			The human OCT-4 isoforms differ in their ability to confer self-renewal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; HUMAN CHORIONIC-GONADOTROPIN; TRANSCRIPTION FACTOR OCT-3/4; POU-DOMAIN; CHROMOSOMAL LOCATION; MOUSE EMBRYO; GERM-LINE; MAMMALIAN EMBRYO; ES CELLS; GENE	OCT-4 transcription factors play an important role in maintaining the pluripotent state of embryonic stem cells and may prevent expression of genes activated during differentiation. Human OCT-4 isoformm RNAs encode proteins that have identical POU DNA binding domains and C-terminal domains but differ in their N-terminal domains. We report here the cloning and characterization of the human OCT-4B isoform. Human OCT-4B cDNA encodes a 265-amino acid protein with a predicted molecular mass of 30 kDa. Embryonic stem (ES) cell-based complementation assays using ZHBTc4 ES cells showed that unlike human OCT-4A, OCT-4B cannot sustain ES cell self-renewal. In addition, OCT-4B does not bind to a probe carrying the OCT-4 consensus binding sequence, and we demonstrate that two separate regions of its N-terminal domain are responsible for inhibiting DNA binding. We also demonstrate that OCT-4B is mainly localized to the cytoplasm. Overexpression of OCT-4B did not activate transcription from OCT-4-dependent promoters, although OCT-4A did as reported previously. Furthermore, transcriptional activation by human OCT-4A was not inhibited by co-expression of OCT-4B. Taken together, these data suggest that the DNA binding, transactivation, and abilities to confer self-renewal of the human OCT-4 isoforms differ.	Sogang Univ, Dept Life Sci, Mol & Cellular Biol Lab, Seoul 121742, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Sogang University; Korea Advanced Institute of Science & Technology (KAIST)	Kim, J (corresponding author), Sogang Univ, Dept Life Sci, Mol & Cellular Biol Lab, Seoul 121742, South Korea.	jkim@sogang.ac.kr	Han, Yong-Mahn/C-1652-2011; Kim, Hye Kyoung/GQB-4102-2022					AAMLID KH, 1990, CARBOHYD RES, V202, P117, DOI 10.1016/0008-6215(90)84075-6; Abate-Shen C, 2003, CANCER CELL, V4, P329, DOI 10.1016/S1535-6108(03)00277-0; ABDELRAHMAN B, 1995, HUM REPROD, V10, P2787, DOI 10.1093/oxfordjournals.humrep.a135792; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Brehm A, 1999, MOL CELL BIOL, V19, P2635; Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Butteroni C, 2000, J MOL BIOL, V304, P529, DOI 10.1006/jmbi.2000.4238; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Ezashi T, 2001, MOL CELL BIOL, V21, P7883, DOI 10.1128/MCB.21.23.7883-7891.2001; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Goto T, 1999, MOL HUM REPROD, V5, P851, DOI 10.1093/molehr/5.9.851; Hansis C, 2000, MOL HUM REPROD, V6, P999, DOI 10.1093/molehr/6.11.999; HEBERT JM, 1991, DEVELOPMENT, V112, P407; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Kraft HJ, 1996, J BIOL CHEM, V271, P12873, DOI 10.1074/jbc.271.22.12873; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Lamb KA, 1998, MOL REPROD DEV, V51, P218; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee HJ, 2004, FEBS LETT, V564, P188, DOI 10.1016/S0014-5793(04)00314-X; Lee JW, 2005, STEM CELLS, V23, P738, DOI 10.1634/stemcells.2004-0375; Li WH, 2001, NATURE, V409, P847, DOI 10.1038/35057039; Liu LM, 1996, J BIOL CHEM, V271, P16683, DOI 10.1074/jbc.271.28.16683; Liu LM, 1997, MOL ENDOCRINOL, V11, P1651, DOI 10.1210/me.11.11.1651; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2005, CELL, V123, P917, DOI 10.1016/j.cell.2005.08.040; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Ovitt CE, 1998, MOL HUM REPROD, V4, P1021, DOI 10.1093/molehr/4.11.1021; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pan GJ, 2004, J BIOL CHEM, V279, P37013, DOI 10.1074/jbc.M405117200; Park JH, 2003, BIOL REPROD, V69, P2007, DOI 10.1095/biolreprod.103.017467; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9&lt;722::AID-BIES5&gt;3.0.CO;2-I; Rho JY, 2006, HUM REPROD, V21, P405, DOI 10.1093/humrep/dei328; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Sambrook J, 2001, MOL CLONING LAB MANU; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SIRACUSA LD, 1991, GENOMICS, V10, P313, DOI 10.1016/0888-7543(91)90314-5; TAKEDA J, 1992, NUCLEIC ACIDS RES, V20, P4613, DOI 10.1093/nar/20.17.4613; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; Vigano MA, 1996, NUCLEIC ACIDS RES, V24, P2112, DOI 10.1093/nar/24.11.2112; Yeom YI, 1996, DEVELOPMENT, V122, P881; YEOM YI, 1991, MECH DEVELOP, V35, P171	58	232	249	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33554	33565		10.1074/jbc.M603937200	http://dx.doi.org/10.1074/jbc.M603937200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16951404	hybrid			2022-12-25	WOS:000241621400065
J	Spann, NJ; Kang, S; Li, AC; Chen, AZ; Newberry, EP; Davidson, NO; Hui, STY; Davis, RA				Spann, Nathanael J.; Kang, Sohye; Li, Andrew C.; Chen, Amelia Z.; Newberry, Elizabeth P.; Davidson, Nicholas O.; Hui, Simon T. Y.; Davis, Roger A.			Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-ALPHA; UBIQUITIN-PROTEASOME PATHWAY; TISSUE-CULTURE MODEL; APOLIPOPROTEIN-B; EMBRYONIC LETHALITY; PLASMA-CHOLESTEROL; RESPONSE ELEMENT; MTP INHIBITOR; FAO CELL; APO-B	Unlike the livers of humans and mice, and most hepatoma cells, which accumulate triglycerides when treated with microsomal triglyceride transfer protein (MTP) inhibitors, L35 rat hepatoma cells do not express MTP and cannot secrete very low density lipoprotein (VLDL), yet they do not accumulate triglyceride. In these studies we show that transcriptional co-repression of the two lipid transfer proteins, liver fatty acid-binding protein (L-FABP) and MTP, which cooperatively shunt fatty acids into de novo synthesized glycerolipids and the transfer of lipids into VLDL, respectively, act together to maintain hepatic lipid homeostasis. FAO rat hepatoma cells express L-FABP and MTP and demonstrate the ability to assemble and secrete VLDL. In contrast, L35 cells, derived as a single cell clone from FAO cells, do not express L-FABP or MTP nor do they assemble and secrete VLDL. We used these hepatoma cells to elucidate how a conserved DR1 promoter element present in the promoters of L-FABP and MTP affects transcription, expression, and VLDL production. In FAO cells, the DR1 elements of both L-FABP and MTP promoters are occupied by peroxisome proliferator-activated receptor alpha-retinoid x receptor alpha (RXR alpha), with which PGC-1 beta activates transcription. In contrast, in L35 cells the DR1 elements of both L-FABP and MTP promoters are occupied by chicken ovalbumin upstream promoter transcription factor II, and transcription is diminished. The combined findings indicate that peroxisome proliferator-activated receptor alpha-RXR alpha and PGC-1 beta coordinately up-regulate L-FABP and MTP expression, by competing with chicken ovalbumin upstream promoter transcription factor II for the DR1 sites in the proximal promoters of each gene. Additional studies show that ablation of L-FABP prevents hepatic steatosis caused by treating mice with an MTP inhibitor. Our findings show that reducing both L-FABP and MTP is an effective means to reduce VLDL secretion without causing hepatic steatosis.	San Diego State Univ, Dept Biol, Inst Heart, San Diego, CA 92182 USA; Univ Calif San Diego, Dept Cellular & Mol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63110 USA	California State University System; San Diego State University; University of California System; University of California San Diego; University of California System; University of California San Diego; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Davis, RA (corresponding author), San Diego State Univ, Dept Biol, Inst Heart, LS307,5500 Campanile Dr, San Diego, CA 92182 USA.	rdavis@sunstroke.sdsu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, R37HL038180, R01HL051648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056260, P30DK052574] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57974, HL38180, HL51648] Funding Source: Medline; NIDDK NIH HHS [DK52574, DK56260] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ameen C, 2005, J BIOL CHEM, V280, P1224, DOI 10.1074/jbc.M412107200; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Bartels ED, 2002, DIABETES, V51, P1233, DOI 10.2337/diabetes.51.4.1233; BASS NM, 1990, MOL CELL BIOCHEM, V98, P167; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Bjorkegren J, 2002, J BIOL CHEM, V277, P5476, DOI 10.1074/jbc.M108514200; BOOGAERTS JR, 1984, AM J PHYSIOL, V246, pE77, DOI 10.1152/ajpendo.1984.246.1.E77; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; Cabrero A, 2003, MOL PHARMACOL, V64, P764, DOI 10.1124/mol.64.3.764; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; Chandler CE, 2003, J LIPID RES, V44, P1887, DOI 10.1194/jlr.M300094-JLR200; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Davis RA, 1997, J NUTR, V127, pS795, DOI 10.1093/jn/127.5.795S; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; Davis RA, 2001, ARTERIOSCL THROM VAS, V21, P887, DOI 10.1161/01.ATV.21.6.887; DAVIS RA, 1999, BIOCHIM BIOPHYS ACTA, V1441, P1; DU EZ, 1994, J BIOL CHEM, V269, P24169; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fu J, 2005, NEUROPHARMACOLOGY, V48, P1147, DOI 10.1016/j.neuropharm.2005.02.013; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Hui TY, 2002, J LIPID RES, V43, P785; Kang S, 2003, J BIOL CHEM, V278, P30478, DOI 10.1074/jbc.M304201200; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Ksander GM, 2001, J MED CHEM, V44, P4677, DOI 10.1021/jm010294e; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; Liao W, 2003, J LIPID RES, V44, P978, DOI 10.1194/jlr.M300020-JLR200; Lieu HD, 2003, CIRCULATION, V107, P1315, DOI 10.1161/01.CIR.0000054781.50889.0C; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; Pauley CJ, 2002, CELL SIGNAL, V14, P351, DOI 10.1016/S0898-6568(01)00260-1; Phelps C, 2006, P NATL ACAD SCI USA, V103, P7077, DOI 10.1073/pnas.0510080103; Poirier H, 1997, FEBS LETT, V412, P480, DOI 10.1016/S0014-5793(97)00830-2; Poirier H, 2001, BIOCHEM J, V355, P481, DOI 10.1042/0264-6021:3550481; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rustaeus S, 1999, J NUTR, V129, p463S, DOI 10.1093/jn/129.2.463S; SCARINO ML, 1987, EXP CELL RES, V170, P1, DOI 10.1016/0014-4827(87)90112-1; SCARINO ML, 1987, EXP CELL RES, V170, P15, DOI 10.1016/0014-4827(87)90113-3; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; Shiomi M, 2001, EUR J PHARMACOL, V431, P127, DOI 10.1016/S0014-2999(01)01419-4; Siri P, 2001, J BIOL CHEM, V276, P46064, DOI 10.1074/jbc.M108909200; SWIFT LL, 1995, J LIPID RES, V36, P395; Ueshima K, 2005, BIOL PHARM BULL, V28, P247, DOI 10.1248/bpb.28.247; Veniant MM, 1999, J NUTR, V129, p451S, DOI 10.1093/jn/129.2.451S; Wall ME, 2005, J MOL BIOL, V349, P501, DOI 10.1016/j.jmb.2005.04.022; Wang SL, 1997, J BIOL CHEM, V272, P19351, DOI 10.1074/jbc.272.31.19351; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wolfrum C, 2006, CELL METAB, V3, P99, DOI 10.1016/j.cmet.2006.01.001; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	64	56	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33066	33077		10.1074/jbc.M607148200	http://dx.doi.org/10.1074/jbc.M607148200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950764	hybrid			2022-12-25	WOS:000241621400015
J	Attrill, H; Imamura, A; Sharma, RS; Kiso, M; Crocker, PR; van Aalten, DMF				Attrill, Helen; Imamura, Akihiro; Sharma, Ritu S.; Kiso, Makoto; Crocker, Paul R.; van Aalten, Daan M. F.			Siglec-7 undergoes a major conformational change when complexed with the alpha(2,8)-disialylganglioside GT1b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; MOLECULAR-DYNAMICS SIMULATIONS; MOUSE MONOCLONAL-ANTIBODY; NATURAL-KILLER-CELLS; IMMUNOGLOBULIN SUPERFAMILY; CD33-RELATED SIGLECS; CONFORMER SELECTION; INHIBITORY RECEPTOR; GANGLIOSIDE GD3; BINDING DOMAIN	The siglecs are a group of mammalian sialic acid binding receptors expressed predominantly in the immune system. The CD33-related siglecs show complex recognition patterns for sialylated glycans. Siglec-7 shows a preference for alpha(2,8)-disialylated ligands and provides a structural template for studying the key interactions that drive this selectivity. We have co-crystallized Siglec-7 with a synthetic oligosaccharide corresponding to the alpha(2,8)-disialylated ganglioside GT1b. The crystal structure of the complex offers a first glimpse into how this important family of lectins binds the structurally diverse gangliosides. The structure reveals that the C-C' loop, a region implicated in previous studies as driving siglec specificity, undergoes a dramatic conformational shift, allowing it to interact with the underlying neutral glycan core of the ganglioside. The structural data in combination with mutagenesis studies show that binding of the ganglioside is driven by extensive hydrophobic contacts together with key polar interactions and that the binding site structure is complementary to preferred solution conformations of GT1b.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; Gifu Univ, Dept Appl Bioorgan Chem, Fac Appl Biol Sci, Gifu 5011193, Japan	University of Dundee; University of Dundee; Gifu University	van Aalten, DMF (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	dava@davapc1.bioch.dundee.ac.uk		Attrill, Helen/0000-0003-3212-6364; van Aalten, Daan/0000-0002-1499-6908; Crocker, Paul/0000-0001-6230-0293	NIGMS NIH HHS [GM 62116] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alphey MS, 2003, J BIOL CHEM, V278, P3372, DOI 10.1074/jbc.M210602200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Angata T, 2002, BBA-GEN SUBJECTS, V1572, P294, DOI 10.1016/S0304-4165(02)00316-1; Attrill H, 2006, BIOCHEM J, V397, P271, DOI 10.1042/BJ20060103; Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841; AVRIL T, 2006, IN PRESS J LEUKOCYTE; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Blixt O, 2003, J BIOL CHEM, V278, P31007, DOI 10.1074/jbc.M304331200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Crocker PR, 1999, BIOCHEM J, V341, P355, DOI 10.1042/0264-6021:3410355; Crocker PR, 2005, CURR OPIN PHARMACOL, V5, P431, DOI 10.1016/j.coph.2005.03.003; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; de Graffenried CL, 2004, CURR OPIN CELL BIOL, V16, P356, DOI 10.1016/j.ceb.2004.06.007; Dimasi N, 2004, ACTA CRYSTALLOGR D, V60, P401, DOI 10.1107/S0907444903028439; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Feizi T, 2003, CURR OPIN STRUC BIOL, V13, P602, DOI 10.1016/j.sbi.2003.09.001; Fotinou C, 2001, J BIOL CHEM, V276, P32274, DOI 10.1074/jbc.M103285200; Fox DA, 2001, IMMUNOL INVEST, V30, P67, DOI 10.1081/IMM-100104017; FRUTTIGER M, 1995, EUR J NEUROSCI, V7, P511, DOI 10.1111/j.1460-9568.1995.tb00347.x; Gabius HJ, 2004, CHEMBIOCHEM, V5, P740, DOI 10.1002/cbic.200300753; Gilleron M, 1998, EUR J BIOCHEM, V252, P416, DOI 10.1046/j.1432-1327.1998.2520416.x; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hirabayashi J, 2004, GLYCOCONJUGATE J, V21, P35, DOI 10.1023/B:GLYC.0000043745.18988.a1; Ikehara Y, 2004, J BIOL CHEM, V279, P43117, DOI 10.1074/jbc.M403538200; ISHIDA H, 1993, CARBOHYD RES, V246, P75, DOI 10.1016/0008-6215(93)84025-2; Ito A, 2001, FEBS LETT, V504, P81, DOI 10.1016/S0014-5793(01)02733-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kannagi R, 2002, CURR OPIN STRUC BIOL, V12, P599, DOI 10.1016/S0959-440X(02)00365-2; Kelm S, 2002, J EXP MED, V195, P1207, DOI 10.1084/jem.20011783; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; Lutteke T, 2005, NUCLEIC ACIDS RES, V33, pD242; Merritt EA, 1998, J MOL BIOL, V282, P1043, DOI 10.1006/jmbi.1998.2076; Merritt EA, 1997, PROTEIN SCI, V6, P1516, DOI 10.1002/pro.5560060716; Munday J, 1999, J LEUKOCYTE BIOL, V66, P705, DOI 10.1002/jlb.66.5.705; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nicoll G, 2003, EUR J IMMUNOL, V33, P1642, DOI 10.1002/eji.200323693; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; Rapoport E, 2003, BIOORG MED CHEM LETT, V13, P675, DOI 10.1016/S0960-894X(02)00998-8; Roseman S, 2001, J BIOL CHEM, V276, P41527, DOI 10.1074/jbc.R100053200; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Siebert HC, 2003, BIOCHEMISTRY-US, V42, P14762, DOI 10.1021/bi035477c; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Suresh MX, 2003, J THEOR BIOL, V222, P389, DOI 10.1016/S0022-5193(03)00050-X; URMACHER C, 1989, AM J DERMATOPATH, V11, P577, DOI 10.1097/00000372-198912000-00013; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; Vasudevan SV, 2002, BIOPOLYMERS, V63, P168, DOI 10.1002/bip.10019; Vasudevan SV, 2002, J MOL STRUC-THEOCHEM, V583, P215, DOI 10.1016/S0166-1280(01)00813-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WIKSTRAND CJ, 1994, PROG BRAIN RES, V101, P213; Yamaji T, 2002, J BIOL CHEM, V277, P6324, DOI 10.1074/jbc.M110146200	60	67	76	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32774	32783		10.1074/jbc.M601714200	http://dx.doi.org/10.1074/jbc.M601714200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16895906	hybrid			2022-12-25	WOS:000241414500076
J	Bartos, JD; Wang, W; Pike, JE; Bambara, RA				Bartos, Jeremy D.; Wang, Wensheng; Pike, Jason E.; Bambara, Robert A.			Mechanisms by which Bloom protein can disrupt recombination intermediates of Okazaki fragment maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; SYNDROME HELICASE; FLAP ENDONUCLEASE-1; DNA-REPLICATION; BINDING DOMAIN; WERNER; FEN1; STIMULATION; ASSOCIATION; SUPPRESSES	Bloom syndrome is a familial genetic disorder associated with sunlight sensitivity and a high predisposition to cancers. The mutated gene, Bloom protein (BLM), encodes a DNA helicase that functions in genome maintenance via roles in recombination repair and resolution of recombination structures. We designed substrates representing illegitimate recombination intermediates formed when a displaced DNA flap generated during maturation of Okazaki fragments escapes cleavage by flap endonuclease-1 and anneals to a complementary ectopic DNA site. Results show that displaced, replication protein A (RPA)-coated flaps could readily bind and ligate at the complementary site to initiate recombination. RPA also displayed a strand-annealing activity that hastens the rate of recombination intermediate formation. BLM helicase activity could directly disrupt annealing at the ectopic site and promote flap endonuclease-1 cleavage. Additionally, BLM has its own strand-annealing and strand-exchange activities. RPA inhibited the BLM strand-annealing activity, thereby promoting helicase activity and complex dissolution. BLM strand exchange could readily dissociate invading flaps, e. g. in a D-loop, if the exchange step did not involve annealing of RPA-coated strands. Use of ATP to activate the helicase function did not aid flap displacement by exchange, suggesting that this is a helicase- independent mechanism of complex dissociation. When RPA could bind, it displayed its own strand-exchange activity. We interpret these results to explain how BLM is well equipped to deal with alternative recombination intermediate structures.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	Robert_Bambara@urmc.rochester.edu			NATIONAL CANCER INSTITUTE [T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09363] Funding Source: Medline; NIGMS NIH HHS [GM 024441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae KH, 2003, NUCLEIC ACIDS RES, V31, P3006, DOI 10.1093/nar/gkg422; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Cheok CF, 2005, BIOCHEM SOC T, V33, P1456, DOI 10.1042/BST0331456; Cheok CF, 2005, NUCLEIC ACIDS RES, V33, P3932, DOI 10.1093/nar/gki712; Chester N, 1998, GENE DEV, V12, P3382, DOI 10.1101/gad.12.21.3382; Doherty KM, 2005, J BIOL CHEM, V280, P29494, DOI 10.1074/jbc.M500653200; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Garcia PL, 2004, EMBO J, V23, P2882, DOI 10.1038/sj.emboj.7600301; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; GERMAN J, 1998, MOL METABOLIC BASIS, P301; Henricksen LA, 2002, J BIOL CHEM, V277, P22361, DOI 10.1074/jbc.M201765200; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Imamura O, 2003, P NATL ACAD SCI USA, V100, P8193, DOI 10.1073/pnas.1431624100; Kao HI, 2004, J BIOL CHEM, V279, P50840, DOI 10.1074/jbc.M409231200; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; Liao SR, 2000, GENE DEV, V14, P2570, DOI 10.1101/gad.822400; Lillard-Wetherell K, 2004, HUM MOL GENET, V13, P1919, DOI 10.1093/hmg/ddh193; Liu Y, 2004, MOL CELL BIOL, V24, P4049, DOI 10.1128/MCB.24.9.4049-4064.2004; Liu Z, 1999, STRUCTURE, V7, P1557, DOI 10.1016/S0969-2126(00)88346-X; LONN U, 1990, CANCER RES, V50, P3141; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Machwe A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-1; Machwe A, 2005, J BIOL CHEM, V280, P23397, DOI 10.1074/jbc.M414130200; Macris MA, 2006, DNA REPAIR, V5, P172, DOI 10.1016/j.dnarep.2005.09.005; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Ralf C, 2006, J BIOL CHEM, V281, P22839, DOI 10.1074/jbc.M604268200; Ranalli TA, 2002, J BIOL CHEM, V277, P1719, DOI 10.1074/jbc.M109053200; Schawalder J, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-15; Sharma S, 2004, J BIOL CHEM, V279, P9847, DOI 10.1074/jbc.M309898200; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Tachibana A, 2004, ADV BIOPHYS, V38, P21, DOI 10.1016/S0065-227X(04)80046-7; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang WS, 2005, J BIOL CHEM, V280, P5391, DOI 10.1074/jbc.M412359200; Wu L, 2002, NUCLEIC ACIDS RES, V30, P4823, DOI 10.1093/nar/gkf611; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253	49	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32227	32239		10.1074/jbc.M606310200	http://dx.doi.org/10.1074/jbc.M606310200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16950766	hybrid			2022-12-25	WOS:000241414500020
J	Palmer, DA; Thompson, JK; Li, L; Prat, A; Wang, P				Palmer, Daniel A.; Thompson, Jill K.; Li, Lie; Prat, Ashton; Wang, Ping			Gib2, a novel G beta-like/RACK1 homolog, functions as a G beta subunit in cAMP signaling and is essential in Cryptococcus neoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WD-REPEAT PROTEINS; G-ALPHA SUBUNIT; SCHIZOSACCHAROMYCES-POMBE; PHOSPHODIESTERASE PDE4D5; SACCHAROMYCES-CEREVISIAE; MAMMALIAN RACK1; GENE-EXPRESSION; GAMMA-SUBUNITS; SWISS-MODEL; KINASE-C	Canonical G proteins are heterotrimeric, consisting of alpha, beta, and gamma subunits. Despite multiple G alpha subunits functioning in fungi, only a single G beta subunit per species has been identified, suggesting that non-conventional G protein signaling exists in this diverse group of eukaryotic organisms. Using the G alpha subunit Gpa1 that functions in cAMP signaling as bait in a two-hybrid screen, we have identified a novel G beta-like/RACK1 protein homolog, Gib2, from the human pathogenic fungus Cryptococcus neoformans. Gib2 contains a seven WD-40 repeat motif and is predicted to form a seven-bladed beta propeller structure characteristic of beta transducins. Gib2 is also shown to interact, respectively, with two G gamma subunit homologs, Gpg1 and Gpg2, similar to the conventional G beta subunit Gpb1. In contrast to Gpb1 whose overexpression promotes mating response, overproduction of Gib2 suppresses defects of gpa1 mutation in both melanization and capsule formation, the phenotypes regulated by cAMP signaling and associated with virulence. Furthermore, depletion of Gib2 by antisense suppression results in a severe growth defect, suggesting that Gib2 is essential. Finally, Gib2 is shown to also physically interact with a downstream target of Gpa1-cAMP signaling, Smg1, and the protein kinase C homolog Pkc1, indicating that Gib2 is also a multifunctional RACK1-like protein.	Louisiana State Univ, Hlth Sci Ctr, Res Inst Children, Dept Pediat, New Orleans, LA 70118 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70118 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Wang, P (corresponding author), 200 Henry Clay Ave, New Orleans, LA 70118 USA.	pwang@lsuhsc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054958] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 054958] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alspaugh JA, 1998, FUNGAL GENET BIOL, V25, P1, DOI 10.1006/fgbi.1998.1079; Alspaugh JA, 2002, EUKARYOT CELL, V1, P75, DOI 10.1128/EC.1.1.75-84.2002; Alspaugh JA, 1997, GENE DEV, V11, P3206, DOI 10.1101/gad.11.23.3206; Bahn YS, 2004, EUKARYOT CELL, V3, P1476, DOI 10.1128/EC.3.6.1476-1491.2004; Batlle M, 2003, J CELL SCI, V116, P701, DOI 10.1242/jcs.00266; CARDENAS ME, 1995, EMBO J, V14, P2772, DOI 10.1002/j.1460-2075.1995.tb07277.x; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chen SH, 2005, J BIOL CHEM, V280, P33445, DOI 10.1074/jbc.M505422200; Chen SH, 2004, J BIOL CHEM, V279, P17861, DOI 10.1074/jbc.M313727200; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; D'Souza CA, 2001, MOL CELL BIOL, V21, P3179, DOI 10.1128/MCB.21.9.3179-3191.2001; Davidson RC, 2002, MICROBIOL-SGM, V148, P2607, DOI 10.1099/00221287-148-8-2607; Dell EJ, 2002, J BIOL CHEM, V277, P49888, DOI 10.1074/jbc.M202755200; Fan WH, 2005, EUKARYOT CELL, V4, P1420, DOI 10.1128/EC.4.8.1420-1433.2005; Fraser JA, 2005, EUKARYOT CELL, V4, P401, DOI 10.1128/EC.4.2.401-406.2005; Gerbasi VR, 2004, MOL CELL BIOL, V24, P8276, DOI 10.1128/MCB.24.18.8276-8287.2004; Gorlach JM, 2002, MICROBIOL-SGM, V148, P213, DOI 10.1099/00221287-148-1-213; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUILLEMOT F, 1989, P NATL ACAD SCI USA, V86, P4594, DOI 10.1073/pnas.86.12.4594; Harashima T, 2005, MOL BIOL CELL, V16, P4557, DOI 10.1091/mbc.E05-05-0403; Harashima T, 2002, MOL CELL, V10, P163, DOI 10.1016/S1097-2765(02)00569-5; Heung LJ, 2004, J BIOL CHEM, V279, P21144, DOI 10.1074/jbc.M312995200; Hicks JK, 2005, EUKARYOT CELL, V4, P1971, DOI 10.1128/EC.4.12.1971-1981.2005; Hoffman CS, 2005, EUKARYOT CELL, V4, P495, DOI 10.1128/EC.4.3.495-503.2005; Hoffmann B, 1999, MOL MICROBIOL, V31, P807, DOI 10.1046/j.1365-2958.1999.01219.x; Kasahara S, 1997, MOL PLANT MICROBE IN, V10, P984, DOI 10.1094/MPMI.1997.10.8.984; KAYS AM, 2004, SIGNAL TRANSDUCTION, P175; Landry S, 2001, GENETICS, V157, P1159; Lengeler KB, 2000, MICROBIOL MOL BIOL R, V64, P746, DOI 10.1128/MMBR.64.4.746-785.2000; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Loftus BJ, 2005, SCIENCE, V307, P1321, DOI 10.1126/science.1103773; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; MITCHELL TG, 1995, CLIN MICROBIOL REV, V8, P515, DOI 10.1128/CMR.8.4.515; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Nielsen K, 2003, INFECT IMMUN, V71, P4831, DOI 10.1128/IAI.71.9.4831-4841.2003; Nishimura M, 2003, MOL MICROBIOL, V50, P231, DOI 10.1046/j.1365-2958.2003.03676.x; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Pukkila-Worley R, 2005, EUKARYOT CELL, V4, P190, DOI 10.1128/EC.4.1.190-201.2005; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rosen S, 1999, EMBO J, V18, P5592, DOI 10.1093/emboj/18.20.5592; SAMBROOK J, 2001, EXPRESSION CLONED GE; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shor B, 2003, J BIOL CHEM, V278, P49119, DOI 10.1074/jbc.M303968200; Sia RA, 2000, FUNGAL GENET BIOL, V29, P153, DOI 10.1006/fgbi.2000.1192; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; TOFFALETTI DL, 1993, J BACTERIOL, V175, P1405, DOI 10.1128/JB.175.5.1405-1411.1993; Wang P, 1999, CURR OPIN MICROBIOL, V2, P358, DOI 10.1016/S1369-5274(99)80063-0; Wang P, 2000, MOL CELL BIOL, V20, P352, DOI 10.1128/MCB.20.1.352-362.2000; Wang P, 2004, CURR GENET, V46, P247, DOI 10.1007/s00294-004-0529-1; Wang P, 2004, EUKARYOT CELL, V3, P1028, DOI 10.1128/EC.3.4.1028-1035.2004; Wang P, 2002, EUKARYOT CELL, V1, P257, DOI 10.1128/EC.1.2.257-272.2002; Wang P, 2005, EVOL GENET, P321; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WICKES BL, 1995, MOL MICROBIOL, V16, P1099, DOI 10.1111/j.1365-2958.1995.tb02335.x; Xue CY, 2006, MOL BIOL CELL, V17, P667, DOI 10.1091/mbc.E05-07-0699; Yang Q, 2002, EUKARYOT CELL, V1, P378, DOI 10.1128/EC.1.3.378-390.2002; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	66	54	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32596	32605		10.1074/jbc.M602768200	http://dx.doi.org/10.1074/jbc.M602768200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16950773	hybrid			2022-12-25	WOS:000241414500057
J	Yoon, HJ; Feoktistova, A; Chen, JS; Jennings, JL; Link, AJ; Gould, KL				Yoon, Hyun-Joo; Feoktistova, Anna; Chen, Jun-Song; Jennings, Jennifer L.; Link, Andrew J.; Gould, Kathleen L.			Role of Hcn1 and its phosphorylation in fission yeast anaphase-promoting complex/cyclosome function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-UBIQUITIN LIGASE; GENE-EXPRESSION PROGRAM; SCHIZOSACCHAROMYCES-POMBE; CELL-SEPARATION; SACCHAROMYCES-CEREVISIAE; SPINDLE CHECKPOINT; MITOTIC REGULATION; DESTRUCTION BOX; PROTEIN-KINASES; BUDDING YEAST	The anaphase-promoting complex/cyclosome (APC/C) is a conserved multisubunit ubiquitin ligase required for the degradation of key cell cycle regulators. The APC/C becomes active at the metaphase/anaphase transition and remains active during G(1) phase. One mechanism linked to activation of the APC/C is phosphorylation. Although many sites of mitotic phosphorylation have been identified in core components of the APC/C, the consequence of any individual phosphorylation event has not been elucidated in vivo. In this study, we show that Hcn1 is an essential core component of the fission yeast APC/C and is critical for maintaining complex integrity. Moreover, Hcn1 is a phosphoprotein in vivo. Phosphorylation of Hcn1 occurs at a single Cdk1 site in vitro and in vivo. Mutation of this site to alanine, but not aspartic acid, compromises APC/C function and leads to a specific defect in the completion of cell division.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Vanderbilt University	Gould, KL (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.	kathy.gould@vanderbilt.edu		Gould, Kathleen/0000-0002-3810-4070	NATIONAL CANCER INSTITUTE [P50CA098131] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047728, R01GM064779] Funding Source: NIH RePORTER; NCI NIH HHS [CA 098131] Funding Source: Medline; NHLBI NIH HHS [HL 68744] Funding Source: Medline; NIEHS NIH HHS [ES 11993] Funding Source: Medline; NIGMS NIH HHS [GM 64779, GM 47728] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso-Nunez ML, 2005, MOL BIOL CELL, V16, P2003, DOI 10.1091/mbc.E04-06-0442; Bahler J, 2005, CELL CYCLE, V4, P39, DOI 10.4161/cc.4.1.1336; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Berry LD, 1999, MOL CELL BIOL, V19, P2535; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Burns CG, 2002, MOL CELL BIOL, V22, P801, DOI 10.1128/MCB.22.3.801-815.2002; Burton JL, 2005, MOL CELL, V18, P533, DOI 10.1016/j.molcel.2005.04.022; Chen RH, 2004, EMBO J, V23, P3113, DOI 10.1038/sj.emboj.7600308; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; D'Angiolella V, 2003, GENE DEV, V17, P2520, DOI 10.1101/gad.267603; Dekker N, 2004, MOL BIOL CELL, V15, P3903, DOI 10.1091/mbc.E04-04-0319; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; Gould KL, 2004, METHODS, V33, P239, DOI 10.1016/j.ymeth.2003.11.019; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; He XW, 1998, J CELL SCI, V111, P1635; James P, 1996, GENETICS, V144, P1425; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KEENEY JB, 1994, GENETICS, V136, P849; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Martin-Cuadrado AB, 2003, J CELL SCI, V116, P1689, DOI 10.1242/jcs.00377; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Ohi MD, 2002, MOL CELL BIOL, V22, P2011, DOI 10.1128/MCB.22.7.2011-2024.2002; Passmore LA, 2005, MOL CELL, V20, P855, DOI 10.1016/j.molcel.2005.11.003; Peng X, 2005, MOL BIOL CELL, V16, P1026, DOI 10.1091/mbc.E04-04-0299; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Petit CS, 2005, J CELL SCI, V118, P5731, DOI 10.1242/jcs.02687; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Rustici G, 2004, NAT GENET, V36, P809, DOI 10.1038/ng1377; Schwickart M, 2004, MOL CELL BIOL, V24, P3562, DOI 10.1128/MCB.24.8.3562-3576.2004; Searle JS, 2004, NAT CELL BIOL, V6, P138, DOI 10.1038/ncb1092; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; Siam R, 2004, METHODS, V33, P189, DOI 10.1016/j.ymeth.2003.11.013; Thornton BR, 2006, GENE DEV, V20, P449, DOI 10.1101/gad.1396906; Ufano S, 2004, J CELL SCI, V117, P545, DOI 10.1242/jcs.00880; Vanoosthuyse V, 2005, TRENDS CELL BIOL, V15, P231, DOI 10.1016/j.tcb.2005.03.003; Vodermaier HC, 2003, CURR BIOL, V13, P1459, DOI 10.1016/S0960-9822(03)00581-5; Wendt KS, 2001, NAT STRUCT BIOL, V8, P784, DOI 10.1038/nsb0901-784; Yamada H, 1997, J CELL SCI, V110, P1793; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamashita YM, 1999, GENES CELLS, V4, P445, DOI 10.1046/j.1365-2443.1999.00274.x; Yanagida M, 1998, TRENDS CELL BIOL, V8, P144, DOI 10.1016/S0962-8924(98)01236-7; Yoon HJ, 2002, CURR BIOL, V12, P2048, DOI 10.1016/S0960-9822(02)01331-3; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 2004, MOL CELL, V13, P2, DOI 10.1016/S1097-2765(03)00530-6	61	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32284	32293		10.1074/jbc.M603867200	http://dx.doi.org/10.1074/jbc.M603867200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16950791	hybrid			2022-12-25	WOS:000241414500025
J	Qi, XP; Lewin, AS; Sun, L; Hauswirth, WW; Guy, J				Qi, Xiaoping; Lewin, Alfred S.; Sun, Liang; Hauswirth, William W.; Guy, John			Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL OPTIC NEURITIS; MULTIPLE-SCLEROSIS PATIENTS; NITRIC-OXIDE SYNTHASE; COMPLEX-I DEFICIENCY; AXONAL DEGENERATION; SUPEROXIDE-DISMUTASE; TYROSINE NITRATION; MASS-SPECTROMETRY; HYDROGEN-PEROXIDE; OXIDATIVE DAMAGE	The mechanisms of axonal and neuronal degeneration causing visual and neurologic disability in multiple sclerosis are poorly understood. Here we explored the contribution of mitochondria to neurodegeneration in the experimental autoimmune encephalomyelitis animal model of multiple sclerosis. Oxidative injury to the murine mitochondrion preceded the infiltration of inflammatory cells, classically heralded as the mediators of demyelination and axonal injury by transection. Nitration of mitochondrial proteins affected key subunits of complexes I and IV of the respiratory chain and a chaperone critical to the stabilization and translocation of proteins into the organelle. Oxidative products were associated with loss of mitochondrial membrane potential and apoptotic cell death. Reductions in the rate of synthesis of adenosine triphosphate were severe and even greater than those associated with disorders caused by mutated mitochondrial DNA. Mitochondrial vacuolization, swelling, and dissolution of cristae occurred in axons as early as 3 days after sensitization for experimental autoimmune encephalomyelitis. Our findings implicate mitochondrial dysfunction induced by protein inactivation and mediated by oxidative stress initiates a cascade of molecular events leading to apoptosis and neurodegeneration in experimental autoimmune encephalomyelitis that is not mediated by inflammatory cells.	Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Guy, J (corresponding author), Univ Florida, Coll Med, Dept Ophthalmol, Box 100284, Gainesville, FL 32610 USA.	johnguy@eye.ufl.edu		Lewin, Alfred/0000-0002-4192-9727	NEI NIH HHS [EY07982, EY12355] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007982, R01EY012355] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Baker D, 2003, GENE THER, V10, P844, DOI 10.1038/sj.gt.3302025; Barreiro E, 2002, AM J RESP CELL MOL, V26, P438, DOI 10.1165/ajrcmb.26.4.4634; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Bjartmar C, 2003, NEUROTOX RES, V5, P157, DOI 10.1007/BF03033380; Druzhyna NM, 2005, J BIOL CHEM, V280, P21673, DOI 10.1074/jbc.m411531200; Dutta R, 2006, ANN NEUROL, V59, P478, DOI 10.1002/ana.20736; Emahazion T, 1998, CYTOGENET CELL GENET, V82, P114, DOI 10.1159/000015081; Fernandez-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8; Giuliani F, 2003, Int MS J, V10, P122; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; Guy J, 1998, P NATL ACAD SCI USA, V95, P13847, DOI 10.1073/pnas.95.23.13847; GUY J, 1990, ARCH OPHTHALMOL-CHIC, V108, P1614, DOI 10.1001/archopht.1990.01070130116041; GUY J, 1993, OPHTHALMIC RES, V25, P253, DOI 10.1159/000267321; GUY J, 1989, ARCH OPHTHALMOL-CHIC, V107, P1359, DOI 10.1001/archopht.1989.01070020429048; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Hobom M, 2004, BRAIN PATHOL, V14, P148, DOI 10.1111/j.1750-3639.2004.tb00047.x; Kalman B, 2003, NEUROMOL MED, V3, P147, DOI 10.1385/NMM:3:3:147; Kalman B, 2006, CURR NEUROL NEUROSCI, V6, P244, DOI 10.1007/s11910-006-0012-0; Kawai A, 2001, J CELL SCI, V114, P3565; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Kumleh HH, 2006, J NEUROL SCI, V243, P65, DOI 10.1016/j.jns.2005.11.030; Ladha JS, 2005, CELL DEATH DIFFER, V12, P1417, DOI 10.1038/sj.cdd.4401668; Lisdero CL, 2004, METHOD ENZYMOL, V382, P67; Lu FM, 2000, J NEUROL SCI, V177, P95, DOI 10.1016/S0022-510X(00)00343-9; Maatta JA, 2000, SCAND J IMMUNOL, V51, P87; Melov S, 2000, ANN NY ACAD SCI, V908, P219; Meyer R, 2001, J NEUROSCI, V21, P6214, DOI 10.1523/JNEUROSCI.21-16-06214.2001; Murray J, 2003, J BIOL CHEM, V278, P37223, DOI 10.1074/jbc.M305694200; Owens T, 2003, CURR OPIN NEUROL, V16, P259, DOI 10.1097/00019052-200306000-00003; Petzold A, 2004, J NEUROL NEUROSUR PS, V75, P1178, DOI 10.1136/jnnp.2003.017236; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Qi XP, 2004, ANN NEUROL, V56, P182, DOI 10.1002/ana.20175; Qi XP, 1997, INVEST OPHTH VIS SCI, V38, P1203; Qi XP, 2003, ANN NEUROL, V53, P198, DOI 10.1002/ana.10426; RAO NA, 1981, INVEST OPHTH VIS SCI, V20, P159; RAO NA, 1977, INVEST OPHTH VIS SCI, V16, P338; Schilling B, 2005, FEBS LETT, V579, P2485, DOI 10.1016/j.febslet.2005.03.061; Smith KJ, 2002, LANCET NEUROL, V1, P232, DOI 10.1016/S1474-4422(02)00102-3; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Trip SA, 2005, ANN NEUROL, V58, P383, DOI 10.1002/ana.20575; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; Zemojtel T, 2006, FEBS LETT, V580, P455, DOI 10.1016/j.febslet.2005.12.038	44	112	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31950	31962		10.1074/jbc.M603717200	http://dx.doi.org/10.1074/jbc.M603717200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920708	Bronze			2022-12-25	WOS:000241235300081
J	Treeck, M; Struck, NS; Haase, S; Langer, C; Herrmann, S; Healer, J; Cowman, AF; Gilberger, TW				Treeck, Moritz; Struck, Nicole S.; Haase, Silvia; Langer, Christine; Herrmann, Susann; Healer, Julie; Cowman, Alan F.; Gilberger, Tim W.			A conserved region in the EBL proteins is implicated in microneme targeting of the malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE ANTIGEN-1; TOXOPLASMA-GONDII; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; QUALITY-CONTROL; ERYTHROCYTE INVASION; LIFE-CYCLE; RECEPTOR; GOLGI; TRAFFICKING	The proliferation of the malaria parasite Plasmodium falciparum within the human host is dependent upon invasion of erythrocytes. This process is accomplished by the merozoite, a highly specialized form of the parasite. Secretory organelles including micronemes and rhoptries play a pivotal role in the invasion process by storing and releasing parasite proteins. The mechanism of protein sorting to these compartments is unclear. Using a transgenic approach we show that trafficking of the most abundant micronemal proteins (members of the EBL-family: EBA-175, EBA-140/BAEBL, and EBA-181/JSEBL) is independent of their cytoplasmic and transmembrane domains, respectively. To identify the minimal sequence requirements for microneme trafficking, we generated parasites expressing EBAGFP chimeric proteins and analyzed their distribution within the infected erythrocyte. This revealed that: (i) a conserved cysteine-rich region in the ectodomain is necessary for protein trafficking to the micronemes and (ii) correct sorting is dependent on accurate timing of expression.	Bernhard Nocht Inst Trop Med, Res Grp Malaria 2, D-20359 Hamburg, Germany; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Bernhard Nocht Institut fur Tropenmedizin; Walter & Eliza Hall Institute	Gilberger, TW (corresponding author), Bernhard Nocht Inst Trop Med, Res Grp Malaria 2, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	gilberger@bni-hamburg.de	Treeck, Moritz/Q-9078-2019; Cowman, Alan F/C-7642-2013; Treeck, Moritz/O-6662-2017; Treeck, Moritz/X-8007-2019	Treeck, Moritz/0000-0002-9727-6657; Cowman, Alan F/0000-0001-5145-9004; Treeck, Moritz/0000-0002-9727-6657; HERRMANN, SUSANN/0000-0002-4953-5685; Haase, Silvia/0000-0003-0870-3715; Gilberger, Tim-Wolf/0000-0002-7965-8272				Adams JH, 2001, TRENDS PARASITOL, V17, P297, DOI 10.1016/S1471-4922(01)01948-1; Arvan P, 2002, TRAFFIC, V3, P771, DOI 10.1034/j.1600-0854.2002.31102.x; Bannister LH, 2000, PARASITOL TODAY, V16, P427, DOI 10.1016/S0169-4758(00)01755-5; BANNISTER LH, 1995, ANN TROP MED PARASIT, V89, P105, DOI 10.1080/00034983.1995.11812940; Bannister LH, 2003, J CELL SCI, V116, P3825, DOI 10.1242/jcs.00665; BANTING G, 1995, TRENDS CELL BIOL, V5, P340, DOI 10.1016/S0962-8924(00)89060-1; Baum J, 2006, J BIOL CHEM, V281, P5197, DOI 10.1074/jbc.M509807200; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bozdech Z, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r9; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006; Crabb BS, 2004, METH MOL B, V270, P263; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Deloche O, 2001, MOL BIOL CELL, V12, P475, DOI 10.1091/mbc.12.2.475; Di Cristina M, 2000, MOL CELL BIOL, V20, P7332, DOI 10.1128/MCB.20.19.7332-7341.2000; DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599; Gilberger TW, 2003, J CELL BIOL, V162, P317, DOI 10.1083/jcb.200301046; Gilberger TW, 2003, J BIOL CHEM, V278, P14480, DOI 10.1074/jbc.M211446200; Haldar Kasturi, 1993, Seminars in Cell Biology, V4, P345, DOI 10.1006/scel.1993.1041; Harris PK, 2005, PLOS PATHOG, V1, P241, DOI 10.1371/journal.ppat.0010029; Healer J, 2004, MOL MICROBIOL, V52, P159, DOI 10.1111/j.1365-2958.2003.03974.x; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoppe HC, 2000, NAT CELL BIOL, V2, P449, DOI 10.1038/35017090; Howell SA, 2003, J BIOL CHEM, V278, P23890, DOI 10.1074/jbc.M302160200; Humair D, 2001, PLANT CELL, V13, P781, DOI 10.1105/tpc.13.4.781; Jiang LW, 1998, J CELL BIOL, V143, P1183, DOI 10.1083/jcb.143.5.1183; Joiner KA, 2002, J CELL BIOL, V157, P557, DOI 10.1083/jcb.200112144; Karsten V, 1998, J CELL BIOL, V141, P1323, DOI 10.1083/jcb.141.6.1323; Karsten V, 2004, J BIOL CHEM, V279, P26052, DOI 10.1074/jbc.M400480200; Keller P, 1997, J CELL SCI, V110, P3001; Kocken CHM, 1998, J BIOL CHEM, V273, P15119, DOI 10.1074/jbc.273.24.15119; LANGRETH SG, 1978, J PROTOZOOL, V25, P443, DOI 10.1111/j.1550-7408.1978.tb04167.x; Lefrancois S, 2003, EMBO J, V22, P6430, DOI 10.1093/emboj/cdg629; Margos G, 2004, PARASITOLOGY, V129, P273, DOI 10.1017/S0031182004005657; Marti M, 2005, J CELL BIOL, V171, P587, DOI 10.1083/jcb.200508051; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Mayer DCG, 2004, P NATL ACAD SCI USA, V101, P2518, DOI 10.1073/pnas.0307318101; Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398; Meissner M, 2002, J CELL SCI, V115, P563; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Noe AR, 2000, MOL BIOCHEM PARASIT, V108, P169, DOI 10.1016/S0166-6851(00)00198-5; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; Przyborski JM, 2005, EMBO J, V24, P2306, DOI 10.1038/sj.emboj.7600720; Przyborski JM, 2005, PARASITOLOGY, V130, P373, DOI 10.1017/S0031182004006729; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509; Reiss M, 2001, J CELL BIOL, V152, P563, DOI 10.1083/jcb.152.3.563; Robinson DG, 2005, TRAFFIC, V6, P615, DOI 10.1111/j.1600-0854.2005.00303.x; Sato K, 2003, MOL BIOL CELL, V14, P3055, DOI 10.1091/mbc.E03-02-0115; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Striepen B, 2001, MOL BIOCHEM PARASIT, V113, P45, DOI 10.1016/S0166-6851(00)00379-0; Struck NS, 2005, J CELL SCI, V118, P5603, DOI 10.1242/jcs.02673; Taraschi TF, 1998, EXP PARASITOL, V88, P184, DOI 10.1006/expr.1998.4254; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Thiele C, 1997, CURR BIOL, V7, pR496, DOI 10.1016/S0960-9822(06)00247-8; Thompson JK, 2001, MOL MICROBIOL, V41, P47, DOI 10.1046/j.1365-2958.2001.02484.x; Tolia NH, 2005, CELL, V122, P183, DOI 10.1016/j.cell.2005.05.033; Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009; Topolska AE, 2004, J BIOL CHEM, V279, P4648, DOI 10.1074/jbc.M307859200; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; van Dooren GG, 2005, MOL MICROBIOL, V57, P405, DOI 10.1111/j.1365-2958.2005.04699.x; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	76	54	54	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31995	32003		10.1074/jbc.M606717200	http://dx.doi.org/10.1074/jbc.M606717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16935855	Bronze			2022-12-25	WOS:000241235300085
J	Lepage, PK; Lussier, MP; Barajas-Martinez, H; Bousquet, SM; Blanchard, AP; Francoeur, N; Dumaine, R; Boulay, G				Lepage, Pascale K.; Lussier, Marc P.; Barajas-Martinez, Hector; Bousquet, Simon M.; Blanchard, Alexandre P.; Francoeur, Nancy; Dumaine, Robert; Boulay, Guylain			Identification of two domains involved in the assembly of transient receptor potential canonical channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; CATION CHANNELS; TRPC CHANNELS; K+ CHANNEL; SUBUNIT; CALCIUM; PROTEINS; DETERMINANTS; NOMENCLATURE	Transient receptor potential canonical (TRPC) channels are associated with calcium entry activity in nonexcitable cells. TRPCs can form homo- or heterotetrameric channels, in which case they can assemble together within a subfamily groups. TRPC1, 4, and 5 represent one group, and TRPC3, 6, and 7 represent the other. The molecular determinants involved in promoting subunit tetramerization are not known. To identify them, we generated chimeras by swapping the different domains of TRPC4 with the same regions in TRPC6. We showed that TRPC4 coimmunoprecipitated with the chimeras containing the ankyrin repeats and coiled-coil domains of TRPC4 into TRPC6. However, chimeras containing only the ankyrin repeats or only the coiled-coil domain of TRPC4 did not coimmunoprecipitate with TRPC4. We also showed that a second domain of interaction composed of the pore region and the C-terminal tail is involved in the oligomerization of TRPC4. However, chimeras containing only the pore region or only the C-terminal tail of TRPC4 did not coimmunoprecipitate with TRPC4. Furthermore, we showed that the N terminus of TRPC6 coimmunoprecipitated with the C terminus of TRPC6. Overexpression in HEK293T cells of chimeras that contained an N terminus and a C terminus from different subfamily groups increased intracellular calcium entry subsequent to stimulation of G(q) protein-coupled receptors. These results suggest that two types of interactions are involved in the assembly of the four subunits of the TRPC channel. The first interaction occurs between the N termini and involves two regions. The second interaction occurs between the N terminus and the C terminus and does not appear to be necessary for the activity of TRPCs.	Univ Sherbrooke, Dept Pharmacol, Fac Med & Hlth Sci, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Dept Physiol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Dept Biophys, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke; University of Sherbrooke	Boulay, G (corresponding author), Univ Sherbrooke, Dept Pharmacol, Fac Med & Hlth Sci, 3001,12 Ave N, Sherbrooke, PQ J1H 5N4, Canada.	Guylain.Boulay@USherbrooke.ca	Boulay, Guylain/D-9773-2010	Lussier, Marc/0000-0001-5568-0072				Ambudkar IS, 2006, TRENDS PHARMACOL SCI, V27, P25, DOI 10.1016/j.tips.2005.11.008; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Chang Q, 2004, J BIOL CHEM, V279, P54304, DOI 10.1074/jbc.M406222200; Clapham DE, 2005, PHARMACOL REV, V57, P427, DOI 10.1124/pr.57.4.6; Engelke M, 2002, FEBS LETT, V523, P193, DOI 10.1016/S0014-5793(02)02971-X; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Ju M, 2003, J BIOL CHEM, V278, P12769, DOI 10.1074/jbc.M212973200; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; Lussier MP, 2005, J BIOL CHEM, V280, P19393, DOI 10.1074/jbc.M500391200; Mio K, 2005, BIOCHEM BIOPH RES CO, V333, P768, DOI 10.1016/j.bbrc.2005.05.181; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Niemeyer BA, 2005, N-S ARCH PHARMACOL, V371, P285, DOI 10.1007/s00210-005-1053-7; Sambrook J, 2001, MOL CLONING LAB MANU; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schaefer M, 2005, PFLUG ARCH EUR J PHY, V451, P35, DOI 10.1007/s00424-005-1467-6; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; SHEN NV, 1993, NEURON, V11, P67; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5	36	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30356	30364		10.1074/jbc.M603930200	http://dx.doi.org/10.1074/jbc.M603930200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16916799	hybrid			2022-12-25	WOS:000241075900009
J	Wang, Q; Abreu, MTH; Siminovitch, K; Downey, GP; McCulloch, CA				Wang, Qin; Abreu, Maria Teresa Herrera; Siminovitch, Katherine; Downey, Gregory P.; McCulloch, Christopher A.			Phosphorylation of SHP-2 regulates interactions between the endoplasmic reticulum and focal adhesions to restrict interleukin-1-induced Ca2+ signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-2; CELL-ADHESION; GENE-EXPRESSION; ERK ACTIVATION; RECEPTOR; KINASE; FIBROBLASTS; TRANSDUCTION; SUPERFAMILY; MIGRATION	Interleukin-1 (IL-1)-induced Ca2+ signaling in fibroblasts is constrained by focal adhesions. This process involves the protein-tyrosine phosphatase SHP-2, which is critical for IL-1-induced phosphorylation of phospholipase C gamma 1, thereby enhancing IL-1-induced Ca2+ release and ERK activation. Currently, the mechanisms by which SHP-2 modulates Ca2+ release from the endoplasmic reticulum are not defined. We used immunoprecipitation and fluorescence protein-tagged SHP-2 or endoplasmic reticulum (ER)-protein expression vectors, and an ER-specific calcium indicator, to examine the functional relationships between SHP-2, focal adhesions, and IL-1-induced Ca2+ release from the ER. By total internal reflection fluorescence microscopy to image sub-plasma membrane compartments, SHP-2 co-localized with the ER-associated proteins calnexin and calreticulin at sites of focal adhesion formation in fibroblasts. IL-1 beta promoted time-dependent recruitment of SHP-2 and ER proteins to focal adhesions; this process was blocked in cells treated with small interfering RNA for SHP-2 and in cells expressing a Y542F SHP-2 mutant. IL-1 stimulated inositol 1,4,5-trisphosphate receptor-mediated Ca2+ release from the ER subjacent to the plasma membrane that was tightly localized around fibronectin-coated beads and was reduced 4-fold in cells expressing Tyr-542 SHP-2 mutant. In subcellular fractions enriched for ER proteins, immunoprecipitation demonstrated that IL-1-enhanced association of SHP-2 with the type 1 inositol 1,4,5-trisphosphate receptor was dependent on Tyr-542 of SHP-2. We conclude that Tyr-542 of SHP-2 modulates IL-1-induced Ca2+ signals and association of the ER with focal adhesions.	Univ Toronto, CIHR Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Med, Div Respirol, Toronto, ON M5G 2M9, Canada; Mt Sinai Hosp, Samuel Lunenfeld Inst, Toronto, ON M5G 1X5, Canada; Toronto Gen Hosp, Res Inst, Hlth Network, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	McCulloch, CA (corresponding author), Univ Toronto, CIHR Grp Matrix Dynam, Rm 244,Fitzgerald Bld,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca	Siminovitch, Katherine/K-1475-2013	Downey, Gregory P/0000-0003-3253-5862				Abreu MTH, 2006, J CELL PHYSIOL, V207, P132, DOI 10.1002/jcp.20544; Alahari SK, 2002, INT REV CYTOL, V220, P145; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Arora PD, 2003, EXP CELL RES, V286, P366, DOI 10.1016/S0014-4827(03)00096-X; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Boyle DL, 1997, ARTHRITIS RHEUM, V40, P1772, DOI 10.1002/art.1780401008; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Heritage D, 2001, J BIOL CHEM, V276, P22655, DOI 10.1074/jbc.M102409200; HONIG J, 1989, J PERIODONTAL RES, V24, P362, DOI 10.1111/j.1600-0765.1989.tb00883.x; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Ioannou M, 1998, MOL PHARMACOL, V53, P1089; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Lo YYC, 1998, J BIOL CHEM, V273, P7059, DOI 10.1074/jbc.273.12.7059; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Luo L, 1997, BIOCHEM J, V324, P653, DOI 10.1042/bj3240653; Ma HT, 2003, BIOCHEM J, V376, P667, DOI 10.1042/BJ20031345; MacGillivray M, 2003, J BIOL CHEM, V278, P27190, DOI 10.1074/jbc.M213083200; MacGillivray MK, 2000, J BIOL CHEM, V275, P23509, DOI 10.1074/jbc.M003186200; Manes S, 1999, MOL CELL BIOL, V19, P3125; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Sugiyama T, 2000, FEBS LETT, V466, P29, DOI 10.1016/S0014-5793(99)01732-9; Tran H, 2002, J CELL SCI, V115, P2031; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Van Coppenolle F, 2004, J CELL SCI, V117, P4135, DOI 10.1242/jcs.01274; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; Wang Q, 2005, J BIOL CHEM, V280, P8397, DOI 10.1074/jbc.M410462200; Wang Q, 2003, FASEB J, V17, pA1072; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	48	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31093	31105		10.1074/jbc.M606392200	http://dx.doi.org/10.1074/jbc.M606392200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16905534	hybrid			2022-12-25	WOS:000241075900085
J	Worby, CA; Gentry, MS; Dixon, JE				Worby, Carolyn A.; Gentry, Matthew S.; Dixon, Jack E.			Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE MYOCLONUS EPILEPSY; PROTEIN-TYROSINE-PHOSPHATASE; GLYCOGEN-TARGETING SUBUNITS; AMINO-ACID-SEQUENCE; BINDING DOMAIN; FUNCTIONAL-CHARACTERIZATION; POLYGLUCOSAN BODIES; BIOCHEMICAL ASPECTS; STARCH DEGRADATION; CLINICAL-FEATURES	Laforin is the only phosphatase in the animal kingdom that contains a carbohydrate-binding module. Mutations in the gene encoding laforin result in Lafora disease, a fatal autosomal recessive neurodegenerative disorder, which is diagnosed by the presence of intracellular deposits of insoluble complex carbohydrates known as Lafora bodies. We demonstrate that laforin interacts with proteins known to be involved in glycogen metabolism and rule out several of these proteins as potential substrates. Surprisingly, we find that laforin displays robust phosphatase activity against a phosphorylated complex carbohydrate. Furthermore, this activity is unique to laforin, since several other phosphatases are unable to dephosphorylate polysaccharides. Finally, fusing the carbohydrate-binding module of laforin to the dual specific phosphatase VHR does not result in the ability of this phosphatase to dephosphorylate polysaccharides. Therefore, we hypothesize that laforin is unique in its ability to utilize a phosphorylated complex carbohydrate as a substrate and that this function may be necessary for the maintenance of normal cellular glycogen.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Dixon, JE (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jedixon@ucsd.edu			NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, R01DK018849] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009523, T32CA09523] Funding Source: Medline; NIDDK NIH HHS [R01 DK018849-34, R37 DK018024-34, R37 DK018024, R01 DK018849] Funding Source: Medline; PHS HHS [18849, 18024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Baunsgaard L, 2005, PLANT J, V41, P595, DOI 10.1111/j.1365-313X.2004.02322.x; BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506; Blennow A, 2002, TRENDS PLANT SCI, V7, P445, DOI 10.1016/S1360-1385(02)02332-4; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; BUSARD HLSM, 1987, ANN NEUROL, V21, P599, DOI 10.1002/ana.410210613; BUSARD HLSM, 1987, CLIN NEUROPATHOL, V6, P1; CARPENTER S, 1981, NEUROLOGY, V31, P1564, DOI 10.1212/WNL.31.12.1564; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chan EM, 2004, HUM MOL GENET, V13, P1117, DOI 10.1093/hmg/ddh130; Chan EM, 2003, NAT GENET, V35, P125, DOI 10.1038/ng1238; COLEMAN DL, 1974, ARCH NEUROL-CHICAGO, V31, P396, DOI 10.1001/archneur.1974.00490420062007; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Edwards TA, 2003, GENE DEV, V17, P2508, DOI 10.1101/gad.1119403; Fernandez-Sanchez ME, 2003, HUM MOL GENET, V12, P3161, DOI 10.1093/hmg/ddg340; GAMBETTI P, 1971, ARCH NEUROL-CHICAGO, V25, P483, DOI 10.1001/archneur.1971.00490060017002; Ganesh S, 2000, HUM MOL GENET, V9, P2251, DOI 10.1093/oxfordjournals.hmg.a018916; Ganesh S, 2004, BIOCHEM BIOPH RES CO, V313, P1101, DOI 10.1016/j.bbrc.2003.12.043; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; Gentry MS, 2005, P NATL ACAD SCI USA, V102, P8501, DOI 10.1073/pnas.0503285102; Halse R, 1999, J BIOL CHEM, V274, P776, DOI 10.1074/jbc.274.2.776; HARRIMAN DGF, 1955, BRAIN, V78, P325, DOI 10.1093/brain/78.3.325; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Ianzano L, 2004, HUM MUTAT, V23, P170, DOI 10.1002/humu.10306; Ianzano Leonarda, 2005, Hum Mutat, V26, P397, DOI 10.1002/humu.9376; JANEWAY R, 1967, ARCH NEUROL-CHICAGO, V16, P565, DOI 10.1001/archneur.1967.00470240003001; Kerk D, 2006, PLANT J, V46, P400, DOI 10.1111/j.1365-313X.2006.02704.x; KRISMAN CR, 1985, ANAL BIOCHEM, V147, P491, DOI 10.1016/0003-2697(85)90303-3; Lafora GR, 1911, Z GESAMTE NEUROL PSY, V6, P1, DOI 10.1007/BF02863929; Lehesjoki AE, 2002, ADV NEUROL, V89, P193; Lohi H, 2005, HUM MOL GENET, V14, P2727, DOI 10.1093/hmg/ddi306; LOMAKO J, 1994, BIOFACTORS, V4, P167; LOMAKO J, 1993, FEBS LETT, V329, P263, DOI 10.1016/0014-5793(93)80234-L; Lorberth R, 1998, NAT BIOTECHNOL, V16, P473, DOI 10.1038/nbt0598-473; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Mikkelsen R, 2004, BIOCHEM J, V377, P525, DOI 10.1042/BJ20030999; Minassian BA, 1998, NAT GENET, V20, P171, DOI 10.1038/2470; Minassian BA, 2002, ADV NEUROL, V89, P199; Niittyla T, 2006, J BIOL CHEM, V281, P11815, DOI 10.1074/jbc.M600519200; NISHIMURA RN, 1980, ANN NEUROL, V8, P409, DOI 10.1002/ana.410080412; Pagliarini DJ, 2004, J BIOL CHEM, V279, P38590, DOI 10.1074/jbc.M404959200; Paldi T, 2003, BIOCHEM J, V372, P905, DOI 10.1042/BJ20021527; Pederson BA, 2003, BIOCHEM BIOPH RES CO, V305, P826, DOI 10.1016/S0006-291X(03)00862-3; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Ritte G, 2000, PLANT J, V21, P387, DOI 10.1046/j.1365-313x.2000.00683.x; Romsicki Y, 2003, ARCH BIOCHEM BIOPHYS, V414, P40, DOI 10.1016/S0003-9861(03)00178-4; SAKAI M, 1970, NEUROLOGY, V20, P160, DOI 10.1212/WNL.20.2.160; SAKAI M, 1969, ARCH NEUROL-CHICAGO, V21, P526, DOI 10.1001/archneur.1969.00480170098011; Satow R, 2002, BIOCHEM BIOPH RES CO, V295, P85, DOI 10.1016/S0006-291X(02)00641-1; SCHNABEL R, 1968, Pathologia Europaea, V3, P218; Serratosa JM, 1999, HUM MOL GENET, V8, P345, DOI 10.1093/hmg/8.2.345; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7; Vikso-Nielsen A, 2002, CARBOHYD RES, V337, P327, DOI 10.1016/S0008-6215(01)00326-3; Wang JY, 2002, J BIOL CHEM, V277, P2377, DOI 10.1074/jbc.C100686200; WANG QM, 1994, J BIOL CHEM, V269, P14566; Wang W, 2004, BIOCHEM BIOPH RES CO, V325, P726, DOI 10.1016/j.bbrc.2004.10.083; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; YOKOI S, 1968, ARCH NEUROL-CHICAGO, V19, P15, DOI 10.1001/archneur.1968.00480010033002; YOKOI S, 1967, J NEUROPATH EXP NEUR, V26, P125; YOKOI S, 1975, CLIN CHIM ACTA, V62, P415; Yu TS, 2001, PLANT CELL, V13, P1907, DOI 10.1105/tpc.13.8.1907	68	150	151	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30412	30418		10.1074/jbc.M606117200	http://dx.doi.org/10.1074/jbc.M606117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16901901	Green Accepted, hybrid			2022-12-25	WOS:000241075900015
J	Jiang, YP; Ballou, LM; Lu, ZJ; Wan, L; Kelly, DJ; Cohen, IS; Lin, RZ				Jiang, Ya-Ping; Ballou, Lisa M.; Lu, Zhongju; Wan, Li; Kelly, Damon J.; Cohen, Ira S.; Lin, Richard Z.			Reversible heart failure in G alpha(q) transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOMYOPATHY; HYPERTROPHY; SUPPORT; MODEL	For many patients with cardiac insufficiency, the disease progresses inexorably to organ dilatation, pump failure, and death. Although there are examples of reversible heart failure in man, our understanding of how the myocardium repairs itself is limited. A well defined animal model of reversible heart failure would allow us to better investigate these restorative processes. Receptors that activate G alpha(q), a signal transduction molecule in the heterotrimeric G protein superfamily, are thought to play a key role in the development of heart failure. We demonstrated previously that mice expressing a recombinant G alpha(q) protein, the activity of which can be turned on or off at will in cardiac myocytes, develop a dilated cardiomyopathy with generalized edema and heart failure following activation of the protein ( Fan, G., Jiang, Y.-P., Lu, Z., Martin, D. W., Kelly, D. J., Zuckerman, J. M., Ballou, L. M., Cohen, I. S., and Lin, R. Z. ( 2005) J. Biol. Chem. 280, 40337 - 40346). Here we report that the contractile dysfunction and pathological structural changes in the myocardium improved significantly after termination of the G alpha(q) signal, even in animals with overt heart failure. Abnormalities in two proteins that regulate Ca2+ handling in myocytes, phospholamban and the voltage-dependent L-type Ca2+ channel, were also reversed, as was the increased expression of genes that are associated with heart failure. These results indicate that the heart has a substantial reparative capacity if the molecular signals responsible for the myocardial dysfunction can be identified and blocked.	SUNY Stony Brook, Dept Med, Div Hematol & Oncol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Mol Cardiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; Dept Vet Affairs Med Ctr, Northport, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lin, RZ (corresponding author), SUNY Stony Brook, Dept Med, Div Hematol & Oncol, Stony Brook, NY 11794 USA.	richard.lin@sunysb.edu	wan, li/GRY-7634-2022; Lin, Richard/J-1754-2014; Lu, zhongjul/AAT-5531-2021	Lin, Richard/0000-0002-3473-7276; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028958, R01HL067101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062722] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67101, HL28958] Funding Source: Medline; NIDDK NIH HHS [DK62722] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akashi YJ, 2003, QJM-INT J MED, V96, P563, DOI 10.1093/qjmed/hcg096; Dipla K, 1998, CIRCULATION, V97, P2316, DOI 10.1161/01.CIR.97.23.2316; Fan GF, 2005, J BIOL CHEM, V280, P40337, DOI 10.1074/jbc.M506810200; Hollenberg SM, 1997, J HEART LUNG TRANSPL, V16, pS7; Lu ZJ, 2005, J BIOL CHEM, V280, P40347, DOI 10.1074/jbc.M508441200; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Moorjani N, 2003, EUR J CARDIO-THORAC, V24, P920, DOI 10.1016/S1010-7940(03)00514-1; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656	9	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29988	29992		10.1074/jbc.M604699200	http://dx.doi.org/10.1074/jbc.M604699200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16893886	hybrid			2022-12-25	WOS:000240896300059
J	Kudrin, A; Scott, M; Martin, S; Chung, CW; Donn, R; McMaster, A; Ellison, S; Ray, D; Ray, K; Binks, M				Kudrin, Alex; Scott, Martin; Martin, Steven; Chung, Chun-wa; Donn, Rachelle; McMaster, Andrew; Ellison, Stuart; Ray, David; Ray, Keith; Binks, Michael			Human Macrophage Migration Inhibitory Factor A PROVEN IMMUNOMODULATORY CYTOKINE?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Macrophage migration inhibitory factor (MIF) is a pro-inflammatory mediator with the ability to induce various immunomodulatory responses and override glucocorticoid-driven immunosuppression. Some of these functions have been linked to the unusual enzymatic properties of the protein, namely tautomerase and oxidoreductase activities. However, there are conflicting reports regarding the functional role of these enzymatic properties in normal physiological homeostasis and disease progression. Therefore, we have produced a highly pure, virtually endotoxin-free recombinant MIF preparation and fully characterized this using a variety of biochemical and biophysical approaches. The recombinant protein, with demonstrable enzymatic activity, was then used to systematically examine the biological activity of MIF. Surprisingly, treatment with MIF alone failed to induce cytokine expression, with the exception of IL-8. However, co-treatment of lipopolysaccharide (LPS) in conjunction with MIF produced synergistic secretion of tumor necrosis factor-alpha, interleukin (IL)-1, and IL-8 compared with LPS alone. The potentiating effect of MIF was seen at physiologically relevant concentrations. These data suggest that MIF has no conventional cytokine activity but, rather, acts to modulate and amplify the response to LPS.	[Kudrin, Alex; Ray, Keith; Binks, Michael] GlaxoSmithKline, Dept Dis Biol Rheumatol & Inflammat, Stevenage SG1 2NY, Herts, England; [Scott, Martin; Martin, Steven; Chung, Chun-wa] GlaxoSmithKline, Discovery Res, Stevenage SG1 2NY, Herts, England; [Donn, Rachelle; Ray, David] Univ Manchester, Ctr Mol Med, Manchester M13 9PT, Lancs, England; [Donn, Rachelle; McMaster, Andrew; Ellison, Stuart] Univ Manchester, Arthrit Res Campaign Epidemiol Unit, Manchester M13 9PT, Lancs, England	GlaxoSmithKline; GlaxoSmithKline; University of Manchester; University of Manchester	Ray, K (corresponding author), GlaxoSmithKline, Dept Dis Biol, Stevenage SG1 2NY, Herts, England.	keith.p.ray@gsk.com		Donn, Rachelle/0000-0001-6976-9828; Ray, David/0000-0002-4739-6773				Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; Berghe WV, 1998, J BIOL CHEM, V273, P3285, DOI DOI 10.1074/JBC.273.6.3285; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Donn R, 2004, ARTHRITIS RHEUM-US, V50, P1604, DOI 10.1002/art.20178; Doppler W, 2001, MOL CELL BIOL, V21, P3266, DOI 10.1128/MCB.21.9.3266-3279.2001; Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100; Hermanowski-Vosatka A, 1999, BIOCHEMISTRY-US, V38, P12841, DOI 10.1021/bi991352p; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Ichiyama H, 2004, CYTOKINE, V26, P187, DOI 10.1016/j.cyto.2004.02.007; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; Kleemann R, 2002, J INTERF CYTOK RES, V22, P351, DOI 10.1089/107999002753675785; Kleemann R, 2000, EUR J BIOCHEM, V267, P7183, DOI 10.1046/j.1432-1327.2000.01823.x; Lacey D, 2003, ARTHRITIS RHEUM, V48, P103, DOI 10.1002/art.10733; Lan HY, 1996, AM J PATHOL, V149, P1119; Leech M, 1999, ARTHRITIS RHEUM, V42, P1601, DOI 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; Makita H, 1998, AM J RESP CRIT CARE, V158, P573, DOI 10.1164/ajrccm.158.2.9707086; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Nguyen MT, 2003, J BIOL CHEM, V278, P33654, DOI 10.1074/jbc.M301735200; Onodera S, 2000, J BIOL CHEM, V275, P444, DOI 10.1074/jbc.275.1.444; Onodera S, 2004, ARTHRITIS RHEUM-US, V50, P1437, DOI 10.1002/art.20190; Orita M, 2002, CURR PHARM DESIGN, V8, P1297, DOI 10.2174/1381612023394674; Petrenko O, 2005, MOL CELL, V17, P225, DOI 10.1016/j.molcel.2004.11.052; Philo JS, 2004, BIOPHYS CHEM, V108, P77, DOI 10.1016/j.bpc.2003.10.010; Roger T, 2005, EUR J IMMUNOL, V35, P3405, DOI 10.1002/eji.200535413; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Santos LL, 2004, J RHEUMATOL, V31, P1038; Schober A, 2004, CIRCULATION, V109, P380, DOI 10.1161/01.CIR.0000109201.72441.09; Senter PD, 2002, P NATL ACAD SCI USA, V99, P144, DOI 10.1073/pnas.011569399; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Sugie K, 1999, INT IMMUNOL, V11, P1149, DOI 10.1093/intimm/11.7.1149; Sugimoto H, 1999, BIOCHEMISTRY-US, V38, P3268, DOI 10.1021/bi982184o; Swope M, 1998, EMBO J, V17, P3534, DOI 10.1093/emboj/17.13.3534; Taylor AB, 1999, BIOCHEMISTRY-US, V38, P7444, DOI 10.1021/bi9904048; Tierney T, 2005, ENDOCRINOLOGY, V146, P35, DOI 10.1210/en.2004-0946; Tomura T, 1999, J IMMUNOL, V162, P195; Watarai H, 2000, P NATL ACAD SCI USA, V97, P13251, DOI 10.1073/pnas.230445397	51	45	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29641	29651	PMID 16893895	10.1074/jbc.M601103200	http://dx.doi.org/10.1074/jbc.M601103200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V45DH	16893895	hybrid			2022-12-25	WOS:000209796800001
J	Morris, GE; Parker, LC; Ward, JR; Jones, EC; Whyte, MKB; Brightling, CE; Bradding, P; Dower, SK; Sabroe, I				Morris, Gavin E.; Parker, Lisa C.; Ward, Jon R.; Jones, Elizabeth C.; Whyte, Moira K. B.; Brightling, Christopher E.; Bradding, Peter; Dower, Steven K.; Sabroe, Ian			Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses	FASEB JOURNAL			English	Article						airway smooth muscle; TLR; asthma	DOUBLE-STRANDED-RNA; AIRWAY SMOOTH-MUSCLE; HOUSE-DUST ENDOTOXIN; MAST-CELLS; DIFFERENTIAL EXPRESSION; CHEMOKINE RECEPTORS; HUMAN LUNG; T-CELLS; RECOGNITION; ACTIVATION	Viral and bacterial pathogens cause inflammation via Toll-like receptor (TLR) signaling. We have shown that effective responses to LPS may depend on cooperative interactions between TLR-expressing leukocytes and TLR-negative tissue cells. The aim of this work was to determine the roles of such networks in response to agonists of TLRs associated with antiviral and autoimmune responses. The TLR3 agonist poly( I: C) activated epithelial cells, primary endothelial cells, and two types of primary human smooth muscle cells ( airway [ASMC] and vascular) directly, while the TLR7/8 agonist R848 required the presence of leukocytes to activate ASMC. In keeping with these data, ASMC expressed TLR3 but not TLR7 or TLR8. Activation of ASMC by poly( I: C) induced a specific cytokine repertoire characterized by induction of CXCL10 generation and the potential to recruit mast cells. We subsequently explored the ability of TLR agonists to cooperate in the induction of inflammation. Dual stimulation with LPS and poly( I: C) caused enhanced cytokine generation from epithelial and smooth muscle cells when in the presence of leukocytes. Thus, inflammatory responses to pathogens are regulated by networks in which patterns of TLR expression and colocalization of tissue cells and leukocytes are critical.	Univ Sheffield, Acad Unit Resp Med, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Acad Unit Cell Biol, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England; Leicester Warwick Med Sch, Inst Lung Hlth, Dept Infect Inflammat & Immun, Leicester, Leics, England; Univ Hosp Leicester, Leicester, Leics, England	University of Sheffield; University of Sheffield; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester	Sabroe, I (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Acad Unit Resp Med, Div Genom Med, M Floor, Sheffield S10 2JF, S Yorkshire, England.	i.sabroe@sheffield.ac.uk	Sabroe, Ian/AAE-5858-2019; Sabroe, Ian/I-5981-2013; Whyte, Moira/E-6210-2010	Sabroe, Ian/0000-0001-9750-8975; brightling, chris/0000-0002-9345-4903; Bradding, Peter/0000-0001-8403-0319; Morris, Gavin/0000-0003-4054-6959; dower, steve/0000-0002-4675-4225	Medical Research Council [G116/170] Funding Source: Medline; MRC [G116/170] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Applequist SE, 2002, INT IMMUNOL, V14, P1065, DOI 10.1093/intimm/dxf069; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Brightling CE, 2005, J LEUKOCYTE BIOL, V77, P759, DOI 10.1189/jlb.0904511; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Doyle SE, 2003, J IMMUNOL, V170, P3565, DOI 10.4049/jimmunol.170.7.3565; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Hakonarson H, 1998, J CLIN INVEST, V102, P1732, DOI 10.1172/JCI4141; Harii N, 2005, MOL ENDOCRINOL, V19, P1231, DOI 10.1210/me.2004-0100; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Hollingsworth JW, 2005, AM J RESP CRIT CARE, V171, P806, DOI 10.1164/rccm.200407-953OC; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lee HK, 2006, IMMUNITY, V24, P153, DOI 10.1016/j.immuni.2005.12.012; Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Matsushima H, 2004, J IMMUNOL, V173, P531, DOI 10.4049/jimmunol.173.1.531; Morris GE, 2005, AM J RESP CRIT CARE, V171, P814, DOI 10.1164/rccm.200403-406OC; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Orinska Z, 2005, BLOOD, V106, P978, DOI 10.1182/blood-2004-07-2656; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Parker LC, 2004, J IMMUNOL, V172, P4977, DOI 10.4049/jimmunol.172.8.4977; Patole PS, 2005, J AM SOC NEPHROL, V16, P1326, DOI 10.1681/ASN.2004100820; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Rudd BD, 2005, J VIROL, V79, P3350, DOI 10.1128/JVI.79.6.3350-3357.2005; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; Sabroe I, 2002, J IMMUNOL, V168, P4701, DOI 10.4049/jimmunol.168.9.4701; Schilling D, 2002, J IMMUNOL, V169, P5874, DOI 10.4049/jimmunol.169.10.5874; Schreiner B, 2005, FASEB J, V19, P118, DOI 10.1096/fj.05-4342fje; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305, DOI 10.1164/ajrccm.163.2.ed2000a; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Tissari J, 2005, J IMMUNOL, V174, P4289, DOI 10.4049/jimmunol.174.7.4289; Triantafilou K, 2005, CELL MICROBIOL, V7, P1117, DOI 10.1111/j.1462-5822.2005.00537.x; Vijay-Kumar M, 2005, J IMMUNOL, V174, P6322, DOI 10.4049/jimmunol.174.10.6322; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249	54	70	74	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2153	+		10.1096/fj.06-5910fje	http://dx.doi.org/10.1096/fj.06-5910fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935934				2022-12-25	WOS:000241156900047
J	Donaldson, JR; Courcelle, CT; Courcelle, J				Donaldson, Janet R.; Courcelle, Charmain T.; Courcelle, Justin			RuvABC is required to resolve Holliday junctions that accumulate following replication on damaged templates in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATION-DEFICIENT MUTANTS; INDUCED DNA-DAMAGE; ULTRAVIOLET-LIGHT; LAGGING-STRAND; IN-VITRO; GENETIC-RECOMBINATION; FORK REVERSAL; LESION BYPASS; POL-V; POSTREPLICATION REPAIR	RuvABC is a complex that promotes branch migration and resolution of Holliday junctions. Although ruv mutants are hypersensitive to UV irradiation, the molecular event(s) that necessitate RuvABC processing in vivo are not known. Here, we used a combination of two-dimensional gel analysis and electron microscopy to reveal that although ruvAB and ruvC mutants are able to resume replication following arrest at UV-induced lesions, molecules that replicate in the presence of DNA damage accumulate unresolved Holliday junctions. The failure to resolve the Holliday junctions on the fully replicated molecules correlates with a delayed loss of genomic integrity that is likely to account for the loss of viability in these cells. The strand exchange intermediates that accumulate in ruv mutants are distinct from those observed at arrested replication forks and are not subject to resolution by RecG. These results indicate that the Holliday junctions observed in ruv mutants are intermediates of a repair pathway that is distinct from that of the recovery of arrested replication forks. A model is proposed in which RuvABC is required to resolve junctions that arise during the repair of a subset of nonarresting lesions after replication has passed through the template.	Portland State Univ, Dept Biol, Portland, OR 97207 USA	Portland State University	Donaldson, JR (corresponding author), Natl Inst Hlth, NIDDK, GBB 5 Mem Dr,MSC 0538, Bethesda, MD 20892 USA.	donaldsonjr@niddk.nih.gov			NIGMS NIH HHS [F32 GM068566] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM068566] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL L, 1983, ANAL BIOCHEM, V130, P527, DOI 10.1016/0003-2697(83)90628-0; BRIDGES BA, 1974, J BACTERIOL, V117, P1077, DOI 10.1128/JB.117.3.1077-1081.1974; CHAN GL, 1985, BIOCHEMISTRY-US, V24, P5723, DOI 10.1021/bi00342a006; Chow KH, 2004, J BIOL CHEM, V279, P3492, DOI 10.1074/jbc.M311012200; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; Courcelle CT, 2006, P NATL ACAD SCI USA, V103, P9154, DOI 10.1073/pnas.0600785103; Courcelle CT, 2005, J BACTERIOL, V187, P6953, DOI 10.1128/JB.187.20.6953-6961.2005; Courcelle J, 2003, SCIENCE, V299, P1064, DOI 10.1126/science.1081328; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Courcelle J, 2004, RES MICROBIOL, V155, P231, DOI 10.1016/j.resmic.2004.01.018; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; Courcelle J, 1999, J BACTERIOL, V181, P916, DOI 10.1128/JB.181.3.916-922.1999; DAVIS BD, 1949, P NATL ACAD SCI USA, V35, P1, DOI 10.1073/pnas.35.1.1; DELUCIA P, 1969, NATURE, V224, P1164, DOI 10.1038/2241164a0; Dickman MJ, 2002, EUR J BIOCHEM, V269, P5492, DOI 10.1046/j.1432-1033.2002.03250.x; Donaldson JR, 2004, GENETICS, V166, P1631, DOI 10.1534/genetics.166.4.1631; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Eggleston AK, 2000, J BIOL CHEM, V275, P26467, DOI 10.1074/jbc.M001496200; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; Flores MJ, 2002, MOL MICROBIOL, V44, P783, DOI 10.1046/j.1365-2958.2002.02913.x; Flores MJ, 2001, EMBO J, V20, P619, DOI 10.1093/emboj/20.3.619; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; Fuchs RPP, 2001, BIOCHEM SOC T, V29, P191, DOI 10.1042/0300-5127:0290191; GANESAN AK, 1974, J MOL BIOL, V87, P103, DOI 10.1016/0022-2836(74)90563-4; Grompone G, 2004, EMBO REP, V5, P607, DOI 10.1038/sj.embor.7400167; Grompone G, 2002, MOL MICROBIOL, V44, P1331, DOI 10.1046/j.1365-2958.2002.02962.x; Harris RS, 1996, GENETICS, V142, P681; Heller RC, 2005, MOL CELL, V17, P733, DOI 10.1016/j.molcel.2005.01.019; Heller RC, 2006, NATURE, V439, P557, DOI 10.1038/nature04329; Heller RC, 2005, J BIOL CHEM, V280, P34143, DOI 10.1074/jbc.M507224200; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; HORI ZI, 1970, PHOTOCHEM PHOTOBIOL, V11, P99, DOI 10.1111/j.1751-1097.1970.tb05976.x; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; HOWARDFL.P, 1969, J BACTERIOL, V97, P1134, DOI 10.1128/JB.97.3.1134-1141.1969; Ishioka K, 1998, GENES CELLS, V3, P209, DOI 10.1046/j.1365-2443.1998.00185.x; Jaktaji RP, 2003, MOL MICROBIOL, V47, P1091, DOI 10.1046/j.1365-2958.2003.03357.x; JOHNSON RC, 1977, NATURE, V267, P80, DOI 10.1038/267080a0; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Lucas I, 2000, NUCLEIC ACIDS RES, V28, P2187, DOI 10.1093/nar/28.10.2187; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, J BIOL CHEM, V276, P41938, DOI 10.1074/jbc.M107945200; McInerney P, 2004, J BIOL CHEM, V279, P21543, DOI 10.1074/jbc.M401649200; MENEGHINI R, 1976, BIOCHIM BIOPHYS ACTA, V425, P419, DOI 10.1016/0005-2787(76)90006-X; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Nowosielska A, 2006, NUCLEIC ACIDS RES, V34, P2258, DOI 10.1093/nar/gkl222; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; Pages V, 2003, SCIENCE, V300, P1300, DOI 10.1126/science.1083964; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Rangarajan S, 2002, MOL MICROBIOL, V43, P617, DOI 10.1046/j.1365-2958.2002.02747.x; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; ROTHMAN RH, 1977, MOL GEN GENET, V155, P279, DOI 10.1007/BF00272806; RUPP WD, 1971, J MOL BIOL, V61, P25, DOI 10.1016/0022-2836(71)90204-X; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; RYDER L, 1994, J BACTERIOL, V176, P1570, DOI 10.1128/jb.176.6.1570-1577.1994; Sambrook J, 2001, MOL CLONING LAB MANU; Seigneur M, 2000, MOL MICROBIOL, V38, P565, DOI 10.1046/j.1365-2958.2000.02152.x; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Servant L, 2002, J BIOL CHEM, V277, P50046, DOI 10.1074/jbc.M207101200; SETLOW RB, 1963, SCIENCE, V142, P1464, DOI 10.1126/science.142.3598.1464; SHAH R, 1994, NUCLEIC ACIDS RES, V22, P2490, DOI 10.1093/nar/22.13.2490; Shah R, 1997, EMBO J, V16, P1464, DOI 10.1093/emboj/16.6.1464; Shen X, 2003, J BIOL CHEM, V278, P52546, DOI 10.1074/jbc.M310127200; STORM PK, 1971, MUTAT RES, V13, P9, DOI 10.1016/0027-5107(71)90121-7; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; THRESHER R, 1992, METHOD ENZYMOL, V211, P481; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P	74	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28811	28821		10.1074/jbc.M603933200	http://dx.doi.org/10.1074/jbc.M603933200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16895921	hybrid			2022-12-25	WOS:000240680500035
J	Pino, V; Ramsauer, VP; Salas, P; Carraway, CAC; Carraway, KL				Pino, Vanessa; Ramsauer, Victoria P.; Salas, Pedro; Carraway, Coralie A. Carothers; Carraway, Kermit L.			Membrane mucin Muc4 induces density-dependent changes in ERK activation in mammary epithelial and tumor cells - Role in reversal of contact inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; SURFACE SIALOMUCIN COMPLEX; INTRAMEMBRANE ERBB2 LIGAND; MUC4/SIALOMUCIN COMPLEX; MOLECULAR-CLONING; PHOSPHORYLATION; RECEPTOR; KINASE; CANCER; OVEREXPRESSION	The membrane mucin Muc4 has been shown to alter cellular behavior through both anti-adhesive effects on cell-cell and cell-extracellular matrix interactions and its ability to act as an intramembrane ligand for the receptor tyrosine kinase ErbB2. The ERK pathway is regulated by both cell-matrix and cell-cell adhesion. An analysis of the effects of Muc4 expression on ERK phosphorylation in mammary tumor and epithelial cells, which exhibit both adhesion-dependent growth and contact inhibition of growth, showed that the effects are density dependent, with opposing effects on proliferating cells and contact-inhibited cells. In these cells, cell-matrix interactions through integrins are required for activation of the ERK mitogenesis pathway. However, cell-cell interactions via cadherins inhibit the ERK pathway. Expression of Muc4 reverses both of these effects. In contact-inhibited cells, Muc4 appears to activate the ERK pathway at the level of Raf-1; this activation does not depend on Ras activation. The increase in ERK activity correlates with an increase in cyclin D-1 expression in these cells. This abrogation of contact inhibition is dependent on the number of mucin repeats in the mucin subunit of Muc4, indicative of an anti-adhesive effect. The mechanism by which Muc4 disrupts contact inhibition involves a Muc4-induced relocalization of E-cadherin from adherens junctions at the lateral membrane of the cells to the apical membrane. Muc4-induced abrogation of contact inhibition may be an important mechanism by which tumors progress from an early, more benign state to invasiveness.	Univ Miami, Sch Med, Dept Anat & Cell Biol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Anat & Cell Biol, R-124,POB 016960, Miami, FL 33101 USA.	kcarrawa@med.miami.edu	Salas, Pedro J./AAS-9455-2021; Palau, Victoria E/F-3520-2012	Palau, Victoria E/0000-0003-2761-7003; Salas, Pedro/0000-0002-7411-1366	NCI NIH HHS [CA 74072, CA52498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052498, R01CA074072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI J, 1991, J CELL BIOL, V115, P1751, DOI 10.1083/jcb.115.6.1751; Balkovetz DF, 1999, LIFE SCI, V64, P1393, DOI 10.1016/S0024-3205(99)00073-9; Balkovetz DF, 1997, J BIOL CHEM, V272, P3471, DOI 10.1074/jbc.272.6.3471; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; ISHIBASHI K, 1992, BIOCHEM BIOPH RES CO, V182, P960, DOI 10.1016/0006-291X(92)91825-B; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Li SX, 2004, AM J PHYSIOL-CELL PH, V287, pC432, DOI 10.1152/ajpcell.00020.2004; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Nagy P, 2005, CANCER RES, V65, P473; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Ramsauer VP, 2006, MOL BIOL CELL, V17, P2931, DOI 10.1091/mbc.E05-09-0895; Ramsauer VP, 2003, J BIOL CHEM, V278, P30142, DOI 10.1074/jbc.M303220200; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; VANDEURS B, 1987, J HISTOCHEM CYTOCHEM, V35, P461, DOI 10.1177/35.4.3546491; WU K, 1994, J BIOL CHEM, V269, P11950	29	22	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29411	29420		10.1074/jbc.M604858200	http://dx.doi.org/10.1074/jbc.M604858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16891313	hybrid			2022-12-25	WOS:000240680500096
J	Wang, Z; Wade, P; Mandell, KJ; Akyildiz, A; Parkos, CA; Mrsny, RJ; Nusrat, A				Wang, Z.; Wade, P.; Mandell, K. J.; Akyildiz, A.; Parkos, C. A.; Mrsny, R. J.; Nusrat, A.			Raf 1 represses expression of the tight junction protein occludin via activation of the zinc-finger transcription factor Slug	ONCOGENE			English	Article						TJ; occluding; Slug; Raf 1	EPITHELIAL-MESENCHYMAL TRANSITIONS; MEMBRANE-PROTEIN; DOWN-REGULATION; FACTOR SNAIL; TUMOR-CELLS; CANCER; KINASE; BREAST; RAS; DIFFERENTIATION	Although dysregulation of tight junction (TJ) proteins is observed in epithelial malignancy, their participation in epithelial transformation is poorly understood. Recently we demonstrated that expression of oncogenic Raf 1 in Pa4 epithelial cells disrupts TJs and induces an oncogenic phenotype by downregulating expression of the TJ protein, occludin. Here we report the mechanism by which Raf 1 regulates occludin expression. Raf 1 inhibited occludin transcription by repressing a minimal segment of the occludin promoter in concert with upregulation of the transcriptional repressor, Slug without influencing the well-documented transcriptional repressor, Snail. Overexpression of Slug in Pa4 cells recapitulated the effect of Raf 1 on occludin expression, and depletion of Slug by small interfering RNA abrogated the effect of Raf 1 on occludin. Finally, chromatin immunoprecipitation assays and site- directed mutagenesis demonstrated a direct interaction between Slug and an E-box within the minimal Raf 1-responsive segment of the occludin promoter. These findings support a role of Slug in mediating Raf 1-induced transcriptional repression of occludin and subsequent epithelial to mesenchymal transition.	Emory Univ, Dept Pathol, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA; Unity Pharmaceut, Los Altos Hills, CA USA	Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Nusrat, A (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, 615 Michael St,Room 105E, Atlanta, GA 30322 USA.	anusrat@emory.edu	Nusrat, Asma/B-3887-2009; Parkos, Charles a/B-3896-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059888, R01DK061379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [DK 61379, DK 59888] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BIRCHMEIER W, 1993, J CELL SCI, P159; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BULKHOLM IK, 1998, J PATHOL, V185, P262; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kimura Y, 1997, AM J PATHOL, V151, P45; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; Lan MD, 2004, CARCINOGENESIS, V25, P2385, DOI 10.1093/carcin/bgh248; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; Matter K, 2005, CURR OPIN CELL BIOL, V17, P453, DOI 10.1016/j.ceb.2005.08.003; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Matter K, 1998, J CELL SCI, V111, P511; McCarthy KM, 1996, J CELL SCI, V109, P2287; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nottage M, 2002, CURR PHARM DESIGN, V8, P2231, DOI 10.2174/1381612023393107; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Ruch RJ, 1998, EXP LUNG RES, V24, P523, DOI 10.3109/01902149809087384; Tobioka H, 2004, VIRCHOWS ARCH, V445, P472, DOI 10.1007/s00428-004-1054-9; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; VanItallie CM, 1997, J CELL SCI, V110, P1113; Wang ZL, 2005, ONCOGENE, V24, P4412, DOI 10.1038/sj.onc.1208634; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498	37	58	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1222	1230		10.1038/sj.onc.1209902	http://dx.doi.org/10.1038/sj.onc.1209902			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924233				2022-12-25	WOS:000244406400012
J	Carter, DM; Miousse, IR; Gagnon, JN; Martinez, E; Clements, A; Lee, J; Hancock, MA; Gagnon, H; Pawelek, PD; Coulton, JW				Carter, David M.; Miousse, Isabelle R.; Gagnon, Jean-Nicolas; Martinez, Eric; Clements, Abigail; Lee, Jongchan; Hancock, Mark A.; Gagnon, Hubert; Pawelek, Peter D.; Coulton, James W.			Interactions between TonB from Escherichia coli and the periplasmic protein FhuD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE RECEPTOR; IRON(III) HYDROXAMATE TRANSPORT; C-TERMINAL DOMAIN; BINDING-PROTEIN; CRYSTAL-STRUCTURE; REVEALS; COMPLEX; ULTRACENTRIFUGATION; SIDEROPHORES; SYSTEM	For uptake of ferrichrome into bacterial cells, FhuA, a TonB-dependent outer membrane receptor of Escherichia coli, is required. The periplasmic protein FhuD binds and transfers ferrichrome to the cytoplasmic membrane-associated permease FhuB/C. We exploited phage display to map protein-protein interactions in the E. coli cell envelope that contribute to ferrichrome transport. By panning random phage libraries against TonB and against FhuD, we identified interaction surfaces on each of these two proteins. Their interactions were detected in vitro by dynamic light scattering and indicated a 1: 1 TonB-FhuD complex. FhuD residue Thr-181, located within the siderophore-binding site and mapping to a predicted TonB-interaction surface, was mutated to cysteine. FhuD T181C was reacted with two thiol-specific fluorescent probes; addition of the siderophore ferricrocin quenched fluorescence emissions of these conjugates. Similarly, quenching of fluorescence from both probes confirmed binding of TonB and established an apparent K-D of similar to 300 nM. Prior saturation of the siderophore-binding site of FhuD with ferricrocin did not alter affinity of TonB for FhuD. Binding, further characterized with surface plasmon resonance, indicated a higher affinity complex with KD values in the low nanomolar range. Addition of FhuD to a preformed TonB-FhuA complex resulted in formation of a ternary complex. These observations led us to propose a novel mechanism in which TonB acts as a scaffold, directing FhuD to regions within the periplasm where it is poised to accept and deliver siderophore.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Sheldon Biotechnol Ctr, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Coulton, JW (corresponding author), McGill Univ, Dept Microbiol & Immunol, 3775 Univ St, Montreal, PQ H3A 2B4, Canada.	james.coulton@mcgill.ca	Pawelek, Peter/E-7950-2014; Martinez, Eric/ABA-1229-2020; Miousse, Isabelle R./K-3512-2013	Pawelek, Peter/0000-0002-8361-6593; Martinez, Eric/0000-0001-8568-3725; Miousse, Isabelle R./0000-0001-6543-3219; Carter, David Miles/0000-0002-2517-8599; Clements, Abigail/0000-0003-2285-777X				Borths EL, 2005, BIOCHEMISTRY-US, V44, P16301, DOI 10.1021/bi0513103; Borths EL, 2002, P NATL ACAD SCI USA, V99, P16642, DOI 10.1073/pnas.262659699; Carter DM, 2006, J MOL BIOL, V357, P236, DOI 10.1016/j.jmb.2005.12.039; Chang CS, 2001, J BIOL CHEM, V276, P27535, DOI 10.1074/jbc.M102778200; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; Clarke TE, 2002, J BIOL CHEM, V277, P13966, DOI 10.1074/jbc.M109385200; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Karpowich NK, 2003, J BIOL CHEM, V278, P8429, DOI 10.1074/jbc.M212239200; Khursigara CM, 2005, PROTEIN SCI, V14, P1266, DOI 10.1110/ps.051342505; Khursigara CM, 2005, BIOCHEMISTRY-US, V44, P3441, DOI 10.1021/bi047882p; Khursigara CM, 2004, J BIOL CHEM, V279, P7405, DOI 10.1074/jbc.M311784200; Kodding J, 2005, J BIOL CHEM, V280, P3022, DOI 10.1074/jbc.M411155200; KOSTER W, 1990, J BIOL CHEM, V265, P21407; Krewulak KD, 2004, IRON TRANSPORT IN BACTERIA, P113; Krewulak KD, 2005, BIOMETALS, V18, P375, DOI 10.1007/s10534-005-3712-z; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Lawrence MC, 1998, STRUCTURE, V6, P1553, DOI 10.1016/S0969-2126(98)00153-1; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Mademidis A, 1997, MOL MICROBIOL, V26, P1109, DOI 10.1046/j.1365-2958.1997.6592008.x; Mader C, 2004, J BACTERIOL, V186, P1758, DOI 10.1128/JB.186.6.1758-1768.2004; Mandava S, 2004, PROTEOMICS, V4, P1439, DOI 10.1002/pmic.200300680; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nakajima H, 2005, BIOCHEM BIOPH RES CO, V328, P1091, DOI 10.1016/j.bbrc.2005.01.056; Pawelek PD, 2006, SCIENCE, V312, P1399, DOI 10.1126/science.1128057; Peacock RS, 2006, BIOMETALS, V19, P127, DOI 10.1007/s10534-005-5420-0; Peacock RS, 2005, J MOL BIOL, V345, P1185, DOI 10.1016/j.jmb.2004.11.026; ROHRBACH MR, 1995, J BACTERIOL, V177, P7186, DOI 10.1128/jb.177.24.7186-7193.1995; ROHRBACH MR, 1995, MOL GEN GENET, V248, P33, DOI 10.1007/BF02456611; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SCHULTZHAUSER G, 1992, J BACTERIOL, V174, P2305, DOI 10.1128/JB.174.7.2305-2311.1992; Shultis DD, 2006, SCIENCE, V312, P1396, DOI 10.1126/science.1127694; Sprencel C, 2000, J BACTERIOL, V182, P5359, DOI 10.1128/JB.182.19.5359-5364.2000; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; Yang YR, 1996, BIOPHYS CHEM, V59, P289, DOI 10.1016/0301-4622(96)00018-X	37	39	40	4	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35413	35424		10.1074/jbc.M607611200	http://dx.doi.org/10.1074/jbc.M607611200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16928679	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000241933700075
J	Bao, LP; Li, YK; Deng, SX; Landry, D; Tabas, I				Bao, Liping; Li, Yankun; Deng, Shi-Xian; Landry, Donald; Tabas, Ira			Sitosterol-containing lipoproteins trigger free sterol-induced caspase-independent death in ACAT-competent macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-HEART-DISEASE; ACYL-COENZYME-A; CHOLESTEROL ACYLTRANSFERASE ACAT; HUMAN ATHEROSCLEROTIC LESIONS; ACTIVATED PROTEIN-KINASES; LOW-DENSITY-LIPOPROTEIN; SERUM PLANT STEROLS; CELL-DEATH; INFLAMMATORY RESPONSE; ENDOPLASMIC-RETICULUM	Sitosterolemia is a disease characterized by very high levels of sitosterol and other plant sterols and premature atherothrombotic vascular disease. One theory holds that plant sterols can directly promote atherosclerosis, but the mechanism is not known. Unesterified, or "free," cholesterol (FC) is a potent inducer of macrophage death, which causes plaque necrosis, a precursor to atherothrombosis. FC-induced macrophage death, however, requires dysfunction of the sterol esterifying enzyme acyl-coenzyme A-cholesterol acyltransferase (ACAT), which likely occurs slowly during lesion progression. In contrast, plant sterols are relatively poorly esterified by ACAT, and so they may cause macrophage death and plaque necrosis in an accelerated manner. In support of this hypothesis, we show here that macrophages incubated with sitosterol-containing lipoproteins accumulate free sterols and undergo death in the absence of an ACAT inhibitor. As with FC loading, sitosterol-induced macrophage death requires sterol trafficking to the endoplasmic reticulum, and sitosterol-enriched endoplasmic reticulum membranes show evidence of membrane protein dysfunction. However, whereas FC induces caspase-dependent apoptosis through activation of the unfolded protein response and JNK, sitosterol-induced death is caspase-independent and involves neither the unfolded protein response nor JNK. Rather, cell death shows signs of necroptosis and autophagy and is suppressed by inhibitors of both processes. These data establish two new concepts. First, a relatively subtle change in sterol structure fundamentally alters the type of death program triggered in macrophages. Understanding the basis of this alteration should provide new insights into the molecular basis of death pathway signaling. Second, sitosterol-induced macrophage death does not require ACAT dysfunction and so may occur in an accelerated fashion. Pending future in vivo studies, this concept may provide at least one mechanism for accelerated plaque necrosis and atherothrombotic disease in patients with sitosterolemia.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu			NHLBI NIH HHS [HL081181, HL75662] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075662, R01HL081181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa M, 2004, CARDIOVASC PATHOL, V13, P125, DOI 10.1016/S1054-8807(04)00004-3; Araki T, 2006, CELL BIOL INT, V30, P93, DOI 10.1016/j.cellbi.2005.10.020; Assmann G, 2006, NUTR METAB CARDIOVAS, V16, P13, DOI 10.1016/j.numecd.2005.04.001; Awad AB, 2000, J NUTR, V130, P2127, DOI 10.1093/jn/130.9.2127; Awad AB, 2004, PROSTAG LEUKOTR ESS, V70, P511, DOI 10.1016/j.plefa.2003.11.005; Awad AB, 2003, ONCOL REP, V10, P497; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BHATTACHARYYA AK, 1974, J CLIN INVEST, V53, P1033, DOI 10.1172/JCI107640; BOBERG KM, 1991, SCAND J CLIN LAB INV, V51, P509, DOI 10.3109/00365519109104559; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Burke AP, 2003, J AM COLL CARDIOL, V41, p240A; Cao J, 2004, J BIOL CHEM, V279, P35903, DOI 10.1074/jbc.M402353200; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Cook AD, 2003, J IMMUNOL, V171, P4816, DOI 10.4049/jimmunol.171.9.4816; Darzynkiewicz Z, 1998, Hum Cell, V11, P3; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310; Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; FIELD FJ, 1983, J LIPID RES, V24, P409; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; GLUECK CJ, 1991, METABOLISM, V40, P842, DOI 10.1016/0026-0495(91)90013-M; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Halling KK, 2004, BBA-BIOMEMBRANES, V1664, P161, DOI 10.1016/j.bbamem.2004.05.006; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hegyi L, 1996, J PATHOL, V180, P423, DOI 10.1002/(SICI)1096-9896(199612)180:4<423::AID-PATH677>3.0.CO;2-1; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Katayama S, 2003, INTERNAL MED, V42, P591, DOI 10.2169/internalmedicine.42.591; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; Klett EL, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-5; Kolodgie FD, 2004, HEART, V90, P1385, DOI 10.1136/hrt.2004.041798; Kolovou G, 1996, EUR HEART J, V17, P965; KRIEGER M, 1986, METHOD ENZYMOL, V128, P608; KRUTH HS, 1984, EXP MOL PATHOL, V40, P288, DOI 10.1016/0014-4800(84)90046-7; KWITEROVICH PO, 1981, LANCET, V1, P466; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; LEIKIN AI, 1989, BIOCHIM BIOPHYS ACTA, V1005, P187, DOI 10.1016/0005-2760(89)90186-0; Li YK, 2006, J BIOL CHEM, V281, P6707, DOI 10.1074/jbc.M510579200; Li YK, 2005, J BIOL CHEM, V280, P21763, DOI 10.1074/jbc.M501759200; Li YK, 2004, J BIOL CHEM, V279, P37030, DOI 10.1074/jbc.M405195200; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; Liu J, 2005, BIOCHEM J, V391, P389, DOI 10.1042/BJ20050428; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MAJNO G, 1995, AM J PATHOL, V146, P3; Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399; McConkey DJ, 1998, TOXICOL LETT, V99, P157, DOI 10.1016/S0378-4274(98)00155-6; MELLIES MJ, 1976, J LAB CLIN MED, V88, P914; Miettinen TA, 2005, J AM COLL CARDIOL, V45, P1794, DOI 10.1016/j.jacc.2005.02.063; Miettinen TA, 1998, BMJ-BRIT MED J, V316, P1127, DOI 10.1136/bmj.316.7138.1127; Mora MP, 1999, CHEM PHYS LIPIDS, V101, P255, DOI 10.1016/S0009-3084(99)00067-5; MORI M, 2004, 44 ANN M AM SOC CELL, pA324; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; Nguyen LB, 2001, METABOLISM, V50, P1224, DOI 10.1053/meta.2001.26707; Nissen SE, 2006, NEW ENGL J MED, V354, P1253, DOI 10.1056/NEJMoa054699; Rajaratnam RA, 2000, J AM COLL CARDIOL, V35, P1185, DOI 10.1016/S0735-1097(00)00527-1; RAPP JH, 1983, J LIPID RES, V24, P1329; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; RUJANAVECH C, 1986, J BIOL CHEM, V261, P7215; Saito T, 2005, BIOSCI BIOTECH BIOCH, V69, P2207, DOI 10.1271/bbb.69.2207; Salen G, 2004, CIRCULATION, V109, P966, DOI 10.1161/01.CIR.0000116766.31036.03; SALEN G, 1992, J LIPID RES, V33, P945; SALEN G, 1985, J LIPID RES, V26, P1126; SCHULER I, 1990, BIOCHIM BIOPHYS ACTA, V1028, P82, DOI 10.1016/0005-2736(90)90268-S; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Sehayek E, 2005, ARTERIOSCL THROM VAS, V25, P5, DOI 10.1161/01.ATV.0000151984.34920.aa; SHIO H, 1979, LAB INVEST, V41, P160; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; Sudhop T, 2004, Z KARDIOL, V93, P921, DOI 10.1007/s00392-004-0165-2; Sudhop T, 2002, METABOLISM, V51, P1519, DOI 10.1053/meta.2002.36298; Sutherland WHF, 1998, NUTR METAB CARDIOVAS, V8, P386; Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; TABAS I, 1989, J CLIN INVEST, V84, P1713, DOI 10.1172/JCI114354; Tardif JC, 2004, CIRCULATION, V110, P3372, DOI 10.1161/01.CIR.0000147777.12010.EF; Temel RE, 2003, J BIOL CHEM, V278, P47594, DOI 10.1074/jbc.M308235200; von Bergmann K, 2005, AM J CARDIOL, V96, p10D, DOI 10.1016/j.amjcard.2005.03.014; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Wilund KR, 2004, ARTERIOSCL THROM VAS, V24, P2326, DOI 10.1161/01.ATV.0000149140.00499.92; Xu F, 2005, P NATL ACAD SCI USA, V102, P14551, DOI 10.1073/pnas.0503590102; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G	96	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33635	33649		10.1074/jbc.M606339200	http://dx.doi.org/10.1074/jbc.M606339200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16935859	hybrid			2022-12-25	WOS:000241621400072
J	Panasenko, O; Landrieux, E; Feuermann, M; Finka, A; Paquet, N; Collart, MA				Panasenko, Olesya; Landrieux, Emilie; Feuermann, Marc; Finka, Andrija; Paquet, Nicole; Collart, Martine A.			The yeast Ccr4-not complex controls ubiquitination of the nascent-associated polypeptide (NAC-EGD) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEADENYLASE; DIFFERENTIALLY AFFECTS; TRANSCRIPTION; PROTEIN; EXPRESSION; SUBUNITS; REVEALS; ELEMENT; MOTIF; UBC4	In this work, we determine that the Saccharomyces cerevisiae Ccr4-Not complex controls ubiquitination of the conserved ribosome-associated heterodimeric EGD (enhancer of Gal4p DNA binding) complex, which consists of the Egd1p and Egd2p subunits in yeast and is named NAC (nascent polypeptide-associated complex) in mammals. We show that the EGD complex subunits are ubiquitinated proteins, whose ubiquitination status is regulated during cell growth. Egd2p has a UBA domain that is not essential for interaction with Egd1p but is required for stability of Egd2p and Egd1p. Ubiquitination of Egd1p requires Not4p. Ubiquitination of Egd2p also requires Not4p, an intact Not4p RING finger domain, and all other subunits of the Ccr4-Not complex tested. In the absence of Not4p, Egd2p mis-localizes to punctuate structures. Finally, the EGD complex can be ubiquitinated in vitro by Not4p and Ubc4p, one of the E2 enzymes with which Not4p can interact. Taken together our results reveal that the EGD ribosome-associated complex is ubiquitinated in a regulated manner, and they show a new role for the Ccr4-Not complex in this ubiquitination.	Univ Geneva, Sch Med, Dept Microbiol & Mol Med, CH-1211 Geneva 4, Switzerland	University of Geneva	Collart, MA (corresponding author), Univ Geneva, Sch Med, Dept Microbiol & Mol Med, CH-1211 Geneva 4, Switzerland.	martine.collart@medecine.unige.ch	Panasenko, Olesya/AAC-1194-2021; Finka, Andrija/A-6387-2009	Panasenko, Olesya/0000-0002-0990-7472; Finka, Andrija/0000-0001-7608-4771; Feuermann, Marc/0000-0002-4187-2863; Collart, Martine/0000-0001-6955-1773				Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; Chuang SM, 2005, GENETICS, V171, P1477, DOI 10.1534/genetics.105.046888; Collart MA, 2004, PROG NUCLEIC ACID RE, V77, P289, DOI 10.1016/S0079-6603(04)77008-7; Collart MA, 2003, GENE, V313, P1, DOI 10.1016/S0378-1119(03)00672-3; COLLART MA, 1993, EMBO J, V12, P177, DOI 10.1002/j.1460-2075.1993.tb05643.x; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; Creton S, 2002, GENE DEV, V16, P3265, DOI 10.1101/gad.234002; Denis CL, 2003, PROG NUCLEIC ACID RE, V73, P221, DOI 10.1016/S0079-6603(03)01007-9; Franke J, 2001, J CELL SCI, V114, P2641; Grallath S, 2006, EMBO REP, V7, P78, DOI 10.1038/sj.embor.7400551; Hanzawa H, 2001, J BIOL CHEM, V276, P10185, DOI 10.1074/jbc.M009298200; Heessen S, 2005, MOL CELL, V18, P225, DOI 10.1016/j.molcel.2005.03.015; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Horak J, 2003, BBA-BIOMEMBRANES, V1614, P139, DOI 10.1016/S0005-2736(03)00195-0; Kiel JAKW, 2005, J BIOL CHEM, V280, P1921, DOI 10.1074/jbc.M403632200; Kus BM, 2004, PROTEINS, V54, P455, DOI 10.1002/prot.10620; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenssen E, 2005, MOL CELL BIOL, V25, P488, DOI 10.1128/MCB.25.1.488-498.2005; Lenssen E, 2002, MOL MICROBIOL, V43, P1023, DOI 10.1046/j.1365-2958.2002.02799.x; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; PARTHUN MR, 1992, MOL CELL BIOL, V12, P5683, DOI 10.1128/MCB.12.12.5683; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Quelo I, 2004, J BIOL CHEM, V279, P43893, DOI 10.1074/jbc.M406310200; Reimann B, 1999, YEAST, V15, P397, DOI 10.1002/(SICI)1097-0061(19990330)15:5<397::AID-YEA384>3.3.CO;2-L; Rospert S, 2002, CELL MOL LIFE SCI, V59, P1632, DOI 10.1007/PL00012490; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Spreter T, 2005, J BIOL CHEM, V280, P15849, DOI 10.1074/jbc.M500160200; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Wegrzyn RD, 2006, J BIOL CHEM, V281, P2847, DOI 10.1074/jbc.M511420200; Winkler GS, 2004, J MOL BIOL, V337, P157, DOI 10.1016/j.jmb.2004.01.031; Yoshida K, 2005, GENES CELLS, V10, P465, DOI 10.1111/j.1365-2443.2005.00848.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHENG XM, 1990, NATURE, V344, P556, DOI 10.1038/344556a0; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	38	75	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31389	31398		10.1074/jbc.M604986200	http://dx.doi.org/10.1074/jbc.M604986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16926149	Bronze			2022-12-25	WOS:000241235300023
J	Faehnle, CR; Le Coq, J; Liu, XY; Viola, RE				Faehnle, Christopher R.; Le Coq, Johanne; Liu, Xuying; Viola, Ronald E.			Examination of key intermediates in the catalytic cycle of aspartate-beta-semialdehyde dehydrogenase from a Gram-positive infectious bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID BIOSYNTHESIS; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; FAMILY; IDENTIFICATION; PURIFICATION; REFINEMENT; PROGRAM; GENES; MODEL	Aspartate-beta-semialdehyde dehydrogenase (ASADH) catalyzes a critical branch point transformation in amino acid biosynthesis. The products of the aspartate pathway are essential in microorganisms, and this entire pathway is absent in mammals, making this enzyme an attractive target for antibiotic development. The first structure of an ASADH from a Gram-positive bacterium, Streptococcus pneumoniae, has now been determined. The overall structure of the apoenzyme has a similar fold to those of the Gram-negative and archaeal ASADHs but contains some interesting structural variations that can be exploited for inhibitor design. Binding of the coenzyme NADP, as well as a truncated nucleotide analogue, into an alternative conformation from that observed in Gram-negative ASADHs causes an enzyme domain closure that precedes catalysis. The covalent acyl-enzyme intermediate was trapped by soaking the substrate into crystals of the coenzyme complex, and the structure of this elusive intermediate provides detailed insights into the catalytic mechanism.	Univ Toledo, Dept Chem, Toledo, OH 43606 USA	University of Toledo	Viola, RE (corresponding author), Univ Toledo, Dept Chem, 2801 W Bancroft St, Toledo, OH 43606 USA.	ron.viola@utoledo.edu	liu, xuying/G-7258-2012; Le Coq, Johanne/L-6321-2014; Viola, Ronald/C-5904-2011					Becker D, 2006, NATURE, V440, P303, DOI 10.1038/nature04616; BIELLMANN JF, 1980, EUR J BIOCHEM, V104, P53, DOI 10.1111/j.1432-1033.1980.tb04398.x; BIELLMANN JF, 1980, EUR J BIOCHEM, V104, P59, DOI 10.1111/j.1432-1033.1980.tb04399.x; Blanco J, 2003, P NATL ACAD SCI USA, V100, P12613, DOI 10.1073/pnas.1634958100; Blanco J, 2003, PROTEIN SCI, V12, P27, DOI 10.1110/ps.0230803; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CIRILLO JD, 1994, MOL MICROBIOL, V11, P629, DOI 10.1111/j.1365-2958.1994.tb00342.x; Cleland W W, 1979, Methods Enzymol, V63, P103; COHEN GN, 1980, MULTIFUNCTIONAL PROT, P49; Faehnle CR, 2005, J MOL BIOL, V353, P1055, DOI 10.1016/j.jmb.2005.09.027; Hadfield A, 1999, J MOL BIOL, V289, P991, DOI 10.1006/jmbi.1999.2828; Hadfield A, 2001, BIOCHEMISTRY-US, V40, P14475, DOI 10.1021/bi015713o; Harb OS, 1998, INFECT IMMUN, V66, P1898, DOI 10.1128/IAI.66.5.1898-1903.1998; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; KARSTEN WE, 1991, BIOCHIM BIOPHYS ACTA, V1077, P209, DOI 10.1016/0167-4838(91)90060-D; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; Moore RA, 2002, PROTEIN EXPRES PURIF, V25, P189, DOI 10.1006/prep.2002.1626; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Paidhungat M, 2000, J BACTERIOL, V182, P5505, DOI 10.1128/JB.182.19.5505-5512.2000; Pavelka MS, 1996, J BACTERIOL, V178, P6496, DOI 10.1128/jb.178.22.6496-6507.1996; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; Viola RE, 2001, ACCOUNTS CHEM RES, V34, P339, DOI 10.1021/ar000057q; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	26	34	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31031	31040		10.1074/jbc.M605926200	http://dx.doi.org/10.1074/jbc.M605926200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16895909	hybrid			2022-12-25	WOS:000241075900079
J	Nishi, E; Hiraoka, Y; Yoshida, K; Okawa, K; Kita, T				Nishi, Eiichiro; Hiraoka, Yoshinori; Yoshida, Kazuhiro; Okawa, Katsuya; Kita, Toru			Nardilysin enhances ectodomain shedding of heparin-binding epidermal growth factor-like growth factor through activation of tumor necrosis factor-alpha-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE DIBASIC CONVERTASE; PROTEIN-COUPLED RECEPTORS; BUD-SITE SELECTION; FACTOR HB-EGF; METALLOPROTEINASE CLEAVAGE; NRD CONVERTASE; CELL-SURFACE; PROHB-EGF; METALLOENDOPEPTIDASE; DISINTEGRIN	Like other members of the epidermal growth factor family, heparin-binding epidermal growth factor-like growth factor (HB-EGF) is synthesized as a transmembrane protein that can be shed enzymatically to release a soluble growth factor. Ectodomain shedding is essential to the biological functions of HB-EGF and is strictly regulated. However, the mechanism that induces the shedding remains unclear. We have recently identified nardilysin (N-arginine dibasic convertase (NRDc)), a metalloendopeptidase of the M16 family, as a protein that specifically binds HB-EGF (Nishi, E., Prat, A., Hospital, V., Elenius, K., and Klagsbrun, M. (2001) EMBO J. 20, 3342-3350). Here, we show that NRDc enhances ectodomain shedding of HB-EGF. When expressed in cells, NRDc enhanced the shedding in cooperation with tumor necrosis factor-alpha-converting enzyme (TACE; ADAM17). NRDc formed a complex with TACE, a process promoted by phorbol esters, general activators of ectodomain shedding. NRDc enhanced TACE-induced HB-EGF cleavage in a peptide cleavage assay, indicating that the interaction with NRDc potentiates the catalytic activity of TACE. The metalloendopeptidase activity of NRDc was not required for the enhancement of HB-EGF shedding. Notably, a reduction in the expression of NRDc caused by RNA interference was accompanied by a decrease in ectodomain shedding of HB-EGF. These results indicate the essential role of NRDc in HB-EGF ectodomain shedding and reveal how the shedding is regulated by the modulation of sheddase activity.	Kyoto Univ, Grad Sch Med, Horizontal Med Res Org, Mol Pathol Unit,Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Biomol Characterizat Unit, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Nishi, E (corresponding author), Kyoto Univ, Grad Sch Med, Horizontal Med Res Org, Mol Pathol Unit,Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	nishi@kuhp.kyoto-u.ac.jp	Nishi, Eiichiro/A-8246-2019	Nishi, Eiichiro/0000-0002-8188-8026				ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Chesneau V, 1996, J CELL SCI, V109, P2737; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; Fumagalli P, 1998, GENOMICS, V47, P238, DOI 10.1006/geno.1997.5078; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Hospital V, 2002, BIOCHEM J, V367, P229, DOI 10.1042/BJ20020822; Hospital V, 2000, BIOCHEM J, V349, P587, DOI 10.1042/0264-6021:3490587; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nishi E, 2004, GROWTH FACTORS, V22, P253, DOI 10.1080/08977190400008448; Nishi E, 2001, EMBO J, V20, P3342, DOI 10.1093/emboj/20.13.3342; PIEROTTI AR, 1994, P NATL ACAD SCI USA, V91, P6078, DOI 10.1073/pnas.91.13.6078; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schlondorff J, 1999, J CELL SCI, V112, P3603; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tanaka Y, 2005, CLIN CANCER RES, V11, P4783, DOI 10.1158/1078-0432.CCR-04-1426; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Yamazaki S, 2003, J CELL BIOL, V163, P469, DOI 10.1083/jcb.200307035; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	40	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31164	31172		10.1074/jbc.M601316200	http://dx.doi.org/10.1074/jbc.M601316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16923819	hybrid			2022-12-25	WOS:000241075900091
J	Sajjan, US; Jia, Y; Newcomb, DC; Bentley, JK; Lukacs, NW; LiPuma, JJ; Hershenson, MB				Sajjan, Umadevi S.; Jia, Yue; Newcomb, Dawn C.; Bentley, J. Kelley; Lukacs, Nicholas W.; LiPuma, John J.; Hershenson, Marc B.			H-influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression	FASEB JOURNAL			English	Article						chronic obstructive pulmonary disease; IL-8; epithelial-derived neutrophil attractant-78; growth-related oncogene-alpha; chemokine	NF-KAPPA-B; DOUBLE-STRANDED-RNA; OBSTRUCTIVE PULMONARY-DISEASE; LOWER RESPIRATORY-TRACT; TOLL-LIKE RECEPTOR-3; INFLAMMATORY MARKERS; BRONCHIAL INFLAMMATION; ACUTE EXACERBATIONS; ADHESION MOLECULES; CYSTIC-FIBROSIS	Rhinovirus (RV) is an important trigger of chronic obstructive pulmonary disease (COPD) exacerbations. In addition, respiratory viruses are more likely to be isolated in patients with a history of frequent exacerbations, suggesting that these patients are more susceptible to viral infection. To examine potential mechanisms for cooperative effects between bacterial and viral infection in COPD, we studied the responses of cultured human airway epithelial cells to nontypeable Hemophilus influenzae and RV. In both 16HBE14o- and primary mucociliary-differentiated cells, preincubation with H. influenzae enhanced RV serotype 39-induced protein expression of interleukin (IL)-8, epithelial-derived neutrophil attractant-78, and growth-related oncogene-alpha. H. influenzae infection also increased the binding of RV39 to cultured cells, as well as expression of intercellular adhesion molecule (ICAM)-1 and Toll-like receptor (TLR)-3, receptors for RV and dsRNA, respectively. Neutralizing antibody against tumor necrosis factor-alpha inhibited IL-8 expression induced by H. influenzae and RV39. Finally, siRNA against TLR3 attenuated RV-induced IL-8 expression. We conclude that H. influenzae infection increases airway epithelial cell ICAM-1 and TLR3 expression, leading to enhanced binding of RV and a potentiation of RV-induced chemokine release. These data provide a cellular mechanism by which H. influenzae infection may increase the susceptibility of COPD patients to RV-induced exacerbations.	Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hershenson, MB (corresponding author), Univ Michigan, Dept Pediat & Communicable Dis, 1150 W Med Ctr Dr,Rm 3570,MSRBII,Box 0688, Ann Arbor, MI 48109 USA.	mhershen@umich.edu	Lukacs, Nicholas W/ABH-5583-2020	Bentley, John Kelley/0000-0001-8865-7979	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081420, R01HL082550, P50HL056399] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56399, HL82550, HL81420] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaron SD, 2001, AM J RESP CRIT CARE, V163, P349, DOI 10.1164/ajrccm.163.2.2003122; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bandi V, 2001, AM J RESP CRIT CARE, V164, P2114, DOI 10.1164/ajrccm.164.11.2104093; Bayer N, 2001, J BIOL CHEM, V276, P3952, DOI 10.1074/jbc.M004722200; BeckSchimmer B, 1997, AM J RESP CELL MOL, V17, P344, DOI 10.1165/ajrcmb.17.3.2861; Bhowmik A, 2000, THORAX, V55, P114, DOI 10.1136/thorax.55.2.114; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; Casola A, 2002, VIROLOGY, V298, P8, DOI 10.1006/viro.2002.1475; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; DISTEFANO A, 1994, AM J RESP CRIT CARE, V149, P803, DOI 10.1164/ajrccm.149.3.7509705; Duits LA, 2003, FEMS IMMUNOL MED MIC, V38, P59, DOI 10.1016/S0928-8244(03)00106-8; Eller J, 1998, CHEST, V113, P1542, DOI 10.1378/chest.113.6.1542; Frick AG, 2000, J IMMUNOL, V164, P4185, DOI 10.4049/jimmunol.164.8.4185; Furrie E, 2005, IMMUNOLOGY, V115, P565, DOI 10.1111/j.1365-2567.2005.02200.x; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gern JE, 2003, AM J RESP CELL MOL, V28, P731, DOI 10.1165/rcmb.2002-0055OC; Gompertz S, 2001, EUR RESPIR J, V17, P1112, DOI 10.1183/09031936.01.99114901; Greenberg SB, 2000, AM J RESP CRIT CARE, V162, P167, DOI 10.1164/ajrccm.162.1.9911019; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Isogawa M, 2005, J VIROL, V79, P7269, DOI 10.1128/JVI.79.11.7269-7272.2005; Johnston SL., 1997, DIAGNOSTIC PROCEDURE, P553; Kim J, 2000, J IMMUNOL, V165, P3384, DOI 10.4049/jimmunol.165.6.3384; Lopez-Souza N, 2004, AM J PHYSIOL-LUNG C, V286, pL373, DOI 10.1152/ajplung.00300.2003; MONSO E, 1995, AM J RESP CRIT CARE, V152, P1316, DOI 10.1164/ajrccm.152.4.7551388; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; Murphy TF, 2004, AM J RESP CRIT CARE, V170, P266, DOI 10.1164/rccm.200403-354OC; Newcomb DC, 2005, J BIOL CHEM, V280, P36952, DOI 10.1074/jbc.M502449200; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Qiu YS, 2003, AM J RESP CRIT CARE, V168, P968, DOI 10.1164/rccm.200208-794OC; Ritter Mirko, 2005, J Inflamm (Lond), V2, P16, DOI 10.1186/1476-9255-2-16; Rohde G, 2003, THORAX, V58, P37, DOI 10.1136/thorax.58.1.37; Rudd BD, 2005, J VIROL, V79, P3350, DOI 10.1128/JVI.79.6.3350-3357.2005; Sajjan U, 2004, INFECT IMMUN, V72, P4188, DOI 10.1128/IAI.72.7.4188-4199.2004; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; Seemungal TAR, 2000, EUR RESPIR J, V16, P677, DOI 10.1034/j.1399-3003.2000.16d19.x; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Sethi Sanjay, 2004, Proc Am Thorac Soc, V1, P109, DOI 10.1513/pats.2306029; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Soler N, 1999, EUR RESPIR J, V14, P1015, DOI 10.1183/09031936.99.14510159; Suzuki T, 2002, AM J RESP CRIT CARE, V165, P1113, DOI 10.1164/ajrccm.165.8.2103094; Wedzicha Jadwiga A, 2004, Proc Am Thorac Soc, V1, P115, DOI 10.1513/pats.2306030; Winter LE, 2003, INFECT IMMUN, V71, P6884, DOI 10.1128/IAI.71.12.6884-6891.2003	47	102	108	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2121	+		10.1096/fj.06-5806fje	http://dx.doi.org/10.1096/fj.06-5806fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16914605	Green Submitted			2022-12-25	WOS:000241156900025
J	Naderi, A; Teschendorff, AE; Barbosa-Morais, NI; Pinder, SE; Green, AR; Powe, DG; Robertson, JFR; Aparicio, S; Ellis, IO; Brenton, JD; Caldas, C				Naderi, A.; Teschendorff, A. E.; Barbosa-Morais, N. I.; Pinder, S. E.; Green, A. R.; Powe, D. G.; Robertson, J. F. R.; Aparicio, S.; Ellis, I. O.; Brenton, J. D.; Caldas, C.			A gene-expression signature to predict survival in breast cancer across independent data sets	ONCOGENE			English	Article						breast cancer; microarray; prognosis; gene-signature; survival; Cox-clustering	MICROARRAY PLATFORMS; CLASSIFICATION; VALIDATION; PROGNOSIS; ADJUVANT	Prognostic signatures in breast cancer derived from microarray expression pro. ling have been reported by two independent groups. These signatures, however, have not been validated in external studies, making clinical application problematic. We performed microarray expression pro. ling of 135 early-stage tumors, from a cohort representative of the demographics of breast cancer. Using a recently proposed semisupervised method, we identified a prognostic signature of 70 genes that significantly correlated with survival ( hazard ratio (HR): 5.97, 95% confidence interval: 3.0-11.9, P = 2.7e-07). In multivariate analysis, the signature performed independently of other standard prognostic classifiers such as the Nottingham Prognostic Index and the 'Adjuvant!' software. Using two different prognostic classification schemes and measures, nearest centroid ( HR) and risk ordering (D-index), the 70-gene classifier was also found to be prognostic in two independent external data sets. Overall, the 70- gene set was prognostic in our study and the two external studies which collectively include 715 patients. In contrast, we found that the two previously described prognostic gene sets performed less optimally in external validation. Finally, a common prognostic module of 29 genes that associated with survival in both our cohort and the two external data sets was identified. In spite of these results, further studies that pro. le larger cohorts using a single microarray platform, will be needed before prospective clinical use of molecular classifiers can be contemplated.	Univ Cambridge, Canc Genom Program, Dept Oncol, Hutchison Res Ctr,MRC, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Pathol, MRC, Hutchison Res Ctr, Cambridge CB2 2XZ, England; Univ Nottingham, Nottingham NG7 2RD, England; Nottingham City Hosp NHS Trust, Dept Mol Med Sci, Nottingham, England; Nottingham City Hosp NHS Trust, Dept Med & Surg Sci, Nottingham, England; Nottingham City Hosp NHS Trust, Dept Histopathol, Nottingham, England; Univ Lisbon, Fac Med, Inst Mol Med, P-1699 Lisbon, Portugal	University of Cambridge; University of Cambridge; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Universidade de Lisboa	Brenton, JD (corresponding author), Univ Cambridge, Canc Genom Program, Dept Oncol, Hutchison Res Ctr,MRC, Hills Rd, Cambridge CB2 2XZ, England.	jdb1003@cam.ac.uk; cc234@cam.ac.uk	Brenton, James D/B-3174-2008; Caldas, Carlos/U-7250-2019; Barbosa-Morais, Nuno L/I-2743-2013; Caldas, Carlos/A-7543-2008; Green, Andrew/AAF-1991-2020	Brenton, James D/0000-0002-5738-6683; Caldas, Carlos/0000-0003-3547-1489; Barbosa-Morais, Nuno L/0000-0002-1215-0538; Aparicio, Samuel/0000-0002-0487-9599; /0000-0003-4167-8910; Ellis, Ian/0000-0001-5292-8474; Naderi, Ali/0000-0001-7142-7616; Green, Andrew/0000-0002-0488-5913				Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Cox D. R., 1984, ANAL SURVIVAL DATA; Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953; Degot S, 2004, J BIOL CHEM, V279, P33702, DOI 10.1074/jbc.M402754200; Eden P, 2004, EUR J CANCER, V40, P1837, DOI 10.1016/j.ejca.2004.02.025; Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Naderi A, 2005, MOL BIOTECHNOL, V30, P151, DOI 10.1385/MB:30:2:151; Naderi A, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-9; Olivotto IA, 2005, J CLIN ONCOL, V23, P2716, DOI 10.1200/JCO.2005.06.178; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Royston P, 2004, STAT MED, V23, P723, DOI 10.1002/sim.1621; Shen RL, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-94; Sollich P, 1996, ADV NEUR IN, V8, P190; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Tan PK, 2003, NUCLEIC ACIDS RES, V31, P5676, DOI 10.1093/nar/gkg763; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	25	186	194	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1507	1516		10.1038/sj.onc.1209920	http://dx.doi.org/10.1038/sj.onc.1209920			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936776				2022-12-25	WOS:000244558800016
J	Cui, T; Schopfer, FJ; Zhang, J; Chen, K; Ichikawa, T; Baker, PRS; Batthyany, C; Chacko, BK; Feng, X; Patel, RP; Agarwal, A; Freeman, BA; Chen, YE				Cui, Taixing; Schopfer, Francisco J.; Zhang, Jifeng; Chen, Kai; Ichikawa, Tomonaga; Baker, Paul R. S.; Batthyany, Carlos; Chacko, Balu K.; Feng, Xu; Patel, Rakesh P.; Agarwal, Anupam; Freeman, Bruce A.; Chen, Yuqing E.			Nitrated fatty acids: Endogenous anti-inflammatory signaling mediators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OXIDIZED LIPID DERIVATIVES; HUMAN BLOOD-PLASMA; NITRIC-OXIDE; NITROLINOLEIC ACID; NITROGEN-DIOXIDE; GENE-EXPRESSION; DNA-BINDING; PROTEINS; TRANSDUCTION	Nitroalkene derivatives of linoleic acid (LNO2) and oleic acid (OA-NO2) are present; however, their biological functions remain to be fully defined. Herein, we report that LNO2 and OA-NO2 inhibit lipopolysaccharide-induced secretion of proinflammatory cytokines in macrophages independent of nitric oxide formation, peroxisome proliferator-activated receptor-gamma activation, or induction of heme oxygenase-1 expression. The electrophilic nature of fatty acid nitroalkene derivatives resulted in alkylation of recombinant NF-kappa B p65 protein in vitro and a similar reaction with p65 in intact macrophages. The nitroalkylation of p65 by fatty acid nitroalkene derivatives inhibited DNA binding activity and repressed NF-kappa B-dependent target gene expression. Moreover, nitroalkenes inhibited endothelial tumor necrosis factor-alpha-induced vascular cell adhesion molecule 1 expression and monocyte rolling and adhesion. These observations indicate that nitroalkenes such as LNO2 and OA-NO2, derived from reactions of unsaturated fatty acids and oxides of nitrogen, are a class of endogenous anti-inflammatory mediators.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Michigan, Ctr Med, Ctr Cardiovasc, Ann Arbor, MI 48109 USA; Univ Alabama, Dept Med, Div Nephrol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Freeman, BA (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA.	freerad@pitt.edu	Schopfer, Francisco/AAW-6505-2021; Schopfer, Francisco Jose/AAE-8125-2020; Freeman, Bruce A/H-9342-2012; Batthyany, Carlos I./A-6478-2009	Schopfer, Francisco Jose/0000-0001-9526-695X; Batthyany, Carlos/0000-0002-0627-1982; Patel, Rakesh/0000-0002-1526-4303; Cui, Taixing/0000-0002-9528-7299	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058115, R01HL075397, T32HL007457, R01HL068878, R01HL064937, R01HL070146, R37HL058115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008248] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL064937-05A1, HL70146, R01 HL068878, R37 HL058115, HL068878, R01 HL075397, HL075397, HL58115, R01 HL064937, R01 HL070146, HL64937, R01 HL058115-09, T32HL07457, R01 HL058115] Funding Source: Medline; NIGMS NIH HHS [S06 GM008248, S06GM08248] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez-Maqueda M, 2004, J BIOL CHEM, V279, P21929, DOI 10.1074/jbc.M400492200; Baker PRS, 2005, J BIOL CHEM, V280, P42464, DOI 10.1074/jbc.M504212200; Baker PRS, 2004, P NATL ACAD SCI USA, V101, P11577, DOI 10.1073/pnas.0402587101; Balazy M, 2001, J PHARMACOL EXP THER, V299, P611; Baldus S, 2002, FREE RADICAL BIO MED, V33, P1010, DOI 10.1016/S0891-5849(02)00993-0; Batthyany C, 2006, J BIOL CHEM, V281, P20450, DOI 10.1074/jbc.M602814200; Ceaser EK, 2004, BIOCHEM SOC T, V32, P151, DOI 10.1042/BST0320151; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Coles B, 2002, CIRC RES, V91, P375, DOI 10.1161/01.RES.0000032114.68919.EF; Coles B, 2002, J BIOL CHEM, V277, P5832, DOI 10.1074/jbc.M105209200; Crabb JW, 2002, PROTEIN SCI, V11, P831, DOI 10.1110/ps.4400102; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; ESTERBAUER H, 1975, Z NATURFORSCH C, V30, P466; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Garcia-Pineres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Han YS, 2005, J PHARMACOL EXP THER, V312, P1097, DOI 10.1124/jpet.104.079707; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Ishii T, 2003, BIOCHEMISTRY-US, V42, P3474, DOI 10.1021/bi027172o; Kalyanaraman B, 2004, P NATL ACAD SCI USA, V101, P11527, DOI 10.1073/pnas.0404309101; Kang LT, 1997, ANAL BIOCHEM, V250, P119, DOI 10.1006/abio.1997.2202; Lee TS, 2003, J BIOL CHEM, V278, P19325, DOI 10.1074/jbc.M300498200; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Lim DG, 2002, P NATL ACAD SCI USA, V99, P15941, DOI 10.1073/pnas.232409599; Lima ES, 2005, FREE RADICAL BIO MED, V39, P532, DOI 10.1016/j.freeradbiomed.2005.04.005; Lima ES, 2003, J LIPID RES, V44, P1660, DOI 10.1194/jlr.M200467-JLR200; Lima ES, 2002, BIOCHEMISTRY-US, V41, P10717, DOI 10.1021/bi025504j; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; O'Donnell VB, 1999, CHEM RES TOXICOL, V12, P83, DOI 10.1021/tx980207u; Osterud B, 2003, PHYSIOL REV, V83, P1069, DOI 10.1152/physrev.00005.2003; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; Schopfer FJ, 2005, J BIOL CHEM, V280, P19289, DOI 10.1074/jbc.M414689200; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; Serhan CN, 2001, J CLIN INVEST, V107, P1481, DOI 10.1172/JCI13375; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; Thomassen MJ, 1997, AM J RESP CELL MOL, V17, P279, DOI 10.1165/ajrcmb.17.3.2998m; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Zhang HF, 2001, ARTERIOSCL THROM VAS, V21, P529, DOI 10.1161/01.ATV.21.4.529	46	279	294	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35686	35698		10.1074/jbc.M603357200	http://dx.doi.org/10.1074/jbc.M603357200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16887803	Green Accepted, hybrid			2022-12-25	WOS:000242100500013
J	Georgopoulou, N; Hurel, C; Politis, PK; Gaitanou, M; Matsas, R; Thomaidou, D				Georgopoulou, Niki; Hurel, Catherine; Politis, Panagiotis K.; Gaitanou, Maria; Matsas, Rebecca; Thomaidou, Dimitra			BM88 is a dual function molecule inducing cell cycle exit and neuronal differentiation of neuroblastoma cells via cyclin D1 down-regulation and retinoblastoma protein hypophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; TRANSCRIPTION FACTOR; CYTOPLASMIC SEQUESTRATION; INHIBITOR P21(WAF1/CIP1); CORTICAL PROGENITORS; FATE SPECIFICATION; RESTRICTION POINT; CEREBRAL-CORTEX; CDK INHIBITORS; GROWTH-FACTOR	Control of cell cycle progression/exit and differentiation of neuronal precursors is of paramount importance during brain development. BM88 is a neuronal protein associated with terminal neuron-generating divisions in vivo and is implicated in mechanisms underlying neuronal differentiation. Here we have used mouse neuroblastoma Neuro 2a cells as an in vitro model of neuronal differentiation to dissect the functional properties of BM88 by implementing gain- and loss-of-function approaches. We demonstrate that stably transfected cells overexpressing BM88 acquire a neuronal phenotype in the absence of external stimuli, as judged by enhanced expression of neuronal markers and neurite outgrowth-inducing signaling molecules. In addition, cell cycle measurements involving cell growth assays, BrdUrd incorporation, and fluorescence-activated cell sorting analysis revealed that the BM88-transfected cells have a prolonged G(1) phase, most probably corresponding to cell cycle exit at the G(0) restriction point, as compared with controls. BM88 overexpression also results in increased levels of the cell cycle regulatory protein p53, and accumulation of the hypophosphorylated form of the retinoblastoma protein leading to cell cycle arrest, with concomitant decreased levels and, in many cells, cytoplasmic localization of cyclin D1. Conversely, BM88 gene silencing using RNA interference experiments resulted in acceleration of cell proliferation accompanied by impairment of retinoic acid-induced neuronal differentiation of Neuro 2a cells. Taken together, our results suggest that BM88 plays an essential role in regulating cell cycle exit and differentiation of Neuro 2a cells toward a neuronal phenotype and further support its involvement in the proliferation/differentiation transition of neural stem/progenitor cells during embryonic development.	Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, Athens 11521, Greece		Matsas, R (corresponding author), Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, 127 Vassilissis Sofias Ave, Athens 11521, Greece.	rmatsa@mail.pasteur.gr; thomaidou@mail.pasteur.gr	Politis, Panagiotis/AAO-2423-2020	Politis, Panagiotis/0000-0002-2556-2857				Baek SH, 2003, P NATL ACAD SCI USA, V100, P3245, DOI 10.1073/pnas.0330217100; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Carey RG, 2002, J NEUROSCI, V22, P1583, DOI 10.1523/JNEUROSCI.22-05-01583.2002; Cesi V, 2002, CELL DEATH DIFFER, V9, P1232, DOI 10.1038/sj.cdd.4401103; Chae JH, 2004, MOL CELLS, V18, P271; Cheah P L, 2001, Malays J Pathol, V23, P9; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cremisi F, 2003, CURR OPIN NEUROBIOL, V13, P26, DOI 10.1016/S0959-4388(03)00005-9; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; DelSal G, 1996, CRIT REV ONCOGENESIS, V7, P127, DOI 10.1615/CritRevOncog.v7.i1-2.80; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIAZNIDO J, 1991, J CELL SCI, P51; Dou CL, 1999, CEREB CORTEX, V9, P543, DOI 10.1093/cercor/9.6.543; Dubreuil V, 2000, DEVELOPMENT, V127, P5191; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Dunkern TR, 2003, DNA REPAIR, V2, P49, DOI 10.1016/S1568-7864(02)00185-4; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Dyer MA, 2001, J NEUROSCI, V21, P4259, DOI 10.1523/JNEUROSCI.21-12-04259.2001; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Farah MH, 2000, DEVELOPMENT, V127, P693; Furukawa Y, 1997, Hum Cell, V10, P159; Gaitanou M, 2001, BIOCHEM J, V355, P715, DOI 10.1042/bj3550715; Gaitanou M, 1997, J NEUROSCI RES, V48, P507, DOI 10.1002/(SICI)1097-4547(19970615)48:6<507::AID-JNR3>3.3.CO;2-2; Gallo R, 2002, J CELL BIOL, V158, P731, DOI 10.1083/jcb.200202024; Gill RM, 1998, EXP CELL RES, V244, P157, DOI 10.1006/excr.1998.4197; Gomez J, 1998, J NEUROSCI RES, V51, P119, DOI 10.1002/(SICI)1097-4547(19980101)51:1<119::AID-JNR13>3.0.CO;2-6; Gostissa M, 2003, CURR OPIN CELL BIOL, V15, P351, DOI 10.1016/S0955-0674(03)00038-3; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haubst N, 2004, DEVELOPMENT, V131, P6131, DOI 10.1242/dev.01524; Heins N, 2001, MOL CELL NEUROSCI, V18, P485, DOI 10.1006/mcne.2001.1046; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu M, 1999, DEV BIOL, V207, P309, DOI 10.1006/dbio.1998.9031; Jiao JW, 2005, EMBO J, V24, P1068, DOI 10.1038/sj.emboj.7600589; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kiselyov VV, 2005, J NEUROCHEM, V94, P1169, DOI 10.1111/j.1471-4159.2005.03284.x; Koutmani Y, 2004, EUR J NEUROSCI, V20, P2509, DOI 10.1111/j.1460-9568.2004.03724.x; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Le Gac G, 2006, J BIOL CHEM, V281, P24161, DOI 10.1074/jbc.M603724200; Liu YH, 2004, MOL CELL BIOL, V24, P2662, DOI 10.1128/MCB.24.7.2662-2672.2004; Lukaszewicz AS, 2002, J NEUROSCI, V22, P6610; MAMALAKI A, 1995, J BIOL CHEM, V270, P14201, DOI 10.1074/jbc.270.23.14201; Matsas R, 1997, ADV EXP MED BIOL, V429, P3; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; Mendoza-Rodriguez CA, 2001, REV INVEST CLIN, V53, P266; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Musgrove EA, 2006, GROWTH FACTORS, V24, P13, DOI 10.1080/08977190500361812; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Ohnuma S, 2002, DEVELOPMENT, V129, P2435; Ohnuma S, 2001, CURR OPIN NEUROBIOL, V11, P66, DOI 10.1016/S0959-4388(00)00175-6; Ohnuma S, 2003, NEURON, V40, P199, DOI 10.1016/S0896-6273(03)00632-9; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Papadodima O, 2005, J NEUROCHEM, V95, P146, DOI 10.1111/j.1471-4159.2005.03350.x; PATSAVOUDI E, 1995, J NEUROSCI RES, V40, P506, DOI 10.1002/jnr.490400410; PATSAVOUDI E, 1989, NEUROSCIENCE, V30, P463, DOI 10.1016/0306-4522(89)90266-2; PATSAVOUDI E, 1991, J NEUROCHEM, V56, P782, DOI 10.1111/j.1471-4159.1991.tb01992.x; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Sanchez I, 2005, SEMIN CELL DEV BIOL, V16, P311, DOI 10.1016/j.semcdb.2005.02.007; Schuurmans C, 2002, CURR OPIN NEUROBIOL, V12, P26, DOI 10.1016/S0959-4388(02)00286-6; Schuurmans C, 2004, EMBO J, V23, P2892, DOI 10.1038/sj.emboj.7600278; Seo S, 2005, GENE DEV, V19, P1723, DOI 10.1101/gad.1319105; Seo S, 2006, CELL CYCLE, V5, P374, DOI 10.4161/cc.5.4.2438; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sidera K, 2004, J BIOL CHEM, V279, P45379, DOI 10.1074/jbc.M405486200; Spencer ML, 2004, J BIOL CHEM, V279, P37069, DOI 10.1074/jbc.M402507200; Sumrejkanchanakij P, 2006, BIOCHEM BIOPH RES CO, V340, P302, DOI 10.1016/j.bbrc.2005.11.181; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Suzui M, 2002, CANCER RES, V62, P3997; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Weissman TA, 2004, NEURON, V43, P647, DOI 10.1016/j.neuron.2004.08.015; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Wu GS, 1996, CLIN CANCER RES, V2, P623; Yan GZ, 1997, J NEUROSCI, V17, P6122; Yano M, 2005, J BIOL CHEM, V280, P12690, DOI 10.1074/jbc.M411119200; Zhai WG, 2005, CELL, V123, P1241, DOI 10.1016/j.cell.2005.10.030	84	48	49	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33606	33620		10.1074/jbc.M602689200	http://dx.doi.org/10.1074/jbc.M602689200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16893893	hybrid			2022-12-25	WOS:000241621400070
J	Daviau, A; Proulx, R; Robitaille, K; Di Fruscio, M; Tanguay, RM; Landry, J; Patterson, C; Durocher, Y; Blouin, R				Daviau, Alex; Proulx, Roxanne; Robitaille, Karine; Di Fruscio, Marco; Tanguay, Robert M.; Landry, Jacques; Patterson, Cam; Durocher, Yves; Blouin, Richard			Down-regulation of the mixed-lineage dual leucine zipper-bearing kinase by heat shock protein 70 and its co-chaperone CHIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; N-TERMINAL KINASE; DIFFERENTIAL ACTIVATION; PROTEASOMAL DEGRADATION; MOLECULAR CHAPERONES; NEGATIVE REGULATOR; INHIBITORY PROTEIN; CELLULAR FUNCTIONS; APAF-1 APOPTOSOME; UBIQUITIN LIGASE	Dual leucine zipper-bearing kinase (DLK) is a mixed-lineage kinase family member that acts as an upstream activator of the c-Jun N-terminal kinases. As opposed to other components of this pathway, very little is currently known regarding the mechanisms by which DLK is regulated in mammalian cells. Here we identify the stress-inducible heat shock protein 70 (Hsp70) as a negative regulator of DLK expression and activity. Support for this notion derives from data showing that Hsp70 induces the proteasomal degradation of DLK when both proteins are co-expressed in COS-7 cells. Hsp70-mediated degradation occurs with expression of wild-type DLK, which functions as a constitutively activated protein in these cells but not kinase-defective DLK. Interestingly, the Hsp70 co-chaperone CHIP, an E3 ubiquitin ligase, seems to be indispensable for this process since Hsp70 failed to induce DLK degradation in COS-7 cells expressing a CHIP mutant unable to catalyze ubiquitination or in immortalized fibroblasts derived from CHIP knock-out mice. Consistent with these data, we have found that endogenous DLK becomes sensitive to CHIP-dependent proteasomal degradation when it is activated by okadaic acid and that down-regulation of Hsp70 levels with an Hsp70 antisense attenuates this sensitivity. Therefore, our studies suggest that Hsp70 contributes to the regulation of activated DLK by promoting its CHIP-dependent proteasomal degradation.	Univ Sherbrooke, Fac Sci, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada; Univ Laval, Dept Med, Lab Genet Cellulaire & Dev, Ste Foy, PQ G1K 7P4, Canada; Univ Laval, CHU Quebec, Ctr Rech Cancerol, Hotel Dieu Quebec, Quebec City, PQ G1R 2J6, Canada; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Natl Res Council Canada, Biotechnol Res Inst, Anim Cell Technol & Downstream Proc Grp, Montreal, PQ H4P 2R2, Canada	University of Sherbrooke; Laval University; Laval University; University of North Carolina; University of North Carolina Chapel Hill; National Research Council Canada	Blouin, R (corresponding author), Univ Sherbrooke, Fac Sci, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada.	Richard.Blouin@USherbrooke.ca	Durocher, Yves/K-8709-2019					Alberti S, 2003, CELL STRESS CHAPERON, V8, P225, DOI 10.1379/1466-1268(2003)008<0225:BNEFOH>2.0.CO;2; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cuenda A, 1998, BIOCHEM J, V333, P11, DOI 10.1042/bj3330011; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Douziech M, 1999, J HISTOCHEM CYTOCHEM, V47, P1287, DOI 10.1177/002215549904701008; EZOE K, 1994, ONCOGENE, V9, P935; Fan CY, 2003, CELL STRESS CHAPERON, V8, P309, DOI 10.1379/1466-1268(2003)008<0309:MFROHF>2.0.CO;2; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Fukuyama K, 2000, J BIOL CHEM, V275, P21247, DOI 10.1074/jbc.M001488200; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Imai J, 2003, CELL CYCLE, V2, P585, DOI 10.4161/cc.2.6.586; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Maki CG, 1996, CANCER RES, V56, P2649; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Maroney AC, 1998, J NEUROSCI, V18, P104; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nakata K, 2005, CELL, V120, P407, DOI 10.1016/j.cell.2004.12.017; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Nihalani D, 2003, J BIOL CHEM, V278, P28694, DOI 10.1074/jbc.M304212200; Odunuga OO, 2004, BIOESSAYS, V26, P1058, DOI 10.1002/bies.20107; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Saporito MS, 2002, PROGR MED CHEM, V40, P23, DOI 10.1016/S0079-6468(08)70081-X; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	67	23	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31467	31477		10.1074/jbc.M607612200	http://dx.doi.org/10.1074/jbc.M607612200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16931512	Bronze, Green Published			2022-12-25	WOS:000241235300031
J	Ingley, E; Schneider, JR; Payne, CJ; McCarthy, DJ; Harder, KW; Hibbs, ML; Klinken, SP				Ingley, Evan; Schneider, Jessica R.; Payne, Christine J.; McCarthy, David J.; Harder, Kenneth W.; Hibbs, Margaret L.; Klinken, S. Peter			Csk-binding protein mediates sequential enzymatic down-regulation and degradation of Lyn in erythropoietin-stimulated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSPHINGOLIPID-ENRICHED MICRODOMAINS; SRC FAMILY KINASE; TYROSINE KINASE; NEGATIVE REGULATION; INDUCED DIFFERENTIATION; ERYTHROID-CELLS; LIPID RAFTS; SH2 DOMAIN; RECEPTOR; ACTIVATION	We have shown previously that the Src family kinase Lyn is involved in differentiation signals emanating from activated erythropoietin (Epo) receptors. The importance of Lyn to red cell maturation has been highlighted by Lyn(-/-) mice developing anemia. Here we show that Lyn interacts with C-terminal Src kinase-binding protein (Cbp), an adaptor protein that recruits negative regulators C-terminal Src kinase (Csk)/Csk-like protein-tyrosine kinase (Ctk). Lyn phosphorylated Cbp on several tyrosine residues, including Tyr(314), which recruited Csk/Ctk to suppress Lyn kinase activity. Intriguingly, phosphorylated Tyr(314) also bound suppressor of cytokine signaling 1 (SOCS1), another well characterized negative regulator of cell signaling, resulting in elevated ubiquitination, and degradation of Lyn. In Epo-responsive primary cells and cell lines, Lyn rapidly phosphorylated Cbp, suppressing Lyn kinase activity via Csk/Ctk within minutes of Epo stimulation; hours later, SOCS1 bound to Cbp and was involved in the ubiquitination and turnover of Lyn protein. Thus, a single phosphotyrosine residue on Cbp coordinates a two-phase process involving distinct negative regulatory pathways to inactivate, then degrade, Lyn.	Univ Western Australia, Cell Signalling Grp, Lab Canc Med, Western Australian Inst Med Res, Perth, WA 6000, Australia; Univ Western Australia, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Melbourne, Vic 3050, Australia	University of Western Australia; University of Western Australia; University of Western Australia; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Ingley, E (corresponding author), Univ Western Australia, Cell Signalling Grp, Lab Canc Med, Western Australian Inst Med Res, Level 6,Med Res Fdn Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.	eingley@waimr.uwa.edu.au	Ingley, Evan/C-2401-2013; Hibbs, Margaret L/D-7013-2011	Ingley, Evan/0000-0002-8112-9134; Hibbs, Margaret L/0000-0002-3751-6751				Arai A, 2001, J BIOL CHEM, V276, P33282, DOI 10.1074/jbc.M102924200; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Bhattacharyya SP, 2001, IMMUNOL LETT, V75, P131, DOI 10.1016/S0165-2478(00)00289-3; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; Chin H, 1998, BLOOD, V91, P3734; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Crouin C, 2001, FEBS LETT, V495, P148, DOI 10.1016/S0014-5793(01)02373-0; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Harashima A, 2002, BLOOD, V100, P4440, DOI 10.1182/blood-2002-03-0864; Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074-7613(01)00208-4; Harder KW, 2004, BLOOD, V104, P3901, DOI 10.1182/blood-2003-12-4396; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; HAWLEY RG, 1994, GENE THER, V1, P136; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; Ingley E, 1999, FEBS LETT, V459, P69, DOI 10.1016/S0014-5793(99)01188-6; Ingley E, 2005, ONCOGENE, V24, P336, DOI 10.1038/sj.onc.1208199; Ingley E, 2004, IUBMB LIFE, V56, P177, DOI 10.1080/15216540410001703956; Ingley E, 2001, J BIOL CHEM, V276, P43428, DOI 10.1074/jbc.M106645200; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; Kyo S, 2003, GENES CELLS, V8, P825, DOI 10.1046/j.1365-2443.2003.00679.x; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Liu E, 2003, EMBO J, V22, P5036, DOI 10.1093/emboj/cdg503; Lowell CA, 2004, MOL IMMUNOL, V41, P631, DOI 10.1016/j.molimm.2004.04.010; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382; Ohtake H, 2002, J IMMUNOL, V168, P2087, DOI 10.4049/jimmunol.168.5.2087; OKADA M, 1991, J BIOL CHEM, V266, P24249; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Sarna MK, 2003, ONCOGENE, V22, P3221, DOI 10.1038/sj.onc.1206381; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Shima T, 2003, P NATL ACAD SCI USA, V100, P14897, DOI 10.1073/pnas.2432139100; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Tilbrook PA, 2001, CANCER RES, V61, P2453; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Xu SL, 2005, MOL CELL BIOL, V25, P8486, DOI 10.1128/MCB.25.19.8486-8495.2005; Yasuda K, 2002, J IMMUNOL, V169, P2813, DOI 10.4049/jimmunol.169.6.2813; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	57	37	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31920	31929		10.1074/jbc.M602637200	http://dx.doi.org/10.1074/jbc.M602637200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920712	Green Published			2022-12-25	WOS:000241235300078
J	Kukimoto-Niino, M; Takagi, T; Akasaka, R; Murayama, K; Uchikubo-Kamo, T; Terada, T; Inoue, M; Watanabe, S; Tanaka, A; Hayashizaki, Y; Kigawa, T; Shirouzu, M; Yokoyama, S				Kukimoto-Niino, Mutsuko; Takagi, Tetsuo; Akasaka, Ryogo; Murayama, Kazutaka; Uchikubo-Kamo, Tomomi; Terada, Takaho; Inoue, Makoto; Watanabe, Satoru; Tanaka, Akiko; Hayashizaki, Yoshihide; Kigawa, Takanori; Shirouzu, Mikako; Yokoyama, Shigeyuki			Crystal structure of the RUN domain of the RAP2-interacting protein x	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-BINDING DOMAIN; CAENORHABDITIS-ELEGANS; PUTATIVE EFFECTOR; DEATH DOMAIN; FYVE-FINGER; RAP2; IDENTIFICATION; ACTIVATION; KINASE; SUPERFAMILY	Rap2-interacting protein x (RPIPx) is a homolog of RPIP8, a specific effector of Rap2 GTPase. The N-terminal region of RPIP8, which contains the RUN domain, interacts with Rap2. Using cell-free synthesis and NMR, we determined that the region encompassing residues 83-255 of mouse RPIPx, which is 40-residues larger than the predicted RUN domain (residues 113-245), is the minimum fragment that forms a correctly folded protein. This fragment, the RPIPx RUN domain, interacted specifically with Rap2B in vitro in a nucleotide-dependent manner. The crystal structure of the RPIPx RUN domain was determined at 2.0 angstrom of resolution by the multiwavelength anomalous dispersion (MAD) method. The RPIPx RUN domain comprises eight anti-parallel alpha-helices, which form an extensive hydrophobic core, followed by an extended segment. The residues in the core region are highly conserved, suggesting the conservation of the RUN domain-fold among the RUN domain-containing proteins. The residues forming a positively charged surface are conserved between RPIP8 and its homologs, suggesting that this surface is important for Rap2 binding. In the crystal the putative Rap2 binding site of the RPIPx RUN domain interacts with the extended segment in a segment-swapping manner.	RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Tohoku Univ, Biomed Engn Res Org, Sendai, Miyagi 9808575, Japan; Tokyo Inst Technol, Yokohama, Kanagawa 2268502, Japan; Univ Tokyo, Grad Sch Sci, Tokyo 1130033, Japan	RIKEN; Tohoku University; Tokyo Institute of Technology; University of Tokyo	Yokoyama, S (corresponding author), RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Hayashizaki, Yoshihide/N-6590-2015; Kukimoto-Niino, Mutsuko/C-6704-2017; watanabe, satoru s/E-9501-2012; Kigawa, Takanori/A-7679-2010; Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016	Kukimoto-Niino, Mutsuko/0000-0002-4178-1611; watanabe, satoru s/0000-0001-5329-9278; Kigawa, Takanori/0000-0003-0146-9719; Yokoyama, Shigeyuki/0000-0003-3133-7338; 				Bayer M, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-15; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Callebaut I, 2001, TRENDS BIOCHEM SCI, V26, P79, DOI 10.1016/S0968-0004(00)01730-8; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Christian SL, 2003, J BIOL CHEM, V278, P41756, DOI 10.1074/jbc.M303180200; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; DeLano W, 2002, PYMOL 0 99; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; EMERSON SD, 1995, BIOCHEMISTRY-US, V34, P6911, DOI 10.1021/bi00021a001; Esser D, 1998, BIOCHEMISTRY-US, V37, P13453, DOI 10.1021/bi9811664; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Janoueix-Lerosey I, 1998, EUR J BIOCHEM, V252, P290, DOI 10.1046/j.1432-1327.1998.2520290.x; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawabata T, 2003, NUCLEIC ACIDS RES, V31, P3367, DOI 10.1093/nar/gkg581; Kigawa T, 1998, FEBS LETT, V441, P413, DOI 10.1016/S0014-5793(98)01596-8; Kigawa Takanori, 2004, Journal of Structural and Functional Genomics, V5, P63, DOI 10.1023/B:JSFG.0000029204.57846.7d; Kigawa Takanori, 2002, Journal of Structural and Functional Genomics, V2, P29, DOI 10.1023/A:1013203532303; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Machida N, 2004, J BIOL CHEM, V279, P15711, DOI 10.1074/jbc.C300542200; Mari M, 2001, J BIOL CHEM, V276, P42501, DOI 10.1074/jbc.M104885200; Matsuda S, 2000, BBA-GENE STRUCT EXPR, V1491, P321, DOI 10.1016/S0167-4781(00)00049-X; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ogura K, 1997, GENE DEV, V11, P1801, DOI 10.1101/gad.11.14.1801; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedelacq JD, 2002, NAT BIOTECHNOL, V20, P927, DOI 10.1038/nbt732; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Raguz S, 2005, INT J CANCER, V117, P934, DOI 10.1002/ijc.21252; SAKODA T, 1992, ONCOGENE, V7, P1705; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Sukits SF, 2001, J MOL BIOL, V310, P895, DOI 10.1006/jmbi.2001.4790; Taira K, 2004, J BIOL CHEM, V279, P49488, DOI 10.1074/jbc.M406370200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; TERWILLIGER TC, 2002, CRYSTALLOGR D, V59, P1174; Vaughn DE, 1999, J MOL BIOL, V293, P439, DOI 10.1006/jmbi.1999.3177; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wang SR, 2003, BRAIN RES REV, V41, P13, DOI 10.1016/S0165-0173(02)00217-5; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Yan N, 2005, NATURE, V437, P831, DOI 10.1038/nature04002; YATANI A, 1991, J BIOL CHEM, V266, P22872; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712	60	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31843	31853		10.1074/jbc.M604960200	http://dx.doi.org/10.1074/jbc.M604960200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16928684				2022-12-25	WOS:000241235300071
J	Reinert, RB; Oberle, LM; Wek, SA; Bunpo, P; Wang, XP; Mileva, I; Goodwin, LO; Aldrich, CJ; Durden, DL; McNurlan, MA; Wek, RC; Anthony, TG				Reinert, Rachel B.; Oberle, L. Morgan; Wek, Sheree A.; Bunpo, Piyawan; Wang, Xue Ping; Mileva, Izolda; Goodwin, Leslie O.; Aldrich, Carla J.; Durden, Donald L.; McNurlan, Margaret A.; Wek, Ronald C.; Anthony, Tracy G.			Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; INITIATION FACTOR-2-ALPHA KINASE; UNFOLDED PROTEIN RESPONSE; MESSENGER-RNA TRANSLATION; AMINO-ACID DEPRIVATION; ANTI-LYMPHOMA ACTIVITY; CELL-CYCLE ARREST; GENE-EXPRESSION; EUKARYOTIC INITIATION-FACTOR-2; ESCHERICHIA-COLI	L-Asparaginase is important in the induction regimen for treating acute lymphoblastic leukemia. Cytotoxic complications are clinically significant problems lacking mechanistic insight. To reveal tissue-specific molecular responses to this drug, mice were administered asparaginase from either Escherichia coli ( clinically used) or Wolinella succinogenes ( novel, glutaminase-free form). Both enzymes abolished serum asparagine, but only the E. coli form reduced circulating glutamine. E. coli asparaginase reduced protein synthesis in liver and spleen but not pancreas via increased phosphorylation of the translation factor eIF2. In contrast, treatment with Wolinella caused no untoward changes in protein synthesis in any tissue examined. Treating mice deleted for the eIF2 kinase, GCN2, with the E. coli enzyme showed eIF2 phosphorylation to be GCN2-dependent, but only initially. Furthermore, although eIF2 phosphorylation was not increased in the pancreas or by Wolinella asparaginase, expression of the amino acid stress response genes, asparagine synthetase and CHOP/GADD153, increased as a result of both enzymes, even in tissues demonstrating no change in eIF2 phosphorylation. Finally, signaling downstream of the mammalian target of rapamycin kinase was repressed in liver and pancreas by E. coli but not Wolinella asparaginase. These data demonstrate that the nutrient stress response to asparaginase is tissue-specific and exacerbated by glutamine depletion. Importantly, increased expression of asparagine synthetase and CHOP does not require eIF2 phosphorylation, signifying alternate or auxiliary means of inducing gene expression under conditions of amino acid depletion in the whole animal.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Evansville, IN 47712 USA; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA; N Shore Long Isl Jewish Res Inst, Manhasset, NY 11030 USA; Indiana Univ Sch Med, Dept Microbiol & Immunol, Evansville, IN 47712 USA; Emory Univ, Sch Med, AFLAC, Ctr Canc & Blood Disorders, Atlanta, GA 30322 USA; SUNY Stony Brook, Dept Surg, Stony Brook, NY 11794 USA	Indiana University System; Indiana University System; Indiana University-Purdue University Indianapolis; Northwell Health; Indiana University System; Emory University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Anthony, TG (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 8600 Univ Blvd, Evansville, IN 47712 USA.	tganthon@iupui.edu	Anthony, Tracy/K-7951-2017	Anthony, Tracy/0000-0002-8586-5884; Reinert, Rachel/0000-0001-7778-4219	NIA NIH HHS [R01AG17446] Funding Source: Medline; NIGMS NIH HHS [R01GM49164] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017446] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Anand P, 2006, J NUTR, V136, P27, DOI 10.1093/jn/136.1.27; Anthony JC, 2000, J NUTR, V130, P2413; Anthony TG, 2004, J BIOL CHEM, V279, P36553, DOI 10.1074/jbc.M404559200; Anthony TG, 2001, AM J PHYSIOL-ENDOC M, V281, pE430, DOI 10.1152/ajpendo.2001.281.3.E430; Appel IM, 2006, BLOOD, V107, P4244, DOI 10.1182/blood-2005-06-2597; Aslanian AM, 2001, BIOCHEM J, V358, P59, DOI 10.1042/0264-6021:3580059; Bark TH, 1998, AM J PHYSIOL-ENDOC M, V275, pE118, DOI 10.1152/ajpendo.1998.275.1.E118; BOSMANN HB, 1970, LIFE SCI 2-BIOCH GEN, V9, P851; Bregendahl K, 2004, J NUTR, V134, P2722, DOI 10.1093/jn/134.10.2722; BROOME JD, 1981, CANCER TREAT REP, V65, P111; BROOME JD, 1965, J NATL CANCER I, V35, P967; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; CAIRO MS, 1982, AM J PEDIAT HEMATOL, V4, P335; Caso G, 2002, AM J PHYSIOL-ENDOC M, V282, pE1029, DOI 10.1152/ajpendo.00215.2001; CELLE G, 1977, ARZNEIMITTEL-FORSCH, V27-2, P2046; Chan Ka Wah, 2002, Curr Probl Pediatr Adolesc Health Care, V32, P40, DOI 10.1067/mps.2002.121790; DISTASIO JA, 1982, INT J CANCER, V30, P343, DOI 10.1002/ijc.2910300314; DISTASIO JA, 1977, P SOC EXP BIOL MED, V155, P528; DISTASIO JA, 1982, CANCER RES, V42, P252; DISTASIO JA, 1976, J BIOL CHEM, V251, P6929; DURDEN DL, 1980, CANCER RES, V40, P1125; DURDEN DL, 1983, CANCER RES, V43, P1602; Fine BM, 2005, CANCER RES, V65, P291; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; Grigoryan RS, 2004, IN VIVO, V18, P107; Hamanaka RB, 2005, MOL BIOL CELL, V16, P5493, DOI 10.1091/mbc.E05-03-0268; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HILL JM, 1967, J AMER MED ASSOC, V202, P882, DOI 10.1001/jama.202.9.882; Holcenberg J, 2004, J PEDIAT HEMATOL ONC, V26, P273, DOI 10.1097/00043426-200405000-00001; HOLCENBERG JS, 1975, CANCER RES, V35, P1320; Huang QH, 1999, BIOCHEM J, V341, P225, DOI 10.1042/0264-6021:3410225; Hutson RG, 1997, AM J PHYSIOL-CELL PH, V272, pC1691, DOI 10.1152/ajpcell.1997.272.5.C1691; Iiboshi Y, 1999, BIOCHEM BIOPH RES CO, V260, P534, DOI 10.1006/bbrc.1999.0920; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Jousse C, 2004, BIOCHEM BIOPH RES CO, V313, P447, DOI 10.1016/j.bbrc.2003.07.020; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; KAFKEWITZ D, 1983, AM J CLIN NUTR, V37, P1025; Kimball Sr, 2004, TOP CURR GENET, V7, P113; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; Krejci O, 2004, LEUKEMIA, V18, P434, DOI 10.1038/sj.leu.2403259; LEONARD JV, 1986, LANCET, V1, P162; LOOS M, 1972, CANCER RES, V32, P2292; LUNDHOLM K, 1991, ACTA PHYSIOL SCAND, V141, P207, DOI 10.1111/j.1748-1716.1991.tb09069.x; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; McNurlan MA, 1997, J CLIN INVEST, V100, P2125, DOI 10.1172/JCI119747; MESCHI F, 1981, HORM RES, V15, P237, DOI 10.1159/000179462; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Newsholme P, 2003, CELL BIOCHEM FUNCT, V21, P1, DOI 10.1002/cbf.1003; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; OLLENSCHLAGER G, 1988, EUR J CLIN INVEST, V18, P512, DOI 10.1111/j.1365-2362.1988.tb01049.x; Panosyan EH, 2004, ANTICANCER RES, V24, P1121; Panwalkar A, 2004, CANCER-AM CANCER SOC, V100, P657, DOI 10.1002/cncr.20026; Pinheiro JPV, 2004, BRIT J HAEMATOL, V125, P117, DOI 10.1111/j.1365-2141.2004.04863.x; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Reiff A, 2001, CLIN EXP RHEUMATOL, V19, P639; Reiter AK, 2004, INT J BIOCHEM CELL B, V36, P2169, DOI 10.1016/j.biocel.2004.04.004; Richards NGJ, 2006, ANNU REV BIOCHEM, V75, P629, DOI 10.1146/annurev.biochem.75.103004.142520; Rotoli BM, 2005, CELL PHYSIOL BIOCHEM, V15, P281, DOI 10.1159/000087238; Ruud E, 2006, PEDIATR HEMAT ONCOL, V23, P207, DOI 10.1080/08880010500506701; Sans MD, 2004, AM J PHYSIOL-GASTR L, V287, pG667, DOI 10.1152/ajpgi.00505.2003; Sans MD, 2003, AM J PHYSIOL-GASTR L, V285, pG517, DOI 10.1152/ajpgi.00540.2002; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Stams WAG, 2003, BLOOD, V101, P2743, DOI 10.1182/blood-2002-08-2446; VILLA P, 1986, TOXICOL LETT, V32, P235, DOI 10.1016/0378-4274(86)90113-X; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WARRELL RP, 1982, CANCER TREAT REP, V66, P1479; Wek RC, 2004, TOP CURR GENET, V7, P171; WU MC, 1978, INT J CANCER, V22, P728, DOI 10.1002/ijc.2910220615; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002	77	81	92	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31222	31233		10.1074/jbc.M604511200	http://dx.doi.org/10.1074/jbc.M604511200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16931516				2022-12-25	WOS:000241235300007
J	Reinke, A; Chen, JCY; Aronova, S; Powers, T				Reinke, Aaron; Chen, Jenny C. -Y.; Aronova, Sofia; Powers, Ted			Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN TARGET; CELL-GROWTH; SIGNALING PATHWAY; BINDING PARTNER; RADIOSENSITIZING AGENT; PROTEIN-KINASES; SERINE RESIDUE; RAPAMYCIN TOR	The target of rapamycin (TOR) kinase is an important regulator of growth in eukaryotic cells. In budding yeast, Tor1p and Tor2p function as part of two distinct protein complexes, TORC1 and TORC2, where TORC1 is specifically inhibited by the antibiotic rapamycin. Significant insight into TORC1 function has been obtained using rapamycin as a specific small molecule inhibitor of TOR activity. Here we show that caffeine acts as a distinct and novel small molecule inhibitor of TORC1: (i) deleting components specific to TORC1 but not TORC2 renders cells hypersensitive to caffeine; (ii) rapamycin and caffeine display remarkably similar effects on global gene expression; and (iii) mutations were isolated in Tor1p, a component specific to TORC1, that confers significant caffeine resistance both in vivo and in vitro. Strongest resistance requires two simultaneous mutations in TOR1, the first at either one of two highly conserved positions within the FRB (rapamycin binding) domain and a second at a highly conserved position within the ATP binding pocket of the kinase domain. Biochemical and genetic analyses of these mutant forms of Tor1p support a model wherein functional interactions between the FRB and kinase domains, as well as between the FRB domain and the TORC1 component Kog1p, regulate TOR activity as well as contribute to the mechanism of caffeine resistance.	Univ Calif Davis, Coll Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Powers, T (corresponding author), Univ Calif Davis, Coll Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA.	tpowers@ucdavis.edu		Chen, CJ/0000-0003-3766-4612; Reinke, Aaron/0000-0001-7612-5342				Alaimo PJ, 2005, BIOORGAN MED CHEM, V13, P2825, DOI 10.1016/j.bmc.2005.02.021; Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; Block WD, 2004, NUCLEIC ACIDS RES, V32, P1967, DOI 10.1093/nar/gkh508; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHEN JC, 2006, CURR GENET, V49, P1; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; Cortez D, 2003, J BIOL CHEM, V278, P37139, DOI 10.1074/jbc.M307088200; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; deHart AKA, 2003, MOL BIOL CELL, V14, P4676, DOI 10.1091/mbc.E03-05-0323; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; Ho HL, 2005, CURR GENET, V47, P273, DOI 10.1007/s00294-005-0570-8; Kaufmann WK, 2003, MUTAT RES-FUND MOL M, V532, P85, DOI 10.1016/j.mrfmmm.2003.08.012; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Reinke A, 2004, J BIOL CHEM, V279, P14752, DOI 10.1074/jbc.M313062200; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Scott PH, 1998, J BIOL CHEM, V273, P34496, DOI 10.1074/jbc.273.51.34496; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; STAN R, 1994, J BIOL CHEM, V269, P32027; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Yonezawa K, 2004, BIOCHEM BIOPH RES CO, V313, P437, DOI 10.1016/j.bbrc.2003.07.018; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	52	143	144	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31616	31626		10.1074/jbc.M603107200	http://dx.doi.org/10.1074/jbc.M603107200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16923813				2022-12-25	WOS:000241235300047
J	Yong, J; Tan, I; Lim, L; Leung, T				Yong, Jeffery; Tan, Ivan; Lim, Louis; Leung, Thomas			Phosphorylation of myosin phosphatase targeting subunit 3 (MYPT3) and regulation of protein phosphatase 1 by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKAP SIGNALING COMPLEXES; LIGHT-CHAIN-PHOSPHATASE; SMOOTH-MUSCLE; BINDING SUBUNIT; RHO-KINASE; DEPHOSPHORYLATION; IDENTIFICATION; TRANSDUCTION; CLONING	Myosin phosphatase targeting subunit 3 (MYPT3) and transforming growth factor-beta-inhibited membrane-associated protein (TIMAP) are two closely related myosin-binding targeting subunits of protein phosphatase 1 (PP1c) with a characteristic CAAX ( where AA indicates aliphatic amino acid) box at the C termini. Here we show that MYPT3 can be a substrate for protein kinase A (PKA). We first mapped the multiple phosphorylation sites within a central conserved motif. Deletion or mutations of this motif resulted in enhancement of the associated PP1c activity, suggesting that phosphorylation of MYPT3 may play an important role in regulating PP1c catalytic activity. However, unlike the other known MYPTs, which upon phosphorylation inhibit PP1c, PKA phosphorylation of MYPT3 resulted in PP1c activation, indicating a different mode of action. There is a direct interaction between the central conserved phosphorylated site motif with the N-terminal ankyrin repeat region; this interaction was significantly reduced with MYPT3 phosphorylation or acidic phosphorylation site mutations, with concomitant alterations in biochemical and morphological consequences. We therefore propose a novel mechanism for the phosphorylation of MYPT3 by PKA and activation of the catalytic activity through direct interaction of a central region of MYPT3 with its N-terminal region.	Natl Univ Singapore, GSK, IMCB Grp, Inst Mol & Cell Biol, Singapore 138673, Singapore; UCL, Inst Neurol, Dept Mol Neurosci, London WC1N 1PJ, England	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; National University of Singapore; University of London; University College London	Leung, T (corresponding author), Natl Univ Singapore, GSK, IMCB Grp, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	mcbthoml@imcb.a-star.edu.sg						Alto N, 2002, DIABETES, V51, pS385, DOI 10.2337/diabetes.51.2007.S385; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; Cao WS, 2002, AM J PHYSIOL-CELL PH, V283, pC327, DOI 10.1152/ajpcell.00442.2001; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Cohen PTW, 2002, J CELL SCI, V115, P241; Diviani D, 2004, EMBO J, V23, P2811, DOI 10.1038/sj.emboj.7600287; Diviani D, 2001, J CELL SCI, V114, P1431; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Gailly P, 1996, EUR J BIOCHEM, V239, P326, DOI 10.1111/j.1432-1033.1996.0326u.x; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; Hartshorne DJ, 2004, J BIOL CHEM, V279, P37211, DOI 10.1074/jbc.R400018200; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Hirano K, 2003, MOL CELL BIOCHEM, V248, P105, DOI 10.1023/A:1024180101032; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Langeberg LK, 2005, J CELL SCI, V118, P3217, DOI 10.1242/jcs.02416; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; LUO K, 1990, ONCOGENE, V5, P921; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Muranyi A, 2001, FEBS LETT, V493, P80, DOI 10.1016/S0014-5793(01)02283-9; Patel KG, 2001, J NEUROSCI, V21, P7954; Shin HM, 2002, CIRC RES, V90, P546, DOI 10.1161/01.RES.0000012822.23273.EC; Skinner JA, 2001, BIOCHEM J, V356, P257, DOI 10.1042/0264-6021:3560257; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Srinivas SP, 2004, EXP EYE RES, V79, P543, DOI 10.1016/j.exer.2004.06.027; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takizawa N, 2003, AM J PHYSIOL-CELL PH, V284, pC250, DOI 10.1152/ajpcell.00153.2002; Tan I, 2001, J BIOL CHEM, V276, P21209, DOI 10.1074/jbc.M102615200; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Vereshchagina N, 2004, MOL BIOL CELL, V15, P4395, DOI 10.1091/mbc.E04-02-0139; Wakatsuki T, 2003, J CELL SCI, V116, P1617, DOI 10.1242/jcs.00340; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Wooldridge AA, 2004, J BIOL CHEM, V279, P34496, DOI 10.1074/jbc.M405957200; WOOTEN MW, 2002, SCI STKE, pPL15	42	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31202	31211		10.1074/jbc.M607287200	http://dx.doi.org/10.1074/jbc.M607287200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920702				2022-12-25	WOS:000241235300005
J	Asinas, AE; Weis, RM				Asinas, Abdalin E.; Weis, Robert M.			Competitive and cooperative interactions in receptor signaling complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHEMOTAXIS; BACTERIAL CHEMOTAXIS; COVALENT MODIFICATION; ASPARTATE RECEPTOR; CYTOPLASMIC DOMAIN; SENSORY RECEPTOR; KINASE CHEA; CHEMORECEPTORS; TRANSDUCTION; MODEL	In bacterial chemotaxis, clustered transmembrane receptors and the adaptor protein Che W regulate the kinase CheA. Receptors outnumber CheA, yet it is poorly understood how interactions among receptors contribute to regulation. To address this problem, receptor clusters were simulated using liposomes decorated with the cytoplasmic domains of receptors, which supported CheA binding and stimulation. Competitive and cooperative interactions were revealed through the use of known receptor signaling mutants, which were used in mixtures with the wild type domain. Competitive effects among the receptor domains sorted cleanly into two categories defined by either stronger or weaker interactions with CheA. Cooperative effects were also evident in CheA binding and activity. In the transition from the stimulating to the inhibiting states, both the cooperativity of the transition and the persistence of stimulation by the wild type domain increased with receptor modification, as in the intact receptor. We conclude that competitive and cooperative receptor interactions both contribute to CheA regulation and that liposome-mediated assembly is effective in addressing these general membrane phenomena.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Weis, RM (corresponding author), Univ Massachusetts, Dept Chem, LGRT 701,710 N Pleasant St, Amherst, MA 01003 USA.	rmweis@chem.umass.edu			NIGMS NIH HHS [5R01GM053210, T32 GM008515] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008515, R01GM053210] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames P, 2002, P NATL ACAD SCI USA, V99, P7060, DOI 10.1073/pnas.092071899; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; Bornhorst JA, 2003, J MOL BIOL, V326, P1597, DOI 10.1016/S0022-2836(03)00026-3; Boukhvalova MS, 2002, J BIOL CHEM, V277, P22251, DOI 10.1074/jbc.M110908200; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Francis NR, 2004, P NATL ACAD SCI USA, V101, P17480, DOI 10.1073/pnas.0407826101; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Gestwicki JE, 2002, NATURE, V415, P81, DOI 10.1038/415081a; Griswold IJ, 2002, NAT STRUCT BIOL, V9, P121, DOI 10.1038/nsb753; Irieda H, 2006, J BIOL CHEM, V281, P23880, DOI 10.1074/jbc.M600018200; Kentner D, 2006, MOL MICROBIOL, V61, P407, DOI 10.1111/j.1365-2958.2006.05250.x; Keymer JE, 2006, P NATL ACAD SCI USA, V103, P1786, DOI 10.1073/pnas.0507438103; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Kott L, 2004, BBA-PROTEINS PROTEOM, V1696, P131, DOI 10.1016/j.bbapap.2003.10.001; Lamanna AC, 2005, MOL MICROBIOL, V57, P774, DOI 10.1111/j.1365-2958.2005.04728.x; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; Levit MN, 2002, J BIOL CHEM, V277, P36748, DOI 10.1074/jbc.M204317200; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; Liberman L, 2004, J BACTERIOL, V186, P6643, DOI 10.1128/JB.186.19.6643-6646.2004; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; Lybarger SR, 2005, MOL MICROBIOL, V56, P1078, DOI 10.1111/j.1365-2958.2005.04593.x; Lybarger SR, 2001, J BACTERIOL, V183, P3261, DOI 10.1128/JB.183.11.3261-3267.2001; MADDOCK JR, 1993, SCIENCE, V259, P1717; Mello BA, 2005, P NATL ACAD SCI USA, V102, P17354, DOI 10.1073/pnas.0506961102; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; Park SY, 2006, NAT STRUCT MOL BIOL, V13, P400, DOI 10.1038/nsmb1085; Parkinson JS, 2005, CURR OPIN MICROBIOL, V8, P116, DOI 10.1016/j.mib.2005.02.008; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Shimizu TS, 2000, NAT CELL BIOL, V2, P792, DOI 10.1038/35041030; Shrout AL, 2003, BIOCHEMISTRY-US, V42, P13379, DOI 10.1021/bi0352769; Sourjik V, 2004, TRENDS MICROBIOL, V12, P569, DOI 10.1016/j.tim.2004.10.003; Sourjik V, 2004, NATURE, V428, P437, DOI 10.1038/nature02406; Studdert CA, 2004, P NATL ACAD SCI USA, V101, P2117, DOI 10.1073/pnas.0308622100; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; Ulrich LE, 2005, BIOINFORMATICS, V21, P45, DOI 10.1093/bioinformatics/bti1204; Weis RM, 2003, J BACTERIOL, V185, P3636, DOI 10.1128/JB.185.12.3636-3643.2003	41	22	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30512	30523		10.1074/jbc.M606267200	http://dx.doi.org/10.1074/jbc.M606267200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16920717	hybrid			2022-12-25	WOS:000241075900027
J	Jancura, D; Berka, V; Antalik, M; Bagelova, J; Gennis, RB; Palmer, G; Fabian, M				Jancura, Daniel; Berka, Vladimir; Antalik, Marian; Bagelova, Jaroslava; Gennis, Robert B.; Palmer, Graham; Fabian, Marian			Spectral and kinetic equivalence of oxidized cytochrome c oxidase as isolated and "activated" by reoxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; PROTON TRANSLOCATION; CATALYTIC CENTER; PULSED FORM; SLOW FORMS; REDUCTION; EPR; MITOCHONDRIA; EQUILIBRIUM; PROTEIN	The spectral and kinetic characteristics of two oxidized states of bovine heart cytochrome c oxidase (CcO) have been compared. The first is the oxidized state of enzyme isolated in the fast form (O) and the second is the form that is obtained immediately after oxidation of fully reduced CcO with O-2 (O-H). No observable differences were found between O and O-H states in: (i) the rate of anaerobic reduction of heme a(3) for both the detergent-solubilized enzyme and for enzyme embedded in its natural membraneous environment, (ii) the one-electron distribution between heme a(3) and Cu-B in the course of the full anaerobic reduction, (iii) the optical and (iv) EPR spectra. Within experimental error of these characteristics both forms are identical. Based on these observations it is concluded that the reduction potentials and the ligation states of heme a(3) and Cu-B are the same for CcO in the O and O-H states.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Safarik Univ, Dept Biophys, Kosice 04154, Slovakia; Slovak Acad Sci, Inst Expt Phys, Dept Biophys, Kosice 04353, Slovakia; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	Rice University; University of Texas System; University of Texas Health Science Center Houston; University of Pavol Jozef Safarik Kosice; Slovak Academy of Sciences; University of Illinois System; University of Illinois Urbana-Champaign	Fabian, M (corresponding author), Rice Univ, Dept Biochem & Cell Biol, 6100 Main,MS 140, Houston, TX 77005 USA.	fabian@rice.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055807] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL016101] Funding Source: Medline; NIGMS NIH HHS [GM55807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1976, BIOCHIM BIOPHYS ACTA, V422, P260, DOI 10.1016/0005-2744(76)90137-6; Antalik M, 2005, BIOCHEMISTRY-US, V44, P14881, DOI 10.1021/bi050824z; ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; ARMSTRONG F, 1983, BIOCHIM BIOPHYS ACTA, V722, P61, DOI 10.1016/0005-2728(83)90157-3; BAKER GM, 1987, J BIOL CHEM, V262, P595; BEINERT H, 1982, OXIDASES RELATED RED, P139; BLAIR DF, 1983, CHEM SCRIPTA, V21, P43; Bloch D, 2004, P NATL ACAD SCI USA, V101, P529, DOI 10.1073/pnas.0306036101; BRANDT U, 1989, EUR J BIOCHEM, V182, P705, DOI 10.1111/j.1432-1033.1989.tb14882.x; BRUNORI M, 1979, J BIOL CHEM, V254, P769; Fabian M, 2004, J BIOL CHEM, V279, P16170, DOI 10.1074/jbc.M311834200; Fabian M, 2001, BIOCHEMISTRY-US, V40, P6061, DOI 10.1021/bi010059y; Farver O, 2000, EUR J BIOCHEM, V267, P950, DOI 10.1046/j.1432-1327.2000.01072.x; GEREN LM, 1995, J BIOL CHEM, V270, P2466, DOI 10.1074/jbc.270.6.2466; HARTZELL CR, 1973, P NATL ACAD SCI USA, V70, P2477, DOI 10.1073/pnas.70.9.2477; JACOBS EE, 1960, J BIOL CHEM, V235, P531; KOBAYASHI K, 1989, J BIOL CHEM, V264, P7976; LANNE B, 1979, BIOCHIM BIOPHYS ACTA, V545, P205, DOI 10.1016/0005-2728(79)90200-7; LENAZ G, 1967, METHOD ENZYMOL, V10, P499; Liao GL, 1996, BBA-BIOENERGETICS, V1274, P109, DOI 10.1016/0005-2728(96)00014-X; MALATESTA F, 1990, P NATL ACAD SCI USA, V87, P7410, DOI 10.1073/pnas.87.19.7410; MARGALIT R, 1973, EUR J BIOCHEM, V32, P492, DOI 10.1111/j.1432-1033.1973.tb02633.x; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; Moody AJ, 1996, BBA-BIOENERGETICS, V1276, P6; MOODY AJ, 1991, FEBS LETT, V293, P101, DOI 10.1016/0014-5793(91)81161-Z; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; PALMER G, 1988, CHEM SCRIPTA, V28A, P41; PAN LP, 1993, BIOCHEMISTRY-US, V32, P8492, DOI 10.1021/bi00084a014; PEISACH J, 1971, J BIOL CHEM, V246, P3342; Ruitenberg M, 2002, NATURE, V417, P99, DOI 10.1038/417099a; SHAW RW, 1978, J BIOL CHEM, V253, P6637; SOULIMANE T, 1995, EUR J BIOCHEM, V227, P588, DOI 10.1111/j.1432-1033.1995.tb20429.x; Szundi I, 2001, BIOCHEMISTRY-US, V40, P2186, DOI 10.1021/bi002341v; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VANGELDE.BF, 1969, BIOCHIM BIOPHYS ACTA, V189, P1, DOI 10.1016/0005-2728(69)90219-9; Verkhovsky MI, 1999, NATURE, V400, P480, DOI 10.1038/22813; VERKHOVSKY MI, 1995, BIOCHEMISTRY-US, V34, P7483, DOI 10.1021/bi00022a023; Wang KF, 2002, BIOCHEMISTRY-US, V41, P2298, DOI 10.1021/bi0114630; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WINKLER JR, 1995, BIOPHYS CHEM, V54, P199, DOI 10.1016/0301-4622(94)00156-E; WRIGGLESWORTH JM, 1988, BIOCHIM BIOPHYS ACTA, V936, P452, DOI 10.1016/0005-2728(88)90023-0	43	41	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30319	30325		10.1074/jbc.M605955200	http://dx.doi.org/10.1074/jbc.M605955200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16905536	hybrid			2022-12-25	WOS:000241075900005
J	Tocheva, EI; Fortin, PD; Eltis, LD; Murphy, MEP				Tocheva, Elitza I.; Fortin, Pascal D.; Eltis, Lindsay D.; Murphy, Michael E. P.			Structures of ternary complexes of BphK, a bacterial glutathione S-transferase that reductively dechlorinates polychlorinated biphenyl metabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN LB400; MICROBIAL-DEGRADATION; DEHALOGENATION; PURIFICATION; ROLES; BOND; EVOLUTION; MOLSCRIPT; CLEAVAGE; REVEALS	Prokaryotic glutathione S-transferases are as diverse as their eukaryotic counterparts but are much less well characterized. BphK from Burkholderia xenovorans LB400 consumes two GSH molecules to reductively dehalogenate chlorinated 2-hydroxy-6oxo-6-phenyl-2,4-dienoates (HOPDAs), inhibitory polychlorinated biphenyl metabolites. Crystallographic structures of two ternary complexes of BphK were solved to a resolution of 2.1 angstrom. In the BphK-GSH-HOPDA complex, GSH and HOPDA molecules occupy the G- and H-subsites, respectively. The thiol nucleophile of the GSH molecule is positioned for S(N)2 attack at carbon 3 of the bound HOPDA. The respective sulfur atoms of conserved Cys-10 and the bound GSH are within 3.0 angstrom, consistent with product release and the formation of a mixed disulfide intermediate. In the BphK-(GSH)(2) complex, a GSH molecule occupies each of the two subsites. The three sulfur atoms of the two GSH molecules and Cys-10 are aligned suitably for a disulfide exchange reaction that would regenerate the resting enzyme and yield disulfide-linked GSH molecules. A second conserved residue, His-106, is adjacent to the thiols of Cys-10 and the GSH bound to the G-subsite and thus may stabilize a transition state in the disulfide exchange reaction. Overall, the structures support and elaborate a proposed dehalogenation mechanism for BphK and provide insight into the plasticity of the H-subsite.	Univ British Columbia, Inst Life Sci, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Murphy, MEP (corresponding author), Univ British Columbia, Inst Life Sci, Dept Microbiol & Immunol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	michael.murphy@ubc.ca	Eltis, Lindsay D/J-8272-2015; Murphy, Michael/R-6805-2017	Eltis, Lindsay D/0000-0002-6774-8158; Murphy, Michael/0000-0003-2589-0014; Fortin, Pascal/0000-0001-9796-791X				Allocati N, 2000, BIOCHEM J, V351, P341, DOI 10.1042/0264-6021:3510341; Allocati N, 2006, BIOCHEM J, V394, P11, DOI 10.1042/BJ20051367; Anandarajah K, 2000, BIOCHEMISTRY-US, V39, P5303, DOI 10.1021/bi9923813; ARCA P, 1990, FEBS LETT, V263, P77, DOI 10.1016/0014-5793(90)80709-R; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bartels F, 1999, MICROBIOL-SGM, V145, P2821, DOI 10.1099/00221287-145-10-2821; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGI HB, 1974, TETRAHEDRON, V30, P1563, DOI 10.1016/S0040-4020(01)90678-7; Casalone E, 1998, FEBS LETT, V423, P122, DOI 10.1016/S0014-5793(98)00080-5; CATELANI D, 1974, BIOCHEM J, V143, P431, DOI 10.1042/bj1430431; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DIILIO C, 1988, BIOCHEM J, V255, P971, DOI 10.1042/bj2550971; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fortin PD, 2006, J BACTERIOL, V188, P4424, DOI 10.1128/JB.01849-05; Furukawa K, 2000, J GEN APPL MICROBIOL, V46, P283, DOI 10.2323/jgam.46.283; Gilmartin N, 2005, FEMS MICROBIOL LETT, V249, P23, DOI 10.1016/j.femsle.2005.05.056; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; HOFER B, 1994, GENE, V144, P9, DOI 10.1016/0378-1119(94)90196-1; IIZUKA M, 1989, J BACTERIOL, V171, P6039, DOI 10.1128/jb.171.11.6039-6042.1989; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kiefer PM, 2002, BIOCHEMISTRY-US, V41, P1315, DOI 10.1021/bi0117504; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Masai E, 2003, J BACTERIOL, V185, P1768, DOI 10.1128/JB.185.6.1768-1775.2003; Masai E, 1999, J IND MICROBIOL BIOT, V23, P364, DOI 10.1038/sj.jim.2900747; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nishida M, 1998, J MOL BIOL, V281, P135, DOI 10.1006/jmbi.1998.1927; Oakley AJ, 2005, CURR OPIN STRUC BIOL, V15, P716, DOI 10.1016/j.sbi.2005.10.005; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perito B, 1996, BIOCHEM J, V318, P157, DOI 10.1042/bj3180157; Polekhina G, 2001, BIOCHEMISTRY-US, V40, P1567, DOI 10.1021/bi002249z; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Seah SYK, 2000, J BIOL CHEM, V275, P15701, DOI 10.1074/jbc.275.21.15701; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vuilleumier S, 2002, APPL MICROBIOL BIOT, V58, P138, DOI 10.1007/s00253-001-0836-0; Vuilleumier S, 1997, J BACTERIOL, V179, P1431, DOI 10.1128/jb.179.5.1431-1441.1997; Warner JR, 2005, BIOCHEMISTRY-US, V44, P10360, DOI 10.1021/bi050666b; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	45	21	23	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30933	30940		10.1074/jbc.M603125200	http://dx.doi.org/10.1074/jbc.M603125200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16920719	hybrid			2022-12-25	WOS:000241075900069
J	Choi, SH; Mendrola, JM; Lemmon, MA				Choi, S. H.; Mendrola, J. M.; Lemmon, M. A.			EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer	ONCOGENE			English	Article						EGFR; ErbB; somatic mutations; constitutive activation; internalization; autoinhibition	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; KINASE DOMAIN; TYROSINE KINASE; TRANSFORMATION; INHIBITOR; ONCOGENE; MUTANTS; PROGRESSION; EXPRESSION	Several somatic mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have been identified that predict clinical response of non-small-cell lung carcinoma (NSCLC) patients to getfitnib. To test the hypothesis that these mutations cause constitutive EGF receptor signaling, and to investigate its mechanistic basis, we expressed representative examples in a null background and analysed their biochemical properties. Each mutation caused significant EGF-independent tyrosine phosphorylation of EGFR, and allowed the receptor to promote Ba/F3 cell mitogenesis in the absence of EGF, arguing that these are oncogenic mutations. Active mutated receptors are present at the cell surface and are fully competent to bind EGF. Recent structural studies show that the inactive EGFR tyrosine kinase domain is autoinhibited by intramolecular interactions between its activation loop and alpha C helix. We find that mutations predicted to disrupt this autoinhibitory interaction (including several that have not been described in NSCLC) elevate EGF-independent tyrosine kinase activity, thus providing new insight into how somatic mutations activate EGFR and other ErbB family members.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, 809C Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.	mlemmon@mail.med.upenn.edu		Lemmon, Mark/0000-0002-3379-5319	NATIONAL CANCER INSTITUTE [R01CA096768] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA096768, R01-CA096768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann J, 2005, CANCER RES, V65, P226; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; Dent R, 2006, CANCER TREAT REV, V32, P144, DOI 10.1016/j.ctrv.2006.01.005; DI FP, 1987, CELL, V51, P1063; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; HUDZIAK RM, 1991, J BIOL CHEM, V266, P24109; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Ozcan F, 2006, P NATL ACAD SCI USA, V103, P5735, DOI 10.1073/pnas.0601469103; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Sakai K, 2006, FASEB J, V20, P311, DOI 10.1096/fj.05-4034fje; SCHECHTER Y, 1979, NATURE, V278, P835, DOI 10.1038/278835a0; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Walker F, 2004, J BIOL CHEM, V279, P22387, DOI 10.1074/jbc.M401244200; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	41	59	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2007	26	11					1567	1576		10.1038/sj.onc.1209957	http://dx.doi.org/10.1038/sj.onc.1209957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953218				2022-12-25	WOS:000244782500006
J	Spraggon, L; Dudnakova, T; Slight, J; Lustig-Yariv, O; Cotterell, J; Hastie, N; Miles, C				Spraggon, L.; Dudnakova, T.; Slight, J.; Lustig-Yariv, O.; Cotterell, J.; Hastie, N.; Miles, C.			hnRNP-U directly interacts with WT1 and modulates WT1 transcriptional activation	ONCOGENE			English	Article						hnRNP-U; WT1; zinc fingers; Wilms' tumour	WILMS-TUMOR GENE; RNA-POLYMERASE-II; SUPPRESSOR GENE; PROTEIN WT1; EXPRESSION; BINDING; RIBONUCLEOPROTEIN; INHIBITION; MUTATIONS; RECEPTOR	The Wilms' tumour suppressor gene, WT1, encodes a zinc-finger protein that is mutated in Wilms' tumours and highly expressed in a wide variety of other malignancies. WT1 is a transcription factor that is likely to have additional, post-transcriptional, regulatory roles, although the molecular mechanisms by which WT1 acts remain poorly understood. We have combined genetic and biochemical approaches to show, that endogenous WT1 binds to heterogeneous nuclear ribonuclear protein U (hnRNP-U), that this interaction does not require any other proteins or nucleic acids, involves the zinc-fingers of WT1 and the middle domain of hnRNP-U, and that hnRNP-U can modulate WT1 transcriptional activation of a bona. de WT1 target gene. These findings increase our knowledge of how WT1 exerts its transcriptional regulatory role and suggests that hnRNP-U may be a candidate Wilms' tumour gene at 1q44.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Newcastle Upon Tyne, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Columbia Univ, Coll Phys & Surg, New York, NY USA	University of Edinburgh; Newcastle University - UK; Columbia University	Hastie, N (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crew Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	nick.hastie@hgu.mrc.ac.uk	Spraggon, Lee/E-5900-2012	Dudnakova, Tatyana/0000-0002-8388-8871	Medical Research Council [MC_U127527180] Funding Source: Medline; MRC [MC_U127527180] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bergmann L, 1997, LEUKEMIA LYMPHOMA, V25, P435, DOI 10.3109/10428199709039030; BRESLOW N, 1988, CANCER RES, V48, P1653; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Carpenter B, 2004, MOL CELL BIOL, V24, P537, DOI 10.1128/MCB.24.2.537-549.2004; Challen G, 2005, PHYSIOL GENOMICS, V23, P159, DOI 10.1152/physiolgenomics.00043.2005; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Heilbronn R, 2003, NUCLEIC ACIDS RES, V31, P6206, DOI 10.1093/nar/gkg827; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim MK, 1999, MOL CELL BIOL, V19, P6833; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kukalev A, 2005, NAT STRUCT MOL BIOL, V12, P238, DOI 10.1038/nsmb904; Ladomery MR, 1999, J BIOL CHEM, V274, P36520, DOI 10.1074/jbc.274.51.36520; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lee TH, 2002, J BIOL CHEM, V277, P44826, DOI 10.1074/jbc.M205667200; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Loeb DM, 2001, CANCER RES, V61, P921; Miles CG, 2003, MOL CELL BIOL, V23, P2608, DOI 10.1128/MCB.23.7.2608-2613.2003; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Natoli TA, 2002, MOL CELL BIOL, V22, P4433, DOI 10.1128/MCB.22.12.4433-4438.2002; Niksic M, 2004, HUM MOL GENET, V13, P463, DOI 10.1093/hmg/ddh040; Oji Y, 2004, NEOPLASMA, V51, P17; Oji Y, 2003, CANCER SCI, V94, P712, DOI 10.1111/j.1349-7006.2003.tb01507.x; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; REDDY JC, 1995, J BIOL CHEM, V270, P29976; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; RODECK U, 1994, INT J CANCER, V59, P78, DOI 10.1002/ijc.2910590116; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; SCHAFER V, 1997, PFLANZENBAUWISS, V1, P133; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Wagner N, 2004, J AM SOC NEPHROL, V15, P3044, DOI 10.1097/01.ASN.0000146687.99058.25; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; Williams RD, 2004, GENE CHROMOSOME CANC, V41, P65, DOI 10.1002/gcc.20060; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9	44	25	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1484	1491		10.1038/sj.onc.1209922	http://dx.doi.org/10.1038/sj.onc.1209922			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16924231				2022-12-25	WOS:000244558800013
J	Alanen, HI; Williamson, RA; Howard, MJ; Hatahet, FS; Salo, KEH; Kauppila, A; Kellokumpu, S; Ruddock, LW				Alanen, Heli I.; Williamson, Richard A.; Howard, Mark J.; Hatahet, Feras S.; Salo, Kirsi E. H.; Kauppila, Annika; Kellokumpu, Sakari; Ruddock, Lloyd W.			ERp27, a new non-catalytic endoplasmic reticulum-located human protein disulfide isomerase family member, interacts with ERp57	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING SITE; BOND FORMATION; MOLECULAR CHARACTERIZATION; LOADING COMPLEX; B' DOMAIN; THIOREDOXIN; CALRETICULIN; PEPTIDE; CATALYSIS; PATHWAY	Protein folding and quality control in the endoplasmic reticulum are critical processes for which our current understanding is far from complete. Here we describe the functional characterization of a new human 27.7-kDa protein (ERp27). We show that ERp27 is a two-domain protein located in the endoplasmic reticulum that is homologous to the non-catalytic b and b' domains of protein disulfide isomerase. ERp27 was shown to bind Delta-so-matostatin, the standard test peptide for protein disulfide isomerase-substrate binding, and this ability was localized to the second domain of ERp27. An alignment of human ERp27 and human protein disulfide isomerase allowed for the putative identification of the peptide binding site of ERp27 indicating conservation of the location of the primary substrate binding site within the protein disulfide isomerase family. NMR studies revealed a significant conformational change in the b'-like domain of ERp27 upon substrate binding, which was not just localized to the substrate binding site. In addition, we report that ERp27 is bound by ERp57 both in vitro and in vivo by a similar mechanism by which ERp57 binds calreticulin.	Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Kent	Ruddock, LW (corresponding author), Univ Oulu, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.	Lloyd.ruddock@oulu.fi		Ruddock, Lloyd/0000-0002-6247-686X; Howard, Mark/0000-0002-0762-2887	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Bass R, 2004, J BIOL CHEM, V279, P5257, DOI 10.1074/jbc.M304951200; Bedard K, 2005, INT REV CYTOL, V245, P91, DOI 10.1016/S0074-7696(05)45004-4; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; DeSilva MG, 1997, DNA CELL BIOL, V16, P269, DOI 10.1089/dna.1997.16.269; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Elliott T, 2005, IMMUNOL REV, V207, P89, DOI 10.1111/j.0105-2896.2005.00311.x; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; KELLOKUMPU S, 1988, SCIENCE, V242, P1308, DOI 10.1126/science.2461589; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Koivunen P, 2005, J BIOL CHEM, V280, P5227, DOI 10.1074/jbc.M412480200; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Liepinsh E, 2001, STRUCTURE, V9, P457, DOI 10.1016/S0969-2126(01)00607-4; Ma QJ, 2003, J BIOL CHEM, V278, P44600, DOI 10.1074/jbc.M307966200; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Martin V, 2006, J BIOL CHEM, V281, P2338, DOI 10.1074/jbc.M508302200; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; Nyfeler B, 2005, P NATL ACAD SCI USA, V102, P6350, DOI 10.1073/pnas.0501976102; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Raje S, 2003, BIOCHEMISTRY-US, V42, P4560, DOI 10.1021/bi030003z; Ruddock LW, 2000, PROTEIN SCI, V9, P758; Ruddock LW, 1996, BIOCHEM J, V315, P1001, DOI 10.1042/bj3151001; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Wright CA, 2004, BIOL CHEM, V385, P763, DOI 10.1515/BC.2004.100	53	44	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33727	33738		10.1074/jbc.M604314200	http://dx.doi.org/10.1074/jbc.M604314200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16940051	hybrid			2022-12-25	WOS:000241621400080
J	Locatelli-Hoops, S; Remmel, N; Klingenstein, R; Breiden, B; Rossocha, M; Schoeniger, M; Koenigs, C; Saenger, W; Sandhoff, K				Locatelli-Hoops, Silvia; Remmel, Natascha; Klingenstein, Ralf; Breiden, Bernadette; Rossocha, Maksim; Schoeniger, Maike; Koenigs, Christine; Saenger, Wolfram; Sandhoff, Konrad			Saposin A mobilizes lipids from low cholesterol and high bis(monoacylglycerol) phosphate-containing membranes - Patient variant Saposin A lacks lipid extraction capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSYLCERAMIDE BETA-GLUCOSIDASE; ACTIVATOR PROTEIN GENE; NIEMANN-PICK-DISEASE; GAUCHERS-DISEASE; PROSAPOSIN GENE; DEGRADATION; DEFICIENCY; MUTATION; BINDING; RECONSTITUTION	Saposin A (Sap-A) is one of five known sphingolipid activator proteins required for the lysosomal degradation of sphingolipids and for the loading of lipid antigens onto antigen-presenting molecules of the CD1 type. Sap-A assists in the degradation of galactosylceramide by galactosylceramide-beta-galactosidase in vivo, which takes place at the surface of intraendosomal/intralysosomal vesicles. Sap-A is believed to mediate the interaction between the enzyme and its membrane-bound substrate. Its dysfunction causes a variant form of Krabbe disease. In the present study we prepared glycosylated Sap-A free of other Saps, taking advantage of the Pichia pastoris expression system. Using liposomes and surface plasmon resonance spectroscopy, we tested the binding and lipid mobilization capacity of Sap-A under different conditions. Along the endocytic pathway, the pH value decreases, and the lipid composition of intraendosomal and intralysosomal membranes changes drastically. In the inner membranes the cholesterol concentration decreases, and that of the anionic phospholipid bis(monoacylglycero) phosphate increases. Here, we show that Sap-A is able to bind to liposomes and to mobilize lipids out of them at acidic pH values below pH 4.7. Low cholesterol levels and increasing concentrations of bis(monoacylglycero)phosphate favor lipid extraction significantly. Galactosylceramide as a bilayer component is not essential for lipid mobilization by Sap-A, which requires intact disulfide bridges for activity. We also show for the first time that glycosylation of Sap-A is essential for its lipid extraction activity. Variant Sap-A proteins, which cause storage of galactosylceramide in humans (Krabbe disease, Spiegel, R., Bach, G., Sury, V., Mengistu, G., Meidan, B., Shalev, S., Shneor, Y., Mandel, H., and Zeigler, M. (2005) Mol. Genet. Metab. 84, 160-166) and in mutant mice (Matsuda, J., Vanier, M. T., Saito, Y., Tohyama, J., and Suzuki, K. (2001) Hum. Mol. Genet. 10, 1191-1199) are deficient in lipid extraction capacity.	Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Free Univ Berlin, Inst Chem, Abt Kristallog, D-14195 Berlin, Germany	University of Bonn; Free University of Berlin	Sandhoff, K (corresponding author), Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.	sandhoff@uni-bonn.de	Breiden, Bernadette/F-2422-2014; Breiden, Bernadette/S-3005-2019	Breiden, Bernadette/0000-0002-4838-4109; Breiden, Bernadette/0000-0002-4838-4109; Rossmann, Maxim/0000-0001-8811-3277				BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; Bitto E, 2000, BIOCHEMISTRY-US, V39, P13469, DOI 10.1021/bi001275u; BLEISTEIN J, 1980, H-S Z PHYSIOL CHEM, V361, P595; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; Burkhardt JK, 1997, EUR J CELL BIOL, V73, P10; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; Chu ZT, 2005, EXP CELL RES, V303, P300, DOI 10.1016/j.yexcr.2004.09.029; Cooper MA, 2000, ANAL BIOCHEM, V277, P196, DOI 10.1006/abio.1999.4389; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; HAJRA AK, 1966, J LIPID RES, V7, P379; Harzer K, 2003, FEBS LETT, V537, P177, DOI 10.1016/S0014-5793(03)00100-5; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; Henseler M, 1996, J BIOL CHEM, V271, P8416, DOI 10.1074/jbc.271.14.8416; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; Honing S, 2005, MOL CELL, V18, P519, DOI 10.1016/j.molcel.2005.04.019; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kolter T, 2005, ANNU REV CELL DEV BI, V21, P81, DOI 10.1146/annurev.cellbio.21.122303.120013; Kolter T, 2005, J BIOL CHEM, V280, P41125, DOI 10.1074/jbc.R500015200; Lang C, 1995, APPL MICROBIOL BIOT, V44, P147, DOI 10.1007/s002530050533; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Matsuda J, 2001, HUM MOL GENET, V10, P1191, DOI 10.1093/hmg/10.11.1191; Matsuda J, 2004, HUM MOL GENET, V13, P2709, DOI 10.1093/hmg/ddh281; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mobius W, 2003, TRAFFIC, V4, P222; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; Patterson MC, 2003, NEUROLOGIST, V9, P301, DOI 10.1097/01.nrl.0000094627.78754.5b; PONTING CP, 1994, PROTEIN SCI, V3, P359; PRENCE EM, 1995, BIOCHEM J, V310, P571, DOI 10.1042/bj3100571; QI XY, 1994, J BIOL CHEM, V269, P16746; Qi XY, 2001, J BIOL CHEM, V276, P27010, DOI 10.1074/jbc.M101075200; Salvioi R, 2000, FEBS LETT, V472, P17, DOI 10.1016/S0014-5793(00)01417-4; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; Sandhoff K., 2001, METABOLIC ANDMOLECUL, P3371; SARMIENTOS F, 1986, EUR J BIOCHEM, V160, P527, DOI 10.1111/j.1432-1033.1986.tb10071.x; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; Spiegel R, 2005, MOL GENET METAB, V84, P160, DOI 10.1016/j.ymgme.2004.10.004; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; STREMMEL W, 1976, H-S Z PHYSIOL CHEM, V357, P803, DOI 10.1515/bchm2.1976.357.1.803; Umebayashi K, 2003, CELL STRUCT FUNCT, V28, P443, DOI 10.1247/csf.28.443; VACCARO AM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P55, DOI 10.1016/0005-2736(93)90024-T; VACCARO AM, 1993, FEBS LETT, V336, P159, DOI 10.1016/0014-5793(93)81631-9; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; Vaccaro AM, 1997, J BIOL CHEM, V272, P16862, DOI 10.1074/jbc.272.27.16862; Vanier MT, 1999, NEUROCHEM RES, V24, P481, DOI 10.1023/A:1022575511354; WENGER DA, 1982, BIOCHIM BIOPHYS ACTA, V712, P639, DOI 10.1016/0005-2760(82)90293-4; Werth N, 2001, J BIOL CHEM, V276, P12685, DOI 10.1074/jbc.M007970200; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114; Wilkening G, 2000, J BIOL CHEM, V275, P35814, DOI 10.1074/jbc.M006568200; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271; Winau F, 2004, NAT IMMUNOL, V5, P169, DOI 10.1038/ni1035; You HX, 2004, CHEM PHYS LIPIDS, V132, P15, DOI 10.1016/j.chemphyslip.2004.09.002; Zhou DP, 2004, SCIENCE, V303, P523, DOI 10.1126/science.1092009	58	57	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32451	32460		10.1074/jbc.M607281200	http://dx.doi.org/10.1074/jbc.M607281200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16905746	hybrid			2022-12-25	WOS:000241414500043
J	Tidow, H; Veprintsev, DB; Freund, SMV; Fersht, AR				Tidow, Henning; Veprintsev, Dmitry B.; Freund, Stefan M. V.; Fersht, Alan R.			Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULL-LENGTH P53; CORE DOMAIN; TUMOR-SUPPRESSOR; MUTANT P53; COOPERATIVE BINDING; APOPTOTIC FUNCTION; CRYSTAL-STRUCTURE; CANCER MUTATIONS; STRUCTURAL BASIS; WILD-TYPE	The tumor suppressor p53 is frequently mutated in human cancers. Upon activation it can induce cell cycle arrest or apoptosis. ASPP2 can specifically stimulate the apoptotic function of p53 but not cell cycle arrest, but the mechanism of enhancing the activation of pro-apoptotic genes over cell cycle arrest genes remains unknown. In this study, we analyzed the binding of 53BP2 (p53-binding protein 2, the C-terminal domain of ASPP2) to p53 core domain and various mutants using biophysical techniques. We found that several p53 core domain mutations (R181E, G245S, R249S, R273H) have different effects on the binding of DNA response elements and 53BP2. Further, we investigated the existence of a ternary complex consisting of 53BP2, p53, and DNA response elements to gain insight into the specific pro-apoptotic activation of p53. We found that binding of 53BP2 and DNA to p53 is mutually exclusive in the case of GADD45, p21, Bax, and PIG3. Both pro-apoptotic and non-apoptotic response elements were competed off p53 by 53BP2 with no indication of a ternary complex.	MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge	Fersht, AR (corresponding author), MRC, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	arf25@cam.ac.uk	Veprintsev, Dmitry B/H-2228-2012; Fersht, Alan R/B-2189-2008; Tidow, Henning/K-3420-2015	Veprintsev, Dmitry B/0000-0002-3583-5409; Tidow, Henning/0000-0002-4702-9332	MRC [MC_U105474168] Funding Source: UKRI; Medical Research Council [MC_U105474168] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ang HC, 2006, J BIOL CHEM, V281, P21934, DOI 10.1074/jbc.M604209200; Baroni TE, 2004, P NATL ACAD SCI USA, V101, P4930, DOI 10.1073/pnas.0401162101; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Dehner A, 2005, ANGEW CHEM INT EDIT, V44, P5247, DOI 10.1002/anie.200501887; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Ekblad CMS, 2004, PROTEIN SCI, V13, P617, DOI 10.1110/ps.03461404; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Friedler A, 2005, J BIOL CHEM, V280, P8051, DOI 10.1074/jbc.M411176200; Friedler A, 2005, STRUCTURE, V13, P629, DOI 10.1016/j.str.2005.01.020; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; Lane D, 2001, NATURE, V414, P25, DOI 10.1038/35102132; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu X, 2005, CURR OPIN GENET DEV, V15, P27, DOI 10.1016/j.gde.2004.12.008; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Rippin TM, 2002, J MOL BIOL, V319, P351, DOI 10.1016/S0022-2836(02)00326-1; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Trigiante G, 2006, NAT REV CANCER, V6, P217, DOI 10.1038/nrc1818; Veprintsev DB, 2006, P NATL ACAD SCI USA, V103, P2115, DOI 10.1073/pnas.0511130103; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Zupnick A, 2006, J BIOL CHEM, V281, P20464, DOI 10.1074/jbc.M603387200	48	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32526	32533		10.1074/jbc.M604725200	http://dx.doi.org/10.1074/jbc.M604725200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16887812	hybrid			2022-12-25	WOS:000241414500050
J	Gao, SQ; Zhang, R; Greenberg, ME; Sun, M; Chen, X; Levison, BS; Salomon, RG; Hazen, SL				Gao, Shengqiang; Zhang, Renliang; Greenberg, Michael E.; Sun, Mingjiang; Chen, Xi; Levison, Bruce S.; Salomon, Robert G.; Hazen, Stanley L.			Phospholipid hydroxyalkenals, a subset of recently discovered endogenous CD36 ligands, spontaneously generate novel furan-containing phospholipids lacking CD36 binding activity in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR CD36; ACTIVATING-FACTOR ACETYLHYDROLASE; RETINAL-PIGMENT EPITHELIUM; LOW-DENSITY LIPOPROTEINS; FOAM CELL-FORMATION; OXIDIZED PHOSPHOLIPIDS; FATTY-ACIDS; PHAGOCYTOSIS; LDL; ATHEROSCLEROSIS	We recently identified a novel family of oxidized choline glycerophospholipid (oxPC) molecular species enriched in atheroma that serve as endogenous ligands for the scavenger receptor CD36 (oxPC(CD36)), facilitating macrophage cholesterol accumulation and foam cell formation (Podrez, E. A., Poliakov, E., Shen, Z., et al. ( 2002) J. Biol. Chem. 277, 38517 38523). A high affinity CD36 recognition motif was defined within oxPCCD36, an oxidatively truncated sn-2 acyl group with a terminal gamma-hydroxy ( or oxo)-alpha, beta-unsaturated carbonyl. The fate of these species once formed in vivo is unknown. Here we show that a subset of oxPCCD36, a phosphatidylcholine molecular species possessing sn-2 esterified fatty acyl hydroxyalkenal groups, can undergo a slow intramolecular cyclization and dehydration reaction to form novel oxPC species possessing a sn-2 acyl group that incorporates a terminal furyl moiety (oxPC-furan). Using high performance liquid chromatography with on-line tandem mass spectrometry in combination with unambiguous organic synthesis, we confirm that oxPC-furans, ultimately derived from phospholipids with sn-2 esterified docosahexaenoic, arachidonic, or linoleic acids, are formed during exposure of model membranes and isolated lipoproteins to physiological oxidant systems. In vivo generation of oxPC-furans at sites of enhanced oxidant stress is also demonstrated, such as within brain tissues following cerebral ischemia. Cell binding studies reveal that in contrast to their oxPCCD36 precursors, oxPC-furans lack CD36 binding activity. Taken together, the present studies identify oxPC-furans as a novel family of oxidized phospholipids that are formed in vivo from phospholipid hydroxyalkenals but that lack CD36 binding activity.	Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Hazen, SL (corresponding author), Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, 9500 Euclid Ave,NE-10, Cleveland, OH 44195 USA.	hazens@ccf.org	Salomon, Robert G/C-3463-2008; Hazen, Stanley L/ABD-5845-2021	Salomon, Robert/0000-0001-9456-3557; Levison, Bruce/0000-0002-1816-368X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053315, P01HL076491, R01HL070621, R01HL061878, P50HL077107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR018390] Funding Source: Medline; NHLBI NIH HHS [P01 HL076491, HL70621, R01 HL053315, HL61878, HL53315, P01 HL077107] Funding Source: Medline; NIGMS NIH HHS [GM21249, R01 GM021249] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldini G, 2002, BIOCHEM BIOPH RES CO, V298, P699, DOI 10.1016/S0006-291X(02)02545-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Daviet L, 1997, THROMB HAEMOSTASIS, V78, P65; Dean RT, 1997, BIOCHEM J, V324, P1; Deng YJ, 2000, J ORG CHEM, V65, P6660, DOI 10.1021/jo000809u; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289; Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t; Huh HY, 1996, BLOOD, V87, P2020; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Lesnefsky EJ, 2000, ANAL BIOCHEM, V285, P246, DOI 10.1006/abio.2000.4783; Marathe GK, 2003, J BIOL CHEM, V278, P3937, DOI 10.1074/jbc.M211126200; Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061; MORRIS LJ, 1966, CHEM IND-LONDON, P1493; Nakata A, 1999, ARTERIOSCL THROM VAS, V19, P1333, DOI 10.1161/01.ATV.19.5.1333; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; Requena JR, 1996, NEPHROL DIAL TRANSPL, V11, P48; Ryeom SW, 1996, J CELL SCI, V109, P387; Salomon RG, 2005, ANN NY ACAD SCI, V1043, P327, DOI 10.1196/annals.1333.040; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1991, CHEST, V99, pS6, DOI 10.1378/chest.99.3_Supplement.6S-a; Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8; Spiteller G, 2005, LIPIDS, V40, P755, DOI 10.1007/s11745-005-1438-5; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; Sun MJ, 2004, J AM CHEM SOC, V126, P5699, DOI 10.1021/ja038756w; Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200; Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383; Swigut T, 2003, J VIROL, V77, P8116, DOI 10.1128/JVI.77.14.8116-8126.2003; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; White DC, 2005, APPL ENVIRON MICROB, V71, P8426, DOI 10.1128/AEM.71.12.8426-8433.2005; WIMMER MJ, 1975, J BIOL CHEM, V250, P710; Yamaguchi A, 2000, THROMB RES, V97, P317, DOI 10.1016/S0049-3848(99)00179-6	40	27	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31298	31308		10.1074/jbc.M604039200	http://dx.doi.org/10.1074/jbc.M604039200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16908526	Bronze			2022-12-25	WOS:000241235300014
J	Gee, K; Angel, JB; Ma, W; Mishra, S; Gajanayaka, N; Parato, K; Kumar, A				Gee, Katrina; Angel, Jonathan B.; Ma, Wei; Mishra, Sasmita; Gajanayaka, Niranjala; Parato, Karl; Kumar, Ashok			Intracellular HIV-Tat expression induces IL-10 synthesis by the CREB-1 transcription factor through Ser(133) phosphorylation and its regulation by the ERK1/2 MAPK in human monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; N-TERMINAL KINASE; PERIPHERAL-BLOOD LYMPHOCYTES; T-CELL; MONONUCLEAR-CELLS; GENE-EXPRESSION; INTERLEUKIN-10 PRODUCTION; DISEASE PROGRESSION; HUMAN MACROPHAGES; INTERFERON-GAMMA	Human immunodeficiency virus (HIV)-Tat plays an important role in virus replication and in various aspects of host immune responses, including dysregulation of cytokine production. IL-10, an anti-inflammatory cytokine, is up-regulated during the course of HIV infection representing an important pathway by which HIV may induce immunodeficiency. Here we show that extracellular as well as intracellular Tat induced IL-10 expression in normal human monocytes and promonocytic THP-1 cells. The signaling pathways involved in the regulation of IL-10 production by endogenous Tat remain unknown. To understand the molecular mechanism underlying intracellular Tat-induced IL-10 transcription, we employed a retroviral expression system to investigate the role of MAPKs and the transcription factor(s) involved. Our results suggest that an inhibitor specific for the ERK1/2, PD98059, selectively blocked intracellular Tat-induced IL-10 expression in THP-1 cells. Furthermore, intracellular Tat activated the CREB-1 transcription factor through Ser(133) phosphorylation that was regulated by ERK MAPK as determined by IL-10 promoter analysis and gel shift assays. Overall, our results suggest that intracellular HIV-Tat induces IL-10 transcription by ERK MAPK-dependent CREB-1 transcription factor activation through Ser(133) phosphorylation.	Childrens Hosp Eastern Ontario, Res Inst, Div Virol, Dept Pathol & Lab Med, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Res Inst, Dept Biochem, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Res Inst, Dept Immunol & Microbiol, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Res Inst, Div Virol & Mol Immunol, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Div Infect Dis, Dept Med, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Kumar, A (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Div Virol, Dept Pathol & Lab Med, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	akumar@uottawa.ca	Gee, Katrina/H-3093-2016	Angel, Jonathan B/0000-0003-3102-4462; Gee, Katrina/0000-0002-7535-2882				Abraham S, 2005, J NEUROIMMUNOL, V160, P219, DOI 10.1016/j.jneuroim.2004.11.009; AKRIDGE RE, 1994, J IMMUNOL, V153, P5782; Ancuta P, 2001, J IMMUNOL, V166, P4244, DOI 10.4049/jimmunol.166.6.4244; Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; Badou A, 2000, J VIROL, V74, P10551, DOI 10.1128/JVI.74.22.10551-10562.2000; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; Bennasser Y, 2002, VIROLOGY, V303, P174, DOI 10.1006/viro.2002.1676; Bennasser Y, 2002, FASEB J, V16, P546, DOI 10.1096/fj.01-0775com; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Borgatti P, 1997, EUR J IMMUNOL, V27, P2805, DOI 10.1002/eji.1830271110; Brenner S, 2003, J BIOL CHEM, V278, P5597, DOI 10.1074/jbc.M207448200; BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757; Brigati C, 2003, FEMS MICROBIOL LETT, V220, P57, DOI 10.1016/S0378-1097(03)00067-3; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204; CUPP C, 1993, ONCOGENE, V8, P2231; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; Deisseroth K, 2002, NEURON, V34, P179, DOI 10.1016/S0896-6273(02)00664-5; DEL PG, 1993, J IMMUNOL, V150, P353; DIAZMITOMA F, 1995, CLIN EXP IMMUNOL, V102, P31; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Foey AD, 1998, J IMMUNOL, V160, P920; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; Gavaravarapu S, 2000, BIOCHEM BIOPH RES CO, V269, P758, DOI 10.1006/bbrc.2000.2358; Gibellini D, 1998, J IMMUNOL, V160, P3891; Gonzalez E, 2001, J IMMUNOL, V166, P4560, DOI 10.4049/jimmunol.166.7.4560; Ito M, 1998, AIDS RES HUM RETROV, V14, P845, DOI 10.1089/aid.1998.14.845; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kollmann TR, 1996, P NATL ACAD SCI USA, V93, P3126, DOI 10.1073/pnas.93.7.3126; Kumar A, 1998, CLIN EXP IMMUNOL, V114, P78; Kumar A, 1998, J IMMUNOL, V161, P776; Landay AL, 1996, J INFECT DIS, V173, P1085, DOI 10.1093/infdis/173.5.1085; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; Lim SP, 2000, J VIROL, V74, P1632, DOI 10.1128/JVI.74.4.1632-1640.2000; Ma W, 2004, J IMMUNOL, V172, P318, DOI 10.4049/jimmunol.172.1.318; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; Mocellin S, 2003, TRENDS IMMUNOL, V24, P36, DOI 10.1016/S1471-4906(02)00009-1; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Muller F, 1998, J INFECT DIS, V177, P586, DOI 10.1086/514222; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Ostrowski MA, 2001, J INFECT DIS, V184, P1268, DOI 10.1086/324005; Patterson BK, 1999, CLIN IMMUNOL, V91, P254, DOI 10.1006/clim.1999.4713; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Rahimi AAR, 2005, J IMMUNOL, V174, P7823, DOI 10.4049/jimmunol.174.12.7823; Schols D, 1996, J VIROL, V70, P4953, DOI 10.1128/JVI.70.8.4953-4960.1996; SHARMA V, 1995, BIOCHEM BIOPH RES CO, V208, P704, DOI 10.1006/bbrc.1995.1395; Shin HD, 2000, P NATL ACAD SCI USA, V97, P14467, DOI 10.1073/pnas.97.26.14467; Stylianou E, 1999, CLIN EXP IMMUNOL, V116, P115; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WHITE MRH, 1995, J CELL SCI, V108, P441; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466; Yang YD, 2003, J VIROL, V77, P6700, DOI 10.1128/JVI.77.12.6700-6708.2003; Zhou JH, 2001, J IMMUNOL, V167, P4436, DOI 10.4049/jimmunol.167.8.4436	64	42	45	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31647	31658		10.1074/jbc.M512109200	http://dx.doi.org/10.1074/jbc.M512109200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920714				2022-12-25	WOS:000241235300050
J	Moreschi, I; Bruzzone, S; Nicholas, RA; Fruscione, F; Sturla, L; Benvenuto, F; Usai, C; Meis, S; Kassack, MU; Zocchi, E; De Flora, A				Moreschi, Iliana; Bruzzone, Santina; Nicholas, Robert A.; Fruscione, Floriana; Sturla, Laura; Benvenuto, Federica; Usai, Cesare; Meis, Sabine; Kassack, Matthias U.; Zocchi, Elena; De Flora, Antonio			Extracellular NAD(+) is an agonist of the human P2Y(11) purinergic receptor in human granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; REGULATES INTRACELLULAR CALCIUM; T-CELL DEATH; PHOSPHOLIPASE-C; CD38; ACTIVATION; NEUTROPHILS; RELEASE; CYCLASE; NAD+	Micromolar concentrations of extracellular beta-NAD(+) (NAD(e)(+)) activate human granulocytes (superoxide and NO generation and chemotaxis) by triggering: (i) overproduction of cAMP, (ii) activation of protein kinase A, (iii) stimulation of ADP-ribosyl cyclase and overproduction of cyclic ADP-ribose (cADPR), a universal Ca2+ mobilizer, and (iv) influx of extracellular Ca2+. Here we demonstrate that exposure of granulocytes to millimolar rather than to micromolar NAD(e)(+) generates both inositol 1,4,5-trisphosphate (IP3) and cAMP, with a two-step elevation of intracellular calcium levels ([Ca2+](i)): a rapid, IP3-mediated Ca2+ release, followed by a sustained influx of extracellular Ca2+ mediated by cADPR. Suramin, an inhibitor of P2Y receptors, abrogated NAD(e)(+)-induced intracellular increases of IP3, cAMP, cADPR, and [Ca2+](i), suggesting a role for a P2Y receptor coupled to both phospholipase C and adenylyl cyclase. The P2Y(11) receptor is the only known member of the P2Y receptor subfamily coupled to both phospholipase C and adenylyl cyclase. Therefore, we performed experiments on hP2Y(11)-transfected 1321N1 astrocytoma cells: micromolar NAD(e)(+) promoted a two-step elevation of the [Ca2+](i) due to the enhanced intracellular production of IP3, cAMP, and cADPR in 1321N1-hP2Y(11) but not in untransfected 1321N1 cells. In human granulocytes NF157, a selective and potent inhibitor of P2Y11, and the down-regulation of P2Y11 expression by short interference RNA prevented NAD(e)(+)-induced intracellular increases of ([Ca2+](i)): and chemotaxis. These results demonstrate that beta-NAD(e)(+) is an agonist of the P2Y(11) purinoceptor and that P2Y11 is the endogenous receptor in granulocytes mediating the sustained ([Ca2+](i)): increase responsible for their functional activation.	Univ Genoa, Biochem Sect, Dept Expt Med, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Genoa, Neuroimmunol Unit, Dept Neurosci Ophthalmol & Genet, Genoa, Italy; Univ Genoa, CEBR, Genoa, Italy; CNR, Inst Biophys, I-16149 Genoa, Italy; Univ Bonn, Inst Pharmaceut, D-53121 Bonn, Germany	University of Genoa; University of Genoa; University of North Carolina; University of North Carolina Chapel Hill; University of Genoa; University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); University of Bonn	Bruzzone, S (corresponding author), Univ Genoa, Biochem Sect, Dept Expt Med, Viale Benedetto 15-1, I-16132 Genoa, Italy.	santina.bruzzone@unige.it	fruscione, floriana/AAA-8747-2020; Bruzzone, Santina/A-4264-2015	Bruzzone, Santina/0000-0003-2034-3716; fruscione, floriana/0000-0002-4054-645X; Usai, Cesare/0000-0001-8863-7759	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071131] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071131] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beigi RD, 2003, BRIT J PHARMACOL, V140, P507, DOI 10.1038/sj.bjp.0705470; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruzzone S, 2006, BIOCHEM J, V393, P697, DOI 10.1042/BJ20051302; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; Bruzzone S, 2001, FASEB J, V15, P10; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Davies EV, 1998, INT J MOL MED, V1, P485; De Flora A, 2004, ANN NY ACAD SCI, V1028, P176, DOI 10.1196/annals.1322.021; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P227; Esguerra M, 2002, GLIA, V39, P314, DOI 10.1002/glia.10115; Gasser A, 2006, J BIOL CHEM, V281, P2489, DOI 10.1074/jbc.M506525200; Gerth A, 2004, BIOCHEM J, V382, P849, DOI 10.1042/BJ20040979; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; Guse AH, 2005, FEBS J, V272, P4590, DOI 10.1111/j.1742-4658.2005.04863.x; Kawamura H, 2005, J IMMUNOL, V174, P1971, DOI 10.4049/jimmunol.174.4.1971; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Krebs C, 2005, J IMMUNOL, V174, P3298, DOI 10.4049/jimmunol.174.6.3298; la Sala A, 2003, J LEUKOCYTE BIOL, V73, P339, DOI 10.1189/jlb.0802418; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 2002, CYCLIC ADP RIBOSE NA; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Meshki J, 2004, AM J PHYSIOL-CELL PH, V286, pC264, DOI 10.1152/ajpcell.00287.2003; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Partida-Sanchez S, 2004, J IMMUNOL, V172, P1896, DOI 10.4049/jimmunol.172.3.1896; Qi AD, 2001, BRIT J PHARMACOL, V132, P318, DOI 10.1038/sj.bjp.0703788; Rah SY, 2005, J BIOL CHEM, V280, P2888, DOI 10.1074/jbc.M409592200; Ralevic V, 1998, PHARMACOL REV, V50, P413; Romanello M, 2002, BIOCHEM BIOPH RES CO, V299, P424, DOI 10.1016/S0006-291X(02)02665-7; Schwarzmann N, 2002, J BIOL CHEM, V277, P50636, DOI 10.1074/jbc.M209061200; Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8; Smyth LM, 2004, J BIOL CHEM, V279, P48893, DOI 10.1074/jbc.M407266200; Spassova MA, 2004, BBA-MOL CELL RES, V1742, P9, DOI 10.1016/j.bbamcr.2004.09.001; Sun L, 1999, J CELL BIOL, V146, P1161, DOI 10.1083/jcb.146.5.1161; Torres B, 2002, J BIOL CHEM, V277, P7761, DOI 10.1074/jbc.M110352200; Ullmann H, 2005, J MED CHEM, V48, P7040, DOI 10.1021/jm050301p; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; White PJ, 2003, MOL PHARMACOL, V63, P1356, DOI 10.1124/mol.63.6.1356; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x; ZIEGLER M, 2004, BIOCHEM J, V382, P5	43	109	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31419	31429		10.1074/jbc.M606625200	http://dx.doi.org/10.1074/jbc.M606625200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16926152	Bronze, Green Published			2022-12-25	WOS:000241235300026
J	Rould, MA; Wan, Q; Joel, PB; Lowey, S; Trybus, KM				Rould, Mark A.; Wan, Qun; Joel, Peteranne B.; Lowey, Susan; Trybus, Kathleen M.			Crystal structures of expressed non-polymerizable monomeric actin in the ADP and ATP states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; FILAMENT; COMPLEX; CRYSTALLOGRAPHY; LOCALIZATION; HYDROLYSIS; BINDING; CELLS; MODEL	Actin filament growth and disassembly, as well as affinity for actin-binding proteins, is mediated by the nucleotide-bound state of the component actin monomers. The structural differences between ATP-actin and ADP-actin, however, remain controversial. We expressed a cytoplasmic actin in Sf9 cells, which was rendered non-polymerizable by virtue of two point mutations in subdomain 4 (A204E/P243K). This homogeneous monomer, called AP-actin, was crystallized in the absence of toxins, binding proteins, or chemical modification, with ATP or ADP at the active site. The two surface mutations do not perturb the structure. Significant differences between the two states are confined to the active site region and sensor loop. The active site cleft remains closed in both states. Minor structural shifts propagate from the active site toward subdomain 2, but dissipate before reaching the DNase binding loop ( D- loop), which remains disordered in both the ADP and ATP states. This result contrasts with previous structures of actin made monomeric by modification with tetramethylrhodamine, which show formation of an alpha-helix at the distal end of the D- loop in the ADP-bound but not the ATP-bound form (Otterbein, L. R., Graceffa, P., and Dominguez, R. (2001) Science 293, 708-711). Our reanalysis of the TMR-modified actin structures suggests that the nucleotide-dependent formation of the D- loop helix may result from signal propagation through crystal packing interactions. Whereas the observed nucleotide-dependent changes in the structure present significantly different surfaces on the exterior of the actin monomer, current models of the actin filament lack any actin-actin interactions that involve the region of these key structural changes.	Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA.	kathleen.trybus@uvm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038113, R29HL038113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Bookwalter CS, 2006, J BIOL CHEM, V281, P16777, DOI 10.1074/jbc.M512935200; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlier M F, 1990, Adv Biophys, V26, P51, DOI 10.1016/0065-227X(90)90007-G; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; Dominguez R, 2004, TRENDS BIOCHEM SCI, V29, P572, DOI 10.1016/j.tibs.2004.09.004; Dominguez R, 2003, BIOPHYS J, V85, P2073, DOI 10.1016/S0006-3495(03)74635-9; Graceffa P, 2003, J BIOL CHEM, V278, P34172, DOI 10.1074/jbc.M303689200; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Joel PB, 2004, BIOCHEMISTRY-US, V43, P11554, DOI 10.1021/bi048899a; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Klenchin VA, 2003, NAT STRUCT BIOL, V10, P1058, DOI 10.1038/nsb1006; Kudryashov DS, 2003, BIOPHYS J, V85, P2466, DOI 10.1016/S0006-3495(03)74669-4; Kudryashov DS, 2005, P NATL ACAD SCI USA, V102, P13105, DOI 10.1073/pnas.0506429102; Kudryashov DS, 2004, BIOPHYS J, V87, P1136, DOI 10.1529/biophysj.104.042242; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Minehardt TJ, 2006, BIOPHYS J, V90, P2445, DOI 10.1529/biophysj.105.072900; Nolen BJ, 2004, P NATL ACAD SCI USA, V101, P15627, DOI 10.1073/pnas.0407149101; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, FEBS LETT, V170, P94, DOI 10.1016/0014-5793(84)81376-9; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rould MA, 2003, METHOD ENZYMOL, V374, P145, DOI 10.1016/S0076-6879(03)74007-5; ROULD MA, 2006, IN PRESS METHODS MOL, V364; Sablin EP, 2002, P NATL ACAD SCI USA, V99, P10945, DOI 10.1073/pnas.152329899; Simanshu DK, 2005, J MOL BIOL, V352, P876, DOI 10.1016/j.jmb.2005.07.069; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; Volkman L, 1996, VIROLOGY, V225, P369, DOI 10.1006/viro.1996.0611; Vorobiev S, 2003, P NATL ACAD SCI USA, V100, P5760, DOI 10.1073/pnas.0832273100	38	101	102	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31909	31919		10.1074/jbc.M601973200	http://dx.doi.org/10.1074/jbc.M601973200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16920713	Bronze			2022-12-25	WOS:000241235300077
J	Lopez-Soto, A; Quinones-Lombrana, A; Lopez-Arbesu, R; Lopez-Larrea, C; Gonzalez, S				Lopez-Soto, Alejandro; Quinones-Lombrana, Adolfo; Lopez-Arbesu, Ruben; Lopez-Larrea, Carlos; Gonzalez, Segundo			Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-RELATED CHAIN; NATURAL CYTOTOXICITY RECEPTORS; GENE PROMOTER; FACTOR SP3; T-CELLS; BINDING-PROTEINS; KILLER-CELLS; FACTOR AP-2; NK CELLS; EXPRESSION	Tumor cells expressing ligands of the NKG2D receptor stimulate anti-tumor immunity mediated by natural killer and T cells. In humans, NKG2D ligands (NKG2DL) are encoded by MIC and ULBP proteins. NKG2DL exhibit highly restricted expression in healthy tissues but are widely expressed in tumors. However, regulation of each NKG2DL differs substantially in different cancer cells. In this study, we characterized the mechanisms that regulate the expression of ULBP1. We show that the transcription of ULBP1 strictly depends on the binding of Sp1 and Sp3 to a CRE(1) site located in the ULBP1 minimal promoter. The mutation or deletion of this Sp1/Sp3 binding site abolished the transcription of ULBP1. It also diminished the transactivation of ULBP1 promoter by Sp3 overexpression, but not by Sp1, indicating that Sp3 is the main transcription factor that regulates ULBP1 through the CRE(1) site. Experiments in SL2 cells showed that the ULBP1 promoter was inactive in the absence of the Sp proteins and indicate that Sp3 is the essential activator of ULBP1 transcription, because the overexpression of Sp3 up-regulated its promoter activity > 500-fold. Additionally, we demonstrated that AP-2 alpha repressed the expression of ULBP1 in HeLa cells by interfering with the binding of Sp3 and Sp1 to the ULBP1 promoter. These data indicate that Sp1, Sp3, and AP-2 alpha may play an important role in the immunosurveillance against cancer. Finally, the definition of ULBP1 regulation may have implications for development of new therapeutic strategies against cancer cells.	Univ Oviedo, Dept Biol Func, Fac Med, Inst Univ Oncol Principado Asturias, Oviedo, Spain; Hosp Univ Cent Asturias, Unidad Histocompatibilidad & Transplantes, Oviedo, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias; Central University Hospital Asturias	Gonzalez, S (corresponding author), Univ Oviedo, Dept Biol Func, Fac Med, Inst Univ Oncol Principado Asturias, Oviedo, Spain.	segundog@uniovi.es	López-Soto, Alejandro/A-9779-2018; Gonzalez, Segundo/AAK-8719-2021; Quinones Lombrana, Adolfo/AAJ-6592-2021; Lombrana, Adolfo Quinones/AAF-1086-2019	López-Soto, Alejandro/0000-0002-6360-5205; Gonzalez, Segundo/0000-0003-4631-9255; Quinones Lombrana, Adolfo/0000-0001-6935-2934; Lombrana, Adolfo Quinones/0000-0002-3784-3760; Lopez-Larrea, Carlos/0000-0001-9988-1730				Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Anttila MA, 2000, BRIT J CANCER, V82, P1974; Bacon L, 2004, J IMMUNOL, V173, P1078, DOI 10.4049/jimmunol.173.2.1078; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Carbone E, 2005, BLOOD, V105, P251, DOI 10.1182/blood-2004-04-1422; Cerwenka A, 2001, IMMUNOL REV, V181, P158, DOI 10.1034/j.1600-065X.2001.1810113.x; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(09)00098-3; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Diefenbach A, 2001, IMMUNOL REV, V181, P170, DOI 10.1034/j.1600-065X.2001.1810114.x; Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Gonzalez S, 1996, J IMMUNOL, V157, P2282; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Heimberger AB, 2005, CLIN CANCER RES, V11, P267; Huang HC, 1999, P NATL ACAD SCI USA, V96, P962, DOI 10.1073/pnas.96.3.962; JAN CN, 2003, BIOCHEM BIOPH RES CO, V305, P129; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Koutsodontis G, 2004, ONCOGENE, V23, P9190, DOI 10.1038/sj.onc.1208141; Li DQ, 2002, CANCER RES, V62, P4023; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Li M, 2004, BIOCHEM J, V382, P323, DOI 10.1042/BJ20040593; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Pende D, 2002, CANCER RES, V62, P6178; Pende D, 2001, EUR J IMMUNOL, V31, P1076, DOI 10.1002/1521-4141(200104)31:4<1076::AID-IMMU1076>3.0.CO;2-Y; Poggi A, 2004, CANCER RES, V64, P9172, DOI 10.1158/0008-5472.CAN-04-2417; Radosavljevic M, 2002, GENOMICS, V79, P114, DOI 10.1006/geno.2001.6673; Raffaghello L, 2004, NEOPLASIA, V6, P558, DOI 10.1593/neo.04316; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Sutherland CL, 2006, BLOOD, V108, P1313, DOI 10.1182/blood-2005-11-011320; Vetter CS, 2002, J INVEST DERMATOL, V118, P600, DOI 10.1046/j.1523-1747.2002.01700.x; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Waldhauer I, 2006, CANCER RES, V66, P2520, DOI 10.1158/0008-5472.CAN-05-2520; Wang X, 2006, J CELL BIOL, V172, P409, DOI 10.1083/jcb.200510002; Wu J, 2003, J IMMUNOL, V170, P4196, DOI 10.4049/jimmunol.170.8.4196; Yang WS, 1998, J LIPID RES, V39, P2054; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	61	53	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30419	30430		10.1074/jbc.M604868200	http://dx.doi.org/10.1074/jbc.M604868200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16901903	hybrid			2022-12-25	WOS:000241075900016
J	Banu, N; Teichman, J; Dunlap-Brown, M; Villegas, G; Tufro, A				Banu, Nazifa; Teichman, Jason; Dunlap-Brown, Marya; Villegas, Guillermo; Tufro, Alda			Semaphorin 3C regulates endothelial cell function by increasing integrin activity	FASEB JOURNAL			English	Article						class 3 semaphorins; endothelial cell adhesion; migration; tube formation; VEGF(120) secretion	GROWTH-FACTOR; NEUROPILIN-1; RECEPTOR; GUIDANCE; PLEXIN; GENE; PHOSPHORYLATION; BIOAVAILABILITY; MORPHOGENESIS; EXPRESSION	Class 3 semaphorins ( sema 3) are secreted guidance proteins. Sema 3A expressed by endothelial cells controls vascular morphogenesis through integrin inhibition. Sema 3C is required for normal cardiovascular patterning. Here we examined the potential role of sema 3C as regulator of endothelial cell function in vitro using mouse glomerular endothelial cells (MGEC). We determined that MGEC express sema 3C mRNA and protein and its receptors mRNA. Recombinant sema 3C induced MGEC proliferation 18 +/- 2% above control, as assessed by bromodeoxyuridine ( BrdU) incorporation, and reduced starvation-induced apoptosis by 46 +/- 3%, as indicated by an in situ marker of activated caspase 3. Sema 3C increased MGEC adhesion to fibronectin 79 +/- 13% and to collagen 55 +/- 12% as compared with control. Sema 3C-induced MGEC adhesion was prevented by integrin blocking antibodies and involved beta(1) integrin serine phosphorylation. Sema 3C-induced MGEC adhesion and proliferation were similar to those induced by vascular endothelial growth factor (VEGF)-A. Sema 3C induced a 44 +/- 11% increase in MGEC directional migration and stimulated MGEC capillary-like network formation on collagen I gels. Collectively, our data indicate that sema 3C promotes glomerular endothelial cell proliferation, adhesion, directional migration, and tube formation in vitro by stimulating integrin phosphorylation and VEGF(120) secretion, functions that are similar to VEGF-A and opposite to sema 3A.	Albert Einstein Coll Med, Dept Pediat Nephrol, Dept Dev & Mol Biol, Div Nephrol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Nephrol, Dept Internal Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Nephrol, Dept Pediat, Bronx, NY 10461 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Virginia	Tufro, A (corresponding author), Albert Einstein Coll Med, Dept Pediat Nephrol, Dept Dev & Mol Biol, Div Nephrol, 1300 Morris Pk Ave,Forchheimer Bldg,Room 708, Bronx, NY 10461 USA.	atufro@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064187, P50DK064236, R01DK059333] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50-DK-064236, R01-DK-59333, R10-DK-64187] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bagnard D, 2000, J NEUROSCI, V20, P1030, DOI 10.1523/JNEUROSCI.20-03-01030.2000; Barberis D, 2005, J CELL SCI, V118, P4689, DOI 10.1242/jcs.02590; Barberis D, 2004, FASEB J, V18, P592, DOI 10.1096/fj.03-0957fje; Basile JR, 2005, MOL CELL BIOL, V25, P6889, DOI 10.1128/MCB.25.16.6889-6898.2005; Bates D, 2003, DEV BIOL, V255, P77, DOI 10.1016/S0012-1606(02)00045-3; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Brown CB, 2001, DEVELOPMENT, V128, P3071; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Christensen CRL, 1998, CANCER RES, V58, P1238; Damon DH, 2006, AM J PHYSIOL-HEART C, V290, pH1220, DOI 10.1152/ajpheart.01232.2004; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; Eichmann A, 2005, CURR OPIN NEUROBIOL, V15, P108, DOI 10.1016/j.conb.2005.01.008; Fagerholm SC, 2004, TRENDS BIOCHEM SCI, V29, P504, DOI 10.1016/j.tibs.2004.07.005; Feiner L, 2001, DEVELOPMENT, V128, P3061; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gitler AD, 2004, DEV CELL, V7, P107, DOI 10.1016/j.devcel.2004.06.002; Goshima Y, 2002, J CLIN INVEST, V109, P993, DOI 10.1172/JCI200215467; Guan F, 2006, KIDNEY INT, V69, P1564, DOI 10.1038/sj.ki.5000313; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Ito T, 2000, MECH DEVELOP, V97, P35, DOI 10.1016/S0925-4773(00)00401-9; Kagoshima M, 2001, GENES CELLS, V6, P559, DOI 10.1046/j.1365-2443.2001.00441.x; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Miller LE, 2004, ARTHRITIS RHEUM-US, V50, P1156, DOI 10.1002/art.20110; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Moreno-Flores MT, 2003, J NEUROCHEM, V87, P879, DOI 10.1046/j.1471-4159.2003.02051.x; Mulrooney JP, 2001, J CELL SCI, V114, P2525; Neufeld G, 2005, FRONT BIOSCI-LANDMRK, V10, P751, DOI 10.2741/1569; NG YS, 2005, EXP CELL RES, V102, P18902; Pascual M, 2005, HIPPOCAMPUS, V15, P184, DOI 10.1002/hipo.20040; Renzi MJ, 1999, J NEUROSCI, V19, P7870; Risau W, 1998, KIDNEY INT, V54, pS3, DOI 10.1046/j.1523-1755.1998.06701.x; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Tamagnone L, 2004, EMBO REP, V5, P356, DOI 10.1038/sj.embor.7400114; Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008; Tufro A, 2000, DEV BIOL, V227, P558, DOI 10.1006/dbio.2000.9845; Villegas G, 2002, MECH DEVELOP, V119, pS149, DOI 10.1016/S0925-4773(03)00108-4; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Yamada T, 1997, P NATL ACAD SCI USA, V94, P14713, DOI 10.1073/pnas.94.26.14713	45	92	102	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2150	+		10.1096/fj.05-5698fje	http://dx.doi.org/10.1096/fj.05-5698fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16940438				2022-12-25	WOS:000241156900045
J	Li, TG; Kong, XY; Owsley, E; Ellis, E; Strom, S; Chiang, JYL				Li, Tiangang; Kong, Xiaoying; Owsley, Erika; Ellis, Ewa; Strom, Stephen; Chiang, John Y. L.			Insulin regulation of cholesterol 7 alpha-hydroxylase expression in human hepatocytes - Roles of forkhead box O1 and sterol regulatory element-binding protein 1c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FKHR; BILE-ACID SYNTHESIS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; GENE-EXPRESSION; PHOSPHOENOLPYRUVATE CARBOXYKINASE; NUCLEAR FACTOR-4; FATTY-ACID; X-RECEPTOR; LIVER; FOXO1	Bile acid synthesis and pool size increases in diabetes, whereas insulin inhibits bile acid synthesis. The objective of this study is to elucidate the mechanism of insulin regulation of cholesterol 7 alpha-hydroxylase gene expression in human hepatocytes. Real-time PCR assays showed that physiological concentrations of insulin rapidly stimulated cholesterol 7 alpha-hydroxylase (CYP7A1) mRNA expression in primary human hepatocytes but inhibited CYP7A1 expression after extended treatment. The insulin-regulated forkhead box O1 (FoxO1) and steroid regulatory element-binding protein-1c (SREBP-1c) strongly inhibited hepatocyte nuclear factor 4 alpha and peroxisome proliferator-activated receptor gamma-coactivator-1 alpha trans-activation of the CYP7A1 gene. FoxO1 binds to an insulin response element in the rat CYP7A1 promoter, which is not present in the human CYP7A1 gene. Insulin rapidly phosphorylates and inactivates FoxO1, whereas insulin induces nuclear SREBP-1c expression in human primary hepatocytes. Chromatin immunoprecipitation assay shows that insulin reduced FoxO1 and peroxisome proliferators-activated receptor gamma-coactivator-1 alpha but increased SREBP-1c recruitment to CYP7A1 chromatin. We conclude that insulin has dual effects on human CYP7A1 gene transcription; physiological concentrations of insulin rapidly inhibit FoxO1 activity leading to stimulation of the human CYP7A1 gene, whereas prolonged insulin treatment induces SREBP-1c, which inhibits human CYP7A1 gene transcription. Insulin may play a major role in the regulation of bile acid synthesis and dyslipidemia in diabetes.	Northeastern Ohio Univ Coll Med & Pharm, Dept Microbiol Immunol & Biochem, Rootstown, OH 44272 USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA	Northeast Ohio Medical University (NEOMED); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chiang, JYL (corresponding author), Northeastern Ohio Univ Coll Med & Pharm, Dept Microbiol Immunol & Biochem, 4209 State Route 44,Rootstown, Rootstown, OH 44272 USA.	jchiang@neoucom.edu	Ellis, Ewa C S/D-5370-2014; Chiang, John Y. L./G-2658-2011	Ellis, Ewa C S/0000-0002-3057-5337; Chiang, John Y. L./0000-0001-9360-7650; Strom, Stephen/0000-0002-2889-3387	NIDDK NIH HHS [R01 DK044442, DK44442, R56 DK044442, R01 DK058379, R37 DK058379, DK92310, DK58379] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044442, R37DK058379, R56DK044442, R01DK058379, N01DK092310] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altomonte J, 2004, J CLIN INVEST, V114, P1493, DOI 10.1172/JCI200419992; ANDERSEN E, 1988, EUR J CLIN INVEST, V18, P166, DOI 10.1111/j.1365-2362.1988.tb02408.x; BENNION LJ, 1977, NEW ENGL J MED, V296, P1365, DOI 10.1056/NEJM197706162962401; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Cariou B, 2005, ENDOCRINOLOGY, V146, P981, DOI 10.1210/en.2004-1595; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Chiang JYL, 2003, AM J PHYSIOL-GASTR L, V284, pG349, DOI 10.1152/ajpgi.00417.2002; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; CRESTANI M, 1995, J LIPID RES, V36, P2419; Crestani M, 1998, J LIPID RES, V39, P2192; De Fabiani E, 2000, BIOCHEM J, V347, P147; Engelking LJ, 2004, J CLIN INVEST, V113, P1168, DOI 10.1172/JCI200420978; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; HASSAN AS, 1980, P SOC EXP BIOL MED, V164, P449; Hegarty BD, 2005, P NATL ACAD SCI USA, V102, P791, DOI 10.1073/pnas.0405067102; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ishida H, 2000, J BIOCHEM, V127, P57, DOI 10.1093/oxfordjournals.jbchem.a022584; LI T, 2004, AM J PHYSIOL-GASTR L, V288, P74; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Reaven G, 2004, RECENT PROG HORM RES, V59, P207, DOI 10.1210/rp.59.1.207; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Song KH, 2006, J BIOL CHEM, V281, P10081, DOI 10.1074/jbc.M513420200; Song KH, 2006, HEPATOLOGY, V43, P117, DOI 10.1002/hep.20919; Stayrook KR, 2005, ENDOCRINOLOGY, V146, P984, DOI 10.1210/en.2004-0965; Stroup D, 2000, J LIPID RES, V41, P1; Tobin KAR, 2002, J BIOL CHEM, V277, P10691, DOI 10.1074/jbc.M109771200; TWISK J, 1995, HEPATOLOGY, V21, P501, DOI 10.1016/0270-9139(95)90113-2; VILLANUEVA GR, 1990, J LAB CLIN MED, V115, P441; Wang DP, 1996, J LIPID RES, V37, P1831; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Yamagata K, 2004, J BIOL CHEM, V279, P23158, DOI 10.1074/jbc.M314322200; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200	44	69	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28745	28754		10.1074/jbc.M605815200	http://dx.doi.org/10.1074/jbc.M605815200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16885156	Green Accepted, hybrid			2022-12-25	WOS:000240680500028
J	Stanton, SE; McReynolds, LJ; Evans, T; Schreiber-Agus, N				Stanton, Sasha E.; McReynolds, Lisa J.; Evans, Todd; Schreiber-Agus, Nicole			Yaf2 inhibits caspase 8-mediated apoptosis and regulates cell survival during zebrafish embryogenesis*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GROUP PROTEINS; POLYCOMB; DEATH; INTERACTS; GENES; RYBP; POSTIMPLANTATION; DEGENERATION; ACTIVATION	Rybp (DEDAF) is a member of the Rybp/Yaf2 protein family and has been shown to encode proapoptotic functions and to be essential for mouse embryogenesis. The related Yaf2 protein has not been studied extensively at the cellular or organismal levels. Here we describe zebrafish yaf2 (zyaf2) and show that it is widely expressed during early embryogenesis, with subsequent enrichment of transcripts in the anterior head region. Depletion of zYaf2 during embryogenesis using specific morpholinos activates a wide-spread program of apoptosis and causes developmental arrest before the one somite stage. Partial depletion of Yaf2, achieved by injecting lower dosages of morpholino, circumvents the early arrest but leads to CNS degeneration associated with excessive apoptosis. These phenotypes can be rescued by co-injection of human YAF2 mRNA with the morpholinos or by treatment with a pan-caspase inhibitor or a caspase 8-specific inhibitor. Finally, the observed activation of caspase 8 in the morphants is in accord with the ability of Yaf2 to inhibit caspase 8-mediated apoptosis in cultured cells. Our findings implicate Yaf2 as a survival factor during early zebrafish development and organogenesis. This may suggest that Yaf2 and Rybp can encode opposing functions in the regulation of apoptosis.	Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Schreiber-Agus, N (corresponding author), Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA.	agus@aecom.yu.edu			NCI NIH HHS [CA92558] Funding Source: Medline; NHLBI NIH HHS [HL64282, HL56182] Funding Source: Medline; NIGMS NIH HHS [T32 GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA092558, R01CA092558] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056182, R37HL056182, R01HL064282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdelilah S, 1996, DEVELOPMENT, V123, P217; Bannasch D, 2001, ONCOGENE, V20, P5913, DOI 10.1038/sj.onc.1204747; Bejarano F, 2005, MECH DEVELOP, V122, P1118, DOI 10.1016/j.mod.2005.06.001; Cernilogar FM, 2005, BIOCHEM CELL BIOL, V83, P322, DOI 10.1139/o05-040; Chen M, 2002, APOPTOSIS, V7, P313, DOI 10.1023/A:1016167228059; Cole LK, 2001, DEV BIOL, V240, P123, DOI 10.1006/dbio.2001.0432; Danen-van Oorschot AAAM, 2004, CELL DEATH DIFFER, V11, P564, DOI 10.1038/sj.cdd.4401391; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dejardin J, 2005, PROG MOLEC, V38, P31; FurutaniSeiki M, 1996, DEVELOPMENT, V123, P229; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greenwood J, 2005, SEMIN CELL DEV BIOL, V16, P215, DOI 10.1016/j.semcdb.2004.12.002; Holley SA, 2002, SEMIN CELL DEV BIOL, V13, P481, DOI 10.1016/S1084952102001015; Ikegami R, 1999, DEV BIOL, V209, P409, DOI 10.1006/dbio.1999.9243; Inohara N, 2000, CELL DEATH DIFFER, V7, P509, DOI 10.1038/sj.cdd.4400679; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; Kane DA, 1996, DEVELOPMENT, V123, P57; Kaneko T, 2003, GENE, V315, P183, DOI 10.1016/S0378-1119(03)00800-X; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lee JC, 2005, APOPTOSIS, V10, P1483, DOI 10.1007/s10495-005-1833-z; Madge B, 2003, CANCER LETT, V193, P171, DOI 10.1016/S0304-3835(02)00696-1; Mehlen P, 2005, J NEUROBIOL, V64, P357, DOI 10.1002/neu.20167; Negron JF, 2004, DEV DYNAM, V231, P161, DOI 10.1002/dvdy.20124; Ni T, 2005, IUBMB LIFE, V57, P779, DOI 10.1080/15216540500389013; Nowak M, 2005, CELL DEATH DIFFER, V12, P52, DOI 10.1038/sj.cdd.4401519; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pirity MK, 2005, MOL CELL BIOL, V25, P7193, DOI 10.1128/MCB.25.16.7193-7202.2005; Pirrotta V, 2006, E SCHERING RES FDN W, V57, P97; Raaphorst FM, 2005, INT J HEMATOL, V81, P281, DOI 10.1532/IJH97.05023; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Ribble D, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-12; Rodriguez M, 1997, BIOCHEM CELL BIOL, V75, P579, DOI 10.1139/bcb-75-5-579; Sanders LH, 2003, DEV DYNAM, V227, P291, DOI 10.1002/dvdy.10308; Sawa C, 2002, J BIOL CHEM, V277, P22484, DOI 10.1074/jbc.M203060200; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Twomey C, 2005, J CELL MOL MED, V9, P345, DOI 10.1111/j.1582-4934.2005.tb00360.x; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Yabu T, 2001, BIOCHEM J, V360, P39, DOI 10.1042/0264-6021:3600039; Zheng LX, 2001, J BIOL CHEM, V276, P31945, DOI 10.1074/jbc.M102799200	46	28	30	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28782	28793		10.1074/jbc.M603348200	http://dx.doi.org/10.1074/jbc.M603348200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16891308	hybrid			2022-12-25	WOS:000240680500032
J	Su, X; Lodhi, IJ; Saltiel, AR; Stahl, PD				Su, Xiong; Lodhi, Irfan J.; Saltiel, Alan R.; Stahl, Philip D.			Insulin-stimulated interaction between insulin receptor substrate 1 and p85 alpha and activation of protein kinase B/Akt require Rab5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAB5; CLATHRIN-MEDIATED ENDOCYTOSIS; PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL-GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; 3T3-L1 ADIPOCYTES; MEMBRANE; TRAFFICKING	Binding of insulin to the insulin receptor initiates a cascade of protein phosphorylation and effector recruitment events leading to the activation of multiple distinct signaling pathways. Previous studies suggested that the diversity and specificity of insulin signal transduction are accomplished by both subcellular localization of receptor and the selective activation of downstream signaling molecules. The small GTPase Rab5 is a key regulator of endocytosis. Three Rab5 isoforms (Rab5a, -5b, and -5c) have been identified. Here we exploited the RNA interference technique to specifically knock down individual Rab5 isoforms to determine the cellular function of Rab5 in distinct insulin signaling pathways. Small interference RNA against a single Rab5 isoform had no effect on protein kinase B (PKB)/Akt or MAPK activation by insulin in NIH3T3 cells overexpressing human insulin receptor. However, simultaneous knockdown of all three Rab5 isoforms dramatically attenuated PKB/Akt activation by insulin without affecting MAPK activation. This inhibition of PKB/Akt activation was because of the impaired interaction between insulin receptor substrate 1 and the p85 alpha subunit of phosphatidylinositol 3-kinase. These results indicate a requirement of Rab5 in presenting p85 to insulin receptor substrate 1. Additional evidence supporting a role for Rab5 was suggested by studies with GAPex-5, a vps9 domain containing exchange factor. Down-regulation of GAPex-5 impaired insulin-stimulated PKB/Akt activation. Collectively, this study indicates the involvement of Rab5 in insulin signaling.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Michigan, Inst Life Sci, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	Washington University (WUSTL); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid, St Louis, MO 63110 USA.	pstahl@cellbiology.wustl.edu	Stahl, Philip/D-6315-2012; Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828; Lodhi, Irfan/0000-0002-6246-9862	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061618, R21DK065844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK061618-04, 5R21DK065844-02] Funding Source: Medline; NIGMS NIH HHS [2R01GM42259-33] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DH, 2005, METHOD ENZYMOL, V403, P552, DOI 10.1016/S0076-6879(05)03048-X; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bevan P, 2001, J CELL SCI, V114, P1429; BUCCI C, 1995, FEBS LETT, V366, P65, DOI 10.1016/0014-5793(95)00477-Q; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chamberlain MD, 2005, METHOD ENZYMOL, V403, P541, DOI 10.1016/S0076-6879(05)03047-8; Chamberlain MD, 2004, J BIOL CHEM, V279, P48607, DOI 10.1074/jbc.M409769200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Chiariello M, 1999, FEBS LETT, V453, P20, DOI 10.1016/S0014-5793(99)00686-9; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; Devon RS, 2005, NEUROBIOL DIS, V18, P243, DOI 10.1016/j.nbd.2004.10.002; Di Guglielmo GM, 1998, MOL CELL BIOCHEM, V182, P59, DOI 10.1023/A:1006883311233; Fiory F, 2004, J BIOL CHEM, V279, P11137, DOI 10.1074/jbc.M308751200; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; Hunker CM, 2006, BIOCHEM BIOPH RES CO, V340, P967, DOI 10.1016/j.bbrc.2005.12.099; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Knight JB, 2000, ENDOCRINOLOGY, V141, P208, DOI 10.1210/en.141.1.208; KNUTSON VP, 1982, P NATL ACAD SCI-BIOL, V79, P2822, DOI 10.1073/pnas.79.9.2822; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Kurosu H, 2001, J BIOCHEM-TOKYO, V130, P73, DOI 10.1093/oxfordjournals.jbchem.a002964; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Lanzetti L, 2001, EXP CELL RES, V271, P45, DOI 10.1006/excr.2001.5369; Lee YH, 2004, ARCH PHARM RES, V27, P361, DOI 10.1007/BF02980074; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; LI GP, 1993, J BIOL CHEM, V268, P24475; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Murata H, 2003, J BIOL CHEM, V278, P21607, DOI 10.1074/jbc.M302934200; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Pitterle DM, 1999, AM J PHYSIOL-ENDOC M, V276, pE94, DOI 10.1152/ajpendo.1999.276.1.E94; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Rodman JS, 2000, J CELL SCI, V113, P183; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sato M, 2005, NAT CELL BIOL, V7, P559, DOI 10.1038/ncb1261; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shepherd PR, 2005, ACTA PHYSIOL SCAND, V183, P3, DOI 10.1111/j.1365-201X.2004.01382.x; Shin HW, 2005, J CELL BIOL, V170, P607, DOI 10.1083/jcb.200505128; Simpson JC, 2005, BIOCHEM SOC SYMP, V72, P99, DOI 10.1042/bss0720099; Su X, 2004, J BIOL CHEM, V279, P21740, DOI 10.1074/jbc.M314166200; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; Vainshtein I, 2001, J BIOL CHEM, V276, P8073, DOI 10.1074/jbc.M008436200; van der Bliek AM, 2005, NAT CELL BIOL, V7, P548, DOI 10.1038/ncb0605-548; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang B, 1996, BIOCHEM BIOPH RES CO, V227, P27, DOI 10.1006/bbrc.1996.1462; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	58	53	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27982	27990		10.1074/jbc.M602873200	http://dx.doi.org/10.1074/jbc.M602873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16880210	hybrid			2022-12-25	WOS:000240534400035
J	Pederson, T				Pederson, Thoru			New surprises in genetic coding and how an ingenious experiment was almost scooped, by evolution	FASEB JOURNAL			English	Editorial Material							SOLUBLE RIBONUCLEIC ACID; AMIDOTRANSFERASE	In 1962, one of the most creative and cogent experiments on the protein coding problem was published. Now it has been discovered that archaebacteria had been doing a related kind of "experiment" all along. Both involve a trick: changing an amino acid that is already attached to a "correct" transfer RNA.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell Dynam, 377 Plantat St, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu						CHAPEVILLE F, 1962, P NATL ACAD SCI USA, V48, P1086, DOI 10.1073/pnas.48.6.1086; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; DEVLIN TM, 1992, TXB BIOCH CLIN CORRE, P504; HOAGLAND MB, 1958, J BIOL CHEM, V231, P241; Judson HF, 1979, 8 DAY CREATION; Kay L. E., 2000, WHO WROTE BOOK LIFE; O'Donoghue P, 2005, P NATL ACAD SCI USA, V102, P19003, DOI 10.1073/pnas.0509617102; Pederson T, 2005, FASEB J, V19, P1583, DOI 10.1096/fj.05-1002ufm; Sauerwald A, 2005, SCIENCE, V307, P1969, DOI 10.1126/science.1108329; Sethi A, 2005, P NATL ACAD SCI USA, V102, P4045, DOI 10.1073/pnas.0409715102; Tumbula D, 1999, GENETICS, V152, P1269	13	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1759	1760		10.1096/fj.06-0902ufm	http://dx.doi.org/10.1096/fj.06-0902ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940146				2022-12-25	WOS:000240267000002
J	Wada, K; Arita, M; Nakajima, A; Katayama, K; Kudo, C; Kamisaki, Y; Serhan, CN				Wada, Koichiro; Arita, Makoto; Nakajima, Atsushi; Katayama, Kazufumi; Kudo, Chiho; Kamisaki, Yoshinori; Serhan, Charles N.			Leukotriene B-4 and lipoxin A(4) are regulatory signals for neural stem cell proliferation and differentiation	FASEB JOURNAL			English	Article						inflammatory mediators; neural inflammation; BLT receptor; ALX receptors; neuron	ACUTE-INFLAMMATION; POTENT INHIBITORS; ACTIVATION; P27(KIP1); RECEPTOR	Leukotrienes (LTs) and lipoxins (LXs) are lipid mediators that play a key role in regulating acute inflammatory responses. Their roles in neural stem cell (NSC) functions are of interest. We showed here that LTB4 and LXA(4) regulated proliferation and differentiation of murine NSCs that were isolated from embryo brains. Proliferation of NSCs was stimulated by LTB4 (3 to 100 nM) and blocked by receptor antagonist (IC50 = 2.7 mu M). In contrast, LXA(4), and its aspirin-triggered-15-epi-LXA(4) stable analog attenuated growth of NSCs at as little as 1 nM. Both lipoxygenase (LOX) inhibitors and LTB4 receptor antagonists caused apoptosis and cell death. Gene chip analysis revealed that growth-related gene expressions such as epidermal growth factor (EGF) receptor, cyclin E, p27, and caspase 8 were tightly regulated by LTB4; LXA(4) gave the opposite gene expressions. In addition to proliferation, LTB4 induced differentiation of NSCs into neurons as monitored by neurite outgrowth and MAP2 expression. These results indicate for the first time that LTB4 and LXA(4) directly regulate proliferation and differentiation of NSCs, suggesting these new pathways may be useful in restoring stem cells. - Wada, K., Arita, M., Nakajima, A., Katayama, K., Kudo, C., Kamisaki, Y., Serhan, C. N. Leukotriene B-4 and lipoxin A(4) are regulatory signals for neural stem cell proliferation and differentiation.	Osaka Univ, Dept Pharmacol, Grad Sch Dent, Suita, Osaka 5650871, Japan; Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Yokohama City Univ, Sch Med, Dept Internal Med 3, Yokohama, Kanagawa 232, Japan	Osaka University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yokohama City University	Wada, K (corresponding author), Osaka Univ, Dept Pharmacol, Grad Sch Dent, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	kwada@dent.osaka-u.ac-jp		Arita, Makoto/0000-0001-9902-0463	NIGMS NIH HHS [4R37 GM038675] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Claria J, 1996, MOL MED, V2, P583, DOI 10.1007/BF03401642; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Fierro IM, 2002, J PHARMACOL EXP THER, V300, P385, DOI 10.1124/jpet.300.2.385; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; Goulet JL, 2000, J IMMUNOL, V164, P4899, DOI 10.4049/jimmunol.164.9.4899; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; Gritti A, 1996, J NEUROSCI, V16, P1091; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kudo C, 2004, J NEUROCHEM, V88, P1416, DOI 10.1046/j.1471-4159.2003.02270.x; Kudo C, 2003, BIOCHEM PHARMACOL, V66, P289, DOI 10.1016/S0006-2952(03)00235-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Manev H, 2000, J NEUROCHEM, V74, pS64; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; Mitchell D, 2004, AM J PATHOL, V164, P937, DOI 10.1016/S0002-9440(10)63181-1; Reh TA, 2002, NAT NEUROSCI, V5, P392, DOI 10.1038/nn0502-392; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Torii MA, 1999, DEVELOPMENT, V126, P443; Vaughn MW, 2002, J IMMUNOL, V169, P3363, DOI 10.4049/jimmunol.169.6.3363; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhao L, 2004, TRENDS CARDIOVAS MED, V14, P191, DOI 10.1016/j.tcm.2004.04.003	29	113	116	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1785	1792		10.1096/fj.06-5809com	http://dx.doi.org/10.1096/fj.06-5809com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940150				2022-12-25	WOS:000240267000006
J	Pickering, BM; de Mel, S; Lee, M; Howell, M; Habens, F; Dallman, CL; Neville, LA; Potter, KN; Mann, J; Mann, DA; Johnson, PWM; Stevenson, FK; Packham, G				Pickering, B. M.; de Mel, S.; Lee, M.; Howell, M.; Habens, F.; Dallman, C. L.; Neville, L. A.; Potter, K. N.; Mann, J.; Mann, D. A.; Johnson, P. W. M.; Stevenson, F. K.; Packham, G.			Pharmacological inhibitors of NF-kappa B accelerate apoptosis in chronic lymphocytic leukaemia cells	ONCOGENE			English	Article						NF-kappa B; nuclear factor kappa B; Bcl-2; apoptosis; chronic lymphocytic leukaemia	CD38 EXPRESSION; BCL-X; SURVIVAL; ACTIVATION; CLL; PATHWAY; ZAP-70; GENES; BAFF; MODULATION	Nuclear factor-kappaB NF-kappa B) is a transcription factor that plays a critical role in the inappropriate survival of various types of malignant cells. Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy in the Western world. Although overexpression and regulation of NF-kappa B has been described in CLL, its function remains unclear. Exposure of CLL cells to BAY117082 or Kamebakaurin, potent pharmacological inhibitors of the NF-kappa B pathway, accelerated apoptosis in approximately 70% of cases. Sensitivity to NF-kappa B pathway inhibitors was not related to the prognostic markers VH status, CD38 or Zap70 expression, or to the levels of nuclear NF-kappa B. Normal peripheral B cells were resistant to the apoptosis-inducing effects of these compounds. Cell death induced by the inhibitors was associated with activation of caspase-9 and -3, and loss of mitochondrial membrane polarization, but did not involve changes in the expression of Bcl-2 or Mcl-1. Inhibitors caused an increase in c-jun NH2-terminal kinase activity in CLL, but this did not appear to be important for apoptosis. Microarray analysis identified some potential novel NF-kappa B target genes, including interleukin-16- and the Bcl-2- related survival protein Bcl-w. These results demonstrate that a substantial proportion of CLL are dependent on NF-kappa B for enhanced survival and suggest that inhibition of NF-kappa B may have therapeutic potential.	Southampton Gen Hosp, Canc Res UK Clin Ctr, Southampton SO16 6YD, Hants, England; Southampton Gen Hosp, Canc Sci Div, Mol Immunol Grp, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair,Liver Grp, Southampton, Hants, England	Cancer Research UK; University of Southampton; University of Southampton; University of Southampton	Packham, G (corresponding author), Southampton Gen Hosp, Canc Res UK Clin Ctr, Somers Canc Res Bldg MP824,Tremona Rd, Southampton SO16 6YD, Hants, England.	g.k.packham@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Packham, Graham/0000-0002-9232-5691; Stevenson, Freda/0000-0002-0933-5021; Mann, Derek/0000-0003-0950-243X				Bernal A, 2001, BLOOD, V98, P3050, DOI 10.1182/blood.V98.10.3050; Brenner C, 2003, J CLIN IMMUNOL, V23, P73, DOI 10.1023/A:1022541009662; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Castro JE, 2005, BLOOD, V106, P2506, DOI 10.1182/blood-2005-03-1099; Chen LG, 2005, BLOOD, V105, P2036, DOI 10.1182/blood-2004-05-1715; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Dallman C, 2005, METH MOLEC MED, V115, P1; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; DeMeester SL, 1998, SHOCK, V10, P1, DOI 10.1097/00024382-199807000-00001; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Ghia P, 2000, ADV CANCER RES, V79, P157, DOI 10.1016/S0065-230X(00)79005-1; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Granziero L, 2001, BLOOD, V97, P2777, DOI 10.1182/blood.V97.9.2777; Hamblin TJ, 2002, BLOOD, V99, P1023, DOI 10.1182/blood.V99.3.1023; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kern C, 2004, BLOOD, V103, P679, DOI 10.1182/blood-2003-02-0540; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Morabito F, 2001, LEUKEMIA RES, V25, P927, DOI 10.1016/S0145-2126(01)00049-2; Munzert G, 2002, BLOOD, V100, P3749, DOI 10.1182/blood.V100.10.3749; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; Oakley F, 2003, J BIOL CHEM, V278, P24359, DOI 10.1074/jbc.M211051200; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Packham G, 2005, IMMUNOLOGY, V114, P441, DOI 10.1111/j.1365-2567.2005.02117.x; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Pepper C, 1999, BRIT J HAEMATOL, V107, P611, DOI 10.1046/j.1365-2141.1999.01726.x; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Petlickovski A, 2005, BLOOD, V105, P4820, DOI 10.1182/blood-2004-07-2669; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; Ravid T, 2004, CURR BIOL, V14, pR898, DOI 10.1016/j.cub.2004.09.074; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Rodriguez A, 2004, CLIN CANCER RES, V10, P6796, DOI 10.1158/1078-0432.CCR-04-0753; Romano MF, 1998, BLOOD, V92, P990; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Schattner EJ, 2000, LEUKEMIA LYMPHOMA, V37, P461, DOI 10.3109/10428190009058499; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sembries S, 1999, BLOOD, V93, P624, DOI 10.1182/blood.V93.2.624.402k10_624_631; Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Tran NL, 2005, J BIOL CHEM, V280, P3483, DOI 10.1074/jbc.M409906200; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306; Wilson KC, 2004, GROWTH FACTORS, V22, P97, DOI 10.1080/08977190410001704679; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zaninoni A, 2003, EXP HEMATOL, V31, P185, DOI 10.1016/S0301-472X(02)01046-9	58	66	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1166	1177		10.1038/sj.onc.1209897	http://dx.doi.org/10.1038/sj.onc.1209897			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924235				2022-12-25	WOS:000244406400007
J	Chao, C; Goluszko, E; Lee, YT; Kolokoltsov, AA; Davey, RA; Uchida, T; Townsend, CM; Hellmich, MR				Chao, C.; Goluszko, E.; Lee, Y-T; Kolokoltsov, A. A.; Davey, R. A.; Uchida, T.; Townsend, C. M., Jr.; Hellmich, M. R.			Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1 alpha expression and tumor growth	ONCOGENE			English	Article						Src kinase; gastrin receptor; gastrointestinal cancer	CHOLECYSTOKININ-B/GASTRIN RECEPTOR; COLORECTAL-CANCER; TYROSINE KINASE; PREMALIGNANT EPITHELIA; PANCREATIC-CARCINOMA; BARRETTS-ESOPHAGUS; COLON CANCER; CELL-GROWTH; GASTRIN; ACTIVATION	Gastrointestinal (GI) cancers ectopically express multiple splice variants of the cholecystokinin-2 (CCK2)/gastrin receptor; however, their relative contributions to the cancer phenotype are unknown. The aim of this study was to compare the effects of CCK2 receptor (CCK2R) and CCK2i4svR expression on cell growth both in vitro and in vivo using a human epithelial cell model, HEK239. In vitro, receptor variant expression did not affect cell proliferation either in the absence or presence of agonist. However, in vivo, the expression of CCK2i4svR, but not CCK2R, increases HEK293 tumor growth in a constitutive, Src-dependent manner. Enhanced tumorigenicity of CCK2i4svR is associated with an Src- dependent increase in the transcription factor, hypoxia-inducible factor-1 alpha, its downstream target, vascular endothelial growth factor and tumor micro-vessel density, suggesting that CCK2i4svR may contribute to the growth and spread of GI cancers through agonist-independent mechanisms that enhance tumor angiogenesis.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77550 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Hellmich, MR (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mhellmic@utmb.edu		Davey, Robert/0000-0001-9168-2892	NIDDK NIH HHS [R01 DK48345, R01 DK58119] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048345, R01DK058119] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; Chao C, 2005, J BIOL CHEM, V280, P33368, DOI 10.1074/jbc.M506337200; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Ding WQ, 2002, CANCER RES, V62, P947; Dockray G, 2005, PFLUG ARCH EUR J PHY, V449, P344, DOI 10.1007/s00424-004-1347-5; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guo Y S, 2000, J Hepatobiliary Pancreat Surg, V7, P276, DOI 10.1007/s005340070049; Harris JC, 2004, CANCER RES, V64, P1915, DOI 10.1158/0008-5472.CAN-03-2713; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Iravani S, 1998, LAB INVEST, V78, P365; Ishizawar RC, 2004, J BIOL CHEM, V279, P23773, DOI 10.1074/jbc.M312368200; Iwase K, 1997, GASTROENTEROLOGY, V113, P782, DOI 10.1016/S0016-5085(97)70172-0; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Kolokoltsov AA, 2005, J VIROL, V79, P756, DOI 10.1128/JVI.79.2.756-763.2005; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MCGREGOR DB, 1982, ANN SURG, V195, P219, DOI 10.1097/00000658-198202000-00017; McWilliams DF, 1998, GUT, V42, P795, DOI 10.1136/gut.42.6.795; MIYAKE A, 1995, BIOCHEM BIOPH RES CO, V208, P230, DOI 10.1006/bbrc.1995.1328; Moore TC, 2004, REGUL PEPTIDES, V120, P195, DOI 10.1016/j.regpep.2004.03.012; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Olszewska-Pazdrak B, 2004, J BIOL CHEM, V279, P40400, DOI 10.1074/jbc.C400208200; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SIRINEK KR, 1985, AM J SURG, V149, P35, DOI 10.1016/S0002-9610(85)80006-4; Smith AM, 2000, ALIMENT PHARM THERAP, V14, P1231, DOI 10.1046/j.1365-2036.2000.00842.x; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541; SMITH JP, 1995, AM J PHYSIOL-REG I, V268, pR135, DOI 10.1152/ajpregu.1995.268.1.R135; Smith JP, 1998, INT J ONCOL, V12, P411; Smith JP, 2002, INT J MOL MED, V10, P689; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; WINSETT OE, 1986, SURGERY, V99, P302; Wroblewski LE, 2002, BIOCHEM J, V365, P873, DOI 10.1042/BJ20020068	38	28	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1013	1019		10.1038/sj.onc.1209862	http://dx.doi.org/10.1038/sj.onc.1209862			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909104				2022-12-25	WOS:000244245400007
J	Mancini, A; El Bounkari, O; Norrenbrock, AF; Scherr, M; Schaefer, D; Eder, M; Banham, AH; Pulford, K; Lyne, L; Whetton, AD; Tamura, T				Mancini, A.; El Bounkari, O.; Norrenbrock, A-F; Scherr, M.; Schaefer, D.; Eder, M.; Banham, A. H.; Pulford, K.; Lyne, L.; Whetton, A. D.; Tamura, T.			FMIP controls the adipocyte lineage commitment of C2C12 cells by downmodulation of C/EBPalpha	ONCOGENE			English	Article						adipocyte/muscle differentiation; insulin signaling; C/EBP; mesenchymal stem cells; mRNA export complex	BINDING-PROTEIN-ALPHA; MITOTIC CLONAL EXPANSION; TRANSCRIPTIONAL REGULATION; REGULATED EXPRESSION; INTERACTING PROTEIN; ECTOPIC EXPRESSION; GENE-EXPRESSION; DIFFERENTIATION; GRANULOCYTE; BETA	Fms interacting protein ( FMIP) is a substrate for Fms tyrosine kinase, and a nuclear/cytoplasm shuttling protein with a leucine zipper. As the phosphorylation of FMIP is observed in insulin-stimulated preadipocytes, we examined the role of FMIP in adipocyte differentiation, using the mesenchymal multipotent stem cells, C2C12 cells, that can differentiate into adipocytes, muscle cells and osteoblasts. Ectopic expression of FMIP in C2C12 impairs the adipocyte differentiation induced by treatment with insulin, dexamethasone and 3-isobutyl-1-methylxanthine. These cells exhibit muscle phenotype with multinuclear morphology. Furthermore, knockdown of endogenous FMIP expression by small interfering RNA improves adipocytic lineage commitment of C2C12 cells, while impairing muscle differentiation. Upon stimulation with insulin, CCAAT/enhancer binding protein ( C/EBP)beta, but not C/EBPalpha, is upregulated in cells expressing ectopic FMIP, whereas in FMIP knockdown cells, C/EBPalpha is constitutively expressed. Ectopic expression of C/EBPalpha counteracts the effects of FMIP, whereas C/EBPalpha knockdown partially mimics the effects of FMIP in this system. Northern blot analysis and reverse transcriptase-polymerase chain reaction study reveal that ectopic FMIP-expressing cells do not contain the polyadenylated C/EBPalpha mRNA, but contain the C/EBPalpha pre-mRNA, suggesting that FMIP plays a role in RNA processing and/or export. Indeed, a member of the THO complex that plays a role in mRNA export, THOC1, is co-precipitated with FMIP. The data we have acquired on FMIP suggest that it is a target for tyrosine kinase receptors that potentiate mRNA export.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England; Univ Manchester, Christie Hosp, Fac Med & Human Sci, Canc Studies Div, Manchester M13 9PL, Lancs, England	Hannover Medical School; University of Oxford; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@mh-hannover.de	Banham, Alison H/B-2966-2009; Pulford, Karen/B-3609-2009	Pulford, Karen/0000-0002-2989-789X; WHETTON, ANTHONY D/0000-0002-1098-3878; Banham, Alison/0000-0002-3197-273X				CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Fux C, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh001; Gridley S, 2005, CELL SIGNAL, V17, P59, DOI 10.1016/j.cellsig.2004.05.013; Helftenbein G, 1996, ONCOGENE, V12, P931; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Koch A, 2005, ONCOGENE, V24, P3436, DOI 10.1038/sj.onc.1208558; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841; MASON DY, 1983, TECHNIQUES IMMUNOCYT, P175; Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205; Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Popernack PM, 2001, J HEMATOTH STEM CELL, V10, P631, DOI 10.1089/152581601753193841; Rehwinkel J, 2004, NAT STRUCT MOL BIOL, V11, P558, DOI 10.1038/nsmb759; Scherr M, 2002, BLOOD, V99, P709, DOI 10.1182/blood.V99.2.709; Scherr M, 2003, CELL CYCLE, V2, P251, DOI 10.4161/cc.2.3.376; Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101	32	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1020	1027		10.1038/sj.onc.1209853	http://dx.doi.org/10.1038/sj.onc.1209853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909111				2022-12-25	WOS:000244245400008
J	Seiradake, E; Lortat-Jacob, H; Billet, O; Kremer, EJ; Cusack, S				Seiradake, Elena; Lortat-Jacob, Hugues; Billet, Olivier; Kremer, Eric J.; Cusack, Stephen			Structural and mutational analysis of human Ad37 and canine adenovirus 2 fiber heads in complex with the D1 domain of coxsackie and adenovirus receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SIALIC-ACID; CELLULAR RECEPTOR; BINDING; PROTEIN; VECTORS; MODEL; CAR; TRANSDUCTION; ATTACHMENT	Adenovirus fibers from most serotypes bind the D1 domain of coxsackie and adenovirus receptor (CAR), although the binding residues are not strictly conserved. To understand this further, we determined the crystal structures of canine adenovirus serotype 2 (CAV-2) and the human adenovirus serotype 37 (HAd37) in complex with human CAR D1 at 2.3 and 1.5 A resolution, respectively. Structure comparison with the HAd12 fiber head-CAR D1 complex showed that the overall topology of the interaction is conserved but that the interfaces differ in number and identity of interacting residues, shape complementarity, and degree of conformational adaptation. Using surface plasmon resonance, we characterized the binding affinity to CAR D1 of wild type and mutant CAV-2 and HAd37 fiber heads. We found that CAV-2 has the highest affinity but fewest direct interactions, with the reverse being true for HAd37. Moreover, we found that conserved interactions can have a minor contribution, whereas serotype-specific interactions can be essential. These results are discussed in the light of virus evolution and design of adenovirus vectors for gene transfer.	European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; Univ Grenoble 1, CNRS, UMR 5075, CEA,Inst Biol Struct, Grenoble, France; CNRS, UMR 5535, F-34293 Montpellier, France; Inst Genet Mol Montpellier, F-34293 Montpellier, France; Inst Federatif Rech 122, F-34293 Montpellier, France	European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier	Cusack, S (corresponding author), European Mol Biol Lab, Grenoble Outstn, 6 Rue Jules Horowitz,BP 181, F-38042 Grenoble 9, France.	eric.kremer@igmm.cnrs.fr; cusack@embl-grenoble.fr	Kremer, Eric J/D-3734-2013; Kremer, EJ/P-9838-2019	Kremer, EJ/0000-0001-6114-7530; Cusack, Stephen/0000-0002-9324-0796				Abrescia NGA, 2004, NATURE, V432, P68, DOI 10.1038/nature03056; Albinsson B, 1999, VIRUS RES, V64, P125, DOI 10.1016/S0168-1702(99)00087-8; Amalfitano Andrea, 2002, Current Gene Therapy, V2, P111, DOI 10.2174/1566523024605618; Arnberg N, 2000, J VIROL, V74, P42, DOI 10.1128/JVI.74.1.42-48.2000; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benko M, 2003, CURR TOP MICROBIOL, V272, P3; Benson SD, 2004, MOL CELL, V16, P673, DOI 10.1016/j.molcel.2004.11.016; Benson SD, 1999, CELL, V98, P825, DOI 10.1016/S0092-8674(00)81516-0; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; BOTH GW, 2002, ADENOVIRAL VECTORS G, P447; Burmeister WP, 2004, J VIROL, V78, P7727, DOI 10.1128/JVI.78.14.7727-7736.2004; Chakrabarti S, 2002, BLOOD, V100, P1619, DOI 10.1182/blood-2002-02-0377; Chillon M, 2001, HUM GENE THER, V12, P1815, DOI 10.1089/104303401750476302; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Cusack S, 2005, CURR OPIN STRUC BIOL, V15, P237, DOI 10.1016/j.sbi.2005.03.004; Denby L, 2004, HUM GENE THER, V15, P1054, DOI 10.1089/1043034042431083; Durmort C, 2001, VIROLOGY, V285, P302, DOI 10.1006/viro.2001.0967; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fabry CMS, 2005, EMBO J, V24, P1645, DOI 10.1038/sj.emboj.7600653; Gaggar A, 2003, NAT MED, V9, P1408, DOI 10.1038/nm952; Glasgow JN, 2004, VIROLOGY, V324, P103, DOI 10.1016/j.virol.2004.03.028; Honda T, 2000, MOL BRAIN RES, V77, P19, DOI 10.1016/S0169-328X(00)00036-X; Howitt J, 2003, J BIOL CHEM, V278, P26208, DOI 10.1074/jbc.M301492200; Iwase K, 1999, J COMPUT AID MOL DES, V13, P499, DOI 10.1023/A:1008011422113; Jiang SK, 2004, BIOCHEMISTRY-US, V43, P1847, DOI 10.1021/bi035490x; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Keriel A, 2006, J VIROL, V80, P1487, DOI 10.1128/JVI.80.3.1487-1496.2006; Kirby I, 2001, J VIROL, V75, P7210, DOI 10.1128/JVI.75.15.7210-7214.2001; Klonjkowski B, 1997, HUM GENE THER, V8, P2103, DOI 10.1089/hum.1997.8.17-2103; Kojaoghlanian T, 2003, REV MED VIROL, V13, P155, DOI 10.1002/rmv.386; Kremer EJ, 2000, J VIROL, V74, P505, DOI 10.1128/JVI.74.1.505-512.2000; Kremer EJ, 2005, CURR GENOMICS, V6, P13, DOI 10.2174/1389202053202111; Kremer EJ, 2004, J GENE MED, V6, pS139, DOI 10.1002/jgm.497; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Law LK, 2005, MOL THER, V12, P599, DOI 10.1016/j.ymthe.2005.05.017; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Leissner P, 2001, GENE THER, V8, P49, DOI 10.1038/sj.gt.3301343; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lortat-Jacob H, 2001, J BIOL CHEM, V276, P9009, DOI 10.1074/jbc.M009304200; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Paillard F, 1997, HUM GENE THER, V8, P2007, DOI 10.1089/hum.1997.8.17-2007; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Prota AE, 2003, P NATL ACAD SCI USA, V100, P5366, DOI 10.1073/pnas.0937718100; Raschperger E, 2006, EXP CELL RES, V312, P1566, DOI 10.1016/j.yexcr.2006.01.025; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; Rux JJ, 2000, MOL THER, V1, P18, DOI 10.1006/mthe.1999.0001; Rux JJ, 2003, J VIROL, V77, P9553, DOI 10.1128/JVI.77.17.9553-9566.2003; Saban SD, 2005, J MOL BIOL, V349, P526, DOI 10.1016/j.jmb.2005.04.034; Segerman A, 2003, J VIROL, V77, P1157, DOI 10.1128/JVI.77.2.1157-1162.2003; Seiradake E, 2005, J VIROL, V79, P14088, DOI 10.1128/JVI.79.22.14088-14094.2005; Shayakhmetov DM, 2000, J VIROL, V74, P10274, DOI 10.1128/JVI.74.22.10274-10286.2000; Sirena D, 2004, J VIROL, V78, P4454, DOI 10.1128/JVI.78.9.4454-4462.2004; Soudais C, 2000, J VIROL, V74, P10639, DOI 10.1128/JVI.74.22.10639-10649.2000; Soudais C, 2003, FASEB J, V17, P391, DOI 10.1096/fj.03-0438fje; Soudais C, 2001, FASEB J, V15, P2283, DOI 10.1096/fj.01-0321fje; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; van Raaij MJ, 1999, VIROLOGY, V262, P333, DOI 10.1006/viro.1999.9849; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wu E, 2004, J VIROL, V78, P3897, DOI 10.1128/JVI.78.8.3897-3905.2004; Wu E, 2003, J VIROL, V77, P7225, DOI 10.1128/JVI.77.13.7225-7235.2003; Wu E, 2001, VIROLOGY, V279, P78, DOI 10.1006/viro.2000.0703; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; Zubieta C, 2005, MOL CELL, V17, P121, DOI 10.1016/j.molcel.2004.11.041	73	71	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33704	33716		10.1074/jbc.M605316200	http://dx.doi.org/10.1074/jbc.M605316200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16923808	Green Published, hybrid			2022-12-25	WOS:000241621400078
J	Kramer, HF; Witczak, CA; Taylor, EB; Fujii, N; Hirshman, MF; Goodyear, LJ				Kramer, Henning F.; Witczak, Carol A.; Taylor, Eric B.; Fujii, Nobuharu; Hirshman, Michael F.; Goodyear, Laurie J.			AS160 regulates insulin- and contraction-stimulated glucose uptake in mouse skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; GLUT4 TRANSLOCATION; TRANSPORT; PHOSPHORYLATION; EXERCISE; MICE; EXPRESSION; SUBSTRATE; GLYCOGEN; SIGNALS	Insulin and contraction are potent stimulators of GLUT4 translocation and increase skeletal muscle glucose uptake. We recently identified the Rab GTPase-activating protein ( GAP) AS160 as a putative point of convergence linking distinct upstream signaling cascades induced by insulin and contraction in mouse skeletal muscle. Here, we studied the functional implications of these AS160 signaling events by using an in vivo electroporation technique to overexpress wild type and three AS160 mutants in mouse tibialis anterior muscles: 1) AS160 mutated to prevent phosphorylation on four regulatory phospho-Akt-substrate sites (4P); 2) AS160 mutated to abolish Rab GTPase activity (R/K); and 3) double mutant AS160 containing both 4P and R/K mutations (2M). One week following gene injection, protein expression for all AS160 isoforms was elevated over 7-fold. To determine the effects of AS160 on insulin- and contraction-stimulated glucose uptake in transfected muscles, we measured [H-3]2-deoxyglucose uptake in vivo following intravenous glucose administration and in situ muscle contraction, respectively. Insulin-stimulated glucose uptake was significantly inhibited in muscles overexpressing 4P mutant AS160. However, this inhibition was completely prevented by concomitant disruption of AS160 Rab GAP activity. Transfection with 4P mutant AS160 also significantly impaired contraction-stimulated glucose uptake, as did overexpression of wild type AS160. In contrast, overexpressing mutant AS160 lacking Rab GAP activity resulted in increases in both sham and contraction-stimulated muscles. These data suggest that AS160 regulates both insulin- and contraction-stimulated glucose metabolism in mouse skeletal muscle in vivo and that the effects of mutant AS160 on the actions of insulin and contraction are not identical. Our findings directly implicate AS160 as a critical convergence factor for independent stimulators of skeletal muscle glucose uptake.	Joslin Diabet Ctr, Metab Sect, Boston, MA 02215 USA; Joslin Diabet Ctr, Dept Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Goodyear, LJ (corresponding author), Joslin Diabet Ctr, Metab Sect, Boston, MA 02215 USA.	laurie.goodyear@joslin.harvard.edu	Fujii, Nobuharu/J-2724-2014	Fujii, Nobuharu/0000-0002-0974-3033; Taylor, Eric/0000-0003-4549-6567	NIAMS NIH HHS [AR45670, AR42238, AR051663] Funding Source: Medline; NIDDK NIH HHS [F32 DK075851] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045670, R29AR042238, F32AR051663, R01AR042238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK075851] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLBORG G, 1975, J APPL PHYSIOL, V39, P718, DOI 10.1152/jappl.1975.39.5.718; Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; Bjornholm M, 2005, BIOCHEM SOC T, V33, P354; Bruss MD, 2005, DIABETES, V54, P41, DOI 10.2337/diabetes.54.1.41; DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938; Duvivier-Kali VF, 2004, AM J TRANSPLANT, V4, P1991, DOI 10.1111/j.1600-6143.2004.00628.x; Eguez L, 2005, CELL METAB, V2, P263, DOI 10.1016/j.cmet.2005.09.005; FERRE P, 1985, BIOCHEM J, V228, P103, DOI 10.1042/bj2280103; Fujii N, 2005, J BIOL CHEM, V280, P39033, DOI 10.1074/jbc.M504208200; Fujii N, 2004, AM J PHYSIOL-CELL PH, V287, pC200, DOI 10.1152/ajpcell.00415.2003; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Ho RC, 2004, AM J PHYSIOL-REG I, V286, pR342, DOI 10.1152/ajpregu.00563.2003; Jessen N, 2005, J APPL PHYSIOL, V99, P330, DOI 10.1152/japplphysiol.00175.2005; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kennedy JW, 1999, DIABETES, V48, P1192, DOI 10.2337/diabetes.48.5.1192; Koistinen HA, 2002, ANN MED, V34, P410, DOI 10.1080/078538902321012351; Kramer HF, 2006, DIABETES, V55, P2067, DOI 10.2337/db06-0150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larance M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200; Meeson AP, 2001, CIRC RES, V88, P713, DOI 10.1161/hh0701.089753; MEGENEY LA, 1992, AM J PHYSIOL, V262, pE20, DOI 10.1152/ajpendo.1992.262.1.E20; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; PASSONNEAU JV, 1967, ANAL BIOCHEM, V19, P315, DOI 10.1016/0003-2697(67)90167-4; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Thong FSL, 2005, PHYSIOLOGY, V20, P271, DOI 10.1152/physiol.00017.2005; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Watson RT, 2006, TRENDS BIOCHEM SCI, V31, P215, DOI 10.1016/j.tibs.2006.02.007; Winzell MS, 2004, DIABETES, V53, pS92, DOI 10.2337/diabetes.53.suppl_3.S92; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	30	223	227	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31478	31485		10.1074/jbc.M605461200	http://dx.doi.org/10.1074/jbc.M605461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16935857				2022-12-25	WOS:000241235300032
J	Shanmugam, N; Ransohoff, RM; Natarajan, R				Shanmugam, Narkunaraja; Ransohoff, Richard M.; Natarajan, Rama			Interferon-gamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with s100b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; GENE-EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; MOLECULAR-MECHANISMS; OXIDANT STRESS; RECEPTOR; CELLS; INDUCTION; CYTOKINE; GLUCOSE	Chemokines mediate the recruitment and activation of blood monocyte/ macrophages and lymphocytes to sites of inflammation. Expression of the chemokine IP-10 (interferon-gamma-inducible protein) has been documented in several inflammatory and autoimmune disorders including type 1 diabetes. However, the mechanism of its expression in monocytes or its functional role in diabetes is not known. Advanced glycation end products acting via their receptor, RAGE, play major roles in diabetic complications. In this study, we observed for the first time that S100b, an inflammatory protein as well as a specific RAGE ligand, significantly increased IP-10 mRNA and protein levels in THP-1 monocytes as well as peripheral blood monocytes. Promoter luciferase assays showed that IP-10 mRNA accumulation by S100b was not via increased transcription. On the other hand, S100b significantly increased IP-10 mRNA half-life and stability. This appeared to be mediated by S100b-induced binding of specific RNA-binding protein(s) to a 3'-untranslated region-responsive region of the IP-10 mRNA. Our results demonstrate for the first time that diabetic stimuli such as RAGE ligands can induce inflammatory gene expression in monocytes via increased message stability.	Beckman Res Inst, Gonda Diabet Res Ctr, Duarte, CA 91010 USA; Lerner Res Inst, Cleveland, OH 44195 USA	City of Hope; Beckman Research Institute of City of Hope; Cleveland Clinic Foundation	Natarajan, R (corresponding author), Beckman Res Inst, Dept Diabet, 1500 E Duarte Rd, Duarte, CA USA.	rnatarajan@coh.org			NCRR NIH HHS [M01RR00043] Funding Source: Medline; NIDDK NIH HHS [R01 DK065073] Funding Source: Medline; NINDS NIH HHS [R01 NS32151] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032151] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basta G, 2005, ARTERIOSCL THROM VAS, V25, P1401, DOI 10.1161/01.ATV.0000167522.48370.5e; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36; Derrigo M, 2000, INT J MOL MED, V5, P111; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; Guha M, 2000, J BIOL CHEM, V275, P17728, DOI 10.1074/jbc.275.23.17728; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; KHABAR KS, 2005, J INTERFERON CYTOKIN, V1, P1; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Majumder S, 1998, J NEUROSCI RES, V54, P169, DOI 10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C; MOROHOSHI M, 1995, ANN NY ACAD SCI, V748, P562; Neville Lewis F., 1997, Cytokine and Growth Factor Reviews, V8, P207, DOI 10.1016/S1359-6101(97)00015-4; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Shanmugam N, 2004, DIABETES, V53, P795, DOI 10.2337/diabetes.53.3.795; Shanmugam N, 2003, J BIOL CHEM, V278, P34834, DOI 10.1074/jbc.M302828200; Shanmugam N, 2003, DIABETES, V52, P1256, DOI 10.2337/diabetes.52.5.1256; Shaw SS, 2003, DIABETES, V52, P2381, DOI 10.2337/diabetes.52.9.2381; Shimada A, 2001, DIABETES CARE, V24, P510, DOI 10.2337/diacare.24.3.510; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Sun DX, 2006, NAT IMMUNOL, V7, P375, DOI 10.1038/ni1308; Vlassara H, 2001, DIABETES-METAB RES, V17, P436, DOI 10.1002/dmrr.233; Vockerodt M, 2005, INT J CANCER, V114, P598, DOI 10.1002/ijc.20759; Westwood ME, 1996, IMMUNOL LETT, V50, P17, DOI 10.1016/0165-2478(96)02496-0	31	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31212	31221		10.1074/jbc.M602445200	http://dx.doi.org/10.1074/jbc.M602445200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16931519				2022-12-25	WOS:000241235300006
J	De Cristofaro, R; Peyvandi, F; Baronciani, L; Palla, R; Lavoretano, S; Lombardi, R; Di Stasio, E; Federici, AB; Mannucci, PM				De Cristofaro, Raimondo; Peyvandi, Flora; Baronciani, Luciano; Palla, Roberta; Lavoretano, Silvia; Lombardi, Rossana; Di Stasio, Enrico; Federici, Augusto B.; Mannucci, Pier Mannuccio			Molecular mapping of the chloride-binding site in von Willebrand factor (VWF) - Energetics and conformational effects on the VWF/ADAMTS-13 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IB; FACTOR A2 DOMAIN; FACTOR A1 DOMAIN; VONWILLEBRAND-FACTOR; CRYSTAL-STRUCTURE; DISEASE; CLEAVAGE; COMPLEX; SURFACE; ALPHA	Physiological concentrations of NaCl inhibit the hydrolysis of von Willebrand factor (VWF) by ADAMTS-13. This effect is because of the specific binding of chloride ions to VWF. Urea-induced unfolding was measured in the presence of NaCl, CH3COONa, and NaClO4 at pH 8.0, 25 degrees C, for multimeric VWF, the recombinant A1-A2-A3 VWF domains, and the A1 domain. Chloride stabilizes the folded conformation of the A1-A2-A3 and A1 domains more efficiently than acetate but less strongly than perchlorate. Spectroscopic evidence showed that chloride binds to both the A1 and A1-A2 domain but not to the isolated A2 domain. Binding of Cl- to both wild type (WT) and the natural mutant p. R1306W A1-A2-A3 domains of VWF has a large heat capacity change equal to -1 and -0.4 kcal mol(-1) K-1 for WT and p. R1306W A1-A2-A3 domains, respectively. This result implies that a burial of a vast apolar surface area is caused by conformational transitions linked to chloride binding. At any temperature, chloride affinity was higher for WT than for the mutant p. R1306W form. Chloride ions inhibit hydrolysis by ADAMTS-13 of the A1-A2-A3 and A1-A2 domains in the presence of either urea or high shear stress, whereas this effect was either absent or negligible in experiments using A2 and A2-A3 domains. These findings show that the A1 domain contains the binding site of chloride ions that control allosterically the proteolysis by ADAMTS-13 of the Tyr(1605)-Met(1606) bond in the A2 domain and that the R1306W mutation of type 2B VWD quenches the binding of chloride ion to the A1 domain.	Catholic Univ, Sch Med, Hemostasis Res Ctr, Inst Internal Med & Geriatr, I-00168 Rome, Italy; Univ Milan, A Bianchi Bonomi Hemophilia & Thrombosis Ctr, I-20122 Milan, Italy; Univ Milan, Dept Med & Med Specialities, IRCCS, Maggiore Hosp, I-20122 Milan, Italy; Catholic Univ, Sch Med, Inst Biochem & Clin Biochem, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	De Cristofaro, R (corresponding author), Catholic Univ, Sch Med, Hemostasis Res Ctr, Inst Internal Med & Geriatr, Largo F Vito,1, I-00168 Rome, Italy.	rdecristofaro@rm.unicatt.it	De Cristofaro, Raimondo/K-3942-2018; Peyvandi, Flora/AAK-7437-2020; di stasio, enrico/AAL-3082-2020	De Cristofaro, Raimondo/0000-0002-8066-8849; Peyvandi, Flora/0000-0001-7423-9864; Palla, Roberta/0000-0001-8837-2367				Adachi T, 2006, BIOCHEM BIOPH RES CO, V339, P1178, DOI 10.1016/j.bbrc.2005.11.126; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; Baronciani L, 2005, J THROMB HAEMOST, V3, P2689, DOI 10.1111/j.1538-7836.2005.01638.x; Baronciani L, 2003, BLOOD CELL MOL DIS, V30, P264, DOI 10.1016/S1079-9796(03)00033-0; Baskakov IV, 1999, PROTEIN SCI, V8, P1314, DOI 10.1110/ps.8.6.1314; BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; Chung DW, 2002, BIOCHEMISTRY-US, V41, P11065, DOI 10.1021/bi0204692; Collins KD, 2004, METHODS, V34, P300, DOI 10.1016/j.ymeth.2004.03.021; COLOMBATTI A, 1991, BLOOD, V77, P2305; De Cristofaro R, 2005, J BIOL CHEM, V280, P23295, DOI 10.1074/jbc.M501143200; DEMARCO L, 1990, J CLIN INVEST, V86, P785, DOI 10.1172/JCI114775; Dong JF, 2005, J THROMB HAEMOST, V3, P1710, DOI 10.1111/j.1538-7836.2005.01360.x; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Federici AB, 1997, THROMB HAEMOSTASIS, V78, P1132; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Hassenpflug WA, 2006, BLOOD, V107, P2339, DOI 10.1182/blood-2005-04-1758; HILBERT L, 1994, BLOOD, V83, P1542; Hinshelwood J, 2000, J MOL BIOL, V301, P1267, DOI 10.1006/jmbi.2000.4044; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; Hoylaerts MF, 1997, BIOCHEM J, V324, P185, DOI 10.1042/bj3240185; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Lammle B, 2005, J THROMB HAEMOST, V3, P1663, DOI 10.1111/j.1538-7836.2005.01425.x; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; Miyata S, 1996, J BIOL CHEM, V271, P9046, DOI 10.1074/jbc.271.15.9046; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; Nolasco LH, 2005, BLOOD, V106, P4199, DOI 10.1182/blood-2005-05-2111; PETERSON DM, 1987, BLOOD, V69, P625; PTITSYN OB, 1995, TRENDS BIOCHEM SCI, V20, P376, DOI 10.1016/S0968-0004(00)89081-7; Rastegar-Lari G, 2002, BIOCHEMISTRY-US, V41, P6668, DOI 10.1021/bi020044f; READ MS, 1989, BLOOD, V74, P1031; RUGGERI ZM, 1980, NEW ENGL J MED, V302, P1047, DOI 10.1056/NEJM198005083021902; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; Sutherland JJ, 2004, J MOL MODEL, V10, P259, DOI 10.1007/s00894-004-0194-9; Takayama Y, 2005, J BIOL CHEM, V280, P18504, DOI 10.1074/jbc.M410265200; Varughese KI, 2002, CURR PROTEIN PEPT SC, V3, P301, DOI 10.2174/1389203023380620; Zanardelli S, 2006, J BIOL CHEM, V281, P1555, DOI 10.1074/jbc.M508316200	43	15	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30400	30411		10.1074/jbc.M603321200	http://dx.doi.org/10.1074/jbc.M603321200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16899464	hybrid			2022-12-25	WOS:000241075900014
J	Kabuta, T; Suzuki, Y; Wada, K				Kabuta, Tomohiro; Suzuki, Yasuyuki; Wada, Keiji			Degradation of amyotrophic lateral sclerosis-linked mutant Cu,Zn-superoxide dismutase proteins by macroautophagy and the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU/ZN SUPEROXIDE-DISMUTASE; MOTOR-NEURON DEGENERATION; CELL-DEATH; ALPHA-SYNUCLEIN; AUTOPHAGY; MICE; SOD1; HUNTINGTIN; ALS; SUPEROXIDE-DISMUTASE-1	Mutations in the Cu, Zn-superoxide dismutase (SOD1) gene cause similar to 20% of familial cases of amyotrophic lateral sclerosis (fALS). Accumulating evidence indicates that a gain of toxic function of mutant SOD1 proteins is the cause of the disease. It has also been shown that the ubiquitin-proteasome pathway plays a role in the clearance and toxicity of mutant SOD1. In this study, we investigated the degradation pathways of wild-type and mutant SOD1 in neuronal and nonneuronal cells. We provide here the first evidence that wild-type and mutant SOD1 are degraded by macroautophagy as well as by the proteasome. Based on experiments with inhibitors of these degradation pathways, the contribution of macroautophagy to mutant SOD1 clearance is comparable with that of the proteasome pathway. Using assays that measure cell viability and cell death, we observed that under conditions where expression of mutant SOD1 alone does not induce toxicity, macroautophagy inhibition induced mutant SOD1-mediated cell death, indicating that macroautophagy reduces the toxicity of mutant SOD1 proteins. We therefore propose that both macroautophagy and the proteasome are important for the reduction of mutant SOD1-mediated neurotoxicity in fALS. Inhibition of macroautophagy also increased SOD1 levels in detergent-soluble and -insoluble fractions, suggesting that both detergent- soluble and -insoluble SOD1 are degraded by macroautophagy. These findings may provide further insights into the mechanisms of pathogenesis of fALS.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Degenerat Neurol Dis, Kodaira, Tokyo 1878502, Japan	National Center for Neurology & Psychiatry - Japan	Wada, K (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Degenerat Neurol Dis, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.	wada@ncnp.go.jp	Kabuta, Tomohiro/B-2948-2015; Wada, Keiji/AAV-1500-2021	Kabuta, Tomohiro/0000-0002-3058-2596; 				Aquilano K, 2003, J NEUROCHEM, V85, P1324, DOI 10.1046/j.1471-4159.2003.01783.x; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Di Noto L, 2005, J BIOL CHEM, V280, P39907, DOI 10.1074/jbc.M506247200; Garcia-Echeverria C, 2002, MINI-REV MED CHEM, V2, P247, DOI 10.2174/1389557023406142; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabuta T, 2002, J BIOL CHEM, V277, P6846, DOI 10.1074/jbc.M107058200; Kato S, 2000, AMYOTROPH LATERAL SC, V1, P163, DOI 10.1080/14660820050515160; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee JP, 2002, J NEUROCHEM, V82, P1229, DOI 10.1046/j.1471-4159.2002.01056.x; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ostrowska H, 2000, INT J BIOCHEM CELL B, V32, P747, DOI 10.1016/S1357-2725(00)00021-2; Pramatarova A, 2001, J NEUROSCI, V21, P3369, DOI 10.1523/JNEUROSCI.21-10-03369.2001; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; RABOUILLE C, 1993, J CELL BIOL, V120, P897, DOI 10.1083/jcb.120.4.897; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Urushitani M, 2006, NAT NEUROSCI, V9, P108, DOI 10.1038/nn1603; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200	46	174	175	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30524	30533		10.1074/jbc.M603337200	http://dx.doi.org/10.1074/jbc.M603337200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16920710	hybrid			2022-12-25	WOS:000241075900028
J	Laplante, P; Raymond, MA; Labelle, A; Abe, JI; Iozzo, RV; Hebert, MJ				Laplante, Patrick; Raymond, Marc-Andre; Labelle, Andree; Abe, Jun-Ichi; Iozzo, Renato V.; Hebert, Marie-Josee			Perlecan proteolysis induces an alpha 2 beta 1 integrin- and Src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIABILITY SIGNALING PATHWAY; I COLLAGEN MATRICES; ENDOTHELIAL APOPTOSIS; PULMONARY-FIBROSIS; PHOSPHATIDYLINOSITOL 3-KINASE; SYSTEMIC-SCLEROSIS; CARDIAC ALLOGRAFTS; VASCULAR-DISEASE; GROWTH-FACTOR; P85 SUBUNIT	Dysregulation of apoptosis in endothelial cells (EC) and fibroblasts contributes to fibrosis. We have shown previously that apoptosis of EC triggers the proteolysis of extracellular matrix components and the release of a C-terminal fragment of perlecan, which in turn inhibits apoptosis of fibroblasts. Here we have defined the receptors and pathways implicated in this anti-apoptotic response in fibroblasts. Neutralizing alpha 2 beta 1 integrin activity in fibroblasts exposed to either medium conditioned by apoptotic EC (SSC) or a recombinant perlecan C-terminal fragment (LG3) prevented resistance to apoptosis and is associated with decreased levels of Akt phosphorylation. Co-incubation of fibroblasts for 24 h with SSC or LG3 in the presence of PP2 (AG1879), a biochemical inhibitor of Src family kinases (SFKs) and focal adhesion kinase, showed a significantly decreased anti-apoptotic response. However, focal adhesion kinase gene silencing with RNA interference did not inhibit the anti-apoptotic response in fibroblasts. Src phosphorylation was increased in fibroblasts exposed to SSC, and transfection of fibroblasts with constitutively active Src mutants induced an anti-apoptotic response that was not further increased by SSC. Also, Src(-/-)Fyn(-/-) fibroblasts failed to mount an anti-apoptotic response in presence of SSC for 24 h but developed a complete anti-apoptotic response when exposed to SSC for 7 days. These results suggest that extracellular matrix fragments produced by apoptotic EC initiate a state of resistance to apoptosis in fibroblasts via an alpha 2 beta 1 integrin/SFK (Src and Fyn)/phosphatidylinositol 3-kinase (PI3K)-dependent pathway. In the long term, additional SFK members are recruited for sustaining the anti-apoptotic response, which could play crucial roles in abnormal fibrogenic healing.	Univ Montreal, CRCHUM, Montreal, PQ H2L 4M1, Canada; Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Universite de Montreal; University of Rochester; Jefferson University	Hebert, MJ (corresponding author), Univ Montreal, CRCHUM, 1560 Sherbrooke E, Montreal, PQ H2L 4M1, Canada.	marie-josee.hebert.chum@ssss.gouv.qc.ca	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112				Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Armulik A, 2004, MOL BIOL CELL, V15, P2558, DOI 10.1091/mbc.E03-09-0700; Arora PD, 1999, AM J PATHOL, V155, P2087, DOI 10.1016/S0002-9440(10)65527-7; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bix G, 2004, J CELL BIOL, V166, P97, DOI 10.1083/jcb.200401150; Cailhier JF, 2006, AM J TRANSPLANT, V6, P247, DOI 10.1111/j.1600-6143.2005.01165.x; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Choy JC, 2004, AM J PATHOL, V165, P127, DOI 10.1016/S0002-9440(10)63281-6; Desmouliere A, 2003, LAB INVEST, V83, P1689, DOI 10.1097/01.LAB.0000101911.53973.90; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Duxbury MS, 2003, BIOCHEM BIOPH RES CO, V311, P786, DOI 10.1016/j.bbrc.2003.10.060; Fukai F, 1998, EXP CELL RES, V242, P92, DOI 10.1006/excr.1998.4076; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Haber PS, 1999, AM J PATHOL, V155, P1087, DOI 10.1016/S0002-9440(10)65211-X; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jun JB, 2003, CURR OPIN RHEUMATOL, V15, P756, DOI 10.1097/00002281-200311000-00012; KUHN C, 1991, AM J PATHOL, V138, P1257; Laplante P, 2005, J IMMUNOL, V174, P5740, DOI 10.4049/jimmunol.174.9.5740; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; Maquart F, 2005, BIOCHIMIE, V87, P353, DOI 10.1016/j.biochi.2004.10.006; Michel JB, 2003, ARTERIOSCL THROM VAS, V23, P2146, DOI 10.1161/01.ATV.0000099882.52647.E4; Moissoglu K, 2005, BIOCHEM BIOPH RES CO, V330, P673, DOI 10.1016/j.bbrc.2005.03.025; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Raymond MA, 2005, BIOCHEM BIOPH RES CO, V338, P1374, DOI 10.1016/j.bbrc.2005.10.105; Raymond MA, 2004, FASEB J, V18, P705, DOI 10.1096/fj.03-0573fje; Raymond MA, 2002, BIOCHEM BIOPH RES CO, V291, P261, DOI 10.1006/bbrc.2002.6449; Sgonc R, 1996, J CLIN INVEST, V98, P785, DOI 10.1172/JCI118851; Shimizu A, 2002, LAB INVEST, V82, P673, DOI 10.1097/01.LAB.0000017370.74529.89; Shimizu A, 2002, KIDNEY INT, V61, P1867, DOI 10.1046/j.1523-1755.2002.00309.x; Suzuki J, 2000, CARDIOVASC RES, V45, P783, DOI 10.1016/S0008-6363(99)00356-9; Thannickal VJ, 2004, ANNU REV MED, V55, P395, DOI 10.1146/annurev.med.55.091902.103810; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Velling T, 2004, EMBO REP, V5, P901, DOI 10.1038/sj.embor.7400234; Vittal R, 2005, AM J PATHOL, V166, P367, DOI 10.1016/S0002-9440(10)62260-2; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; ZHANG K, 1994, AM J PATHOL, V145, P114	44	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30383	30392		10.1074/jbc.M606412200	http://dx.doi.org/10.1074/jbc.M606412200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16882656	hybrid			2022-12-25	WOS:000241075900012
J	Lin, Q; Lee, YJ; Yun, Z				Lin, Qun; Lee, Yi-Jang; Yun, Zhong			Differentiation arrest by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; INDUCIBLE FACTOR; PROMOTES; PREF-1; REPRESSION; PROTEIN; HIF-1; GENE	The stem cell niche is a unique tissue microenvironment that regulates the self-renewal and differentiation of stem cells. Although several stromal cells and molecular pathways have been identified, the microenvironment of the stem cell niche remains largely unclear. Recent evidence suggests that stem cells are localized in areas with low oxygen. We have hypothesized that hypoxia maintains the undifferentiated phenotype of stem/precursor cells. In this report, we demonstrate that hypoxia reversibly arrests preadipocytes in an undifferentiated state. Consistent with this observation, hypoxia maintains the expression of pref-1, a key stem/precursor cell gene that negatively regulates adipogenic differentiation. We further demonstrate that the hypoxia-inducible factor-1 (HIF-1) constitutes an important mechanism for the inhibition of adipogenic differentiation by hypoxia. Our findings suggest that hypoxia in the stem cell niche is critical for the maintenance of the undifferentiated stem or precursor cell phenotype.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA	Yale University	Yun, Z (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St,HRT 313, New Haven, CT 06510 USA.	zhong.yun@yale.edu						Azuma Y, 2003, CLIN CANCER RES, V9, P4944; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chen BY, 2006, BIOCHEM BIOPH RES CO, V341, P549, DOI 10.1016/j.bbrc.2006.01.004; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Eckfeldt CE, 2005, NAT REV MOL CELL BIO, V6, P726, DOI 10.1038/nrm1713; Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102; Helczynska K, 2003, CANCER RES, V63, P1441; Jiang MS, 2000, P NATL ACAD SCI USA, V97, P12519, DOI 10.1073/pnas.220426097; Jogi A, 2003, CANCER LETT, V197, P145, DOI 10.1016/S0304-3835(03)00095-8; Lee JS, 2003, PLAST RECONSTR SURG, V111, P461, DOI 10.1097/00006534-200301000-00083; Maltepe E, 2005, DEVELOPMENT, V132, P3393, DOI 10.1242/dev.01923; Maxwell PH, 2005, EXP PHYSIOL, V90, P791, DOI 10.1113/expphysiol.2005.030924; Mikkers H, 2005, EMBO J, V24, P2715, DOI 10.1038/sj.emboj.7600749; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Ntambi JM, 2000, J NUTR, V130, p3122S, DOI 10.1093/jn/130.12.3122S; Rosen ED, 2000, GENE DEV, V14, P1293; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Shimba S, 2004, J BIOL CHEM, V279, P40946, DOI 10.1074/jbc.M400840200; Smas CM, 1999, J BIOL CHEM, V274, P12632, DOI 10.1074/jbc.274.18.12632; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Villena JA, 2002, HORM METAB RES, V34, P664, DOI 10.1055/s-2002-38244; Yun Z, 2005, MOL CELL BIOL, V25, P3040, DOI 10.1128/MCB.25.8.3040-3055.2005; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4	26	149	168	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30678	30683		10.1074/jbc.C600120200	http://dx.doi.org/10.1074/jbc.C600120200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16926163	hybrid			2022-12-25	WOS:000241075900044
J	Adhikari, S; Toretsky, JA; Yuan, LS; Roy, R				Adhikari, Sanjay; Toretsky, Jeffery A.; Yuan, Linshan; Roy, Rabindra			Magnesium, essential for base excision repair enzymes, inhibits substrate binding of N-methylpurine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDONUCLEASE-III; ALKYLATION SENSITIVITY; ESCHERICHIA-COLI; RESIDUES; PURIFICATION; MUTATION; PROTEIN; RAT	N-Methylpurine-DNA glycosylase (MPG) initiates base excision repair in DNA by removing a wide variety of alkylated, deaminated, and lipid peroxidation-induced purine adducts. MPG activity and other DNA glycosylases do not have an absolute requirement for a cofactor. In contrast, all downstream activities of major base excision repair proteins, such as apurinic/apyrimidinic endonuclease, DNA polymerase beta, and ligases, require Mg2+. Here we have demonstrated that Mg2+ can be significantly inhibitory toward MPG activity depending on its concentration but independent of substrate type. The pre-steady-state kinetics suggests that Mg2+ at high but physiologic concentrations decreases the amount of active enzyme concentrations. Steady-state inhibition kinetics showed that Mg2+ affected K-m, but not V-max, and the inhibition could be reversed by EDTA but not by DNA. At low concentration, Mg2+ stimulated the enzyme activity only with hypoxanthine but not ethenoadenine. Real-time binding experiments using surface plasmon resonance spectroscopy showed that the pronounced inhibition of activity was due to inhibition in substrate binding. Nonetheless, the glycosidic bond cleavage step was not affected. These results altogether suggest that Mg2+ inhibits MPG activity by abrogating substrate binding. Because Mg2+ is an absolute requirement for the downstream activities of the major base excision repair enzymes, it may act as a regulator for the base excision repair pathway for efficient and balanced repair of damaged bases, which are often less toxic and/or mutagenic than their subsequent repair product intermediates.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA	Georgetown University	Roy, R (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, LL Level,S-122,3800 Reservoir Rd,NW, Washington, DC 20057 USA.	rr228@georgetown.edu			NCI NIH HHS [CA 92306, R01 CA092306, CA 88004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088004, R01CA092306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abner CW, 2001, J BIOL CHEM, V276, P13379, DOI 10.1074/jbc.M010641200; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BJORAS M, 1995, BIOCHEMISTRY-US, V34, P4577, DOI 10.1021/bi00014a010; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; Bronzetti Giorgio, 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P197; DOSANJH MK, 1994, BIOCHEMISTRY-US, V33, P1624, DOI 10.1021/bi00173a002; Eide L, 2001, BIOCHEMISTRY-US, V40, P6653, DOI 10.1021/bi0028901; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P59; HATCHET Z, 1994, J BIOL CHEM, V269, P18814; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; KROEGER H, 1974, J CELL PHYSIOL, V83, P19, DOI 10.1002/jcp.1040830104; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LARSON K, 1985, MUTAT RES, V233, P211; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; Li-Smerin YY, 2001, J PHYSIOL-LONDON, V533, P729, DOI 10.1111/j.1469-7793.2001.t01-1-00729.x; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Liu X, 2002, J MOL BIOL, V321, P265, DOI 10.1016/S0022-2836(02)00623-X; Lukacs Geza L., 1996, Scanning Microscopy, V10, P1191; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; Morland I, 2005, DNA REPAIR, V4, P381, DOI 10.1016/j.dnarep.2004.11.002; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Posnick LM, 1999, J BACTERIOL, V181, P6763, DOI 10.1128/JB.181.21.6763-6771.1999; Rinne ML, 2005, NUCLEIC ACIDS RES, V33, P2859, DOI 10.1093/nar/gki601; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Roy R, 2000, J BIOL CHEM, V275, P4278, DOI 10.1074/jbc.275.6.4278; Roy R, 1996, CARCINOGENESIS, V17, P2177, DOI 10.1093/carcin/17.10.2177; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; Sobol RW, 2003, J BIOL CHEM, V278, P39951, DOI 10.1074/jbc.M306592200; Sousa MC, 2001, ACTA CRYSTALLOGR D, V57, P1950, DOI 10.1107/S090744490101575X; Speina E, 2005, ACTA BIOCHIM POL, V52, P167; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67	37	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29525	29532		10.1074/jbc.M602673200	http://dx.doi.org/10.1074/jbc.M602673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16901897	hybrid			2022-12-25	WOS:000240896300014
J	Bedet, C; Bruusgaard, JC; Vergo, S; Groth-Pedersen, L; Eimer, S; Triller, A; Vannier, C				Bedet, Cecile; Bruusgaard, Jo C.; Vergo, Sandra; Groth-Pedersen, Line; Eimer, Stefan; Triller, Antoine; Vannier, Christian			Regulation of gephyrin assembly and glycine receptor synaptic stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CLUSTERING INTERACTIONS; FLUORESCENT PROTEIN; POTASSIUM CHANNEL; STRUCTURAL BASIS; SPLICE VARIANTS; PLASMA-MEMBRANE; BETA-SUBUNIT	Gephyrin is required for the formation of clusters of the glycine receptor ( GlyR) in the neuronal postsynaptic membrane. It can make trimers and dimers through its N- and C-terminal G and E domains, respectively. Gephyrin oligomerization could thus create a submembrane lattice providing GlyR-binding sites. We investigated the relationships between the stability of cell surface GlyR and the ability of gephyrin splice variants to form oligomers. Using truncated and full-length gephyrins we found that the 13-amino acid sequence ( cassette 5) prevents G domain trimerization. Moreover, E domain dimerization is inhibited by the gephyrin central L domain. All of the gephyrin variants bind GlyR beta subunit cytoplasmic loop with high affinity regardless of their cassette composition. Coexpression experiments in COS-7 cells demonstrated that GlyR bound to gephyrin harboring cassette 5 cannot be stabilized at the cell surface. This gephyrin variant was found to deplete synapses from both GlyR and gephyrin in transfected neurons. These data suggest that the relative expression level of cellular variants influence the overall oligomerization pattern of gephyrin and thus the turnover of synaptic GlyR.	Ecole Normale Super, INSERM, Lab Biol Cellulaire Synapse Normale & Pathol, U789, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Vannier, C (corresponding author), Ecole Normale Super, INSERM, Lab Biol Cellulaire Synapse Normale & Pathol, U789, 46 Rue Ulm, F-75005 Paris, France.	vannier@wotan.ens.fr	Eimer, Stefan/B-1865-2013	Bruusgaard, Jo Christiansen/0000-0001-8163-5849; TRILLER, Antoine/0000-0002-7530-1233				Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; David-Watine B, 2001, GENE, V271, P239, DOI 10.1016/S0378-1119(01)00511-X; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Hanus C, 2004, J NEUROSCI, V24, P1119, DOI 10.1523/JNEUROSCI.4380-03.2004; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; KAMDAR KP, 1994, GENETICS, V137, P791; Kim EY, 2006, EMBO J, V25, P1385, DOI 10.1038/sj.emboj.7601029; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Kneussel M, 1999, J NEUROCHEM, V72, P1323, DOI 10.1046/j.1471-4159.1999.0721323.x; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; Meier J, 2000, MOL CELL NEUROSCI, V16, P566, DOI 10.1006/mcne.2000.0899; Meier J, 2000, J CELL SCI, V113, P2783; Meier J, 2004, J NEUROSCI, V24, P1398, DOI 10.1523/JNEUROSCI.4260-03.2004; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nusser Z, 2000, CURR OPIN NEUROBIOL, V10, P337, DOI 10.1016/S0959-4388(00)00086-6; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; Ramming M, 2000, P NATL ACAD SCI USA, V97, P10266, DOI 10.1073/pnas.97.18.10266; Rees MI, 2003, J BIOL CHEM, V278, P24688, DOI 10.1074/jbc.M301070200; Rosenberg M, 2001, J NEUROSCI, V21, P5036, DOI 10.1523/JNEUROSCI.21-14-05036.2001; SCHMITT B, 1987, BIOCHEMISTRY-US, V26, P805, DOI 10.1021/bi00377a022; Schrader N, 2004, J BIOL CHEM, V279, P18733, DOI 10.1074/jbc.M311245200; Schwarz G, 2001, J MOL BIOL, V312, P405, DOI 10.1006/jmbi.2001.4952; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Sola M, 2004, EMBO J, V23, P2510, DOI 10.1038/sj.emboj.7600256; Sola M, 2001, J BIOL CHEM, V276, P25294, DOI 10.1074/jbc.M101923200; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; VANNIER C, 2004, EXCITATORY INHIBITOR, P59; Wong W, 2002, J BIOL CHEM, V277, P20423, DOI 10.1074/jbc.M109412200; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3	39	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30046	30056		10.1074/jbc.M602155200	http://dx.doi.org/10.1074/jbc.M602155200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16882665	hybrid			2022-12-25	WOS:000240896300065
J	Gao, BX; Lee, SM; Fang, DY				Gao, Beixue; Lee, Sang-Myeong; Fang, Deyu			The tyrosine kinase C-Abl protects c-Jun from ubiquitination-mediated degradation in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE FUNCTION; LIGASE ITCH; PHOSPHORYLATION; MICE; IMATINIB	The cross-talk of ubiquitination with other types of posttranscriptional modifications, such as phosphorylation, regulates the stability of many proteins. We have previously demonstrated that c-Jun is a substrate of Itch, a HECT- type E3 ubiquitin ligase. c-Jun is also a substrate of the tyrosine kinase c-Abl. Here we report that genetic ablation of c-Abl accelerated c- Jun degradation. Phosphorylation of the tyrosine within the PPXY motif by c-Abl inhibited c- Jun ubiquitination and its binding by Itch. The nuclear localization of c-Abl, triggered by T- cell activation signals, was essential for its activity in regulating c- Jun transcription activity. These findings define a potential molecular mechanism for the immunodeficiency in mice lacking the c-abl gene.	Univ Missouri, Sch Med, Dept Otolaryngol Head & Neck Surg, Columbia, MO 65212 USA; Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Fang, DY (corresponding author), Univ Missouri, Sch Med, Dept Otolaryngol Head & Neck Surg, Columbia, MO 65212 USA.	FangD@Missouri.edu	Fang, Deyu/I-7245-2013	Fang, Deyu/0000-0002-4211-2751				Banerjee A, 1999, BIOCHEMISTRY-US, V38, P5438, DOI 10.1021/bi981572n; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; BENNETT JP, 1979, NATURE, V282, P851, DOI 10.1038/282851a0; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Gao M, 2005, MOL CELL, V19, P581, DOI 10.1016/j.molcel.2005.08.017; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hardin JD, 1996, CELL IMMUNOL, V172, P100, DOI 10.1006/cimm.1996.0220; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Mattiuzzi GN, 2003, CLIN CANCER RES, V9, P976; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Peng B, 2004, J CLIN ONCOL, V22, P935, DOI 10.1200/JCO.2004.03.050; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Yang C, 2006, MOL CELL, V21, P135, DOI 10.1016/j.molcel.2005.11.014; Yoshida K, 2005, CELL CYCLE, V4, P777, DOI 10.4161/cc.4.6.1746; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Zipfel PA, 2004, CURR BIOL, V14, P1222, DOI 10.1016/j.cub.2004.07.021	37	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29711	29718		10.1074/jbc.M604596200	http://dx.doi.org/10.1074/jbc.M604596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16901904	hybrid			2022-12-25	WOS:000240896300033
J	Smith, PL; Maloney, KN; Pothen, RG; Clardy, J; Clapham, DE				Smith, Paula L.; Maloney, Katherine N.; Pothen, Randy G.; Clardy, Jon; Clapham, David E.			Bisandrographolide from Andrographis paniculata activates TRPV4 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING TRPV4; EPOXYEICOSATRIENOIC ACIDS; CARDIOVASCULAR ACTIVITY; CAPSAICIN RECEPTOR; ANESTHETIZED RAT; ION-CHANNEL; KERATINOCYTES; HEAT; SKIN; 14-DEOXY-11,12-DIDEHYDROANDROGRAPHOLIDE	Many transient receptor potential ( TRP) channels are activated or blocked by various compounds found in plants; two prominent examples include the activation of TRPV1 channels by capsaicin and the activation of TRPM8 channels by menthol. We sought to identify additional plant compounds that are active on other types of TRP channels. Wescreenedalibraryofextractsfrom50Chinese herbal plants using a calcium-imaging assay to find compounds active on TRPV3 and TRPV4 channels. An extract from the plant Andrographis paniculata potently activated TRPV4 channels. The extract was fractionated further, and the active compound was identified as bisandrographolide A ( BAA). We used purified compoundtocharacterizetheactivityofBAAoncertainTRPVchannel subtypes. Although BAA activated TRPV4 channels with an EC50 of 790 - 950 nM, it did not activate or block activation of TRPV1, TRPV2, or TRPV3 channels. BAA activated a large TRPV4- like current in immortalized mouse keratinocytes ( 308 cells) that have been shown to express TRPV4 protein endogenously. This compound also activated TRPV4 currents in cell- free outside- out patches from HEK293T cells overexpressing TRPV4 cDNA, suggesting that BAA can activate the channel in a membrane- delimited manner. Another related compound, andrographolide, found in abundance in the plant Andrographis was unable to activate or block activation of TRPV4 channels. These experiments show that BAAactivates TRPV4 channels, and we discuss the possibility that activation ofTRPV4byBAAcould play a role in some of the effects of Andrographis extract described in traditional medicine.	Childrens Hosp, Howard Hughes Med Inst, Dept Cardiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Dept Cardiol, 1309 Enders Res Bldg,320 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/R-5974-2019; Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428	NATIONAL CANCER INSTITUTE [R01CA024487] Funding Source: NIH RePORTER; NCCIH NIH HHS [R21AT00197] Funding Source: Medline; NCI NIH HHS [CA24487] Funding Source: Medline; NHLBI NIH HHS [T32 HL007572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; *CAMBR SOFT CORP, 2004, TRAD CHIN MED DAT VE; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; Earley S, 2005, CIRC RES, V97, P1270, DOI 10.1161/01.RES.0000194321.60300.d6; Gopinath Preethi, 2005, BMC Womens Health, V5, P2, DOI 10.1186/1472-6874-5-2; Guler AD, 2002, J NEUROSCI, V22, P6408; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Ladd PA, 2003, J BIOL CHEM, V278, P35184, DOI 10.1074/jbc.M301666200; Lansdown ABG, 2002, WOUND REPAIR REGEN, V10, P271, DOI 10.1046/j.1524-475X.2002.10502.x; Lee HS, 2005, J NEUROSCI, V25, P1304, DOI 10.1523/JNEUROSCI.4745.04.2005; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; MATSUDA T, 1994, CHEM PHARM BULL, V42, P1216, DOI 10.1248/cpb.42.1216; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Moqrich A, 2005, SCIENCE, V307, P1468, DOI 10.1126/science.1108609; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207; Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692; YUSPA SH, 1983, J INVEST DERMATOL, V81, pS162, DOI 10.1111/1523-1747.ep12540999; Zhang CY, 1997, J ETHNOPHARMACOL, V56, P97, DOI 10.1016/S0378-8741(97)01509-2; Zhang CY, 1998, PHARMACOL RES, V38, P413, DOI 10.1006/phrs.1998.0373; Zhang CY, 1996, CLIN EXP PHARMACOL P, V23, P675, DOI 10.1111/j.1440-1681.1996.tb01756.x; Zhang CY, 1999, PHYTOTHER RES, V13, P157, DOI 10.1002/(SICI)1099-1573(199903)13:2&lt;157::AID-PTR388&gt;3.0.CO;2-B; Zhang CY, 1998, CLIN EXP PHARMACOL P, V25, P424, DOI 10.1111/j.1440-1681.1998.tb02226.x; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	37	104	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29897	29904		10.1074/jbc.M605394200	http://dx.doi.org/10.1074/jbc.M605394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16899456	hybrid			2022-12-25	WOS:000240896300051
J	Hershfield, JR; Madhavarao, CN; Moffett, JR; Benjamins, JA; Garbern, JY; Namboodiri, A				Hershfield, Jeremy R.; Madhavarao, Chikkathur N.; Moffett, John R.; Benjamins, Joyce A.; Garbern, James Y.; Namboodiri, Aryan			Aspartoacylase is a regulated nuclear-cytoplasmic enzyme	FASEB JOURNAL			English	Article						Canavan Disease; N-acetylaspartate; aminoacylase; kidney; oligodendrocytes; Tremor rat	ACETYL-L-ASPARTATE; MYELIN LIPID-SYNTHESIS; N-ACETYLASPARTATE; CANAVAN-DISEASE; IMMUNOHISTOCHEMICAL LOCALIZATION; GENE-TRANSFER; NUCLEOCYTOPLASMIC TRANSPORT; NERVOUS-SYSTEM; RAT; BRAIN	Mutations in the gene for aspartoacylase (ASPA), which catalyzes deacetylation of N-acetyl-L-aspartate in the central nervous system (CNS), result in Canavan Disease, a fatal dysmyelinating disease. Consistent with its role in supplying acetate for myelin lipid synthesis, ASPA is thought to be cytoplasmic. Here we describe the occurrence of ASPA within nuclei of rat brain and kidney, and in cultured rodent oligodendrocytes. Immunohistochemistry showed cytoplasmic and nuclear ASPA staining, the specificity of which was demonstrated by its absence from tissues of the Tremor rat, an ASPA-null mutant. Subcellular fractionation analysis revealed low enzyme activity against NAA in nuclear fractions from normal rats. Whereas two recent reports have indicated that ASPA exists as a dimer, size-exclusion chromatography of subcellular fractions showed ASPA is an active monomer in both subcellular fractions. Western blotting detected ASPA as a single 38 kD band. Because ASPA is small enough to passively diffuse into the nucleus, we constructed, expressed, and detected in COS-7 cells a green fluorescent protein-human ASPA (GFP-hASPA) fusion protein larger than the permissible size for the nuclear pore complex. GFP-hASPA was enzymatically active and showed mixed nuclear-cytoplasmic distribution. We conclude that ASPA is a regulated nuclear-cytoplasmic protein that may have distinct functional roles in the two cellular compartments.	Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI USA	Uniformed Services University of the Health Sciences - USA; Wayne State University; Wayne State University	Namboodiri, A (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	anamboodiri@usuhs.mil		Madhavarao, Chikkathur/0000-0003-3392-1159	NINDS NIH HHS [NS 39387] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039387, R56NS039387] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe A, 2000, BIOCHEM BIOPH RES CO, V268, P14, DOI 10.1006/bbrc.1999.2069; Armstrong RC, 1998, METHODS, V16, P282, DOI 10.1006/meth.1998.0685; Baslow MH, 1999, J MOL NEUROSCI, V13, P47, DOI 10.1385/JMN:13:1-2:47; Benjamins JA, 2003, NEUROCHEM RES, V28, P143, DOI 10.1023/A:1021612615554; BENUCK M, 1968, BIOCHIM BIOPHYS ACTA, V152, P611, DOI 10.1016/0005-2760(68)90101-X; Besley GTN, 1999, J INHERIT METAB DIS, V22, P263, DOI 10.1023/A:1005534105933; Bhakoo KK, 2001, J NEUROCHEM, V79, P211, DOI 10.1046/j.1471-4159.2001.00561.x; Bird CH, 2001, MOL CELL BIOL, V21, P5396, DOI 10.1128/MCB.21.16.5396-5407.2001; BIRNBAUM SM, 1952, J BIOL CHEM, V194, P455; BIRNBAUM SM, 1955, METHOD ENZYMOL, V2, P115, DOI 10.1016/S0076-6879(55)02176-9; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; COOK RM, 1993, J BIOL CHEM, V268, P17010; DADAMO AF, 1966, J NEUROCHEM, V13, P961, DOI 10.1111/j.1471-4159.1966.tb10292.x; DADAMO AF, 1978, LIFE SCI, V23, P791, DOI 10.1016/0024-3205(78)90513-1; DADAMO AF, 1973, J NEUROCHEM, V20, P1275, DOI 10.1111/j.1471-4159.1973.tb00097.x; DADAMO AF, 1968, EXP BRAIN RES, V5, P267; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Elpeleg ON, 1999, J INHERIT METAB DIS, V22, P531, DOI 10.1023/A:1005512524957; FLEMING MC, 1966, J NEUROCHEM, V13, P779, DOI 10.1111/j.1471-4159.1966.tb05872.x; Foletti A, 2003, CELL MOL LIFE SCI, V60, P2254, DOI 10.1007/s00018-003-3258-6; Gill SK, 2003, J BIOL CHEM, V278, P20217, DOI 10.1074/jbc.M213153200; KAUL R, 1993, NAT GENET, V5, P118, DOI 10.1038/ng1093-118; KAUL R, 1994, AM J HUM GENET, V55, P34; KAUL R, 1991, J NEUROCHEM, V56, P129, DOI 10.1111/j.1471-4159.1991.tb02571.x; Kirmani BF, 2003, DEV BRAIN RES, V140, P105, DOI 10.1016/S0165-3806(02)00592-8; Kirmani BF, 2002, MOL BRAIN RES, V107, P176, DOI 10.1016/S0169-328X(02)00490-4; Kitada K, 2000, J NEUROCHEM, V74, P2512, DOI 10.1046/j.1471-4159.2000.0742512.x; Klugmann M, 2003, NEUROREPORT, V14, P1837, DOI 10.1097/00001756-200310060-00016; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Leone P, 1999, CURR OPIN MOL THER, V1, P487; Leone P, 2000, ANN NEUROL, V48, P27, DOI 10.1002/1531-8249(200007)48:1<27::AID-ANA6>3.0.CO;2-6; LINNINGTON C, 1984, J NEUROIMMUNOL, V6, P387, DOI 10.1016/0165-5728(84)90064-X; Ma ZL, 2004, ARCH BIOCHEM BIOPHYS, V422, P153, DOI 10.1016/j.abb.2003.11.024; Madhavarao CN, 2005, P NATL ACAD SCI USA, V102, P5221, DOI 10.1073/pnas.0409184102; Madhavarao CN, 2004, J COMP NEUROL, V472, P318, DOI 10.1002/cne.20080; Madhavarao CN, 2002, ANAL BIOCHEM, V308, P314, DOI 10.1016/S0003-2697(02)00225-7; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Matalon R, 2000, J GENE MED, V2, P165; MATALON R, 1988, AM J MED GENET, V29, P463, DOI 10.1002/ajmg.1320290234; Matalon R, 1999, NEUROCHEM RES, V24, P507, DOI 10.1023/A:1022531829100; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; MOFFETT JR, 1991, NEUROREPORT, V2, P131, DOI 10.1097/00001756-199103000-00005; Moore RA, 2003, ARCH BIOCHEM BIOPHYS, V413, P1, DOI 10.1016/S0003-9861(03)00055-9; Munster AK, 2002, J BIOL CHEM, V277, P19688, DOI 10.1074/jbc.M201093200; Namboodiri MAA, 2000, MOL BRAIN RES, V77, P285, DOI 10.1016/S0169-328X(00)00068-1; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Pushkin A, 2004, AM J PHYSIOL-CELL PH, V286, pC848, DOI 10.1152/ajpcell.00192.2003; Resendes MC, 1999, J BIOL CHEM, V274, P19417, DOI 10.1074/jbc.274.27.19417; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P3961; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P1354; Sheng Z, 2004, J BIOL CHEM, V279, P40153, DOI 10.1074/jbc.M400123200; Uttamsingh V, 2000, DRUG METAB DISPOS, V28, P625; YAMADA J, 1985, EXP ANIM TOKYO, V34, P183, DOI 10.1538/expanim1978.34.2_183; Yamaki A, 2004, BIOCHEM BIOPH RES CO, V313, P482, DOI 10.1016/j.bbrc.2003.11.168; Yang YH, 2004, J BIOL CHEM, V279, P38820, DOI 10.1074/jbc.M401663200; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x	61	40	41	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2139	+		10.1096/fj.05-5358fje	http://dx.doi.org/10.1096/fj.05-5358fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935940				2022-12-25	WOS:000241156900037
J	Zhao, XX; Wang, DM; Zhao, ZW; Xiao, YY; Sengupta, S; Xiao, YJ; Zhang, RL; Lauber, K; Wesselborg, S; Feng, L; Rose, TM; Shen, Y; Zhang, JJ; Prestwich, G; Xu, Y				Zhao, Xiaoxian; Wang, Dongmei; Zhao, Zhenwen; Xiao, Yingyi; Sengupta, Saubhik; Xiao, Yijin; Zhang, Renliang; Lauber, Kirsten; Wesselborg, Sebastian; Feng, Li; Rose, Tyler M.; Shen, Yue; Zhang, Junjie; Prestwich, Glenn; Xu, Yan			Caspase-3-dependent activation of calcium-independent phospholipase A(2) enhances cell migration in non-apoptotic ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; P388D(1) MACROPHAGES; EXTRACELLULAR-MATRIX; MESOTHELIAL CELLS; EPITHELIAL TUMORS; ARACHIDONIC-ACID; SPLICE VARIANTS; PROTEIN-KINASE; EXPRESSION; LAMININ	Calcium-independent phospholipase A(2) (iPLA(2)) plays a pivotal role in phospholipid remodeling and many other biological processes, including inflammation and cancer development. iPLA(2) can be activated by caspase-3 via a proteolytic process in apoptotic cells. In this study we identify novel signaling and functional loops of iPLA2 activation leading to migration of non-apoptotic human ovarian cancer cells. The extracellular matrix protein, laminin-10/11, but not collagen I, induces integrin- and caspase-3-dependent cleavage and activation of overexpressed and endogenous iPLA(2). The truncated iPLA2 (amino acids 514-806) generates lysophosphatidic acid and arachidonic acid. Arachidonic acid is important for enhancing cell migration toward laminin-10/11. Lysophosphatidic acid activates Akt that in turn acts in a feedback loop to block the cleavage of poly-(ADP-ribose) polymerase and DNA fragmentation factor as well as prevent apoptosis. By using pharmacological inhibitors, blocking antibodies, and genetic approaches (such as point mutations, dominant negative forms of genes, and siRNAs against specific targets), we show that beta(1), but not beta(4), integrin is involved in iPLA(2) activation and cell migration to laminin-10/11. The role of caspase-3 in iPLA(2) activation and cell migration are supported by several lines of evidence. 1) Point mutation of Asp(513) (a cleavage site of caspase-3 in iPLA(2)) to Ala blocks laminin-10/11-induced cleavage and activation of overexpressed iPLA2, whereas mutation of Asp(733) to Ala has no such effect, 2) treatment of inhibitors or a small interfering RNA against caspase-3 results in decreased cell migration toward laminin-10/11, and 3) selective caspase-3 inhibitor blocks cleavage of endogenous iPLA(2) induced by laminin-10/11. Importantly, small interfering RNA-mediated down-regulation of endogenous iPLA(2) expression in ovarian carcinoma HEY cells results in decreased migration toward laminin, suggesting that our findings are pathophysiologically important.	Indiana Univ, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin, Mass Spectrometry Core 2, Cleveland, OH 44195 USA; Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Utah, Dept Med Chem, Salt Lake City, UT 84108 USA; Natl Inst Biol Sci, Beijing 102206, Peoples R China; Cleveland Clin, Dept Obstet & Gynecol, Cleveland, OH 44195 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Eberhard Karls University of Tubingen; Utah System of Higher Education; University of Utah; National Institute of Biological Sciences, Beijing; Cleveland Clinic Foundation	Xu, Y (corresponding author), Indiana Univ, Dept Obstet & Gynecol, 975 W Walnut St IB355A, Indianapolis, IN 46202 USA.	xu2@iupui.edu		Wesselborg, Sebastian/0000-0002-5236-942X; Zhang, Junjie/0000-0001-8809-1485	NCI NIH HHS [R01-CA89228, R01 CA095042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095042, R01CA089228] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; BARTOLAZZI A, 1993, ANTICANCER RES, V13, P1; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BYERS LJ, 1995, CANCER LETT, V88, P67, DOI 10.1016/0304-3835(94)03625-S; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; Carnevale KA, 2001, J IMMUNOL, V167, P3414, DOI 10.4049/jimmunol.167.6.3414; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Feng L, 2002, CHEM BIOL, V9, P795, DOI 10.1016/S1074-5521(02)00168-0; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Gilroy DW, 2004, FASEB J, V18, P489, DOI 10.1096/fj.03-0837com; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kikkawa Y, 2000, J CELL SCI, V113, P869; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Laye JP, 2003, DRUG DISCOV TODAY, V8, P710, DOI 10.1016/S1359-6446(03)02754-5; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Maatta M, 2001, J HISTOCHEM CYTOCHEM, V49, P711; Manguikian AD, 2004, J BIOL CHEM, V279, P52881, DOI 10.1074/jbc.M410659200; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; O'Brien MA, 2001, BIOTECHNIQUES, V30, P886, DOI 10.2144/01304pf01; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Rose TM, 2006, ACS CHEM BIOL, V1, P83, DOI 10.1021/cb5000014; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tay HK, 2004, J BIOL CHEM, V279, P22505, DOI 10.1074/jbc.M308788200; Vivinus-Nebot M, 1999, J CELL BIOL, V144, P563, DOI 10.1083/jcb.144.3.563; von der Mark H, 2002, J BIOL CHEM, V277, P6012, DOI 10.1074/jbc.M102188200; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Yoshida Y, 2001, INT J ONCOL, V18, P913; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023; Zhang HM, 2002, CIRC RES, V90, P1251, DOI 10.1161/01.RES.0000024690.69379.5C; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	50	88	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29357	29368		10.1074/jbc.M513105200	http://dx.doi.org/10.1074/jbc.M513105200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16882668	hybrid			2022-12-25	WOS:000240680500091
J	Prabhu, S; Saadat, D; Zhang, M; Halbur, L; Fruehauf, JP; Ong, ST				Prabhu, S.; Saadat, D.; Zhang, M.; Halbur, L.; Fruehauf, J. P.; Ong, S. T.			A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation	ONCOGENE			English	Article						CML; eIF4F; mTOR; cap-dependent translation	CHRONIC MYELOGENOUS LEUKEMIA; CAP-DEPENDENT TRANSLATION; IMATINIB MESYLATE STI571; P70 S6 KINASE; MAMMALIAN TARGET; CYTOGENETIC RESPONSES; CYCLIN D2; RAPAMYCIN; BCR/ABL; INHIBITOR	The oncogenic kinase Bcr-Abl is thought to cause chronic myelogenous leukemia (CML) by altering the transcription of specific genes with growth- and survival-promoting functions. Recently, Bcr-Abl has also been shown to activate an important regulator of protein synthesis, the mammalian target of rapamycin ( mTOR), which suggests that dysregulated translation may also contribute to CML pathogenesis. In this study, we found that both Bcr-Abl and the rapamycin-sensitive mTORC1 complex contribute to the phosphorylation ( inactivation) of 4E-BP1, an inhibitor of the eIF4E translation initiation factor. Experiments with rapamycin and the Bcr-Abl inhibitor, imatinib mesylate, in Bcr-Abl-expressing cell lines and primary CML cells indicated that Bcr-Abl and mTORC1 induced formation of the translation initiation complex, eIF4F. This was characterized by reduced 4E-BP1 binding and increased eIF4G binding to eIF4E, two events that lead to the assembly of eIF4F. One target transcript is cyclin D3, which is regulated in Bcr-Abl-expressing cells by both Bcr-Abl and mTORC1 in a translational manner. In addition, the combination of imatinib and rapamycin was found to act synergistically against committed CML progenitors from chronic and blast phase patients. These experiments establish a novel mechanism of action for Bcr-Abl, and they provide insights into the modes of action of imatinib mesylate and rapamycin in treatment of CML. They also suggest that aberrant cap-dependent mRNA translation may be a therapeutic target in BcrAbl-driven malignancies.	Univ Calif Irvine, Dept Med, Div Hematol Oncol, Irvine, CA 92697 USA; Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA 92697 USA; Univ Calif Irvine, Canc Res Inst, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Immunol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Ong, ST (corresponding author), Univ Calif Irvine, Dept Med, Div Hematol Oncol, 839 Med Sci Court,116 Sprague Hall, Irvine, CA 92697 USA.	ongt@uci.edu		Ong, S. Tiong/0000-0001-9460-3483	NCI NIH HHS [1R21 CA105514, R21 CA112936-01A1, R21 CA112936, R01 CA107041-02, R01 CA107041-01A1, 1R21 CA112936, R21 CA105514, R01 CA107041, 1R01 CA107041] Funding Source: Medline; NIBIB NIH HHS [R01 EB004436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107041, R21CA112936, R21CA105514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB004436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bordeleau ME, 2005, P NATL ACAD SCI USA, V102, P10460, DOI 10.1073/pnas.0504249102; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Chou T C, 1994, Contrib Gynecol Obstet, V19, P91; Chu S, 2004, BLOOD, V103, P3167, DOI 10.1182/blood-2003-04-1271; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dancey JE, 2002, HEMATOL ONCOL CLIN N, V16, P1101, DOI 10.1016/S0889-8588(02)00051-5; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Edinger AL, 2003, CANCER RES, V63, P8451; Fruman DA, 2002, P NATL ACAD SCI USA, V99, P359, DOI 10.1073/pnas.012605099; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Hleb M, 2004, J BIOL CHEM, V279, P31948, DOI 10.1074/jbc.M400638200; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jena N, 2002, CANCER RES, V62, P535; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; La Rosee P, 2002, CANCER RES, V62, P7149; Low WK, 2005, MOL CELL, V20, P709, DOI 10.1016/j.molcel.2005.10.008; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Ly C, 2003, CANCER RES, V63, P5716; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Meier-Kriesche HU, 2000, CLIN THER, V22, pB93, DOI 10.1016/S0149-2918(00)89026-8; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Morley SJ, 1997, RNA, V3, P1085; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Notari M, 2006, BLOOD, V107, P2507, DOI 10.1182/blood-2005-09-3732; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Ottmann OG, 2002, BLOOD, V100, P1965, DOI 10.1182/blood-2001-12-0181; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Parmar S, 2005, BLOOD, V106, P2436, DOI 10.1182/blood-2004-10-4003; Perrotti D, 2005, CELL DEATH DIFFER, V12, P534, DOI 10.1038/sj.cdd.4401606; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	61	42	46	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1188	1200		10.1038/sj.onc.1209901	http://dx.doi.org/10.1038/sj.onc.1209901			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16936779	Green Accepted			2022-12-25	WOS:000244406400009
J	Marzec, M; Kasprzycka, M; Liu, X; Raghunath, PN; Wlodarski, P; Wasik, MA				Marzec, M.; Kasprzycka, M.; Liu, X.; Raghunath, P. N.; Wlodarski, P.; Wasik, M. A.			Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf	ONCOGENE			English	Article						NPM/ALK tyrosine kinase; MEK/ERK pathway; T-cell lymphoma	NON-HODGKINS-LYMPHOMA; ANAPLASTIC LYMPHOMA; CONSTITUTIVE ACTIVATION; REGULATED KINASE; CELL LYMPHOMA; DEPENDENT PATHWAY; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; PROTEIN-KINASES; ALK	The mechanisms of cell transformation mediated by the highly oncogenic, chimeric NPM/ALK tyrosine kinase remain only partially understood. Here we report that cell lines and native tissues derived from the NPM/ALK-expressing T-cell lymphoma (ALK+ TCL) display phosphorylation of the extracellular signal-regulated protein kinase (ERK) 1/2 complex. Transfection of BaF3 cells with NPM/ALK induces phosphorylation of EKR1/2 and of its direct activator mitogen-induced extracellular kinase (MEK) 1/2. Depletion of NPM/ALK by small interfering RNA (siRNA) or its inhibition by WHI-154 abrogates the MEK1/2 and ERK1/2 phosphorylation. The NPM/ALK-induced MEK/ERK activation is independent of c-Raf as evidenced by the lack of MEK1/2 and ERK1/2 phosphorylation upon c-Raf inactivation by two different inhibitors, RI and ZM336372, and by its siRNA-mediated depletion. In contrast, ERK1/2 activation is strictly MEK1/2 dependent as shown by suppression of the ERK1/2 phosphorylation by the MEK1/2 inhibitor U0126. The U0126-mediated inhibition of ERK1/2 activation impaired proliferation and viability of the ALK+ TCL cells and expression of antiapoptotic factor Bcl-xL and cell cycle-promoting CDK4 and phospho-RB. Finally, siRNA-mediated depletion of both ERK1 and ERK2 inhibited cell proliferation, whereas depletion of ERK 1 (but not ERK2) markedly increased cell apoptosis. These findings identify MEK/ERK as a new signaling pathway activated by NPM/ALK and indicate that the pathway represents a novel therapeutic target in the ALK-induced malignancies.	Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Wasik, MA (corresponding author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, 3400 Spruce St,7-106 Founders Pavil, Philadelphia, PA 19104 USA.	wasik@mail.med.upenn.edu	Marzec, Michal/O-6387-2016	Marzec, Michal/0000-0001-9698-6019; Wlodarski, Pawel/0000-0002-0683-1791	NCI NIH HHS [R01-CA89194, R01-CA96856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096856, R01CA089194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Crockett DK, 2004, ONCOGENE, V23, P2617, DOI 10.1038/sj.onc.1207398; Epling-Burnett PK, 2004, ONCOGENE, V23, P9220, DOI 10.1038/sj.onc.1208122; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; Matsumoto S, 2005, J BIOL CHEM, V280, P25687, DOI 10.1074/jbc.M412784200; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Pratt G, 2002, J CLIN PATHOL-MOL PA, V55, P273, DOI 10.1136/mp.55.5.273; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; SHIOTA M, 1994, ONCOGENE, V9, P1567; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Ussar S, 2004, J BIOL CHEM, V279, P43861, DOI 10.1074/jbc.M406240200; Wan WH, 2006, BLOOD, V107, P1617, DOI 10.1182/blood-2005-08-3254; Wang XF, 2004, ONCOGENE, V23, P1885, DOI 10.1038/sj.onc.1207312; Wasik Mariusz A, 2002, Am J Clin Pathol, V118 Suppl, pS81; Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180; Wu WS, 2006, CANCER LETT, V239, P27, DOI 10.1016/j.canlet.2005.07.034; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	34	68	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					813	821		10.1038/sj.onc.1209843	http://dx.doi.org/10.1038/sj.onc.1209843			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909118				2022-12-25	WOS:000244063800003
J	Siegenthaler, RK; Christen, P				Siegenthaler, Rahel K.; Christen, Philipp			Tuning of DnaK chaperone action by nonnative protein sensor DnaJ and thermosensor GrpE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HEAT-SHOCK-PROTEIN; MOLECULAR-CHAPERONE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; HSP70 CHAPERONES; SYSTEM; BINDING; TEMPERATURE	DnaK, an Hsp70 molecular chaperone, processes its substrates in an ATP-driven cycle, which is controlled by the co-chaperones DnaJ and GrpE. The kinetic analysis of substrate binding and release has as yet been limited to fluorescence-labeled peptides. Here, we report a comprehensive kinetic analysis of the chaperone action with protein substrates. The kinetic partitioning of the (ATP(.)DnaK)(.)substrate complexes between dissociation and conversion into stable (ADP(.)DnaK)(.)substrate complexes is determined by DnaJ. In the case of substrates that allow the formation of ternary (ATP(.)DnaK)(.)substrate DnaJ complexes, the cis-effect of DnaJ markedly accelerates ATP hydrolysis. This triage mechanism efficiently selects from the (ATP(.)DnaK)(.)substrate complexes those to be processed in the chaperone cycle; at 45 C, the fraction of protein complexes fed into the cycle is 20 times higher than that of peptide complexes. The thermosensor effect of the ADP/ATP exchange factor GrpE retards the release of substrate from the cycle at higher temperatures; the fraction of total DnaK in stable (ADP(.)DnaK)(.)substrate complexes is 2 times higher at 45 C than at 25 degrees C. Monitoring the cellular situation by DnaJ as nonnative protein sensor and GrpE as thermosensor thus directly adapts the operational mode of the DnaK system to heat shock conditions.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	christen@bioc.unizh.ch						ABELES AL, 1986, J BIOL CHEM, V261, P3548; Ben-Zvi A, 2004, J BIOL CHEM, V279, P37298, DOI 10.1074/jbc.M405627200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chattopadhyay R, 2002, J BIOL CHEM, V277, P33641, DOI 10.1074/jbc.M203197200; Chowdary TK, 2004, BIOCHEM J, V381, P379, DOI 10.1042/BJ20031958; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; FEIFEL B, 1998, THESIS U ZURICH ZURI; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Gelinas AD, 2003, BIOCHEMISTRY-US, V42, P9050, DOI 10.1021/bi034416b; Gelinas AD, 2002, J MOL BIOL, V323, P131, DOI 10.1016/S0022-2836(02)00915-4; Grimshaw JPA, 2003, J BIOL CHEM, V278, P19048, DOI 10.1074/jbc.M300924200; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Groemping Y, 2001, J MOL BIOL, V314, P167, DOI 10.1006/jmbi.2001.5116; Han WJ, 2004, FEBS LETT, V563, P146, DOI 10.1016/S0014-5793(04)00290-X; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jiang JW, 2005, MOL CELL, V20, P513, DOI 10.1016/j.molcel.2005.09.028; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIU X, 2002, THESIS U ZURICH ZURI; Mayer MP, 2000, BIOL CHEM, V381, P877, DOI 10.1515/BC.2000.109; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Moro F, 2006, J MOL BIOL, V358, P1367, DOI 10.1016/j.jmb.2006.03.027; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pierpaoli EV, 1998, BIOCHEMISTRY-US, V37, P16741, DOI 10.1021/bi981762y; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Rizvi SM, 2004, MOL CELL, V15, P913, DOI 10.1016/j.molcel.2004.09.001; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; Siegenthaler RK, 2005, J BIOL CHEM, V280, P14395, DOI 10.1074/jbc.M413803200; Siegenthaler RK, 2004, FEBS LETT, V562, P105, DOI 10.1016/S0014-5793(04)00190-5; Slepenkov SV, 2002, MOL MICROBIOL, V45, P1197, DOI 10.1046/j.1365-2958.2002.03093.x; Tanaka N, 2002, P NATL ACAD SCI USA, V99, P15398, DOI 10.1073/pnas.242317099; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Wick LM, 2004, ADV BIOCHEM ENG BIOT, V89, P1; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	53	36	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34448	34456		10.1074/jbc.M606382200	http://dx.doi.org/10.1074/jbc.M606382200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16940296	hybrid			2022-12-25	WOS:000241767600065
J	Wood, JE; Schneider, H; Rudd, CE				Wood, Joanne E.; Schneider, Helga; Rudd, Christopher E.			TcR and TcR-CD28 engagement of protein kinase B (PKB/AKT) and glycogen synthase kinase-3 (GSK-3) operates independently of guanine nucleotide exchange factor VAV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; TYROSINE PHOSPHORYLATION; CD28; ACTIVATION; PROLIFERATION; DISTINCT; SURVIVAL; BINDING	TcR zeta/CD3 and TcR zeta/CD3-CD28 signaling requires the guanine nucleotide exchange factor (GEF) Vav-1 as well as the activation of phosphatidylinositol 3-kinase, protein kinase B (PKB/AKT), and its inactivation of glycogen synthase kinase-3 (GSK-3). Whether these two pathways are connected or operate independently of each other in T-cells has been unclear. Here, we report that anti-CD3 and anti-CD3/CD28 can induce PKB and GSK-3 alpha phosphorylation in the Vav-1(-/-) Jurkat cell line J. Vav.1 and in primary CD4-positive Vav-1(-/-) T-cells. Reduced GSK-3 alpha phosphorylation was observed in Vav-1,2,3(-/-) T-cells together with a complete loss of FOXO1 phosphorylation. Furthermore, PKB and GSK-3 phosphorylation was unperturbed in the presence of GEF-inactive Vav-1 that inhibited interleukin-2 gene activation and a form of Src homology 2 domain-containing lymphocytic protein of 76-kDa (SLP-76) that is defective in binding to Vav-1. The pathway also was intact under conditions of c-Jun N-terminal kinase (JNK) inhibition and disruption of the actin cytoskeleton by cytochalasin D. Both events are downstream targets of Vav-1. Overall, our findings indicate that the TcR and TcR-CD28 driven PKB-GSK-3 pathway can operate independently of Vav-1 in T-cells.	Univ London Imperial Coll Sci Technol & Med, Dept Immunol, Mol Immunol Sect, London W12 0NN, England; Univ Cambridge, Dept Pathol, Div Immunol, Cell Signalling Sect, Cambridge CB2 1QP, England	Imperial College London; University of Cambridge	Rudd, CE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Immunol, Mol Immunol Sect, London W12 0NN, England.	cer51@cam.ac.uk	Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022	Rudd, Christopher E/0000-0001-5295-9019	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; Appleman LJ, 2002, J IMMUNOL, V168, P2729, DOI 10.4049/jimmunol.168.6.2729; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; Burr JS, 2001, J IMMUNOL, V166, P5331, DOI 10.4049/jimmunol.166.9.5331; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Cefai D, 1996, INT IMMUNOL, V8, P1609, DOI 10.1093/intimm/8.10.1609; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Crespo P, 1996, ONCOGENE, V13, P455; Dahl AM, 2000, J EXP MED, V191, P2031, DOI 10.1084/jem.191.12.2031; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Harada Y, 2001, J IMMUNOL, V166, P3797, DOI 10.4049/jimmunol.166.6.3797; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Holdorf AD, 1999, J EXP MED, V190, P375, DOI 10.1084/jem.190.3.375; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; Lawlor MA, 2001, J CELL SCI, V114, P2903; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Martin M, 2001, J EXP MED, V194, P1675, DOI 10.1084/jem.194.11.1675; Michel F, 2000, J IMMUNOL, V165, P3820, DOI 10.4049/jimmunol.165.7.3820; Moller A, 2001, J BIOL CHEM, V276, P20022, DOI 10.1074/jbc.M011139200; Musci MA, 1997, J IMMUNOL, V159, P1639; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Okkenhaug K, 2001, NAT IMMUNOL, V2, P325, DOI 10.1038/86327; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Piccolella E, 2003, J IMMUNOL, V170, P2895, DOI 10.4049/jimmunol.170.6.2895; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; Raab M, 2001, IMMUNITY, V15, P921, DOI 10.1016/S1074-7613(01)00248-5; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rivas FV, 2004, MOL CELL BIOL, V24, P1628, DOI 10.1128/MCB.24.4.1628-1639.2004; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Tybulewicz VL, 2005, CURR OPIN IMMUNOL, V17, P267, DOI 10.1016/j.coi.2005.04.003; Vigorito E, 2004, BIOCHEM SOC T, V32, P781, DOI 10.1042/BST0320781; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9	58	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32385	32394		10.1074/jbc.M604878200	http://dx.doi.org/10.1074/jbc.M604878200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16905544	hybrid			2022-12-25	WOS:000241414500036
J	Carayol, N; Chen, J; Yang, F; Jin, TC; Jin, LJ; States, D; Wang, CY				Carayol, Nathalie; Chen, Ji; Yang, Fan; Jin, Taocong; Jin, Lijian; States, David; Wang, Cun-Yu			A dominant function of IKK/NF-kappa B signaling in global lipopolysaccharide-induced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC INFLAMMATORY DISEASES; NECROSIS-FACTOR-ALPHA; PORPHYROMONAS-GINGIVALIS; TNF RECEPTOR; SELECTIVE-INHIBITION; ECTODERMAL DYSPLASIA; PERIODONTAL-DISEASE; INDUCED APOPTOSIS; IMMUNE-RESPONSES; KINASE COMPLEX	Porphyromonas gingivalis is an etiologic pathogen of periodontitis that is one of the most common inflammatory diseases. Recently, we found that P. gingivalis LPS activated the transcription factor nuclear factor-kappa B (NF-kappa B) through the I kappa B kinase complex (IKK). NF-kappa B is a transcription factor that controls inflammation and host responses. In this study, we examined the role of IKK/NF-kappa B in P. gingivalis LPS-induced gene expression on a genome-wide basis using a combination of microarray and biochemical approaches. A total of 88 early response genes were found to be induced by P. gingivalis LPS in a human THP.1 monocytic cell lines. Interestingly, the induction of most of these genes was abolished or attenuated under the inactivation of IKK/NF-kappa B. Among those IKK/NF-kappa B-dependent genes, 20 genes were NF-kappa B-inducible genes reported previously, and 59 genes represented putative novel NF-kappa B target genes. Using transcription factor binding analysis, we found that most of these putative NF-kappa B target genes contained one or multiple NF-kappa B-binding sites. Also, some transcription factor-binding motifs were overrepresented in the promoter of both known and putative NF-kappa B-dependent genes, indicating that these genes may be regulated in a similar fashion. Furthermore, we found that several transcription factors associated with metabolic and inflammatory responses, including nuclear receptors, activator of protein-1, and early growth responses, were induced by P. gingivalis LPS through IKK/NF-kappa B, indicating that IKK/NF-kappa B may utilize these transcription factors to mediate secondary responses. Taken together, our results demonstrate that IKK/NF-kappa B signaling plays a dominant role in P. gingivalis LPS-induced early response gene expression, suggesting that IKK/NF-kappa B is a therapeutic target for periodontitis.	Univ Michigan, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Bioinformat Training Program, Ann Arbor, MI 48109 USA; Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Hong Kong	Wang, CY (corresponding author), Univ Michigan, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, Ann Arbor, MI 48109 USA.	cunywang@umich.edu	Jin, Lijian/B-2148-2009	Jin, Lijian/0000-0003-4305-1337	NIDCR NIH HHS [R01DE16513, R01DE15973] Funding Source: Medline; NLM NIH HHS [R01-LM08106] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015973] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM008106] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Assuma R, 1998, J IMMUNOL, V160, P403; Bannerman DD, 2002, J BIOL CHEM, V277, P8048, DOI 10.1074/jbc.M111249200; Birney E, 2003, COLD SPRING HARB SYM, V68, P213, DOI 10.1101/sqb.2003.68.213; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Chang J, 2005, J DENT RES, V84, P994, DOI 10.1177/154405910508401105; Chen S, 2002, J DENT RES, V81, P98, DOI 10.1177/154405910208100203; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Darveau RP, 1997, PERIODONTOL 2000, V14, P12, DOI 10.1111/j.1600-0757.1997.tb00190.x; Decker EL, 2003, NUCLEIC ACIDS RES, V31, P911, DOI 10.1093/nar/gkg186; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gibson FC, 2006, J DENT RES, V85, P106, DOI 10.1177/154405910608500202; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Huang GTJ, 2004, MICROB PATHOGENESIS, V37, P303, DOI 10.1016/j.micpath.2004.10.003; Hull C, 2002, J IMMUNOL, V169, P2611, DOI 10.4049/jimmunol.169.5.2611; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; MANGAN DF, 1993, J PERIODONTOL, V64, P461; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Muthukuru M, 2006, INFECT IMMUN, V74, P1431, DOI 10.1128/IAI.74.2.1431-1435.2006; Niederman R, 2001, J CLIN PERIODONTOL, V28, P569, DOI 10.1034/j.1600-051x.2001.028006569.x; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; Ramamurthy NS, 2002, J PERIODONTAL RES, V37, P1, DOI 10.1034/j.1600-0765.2002.00342.x; Salvi G E, 1998, Ann Periodontol, V3, P40, DOI 10.1902/annals.1998.3.1.40; Salvi GE, 1997, PERIODONTOL 2000, V14, P173, DOI 10.1111/j.1600-0757.1997.tb00197.x; Southerland JH, 2006, PERIODONTOL 2000, V40, P130, DOI 10.1111/j.1600-0757.2005.00138.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Teng YTA, 2006, J DENT RES, V85, P198, DOI 10.1177/154405910608500301; Vasselon T, 2002, INFECT IMMUN, V70, P1033, DOI 10.1128/IAI.70.3.1033-1041.2002; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yang F, 2004, J IMMUNOL, V172, P2446, DOI 10.4049/jimmunol.172.4.2446; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhou Q, 2005, INFECT IMMUN, V73, P935, DOI 10.1128/IAI.73.2.935-943.2005	50	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31142	31151		10.1074/jbc.M603417200	http://dx.doi.org/10.1074/jbc.M603417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16914552	hybrid			2022-12-25	WOS:000241075900089
J	Chang, CB; Brivanlou, AH; Harland, RM				Chang, Chenbei; Brivanlou, Ali H.; Harland, Richard M.			Function of the two xenopus Smad4s in early frog development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; TUMOR SUPPRESSORS SMAD2; TGF-BETA; SKI ACTS; C-SKI; SPEMANNS ORGANIZER; PROTEINS; ONCOPROTEIN; MUTATIONS; PATHWAY	Signals from the transforming growth factor beta family members are transmitted in the cell through specific receptor-activated Smads and a common partner Smad4. Two Smad4 genes (alpha and beta/10, or smad4 and smad4.2) have been isolated from Xenopus, and conflicting data are reported for Smad4 beta/10 actions in mesodermal and neural induction. To further understand the functions of the Smad4s in early frog development, we analyzed their activities in detail. We report that Smad10 is a mutant form of Smad4 beta that harbors a missense mutation of a conserved arginine to histidine in the MH1 domain. The mutation results in enhanced association of Smad10 with the nuclear transcription corepressor Ski and leads to its neural inducing activity through inhibition of bone morphogenetic protein (BMP) signaling. In contrast to Smad10, both Smad4 alpha and Smad4 beta enhanced BMP signals in ectodermal explants. Using antisense morpholino oligonucleotides (MOs) to knockdown endogenous Smad4 protein levels, we discovered that Smad4 beta was required for both activin- and BMP-mediated mesodermal induction in animal caps, whereas Smad4 beta affected only the BMP signals. Neither Smad4 was involved directly in neural induction. Expression of Smad4 beta-MO in early frog embryos resulted in reduction of mesodermal markers and defects in axial structures, which were rescued by either Smad4 alpha or Smad4 beta. Smad4 alpha-MO induced only minor deficiency at late stages. As Smad4 beta, but not Smad4 alpha, is expressed at high levels maternally and during early gastrulation, our data suggest that although Smad4 alpha and Smad4 beta may have similar activities, they are differentially utilized during frog embryogenesis, with only Smad4 beta being essential for mesoderm induction.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Rockefeller Univ, Mol Embryol Lab, New York, NY 10021 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Ctr Integrat Genom, Berkeley, CA 94720 USA	University of Alabama System; University of Alabama Birmingham; Rockefeller University; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Chang, CB (corresponding author), Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA.	cchang@uab.edu			NICHD NIH HHS [R01 HD43345] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD043345] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Chang CB, 1997, DEVELOPMENT, V124, P827; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chu GC, 2004, DEVELOPMENT, V131, P3501, DOI 10.1242/dev.01248; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Harland R, 2000, CURR OPIN GENET DEV, V10, P357, DOI 10.1016/S0959-437X(00)00096-4; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Khokha MK, 2005, DEV CELL, V8, P401, DOI 10.1016/j.devcel.2005.01.013; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LeSuer JA, 1999, DEVELOPMENT, V126, P137; LeSueur JA, 2002, DEV CELL, V2, P771, DOI 10.1016/S1534-5807(02)00172-7; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Suzuki H, 2004, ONCOGENE, V23, P5068, DOI 10.1038/sj.onc.1207690; Takeda M, 2004, MOL BIOL CELL, V15, P963, DOI 10.1091/mbc.E03-07-0478; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	40	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30794	30803		10.1074/jbc.M607054200	http://dx.doi.org/10.1074/jbc.M607054200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16908518	hybrid			2022-12-25	WOS:000241075900055
J	Esue, O; Carson, AA; Tseng, Y; Wirtz, D				Esue, Osigwe; Carson, Ashley A.; Tseng, Yiider; Wirtz, Denis			A direct interaction between actin and vimentin filaments mediated by the tail domain of vimentin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC CROSS-LINKING; INTERMEDIATE-FILAMENTS; MECHANICAL-PROPERTIES; IN-VITRO; VISCOELASTIC PROPERTIES; KERATIN FILAMENTS; ALPHA-ACTININ; PROTEIN; EXPRESSION; CELLS	The assembly and organization of the three major eukaryotic cytoskeleton proteins, actin, microtubules, and intermediate filaments, are highly interdependent. Through evolution, cells have developed specialized multifunctional proteins that mediate the cross-linking of these cytoskeleton filament networks. Here we test the hypothesis that two of these filamentous proteins, F-actin and vimentin filament, can interact directly, i.e. in the absence of auxiliary proteins. Through quantitative rheological studies, we find that a mixture of vimentin/actin filament network features a significantly higher stiffness than that of networks containing only actin filaments or only vimentin filaments. Maximum inter-filament interaction occurs at a vimentin/actin molar ratio of 3 to 1. Mixed networks of actin and tailless vimentin filaments show low mechanical stiffness and much weaker inter-filament interactions. Together with the fact that cells featuring prominent vimentin and actin networks are much stiffer than their counterparts lacking an organized actin or vimentin network, these results suggest that actin and vimentin filaments can interact directly through the tail domain of vimentin and that these inter-filament interactions may contribute to the overall mechanical integrity of cells and mediate cytoskeletal cross-talk.	Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; Univ Florida, Dept Chem Engn, Gainesville, FL 32611 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Grad Training Program, Baltimore, MD 21218 USA; Johns Hopkins Univ, Inst Nanobiotechnol, Baltimore, MD 21218 USA	Johns Hopkins University; State University System of Florida; University of Florida; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	wirtz@jhu.edu	Wirtz, Denis/A-3257-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075305] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM075305] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN V, 1994, CURR BIOL, V4, P1000, DOI 10.1016/S0960-9822(00)00225-6; Anastasi E, 1999, EUR J ENDOCRINOL, V141, P644, DOI 10.1530/eje.0.1410644; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; Bousquet O, 2001, J CELL BIOL, V155, P747, DOI 10.1083/jcb.200104063; CARY RB, 1994, J CELL SCI, V107, P1609; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; Correia I, 1999, J CELL BIOL, V146, P831, DOI 10.1083/jcb.146.4.831; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; CROOP J, 1975, J CELL BIOL, V65, P271, DOI 10.1083/jcb.65.2.271; ECKELT A, 1992, EUR J CELL BIOL, V58, P319; Eckes B, 1998, J CELL SCI, V111, P1897; ENGEL A, 1985, J ULTRA MOL STRUCT R, V90, P323, DOI 10.1016/S0022-5320(85)80010-1; Esue O, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.048301; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; Freshney RI, 1994, CULTURE ANIMAL CELLS; Fuchs E, 2001, GENE DEV, V15, P1, DOI 10.1101/gad.861501; GEISLER N, 1983, FEBS LETT, V163, P22, DOI 10.1016/0014-5793(83)81153-3; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; Helfand BT, 2002, J CELL BIOL, V157, P795, DOI 10.1083/jcb.200202027; Helfand BT, 2004, J CELL SCI, V117, P133, DOI 10.1242/jcs.00936; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Herrmann H, 2004, METHOD CELL BIOL, V78, P3; HERRMANN H, 1989, DEVELOPMENT, V105, P279; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1989, J NEUROSCI, V9, P959; HOLLENBECK PJ, 1989, J CELL SCI, V92, P621; Hutton E, 1998, J CELL BIOL, V143, P487, DOI 10.1083/jcb.143.2.487; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; KOUKLIS PD, 1991, J CELL BIOL, V114, P773, DOI 10.1083/jcb.114.4.773; Leung CL, 1999, J CELL BIOL, V147, P1275, DOI 10.1083/jcb.147.6.1275; Leung CL, 1999, J CELL BIOL, V144, P435, DOI 10.1083/jcb.144.3.435; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; Palmer A, 1999, BIOPHYS J, V76, P1063, DOI 10.1016/S0006-3495(99)77271-1; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; ROGERS KR, 1995, EUR J CELL BIOL, V66, P136; Shah JV, 1998, BIOL BULL, V194, P402, DOI 10.2307/1543125; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STEVEN AC, 1983, J BIOL CHEM, V258, P8323; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; TINT IS, 1991, J CELL SCI, V98, P375; Trickey WR, 2004, J ORTHOPAED RES, V22, P131, DOI 10.1016/S0736-0266(03)00150-5; Tseng Y, 2004, J BIOL CHEM, V279, P1819, DOI 10.1074/jbc.M306090200; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; WANG E, 1981, P NATL ACAD SCI-BIOL, V78, P2363, DOI 10.1073/pnas.78.4.2363; Wang N, 2002, J MUSCLE RES CELL M, V23, P535, DOI 10.1023/A:1023470709071; Wang N, 2000, AM J PHYSIOL-CELL PH, V279, pC188, DOI 10.1152/ajpcell.2000.279.1.C188; Weber KL, 2002, J CELL SCI, V115, P1373; Wickert U, 2005, EUR J CELL BIOL, V84, P379, DOI 10.1016/j.ejcb.2005.01.004; WICKSTROM ML, 1995, TOXICOL PATHOL, V23, P326, DOI 10.1177/019262339502300309; WILLARD M, 1981, J CELL BIOL, V89, P198, DOI 10.1083/jcb.89.2.198; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5	57	110	117	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30393	30399		10.1074/jbc.M605452200	http://dx.doi.org/10.1074/jbc.M605452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16901892	hybrid			2022-12-25	WOS:000241075900013
J	Liang, MH; Chuang, DM				Liang, Min-Huei; Chuang, De-Maw			Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TISSUE-PLASMINOGEN ACTIVATOR; CELL-SURVIVAL; C-JUN; APOPTOSIS; BETA; PHOSPHORYLATION; INDUCTION; EGR-1; GROWTH	Glycogen synthase kinase-3 (GSK-3) exists as two structurally similar isoforms, alpha and beta, whose activities are negatively regulated by serine phosphorylation but positively controlled by tyrosine phosphorylation. We used GSK-3 isoform-specific small interfering RNAs, dominant negative mutants, and pharmacological inhibitors to search for the differential roles for both GSK-3 isoforms in regulating transcriptional activation in cultured rat cerebral cortical neurons. GSK-3 alpha and GSK-3 beta were shown to have differentially regulated transactivation such that GSK-3 alpha silencing/inhibition was more robust than GSK-3 beta silencing/inhibition in causing cAMP-responsive element-and NF-kappa B-dependent transactivation. Moreover, protein-DNA array studies identified two novel GSK-3-regulated transcription factors, early growth response 1 and Smad3/4, which were oppositely affected by GSK-3 alpha or GSK-3 beta silencing or inhibition. Taken together, our results underscore critical variations in the function and regulation of GSK-3 alpha and GSK-3 beta. The development of GSK-3 isoform-specific inhibitors is thus crucial for therapeutic intervention of GSK-3-related neuropathological conditions.	Natl Inst Mental Hlth, Mol Neurobiol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Chuang, DM (corresponding author), Natl Inst Mental Hlth, Mol Neurobiol Sect, Bethesda, MD 20892 USA.	chuang@mail.nih.gov			NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002698, Z01MH002468] Funding Source: NIH RePORTER; NIMH NIH HHS [Z01MH002468-18] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Akassoglou K, 2002, NEURON, V33, P861, DOI 10.1016/S0896-6273(02)00617-7; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Buisson A, 2003, CELL MOL NEUROBIOL, V23, P539, DOI 10.1023/A:1025072013107; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Carmel JB, 2004, EXP NEUROL, V185, P81, DOI 10.1016/j.expneurol.2003.09.007; Cibelli G, 2002, J NEUROSCI RES, V67, P450, DOI 10.1002/jnr.10141; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Docagne F, 2002, MOL CELL NEUROSCI, V21, P634, DOI 10.1006/mcne.2002.1206; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; GOODE N, 1992, J BIOL CHEM, V267, P16878; Gould TD, 2004, INT J NEUROPSYCHOPH, V7, P387, DOI 10.1017/S1461145704004535; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Hashimoto R, 2002, J NEUROCHEM, V80, P589, DOI 10.1046/j.0022-3042.2001.00728.x; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; Jope RS, 2002, MOL PSYCHIATR, V7, pS35, DOI 10.1038/sj.mp.4001017; Lee JH, 2004, J NEUROCHEM, V91, P634, DOI 10.1111/j.1471-4159.2004.02770.x; Levkovitz Y, 2001, J NEUROSCI, V21, P5893, DOI 10.1523/JNEUROSCI.21-16-05893.2001; Liu CT, 1998, CANCER GENE THER, V5, P3; Melchor JP, 2003, J NEUROSCI, V23, P8867; O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753-03.2004; Pawlak R, 2003, NAT NEUROSCI, V6, P168, DOI 10.1038/nn998; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Pignatelli M, 2003, BIOCHEM J, V373, P739, DOI 10.1042/BJ20021918; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Sasaki C, 2001, NEUROL RES, V23, P588, DOI 10.1179/016164101101199054; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Soeda S, 2001, MOL BRAIN RES, V91, P96, DOI 10.1016/S0169-328X(01)00133-4; Su Y, 2004, BIOCHEMISTRY-US, V43, P6899, DOI 10.1021/bi035627j; Tabrizi P, 1999, ARTERIOSCL THROM VAS, V19, P2801, DOI 10.1161/01.ATV.19.11.2801; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; WANG QM, 1994, BIOCHEMISTRY-US, V33, P143, DOI 10.1021/bi00167a018; WANG QM, 1994, J BIOL CHEM, V269, P14566; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x	46	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30479	30484		10.1074/jbc.M607468200	http://dx.doi.org/10.1074/jbc.M607468200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16912034	hybrid			2022-12-25	WOS:000241075900023
J	Moran, P; Li, W; Fan, B; Vij, R; Eigenbrot, C; Kirchhofer, D				Moran, Paul; Li, Wei; Fan, Bin; Vij, Rajesh; Eigenbrot, Charles; Kirchhofer, Daniel			Pro-urokinase-type plasminogen activator is a substrate for hepsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; SERINE-PROTEASE INHIBITOR; BENIGN PROSTATIC HYPERPLASIA; OVARIAN-CANCER; CLINICOPATHOLOGICAL PARAMETERS; BLOOD-COAGULATION; MICE DEFICIENT; CELL-GROWTH; IN-VIVO; EXPRESSION	Hepsin, a type II transmembrane serine protease, is strongly up-regulated in prostate cancer. Hepsin overexpression in a mouse prostate cancer model resulted in tumor progression and metastasis, associated with basement membrane disorganization. We investigated whether hepsin enzymatic activity was linked to the basement membrane defects by examining its ability to initiate the plasminogen/plasmin proteolytic pathway. Because plasminogen is not processed by hepsin, we investigated the upstream activators, urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator. Enzymatic assays with a recombinant soluble form of hepsin demonstrated that hepsin did not cleave pro-tissue-type plasminogen activator but efficiently converted pro-uPA into high molecular weight uPA by cleavage at the Lys(158)-Ile(159) (P-1-P-1') peptide bond. uPA generated by hepsin displayed enzymatic activity toward small synthetic and macromolecular substrates indistinguishable from uPA produced by plasmin. The catalytic efficiency of pro-uPA activation by hepsin (k(cat)/K-m 4.8 x 105 m(-1) s(-1)) was similar to that of plasmin, which is considered the most potent pro-uPA activator and was about 6-fold higher than that of matriptase. Conversion of pro-uPA was also demonstrated with cell surface-expressed full-length hepsin. A stable hepsin-overexpressing LnCaP cell line converted pro-uPA into high molecular weight uPA at a rate of 6.6 +/- 1.9 nM uPA h(-1), which was about 3-fold higher than LnCaP cells expressing lower hepsin levels on their surface. In conclusion, the ability of hepsin to efficiently activate pro-uPA suggests that it may initiate plasmin-mediated proteolytic pathways at the tumor/stroma interface that lead to basement membrane disruption and tumor progression.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Antibody Technol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Kirchhofer, D (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	dak@gene.com						Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bachmann F., 1994, HEMOSTASIS THROMBOSI, V3rd, P1592; BRUNNER G, 1992, BLOOD, V79, P2099; Chen ZX, 2003, J UROLOGY, V169, P1316, DOI 10.1097/01.ju.0000050648.40164.0d; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLLEN D, 1986, J BIOL CHEM, V261, P1259; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; Hall CL, 2004, PROSTATE, V59, P167, DOI 10.1002/pros.20009; Helenius MA, 2001, CANCER RES, V61, P5340; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; HONGO JAS, 1995, HYBRIDOMA, V14, P253, DOI 10.1089/hyb.1995.14.253; Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; Jin JS, 2006, MODERN PATHOL, V19, P447, DOI 10.1038/modpathol.3800495; Johnson MD, 2003, EXPERT REV MOL DIAGN, V3, P331, DOI 10.1586/14737159.3.3.331; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; KAZAMA Y, 1995, J BIOL CHEM, V270, P66, DOI 10.1074/jbc.270.1.66; Kirchhofer D, 2005, FEBS LETT, V579, P1945, DOI 10.1016/j.febslet.2005.01.085; Kirchhofer D, 2003, J BIOL CHEM, V278, P36341, DOI 10.1074/jbc.M304643200; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Knudsen BS, 2004, ADV CANCER RES, V91, P31, DOI 10.1016/S0065-230X(04)91002-0; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; LIJNEN HR, 1987, EUR J BIOCHEM, V169, P359, DOI 10.1111/j.1432-1033.1987.tb13620.x; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2000, BIOCHEMISTRY-US, V39, P508, DOI 10.1021/bi991701f; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; NAULAND U, 1994, EUR J BIOCHEM, V223, P497, DOI 10.1111/j.1432-1033.1994.tb19018.x; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Olivero AG, 2005, J BIOL CHEM, V280, P9160, DOI 10.1074/jbc.M409068200; Riddick ACP, 2005, BRIT J CANCER, V92, P2171, DOI 10.1038/sj.bjc.6602630; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; Saleem M, 2006, CANCER EPIDEM BIOMAR, V15, P217, DOI 10.1158/1055-9965.EPI-05-0737; Sheng SJ, 2001, CANCER METAST REV, V20, P287, DOI 10.1023/A:1015539612576; Shia S, 2005, J MOL BIOL, V346, P1335, DOI 10.1016/j.jmb.2004.12.048; Somoza JR, 2003, STRUCTURE, V11, P1123, DOI 10.1016/S0969-2126(03)00148-5; Srikantan V, 2002, CANCER RES, V62, P6812; STACK MS, 1994, J BIOL CHEM, V269, P9416; Stamey TA, 2001, J UROLOGY, V166, P2171, DOI 10.1016/S0022-5347(05)65528-0; Stephan C, 2004, J UROLOGY, V171, P187, DOI 10.1097/01.ju.0000101622.74236.94; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tanimoto H, 1997, CANCER RES, V57, P2884; TORRESROSADO A, 1993, P NATL ACAD SCI USA, V90, P7181, DOI 10.1073/pnas.90.15.7181; VanVeldhuizen PJ, 1996, AM J MED SCI, V312, P8, DOI 10.1097/00000441-199607000-00002; Vu TKH, 1997, J BIOL CHEM, V272, P31315, DOI 10.1074/jbc.272.50.31315; Welsh JB, 2001, CANCER RES, V61, P5974; WOLF BB, 1993, J BIOL CHEM, V268, P16327; Wu QY, 1998, J CLIN INVEST, V101, P321, DOI 10.1172/JCI1617; Xuan JA, 2006, CANCER RES, V66, P3611, DOI 10.1158/0008-5472.CAN-05-2983; Yasuda S, 2005, BLOOD, V105, P3893, DOI 10.1182/blood-2003-10-3501; Yu IS, 2000, THROMB HAEMOSTASIS, V84, P865, DOI 10.1055/s-0037-1614129	59	76	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30439	30446		10.1074/jbc.M605440200	http://dx.doi.org/10.1074/jbc.M605440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16908524	hybrid			2022-12-25	WOS:000241075900018
J	Yogev-Falach, M; Bar-Am, O; Amit, T; Weinreb, O; Youdim, MBH				Yogev-Falach, Merav; Bar-Am, Orit; Amit, Tamar; Weinreb, Orly; Youdim, Moussa B. H.			A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing	FASEB JOURNAL			English	Article						amyloid precursor protein; alpha-secretase; acetylcholinesterase inhibitor; Alzheimer disease	AMYLOID PRECURSOR PROTEIN; ANTI-PARKINSON DRUG; CHOLINESTERASE-INHIBITORS; ALZHEIMERS-DISEASE; KINASE-C; ACETYLCHOLINESTERASE INHIBITORS; RESPONSIVE ELEMENT; RASAGILINE; EXPRESSION; DERIVATIVES	The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on multiple targets has stimulated the development of the bifunctional drug ladostigil (TV3326) [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate]. Ladostigil combines the neuroprotective effects of the antiparkinson drug rasagiline, a selective monoamine oxidase (MAO)-B inhibitor, with the cholinesterase (ChE) inhibitory activity of rivastigmine in a single molecule, as a potential treatment for Alzheimer's disease (AD) and Lewy Body disease. Here, we assessed the dual effects of lodostigil in terms of the molecular mechanism of neuroprotection and amyloid precursor protein (APP) regulation/processing by using an apoptotic model of neuroblastoma SK-N-SH cells. Ladostigil dose-dependently decreased cell death via inhibition of the cleavage and prevention of caspase-3 activation (IC50 = 1.05 mu M) through a mechanism related to regulation of the Bcl-2 family proteins, which resulted in reduced levels of Bad and Bax and induced levels of Bcl-2 gene and protein expression. We have also followed APP regulation/processing and found that ladostigil markedly decreased apoptotic-induced levels of holo-APP protein without altering APP mRNA levels, suggesting a posttranscriptional mechanism. In addition, the drug-elevated phosphorylated protein kinase C (pPKC) levels and stimulated the release of the nonamyloidogenic alpha-secretase proteolytic pathway. Similar to ladostigil, its S-isomer, TV3279, which is a ChE inhibitor but lacks MAO inhibitory activity, exerted neuroprotective properties and regulated APP processing, indicating that these effects are independent of MAO inhibition.	Technion Israel Inst Technol, Dept Pharmacol, Rappaport Family Inst Res Med Sci, Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Eve Topf Ctr Excellence Neurodegenerat Dis Res, Rappaport Family Inst Res Med Sci, Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Dept Pharmacol, Rappaport Family Inst Res Med Sci, Fac Med, POB 9697, IL-31096 Haifa, Israel.	youdim@tx.technion.ac.il						Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Ba F, 2003, J NEUROSCI METH, V123, P11, DOI 10.1016/S0165-0270(02)00324-2; Bar-Am O, 2005, FASEB J, V19, P1899, DOI 10.1096/fj.05-3794fje; Bar-Am O, 2004, J NEUROCHEM, V89, P1119, DOI 10.1111/j.1471-4159.2004.02425.x; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; Calderon FH, 1998, MOL PSYCHIATR, V3, P247, DOI 10.1038/sj.mp.4000383; Chong YH, 1996, LIFE SCI, V59, P545, DOI 10.1016/0024-3205(96)00335-9; Coyle J, 2001, BIOL PSYCHIAT, V49, P289, DOI 10.1016/S0006-3223(00)01101-X; DeKosky ST, 2002, ANN NEUROL, V51, P145, DOI 10.1002/ana.10069; Francis PT, 2005, TRENDS PHARMACOL SCI, V26, P104, DOI 10.1016/j.tips.2004.12.010; Francis PT, 1999, J NEUROL NEUROSUR PS, V66, P137, DOI 10.1136/jnnp.66.2.137; Giacobini E, 2004, PHARMACOL RES, V50, P433, DOI 10.1016/j.phrs.2003.11.017; Greig NH, 2005, P NATL ACAD SCI USA, V102, P17213, DOI 10.1073/pnas.0508575102; Joseph JA, 2005, NEUROCHEM RES, V30, P927, DOI 10.1007/s11064-005-6967-4; Lahiri DK, 1996, J MOL NEUROSCI, V7, P41, DOI 10.1007/BF02736847; Maruyama W, 2003, NEUROSCI LETT, V341, P233, DOI 10.1016/S0304-3940(03)00211-8; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; MARUYAMA W, 2000, ANN NY ACAD SCI, V939, P320; Mazzucchelli M, 2003, J NEURAL TRANSM, V110, P935, DOI 10.1007/s00702-003-0006-x; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Pakaski M, 2003, CNS NEUROL DISORD-DR, V2, P163, DOI 10.2174/1568007033482869; Racchi M, 2001, MOL PSYCHIATR, V6, P520, DOI 10.1038/sj.mp.4000878; Racchi M, 2004, PHARMACOL RES, V50, P441, DOI 10.1016/j.phrs.2003.12.027; Rogers JT, 2004, CURR DRUG TARGETS, V5, P535, DOI 10.2174/1389450043345272; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shaw KTY, 2001, P NATL ACAD SCI USA, V98, P7605, DOI 10.1073/pnas.131152998; Sterling J, 2002, J MED CHEM, V45, P5260, DOI 10.1021/jm020120c; von Bernhardi R, 2003, NEUROBIOL DIS, V14, P447, DOI 10.1016/j.nbd.2003.08.014; Wadia JS, 1998, J NEUROSCI, V18, P932; Weinreb O, 2004, FASEB J, V18, P1471, DOI 10.1096/fj.04-1916fje; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; Weinstock M, 2000, ADV RES NEURODEGENER, V8, P157; Yang L, 2002, NEUROSCI RES, V42, P261, DOI 10.1016/S0168-0102(02)00005-6; YI H, 2005, IN PRESS J NEURAL T; Yogev-Falach M, 2003, FASEB J, V17, P2325, DOI 10.1096/fj.03-0078fje; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Youdim MBH, 2005, TRENDS PHARMACOL SCI, V26, P27, DOI 10.1016/j.tips.2004.11.007; Youdim MBH, 2002, MECH AGEING DEV, V123, P1081, DOI 10.1016/S0047-6374(01)00391-8; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; YOUDIM MBH, 2001, DRUGS PREVENT CELL D, V86; Zhang HY, 2004, NEUROSCI LETT, V360, P21, DOI 10.1016/j.neulet.2004.01.055; Zimmermann M, 2004, J NEUROCHEM, V90, P1489, DOI 10.1111/j.1471-4159.2004.02680.x	46	80	83	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2177	+		10.1096/fj.05-4910fje	http://dx.doi.org/10.1096/fj.05-4910fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935943				2022-12-25	WOS:000241156900063
J	Zanardo, RCO; Brancaleone, V; Distrutti, E; Fiorucci, S; Cirino, G; Wallace, JL				Zanardo, Renata C. O.; Brancaleone, Vincenzo; Distrutti, Eleonora; Fiorucci, Stefano; Cirino, Giuseppe; Wallace, John L.			Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation	FASEB JOURNAL			English	Article						CNS; H2S donor; leukocyte adhesion	RAT; ADHESION; INHIBITION; DAMAGE; BLOOD	Hydrogen sulfide (H2S) is increasingly recognized as an important signaling molecule in the cardiovascular and nervous systems. Recently, H2S donors were reported to induce neutrophil apoptosis and to suppress expression of some leukocyte and endothelial adhesion molecules. Using rats, we examined the possibility that H2S is an endogenous regulator of key inflammatory events at the leukocyte-endothelial interface. Via intravital microscopy, we observed that H2S donors (NaHS and Na2S) inhibited aspirin-induced leukocyte adherence in mesenteric venules (ED50 of 5.0 mu mol/kg for Na2S), likely via activation of ATP-sensitive K+ (K-ATP) channels. Inhibition of endogenous H2S synthesis elicited leukocyte adherence. Leukocyte infiltration in an air pouch model was also suppressed by H2S donors (NaHS, Lawesson's reagent, and N-acetylcysteine; ED50 of 42.7, 1.3, and 29.9 mu mol/kg, respectively) and exacerbated by inhibition of endogenous H2S synthesis. Carrageenan-induced paw edema was suppressed by H2S donors (NaHS and Na2S; ED(50)s of 35 and 28 mu mol/kg, respectively) to the same extent as by diclofenac and enhanced by an inhibitor of H2S synthesis. Suppression of edema formation by H2S donors was mimicked by a K-ATP channel agonist and reversed by an antagonist of this channel. These results suggest that endogenous H2S is an important mediator of acute inflammation, acting at the leukocyte-endothelium interface. These findings have important implications for anti-inflammatory drug development.	Univ Calgary, Dept Pharmacol & Therapeut, Inflammat Res Network, Calgary, AB T2N 4N1, Canada; Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; Univ Perugia, Div Gastroenterol & Hepatol, I-06100 Perugia, Italy	University of Calgary; University of Naples Federico II; University of Perugia	Wallace, JL (corresponding author), Univ Calgary, Dept Pharmacol & Therapeut, Inflammat Res Network, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	wallacej@ucalgary.ca	Fiorucci, Stefano/I-1251-2012; Wallace, John/AAL-3763-2021	brancaleone, vincenzo/0000-0002-0063-659X; Cirino, Giuseppe/0000-0003-3954-4083				Abe K, 1996, J NEUROSCI, V16, P1066; ANTUNES E, 1990, BRIT J PHARMACOL, V101, P986, DOI 10.1111/j.1476-5381.1990.tb14193.x; ASAKO H, 1992, GASTROENTEROLOGY, V103, P146, DOI 10.1016/0016-5085(92)91107-F; Bhatia M, 2005, FASEB J, V19, P623, DOI 10.1096/fj.04-3023fje; Bhatia M, 2005, BRIT J PHARMACOL, V145, P141, DOI 10.1038/sj.bjp.0706186; Boehning D, 2003, ANNU REV NEUROSCI, V26, P105, DOI 10.1146/annurev.neuro.26.041002.131047; Distrutti E, 2006, J PHARMACOL EXP THER, V316, P325, DOI 10.1124/jpet.105.091595; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Fujii K, 2005, ANTIOXID REDOX SIGN, V7, P788, DOI 10.1089/ars.2005.7.788; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Kamath AF, 2006, BLOOD, V107, P591, DOI 10.1182/blood-2005-06-2506; Li L, 2005, FASEB J, V19, P1196, DOI 10.1096/fj.04-3583fje; Mariggio MA, 1998, IMMUNOPHARM IMMUNOT, V20, P399, DOI 10.3109/08923979809034822; Mok YYP, 2004, BRIT J PHARMACOL, V143, P881, DOI 10.1038/sj.bjp.0706014; Moore PK, 2003, TRENDS PHARMACOL SCI, V24, P609, DOI 10.1016/j.tips.2003.10.007; Richardson CJ, 2000, CLIN CHIM ACTA, V293, P115, DOI 10.1016/S0009-8981(99)00245-4; Searcy DG, 1998, J EXP ZOOL, V282, P310, DOI 10.1002/(SICI)1097-010X(19981015)282:3<310::AID-JEZ4>3.0.CO;2-P; SEDGWICK AD, 1985, BRIT J EXP PATHOL, V66, P455; SMITH SB, 1977, BIOCHEM J, V162, P453, DOI 10.1042/bj1620453; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462; Wallace JL, 1999, BRIT J PHARMACOL, V126, P1200, DOI 10.1038/sj.bjp.0702420; WALLACE JL, 1991, GASTROENTEROLOGY, V100, P878, DOI 10.1016/0016-5085(91)90259-N; WALLACE JL, 1993, AM J PHYSIOL, V265, pG993, DOI 10.1152/ajpgi.1993.265.5.G993; Wallace JL, 2003, FUND CLIN PHARMACOL, V17, P11, DOI 10.1046/j.1472-8206.2003.00125.x; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Weiss N, 2002, ARTERIOSCL THROM VAS, V22, P34, DOI 10.1161/hq1201.100456; Whiteman M, 2005, BIOCHEM BIOPH RES CO, V326, P794, DOI 10.1016/j.bbrc.2004.11.110; Whiteman M, 2004, J NEUROCHEM, V90, P765, DOI 10.1111/j.1471-4159.2004.02617.x; Zhao WM, 2002, AM J PHYSIOL-HEART C, V283, pH474, DOI 10.1152/ajpheart.00013.2002	30	688	746	2	113	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2118	+		10.1096/fj.06-6270fje	http://dx.doi.org/10.1096/fj.06-6270fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16912151				2022-12-25	WOS:000241156900023
J	Kravchenko, VV; Kaufmann, GF; Mathison, JC; Scott, DA; Katz, AZ; Wood, MR; Brogan, AP; Lehmann, M; Mee, JM; Iwata, K; Pan, Q; Fearns, C; Knaus, UG; Meijler, MM; Janda, KD; Ulevitch, RJ				Kravchenko, Vladimir V.; Kaufmann, Gunnar F.; Mathison, John C.; Scott, David A.; Katz, Alexander Z.; Wood, Malcolm R.; Brogan, Andrew P.; Lehmann, Mandy; Mee, Jenny M.; Iwata, Kazunori; Pan, Qilin; Fearns, Colleen; Knaus, Ulla G.; Meijler, Michael M.; Janda, Kim D.; Ulevitch, Richard J.			N-(3-oxo-acyl)homoserine lactones signal cell activation through a mechanism distinct from the canonical pathogen-associated molecular pattern recognition receptor pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-3-OXODODECANOYL HOMOSERINE LACTONE; C-JUN INDUCTION; NF-KAPPA-B; PSEUDOMONAS-AERUGINOSA; PROTEIN-SYNTHESIS; GENE-EXPRESSION; PHORBOL ESTER; TARGET GENES; VIRULENCE; APOPTOSIS	Innate immune system receptors function as sensors of infection and trigger the immune responses through ligand-specific signaling pathways. These ligands are pathogen-associated products, such as components of bacterial walls and viral nuclear acids. A common response to such ligands is the activation of mitogen-activated protein kinase p38, whereas double-stranded viral RNA additionally induces the phosphorylation of eukaryotic translation initiation factor 2 alpha(eIF2 alpha). Here we have shown that p38 and eIF2 alpha phosphorylation represent two biochemical markers of the effects induced by N-(3-oxo-acyl) homoserine lactones, the secreted products of a number of Gram-negative bacteria, including the human opportunistic pathogen Pseudomonas aeruginosa. Furthermore, N-(3-oxo-dodecanoyl) homoserine lactone induced distension of mitochondria and the endoplasmic reticulum as well as c-jun gene transcription. These effects occurred in a wide variety of cell types including alveolar macrophages and bronchial epithelial cells, requiring the structural integrity of the lactone ring motif and its natural stereochemistry. These findings suggest that N-(3-oxo-acyl) homoserine lactones might be recognized by receptors of the innate immune system. However, we provide evidence that N-(3-oxo-dodecanoyl) homoserine lactone-mediated signaling does not require the presence of the canonical innate immune system receptors, Toll-like receptors, or two members of the NLR/Nod/Caterpillar family, Nod1 and Nod2. These data offer a new understanding of the effects of N-(3-oxo-dodecanoyl) homoserine lactone on host cells and its role in persistent airway infections caused by P. aeruginosa.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Core Microscopy Facil, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Worm Inst Res & Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Janda, KD (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	kdjanda@scripps.edu; ulevitch@scripps.edu	Ulevitch, Richard J/Q-3393-2017	Meijler, Michael/0000-0001-7095-1467	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI055781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI055781] Funding Source: Medline; NIGMS NIH HHS [5P01GM037696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BUSCHER M, 1988, ONCOGENE, V3, P301; Charlton TS, 2000, ENVIRON MICROBIOL, V2, P530, DOI 10.1046/j.1462-2920.2000.00136.x; Chen LC, 2004, BBA-MOL CELL BIOL L, V1683, P38, DOI 10.1016/j.bbalip.2004.04.003; Chen YJ, 2000, J BIOMED SCI, V7, P122, DOI 10.1159/000025437; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; Erickson DL, 2002, INFECT IMMUN, V70, P1783, DOI 10.1128/IAI.70.4.1783-1790.2002; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Herrlich P, 1997, BIOL CHEM, V378, P1217; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Hooi DSW, 2004, INFECT IMMUN, V72, P6463, DOI 10.1128/IAI.72.11.6463-6470.2004; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JONES S, 1993, EMBO J, V12, P2477, DOI 10.1002/j.1460-2075.1993.tb05902.x; Kaufmann GF, 2005, P NATL ACAD SCI USA, V102, P309, DOI 10.1073/pnas.0408639102; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Lazdunski AM, 2004, NAT REV MICROBIOL, V2, P581, DOI 10.1038/nrmicro924; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li L, 2004, ONCOGENE, V23, P4894, DOI 10.1038/sj.onc.1207612; Lieberman David, 2003, Am J Respir Med, V2, P459; Lyczak JB, 2002, CLIN MICROBIOL REV, V15, P194, DOI 10.1128/CMR.15.2.194-222.2002; MATHISON JC, 1990, J CLIN INVEST, V85, P1108, DOI 10.1172/JCI114542; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; MUNOZ E, 1992, EUR J IMMUNOL, V22, P2101, DOI 10.1002/eji.1830220821; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; PEARSON JP, 1995, P NATL ACAD SCI USA, V92, P1490, DOI 10.1073/pnas.92.5.1490; ROLSTON KVI, 1992, CANCER INVEST, V10, P43, DOI 10.3109/07357909209032787; Rumbaugh KP, 1999, INFECT IMMUN, V67, P5854, DOI 10.1128/IAI.67.11.5854-5862.1999; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shiner EK, 2005, FEMS MICROBIOL REV, V29, P935, DOI 10.1016/j.femsre.2005.03.001; Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627; Smith RS, 2003, J CLIN INVEST, V112, P1460, DOI 10.1172/JCI200320364; Smith RS, 2002, J IMMUNOL, V169, P2636, DOI 10.4049/jimmunol.169.5.2636; Smith RS, 2001, J IMMUNOL, V167, P366, DOI 10.4049/jimmunol.167.1.366; Son DS, 2004, ENDOCRINOLOGY, V145, P1218, DOI 10.1210/en.2003-0860; Steinhauser ME, 1999, J IMMUNOL, V162, P392; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Tan SL, 1998, J NEUROCHEM, V71, P95; Tateda K, 2003, INFECT IMMUN, V71, P5785, DOI 10.1128/IAI.71.10.5785-5793.2003; Telford G, 1998, INFECT IMMUN, V66, P36, DOI 10.1128/IAI.66.1.36-42.1998; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yamaguchi K, 2005, J BIOL CHEM, V280, P32569, DOI 10.1074/jbc.M503201200; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262	68	103	104	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28822	28830		10.1074/jbc.M606613200	http://dx.doi.org/10.1074/jbc.M606613200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16893899	hybrid			2022-12-25	WOS:000240680500036
J	Lebedeva, IV; Su, ZZ; Emdad, L; Kolomeyer, A; Sarkar, D; Kitada, S; Waxman, S; Reed, JC; Fisher, PB				Lebedeva, I. V.; Su, Z-Z; Emdad, L.; Kolomeyer, A.; Sarkar, D.; Kitada, S.; Waxman, S.; Reed, J. C.; Fisher, P. B.			Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells	ONCOGENE			English	Article						mda-7/IL-24; K-ras single-chain antibody; K-ras AS; bipartite adenovirus; colorectal carcinoma; Bcl-family of proteins	DIFFERENTIATION-ASSOCIATED GENE-7; MELANOMA-DIFFERENTIATION; BCL-2 EXPRESSION; IN-VITRO; BYSTANDER ACTIVITY; MDA-7/IL-24; MDA-7; PROTEIN; LINES; ADENOVIRUS	Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) is a cancer-specific, growth-suppressing and apoptosis-inducing gene with broad-spectrum antitumor activity. However, when administered by means of a replication-incompetent adenovirus, Ad.mda-7, several colorectal carcinoma cell lines are resistant to its antiproliferative and antisurvival effects. We have presently endeavored to determine if K-ras mutations, present in similar to 40-50% of colorectal cancers and which may mediate resistance to chemotherapy and radiotherapy, represent a predisposing genetic factor mitigating reduced sensitivity to Ad.mda-7. To suppress ras expression, three structurally different replication-incompetent adenoviral vectors were engineered that express (1) an intracellular, neutralizing single-chain antibody (scAb) to p21 ras (Ad.K-ras scAb), (2) an antisense (AS) K-ras gene (Ad.K-ras AS) or (3) both mda-7/IL-24 and a K-ras AS gene in a single bipartite virus (Ad.m7.KAS). Simultaneous inhibition of K-ras and expression of mda-7/IL-24 enhanced killing of colorectal carcinoma cells with mutated K-ras, but not with wild-type K-ras. The extent of killing depended on the degree of K-ras downregulation, with Ad.K-ras AS being generally more efficient than Ad.K-ras scAb in combination with Ad.mda-7. These findings support an effective dual-combinatorial approach for the therapy of colorectal cancers that employs a unique cancer-specific suppressor gene (mda-7/IL-24) with targeted inhibition of oncogene (ras) expression.	Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Pathol, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Med Ctr, Herbert Irving Comprehens Canc Ctr,Dept Urol, New York, NY USA; Mt Sinai Sch Med, Div Hematol Oncol, Dept Med, New York, NY USA; Burnham Inst, La Jolla, CA USA; Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; Sanford Burnham Prebys Medical Discovery Institute; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Pathol, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NCI NIH HHS [R01 CA097318, R01 CA098712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097318, R01CA098712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Aoki K, 1997, MOL CARCINOGEN, V20, P251, DOI 10.1002/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; Brand K, 1999, GENE THER, V6, P1054, DOI 10.1038/sj.gt.3300914; Canevari S, 2002, J NATL CANCER I, V94, P1031; Cardinale A, 1998, FEBS LETT, V439, P197, DOI 10.1016/S0014-5793(98)01369-6; Chada S, 2006, CANCER GENE THER, V13, P490, DOI 10.1038/sj.cgt.7700915; Chada S, 2004, MOL THER, V10, P1085, DOI 10.1016/j.ymthe.2004.08.020; Chada S, 2004, INT IMMUNOPHARMACOL, V4, P649, DOI 10.1016/j.intimp.2004.01.017; Cochet O, 1998, CANCER RES, V58, P1170; Cunningham CC, 2005, MOL THER, V11, P149, DOI 10.1016/j.ymthe.2004.09.019; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Fisher PB, 2005, CANCER RES, V65, P10128, DOI 10.1158/0008-5472.CAN-05-3127; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; GUPTA P, 2006, IN PRESS PHARM THER; HAGUE A, 1994, ONCOGENE, V9, P3367; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Jiang HP, 1995, ONCOGENE, V11, P2477; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V148, P1567; Krajewski S, 1997, CLIN CANCER RES, V3, P199; Lebedeva IV, 2006, CANCER RES, V66, P2403, DOI 10.1158/0008-5472.CAN-05-3510; Lebedeva IV, 2005, ONCOGENE, V24, P585, DOI 10.1038/sj.onc.1208183; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2005, MOL THER, V11, P4, DOI 10.1016/j.ymthe.2004.08.012; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; Oida Y, 2005, MOL CANCER THER, V4, P291; Ramesh R, 2003, CANCER RES, V63, P5105; Russell JS, 1999, CANCER RES, V59, P5239; Russo P, 2002, INT J CANCER, V100, P266, DOI 10.1002/ijc.10461; Sarkar D, 2005, P NATL ACAD SCI USA, V102, P14034, DOI 10.1073/pnas.0506837102; Sarkar D, 2005, CANCER RES, V65, P9056, DOI 10.1158/0008-5472.CAN-05-1261; SARKAR D, IN PRESS ANTIINFLAMM; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SKLAR MD, 1988, CANCER RES, V48, P793; Su ZZ, 2006, ONCOGENE, V25, P2339, DOI 10.1038/sj.onc.1209271; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 2005, ONCOGENE, V24, P7552, DOI 10.1038/sj.onc.1208911; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Tong AW, 2005, MOL THER, V11, P160, DOI 10.1016/j.ymthe.2004.09.021; Viale Pamela Hallquist, 2005, Clin J Oncol Nurs, V9, P541, DOI 10.1188/05.CJON.541-552; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Ward RL, 1997, CANCER, V79, P1106, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1106::AID-CNCR8>3.0.CO;2-D; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; Zhao LL, 2005, HUM GENE THER, V16, P845, DOI 10.1089/hum.2005.16.845	60	23	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					733	744		10.1038/sj.onc.1209813	http://dx.doi.org/10.1038/sj.onc.1209813			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16924242				2022-12-25	WOS:000243902200010
J	Vigneron, A; Cherier, J; Barre, B; Gamelin, E; Coqueret, O				Vigneron, Arnaud; Cherier, Julia; Barre, Benjamin; Gamelin, Erick; Coqueret, Olivier			The cell cycle inhibitor p21(waf1) binds to the myc and cdc25A promoters upon DNA damage and induces transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; DEPENDENT KINASES; S PHASE; TARGET; P21; P53; ASSOCIATION; PROTEINS; ARREST; REPLICATION	In addition to its function as a cyclin-dependent kinase (cdk) inhibitor, p21(waf1) fulfills additional roles involved in DNA replication and transcriptional regulation that could also contribute to cell cycle arrest. In this study, we have shown that p21(waf1) functions as a transcriptional repressor of the myc and cdc25A genes. Ectopic expression of the cell cycle inhibitor down-modulates myc and cdc25A transcription but has no effect on cdk4 levels. Using chromatin immunoprecipitation, we found that p21(waf1) is recruited to the promoters of these two genes together with the STAT3 and E2F1 transcription factors. Its presence on DNA is associated with an inhibition of the recruitment of the p300 histone acetylase and with a down-regulation of histone H4 acetylation. The same effect was also observed following DNA damage because topoisomerase inhibitors such as sn38 or doxorubicin also induce the association of p21(waf1) with DNA. Following transcriptional repression of the myc and cdc25A genes, cells were arrested in the fraction with 4 N DNA content. By contrast, the expression of these two genes remains elevated in the absence of the cell cycle inhibitor, and p21(waf1-/-) cells re-replicate their DNA and become polyploid. In light of these results, we propose that p21(waf1) simultaneously targets cdk and transcriptional regulators to prevent the expression of oncogenic pathways upon DNA damage.	Canc Ctr Paul Papin, INSERM U564, F-49033 Angers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut de Cancerologie de l'Ouest (ICO)	Coqueret, O (corresponding author), Ctr Reg Lutte Contre Canc Paul Papin, INSERM U564, 2 Rue Moll, F-49033 Angers, France.	olivier.coqueret@univ-angers.fr	Vigneron, Arnaud/ABC-7306-2021; Coqueret, Olivier/K-9660-2015	Vigneron, Arnaud/0000-0003-4161-0676; Coqueret, Olivier/0000-0002-2843-7867				Andreassen PR, 2001, CANCER RES, V61, P7660; Barre B, 2005, J BIOL CHEM, V280, P15673, DOI 10.1074/jbc.M413203200; Barre B, 2003, J BIOL CHEM, V278, P2990, DOI 10.1074/jbc.M210422200; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Fritah A, 2005, MOL CELL BIOL, V25, P2419, DOI 10.1128/MCB.25.6.2419-2430.2005; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Giraud S, 2004, ONCOGENE, V23, P7391, DOI 10.1038/sj.onc.1207972; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gregory DJ, 2002, CELL CYCLE, V1, P343, DOI 10.4161/cc.1.5.153; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perkins ND, 2002, CELL CYCLE, V1, P39, DOI 10.4161/cc.1.1.98; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Secombe J, 2004, CELL, V117, P153, DOI 10.1016/S0092-8674(04)00336-8; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Van Le H, 2005, J BIOL CHEM, V280, P32018, DOI 10.1074/jbc.M504689200; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101	42	61	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34742	34750		10.1074/jbc.M602492200	http://dx.doi.org/10.1074/jbc.M602492200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16923815	hybrid			2022-12-25	WOS:000241933700005
J	Colnaghi, R; Connell, CM; Barrett, RMA; Wheatley, SP				Colnaghi, Rita; Connell, Claire M.; Barrett, Rachel M. A.; Wheatley, Sally P.			Separating the anti-apoptotic and mitotic roles of survivin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT; CENTROMERES; EXPRESSION; SPINDLE; PROTEIN	Survivin is a bifunctional protein that acts as a suppressor of apoptosis and has an essential role in mitosis. To date whether these two functions can be divorced has not been addressed. Here we show that the linker region between the BIR ( baculovirus inhibitor of apoptosis repeat) domain of survivin and COOH-terminal alpha helix may be the key to separating its roles. When overexpressed survivin is present in interphase cells and shuttles between the cytoplasm and nucleus. Here we identify a rev-like nuclear exportation signal (NES) in the central domain of survivin and demonstrate that point mutations within this region cause accumulation of survivin in the nucleus. Interestingly cells expressing NES mutants exhibit reduced survival after X-irradiation. Moreover, cells expressing survivin(L98A)-green fluorescent protein (GFP) showed increased poly( ADPribose) polymerase-cleavage and caspase-3 activity after tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) treatment compared with cells expressing full-length survivin-green fluorescent protein. These data suggest a direct link between the interphase localization of survivin and cellular responsiveness to apoptotic stimuli. Using a cell proliferation assay, we also found that ectopic expression of NES mutants can complement for depletion of endogenous survivin, indicating that they can execute the mitotic duties of survivin. Thus we demonstrate for the first time that 1) survivin has a functional NES; 2) nuclear accumulation of overexpressed survivin correlates with increased sensitivity of cells to ionising radiation; and 3) the anti-apoptotic and mitotic roles of survivin can be separated through mutation of its NES. Separating these two functions of survivin could open up new possibilities for therapeutic strategies aimed at eliminating cancer cells yet preserving normal cell viability.	Univ Sussex, Dept Life Sci, Genom Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Sussex	Wheatley, SP (corresponding author), Univ Sussex, Dept Life Sci, Genom Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	s.p.wheatley@sussex.ac.uk			Medical Research Council [G0300662B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Beardmore VA, 2004, J CELL SCI, V117, P4033, DOI 10.1242/jcs.01242; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chakravarti A, 2004, ONCOGENE, V23, P7494, DOI 10.1038/sj.onc.1208049; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li FZ, 2005, INT J CANCER, V114, P509, DOI 10.1002/ijc.20768; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; Noton EA, 2006, J BIOL CHEM, V281, P1286, DOI 10.1074/jbc.M508773200; Okada E, 2001, CANCER LETT, V163, P109, DOI 10.1016/S0304-3835(00)00677-7; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; RODRIGUEZ J, 2006, ONCOGENE, P1; Rodriguez JA, 2002, EXP CELL RES, V275, P44, DOI 10.1006/excr.2002.5492; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; Tonini G, 2005, BRIT J CANCER, V92, P2225, DOI 10.1038/sj.bjc.6602632; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Wheatley SP, 2005, INT REV CYTOL, V247, P35, DOI 10.1016/S0074-7696(05)47002-3; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X	21	103	118	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33450	33456		10.1074/jbc.C600164200	http://dx.doi.org/10.1074/jbc.C600164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16950794	hybrid, Green Accepted			2022-12-25	WOS:000241621400055
J	Barthel, SR; Annis, DS; Mosher, DF; Johansson, MW				Barthel, Steven R.; Annis, Douglas S.; Mosher, Deane F.; Johansson, Mats W.			Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins alpha 4 beta 1 (CD49d/29) and alpha M beta 2 (CD11b/18) of eosinophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; ALPHA(4) INTEGRIN; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; COUNTER-RECEPTOR; BINDING-SITES; I DOMAIN; EXTRACELLULAR SEGMENT; DEPENDENT ADHESION; AIRWAY EOSINOPHILS	We have studied adhesion of eosinophils to various forms of vascular cell adhesion molecule 1 (VCAM-1, CD106), an integrin counter-receptor implicated in eosinophil recruitment to the airway in asthma. Full-length 7d-VCAM-1, with seven immunoglobulin-like modules, contains integrin-binding sites in modules 1 and 4. The alternatively spliced six-module protein, 6d-VCAM-1, lacks module 4. In static assays, unactivated purified human blood eosinophils adhered similarly to recombinant soluble human 6d-VCAM-1 and 7d-VCAM-1 coated onto polystyrene microtiter wells. Further experiments, however, revealed differences in recognition of modules 1 and 4. Antibody blocking indicated that eosinophil adhesion to 6d-VCAM-1 or a VCAM-1 construct containing only modules 1-3, 1-3VCAM-1, is mediated by alpha 4 beta 1 (CD49d/29), whereas adhesion to a construct containing modules 4-7,4-7VCAM-1, is mediated by both alpha 4 beta 1 and alpha M beta 2 (CD11b/18). Inhibitors of phosphoinositide 3-kinase, which block adhesion of eosinophils mediated by alpha M beta 2, blocked adhesion to 4-7VCAM-1 but had no effect on adhesion to 6d-VCAM-1. Consistent with the antibody and pharmacological blocking experiments, eosinophilic leukemic cell lines lacking alpha M beta 2 did not adhere to 4-7VCAM-1 but did adhere to 6d-VCAM-1 or 1-3VCAM-1. Activation of eosinophils by interleukin (IL)-5 enhanced static adhesion to 6d-VCAM-1, 7d-VCAM-1, or 4-7VCAM-1; IL-5-enhanced adhesion to all 3 constructs was blocked by anti-alpha M beta 2. Adhesion of unstimulated eosinophils to 7d-VCAM-1 under flow conditions was inhibited by anti-alpha 4 or anti-alpha M. IL-5 treatment decreased eosinophil adhesion to 7d-VCAM-1 under flow, and anti-alpha M had the paradoxical effect of increasing adhesion. These results demonstrate that alpha M beta 2 modulates alpha 4 beta 1-mediated eosinophil adhesion to VCAM-1 under both static and flow conditions.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, 4285A Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	dfmosher@facstaff.wisc.edu		Johansson, Mats/0000-0001-5699-978X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007899, P50HL056396] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 03186] Funding Source: Medline; NHLBI NIH HHS [T32 HL007899, HL 56396, T32 HL 007899, P50 HL056396] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe Y, 1996, J IMMUNOL, V157, P5061; ALEXANDER AG, 1994, THORAX, V49, P1231, DOI 10.1136/thx.49.12.1231; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Barthel SR, 2006, AM J RESP CELL MOL, V35, P378, DOI 10.1165/rcmb.2006-0027OC; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Broide D, 2001, IMMUNOL REV, V179, P163, DOI 10.1034/j.1600-065X.2001.790116.x; Brown DC, 1999, BRIT J HAEMATOL, V107, P86, DOI 10.1046/j.1365-2141.1999.01671.x; CARLOS TM, 1990, BLOOD, V76, P965; Chan JR, 2000, J IMMUNOL, V164, P746, DOI 10.4049/jimmunol.164.2.746; CHANG R, 1981, PHYS CHEM APPL BIOL, P72; CHIU HH, 1995, J IMMUNOL, V155, P5257; Cho JH, 2006, BLOOD, V107, P3555, DOI 10.1182/blood-2005-10-4168; CHULUYAN HE, 1995, J IMMUNOL, V155, P3135; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; Deng Huojin, 1998, Zhonghua Jiehe He Huxi Zazhi, V21, P108; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; EBISAWA M, 1994, J IMMUNOL, V153, P2153; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Grayson MH, 1998, J EXP MED, V188, P2187, DOI 10.1084/jem.188.11.2187; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HESSION C, 1991, J BIOL CHEM, V266, P6682; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; Hogg N, 2001, J LEUKOCYTE BIOL, V69, P893; Hughes JM, 2001, ALLERGY, V56, P412, DOI 10.1034/j.1398-9995.2001.056005412.x; Humphries MJ, 2004, BIOCHEM SOC T, V32, P407, DOI 10.1042/BST0320407; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jia GQ, 1999, INT IMMUNOL, V11, P1, DOI 10.1093/intimm/11.1.1; Johansson MW, 2006, J ALLERGY CLIN IMMUN, V117, P1502, DOI 10.1016/j.jaci.2006.02.032; Johansson MW, 2004, AM J RESP CELL MOL, V31, P413, DOI 10.1165/rcmb.2004-0099OC; KILGER G, 1995, J BIOL CHEM, V270, P5979, DOI 10.1074/jbc.270.11.5979; Kitayama J, 1997, J IMMUNOL, V159, P3929; Kotsimbos ATC, 1997, MEM I OSWALDO CRUZ, V92, P75, DOI 10.1590/S0074-02761997000800012; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; Lalani T, 1999, ANN ALLERG ASTHMA IM, V82, P317, DOI 10.1016/S1081-1206(10)63281-4; Leitinger B, 2000, MOL BIOL CELL, V11, P677, DOI 10.1091/mbc.11.2.677; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Matsumoto K, 1997, J ALLERGY CLIN IMMUN, V99, P648, DOI 10.1016/S0091-6749(97)70027-7; Meerschaert J, 1999, J IMMUNOL, V163, P6217; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; Mould AP, 2005, J BIOL CHEM, V280, P4238, DOI 10.1074/jbc.M412240200; NEEDHAM LA, 1994, CELL ADHES COMMUN, V2, P87, DOI 10.3109/15419069409004429; Newham P, 1997, J BIOL CHEM, V272, P19429, DOI 10.1074/jbc.272.31.19429; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4, DOI 10.1165/ajrcmb.12.1.7529029; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Patel KD, 1999, J IMMUNOL, V162, P6209; PEPINSKY B, 1992, J BIOL CHEM, V267, P17820; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; Sano M, 2005, AM J RESP CELL MOL, V33, P65, DOI 10.1165/rcmb.2005-0076OC; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; Springer TA, 2004, ADV PROTEIN CHEM, V68, P29; Sriramarao P, 1996, J IMMUNOL, V157, P4672; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; STRATH M, 1985, J IMMUNOL METHODS, V83, P209, DOI 10.1016/0022-1759(85)90242-X; Tachimoto H, 2000, CHEM IMMUNOL, V76, P45; Taylor P, 2001, ACTA CRYSTALLOGR D, V57, P1579, DOI 10.1107/S0907444901011209; ten Hacken NHT, 1998, CLIN EXP ALLERGY, V28, P1518; ULTMAN LH, 2001, J IMMUNOL, V166, P588; Van der Vieren M, 1999, J IMMUNOL, V163, P1984; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; Walsh GM, 1996, IMMUNOLOGY, V89, P112, DOI 10.1046/j.1365-2567.1996.d01-713.x; WALSH GM, 1990, IMMUNOLOGY, V71, P258; Wardlaw AJ, 2001, CLIN MED, V1, P214, DOI 10.7861/clinmedicine.1-3-214; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zhu XD, 1999, J IMMUNOL, V163, P3423	87	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32175	32187		10.1074/jbc.M600943200	http://dx.doi.org/10.1074/jbc.M600943200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16943205	hybrid			2022-12-25	WOS:000241414500015
J	Kim, JY; Zeng, WZ; Kiselyov, K; Yuan, JP; Dehoff, MH; Mikoshiba, K; Worley, PF; Muallem, S				Kim, Joo Young; Zeng, Weizong; Kiselyov, Kirill; Yuan, Joseph P.; Dehoff, Marlin H.; Mikoshiba, Katsuhiko; Worley, Paul F.; Muallem, Shmuel			Homer 1 mediates store- and inositol 1,4,5-trisphosphate receptor-dependent translocation and retrieval of TRPC3 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATED CA2+ ENTRY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; METABOTROPIC GLUTAMATE RECEPTORS; N-TERMINAL DOMAIN; CHANNEL FUNCTION; IP3 RECEPTOR; CATION CHANNEL; CALCIUM INFLUX; HTRP3 CHANNELS; HEK-293 CELLS	Store-operated Ca2+ channels (SOCs) mediate receptor-stimulated Ca2+ influx. Accumulating evidence indicates that members of the transient receptor potential (TRP) channel family are components of SOCs in mammalian cells. Agonist stimulation activates SOCs and TRP channels directly and by inducing translocation of channels in intracellular vesicles to the plasma membrane (PM). The mechanism of TRP channel translocation in response to store depletion and agonist stimulation is not known. Here we use TRPC3 as a model to show that IP3 and the scaffold Homer 1 (H1) regulate the rate of translocation and retrieval of TRPC3 from the PM. In resting cells, TRPC3 exists in TRPC3-H1b/c-IP(3)Rs complexes that are located in part at the PM and in part in intracellular vesicles. Binding of IP3 to the IP(3)Rs dissociates the interaction between IP(3)Rs and H1 but not between H1 and TRPC3 to form IP(3)Rs-TRPC3-H1b/c. TIRFM and biotinylation assays show robust receptor- and store-dependent translocation of the TRPC3 to the PM and their retrieval upon termination of cell stimulation. The translocation requires depletion of stored Ca2+ and is prevented by inhibition of the IP(3)Rs. In HEK293, dissociating the H1b/c-IP3R complex with H1a results in TRPC3 translocation to the PM, where it is spontaneously active. The TRPC3-H1b/c-IP(3)Rs complex is reconstituted by infusing H1c into these cells. Reconstitution is inhibited by IP3. Deletion of H1 in mice markedly reduces the rates of translocation and retrieval of TRPC3. Conversely, infusion of H1c into H1(-/-) cells eliminates spontaneous channel activity and increases the rate of channel activation by agonist stimulation. The effects of H1c are inhibited by IP3. These findings together with our earlier studies demonstrating gating of TRPC3 by IP(3)Rs were used to develop a model in which assembly of the TRPC3-H1b/c-IP(3)Rs complexes by H1b/c mediates both the translocation of TRPC3-containing vesicles to the PM and gating of TRPC3 by IP(3)Rs.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Yonsei Univ, Coll Med, Dept Pharmacol, Inst Gastroenterol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea 21 Project Med Sci, Seoul 120752, South Korea; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan	Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Tokyo	Worley, PF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	pworley@jhmi.edu; Shmuel.Muallem@UTSouthwestern.edu	Mikoshiba, Katsuhiko/N-7943-2015; Kim, Joo Young/X-7562-2019	Kim, Joo Young/0000-0003-2623-1491; Kiselyov, Kirill/0000-0001-6683-2895	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 12309] Funding Source: Medline; NIDDK NIH HHS [DK 38938] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandyopadhyay BC, 2005, J BIOL CHEM, V280, P12908, DOI 10.1074/jbc.M410013200; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Fagni Laurent, 2002, Sci STKE, V2002, pre8, DOI 10.1126/stke.2002.137.re8; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gudermann Thomas, 2004, Novartis Found Symp, V258, P103; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; MUALLEM S, 1986, J BIOL CHEM, V261, P2660; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Obukhov AG, 2004, J CELL PHYSIOL, V201, P227, DOI 10.1002/jcp.20057; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Roderick HL, 2003, CURR BIOL, V13, pR976, DOI 10.1016/j.cub.2003.11.048; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Yildirim E, 2005, P NATL ACAD SCI USA, V102, P3307, DOI 10.1073/pnas.0409908102; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zeng WZ, 2003, CURR BIOL, V13, P872, DOI 10.1016/S0960-9822(03)00330-0; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698	55	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32540	32549		10.1074/jbc.M602496200	http://dx.doi.org/10.1074/jbc.M602496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16887806	hybrid			2022-12-25	WOS:000241414500052
J	Woo, CH; Massett, MP; Shishido, T; Itoh, S; Ding, B; McClain, C; Che, WY; Vulapalli, SR; Yan, C; Abe, J				Woo, Chang-Hoon; Massett, Michael P.; Shishido, Tetsuro; Itoh, Seigo; Ding, Bo; McClain, Carolyn; Che, Wenyi; Vulapalli, Sreesatya Raju; Yan, Chen; Abe, Jun-ichi			ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPAR delta) stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; EPIDERMAL-GROWTH-FACTOR; CARBON-MONOXIDE; PROTEIN-KINASE; SKELETAL-MUSCLE; ENDOTHELIAL-CELLS; TRANSCRIPTIONAL ACTIVATION; INSULIN-RESISTANCE; GENE-EXPRESSION; MAP KINASE	Peroxisome proliferator-activated receptors ( PPAR) decrease the production of cytokine and inducible nitric-oxide synthase ( iNOS) expression, which are associated with aging-related inflammation and insulin resistance. Recently, the involvement of the induction of heme oxygenase-1 (HO-1) in regulating inflammation has been suggested, but the exact mechanisms for reducing inflammation by HO-1 remains unclear. We found that overexpression of HO-1 and [Ru(CO)(3)Cl-2](2), a carbon monoxide (CO)-releasing compound, increased not only ERK5 kinase activity, but also its transcriptional activity measured by luciferase assay with the transfection of the Gal4-ERK5 reporter gene. This transcriptional activity is required for coactivation of PPAR delta by ERK5 in C2C12 cells. [Ru(CO)(3)Cl-2](2) activated PPAR delta transcriptional activity via the MEK5/ERK5 signaling pathway. The inhibition of NF-kappa B activity by ERK5 activation was reversed by a dominant negative form of PPAR delta suggesting that ERK5/PPAR delta activation is required for the anti-inflammatory effects of CO and HO-1. Based on these data, we propose a new mechanism by which CO and HO-1 mediate anti-inflammatory effects via activating ERK5/PPAR delta, and ERK5 mediates CO and HO-1-induced PPAR delta activation via its interaction with PPAR delta.	Univ Rochester, Cardiovasc Res Inst, Rochester, NY 14642 USA	University of Rochester	Abe, J (corresponding author), Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.	jun-ichi_abe@urmc.rochester.edu		Yan, Chen/0000-0002-1397-6358	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL077789] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 077789-01A1] Funding Source: Medline; NIGMS NIH HHS [GM 071485-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akaike M, 2004, MOL CELL BIOL, V24, P8691, DOI 10.1128/MCB.24.19.8691-8704.2004; Amersi F, 2002, HEPATOLOGY, V35, P815, DOI 10.1053/jhep.2002.32467; Araujo JA, 2003, J IMMUNOL, V171, P1572, DOI 10.4049/jimmunol.171.3.1572; Barreiro E, 2002, AM J PHYSIOL-LUNG C, V283, pL476, DOI 10.1152/ajplung.00495.2001; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; Berger Joel, 2002, Diabetes Technol Ther, V4, P163, DOI 10.1089/15209150260007381; Bruce CR, 2003, DIABETES, V52, P2338, DOI 10.2337/diabetes.52.9.2338; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Camp HS, 1997, J BIOL CHEM, V272, P10811; Ceriello A, 2002, DIABETES, V51, P1076, DOI 10.2337/diabetes.51.4.1076; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; Elizalde M, 2000, J LIPID RES, V41, P1244; Grimaldi PA, 2005, BIOCHIMIE, V87, P5, DOI 10.1016/j.biochi.2004.11.009; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kawamura K, 2005, ARTERIOSCL THROM VAS, V25, P155, DOI 10.1161/01.ATV.0000148405.18071.6a; Lavrovsky Y, 2000, EXP GERONTOL, V35, P521, DOI 10.1016/S0531-5565(00)00118-2; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lerner-Marmarosh N, 2003, ARTERIOSCL THROM VAS, V23, P1775, DOI 10.1161/01.ATV.0000094432.98445.36; Letavernier E, 2005, J AM SOC NEPHROL, V16, P2395, DOI 10.1681/ASN.2004090802; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Morse D, 2003, J BIOL CHEM, V278, P36993, DOI 10.1074/jbc.M302942200; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Rival Y, 2002, EUR J PHARMACOL, V435, P143, DOI 10.1016/S0014-2999(01)01589-8; Ryter SW, 2002, MOL CELL BIOCHEM, V234, P249, DOI 10.1023/A:1015957026924; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sugita H, 2005, J BIOL CHEM, V280, P14203, DOI 10.1074/jbc.M411226200; Tannous M, 1999, DIABETOLOGIA, V42, P539, DOI 10.1007/s001250051192; Teng ZP, 2004, NEUROBIOL DIS, V17, P179, DOI 10.1016/j.nbd.2004.07.009; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; Thorup C, 1999, AM J PHYSIOL-RENAL, V277, pF882, DOI 10.1152/ajprenal.1999.277.6.F882; Tisdale MJ, 1997, J NATL CANCER I, V89, P1763, DOI 10.1093/jnci/89.23.1763; Torres SH, 2004, J ENDOCRINOL, V181, P419, DOI 10.1677/joe.0.1810419; Vulapalli SR, 2002, AM J PHYSIOL-HEART C, V283, pH688, DOI 10.1152/ajpheart.00133.2002; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200	48	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32164	32174		10.1074/jbc.M602369200	http://dx.doi.org/10.1074/jbc.M602369200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16943204	hybrid			2022-12-25	WOS:000241414500014
J	Gong, XQ; Shao, Q; Lounsbury, CS; Bai, DL; Laird, DW				Gong, Xiang-Qun; Shao, Qing; Lounsbury, Crystal S.; Bai, Donglin; Laird, Dale W.			Functional characterization of a GJA1 frameshift mutation causing oculodentodigital dysplasia and palmoplantar keratoderma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTO-DIGITAL DYSPLASIA; JUNCTIONAL INTERCELLULAR COMMUNICATION; NEONATAL MICE LACKING; CONNEXIN PHOSPHORYLATION; CONGENITAL CATARACT; MEMBRANE CHANNELS; TUMOR CELLS; CURLY HAIR; GAP; DISEASE	A frameshift mutation generated from a dinucleotide deletion (780-781del) in the GJA1 gene encoding Cx43 results in a frameshift yielding 46 aberrant amino acids after residue 259 and a shortened protein of 305 residues compared with the 382 in wild-type Cx43. This frameshift mutant (fs260) causes oculodentodigital dysplasia (ODDD) that includes the added condition of palmoplantar keratoderma. When expressed in a variety of cell lines, the fs260 mutant was typically localized to the endoplasmic reticulum and other intracellular compartments. The fs260 mutant, but not the G138R ODDD-linked Cx43 mutant or a Cx43 mutant truncated at residue 259 (T259), reduced the number of apparent gap junction plaques formed from endogenous Cx43 in normal rat kidney cells or keratinocytes. Interestingly, mutation of a putative FF endoplasmic reticulum retention motif encoded within the 46 aberrant amino acid domain failed to restore efficient assembly of the fs260 mutant into gap junctions. Dual whole cell patch-clamp recording revealed that fs260-expressing N2A cells exerted severely reduced electrical coupling in comparison to wild-type Cx43 or the T259 mutant, whereas single patch capacitance recordings showed that fs260 could also dominantly inhibit the function of wild-type Cx43. Co-expression studies further revealed that the dominant negative effect of fs260 on wild-type Cx43 was dose-dependent, and at a predicted 1:1 expression ratio the fs260 mutant reduced wild-type Cx43-mediated gap junctional conductance by over 60%. These results suggest that the 46 aberrant amino acid residues associated with the frameshift mutant are, at least in part, responsible for the manifestation of palmoplantar keratoderma symptoms.	Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Laird, DW (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, Dent Sci Bldg,Rm 00077, London, ON N6A 5C1, Canada.	dale.laird@schulich.uwo.ca	Laird, Dale w/E-4176-2015; Laird, Dale W/AAL-2407-2020; Bai, Donglin/A-5799-2008; Bai, Donglin/ABB-9924-2021	Laird, Dale W/0000-0002-4568-3285; Bai, Donglin/0000-0003-1112-6947; Bai, Donglin/0000-0003-1112-6947				Debeer P, 2005, EUR J MED GENET, V48, P377, DOI 10.1016/j.ejmg.2005.05.003; deRoos ADG, 1996, PFLUG ARCH EUR J PHY, V431, P556, DOI 10.1007/s004240050035; Duffy HS, 2002, J PHYSIOL-PARIS, V96, P243, DOI 10.1016/S0928-4257(02)00012-8; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; Flenniken AM, 2005, DEVELOPMENT, V132, P4375, DOI 10.1242/dev.02011; Frasson Maria, 2004, Ophthalmic Genet, V25, P227, DOI 10.1080/13816810490513424; Harks EGA, 2001, J PHARMACOL EXP THER, V298, P1033; Herve JC, 2004, BBA-BIOMEMBRANES, V1662, P22, DOI 10.1016/j.bbamem.2003.10.022; Kelly SC, 2006, EUR J DERMATOL, V16, P241; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; Kim DY, 1999, J BIOL CHEM, V274, P5581, DOI 10.1074/jbc.274.9.5581; Kjaer AW, 2004, AM J MED GENET A, V127A, P152, DOI 10.1002/ajmg.a.20614; Kretz M, 2004, EUR J CELL BIOL, V83, P647, DOI 10.1078/0171-9335-00422; Kumar NM, 1999, NOVART FDN SYMP, V219, P6; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Laird DW, 2005, BBA-BIOMEMBRANES, V1711, P172, DOI 10.1016/j.bbamem.2004.09.009; LAIRD DW, 1990, J CELL SCI, V97, P109; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Lan Z, 2005, BIOCHEMISTRY-US, V44, P2385, DOI 10.1021/bi048306w; Maass K, 2004, MOL BIOL CELL, V15, P4597, DOI 10.1091/mbc.E04-04-0324; Mackay D, 1999, AM J HUM GENET, V64, P1357, DOI 10.1086/302383; Maher AC, 2005, CELL COMMUN ADHES, V12, P219, DOI 10.1080/15419060500511818; McLachlan E, 2005, CELL COMMUN ADHES, V12, P279, DOI 10.1080/15419060500514143; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Minogue PJ, 2005, J BIOL CHEM, V280, P40788, DOI 10.1074/jbc.M504765200; Moreno AP, 2005, BBA-BIOMEMBRANES, V1711, P164, DOI 10.1016/j.bbamem.2005.02.016; Moreno AP, 2002, CIRC RES, V90, P450, DOI 10.1161/hh0402.105667; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Pal JD, 2000, AM J PHYSIOL-CELL PH, V279, pC596, DOI 10.1152/ajpcell.2000.279.3.C596; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; Pizzuti Antonio, 2004, Hum Mutat, V23, P286, DOI 10.1002/humu.9220; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Richard G, 2003, CLIN EXP DERMATOL, V28, P397, DOI 10.1046/j.1365-2230.2003.01312.x; Richardson RR, 2004, J MED GENET, V41, P60, DOI 10.1136/jmg.2003.012005; Roscoe W, 2005, J BIOL CHEM, V280, P11458, DOI 10.1074/jbc.M409564200; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Seki A, 2004, HEART RHYTHM, V1, P227, DOI 10.1016/j.hrthm.2004.03.066; Shibayama J, 2005, CIRC RES, V96, pE83, DOI 10.1161/01.RES.0000168369.79972.d2; Solan JL, 2005, BBA-BIOMEMBRANES, V1711, P154, DOI 10.1016/j.bbamem.2004.09.013; Thomas T, 2004, J BIOL CHEM, V279, P19157, DOI 10.1074/jbc.M314117200; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; van Steensel MAM, 2005, AM J MED GENET A, V132A, P171, DOI 10.1002/ajmg.a.30412; VanSlyke JK, 2002, J CELL BIOL, V157, P381, DOI 10.1083/jcb.200111045; Vasconcellos JPC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1422, DOI 10.1001/archopht.123.10.1422; Vitiello C, 2005, AM J MED GENET A, V133A, P58, DOI 10.1002/ajmg.a.30554; Wei CJ, 2004, ANNU REV CELL DEV BI, V20, P811, DOI 10.1146/annurev.cellbio.19.111301.144309; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076	51	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31801	31811		10.1074/jbc.M605961200	http://dx.doi.org/10.1074/jbc.M605961200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16891658	Bronze			2022-12-25	WOS:000241235300067
J	Mueller, M; Stamme, C; Draing, C; Hartung, T; Seydel, U; Schromm, AB				Mueller, Mareike; Stamme, Cordula; Draing, Christian; Hartung, Thomas; Seydel, Ulrich; Schromm, Andra B.			Cell activation of human macrophages by lipoteichoic acid is strongly attenuated by lipopolysaccharide-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-RESPONSES; TOLL-LIKE RECEPTORS; STAPHYLOCOCCUS-AUREUS; ANTIMICROBIAL SUSCEPTIBILITY; BACTERIAL PEPTIDOGLYCAN; (LPS)-BINDING PROTEIN; CYTOKINE INDUCTION; HUMAN MONOCYTES; SOLUBLE CD14; K+ CHANNEL	Lipoteichoic acid (LTA) represents immunostimulatory molecules expressed by Gram-positive bacteria. They activate the innate immune system via Toll-like receptors. We have investigated the role of serum proteins in activation of human macrophages by LTA from Staphylococcus aureus and found it to be strongly attenuated by serum. In contrast, the same cells showed a sensitive response to LTA and a significantly enhanced production of tumor necrosis factor alpha under serum-free conditions. We show that LTA interacts with the serum protein lipopolysaccharide-binding protein (LBP) and inhibits the integration of LBP into phospholipid membranes, indicating the formation of complexes of LTA and soluble LBP. The addition of recombinant human LBP to serum-free medium inhibited the production of tumor necrosis factor alpha and interleukins 6 and 8 after stimulation of human macrophages with LTA in a dose-dependent manner. Using anti-LBP antibodies, this inhibitory effect could be attributed to soluble LBP, whereas LBP in its recently described transmembrane configuration did not modulate cell activation. Also, using primary alveolar macrophages from rats, we show a sensitive cytokine response to LTA under serum-free culture conditions that was strongly attenuated in the presence of serum. In summary, our data suggest that innate immune recognition of LTA is organ-specific with negative regulation by LBP in serum-containing compartments and sensitive recognition in serum-free compartments like the lung.	Res Ctr Borstel, Dept Immunochem & Biochem Microbiol, Leibniz Ctr Med & Biosci, Div Biophys, D-23845 Borstel, Germany; Res Ctr Borstel, Dept Immunochem & Biochem Microbiol, Leibniz Ctr Med & Biosci, Div Cellular Pneumol, D-23845 Borstel, Germany; Res Ctr Borstel, Dept Immunochem & Biochem Microbiol, Leibniz Ctr Med & Biosci, Div Immunobiophys, D-23845 Borstel, Germany; Univ Konstanz, Dept Biochem Pharmacol, D-7750 Constance, Germany; Univ Lubeck, Dept Anaesthesiol, D-23538 Lubeck, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel; Forschungszentrum Borstel; University of Konstanz; University of Lubeck	Schromm, AB (corresponding author), Res Ctr Borstel, Dept Immunochem & Biochem Microbiol, Emmy Noether Grp Immunobiophys, Parkallee 10, D-23845 Borstel, Germany.	aschromm@fz-borstel.de	Schromm, Andra/O-3936-2018					Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Blondin C, 1997, EUR J IMMUNOL, V27, P3303, DOI 10.1002/eji.1830271229; Blunck R, 2001, J IMMUNOL, V166, P1009, DOI 10.4049/jimmunol.166.2.1009; Branger J, 2004, INT IMMUNOL, V16, P1605, DOI 10.1093/intimm/dxh161; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146, DOI 10.1165/ajrcmb.23.2.3855; Diekema DJ, 2000, INT J ANTIMICROB AG, V13, P257, DOI 10.1016/S0924-8579(99)00131-4; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Fluit AC, 2001, EUR J CLIN MICROBIOL, V20, P617; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; Gao JJ, 2001, INFECT IMMUN, V69, P751, DOI 10.1128/IAI.69.2.751-757.2001; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Gutsmann T, 2001, BIOL CHEM, V382, P425, DOI 10.1515/BC.2001.052; Gutsmann T, 2001, INFECT IMMUN, V69, P6942, DOI 10.1128/IAI.69.11.6942-6950.2001; Hamann L, 2005, INFECT IMMUN, V73, P193, DOI 10.1128/IAI.73.1.193-200.2005; HAZIOT A, 1988, J IMMUNOL, V141, P547; Heine H, 2003, EUR J IMMUNOL, V33, P1399, DOI 10.1002/eji.200323381; Henneke P, 2005, J IMMUNOL, V174, P6449, DOI 10.4049/jimmunol.174.10.6449; Hermann C, 2002, EUR J IMMUNOL, V32, P541, DOI 10.1002/1521-4141(200202)32:2<541::AID-IMMU541>3.0.CO;2-P; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Lehner MD, 2001, J IMMUNOL, V166, P5161, DOI 10.4049/jimmunol.166.8.5161; Lotz S, 2004, J LEUKOCYTE BIOL, V75, P467, DOI 10.1189/jlb.0803360; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; Martin TR, 2000, AM J RESP CELL MOL, V23, P128, DOI 10.1165/ajrcmb.23.2.f189; Morath S, 2002, J EXP MED, V195, P1635, DOI 10.1084/jem.20020322; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Mueller M, 2005, J IMMUNOL, V174, P1091, DOI 10.4049/jimmunol.174.2.1091; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; Pfaller MA, 1998, ANTIMICROB AGENTS CH, V42, P1762, DOI 10.1128/AAC.42.7.1762; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rietschel ET, 1998, MICROB DRUG RESIST, V4, P37, DOI 10.1089/mdr.1998.4.37; Schroder NWJ, 2004, J IMMUNOL, V173, P2683, DOI 10.4049/jimmunol.173.4.2683; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Schroder NWJ, 2000, J IMMUNOL, V165, P2683, DOI 10.4049/jimmunol.165.5.2683; Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x; Schromm AB, 1996, FEBS LETT, V399, P267, DOI 10.1016/S0014-5793(96)01338-5; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Seydel U, 2003, EUR J IMMUNOL, V33, P1586, DOI 10.1002/eji.200323649; Seydel U, 2001, J ENDOTOXIN RES, V7, P243, DOI 10.1177/09680519010070030901; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Stillwell M, 1989, Infect Dis Clin North Am, V3, P155; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Triantafilou M, 2004, BIOCHEM J, V381, P527, DOI 10.1042/BJ20040172; Villavicencio RT, 1996, AM J SURG, V172, P291, DOI 10.1016/S0002-9610(96)00102-X; Weber JR, 2003, IMMUNITY, V19, P269, DOI 10.1016/S1074-7613(03)00205-X; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wu YD, 2004, AM J RESP CELL MOL, V31, P587, DOI 10.1165/rcmb.2004-0003OC; Zweigner J, 2001, BLOOD, V98, P3800, DOI 10.1182/blood.V98.13.3800	56	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31448	31456		10.1074/jbc.M605966200	http://dx.doi.org/10.1074/jbc.M605966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16928689	Bronze			2022-12-25	WOS:000241235300029
J	Totani, K; Ihara, Y; Matsuo, I; Ito, Y				Totani, Kiichiro; Ihara, Yoshito; Matsuo, Ichiro; Ito, Yukishige			Substrate specificity analysis of endoplasmic reticulum glucosidase II using synthetic high mannose-type glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL GLUCOSIDASES; ER-ASSOCIATED DEGRADATION; MISFOLDED GLYCOPROTEINS; QUALITY-CONTROL; SUGAR CHAINS; RAT-LIVER; DIHYDROFOLATE-REDUCTASE; N-GLYCANS; PROTEIN; CALNEXIN	Glucosidase II (Glc'ase II) is a glycan-processing enzyme that trims two alpha 1,3-linked Glc residues in succession from the glycoprotein oligosaccharide Glc2Man9GlcNAc2 to give Glc1Man9GlcNAc2 and Man9GlcNAc2 in the endoplasmic reticulum (ER). Monoglucosylated glycans, such as Glc1Man9GlcNAc2, generated by this process play a key role in glycoprotein quality control in the ER, because they are primary ligands for the lectin chaperones calnexin (CNX) and calreticulin (CRT). A precise analysis of the substrate specificity of Glc'ase II is expected to further our understanding of the molecular basis to glycoprotein quality control, because Glc'ase II potentially competes with CNX/CRT for the same glycans, Glc1Man7-9GlcNAc2. In this study, a quantitative analysis of the specificity of Glc'ase II using a series of structurally defined synthetic glycans was carried out. In the presence of CRT, Glc'ase II-mediated trimming from Glc2Man9GlcNAc2 stopped at Glc1Man9GlcNAc2, supporting the notion that the glycan structure delivered to the CNX/CRT cycle is Glc1Man9GlcNAc2. Unexpectedly, our experiments showed that Glc1Man8(B)GlcNAc2 had nearly the same reactivity as Glc1Man9GlcNAc2, which was markedly greater than that of its positional isomer Glc1Man8(C) GlcNAc2. An analysis with glycoprotein-like probes revealed the stepwise formation of Glc1Man9GlcNAc2 and Man9GlcNAc2 from Glc2Man9GlcNAc2, even in the presence of CRT. It was also shown that Glc1Man8(B) GlcNAc2 had even greater reactivity than Glc1Man9GlcNAc2 at the glycoprotein level. Moreover, inhibitory activities by nonglucosylated glycans suggested that Glc'ase II recognized the C arm (Man alpha 1,2Man alpha 1,6Man-) of high man-nose-type glycans.	RIKEN, Wako, Saitama 3510198, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3321102, Japan; Nagasaki Univ, Dept Biochem & Mol Biol Dis, Atom Bomb Dis Inst, Grad Sch Biomed Sci, Nagasaki 8528523, Japan	RIKEN; Japan Science & Technology Agency (JST); Nagasaki University	Ito, Y (corresponding author), RIKEN, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	yukito@riken.jp	Ito, Yukishige/M-5119-2014; Ito, Yukishige/ACL-6203-2022	Ito, Yukishige/0000-0001-6251-7249; Ito, Yukishige/0000-0001-6251-7249				ALONSO JM, 1993, EUR J BIOCHEM, V215, P37, DOI 10.1111/j.1432-1033.1993.tb18004.x; APPLEMAN JR, 1988, J BIOL CHEM, V263, P9187; BALSH S, 1991, J BIOL CHEM, V266, P21458; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Deprez P, 2005, MOL CELL, V19, P183, DOI 10.1016/j.molcel.2005.05.029; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; GRINNA LS, 1979, J BIOL CHEM, V254, P8814; Hagihara S, 2005, J MED CHEM, V48, P3126, DOI 10.1021/jm0489511; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Ito Y, 2005, CURR OPIN STRUC BIOL, V15, P481, DOI 10.1016/j.sbi.2005.08.012; Jakob CA, 2001, EMBO REP, V2, P423; Jorgensen CS, 2000, EUR J BIOCHEM, V267, P2945, DOI 10.1046/j.1432-1033.2000.01309.x; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; KORNFELD S, 1978, J BIOL CHEM, V253, P7771; Matsuo I, 2003, J AM CHEM SOC, V125, P3402, DOI 10.1021/ja021288q; Matsuo I, 2003, CARBOHYD RES, V338, P2163, DOI 10.1016/S0008-6215(03)00357-4; Matsuo I, 2006, TETRAHEDRON, V62, P8262, DOI 10.1016/j.tet.2006.06.045; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Munro S, 2001, CURR BIOL, V11, pR499, DOI 10.1016/S0960-9822(01)00302-5; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Petrescu AJ, 1997, EMBO J, V16, P4302, DOI 10.1093/emboj/16.14.4302; Szathmary R, 2005, MOL CELL, V19, P765, DOI 10.1016/j.molcel.2005.08.015; Totani K, 2005, ANGEW CHEM INT EDIT, V44, P7950, DOI 10.1002/anie.200502723; Totani K, 2004, BIOORG MED CHEM LETT, V14, P2285, DOI 10.1016/j.bmcl.2004.01.106; Totani K, 2006, BIOORGAN MED CHEM, V14, P5220, DOI 10.1016/j.bmc.2006.04.001; Trombetta ES, 2005, METHODS, V35, P328, DOI 10.1016/j.ymeth.2004.10.004; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Trombetta ES, 2003, GLYCOBIOLOGY, V13, p77R, DOI 10.1093/glycob/cwg075; Trombetta ES, 2001, BIOCHEMISTRY-US, V40, P10717, DOI 10.1021/bi010629u; Wilkinson BM, 2006, J BIOL CHEM, V281, P6325, DOI 10.1074/jbc.M510455200; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890	39	84	85	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31502	31508		10.1074/jbc.M605457200	http://dx.doi.org/10.1074/jbc.M605457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16940048	Bronze			2022-12-25	WOS:000241235300035
J	Ichihara-Tanaka, K; Oohira, A; Rumsby, M; Muramatsu, T				Ichihara-Tanaka, Keiko; Oohira, Atsuhiko; Rumsby, Martin; Muramatsu, Takashi			Neuroglycan C is a novel midkine receptor involved in process elongation of oligodendroglial precursor-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; BINDING GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; PART-TIME PROTEOGLYCAN; DIFFERENTIATION FACTOR; PLEIOTROPHIN; BRAIN; EXPRESSION; SURVIVAL; CG-4	Midkine is a heparin-binding growth factor that promotes cell attachment and process extension in undifferentiated bipolar CG-4 cells, an oligodendroglial precursor cell line. We found that CG-4 cells expressed a non-proteoglycan form of neuroglycan C, known as a part-time transmembrane proteoglycan. We demonstrated that neuroglycan C before or after chondroitinase ABC treatment bound to a midkine affinity column. Neuroglycan C lacking chondroitin sulfate chains was eluted with 0.5 M NaCl as a major fraction from the column. We confirmed that CG-4 cells expressed two isoforms of neuroglycan C, I, and III, by isolating cDNA. Among three functional domains of the extracellular part of neuroglycan C, the chondroitin sulfate attachment domain and acidic amino acid cluster box domain showed affinity for midkine, but the epidermal growth factor domain did not. Furthermore, cell surface neuroglycan C could be cross-linked with soluble midkine. Process extension on midkine-coated dishes was inhibited by either a monoclonal antineuroglycan C antibody C1 or a glutathione S-transferase-neuroglycan C fusion protein. Finally, stable transfectants of B104 neuroblastoma cells overexpressing neuroglycan C-I or neuroglycan C-III attached to the midkine substrate, spread well, and gave rise to cytoskeletal changes. Based on these results, we conclude that neuroglycan C is a novel component of midkine receptors involved in process elongation.	Aichi Gakuin Univ, Dept Hlth Sci, Fac Psychol & Phys Sci, Aichi 4700198, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Human Serv Ctr, Dept Perinatol, Inst Dev Res, Kasugai, Aichi 4800392, Japan; Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England	Aichi Gakuin University; Nagoya University; University of York - UK	Muramatsu, T (corresponding author), Aichi Gakuin Univ, Dept Hlth Sci, Fac Psychol & Phys Sci, 12 Araike Cho, Aichi 4700198, Japan.	tmurama@dpc.aichi-gakuin.ac.jp	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				Akhter S, 1998, J BIOCHEM-TOKYO, V123, P1127; Aono S, 2006, J NEUROSCI RES, V83, P110, DOI 10.1002/jnr.20698; Aono S, 2000, J BIOL CHEM, V275, P337, DOI 10.1074/jbc.275.1.337; Aono S, 2004, J BIOL CHEM, V279, P46536, DOI 10.1074/jbc.M403263200; Horiba M, 2000, J CLIN INVEST, V105, P489, DOI 10.1172/JCI7208; ICHIHARATANAKA K, 1990, J BIOL CHEM, V265, P401; Inoh K, 2004, BIOCHEM BIOPH RES CO, V317, P108, DOI 10.1016/j.bbrc.2004.03.015; Juttner R, 2005, NEURON, V46, P233, DOI 10.1016/j.neuron.2005.02.027; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kawai H, 2004, AM J PATHOL, V165, P1603, DOI 10.1016/S0002-9440(10)63417-7; Kinugasa Y, 2004, BIOCHEM BIOPH RES CO, V321, P1045, DOI 10.1016/j.bbrc.2004.07.066; Kojima S, 1997, J BIOL CHEM, V272, P9410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maruyama K, 2004, ARTHRITIS RHEUM-US, V50, P1420, DOI 10.1002/art.20175; MATSUMOTO K, 1994, NEUROSCI LETT, V178, P216, DOI 10.1016/0304-3940(94)90762-5; Muramatsu H, 2004, J CELL SCI, V117, P5405, DOI 10.1242/jcs.01423; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Oohira A, 2004, GLYCOCONJUGATE J, V21, P53, DOI 10.1023/B:GLYC.0000043748.90896.83; Owada K, 1999, J NEUROCHEM, V73, P2084; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Rumsby M, 2001, NEUROSCI RES COMMUN, V28, P31, DOI 10.1002/1520-6769(200101/02)28:1<31::AID-NRC4>3.0.CO;2-F; Rumsby M, 1999, GLIA, V26, P361, DOI 10.1002/(SICI)1098-1136(199906)26:4<361::AID-GLIA10>3.0.CO;2-Q; Sakaguchi N, 2003, NEUROSCI RES, V45, P219, DOI 10.1016/S0168-0102(02)00226-2; Sato W, 2001, J IMMUNOL, V167, P3463, DOI 10.4049/jimmunol.167.6.3463; Shuo T, 2003, GLYCOCONJUGATE J, V20, P267, DOI 10.1023/B:GLYC.0000025821.22618.33; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trinczek B, 2004, J BIOL CHEM, V279, P5915, DOI 10.1074/jbc.M304528200; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; Yamauchi S, 2002, J BIOL CHEM, V277, P20583, DOI 10.1074/jbc.M200909200; Yasuda Y, 1998, NEUROSCI RES, V32, P313, DOI 10.1016/S0168-0102(98)00098-4; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	40	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30857	30864		10.1074/jbc.M602228200	http://dx.doi.org/10.1074/jbc.M602228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16901907	hybrid			2022-12-25	WOS:000241075900061
J	Kihara, M; Chatani, E; Iwata, K; Yamamoto, K; Matsuura, T; Nakagawa, A; Naiki, H; Goto, Y				Kihara, Miho; Chatani, Eri; Iwata, Kentaro; Yamamoto, Kaori; Matsuura, Takanori; Nakagawa, Atsushi; Naiki, Hironobu; Goto, Yuji			Conformation of amyloid fibrils of beta(2)-microglobulin probed by tryptophan mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-MICROGLOBULIN REVEALS; PROTEIN; MATURATION; EXTENSION; PROGRAM; SULFATE; MODEL; CHAIN	beta(2)-Microglobulin (beta 2-m), a protein responsible for dialysis-related amyloidosis, adopts an immunoglobulin domain fold in its native state. Although beta 2-m has Trp residues at positions 60 and 95, both are located near the surface of the domain. Hence, beta 2-m does not have a conserved Trp common to other immunoglobulin domains, which is buried in close proximity to the disulfide bond. To study the structure of amyloid fibrils in relation to their native fold, we prepared a series of Trp mutants. Trp(60) and Trp(95) were both replaced with Phe, and a single Trp was introduced at various positions. Among various mutants, W39-beta 2-m, in which a Trp was introduced at the position corresponding to the conserved Trp, exhibited a remarkable quenching of fluorescence in the native state, as observed for other immunoglobulin domains. An x-ray structural analysis revealed that W39-beta 2-m assumes the native fold with Trp39 located in the vicinity of the disulfide bond. Comparison of the fluorescence spectra of various mutants for the native and fibrillar forms indicated that, while the Trp residues introduced in the middle of the beta 2-m sequence tend to be buried in the fibrils, those located in the C-terminal region are more exposed. In addition, the fluorescence spectra of fibrils prepared at pH 2.5 and 7.0 revealed a large difference in the fluorescence intensity for W60-beta 2-m, implying a major structural difference between them.	Osaka Univ, Inst Prot Res, Suita, Osaka 565, Japan; Japan Sci & Technol Agcy, CREST, Suita, Osaka 5650871, Japan; Univ Fukui, Fac Med Sci, Dept Pathol Sci, Matsuoka, Fukui 9101193, Japan; Japan Sci & Technol Agcy, CREST, Matsuoka, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Suita, Osaka 565, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014; Nakagawa, Atsushi/D-4329-2009; Nakagawa, Atsushi/M-5731-2019; Matsuura, Takanori/J-1413-2012	Nakagawa, Atsushi/0000-0002-1700-7861; Nakagawa, Atsushi/0000-0002-1700-7861; Matsuura, Takanori/0000-0003-2001-9537				AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ban T, 2004, J MOL BIOL, V344, P757, DOI 10.1016/j.jmb.2004.09.078; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chatani E, 2005, J MOL BIOL, V352, P941, DOI 10.1016/j.jmb.2005.07.043; Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; Corazza A, 2004, J BIOL CHEM, V279, P9176, DOI 10.1074/jbc.M310779200; COWGILL RW, 1970, BIOCHIM BIOPHYS ACTA, V207, P556; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dzwolak W, 2004, PROTEIN SCI, V13, P1927, DOI 10.1110/ps.03607204; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Floege J, 2001, KIDNEY INT, V59, pS164, DOI 10.1046/j.1523-1755.2001.59780164.x; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GOTO Y, 1988, BIOCHEMISTRY-US, V27, P1670, DOI 10.1021/bi00405a043; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Ivanova MI, 2004, P NATL ACAD SCI USA, V101, P10584, DOI 10.1073/pnas.0403756101; Jones EM, 2005, CELL, V121, P63, DOI 10.1016/j.cell.2005.01.034; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kihara M, 2005, J BIOL CHEM, V280, P12012, DOI 10.1074/jbc.M411949200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; MCPHERSON A, 1992, J CRYST GROWTH, V122, P161, DOI 10.1016/0022-0248(92)90239-F; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; Narimoto T, 2004, FEBS LETT, V576, P313, DOI 10.1016/j.febslet.2004.09.024; Ohhashi Y, 2005, J BIOL CHEM, V280, P32843, DOI 10.1074/jbc.M506501200; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Tanaka M, 2005, CELL, V121, P49, DOI 10.1016/j.cell.2005.03.008; Trinh CH, 2002, P NATL ACAD SCI USA, V99, P9771, DOI 10.1073/pnas.152337399; TSUNENAGA M, 1987, BIOCHEMISTRY-US, V26, P6044, DOI 10.1021/bi00393a015; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Verdone G, 2002, PROTEIN SCI, V11, P487, DOI 10.1110/ps.29002; Yamaguchi K, 2005, J MOL BIOL, V352, P952, DOI 10.1016/j.jmb.2005.07.061; Yamamoto S, 2004, BIOCHEMISTRY-US, V43, P11075, DOI 10.1021/bi049262u	43	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					31061	31069		10.1074/jbc.M605358200	http://dx.doi.org/10.1074/jbc.M605358200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16901902	hybrid			2022-12-25	WOS:000241075900082
J	Saura, M; Zaragoza, C; Bao, C; Herranz, B; Rodriguez-Puyol, M; Lowenstein, CJ				Saura, Marta; Zaragoza, Carlos; Bao, Clare; Herranz, Beatriz; Rodriguez-Puyol, M.; Lowenstein, Charles J.			Stat3 mediates interelukin-6 inhibition of human endothelial nitric-oxide synthase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; MESSENGER-RNA; GROWTH-FACTOR; GENE; INFLAMMATION; RISK; TRANSCRIPTION	Chronic activation of the acute phase response (APR) is associated with atherosclerosis. Elevated levels of interleukin-6, the major inducer of the APR, are associated with an increased risk of cardiovascular events. One of the clinical hallmarks of atherogenesis is endothelial dysfunction, characterized by a decrease in endothelial production of nitric oxide ( NO). We hypothesized that interleukin-6 (IL-6) decreases endothelial NO synthase ( eNOS) expression. We now show that IL-6 treatment of human aortic endothelial cells ( HAEC) decreases steady-state levels of human eNOS mRNA and protein. This decrease in eNOS expression is caused in part by IL-6 inhibition of transactivation of the human eNOS promoter. To explore the mechanism by which IL-6 affects eNOS expression, we examined activation of signal transducer and transactivator-3 (Stat3). The IL-6 receptor (IL-6R) is expressed in HAEC, and Stat3 is phosphorylated in response to IL-6 stimulation of the IL-6R. We identified four consensus sequences for Stat3 binding (SIE) in the eNOS promoter at positions -1520, -1024, -840, and -540. Transfection of eNOS promoter mutants revealed that the SIE at -1024 mediates Stat3 inhibition of eNOS promoter activity. Gel-shift analysis of nuclear extracts from HAEC treated with IL-6 confirms that Stat3 binds to a complex containing the SIE at -1024. RNA silencing of STAT3 blocks the inhibitory effect of IL-6 on eNOS expression. Our data show that IL-6 has direct effects upon endothelial cells, inhibiting eNOS expression in part through Stat3. Decreased levels of eNOS may be an important component of the pro-atherogenic effect of the APR.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Univ Alcala de Henares, Dept Physiol, Madrid 28871, Spain; CNIC, Madrid 28760, Spain	Johns Hopkins University; Universidad de Alcala; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Lowenstein, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 950 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	clowenst@jhmi.edu	Puyol, Manuel Rodriguez/AAG-7049-2020; Zaragoza Sanchez, Carlos/G-8718-2011; Zaragoza, Carlos/AAH-9275-2019	Puyol, Manuel Rodriguez/0000-0002-5230-6664; Lowenstein, Charles/0000-0003-0485-7514; Zaragoza, Carlos/0000-0002-1706-8592; Herranz Sanchez, Beatriz/0000-0002-7847-7058	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL065608, P01HL056091, R01HL074061, R01HL063706] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Alonso J, 1997, MOL CELL BIOL, V17, P5719, DOI 10.1128/MCB.17.10.5719; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Desiderio S, 2003, ANN NY ACAD SCI, V987, P280, DOI 10.1111/j.1749-6632.2003.tb06062.x; Dudzinski DM, 2006, ANNU REV PHARMACOL, V46, P235, DOI 10.1146/annurev.pharmtox.44.101802.121844; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; Paffen E, 2006, CARDIOVASC RES, V71, P30, DOI 10.1016/j.cardiores.2006.03.004; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Rader DJ, 2000, NEW ENGL J MED, V343, P1179, DOI 10.1056/NEJM200010193431609; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; Saura M, 2002, CIRC RES, V91, P806, DOI 10.1161/01.RES.0000040397.23817.E5; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEARLES CD, 2006, IN PRESS AM J PHYSL; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Venugopal SK, 2002, CIRCULATION, V106, P1439, DOI 10.1161/01.CIR.0000033116.22237.F9; Verma S, 2005, NAT CLIN PRACT CARD, V2, P29, DOI 10.1038/ncpcardio0074; Verma S, 2002, CIRCULATION, V106, P913, DOI 10.1161/01.CIR.0000029802.88087.5E; Walford G, 2003, J THROMB HAEMOST, V1, P2112, DOI 10.1046/j.1538-7836.2003.00345.x; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	43	63	64	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30057	30062		10.1074/jbc.M606279200	http://dx.doi.org/10.1074/jbc.M606279200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16887796	hybrid			2022-12-25	WOS:000240896300066
J	Veereshwarayya, V; Kumar, P; Rosen, KM; Mestril, R; Querfurth, HW				Veereshwarayya, Vimal; Kumar, Pravir; Rosen, Kenneth M.; Mestril, Ruben; Querfurth, Henry W.			Differential effects of mitochondrial heat shock protein 60 and related molecular chaperones to prevent intracellular beta-amyloid-induced inhibition of complex IV and limit apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ALZHEIMERS-DISEASE; CELL-DEATH; A-BETA; CYTOCHROME-OXIDASE; DROSOPHILA; BRAIN; SUPPRESSION; EXPRESSION; NEURONS	Defects in mitochondrial oxidative metabolism, in particular decreased activity of cytochrome c oxidase, have been reported in Alzheimer disease tissue and in cultured cells that overexpress amyloid precursor protein. Mitochondrial dysfunction contributes to neurodegeneration in Alzheimer disease partly through formation of reactive oxygen species and the release of sequestered molecules that initiate programmed cell death pathways. The heat shock proteins (HSP) are cytoprotective against a number of stressors, including accumulations of mis-folded proteins and reactive oxygen species. We reported on the property of Hsp70 to protect cultured neurons from cell death caused by intraneuronal beta-amyloid. Here we demonstrate that Hsp60, Hsp70, and Hsp90 both alone and in combination provide differential protection against intracellular beta-amyloid stress through the maintenance of mitochondrial oxidative phosphorylation and functionality of tricarboxylic acid cycle enzymes. Notably, beta-amyloid was found to selectively inhibit complex IV activity, an effect selectively neutralized by Hsp60. The combined effect of HSPs was to reduce the free radical burden, preserve ATP generation, decrease cytochrome c release, and prevent caspase-9 activation, all important mediators of beta-amyloid-induced neuronal dysfunction and death.	Tufts Univ, Sch Med, Caritas St Elizabeths Med Ctr, Dept Neurol, Brighton, MA 02135 USA; Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA	St. Elizabeth's Medical Center; Tufts University; Loyola University Chicago	Querfurth, HW (corresponding author), Tufts Univ, Sch Med, Caritas St Elizabeths Med Ctr, Dept Neurol, 736 Cambridge St, Brighton, MA 02135 USA.	henry.querfurth@tufts.edu	Kumar, Pravir/AAR-1207-2020; Kumar, Pravir/B-2164-2015	Kumar, Pravir/0000-0001-7444-2344; Mestril, Ruben/0000-0003-3631-2236	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041373] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41373] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; BUTTERWORTH RF, 1990, METAB BRAIN DIS, V5, P179, DOI 10.1007/BF00997071; Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x; Caspersen C, 2005, FASEB J, V19, P2040, DOI 10.1096/fj.05-3735fje; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Glabe CC, 2005, SUB CELL BIOCHEM, V38, P167; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hongpaisan J, 2004, J NEUROSCI, V24, P10878, DOI 10.1523/JNEUROSCI.3278-04.2004; HOSOKAWA N, 1990, CELL STRUCT FUNCT, V15, P393, DOI 10.1247/csf.15.393; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Ibanez V, 1998, NEUROLOGY, V50, P1585, DOI 10.1212/WNL.50.6.1585; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; LeBlanc Andrea C., 2005, Current Alzheimer Research, V2, P389, DOI 10.2174/156720505774330573; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; Manfredi G, 2001, METHOD CELL BIOL, V65, P133, DOI 10.1016/S0091-679X(01)65008-8; Mark RJ, 1997, J NEUROCHEM, V68, P255; Mastrogiacomo F, 1996, ANN NEUROL, V39, P592, DOI 10.1002/ana.410390508; Mattson MP, 1998, INT REV NEUROBIOL, V42, P103, DOI 10.1016/S0074-7742(08)60609-1; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; Nollen EAA, 1999, MOL CELL BIOL, V19, P2069; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; Pereira C, 1999, NEUROBIOL DIS, V6, P209, DOI 10.1006/nbdi.1999.0241; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Perkins G, 1997, J STRUCT BIOL, V119, P260, DOI 10.1006/jsbi.1997.3885; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Rong Y, 2000, ANTICANCER RES, V20, P4339; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; SIMS NR, 1987, BRAIN RES, V436, P30, DOI 10.1016/0006-8993(87)91553-8; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SORBI S, 1983, ANN NEUROL, V13, P72, DOI 10.1002/ana.410130116; Swerdlow RH, 2002, INT REV NEUROBIOL, V53, P341; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; VEERESHWARAYYA V, 2005, 35 ANN M SOC NEUR WA; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Zamostiano R, 1999, NEUROSCI LETT, V264, P9, DOI 10.1016/S0304-3940(99)00168-8	52	105	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29468	29478		10.1074/jbc.M602533200	http://dx.doi.org/10.1074/jbc.M602533200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16887805	hybrid			2022-12-25	WOS:000240896300009
J	Yorimitsu, T; Nair, U; Yang, ZF; Klionsky, DJ				Yorimitsu, Tomohiro; Nair, Usha; Yang, Zhifen; Klionsky, Daniel J.			Endoplasmic reticulum stress triggers autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLE TARGETING PATHWAY; UNFOLDED-PROTEIN RESPONSE; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; MOLECULAR MACHINERY; YEAST VACUOLE; CYTOPLASM; DEGRADATION; VESICLE; CARGO	Eukaryotic cells have evolved strategies to respond to stress conditions. For example, autophagy in yeast is primarily a response to the stress of nutrient limitation. Autophagy is a catabolic process for the degradation and recycling of cytosolic, long lived, or aggregated proteins and excess or defective organelles. In this study, we demonstrate a new pathway for the induction of autophagy. In the endoplasmic reticulum ( ER), accumulation of misfolded proteins causes stress and activates the unfolded protein response to induce the expression of chaperones and proteins involved in the recovery process. ER stress stimulated the assembly of the pre-autophagosomal structure. In addition, autophagosome formation and transport to the vacuole were stimulated in an Atg protein-dependent manner. Finally, Atg1 kinase activity reflects both the nutritional status and autophagic state of the cell; starvation-induced autophagy results in increased Atg1 kinase activity. We found that Atg1 had high kinase activity during ER stress-induced autophagy. Together, these results indicate that ER stress can induce an autophagic response.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Klionsky, DJ (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	klionsky@umich.edu			NIGMS NIH HHS [GM53396, R01 GM053396] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413; Back SH, 2005, METHODS, V35, P395, DOI 10.1016/j.ymeth.2005.03.001; Budovskaya YV, 2005, P NATL ACAD SCI USA, V102, P13933, DOI 10.1073/pnas.0501046102; Cheong H, 2005, MOL BIOL CELL, V16, P3438, DOI 10.1091/mbc.E04-10-0894; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Hamasaki M, 2005, TRAFFIC, V6, P56, DOI 10.1111/j.1600-0854.2004.00245.x; Hamasaki M, 2003, CELL STRUCT FUNCT, V28, P49; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Hutchins MU, 2001, J BIOL CHEM, V276, P20491, DOI 10.1074/jbc.M101150200; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Iwata A, 2005, P NATL ACAD SCI USA, V102, P13135, DOI 10.1073/pnas.0505801102; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; KOUROKU Y, 2006, IN PRESS CELL DEATH; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Reggiori F, 2004, MOL BIOL CELL, V15, P2189, DOI 10.1091/mbc.E03-07-0479; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Shintani T, 2004, J BIOL CHEM, V279, P29889, DOI 10.1074/jbc.M404399200; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Shintani T, 2002, DEV CELL, V3, P825, DOI 10.1016/S1534-5807(02)00373-8; Spear ED, 2003, MOL BIOL CELL, V14, P2756, DOI 10.1091/mbc.E02-11-0717; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Yorimitsu T, 2005, MOL BIOL CELL, V16, P1593, DOI 10.1091/mbc.E04-11-1035	44	772	802	2	83	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30299	30304		10.1074/jbc.M607007200	http://dx.doi.org/10.1074/jbc.M607007200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16901900	Green Accepted, hybrid			2022-12-25	WOS:000240896300090
J	Spruill, LS; McDermott, PJ				Spruill, Laura S.; McDermott, Paul J.			Regulation of c-jun mRNA expression in adult cardiocytes by MAP kinase interacting kinase-1 (MNK1)	FASEB JOURNAL			English	Article						cardiac hypertrophy; translation; eIF4E; protein synthesis; mRNA stability	INITIATION-FACTOR 4E; ELECTRICALLY STIMULATED CONTRACTION; ACTIVATED PROTEIN-KINASES; GENE-EXPRESSION; SYNTHESIS RATES; FACTOR EIF-4E; PHOSPHORYLATION; TRANSLATION; EIF4E; MECHANISMS	Hypertrophic growth of adult myocardium is associated with increased expression of the early response gene c-jun. The purpose of this study was to determine whether eukaryotic initiation factor (elF) 4E (eIF4E) regulates translational efficiency of c-jun mRNA as measured by flux into polysomes. Adult feline cardiomyocytes in primary culture were treated with 0.2 mu M 12-O-tetradecanoylphorbol 13-acetate (TPA), and c-jun mRNA was quantified in total, monosome, and polysome fractions by real-time polymerase chain reaction. After 1 h, TPA increased total c-jun mRNA by 10.5-fold. The corresponding flux into polysomes was significantly lower (5-fold). Adenoviral-mediated overexpression of either eIF4E or a nonphosphorylatable mutant (S209/A) did not affect total c-jun mRNA or its flux between monosomes and polysomes. Similar results were obtained following overexpression of the eIF4E kinase Mnk1. Thus, translational efficiency of c-jun mRNA was not affected by changes in activity or amount of eIF4E. In contrast, a kinase-deficient Mnk1 mutant significantly reduced total c-jun mRNA from 9.8-fold to 6.0-fold while flux between monosomes and polysomes remained constant. The decrease in total c-jun mRNA resulted from increased decay of c-jun mRNA incorporated into the polysomes. We conclude that Mnk1 activity stabilizes c-jun mRNA in polysomes independent of eIF4E phosphorylation.	Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Charleston, SC 29403 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	McDermott, PJ (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Strom Thurmond Biomed Res Bldg,Rm 303,114 Dohty, Charleston, SC 29403 USA.	mcdermp@musc.edu			NHLBI NIH HHS [P01 HL-48788] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berenji K, 2005, AM J PHYSIOL-HEART C, V289, pH8, DOI 10.1152/ajpheart.01303.2004; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; Davuluri RV, 2000, GENOME RES, V10, P1807, DOI 10.1101/gr.GR-1460R; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Hannan RD, 2003, CLIN EXP PHARMACOL P, V30, P517, DOI 10.1046/j.1440-1681.2003.03873.x; IVESTER CT, 1995, J BIOL CHEM, V270, P21950, DOI 10.1074/jbc.270.37.21950; IVESTER CT, 1993, AM J PHYSIOL, V265, pH666; KATO S, 1995, AM J PHYSIOL-HEART C, V268, pH2495; Kayahara M, 2005, MOL CELL BIOL, V25, P3784, DOI 10.1128/MCB.25.9.3784-3792.2005; Kim-Mitsuyama S, 2006, GENE THER, V13, P348, DOI 10.1038/sj.gt.3302670; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; MADER S, 1995, MOL CELL BIOL, V15, P4990; MARINO TA, 1985, AM J PHYSIOL, V249, pH371, DOI 10.1152/ajpheart.1985.249.2.H371; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; Morgan HE, 1997, MOL CELL BIOCHEM, V176, P145, DOI 10.1023/A:1006855818855; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nadruz W, 2004, AM J PHYSIOL-HEART C, V286, pH760, DOI 10.1152/ajpheart.00430.2003; Nadruz W, 2003, CIRC RES, V92, P243, DOI 10.1161/01.RES.0000053184.94618.97; Nagatomo Y, 1999, AM J PHYSIOL-HEART C, V277, pH2176; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Ramirez CV, 2002, J MOL BIOL, V318, P951, DOI 10.1016/S0022-2836(02)00162-6; Saghir AN, 2001, BIOCHEM J, V356, P557, DOI 10.1042/0264-6021:3560557; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; Taimor G, 2004, AM J PHYSIOL-HEART C, V286, pH2369, DOI 10.1152/ajpheart.00741.2003; Tourriere H, 2002, BIOCHIMIE, V84, P821, DOI 10.1016/S0300-9084(02)01445-1; Tuxworth WJ, 2004, BIOCHEM J, V378, P73, DOI 10.1042/BJ20031027; Tuxworth WJ, 1999, AM J PHYSIOL-HEART C, V277, pH1273, DOI 10.1152/ajpheart.1999.277.4.H1273; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; Wagner RA, 2004, J MOL CELL CARDIOL, V37, P1159, DOI 10.1016/j.yjmcc.2004.09.003; Wang LJ, 2000, AM J PHYSIOL-HEART C, V278, pH1056, DOI 10.1152/ajpheart.2000.278.4.H1056; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Zhao MM, 2004, PHYSIOL GENOMICS, V19, P93, DOI 10.1152/physiolgenomics.00040.2004; Zuberek J, 2003, RNA, V9, P52, DOI 10.1261/rna.2133403; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	48	8	8	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2133	+		10.1096/fj.06-6245fje	http://dx.doi.org/10.1096/fj.06-6245fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16940435				2022-12-25	WOS:000241156900033
J	Jian, JL; Zhu, CS; Xu, ZW; Ouyang, WM; Ma, DC; Zhang, Y; Chen, LJ; Yang, AG; Jin, BQ				Jian, Jin-Long; Zhu, Can-Sheng; Xu, Zhu-Wei; Ouyang, Wei-Ming; Ma, Dong-Chu; Zhang, Yuan; Chen, Li-Jie; Yang, An-Gang; Jin, Bo-Quan			Identification and characterization of the CD226 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL DIFFERENTIATION; NKT CELLS; DNAM-1; AP-1; ACTIVATION; ADHESION; PLATELET; TLISA1; TPA; LYMPHOCYTES	CD226 is one of the main activating receptors on natural killer cells, and it can induce cytotoxicity to target cells through interaction with its ligands CD155 or CD112. CD226 is also involved in T cell differentiation, activation, and cytotoxicity. The expression of CD226 on natural killer cells and T cells can be regulated by cytokines and chemical stimuli; however, the mechanism of the regulation of the CD226 gene is still unknown. In this study, we have identified two promoters in the human CD226 gene named P1 and P2, which are located at -810 to -287 bp and +33 to +213 bp, respectively, and a negative regulation element between P1 and P2. Both P1 and P2 can be regulated by phorbol ester (12-O-tetradecanoylphorbol-13-acetate) and calcium ionophore (A23187). Bioinformatics analysis shows that, within this CD226 gene region, there are putative binding sites for transcription factors AP-1, Sp1, PEA3, and Ets-1. We have found that transcription factor activating protein-1 (AP-1) can up-regulate CD226 promoters P1 and P2 in human hepatocarcinoma cells, a hepatocarcinoma cell line with low expression of endogenous AP-1 and Ets-1. Interestingly, the transcription factor Ets-1 promotes AP-1-induced P2 activity but inhibits AP-1-induced P1 activity for which a 10-bp AP-1/Ets-1 composite site (CCTTCCTTCC) in P1 may be responsible.	Fourth Mil Med Univ, Dept Immunol, Xian 710032, Shannxi Provinc, Peoples R China; No Hosp, Dept Expt Med, Shenyang 110015, Liaoning Provin, Peoples R China	Air Force Military Medical University	Jin, BQ (corresponding author), Fourth Mil Med Univ, Dept Immunol, 17 Changle Rd, Xian 710032, Shannxi Provinc, Peoples R China.	immu_jin@fmmu.edu.cn		Ma, Dongchu/0000-0002-3229-9719				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; BURNS GF, 1985, J EXP MED, V161, P1063, DOI 10.1084/jem.161.5.1063; Castriconi R, 2004, CANCER RES, V64, P9180, DOI 10.1158/0008-5472.CAN-04-2682; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; Deng T, 2005, J IMMUNOL, V174, P1281, DOI 10.4049/jimmunol.174.3.1281; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hai M, 2001, J NEUROSCI RES, V65, P508, DOI 10.1002/jnr.1181; JIN B, 1989, IMMUNOLOGY, V66, P570; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kojima H, 2003, J BIOL CHEM, V278, P36748, DOI 10.1074/jbc.M300702200; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Ma DC, 2005, EUR J HAEMATOL, V74, P228, DOI 10.1111/j.1600-0609.2004.00345.x; Pende D, 2005, BLOOD, V105, P2066, DOI 10.1182/blood-2004-09-3548; Ralston KJ, 2004, J BIOL CHEM, V279, P33816, DOI 10.1074/jbc.M401040200; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; SCOTT JL, 1989, J BIOL CHEM, V264, P13475; Sherrington PD, 1997, J BIOL CHEM, V272, P21735, DOI 10.1074/jbc.272.35.21735; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya A, 1998, J IMMUNOL, V161, P1671; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; Shibuya K, 2003, J EXP MED, V198, P1829, DOI 10.1084/jem.20030958; Shirakawa J, 2005, INT IMMUNOL, V17, P217, DOI 10.1093/intimm/dxh199; Tao L, 2001, J CELL BIOCHEM, V82, P522, DOI 10.1002/jcb.1173; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Xiao ZS, 2003, J CELL BIOCHEM, V88, P493, DOI 10.1002/jcb.10375; Yang S, 2005, J IMMUNOL, V175, P4914, DOI 10.4049/jimmunol.175.8.4914	29	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28731	28736		10.1074/jbc.M601786200	http://dx.doi.org/10.1074/jbc.M601786200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16887814	hybrid			2022-12-25	WOS:000240680500026
J	Lee, MG; Huh, JS; Chung, SK; Lee, JH; Byun, DS; Ryu, BK; Kang, MJ; Chae, KS; Lee, SJ; Lee, CH; Kim, JI; Chang, SG; Chi, SG				Lee, M. -G; Huh, J. -S; Chung, S. -K; Lee, J. -H; Byun, D. -S; Ryu, B. -K; Kang, M. -J; Chae, K. -S; Lee, S. -J; Lee, C. -H; Kim, J. I.; Chang, S. -G; Chi, S. -G			Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses	ONCOGENE			English	Article						xAF1; promoter hypermethylation; CpG site; urogenital cancer; apoptosis; p53	XIAP-ASSOCIATED FACTOR-1; HUMAN BLADDER-CANCER; X-LINKED INHIBITOR; IAP; GENE; PROTEINS; CELLS; FAMILY; IDENTIFICATION; IMMUNOTHERAPY	XIAP-associated factor 1 (XAF1) is a new candidate tumor suppressor, which has been known to exert proapoptotic effects by interfering with the caspase-inhibiting activity of XIAP. To explore the XAF1' s candidacy for a suppressor in urogenital tumorigenesis, we investigated the XAF1 status in a series of cancer cell lines and primary tumors derived from the bladder, kidney and prostate. Expression of XAF1 transcript was undetectable or extremely low in 60% (3/5) of bladder, 66% (10/15) of kidney, and 100% (3/3) prostate cancer cell lines. Abnormal reduction of XAF1 was also found in 33% (18/55) of primary bladder and 40% (8/20) of primary kidney tumors, and showed a correlation with advanced stage and high grade of bladder tumor. Hypermethylation at 14 CpG sites in the 50 proximal region of the XAF1 promoter was highly prevalent in cancers versus adjacent normal or benign tissues and tightly associated with reduced gene expression. XAF1 expression enhanced the apoptotic response of tumor cells to chemotherapeutic agents, such as etoposide or 5-FU. While XAF1 expression did not influence the subcellular distribution or expression of XIAP, it elevated the protein stability of p53 and its target gene expression. Moreover, the apoptosis-sensitizing and growth suppression function of XAF1 was markedly impeded by blockade of p53 function. Collectively, our study demonstrates that epigenetic alteration of XAF1 is frequent in human urogenital cancers and may contribute to the malignant progression of tumors by rendering tumor cells a survival advantage partially through the attenuated p53 response to apoptotic stresses.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Jeju Natl Univ, Coll Med, Dept Urol, Cheju, South Korea; Kyung Hee Univ, Sch Med, Dept Urol, Seoul, South Korea	Korea University; Jeju National University; Kyung Hee University	Chi, SG (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	chi6302@korea.ac.kr	Kang, Min-Ju/AAY-8706-2021	KANG, MIN-JU/0000-0001-5040-1388				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asselin E, 2001, CANCER RES, V61, P1862; Benedict WF, 2004, MOL THER, V10, P525, DOI 10.1016/j.ymthe.2004.05.027; Byun DS, 2003, CANCER RES, V63, P7068; Chi SG, 1998, GASTROENTEROLOGY, V115, P1084, DOI 10.1016/S0016-5085(98)70078-2; Chi SG, 1999, CANCER RES, V59, P2791; CHI SG, 1994, J NATL CANCER I, V86, P926, DOI 10.1093/jnci/86.12.926; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; JACKSON AM, 1995, CLIN EXP IMMUNOL, V99, P369, DOI 10.1111/j.1365-2249.1995.tb05560.x; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Lee MG, 2001, CANCER RES, V61, P6688; Li J, 1998, ENDOCRINOLOGY, V139, P1321, DOI 10.1210/en.139.3.1321; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Ludwig AT, 2004, CANCER RES, V64, P3386, DOI 10.1158/0008-5472.CAN-04-0374; Luo Y, 1999, J IMMUNOL, V162, P2399; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Papageorgiou A, 2004, CANCER RES, V64, P8973, DOI 10.1158/0008-5472.CAN-04-1909; Perrelet D, 2004, J NEUROSCI, V24, P3777, DOI 10.1523/JNEUROSCI.0413-04.2004; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sasaki H, 2000, CANCER RES, V60, P5659; Siegelin M, 2005, NEUROBIOL DIS, V20, P509, DOI 10.1016/j.nbd.2005.04.006; Steidl C, 2002, J PATHOL, V198, P115, DOI 10.1002/path.1175; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tamm I, 2000, CLIN CANCER RES, V6, P1796; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Tricoli JV, 1996, GENE CHROMOSOME CANC, V15, P108, DOI 10.1002/(SICI)1098-2264(199602)15:2<108::AID-GCC5>3.0.CO;2-7; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X	37	68	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5807	5822		10.1038/sj.onc.1209867	http://dx.doi.org/10.1038/sj.onc.1209867			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16909101				2022-12-25	WOS:000240765800011
J	Yang, MH; Chang, SY; Chiou, SH; Liu, CJ; Chi, CW; Chen, PM; Teng, SC; Wu, KJ				Yang, M-H; Chang, S-Y; Chiou, S-H; Liu, C-J; Chi, C-W; Chen, P-M; Teng, S-C; Wu, K-J			Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer	ONCOGENE			English	Article						head and neck cancer; epithelial-mesenchymal transition; metastasis; NBS1; Snail	TRANSCRIPTION FACTOR SNAIL; SQUAMOUS-CELL CARCINOMAS; DISTANT METASTASES; TUMOR-CELLS; EXPRESSION; INVASION; GENE; INVOLVEMENT; REPRESSOR; COMPLEX	Major causes of head and neck squamous cell carcinoma (HNSCC)-related deaths are cervical node and distant metastasis. We previously demonstrated that overexpression of the DNA double-strand break repair protein Nijmegen breakage syndrome 1 (NBS1) is a prognostic marker of advanced HNSCCs. Epithelial-mesenchymal transition (EMT) was demonstrated to be the major mechanism responsible for mediating invasiveness and metastasis of late-stage cancers. We therefore investigated the role of NBS1 overexpression in mediating EMT and metastasis. NBS1 overexpression was associated with metastasis of HNSCC patients using tissue microarray immunohistochemistry approach. Induction of EMT was observed in an NBS1-overexpressing HNSCC cell line (FADUNBS), whereas short-interference RNA ( siRNA)mediated repression of endogenous NBS1 reversed the shift of EMT markers. Increased migration/invasiveness of FADUNBS was shown by in vitro and in vivo assays. NBS1 overexpression upregulated the expression of an EMT regulator Snail and its downstreamtarget matrix metalloproteinase-2. EMT phenotypes and increased migration/invasiveness of FADUNBS cells were reversed by siRNA-mediated repression of Snail expression or a phosphatidylinositol 3-kinase-specific inhibitor. In HNSCC samples, co-expression of NBS1/Snail in primary tumors correlated with metastasis and the worst prognosis. These results indicate that NBS1 overexpression induces EMT through the upregulation of Snail expression, and coexpression of NBS1/Snail predicts metastasis in HNSCCs.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; Vet Gen Hosp, Dept Med, Div Med Oncol, Taipei, Taiwan; Vet Gen Hosp, Genom Med Res Ctr, Taipei, Taiwan; Vet Gen Hosp, Dept Otolaryngol, Taipei, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan; Taipei Mackay Mem Hosp, Dept Dent, Taipei, Taiwan; Natl Yang Ming Univ, Dept Pharmacol, Taipei 112, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10764, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Mackay Memorial Hospital; National Yang Ming Chiao Tung University; National Taiwan University	Wu, KJ (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, 155 Linong St,Sect 2, Taipei 112, Taiwan.	kjwu2@ym.edu.tw	Yang, Muh-Hwa/AAE-4691-2020; Wu, Kou-Juey/P-4654-2015	TENG, SHU-CHUN/0000-0002-6492-2560				Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bentz BG, 2000, HEAD NECK-J SCI SPEC, V22, P71, DOI 10.1002/(SICI)1097-0347(200001)22:1<71::AID-HED11>3.0.CO;2-G; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen WE, 2005, WIREL NETW MOB COMP, V1, P3; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Ferlito A, 2001, ORL J OTO-RHINO-LARY, V63, P189, DOI 10.1159/000055738; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; LEEMANS CR, 1993, CANCER, V71, P452, DOI 10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B; Lu WS, 2004, CANCER LETT, V214, P205, DOI 10.1016/j.canlet.2003.08.012; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; *ROC DEP HLTH EX Y, 2005, CANC REG ANN REP TAI; Sauter ER, 1999, CLIN CANCER RES, V5, P775; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tsai HJ, 2006, J BIOL CHEM, V281, P13717, DOI 10.1074/jbc.M600649200; Yang MH, 2006, CLIN CANCER RES, V12, P507, DOI 10.1158/1078-0432.CCR-05-1231; Yokoyama K, 2003, INT J ONCOL, V22, P891; Zhang Y, 2005, CANCER RES, V65, P5544, DOI 10.1158/0008-5472.CAN-04-4368; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	26	122	124	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1459	1467		10.1038/sj.onc.1209929	http://dx.doi.org/10.1038/sj.onc.1209929			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936774				2022-12-25	WOS:000244558800010
J	Zhao, XL; Weisleder, N; Han, XH; Pan, Z; Parness, J; Brotto, M; Ma, JJ				Zhao, Xiaoli; Weisleder, Noah; Han, Xuehai; Pan, Zui; Parness, Jerome; Brotto, Marco; Ma, Jianjie			Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT HYPERTHERMIA; CA2+ RELEASE; SARCOPLASMIC-RETICULUM; DANTROLENE INHIBITION; INTRACELLULAR CA2+; CELLS; MUTATION; CHANNEL; IDENTIFICATION; FIBERS	Dantrolene reduces the elevated myoplasmic Ca2+ generated during malignant hyperthermia, a pharmacogenetic crisis triggered by volatile anesthetics. Although specific binding of dantrolene to the type 1 ryanodine receptor (RyR1), the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum, has been demonstrated, there is little evidence for direct dantrolene inhibition of RyR1 channel function. Recent studies suggest store-operated Ca2+ entry (SOCE) contributes to skeletal muscle function, but the effect of dantrolene on this pathway has not been examined. Here we show that azumolene, an equipotent dantrolene analog, inhibits a component of SOCE coupled to activation of RyR1 by caffeine and ryanodine, whereas the SOCE component induced by thapsigargin is not affected. Our data suggest that azumolene distinguishes between two mechanisms of cellular signaling to SOCE in skeletal muscle, one that is coupled to and one independent from RyR1.	Univ Med & Dent New Jersey, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA 15213 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Brotto, M (corresponding author), Univ Med & Dent New Jersey, Dept Physiol & Biophys, 683 Hoes Lane, Piscataway, NJ 08854 USA.	brottoma@umdnj.edu	Weisleder, Noah L/A-7098-2013	Weisleder, Noah L/0000-0002-2619-8022; Weisleder, Noah/0000-0003-2710-3088; Pan, Zui/0000-0003-4105-901X	NCI NIH HHS [R01-CA95739] Funding Source: Medline; NHLBI NIH HHS [R01-HL69000] Funding Source: Medline; NIAMS NIH HHS [R01-AR45593] Funding Source: Medline; NIA NIH HHS [R01-AG15556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095739] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aleman M, 2004, MUSCLE NERVE, V30, P356, DOI 10.1002/mus.20084; ALLEN PD, 1992, ANESTHESIOLOGY, V76, P132, DOI 10.1097/00000542-199201000-00019; Cherednichenko G, 2004, P NATL ACAD SCI USA, V101, P15793, DOI 10.1073/pnas.0403485101; CHEREDNICHENKO G, 2005, BIOPH SOC ANN M ABST, V88, P639; Cheung A, 2002, NAT CELL BIOL, V4, P83, DOI 10.1038/ncb734; Choi SY, 1999, J PHARMACOL EXP THER, V291, P107; Collet C, 2004, BIOPHYS J, V87, P268, DOI 10.1529/biophysj.103.039305; Fagerlund T, 1996, CLIN GENET, V49, P186; Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; Gailly P, 2002, BBA-PROTEINS PROTEOM, V1600, P38, DOI 10.1016/S1570-9639(02)00442-9; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; Hurne AM, 2005, J BIOL CHEM, V280, P36994, DOI 10.1074/jbc.M506441200; Kobayashi S, 2005, J BIOL CHEM, V280, P6580, DOI 10.1074/jbc.M408375200; Krause T, 2004, ANAESTHESIA, V59, P364, DOI 10.1111/j.1365-2044.2004.03658.x; LESLIE GC, 1989, BRIT J PHARMACOL, V97, P1151, DOI 10.1111/j.1476-5381.1989.tb12573.x; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; MORTIER W, 1982, BRAIN DEV-JPN, V4, P347, DOI 10.1016/S0387-7604(82)80018-1; Nelson TE, 1996, ANESTHESIOLOGY, V84, P1368, DOI 10.1097/00000542-199606000-00013; Nelson Thomas E., 2002, Current Molecular Medicine (Hilversum), V2, P347, DOI 10.2174/1566524023362429; OHTA T, 1990, EUR J PHARMACOL, V178, P11; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; Paul-Pletzer K, 2002, J BIOL CHEM, V277, P34918, DOI 10.1074/jbc.M205487200; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Roberts MC, 2001, ANESTHESIOLOGY, V95, P716, DOI 10.1097/00000542-200109000-00026; Sampieri A, 2005, J BIOL CHEM, V280, P24804, DOI 10.1074/jbc.M501487200; Shin DW, 2003, J BIOL CHEM, V278, P3286, DOI 10.1074/jbc.M209045200; Shin DW, 2002, BIOPHYS J, V83, P2539, DOI 10.1016/S0006-3495(02)75265-X; Szentesi P, 2001, J GEN PHYSIOL, V118, P355, DOI 10.1085/jgp.118.4.355; TAKAGI A, 1983, MUSCLE NERVE, V6, P510, DOI 10.1002/mus.880060707; Tilgen N, 2001, HUM MOL GENET, V10, P2879, DOI 10.1093/hmg/10.25.2879; Treves S, 2005, NEUROMUSCULAR DISORD, V15, P577, DOI 10.1016/j.nmd.2005.06.008; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V234, P125, DOI 10.1006/bbrc.1997.6590; Vazquez G, 1998, J BIOL CHEM, V273, P33954, DOI 10.1074/jbc.273.51.33954; Wang X, 2005, NAT CELL BIOL, V7, P525, DOI 10.1038/ncb1254; Weirich J, 2004, CELL CALCIUM, V35, P9, DOI 10.1016/S0143-4160(03)00156-8; Zhang YF, 2005, J PHARMACOL EXP THER, V314, P94, DOI 10.1124/jpet.105.084046; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200; Zhao XL, 2005, PHYSIOL GENOMICS, V23, P72, DOI 10.1152/physiolgenomics.00020.2005	41	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33477	33486		10.1074/jbc.M602306200	http://dx.doi.org/10.1074/jbc.M602306200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16945924	hybrid			2022-12-25	WOS:000241621400058
J	Park, SG; Chung, C; Kang, H; Kim, JY; Jung, GH				Park, Sung Gyoo; Chung, Chan; Kang, Hang; Kim, Ji-Yeon; Jung, Guhung			Up-regulation of cyclin D1 by HBx is mediated by NF-kappa B2/BCL3 complex through kappa B site of cyclin D1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-X PROTEIN; CANCER; TRANSCRIPTION; EXPRESSION; ASSOCIATION; ACTIVATION; BCL-3; INTERACTS; ALPHA; GENE	Cyclin D1 is frequently overexpressed in hepatocellular carcinoma (HCC) exhibiting increased malignant phenotypes. It has also been known that the hepatitis Bx (HBx) protein is strongly associated with HCC development and progression. Although overexpression of both proteins is related to HCC, the relationship between the two has not been well studied. Here we show that HBx up-regulates cyclin D1 and that this process is mediated by the NF-kappa B2(p52)/BCL-3 complex. Our experiments indicate that HBx up-regulates BCL-3 in the mRNA level, which subsequently results in the up-regulation of the NF-kappa B2(p52)/BCL-3 complex in the nucleus. Moreover, impaired HBx-mediated BCL-3 up-regulation by small interfering RNA for BCL-3 reduced HBx-mediated cyclin D1 up-regulation. Down-regulation of the HBx protein level by p53 also reduced HBx-mediated cyclin D1 up-regulation. From these results, we conclude that the up-regulation of cyclin D1 by HBx is mediated by the up-regulation of NF-kappa B2(p52)/BCL-3 in the nucleus. This HBx-mediated cyclin D1 up-regulation might play an important role in the HBx-mediated HCC development and progression.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Microbiol, Seoul 151742, South Korea; Seoul Natl Univ, Sch Engn, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Jung, GH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	drjung@snu.ac.kr	Park, Sung-Gyoo/H-8652-2019	Chung, Chan/0000-0003-0510-8996				Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Ghosh G, 2004, CURR OPIN STRUC BIOL, V14, P21, DOI 10.1016/j.sbi.2004.01.004; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim KH, 2003, EMBO J, V22, P2104, DOI 10.1093/emboj/cdg210; Klein A, 2003, ONCOGENE, V22, P2910, DOI 10.1038/sj.onc.1206539; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Lee SH, 2005, BBA-MOL BASIS DIS, V1741, P75, DOI 10.1016/j.bbadis.2004.10.004; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Park SG, 2006, FEBS LETT, V580, P822, DOI 10.1016/j.febslet.2006.01.004; Park SG, 2005, GASTROENTEROLOGY, V128, P2042, DOI 10.1053/j.gastro.2005.03.002; Park SG, 2003, J BIOL CHEM, V278, P39851, DOI 10.1074/jbc.M301618200; Park SG, 2001, J VIROL, V75, P6962, DOI 10.1128/JVI.75.15.6962-6968.2001; Park YG, 2001, BIOCHEM BIOPH RES CO, V281, P1213, DOI 10.1006/bbrc.2001.4521; Rabe C, 2001, DIGEST DIS, V19, P279, DOI 10.1159/000050694; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Sato Y, 1999, J GASTROENTEROL, V34, P486, DOI 10.1007/s005350050301; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Tanaka Y, 2004, BIOCHEM BIOPH RES CO, V318, P461, DOI 10.1016/j.bbrc.2004.04.046; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994; Zuckerman AJ, 1999, BRIT MED J, V318, P1213	42	80	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31770	31777		10.1074/jbc.M603194200	http://dx.doi.org/10.1074/jbc.M603194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16940298	Bronze			2022-12-25	WOS:000241235300064
J	Dasari, VR; Anandatheerthavarada, HK; Robin, MA; Boopathi, E; Biswas, G; Fang, JK; Nebert, DW; Avadhani, NG				Dasari, Venkata Ramesh; Anandatheerthavarada, Hindupur K.; Robin, Marie-Anne; Boopathi, Ettickan; Biswas, Gopa; Fang, Ji-Kang; Nebert, Daniel W.; Avadhani, Narayan G.			Role of protein kinase C-mediated protein phosphorylation in mitochondrial translocation of mouse CYP1A1, which contains a non-canonical targeting signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE CYTOCHROMES P450; BETA-NAPHTHOFLAVONE; RAT-LIVER; ACTIVATION; LOCALIZATION; SEQUENCE; P-450; TRAFFICKING; METABOLISM; MODULATION	A large number of mitochondrial proteins lack canonical mitochondrial-targeting signals. The bimodal transport of cytochromes P450 (CYPs) to endoplasmic reticulum and mitochondria (MT), reported previously by us, likely represents one mode of non-canonical protein targeting to MT. Herein, we have studied the mechanism of mouse MT-CYP1A1 targeting to gain insight into the regulatory features and evolutionary conservation of bimodal targeting mechanism. Mouse MT-CYP1A1 consists of two NH2-terminal-truncated molecular species, + 91A1 and + 331A1. Mutations Pro-2 -> Leu and Tyr-5 -> Leu, which increase the signal recognition particle (SRP) binding, diminished MT targeting of the protein in intact cells. By contrast, mutations Leu-7 -> Asn and Leu-17 -> 3 Asn, which decreased SRP-binding affinity, enhanced MT targeting, thus suggesting that SRP binding is an important regulatory step that modulates bimodal targeting. Protein kinase C(PKC)-mediated phosphorylation of nascent chains at Thr-35 vastly decreased affinity for SRP binding suggesting an important regulatory step. In support of these results, COS cell transfection experiments show that phosphomimetic mutation Thr-353Asp or induced cellular PKC caused increased CYP1A1 targeting to MT and correspondingly lower levels to the endoplasmic reticulum. Results suggest evolutionary conservation of chimeric signals and bimodal targeting of CYP1A1 in different species. The mouse MT-CYP1A1 is an extrinsic membrane protein, which exhibited high FDX1 plus FDXR-mediated N-demethylation of a number of tricyclic antidepressants, pain killers, antipsychotics, and narcotics that are poor substrates for microsomal CYP1A1.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA	University of Pennsylvania; University of Pennsylvania; University of Cincinnati; University of Cincinnati	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Dasari, Venkata Ramesh/B-3098-2009	Dasari, Venkata Ramesh/0000-0003-0819-2935; Ettickan, Boopathi/0000-0001-9431-7719	NIEHS NIH HHS [ES-08147] Funding Source: Medline; NIGMS NIH HHS [GM-34883] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1998, BIOCHEMISTRY-US, V37, P1150, DOI 10.1021/bi972046j; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; Bhagwat SV, 1999, TOXICOL APPL PHARM, V156, P231, DOI 10.1006/taap.1999.8646; Boopathi E, 2000, J BIOL CHEM, V275, P34415, DOI 10.1074/jbc.M004431200; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; Colombo S, 2005, J CELL BIOL, V168, P735, DOI 10.1083/jcb.200407082; Egashira T, 1999, JPN J PHARMACOL, V81, P115, DOI 10.1254/jjp.81.115; Gabaldon T, 2004, BBA-BIOENERGETICS, V1659, P212, DOI 10.1016/j.bbabio.2004.07.011; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; HEINE UI, 1991, CELL REGUL, V2, P467, DOI 10.1091/mbc.2.6.467; IOANNIDES C, 1990, DRUG METAB REV, V22, P1, DOI 10.3109/03602539008991444; Kalsotra A, 2004, TOXICOL APPL PHARM, V199, P295, DOI 10.1016/j.taap.2003.12.033; KIMURA S, 1984, J BIOL CHEM, V259, P705; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kurys G, 2000, J BIOL CHEM, V275, P30653, DOI 10.1074/jbc.M002373200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Little MH, 2001, AM J PHYSIOL-CELL PH, V281, pC486, DOI 10.1152/ajpcell.2001.281.2.C486; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; NIRANJAN BG, 1984, J BIOL CHEM, V259, P2495; Niwa T, 1999, XENOBIOTICA, V29, P187, DOI 10.1080/004982599238731; Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rane NS, 2004, EMBO J, V23, P4550, DOI 10.1038/sj.emboj.7600462; RAZA H, 1988, J BIOL CHEM, V263, P9533; Robin MA, 2003, J BIOL CHEM, V278, P18960, DOI 10.1074/jbc.M301807200; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Roh HK, 2001, BRIT J CLIN PHARMACO, V52, P265, DOI 10.1046/j.0306-5251.2001.01437.x; Scharfe C, 2000, NUCLEIC ACIDS RES, V28, P155, DOI 10.1093/nar/28.1.155; SOURKES TL, 1981, BASIC NEUROCHEMISTRY, P737; Stojanovski D, 2003, EXP PHYSIOL, V88, P57, DOI 10.1113/eph8802501; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; WATKINS PB, 1989, J CLIN INVEST, V83, P688, DOI 10.1172/JCI113933; WRIGHTON SA, 1985, BIOCHEMISTRY-US, V24, P2171, DOI 10.1021/bi00330a010; YANG HYL, 1988, MOL PHARMACOL, V34, P67	45	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30834	30847		10.1074/jbc.M510725200	http://dx.doi.org/10.1074/jbc.M510725200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16899466	hybrid			2022-12-25	WOS:000241075900059
J	Nagashima, K; Kubota, Y; Shibata, T; Sakaguchi, C; Shinagawa, H; Hishida, T				Nagashima, Kohji; Kubota, Yoshino; Shibata, Tatsuya; Sakaguchi, Chikako; Shinagawa, Hideo; Hishida, Takashi			Degradation of Escherichia coli RecN aggregates by ClpXP protease and its implications for DNA damage tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STALLED REPLICATION FORKS; DOUBLE-STRAND BREAKS; SMC PROTEINS; RECOGNITION SIGNALS; SISTER CHROMATIDS; TAGGING SYSTEM; IN-VIVO; REPAIR; GENE; GENOME	Protein degradation in bacteria plays a dynamic and critical role in the cellular response to environmental stimuli such as heat shock and DNA damage and in removing damaged proteins or protein aggregates. Escherichia coli recN is a member of the structural maintenance of chromosomes family and is required for DNA double strand break (DSB) repair. This study shows that RecN protein has a short half-life and its degradation is dependent on the cytoplasmic protease ClpXP and a degradation signal at the C terminus of RecN. In cells with DNA DSBs, green fluorescent protein-RecN localized in discrete foci on nucleoids and formed visible aggregates in the cytoplasm, both of which disappeared rapidly in wild-type cells when DSBs were repaired. In contrast, in Delta clpX cells, RecN aggregates persisted in the cytoplasm after release from DNA damage. Furthermore, analysis of cells experiencing chronic DNA damage revealed that proteolytic removal of RecN aggregates by ClpXP was important for cell viability. These data demonstrate that ClpXP is a critical factor in the cellular clearance of cytoplasmic RecN aggregates from the cell and therefore plays an important role in DNA damage tolerance.	Osaka Univ, Lab Genome Dynam, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; BioAcademia Inc, Osaka 5650085, Japan	Osaka University	Hishida, T (corresponding author), Osaka Univ, Lab Genome Dynam, Res Inst Microbial Dis, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	hishida@biken.osaka-u.ac.jp		Hishida, Takashi/0000-0002-9752-6599				Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; FINCH PW, 1985, J BACTERIOL, V164, P653, DOI 10.1128/JB.164.2.653-658.1985; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Gonzalez M, 2000, EMBO J, V19, P5251, DOI 10.1093/emboj/19.19.5251; Gottesman S, 1999, CURR OPIN MICROBIOL, V2, P142, DOI 10.1016/S1369-5274(99)80025-3; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hirano T, 2005, PHILOS T R SOC B, V360, P507, DOI 10.1098/rstb.2004.1606; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; IWASAKI H, 1989, MOL GEN GENET, V219, P328, DOI 10.1007/BF00261196; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kidane D, 2004, MOL MICROBIOL, V52, P1627, DOI 10.1111/j.1365-2958.2004.04102.x; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Lehmann AR, 2005, DNA REPAIR, V4, P309, DOI 10.1016/j.dnarep.2004.07.009; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; LLOYD RG, 1983, MOL GEN GENET, V190, P162, DOI 10.1007/BF00330340; Losada A, 2005, GENE DEV, V19, P1269, DOI 10.1101/gad.1320505; Meddows TR, 2005, MOL MICROBIOL, V57, P97, DOI 10.1111/j.1365-2958.2005.04677.x; Miller J. H., 1992, LAB MANUAL HDB ESCHE; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Neher SB, 2003, GENE DEV, V17, P1084, DOI 10.1101/gad.1078003; PICKSLEY SM, 1984, MOL GEN GENET, V195, P267, DOI 10.1007/BF00332758; Porankiewicz J, 1999, MOL MICROBIOL, V32, P449, DOI 10.1046/j.1365-2958.1999.01357.x; Qu JN, 1996, J BACTERIOL, V178, P3457, DOI 10.1128/jb.178.12.3457-3461.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SARGENTINI NJ, 1983, RADIAT RES, V93, P461, DOI 10.2307/3576026; Shibata T, 2005, GENES CELLS, V10, P181, DOI 10.1111/j.1365-2443.2005.00831.x; Tatsuta T, 1998, MOL MICROBIOL, V30, P583, DOI 10.1046/j.1365-2958.1998.01091.x; Wang JM, 1998, J STRUCT BIOL, V124, P151, DOI 10.1006/jsbi.1998.4058; WANG TCV, 1988, J BACTERIOL, V170, P2555, DOI 10.1128/jb.170.6.2555-2559.1988; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702	39	27	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30941	30946		10.1074/jbc.M606566200	http://dx.doi.org/10.1074/jbc.M606566200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16914543	hybrid			2022-12-25	WOS:000241075900070
J	Frey, N; Brixius, K; Schwinger, RHG; Benis, T; Karpowski, A; Lorenzen, HP; Luedde, M; Katus, HA; Franz, WM				Frey, Norbert; Brixius, Klara; Schwinger, Robert H. G.; Benis, Thomas; Karpowski, Alex; Lorenzen, Hans P.; Luedde, Mark; Katus, Hugo A.; Franz, Wolfgang M.			Alterations of tension-dependent ATP utilization in a transgenic rat model of hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC TROPONIN-T; PROTEIN-KINASE-C; MOUSE MODEL; DIASTOLIC DYSFUNCTION; CELLULAR MECHANISMS; THIN FILAMENT; IN-VIVO; MUTATIONS; MUSCLE; PHOSPHORYLATION	Although it is established that familial hypertrophic cardiomyopathy ( FHC) is caused by mutations in several sarcomeric proteins, including cardiac troponin T ( TnT), its pathogenesis is still not completely understood. Previously, we established a transgenic rat model of FHC expressing a human TnT molecule with a truncation mutation ( DEL- TnT). This study investigated whether contractile dysfunction and electrical vulnerability observed in DEL- TnT rats might be due to alterations of intracellular Ca2+ homeostasis, myofibrillar Ca2+ sensitivity, and/ or myofibrillar ATP utilization. Simultaneous measurements of the force of contraction and intracellular Ca2+ transients were performed in right ventricular trabeculae of DEL- TnT hearts at 0.25 and 1.0 Hz. Rats expressing wild-type human TnT as well as nontransgenic rats served as controls. In addition, calcium- dependent ATPase activity and tension development were investigated in skinned cardiac muscle fibers. Force of contraction was significantly decreased in DEL- TnT compared with nontransgenic rats and TnT. Time parameters of Ca2+ transients were unchanged at 0.25 Hz but prolonged at 1.0 Hz in DEL- TnT. The amplitude of the fura-2 transient was similar in all groups investigated, whereas diastolic and systolic fura-2 ratios were found elevated in rats expressing nontruncated human troponin T. In DEL- TnT rats, myofibrillar Ca2+ dependent tension development as well as Ca2+ sensitivity of tension were significantly decreased, whereas tension- dependent ATP consumption ("tension cost") was markedly increased. Thus, a C-terminal truncation of the cardiac TnT molecule impairs the force- generating capacity of the cycling cross- bridges resulting in increased tension- dependent ATP utilization. Taken together, our data support the hypothesis of energy compromise a contributing factor in the pathogenesis of FHC.	Univ Heidelberg, Dept Med 3, D-69120 Heidelberg, Germany; Univ Cologne, Clin Internal Med 3, Lab Muscle Res & Mol Cardiol, D-50924 Cologne, Germany; Klinikum Weiden, Med Klin 2, D-92637 Weiden, Germany; Univ Hamburg, Dept Surg, D-20249 Hamburg, Germany; Klinikum Hannover Oststadt, Dept Med 1, D-30659 Hannover, Germany; Univ Munich, Med Clin & Policlin 1, D-81377 Munich, Germany	Ruprecht Karls University Heidelberg; University of Cologne; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University of Munich	Frey, N (corresponding author), Univ Heidelberg, Dept Med 3, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	Norbert_Frey@med.uni-heidelberg.de	Frey, Norbert/M-7749-2019; Frey, Norbert/A-9695-2010	Frey, Norbert/0000-0001-7611-378X; 				Alpert NR, 2002, AM J PHYSIOL-HEART C, V283, pH1446, DOI 10.1152/ajpheart.00274.2002; Arad M, 2002, HUM MOL GENET, V11, P2499, DOI 10.1093/hmg/11.20.2499; Ashrafian H, 2003, TRENDS GENET, V19, P263, DOI 10.1016/S0168-9525(03)00081-7; BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130; Bottinelli R, 1998, CIRC RES, V82, P106; Brixius K, 2000, J PHARMACOL EXP THER, V295, P1284; Brixius K, 1997, J APPL PHYSIOL, V83, P652, DOI 10.1152/jappl.1997.83.2.652; Crilley JG, 2003, J AM COLL CARDIOL, V41, P1776, DOI 10.1016/S0735-1097(02)03009-7; Cuda G, 1997, J MUSCLE RES CELL M, V18, P275, DOI 10.1023/A:1018613907574; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Franz WM, 2001, LANCET, V358, P1627, DOI 10.1016/S0140-6736(01)06657-0; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Frey N, 2000, CARDIOVASC RES, V47, P254, DOI 10.1016/S0008-6363(00)00114-0; Gomes AV, 2004, MOL CELL BIOCHEM, V263, P115, DOI 10.1023/B:MCBI.0000041853.20588.a0; GREASER ML, 1971, J BIOL CHEM, V246, P4226; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HILL AV, 1910, J PHYSIOL-LONDON, V40, P463; Javadpour MM, 2003, J CLIN INVEST, V112, P768, DOI 10.1172/JC1200315967; Knollmann BC, 2003, CIRC RES, V92, P428, DOI 10.1161/01.RES.0000059562.91384.1A; Lehman W, 2001, J MOL BIOL, V307, P739, DOI 10.1006/jmbi.2001.4514; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Marian AJ, 2001, J MOL CELL CARDIOL, V33, P655, DOI 10.1006/jmcc.2001.1340; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Montgomery DE, 2001, J PHYSIOL-LONDON, V536, P583, DOI 10.1111/j.1469-7793.2001.0583c.xd; Montgomery DE, 2001, AM J PHYSIOL-HEART C, V280, pH1011, DOI 10.1152/ajpheart.2001.280.3.H1011; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; Oberst L, 1998, J CLIN INVEST, V102, P1498, DOI 10.1172/JCI4088; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; Schwinger RHG, 2000, BASIC RES CARDIOL, V95, P12, DOI 10.1007/s003950050003; Semsarian C, 2002, J CLIN INVEST, V109, P1013, DOI 10.1172/JCI200214677; Solaro RJ, 1996, J MOL CELL CARDIOL, V28, P217; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; Stelzer JE, 2004, AM J PHYSIOL-HEART C, V287, pH1756, DOI 10.1152/ajpheart.00172.2004; Sumandea MP, 2003, J BIOL CHEM, V278, P35135, DOI 10.1074/jbc.M306325200; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tyska MJ, 2000, CIRC RES, V86, P737, DOI 10.1161/01.RES.86.7.737; Vahebi S, 2005, CIRC RES, V96, P740, DOI 10.1161/01.RES.0000162457.56568.7d; Zobel C, 1998, J MOL MED, V76, P533, DOI 10.1007/s001090050247	50	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29575	29582		10.1074/jbc.M507740200	http://dx.doi.org/10.1074/jbc.M507740200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16882671	hybrid			2022-12-25	WOS:000240896300019
J	Lad, Y; McHugh, B; Hodkinson, PS; MacKinnon, AC; Haslett, C; Ginsberg, MH; Sethi, T				Lad, Yatish; McHugh, Brian; Hodkinson, Philip S.; MacKinnon, Alison C.; Haslett, Christopher; Ginsberg, Mark H.; Sethi, Tariq			Phospholipase C epsilon suppresses integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TALIN-BINDING; CELL-ADHESION; R-RAS; AFFINITY MODULATION; KINASE PATHWAY; MAP KINASE; PROTEIN; DOMAIN; RECEPTOR; IDENTIFICATION	Phospholipase C epsilon(PLC epsilon) is a newly described effector of the small GTP-binding protein H-Ras. Utilizing H-Ras effector mutants, we show that mutants H-Ras(G12V/E37G) and H-Ras(G12V/D38N) suppressed integrin activation in an ERK-independent manner. H-Ras(G12V/D38N) specifically activated the PLC epsilon effector pathway and suppressed integrin activation. Inhibition of PLC epsilon activation with a kinase-dead PLC epsilon mutant prevented H-Ras(G12V/D38N) from suppressing integrin activation, and low level expression of H-Ras(G12V/D38N) could synergize with wild-type PLC epsilon to suppress integrins. In addition, knockdown of endogenous PLC epsilon with small interfering RNA blocked H-Ras(G12V/D38N)-mediated integrin suppression. Suppressing integrin function with the H-Ras(G12V/D38N) mutant reduced cell adhesion to von Willebrand factor and fibronectin; this reduction in cell adhesion was blocked by coexpression of the kinase-dead PLC epsilon mutant. These results show that H-Ras suppresses integrin affinity via independent Raf and PLC epsilon signaling pathways and demonstrate a new physiological function for PLC epsilon in the regulation of integrin activation.	Univ Edinburgh, Queens Med Res Inst, Med Res Council Ctr Inflammat Res, Edinburgh EH16 4SA, Midlothian, Scotland; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of Edinburgh; University of California System; University of California San Diego	Sethi, T (corresponding author), Univ Edinburgh, Queens Med Res Inst, Med Res Council Ctr Inflammat Res, 47 Little France Crescent, Edinburgh EH16 4SA, Midlothian, Scotland.	t.sethi@ed.ac.uk		McHugh, Brian/0000-0003-4747-0643	MRC [G84/6336] Funding Source: UKRI; Medical Research Council [G9900991B] Funding Source: researchfish; Medical Research Council [G84/6336] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Bai YF, 2004, CANCER RES, V64, P8808, DOI 10.1158/0008-5472.CAN-04-3143; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Brinkmann T, 2002, J BIOL CHEM, V277, P12525, DOI 10.1074/jbc.M109176200; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chou FL, 2003, J BIOL CHEM, V278, P52587, DOI 10.1074/jbc.M309322200; de Bruyn KMT, 2003, J BIOL CHEM, V278, P22412, DOI 10.1074/jbc.M212036200; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Hansen M, 2002, ONCOGENE, V21, P4448, DOI 10.1038/sj.onc.1205538; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hughes PE, 2002, MOL BIOL CELL, V13, P2256, DOI 10.1091/mbc.01-10-0480; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Ramos JW, 1996, J CELL BIOL, V134, P227, DOI 10.1083/jcb.134.1.227; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Shibayama H, 1998, CELL IMMUNOL, V187, P27, DOI 10.1006/cimm.1998.1318; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Song CH, 2002, ONCOGENE, V21, P8105, DOI 10.1038/sj.onc.1206003; Sorli SC, 2005, ONCOGENE, V24, P90, DOI 10.1038/sj.onc.1208168; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	52	10	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29501	29512		10.1074/jbc.M513471200	http://dx.doi.org/10.1074/jbc.M513471200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16895916	hybrid			2022-12-25	WOS:000240896300012
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, Tip W.; Bartlett, M. Claire; Clarke, David M.			Insertion of an arginine residue into the transmembrane segments corrects protein misfolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; CYSTIC-FIBROSIS MUTATION; CONDUCTANCE REGULATOR; DRUG-BINDING; ENDOPLASMIC-RETICULUM; DELTA-F508 MUTATION; DISRUPTS PACKING; CELL-SURFACE; CFTR; EXPRESSION	Deletion of Phe-508 (Delta F508) in cystic fibrosis transmembrane conductance regulator causes cystic fibrosis because of misfolding of the protein. P-glycoprotein (P-gp) containing the equivalent mutation (Delta Y490) is also misfolded but can be rescued with drug substrates. Whether rescue is due to direct binding of drug substrate to the transmembrane (TM) segments or to indirect effects on cellular protein folding pathways is still controversial. P-gp-drug substrate interactions likely involve hydrogen bonds. If the mechanism of drug rescue involves changes to TM packing then we should be able to identify suppressor mutations in the TM segments that can mimic the drug rescue effects. We predicted that an arginine residue in the TM segments predicted to line the drug-binding pocket of P-gp (I306(TM5) or F343(TM6)) might suppress Delta Y490 P-gp protein misfolding because it has the highest propensity to form hydrogen bonds. We show that R306(TM5) or R343(TM6) increased the relative amount of mature Delta Y490 P-gp by 6-fold. Most other changes to Ile-306 or Phe-343 did not enhance maturation of Delta Y490 P-gp. The I306R mutant also promoted maturation of misprocessed mutants that had mutations in the second nucleotide-binding domain (L1260A), the cytoplasmic loops (G251V, F804A), the linker region (P709A), or in TM segments (G300V, G722A). These results show that arginine residues in the TM domains can mimic the drug rescue effects and are effective suppressor mutations for processing mutations located throughout the molecule.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, 1 Kings Coll Circle,Rm 7342,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Bobadilla JL, 2002, HUM MUTAT, V19, P575, DOI 10.1002/humu.10041; Chen EY, 2004, J BIOL CHEM, V279, P39620, DOI 10.1074/jbc.M407887200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; Ecker GF, 2002, MOL PHARMACOL, V61, P637, DOI 10.1124/mol.61.3.637; Goldfarb SB, 2006, P NATL ACAD SCI USA, V103, P5817, DOI 10.1073/pnas.0507903103; Harada K, 2006, J BIOL CHEM, V281, P12841, DOI 10.1074/jbc.M512975200; HOOF T, 1994, J BIOL CHEM, V269, P20575; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Kleizen B, 2005, MOL CELL, V20, P277, DOI 10.1016/j.molcel.2005.09.007; Lewis HA, 2005, J BIOL CHEM, V280, P1346, DOI 10.1074/jbc.M410968200; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2004, BIOCHEMISTRY-US, V43, P12081, DOI 10.1021/bi049045t; Loo TW, 2003, J BIOL CHEM, V278, P50136, DOI 10.1074/jbc.M310448200; Loo TW, 1999, FASEB J, V13, P1724, DOI 10.1096/fasebj.13.13.1724; Loo TW, 2003, J BIOL CHEM, V278, P20449, DOI 10.1074/jbc.C300154200; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 2002, J BIOL CHEM, V277, P27585, DOI 10.1074/jbc.C200330200; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P28683; Omote H, 2006, BIOPHYS J, V90, P4046, DOI 10.1529/biophysj.105.077743; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Partridge AW, 2004, PROTEINS, V54, P648, DOI 10.1002/prot.10611; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rothnie A, 2004, J BIOL CHEM, V279, P34913, DOI 10.1074/jbc.M405336200; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Vij N, 2006, J BIOL CHEM, V281, P17369, DOI 10.1074/jbc.M600509200; Zhang H, 2006, J BIOL CHEM, V281, P11312, DOI 10.1074/jbc.M512013200	34	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29436	29440		10.1074/jbc.C600209200	http://dx.doi.org/10.1074/jbc.C600209200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16926162	hybrid			2022-12-25	WOS:000240896300005
J	Berbee, JFP; van der Hoogt, CC; Kleemann, R; Schippers, EF; Kitchens, RL; van Dissel, JT; Bakker-Woudenberg, IAJM; Havekes, LM; Rensen, PCN				Berbee, Jimmy F. P.; van der Hoogt, Caroline C.; Kleemann, Robert; Schippers, Emile F.; Kitchens, Richard L.; van Dissel, Jaap T.; Bakker-Woudenberg, Irma A. J. M.; Havekes, Louis M.; Rensen, Patrick C. N.			Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in Gram-negative sepsis	FASEB JOURNAL			English	Article						inflammation; lipoprotein; macrophage; TNF-alpha; transgenic mice	TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTOR-4; HIGH-DENSITY-LIPOPROTEINS; FACTOR-ALPHA; TRANSGENIC MICE; IMMUNE-RESPONSE; ANIMAL-MODELS; LDL RECEPTOR; HOST-DEFENSE; APOC-I	Gram-negative sepsis is a major death cause in intensive care units. Accumulating evidence indicates the protective role of plasma lipoproteins such as high-density lipoprotein (HDL) in sepsis. It has recently been shown that septic HDL is almost depleted from apolipoprotein CI (apoCI), suggesting that apoCI may be a protective factor in sepsis. Sequence analysis revealed that apoCI possesses a highly conserved consensus KVKEKLK binding motif for lipopolysaccharide (LPS), an outer-membrane component of Gram-negative bacteria. Through avid binding to LPS involving this motif, apoCI improved the presentation of LPS to macrophages in vitro and in mice, thereby stimulating the inflammatory response to LPS. Moreover, apoCI dose-dependently increased the early inflammatory response to Klebsiella pneumoniae-induced pneumonia, reduced the number of circulating bacteria, and protected mice against fatal sepsis. Our data support the hypothesis that apoCI is a physiological protector against infection by enhancing the early inflammatory response to LPS and suggest that timely increase of apoCI levels could be used to efficiently prevent and treat early sepsis.	Leiden Univ, Dept Biomed Res, TNO Qual Life, Med Ctr, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Vasc Surg, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, Dallas, TX USA; Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Erasmus University Rotterdam; Erasmus MC	Rensen, PCN (corresponding author), Leiden Univ, Med Ctr, Dept Endocrinol & Metab, C4-R81,Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.	p.c.n.rensen@lumc.nl	Rensen, Patrick C.N./D-7176-2018	Rensen, Patrick C.N./0000-0002-8455-4988	NIAID NIH HHS [AI045896] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045896] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; BAGBY GJ, 1991, J INFECT DIS, V163, P83, DOI 10.1093/infdis/163.1.83; Bakker-Woudenberg IAJM, 2003, J MICROBIOL METH, V54, P295, DOI 10.1016/S0167-7012(03)00118-0; Barlage S, 2001, J LIPID RES, V42, P281; Berbee JFP, 2005, J LIPID RES, V46, P297, DOI 10.1194/jlr.M400301-JLR200; Bernheiden M, 2001, J ENDOTOXIN RES, V7, P447, DOI 10.1179/096805101101533061; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Branger J, 2004, INFECT IMMUN, V72, P788, DOI 10.1128/IAI.72.2.788-794.2004; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; Cohn JS, 2003, ATHEROSCLEROSIS, V169, P63, DOI 10.1016/S0021-9150(03)00139-4; CROSS AS, 1993, INFECT IMMUN, V61, P2741, DOI 10.1128/IAI.61.7.2741-2747.1993; de Bont N, 2000, EUR J CLIN INVEST, V30, P818; de Haas CJC, 1999, INFECT IMMUN, V67, P2790, DOI 10.1128/IAI.67.6.2790-2796.1999; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; Echtenacher B, 2001, INFECT IMMUN, V69, P7271, DOI 10.1128/IAI.69.12.7172-7276.2001; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1197, DOI 10.1164/rccm.200204-302OC; FLEGEL WA, 1993, INFECT IMMUN, V61, P5140, DOI 10.1128/IAI.61.12.5140-5146.1993; HAGBERG L, 1984, INFECT IMMUN, V46, P839, DOI 10.1128/IAI.46.3.839-844.1984; HARRIS HW, 1990, J CLIN INVEST, V86, P696, DOI 10.1172/JCI114765; Harris HW, 2000, J ENDOTOXIN RES, V6, P421, DOI 10.1177/09680519000060060301; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; Jong MC, 1996, J CLIN INVEST, V98, P2259, DOI 10.1172/JCI119036; Kleemann R, 2003, BLOOD, V101, P545, DOI 10.1182/blood-2002-06-1762; LARRICK JW, 1994, J IMMUNOL, V152, P231; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; MASTROENI P, 1991, MICROB PATHOGENESIS, V11, P33, DOI 10.1016/0882-4010(91)90091-N; Moore TA, 2003, SHOCK, V20, P309, DOI 10.1097/01.shk.0000087203.34916.45; Mullarkey M, 2003, J PHARMACOL EXP THER, V304, P1093, DOI 10.1124/jpet.102.044487; Nara C, 2004, J MED MICROBIOL, V53, P727, DOI 10.1099/jmm.0.45592-0; Netea MG, 2003, TRENDS IMMUNOL, V24, P254, DOI 10.1016/S1471-4906(03)00079-6; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; REHM SR, 1980, J CLIN INVEST, V66, P194, DOI 10.1172/JCI109844; Rensen PCN, 1997, J LIPID RES, V38, P1070; Rensen PCN, 1997, J CLIN INVEST, V99, P2438, DOI 10.1172/JCI119427; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Santo SMSE, 2005, J LIPID RES, V46, P1097, DOI 10.1194/jlr.C500007-JLR200; Schurr JR, 2005, INFECT IMMUN, V73, P532, DOI 10.1128/IAI.73.1.532-545.2005; Shachter NS, 1996, J CLIN INVEST, V98, P846, DOI 10.1172/JCI118857; Solomon SB, 2006, J INFECT DIS, V193, P634, DOI 10.1086/500147; Troelstra A, 1997, INFECT IMMUN, V65, P2272, DOI 10.1128/IAI.65.6.2272-2277.1997; van Dissel JT, 1998, LANCET, V351, P950, DOI 10.1016/S0140-6736(05)60606-X; Van Oosten MV, 2001, J BIOL CHEM, V276, P8820, DOI 10.1074/jbc.M009915200; vanderPoll T, 1997, AM J RESP CRIT CARE, V155, P603, DOI 10.1164/ajrccm.155.2.9032201; VANFURTH R, 1994, J INFECT DIS, V170, P234, DOI 10.1093/infdis/170.1.234; VANREE JH, 1995, BIOCHEM J, V305, P905, DOI 10.1042/bj3050905; Wang MJ, 1999, IMMUNOLOGY, V98, P90; Wang XR, 2002, J IMMUNOL, V168, P810, DOI 10.4049/jimmunol.168.2.810; WEINBERG RB, 1994, J LIPID RES, V35, P2212; WESTENDORP RGJ, 1995, J INFECT DIS, V171, P1057, DOI 10.1093/infdis/171.4.1057; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6; WOODS JP, 1988, INFECT IMMUN, V56, P1950, DOI 10.1128/IAI.56.8.1950-1955.1988	56	62	63	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2162	+		10.1096/fj.05-5639fje	http://dx.doi.org/10.1096/fj.05-5639fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16935938				2022-12-25	WOS:000241156900053
J	Dimitrov, S; Lange, T; Benedict, C; Nowell, MA; Jones, SA; Scheller, J; Rose-John, S; Born, J				Dimitrov, Stoyan; Lange, Tanja; Benedict, Christian; Nowell, Mari A.; Jones, Simon A.; Scheller, Juergen; Rose-John, Stefan; Born, Jan			Sleep enhances IL-6 trans-signaling in humans	FASEB JOURNAL			English	Article						neuroimmunology; cytokine receptors; cytokines; hormones	NECROSIS-FACTOR-ALPHA; INTERLEUKIN-6 RECEPTOR; CYTOKINE PRODUCTION; GROWTH-HORMONE; IMMUNE-SYSTEM; PLASMA-LEVELS; SERUM; MODEL; DEPRIVATION; PERFORMANCE	Sleep is commonly considered to support immune defense. The underlying sleep-immune interaction appears to rely critically on cytokines, like interleukin-6 (IL-6), that combine effects on immune and neuronal functions. The IL-6 signal is conveyed in two ways: it stimulates a restricted group of (mostly immune) cells via membrane-bound IL-6 receptors (mIL-6R) by forming a complex with soluble IL-6R (sIL-6R), and it stimulates (via membrane-bound gp130) a great variety of other cell types-a process termed trans-signaling. Focusing on the receptor side of IL-6 signaling, we examined the effect of sleep on sIL-6R plasma concentrations, mIL-6R expression, plasma sgp130, and numbers of IL-6-producing monocytes in healthy humans who were tested during a regular sleep-wake cycle and 24 h of wakefulness while blood was sampled repeatedly. Sleep strongly enhanced concentrations of sIL-6R, exceeding wake levels by 70% at the end of sleep. This rise was due to an increase in the PC (proteolytic cleavage) rather than the DS (differentially spliced) variant of sIL-6R. Sleep did not affect IL-6-producing monocytes, mIL-6R density, or sgp130 concentrations. The selective increase in sIL-6R implicates an enhanced trans-signaling capacity whereby sleep distinctly widens the profile of IL-6 actions, enabling an integrated influence on brain and peripheral organs.	Med Univ Lubeck, Dept Neuroendocrinol, D-23538 Lubeck, Germany; Med Univ Lubeck, Dept Internal Med, D-23538 Lubeck, Germany; Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff, Wales; Univ Kiel, Dept Biochem, Kiel, Germany	University of Lubeck; University of Lubeck; Cardiff University; University of Kiel	Born, J (corresponding author), Med Univ Lubeck, Dept Neuroendocrinol, Ratzeburger Allee 160,Haus 23A, D-23538 Lubeck, Germany.	born@kfg.uni-luebeck.de	Rose-John, Stefan/A-7998-2010; Benedict, Christian/K-2190-2017; Lange, Tanja/Z-1688-2018; Born, Jan/K-2596-2016; Jones, Simon Arnett/Q-7017-2018	Rose-John, Stefan/0000-0002-7519-3279; Benedict, Christian/0000-0002-8911-4068; Lange, Tanja/0000-0001-8309-2112; Dimitrov, Stoyan/0000-0002-1184-1441; Born, Jan/0000-0002-1847-6248; Nowell, Mari/0000-0003-0053-0127; Jones, Simon Arnett/0000-0001-7297-9711				Adamopoulos S, 2002, AM HEART J, V144, P359, DOI 10.1067/mhj.2002.124052; Balschun D, 2004, FASEB J, V18, P1788, DOI 10.1096/fj.04-1625fje; Brattsand R, 1996, ALIMENT PHARM THERAP, V10, P81, DOI 10.1046/j.1365-2036.1996.22164025.x; Bryant PA, 2004, NAT REV IMMUNOL, V4, P457, DOI 10.1038/nri1369; Chen CK, 2004, ASIAN J CONTROL, V6, P130, DOI 10.1111/j.1934-6093.2004.tb00191.x; Cichy J, 1997, J IMMUNOL, V159, P5648; Ciftci TU, 2004, CYTOKINE, V28, P87, DOI 10.1016/j.cyto.2004.07.003; Cutolo M, 2003, ANN RHEUM DIS, V62, P593, DOI 10.1136/ard.62.7.593; Debus G., 1978, EIGENSCHAFTSWORTERLI; Dimitrov S, 2004, BRAIN BEHAV IMMUN, V18, P341, DOI 10.1016/j.bbi.2003.08.004; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Franchimont N, 2005, ARTHRITIS RHEUM, V52, P84, DOI 10.1002/art.20727; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gaillard JP, 1999, EUR CYTOKINE NETW, V10, P337; Guan ZW, 2005, BRAIN BEHAV IMMUN, V19, P526, DOI 10.1016/j.bbi.2005.01.005; Haack M, 2002, PSYCHONEUROENDOCRINO, V27, P921, DOI 10.1016/S0306-4530(02)00006-9; Horiuchi S, 1998, IMMUNOLOGY, V95, P360, DOI 10.1046/j.1365-2567.1998.00622.x; Hu J, 2003, BRAIN BEHAV IMMUN, V17, P498, DOI 10.1016/j.bbi.2003.03.001; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Irwin M, 2002, BRAIN BEHAV IMMUN, V16, P503, DOI 10.1016/S0889-1591(02)00003-X; Jones R. A. C., 2001, Integrated Pest Management Reviews, V6, P15, DOI 10.1023/A:1020494604184; Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241; Krueger JM, 2003, ANN NY ACAD SCI, V992, P9, DOI 10.1111/j.1749-6632.2003.tb03133.x; Krueger JM, 1999, J SLEEP RES, V8, P53; Lenkei R, 1998, CYTOMETRY, V33, P188, DOI 10.1002/(SICI)1097-0320(19981001)33:2<188::AID-CYTO13>3.0.CO;2-Q; Majde JA, 2005, J ALLERGY CLIN IMMUN, V116, P1188, DOI 10.1016/j.jaci.2005.08.005; Marshall L, 2002, INT REV NEUROBIOL, V52, P93; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; McLoughlin RM, 2004, J IMMUNOL, V172, P5676, DOI 10.4049/jimmunol.172.9.5676; McLoughlin RM, 2005, P NATL ACAD SCI USA, V102, P9589, DOI 10.1073/pnas.0501794102; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; MOJON A, 1992, CHRONOBIOL INT, V9, P403, DOI 10.3109/07420529209064552; Nowell MA, 2003, J IMMUNOL, V171, P3202, DOI 10.4049/jimmunol.171.6.3202; Obal F, 2004, SLEEP MED REV, V8, P367, DOI 10.1016/j.smrv.2004.03.005; Petrovsky N, 2001, IMMUNOL CELL BIOL, V79, P350, DOI 10.1046/j.1440-1711.2001.01029.x; Petrovsky N, 1997, J IMMUNOL, V158, P5163; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Redwine L, 2000, J CLIN ENDOCR METAB, V85, P3597, DOI 10.1210/jc.85.10.3597; Rose-John S, 2004, IMMUNITY, V20, P2, DOI 10.1016/S1074-7613(04)00003-2; Rose-John S, 2003, ACTA BIOCHIM POL, V50, P603; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SCHOBITZ B, 1995, FASEB J, V9, P659, DOI 10.1096/fasebj.9.8.7768358; Schroers A, 2005, PROTEIN SCI, V14, P783, DOI 10.1110/ps.041117105; Seres J, 2004, NEUROIMMUNOMODULAT, V11, P316, DOI 10.1159/000079412; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P165, DOI 10.1067/mai.2001.112270; SOTHERN RB, 1995, J ALLERGY CLIN IMMUN, V95, P1029, DOI 10.1016/S0091-6749(95)70104-4; Spath-Schwalbe E, 1998, J CLIN ENDOCR METAB, V83, P1573, DOI 10.1210/jc.83.5.1573; SPATHSCHWALBE E, 1994, J CLIN ENDOCR METAB, V79, P1212, DOI 10.1210/jc.79.4.1212; Sutherland ER, 2005, J ALLERGY CLIN IMMUN, V116, P1179, DOI 10.1016/j.jaci.2005.09.028; Tancredi V, 2000, J NEUROCHEM, V75, P634, DOI 10.1046/j.1471-4159.2000.0750634.x; Van Cauter E, 2000, GROWTH HORM IGF RES, V10, P57; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P2119, DOI 10.1210/jc.2003-031562; Vgontzas AN, 2005, NEUROIMMUNOMODULAT, V12, P131, DOI 10.1159/000084844; Vgontzas AN, 1999, J CLIN ENDOCR METAB, V84, P2603, DOI 10.1210/jc.84.8.2603; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P4409, DOI 10.1210/jc.2003-031929	56	80	81	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2174	+		10.1096/fj.06-5754fje	http://dx.doi.org/10.1096/fj.06-5754fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16912152				2022-12-25	WOS:000241156900061
J	Kakimoto, T; Katoh, H; Negishi, M				Kakimoto, Tetsuhiro; Katoh, Hironori; Negishi, Manabu			Regulation of neuronal morphology by Toca-1, an F-BAR/EFC protein that induces plasma membrane invagination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; N-WASP; INTERSTITIAL BRANCHES; HIPPOCAMPAL-NEURONS; ACTIN CYTOSKELETON; AXONAL GROWTH; GTPASE; ENDOCYTOSIS; RAPOSTLIN; EFFECTOR	Actin reorganization is important for regulation of neuronal morphology. Neural Wiskott-Aldrich syndrome protein (N-WASP) is an important regulator of actin polymerization and also known to be strongly expressed in brain. Recently, Toca-1 (transducer of Cdc42-dependent actin assembly) has been shown to be required for Cdc42 to activate N-WASP from biochemical experiments. Toca-1 has three functional domains: an F-BAR/EFC domain at the N terminus, an HR1 at the center, and an SH3 domain at the C terminus. The F-BAR/EFC domain induces tubular invagination of plasma membrane, while Toca-1 binds both N-WASP and Cdc42 through the SH3 domain and the HR1, respectively. However, the physiological role of Toca-1 is completely unknown. Here we have investigated the neural function of Toca-1. Toca-1 is strongly expressed in neurons including hippocampal neurons in developing brain at early times. Knockdown of Toca-1 in PC12 cells significantly enhances neurite elongation. Consistently, overexpression of Toca-1 suppresses neurite elongation through the F-BAR/EFC domain with a membrane invaginating property, suggesting an implication of membrane trafficking in the neural function of Toca-1. In addition, knockdown of N-WASP, to our surprise, also enhances neurite elongation in PC12 cells, which is in clear contrast to the previous report that dominant negative mutants of N-WASP suppress neurite extension in PC12 cells. On the other hand, knockdown of Toca-1 in cultured rat hippocampal neurons enhances axon branching a little but not axon elongation, while knockdown of N-WASP enhances both axon elongation and branching. These results suggest that a vesicle trafficking regulator Toca-1 regulates different aspects of neuronal morphology from N-WASP.	Kyoto Univ, Grad Sch Biostudies, Lab Mol Neurobiol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Lab Mol Neurobiol, Sakyo Ku, Kyoto 6068501, Japan.	mnegishi@pharm.kyoto-u.ac.jp	kakimoto, tetsuhiro/W-1403-2019	Kakimoto, Tetsuhiro/0000-0003-1349-5690; Katoh, Hironori/0000-0002-8191-8117				Banzai Y, 2000, J BIOL CHEM, V275, P11987, DOI 10.1074/jbc.275.16.11987; Dent EW, 1999, J NEUROSCI, V19, P8894, DOI 10.1523/JNEUROSCI.19-20-08894.1999; Fujita H, 2002, J BIOL CHEM, V277, P45428, DOI 10.1074/jbc.M208090200; Futerman AH, 1996, TRENDS NEUROSCI, V19, P144, DOI 10.1016/S0166-2236(96)80025-7; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Ishikawa Y, 2003, J NEUROSCI, V23, P11065; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Jareb M, 1997, J NEUROSCI, V17, P8955; Kakimoto T, 2004, J BIOL CHEM, V279, P14104, DOI 10.1074/jbc.M312763200; Kamioka Y, 2004, J BIOL CHEM, V279, P40091, DOI 10.1074/jbc.M404899200; Katoh H, 2006, BRAIN RES, V1073, P103, DOI 10.1016/j.brainres.2005.12.085; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Miki H, 2003, J BIOCHEM, V134, P309, DOI 10.1093/jb/mvg146; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Strasser GA, 2004, NEURON, V43, P81, DOI 10.1016/j.neuron.2004.05.015; Szebenyi G, 1998, J NEUROSCI, V18, P7930; Tsujita K, 2006, J CELL BIOL, V172, P269, DOI 10.1083/jcb.200508091	22	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29042	29053		10.1074/jbc.M604025200	http://dx.doi.org/10.1074/jbc.M604025200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16885158	hybrid			2022-12-25	WOS:000240680500059
J	Rouget, C; Papin, C; Mandart, E				Rouget, Christel; Papin, Catherine; Mandart, Elisabeth			Cytoplasmic CstF-77 protein belongs to a masking complex with cytoplasmic polyadenylation element-binding protein in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; CLEAVAGE STIMULATION FACTOR; SPECIFICITY FACTOR; PROCESSING BODIES; COILED BODIES; POLY(A) POLYMERASE; 3'-END FORMATION; STRESS GRANULES; FORKED PROTEIN; LAEVIS OOCYTES	Regulated mRNA translation is a hallmark of oocytes and early embryos, of which cytoplasmic polyadenylation is a major mechanism. This process involves multiple protein components, including the CPSF (cleavage and polyadenylation specificity factor), which is also required for nuclear polyadenylation. The CstF (cleavage stimulatory factor), with CPSF, is required for the pre-mRNA cleavage before nuclear polyadenylation. However, some evidence suggests that the CstF-77 subunit might have a function independent of nuclear polyadenylation, which could be related to the cell cycle. As such, we addressed the question whether CstF-77 might have a role in cytoplasmic polyadenylation. We investigated the function of the CstF-77 protein in Xenopus oocytes, and show that CstF-77 has indeed a role in the cytoplasm. The Xenopus CstF-77 protein (X77K) localizes mainly to the nucleus, but also in punctuate cytoplasmic foci. We show that X77K resides in a cytoplasmic complex with eIF4E, CPEB (cytoplasmic polyadenylation element-binding protein), CPSF-100 and XGLD2, but is not required for cytoplasmic polyadenylation per se. Impairment of X77K function in ovo leads to an acceleration of the G(2)/M transition, with a premature synthesis of Mos and AuroraA proteins. However, the kinetic of Mos mRNA polyadenylation is not modified. Furthermore, X77K represses mRNA translation in vitro. These results suggest that X77K could be involved in masking of mRNA prior to polyadenylation.	CNRS, CRBM, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mandart, E (corresponding author), CNRS, CRBM, 1919 Route Mende, F-34293 Montpellier 05, France.	elisabeth.mandart@crbm.cnrs.fr						Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Audibert A, 1998, MECH DEVELOP, V72, P53, DOI 10.1016/S0925-4773(98)00017-3; Audibert A, 1999, MECH DEVELOP, V82, P41, DOI 10.1016/S0925-4773(99)00011-8; Barnard DC, 2004, CELL, V119, P641, DOI 10.1016/j.cell.2004.10.029; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; Bleoo S, 2001, MOL BIOL CELL, V12, P3046, DOI 10.1091/mbc.12.10.3046; BONNEAUD N, 1994, J CELL SCI, V107, P913; Brendolise C, 2002, MOL GENET GENOMICS, V267, P515, DOI 10.1007/s00438-002-0684-3; Brengues M, 2005, SCIENCE, V310, P486, DOI 10.1126/science.1115791; Cao QP, 2002, EMBO J, V21, P3852, DOI 10.1093/emboj/cdf353; Charlesworth A, 2004, J BIOL CHEM, V279, P17650, DOI 10.1074/jbc.M313837200; Charlesworth A, 2002, EMBO J, V21, P2798, DOI 10.1093/emboj/21.11.2798; Collier B, 2005, EMBO J, V24, P2656, DOI 10.1038/sj.emboj.7600738; Dickson KS, 1999, MOL CELL BIOL, V19, P5707; Edmonds M, 2002, PROG NUCLEIC ACID RE, V71, P285, DOI 10.1016/S0079-6603(02)71046-5; Gall JG, 2003, NAT REV MOL CELL BIO, V4, P975, DOI 10.1038/nrm1262; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hofmann I, 2002, MOL BIOL CELL, V13, P1665, DOI 10.1091/mbc.01-12-0567; Kaufmann I, 2004, EMBO J, V23, P616, DOI 10.1038/sj.emboj.7600070; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Ladomery M, 1997, NUCLEIC ACIDS RES, V25, P965, DOI 10.1093/nar/25.5.965; Mandart E, 1998, MOL GEN GENET, V258, P16, DOI 10.1007/s004380050702; MANDART E, 1995, MOL CELL BIOL, V15, P6979; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Minshall N, 2001, RNA, V7, P1728, DOI 10.1017/S135583820101158X; Minshall N, 2004, NUCLEIC ACIDS RES, V32, P1325, DOI 10.1093/nar/gkh303; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; Nakahata S, 2001, J BIOL CHEM, V276, P20945, DOI 10.1074/jbc.M010528200; Nakamura A, 2004, DEV CELL, V6, P69, DOI 10.1016/S1534-5807(03)00400-3; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Padmanabhan K, 2006, GENE DEV, V20, P199, DOI 10.1101/gad.1383106; Papin C, 2000, DEV BIOL, V217, P166, DOI 10.1006/dbio.1999.9531; Preker PJ, 1998, TRENDS BIOCHEM SCI, V23, P15, DOI 10.1016/S0968-0004(97)01156-0; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; Reverte CG, 2001, DEV BIOL, V231, P447, DOI 10.1006/dbio.2001.0153; Rouhana L, 2005, RNA, V11, P1117, DOI 10.1261/rna.2630205; Rouillard JM, 2000, MOL GEN GENET, V262, P1103, DOI 10.1007/PL00008653; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SALLES FJ, 1995, PCR METH APPL, V4, P317; Schul W, 1999, MOL BIOL CELL, V10, P3815, DOI 10.1091/mbc.10.11.3815; Schul W, 1996, EMBO J, V15, P2883, DOI 10.1002/j.1460-2075.1996.tb00649.x; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Wallace AM, 1999, P NATL ACAD SCI USA, V96, P6763, DOI 10.1073/pnas.96.12.6763; Wang LT, 2002, NATURE, V419, P312, DOI 10.1038/nature01039; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; Wilczynska A, 2005, J CELL SCI, V118, P981, DOI 10.1242/jcs.01692; WILUSZ J, 1990, MOL CELL BIOL, V10, P1244, DOI 10.1128/MCB.10.3.1244; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	58	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28687	28698		10.1074/jbc.M601116200	http://dx.doi.org/10.1074/jbc.M601116200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16882666	Green Submitted, hybrid			2022-12-25	WOS:000240680500022
J	Savinov, AY; Rozanov, DV; Strongin, AY				Savinov, Alexei Y.; Rozanov, Dmitri V.; Strongin, Alex Y.			Mechanistic insights into targeting T cell membrane proteinase to promote islet beta-cell rejuvenation in type 1 diabetes	FASEB JOURNAL			English	Article						IDDM; monoclonal antibody; CD44; MT1-MMP	MATRIX-METALLOPROTEINASE CLEAVES; CD44; MT1-MMP; MICE; ACTIVATION; INHIBITOR; REVERSAL; PRINOMASTAT; COLLAGENASE; PROTEOLYSIS	It has been well established that invasionpromoting membrane type-1 matrix metalloproteinase (MT1-MMP), a multifunctional membrane-tethered enzyme, functions in cancer cells as a mediator of pericellular proteolysis and directly cleaves several cell surface receptors, including CD44. In this report, we confirm that adhesion of diabetogenic T cells promotes the activation of endogenous MT1-MMP. Activated protease then cleaves CD44 in adherent T cells. We have validated that the T cell CD44 receptor is critical for the adhesion of diabetogenic insulin-specific, CD8-positive, K-d-restricted cells to the matrix as well as for the subsequent transmigration of the adherent T cells through the endothelium and homing of the transmigrated T cells into the pancreatic islets. We have determined that the inhibition of MT1-MMP by low dosages of AG3340 (a subnanomolar range hydroxamate inhibitor of MMPs that has been widely tested in cancer patients) inhibited both T cell MT1-MMP activity and MT1-MMP- dependent shedding of CD44, immobilized T cells on the endothelium, repressed the homing of diabetogenic T cells into the pancreatic islets, reduced insulitis and mononuclear cell infiltration, and promoted either the recovery or the rejuvenation of the functional insulin-producing beta cells in diabetic NOD mice with freshly developed type I diabetes (IDDM). We believe our data constitute a mechanistic and substantive rationale for clinical trials of selected MT1-MMP inhibitors in the therapy of IDDM in humans. - Savinov, A. Y., Rozanov, D. V., Strongin, A. Y. Mechanistic insights into targeting T cell membrane proteinase to promote islet beta-cell rejuvenation in type 1 diabetes.	Burnham Inst Med Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Strongin, AY (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NATIONAL CANCER INSTITUTE [R01CA077470, R01CA083017] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NCI NIH HHS [CA83017, CA77470] Funding Source: Medline; NCRR NIH HHS [RR020843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ablamunits V, 1999, CLIN EXP IMMUNOL, V115, P260, DOI 10.1046/j.1365-2249.1999.00802.x; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Annabi B, 2005, CLIN EXP METASTAS, V22, P429, DOI 10.1007/s10585-005-2669-1; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bissett D, 2005, J CLIN ONCOL, V23, P842, DOI 10.1200/JCO.2005.03.170; Chong AS, 2006, SCIENCE, V311, P1774, DOI 10.1126/science.1123510; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ezaki T, 2001, AM J PATHOL, V158, P2043, DOI 10.1016/S0002-9440(10)64676-7; Griffioen A W, 2000, IDrugs, V3, P336; Hande KR, 2004, CLIN CANCER RES, V10, P909, DOI 10.1158/1078-0432.CCR-0981-3; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Homann D, 2004, CLIN IMMUNOL, V112, P202, DOI 10.1016/j.clim.2004.03.020; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Lee MH, 2002, PROTEIN SCI, V11, P2493, DOI 10.1110/ps.0216202; Luo ZR, 2005, TRANSPLANTATION, V79, P1091, DOI 10.1097/01.TP.0000161223.54452.A2; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nakamura H, 2004, CANCER RES, V64, P876, DOI 10.1158/0008-5472.CAN-03-3502; Nishio J, 2006, SCIENCE, V311, P1775, DOI 10.1126/science.1124004; Pomerleau DP, 2005, DIABETES, V54, P1603, DOI 10.2337/diabetes.54.5.1603; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Savinov AY, 2005, J BIOL CHEM, V280, P27755, DOI 10.1074/jbc.M506016200; Savinov AY, 2003, J EXP MED, V197, P643, DOI 10.1084/jem.20021378; Savinov AY, 2001, J IMMUNOL, V167, P6637, DOI 10.4049/jimmunol.167.11.6637; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suenaga N, 2005, ONCOGENE, V24, P859, DOI 10.1038/sj.onc.1208258; Suri A, 2006, SCIENCE, V311, P1778, DOI 10.1126/science.1123500; TRAISMAN HS, 1973, CLIN PEDIATR, V12, P357, DOI 10.1177/000992287301200612; Weiss L, 2000, P NATL ACAD SCI USA, V97, P285, DOI 10.1073/pnas.97.1.285; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465; Zhou YP, 2005, DIABETES, V54, P2612, DOI 10.2337/diabetes.54.9.2612; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	41	11	11	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2006	20	11					1793	1801		10.1096/fj.06-6207com	http://dx.doi.org/10.1096/fj.06-6207com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RZ	16940151				2022-12-25	WOS:000240267000007
